<SEC-DOCUMENT>0001628280-16-012462.txt : 20160309
<SEC-HEADER>0001628280-16-012462.hdr.sgml : 20160309
<ACCEPTANCE-DATETIME>20160309134736
ACCESSION NUMBER:		0001628280-16-012462
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		100
CONFORMED PERIOD OF REPORT:	20151231
FILED AS OF DATE:		20160309
DATE AS OF CHANGE:		20160309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arbutus Biopharma Corp
		CENTRAL INDEX KEY:			0001447028
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980597776
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34949
		FILM NUMBER:		161494010

	BUSINESS ADDRESS:	
		STREET 1:		100-8900 GLENLYON PARKWAY
		CITY:			BURNABY
		STATE:			A1
		ZIP:			V5J 5J8
		BUSINESS PHONE:		604-419-3200

	MAIL ADDRESS:	
		STREET 1:		100-8900 GLENLYON PARKWAY
		CITY:			BURNABY
		STATE:			A1
		ZIP:			V5J 5J8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKMIRA PHARMACEUTICALS Corp
		DATE OF NAME CHANGE:	20110607

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKMIRA PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20081003
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>arbutus10k2015.htm
<DESCRIPTION>10-K 2015
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>10-K</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sAE55876035A3AB43CC69EF636FE2E329"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Form 10-K</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Fiscal Year Ended December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Transition Period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: [001-34949]</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:17pt;"><font style="font-family:inherit;font-size:17pt;font-weight:bold;">Arbutus Biopharma Corporation</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact Name of Registrant as Specified in Its Charter)</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="48%"></td><td width="4%"></td><td width="48%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">British Columbia, Canada</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">980,597,776</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporation or Organization)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100-8900 Glenlyon Parkway, Burnaby, BC V5J 5J8</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">604-419-3200</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;(Registrant&#8217;s Telephone Number, Including Area Code):</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Title of Each Class</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name of Each Exchange on Which Registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares, without par value</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The NASDAQ Stock Market LLC</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(g) of the Act:</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. Yes </font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes </font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</font></div><br><div></div><hr style="page-break-after:always"><a name="sAE55876035A3AB43CC69EF636FE2E329"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="25%"></td><td width="20%"></td><td width="30%"></td><td width="25%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large accelerated filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated filer </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller reporting company </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Do not check if a smaller reporting company)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant is an accelerated filer as the aggregate market capitalization of voting and non-voting equity held by non-affiliates as at June 30, 2015 was $644,038,348. As of February 29, 2016, the registrant had 54,625,703 Common Shares, no par value,&#160;outstanding.&#160;</font></div><a name="s7E21A708F6631918B762EF637038E9B9"></a><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Portions of the registrant&#8217;s definitive proxy statement for its 2016 annual meeting of stockholders, which the registrant intends to file pursuant to Regulation&#160;14A with the Securities and Exchange Commission not later than 120&#160;days after the registrant&#8217;s fiscal year end of December&#160;31, 2015, are incorporated by reference into Part&#160;III of this Form&#160;10-K.</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div></div><hr style="page-break-after:always"><a name="sE39C0C30C51D565E0AB7EF63706ACA9C"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="14%"></td><td width="78%"></td><td width="8%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Page</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5BC0E94EEFB52C0298F5EF637089D026"><font style="font-family:inherit;font-size:10pt;">PART I</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5BC0E94EEFB52C0298F5EF637089D026">6</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEA12E34D6EDC60151D6BEF6370BA5829"><font style="font-family:inherit;font-size:10pt;">Item 1.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEA12E34D6EDC60151D6BEF6370BA5829"><font style="font-family:inherit;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEA12E34D6EDC60151D6BEF6370BA5829">6</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC95EE5CFFC0E6F4FF501EF6370E64624"><font style="font-family:inherit;font-size:10pt;">Item 1A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC95EE5CFFC0E6F4FF501EF6370E64624"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC95EE5CFFC0E6F4FF501EF6370E64624">23</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4BB9C3DE42837193677DEF63710E5087"><font style="font-family:inherit;font-size:10pt;">Item 1B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4BB9C3DE42837193677DEF63710E5087"><font style="font-family:inherit;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4BB9C3DE42837193677DEF63710E5087">37</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3E6481859B9199A875FFEF637132E5FD"><font style="font-family:inherit;font-size:10pt;">Item 2.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3E6481859B9199A875FFEF637132E5FD"><font style="font-family:inherit;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3E6481859B9199A875FFEF637132E5FD">37</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5DEC9E881BEE8F2D5B84EF63716490EE"><font style="font-family:inherit;font-size:10pt;">Item 3.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5DEC9E881BEE8F2D5B84EF63716490EE"><font style="font-family:inherit;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5DEC9E881BEE8F2D5B84EF63716490EE">37</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s78F46A8071C6B2548E84EF6371836E10"><font style="font-family:inherit;font-size:10pt;">Item 4.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s78F46A8071C6B2548E84EF6371836E10"><font style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s78F46A8071C6B2548E84EF6371836E10">38</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6F8FA6846179EDA16B27EF6371B582FC"><font style="font-family:inherit;font-size:10pt;">PART II</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6F8FA6846179EDA16B27EF6371B582FC">39</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s26D1DD6595EA2C0547E9EF636910600F"><font style="font-family:inherit;font-size:10pt;">Item 5.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s26D1DD6595EA2C0547E9EF636910600F"><font style="font-family:inherit;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s26D1DD6595EA2C0547E9EF636910600F">39</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s792B953B9C9006A6DF00EF6372079B93"><font style="font-family:inherit;font-size:10pt;">Item 6.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s792B953B9C9006A6DF00EF6372079B93"><font style="font-family:inherit;font-size:10pt;">Selected Consolidated Financial Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s792B953B9C9006A6DF00EF6372079B93">41</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s428B57725AAE04F2308EEF63722C2025"><font style="font-family:inherit;font-size:10pt;">Item 7.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s428B57725AAE04F2308EEF63722C2025"><font style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s428B57725AAE04F2308EEF63722C2025">41</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s329D16593B6D10C62FF0EF6373FBF0F8"><font style="font-family:inherit;font-size:10pt;">Item 7A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s329D16593B6D10C62FF0EF6373FBF0F8"><font style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures about Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s329D16593B6D10C62FF0EF6373FBF0F8">66</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB6A6324F1EA2B633E115EF6374205D17"><font style="font-family:inherit;font-size:10pt;">Item 8.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB6A6324F1EA2B633E115EF6374205D17"><font style="font-family:inherit;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB6A6324F1EA2B633E115EF6374205D17">68</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4C3DA7978055C5DFC6E7EF6377B2897F"><font style="font-family:inherit;font-size:10pt;">Item 9.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4C3DA7978055C5DFC6E7EF6377B2897F"><font style="font-family:inherit;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4C3DA7978055C5DFC6E7EF6377B2897F">103</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s60490C2E66E4388215A8EF6377E43F76"><font style="font-family:inherit;font-size:10pt;">Item 9A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s60490C2E66E4388215A8EF6377E43F76"><font style="font-family:inherit;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s60490C2E66E4388215A8EF6377E43F76">103</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA2F32B9C7741B41F841FEF637808A515"><font style="font-family:inherit;font-size:10pt;">Item 9B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA2F32B9C7741B41F841FEF637808A515"><font style="font-family:inherit;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA2F32B9C7741B41F841FEF637808A515">104</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6FEBC09BA31CC0C64885EF63783AC6A0"><font style="font-family:inherit;font-size:10pt;">PART III</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6FEBC09BA31CC0C64885EF63783AC6A0">105</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD91E430BD43561122A4AEF637858D988"><font style="font-family:inherit;font-size:10pt;">Item 10.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD91E430BD43561122A4AEF637858D988"><font style="font-family:inherit;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD91E430BD43561122A4AEF637858D988">105</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEBBA542F7E63919A2B18EF63788A5690"><font style="font-family:inherit;font-size:10pt;">Item 11.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEBBA542F7E63919A2B18EF63788A5690"><font style="font-family:inherit;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEBBA542F7E63919A2B18EF63788A5690">105</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC23CC36FA9D9272D3D49EF6378ABFA92"><font style="font-family:inherit;font-size:10pt;">Item 12.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC23CC36FA9D9272D3D49EF6378ABFA92"><font style="font-family:inherit;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC23CC36FA9D9272D3D49EF6378ABFA92">105</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC9C9DA1352761A0EA164EF6378DEF518"><font style="font-family:inherit;font-size:10pt;">Item 13.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC9C9DA1352761A0EA164EF6378DEF518"><font style="font-family:inherit;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC9C9DA1352761A0EA164EF6378DEF518">105</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3B8BB0908888F85C5E03EF6379028140"><font style="font-family:inherit;font-size:10pt;">Item 14.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3B8BB0908888F85C5E03EF6379028140"><font style="font-family:inherit;font-size:10pt;">Principal Accountant Fees and Services</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3B8BB0908888F85C5E03EF6379028140">105</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE6F06B38C7712DCEA164EF6379340F74"><font style="font-family:inherit;font-size:10pt;">PART IV</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE6F06B38C7712DCEA164EF6379340F74">106</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s511D9AC555271B3BAD26EF637953C977"><font style="font-family:inherit;font-size:10pt;">Item 15.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s34E8DB1CFF9CDD2FFEBDEF6379A589F5"><font style="font-family:inherit;font-size:10pt;">Exhibits and Financial Statement Schedules</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s34E8DB1CFF9CDD2FFEBDEF6379A589F5">108</a></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><a name="sE39C0C30C51D565E0AB7EF63706ACA9C"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This annual report on Form 10-K contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;). </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Forward-looking statements in this annual report include statements about Arbutus&#8217; strategy, future operations, clinical trials, prospects and the plans of management; the composition and roles of the management team; Arbutus&#8217; continued listing on NASDAQ; the effects of Arbutus&#8217; products on the treatment of cancer, chronic Hepatitis B infection, infectious disease, alcohol use disorder, and other diseases; using a combination of HBV drug candidates to effect patient benefit and develop a potential cure; intervening at different points in the viral life cycle; evaluating combinations of two or more drug candidates in cohorts of patients with chronic HBV infection, and using the results to adaptively design additional treatment regimens for the next cohorts; evaluating different treatment durations to determine the optimal finite duration of therapy, and continuing this iterative process until we select combination therapy regimens and treatment durations to conduct Phase III clinical trials intended to ultimately support regulatory filings for marketing approval; continuing to expand our HBV pipeline through internal development, acquisitions and in-licenses; the format and timing of the ARB-1467 Phase II multi-dosing study, including the expectation of single dose and multi-dose HBsAg reduction data in the second half of 2016; incorporating technological and product design advancements that may result in an improvement in safety and/or efficacy; the potential of ARB-1740 to be effective at lower clinical doses than ARB-1467; filing an IND (or equivalent filing) for ARB-1740 in the second half of 2016; the expectation for inhibition of cccDNA formation to reduce the amount of cccDNA in the infected liver by blocking the formation of new cccDNA, with faster declines in cccDNA levels in patients than is seen with nucleot(s)ide analogs alone; filing an IND (or equivalent filing) for our lead cccDNA formation inhibitor in the second half of 2016; blocking viral replication with core protein inhibitors as oral therapeutics for the treatment of chronic HBV infection; filing an IND (or equivalent filing) for our lead core protein inhibitor candidate in the second half of 2016; using immune stimulation by toll-like receptor (TLR) agonists to overcome the immunologic blocks that allow chronic HBV persistence; initiating clinical development of ARB-1598 in chronically infected HBV patients in 2016; the development of multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, with the immune response of patients treated with this therapy able to reengage and thereby mount a more credible response to a hepatitis B virus infection; developing cccDNA epigenetic modifiers to inhibit the formation of new virus and sub viral particles from cccDNA; developing STING agonists so the body can produce additional interferon alpha and beta, with the plan to identify potent, orally active small molecule human STING agonists that possess the desired characteristics to progress into human clinical studies; continuing to explore opportunities to generate value from our LNP platform technology; partnering or external funding opportunities to maximize the value of our oncology related assets; an assessment of efficacy of TKM-PLK1 in terms of tumor response in approximately 20 subjects upon completion of the expansion cohort of the Phase I/II clinical, with results expected in 2016; partnering or external funding to maximize the value of RNAi product assets; partnering or external funding to maximize the value of TKM-HTG; TKM-ALDH inducing prolonged ethanol sensitivity that will enable it to overcome the compliance limitations associated with daily dosing; partnering or external funding to maximize the value of TKM-ALDH; receiving low single digit royalties as Alnylam&#8217;s LNP-enabled products are commercialized; New Drug Application (NDA) filing for this patisiran in 2017; initiate the Phase I clinical trial of DCR-PH1 in patients with PH1 in 2016; arbitration proceedings with the University of British Columbia in connection with alleged unpaid royalties; the expected return from strategic alliances, licensing agreements, and research collaborations; receiving payments for the Alnylam license agreement; the result of negotiations with Monsanto regarding the close out terms, which could involve termination or exercise of the option to acquire rights to our proprietary LNP technology for use in agriculture; the terms of a potential licensing agreement with Cytos; royalty and milestone payments to Blumberg and Drexel under the license agreement; royalty and milestone payments to Enantigen&#8217;s stockholders; a potential exclusive, royalty bearing, worldwide license with Blumberg; expanding our exclusive license agreement with NeuroVive; the expectation for revenue to continue to fluctuate due to the irregular nature of licensing and milestone receipts under our collaboration and licensing contracts; the expectation to see future changes in the fair value of our warrant liability; not recording significant revenue from the DoD contract beyond 2015; the length of the Monsanto option period being approximately four years; the expectation to complete services to Dicerna in March 2017; the plan to use March 2015 public offering proceeds to develop and advance product candidates through clinical trials, as well as for working capital and general corporate purposes; having sufficient cash resources for at least the next 12 months; milestone payments and royalties to Arcturus under their license agreement; when we will to adopt recent accounting updates; continuing to incur substantial expenses and hold cash and investment balances in Canadian dollars; Arbutus&#8217; intent to retain earnings, if any, to finance the growth and development of their business and not to pay dividends or to make any other distributions in the near future; anticipated royalty receipts; statements with respect to revenue and expense fluctuation and guidance; predicted tax treatment; not expecting the enrollment of first patient in Phase 1b clinical trial in HBV patients to occur in the next twelve-month period; discontinuing the OCB-030 development program; and the quantum and timing of potential funding.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">With respect to the forward-looking statements contained in this annual report, Arbutus has made numerous assumptions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><a name="sE39C0C30C51D565E0AB7EF63706ACA9C"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our actual results could differ materially from those discussed in the forward-looking statements as a result of a number of important factors, including the factors discussed in this annual report on Form 10-K, including those discussed in Item 1A of this report under the heading &#8220;Risk Factors,&#8221; and the risks discussed in our other filings with the Securities and Exchange Commission and Canadian Securities Regulators. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management&#8217;s analysis, judgment, belief or expectation only as of the date hereof. We explicitly disclaim any obligation to update these forward-looking statements to reflect events or circumstances that arise after the date hereof, except as required by law.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><a name="s5BC0E94EEFB52C0298F5EF637089D026"></a><br><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><a name="sEA12E34D6EDC60151D6BEF6370BA5829"></a><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.         Business</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, and &#8220;our&#8221;) is a publicly traded industry-leading therapeutic solutions company focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B (HBV) infection, which leads to serious liver disease. &#160;Effective July 31, 2015, our corporate name changed from Tekmira Pharmaceuticals Corporation to Arbutus Biopharma Corporation. Our pipeline is focused on finding a cure for chronic HBV infection. This HBV pipeline consists of multiple drug candidates, with complementary mechanisms of action, which we expect to use in combination to effect patient benefit. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HBV represents a significant unmet medical need and is the cause of the most common serious liver infection in the world. The World Health Organization estimates that 350 million people worldwide are chronically infected, and other estimates suggest this could include approximately 2 million people in the United States (Kowdley </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">et al.,</font><font style="font-family:inherit;font-size:10pt;">&#32;2012). Individuals chronically infected with HBV are at an increased risk of developing significant liver disease, including cirrhosis, or permanent scarring of the liver, as well as liver failure and hepatocellular carcinoma (HCC) or liver cancer. According to the Hepatitis B Foundation, HBV is the cause of up to 80% of liver cancers. Individuals with liver cancer typically have a five-year survival rate of only 15%. The WHO estimates that more than 780,000 people die every year due to the consequences of hepatitis B virus disease. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Given the complex biology of HBV (as shown in the graphic below), we believe combination therapies are the key to HBV treatment and a potential cure, and development can be accelerated when multiple components of a combination therapy regimen are controlled by the same company. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;"><img src="hbvlifecycle.jpg" style="height:369px;width:684px;"></div><br><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">HBV Focused Product Pipeline</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a pipeline focused on finding a cure for chronic HBV infection, with the objective of developing a combination of products that intervene at different points in the viral life cycle. Given our strong scientific and research capabilities in-house, we are able to conduct preclinical combination studies to evaluate combinations of our proprietary pipeline candidates. Once compounds within the portfolio with sufficient activity have been identified, we intend, subject to discussions with regulatory authorities, to evaluate combinations of two or more drug candidates in cohorts of patients with chronic HBV infection. We expect to use these results to adaptively design additional treatment regimens for the next cohorts. We also plan to evaluate different treatment durations to determine the optimal finite duration of therapy. We plan to continue this iterative process until we select combination therapy regimens and treatment durations to conduct Phase III clinical trials intended to ultimately support regulatory filings for marketing approval.&#160;Our pipeline of HBV product candidates includes:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;"><img src="hbvpipeline.jpg" style="height:366px;width:684px;"></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to continue to expand our HBV pipeline through internal development, acquisitions and in-licenses. We also have a research collaboration agreement with The Baruch S.&#160;Blumberg Institute, a non-profit research institute established by the Hepatitis B Foundation, that provides exclusive rights to in-license any intellectual property generated through the collaboration. For more information about this agreement please refer to the &#8220;Strategic Alliances, Licensing Agreements, and Research Collaborations&#8221; section of this annual report on Form 10-K below.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">RNAi (ARB-1467 &amp; ARB-1740)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The development of RNA Interference (RNAi) drugs allows for a completely novel approach to treating disease, which&#160;is why RNAi is considered one of the most promising and rapidly advancing frontiers in drug discovery. While there are no RNAi therapeutics approved for commercial use, there are a number of RNAi products currently in human clinical trials. RNAi products are broadly applicable as they can eliminate the production of disease-causing proteins from cells, creating opportunities for therapeutic intervention that have not been achievable with conventional drugs. Our extensive experience in antiviral drug development has been applied to our RNAi program to develop therapeutics for chronic hepatitis B infection. Small molecule nucleotide therapy has been the standard of care for chronic HBV infected patients. However, many of these patients continue to express a viral protein called HBV surface antigen (HBsAg). This protein causes inflammation in the liver leading to cirrhosis and, in some cases, HCC and death.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our lead RNAi HBV candidate, ARB-1467 (formerly TKM-HBV), is designed to eliminate HBsAg expression in patients chronically infected with HBV. Reducing HBsAg is thought to be a key prerequisite to enable a patient&#8217;s immune system to raise an adequate immune response against the virus. The ability of ARB-1467 to inhibit numerous viral elements in addition to HBsAg increases the likelihood of affecting the viral infection. ARB-1467 is being developed as a multi-component (3-trigger) RNAi therapeutic that simultaneously targets three sites on the HBV genome, including the HBsAg coding region. Targeting three distinct and highly conserved sites on the HBV genome is intended to facilitate potent knockdown of all viral mRNA transcripts and viral antigens across a broad range of HBV genotypes and reduce the risk of developing antiviral resistance.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;"><img src="arb1467triggers.jpg" style="height:122px;width:684px;"></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARB-1467 results in potent and rapid reduction in HBsAg in several preclinical models. In these models, ARB-1467 treatment resulted in reductions in both intrahepatic and serum HBsAg, as well as reductions in HBV DNA, cccDNA, Hepatitis B e antigen (HBeAg) and HBcAg (Hepatitis B c antigen). A rapid 1 log reduction in serum HBsAg was achieved with a single 1 mg/kg dose of ARB-1467 in the humanized mouse model. 1-2 log viral reductions from similar single-dose LNP treatments in two other true-infection animal models were also demonstrated. Preclinical studies conducted on infected primary human hepatocytes showed that ARB-1467 had robust and consistent activity against different viral strains representing the major clinical genotypes A, B, C and D. Our data shows that inclusion of three RNAi triggers results in a more broadly effective knockdown of hepatitis B viral elements than a single trigger alone. The mode of action of ARB-1467 complements standard of care nucleoside/nucleotide (NUC) therapy, and lack of drug antagonism has been demonstrated with entecavir, lamivudine and tenofovir on infected primary human hepatocytes, making combination therapy a viable option. This data was presented at the DIA/FDA Oligonucleotide-Based Therapeutics Conference in Washington, DC, in September 2015. We presented additional data at the 2015 International Meeting on Molecular Biology of Hepatitis B Viruses in Dolce Bad Nauheim, Germany, in October 2015, and at the 2015 AASLD Liver Meeting in San Francisco in November 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In early 2015, we advanced two RNAi product candidates (ARB-1467 and ARB-1468) into a Phase I Single Ascending Dose (SAD) trial. Both product candidates&#160;employ the same unique combination of three RNAi trigger molecules; however, they differ in their LNP composition.&#160;ARB-1467 employs a third generation LNP, and ARB-1468 employs a new, fourth generation LNP, which incorporates novel lipid chemistry and demonstrates improved potency in preclinical studies. The Phase I clinical trial is a randomized, single-blind, placebo-controlled study, involving single ascending doses of ARB-1467 and ARB-1468. The study is assessing the safety, tolerability and pharmacokinetics of intravenous administration of two LNP formulations (third and fourth generation) of the product in healthy adult subjects. In order to enable maximum dose escalation, steroid premedication was added to the Phase I protocol. No dose limiting toxicities were seen with either formulation through 0.4mg/kg, the highest dose tested in Phase I. At this time, a maximum tolerated dose has not been reached and the protocol has been amended to allow evaluation of higher doses. ARB-1467 was selected to progress to a Phase II multi-dosing study in HBV infected patients.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:center;"><img src="arb1467phase2design.jpg" style="height:271px;width:684px;"></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Phase II study evaluates two dose levels of ARB-1467 administered as three monthly doses in chronic HBV infected patients who are on stable background nucleot(s)ide analog therapy. Eight subjects will be enrolled in each of the two dose cohorts with six subjects receiving ARB-1467, and two receiving placebo. The ARB-1467 Phase II multi-dosing study has been initiated and single dose and multi-dose HBsAg reduction data are expected in the second half of 2016.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we are focused on development of our lead HBV product candidates, we believe in continuous innovation and will incorporate technological and product design advancements that may result in an improvement in safety and/or efficacy. An example of this is our follow-on RNAi HBV candidate, ARB-1740. ARB-1740 is more potent than ARB-1467 in preclinical studies and has the potential to be effective at lower clinical doses than ARB-1467. ARB-1740 employs the same LNP formulation as ARB-1467 (with a different set of three RNAi triggers). We plan to file an IND (or equivalent filing) for ARB-1740 in the second half of 2016.    </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">cccDNA Formation Inhibitors</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing small molecule cccDNA formation inhibitors. The inhibition of cccDNA formation is expected to reduce the amount of cccDNA in the infected liver by blocking the formation of new cccDNA. We acquired the exclusive, worldwide rights to this program through an in-license from the Blumberg Institute. We have made significant progress with the discovery of potent and small molecule cccDNA formation inhibitors. As presented at the 2015 International Meeting on Molecular Biology of Hepatitis B Viruses in October 2015, our cccDNA formation inhibitors demonstrate synergy with approved nucleot(s)ide analogs in preclinical models, which could lead to faster declines in cccDNA levels in patients than is seen with nucleot(s)ide analogs alone. We plan to file an IND (or equivalent filing) for our lead cccDNA formation inhibitor in the second half of 2016.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Core Protein/ Capsid Assembly Inhibitors</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HBV core protein, or capsid, is required for viral replication and core protein may have additional roles in cccDNA function. Current nucleot(s)side analog therapy significantly reduces serum HBV DNA levels in the serum but significant HBV replication continues in the liver, thereby enabling HBV infection to persist. Effective therapy for patients requires new agents which will effectively block viral replication. We are developing core protein inhibitors (also known as capsid assembly inhibitors) as oral therapeutics for the treatment of chronic HBV infection. By inhibiting assembly of the viral capsid, the ability of hepatitis B virus to replicate is impaired, resulting in reduced cccDNA. We acquired exclusive, worldwide rights to these drug candidates through an in-license from Blumberg and Drexel University, or (&#8220;Drexel&#8221;), and through Arbutus Inc.&#8217;s acquisition of Enantigen Therapeutics, Inc. (&#8220;Enantigen&#8221;). We plan to file an IND (or equivalent filing) for our lead candidate in the second half of 2016.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">TLR9 Agonist (ARB-1598)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Immune stimulation by toll-like receptor (TLR) agonists may overcome the immunologic blocks that allow chronic HBV persistence, including direct activation of the host&#8217;s innate antiviral response. Licensed from Cytos Biotechnology Ltd., (&#8220;Cytos&#8221;), ARB-1598 (formerly CYT003) is a biological carrier which is filled with the immunostimulatory oligonucleotide called G10, a TLR-9 agonist. ARB-1598 has been shown to directly activate B cells and stimulates human plasmacytoid dendritic cells to secrete Interferon alpha, and has previously been utilized in human trials in other indications. ARB-1598 also activates other antigen presenting cells indirectly and promotes the development of TH1 type cytokine response, which is thought to be potentially beneficial in promoting anti-HBV T cell immunity. ARB-1598 is undergoing preclinical evaluation to establish its utility for HBV, and if there is a clear support for this application, we plan to initiate clinical development of ARB-1598 in chronically infected HBV patients in 2016. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Research Programs</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Surface Antigen Secretion Inhibitors</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion. By inhibiting the production and secretion of HBV surface antigen from infected cells, we expect that the immune response of patients treated with this therapy can reengage and thereby mount a more credible response to a hepatitis B virus infection. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">cccDNA Epigenetic Modifiers</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to cccDNA formation inhibitors, we are developing cccDNA epigenetic modifiers. By controlling cccDNA transcription, we anticipate that we may be able to inhibit the formation of new virus and sub viral particles from cccDNA. This development program, which is currently in the discovery research stage, is based on proof of concept data generated by Blumberg using known inhibitors of enzymes involved in DNA information processing.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">STING Agonists</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing stimulator of interferon genes (STING) agonists. By activating interferon genes, we anticipate that the body can produce additional interferon alpha and beta, which have antiviral properties. Our development program, which is currently in the discovery research stage, is based on proof of concept data in mice generated by Blumberg which showed that STING agonists can elicit an antiviral response and inhibit HBV replication in mouse liver cells. In collaboration with Blumberg, our plan is to identify potent, orally active small molecule human STING agonists that possess the desired characteristics to progress into human clinical studies.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cyclophilin Inhibitor (OCB-030)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We licensed from NeuroVive Pharmaceutical AB, or (NeuroVive), the exclusive rights to develop and commercialize cyclophilin inhibitor drug candidates, including OCB-030, for the treatment of hepatitis B. After extensive preclinical evaluation of OCB-030 and other competitive cyclophilin inhibitors against HBV, we have concluded that cellular cyclophillins do not play a role in HBV chronic infection and further development of OCB-030 is unwarranted. As a result, we made the decision in October 2015 to discontinue the development of OCB-030 and have suspended our interest in the cyclophilin inhibitor class. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Proprietary Delivery Technology</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development of RNAi therapeutic products is currently limited by the instability of the RNAi trigger molecules in the bloodstream and the inability of these molecules to access target cells or tissues following administration. Delivery technology is necessary to protect these drugs in the bloodstream to allow efficient delivery and cellular uptake by the target cells. Arbutus has developed a proprietary delivery platform called Lipid Nanoparticle, or LNP. The broad applicability of this platform to RNAi development has established Arbutus as a leader in this new area of innovative medicine.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary LNP delivery technology allows for the successful encapsulation of RNAi trigger molecules in LNP administered intravenously, which travel through the bloodstream to target tissues or disease sites. LNPs are designed to protect the triggers, and stay in the circulation long enough to accumulate at disease sites, such as the liver or cancerous tumors. LNPs are then taken up into the target cells by a process called endocytosis. Subsequent activation by the changing environment inside the cell causes the LNP to release the trigger molecules, which can then successfully mediate RNAi.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:center;"><img src="lnptechnology.jpg" style="height:360px;width:566px;"></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ongoing Advancements in LNP Technology</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our LNP technology represents the most widely adopted delivery technology in RNAi, which has enabled several clinical trials and has been administered to hundreds of human subjects. Because LNP can enable a wide variety of nucleic acid triggers, including mRNA, we continue to see new product development and partnering opportunities based on our industry-leading delivery expertise and intellectual property. We presented preclinical data in October 2013 at the International mRNA Health Conference in Tubingen, Germany, and in February 2014 at the AsiaTIDES Conference in Toyko, Japan. This data demonstrated that mRNA encapsulated and delivered using our proprietary LNP technology can be effectively delivered and expressed in the liver in tumors and other specific tissues of therapeutic interest.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus continues to explore opportunities to generate value from its LNP platform technology, which is well suited to deliver therapies based on RNAi, mRNA, gene editing, as well as other technologies.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suspended Non-HBV RNAi Assets</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intent is to focus our efforts on discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. As such, pending completion of ongoing studies associated with TKM-PLK1, we have suspended further development of our non-HBV assets and are exploring different strategic options to maximize the value of these assets. Our non-HBV assets include our LNP-based product candidates TKM-PLK for oncology, TKM-Ebola and TKM-Marburg for hemorrhagic fever viruses, TKM-HTG for metabolic disorders, and TKM-ADLH for severe alcohol use disorder. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Oncology (TKM-PLK1)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our oncology product platform, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. Inhibition of PLK1 expression prevents the tumor cell from completing cell division, resulting in cell cycle arrest and death of the cancer cell. Evidence that patients with elevated levels of PLK1 in their tumors exhibit poorer prognosis and survival rates has been documented in the medical literature. TKM-PLK1 is being evaluated in the following oncology indications where there are limited or ineffective therapies available: Gastrointestinal Neuroendocrine Tumors (GI-NET), Adrenocortical Carcinoma (ACC) and Hepatocellular Carcinoma (HCC). We are exploring partnering or external funding opportunities to maximize the value of our oncology related assets.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">TKM-PLK1: GI-NET and ACC</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GI-NET is the gastrointestinal subset of neuroendocrine tumors with an estimated U.S. prevalence of 55,000 individuals. Prognosis for advanced or metastatic GI-NET, the target population for TKM-PLK1, is poor with 25-54% of patients surviving less than one year. ACC is an extremely rare form of cancer that develops in the adrenal gland. Data from the U.S. National Cancer Institute indicates there are approximately 500 patients in the U.S. with ACC. Survival prognosis for patients with ACC is poor. A large percentage of patients are not good surgical candidates and there is a lack of effective systemic therapies.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We presented Phase I TKM-PLK1 data at the 6th and 8th Annual NET Conferences hosted by the North American Neuroendocrine Tumor Society (NANETS) in October 2013 and October 2015. Based on encouraging results from the dose escalation portion and expansion cohort from our Phase I TKM-PLK1 clinical trial, we expanded into a Phase I/II clinical trial with TKM-PLK1, which enrolled patients within the two therapeutic indications: advanced GI-NET or ACC. This multi-center, single arm, open label study was designed to measure efficacy using RECIST criteria for GI-NET patients and ACC patients as well as evaluate the safety, tolerability and pharmacokinetics of TKM-PLK1 in a population of 63 subjects with advanced solid tumors, including 15 subjects with GI-NET. TKM-PLK1 was administered weekly with each four-week cycle consisting of three once-weekly doses followed by a rest week. We provided an update on the Phase I/II GI-NET clinical study in October 2015 at the NANETS conference. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the GI-NET population, one subject, a "remarkable responder" had a maximal 61.1% decrease in target tumor at cycle 2. This subject remained on-study for 10 cycles and the partial tumor response (PR) was stable throughout this period. Twelve of 13 evaluable subjects had a best response of stable disease (SD) or PR. Duration of SD/PR ranged from two to 14 cycles. In the ACC population one subject, a "remarkable responder" had a maximal 48.7% decrease in target tumor at cycle 14. After&#160;18 cycles, the residual tumor was resected and histopathology showed near-complete necrosis, at which time the subject discontinued the study. Five of eight evaluable subjects had a best response of SD or PR. Duration of SD/PR ranged from two to 18 cycles. Therapy with TKM-PLK1 was received for up to 18 months and was generally well tolerated by the majority of subjects. The TKM-PLK1 GI-NET/ACC trial has concluded.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">TKM-PLK1: HCC</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HCC is one of the most common cancers, one of the most deadly and a common outcome of chronic HBV infection, with over 650,000 deaths each year worldwide according to the Globocan 2012 database. US incidence is estimated at 27,000 individuals with annual growth rates greater than 2%. HCC is an aggressive, hard-to-treat disease with one-year survival rates of less than 50% and five-year rates as low as 4% (National Cancer Institute). To date, Nexavar (sorafenib) is the only agent approved to treat HCC with an improvement in overall survival of just two to three months.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, we initiated another Phase I/II clinical trial with TKM-PLK1, enrolling patients with advanced HCC. Patient dosing has commenced and we have completed the dose escalation portion of this trial. This Phase I/II clinical trial is a multi-center, single arm, open label dose escalation study designed to evaluate the safety, tolerability and pharmacokinetics of TKM-PLK1 as well as determine the maximum tolerated dose in patients with advanced inoperable HCC. It will also include a preliminary assessment of the anti-tumor activity of TKM-PLK1 in this patient population. In August 2015 we announced initiation of patient dosing in the expansion cohort of the clinical trial at multiple sites in Canada, the United States and Asia, and have since completed enrollment. An assessment of efficacy in terms of tumor response in approximately 20 subjects will take place upon trial completion and results are expected in 2016. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Infectious Diseases (TKM-Ebola and TKM-Marburg)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have suspended further development of our RNAi product candidates targeting filoviruses Ebola and Marburg. In December 2014, the U.S. Congress amended the FDA Priority Review Voucher (PRV) Program Act to add filoviruses as a candidate for a PRV. We are exploring partnering or external funding opportunities to maximize the value of these assets.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TKM-Ebola-Kikwit has been developed under a $140 million contract with the U.S. Department of Defense (DoD) awarded in July 2010. Given the unclear development path for TKM-Ebola, development activities have been suspended and the contract with the DoD has been terminated. TKM-Ebola-Kikwit completed the single ascending dose portion of the Phase I clinical trial in healthy human volunteers. Results demonstrated that administration of the TKM-Ebola-Kikwit therapeutic, in the absence of any steroid containing pre-medication, was well-tolerated at a dose level of 0.3 mg/kg, determined to be the maximum tolerated dose. Under the FDA&#8217;s expanded access program, several patients with a confirmed or suspected Ebola virus infection were treated with TKM-Ebola-Kikwit during the ebola outbreak in 2014. In March 2015, a TKM-Ebola-Guinea Phase II single arm trial called Rapid Assessment of Potential Interventions &amp; Drugs for Ebola (RAPIDE) was initiated in Sierra Leone, led by the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) at the University of Oxford, UK, with funding from the Wellcome Trust. In June 2015 we announced closing of the enrollment for the trial as it reached a futility boundary, which was a predefined statistical endpoint. The results of the study have been submitted for publication and the manuscript is under review. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have several publications related to our Ebola and Marburg RNAi therapeutic candidates. In April 2015, we, along with our collaborators at the University of Texas Medical Branch (UTMB) at Galveston, USA, published positive Ebola treatment data in the journal Nature (Thi EP., et al.;&#160;Nature,&#160;April 2015). Data demonstrated 100% survival of nonhuman primates previously infected with the West African Makona strain of Ebola virus even when treatment did not begin until three days after viral exposure a time point at which animals were five to six days away from death. These efficacy results are comparable to those obtained with TKM-Ebola-Kikwit, which also demonstrated up to 100% protection from an otherwise lethal dose of the virus. We have published data demonstrating complete protection of non-human primates against lethal Marburg-Angola strain, (Thi EP., </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">et al.</font><font style="font-family:inherit;font-size:10pt;">; Science Translational Medicine, Aug 2014). Selected data from these programs was presented at the Chemical and Biological Defense Science and Technology Conference in May 2015.  </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Metabolic Disorders (TKM-HTG)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TKM-HTG is a multi-component RNAi therapeutic that simultaneously targets a combination of genes expressed in the liver, which are known to play a significant role in triglyceride metabolism. High triglyceride levels are medically linked to increased risk of cardiovascular disease, fatty liver disease, insulin resistance and pancreatitis. Approximately one million adults in the US and 18 million worldwide suffer from severe HTG. (NHANES 2003-2004 data). Another patient group affected by HTG are those with Familial Chylomicronemia Syndrome (FCS), which is a very rare hereditary condition affecting an estimated 1:1,000,000 people (www.fcs.raredr.com). Additionally, 35% of patients with Type 2 Diabetes (T2D) suffer from mixed hyperlipidemia which is a combination of elevated cholesterol and high triglycerides. With underlying T2D, these patients are at considerable risk from cardiovascular disease. We are exploring partnering or external funding opportunities to maximize the value of this asset.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Alcohol Use Disorder (TKM-ALDH)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TKM-ALDH is designed to knockdown or silence aldehyde dehydrogenase (ALDH) to induce long term acute sensitivity to ethanol, for use in severe alcohol use disorder. Aldehyde dehydrogenase is a key enzyme in ethanol metabolism. Inhibition of ALDH activity, through the silencing of ALDH, results in the build-up of acetaldehyde leading to adverse physiological effects. Human proof of concept for ALDH inhibition already exists in the form of the approved drug disulfiram. However, disulfiram&#8217;s efficacy is compromised by poor compliance because it has to be taken daily. We believe TKM-ALDH will induce prolonged ethanol sensitivity that will enable it to overcome the compliance limitations associated with daily dosing. We are exploring partnering or external funding opportunities to maximize the value of this asset.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Partner Programs</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patisiran (ALN-TTR02)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alnylam Pharmaceuticals, Inc., or Alnylam, has a license to use our intellectual property (IP) to develop and commercialize products and may only grant access to our LNP technology to its partners if it is part of a product sublicense. Alnylam&#8217;s license rights are limited to patents that we have filed, or that claim priority to a patent that was filed, before April 15, 2010. Alnylam does not have rights to our patents filed after April 15, 2010 unless they claim priority to a patent filed before that date. Alnylam will pay us low single digit royalties as Alnylam&#8217;s LNP-enabled products are commercialized. More information about our licensing agreement with Alnylam can be found under the &#8220;Strategic Alliances, Licensing Agreements, and Research Collaborations&#8221; section of this report.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, Alnylam presented positive new data from its Phase II clinical trial with patisiran, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR). These results provide additional support for Alnylam's Phase III APOLLO trial. In October 2014, Alnylam reported positive clinical data for the ongoing patisiran Phase II Open Label Extension (OLE) study in patients with Familial Amyloidotic Polyneuropathy (FAP). The results demonstrated sustained knockdown of serum TTR of up to 90% and a favorable tolerability profile out to one year of treatment. In April 2015, Alnylam announced positive data from the ongoing open-label study with patisiran which demonstrated continued evidence for possible halting of neuropathy progression after the first 12 months of treatment. In addition, patisiran treatment showed robust mean knockdown of serum TTR of up to 88%. Alnylam's ongoing OLE study is an open-label, multi-center trial designed to evaluate the long-term safety and tolerability of patisiran administration in FAP patients that were previously enrolled in a Phase II study. In July 2015, Alnylam announced initiation of a Phase III open label OLE study with patisiran (APOLLO-OLE) to evaluate the long-term safety and tolerability of patisiran in ATTR amyloidosis patients with FAP who were previously enrolled in the APOLLO Phase III study. In September 2015, Alnylam reported evidence of reduced pathogenic, misfolded TTR monomers and oligomers in TTR-mediated amyloidosis patients with FAP, and in November 2015 it reported that patisiran demonstrates continued evidence for potential halting of neuropathy progression and improvement in nerve fiber density in patients with FAP. New Drug Application (NDA) filing for this program is expected in 2017.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patisiran program represents the most clinically advanced application of our LNP delivery technology. Furthermore, Alnylam&#8217;s results demonstrate that multi-dosing with our LNP has been well-tolerated with treatments out to 21 months.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marqibo&#174;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marqibo&#174;, originally developed by Arbutus, is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. Marqibo&#8217;s approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. Our licensee, Spectrum Pharmaceuticals, Inc. (Spectrum), launched Marqibo through its existing hematology sales force in the United States. We are entitled to mid-single digit royalty payments based on Marqibo&#8217;s commercial sales. Spectrum has ongoing trials evaluating Marqibo in three additional indications, which are: first line use in patients with Philadelphia Negative Acute Lymphoblastic Leukemia (Ph-ALL), Pediatric ALL and Non-Hodgkin&#8217;s lymphoma. More information about our licensing agreement with Spectrum can be found under the &#8220;Strategic Alliances, Licensing Agreements, and Research Collaborations&#8221; section of this report.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">DCR-PH1</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, we signed a licensing and collaboration agreement with Dicerna Pharmaceuticals, Inc. to utilize our LNP delivery technology exclusively in Dicerna's primary hyperoxaluria type 1 (PH1) development program. Dicerna will use our third generation LNP technology for delivery of DCR-PH1, Dicerna's product incorporating its Dicer substrate RNA (DsiRNA) molecule, for the treatment of PH1, a rare, inherited liver disorder that often results in kidney failure and for which there are no approved therapies. In December 2015, Dicerna announced initiation of dosing in healthy volunteers with plans to initiate the Phase I clinical trial in patients with PH1 in 2016.&#160;More information about our licensing agreement with Dicerna can be found under the &#8220;Strategic Alliances, Licensing Agreements, and Research Collaborations&#8221; section of this report.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Strategic Alliances, Licensing Agreements, and Research Collaborations</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Alnylam Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alnylam has a license to use our IP to develop and commercialize products and may only grant access to our LNP technology to its partners if it is part of a product sublicense. Alnylam&#8217;s license rights are limited to patents that we have filed, or that claim priority to a patent that was filed, before April 15, 2010. Alnylam does not have rights to our patents filed after April 15, 2010 unless they claim priority to a patent filed before that date. Alnylam will pay low single digit royalties as Alnylam&#8217;s LNP-enabled products are commercialized. Alnylam currently has three LNP-based products in clinical development: ALN-TTR02 (patisiran), ALN-VSP, and ALN-PCS02.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our licensing agreement with Alnylam grants us IP rights for the development and commercialization of RNAi therapeutics for specified targets. In consideration for these three exclusive and 10 non-exclusive licenses, we have agreed to pay single-digit royalties to Alnylam on product sales, with milestone obligations of up to $8.5 million on the non-exclusive licenses and no milestone obligations on the three exclusive licenses.Alnylam has also pursued two other LNP-based products through clinical development: ALN-VSP (liver cancer), and ALN-PCS02 (hypercholesterolemia). Alnylam will pay Arbutus low single digit royalties based on commercial sales of Alnylam&#8217;s LNP-enabled products. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered an arbitration proceeding with Alnylam, as provided for under our licensing agreement, to resolve a matter related to a disputed $5 million milestone payment to Arbutus from Alnylam related to its ALN-VSP product. The arbitration proceeding with Alnylam has concluded resulting in no milestone payment to Arbutus.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acuitas Therapeutics Inc. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consistent with the terms of the settlement agreement signed in November 2012, we finalized and entered a cross-license agreement with Acuitas Therapeutics Inc., or Acuitas in December 2013. The terms of the cross-license agreement provide Acuitas with access to certain of our earlier IP generated prior to April 2010. At the same time, the terms provide us with certain access to Acuitas&#8217; technology and licenses in the RNAi field, along with a percentage of each milestone and royalty payment with respect to certain products. Acuitas has agreed that it will not compete in the RNAi field for a period of five years, ending in November 2017.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Merck &amp; Co., Inc. and Alnylam License Agreement</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the settlement between Protiva Biotherapeutics, Inc. (Protiva), and Merck &amp; Co., Inc. in 2008, we acquired a non-exclusive royalty-bearing world-wide license agreement with Merck. Under the license, Merck will pay up to $17 million in milestones for each product they develop covered by our IP, except for the first product for which Merck will pay up to $15 million in milestones, and will pay royalties on product sales. Merck&#8217;s license rights are limited to patents that Protiva filed, or that claim priority to one of Protiva&#8217;s patents that was filed, before October 9, 2008. Merck does not have rights to Protiva patents filed after October 9, 2008 unless they claim priority to a patent filed before that date. On March 6, 2014, Alnylam announced that they acquired all assets and licenses from Merck, which included our license agreement.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dicerna Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, we signed a licensing agreement and a development and supply agreement with Dicerna to license our LNP delivery technology for exclusive use in Dicerna's PH1 development program. Dicerna will use Arbutus&#8217; third generation LNP technology for delivery of DCR-PH1, Dicerna's product incorporates its DsiRNA molecule, for the treatment of PH1, a rare, inherited liver disorder that often results in kidney failure and for which there are no approved therapies. Under the agreements, Dicerna paid Arbutus $2.5 million upfront and will potentially make payments of $22 million in aggregate development milestones, plus a mid-single-digit royalty on future PH1 sales. This partnership also includes a supply agreement under which we will provide clinical drug supply and regulatory support for the rapid advancement of this product candidate.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Monsanto Company </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2014, we signed an Option Agreement and a Service Agreement with Monsanto Company, or Monsanto, and granted Monsanto an option to obtain a license to use our proprietary LNP delivery technology. The transaction supports the application of LNP technology and related IP for use in agriculture. The potential value of the transaction could reach $86.2 million following the successful completion of milestones. In January 2014, we received $14.5 million of the $17.5 million in near term payments. We received additional payments of $1.5 million each in June 2014 and October 2014 following the achievement of specific program objectives. In May 2015, the arrangement was amended to extend the option period by approximately five months, with payments up to $2.0 million for the extension period. As of December 31, 2015, we have received $19.3 million. Following the completion of the Phase A extension period in October 2015, no further research activities were conducted under the arrangement, as Monsanto did not elect to proceed to Phase B of the research plan. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 4, 2016, Monsanto exercised its option to acquire 100% of the outstanding shares of Protiva Agricultural Development Company Inc., or PADCo, and will pay Arbutus an exercise fee of $1 million. As a result, PADCo is no longer an indirect wholly owned subsidiary of us. In connection with Monsanto&#8217;s exercise of its option, on&#160;March 4, 2016, we entered into an amended Option Agreement. We also entered into an amended Service Agreement on&#160;March 4, 2016 to give effect to the grant back to Protiva of new intellectual property created by Monsanto in connection with the exercise of its option. In addition, we entered into an amended License and Services Agreement to recognize Monsanto&#8217;s early exercise of option before Protiva&#8217;a completion of Phases B and C, and introduce a new Technology Transfer Completion Criteria through the amended Option Agreement. Each of the amended Option Agreement, amended License and Services Agreement and amendment to the Service Agreement have been filed as Exhibits to this annual report on Form 10-K.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Spectrum Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2013, we announced that our licensee, Spectrum, had launched Marqibo&#174; through its existing hematology sales force in the United States. Since then commercial sales have occurred. Arbutus is entitled to mid-single digit royalty </font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">payments based on Marqibo&#174;&#8217;s commercial sales. Marqibo&#174;, which is a novel sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine, was originally developed by Arbutus. We out-licensed the product to Talon Therapeutics in 2006, and in July 2013, Talon was acquired by Spectrum. Marqibo&#174;&#8217;s approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. Spectrum has ongoing trials evaluating Marqibo&#174; in three additional indications, which are: first line use in patients with Ph-ALL, Pediatric ALL and Non-Hodgkin&#8217;s lymphoma.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marina Biotech, Inc. /Arcturus Therapeutics, Inc. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;In November 2012, we disclosed that we had obtained a worldwide, non-exclusive license to a novel RNAi trigger technology called Unlocked Nucleobase Analog (UNA) from Marina Biotech Inc., or Marina, for the development of RNAi therapeutics. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects. In August 2013, Marina assigned its UNA technology to Arcturus Therapeutics, Inc., or Arcturus, and the UNA license agreement between us and Marina was assigned to Arcturus. The terms of the license are otherwise unchanged.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have paid Marina $0.5 million in license fees and there are milestones of up to $3.2 million plus royalties for each product that we develop using UNA technology licensed from Marina.&#160;&#160;We announced on January 21, 2015, that we had initiated a Phase I clinical trial with TKM-HBV (RNAi).&#160;As TKM-HBV utilizes UNA technology in-licensed from Arcturus,&#160;the initiation of the trial triggered a single milestone payment of $250,000 payable by us to Arcturus.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. National Institutes of Health</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 13, 2010 we announced that together with collaborators at the University of Texas Medical Branch (UTMB), we were awarded a new NIH grant, worth $2.4 million, to support research to develop RNAi therapeutics to treat Ebola and Marburg hemorrhagic fever viral infections using our LNP delivery technology. In February 2014, we along with UTMB and other collaborators were awarded additional funding of $3.4 million over five years from the NIH in support of this research.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2010, we announced a research collaboration with Bristol-Myers Squibb Company, BMS. Under this agreement, BMS conducted preclinical work to validate the function of certain genes and shared the data with us to potentially develop RNAi therapeutic drugs against therapeutic targets of interest. We formulated the required RNAi trigger molecules enabled by our LNP technology to silence target genes of interest. BMS paid us $3.0 million concurrent with the signing of the agreement. We provided a predetermined number of LNP batches over the four-year agreement. In May 2011, we announced a further expansion of the collaboration to include broader applications of our LNP technology and additional target validation work. In May 2014, the collaboration expired and all parties&#8217; obligations ended. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Halo-Bio RNAi Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2011, we entered into a license and collaboration agreement with Halo-Bio RNAi Therapeutics, Inc., or Halo-Bio. Under the agreement, Halo-Bio granted to us an exclusive license to its multivalent ribonucleic acid MV-RNA technology. The agreement was amended on August 8, 2012, to adjust future license fees and other contingent payments. To date, we have recorded $0.5 million in fees under our license from Halo-Bio. We terminated the agreement with Halo-Bio on July 31, 2013. There are no further payments due or contingently payable to Halo-Bio.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Aradigm Corporation</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2004, we entered into a licensing agreement with Aradigm Corporation, or Aradigm, under which Aradigm exclusively licensed certain of our liposomal intellectual property for the pulmonary delivery of Ciprofloxacin. As amended, this agreement calls for milestone payments totalling $4.5 and $4.75 million, respectively, for the first two disease indications pursued by Aradigm using our technology, and for low- to mid-single-digit royalties on sales revenue from products using our technology. We terminated the Aradigm license agreement in May 2013.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">University of British Columbia </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain early work on lipid nanoparticle delivery systems and related inventions was undertaken at the University of British Columbia, or UBC. These inventions are licensed to us by UBC under a license agreement, initially entered in 1998 as </font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">amended in 2001, 2006 and 2007. We have granted sublicenses under the UBC license to Alnylam as well as to Spectrum (Talon Therapeutics Inc., acquisition). Alnylam has in turn sublicensed back to us under the licensed UBC patents for discovery, development and commercialization of RNAi products. In mid-2009, we and our subsidiary Protiva entered into a supplemental agreement with UBC, Alnylam and Acuitas Technologies, Inc., in relation to a separate research collaboration to be conducted among UBC, Alnylam and Acuitas to which we have license rights. The settlement agreement signed in late 2012 to resolve the litigation among Alnylam, Acuitas, Arbutus and Protiva provided for the effective termination of all obligations under such supplemental agreement as between and among all litigants.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 10, 2014, the University of British Columbia filed a demand for arbitration against Arbutus Biopharma Corp., BCICAC File No.: DCA-1623. We received UBC&#8217;s Statement of Claims on January 16, 2015. In its Statement of Claims, UBC alleges that it is entitled to $3.5 million in allegedly unpaid royalties based on publicly available information, and an unspecified amount based on non-public information. UBC also seeks interest and costs, including legal fees. We dispute UBC&#8217;s allegation. No dates have been scheduled for this arbitration.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cytos Biotechnology Ltd </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 30, 2014, Arbutus Inc., our wholly owned subsidiary, entered into an exclusive, worldwide, sub-licensable (subject to certain restrictions with respect to licensed viral infections other than hepatitis) license to six different series of compounds from Cytos Biotechnology Ltd., or Cytos. The licensed compounds are Qbeta-derived virus-like particles that encapsulate TLR9, TLR7 or RIG-I agonists and may or may not be conjugated with antigens from the hepatitis virus or other licensed viruses. We have an option to expand this license to include additional viral infections other than influenza and Cytos will retain all rights for influenza, all non-viral infections, and all viral infections (other than hepatitis) for which we have not exercised an option.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, we will be obligated to pay Cytos up to a total of $67 million for each of the six licensed compound series upon the achievement of specified development and regulatory milestones; for hepatitis and each additional licensed viral infection, up to a total of $110 million upon the achievement of specified sales performance milestones; and tiered royalty payments in the high-single to low-double digits, based upon the proportionate net sales of licensed products in any commercialized combination.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Baruch S. Blumberg Institute and Drexel University</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, Arbutus Inc., our wholly owned subsidiary, entered into a license agreement with The Blumberg S. Blumberg Institute, or Blumberg, and Drexel University, or Drexel, that granted an exclusive (except as to certain know-how and subject to retained non-commercial research rights), worldwide, sub-licensable license to three different compound series: cccDNA inhibitors, capsid assembly inhibitors and HCC inhibitors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, Arbutus Inc. paid a license initiation fee of $150,000 and issued warrants to Blumberg and Drexel. No warrants were outstanding as at the date Arbutus merged with Arbutus Inc. Under this license agreement, Arbutus Inc. also agreed to pay up to $3.5 million in development and regulatory milestones per licensed compound series, up to $92.5 million in sales performance milestones per licensed product, and royalties in the mid-single digits based upon the proportionate net sales of licensed products in any commercialized combination. We are obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from the sub-licensees, subject to customary exclusions.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, Arbutus Inc. entered into an additional license agreement with Blumberg and Drexel pursuant to which it received an exclusive (subject to retained non-commercial research rights), worldwide, sub-licensable license under specified patents and know-how controlled by Blumberg and Drexel covering epigenetic modifiers of cccDNA and STING agonists. In consideration for these exclusive licenses, Arbutus Inc. made an upfront payment of $50,000. Under this agreement, we will be required to pay up to $1.0 million for each licensed product upon the achievement of a specified regulatory milestone and a low single digit royalty, based upon the proportionate net sales of compounds covered by this intellectual property in any commercialized combination. We are also obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from its sub-licensees, subject to exclusions.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements between Enantigen and Blumberg and Drexel</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, Arbutus Inc., our wholly owned subsidiary, acquired all of the outstanding shares of Enantigen Therapeutics, Inc., or Enantigen, pursuant to a stock purchase agreement. Through this transaction, Arbutus Inc. acquired a HBV surface antigen secretion inhibitor program and a capsid assembly inhibitor program, each of which are now assets of Arbutus, following our merger with Arbutus Inc.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the stock purchase agreement, we agreed to pay up to a total of $21.0 million to Enantigen&#8217;s selling stockholders upon the achievement of specified development and regulatory milestones, for the first two products that contain either a capsid compound, or a HBV surface antigen compound that is covered by a patent acquired under this agreement; or a capsid compound from an agreed upon list of compounds. The amount paid could be up to a total of $102.5 million in sales performance milestones in connection with the sale of the first commercialized product by us for the treatment of HBV, regardless of whether such product is based upon assets acquired under this agreement; and low single digit royalty on net sales of such first commercialized HBV product, up to a maximum royalty payment of $1.0 million that, if paid, would be offset against our milestone payment obligations.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the stock purchase agreement, we also agreed that Enantigen would fulfill its obligations as they relate to the three patent license agreements with Blumberg and Drexel. Pursuant to each patent license agreement, Enantigen is obligated to pay Blumberg and Drexel up to approximately $500,000 in development and regulatory milestones per licensed product, royalties in the low single digits, and a percentage of revenue it receives from its sub-licensees.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research Collaboration and Funding Agreement with Blumberg</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, Arbutus Inc., our wholly owned subsidiary, entered into a research collaboration and funding agreement with Blumberg under which we will provide $1.0 million per year of research funding for three years, renewable at our option for an additional three years, for Blumberg to conduct research projects in HBV and liver cancer pursuant to a research plan to be agreed upon by the parties. Blumberg has exclusivity obligations to Arbutus with respect to HBV research funded under the agreement. In addition, we have the right to match any third party offer to fund HBV research that falls outside the scope of the research being funded under the agreement. Blumberg has granted us the right to obtain an exclusive, royalty bearing, worldwide license to any intellectual property generated by any funded research project. If we elect to exercise our right to obtain such a license, we will have a specified period of time to negotiate and enter into a mutually agreeable license agreement with Blumberg. This license agreement will include the following pre negotiated upfront, milestone and royalty payments: an upfront payment in the amount of $100,000; up to $8.1 million upon the achievement of specified development and regulatory milestones; up to $92.5 million upon the achievement of specified commercialization milestones; and royalties at a low single to mid-single digit rates based upon the proportionate net sales of licensed products from any commercialized combination.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NeuroVive Pharmaceutical AB </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2014, Arbutus Inc., our wholly owned subsidiary, entered into a license agreement with NeuroVive that granted us an exclusive, worldwide, sub-licensable license to develop, manufacture and commercialize, for the treatment of HBV, oral dosage form sanglifehrin based cyclophilin inhibitors (including OCB-030). Arbutus Inc. became our wholly owned subsidiary by way of a Merger Agreement, which does not trigger any milestone payments. Under this license agreement we have been granted a non-exclusive, royalty free right and license and right of reference to NeuroVive&#8217;s relevant regulatory approvals and filings for the sole purpose of developing, manufacturing and commercializing licensed products for the treatment of HBV. Under this license agreement, we have (1) an option to expand our exclusive license to include treatment of viral diseases other than HBV and (2) an option, exercisable upon specified conditions, to expand our exclusive license to include development, manufacture and commercialization of non-oral variations of licensed products for treatment of viral diseases other than HBV. NeuroVive retains all rights with respect to development, manufacture and commercialization of licensed products and non-oral variations of licensed products for all indications (other than HBV) for which we have not exercised our option.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, Arbutus Inc. paid NeuroVive a license fee of $1 million. We have conducted significant research and analysis on the NeuroVive Product, OCB-030. Based on this research and analysis, we have decided to discontinue the OCB-030 development program. Otherwise, the license agreement and ongoing relationship with NeuroVive remains in full effect at this time.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Patents and Proprietary Rights</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our drug candidates, novel discoveries, product development technologies and other know-how, to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing or in licensing U.S. and foreign patents and patent applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also rely on trademarks, trade secrets, know how, continuing technological innovation and potential in licensing opportunities to develop and maintain our proprietary position.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our proprietary expertise, we own a portfolio of patents and patent applications directed to HBV cccDNA formation inhibitors, HBV core/capsid protein assembly inhibitors, TLR-9 agonists, HBV surface antigens secretion inhibitors, HBV cccDNA epigenetic modifiers, STING agonists, cyclophilin inhibitors, LNP inventions, LNP compositions for delivering nucleic acids such as mRNA and siRNA, the formulation and manufacture of LNP-based pharmaceuticals, chemical modification of RNAi molecules, and RNAi drugs and processes directed at particular disease indications. We have filed many patent applications with the US and European Patent Offices that have been granted. In the US our patents might be challenged by interference or opposition proceedings.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;">In Europe, upon grant, a period of nine months is allowed for notification of opposition to such granted patents.&#160;&#160;If our patents are subjected to interference or opposition proceedings, we would incur significant costs to defend them. Further, our failure to prevail in any such proceedings could limit the patent protection available to our therapeutic HBV programs or RNAi platform, including our product candidates.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a portfolio of approximately 121 patent families, in the U.S. and abroad, that are directed to our therapeutic HBV product candidates and various aspects of LNPs and LNP formulations. The portfolio includes approximately 83 issued U.S. patents, approximately 100 issued non-U.S. patents, and approximately 350 pending patent applications, including the following patents and applications in the United States and Europe (1) :</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="35%"></td><td width="54%"></td><td width="11%"></td></tr><tr><td style="vertical-align:top;background-color:#00497f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#ffffff;font-weight:bold;">Subject Matter</font></div></td><td style="vertical-align:top;background-color:#00497f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#ffffff;font-weight:bold;">Status</font></div></td><td style="vertical-align:top;background-color:#00497f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#ffffff;font-weight:bold;">Expiration</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#ffffff;font-weight:bold;">Date*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">LNP Compositions and Methods of Use (siRNA)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. No. 7,982,027; applications pending in other jurisdictions</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2024</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">LNP Compositions (interferingRNA)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. No. 7,799,565; patents issued in other jurisdictions</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2025</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">LNP Compositions (Nucleic Acid)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. Nos. 8,058,069; 8,492,359 and 8,822,668; applications pending in other jurisdictions</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2029</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">LNP Compositions and Methods of Use (PLK-1)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. No.8,283,333; applications pending in other jurisdictions</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2030</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">LNP Compositions (Nucleic Acid)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. No. 9,006,417</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#44546a;">2031</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">LNP</font></div><div style="padding-bottom:2px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Manufacturing Process</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. Nos. 7,901,708 and 8,329,070; European Pat. Nos. 1519714 and 2338478; application pending in the U.S.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2023</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">LNP</font></div><div style="padding-bottom:2px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Manufacturing Process</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. No. 9,005,654; application pending in Europe</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2026</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Lipid Compositions</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. No. 7,745,651; European Pat. No. 1781593; application pending in the U.S.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2025</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Lipid Compositions</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. Nos. 7,803,397 and 8,936,942; European Pat. No. 1664316</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2024</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Modified siRNA Compositions</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. Nos. 8,101,741, 8,188,263 and 9,074,208; applications pending in  other jurisdictions</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2026</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Modified siRNA Compositions</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. No. 7,915,399</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2027</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">siRNA and LNP Compositions (Ebola Virus)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. No. 7,838,658</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2026</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">siRNA and LNP Compositions and Methods of Treatment (Ebola Virus)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. No. 8,716,464</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2030</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">siRNA and LNP Compositions (PLK1)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. No. 9,006,191; European Pat. No. 2238251</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2028</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Immunostimulatory Compositions, Methods of Use and Production</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">U.S. Pat. No. 8,691,209; European Pat. No. 1450856</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2022</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">siRNA and LNP Compositions (HBV)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patent applications pending in U.S. and other jurisdictions</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2035</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">HBV Capsid Assembly Inhibitor Compositions and Methods of Treatment</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patent applications pending in U.S. and other jurisdictions</font></div></td><td style="vertical-align:top;border-bottom:1px solid #828282;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #828282;border-right:1px solid #828282;border-top:1px solid #828282;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2032</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patent information current as of February 15, 2016.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;padding-left:36px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*         Once issued, the term of a US patent first filed after mid-1995 generally extends until the 20th anniversary of the filing date of the first non-provisional application to which such patent claims priority. It is important to note, however, that the United States Patent &amp; Trademark Office, or USPTO, sometimes requires the filing of a Terminal Disclaimer during prosecution, which may shorten the term of the patent. On the other hand, certain patent term adjustments may be available based on USPTO delays during prosecution. Similarly, in the pharmaceutical area, certain patent term extensions may be available based on the history of the drug in clinical trials. We cannot predict whether or not any such adjustments or extensions will be available or the length of any such adjustments or extensions.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Scientific Advisers</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We seek advice from our scientific advisory board, which consists of a number of leading scientists and physicians, on scientific and medical matters. The current members of our scientific advisory board are:</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="31%"></td><td width="1%"></td><td width="68%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position(s)/Institutional Affiliation(S)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adrian Di Bisceglie, MD</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professor of Internal Medicine and Chairman of the Department of Medicine at St Louis University , St Louis University School of Medicine, Chief of Hepatology</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Charlie Rice, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maurice and Corinne Greenberg Professor in Virology, Rockefeller University</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scott Biller, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Scientific Officer at Agios Pharmaceuticals</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ulrike Protzer, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director, Institute of Virology, Technische Universit&#228;t M&#252;nchen / Helmholtz Zentrum M&#252;nchen - German Center for Environmental Health</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fabien Zoulim, MD, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professor of Medicine, Lyon University, Head of Hepatology Department, Hospices Civils de Lyon</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, 2015, Arbutus had 134 employees, 105 of whom were engaged in research and development. None of our employees are represented by a labor union or covered by a collective bargaining agreement, nor have we experienced any work stoppages. We believe that relations with our employees are good. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate information</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, and &#8220;our&#8221;) is a publicly traded industry-leading therapeutic solutions company focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis HBV infection. Effective July 31, 2015, our corporate name changed from Tekmira Pharmaceuticals Corporation to Arbutus Biopharma Corporation. Also effective July 31, 2015, the corporate name of our wholly owned subsidiary, OnCore Biopharma, Inc. changed to Arbutus Biopharma, Inc. (&#8220;Arbutus Inc.&#8221;). We have two wholly owned subsidiaries:Arbutus Inc., and Protiva Biotherapeutics Inc. (&#8220;Protiva&#8221;). Unless stated otherwise or the context otherwise requires, references herein to &#8220;Arbutus&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to Arbutus Biopharma Corporation, and, unless the context requires otherwise, one or more subsidiaries through which we conduct business.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus was incorporated pursuant to the British Columbia Business Corporations Act, or BCBCA, on October 6, 2005, and commenced active business on April 30, 2007, when Arbutus and its parent company, Inex Pharmaceuticals Corporation, or Inex, Inex, were reorganized under a statutory plan of arrangement (the Reorganization) completed under the provisions of the BCBCA. The Reorganization saw Inex&#8217;s entire business transferred to and continued by Arbutus. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 4, 2015, we completed a business combination pursuant to which OnCore Biopharma, Inc., or OnCore, became our wholly-owned subsidiary.  This combined company intends to focus on developing a curative regimen for HBV patients by combining multiple therapeutic approaches.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus&#8217; head office and principal place of business is located at 100-8900 Glenlyon Parkway, Burnaby, British Columbia, Canada, V5J 5J8 (telephone: (604)&#160;419-3200). The Company&#8217;s registered and records office is located at 700 West Georgia St, 25th Floor, Vancouver, British Columbia, Canada, V7Y 1B3. Arbutus also has a US office located at 3805 Old Easton Road, Doylestown, PA 18902.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investor information</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a reporting issuer in Canada under the securities laws of each of the Provinces of Canada. On March 3, 2015, Arbutus&#8217; common shares were voluntarily delisted from the Toronto Stock Exchange. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus&#8217; common shares trade on the NASDAQ Global Market under the symbol &#8220;ABUS&#8221;. We maintain a website at&#160;http://www.arbutusbio.com. The information on our website is not incorporated by reference into this annual report on Form&#160;10-K and should not be considered to be a part of this annual report on Form&#160;10-K. Our website address is included in this annual report on Form&#160;10-K as an inactive technical reference only. Our reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, including our annual reports on Form&#160;10-K (annual reports on Form 20-F up to year-ended December 31, 2012), our quarterly reports on Form&#160;10-Q (quarterly reports on Form 6-K up to quarter-ended September 30, 2013) and our current reports on Form&#160;8-K, and amendments to those reports, are accessible through our website, free of charge, as soon as reasonably practicable after these reports are filed electronically with, or otherwise furnished to, the SEC. We also make available on our website the charters of our audit committee, executive compensation and human resources committee and corporate governance and nominating committee, whistleblower policy, insider trading policy, and majority voting policy, as well as our code of business conduct and ethics for directors, officers and employees. In addition, we intend to disclose on our web site any amendments to, or waivers from, our code of business conduct and ethics that are required to be disclosed pursuant to the SEC rules.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You may read and copy any materials we file with the SEC at the SEC&#8217;s Public Reference Room at 100&#160;F&#160;Street, NE, Washington, DC 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains a website that contains reports, proxy and information statements, and other information regarding Arbutus and other issuers that file electronically with the SEC. The SEC&#8217;s website address is&#160;http://www.sec.gov.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Executive Officers of the Registrant</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">Set forth below is information about our executive officers, as of March 8, 2016.</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="42%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="50%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Age</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Position(s)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Murray</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer, and Director</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bruce Cousins</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Kowalski</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Medical Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Peter Lutwyche</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Technology Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patrick Higgins</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Business Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Sofia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Scientific Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William Symonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Development Officer and Director</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Elizabeth Howard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President and General Counsel</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Michael Abrams</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managing Director</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dr. Mark Murray </font><font style="font-family:inherit;font-size:10pt;">serves as our President, Chief Executive Officer and a Director since May 2008 when Arbutus and Protiva Biotherapeutics, Inc. merged. Previously, he was the President and CEO and founder of Protiva since its inception in the summer of 2000. Dr. Murray has over 20 years of experience in both the R&amp;D and business development and management facets of the biotechnology industry. Dr. Murray has held senior management positions at ZymoGenetics and Xcyte Therapies prior to joining Protiva. Since entering the biotechnology industry Dr. Murray has successfully completed numerous and varied partnering deals, directed successful research and product development programs, been responsible for strategic planning programs, raised millions of dollars in capital and executed extensive business development initiatives in the U.S., Europe and Asia. During his R&amp;D career, Dr. Murray worked extensively on three programs that resulted in FDA approved drugs, including the first growth factor protein approved for human use, a program he led for several years following his discovery. Dr. Murray obtained his Ph.D. in Biochemistry from the University of Oregon Health Sciences University and was a Damon Runyon-Walter Winchell post-doctoral research fellow for three years at the Massachusetts Institute of Technology.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Bruce Cousins </font><font style="font-family:inherit;font-size:10pt;">serves as our Executive Vice President and Chief Financial Officer. Mr. Cousins brings to Arbutus extensive global financial and pharmaceutical industry experience both working for multi-million dollar companies and leading start-ups through to successful completion of their strategic growth plans. In 2004, Mr. Cousins joined Aspreva Pharmaceuticals and led its highly successful IPO. In 2008, he played a key leadership role in the eventual sale of Aspreva in a $915 million all-cash transaction. Prior to joining Aspreva, Mr. Cousins spent 14 years with Johnson &amp; Johnson (J&amp;J) working in operations and finance, both domestically and internationally. Prior to the pharmaceutical industry, Mr. Cousins was a chartered accountant with Deloitte &amp; Touche. More recently, Mr. Cousins has spent the past few years in the renewable energy sector, and from 2011 to 2013 he was Chief Executive Officer of Carmanah Technologies Corporation, a TSX-listed company. Prior to Carmanah, he held Chief Financial Officer positions at Xantrex Technology Inc. and Ballard Power Systems. Mr. Cousins completed a Bachelor of Commerce degree from McMaster University in 1987 and received a Chartered Accountant designation in 1989.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dr. Mark Kowalski </font><font style="font-family:inherit;font-size:10pt;">serves as our Chief Medical Officer. Dr. Kowalski has extensive experience in Phase I through Phase IV drug development and clinical trials in a wide variety of therapeutic areas including oncology, urology, infectious diseases, analgesia, allergy, rheumatology and cardiovascular diseases. His experience also includes basic scientific research on the molecular biology of HIV as well as clinical practice in internal medicine. Prior to joining Arbutus, Dr. Kowalski worked in the oncology and inflammation therapeutic area at Gilead Sciences, Inc. following Gilead&#8217;s $510-million acquisition of YM BioSciences Inc. Previously, Dr. Kowalski had been CMO and Vice President of Regulatory Affairs at YM BioSciences Inc. Dr. Kowalski&#8217;s experience also encompasses being the CMO and Vice President of Medical/Regulatory Affairs at Viventia Biotechnologies Inc. Prior to Viventia, he was the Senior Director of Medical Affairs at AAIPharma Inc. Dr. Kowalski holds a B.A. from Rutgers University and an M.D. and Ph.D. from the University of Kansas School of Medicine. He completed his postgraduate training in internal medicine and infectious diseases at Duke University and Harvard Medical School.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dr. Peter Lutwyche </font><font style="font-family:inherit;font-size:10pt;">serves as our Chief Technology Officer. Dr. Lutwyche&#8217;s responsibilities at Arbutus include manufacturing, process development and quality control for all Arbutus product candidates, as well as supporting Arbutus' collaborative partners as they advance products that utilize Arbutus's technology. Previously Dr. Lutwyche was Director, Pharmaceutical Development at QLT Inc. During his tenure at QLT, Dr. Lutwyche contributed to the development and commercialization of Visudyne as well as leading manufacturing and chemistry efforts for numerous pre-clinical and clinical stage products. Prior to QLT, he was a research scientist at Inex Pharmaceuticals Corporation working with lipid-based formulations of nucleic acids and antibiotics. Dr. Lutwyche holds a Ph.D. in Chemistry from the University of British Columbia.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mr. Patrick Higgins </font><font style="font-family:inherit;font-size:10pt;">serves as our Chief Business Officer. Mr.&#160;Higgins was a co-founder of our subsidiary Arbutus Biopharma, Inc. (formerly OnCore Biopharma, Inc.) and served as a member of its board of directors since its inception in May 2012 and as its Chief Executive Officer since July 2014. Mr.&#160;Higgins previously served as Executive Vice-President, Marketing and Sales of Pharmasset, Inc., a specialty pharmaceutical company, from 2007 to January 2012 and was a consultant to Pharmasset from 2006 to 2007. From 1995 to 2006, Mr.&#160;Higgins was the Vice-President, Sales and Marketing, Virology at Hoffmann-LaRoche, a pharmaceutical company. Mr.&#160;Higgins received his B.A. degree from Villanova University and his M.B.A. degree from Seton Hall University.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dr. Michael Sofia </font><font style="font-family:inherit;font-size:10pt;">serves as our Chief Scientific Officer. Dr.&#160;Sofia was one of Arbutus Biopharma, Inc. co-founders and served as its Chief Scientific Officer and Head of Research and Development since July 2014. He previously served as President and a member of its board of directors from May 2012 to August 2014. Since April 2012, Dr.&#160;Sofia has been a professor at the Baruch S. Blumberg Institute and since March 2013, Dr.&#160;Sofia has been an adjunct professor at the Drexel University School of Medicine. Previously, Dr.&#160;Sofia was the Senior Vice-President, Chemistry, Site Head and then Senior Adviser at Gilead Sciences, Inc. from January 2012 to December 2012. Prior to that, Dr.&#160;Sofia was the Senior Vice-President, Chemistry at Pharmasset, Inc. from August 2005 to January 2012. From 1999 to 2005, Dr.&#160;Sofia served as a Group Director, New Leads Chemistry at Bristol-Myers Squibb. From 1993 to 1999, Dr.&#160;Sofia established and directed the research programs at Transcell Technologies, first as Director of Chemistry and then as Vice-President of Research. Dr.&#160;Sofia received his B.A. degree from Cornell University, his Ph.D. degree from the University of Illinois at Urbana-Champaign and was an NIH postdoctoral fellow at Columbia University.&#160; Dr. Sofia has won the Economist&#8217;s 2015 Innovation Award in the Bioscience category, for developing a rapid cure for hepatitis C virus infection (HCV).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dr. William Symonds </font><font style="font-family:inherit;font-size:10pt;">serves as our Chief Development Officer. Dr. Symonds served as a director of Arbutus Biopharma, Inc. since August 2014 and as a Senior Adviser since November 2014. Dr. Symonds is currently Senior Vice President, Clinical Research at Roivant Sciences, Inc., a position he has held since May 2014. Prior to that, Dr. Symonds served as Vice-President, Liver Disease Therapeutic Area at Gilead Sciences, Inc. from February 2012 until April 2014, and was the Senior Vice-President, Clinical Pharmacology and Translational Medicine at Pharmasset, Inc. from 2007 to January 2012. From 1993 to 2007, Dr. Symonds held various positions of increasing responsibility at GlaxoSmithKline, most recently as Director, Antiviral Clinical Pharmacology and Discovery Medicine. Dr. Symonds received his Doctor of Pharmacy degree from Campbell University and completed a fellowship in clinical pharmacokinetics at the Clinical Pharmacokinetics Laboratory in Buffalo, New York.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dr. Elizabeth Howard </font><font style="font-family:inherit;font-size:10pt;">serves as our Executive Vice President and General Counsel. Dr. Howard has been practicing law for more than 20 years. &#160;Prior to joining Arbutus in March 2016, she was an intellectual property partner at Orrick Herrington &amp; Sutcliffe LLP, or Orrick, where she co-chaired Orrick's life sciences practice focusing on patent infringement litigation. &#160;Her practice also included trade secrets disputes and handling anti-counterfeiting matters in the pharmaceutical industry. &#160;In addition to litigating in numerous federal district courts and California state courts, Dr. Howard has appeared before the U.S. Patent and Trademark Office in interference proceedings, arbitrated before numerous tribunals, and litigated before the U.S. International Trade Commission (ITC). &#160;Dr. Howard also served as a deputy district attorney in the county of Santa Clara. &#160;Dr. Howard has been listed as a "leading lawyer" in "PLC Which Lawyer" for her litigation successes in life sciences, and named to the Daily Journal's list of "Top 75 IP Litigators in California" in 2013. &#160;Before law school, Dr. Howard was an NSF Plant Molecular Biology Postdoctoral Fellow at the CSIRO Division of Plant Industry in Canberra, Australia, and a Research Geneticist at the University of California, Berkeley. Dr. Howard obtained her doctorate with Dr. Elizabeth Blackburn (2009 Nobel Laureate, Physiology or Medicine). Dr. Howard holds a B.A. with honors from the University of California, Santa Barbara, a Ph.D. in Molecular Biology from the University of California, Berkeley, a J.D. from the University of California, Hastings College of the Law, and is a member of the United States Patent Bar.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dr. Michael Abrams </font><font style="font-family:inherit;font-size:10pt;">serves as our Managing Director of the business unit dedicated to our non-HBV assets.&#160;Prior to joining Arbutus, Dr. Abrams was Chief Innovation Officer and VP, Research and Development at CDRD Ventures Inc. Previously, Dr. Abrams was President and CEO of Inimex. He was the founding CEO of AnorMED, Inc. and led that company as President and CEO for ten years. AnorMED discovered and&#160; developed&#160; Mozobil,&#160; a&#160; drug&#160; for&#160; improving&#160; stem&#160; cell&#160; mobilization&#160; for&#160; patients undergoing stem cell transplantation. Mozobil was approved by the FDA in 2008 and AnorMED was acquired by Genzyme&#160;Corp. in 2006 for $580M. Prior to AnorMED, Dr. Abrams was Manager Biomedical Research for Johnson Matthey, plc where he led the spin-off of the biomedical research group to form AnorMED. From 2009 to 2013, Dr. Abrams served as Board Chairman of Indel Therapeutics. Dr. Abrams has a Ph.D. in Chemistry from the Massachusetts Institute of Technology and a BA in Chemistry from Bowdoin College. In 2009 he was a corecipient of the Georg Charles de Hevesy Nuclear Pioneer Award from the Society of Nuclear Medicine for his work in the invention of the radiopharmaceutical, Cardiolite.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sC95EE5CFFC0E6F4FF501EF6370E64624"></a><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A.          Risk Factors</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our business is subject to numerous risks. We caution you that the following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in filings with the SEC and Canadian securities regulators, press releases, communications with investors and oral statements. All statements other than statements relating to historical matters should be considered forward-looking statements. When used in this report, the words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;may&#8221; &#8220;could&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;will,&#8221; &#8220;target,&#8221; &#8220;goal&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Any or all of our forward-looking statements in this annual report on Form 10-K and in any other public statements we make may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Many factors mentioned in the discussion below will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially from those anticipated in forward-looking statements. We explicitly disclaim any obligation to update any forward-looking statements to reflect events or circumstances that arise after the date hereof, unless required by law. You are advised, however, to consult any further disclosure we make in our reports filed with the SEC and Canadian securities regulators.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Business</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We are in the early stages of our development and because we have a short development history with ribonucleic acid interference (RNAi) and assets relating to HBV, there is a limited amount of information about us upon which you can evaluate our RNAi business and prospects, and our HBV business and prospects.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not begun to market or generate revenues from the commercialization of any RNAi products or our HBV products. We have only a limited history upon which one can evaluate our business and prospects as our therapeutic products are still at an early stage of development and thus we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. For example, to execute our business plan, we will need to successfully:&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">execute research and development activities using RNAi technology; and technologies involved in the development of HBV therapeutics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">build, maintain and protect a strong intellectual property portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">gain acceptance for the development and commercialization of any product we develop;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">develop and maintain successful strategic relationships; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manage our spending and cash requirements as our expenses are expected to increase due to research and preclinical work, clinical trials, regulatory approvals, and commercialization and maintaining our intellectual property portfolio</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:0px;text-align:left;padding-left:102px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unsuccessful in accomplishing these objectives, we may not be able to develop products, raise capital, expand our business or continue our operations.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">The approach we are taking to discover and develop novel drug products is unproven and may never lead to marketable drug products.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;We intend to concentrate our internal research and development efforts in the future primarily on the discovery and development of therapeutics targeting chronic hepatitis B to be able to ultimately develop a cure for the disease. Our future success depends in part on the successful development of these therapeutics.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">Our approach to the treatment of HBV is unproven, and we do not know whether we will be able to develop any drugs of commercial value.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is no known cure for HBV. Any compounds that we develop may not effectively address HBV persistence. Even if we are able to develop compounds that address one or more of these key factors, targeting these key factors has not been proven to cure HBV. We may be unable to acquire additional drug candidates on terms acceptable to us, or at all. Even if we are able to acquire or develop drug candidates that address one of these mechanisms of action in preclinical studies, we may not succeed in demonstrating safety and efficacy of the drug candidate in human clinical trials. If we are unable to identify suitable compounds for preclinical and clinical development, we will not succeed in realizing our goal of a cure for HBV.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also intend to continue research and development efforts on RNAi technology and products based on RNAi technology. While RNAi technology is based on a naturally occurring process that takes place inside cells, which can suppress the production of specific proteins, and has the potential to generate therapeutic drugs that take advantage of that process, neither we nor any other company has received regulatory approval to market a therapeutic product based on RNAi technology. The scientific discoveries that form the basis for our efforts to discover and develop new products are relatively new. While there are a number of RNAi therapeutics in development, very few product candidates based on these discoveries have ever been tested in humans and there can be no assurance that any RNAi therapeutic product will be approved for commercial use.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are not successful in developing a product with our research and development efforts, we may be required to change the scope and direction of our product development activities. In that case, we may not be able to identify and implement successfully an alternative product development strategy.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We expect to depend in part on our existing collaborators for a significant portion of our revenues and to develop, conduct clinical trials with, obtain regulatory approvals for, and manufacture, market and sell some of our product candidates. If these collaborations are unsuccessful, or anticipated milestone payments are not received, our business could be adversely affected.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that we will depend in part on Alnylam, Spectrum, Dicerna, and Monsanto to provide revenue to fund our operations, especially in the near term. Furthermore, our strategy is to enter into various additional arrangements with corporate and academic collaborators, licensors, licensees and others for the research, development, clinical testing, manufacturing, marketing and commercialization of our products. We may be unable to continue to establish such collaborations, and any collaborative arrangements we do establish may be unsuccessful, or we may not receive milestone payments as anticipated.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Should any collaborative partner fail to develop or ultimately successfully commercialize any of the products to which it has obtained rights, our business may be adversely affected. In addition, once initiated, there can be no assurance that any of these collaborations will be continued or result in successfully commercialized products. Failure of a collaborative partner to continue funding any particular program could delay or halt the development or commercialization of any products arising out of such program. In addition, there can be no assurance that the collaborative partners will not pursue alternative technologies or develop alternative products either on their own or in collaboration with others, including our competitors, as a means for developing treatments for the diseases targeted by our programs.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to spend substantial amounts to acquire additional drug candidates, to conduct further research and development and preclinical testing and clinical trials of our drug candidates, to seek regulatory approvals for our drug candidates and to launch and commercialize any drug candidates for which we receive regulatory approval. These expenditures will include costs associated with our and our subsidiary&#8217;s licensing agreements with Blumberg, or Drexel, and Cytos. Under the terms of these agreements, we are obligated to make significant cash payments upon the achievement of specified development, regulatory and sales performance milestones, as well as royalty payments in connection with the sale of licensed products, to our licensors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We rely on third parties to conduct our clinical trials, and if they fail to fulfill their obligations, our development plans may be adversely affected.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our clinical trials. We have contracted with, and we plan to continue to contract with, certain third parties to provide certain services, including site selection, enrollment, monitoring and data management services. Although we depend heavily on these parties, we do not control them and therefore, we cannot be assured that these third parties will adequately perform all of their contractual obligations to us. If our third-party service providers cannot adequately fulfill their obligations to us on a timely and satisfactory basis or if the quality or accuracy of our clinical trial data is compromised due to failure to adhere to our protocols or regulatory requirements, or if such third parties otherwise fail to meet deadlines, our development plans may be delayed or terminated.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We have no sales, marketing or distribution experience and would have to invest significant financial and management resources to establish these capabilities.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no sales, marketing or distribution experience. We currently expect to rely heavily on third parties to launch and market certain of our products, if approved. However, if we elect to develop internal sales, distribution and marketing capabilities, we will need to invest significant financial and management resources. For products where we decide to perform sales, marketing and distribution functions ourselves, we could face a number of additional risks, including:&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not be able to attract and build a significant marketing or sales force;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of establishing a marketing or sales force may not be justifiable in light of the revenues generated by any particular product; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our direct sales and marketing efforts may not be successful.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:0px;text-align:left;padding-left:102px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable to develop our own sales, marketing and distribution capabilities, we will not be able to successfully commercialize our products, if approved, without reliance on third parties.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We will rely on third-party manufacturers to manufacture our products (if approved) in commercial quantities, which could delay, prevent or increase the costs associated with the future commercialization of our products.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our product candidates have not yet been manufactured for commercial use. If any of our product candidates become approved for commercial sale, in order to supply our or our collaborators&#8217; commercial requirements for such an approved product, we will need to establish third-party manufacturing capacity. Any third-party manufacturing partner may be required to fund capital improvements to support the scale-up of manufacturing and related activities. The third-party manufacturer may not be able to establish scaled manufacturing capacity for an approved product in a timely or economic manner, if at all. If a manufacturer is unable to provide commercial quantities of such an approved product, we will have to successfully transfer manufacturing technology to a new manufacturer. Engaging a new manufacturer for such an approved product could require us to conduct comparative studies or utilize other means to determine bioequivalence of the new and prior manufacturers&#8217; products, which could delay or prevent our ability to commercialize such an approved product. If any of these manufacturers is unable or unwilling to increase its manufacturing capacity or if we are unable to establish alternative arrangements on a timely basis or on acceptable terms, the development and commercialization of such an approved product may be delayed or there may be a shortage in supply. Any inability to manufacture our products in sufficient quantities when needed would seriously harm our business.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturers of our approved products, if any, must comply with current good manufacturing practices (cGMP) requirements enforced by the FDA and Health Canada through facilities inspection programs. These requirements include quality control, quality assurance, and the maintenance of records and documentation. Manufacturers of our approved products, if any, may be unable to comply with these cGMP requirements and with other FDA, Health Canada, state, and foreign regulatory requirements. We have little control over our manufacturers&#8217; compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any quantities supplied is compromised due to our manufacturer&#8217;s failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, which would seriously harm our business.&#160;&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Financial Results and Need for Financing</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We will require substantial additional capital to fund our operations. If additional capital is not available, we may need to delay, limit or eliminate our research, development and commercialization processes and may need to undertake a restructuring.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Within the next several years, substantial additional funds will be required to continue with the active development of our pipeline products and technologies. In particular, our funding needs may vary depending on a number of factors including:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">revenues earned from our partners, including Alnylam, Acuitas, Spectrum, Monsanto, and Dicerna;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent to which we continue the development of our product candidates or form collaborative relationships to advance our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our decisions to in-license or acquire additional products or technology for development,</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to attract and retain corporate partners, and their effectiveness in carrying out the development and ultimate commercialization of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether batches of drugs that we manufacture fail to meet specifications resulting in delays and investigational and remanufacturing costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the decisions, and the timing of decisions, made by health regulatory agencies regarding our technology and products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competing technological and market developments; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">prosecuting and enforcing our patent claims and other intellectual property rights.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will seek to obtain funding to maintain and advance our business from a variety of sources including public or private equity or debt financing, collaborative arrangements with pharmaceutical and biotechnology companies and government grants and contracts. There can be no assurance that funding will be available at all or on acceptable terms to permit further development of our products especially in light of the current difficult climate for investment in biotechnology companies.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If adequate funding is not available, we may be required to delay, reduce or eliminate one or more of our research or development programs or reduce expenses associated with non-core activities. We may need to obtain funds through arrangements with collaborators or others that may require us to relinquish most or all of our rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise seek if we were better funded. Insufficient financing may also mean failing to prosecute our patents or relinquishing rights to some of our technologies that we would otherwise develop or commercialize.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We have incurred losses in nearly every year since our inception and we anticipate that we will not achieve sustained profits for the foreseeable future. To date, we have had no product revenues.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With the exception of the year ended December 31, 2006 and December 31, 2012, we have incurred losses each fiscal year since inception until December 31, 2015 and have not received any revenues other than from research and development collaborations, license fees and milestone payments. From inception to December 31, 2015, we have an accumulated net deficit of $ 267.0 million. As we continue our research and development and clinical trials and seek regulatory approval for the sale of our product candidates, we do not expect to attain sustained profitability for the foreseeable future. We do not expect to achieve sustained profits until such time as strategic alliance payments, product sales and royalty payments, if any, generate sufficient revenues to fund our continuing operations. We cannot predict if we will ever achieve profitability and, if we do, we may not be able to remain consistently profitable or increase our profitability.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We are subject to risks associated with currency fluctuations, and changes in foreign currency exchange rates could impact our results of operations.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to January 1, 2016, our functional currency was the Canadian dollar. On January 1, 2016, our functional currency changed from the Canadian dollar to the U.S. dollar based on our analysis of the changes in the primary economic environment in which we operate. As a result, changes in the exchange rate between the Canadian dollar and the U.S. dollar could materially impact our reported results of operations and distort period to period comparisons. In particular, to the extent that foreign currency-denominated (i.e., non-U.S. dollar) monetary assets do not equal the amount of our foreign currency denominated monetary liabilities, foreign currency gains or losses could arise and materially impact our financial statements. As a result of such foreign currency fluctuations, it could be more difficult to detect underlying trends in our business and results of operations. In addition, to the extent that fluctuations in currency exchange rates cause our results of operations to differ from our expectations or the expectations of our investors, the trading price of our common shares could be adversely affected.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may engage in exchange rate hedging activities in an effort to mitigate the impact of exchange rate fluctuations. Any hedging technique we implement may fail to be effective. If our hedging activities are not effective, changes in currency exchange rates may have a more significant impact on the trading price of our common shares.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Managing Our Operations</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If we are unable to attract and retain qualified key management, scientific staff, consultants and advisors, our ability to implement our business plan may be adversely affected.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We depend upon our senior executive officers as well as key scientific, management and other personnel. The competition for qualified personnel in the biotechnology field is intense. We rely heavily on our ability to attract and retain qualified managerial, scientific and technical staff. The loss of the service of any of the members of our senior management, including Dr. Mark Murray, our President and Chief Executive Officer, may adversely affect our ability to develop our technology, add to our pipeline, advance our product candidates and manage our operations.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We may have difficulty managing our growth and expanding our operations successfully as we seek to evolve from a company primarily involved in discovery and preclinical testing into one that develops products through clinical development and commercialization.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As product candidates we develop enter and advance through clinical trials, we will need to expand our development, regulatory, manufacturing, clinical and medical capabilities or contract with other organizations to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various collaborators, suppliers and other organizations. Our ability to manage our operations and growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems or controls.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, our success will also depend on ability to continue to realize the benefits of our merger with OnCore, and Arbutus can offer no assurance that we will continue to realize benefits anticipated to result from the merger.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We could face liability from our controlled use of hazardous and radioactive materials in our research and development processes.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use certain radioactive materials, biological materials and chemicals, including organic solvents, acids and gases stored under pressure, in our research and development activities. Our use of radioactive materials is regulated by the Canadian Nuclear Safety Commission for the possession, transfer, import, export, use, storage, handling and disposal of radioactive materials. Our use of biological materials and chemicals, including the use, manufacture, storage, handling and disposal of such materials and certain waste products is regulated by a number of federal, provincial and local laws and regulations. Although we believe that our safety procedures for handling such materials comply with the standards prescribed by such laws and regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, we could be held liable for any damages that result and any such liability could exceed our resources. We are not specifically insured with respect to this liability.&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our business and operations could suffer in the event of information technology system failures.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures. Such events could cause interruption of our operations. For example, the loss of pre-clinical trial data or data from completed or ongoing clinical trials for our product candidates could result in delays in our regulatory filings and development efforts and significantly increase our costs. To the extent that any disruption or security breach will result in a loss of or damage to our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of our product candidates could be delayed.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If, in the future, our internal control over financial reporting is not effective, it could have a material adverse effect on our stock price and our ability to raise capital.&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have completed an independent audit of our internal control over financial reporting for our fiscal year ending December 31, 2015 and no material weaknesses have been identified. If our internal control over financial reporting is determined in the future to not be effective, whether by our management or by our independent auditors, there could be an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements, which could materially adversely affect our stock price and our ability to raise capital necessary to operate our business. In addition, we may be required to incur costs in improving our internal control system and hiring additional personnel.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We rely on and will incur additional expense in connection with our research collaboration with Blumberg.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, Arbutus Inc. entered into an agreement with Blumberg under which Arbutus Inc.will provide annual funding for a three year period in the amount of $1.0 million per year and which is renewable for an additional three year period at our option, for Blumberg to conduct research projects in HBV and liver cancer pursuant to a research plan to be agreed upon by the parties. In exchange, Arbutus Inc.has the right to obtain an exclusive, royalty bearing, worldwide license to intellectual property generated by Blumberg in the course of the funded research and we believe that Blumberg&#8217;s HBV research platform will continue to be a source of potentially novel hepatitis B targets, drug candidates, assays and other HBV specific technologies. As a result, we are dependent, in part, upon the success of Blumberg in performing its responsibilities under this research collaboration. Blumberg may not cooperate with us or perform its obligations under the agreement. We cannot control the amount and timing of Blumberg&#8217;s resources that will be devoted to research and development activities related to our research collaboration. Further, development costs associated with our research projects may be difficult to anticipate and exceed our expectations. If funding is unable to continue to financially support the collaboration, if we do not obtain exclusive licenses from Blumberg to the resulting intellectual property, or if we fails to comply with our obligations under those license agreements, its development efforts may be materially harmed.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Development, Clinical Testing and Regulatory Approval of Our Product Candidates</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The manufacture and sale of human therapeutic products are governed by a variety of statutes and regulations. There can be no assurance that our product candidates will obtain regulatory approval.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To obtain marketing approval, U.S. and Canadian laws require:&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">controlled research and human clinical testing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establishment of the safety and efficacy of the product for each use sought;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">government review and approval of a submission containing manufacturing, pre-clinical and clinical data;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adherence to Good Manufacturing Practice Regulations during production and storage; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">control of marketing activities, including advertising and labelling</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The product candidates we currently have under development will require significant development, preclinical and clinical testing and investment of significant funds before their commercialization.&#160;&#160;Some of our product candidates, if approved, will require the completion of post-market studies. There can be no assurance that such products will be developed. The process of completing clinical testing and obtaining required approvals is likely to take a number of years and require the use of substantial resources. If we fail to obtain regulatory approvals, our operations will be adversely affected. Further, there can be no assurance that product candidates employing a new technology will be shown to be safe and effective in clinical trials or receive applicable regulatory approvals.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other markets have regulations and restrictions similar to those in the U.S. and Canada. Investors should be aware of the risks, problems, delays, expenses and difficulties which we may encounter in view of the extensive regulatory environment which affects our business in any jurisdiction where we develop product candidates.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If testing of a particular product candidate does not yield successful results, then we will be unable to commercialize that product candidate.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We must demonstrate our product candidates&#8217; safety and efficacy in humans through extensive clinical testing. Our research and development programs are at an early stage of development. We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of any products, including the following:&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">decreased demand for our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impairment of our business reputation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial participants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs of related litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">substantial monetary awards to patients or other claimants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loss of revenues; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to commercialize our product candidates.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:0px;text-align:left;padding-left:102px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we currently have product liability insurance coverage for our clinical trials for expenses or losses, our insurance coverage is limited to $10 million per occurrence, and $10 million in the aggregate, and may not reimburse us or may not be sufficient to reimburse us for any or all expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug candidates and affect the prices we may obtain.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our drug candidates, restrict or regulate post approval activities and affect our ability to profitably sell any products for which we obtain marketing approval.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or collectively the Affordable Care Act, was enacted to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Although it is too early to determine the effect of the Affordable Care Act, the new law appears likely to continue the downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, the recently enacted Drug Supply Chain Security Act imposes new obligations on manufacturers of pharmaceutical products related to product and tracking and tracing. Legislative and regulatory proposals have been made to expand post approval requirements and restrict sales and promotional activities for pharmaceutical products. We are not sure whether additional legislative changes will be enacted, or whether the current regulations, guidance or interpretations will be changed, or what the impact of such changes on our business, if any, may be.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Coverage and adequate reimbursement may not be available for our drug candidates, which could make it difficult for us to sell our products profitably</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market acceptance and sales of any drug candidates that we develop, will depend in part on the extent to which reimbursement for these products and related treatments will be available from third party payors, including government health administration authorities and private health insurers. Third party payors decide which drugs they will pay for and establish reimbursement levels. Third party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for each of our drug candidates will be made on a plan by plan basis. One payors determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement, for the product. </font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, a third party payors decision to provide coverage for a drug does not imply that an adequate reimbursement rate will be approved. Each plan determines whether or not it will provide coverage for a drug, what amount it will pay the manufacturer for the drug, and on what tier of its formulary the drug will be placed. The position of a drug on a formulary generally determines the copayment that a patient will need to make to obtain the drug and can strongly influence the adoption of a drug by patients and physicians. Patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products.&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize any drug candidates that we develop.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, there have been a number of legislative and regulatory proposals to change the healthcare system in the United States and in some foreign jurisdictions that could affect our ability to sell any future drugs profitably. These legislative and regulatory changes may negatively impact the reimbursement for any future drugs, following approval.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Patents, Licenses and Trade Secrets</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other companies or organizations may assert patent rights that prevent us from developing or commercializing our products.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RNA interference is a relatively new scientific field that has generated many different patent applications from organizations and individuals seeking to obtain patents in the field. These applications claim many different methods, compositions and processes relating to the discovery, development and commercialization of RNAi therapeutic products. Because the field is so new, very few of these patent applications have been fully processed by government patent offices around the world, and there is a great deal of uncertainty about which patents will be issued, when, to whom, and with what claims. It is likely that there could be litigation and other proceedings, such as interference and opposition proceedings in various patent offices, relating to patent rights in RNAi.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, there are many issued and pending patents that claim aspects of RNAi trigger chemistry technology that we may need to apply to our product candidates. There are also many issued patents that claim genes or portions of genes that may be relevant for RNAi trigger drug products we wish to develop. Thus, it is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we will not be able to market products or perform research and development or other activities covered by these patents.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our patents and patent applications may be challenged and may be found to be invalid, which could adversely affect our business.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain Canadian, U.S. and international patents and patent applications we own involve complex legal and factual questions for which important legal principles are largely unresolved. For example, no consistent policy has emerged for the breadth of biotechnology patent claims that are granted by the U.S. Patent and Trademark Office or enforced by the U.S. federal courts. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued. Also, we face the following intellectual property risks:&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">some or all patent applications may not result in the issuance of a patent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patents issued may not provide the holder with any competitive advantages;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patents could be challenged by third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the patents of others, including Alnylam, could impede our ability to do business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competitors may find ways to design around our patents; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competitors could independently develop products which duplicate our products.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:0px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A number of industry competitors and institutions have developed technologies, filed patent applications or received patents on various technologies that may be related to or affect our business. Some of these technologies, applications or patents may conflict with our technologies or patent applications. Such conflict could limit the scope of the patents, if any, that we may be able to obtain or result in the denial of our patent applications. In addition, if patents that cover our activities are issued to other companies, there can be no assurance that we would be able to obtain licenses to these patents at a reasonable cost or be able to develop or obtain alternative technology. If we do not obtain such licenses, we could encounter delays in the introduction of products, or could find that the development, manufacture or sale of products requiring such licenses is prohibited. In addition, we could incur substantial costs in defending patent infringement suits brought against us or in filing suits against others to have such patents declared invalid. As publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain we or any licensor was the first creator of inventions covered by pending patent applications or that we or such licensor was the first to file patent applications for such inventions. Any future proceedings could result in substantial costs, even if the eventual outcomes are favorable. There can be no assurance that our patents, if issued, will be held valid or enforceable by a court or that a competitor&#8217;s technology or product would be found to infringe such patents.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our business depends, in part, on our ability to use RNAi technology that we have licensed or will in the future license from third parties, including Alnylam, and, if these licenses were terminated or if we were unable to license additional technology we may need in the future, our business will be adversely affected.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently hold licenses for certain technologies that are or may be applicable to our current and subsequent product candidates. These include a license to patents held or applied for by Alnylam and a license to UNA technology from Arcturus Therapeutics. The licenses are subject to termination in the event of a breach by us of the license, if we fail to cure the breach following notice and the passage of a cure period. The UBC license, which is sublicensed to Alnylam, is subject to termination with respect to one or more particular patents if we and Alnylam were to cease patent prosecution or maintenance activities with respect to such patent(s), or in the event of a breach by us of the license, if we fail to cure the breach following notice and the passage of a cure period. There can be no assurance that these licenses will not be terminated. We may need to acquire additional licenses in the future to technologies developed by others, including Alnylam. For example, Alnylam has granted us a worldwide license for the discovery, development and commercialization of RNAi products directed to thirteen gene targets (three exclusive and ten non-exclusive licenses). Licenses for the five non-exclusive targets and one exclusive target have already been granted. We have rights to select the gene targets for up to two more exclusive licenses and five more nonexclusive licenses from Alnylam, which would be made available to us only if they have not been previously selected by Alnylam or one of its other partners. This will limit the targets available for selection by us, and we may never be able to select gene targets or may be required to make our selection from gene targets that have minimal commercial potential. Furthermore, future license agreements may require us to make substantial milestone payments. We will also be obligated to make royalty payments on the sales, if any, of products resulting from licensed RNAi technology. For some of our licensed RNAi technology, we are responsible for the costs of filing and prosecuting patent applications. The termination of a license or the inability to license future technologies on acceptable terms may adversely affect our ability to develop or sell our products.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our business depends, in part, on our ability to use the technology that we have licensed or will in the future license from third parties, including Blumberg, and Cytos, and, if these licenses were terminated or if we were unable to license additional technology we may need in the future, our business will be adversely affected.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have licensed certain of our intellectual property from Blumberg and Cytos. Our current technology licenses are critical to our business and we expect to enter into additional licenses in the future.&#160;&#160;If we fail to comply with our obligations under these agreements or any future license agreements, we are subject to a bankruptcy, or if we grant a sublicense in the future and our sublicense does not comply with our obligations under these agreements or becomes subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to develop or market products covered by the license or may face other penalties under the agreements, which would have a materially adverse effect on our business. In addition, applicable laws involving bankruptcy or similar proceeding by licensors in some jurisdictions outside the United States may provide the trustee or receiver in such proceeding with the right to set aside or otherwise terminate or seek to modify the license. Any termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or amended agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property and technologies that form the basis of our technology, which may then be in licensed by one or more of our competitors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights which could have a material adverse effect on our business, financial condition and results of operations and could cause the market value of our Common Shares to decline.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There has been significant litigation in the biotechnology industry over contractual obligations, patents and other proprietary rights, and we may become involved in various types of litigation that arise from time to time. Involvement in litigation could consume a substantial portion of our resources, regardless of the outcome of the litigation. Counterparties in litigation may be better able to sustain the costs of litigation because they have substantially greater resources. If claims against us are successful, in addition to any potential liability for damages, we could be required to obtain a license, grant cross-licenses, and pay substantial milestones or royalties in order to continue to develop, manufacture or market the affected products. Involvement and continuation of involvement in litigation may result in significant and unsustainable expense, and divert management&#8217;s attention from ongoing business concerns and interfere with our normal operations. Litigation is also inherently uncertain with respect to the time and expenses associated therewith, and involves risks and uncertainties in the litigation process itself, such as discovery of new evidence or acceptance of unanticipated or novel legal theories, changes in interpretation of the law due to decisions in other cases, the inherent difficulty in predicting the decisions of judges and juries and the possibility of appeals. Ultimately we could be prevented from commercializing a product or be forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property rights and the costs associated with litigation, which could have a material adverse effect on our business, financial condition, and operating results and could cause the market value of our Common Shares to decline.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Confidentiality agreements with employees and others, including collaborators, may not adequately prevent disclosure of trade secrets and other proprietary information.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Much of our know-how and technology may constitute trade secrets. There can be no assurance, however, that we will be able to meaningfully protect our trade secrets. In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, vendors, consultants, outside scientific collaborators and sponsored researchers, and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover trade secrets and proprietary information, and in such cases we could not assert any trade secret rights against such party. Costly and time consuming litigation could continue to be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We have licensed critical portions of our intellectual property from Blumberg and Drexel, and are subject to significant obligations under those license agreements.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rights we hold under our license agreements with Blumberg and Drexel are are important to our business. Our discovery and development platform is built, in part, around patents exclusively in licensed from these parties. For example, the elimination of cccDNA is the most critical element in our combination strategy to cure HBV, and the cccDNA formation inhibitor program is in licensed from Blumberg and Drexel.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have licenses with Blumberg and Drexel, both directly and through its acquisition of Enantigen, that grant us the exclusive (except in some cases as to know how that is not unique or specific to the licensed products or compound series, which are non-exclusive and subject to retained rights for non-commercial research use), worldwide license to make, have made, use, import, offer for sale and sell products incorporating one or more licensed compounds, which include cccDNA inhibitors, capsid assembly inhibitors, inhibitors of secretion of HBV antigens and hepatocellular carcinoma inhibitors, either for general use in humans or for use in the field of HBV research, diagnosis and treatment. Our license with Cytos grants us the exclusive, worldwide, sub licensable (subject to certain restrictions with respect to licensed viral infections other than hepatitis) license, under patents and know-how controlled by Cytos, to research, develop, manufacture and commercialize, for the diagnosis, treatment or prevention of hepatitis viruses in humans, licensed products that incorporate Q beta-derived virus-like particles that are filled with TLR9, TLR7 or RIG-I agonists.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under our agreements with Blumberg, Drexel and Cytos, we are subject to significant obligations, including diligence obligations with respect to development and commercialization activities, payment obligations upon achievement of certain milestones and royalties on product sales, as well as other material obligations. Under our direct agreement with Blumberg and Drexel, we agreed to pay up to $3.5 million in development and regulatory milestones per licensed compound series, up to $92.5 million in sales performance milestones per licensed product, and royalties in the mid-single digits in connection with the sale of licensed products. Under each of the three license agreements that our subsidiary, Enantigen, has with Blumberg and Drexel, we are obligated to pay up to $500,000 in development and regulatory milestones per licensed product and royalties in the low single digits in connection with the sale of licensed products. Under our agreement with Cytos, we agreed to pay up to $67 million upon the achievement of specified development and regulatory milestones for hepatitis and each additional licensed viral infection, in each case for each of the six licensed compound series, up to $110 million upon the achievement of specified sales performance milestones, and tiered royalty payments at a royalty rate in the high-single to low double digits, based upon net sales of licensed products. If these payments become due under the terms of the agreements, we may be negatively affected.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If there is any conflict, dispute, disagreement or issue of non-performance between us and Blumberg, Drexel, or Cytos regarding our rights or obligations under these license agreements, including any conflict, dispute or disagreement arising from our failure to satisfy diligence or payment obligations under such agreements, Blumberg and Drexel or Cytos, as applicable, may have a right to terminate the license. The loss of any of these license agreements could materially and adversely affect our ability to use intellectual property that is critical to our drug discovery and development efforts, as well as its ability to enter into future collaboration, licensing and/or marketing agreements for one or more affected drug candidates or development programs.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Some of our licensors have retained rights to develop and commercialize certain of our drug candidates to treat diseases other than HBV and, as a result, our development and commercialization efforts may be negatively affected.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our license agreements provide us with the rights to develop and commercialize our drug candidates for HBV; however, some of our licensors have retained rights to develop and commercialize certain of its drug candidates to treat diseases other than HBV, and to license those rights to other third parties. For example, Cytos has retained all rights with respect to development of the licensed products for influenza, all non-viral infections and certain viral infections other than hepatitis.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we obtain regulatory approval for our TLR9 agonist for HBV and Cytos obtains regulatory approval for a drug candidate that has the same active ingredient as our TLR9 agonist for another indication, and if each is available outside of a combination therapy, physicians may prescribe the Cytos drug, instead of our drug, to patients with HBV if, for example, the cost of the Cytos drug is less than our drug. In this case, we would not be receiving any payments on the account of such sales and our revenue would be adversely affected.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Competition</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The pharmaceutical market is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we may be unable to successfully commercialize any product candidates that we develop.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical market is intensely competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to target. Many of our competitors have:&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">much greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization process;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">more extensive experience in pre-clinical testing, conducting clinical trials, obtaining regulatory approvals, and in manufacturing, marketing and selling pharmaceutical products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product candidates that are based on previously tested or accepted technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">products that have been approved or are in late stages of development; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborative arrangements in our target markets with leading companies and research institutions.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We will face intense competition from products that have already been approved and accepted by the medical community for the treatment of the conditions for which we are currently developing products. We also expect to face competition from new products that enter the market. We believe a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop products. These products, or other of our competitors&#8217; products, may be more effective, safer, less expensive or marketed and sold more effectively, than any products we develop.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are aware of several companies that are working to develop drugs that would compete against our drug candidates for HBV treatment. As a significant unmet medical need exists for HBV, there are several large and small pharmaceutical companies focused on delivering therapeutics for treatment of HBV. Further, it is likely that additional drugs will become available in the future for the treatment of HBV. We will face competition from other drugs currently approved or that will be approved in the future for the treatment of chronic hepatitis B.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We anticipate significant competition in the HBV market with several early phase product candidates announced. We will also face competition for other product candidates that we expect to develop in the future.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we successfully develop product candidates, and obtain approval for them, we will face competition based on many different factors, including the following:&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">safety and effectiveness of our products</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ease with which our products can be administered and the extent to which patients and physicians accept new routes of administration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">timing and scope of regulatory approvals for these products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">availability and cost of manufacturing, marketing and sales capabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reimbursement coverage; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patent position.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our competitors may develop or commercialize products with significant advantages over any products we develop based on any of the factors listed above or on other factors. Our competitors may therefore be more successful in commercializing their products than we are which could adversely affect our competitive position and business. Competitive products may make any products we develop obsolete or uncompetitive before we can recover the expenses of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and the ability to execute on our business plan. Furthermore, we also face competition from existing and new treatment methods that reduce or eliminate the need for drugs, such as the use of advanced medical devices. The development of new medical devices or other treatment methods for the diseases we are targeting and may target could make our product candidates non-competitive, obsolete or uneconomical.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We face competition from other companies that are working to develop novel products using technology similar to ours. If these companies develop products more rapidly than we do or their technologies, including delivery technologies, are more effective than ours, then our ability to successfully commercialize products will be adversely affected.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We face significant competition from other biotechnology and pharmaceutical companies targeting HBV.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a significant unmet medical need exists for HBV, there are several large and small pharmaceutical companies focused on delivering therapeutics for treatment of HBV. These companies include Johnson and Johnson, Gilead Sciences, Roche Holding AG, Arrowhead Research, GlaxoSmithKline/Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Assembly Biosciences, Bristol-Myers Squibb, Spring Bank Pharmaceuticals, Replicor, and ContraVir Pharmaceuticals. Further, it is likely that additional drugs will become available in the future for the treatment of HBV.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are aware of several companies that are working to develop drugs that would compete against our drug candidates for HBV treatment. Many of our existing or potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of drug candidates, as well as in obtaining regulatory approvals of those drug candidates in the United States and in foreign countries. Our current and potential future competitors also have significantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a small number of our competitors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, drug candidates that are more effective or less costly than any drug candidate that we may develop.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will face competition from other drugs currently approved or that will be approved in the future for the treatment of HBV. Therefore, our ability to compete successfully will depend largely on our ability to:&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discover, develop and commercialize drugs that are superior to other products in the market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">demonstrate through our clinical trials that our drug candidates are differentiated from existing and future therapies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">attract qualified scientific, product development and commercial personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtain patent or other proprietary protection for our drugs and technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtain required regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new drugs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">negotiate competitive pricing and reimbursement with third party payors.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any drug candidate we develop. The inability to compete with existing or subsequently introduced drug candidates would have a material adverse impact on our business, financial condition and prospects.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to in license novel compounds that could make our drug candidates less competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing or receiving FDA approval for or commercializing medicines before we do, which would have a material adverse impact on our business.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to the Ownership of our Common Shares</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If our stock price fluctuates, our investors could incur substantial losses.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The market price of our Common Shares may fluctuate significantly in response to factors that are beyond our control. The stock market in general has recently experienced extreme price and volume fluctuations. The market prices of securities of pharmaceutical and biotechnology companies have been extremely volatile, and have experienced fluctuations that often have been unrelated or disproportionate to the operating performance of these companies. These broad market fluctuations could result in extreme fluctuations in the price of our Common Shares, which could cause our investors to incur substantial losses.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">There is no assurance that an active trading market in our Common Shares will be sustained.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Common Shares are listed for trading on the NASDAQ exchange. However, there can be no assurances that an active trading market in our Common Shares on these stock exchanges will be sustained.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We are incorporated in Canada and the majority of our assets, and some of our officers reside outside the United States, with the result that it may be difficult for investors to enforce any judgments obtained against us or some of our officers.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus, and some of its subsidiaries, are incorporated under the laws of the Province of British Columbia and the majority of Arbutus' assets are located outside the United States. While we have appointed National Registered Agents, Inc. as our agent for service of process to effect service of process within the United States upon us, it may not be possible for you to enforce against us or those persons in the United States, judgments obtained in U.S. courts based upon the civil liability provisions of the U.S. federal securities laws or other laws of the United States. In addition, there is doubt as to whether original action could be brought in Canada against us or our directors or officers based solely upon U.S. federal or state securities laws and as to the enforceability in Canadian courts of judgments of U.S. courts obtained in actions based upon the civil liability provisions of U.S. federal or state securities laws.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If we are deemed to be a &#8220;passive foreign investment company&#8221; for the current or any future taxable year, investors who are subject to United States federal taxation would likely suffer materially adverse U.S. federal income tax consequences.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generally will be a &#8220;passive foreign investment company&#8221; under the meaning of Section 1297 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), (a &#8220;PFIC&#8221;) if (a) 75% or more of our gross income is &#8220;passive income&#8221; (generally, dividends, interest, rents, royalties, and gains from the disposition of assets producing passive income) in any taxable year, or (b) if at least 50% or more of the quarterly average value of our assets produce, or are held for the production of, passive income in any taxable year. A shareholder who is a U.S. person (as such term is defined under applicable U.S. legislation) should be aware that we believe that we were a PFIC during one or more prior taxable years.&#160; We have not yet made a determination as to whether we were a PFIC in respect of our taxable year ended December 31, 2015.&#160; If we are a PFIC for any taxable year during which a U.S. person holds our Common Shares, it would likely result in materially adverse U.S. federal income tax consequences for such U.S. person, including, but not limited to, any gain from the sale of our Common Shares would be taxed as ordinary income, as opposed to capital gain, and such gain and certain distributions on our Common Shares would be subject to an interest charge, except in certain circumstances. It may be possible for U.S. persons to fully or partially mitigate such tax consequences by making a &#8220;qualifying electing fund election,&#8221; as defined in the Code (a &#8220;QEF Election&#8221;), but there is no assurance that we will provide such persons with the information that we are required to provide to them in order to assist them in making a QEF Election.&#160; In addition, U.S. persons that hold Common Shares issuable upon exercise of warrants are generally not eligible to make certain elections available under the Code that are intended to mitigate the adverse tax consequences of PFIC rules with respect to such warrant shares unless such holders also elect to make a deemed taxable sale of their warrant shares. The PFIC rules are extremely complex.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our articles and certain Canadian laws could delay or deter a change of control.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our preferred shares are available for issuance from time to time at the discretion of our board of directors, without shareholder approval. Our articles allow our board, without shareholder approval, to determine the special rights to be attached to our preferred shares, and such rights may be superior to those of our Common Shares.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, limitations on the ability to acquire and hold our Common Shares may be imposed by the Competition Act in Canada. This legislation permits the Commissioner of Competition of Canada to review any acquisition of a significant interest in us. This legislation grants the Commissioner jurisdiction to challenge such an acquisition before the Canadian Competition Tribunal if the Commissioner believes that it would, or would be likely to, result in a substantial lessening or prevention of competition in any market in Canada. The Investment Canada Act subjects an acquisition of control of a company by a non-Canadian to government review if the value of our assets, as calculated pursuant to the legislation, exceeds a threshold amount. A reviewable acquisition may not proceed unless the relevant minister is satisfied that the investment is likely to result in a net benefit to Canada. Any of the foregoing could prevent or delay a change of control and may deprive or limit strategic opportunities for our shareholders to sell their shares.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The exercise of all or any number of outstanding stock options, the award of any additional options, bonus shares or other stock-based awards or any issuance of shares to raise funds or acquire a business may dilute your Common Shares.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have in the past and may in the future grant to some or all of our directors, officers and employees options to purchase our Common Shares and other stock-based awards as non-cash incentives to those persons. The issuance of any equity securities could, and the issuance of any additional shares will, cause our existing shareholders to experience dilution of their ownership interests.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any additional issuance of shares or a decision to acquire other businesses through the sale of equity securities may dilute our investors&#8217; interests, and investors may suffer dilution in their net book value per share depending on the price at which such securities are sold. Such issuance may cause a reduction in the proportionate ownership and voting power of all other shareholders. The dilution may result in a decline in the price of our Common Shares or a change in control.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">We do not expect to pay dividends for the foreseeable future.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not paid any cash dividends to date and we do not intend to declare dividends for the foreseeable future, as we anticipate that we will reinvest future earnings, if any, in the development and growth of our business. Therefore, investors will not receive any funds unless they sell their Common Shares, and shareholders may be unable to sell their shares on favorable terms or at all. We cannot assure you of a positive return on investment or that you will not lose the entire amount of your investment in our Common Shares. Prospective investors seeking or needing dividend income or liquidity should not purchase our Common Shares.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The value of our securities, including our Common Shares, might be affected by matters not related to our operating performance and could subject us to securities litigation.</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The value of our Common Shares may be reduced for a number of reasons, many of which are outside our control, including:&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">general economic and political conditions in Canada, the United States and globally;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">governmental regulation of the health care and pharmaceutical industries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to achieve desired drug discovery outcomes by us or our collaborators;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to obtain industry partner and other third party consents and approvals, when required;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">stock market volatility and market valuations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competition for, among other things, capital, drug targets and skilled personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the need to obtain required approvals from regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">revenue and operating results failing to meet expectations in any particular period;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">investor perception of the health care and pharmaceutical industries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limited trading volume of our Common Shares;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">announcements relating to our business or the businesses of our competitors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability or inability to raise additional funds.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The concentration of the common shares ownership with insiders will likely limit the ability of the other shareholders to influence corporate matters.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of February 29, 2016, executive officers, directors, five percent or greater shareholders, and their respective affiliated entities of the Arbutus beneficially own, in the aggregate, approximately 38% of Arbutus' outstanding common shares. As a result, these shareholders, acting together, have significant influence over most matters that require approval by Arbutus' shareholders, including the election of directors and approval of significant corporate transactions. Corporate actions might be taken even if other shareholders oppose them. This concentration of ownership might also have the effect of delaying or preventing a corporate transaction that other shareholders may view as beneficial.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">If securities analysts do not publish research or reports about the business of Arbutus, or if they publish negative evaluations, the price of Arbutus' Common Shares could decline.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trading market for the Arbutus Common Shares may be impacted by the availability or lack of research and reports that third-party industry or financial analysts publish about Arbutus. There are many large, publicly traded companies active in the biopharmaceutical industry, which may mean it will be less likely that Arbutus receives widespread analyst coverage. Furthermore, if one or more of the analysts who do cover Arbutus downgrade its stock, its stock price would likely decline. If Arbutus does not receive adequate coverage by reputable analysts that have an understanding of Arbutus' business and industry, it could fail to achieve visibility in the market, which in turn could cause its stock price to decline.</font></div><a name="s4BB9C3DE42837193677DEF63710E5087"></a><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1B.       Unresolved Staff Comments</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no unresolved staff comments at the moment.</font></div><a name="s3E6481859B9199A875FFEF637132E5FD"></a><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.       Properties</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our head office and principal place of business is located at 100-8900 Glenlyon Parkway, Burnaby, British Columbia, Canada, V5J 5J8. The Company leases a 51,000 square foot facility.&#160;On June 23, 2014, we signed a renewal agreement to the operating lease for its laboratory and office premises. The renewal is effective August 1, 2014 and expires July 31, 2019, but we have the option to extend the lease to 2024, 2029, and 2034. We believe that the total space available to us under our current lease will meet our needs for the foreseeable future and that additional space would be available to us on commercially reasonable terms if required.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our U.S. Office is located at 3805 Old Easton Road, Doylestown, PA 18902, in an approximately 2,600 square feet of leased office space.</font></div><a name="s5DEC9E881BEE8F2D5B84EF63716490EE"></a><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3.       Legal Proceedings</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are involved with various legal matters arising in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. Although the ultimate resolution of these various matters cannot be determined at this time, we do not believe that such matters, individually or in the aggregate, will have a material adverse effect on our consolidated results of operations, cash flows, or financial condition.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Alnylam Pharmaceuticals Inc. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 21, 2013, we transferred manufacturing process technology to Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. (&#8220;Ascletis&#8221;) to enable them to produce ALN-VSP, a product candidate licensed to them by Alnylam Pharmaceuticals Inc., or Alnylam. We believed that under a licensing agreement with Alnylam, the technology transfer to Ascletis triggered a $5 million&#160;milestone obligation from Alnylam to Arbutus. However, Alnylam demanded a declaration that we had not yet met our milestone obligations. We disputed Alnylam&#8217;s position. To remedy this dispute, the parties commenced arbitration proceedings, as provided for under the agreement.&#160; In addition to seeking a declaration that we had met our obligations under the agreement, we have also stated a claim for breach of contract, breach of the implied covenant of good faith and fair dealing, and fraud.&#160; The arbitration proceeding with Alnylam has concluded resulting in no milestone payment to Arbutus.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">University of British Columbia</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain early work on lipid nanoparticle delivery systems and related inventions was undertaken at the University of British Columbia (UBC). These inventions are licensed to us by UBC under a license agreement, initially entered in 1998 as amended in 2001, 2006 and 2007. We have granted sublicenses under the UBC license to Alnylam as well as to Talon.&#160;&#160;Alnylam has in turn sublicensed back to us under the licensed UBC patents for discovery, development and commercialization of RNAi products. In mid-2009, we and our subsidiary Protiva entered into a supplemental agreement with UBC, Alnylam and Acuitas Technologies, Inc., in relation to a separate research collaboration to be conducted among UBC, Alnylam and Acuitas to which we have license rights. The settlement agreement signed in late 2012 to resolve the litigation among Alnylam, Acuitas, Arbutus and Protiva provided for the effective termination of all obligations under such supplemental agreement as between and among all litigants.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 10, 2014, the University of British Columbia filed a demand for arbitration against us, BCICAC File No.: DCA-1623.&#160; We received UBC&#8217;s Statement of Claims on January 16, 2015.&#160; In its Statement of Claims, UBC alleges that it is entitled to $3.5 million in allegedly unpaid royalties based on publicly available information, and an unspecified amount based on non-public information.&#160; UBC also seeks interest and costs, including legal fees. We dispute UBC&#8217;s allegation.&#160; No dates have been scheduled for this arbitration.</font></div><a name="s78F46A8071C6B2548E84EF6371836E10"></a><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4.        Mine Safety Disclosures</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><a name="s6F8FA6846179EDA16B27EF6371B582FC"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><a name="s26D1DD6595EA2C0547E9EF636910600F"></a><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5.        Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common shares trade on the NASDAQ Global Market under the symbol "ABUS" following our Company name change to Arbutus Biopharma Corporation on July 31, 2015. Since November&#160;15, 2010, our common shares traded on the NASDAQ Global Market under the symbol &#8220;TKMR&#8221;. Our common shares previously traded on the Toronto Stock Exchange (TSX) in Canada under the symbol &#8220;TKM&#8221;, but were voluntarily delisted from as of March 3, 2015. As at February 29, 2016, there were </font><font style="font-family:inherit;font-size:10pt;">130</font><font style="font-family:inherit;font-size:10pt;">&#32;registered holders of common shares and </font><font style="font-family:inherit;font-size:10pt;">54,625,703</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares issued and outstanding. The following table shows the progression in the high and low trading prices of our common shares on the NASDAQ Global Market and the TSX for the periods listed:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NASDAQ</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">High</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(US$)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NASDAQ</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Low</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(US$)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TSX</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">High</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(C$)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">TSX</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Low</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(C$)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Year Ended:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.73</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.76</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Quarter Ended:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.46</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.75</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2015</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.73</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.76</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 30, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.56</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.55</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.66</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Month Ended:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 29, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;N/A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common shares were voluntarily delisted from the Toronto Stock Exchange (TSX) as of the close of business on Tuesday, March 3, 2015. High and low trading prices above are for the period January 1, 2015 to March 2, 2015.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:0px;text-align:justify;padding-left:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Material Modifications to the Rights of Security Holders/Use of Proceeds</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Purchase of Equity Securities by the Issuer and Affiliated Purchasers</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Sales of Unregistered Securities</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Performance Graph</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following performance graph and related information shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933 or Securities Exchange Act of 1934, each as amended, except to the extent that we specifically incorporate it by reference into such filing</font><font style="font-family:inherit;font-size:10pt;">.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following graph compares the cumulative shareholder return on an investment of US$100 in the Common Shares of the Company on the NASDAQ from December 31, 2010, with a cumulative total shareholder return on the NASDAQ Composite and NASDAQ Biotechnology Indices.</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;"><img src="arbutus10k2_chart-35315.jpg" style="height:480px;width:613px;"></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Geographic Breakdown of Shareholders</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;As of February 29, 2016, our shareholder register indicates that our common shares are held as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td width="59%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Location</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Percentage of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Registered</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Record</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canada</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,009,721</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,601,758</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,014,224</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,625,703</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our securities are recorded in registered form on the books of our transfer agent, CST Trust Company, located at 1600-1066 West Hastings Street, Vancouver, BC V6E 3X1. However, the majority of such shares are registered in the name of intermediaries such as brokerage houses and clearing houses (on behalf of their respective brokerage clients). We are permitted, upon request to our transfer agent, to obtain a list of our beneficial shareholders who do not object to their identities being disclosed to us. We are not permitted to obtain from our transfer agent a list of our shareholders who have objected to their identities being disclosed to us.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Shares registered in intermediaries were assumed to be held by residents of the same country in which the clearing house was located.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dividends</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not declared or paid any dividends on our common shares since the date of our incorporation.&#160;&#160;We intend to retain our earnings, if any, to finance the growth and development of our business and do not expect to pay dividends or to make any other distributions in the near future.&#160;&#160;Our board of directors will review this policy from time to time having regard to our financing requirements, financial condition and other factors considered to be relevant.</font></div><a name="s792B953B9C9006A6DF00EF6372079B93"></a><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6.        Selected Consolidated Financial Data</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents selected financial data derived from Arbutus' audited consolidated financial statements for each of the five years for the period ending December&#160;31, 2015. You should read this information in conjunction with our financial statements for the periods presented, as well as Item&#160;1 &#8220; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8221; and Item&#160;7 &#8220; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8221; included elsewhere in this Annual Report.&#160;&#160;Historical results are not necessarily indicative of future results.</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary Financial Information</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Under U.S. GAAP (in thousands of US dollars, except per share amounts)</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td width="36%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2011</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Data</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,873</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,953</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,465</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,105</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,812</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(102,322</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,434</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,152</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,945</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,694</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77,306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares&#8212;basic </font><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,462</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,603</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,303</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,728</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,319</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares&#8212;diluted </font><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) per common share&#8212;basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.92</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.89</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) per common share&#8212;diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Data</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">712,291</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,178</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,716</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,595</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,758</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164,612</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,531</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">864,446</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">316,212</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,045</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206,572</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,965</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of shares outstanding </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,570,691</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,438,169</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,049,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,305,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,149,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><a name="s428B57725AAE04F2308EEF63722C2025"></a><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.          Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in Functional Currency</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to January 1, 2016, our functional currency was the Canadian dollar. As such, all dollar amounts in this MD&amp;A related to periods prior to and including the year-ended December 31, 2015 are presented in U.S. dollars with the functional currency as the Canadian dollar. On January 1, 2016, our functional currency changed from the Canadian dollar to the U.S. dollar based on our analysis of changes in the primary economic environment in which we operate. The change in functional currency is accounted for prospectively from January 1, 2016 and financial statements prior to and including the year-ended December 31, 2015 will not be restated for the change in functional currency. Past translation gains and losses from the application of the U.S. dollar as the reporting currency while the Canadian dollar was the functional currency are included as part of cumulative currency translation adjustment, which is reported as a component of shareholder's equity under accumulated other comprehensive loss.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OVERVIEW</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus is a publicly traded industry-leading therapeutic solutions company focused on discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B Virus (HBV) infection, which leads to serious liver disease. &#160;Our pipeline is focused on finding a cure for chronic HBV infection. This HBV pipeline consists of multiple drug candidates, with complementary mechanisms of action, which we expect to use in combination to effect patient benefit.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HBV represents a significant unmet medical need and is the cause of the most common serious liver infection in the world. The World Health Organization estimates that 350 million people worldwide are chronically infected, and other estimates suggest this could include approximately 2 million people in the United States (Kowdley </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">et al.,</font><font style="font-family:inherit;font-size:10pt;">&#32;2012). Individuals chronically infected with HBV are at an increased risk of developing significant liver disease, including cirrhosis, or permanent scarring of the liver, as well as liver failure and hepatocellular carcinoma (HCC) or liver cancer. According to the Hepatitis B Foundation, HBV is the cause of up to 80% of liver cancers. Individuals with liver cancer typically have a five-year survival rate of only 15%. The WHO estimates that more than 780,000 people die every year due to the consequences of hepatitis B virus disease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Given the complex biology of HBV, we believe combination therapies are the key to HBV treatment and a potential cure, and development can be accelerated when multiple components of a combination therapy regimen are controlled by the same company.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">HBV Focused Product Pipeline</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a pipeline focused on finding a cure for chronic HBV infection, with the objective of developing a combination of products that intervene at different points in the viral life cycle. Given our strong scientific and research capabilities in-house, we are able to conduct preclinical combination studies to evaluate combinations of our proprietary pipeline candidates. Once compounds within the portfolio with sufficient activity have been identified, we intend, subject to discussions with regulatory authorities, to evaluate combinations of two or more drug candidates in cohorts of patients with chronic HBV infection. We expect to use these results to adaptively design additional treatment regimens for the next cohorts. We also plan to evaluate different treatment durations to determine the optimal finite duration of therapy. We plan to continue this iterative process until we select combination therapy regimens and treatment durations to conduct Phase III clinical trials intended to ultimately support regulatory filings for marketing approval.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to continue to expand our HBV pipeline through internal development, acquisitions and in-licenses. We also have a research collaboration agreement with The Baruch S.&#160;Blumberg Institute that provides exclusive rights to in-license any intellectual property generated through the collaboration. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">RNAi (ARB-1467 &amp; ARB-1740)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The development of RNAi drugs allows for a completely novel approach to treating disease, which&#160;is why RNAi is considered one of the most promising and rapidly advancing frontiers in drug discovery. While there are no RNAi therapeutics approved for commercial use, there are a number of RNAi products currently in human clinical trials. RNAi products are broadly applicable as they can eliminate the production of disease-causing proteins from cells, creating opportunities for therapeutic intervention that have not been achievable with conventional drugs. Our extensive experience in antiviral drug development has been applied to our RNAi program to develop therapeutics for chronic hepatitis B infection. Small molecule nucleotide therapy has been the standard of care for chronic HBV infected patients. However, many of these patients continue to express a viral protein called HBV surface antigen (HBsAg). This protein causes inflammation in the liver leading to cirrhosis and, in some cases, HCC and death.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our lead RNAi HBV candidate, ARB-1467 (formerly TKM-HBV), is designed to eliminate HBsAg expression in patients chronically infected with HBV. Reducing HBsAg is thought to be a key prerequisite to enable a patient&#8217;s immune system to raise an adequate immune response against the virus. The ability of ARB-1467 to inhibit numerous viral elements in addition to HBsAg increases the likelihood of affecting the viral infection. ARB-1467 is being developed as a multi-component RNAi therapeutic that simultaneously targets three sites on the HBV genome, including the HBsAg coding region. Targeting three distinct and highly conserved sites on the HBV genome is intended to facilitate potent knockdown of all viral mRNA transcripts and viral antigens across a broad range of HBV genotypes and reduce the risk of developing antiviral resistance.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARB-1467 results in potent and rapid reduction in HBsAg in several preclinical models. In these models, ARB-1467 treatment resulted in reductions in both intrahepatic and serum HBsAg, as well as reductions in HBV DNA, cccDNA, Hepatitis B e antigen (HBeAg) and HBcAg (Hepatitis B c antigen). A rapid 1 log reduction in serum HBsAg was achieved with a single 1 mg/kg dose of ARB-1467 in the humanized mouse model. 1-2 log viral reductions from similar single-dose LNP treatments in two other true-infection animal models were also demonstrated. Preclinical studies conducted on infected primary human hepatocytes showed that ARB-1467 had robust and consistent activity against different viral strains representing the major clinical genotypes A, B, C and D. Our data shows that inclusion of three RNAi triggers results in a more broadly effective knockdown of hepatitis B viral elements than a single trigger alone. The mode of action of ARB-1467 complements standard of care nucleoside/nucleotide (NUC) therapy, and lack of drug antagonism has been demonstrated with entecavir, lamivudine and tenofovir on infected primary human hepatocytes, making combination therapy a viable option. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ARB-1467 was evaluated in a Phase I Single Ascending Dose trial. The Phase I clinical trial is a randomized, single-blind, placebo-controlled study, involving single ascending doses of ARB-1467 and ARB-1468. The study is assessing the safety, tolerability and pharmacokinetics of intravenous administration of the product in healthy adult subjects. In order to enable maximum dose escalation, steroid premedication was added to the Phase I protocol. No dose limiting toxicities were seen with either formulation through 0.4mg/kg, the highest dose tested in Phase I. At this time, a maximum tolerated dose has not been reached and the protocol has been amended to allow evaluation of higher doses. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Phase II study evaluates two dose levels of ARB-1467 administered as three monthly doses in chronic HBV infected patients who are on stable background nucleot(s)ide analog therapy. Eight subjects will be enrolled in each of the two dose cohorts with six subjects receiving ARB-1467, and two receiving placebo. The ARB-1467 Phase II multi-dosing study has been initiated and single dose and multi-dose HBsAg reduction data are expected in the second half of 2016.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we are focused on development of our lead HBV product candidates, we believe in continuous innovation and will incorporate technological and product design advancements that may result in an improvement in safety and/or efficacy. An example of this is our follow-on RNAi HBV candidate, ARB-1740. ARB-1740 is more potent than ARB-1467 in preclinical studies and has the potential to be effective at lower clinical doses than ARB-1467. ARB-1740 employs the same LNP formulation as ARB-1467 (with a different set of three RNAi triggers). We plan to file an IND (or equivalent filing) for ARB-1740 in the second half of 2016.    </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">cccDNA Formation Inhibitors</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing small molecule cccDNA formation inhibitors. The inhibition of cccDNA formation is expected to reduce the amount of cccDNA in the infected liver by blocking the formation of new cccDNA. We acquired the exclusive, worldwide rights to this program through an in-license from the Blumberg Institute. We have made significant progress with the discovery of potent and small molecule cccDNA formation inhibitors. As presented at the 2015 International Meeting on Molecular Biology of Hepatitis B Viruses in October 2015, our cccDNA formation inhibitors demonstrate synergy with approved nucleot(s)ide analogs in preclinical models, which could lead to faster declines in cccDNA levels in patients than is seen with nucleot(s)ide analogs alone. We plan to file an IND (or equivalent filing) for our lead cccDNA formation inhibitor in the second half of 2016.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Core Protein/ Capsid Assembly Inhibitors</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HBV core protein, or capsid, is required for viral replication and core protein may have additional roles in cccDNA function. Current nucleot(s)side analog therapy significantly reduces serum HBV DNA levels in the serum but significant HBV replication continues in the liver, thereby enabling HBV infection to persist. Effective therapy for patients requires new agents which will effectively block viral replication. We are developing core protein inhibitors (also known as capsid assembly inhibitors) as oral therapeutics for the treatment of chronic HBV infection. By inhibiting assembly of the viral capsid, the ability of hepatitis B virus to replicate is impaired, resulting in reduced cccDNA. We acquired exclusive, worldwide rights to these drug candidates through an in-license from Blumberg and Drexel University, or Drexel, and through Arbutus Inc.&#8217;s acquisition of Enantigen Therapeutics, Inc. (Enantigen). We plan to file an IND (or equivalent filing) for our lead candidate in the second half of 2016.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">TLR9 Agonist (ARB-1598)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Immune stimulation by toll-like receptor (TLR) agonists may overcome the immunologic blocks that allow chronic HBV persistence, including direct activation of the host&#8217;s innate antiviral response. Licensed from Cytos Biotechnology Ltd., (&#8220;Cytos&#8221;), ARB-1598 (formerly CYT003) is a biological carrier which is filled with the immunostimulatory oligonucleotide called G10, a TLR-9 agonist. ARB-1598 has been shown to directly activate B cells and stimulates human plasmacytoid dendritic cells to secrete Interferon alpha, and has previously been utilized in human trials in other indications. ARB-1598 also activates other antigen presenting cells indirectly and promotes the development of TH1 type cytokine response, which is thought to be potentially beneficial in promoting anti-HBV T cell immunity. ARB-1598 is undergoing preclinical evaluation to establish its utility for HBV, and if there is a clear support for this application, we plan to initiate clinical development of ARB-1598 in chronically infected HBV patients in 2016.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Research Programs</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Surface Antigen Secretion Inhibitors</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion. By inhibiting the production and secretion of HBV surface antigen from infected cells, we expect that the immune response of patients treated with this therapy can reengage and thereby mount a more credible response to a hepatitis B virus infection.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">cccDNA Epigenetic Modifiers</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to cccDNA formation inhibitors, we are developing cccDNA epigenetic modifiers. By controlling cccDNA transcription, we anticipate that we may be able to inhibit the formation of new virus and sub viral particles from cccDNA. This development program, which is currently in the discovery research stage, is based on proof of concept data generated by Blumberg using known inhibitors of enzymes involved in DNA information processing.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">STING Agonists</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing stimulator of interferon genes (STING) agonists. By activating interferon genes, we anticipate that the body can produce additional interferon alpha and beta, which have antiviral properties. Our development program, which is currently in the discovery research stage, is based on proof of concept data in mice generated by Blumberg which showed that STING agonists can elicit an antiviral response and inhibit HBV replication in mouse liver cells. In collaboration with Blumberg, our plan is to identify potent, orally active small molecule human STING agonists that possess the desired characteristics to progress into human clinical studies.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cyclophilin Inhibitor (OCB-030)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We licensed from NeuroVive Pharmaceutical AB, or (&#8220;NeuroVive&#8221;), the exclusive rights to develop and commercialize cyclophilin inhibitor drug candidates, including OCB-030, for the treatment of hepatitis B. After extensive preclinical evaluation of OCB-030 and other competitive cyclophilin inhibitors against HBV, we have concluded that cellular cyclophillins do not play a role in HBV chronic infection and further development of OCB-030 is unwarranted. As a result, we made the decision in October 2015 to discontinue the development of OCB-030 and have suspended our interest in the cyclophilin inhibitor class.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Proprietary Delivery Technology</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development of RNAi therapeutic products is currently limited by the instability of the RNAi trigger molecules in the bloodstream and the inability of these molecules to access target cells or tissues following administration. Delivery technology is necessary to protect these drugs in the bloodstream to allow efficient delivery and cellular uptake by the target cells. Arbutus has developed a proprietary delivery platform called Lipid Nanoparticle (LNP). The broad applicability of this platform to RNAi develoment has established Arbutus as a leader in this new area of innovative medicine.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary LNP delivery technology allows for the successful encapsulation of RNAi trigger molecules in LNP administered intravenously, which travel through the bloodstream to target tissues or disease sites. LNPs are designed to protect the triggers, and stay in the circulation long enough to accumulate at disease sites, such as the liver or cancerous tumors. LNPs are then taken up into the target cells by a process called endocytosis. Subsequent activation by the changing environment inside the cell causes the LNP to release the trigger molecules, which can then successfully mediate RNAi.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Ongoing Advancements in LNP Technology</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our LNP technology represents the most widely adopted delivery technology in RNAi, which has enabled several clinical trials and has been administered to hundreds of human subjects. Because LNP can enable a wide variety of nucleic acid triggers, including mRNA, we continue to see new product development and partnering opportunities based on our industry-leading delivery expertise and intellectual property. We presented preclinical data in October 2013 at the International mRNA Health Conference in Tubingen, Germany, and in February 2014 at the AsiaTIDES Conference in Toyko, Japan. This data demonstrated that mRNA encapsulated and delivered using our proprietary LNP technology can be effectively delivered and expressed in the liver in tumors and other specific tissues of therapeutic interest.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus continues to explore opportunities to generate value from its LNP platform technology, which is well suited to deliver therapies based on RNAi, mRNA, gene editing, as well as other technologies.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suspended Non-HBV RNAi Assets</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intent is to focus our efforts on discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. As such, pending completion of ongoing studies associated with TKM-PLK1, we have suspended further development of our non-HBV assets and are exploring different strategic options to maximize the value of these assets. Our non-HBV assets include our LNP-based product candidates TKM-PLK for oncology, TKM-Ebola and TKM-Marburg for hemorrhagic fever viruses, TKM-HTG for metabolic disorders, and TKM-ADLH for severe alcohol use disorder. Additional information on these programs can be found in Part&#160;I, Item&#160;1, &#8220;&#8212;&#160;Business-Suspended Non-HBV RNAi Assets,&#8221; of this annual report on Form&#160;10-K.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Partner Programs</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patisiran (ALN-TTR02)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alnylam has a license to use our IP to develop and commercialize products and may only grant access to our LNP technology to its partners if it is part of a product sublicense. Alnylam&#8217;s license rights are limited to patents that we have filed, or that claim priority to a patent that was filed, before April 15, 2010. Alnylam does not have rights to our patents filed after April 15, 2010 unless they claim priority to a patent filed before that date. Alnylam will pay us low single digit royalties as Alnylam&#8217;s LNP-enabled products are commercialized. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, Alnylam announced initiation of a Phase III open label OLE study with patisiran (APOLLO-OLE) to evaluate the long-term safety and tolerability of patisiran in ATTR amyloidosis patients with FAP who were previously enrolled in the APOLLO Phase III study. In September 2015, Alnylam reported evidence of reduced pathogenic, misfolded TTR monomers and oligomers in TTR-mediated amyloidosis patients with FAP, and in November 2015 it reported that patisiran demonstrates continued evidence for potential halting of neuropathy progression and improvement in nerve fiber density in patients with FAP. New Drug Application filing for this program is expected in 2017. The patisiran program represents the most clinically advanced application of our LNP delivery technology. Furthermore, Alnylam&#8217;s results demonstrate that multi-dosing with our LNP has been well-tolerated with treatments out to 21 months.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marqibo&#174;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marqibo&#174;, originally developed by Arbutus, is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. Marqibo&#8217;s approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. Our licensee, Spectrum Pharmaceuticals, Inc. (Spectrum), launched Marqibo through its existing hematology sales force in the United States. We are entitled to mid-single digit royalty payments based on Marqibo&#8217;s commercial sales. Spectrum has ongoing trials evaluating Marqibo in three additional indications, which are: first line use in patients with Philadelphia Negative Acute Lymphoblastic Leukemia (Ph-ALL), Pediatric ALL and Non-Hodgkin&#8217;s lymphoma. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">DCR-PH1</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, we signed a licensing and collaboration agreement with Dicerna Pharmaceuticals, Inc. to utilize our LNP delivery technology exclusively in Dicerna's primary hyperoxaluria type 1 (PH1) development program. Dicerna will use our third generation LNP technology for delivery of DCR-PH1, Dicerna's product incorporating its Dicer substrate RNA (DsiRNA) molecule, for the treatment of PH1, a rare, inherited liver disorder that often results in kidney failure and for which there are no approved therapies. In December 2015, Dicerna announced initiation of dosing in healthy volunteers with plans to initiate the Phase I clinical trial in patients with PH1 in 2016.&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Strategic Alliances, Licensing Agreements, and Research Collaborations</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Alnylam Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alnylam has a license to use our IP to develop and commercialize products and may only grant access to our LNP technology to its partners if it is part of a product sublicense. Alnylam&#8217;s license rights are limited to patents that we have filed, or that claim priority to a patent that was filed, before April 15, 2010. Alnylam does not have rights to our patents filed after April 15, 2010 unless they claim priority to a patent filed before that date. Alnylam will pay low single digit royalties as Alnylam&#8217;s LNP-enabled products are commercialized. Alnylam currently has three LNP-based products in clinical development: ALN-TTR02 (patisiran), ALN-VSP, and ALN-PCS02.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our licensing agreement with Alnylam grants us IP rights for the development and commercialization of RNAi therapeutics for specified targets. In consideration for these three exclusive and 10 non-exclusive licenses, we have agreed to pay single-digit royalties to Alnylam on product sales, with milestone obligations of up to $8.5 million on the non-exclusive licenses and no milestone obligations on the three exclusive licenses. Alnylam has also pursued two other LNP-based products through clinical development: ALN-VSP (liver cancer), and ALN-PCS02 (hypercholesterolemia). Alnylam will pay Arbutus low single digit royalties based on commercial sales of Alnylam&#8217;s LNP-enabled products.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered an arbitration proceeding with Alnylam, as provided for under our licensing agreement, to resolve a matter related to a disputed $5 million milestone payment to Arbutus from Alnylam related to its ALN-VSP product. The arbitration proceeding with Alnylam has concluded resulting in no milestone payment to Arbutus.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acuitas Therapeutics Inc.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consistent with the terms of the settlement agreement signed in November 2012, we finalized and entered a cross-license agreement with Acuitas (formerly AlCana Technologies, Inc.) in December 2013. The terms of the cross-license agreement provide Acuitas with access to certain of our earlier IP generated prior to April 2010. At the same time, the terms provide us with certain access to Acuitas&#8217; technology and licenses in the RNAi field, along with a percentage of each milestone and royalty payment with respect to certain products. Acuitas has agreed that it will not compete in the RNAi field for a period of five years, ending in November 2017.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dicerna Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, we signed a licensing agreement and a development and supply agreement with Dicerna to license our LNP delivery technology for exclusive use in Dicerna's PH1 development program. Dicerna will use Arbutus&#8217; third generation LNP technology for delivery of DCR-PH1, Dicerna's product incorporates its DsiRNA molecule, for the treatment of PH1, a rare, inherited liver disorder that often results in kidney failure and for which there are no approved therapies. Under the agreements, Dicerna paid Arbutus $2.5 million upfront and will potentially make payments of $22 million in aggregate development milestones, plus a mid-single-digit royalty on future PH1 sales. This partnership also includes a supply agreement under which we will provide clinical drug supply and regulatory support for the rapid advancement of this product candidate.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Monsanto Company</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2014, we signed an Option Agreement and a Service Agreement with Monsanto, and granted Monsanto an option to obtain a license to use our proprietary LNP delivery technology. The transaction supports the application of LNP technology and related IP for use in agriculture. The potential value of the transaction could reach $86.2 million following the successful completion of milestones. In January 2014, we received $14.5 million of the $17.5 million in near term payments. We received additional payments of $1.5 million each in June 2014 and October 2014 following the achievement of specific program objectives. In May 2015, the arrangement was amended to extend the option period by approximately five months and we received $1.8 million R&amp;D payment for the extension period. As of December 31, 2015, we have received $19.3 million. </font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the completion of the Phase A extension period in October 2015, no further research activities were conducted under the arrangement, as Monsanto did not elect to proceed to Phase B of the research plan. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 4, 2016, Monsanto exercised its option to acquire 100% of the outstanding shares of PADCo, and will pay Arbutus an exercise fee of $1 million. As a result, PADCo is no longer an indirect wholly owned subsidiary of us. In connection with Monsanto&#8217;s exercise of its option, on&#160;March 4, 2016, we entered into an amended Option Agreement. We also entered into an amended Service Agreement on&#160;March 4, 2016 to give effect to the grant back to Protiva of new intellectual property created by Monsanto in connection with the exercise of its option. In addition, we entered into an amended License and Services Agreement to recognize Monsanto&#8217;s early exercise of option before Protiva&#8217;a completion of Phases B and C, and introduce a new Technology Transfer Completion Criteria through the amended Option Agreement. Each of the amended Option Agreement, amended License and Services Agreement and amendment to the Service Agreement have been filed as Exhibits to this annual report on Form 10-K.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Spectrum Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2013, we announced that our licensee, Spectrum, had launched Marqibo&#174; through its existing hematology sales force in the United States. Since then commercial sales have occurred. Arbutus is entitled to mid-single digit royalty payments based on Marqibo&#174;&#8217;s commercial sales. Marqibo&#174;, which is a novel sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine, was originally developed by Arbutus. We out-licensed the product to Talon Therapeutics in 2006, and in July 2013, Talon was acquired by Spectrum. Marqibo&#174;&#8217;s approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. Spectrum has ongoing trials evaluating Marqibo&#174; in three additional indications, which are: first line use in patients with Ph-ALL, Pediatric ALL and Non-Hodgkin&#8217;s lymphoma.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">University of British Columbia </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain early work on lipid nanoparticle delivery systems and related inventions was undertaken at the University ofBritish Columbia (UBC). These inventions are licensed to us by UBC under a license agreement, initially entered in 1998 as amended in 2001, 2006 and 2007. We have granted sublicenses under the UBC license to Alnylam as well as to Talon. Alnylam has in turn sublicensed back to us under the licensed UBC patents for discovery, development and commercialization of RNAi products. In mid-2009, we and our subsidiary Protiva entered into a supplemental agreement with UBC, Alnylam and Acuitas Technologies, Inc., in relation to a separate research collaboration to be conducted among UBC, Alnylam and Acuitas to which we have license rights. The settlement agreement signed in late 2012 to resolve the litigation among Alnylam, Acuitas, Arbutus and Protiva provided for the effective termination of all obligations under such supplemental agreement as between and among all litigants.On November 10, 2014, the University of British Columbia filed a demand for arbitration against Arbutus Biopharma Corp., BCICAC File No.: DCA-1623. We received UBC&#8217;s Statement of Claims on January 16, 2015. In its Statement of Claims, UBC alleges that it is entitled to $3.5 million in allegedly unpaid royalties based on publicly available information, and an unspecified amount based on non-public information. UBC also seeks interest and costs, including legal fees. We dispute UBC&#8217;s allegation. No dates have been scheduled for this arbitration.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cytos Biotechnology Ltd </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 30, 2014, Arbutus Inc., our wholly owned subsidiary, entered into an exclusive, worldwide, sub-licensable (subject to certain restrictions with respect to licensed viral infections other than hepatitis) license to six different series of compounds. The licensed compounds are Qbeta-derived virus-like particles that encapsulate TLR9, TLR7 or RIG-I agonists and may or may not be conjugated with antigens from the hepatitis virus or other licensed viruses. We have an option to expand this license to include additional viral infections other than influenza and Cytos will retain all rights for influenza, all non-viral infections, and all viral infections (other than hepatitis) for which we have not exercised an option.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, we will be obligated to pay Cytos up to a total of $67 million for each of the six licensed compound series upon the achievement of specified development and regulatory milestones; for hepatitis and each additional licensed viral infection, up to a total of $110 million upon the achievement of specified sales performance milestones; and tiered royalty payments in the high-single to low-double digits, based upon the proportionate net sales of licensed products in any commercialized combination.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The Baruch S. Blumberg Institute and Drexel University</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, Arbutus Inc., our wholly owned subsidiary, entered into a license agreement with Blumberg and Drexel that granted an exclusive (except as to certain know-how and subject to retained non-commercial research rights), worldwide, sub-licensable license to three different compound series: cccDNA inhibitors, capsid assembly inhibitors and HCC inhibitors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, Arbutus Inc. paid a license initiation fee of $150,000 and issued warrants to Blumberg and Drexel. No warrants were outstanding as at the date Arbutus merged with Arbutus Inc. Under this license agreement, Arbutus Inc. also agreed to pay up to $3.5 million in development and regulatory milestones per licensed compound series, up to $92.5 million in sales performance milestones per licensed product, and royalties in the mid-single digits based upon the proportionate net sales of licensed products in any commercialized combination. We are obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from the sub-licensees, subject to customary exclusions.In November 2014, Arbutus Inc. entered into an additional license agreement with Blumberg and Drexel pursuant to which it received an exclusive (subject to retained non-commercial research rights), worldwide, sub-licensable license under specified patents and know-how controlled by Blumberg and Drexel covering epigenetic modifiers of cccDNA and STING agonists. In consideration for these exclusive licenses, Arbutus Inc. made an upfront payment of $50,000. Under this  agreement, we will be required to pay up to $1.0 million for each licensed product upon the achievement of a specified regulatory milestone and a low single digit royalty, based upon the proportionate net sales of compounds covered by this intellectual property in any commercialized combination. We are also obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from its sub-licensees, subject to exclusions.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements between Enantigen and Blumberg and Drexel</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, Arbutus Inc., our wholly owned subsidiary, acquired all of the outstanding shares of Enantigen pursuant to a stock purchase agreement. Through this transaction, Arbutus Inc. acquired a HBV surface antigen secretion inhibitor program and a capsid assembly inhibitor program, each of which are now assets of Arbutus, following our merger with Arbutus Inc.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the stock purchase agreement, we agreed to pay up to a total of $21.0 million to Enantigen&#8217;s selling stockholders upon the achievement of specified development and regulatory milestones, for the first two products that contain either a capsid compound, or a HBV surface antigen compound that is covered by a patent acquired under this agreement; or a capsid compound from an agreed upon list of compounds. The amount paid could be up to a total of $102.5 million in sales performance milestones in connection with the sale of the first commercialized product by us for the treatment of HBV, regardless of whether such product is based upon assets acquired under this agreement; and low single digit royalty on net sales of such first commercialized HBV product, up to a maximum royalty payment of $1.0 million that, if paid, would be offset against our milestone payment obligations.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the stock purchase agreement, we also agreed that Enantigen would fulfill its obligations as they relate to the three patent license agreements with Blumberg and Drexel. Pursuant to each patent license agreement, Enantigen is obligated to pay Blumberg and Drexel up to approximately $500,000 in development and regulatory milestones per licensed product, royalties in the low single digits, and a percentage of revenue it receives from its sub-licensees.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research Collaboration and Funding Agreement with Blumberg</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, Arbutus Inc., our wholly owned subsidiary, entered into a research collaboration and funding agreement with Blumberg under which we will provide $1.0 million per year of research funding for three years, renewable at our option for an additional three years, for Blumberg to conduct research projects in HBV and liver cancer pursuant to a research plan to be agreed upon by the parties. Blumberg has exclusivity obligations to Arbutus with respect to HBV research funded under the agreement. In addition, we have the right to match any third party offer to fund HBV research that falls outside the scope of the research being funded under the agreement. Blumberg has granted us the right to obtain an exclusive, royalty bearing, worldwide license to any intellectual property generated by any funded research project. If we elect to exercise our right to obtain such a license, we will have a specified period of time to negotiate and enter into a mutually agreeable license agreement with Blumberg. This license agreement will include the following pre negotiated upfront, milestone and royalty payments: an upfront payment in the amount of $100,000; up to $8.1 million upon the achievement of specified development and regulatory milestones; up to $92.5 million upon the achievement of specified commercialization milestones; and royalties at a low single to mid-single digit rates based upon the proportionate net sales of licensed products from any commercialized combination.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NeuroVive Pharmaceutical AB</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2014, Arbutus Inc., our wholly owned subsidiary, entered into a license agreement with NeuroVive that granted us an exclusive, worldwide, sub-licensable license to develop, manufacture and commercialize, for the treatment of HBV, oral dosage form sanglifehrin based cyclophilin inhibitors (including OCB-030). Arbutus Inc. became our wholly owned subsidiary by way of a Merger Agreement, which does not trigger any milestone payments. Under this license agreement we have been granted a non-exclusive, royalty free right and license and right of reference to NeuroVive&#8217;s relevant regulatory approvals and filings for the sole purpose of developing, manufacturing and commercializing licensed products for the treatment of HBV. Under this license agreement, we have (1) an option to expand our exclusive license to include treatment of viral diseases other than HBV and (2) an option, exercisable upon specified conditions, to expand our exclusive license to include development, manufacture and commercialization of non-oral variations of licensed products for treatment of viral diseases other than HBV. NeuroVive retains all rights with respect to development, manufacture and commercialization of licensed products and non-oral variations of licensed products for all indications (other than HBV) for which we have not exercised our option.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, Arbutus Inc. paid NeuroVive a license fee of $1 million. We have conducted significant research and analysis on the NeuroVive Product, OCB-030. Based on this research and analysis, we have decided to discontinue the OCB-030 development program. Otherwise, the license agreement and ongoing relationship with NeuroVive remains in full effect at this time.</font></div><a name="s26DD3EB83C5CB16A38C4EF63725EFD40"></a><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The significant accounting policies that we believe to be most critical in fully understanding and evaluating our financial results are revenue recognition, stock-based compensation, share purchase warrant valuation and financial instrument valuation.&#160;&#160;These accounting policies require us to make certain estimates and assumptions.&#160;&#160;We believe that the estimates and assumptions upon which we rely are reasonable, based upon information available to us at the time that these estimates and assumptions are made.&#160;&#160;Actual results may differ from our estimates. Our critical accounting estimates affect our net income or loss calculation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition /</font><font style="font-family:inherit;font-size:10pt;">&#32;Our primary sources of revenue have been derived from research and development collaborations and contracts, and licensing fees comprised of initial fees and milestone payments.&#160;&#160;Payments received under research and development agreements and contracts, which are non-refundable, are recorded as revenue as services are performed and as the related expenditures are incurred pursuant to the agreement, provided collectability is reasonably assured. Revenue earned under research and development manufacturing collaborations where we bear some or all of the risk of a product manufacture failure is recognized when the purchaser accepts the product and there are no remaining rights of return. Revenue earned under research and development collaborations and contracts where we do not bear any risk of product manufacture failure is recognized in the period the work is performed. Revenue earned under contractual arrangements upon the achievement of substantive milestones is recognized in its entirety in the period the payment has been received. We evaluate whether milestones under research and development arrangements are substantive by considering: whether substantive uncertainty exists upon the execution of the arrangement; the event can only be achieved based in whole or in part on our performance or occurrence of a specific outcome resulting from the our performance; any future performance required and payment is reasonable relative to all deliverables; and, payment terms in the arrangement. Initial fees and non-substantive milestone payments are deferred and amortized into income over the estimated period of our involvement as we fulfill our obligations under our agreements.&#160;&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The revenue that we recognize is a critical accounting estimate because of the volume and nature of the revenues we receive.&#160;&#160;Some of the research, development and licensing agreements that we have entered into contain multiple revenue elements that are to be recognized for accounting in accordance with our revenue recognition policy.&#160;&#160;We need to make estimates as to what period the services will be delivered with respect to up-front licensing fees and milestone payments received because these payments are deferred and amortized into income over the estimated period of our ongoing involvement.&#160;&#160;The actual period of our ongoing involvement may differ from the estimated period determined at the time the payment is initially received and recorded as deferred revenue.&#160;&#160;This may result in a different amount of revenue that should have been recorded in the period and a longer or shorter period of revenue amortization. When an estimated period changes we amortize the remaining deferred revenue over the estimated remaining time to completion.&#160;&#160;The rate at which we recognize revenue from payments received for services to be provided under research and development agreements depends on our estimate of work completed to date and total work to be provided. The actual total services provided to earn such payments may differ from our estimates.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our DoD contract for TKM-Ebola is based on cost reimbursement plus an incentive fee. At the beginning of our fiscal year we estimate our labor and overhead rates for the year ahead. During the year, we re-estimate our labor and overhead rates and adjust our revenue accordingly. Our actual labor and overhead rates will differ from our estimate based on actual costs incurred and the proportion of our efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee we can earn under the DoD contract varies based on our costs incurred versus budgeted costs, with the exception of the Ebola-Guinea Amendment, which has a fixed incentive fee. During the contractual period, incentive fee revenue and total costs are impacted by management&#8217;s estimate and judgments which are continuously reviewed and adjusted, as necessary, using the cumulative catch-up method.&#160;&#160;For the years ended December 31, 2013, 2014 and 2015, we believe we were able to reliably estimate the final contract costs so have recognized the portion of expected incentive fee which has been earned to date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our revenue for 2015 was $24.9 million (2014 - $15.0 million, 2013 - $15.5 million) and deferred revenue at December 31, 2015 was $1.1 million (December 31, 2014 - $15.7 million).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based compensation</font><font style="font-family:inherit;font-size:10pt;">&#32;/ The stock-based compensation that we record is a critical accounting estimate due to the value of compensation recorded, the volume of our stock option activity, and the many assumptions that are required to be made to calculate the compensation expense.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation expense is recorded for stock options issued to employees and directors using the fair value method.&#160;&#160;We must calculate the fair value of stock options issued and amortize the fair value to stock compensation expense over the vesting period, and adjust the expense for stock option forfeitures and cancellations.&#160;&#160;We use the Black-Scholes model to calculate the fair value of stock options issued which requires that certain assumptions, including the expected life of the option and expected volatility of the stock, be estimated at the time that the options are issued.&#160;&#160;This accounting estimate is reasonably likely to change from period to period as further stock options are issued and adjustments are made for stock option forfeitures and cancellations. We make an estimate for stock option forfeitures at the time of grant and revise this estimate in subsequent periods if actual forfeitures differ. The term "forfeitures" is distinct from "cancellations" or "expirations" and represents only the unvested portion of the surrendered stock option. For the purpose of calculating fair value, the expected life of stock options granted is five years for employees and eight years for directors and executives. We amortize the fair value of stock options using the straight-line method over the vesting period of the options, generally a period of three years for employees and immediate vesting for directors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recorded stock-based compensation expense in 2015 of $22.1 million (2014 - $3.3 million, 2013 - $0.9 million) which includes compensation expense related to the expiration of repurchase rights on replacement awards issued as consideration in the acquisition of Arbutus Inc. of $16.7 million - refer to business combination section below.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share purchase warrant valuation</font><font style="font-family:inherit;font-size:10pt;">&#32;/ The valuation of share purchase warrants is a critical accounting estimate due to the value of liabilities recorded and the many assumptions that are required to calculate the liability, resulting in the classification of our warrant liability as a level 3 financial instrument.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We classify warrants in our consolidated balance sheet as liabilities and revalue them at each balance sheet date. Any change in valuation is recorded in our statement of operations. We use the Black-Scholes pricing model to value the warrants. Determining the appropriate fair-value model and calculating the fair value of registered warrants requires considerable judgment. A small change in the estimates used may cause a relatively large change in the estimated valuation. Due to ongoing changes in our business and general stock market conditions, we continuously assess our warrant fair value assumptions. We adjust the estimated expected life as appropriate, based on the pattern of exercises of our warrants. During the year-ended December 31, 2015, warrant exercise activity continued to decline; as a result, we increased the remaining expected life of outstanding warrants to nine months and seventeen months effective July 1, 2015. As at December 31, 2015, the remaining expected life is three months and eleven months for outstanding warrants expiring in June 2016 and February 2017, respectively. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our expected volatility is calculated based on our historic share price fluctuations over the same period as our estimated expected life of our outstanding warrants. The risk-free interest rate is based on the Government of Canada rate for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recorded a gain for the change in fair value of warrant liability in 2015 of $3.3 million (2013 &#8211; loss of $10.4 million, 2013 &#8211; loss of $3.5 million).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial instruments valuation</font><font style="font-family:inherit;font-size:10pt;">&#32;/ The valuation of our financial instruments, include  Monsanto&#8217;s option to acquire either the shares or assets of Protiva Agricultural Development Company Inc. and contingent consideration related to estimated potential future milestone payments to the former Enantigen shareholders as described in the business combination section below. These are critical accounting estimate due to the potential value of the liability and the many assumptions we must make to calculate the fair values of these liabilities.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We classify the financial instrument in our consolidated balance sheet as a liability and revalue it at each balance sheet date. Any change in the valuation is recorded in our statement of operations. We used a discounted cash flow model to value the financial instrument. Determining the appropriate fair value model and calculating the fair value of the financial instrument requires considerable judgment, including probability of success and risk-adjusted discount rates. Changes in assumptions used may cause a relatively large change in the estimated valuation. The initial valuation of the financial instrument was determined to be nil for Monsanto's option and no change in the fair value of the financial instrument was recorded as at December 31, 2015. The initial valuation of the contingent consideration was determined to be $6,727,000, and we have determined that the fair value increased to $7,497,000 as at December 31, 2015. We recorded an adjustment for the increase in fair value of $770,000 in our statement of operations and comprehensive loss. The increase in fair value is a result of our research and development progress bringing the contingent payments forward in terms of timing. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business combination</font><font style="font-family:inherit;font-size:10pt;">&#32;/ The purchase price allocation is a critical accounting estimate due to the many assumptions that are required to calculate the fair value of assets acquired and liabilities assumed during a business combination.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for our business combinations using the acquisition method. Under this method, the fair value of the consideration transferred is allocated to the fair values of assets acquired and liabilities assumed. In determining the fair value of the consideration transferred, the acquisition date market price of common shares issued was used. The total consideration transferred is comprised of common shares issued without subjects and common shares issued replacement awards, which are subject to repurchase provisions. As at the acquisition date, we determined the total fair value of the replacement awards and attributed a portion of the replacement awards to pre-combination service as part of the total acquisition consideration, and a portion to post-combination service, which is recognized as compensation expense over the expiry period of repurchase provision rights subsequent to the acquisition date. The fair value of the repurchase awards was determined using the Black-Scholes pricing model with assumed risk-free interest rate of 0.74%, volatility of 81%, a zero dividend yield and an expected life of 4 years. In July 2015, the expiration period of the repurchase rights was amended, resulting in a prospective adjustment to recognize the remaining compensation expense on a straight-line basis over the revised expiration period.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we make estimates to determine the fair values of assets acquired and liabilities assumed, which include judgments in our determinations of acquired intangible assets and assessment of the fair value of existing property and equipment. Assumed liabilities can include other contingency reserves existing at the time of acquisition. Contingent consideration is recorded for cash payments due upon the completion of certain future development and performance milestones. This liability is recorded as at the acquisition date as the fair value of the contingent consideration, estimated using the income method which utilizes various inputs such as probability of success and risk-adjusted discount rates. In addition, contingent consideration is recorded at its fair value at subsequent reporting dates, with any change in fair value from the previous reporting date recorded in the statement of operations and comprehensive loss, as discussed above.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill is recognized on acquisition as the excess of the purchase price over the estimated fair values of net identifiable assets acquired and liabilities assumed. Acquisition related expenses are separately recognized from the business combination and are expensed as incurred.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When establishing fair values, we make significant estimates and assumptions, especially with respect to intangible assets. Intangible assets acquired and recorded by us may include patents, intellectual property, and in-process research and development. Estimates include, but are not limited to the forecasting of future cash flows and discount rates. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our estimates for the fair values of assets acquired and liabilities assumed with respect to our acquisition of Arbutus Inc. are final for the period ended December 31, 2015. We have engaged a third-party valuation specialist to assist us to determine the fair values. Our estimates of fair values are based upon assumptions that we believe to be reasonable, but which are inherently uncertain and unpredictable; therefore, actual results may differ from estimates, thereby impacting our earnings.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill and intangible assets - Impairment </font><font style="font-family:inherit;font-size:10pt;">/ Intangible assets classified as indefinite-lived and goodwill are not amortized, but are evaluated for impairment annually using a measurement date of December 31. In addition, if there is a major event indicating that the carrying value of an asset may not be recoverable, then management will perform an impairment test by comparing the discounted cash flow values to each asset&#8217;s carrying value to determine if a write down is necessary. Such indicators include, but are not limited to on an ongoing basis: (a) industry and market considerations such as an increased competitive environment or an adverse change in legal factors including an adverse assessment by regulators; (b) an accumulation of costs significantly in excess of the amount originally expected for the development of the asset; (c) current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the asset; and (d) if applicable, a sustained decrease in share price.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In assessing impairment, significant judgments are required by management to estimate future cash flows, appropriate discount rates, and other estimates and assumptions that could materially affect the determination of fair value. These judgments include the use of, but are not limited to: projected results of operations and forecast cash flows based on our corporate model as approved by our Board of Directors, third party forecasts and data and other macroeconomic indicators that forecasts market conditions and our estimated future revenues and growth.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, we announced the discontinuance of the cyclophilin drug candidate, OCB-030. Although the final conclusion on discontinuance was made subsequent to the end of the third quarter, it reflected our best estimate as at September 30, 2015, and as such we recorded an estimated impairment charge of $38.0 million in Q3 2015. We revised certain estimates in Q4, and finalized our purchase price allocation which resulted in an incremental adjustment of $1.0 million to the fair value of cyclophilins. The total impairment charge of $39.0 million is reflected in our statement of operations and cumulative loss for the year-ended December 31, 2015. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill is subject to a two-step impairment test. The first step compares the fair value of the reporting unit to the carrying amount, which includes goodwill. If the carrying amount exceeds the implied fair value of the goodwill, the second step measures the amount of the impairment loss. As part of the impairment evaluation of goodwill, we identified only one reporting unit to which the total carrying amount of goodwill has been assigned. We used a valuation specialist to assist us in determining the fair value of the reporting unit under the income approach. For step one of the impairment test, we determined that the fair value of the reporting unit exceeded the carrying value of the reporting unit, and as such, step two was not required. . In addition to the income approach, we considered the market capitalization of approximately $</font><font style="font-family:inherit;font-size:10pt;">242.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million as at December 31, 2015. Although the Company&#8217;s carrying value of </font><font style="font-family:inherit;font-size:10pt;">$547.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;exceeded the market capitalization, we reconciled the income approach determination of fair value with the market capitalization by considering macroeconomic factors, and as such, we do not believe that market capitalization appropriately reflected the value of the Company for the purpose of testing goodwill impairment. No impairment charge on goodwill was recorded for the year ended December 31, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s429719CEF3538510C3BCEF63689CB979"></a><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUMMARY OF QUARTERLY RESULTS</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents our unaudited quarterly results of operations for each of our last eight quarters. These data have been derived from our unaudited condensed consolidated financial statements, which were prepared on the same basis as our annual audited financial statements and, in our opinion, include all adjustments necessary, consisting solely of normal recurring adjustments, for the fair presentation of such information.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in millions $ except per share data) &#8211; unaudited</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td width="29%"></td><td width="8%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="8%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q4</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q3</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q2</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q1</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q4</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q3</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q2</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q1</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborations and contracts:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DoD</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$(0.1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$3.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$3.2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.2</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.7</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alnylam and Acuitas licensing fee and milestone payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.2</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto licensing fees and milestone payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna licensing fee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Spectrum milestone and royalty payments</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.4</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24.4)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62.2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17.9)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22.7)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15.6)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11.2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11.2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10.4)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (losses)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.8)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12.0)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6.2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(44.2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(14.8)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(12.1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6.2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8.6)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(6.1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(18.0)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(5.2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(29.0)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(14.8)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(12.1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(6.2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(8.6)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(6.1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(18.0)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(0.10)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(0.57)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(0.27)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(0.40)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(0.27)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(0.39)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(0.28)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$(0.91)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarterly Trends</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue / </font><font style="font-family:inherit;font-size:10pt;">Our revenue is derived from research and development collaborations and contracts, licensing fees, milestone and royalty payments. Over the past two years, our principal sources of ongoing revenue have been our Monsanto collaboration and our contract with the DoD to advance TKM-Ebola. The DoD contract was terminated in October 2015 and we are currently working through close out procedures with the DoD. Our collaboration with Monsanto effectively ended in October when Phase A research was completed. We expect revenue to continue to fluctuate due to the irregular nature of licensing and milestone receipts under our collaboration and licensing contracts.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In Q3 2010 we signed a contract with the DoD to develop TKM-Ebola and have since incurred significant program costs related to equipment, materials and preclinical and clinical studies. These costs are included in our research, development, collaborations and contracts expenses. These costs are fully reimbursed by the DoD, and this reimbursement amount is recorded as revenue. DoD revenue from the TKM-Ebola program also compensates us for labor and overheads and provides an incentive fee. As described in our critical accounting policies in our Annual Report, we estimate the labor and overhead rates to be charged under our TKM-Ebola contract and update these rate estimates throughout the year. In April 2014, we signed a contract modification to increase the stage one targeted funding by $2.1 million to $43.8 million. The additional funding is to compensate us for unrecovered costs related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required. In Q1 2014, we earned $3.2 million in DoD revenue, due partially to an increase in activity as we moved into a Phase I Clinical Trial. In Q2 2014, we earned $0.9 million in DoD revenue due to lower contract activity as our clinical trial data was with the FDA for review. DoD revenue increased in Q3 2014 with an increase in activity as we prepared a response to the FDA&#8217;s partial clinical hold on our Phase I Clinical Trial. In October 2014, the DoD exercised a contract option adding $7.0 million to the contract for the scale-up and manufacture of TKM-Ebola-Guinea, our product targeting the Ebola-Makona (formerly known as Ebola-Guinea) strain responsible for the outbreak in West Africa. DoD revenue increased in Q4 2014 and Q1 2015 as we purchased materials and manufactured TKM-Ebola-Guinea. In Q2 2015, material purchases and subcontract work related to TKM-Ebola-Guinea were less significant. In July 2015, we announced that activities had been suspended and in October 2015, we received formal notification from the DoD to terminate the TKM-Ebola-Guinea manufacturing and IND submission activities, subject to completion of our post-termination obligations. In Q4, we purchased some lipids back from the DoD and proceeded with contract  close out.  </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2014, we signed an Option Agreement and a Services Agreement with Monsanto for the use of our proprietary delivery technology and related intellectual property in agriculture. Over the option period, which is expected to be approximately four years, Monsanto will make payments to us to maintain their option rights. In Q1 2014, we received $14.5 million of the $17.5 million near term payments, of which $4.5 million relates to research services and $10.0 million for the use of our technology. In June 2014 and October 2014, we received further payments of $1.5 million each, following the completion of specified program developments. In 2015, we received an additional $1.8 million related&#160;to research services. The payments are being recognized as revenue on a straight-line basis over the option period. In Q4 2015, we did not receive further payments from Monsanto for the continuance of research activities under the arrangement. As such, we revised our estimated option period end date to December 31, 2015, resulting in the full release of Monsanto deferred revenue and recognition of $11.8 million in Monsanto revenue in Q4 2015. In March 2016, Monsanto exercised its option to acquire 100% of the outstanding shares of Protiva Agricultural Development Company Inc. (PADCo), for which Monsanto will pay us an exercise fee of $1.0 million in Q1 2016.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, we signed a License Agreement and a Development and Supply Agreement with Dicerna for the use of our proprietary delivery technology and related technology intended to develop, manufacture, and commercialize products related to treatment of PH1. In Q4 2014, we received an upfront payment of $2.5 million, which is being recognized over the period over which we provide services to Dicerna, estimated to complete in Q1 2017. We have recognized Dicerna collaboration revenue for inventory manufacture and provision of development services.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under our licensing and collaboration arrangements with Alnylam and Acuitas, we earn licensing fee revenue from Acuitas as well as further potential development and commercial milestones from Alnylam for the use of our LNP technology.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2013, we began to earn royalties from Spectrum with respect to the commercial sales of Marqibo.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in &#8220;other collaborations and contract revenue&#8221; is revenue from a BMS batch formulation agreement. In August 2014, the collaboration expired and both parties&#8217; obligations under the agreement ended. Revenue recognized in Q3 2014 relates to the release of the deferred revenue balance of $1.6 million.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses /</font><font style="font-family:inherit;font-size:10pt;">&#32;Expenses consist primarily of clinical and pre-clinical trial expenses, personnel expenses, consulting and third party expenses, reimbursable collaboration expenses, consumables and materials, patent filing expenses, facilities, stock-based compensation and general corporate costs. Impairment of intangible assets is also included i operating expenses.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our expenses have increased in the past eight quarters due to an increase in our research and development activities as we seek to move more products into the clinic. In Q1 2014, we dosed the first subject in human clinical trials of TKM-Ebola. In Q2 2014, we initiated a Phase I/II Clinical Trial for TKM-PLK1 in patients with HCC. In Q4 2014, we filed a Canadian Clinical Trial Application (CTA) for TKM-HBV and received clearance to conduct a Phase I Clinical Trial, as well as initiated manufacturing of TKM-Ebola-Guinea for emergency use in West Africa. We also incurred research and development expenses related to identifying new targets. In Q1 2015, we initiated a Phase I Clinical Trial for TKM-HBV and incurred significant material costs related to the TKM-Ebola-Guinea contract with the DoD. In addition, we incurred $9.3 million in costs for professional fees related to completing the merger with Arbutus Inc. (formerly OnCore). In Q2 2015, we incurred an incremental $2.9 million in R&amp;D expenses related to our HBV programs acquired through the merger with Arbutus Inc.  In Q3 2015, we incurred $5.5 million in incremental R&amp;D expenses primarily related to an increase in HBV and HCC clinical trial expenses due to an increase in patient enrollment and a ramp up in spending on Arbutus Inc. HBV programs. Also in Q3 2015, we recorded an estimated impairment charge of $38.0 million as we discontinued our cyclophilin inhibitor program based on our conclusion that cyclophilins do not play a meaningful role in HBV biology. In Q4, 2015, we continued to incur R&amp;D expense related to our HBV programs.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other income (losses) /</font><font style="font-family:inherit;font-size:10pt;">&#32;Other income (losses) consist primarily of changes in the fair value of our warrant liability and foreign exchange differences. Other losses increased in Q1 2014 and Q3 2014 due primarily to the increase in fair value of our warrant liability. Increases in our share price from the previous reporting date result in an increase in the fair value of our warrant liability, and vice versa. We expect to see future changes in the fair value of our warrant liability and these changes will largely depend on the change in the Company&#8217;s share price, any change in our assumed rate of share price volatility, our assumptions for the expected lives of the warrants and warrant exercises.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In Q3 and Q4 2015, we recorded $11.8 million and $5.5 million respectively in foreign exchange gains largely on our cash and investments due to the appreciation of the U.S. dollar against the Canadian dollar from the previous period.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income tax benefit /</font><font style="font-family:inherit;font-size:10pt;">&#32;Income tax benefit relates to the decrease in deferred tax liability associated with the impairment charge recorded on acquired intangible assets. In Q3 2015, we recorded $15.2 million of income tax benefit for the estimated impairment of our cyclophilin inhibitor program, OCB-030. In Q4, we recorded a further $1.0 million in income tax benefit due to the revision of fair value of cyclophilins.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss /</font><font style="font-family:inherit;font-size:10pt;">&#32;Fluctuations in our net loss are explained by changes in revenue, expenses, other income (losses) and income tax as discussed above.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fourth quarter of 2015 /</font><font style="font-family:inherit;font-size:10pt;">&#32;Our Q4 2015 net loss was $5.2 million ($0.10 basic and diluted loss per common share) as compared to a net loss of $6.2 million ($0.27 basic and diluted loss per common share) for Q4 2014.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue was $12.7 million in Q4 2015 as compared to $4.4 million in Q4 2014. The increase was largely due to the recognition of $11.8 million in Monsanto revenue due to our revised estimate of the option period.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research, development, collaborations and contracts expenses increased to $14.9 million in Q4 2015 as compared to $11.9 million in Q4 2014. In Q4 2015, we incurred incremental expenses related to our HBV programs acquired from Arbutus Inc. . In addition, we recorded $6.0 million in non-cash compensation expense related to the expiry of repurchase rights on shares issued as part of the consideration paid for the merger with Arbutus Inc. (refer to notes to the financial statements), of which $1.5 million has been included as part of research, development, collaborations and contracts expense, and $4.5 million included as part of general and administrative expense.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other gains in Q4 2015 primarily consists of a $0.5 million decrease in the fair value of our warrant liability, and a foreign exchange gain of $5.5 million on our US dollar funds. In Q4 2015, we recorded a $0.8 million charge related to the increase in the fair value of contingent consideration - see financial statement notes for further details.</font></div><a name="s67F53503D0624A5906E8EF63686C3906"></a><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RESULTS OF OPERATIONS</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes the results of our operations for the 2015, 2014, and 2013 fiscal years, in millions:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="59%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">127.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(102.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(61.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted income (loss) per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.92</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">712.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">164.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total non-current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">154.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(267.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(205.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(167.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(49.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">547.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31, 2015 compared to the year ended December 31, 2014</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the fiscal year ended December 31, 2015, our net loss was $61.1 million ($1.34 basic and diluted loss per common share) as compared to a net loss of $38.8 million ($1.80 basic and diluted loss per common share) for 2014.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font><font style="font-family:inherit;font-size:10pt;">&#32;/ Revenue is summarized in the following table, in millions:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">% of Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborations and contracts</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DoD</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BMS</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other RNAi collaborators</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total collaborations and contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto licensing fees and milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alnylam milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna licensing fee</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Spectrum milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue contracts are covered in more detail in the overview section of this discussion.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">DoD revenue</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, we announced that Ebola related activities were being suspended and, in Q4 2015, we received formal notification from the DoD terminating the contract, subject to the completion of certain post-termination obligations. We do not expect to record significant revenue from the DoD contract after December 31, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Monsanto revenue</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2014, we received $14.5 million, of which $4.5 million relates to research services and $10.0 million for the use of our technology. In June and October 2014, we received payments of $1.5 million each, following the completion of specified program developments. In May and September 2015, we received $1.05 million and $0.75 million for research services. We are recognizing this revenue on a straight-line basis over the option period. As we did not receive further payments from Monsanto for the continuance of research activities under the arrangement, we revised our estimated option period end date as December 31, 2015, resulting in the full release of Monsanto deferred revenue of $11.8 million, resulting in the recognition of $15.0 million in Monsanto revenue for the year ended December 31, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dicerna revenue</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, we signed a License Agreement and a Development and Supply Agreement with Dicerna for the use of our proprietary delivery technology and related technology intended to develop, manufacture, and commercialize products related to the treatment of PH1. Licensing fee revenue recognized for the year-ended December 31, 2015 relates to the earned portion of the upfront payment of $2.5 million for the use our of technology, which is being recognized over the period over which we provide services to Dicerna, estimated to complete in March 2017. Collaboration revenue for the year-ended December 31, 2015 relates to inventory manufactured for and services provided to Dicerna.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Alnylam and Acuitas revenue</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under our licensing and collaboration arrangements with Alnylam and Acuitas, we earn licensing fee revenue from Acuitas as well as further potential development and commercial milestones from Alnylam for the use of our LNP technology.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">BMS revenue</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2010 we signed a formulation agreement with BMS under which BMS paid us $3.0 million to make a certain number of LNP formulations over the following four year period. The contract expired in 2014 with no further obligation for either party. Revenue recognized in 2014 relates to the manufactured batches shipped to BMS during the year and the subsequent release of the deferred revenue balance upon the expiration of the contract.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Spectrum revenue</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2013, Spectrum announced that they had shipped the first commercial orders of Marqibo. We continue to earn royalties on the sales of Marqibo, which uses a license to our technology.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses</font><font style="font-family:inherit;font-size:10pt;">&#32;/ Expenses are summarized in the following table, in millions:</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">% of Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research, development, collaborations and contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">51.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">26.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">39.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">127.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research, development, collaborations and contracts</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research, development, collaborations and contracts expenses consist primarily of clinical and pre-clinical trial expenses, personnel expenses, consulting and third party expenses, consumables and materials, as well as a portion of stock-based compensation and general corporate costs.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D expenses increased during 2015 as compared to 2014 as we increased our spending on TKM-HBV for which Phase 1 clinical trials were initiated in 2015. We also incurred incremental costs related to an increase in activities for the preclinical HBV programs we acquired from our merger with Arbutus Inc. In addition, we increased research activities related to our collaboration contracts with the DoD, Monsanto, and Dicerna.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&amp;D compensation expense increased in 2015 as compared to 2014 due to an increase in the number of employees in support of our expanded portfolio of product candidates, as well as from our merger with Arbutus Inc. In addition, in the year ended December 31, 2015, we incurred a total of $16.7 million of incremental non-cash compensation expense related to the expiry of repurchase rights on shares issued as part of the consideration paid for the merger with Arbutus Inc. (refer to notes to the financial statements), of which $4.2 million has been included as part of research, development, collaborations and contracts expense, and $12.5 million included as part of general and administrative expense.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A significant portion of our research, development, collaborations and contracts expenses are not tracked by project as they benefit multiple projects or our technology platform and because our most-advanced programs are not yet in late-stage clinical development. However, our collaboration agreements contain cost-sharing arrangements pursuant to which certain costs incurred under the project are reimbursed. Costs reimbursed under collaborations typically include certain direct external costs and hourly or full-time equivalent labor rates for the actual time worked on the project. In addition, we have been reimbursed under government contracts for certain allowable costs including direct internal and external costs. As a result, although a significant portion of our research, development, collaborations and contracts expenses are not tracked on a project-by-project basis, we do, however, track direct external costs attributable to, and the actual time our employees worked on, our collaborations and government contracts.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and administrative</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses increased in 2015 compared to 2014 due largely to an increase in compensation expense linked to our increase in employee base and incremental corporate expenses to support the growth of the Company following the completion of our merger with Arbutus Inc. This includes an incremental non-cash compensation expense we incurred related to the expiry of repurchase rights on shares issued as part of consideration paid for the merger with Arbutus Inc. (see above). Expenses were also higher in 2015 due to legal costs incurred in relation to the May 2015 arbitration hearing against Alnylam.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Acquisition costs</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2015, we incurred $9.7 million in costs for professional fees related to completing the merger with Arbutus Inc. - see overview. This is a one-time cost specific to the merger with Arbutus Inc., and such costs are only incurred when a business combination occurs.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of intangible assets</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year-ended December 31, 2015, we recorded a total impairment charge of $39.0 million based on our decision to discontinue our development of cyclophilin inhibitors. The decision was based on extensive preclinical evaluations of OCB-030, and other competitive cyclophilin inhibitors, following the acquisition of Arbutus Inc., which concluded that cyclophilins do not play a meaningful role in HBV biology.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other income (losses) /</font><font style="font-family:inherit;font-size:10pt;">&#32;Other income (losses) are summarized in the following table, in millions:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange gains</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">21.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Decrease (increase) in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in fair value of contingent consideration </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total other income (losses)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign exchange gains</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year-ended December 31, 2015, we recorded a foreign exchange gain of $21.8 million, which is primarily an unrealized gain related to an appreciation in the value of our U.S. dollar funds from the previous period when converted to our functional currency of Canadian dollars. Cumulative translation adjustments, which result from converting from our functional currency of Canadian dollars to our reporting currency of U.S. dollars, do not impact our net loss calculation and are not included in foreign exchange gains (losses), but are included in cumulative translation adjustment in other comprehensive loss.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Increase in fair value of warrant liability</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with equity and debt financing transactions in 2011 and 2012, we issued warrants to purchase our common share. We are accounting for the warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company&#8217;s own stock, on the understanding that in compliance with applicable securities laws, the registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. At each balance sheet date the warrants are revalued using the Black-Scholes model and the change in value is recorded in the consolidated statement of operations and comprehensive income (loss).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, a decrease in our share price from the previous reporting date results in a decrease in the fair value of our warrant liability and vice versa.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to see future changes in the fair value of our warrant liability and these changes will largely depend on the change in the Company&#8217;s share price, and, to a lesser extent, any change in our assumed rate of share price volatility, our assumptions for the expected lives of the warrants and warrant exercises.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Increase in fair value of contingent consideration</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contingent consideration represents the estimated regulatory, development and sales milestone payments payable to the previous Enantigen shareholders. Enantigen was acquired by Arbutus Inc. in 2014. As at the acquisition date of Arbutus Inc., the contingent consideration had an estimated fair value of approximately $6,727,000. Contingent consideration is a financial liability, and we determine its fair value at each reporting period with any changes in fair value from the previous reporting period recorded in the statement of operations and comprehensive loss. For the period ended December 31, 2015, we performed an evaluation of the fair value of the contingent consideration using the probability weighted assessment of likelihood of milestone payments as described above and determined the fair value of the contingent consideration has increased by $770,000 to $7,497,000. The increase in fair value has been recorded in other losses in the statement of operations and comprehensive loss for the year-ended December 31, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income tax benefit</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year-ended December 31, 2015, we recorded an income tax benefit of $16.2 million due to the decrease in deferred tax liability resulting from the impairment charge we recorded for the discontinuance of our cyclophilin inhibitor program.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31, 2014 compared to the year ended December 31, 2013</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the fiscal year ended December 31, 2014, our net loss was $38.8 million ($1.80 basic and diluted loss per common share) as compared to a net loss of $14.1 million ($0.92 basic and diluted loss per common share) for 2013.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font><font style="font-family:inherit;font-size:10pt;">&#32;/ Revenue is summarized in the following table, in millions:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">% of Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborations and contracts</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DoD</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">56</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BMS</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other RNAi collaborators</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total collaborations and contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto licensing fee</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alnylam milestone payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Dicerna licensing fee</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Spectrum milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">DoD revenue</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, we signed a contract modification with the DoD to increase the stage one targeted funding by a further $2.1 million to $43.8 million. The additional funding is to compensate us for unrecovered costs incurred related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required. In October 2014, the DoD exercised an option valued at $7.0 million, awarded to us to manufacture TKM-Ebola-Guinea targeting the Ebola-Guinea strain responsible for the outbreak in West Africa.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the contract, we are being reimbursed for costs incurred, including an allocation of overheads, and we are being paid an incentive fee.</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DoD revenues and related contract expenses were lower in 2014 as compared to 2013 as we were nearing the end of stage one of the contract and most activities for this stage had been completed. The reduction in stage one revenue in 2014 was offset by the addition of the $7.0 million award for the manufacture of TKM-Ebola-Guinea towards the end of 2014. </font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Monsanto revenue</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2014, we signed an Option Agreement and a Services Agreement (together, the &#8220;Agreements&#8221;) with Monsanto. Under the Agreements, Monsanto has an option to acquire a license to use our proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately four years, we will provide lipid formulations for Monsanto&#8217;s research and development activities, and Monsanto will make certain payments to us to maintain their option rights (see Overview for further discussion).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2014, we received $14.5 million, of which $4.5 million relates to research services and $10.0 million for the use of our technology. In June and September 2014, we received payments of $1.5 million each, following the completion of specified program developments. We are recognizing this revenue on a straight-line basis over the option period. For the year-ended December 31, 2014, we recorded an aggregate of $3.8 million in revenue for the use of our technology and for research activities.</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Alnylam and Acuitas revenue</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 12, 2012, we entered into a new licensing agreement with Alnylam that replaces all earlier licensing, cross-licensing, collaboration, and manufacturing agreements. We also entered into a separate cross license agreement with Acuitas, which includes milestones and royalty payments, and Acuitas has agreed not to compete in the RNAi field for five years.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2013, Alnylam initiated a Phase III trial with ALN-TTR02, also known as patisiran, and an associated $5.0 million development milestone was paid to us in December 2013. In March 2014, we earned a $0.15 million milestone payment from Acuitas following their receipt of a milestone from Alnylam with the initiation of the ALN-TTR02 Phase III trial.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 21, 2013, we transferred manufacturing process technology to Ascletis to enable them to produce ALN-VSP, a product candidate licensed to them by Alnylam. We believe that under our licensing agreement with Alnylam, the technology transfer to Ascletis triggers a $5.0 million milestone obligation from Alnylam to us. However, Alnylam has demanded a declaration that we have not yet met its milestone obligations. We dispute Alnylam&#8217;s position. To remedy this dispute, we have commenced arbitration proceedings with Alnylam, as provided for under the agreement.&#160; The hearing for this arbitration occurred in May, 2015.   We have not recorded any revenue in respect of this milestone. </font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">BMS revenue</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2010 we signed a formulation agreement with BMS under which BMS paid us $3.0 million to make a certain number of LNP formulations over the following four year period. Revenue recognized in 2012 and 2013 relates to LNP batches the company produced in proportion to the maximum LNP formulations that may be required under the contract. As at December 31, 2013, we intended to offer BMS an extension to the agreement&#8217;s end date from May 10, 2014 to December 31, 2014. Extending the agreement would have given BMS more time to order LNP batches. The offer extension resulted in a cumulative revenue adjustment recorded for the year-ended December 31, 2013. In August 2014, we received notification from BMS that the extension would not occur. Revenue recognized for the year-ended December 31, 2014 relates to the batches shipped to BMS during the period and the release of any remaining deferred revenue balance now that the agreement has expired and no further obligation with either party.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dicerna revenue</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, we signed a License Agreement and a Development and Supply Agreement with Dicerna for the use of our proprietary delivery technology and related technology intended to develop, manufacture, and commercialize products related to treatment of PH1. Revenue recognized for the year-ended December 31, 2014 relates to the earned portion of the upfront payment of $2.5 million for the use our of technology, which is being recognized over the period over which we provide services to Dicerna, estimated to complete in March 2017. </font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Spectrum revenue</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2013, Spectrum announced that they had shipped the first commercial orders of Marqibo. For the year-ended December 31, 2014, we earned royalties of $0.2 million on the sales of Marqibo, which uses a license to our technology.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses /</font><font style="font-family:inherit;font-size:10pt;">&#32;Expenses are summarized in the following table, in millions:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">% of Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">% of Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research, development, collaborations and contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">38.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total operating expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">48.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research, development, collaborations and contracts</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research, development, collaborations and contracts expenses consist primarily of clinical and pre-clinical trial expenses, personnel expenses, consulting and third party expenses, consumables and materials, as well as a portion of stock-based compensation and general corporate costs.&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2013, research and development costs were primarily related to our internal earlier-stage research programs, moving TKM-PLK1 into Phase I/II clinical trial, and new targets identification: TKKM-HBV and TKM-ALDH2. In 2014, our research and development costs increased as we incurred incremental costs related to the progress of moving additional products into the clinic: the initiation of Phase I /II clinical trials in patients with HCC resulting in the expansion in the number of clinical trials sites and patients accrual for TKM-PLK1, significant research and preclinical spending on TKM-HBV to file a CTA to move into the clinic, as well as an increase in manufacturing activities under the DoD contract in response to the Ebola outbreak in West Africa. In addition, we incurred incremental research and development spending for new partner collaborations we entered into in 2014, as well as spending on new targets identification - see Overview for further details. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation expenses increased in 2014 as compared to 2013. There was an increase in workforce of 38 employees in 2014 to support our expanded portfolio of product candidates. In addition, R&amp;D stock-based compensation expense increased significantly due, in part, to the increase in our share price.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2014, we also incurred $0.5 million in acquisition costs related to the acquisition of Arbutus Inc. (formerly OnCore) that completed in March 2015 - see overview.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A significant portion of our research, development, collaborations and contracts expenses are not tracked by project as they benefit multiple projects or our technology platform and because our most-advanced programs are not yet in late-stage clinical development. However, our collaboration agreements contain cost-sharing arrangements pursuant to which certain costs incurred under the project are reimbursed. Costs reimbursed under collaborations typically include certain direct external costs and hourly or full-time equivalent labor rates for the actual time worked on the project. In addition, we have been reimbursed under government contracts for certain allowable costs including direct internal and external costs. As a result, although a significant portion of our research, development, collaborations and contracts expenses are not tracked on a project-by-project basis, we do, however, track direct external costs attributable to, and the actual time our employees worked on, our collaborations and government contracts.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and administrative</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses increased in 2014 due largely to an increase in compensation expenses. Our employee base grew in support of our expanding pipeline and we had a significant increase in stock-based compensation expense due, in part, to the increase in our share price. We incurred incremental spending on legal fees and consultants related to new compliance requirements linked to the growth of the Company.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other income (losses) /</font><font style="font-family:inherit;font-size:10pt;">&#32;Other income (losses) are summarized in the following table, in millions:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="71%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange gains</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(10.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total other losses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(5.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Increase in fair value of warrant liability</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with equity and debt financing transactions in 2011 and 2012, we issued warrants to purchase our common share. We are accounting for the warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company&#8217;s own stock, on the understanding that in compliance with applicable securities laws, the registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. At each balance sheet date the warrants are revalued using the Black-Scholes model and the change in value is recorded in the consolidated statement of operations and comprehensive income (loss).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate increase in value of our common share purchase warrants outstanding at December 31, 2014 was $10.4 million as compared to an increase in the value of common share purchase warrants outstanding at the end of 2013 of $3.5 million. The increases are a result of increases in the Company&#8217;s share price from the previous reporting dates.&#160;</font></div><a name="s490A8074849360233130EF6368ECC639"></a><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIQUIDITY AND CAPITAL RESOURCES</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our cash flow activities for the periods indicated, in millions:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="59%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(61.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">21.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(54.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">143.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of foreign exchange rate changes on cash &amp; cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">94.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, beginning of year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">72.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and cash equivalents, end of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">166.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our incorporation, we have financed our operations through the sales of shares, units, debt, revenues from research and development collaborations and licenses with corporate partners, interest income on funds available for investment, and government contracts, grants and tax credits.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, 2015, we had cash and cash equivalents of $166.8 million and short and long-term investments of $24.6 million, totaling $191.4 million as compared to cash, cash equivalents, and short-term investments of $112.2 million at December 31, 2014.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating activities used $54.8 million in cash in 2015 as compared to $12.4 million used in 2014 and $6.7 million used in 2013. The increase in cash used from operating activities was primarily related to the expansion of our research and development as a result of both organic growth and our acquisition of Arbutus Inc. in March 2015. Non-cash items to reconcile net loss used by operating activities include impairment of intangible assets of $39.0 million, with an offsetting income tax benefit of $16.2 million.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing activities provided cash of $7.7 million compared to $43.0 million of cash used in 2014 and $0.7 million used in 2013.&#160;Cash provided in 2015 was due to settlement of guaranteed investment certificates during the year. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 22, 2013, we completed an underwritten public offering of 3,750,000 common shares, at a price of $8.00 per share, representing gross proceeds of $30.0 million. On November 1, 2013, the offering&#8217;s underwriter completed the exercise of its over-allotment option to purchase a further 562,500 shares at $8.00 bringing the aggregate financing gross proceeds to $34.5 million. The cost of the financing, including commissions and professional fees, was $2.5 million, resulting in net proceeds of $32.0 million.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 18, 2014, we completed an underwritten public offering of 2,125,000 common shares, at a price of $28.50 per share, representing gross proceeds of $60.5 million. We are using these proceeds to develop and advance product candidates through clinical trials, as well as for working capital and general corporate purposes.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 25, 2015, we completed an underwritten public offering of 7,500,000 common shares, at a price of $20.25 per share, representing gross proceeds of $151.9 million. The cost of financing, including commissions and professional fees, was approximately $9.7 million, which gave us net proceeds of $142.2 million. We plan to use these proceeds to develop and advance product candidates through clinical trials, as well as for working capital and general corporate purposes.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash requirements /</font><font style="font-family:inherit;font-size:10pt;">&#32;At December 31, 2015 we held $166.8 million in cash and cash equivalents and $24.6 million in short- and long-term investments. On March 25, 2015, we raised net proceeds of $142.2 million from a public offering. We believe we have sufficient cash resources for at least the next 12 months. In the future, substantial additional funds will be required to continue with the active development of our pipeline products and technologies. In particular, our funding needs may vary depending on a number of factors including:</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the need for additional capital to fund future business development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">revenues earned form our current collaborative partnership and licensing agreement with Dicerna;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:0px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">revenues earned from our legacy collaborative partnerships and licensing agreements, including milestone payments from Alnylam and royalties from sales of Marqibo from Spectrum;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent to which we continue the development of our product candidates, add new product candidates to our pipeline, or form collaborative relationships to advance our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our decisions to in-license or acquire additional products or technology for development, in particular for our HBV programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to attract and retain corporate partners, and their effectiveness in carrying out the development and ultimate commercialization of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether batches of drugs that we manufacture fail to meet specifications resulting in delays and investigational and remanufacturing costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the decisions, and the timing of decisions, made by health regulatory agencies regarding our technology and products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competing technological and market developments; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs associated with prosecuting and enforcing our patent claims and other intellectual property rights, including litigation and arbitration arising in the course of our business activities.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:0px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will seek to obtain funding to maintain and advance our business from a variety of sources including public or private equity or debt financing, collaborative arrangements with pharmaceutical companies and government grants and contracts. There can be no assurance that funding will be available at all or on acceptable terms to permit further development of our products especially in light of the current difficult climate for investment in early stage biotechnology companies.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If adequate funding is not available, we may be required to delay, reduce or eliminate one or more of our research or development programs or reduce expenses associated with non-core activities. We may need to obtain funds through arrangements with collaborators or others that may require us to relinquish most or all of our rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise seek if we were better funded. Insufficient financing may also mean failing to prosecute our patents or relinquishing rights to some of our technologies that we would otherwise develop or commercialize.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Material commitments for capital expenditures</font><font style="font-family:inherit;font-size:10pt;">&#32;/ As at the date of this discussion we do not have any material commitments for capital expenditures.</font></div><a name="s19C1D1089A13B5820E82EF6373014466"></a><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OFF-BALANCE SHEET ARRANGEMENTS</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="s80B6856C2C7EC306E135EF6368EFF5DF"></a><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONTRACTUAL OBLIGATIONS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Facility lease</font><font style="font-family:inherit;font-size:10pt;">&#32;/ On June 23, 2014, we signed an agreement to renew the lease for our Burnaby office and lab facility. The lease term is for five years, commencing August 1, 2014 with three additional renewal terms of five years each. On March 24, 2015, our U.S. office signed a one year lease agreement for office and lab facilities. On October 1, 2015, we signed an amendment and extended the lease to December 31, 2016. We have the option to renew for another term of one year.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product development partnership with the Canadian Government /</font><font style="font-family:inherit;font-size:10pt;">&#32;We entered into a Technology Partnerships Canada (TPC) agreement with the Canadian Federal Government on November 12, 1999.&#160;&#160;Under this agreement, TPC agreed to fund 27% of our costs incurred prior to March 31, 2004, in the development of certain oligonucleotide product candidates up to a maximum contribution from TPC of $7.2 million (C$9.3 million).&#160;&#160;As at December 31, 2015, a cumulative contribution of $2.7 million (C$3.7 million) had been received and we do not expect any further funding under this agreement.&#160;&#160;In return for the funding provided by TPC, we agreed to pay royalties on the share of future licensing and product revenue, if any that is received by us on certain non-siRNA oligonucleotide product candidates covered by the funding under the agreement.&#160;&#160;These royalties are payable until a certain cumulative payment amount is achieved or until a pre-specified date.&#160;&#160;In addition, until a cumulative amount equal to the funding actually received under the agreement has been paid to TPC, we agreed to pay a 2.5% royalty on any royalties we receive for Marqibo.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2013, we began to earn royalties on Marqibo and the cumulative amount paid or accrued up to December 31, 2015 was $0.01 million resulting in the contingent amount due to TPC being $2.7 million (C$3.7 million).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">License agreement with Marina Biotech, Inc. (&#8220;Marina&#8221;) /</font><font style="font-family:inherit;font-size:10pt;">&#32;On November 29, 2012, we announced a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleobase Analog (&#8220;UNA&#8221;) from Marina for the development of RNAi therapeutics.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UNA technology can be used in the development of RNAi therapeutics, which treat disease by silencing specific disease causing genes. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the license agreement we will make milestone payments of up to $3.3 million, plus royalties, on each product that we develop that uses Marina&#8217;s UNA technology. The upfront fee and license payment were expensed to research, development, collaborations and contracts expense.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective August 9, 2013, Marina&#8217;s UNA technology was acquired by Arcturus Therapeutics, Inc. (&#8220;Arcturus&#8221;) and the UNA license agreement between us and Marina was assigned to Arcturus. The terms of the license are otherwise unchanged.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingent consideration from OnCore acquisition of Enantigen and License Agreements between Enantigen and Blumberg and Drexel</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, OnCore acquired all of the outstanding shares of Enantigen pursuant to a stock purchase agreement. Through this transaction, OnCore acquired a HBV surface antigen secretion inhibitor program and a capsid assembly inhibitor program, each of which are now assets of Arbutus, following the Company&#8217;s merger with Arbutus Inc. - see notes to the financial statements.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the stock purchase agreement, OnCore agreed to pay up to a total of </font><font style="font-family:inherit;font-size:10pt;">$21.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million to Enantigen&#8217;s selling stockholders upon the achievement of certain triggering events related to Enantigen&#8217;s two programs in pre-clinical development related to HBV therapies. The first triggering event is the enrollment of first patient in Phase 1b clinical trial in HBV patients, which we do not expect to occur in the next twelve-month period.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The regulatory, development and sales milestone payments have an estimated fair value of approximately </font><font style="font-family:inherit;font-size:10pt;">$6.7</font><font style="font-family:inherit;font-size:10pt;">&#32;million as at the date of acquisition of Arbutus Inc., and have been treated as contingent consideration payable in the purchase price allocation. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration is considered as a financial liability, and measured at its fair value at each reporting period with any changes in fair value from the previous reporting period recorded in the statement of operations and comprehensive loss. For the period ended December 31, 2015, we performed an evaluation of the fair value of the contingent consideration using the probability weighted assessment of likelihood of milestone payments as described above. We determined the fair value of the contingent consideration has increased by </font><font style="font-family:inherit;font-size:10pt;">$0.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million to </font><font style="font-family:inherit;font-size:10pt;">$7.5</font><font style="font-family:inherit;font-size:10pt;">&#32;million and the increase in fair value has been recorded in other losses in the statement of operations and comprehensive loss for the year-ended December 31, 2015. </font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Drexel and Blumberg</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, OnCore entered into a license agreement with Blumberg and Drexel that granted an exclusive, worldwide, sub-licensable license to three different compound series: cccDNA inhibitors, capsid assembly inhibitors and HCC inhibitors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, OnCore paid a license initiation fee of </font><font style="font-family:inherit;font-size:10pt;">$0.2</font><font style="font-family:inherit;font-size:10pt;">&#32;million and issued warrants to Blumberg and Drexel. Under this license agreement, OnCore also agreed to pay up to </font><font style="font-family:inherit;font-size:10pt;">$3.5</font><font style="font-family:inherit;font-size:10pt;">&#32;million in development and regulatory milestones per licensed compound series, up to </font><font style="font-family:inherit;font-size:10pt;">$92.5</font><font style="font-family:inherit;font-size:10pt;">&#32;million in sales performance milestones per licensed product, and royalties in the mid-single digits based upon the proportionate net sales of licensed products in any commercialized combination. We are obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from the sub-licensees, subject to customary exclusions.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, OnCore entered into an additional license agreement with Blumberg and Drexel pursuant to which it received an exclusive, worldwide, sub-licensable license under specified patents and know-how controlled by Blumberg and Drexel covering epigenetic modifiers of cccDNA and STING agonists. In consideration for these exclusive licenses, OnCore made an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$0.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million. Under this agreement, we will be required to pay up to </font><font style="font-family:inherit;font-size:10pt;">$1.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million for each licensed product upon the achievement of a specified regulatory milestone and a low single digit royalty, based upon the proportionate&#160;net sales of compounds covered by this intellectual property&#160;in any commercialized combination. We are also obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from its sub-licensees, subject to exclusions.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaboration and Funding Agreement with Blumberg</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, OnCore entered into a research collaboration and funding agreement with Blumberg under which we will provide </font><font style="font-family:inherit;font-size:10pt;">$1.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million per year of research funding for three years, renewable at our option for an additional three years, for Blumberg to conduct research projects in HBV and liver cancer pursuant to a research plan to be agreed upon by the parties. Blumberg has exclusivity obligations to Arbutus with respect to HBV research funded under the agreement. In addition, Arbutus has the right to match any third party offer to fund HBV research that falls outside the scope of the research being funded under the agreement. Blumberg has granted Arbutus the right to obtain an exclusive, royalty bearing, worldwide license to any intellectual property generated by any funded research project. If we elect to exercise its right to obtain such a license, we will have a specified period of time to negotiate and enter into a mutually agreeable license agreement with Blumberg. This license agreement will include the following pre negotiated upfront, milestone and royalty payments: an upfront payment in the amount of </font><font style="font-family:inherit;font-size:10pt;">$0.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million; up to </font><font style="font-family:inherit;font-size:10pt;">$8.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million upon the achievement of specified development and regulatory milestones; up to </font><font style="font-family:inherit;font-size:10pt;">$92.5</font><font style="font-family:inherit;font-size:10pt;">&#32;million upon the achievement of specified commercialization milestones; and royalties at a low single to mid-single digit rates based upon the proportionate&#160;net sales of licensed&#160;products from any commercialized combination.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NeuroVive Pharmaceutical AB (&#8220;NeuroVive&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2014, OnCore entered into a license agreement with NeuroVive that granted them an exclusive, worldwide, sub-licensable license to develop, manufacture and commercialize, for the treatment of HBV, oral dosage form sanglifehrin based cyclophilin inhibitors (including OCB-030). Under this license agreement, Arbutus has been granted a non-exclusive, royalty free right and license and right of reference to NeuroVive&#8217;s relevant regulatory approvals and filings for the sole purpose of developing, manufacturing and commercializing licensed products for the treatment of HBV. Under this license agreement, Arbutus has (1)&#160;an option to expand its exclusive license to include treatment of viral diseases other than HBV and (2)&#160;an option, exercisable upon specified conditions, to expand its exclusive license to include development, manufacture and commercialization of non-oral variations of licensed products for treatment of viral diseases other than HBV. NeuroVive retains all rights with respect to development, manufacture and commercialization of licensed products and non-oral variations of licensed products for all indications (other than HBV) for which we have not exercised our option.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, OnCore paid NeuroVive a license fee of </font><font style="font-family:inherit;font-size:10pt;">$1.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million. As described in the notes to our financial statements, Arbutus Inc. became our wholly owned subsidiary by way of a Merger Agreement, which does not trigger any milestone payments. We have conducted significant research and analysis on the NeuroVive Product, OCB-030. Based on this research and analysis, we have decided to discontinue the OCB-030 development program.&#160; Otherwise, the license agreement and ongoing relationship with NeuroVive remains in full effect.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cytos Biotechnology Ltd (&#8220;Cytos&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;30, 2014, OnCore entered into an exclusive, worldwide, sub-licensable (subject to certain restrictions with respect to licensed viral infections other than hepatitis) license to </font><font style="font-family:inherit;font-size:10pt;">6</font><font style="font-family:inherit;font-size:10pt;">&#32;different series of compounds. The licensed compounds are Qbeta-derived virus-like particles that encapsulate TLR9, TLR7 or RIG-I agonists and may or may not be conjugated with antigens from the hepatitis virus or other licensed viruses.&#160; Arbutus has an option to expand this license to include additional viral infections other than influenza and Cytos will retain all rights for influenza, all non-viral infections, and all viral infections (other than hepatitis) for which it has not exercised its option.&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, we are obligated to pay Cytos up to a total of </font><font style="font-family:inherit;font-size:10pt;">$67.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million for each of the </font><font style="font-family:inherit;font-size:10pt;">6</font><font style="font-family:inherit;font-size:10pt;">&#32;licensed compound series upon the achievement of specified development and regulatory milestones; for hepatitis and each additional licensed viral infection, up to a total of </font><font style="font-family:inherit;font-size:10pt;">$110.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million upon the achievement of specified sales performance milestones; and tiered royalty payments in the high-single to low-double digits, based upon the proportionate&#160;net sales of licensed products in any&#160;commercialized combination.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our contractual obligations as at December 31, 2015:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="31%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in millions)</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Less</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">than&#160;1&#160;year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1 &#8211; 3</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3 &#8211; 5</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">More than</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facility lease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We in-license technology from a number of sources. Pursuant to these in-license agreements, we will be required to make additional payments if and when we achieve specified development, regulatory, financial and commercialization milestones. To the extent we are unable to reasonably predict the likelihood, timing or amount of such payments; we have excluded them from the table above. Our technology in-licenses are further described in the Overview section of this discussion.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have contracts and collaborative arrangements that require us to undertake certain research and development work as further explained elsewhere in this discussion. It is not practicable to estimate the amount of these obligations.</font></div><a name="sD5EFD9B099AAE97AF002EF637358C69B"></a><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">IMPACT OF INFLATION</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inflation has not had a material impact on our operations.</font></div><a name="s4A59758B6A971755255DEF637376A398"></a><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RELATED PARTY TRANSACTIONS</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not entered into any related party transactions in the periods covered by this discussion.</font></div><a name="sA7D4C84CDBF73B3C3A16EF6373A92846"></a><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OUTSTANDING SHARE DATA</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At February 29, 2016, we had 54,625,703 common shares issued and outstanding, outstanding options to purchase an additional 2,432,414 common shares and outstanding warrants to purchase an additional 379,500 common shares.</font></div><a name="s2EAE0329615D80ADAE00EF6373CBA402"></a><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RECENT ACCOUNTING PRONOUNCEMENTS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842).: Recognition and Measurement of Financial Assets and Financial Liabilities. The update supersedes Topic 840, Leases and requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP.  Topic 842 retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. The amendments in this update are effective for fiscal years beginning after December 15, 2018 for public business entities, which for the Company means January 1, 2019. We do not plan to early adopt this update. The extent of the impact of this adoption has not yet been determined.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, the FASB issued ASU 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The update eliminates the requirement to retrospectively adjust the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill during the measurement period when new information is obtained about the facts and circumstances that existed as of the acquisition date, that if known, would have affected the measurement of the amounts initially recognized or would have resulted in the recognition of additional assets or liabilities. The amendments in this update are effective for fiscal years beginning after December 15, 2015, which for the Company means January 1, 2016, and should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update. Early application is permitted for financial statements that have not been issued. We have adopted this update and applied it to the acquisition of Arbutus Inc.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASC 606). The standard is intended to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS by creating a new Topic 606, Revenue from Contracts with Customers. This guidance supersedes the revenue recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition - Construction-Type and Production-Type Contracts. The core principle of the accounting standard is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1) retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date to defer the effective date of Update 2014-09 for all entities by one year. The new guidance would be effective for fiscal years beginning after December 15, 2017, which for us means January 1, 2018. Entities are permitted to adopt in accordance with the original effective date if they choose. We have not yet determined the extent of the impact of adoption.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern. The update is intended to provide guidance in GAAP about management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures. Under amendments to GAAP, the assessment period is within one year after the date that the financial statements are issued (or available to be issued). The amendments are effective for the annual period ending after December 15, 2016, which for us means January 1, 2017, and for annual periods and interim periods thereafter. Early application is permitted. We do not plan to early adopt this update. The extent of the impact of this adoption has not yet been determined.</font></div><a name="s329D16593B6D10C62FF0EF6373FBF0F8"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7A.        Quantitative and Qualitative Disclosures about Market Risk</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest rate risk</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are exposed to market risk related to changes in interest rates, which could adversely affect the value of our interest rate sensitive assets and liabilities.&#160;&#160;We do not hold any instruments for trading purposes and investment decisions are governed by a Board approved Investment Policy. As at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of $</font><font style="font-family:inherit;font-size:10pt;">166.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and short- and long-term investments of $24.6 million, as compared to $</font><font style="font-family:inherit;font-size:10pt;">72.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of cash and cash equivalents and $40.0 million of short-term investments as at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">. We invest our cash reserves in high interest saving accounts and guaranteed investment certificates and term deposits with varying terms to maturity (not exceeding two years) issued by major Canadian banks, selected with regard to the expected timing of expenditures for continuing operations and prevailing interest rates. The fair value of our cash investments as at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;equal to the face value of those investments and the value reported in our balance sheet.&#160;&#160;Due to the relatively short-term nature of the investments that we hold, we do not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to our investment portfolio.&#160;&#160;Our debt instrument sensitive to changes in interest rate is our warrant liability with its fair value determined using the Black-Scholes model, which uses interest rate as an input. We have estimated the effects on our warrant liability based on a one percentage point hypothetical adverse change in interest rates as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">. We determined the hypothetical fair value using the same Black-Scholes model, and determined that an increase in the interest rates of one percentage point would have had an adverse change to our warrant liability of $0.01 million and $0.01 million as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign currency exchange risk</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we are exposed to market risk related to changes in foreign currency exchange rates. We have not entered into any agreements or purchased any instruments to hedge possible currency risks at this time.&#160;&#160;We manage our US dollar exchange rate risk by, whenever possible, using cash received from US dollar revenues and financing to pay US dollar expenses. Given our increasing level of US dollar expenses, our policy is to maintain US and Canadian dollar cash and investment balances based on long term forecasts of currency needs thereby creating a natural currency hedge. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, an adverse change of one percentage point in the foreign currency exchange rates of Canadian to US dollars would have resulted in an incremental loss of </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. We recorded foreign exchange gains of $</font><font style="font-family:inherit;font-size:10pt;">21.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and $</font><font style="font-family:inherit;font-size:10pt;">4.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the fiscal years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2016, our functional currency changed from the Canadian dollar to the U.S. dollar based on our analysis of changes in the primary economic environment in which we operate. We will continue to incur substantial expenses and hold cash and investment balances in Canadian dollars, and as such, will remain subject to risks associated with foreign currency fluctuations.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><a name="sB6A6324F1EA2B633E115EF6374205D17"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.        Financial Statements and Supplementary Data</font></div><div style="line-height:120%;padding-top:20px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="93%"></td><td width="7%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD471288A98951D832462EF6374528F1F"><font style="font-family:inherit;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD471288A98951D832462EF6374528F1F">69</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s73247D3C6545DADA35B6EF63653C32B1"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets at December&#160;31, 2015 and 2014</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s73247D3C6545DADA35B6EF63653C32B1">71</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s27CE379DD08B8740FAD7EF63658D335D"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Income (loss) for the Years Ended December&#160;31 2015, 2014 and 2013</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s27CE379DD08B8740FAD7EF63658D335D">72</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD961F9813F4476B68F64EF6365785035"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December&#160; 31, 2015, 2014 and 2013</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD961F9813F4476B68F64EF6365785035">73</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDD9FA2A9C91FD1517916EF6366641B5A"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2015, 2014 and 2013</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDD9FA2A9C91FD1517916EF6366641B5A">74</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB8C5DF51C493EB1E4C33EF63756BFF53"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB8C5DF51C493EB1E4C33EF63756BFF53">75</a></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><a name="sD471288A98951D832462EF6374528F1F"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Shareholders and Board of Directors of Arbutus Biopharma Corporation</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Arbutus Biopharma Corporation as of December 31, 2015 and December 31, 2014 and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows each of the years in the three-year period ended December 31,&#160;2015. These consolidated financial statements are the responsibility of Arbutus Biopharma Corporation&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with Canadian generally accepted auditing standards and the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Arbutus Biopharma Corporation as of December 31, 2015 and December 31, 2014, and its consolidated results of operations and its consolidated cash flows each of the years in the three-year period ended December 31, 2015 in conformity with US generally accepted accounting principles.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Arbutus Biopharma Corporation&#8217;s internal control over financial reporting as of December 31, 2015, based on the criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated March 9, 2016 expressed an unqualified opinion on the effectiveness of Arbutus Biopharma Corporation&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">/s/ KPMG LLP</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chartered Accountants</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 9, 2016</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vancouver, Canada</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><a name="sD471288A98951D832462EF6374528F1F"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Shareholders and Board of Directors of Arbutus Biopharma Corporation</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited Arbutus Biopharma Corporation&#8217;s internal control over financial reporting as of December&#160;31, 2015, based on criteria established in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Internal Control &#8211; Integrated Framework (2013)</font><font style="font-family:inherit;font-size:10pt;">&#32;issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Arbutus Biopharma Corporation&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</font><font style="font-family:inherit;font-size:10pt;">. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our opinion, Arbutus Biopharma Corporation maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2015, based on criteria established in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Internal Control &#8211; Integrated Framework (2013)</font><font style="font-family:inherit;font-size:10pt;">&#32;issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;</sup></font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with Canadian generally accepted auditing standards and the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Arbutus Biopharma Corporation as of December&#160;31, 2015 and 2014, and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the years in the three-year period ended December 31, 2015, and our report dated March 9, 2016 expressed an unqualified opinion on those consolidated financial statements.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">/s/ KPMG LLP</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chartered Accountants</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 9, 2016</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vancouver, Canada</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><a name="s73247D3C6545DADA35B6EF63653C32B1"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(formerly Tekmira Pharmaceuticals Corporation)</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheets</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Expressed in thousands of US Dollars, except share and per share amounts)</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Prepared in accordance with US GAAP)</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">166,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments (note 2)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,525</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,974</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">128</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">538</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment tax credits receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets (note 7(a))</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,196</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,730</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">183,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment (note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12,912</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,959</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation (note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9,729</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,199</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net of accumulated depreciation (note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,183</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,760</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investments (note 2)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets (note 3)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">352,642</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill (note 3)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">162,514</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">712,291</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,178</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities (note 11)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,827</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue (note 4)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">868</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,779</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants (notes 2 and 6)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,578</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,206</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion (note 4)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,937</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration (note 9)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability (notes 3 and 8)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">146,324</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">164,612</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,143</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders&#8217; equity:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares (note 6)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Authorized - unlimited number with no par value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued and outstanding: 54,570,691 (December 31, 2014 - 22,438,169)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">834,240</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290,004</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">30,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(266,985</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(205,864</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(49,782</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,313</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">547,679</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,035</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">712,291</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,178</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nature of business and future operations (note 1)</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingencies and commitments (note 9)</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent event (note 13)</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to the consolidated financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><a name="s27CE379DD08B8740FAD7EF63658D335D"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(formerly Tekmira Pharmaceuticals Corporation)</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Expressed in thousands of US Dollars, except share and per share amounts)</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Prepared in accordance with US GAAP)</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="59%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue (note 4)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborations and contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13,309</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,738</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,425</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licensing fees, milestone and&#160;royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,564</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,215</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,040</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,873</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,953</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,465</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research, development, collaborations and contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">51,505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">26,438</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,683</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,546</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition costs (note 3)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9,656</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">462</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of intangible assets (note 3)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">39,007</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">127,195</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,387</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,617</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(102,322</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,434</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,152</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other income (losses)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange gains</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">21,771</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,127</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,079</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Decrease (increase) in fair value of warrant liability (note 2)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in fair value of contingent consideration (note 2)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(770</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total other income (losses)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25,016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,403</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,911</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(77,306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax recovery (notes 3 and 8)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(61,121</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,837</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,063</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per common share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.92</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">45,462,324</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,603,136</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,302,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">45,462,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,603,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,302,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumulative translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(27,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,489</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,135</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(88,590</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45,326</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,198</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to the consolidated financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><a name="sD961F9813F4476B68F64EF6365785035"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(formerly Tekmira Pharmaceuticals Corporation)</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statement of Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Expressed in thousands of US Dollars, except share and per share amounts)</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Prepared in accordance with US GAAP)</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td width="30%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Number<br>of shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Share<br>capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Additional paid-in<br>capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated<br>other comprehensive<br>loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total<br>stockholders'<br>equity</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, December 31, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,305,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">181,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(152,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(12,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,919</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">903</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issuance of common shares pursuant to exercise of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125,596</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">735</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(346</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">389</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issuance of common shares pursuant to exercise of warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">305,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issuance of common shares in conjunction with the private offering, net of issuance costs of $2,462,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,312,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,038</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,038</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Currency translation adjustment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,063</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,063</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,048,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">216,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(167,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,194</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issuance of common shares&#160;pursuant to exercise of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">648,506</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,034</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,418</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,616</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issuance of common shares pursuant to exercise of warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">615,763</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issuance of common shares in conjunction with the private offering, net of issuance costs of $4,085,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,125,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,477</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">56,477</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Currency translation adjustment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(38,837</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(38,837</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,438,169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">290,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(205,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88,035</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issuance of common shares pursuant to exercise of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">640,457</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,186</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,535</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,651</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issuance of common shares pursuant to exercise of warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issuance of common shares in conjunction with the public offering, net of issuance costs of $9,700,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,500,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">142,177</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">142,177</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase of equity instruments in conjunction with the acquisition of Arbutus Inc. (note 3)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,973,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">380,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">381,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Currency translation adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(27,469</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(27,469</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(61,121</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(61,121</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">54,570,691</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">834,240</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">30,206</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(266,985</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(49,782</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">547,679</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to the consolidated financial statements.</font></div><div style="line-height:120%;padding-top:4px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><a name="sDD9FA2A9C91FD1517916EF6366641B5A"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(formerly Tekmira Pharmaceuticals Corporation)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statements of Cash Flows</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Expressed in thousands of US Dollars, except share and per share amounts)</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Prepared in accordance with US GAAP)</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="56%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OPERATING ACTIVITIES</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss for the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(61,121</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,837</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,063</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Items not involving cash:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income taxes (notes 3 and 8)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(16,185</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">529</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation - research, development, collaborations and contract expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation - general and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,224</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">940</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized foreign exchange (gains) losses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(21,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(3,341</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,383</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,530</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Impairment of intangible assets (note 3)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">39,007</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change in non-cash operating items:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">628</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,887</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">889</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment tax credits receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">159</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(773</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(776</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,253</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(13,090</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,171</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(153</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(54,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INVESTING ACTIVITIES</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disposition (acquisition) of investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9,645</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41,982</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash acquired through acquisition (note 3)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from sale of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,056</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,682</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(725</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCING ACTIVITIES</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common shares, net of issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">142,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common shares pursuant to exercise of options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,651</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,616</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common shares pursuant to exercise of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">143,870</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,676</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,716</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of foreign currency rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(2,175</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,827</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,561</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">94,592</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,470</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,693</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">72,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">166,779</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,187</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,717</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental cash flow information</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of warrants exercised on a cashless basis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment tax credits received</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition of Arbutus Inc. net of cash acquired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">381,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to the consolidated financial statements.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><a name="sB8C5DF51C493EB1E4C33EF63756BFF53"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(formerly Tekmira Pharmaceuticals Corporation)</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Tabular amounts in thousands of US Dollars, except share and per share amounts)&#160;</font></div><a name="sD1BE690F450CBEB56291EF6365A5CDA7"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.         Nature of business and future operations</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the &#8220;Company&#8221; or &#8220;Arbutus&#8221;) is a Canadian biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (&#8220;HBV&#8221;). The Company is also developing a pipeline focused on advancing novel RNA interference therapeutics (RNAi) leveraging the Company&#8217;s expertise in Lipid Nanoparticle (LNP) technology.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective July 31, 2015, the corporate name changed from Tekmira Pharmaceuticals Corporation (Tekmira) to Arbutus Biopharma Corporation. Also effective July 31, 2015, the corporate name of the wholly-owned subsidiary, OnCore Biopharma, Inc. (OnCore) changed to Arbutus Biopharma, Inc. (Arbutus Inc.). Including Arbutus Inc., the Company has </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">&#32;wholly-owned subsidiaries: Protiva Biotherapeutics Inc. (Protiva), Protiva Biotherapeutics (USA) Inc. (Protiva USA), and Protiva Agricultural Development Company Inc. (&#8220;PADCo&#8221;). In March 2016, Monsanto exercised its option to acquire 100% of the outstanding shares in PADCo - refer to note 13 subsequent events.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company&#8217;s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company&#8217;s ability to continue to fund these programs in the future.</font></div><a name="s1EE933841F02CB149E02EF636532228C"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.         Significant accounting policies</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of presentation</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation) was incorporated on October&#160;6, 2005 as an inactive wholly owned subsidiary of Inex Pharmaceuticals Corporation (Inex). Pursuant to a &#8220;Plan of Arrangement&#8221; effective April&#160;30, 2007, the business and substantially all of the assets and liabilities of Inex were transferred to the Company. The consolidated financial statements for all periods presented herein include the consolidated operations of Inex until April&#160;30, 2007 and the operations of the Company thereafter.&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">&#32;wholly-owned subsidiaries as at December 31, 2015: Arbutus Biopharma, Inc. (formerly OnCore Biopharma, Inc.) Protiva Biotherapeutics Inc. (Protiva), Protiva Biotherapeutics (USA) Inc. (Protiva USA), and Protiva Agricultural Development Company Inc. (&#8220;PADCo&#8221;). Protiva and Protiva USA were acquired on May 30, 2008. PADCo was incorporated on January 9, 2014. Arbutus Inc. was acquired by way of a Merger Agreement on March 4, 2015, which included Arbutus Inc.'s wholly-owned subsidiary, Enantigen Therapeutics, Inc. (Enantigen) - see note 3. Enantigen was merged with Arbutus Inc. on September 30, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements include the accounts of the Company and three of its wholly-owned subsidiaries, Arbutus Inc., Protiva and Protiva USA. All intercompany transactions and balances have been eliminated on consolidation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records its investment in PADCo using the equity method. The Company has determined that PADCo is a variable interest entity (&#8220;VIE&#8221;) of which it is not the primary beneficiary. The Company is not the primary beneficiary as it does not have the power to make decisions that most significantly affect the economic performance of the VIE nor does the Company have the right to receive benefits or the obligation to absorb losses that in either case could potentially be significant to the VIE. PADCo is described further in note 4(b). In March 2016, Monsanto exercised its option to acquire PADCo - refer to note 13 subsequent events.</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring the use of management estimates relate to purchase price allocation, valuation of intangible assets and goodwill, recognition of revenue, stock-based compensation, valuation of warrant liability and financial instrument, and the amounts recorded as accrued liabilities, contingent consideration, and income tax recovery.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and cash equivalents</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents are all highly liquid instruments with an original maturity of three months or less when purchased. Cash equivalents are recorded at cost plus accrued interest. The carrying value of these cash equivalents approximates their fair value.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-term and long-term investments</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company acquired guaranteed investment certificates and a term deposit during the year, which are classified as short-term and long-term investments on the balance sheet respectively. Short-term investments have original maturities exceeding three months, and have remaining maturities less than one year. Long-term investments have remaining maturities exceeding twelve months. Short-term and long-term investments accrue interest daily based on a fixed interest rate for the term. The carrying value of these investments are recorded at cost plus accrued interest, which approximates their fair value. All investments are governed by the Board approved Investment Policy for the Company.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair value of financial instruments</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We measure certain financial instruments and other items at fair value.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 inputs are quoted market prices for identical instruments available in active markets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#8217;s assumptions about market assumptions that would be used to price the asset or liability.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:0px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term and long-term investments, accounts receivable, accounts payable and accrued liabilities, warrants and financial instruments. Long-term investments approximate fair value due to the interest rates being at prevailing market rates.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying values of cash and cash equivalents, short-term investments, accounts receivable and accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As quoted prices for the warrants are not readily available, the Company has used a Black-Scholes pricing model, as described in note 6, to estimate fair value. These are level 3 inputs as defined above.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company used a discounted cash flow model to determine the fair value of the financial instrument related to Monsanto&#8217;s call option to acquire the equity or all of the assets of PADCo, as described in note 4. The fair value was determined at the date of recognition, and at each reporting date. The initial fair value of the financial instrument was nil, and there has been no change to its fair value as at December 31, 2015. The assumptions used in the discounted cash flow model are level 3 inputs as defined above.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the fair value of the contingent consideration, the Company uses a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, time to complete the program development, and overall biotech indices, as in note 9. The fair value was determine at the date of recognition to be </font><font style="font-family:inherit;font-size:10pt;">$6,727,000</font><font style="font-family:inherit;font-size:10pt;">. The Company determined the fair value of the contingent consideration has increased by </font><font style="font-family:inherit;font-size:10pt;">$770,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$7,497,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and the increase in fair value has been recorded in other losses in the statement of operations and comprehensive loss for the year-ended December 31, 2015. The assumptions used in the discounted cash flow model are level 3 inputs as defined above.&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,779</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,779</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Guaranteed investment certificate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,070</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,070</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,374</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,374</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instrument</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,380</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,380</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td width="45%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,187</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,187</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Guaranteed investment certificates</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,161</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,161</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instrument</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company&#8217;s warrants:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td width="23%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability at beginning</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants issued in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warrants exercised</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase (decrease) in fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability at end</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the period</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,379</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,208</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,383</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(455</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(334</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,341</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company&#8217;s contingent consideration:</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="26%"></td><td width="1%"></td><td width="22%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="22%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="22%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability at beginning</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the period </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">value of contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability at end</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the period</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;(1) As at acquisition date of March 4, 2015 - see note 3 below.</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory includes materials assigned for the manufacture of products for collaborative partners and manufacturing costs for products awaiting acceptance by collaborative partners. Inventory is carried at the lower of cost and net realizable value and measured using first-in-first-out method. The cost of inventories includes all costs of purchase, costs of manufacturing and other costs incurred in bringing the inventories to their present location and condition.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Materials purchased for the Company&#8217;s own research and development products are not recorded as inventory but are expensed as incurred.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and equipment</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment is recorded at cost less impairment losses, accumulated depreciation, related government grants and investment tax credits. The Company records depreciation using the straight-line method over the estimated useful lives of the capital assets as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td width="77%"></td><td width="7%"></td><td width="1%"></td><td width="7%"></td><td width="1%"></td><td width="7%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Useful life (years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements are depreciated over their estimated useful lives but in no case longer than the lease term, except where lease renewal is reasonably assured. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If there is a major event indicating that the carrying value of property and equipment may be impaired then management will perform an impairment test and if the carrying value exceeds the recoverable value, based on undiscounted future cash flows, then such assets are written down to their fair values.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and intangible assets</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consist of in-process research and development arising from the Company&#8217;s acquisition of Arbutus Inc. - see note 3. In-process research and development (IPR&amp;D) intangible assets are classified as indefinite-lived and are not amortized. IPR&amp;D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives, which are the respective patent terms. Amortization begins when intangible assets with finite lives are put into use. If there is a major event indicating that the carrying value of intangible assets may be impaired, then management will perform an impairment test and if the carrying value exceeds the recoverable value, based on discounted future cash flows, then such assets are written down to their fair values. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets of Arbutus Inc. - see note 3. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is subject to a two-step impairment test on an annual basis, unless the Company identifies impairment indicators that would require earlier testing. The first step compares the fair value of the reporting unit to its carrying amount, which includes the goodwill. When the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not to be impaired, and the second step of the impairment test is unnecessary. If the carrying amount exceeds the implied fair value of the reporting unit, the second step measures the amount of the impairment loss. If the carrying amount exceeds the fair value of the reporting unit, an impairment loss is recognized equal to that excess.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company reviews the recoverable amount of intangible assets on an annual basis, and the annual evaluation for goodwill is performed as of December 31 each year. In addition, the Company evaluates for events or changes in the business that could indicate impairment and earlier testing. Such indicators include, but are not limited to, on an ongoing basis: (a) industry and market considerations such as increased competitive environment or adverse change in legal factors including an adverse assessment by regulators; (b) an accumulation of costs significantly in excess of the amount originally expected for the development of the asset; (c) current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the asset; and (d) if applicable, a sustained decrease in share price. </font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company earns revenue from research and development collaboration and contract services, licensing fees, milestone and royalty payments. Revenues associated with multiple element arrangements are attributed to the various elements based on their relative fair values or are recognized as a single unit of accounting when relative fair values are not determinable. Non-refundable payments received under collaborative research and development agreements are recorded as revenue as services are performed and related expenditures are incurred. Non-refundable upfront license fees from collaborative licensing and development arrangements are recognized as the Company fulfills its obligations related to the various elements within the agreements, in accordance with the contractual arrangements with third parties and the term over which the underlying benefit is being conferred. The Company evaluates new arrangements for any substantive milestones by considering: whether substantive uncertainty exists upon execution of the arrangement; if the event can only be achieved based in whole or in part on the Company&#8217;s performance, or occurrence of a specific outcome resulting from the Company&#8217;s performance; any future performance required, and payment is reasonable relative to all deliverables; and, the payment terms in the arrangement. Payments received upon the achievement of substantive milestones are recognized as revenue in their entirety. Payments received upon the occurrence of milestones that are non-substantive are deferred and recognized as revenue over the estimated period of performance applicable to the associated collaborative agreement.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue earned under research and development manufacturing collaborations where the Company bears some or all of the risk of a product manufacturing failure is recognized when the purchaser accepts the product and there are no remaining rights of return.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue earned under research and development collaborations where the Company does not bear any risk of product manufacturing failure is recognized in the period the work is performed. For contracts where the manufacturing amount is specified, revenue is recognized as product is manufactured in proportion to the total amount specified under the contract.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue and expenses under the contract with the United States Government Department of Defense (&#8220;DoD&#8221;) are being recorded using the percentage-of-completion method. Contract progress is based on costs incurred to date. Expenses under the contract are recorded in the Company&#8217;s consolidated statement of operations and comprehensive income (loss) as they are incurred. Government contract revenues related to expenses incurred under the contract are recorded in the same period as those expenses. Expenses accrued under the contract but not yet invoiced are recorded in the Company&#8217;s balance sheet as </font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">accrued liabilities and accrued revenues. Equipment purchased under the contract is recorded on the Company&#8217;s balance sheet as deferred expense and deferred revenue and amortized, on a straight-line basis, over the life of the contract.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash or other compensation received in advance of meeting the revenue recognition criteria is recorded on the balance sheet as deferred revenue. Revenue meeting recognition criteria but not yet received or receivable is recorded on the balance sheet as accrued revenue.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases and lease inducements</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leases entered into are classified as either capital or operating leases. Leases which substantially transfer all benefits and risks of ownership of property to the Company are accounted for as capital leases. At the time a capital lease is entered into, an asset is recorded together with its related long-term obligation to reflect the purchase and financing.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other leases are accounted for as operating leases wherein rental payments are expensed as incurred.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease inducements represent leasehold improvement allowances and reduced or free rent periods and are amortized on a straight-line basis over the term of the lease and are recorded as a reduction of rent expense.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and development costs</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are charged as an expense in the period in which they are incurred.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income or loss per share</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income or loss per share is calculated based on the weighted average number of common shares outstanding. Diluted loss per share does not differ from basic loss per share for the years ended December 31, 2015, 2014 and 2013, since the effect of the Company&#8217;s stock options and warrants is anti-dilutive.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the computation of basic and diluted net income (loss) per common share:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="59%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the year ended December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(61,121</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,837</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,063</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">45,462,324</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,603,136</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,302,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.92</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, potential common shares of </font><font style="font-family:inherit;font-size:10pt;">2,899,331</font><font style="font-family:inherit;font-size:10pt;">&#32;were excluded from the calculation of income per common share because their inclusion would be anti-dilutive (</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;">2,221,233</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;">3,064,767</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Government grants and refundable investment tax credits</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government grants and tax credits provided for current expenses is included in the determination of income or loss for the year, as a reduction of the expenses to which it relates. Government grants and tax credits towards the acquisition of property and equipment is deducted from the cost of the related property and equipment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign currency translation and change in reporting currency</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The functional currency of the Company and two of its integrated subsidiaries (Protiva and Protiva USA), is the Canadian dollar, and the functional currency of Arbutus Inc. is the U.S. dollar. Foreign currency monetary assets and liabilities are translated into the functional currency at the rate of exchange prevailing at the balance sheet date. Non-monetary assets and </font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">liabilities are translated at historical exchange rates. The previous month&#8217;s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is using United States dollars as its reporting currency. All assets and liabilities are translated using the exchange rate at the balance sheet date. Revenues, expenses and other income (losses) are translated using the average rate for the period, except for large transactions, for which the exchange rate on the date of the transaction is used. Equity accounts are translated using the historical rate. As the translation differences from the Company&#8217;s functional currency of Canadian dollars to the Company&#8217;s reporting currency of US dollars are unrealized gains and losses, the differences are recorded in other comprehensive income (loss), and do not impact the calculation of Income or Loss per Share.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2016, the Company changed its functional currency from the Canadian dollar to the U.S. dollar based on management's analysis of the changes in the primary economic environment in which the Company operates.  The change in functional currency is accounted for prospectively from January 1, 2016 and financial statements prior to and including the year-ended December 31, 2015 have not been restated for the change in functional currency. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred income taxes</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes are accounted for using the asset and liability method of accounting. Deferred income taxes are recognized for the future income tax consequences attributable to differences between the carrying values of assets and liabilities and their respective income tax bases and for loss carry-forwards. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the periods in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax laws or rates is included in earnings in the period that includes the enactment date. When realization of deferred income tax assets does not meet the more-likely-than-not criterion for recognition, a valuation allowance is provided.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based compensation</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company grants stock options to employees and directors pursuant to a share incentive plan described in note 6. Compensation expense is recorded for issued stock options using the fair value method with a corresponding increase in additional paid-in capital. Any consideration received on the exercise of stock options is credited to share capital.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of stock options is measured at the grant date and amortized on a straight-line basis over the vesting period.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Replacement awards</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Replacement awards are share-based payment awards exchanged for awards held by employees of Arbutus Inc. As part of the Company&#8217;s acquisition of Arbutus Inc., Arbutus shares were exchanged for Arbutus Inc.&#8217;s shares subject to repurchase rights held by Arbutus Inc.&#8217;s employees - see note 3.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at the date of acquisition of Arbutus Inc., the Company determined the total fair value of replacement awards and attributed a portion of the replacement awards to pre-combination service as part of the total acquisition consideration, and a portion to post-combination service, which is recognized as compensation expense over the expiry period of repurchase provision rights subsequent to the acquisition date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The replacement awards consist of common shares that were issued at acquisition. Accordingly, as stock compensation expense related to these awards is recognized, share capital is increased by a corresponding amount. Replacement awards are excluded in the calculation of basic net income (loss) per share until the repurchase rights have expired.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for the warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company&#8217;s own stock, on the understanding that in compliance with applicable securities laws, the registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies warrants in its consolidated balance sheet as a liability which is revalued at each balance sheet date subsequent to the initial issuance. The Company uses the Black-Scholes pricing model to value the warrants. Determining the appropriate fair-value model and calculating the fair value of registered warrants requires considerable judgment. A small change in the estimates used may cause a relatively large change in the estimated valuation. The estimated volatility of the Company&#8217;s common stock at the date of issuance, and at each subsequent reporting period, is based on historic fluctuations in the Company&#8217;s stock price. The risk-free interest rate is based on the Government of </font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canada rate for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is based on the historical pattern of exercises of warrants.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment information</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in a single reporting segment. Substantially all of the Company&#8217;s revenues to date were earned from customers or collaborators based in the United States. Substantially all of the Company&#8217;s premises, property and equipment are located in Canada and the United States.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent accounting pronouncements</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842): Recognition and Measurement of Financial Assets and Financial Liabilities. The update supersedes Topic 840, Leases and requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP.  Topic 842 retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. The amendments in this update are effective for fiscal years beginning after December 15, 2018 for public business entities, which for the Company means January 1, 2019. The Company does not plan to early adopt this update. The extent of the impact of this adoption has not yet been determined.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, the FASB issued ASU 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The update eliminates the requirement to retrospectively adjust the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill during the measurement period when new information is obtained about the facts and circumstances that existed as of the acquisition date, that if known, would have affected the measurement of the amounts initially recognized or would have resulted in the recognition of additional assets or liabilities. The amendments in this update are effective for fiscal years beginning after December 15, 2015, which for the Company means January 1, 2016, and should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update. Early application is permitted for financial statements that have not been issued. The Company has adopted this update and applied it to the acquisition of Arbutus Inc.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASC 606). The standard is intended to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS by creating a new Topic 606, Revenue from Contracts with Customers. This guidance supersedes the revenue recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition - Construction-Type and Production-Type Contracts. The core principle of the accounting standard is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1) retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date to defer the effective date of Update 2014-09 for all entities by one year. The new guidance would be effective for fiscal years beginning after December 15, 2017, which for the Company means January 1, 2018. Entities are permitted to adopt in accordance with the original effective date if they choose. The Company has not yet determined the extent of the impact of adoption.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern. The update is intended to provide guidance in GAAP about management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures. Under amendments to GAAP, the assessment period is within one year after the date that the financial statements are issued (or available to be issued). The amendments are effective for the annual period ending after December 15, 2016, which for the Company means January 1, 2017, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not plan to early adopt this update. The extent of the impact of this adoption has not yet been determined.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><a name="s5a25a9ff59cb43e294bbb15d88376e39"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.           Merger with Arbutus Biopharma, Inc. (formerly OnCore BioPharma, Inc.)</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160; &#160;&#160;Purchase Price Allocation</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 11, 2015, the Company entered into a Merger Agreement to acquire </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the outstanding shares of Arbutus Inc. (formerly OnCore Biopharma, Inc.) and its wholly-owned subsidiary, Enantigen (see note 9). Arbutus Inc. was a privately owned U.S. company focused on discovery, development and commercialization of an all-oral cure regimen for patients with HBV. The merger was approved by the Company&#8217;s shareholders on March 3, 2015 and closed on March 4, 2015. Arbutus Inc.&#8217;s results of operations and fair value of assets acquired and liabilities assumed are included in the Company&#8217;s consolidated financial statements from the date of acquisition.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transaction has been accounted for using the acquisition method based on ASC 805, Business Combinations, with Arbutus (formerly Tekmira) identified as the acquirer, based on managements&#8217; analysis and evaluation of the form of the acquisition, the relative contribution and rights of the predecessor groups post-closing, and the relative number of shares issued by the Company on acquisition of Arbutus Inc. Under the acquisition method, the consideration transferred is measured at fair value; common shares as consideration are issued at the market price as at the acquisition date. The excess of the purchase price over the preliminary fair value assigned to the net assets acquired has been recorded as goodwill. Acquisition costs were expensed as incurred. The Company recorded $</font><font style="font-family:inherit;font-size:10pt;">9,656,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of acquisition costs for the year ended December 31, 2015 (2014 - </font><font style="font-family:inherit;font-size:10pt;">$462,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company issued consideration with a total fair value of </font><font style="font-family:inherit;font-size:10pt;">$381,942,000</font><font style="font-family:inherit;font-size:10pt;">&#32;on acquisition. Of this consideration, </font><font style="font-family:inherit;font-size:10pt;">23,973,315</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares were issued, which is comprised of </font><font style="font-family:inherit;font-size:10pt;">20,347,906</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares issued without subjects and </font><font style="font-family:inherit;font-size:10pt;">3,625,412</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares issued to Arbutus Inc.&#8217;s founding executives and subject to repurchase provisions. The fair value of the common shares issued without subjects has been determined to be the Company&#8217;s NASDAQ closing price of $</font><font style="font-family:inherit;font-size:10pt;">18.26</font><font style="font-family:inherit;font-size:10pt;">&#32;on the date prior to the acquisition&#8217;s consummation, March 4, 2015. The total fair value of the common shares issued subject to repurchase provision has been determined to be $</font><font style="font-family:inherit;font-size:10pt;">66,196,000</font><font style="font-family:inherit;font-size:10pt;">, using the Black-Scholes pricing model with assumed risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">0.74%</font><font style="font-family:inherit;font-size:10pt;">, volatility of </font><font style="font-family:inherit;font-size:10pt;">81%</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;dividend yield and an expected life of </font><font style="font-family:inherit;font-size:10pt;">4 years</font><font style="font-family:inherit;font-size:10pt;">. Of the total fair value, $</font><font style="font-family:inherit;font-size:10pt;">9,262,000</font><font style="font-family:inherit;font-size:10pt;">&#32;has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of </font><font style="font-family:inherit;font-size:10pt;">$56,934,000</font><font style="font-family:inherit;font-size:10pt;">&#32;will be recognized as compensation expense over the period of expiry of repurchase provision rights and is not included in the total acquisition consideration. In July 2015, in conjunction with amendments to the employment contracts of Arbutus Inc.&#8217;s founding executives, the Company amended the repurchase provision rights period of expiry from August 2018 to August 2017. This amendment results in an acceleration of compensation expense recognized in each subsequent period by approximately </font><font style="font-family:inherit;font-size:10pt;">$1,900,000</font><font style="font-family:inherit;font-size:10pt;">&#32;per quarter, effective in Q3 2015. The Company recorded </font><font style="font-family:inherit;font-size:10pt;">$16,687,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in stock-based compensation expense related to services performed during the period of expiration of repurchase provision rights from the acquisition date through to December 31, 2015. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at the acquisition date, </font><font style="font-family:inherit;font-size:10pt;">3,625,412</font><font style="font-family:inherit;font-size:10pt;">&#32;shares were issued and outstanding which were and continue to remain subject to a repurchase provision. Subsequent to the acquisition date and the July 2015 amendment to the repurchase provision rights, the rights expire at a rate of </font><font style="font-family:inherit;font-size:10pt;">302,120</font><font style="font-family:inherit;font-size:10pt;">&#32;on November 30, 2015 and February 29, 2016 and at a rate of </font><font style="font-family:inherit;font-size:10pt;">503,552</font><font style="font-family:inherit;font-size:10pt;">&#32;shares every three months thereafter commencing May 31, 2016.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has further reserved </font><font style="font-family:inherit;font-size:10pt;">184,332</font><font style="font-family:inherit;font-size:10pt;">&#32;shares for the future exercise of Arbutus Inc. stock options. The total fair value of Arbutus Inc. stock options at the date of acquisition has been determined to be $</font><font style="font-family:inherit;font-size:10pt;">3,287,000</font><font style="font-family:inherit;font-size:10pt;">, using the Black-Scholes pricing model with an assumed risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">0.97%</font><font style="font-family:inherit;font-size:10pt;">, volatility of </font><font style="font-family:inherit;font-size:10pt;">78%</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;dividend yield and an expected life of </font><font style="font-family:inherit;font-size:10pt;">8 years</font><font style="font-family:inherit;font-size:10pt;">, which are consistent with the assumption inputs used by the Company to determine the fair value of its options. Of the total fair value, $</font><font style="font-family:inherit;font-size:10pt;">1,127,000</font><font style="font-family:inherit;font-size:10pt;">&#32;has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of </font><font style="font-family:inherit;font-size:10pt;">$2,160,000</font><font style="font-family:inherit;font-size:10pt;">&#32;will be recognized as compensation expense over the vesting period of the stock options through to December 2018. The Company has included </font><font style="font-family:inherit;font-size:10pt;">$463,000</font><font style="font-family:inherit;font-size:10pt;">&#32;compensation expense related to the vesting of Arbutus Inc. stock options from the acquisition date through to December 31, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate fair value of consideration transferred to acquire Arbutus Inc.&#8217;s outstanding shares has been determined to be </font><font style="font-family:inherit;font-size:10pt;">$381,942,000</font><font style="font-family:inherit;font-size:10pt;">, and has been attributed to fair values of assets acquired and liabilities assumed. The Company has refined the preliminary allocation of the purchase price for intangible assets, goodwill, contingent consideration and deferred tax liability from what was disclosed in prior periods. The following table summarizes the Company&#8217;s finalized purchase price allocation as at December 31, 2015:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><a name="s5a25a9ff59cb43e294bbb15d88376e39"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="87%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consideration paid:</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Common shares issued without subjects</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371,553</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Common shares issued subject to repurchase provision</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Common shares issuable for Arbutus Inc. stock options</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,127</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identifiable assets acquired and liabilities assumed:</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Cash</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Accounts receivable</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Property and equipment</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,649</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Goodwill</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,580</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Other non-current liabilities (note 9)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,727</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Deferred income tax liability</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(162,509</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total purchase price allocation</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of intangible assets is estimated to be </font><font style="font-family:inherit;font-size:10pt;">$391,649,000</font><font style="font-family:inherit;font-size:10pt;">. The fair value of each IPR&amp;D asset is estimated using the income approach. The income approach uses valuation techniques to discount future economic benefits attributed to the subject intangible asset to a present value. Present value is based on current market expectations about those future amounts and includes management&#8217;s estimates of risk-adjusted future incremental earnings that may be achieved upon regulatory approval, promotion, and distribution associated with the rights and includes estimated cash flows of approximately </font><font style="font-family:inherit;font-size:10pt;">20 years</font><font style="font-family:inherit;font-size:10pt;">&#32;and a discount rate of approximately </font><font style="font-family:inherit;font-size:10pt;">13.7%</font><font style="font-family:inherit;font-size:10pt;">. The identifiable intangible assets acquired consist of in-process research and development (IPR&amp;D) HBV assets, as summarized in the table below:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="87%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Cyclophilins</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,007</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Immune Modulators</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Antigen Inhibitors</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; cccDNA Sterilizers</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total IPR&amp;D</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">391,649</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All IPR&amp;D acquired is currently classified as indefinite-lived and is not currently being amortized. IPR&amp;D becomes definite-lived upon the completion or abandonment of the associated research and development efforts, and will be amortized from that time over an estimated useful life based on respective patent terms. The fair value of each IPR&amp;D asset will continue to be evaluated on a quarterly basis for indicators of impairment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the fair values above, an amount of $</font><font style="font-family:inherit;font-size:10pt;">162,514,000</font><font style="font-family:inherit;font-size:10pt;">&#32;has been allocated to goodwill, which represents the excess of the purchase price over the fair values assigned to the net assets acquired. Goodwill is attributable to synergies expected to arise after the Company&#8217;s acquisition of Arbutus Inc. The full amount of the value of goodwill has been assigned to the entire Company, since management has determined that the Company has only </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;reporting unit. The goodwill is not deductible for tax purposes, and is not amortized, but will be evaluated for impairment on an annual basis or more often if the Company identifies impairment indicators that would require earlier testing.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reconciliation of preliminary to final purchase price allocation</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2015, the Company finalized the purchase price allocation and made revisions to certain preliminary estimated fair values of assets acquired and liabilities assumed. The following table presents a summary of revisions and adjustments made to the preliminary estimates as previously disclosed to the finalized purchase price allocation:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><a name="s5a25a9ff59cb43e294bbb15d88376e39"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td width="46%"></td><td width="1%"></td><td width="16%"></td><td width="1%"></td><td width="1%"></td><td width="16%"></td><td width="1%"></td><td width="1%"></td><td width="16%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preliminary Amounts Recognized as of Acquisition Date </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measurement Period Adjustments</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(2)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts Recognized as of Acquisition Date (as adjusted)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identifiable assets acquired and liabilities assumed:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Cash</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Accounts receivable</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Property and equipment</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389,652</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,997</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,649</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Goodwill</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,580</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,580</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Other non-current liabilities (note 8)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,736</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,991</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,727</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Deferred income tax liability</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(155,865</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,644</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(162,509</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total purchase price allocation</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preliminary purchase price as of the acquisition date of March 4, 2015 as previously disclosed in the notes to consolidated financial statements included in the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The measurement period is from the acquisition date of March 4, 2015 to the date the Company finalized the purchase price allocation on December 31, 2015. </font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The measurement period adjustment for intangible assets acquired was made as the Company revised certain royalty rates on future sales of various intangible assets acquired. This resulted in an increase in deferred income tax liability associated with the intangible assets. In addition, the Company revised its preliminary tax rate based on management's revised analysis of a combined federal and state tax rate in the jurisdiction in which the Company expects the deferred tax liability to be settled or realized. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The measurement period adjustment for other non-current liabilities relate to the contingent consideration payable to former Enantigen shareholders upon the achievement of certain regulatory, development and sales milestones, as described in note 9. The adjustment relates to management's revision to the probabilities used in a probability weighted assessment of the likelihood of milestones being met and timing of such payments.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the above measurement period adjustments, the increase to goodwill of </font><font style="font-family:inherit;font-size:10pt;">$6,649,000</font><font style="font-family:inherit;font-size:10pt;">&#32;results in a final goodwill allocation of </font><font style="font-family:inherit;font-size:10pt;">$162,514,000</font><font style="font-family:inherit;font-size:10pt;">. As described in note 2 and further below, the Company conducts its annual goodwill impairment test on December 31st.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pro forma information</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amount of net loss of Arbutus Inc. included in the consolidated statements of operations from the acquisition date, through the period ended December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$13,658,000</font><font style="font-family:inherit;font-size:10pt;">. Arbutus Inc. did not earn any revenues from the acquisition date through the year-ended December 31, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the unaudited pro forma results for the year ended December 31, 2015 and 2014. The pro forma financial information combines the results of operations of Arbutus, Arbutus Inc., Protiva, Protiva USA, and Enantigen as though the businesses had been combined as of the beginning of fiscal 2014. The pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the merger had taken place at the beginning of fiscal 2014. The pro forma financial information presented includes acquisition costs, amortization charges for acquired tangible assets, impairment charge on acquired intangible assets (as described in note 3b below), but does not include amortization charges for acquired intangible assets as these assets have not yet been put in use.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><a name="s5a25a9ff59cb43e294bbb15d88376e39"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="47%"></td><td width="1%"></td><td width="24%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="24%"></td><td width="1%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pro forma information</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross Revenue</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,873</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,953</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(109,387</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,088</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(67,416</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(56,491</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.38</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.24</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Impairment evaluations for intangible assets and goodwill</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the recoverable amount of intangible assets on an annual basis and performs an annual evaluation of goodwill as of December 31 each year, unless there is an event or change in the business that could indicate impairment and earlier testing.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of intangible assets</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 28, 2015, the Company announced that the development of the cyclophilin drug candidate, OCB-030 has been discontinued. The decision was based on extensive preclinical evaluations performed by the Company of OCB-030 and other competitive cyclophilin inhibitors following the acquisition of Arbutus Inc., which concluded that cyclophilins do not play a meaningful role in HBV biology. Although the final conclusion was made subsequent to the period end, it reflected management&#8217;s best estimate as at September 30, 2015, and as such, the Company recorded an estimated impairment charge of $</font><font style="font-family:inherit;font-size:10pt;">37,990,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and a corresponding income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$15,196,000</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;related to the decrease in deferred tax liability for the discontinuance of OCB-030 in the consolidated statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As noted above, the Company finalized its purchase price allocation during the fourth quarter of 2015 by making certain revisions to estimates which included adjustments to the fair value of individual intangible assets acquired. The fair value of cyclophilin inhibitors has been adjusted to be </font><font style="font-family:inherit;font-size:10pt;">$39,007,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to management's best estimate of </font><font style="font-family:inherit;font-size:10pt;">$37,990,000</font><font style="font-family:inherit;font-size:10pt;">&#32;previously written off in the third quarter. The incremental adjustment to fair value of </font><font style="font-family:inherit;font-size:10pt;">$1,017,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as well as the corresponding incremental adjustment to income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$989,000</font><font style="font-family:inherit;font-size:10pt;">&#32;are cumulatively reflected in the Company's consolidated statement of operations and comprehensive loss for the year-ended December 31, 2015. For all other IPR&amp;D, fair values of the intangible assets were calculated to be above the respective carrying values; therefore, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;impairment was recorded. The following table summarizes the carrying values, net of impairment of the intangible assets as at December 31, 2015:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="87%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Cyclophilins</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Immune Modulators</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Antigen Inhibitors</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; cccDNA Sterilizers</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total IPR&amp;D</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">352,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Annual impairment evaluation of goodwill</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 31, the Company conducted its annual impairment evaluation of goodwill. Goodwill was recorded as a result of the acquisition of Arbutus Inc. as described in note 3(a), and has a carrying value of $</font><font style="font-family:inherit;font-size:10pt;">162,514,000</font><font style="font-family:inherit;font-size:10pt;">. As part of the evaluation of the recoverability of goodwill, the Company has identified only </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;reporting unit to which the total carrying amount of goodwill has been assigned. The income approach is used to estimate the fair value of the reporting unit, which requires estimating future cash flows and risk-adjusted discount rates. Changes in these estimates and assumptions could materially affect the determination of fair value of the reporting unit and may result in impairment charges in future periods. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></div><hr style="page-break-after:always"><a name="s5a25a9ff59cb43e294bbb15d88376e39"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015, the fair value of the reporting unit exceeded the carrying value of the reporting unit, and as such the second step of the impairment test, which measures the amount of impairment charge, was not required. In addition to the income approach, the Company considered the market capitalization of approximately </font><font style="font-family:inherit;font-size:10pt;">$242,844,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as at December 31, 2015. Although the Company&#8217;s carrying value of </font><font style="font-family:inherit;font-size:10pt;">$547,679,000</font><font style="font-family:inherit;font-size:10pt;">&#32;exceeded the market capitalization, the Company reconciled the income approach determination of fair value with the market capitalization by considering macroeconomic factors, and as such, the Company does not believe that market capitalization appropriately reflected the value of the Company for the purpose of testing goodwill impairment. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;impairment charge on goodwill was recorded for the year ended December 31, 2015.</font></div><a name="s69C00AF7AB10BAEF0322EF636584A6D9"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.           Collaborations, contracts and licensing agreements</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables set forth revenue recognized under collaborations, contracts and licensing agreements:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="59%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborations and contracts</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DoD (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,764</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,407</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,806</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto (b)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BMS (d)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,741</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">526</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna (e)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other RNAi collaborators (g)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development collaborations and contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Licensing fees, milestone and royalty payments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto licensing fees and milestone payments (b)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alnylam and Acuitas licensing fees and milestone payments (c)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna licensing fee (e)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Spectrum royalty payments (f)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total licensing fees, milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,564</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,215</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,040</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,873</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,953</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,465</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth deferred collaborations and contracts revenue:</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DoD (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto current portion (b)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,245</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna current portion (e)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,221</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">868</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,779</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto long-term portion (b)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna long-term portion (e)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,271</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total deferred revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,081</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,716</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160; &#160;&#160;Contract with United States Government&#8217;s Department of Defense (&#8220;DoD&#8221;) to develop TKM-Ebola</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July&#160;14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company&#8217;s lipid nanoparticle technology to treat Ebola virus infection.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company was eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;">$34,700,000</font><font style="font-family:inherit;font-size:10pt;">. This initial funding was for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration (&#8220;FDA&#8221;) and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle (&#8220;LNP&#8221;) formulation and manufacturing technologies. The contract modification increased the stage one targeted funding by an additional </font><font style="font-family:inherit;font-size:10pt;">$6,970,000</font><font style="font-family:inherit;font-size:10pt;">. On April 22, 2014, the Company and the DoD signed a contract modification to further increase the stage one targeted funding by </font><font style="font-family:inherit;font-size:10pt;">$2,100,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$43,819,000</font><font style="font-family:inherit;font-size:10pt;">. The additional funding was to compensate the Company for unrecovered overheads related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required. </font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The DoD had the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract&#8217;s budget this would have provided the Company with up to </font><font style="font-family:inherit;font-size:10pt;">$140,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in funding for the entire program. In December 2014, the DoD exercised an option valued at </font><font style="font-family:inherit;font-size:10pt;">$7,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to manufacture TKM-Ebola-Guinea, developed by the Company targeting the Ebola-Guinea strain responsible for the current outbreak in West Africa.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year, the Company estimates its labor and overhead rates for the year ahead. At the end of the year the actual labor and overhead rates are calculated and revenue is adjusted accordingly. The Company&#8217;s actual labor and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company&#8217;s efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs.&#160;&#160;During the contractual period, incentive fee revenue and total costs are impacted by management&#8217;s estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method.&#160;&#160;For the years ended December 31, 2014 and 2015, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 1, 2015, the Company received formal notification from the DoD that, due to the unclear development path for TKM-Ebola and TKM-Ebola-Guinea, the Ebola-Guinea Manufacturing and the Ebola-Guinea IND submission statements of work had been terminated, subject to the completion of certain post-termination obligations. &#160;The TKM-Ebola portion of the contract was completed in November 2015. The Company is currently conducting contract close out procedures with the DoD. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Option and Services Agreements with Monsanto Company (&#8220;Monsanto&#8221;)</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the &#8220;Agreements&#8221;). Under the Agreements, Monsanto has an option to obtain a license to use the Company&#8217;s proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">&#32;years, the Company will provide lipid formulations for Monsanto&#8217;s research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction is </font><font style="font-family:inherit;font-size:10pt;">$86,200,000</font><font style="font-family:inherit;font-size:10pt;">&#32;following the successful completion of milestones. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2015, the arrangement was amended to extend the option period by approximately </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;months, with payments up to </font><font style="font-family:inherit;font-size:10pt;">$2,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the extension period. From inception of the contract to December 31, 2015, the Company had received </font><font style="font-family:inherit;font-size:10pt;">$19,300,000</font><font style="font-family:inherit;font-size:10pt;">&#32;from Monsanto. The amounts received relate to research services and use of the Company&#8217;s technology over the option period, and are recognized as revenue on a straight-line basis over the extended option period.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the completion of the Phase A extension period in October 2015, no further research activities were conducted under the arrangement, as Monsanto did not elect to proceed to Phase B of the research plan. As such, the Company revised its estimate of the option period, over which payments received from Monsanto is recognized as revenue, to be from inception to December 31, 2015 as the Company believes it no longer has any further obligations to provide future research activities to Monsanto. This resulted in the full release of Monsanto deferred revenue and a recognition of </font><font style="font-family:inherit;font-size:10pt;">$14,981,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in Monsanto revenue for the year-ended December 31, 2015.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Agreements, the Company has established a wholly-owned subsidiary, PADCo. The Company has determined that PADCo is a variable interest entity (&#8220;VIE&#8221;); however, Monsanto is the primary beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company&#8217;s proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements. The Company&#8217;s initial investment is not significant, and the Company has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The Company has included its investment in PADCo in other assets. There were no significant assets or liabilities for PADCo as at December 31, 2015. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;equity income or loss with respect to PADCo recorded for the periods ended December 31, 2014 and December 31, 2015. In March 2016, Monsanto exercised its option to acquire </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the outstanding shares of PADCo and will pay the Company an exercise fee of </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;- refer to note 13 for the subsequent event.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">License and collaboration with Alnylam Pharmaceuticals, Inc. (Alnylam) and Acuitas Therapeutics Inc. (Acuitas)</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Milestone receipts and payments</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2013, Alnylam initiated a Phase III trial with ALN-TTR02, also known as patisiran, and the associated </font><font style="font-family:inherit;font-size:10pt;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;development milestone was paid to the Company in December 2013. In addition, the Company earned a </font><font style="font-family:inherit;font-size:10pt;">$150,000</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone in March 2014 from Acuitas (formerly AlCana Technologies, Inc.) subsequent to Acuitas receiving a milestone payment from Alnylam with respect to Alnylam initiating a Phase III trial for ALN-TTR02.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2013, the Company initiated Phase I/II clinical trial for TKM-PLK1, resulting in a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$375,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to Alnylam.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Arbitration with Alnylam and Ascletis Pharmaceuticals (Hangzhou) Co. Ltd. (&#8220;Ascletis&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 21, 2013, the Company transferred manufacturing process technology to Ascletis to enable them to produce ALN-VSP, a product candidate licensed to them by Alnylam. The Company believed that under its licensing agreement with Alnylam, the technology transfer to Ascletis triggered a $</font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone obligation from Alnylam to the Company. However, Alnylam demanded a declaration that the Company had not yet met its milestone obligations. The Company disputed Alnylam&#8217;s position. To remedy this dispute, the Company and Alnylam commenced arbitration proceedings as provided for under the agreement.&#160; The hearing date for this arbitration took place in May 2015, and in March 2016, the arbitration proceeding with Alnylam has concluded resulting in no milestone payment to the Company. &#160;The Company has not recorded any revenue in respect of this milestone for the year-ended December 31, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;&#160;&#160;Bristol-Myers Squibb (&#8220;BMS&#8221;) collaboration</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 10, 2010 the Company announced the expansion of its research collaboration with BMS. Under the new agreement, BMS uses small interfering RNA (&#8220;siRNA&#8221;) molecules formulated by the Company in LNP technology to silence target genes of interest.&#160;&#160;BMS is conducting the preclinical work to validate the function of certain genes and share the data with the Company.&#160;&#160;The Company can use the preclinical data to develop RNAi therapeutic drugs against the therapeutic targets of interest.&#160;&#160;The Company received </font><font style="font-family:inherit;font-size:10pt;">$3,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;from BMS concurrent with the signing of the agreement and recorded the amount as deferred revenue. The Company is required to provide a pre-determined number of LNP batches over the </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year agreement.&#160;&#160;BMS has a first right to negotiate a licensing agreement on certain RNAi products developed by the Company that evolve from BMS validated gene targets.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from the May 10, 2010 agreement with BMS is being recognized as the Company produces the related LNP batches.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue earned for the year-ended December 31, 2014 relates to batches shipped to BMS during the period. In August 2014, the agreement expired and both companies' obligations under the agreement ended.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;&#160;&#160;License and Development and Supply Agreement with Dicerna Pharmaceuticals, Inc. (&#8220;Dicerna&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 16, 2014, the Company signed a License Agreement and a Development and Supply Agreement (together, the &#8220;Agreements&#8221;) with Dicerna to development, manufacture, and commercialization of products directed to treatment of Primary Hyperoxaluria 1 (&#8220;PH1&#8221;), In consideration for the rights granted under the Agreements, Dicerna paid the Company an upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$2,500,000</font><font style="font-family:inherit;font-size:10pt;">. The Company is also entitled to receive payments from Dicerna on the manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones of </font><font style="font-family:inherit;font-size:10pt;">$22,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee has been established to provide guidance and direction on the progression of the collaboration.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined the deliverables under the Agreements included the rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed under the joint development committee.  The license and participation in the joint development committee have been determined by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has estimated to be approximately </font><font style="font-family:inherit;font-size:10pt;">28</font><font style="font-family:inherit;font-size:10pt;">&#32;months as at December 31, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has determined that manufacturing services and other services provided have standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures charged at comparable market rates with embedded margins on each work order. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing work orders are invoiced at the time of execution of the work order, at the initiation of manufacture, and at the release of materials. The Company has deferred the recognition of revenue on all cash deposit payments received for manufacturing work orders until acceptance of inventory.&#160;&#160;Revenue from service work orders is recognized as the services are performed.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company believes the development and regulatory milestones are substantive, due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development and regulatory events are based in part on the Company&#8217;s performance and the occurrence of a specific outcome resulting from performance. The Company has not received any milestone payments to date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;&#160;&#160;Agreements with Spectrum Pharmaceuticals, Inc. (&#8220;Spectrum&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 6, 2006, the Company signed a number of agreements with Talon Therapeutics, Inc. (&#8220;Talon&#8221;, formerly Hana Biosciences, Inc.) including the grant of worldwide licenses (the &#8220;Talon License Agreement&#8221;) for </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Company&#8217;s chemotherapy products, Marqibo&#174;, Alocrest &#8482; (Optisomal Vinorelbine) and Brakiva &#8482; (Optisomal Topotecan).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 9, 2012, the Company announced that Talon had received accelerated approval for Marqibo from the FDA for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Marqibo is a liposomal formulation of the chemotherapy drug vincristine. In the year ended December 31, 2012, the Company received a milestone of $</font><font style="font-family:inherit;font-size:10pt;">1,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;based on the FDA&#8217;s approval of Marqibo and will receive royalty payments based on Marqibo&#8217;s commercial sales. There are no further milestones related to Marqibo but the Company is eligible to receive total milestone payments of up to </font><font style="font-family:inherit;font-size:10pt;">$18,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;on Alocrest and Brakiva.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Talon was acquired by Spectrum in July 2013. The acquisition did not affect the terms of the license between Talon and the Company. On September 3, 2013, Spectrum announced that they had shipped the first commercial orders of Marqibo. In the year ended December 31, 2015, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$240,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in Marqibo royalty revenue (2014 - </font><font style="font-family:inherit;font-size:10pt;">$190,000</font><font style="font-family:inherit;font-size:10pt;">, 2013 -</font><font style="font-family:inherit;font-size:10pt;">$40,000</font><font style="font-family:inherit;font-size:10pt;">). In the year ended December 31, 2015, the Company accrued </font><font style="font-family:inherit;font-size:10pt;">$6,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in royalties due to TPC in respect of the Marqibo royalty earned by the Company (see note 9).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;&#160;&#160;Other RNAi collaborators</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;The Company had active research agreements with a number of other RNAi collaborators.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></div><hr style="page-break-after:always"><a name="s7C91A7994B0B45C76333EF63656BF292"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.         Property and equipment</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="59%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">December&#160;31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">depreciation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">book value</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,748</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,681</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,189</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">492</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,912</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,729</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,183</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="59%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">December&#160;31, 2014</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">depreciation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">book value</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,281</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,796</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,959</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,199</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,760</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015, all of the Company&#8217;s property and equipment are currently in use and </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;impairment has been recorded.</font></div><a name="sC822BD4D92F7DC380F92EF6365440B3C"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.         Share capital</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160; &#160;Financing</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 22, 2013, the Company completed an underwritten public offering of </font><font style="font-family:inherit;font-size:10pt;">3,750,000</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares, at a price of </font><font style="font-family:inherit;font-size:10pt;">$8.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, representing gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$30,000,000</font><font style="font-family:inherit;font-size:10pt;">. On November 1, 2013, the offering&#8217;s underwriter completed the exercise of its over-allotment option to purchase a further </font><font style="font-family:inherit;font-size:10pt;">562,500</font><font style="font-family:inherit;font-size:10pt;">&#32;shares at </font><font style="font-family:inherit;font-size:10pt;">$8.00</font><font style="font-family:inherit;font-size:10pt;">&#32;bringing the aggregate financing gross proceeds to </font><font style="font-family:inherit;font-size:10pt;">$34,500,000</font><font style="font-family:inherit;font-size:10pt;">. The cost of the financing, including commissions and professional fees, was </font><font style="font-family:inherit;font-size:10pt;">$2,462,000</font><font style="font-family:inherit;font-size:10pt;">, resulting in net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$32,038,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 26, 2014, the Company completed an underwritten public offering of </font><font style="font-family:inherit;font-size:10pt;">2,125,000</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares, at a price of </font><font style="font-family:inherit;font-size:10pt;">$28.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, representing gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$60,562,000</font><font style="font-family:inherit;font-size:10pt;">. The Company also granted the underwriters a </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-day option to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">318,750</font><font style="font-family:inherit;font-size:10pt;">&#32;shares for an additional </font><font style="font-family:inherit;font-size:10pt;">$9,084,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to cover any over-allotments. The underwriters did not exercise the option. The cost of financing, including commissions and professional fees, was </font><font style="font-family:inherit;font-size:10pt;">$4,085,000</font><font style="font-family:inherit;font-size:10pt;">, resulting in net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$56,477,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 25, 2015, the Company announced that it had completed an underwritten public offering of </font><font style="font-family:inherit;font-size:10pt;">7,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares, at a price of </font><font style="font-family:inherit;font-size:10pt;">$20.25</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, representing gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$151,875,000</font><font style="font-family:inherit;font-size:10pt;">. The Company also granted the underwriters a </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-day option to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">1,125,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares for an additional </font><font style="font-family:inherit;font-size:10pt;">$22,781,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to cover any over-allotments. The underwriters did not exercise the option. The cost of financing, including commissions and professional fees, was </font><font style="font-family:inherit;font-size:10pt;">$9,700,000</font><font style="font-family:inherit;font-size:10pt;">, resulting in net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$142,177,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;&#160;&#160;Authorized share capital</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s authorized share capital consists of an unlimited number of common and preferred shares without par value.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;&#160;&#160;Warrants to purchase common shares</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">18,750</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants exercised for </font><font style="font-family:inherit;font-size:10pt;">$42,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash (</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;">610,478</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants for </font><font style="font-family:inherit;font-size:10pt;">$1,583,000</font><font style="font-family:inherit;font-size:10pt;">) and </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants were exercised using the cashless exercise provision (</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;">6,000</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants for </font><font style="font-family:inherit;font-size:10pt;">5,285</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s warrant activity for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="37"></td></tr><tr><td width="12%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="4%"></td><td width="1%"></td><td width="1%"></td><td width="3%"></td><td width="1%"></td><td width="1%"></td><td width="5%"></td><td width="1%"></td><td width="4%"></td><td width="1%"></td><td width="1%"></td><td width="3%"></td><td width="1%"></td><td width="1%"></td><td width="8%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="6%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common shares</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">purchasable upon</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">exercise of</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted average</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">exercise price (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">average exercise</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Range of</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">exercise prices</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Range of</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">exercise prices</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted average remaining contractual life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Aggregate</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">intrinsic value</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Aggregate</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">intrinsic value</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,014,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$2.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$2.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercised</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(616,478</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.09</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.80</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.03</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">398,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercised</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(18,750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.88</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.62</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">379,500</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.95</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.13</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$2.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$2.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.62</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,217</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">879</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value in the table above is calculated based on the difference between the exercise price of the warrants and the quoted price of the Company&#8217;s common stock as of the reporting date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the Company&#8217;s warrants were exercisable as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average Black-Scholes option-pricing assumptions and the resultant fair values are as follows for warrants outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">49.07</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85.22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected average term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.6 years</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5 years</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of warrants outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate fair value of warrants outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">883</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of warrants outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">379,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">398,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The value of the Company&#8217;s warrants are particularly sensitive to changes in the Company&#8217;s share price and the estimated share price volatility.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;&#160;&#160;Stock-based compensation</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;share-based compensation plans; the &#8220;2007 Plan&#8221;, the &#8220;2011 Plan&#8221;, two &#8220;Designated Plans&#8221; (together, the &#8220;Arbutus Plans&#8221;), the &#8220;Protiva Option Plan&#8221;, and the "OnCore Option Plan" (see note 3 above).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 22, 2011, the shareholders of the Company approved an omnibus stock-based compensation plan (the &#8220;2011 Plan&#8221;). The Company&#8217;s pre-existing 2007 Plan was limited to the granting of stock options as equity incentive awards whereas the 2011 Plan also allows for the issuance of tandem stock appreciation rights, restricted stock units and deferred stock units (collectively, and including options, referred to as &#8220;Awards&#8221;). The 2011 Plan replaces the 2007 Plan. The 2007 Plan will continue to govern the options granted thereunder. No further options will be granted under the Company&#8217;s 2007 Plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Company&#8217;s 2007 Plan the Board of Directors granted options to employees, directors and consultants of the Company.&#160;&#160;The exercise price of the options was determined by the Company&#8217;s Board of Directors but was always at least equal to the closing market price of the common shares on the day preceding the date of grant and the term of options granted did not exceed </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">&#32;years.&#160;&#160;The options granted generally vested over </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">&#32;for employees and immediately for directors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Company&#8217;s 2011 Plan the Board of Directors may grant options, and other types of Awards, to employees, directors and consultants of the Company.&#160;&#160;The exercise price of the options is determined by the Company&#8217;s Board of Directors but will be at least equal to the closing market price of the common shares on the day preceding the date of grant and the term may not exceed </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">&#32;years.&#160;&#160;Options granted generally vest over </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">&#32;for employees and immediately for directors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, the Company granted a total of </font><font style="font-family:inherit;font-size:10pt;">200,000</font><font style="font-family:inherit;font-size:10pt;">&#32;options in 2013 to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;executive officers in conjunction with their new appointments as executive officers. These options were granted in accordance with the policies of the Toronto Stock Exchange and pursuant to newly designated share compensation plans (the &#8220;Designated Plans&#8221;). The Designated Plans are governed by substantially the same terms as the 2011 Plan. Hereafter, information on options governed by the 2007 Plan, the 2011 Plan, and the Designated Plans is presented on a consolidated basis as the terms of the four plans are similar. Information on the Protiva Option Plan and the OnCore Option Plan is presented separately.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the Company&#8217;s annual general and special meeting of shareholders on May 8, 2014 and July 9, 2015, the shareholders of the Company approved respectively, a </font><font style="font-family:inherit;font-size:10pt;">800,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and a </font><font style="font-family:inherit;font-size:10pt;">3,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in the number of stock-based compensation awards that the Company is permitted to issue.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock option activity for the Arbutus Plans</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td width="31%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">optioned</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">intrinsic</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">value (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">intrinsic</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">value (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,648,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,301</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.52</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64,085</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.87</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,730,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431,125</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.63</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.34</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(622,752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,530,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,309,625</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.57</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(398,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(151,207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.09</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,290,263</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.53</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.22</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,376</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">994</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options under the Arbutus Plans expire at various dates from March 28, 2016 to December 2, 2025.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information pertaining to stock options outstanding at December 31, 2015 under the Arbutus Plans:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td width="10%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="13%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td><td width="1%"></td><td width="10%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="9%"></td><td width="1%"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Options outstanding December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Options exercisable December 31, 2015</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Range of</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Exercise prices (US$)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Number</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">of options</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">average</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">remaining</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">contractual</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">average</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">exercise</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Number</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">of options</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">average</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">exercise</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">102,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">102,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.52</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.88</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,475</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.66</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,475</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.66</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$2.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$2.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">83,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">83,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$3.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$4.70</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">288,960</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.84</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">268,900</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$5.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$7.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">261,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">175,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$8.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$10.04</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">176,813</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,189</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$10.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$13.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">129,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">79,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$13.40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$17.57</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,126,875</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17.02</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17.57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$17.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,290,263</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.22</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">938,730</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.98</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, 2015, there were </font><font style="font-family:inherit;font-size:10pt;">938,730</font><font style="font-family:inherit;font-size:10pt;">&#32;options exercisable (December 31, 2014 - </font><font style="font-family:inherit;font-size:10pt;">1,088,908</font><font style="font-family:inherit;font-size:10pt;">; December 31, 2013 &#8211; </font><font style="font-family:inherit;font-size:10pt;">1,377,091</font><font style="font-family:inherit;font-size:10pt;">) . The weighted average remaining contractual life of exercisable options as at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">6.1</font><font style="font-family:inherit;font-size:10pt;">&#32;years. </font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of in-the-money options exercisable at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$994,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s non-vested stock option activity and related information for the year ended December 31, 2015 is as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td width="59%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">optioned</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fair value (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fair value (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,309,625</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.89</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(250,461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested options forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148,853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,351,541</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.69</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.34</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average remaining contractual life for options expected to vest at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">9.1</font><font style="font-family:inherit;font-size:10pt;">&#32;years and the weighted average exercise price for these options was </font><font style="font-family:inherit;font-size:10pt;">$15.54</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">C$21.51</font><font style="font-family:inherit;font-size:10pt;">) per share.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of options expected to vest as at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(December 31, 2014 - </font><font style="font-family:inherit;font-size:10pt;">$2,626,000</font><font style="font-family:inherit;font-size:10pt;">; December 31, 2013 -</font><font style="font-family:inherit;font-size:10pt;">$943,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total fair value of options that vested during the year ended December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$1,718,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(2014 - </font><font style="font-family:inherit;font-size:10pt;">$2,505,000</font><font style="font-family:inherit;font-size:10pt;">; 2013 -</font><font style="font-family:inherit;font-size:10pt;">$955,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation assumptions for the Arbutus Plans</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 3, 2015, the Company de-listed from the Toronto Stock Exchange. All stock options granted after March 3, 2015 were denominated in US dollars based on the Company's stock price on the NASDAQ. The methodology and assumptions used  to estimate the fair value of stock options at date of grant under the Black-Scholes option-pricing model remain unchanged. Assumptions on the dividend yield are based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. Assumptions about the Company&#8217;s expected stock-price volatility are based on the historical volatility of the Company&#8217;s publicly traded stock. The risk-free interest rate used for each grant is equal to the </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;coupon rate for instruments with a similar expected life. Expected life assumptions are based on the Company&#8217;s historical data. Based on an analysis of its historical forfeitures, the Company  has applied a forfeiture rate to all unvested options held as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeitures are higher than estimated. The weighted average option pricing assumptions and the resultant fair values are as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td width="59%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">76.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected average option term</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.5 years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.8 years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.6 years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Protiva Option Plan</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 30, 2008, as a condition of the acquisition of Protiva Biotherapeutics Inc., a total of </font><font style="font-family:inherit;font-size:10pt;">350,457</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares of the Company were reserved for the exercise of </font><font style="font-family:inherit;font-size:10pt;">519,073</font><font style="font-family:inherit;font-size:10pt;">&#32;Protiva share options (&#8220;Protiva Options&#8221;). The Protiva Options have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">C$0.30</font><font style="font-family:inherit;font-size:10pt;">, were fully vested and exercisable as of May 30, 2008. As at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the outstanding options expire at various dates from April 3, 2017 to March 1, 2018 and upon exercise each option will be converted into approximately </font><font style="font-family:inherit;font-size:10pt;">0.6752</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company (the same ratio at which Protiva common shares were exchanged for Company common shares at completion of the acquisition of Protiva). The Protiva Options are not part of the Arbutus Plans and the Company is not permitted to grant any further Protiva Options.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth outstanding options under the Protiva Option Plan:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td width="45%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of Protiva</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equivalent number</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Company</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">475,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,350</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(675</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">472,885</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319,274</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(675</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">433,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292,845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(358,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(242,164</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,065</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,445</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.23</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,236</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.22</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average remaining contractual life of exercisable Protiva Options as at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">1.8</font><font style="font-family:inherit;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of Protiva Options outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$187,000</font><font style="font-family:inherit;font-size:10pt;">. The intrinsic value of Protiva Options exercised in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$1,249,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(2014 - </font><font style="font-family:inherit;font-size:10pt;">$378,000</font><font style="font-family:inherit;font-size:10pt;">; 2013 -</font><font style="font-family:inherit;font-size:10pt;">$8,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OnCore Option Plan</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As described in note 3 above, as at the acquisition date, the Company reserved </font><font style="font-family:inherit;font-size:10pt;">184,332</font><font style="font-family:inherit;font-size:10pt;">&#32;shares for the future exercise of OnCore (Arbutus Inc.) stock options. The total fair value of OnCore stock options at the date of acquisition has been determined to be </font><font style="font-family:inherit;font-size:10pt;">$3,287,000</font><font style="font-family:inherit;font-size:10pt;">, using the Black-Scholes pricing model with an assumed risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">0.97%</font><font style="font-family:inherit;font-size:10pt;">, volatility of </font><font style="font-family:inherit;font-size:10pt;">78%</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;dividend yield and an expected life of </font><font style="font-family:inherit;font-size:10pt;">8</font><font style="font-family:inherit;font-size:10pt;">&#32;years, which are consistent with the assumption inputs used by the Company to determine the fair value of its options. Of the total fair value, </font><font style="font-family:inherit;font-size:10pt;">$1,127,000</font><font style="font-family:inherit;font-size:10pt;">&#32;has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of </font><font style="font-family:inherit;font-size:10pt;">$2,160,000</font><font style="font-family:inherit;font-size:10pt;">&#32;will be recognized as compensation expense over the vesting period of the stock options through to December 2018. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the merger, the Company is not permitted to grant any further options under the OnCore Option Plan. The Company has included </font><font style="font-family:inherit;font-size:10pt;">$463,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of compensation expense related to the vesting of Arbutus Inc. stock options from the acquisition date through to December 31, 2015, which includes an estimated forfeiture rate consistent with the Company's forfeiture estimate under the Arbutus Plans.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth outstanding options under the OnCore Option Plan:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td width="59%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of OnCore</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equivalent number</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Company</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, March 4, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,040</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,332</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, 2015, there were </font><font style="font-family:inherit;font-size:10pt;">86,658</font><font style="font-family:inherit;font-size:10pt;">&#32;OnCore options (</font><font style="font-family:inherit;font-size:10pt;">87,269</font><font style="font-family:inherit;font-size:10pt;">&#32;Arbutus equivalent) exercisable with a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.57</font><font style="font-family:inherit;font-size:10pt;">. The weighted average remaining contractual life of exercisable options as at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">8.9</font><font style="font-family:inherit;font-size:10pt;">&#32;years. The aggregate intrinsic value of in-the-money options exercisable at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$337,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the OnCore Option Plan's non-vested stock option activity and related information for the period from acquisition to December 31, 2015 is as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td width="59%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="12%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OnCore Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equivalent number</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Company</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fair value (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested at March 4, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,128</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,354</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested options forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,382</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,063</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.42</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average remaining contractual life for options expected to vest at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">8.9</font><font style="font-family:inherit;font-size:10pt;">&#32;years and the weighted average exercise price for these options was </font><font style="font-family:inherit;font-size:10pt;">$0.57</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of options expected to vest as at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$695,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total fair value of options that vested during the period from acquisition on March 4, 2015 to December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$620,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based compensation expense</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense is comprised of: (1) the vesting options awarded to employees under the Arbutus and OnCore option plans calculated in accordance with the fair value method as described above; and (2) the expiration of repurchase rights related to the post-combination service portion of the total fair value of shares issued to Arbutus Inc.'s employees as described in note 3 above.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total stock-based compensation has been recorded in the consolidated statement of operations and comprehensive income (loss) as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="59%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research, development, collaborations and contracts expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,225</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">940</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">22,093</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,283</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">903</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, 2015, there remains </font><font style="font-family:inherit;font-size:10pt;">$11,972,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of unearned compensation expense related to unvested employee stock options to be recognized as expense over a weighted-average period of approximately </font><font style="font-family:inherit;font-size:10pt;">16</font><font style="font-family:inherit;font-size:10pt;">&#32;months, as well as a remaining </font><font style="font-family:inherit;font-size:10pt;">$35,967,000</font><font style="font-family:inherit;font-size:10pt;">&#32;unearned compensation expense related to unexpired repurchase rights on shares issued to Arbutus Inc. employees to be recognized as expense over a weighted average period of approximately </font><font style="font-family:inherit;font-size:10pt;">12</font><font style="font-family:inherit;font-size:10pt;">&#32;months.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Awards outstanding and available for issuance</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Combining all of the Company&#8217;s share-based compensation plans, at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company has </font><font style="font-family:inherit;font-size:10pt;">2,519,831</font><font style="font-family:inherit;font-size:10pt;">&#32;options outstanding and a further </font><font style="font-family:inherit;font-size:10pt;">3,135,980</font><font style="font-family:inherit;font-size:10pt;">&#32;Awards available for issuance.&#160;</font></div><a name="s7D6D68802D07A9DC159BEF6365B32CED"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.        Government grants and refundable investment tax credits</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government grants and refundable investment tax credits have been recorded as a reduction in research and development expenses. </font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a) Government grants</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2014, the Company entered into a Manufacturing and Clinical Trial Agreement with the University of Oxford to provide the new TKM-Ebola-Guinea therapeutic product for clinical studies in West Africa. The University of Oxford is the representative of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), who conducted clinical studies of TKM-Ebola-Guinea in Ebola virus infected patients, with funding provided by the Wellcome Trust. In January 2015, the Company received </font><font style="font-family:inherit;font-size:10pt;">$1,098,000</font><font style="font-family:inherit;font-size:10pt;">&#32;from ISARIC for materials manufactured and used in the March 2015 TKM-Ebola-Guinea Phase II single arm trial conducted in Sierra Leone. In June 2015, the Company announced closing of the enrollment for the trial as it reached a futility boundary, which was a predefined statistical endpoint. No further funding is expected under this grant. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government grants for the year ended December 31, 2015 include </font><font style="font-family:inherit;font-size:10pt;">$1,245,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in funding from the U.S. National Institutes of Health (2014 - </font><font style="font-family:inherit;font-size:10pt;">$172,000</font><font style="font-family:inherit;font-size:10pt;">). </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b) Refundable investment tax credits</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s estimated claim for refundable Scientific Research and Experimental Development investment tax credits for the year ended December 31, 2015 is </font><font style="font-family:inherit;font-size:10pt;">$196,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(2014 - </font><font style="font-family:inherit;font-size:10pt;">$52,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><a name="sC24ABA14E9B16C002B41EF6365688384"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.         Income taxes</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax (recovery) expense varies from the amounts that would be computed by applying the combined Canadian federal and provincial income tax rate of </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;">&#32;(2014 -  </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;">; 2013 &#8211; </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;">) to the loss before income taxes as shown in the following tables:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td width="59%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computed taxes (recoveries) at Canadian&#160;federal and provincial tax rates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(20,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,486</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Differences due to change in enacted tax rates</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permanent and other differences</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance - other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,676</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,599</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,407</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Difference due to income taxed at foreign rates</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(7,874</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax recovery</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(16,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company has investment tax credits available to reduce Canadian federal income taxes of </font><font style="font-family:inherit;font-size:10pt;">$7,969,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(December&#160;31, 2014 - </font><font style="font-family:inherit;font-size:10pt;">$7,866,000</font><font style="font-family:inherit;font-size:10pt;">) and provincial income taxes of </font><font style="font-family:inherit;font-size:10pt;">$3,869,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(December&#160;31, 2014 - </font><font style="font-family:inherit;font-size:10pt;">$3,401,000</font><font style="font-family:inherit;font-size:10pt;">), expiring between 2027 and 2035. In addition, the Company has research and development credits of </font><font style="font-family:inherit;font-size:10pt;">$483,000</font><font style="font-family:inherit;font-size:10pt;">&#32;available for indefinite carry-forward, which can be used to reduce future taxable income in the U.S.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, 2015, the Company has scientific research and experimental development expenditures of </font><font style="font-family:inherit;font-size:10pt;">$51,823,000</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;(December 31, 2014 - </font><font style="font-family:inherit;font-size:10pt;">$49,907,000</font><font style="font-family:inherit;font-size:10pt;">) available for indefinite carry-forward and </font><font style="font-family:inherit;font-size:10pt;">$24,745,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(December&#160;31, 2014 - </font><font style="font-family:inherit;font-size:10pt;">$25,301,000</font><font style="font-family:inherit;font-size:10pt;">) of net operating losses due to expire between 2027 and 2035 and which can be used to offset future taxable income in Canada.  </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015, the Company has </font><font style="font-family:inherit;font-size:10pt;">$17,235,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of net operating losses due to expire between 2030 and 2035, which can be used to offset future taxable income in the U.S. Future use of a portion of the U.S. loss carry-forwards is subject to limitations under the Internal Revenue Code Section 382. As a result of ownership changes occurred on October 1, 2014 and March 4, 2015, the Company's ability to use these losses may be limited. Losses incurred to date may be further limited if a subsequent change in control occurs.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 23, 2011, the Company was registered as a corporation under the Business Activity Act in the province of British Columbia. Under this program, provincial corporation tax charged on foreign income earned from the Company&#8217;s patents will be eligible for a </font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;">&#32;tax refund up to a maximum of </font><font style="font-family:inherit;font-size:10pt;">C$8,000,000</font><font style="font-family:inherit;font-size:10pt;">. Significant components of the Company&#8217;s deferred tax assets are shown below:</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-capital loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13,932</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,578</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development deductions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13,474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Book amortization in excess of tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,142</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,745</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized for tax purposes in excess of revenue recognized for accounting purposes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">281</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,086</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax value in excess of accounting value in lease inducements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal investment tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,303</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,821</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provincial investment tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(146,324</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront license fees</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(104,830</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,818</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(41,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,818</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(146,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The comparative figures in the above table have been recast to increase the deferred tax assets before valuation allowance by </font><font style="font-family:inherit;font-size:10pt;">$8,424,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and the valuation allowance by </font><font style="font-family:inherit;font-size:10pt;">$8,424,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as at December 31, 2014 to be consistent with current year's disclosure. The comparative figures in the income tax expense reconciliation table have also been recast to reflect these changes. These adjustments have no impact on the consolidated financial position, consolidated results of operations or the consolidated cash flows.&#160;</font></div><a name="sF8278B1675D1B78FE441EF636547D91B"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.         Contingencies and commitments</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property lease</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The minimum rent and estimated operating cost commitment, net of lease inducements, is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="87%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,229,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">938,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">938,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,652,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s lease expense, for the year ended December 31, 2015 of </font><font style="font-family:inherit;font-size:10pt;">$1,158,000</font><font style="font-family:inherit;font-size:10pt;">&#32;has been recorded in the consolidated statements of operations and comprehensive loss (2014 of </font><font style="font-family:inherit;font-size:10pt;">$1,133,000</font><font style="font-family:inherit;font-size:10pt;">; 2013 -</font><font style="font-family:inherit;font-size:10pt;">$1,225,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product development partnership with the Canadian Government</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a Technology Partnerships Canada (TPC) agreement with the Canadian Federal Government on November 12, 1999.&#160;&#160;Under this agreement, TPC agreed to fund </font><font style="font-family:inherit;font-size:10pt;">27%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the costs incurred by the Company, prior to March 31, 2004, in the development of certain oligonucleotide product candidates up to a maximum contribution from TPC of </font><font style="font-family:inherit;font-size:10pt;">$7,179,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">C$9,330,000</font><font style="font-family:inherit;font-size:10pt;">).&#160;&#160;As at December 31, 2015, a cumulative contribution of </font><font style="font-family:inherit;font-size:10pt;">$2,675,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">C$3,702,000</font><font style="font-family:inherit;font-size:10pt;">) had been received and the Company does not expect any further funding under this agreement.&#160;&#160;In return for the funding provided by TPC, the Company agreed to pay royalties on the share of future licensing and product revenue, if any, that is received by the Company on certain non-siRNA oligonucleotide product candidates covered by the funding under the agreement.&#160;&#160;These royalties are payable until a certain cumulative payment amount is achieved or until a pre-specified date.&#160;&#160;In addition, until a cumulative amount equal to the funding actually received under the agreement has been paid to TPC, the Company agreed to pay </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;royalties on any royalties the Company receives for Marqibo. For the year ended December 31, 2015, the Company earned royalties on Marqibo sales in the amount of </font><font style="font-family:inherit;font-size:10pt;">$240,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(see note 4(f)), resulting in </font><font style="font-family:inherit;font-size:10pt;">$6,000</font><font style="font-family:inherit;font-size:10pt;">&#32;recorded by the Company as royalty payable to TPC (2014 - </font><font style="font-family:inherit;font-size:10pt;">$190,000</font><font style="font-family:inherit;font-size:10pt;">; 2013 -</font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;">).&#160;The cumulative amount paid or accrued up to December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$12,000</font><font style="font-family:inherit;font-size:10pt;">, resulting in the contingent amount due to TPC being </font><font style="font-family:inherit;font-size:10pt;">$2,664,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">C$3,687,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">License agreement with Marina Biotech, Inc. (&#8220;Marina&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 29, 2012 the Company announced a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleobase Analog (&#8220;UNA&#8221;) from Marina for the development of RNAi therapeutics.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UNA technology can be used in the development of RNAi therapeutics, which treat disease by silencing specific disease causing genes. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the license agreement the Company paid Marina an upfront fee of </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;">. A further license payment of </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;">&#32;was paid in 2013 and the Company will make milestone payments of up to </font><font style="font-family:inherit;font-size:10pt;">$3,250,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and royalties on each product developed by the Company that uses Marina&#8217;s UNA technology. The payments to Marina are expensed to research, development, collaborations and contracts expense.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective August 9, 2013, Marina&#8217;s UNA technology was acquired by Arcturus Therapeutics, Inc. (&#8220;Arcturus&#8221;) and the UNA license agreement between the Company and Marina was assigned to Arcturus. The terms of the license are otherwise unchanged. On December 22, 2014, the Company received clearance from Health Canada to conduct a Phase I Clinical Study with TKM-HBV, which utilizes Arcturus&#8217; UNA technology. The dosing of first subject in the Phase I clinical trial of TKM-HBV occurred in January 2015, which  resulted in a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to Arcturus.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Arbitration with the University of British Columbia (&#8220;UBC&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain early work on lipid nanoparticle delivery systems and related inventions was undertaken at UBC.&#160;&#160;These inventions are licensed to the Company by UBC under a license agreement, initially entered in 1998 as amended in 2001, 2006 and 2007. The Company has granted sublicenses under the UBC license to Alnylam as well as to Talon.&#160;&#160;Alnylam has in turn sublicensed back to the Company under the licensed UBC patents for discovery, development and commercialization of RNAi products. In 2009, the Company entered into a supplemental agreement with UBC, Alnylam and Acuitas, in relation to a separate research collaboration to be conducted among UBC, Alnylam and Acuitas to which the Company has license rights. The settlement agreement signed in late 2012 to resolve the litigation among the Company, Alnylam, and Acuitas, provided for the effective termination of all obligations under such supplemental agreement as between and among all litigants (see note 4(c)).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 10, 2014, UBC filed a notice of arbitration against the Company and on January 16, 2015, filed a Statement of Claim, which alleges entitlement to </font><font style="font-family:inherit;font-size:10pt;">$3,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in allegedly unpaid royalties based on publicly available information, and an unspecified amount based on non-public information. UBC also seeks interest and costs, including legal fees. The Company is currently disputing UBC&#8217;s allegations, and no dates have been scheduled for this arbitration. However, the Company notes that arbitration is subject to inherent uncertainty and an arbitrator could rule against the Company. The Company has not recorded an estimate of the possible loss associated with this arbitration, due to the uncertainties related to both the likelihood and amount of any possible loss or range of loss. However, the defense of arbitration and related matters are costly and may divert the attention of the Company&#8217;s management and other resources that would otherwise be engaged in other activities. Costs related to the arbitration have been recorded by the Company as incurred.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingent consideration from OnCore acquisition of Enantigen and License Agreements between Enantigen and Blumberg and Drexel</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, OnCore acquired all of the outstanding shares of Enantigen pursuant to a stock purchase agreement. Through this transaction, OnCore acquired a HBV surface antigen secretion inhibitor program and a capsid assembly inhibitor program, each of which are now assets of Arbutus, following the Company&#8217;s merger with Arbutus Inc. - see note 3.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the stock purchase agreement, OnCore agreed to pay up to a total of </font><font style="font-family:inherit;font-size:10pt;">$21,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to Enantigen&#8217;s selling stockholders upon the achievement of certain triggering events related to Enantigen&#8217;s </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;programs in pre-clinical development related to HBV therapies. The first triggering event is the enrollment of first patient in Phase 1b clinical trial in HBV patients, which the Company does not expect to occur in the next twelve-month period.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The regulatory, development and sales milestone payments have an estimated fair value of approximately </font><font style="font-family:inherit;font-size:10pt;">$6,727,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as at the date of acquisition of Arbutus Inc., and have been treated as contingent consideration payable in the purchase price allocation (note 3), based on information available at the date of acquisition, using a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, time to complete the program development, and overall biotech indices.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration is considered as a financial liability, and measured at its fair value at each reporting period with any changes in fair value from the previous reporting period recorded in the statement of operations and comprehensive loss. For the period ended December 31, 2015, the Company performed an evaluation of the fair value of the contingent consideration using the probability weighted assessment of likelihood of milestone payments as described above. The Company determined the fair value of the contingent consideration has increased by </font><font style="font-family:inherit;font-size:10pt;">$770,000</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$7,497,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and the increase in fair value has been recorded in other losses in the statement of operations and comprehensive loss for the year-ended December 31, 2015. </font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Drexel and Blumberg</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, OnCore entered into a license agreement with Blumberg and Drexel that granted an exclusive, worldwide, sub-licensable license to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;different compound series: cccDNA inhibitors, capsid assembly inhibitors and HCC inhibitors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, OnCore paid a license initiation fee of </font><font style="font-family:inherit;font-size:10pt;">$150,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and issued warrants to Blumberg and Drexel. Under this license agreement, OnCore also agreed to pay up to </font><font style="font-family:inherit;font-size:10pt;">$3,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in development and regulatory milestones per licensed compound series, up to </font><font style="font-family:inherit;font-size:10pt;">$92,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in sales performance milestones per licensed product, and royalties in the mid-single digits based upon the proportionate net sales of licensed products in any commercialized combination. The Company is obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from the sub-licensees, subject to customary exclusions.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, OnCore entered into an additional license agreement with Blumberg and Drexel pursuant to which it received an exclusive, worldwide, sub-licensable license under specified patents and know-how controlled by Blumberg and Drexel covering epigenetic modifiers of cccDNA and STING agonists. In consideration for these exclusive licenses, OnCore made an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;">. Under this agreement, the Company will be required to pay up to </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for each licensed product upon the achievement of a specified regulatory milestone and a low single digit royalty, based upon the proportionate&#160;net sales of compounds covered by this intellectual property&#160;in any commercialized combination. The Company is also obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from its sub-licensees, subject to exclusions.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaboration and Funding Agreement with Blumberg</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, Arbutus Inc. entered into a research collaboration and funding agreement with Blumberg under which the Company will provide </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;per year of research funding for </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;years, renewable at the Company&#8217;s option for an additional </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;years, for Blumberg to conduct research projects in HBV and liver cancer pursuant to a research plan to be agreed upon by the parties. Blumberg has exclusivity obligations to Arbutus with respect to HBV research funded under the agreement. In addition, the Company has the right to match any third party offer to fund HBV research that falls outside the scope of the research being funded under the agreement. Blumberg has granted the Company the right to obtain an exclusive, royalty bearing, worldwide license to any intellectual property generated by any funded research project. If the Company elects to exercise its right to obtain such a license, the Company will have a specified period of time to negotiate and enter into a mutually agreeable license agreement with Blumberg. This license agreement will include the following pre negotiated upfront, milestone and royalty payments: an upfront payment in the amount of </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">; up to </font><font style="font-family:inherit;font-size:10pt;">$8,100,000</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the achievement of specified development and regulatory milestones; up to </font><font style="font-family:inherit;font-size:10pt;">$92,500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the achievement of specified commercialization milestones; and royalties at a low single to mid-single digit rates based upon the proportionate&#160;net sales of licensed&#160;products from any commercialized combination.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NeuroVive Pharmaceutical AB (&#8220;NeuroVive&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2014, Arbutus Inc. entered into a license agreement with NeuroVive that granted them an exclusive, worldwide, sub-licensable license to develop, manufacture and commercialize, for the treatment of HBV, oral dosage form sanglifehrin based cyclophilin inhibitors (including OCB-030). Under this license agreement, the Company has been granted a non-exclusive, royalty free right and license and right of reference to NeuroVive&#8217;s relevant regulatory approvals and filings for the sole purpose of developing, manufacturing and commercializing licensed products for the treatment of HBV. Under this license agreement, the Company has (1)&#160;an option to expand its exclusive license to include treatment of viral diseases other than HBV and (2)&#160;an option, exercisable upon specified conditions, to expand its exclusive license to include development, manufacture and commercialization of non-oral variations of licensed products for treatment of viral diseases other than HBV. NeuroVive retains all rights with respect to development, manufacture and commercialization of licensed products and non-oral variations of licensed products for all indications (other than HBV) for which the Company has not exercised its option.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, Arbutus Inc. paid NeuroVive a license fee of </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;">. As described in note 3 above, Arbutus Inc. became our wholly owned subsidiary by way of a Merger Agreement, which does not trigger any milestone payments. We have conducted significant research and analysis on the NeuroVive Product, OCB-030. Based on this research and analysis, we have decided to discontinue the OCB-030 development program.&#160; Otherwise, the license agreement and ongoing relationship with NeuroVive remains in full effect.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cytos Biotechnology Ltd (&#8220;Cytos&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;30, 2014, Arbutus Inc. entered into an exclusive, worldwide, sub-licensable (subject to certain restrictions with respect to licensed viral infections other than hepatitis) license to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;different series of compounds. The licensed compounds are Qbeta-derived virus-like particles that encapsulate TLR9, TLR7 or RIG-I agonists and may or may not be conjugated with antigens from the hepatitis virus or other licensed viruses.&#160; The Company has an option to expand this license to include additional viral infections other than influenza and Cytos will retain all rights for influenza, all non-viral infections, and all viral infections (other than hepatitis) for which it has not exercised its option.&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, the Company is obligated to pay Cytos up to a total of </font><font style="font-family:inherit;font-size:10pt;">$67,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for each of the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;licensed compound series upon the achievement of specified development and regulatory milestones; for hepatitis and each additional licensed viral infection, up to a total of </font><font style="font-family:inherit;font-size:10pt;">$110,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the achievement of specified sales performance milestones; and tiered royalty payments in the high-single to low-double digits, based upon the proportionate&#160;net sales of licensed products in any&#160;commercialized combination.</font></div><a name="s85E56E96B7C17612294AEF636546D434"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.        Concentrations of business risk</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is defined by the Company as an unexpected loss in cash and earnings if a collaborative partner is unable to pay its obligations in due time. The Company&#8217;s main source of credit risk is related to its accounts receivable balance which principally represents temporary financing provided to collaborative partners in the normal course of operations.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not currently maintain a provision for bad debts as the majority of accounts receivable are from collaborative partners or government agencies and are considered low risk.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at December 31, 2015 was the accounts receivable balance of </font><font style="font-family:inherit;font-size:10pt;">$1,008,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(2014 - </font><font style="font-family:inherit;font-size:10pt;">$1,903,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All accounts receivable balances were current as at December 31, 2015 and December 31, 2014.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant collaborators and customers risk</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We depend on a small number of collaborators and customers for a significant portion of our revenues (see note 4).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity Risk</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk results from the Company&#8217;s potential inability to meet its financial liabilities, for example payments to suppliers.&#160;&#160;The Company ensures sufficient liquidity through the management of net working capital and cash balances.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s liquidity risk is primarily attributable to its cash and cash equivalents, and short-term investments. The Company limits exposure to liquidity risk on its liquid assets through maintaining its cash and cash equivalent, and short-term investments with high-credit quality financial institutions. Due to the nature of these investments, the funds are available on demand to provide optimal financial flexibility.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company believes that its current sources of liquidity are sufficient to cover its likely applicable short term cash obligations. The Company&#8217;s financial obligations include accounts payable and accrued liabilities which generally fall due within </font><font style="font-family:inherit;font-size:10pt;">45</font><font style="font-family:inherit;font-size:10pt;">&#32;days. The net liquidity of the Company is considered to be the cash and cash equivalents and short-term investments less accounts payable and accrued liabilities.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and&#160;short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">181,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,827</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">172,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign currency risk</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of the Company&#8217;s operations are subject to foreign currency transaction and translation risk as the Company&#8217;s revenues and expenses are denominated in both Canadian and US dollars. The fluctuation of the US dollar in relation to the Canadian dollar will consequently have an impact upon the Company&#8217;s reported income or loss and may also affect the value of the Company&#8217;s assets, liabilities, and the amount of shareholders&#8217; equity both as recorded in the Company&#8217;s financial statements, in the Canadian functional currency, and as reported, for presentation purposes, in the US dollar.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company manages its US dollar exchange rate risk by, whenever possible, using cash received from US dollar revenues and financing to pay US dollar expenses. Prior to the financing in October 2013 (note 6(a)), which was denominated in US dollars, the Company&#8217;s policy was to convert all but a working capital level of US dollars into Canadian dollars. Given the Company&#8217;s increasing level of US dollar expenses, its policy is now to maintain US and Canadian dollar cash and investment and short-term investment balances based on long term forecasts of currency needs thereby creating a natural currency hedge.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not entered into any agreements or purchased any instruments to hedge possible currency risks. The Company&#8217;s exposure to US dollar currency expressed in Canadian dollars was as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in C$)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents and short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">213,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,071</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,942</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">206,607</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An analysis of the Company&#8217;s sensitivity to foreign currency exchange rate movements is not provided in these financial statements as the Company&#8217;s US dollar cash holdings and expected US dollar revenues are sufficient to cover US dollar expenses for the foreseeable future.</font></div><a name="s9F89828665AE55A12900EF6365A2D57C"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.         Supplementary information</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities is comprised of the following:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td width="73%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development accruals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,358</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,391</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License fee accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fee accruals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">640</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred lease inducements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payroll accruals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,331</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,873</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">591</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,328</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><a name="s842C4E4C5D06DD954AACEF6365628DE5"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12.        Interim financial data (unaudited)</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="31%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,065</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,006</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,420</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,138</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,758</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(102,322</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,982</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(61,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.57</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td width="31%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td><td width="1%"></td><td width="1%"></td><td width="11%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,423</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,844</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,747</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(33,434</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(38,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.91</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div></div><a name="s97ADC9A3ABE86B60AFBAEF6365D11868"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13.         Subsequent events</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a) Protiva USA Reorganization</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2016, the Company undertook a corporate reorganization merging Protiva USA into Arbutus Inc., which acquired Protiva USA's assets and assumed Protiva USA's liabilities in exchange for Arbutus Inc. shares. The reorganization did not result in any adverse Canadian and U.S. tax consequences.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b) Monsanto Option Exercise</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 4, 2016, Monsanto exercised its option to acquire </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the outstanding shares of Protiva Agricultural Development Company Inc. (PADCo), pursuant under its Option Agreement with the Company. Monsanto will pay the Company </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in exercise fee, which the Company will record in the statement of operations and comprehensive loss for the period ended March 31, 2016.</font></div><a name="s4C3DA7978055C5DFC6E7EF6377B2897F"></a><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.        Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><a name="s60490C2E66E4388215A8EF6377E43F76"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9A.       Controls and Procedures</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of the end of our fiscal year ended December&#160;31, 2015, an evaluation of the effectiveness of our &#8220;disclosure controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) was carried out by our management, with the participation of our Chief Executive Officer (CEO) and Chief Financial Officer (CFO). Based upon that evaluation, the CEO and CFO have concluded that as of the end of that fiscal year, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i)&#160;recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission (the &#8220;Commission&#8221;) rules and forms and (ii)&#160;accumulated and communicated to the management of the registrant, including the CEO and CFO, to allow timely decisions regarding required disclosure.</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It should be noted that while the CEO and CFO believe that our disclosure controls and procedures provide a reasonable level of assurance that they are effective, they do not expect that our disclosure controls and procedures or internal control over financial reporting will prevent all errors and fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management&#8217;s Annual Report on internal control over financial reporting</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rule 13a-15(f) of the Securities Exchange Act of 1934. Our internal control system was designed to provide reasonable assurance that all transactions are accurately recorded, that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our assets are safeguarded.</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management has assessed the effectiveness of our internal control over financial reporting as at December&#160;31, 2015. In making its assessment, management used the Committee of Sponsoring Organizations of the Treadway Commission (COSO) framework in Internal Control &#8211; Integrated Framework (2013) to evaluate the effectiveness of our internal control over financial reporting. Based on this assessment, management has concluded that our internal control over financial reporting was effective as of December&#160;31, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Attestation report of the registered public accounting firm</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is an &#8220;accelerated filer&#8221; within the meaning of Rule 12b-2 under the Exchange Act. The independent registered public accounting firm&#8217;s report on the effectiveness of our internal control over financial reporting is included in Item 8 of this annual report on Form 10-K and are incorporated herein by reference.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in internal control over financial reporting</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the period covered by the annual report, being the fiscal year ended December&#160;31, 2015, changes were made to our internal control over financial reporting in order to integrate Arbutus Inc.'s internal control over financial reporting with our internal control over financial reporting. </font></div><a name="sA2F32B9C7741B41F841FEF637808A515"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9B.        Other Information</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></div><hr style="page-break-after:always"><a name="s6FEBC09BA31CC0C64885EF63783AC6A0"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div><a name="sD91E430BD43561122A4AEF637858D988"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 10.        Directors, Executive Officers and Corporate Governance</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated herein by reference to the information contained under the sections captioned &#8220;Proposal&#160;One&#160;&#8212; Election of Directors,&#8221; &#8220;Section&#160;16(a) Beneficial Ownership Reporting Compliance&#8221; and &#8220;Corporate Governance&#8221; of the Proxy Statement. The information required by this item relating to executive officers is included in Part&#160;I, Item&#160;1, &#8220;&#8212;&#160;Business-Executive Officers of the Registrant,&#8221; of this annual report on Form&#160;10-K.</font></div><a name="sEBBA542F7E63919A2B18EF63788A5690"></a><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 11.          Executive Compensation</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated herein by reference to the information contained under the sections captioned &#8220;Information about Executive Officer and Director Compensation,&#8221; &#8220;Compensation Committee Interlocks and Insider Participation,&#8221; &#8220;Employment Arrangements&#8221; and &#8220;Compensation Committee Report&#8221; of the Proxy Statement.</font></div><a name="sC23CC36FA9D9272D3D49EF6378ABFA92"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 12.          Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated herein by reference to the information contained under the sections captioned &#8220;Security Ownership of Certain Beneficial Owners and Management,&#8221; &#8220;Information about Executive Officer and Director Compensation&#8221; and &#8220;Securities Authorized for Issuance Under Equity Compensation Plans&#8221; of the Proxy Statement.</font></div><a name="sC9C9DA1352761A0EA164EF6378DEF518"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 13.         Relationships and Related Transactions, and Director Independence</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated herein by reference to the information contained under the sections captioned &#8220;Corporate Governance,&#8221; &#8220;Employment Arrangements&#8221; and &#8220;Certain Relationships and Related Transactions&#8221; of the Proxy Statement.</font></div><a name="s3B8BB0908888F85C5E03EF6379028140"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 14.        Principal Accountant Fees and Services</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is incorporated herein by reference to the information contained under the sections captioned &#8220;Corporate Governance,&#8221; &#8220;Principal Accountant Fees and Services&#8221; and &#8220;Pre-Approval Policies and Procedures&#8221; of the Proxy Statement.</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div></div><hr style="page-break-after:always"><a name="sE6F06B38C7712DCEA164EF6379340F74"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div><a name="s511D9AC555271B3BAD26EF637953C977"></a><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 15.          Exhibits and Financial Statement Schedules</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;See Index to Consolidated Financial Statements under Item 8 of Part II.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statement Schedules</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;None</font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106</font></div></div><hr style="page-break-after:always"><a name="sC312BCEF302CF9B02DCBEF637998F311"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on </font><font style="font-family:inherit;font-size:10pt;">March&#160;9, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="7%"></td><td width="44%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Mark Murray</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Murray</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on </font><font style="font-family:inherit;font-size:10pt;">March&#160;9, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="48%"></td><td width="1%"></td><td width="51%"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Signatures</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Capacity in Which Signed</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Vivek Ramaswamy</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director (Chairman)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vivek Ramaswamy</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Mark Murray</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer and Director</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark Murray</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Bruce Cousins</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President, Finance and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bruce Cousins</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer and Accounting Officer)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Herbert J. Conrad</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Herbert J. Conrad</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Richard C. Henriques</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Richard C. Henriques</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Frank Karbe</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Frank Karbe</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Keith Manchester</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Keith Manchester</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William T. Symonds</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Development Officer and Director</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William T. Symonds</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></div><hr style="page-break-after:always"><a name="s34E8DB1CFF9CDD2FFEBDEF6379A589F5"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="11%"></td><td width="1%"></td><td width="88%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit<br>Number</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subscription Agreement, between the Company and Alnylam Pharmaceuticals, Inc., dated March 28, 2008 (incorporated herein by reference to Exhibit 2.1 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subscription Agreement, between the Company and Roche Finance Ltd., dated March 31, 2008 (incorporated herein by reference to Exhibit 2.2 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Agreement and Plan of Merger and Reorganization, dated January 11, 2015, by and among Tekmira Pharmaceuticals Corporation, TKM Acquisition Corporation and OnCore Biopharma, Inc. (incorporated herein by reference to Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K/A filed with the SEC on January 26, 2015).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notice of Articles and Articles of the Company (incorporated herein by reference to Exhibit 1.1 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment to the Articles of the Company dated May 14, 2013 (incorporated herein by reference to Exhibit 3.2 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 28, 2014).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Governance Amendment to the Articles of the Company dated March 4, 2015, (incorporated herein by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on March 4, 2015).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Approval of Quorum Policy of the Company, adopted January 31, 2015 (incorporated herein by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on February 5, 2015).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Governance Agreement between the Company and Roivant Sciences Ltd., a Bermuda exempted company, dated January 11, 2015 (incorporated herein by reference to Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K/A filed with the SEC on January 26, 2015).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment No. 1 to the Amended and Restated Agreement, between the Company (formerly Inex Pharmaceuticals Corporation) and Hana Biosciences, Inc., effective as of May 27, 2009 (incorporated herein by reference to Exhibit 4.1 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amended and Restated License Agreement, between Inex Pharmaceuticals Corporation and Hana Biosciences, Inc., dated April 30, 2007 (incorporated herein by reference to Exhibit 4.2 to the Registrant&#8217;s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sublicense Agreement, between Inex Pharmaceuticals Corporation and Alnylam Pharmaceuticals, Inc., dated January 8, 2007 (incorporated herein by reference to Exhibit 4.3 to the Registrant&#8217;s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amended and Restated License and Collaboration Agreement, between the Company and Alnylam Pharmaceuticals, Inc., effective as of May 30, 2008 (incorporated herein by reference to Exhibit 4.4 to the Registrant&#8217;s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Cross-License Agreement, between Alnylam Pharmaceuticals, Inc. and Protiva Biotherapeutics Inc., dated May 30, 2008 (incorporated herein by reference to Exhibit 4.5 to the Registrant&#8217;s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License Agreement, between Inex Pharmaceuticals and Aradigm Corporation, dated December 8, 2004 (incorporated herein by reference to Exhibit 4.6 to the Registrant&#8217;s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Settlement Agreement, between Sirna Therapeutics, Inc. and Merck &amp; Co., Inc. and Protiva Biotherapeutics Inc. and Protiva Biotherapeutics (USA), Inc., effective as of October 9, 2007 (incorporated herein by reference to Exhibit 4.7 to the Registrant&#8217;s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development, Manufacturing and Supply Agreement, between the Company and Alnylam Pharmaceuticals, Inc., dated January 2, 2009 (incorporated herein by reference to Exhibit 4.8 to the Registrant&#8217;s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></div><hr style="page-break-after:always"><a name="s34E8DB1CFF9CDD2FFEBDEF6379A589F5"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="11%"></td><td width="1%"></td><td width="88%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9&#8224;*#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement with Ian Mortimer, dated March 26, 2008 (incorporated herein by reference to Exhibit 4.9 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.10*#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement with Ian MacLachlan, dated May 30, 2008 (incorporated herein by reference to Exhibit 4.10 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.11*#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement with Mark Murray, dated May 30, 2008 (incorporated herein by reference to Exhibit 4.11 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.12*#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement with Peter Lutwyche, dated January 1, 2009 (incorporated herein by reference to Exhibit 4.12 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.13*#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share Option Plan amended through May 12, 2009 (including form stock option agreements) (incorporated herein by reference to Exhibit 4.13 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.14*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease Agreement with Canada Lands Company CLC Limited dated December 15, 1997, as amended (incorporated herein by reference to Exhibit 4.14 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.15*#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Indemnity Agreement (incorporated herein by reference to Exhibit 4.15 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.16*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Award Contract with USASMDC/ARSTRAT effective date July 14, 2010 (incorporated herein by reference to Exhibit 4.16 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.17&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License Agreement between the University of British Columbia and Inex Pharmaceuticals Corporation executed on July 30, 2001 (incorporated herein by reference to Exhibit 4.17 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.18&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment Agreement between the University of British Columbia and Inex Pharmaceuticals Corporation dated July 11, 2006 (incorporated herein by reference to Exhibit 4.18 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.19&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Amendment Agreement between the University of British Columbia and Inex Pharmaceuticals Corporation dated January 8, 2007 (incorporated herein by reference to Exhibit 4.19 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.20&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consent Agreement of the University of British Columbia to Inex/Alnylam Sublicense Agreement dated January 8, 2007 (incorporated herein by reference to Exhibit 4.20 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.21&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendment No. 2 to the Amended and Restated Agreement, between the Company (formerly Inex Pharmaceuticals Corporation) and Hana Biosciences, Inc., effective as of September 20, 2010 (incorporated herein by reference to Exhibit 4.21 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.22&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License and Collaboration Agreement between the Company and Halo-Bio RNAi Therapeutics, Inc. as of August 24, 2011 (incorporated herein by reference to Exhibit 4.22 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2011 filed with the SEC on March 27, 2012).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.23*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loan Agreement with Silicon Valley Bank dated as of December 21, 2011 (incorporated herein by reference to Exhibit 4.23 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2011 filed with the SEC on March 27, 2012).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.24*#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Agreement with Paul Brennan dated August 24, 2010 (incorporated herein by reference to Exhibit 4.24 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2011 filed with the SEC on March 27, 2012).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.25*#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tekmira 2011 Omnibus Share Compensation Plan approved by shareholders on June 22, 2011 (incorporated herein by reference to Exhibit 4.25 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2011 filed with the SEC on March 27, 2012).</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div></div><hr style="page-break-after:always"><a name="s34E8DB1CFF9CDD2FFEBDEF6379A589F5"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="11%"></td><td width="1%"></td><td width="88%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.26&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Settlement Agreement and General Release, by and among Tekmira Pharmaceuticals Corporation, Protiva Biotherapeutics Inc., Alnylam Pharmaceuticals, Inc., and AlCana Technologies, Inc., dated November 12, 2012 (incorporated herein by reference to Exhibit 4.26 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2012 filed with the SEC on March 27, 2013).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.27&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cross-License Agreement by and among Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics Inc., dated November 12, 2012(incorporated herein by reference to Exhibit 4.27 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2012 filed with the SEC on March 27, 2013).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.28&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License Agreement by and among Protiva Biotherapeutics Inc. and Marina Biotech, Inc. dated November 28, 2012 (incorporated herein by reference to Exhibit 4.28 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2012 filed with the SEC on March 27, 2013).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.29*#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Agreement with Diane Gardiner dated March 1, 2013 (incorporated herein by reference to Exhibit 4.29 to the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2012 filed with the SEC on March 27, 2013).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.30*#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Agreement with Mark Kowalski dated August 12, 2013 (incorporated herein by reference to Exhibit 10.30 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 28, 2014).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.31*#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employment Agreement with Bruce Cousins dated October 7, 2013 (incorporated herein by reference to Exhibit 10.31 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 28, 2014).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.32&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Services Agreement by and among Protiva Biotherapeutics Inc., Protiva Agricultural Development Company Inc. and Monsanto Company dated January 12, 2014 (incorporated herein by reference to Exhibit 10.32 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 28, 2014).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.33&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Option Agreement by and among Tekmira Pharmaceuticals Corporation, Protiva Biotherapeutics Inc., Protiva Agricultural Development Company Inc. and Monsanto Canada Inc. dated January 12, 2014 (incorporated herein by reference to Exhibit 10.33 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 28, 2014).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.34&#8224;*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License and Services Agreement by and among Protiva Biotherapeutics Inc., Protiva Agricultural Development Company Inc. and Tekmira Pharmaceuticals Corporation dated January 12, 2014 (incorporated herein by reference to Exhibit 10.34 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 28, 2014).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.35*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forms of Lock-Up Agreement (incorporated herein by reference to Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K/A filed with the SEC on January 26, 2015).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.36*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Registration Rights Agreement (incorporated herein by reference to Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K/A filed with the SEC on January 26, 2015).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.37*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Standstill Agreement (incorporated herein by reference to Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K/A filed with the SEC on January 26, 2015).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.38*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Representation Letter (incorporated herein by reference to Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K/A filed with the SEC on January 26, 2015).</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.39*#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement with Michael Abrams, dated November 14, 2013(incorporated herein by reference to Exhibit 10.39 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31,</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014, filed with the SEC on March 13, 2015)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.40*#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement with Kirk Rosemark, dated December 8, 2014 (incorporated herein by </font></div><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reference to Exhibit 10.40 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31,</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014, filed with the SEC on March 13, 2015)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.41*&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License Agreement, between Tekmira Pharmaceuticals and Protiva Biotherapeutics and Dicerna Pharmaceuticals&#160;dated November 16, 2014 (incorporated herein by reference to Exhibit 10.41 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.42*&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing and Clinical Trial Agreement between Tekmira Pharmaceuticals and Protiva Biotherapeutics and the Chancellor Masters and Scholars of the University of Oxford, dated December 18, 2014 (incorporated herein by reference to Exhibit 10.42 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></div><hr style="page-break-after:always"><a name="s34E8DB1CFF9CDD2FFEBDEF6379A589F5"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="11%"></td><td width="1%"></td><td width="88%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.43*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P0001, dated July 19, 2010, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.43 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.44*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P0002, dated April 15, 2011, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.44 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.45*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P0003, dated June 13, 2011, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.45 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.46*&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P0004, dated October 3, 2011, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.46 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.47*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P0005, dated December 2, 2011, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.47 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) (Exhibit 10.16) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.48*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P0006, dated January 25, 2012, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.48 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015)  </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.49*&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P0007, dated March 5, 2012, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.48 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015)  </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.50*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P0008, dated April 23, 2012, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.50 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015)  </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.51*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P0009, dated June 29, 2012, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.51 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.52*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00010, dated July 16, 2012, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.52 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.53*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00011, dated July 25, 2012, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.53 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.54*&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00012, dated August 2, 2012, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.54 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.55*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00013, dated August 27, 2012, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.55 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.56*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00014, dated August 31, 2012, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.56 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.57*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00015, dated October 1, 2012, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.57 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.58*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00016, dated October&#160;&#160;2, 2012, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.58 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015)  </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.59*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00017, dated October 19, 2012, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.59 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.60*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00018, dated December 31, 2012, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.60 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111</font></div></div><hr style="page-break-after:always"><a name="s34E8DB1CFF9CDD2FFEBDEF6379A589F5"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="11%"></td><td width="1%"></td><td width="88%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.61*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00019, dated January 23, 2013, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.61 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015)  </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.62 *</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00020, dated February 19, 2013, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.62 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015)  </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.63 *</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00021, dated March 29, 2013, to Award Contract, dated July 14, 2010 incorporated herein by reference to Exhibit 10.63 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.64*&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00022, dated April 30, 2013, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.64 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.65*&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00023, dated May 21, 2013, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.65 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015)  </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.66 *</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00024, dated June 19, 2013, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.66 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.67*&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00025, dated April 22, 2014, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.67 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015)  </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.68*&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00026, dated July 25, 2014, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.68 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.69*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00027, dated July 25,&#160;&#160;2014, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.69 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.70 *&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00028, dated September 5, 2014, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.70 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.71 *</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00029, dated September 30, 2014, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.71 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015)  </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.72*&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00030, dated October 31, 2014, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.72 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.73*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00031, dated&#160;&#160;November 17, 2014, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.73 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.74*&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00032, dated&#160;&#160;March 4, 2015, to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.74 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015)  </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.75*&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Modification Contract P00033, dated&#160;&#160;March 4, 2015,&#160;&#160;to Award Contract, dated July 14, 2010 (incorporated herein by reference to Exhibit 10.75 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 13, 2015) </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.76*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Underwriting Agreement for 3,750,000 Common Shares with Stifel, Nicolaus &amp; Company, dated October 17, 2013</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.77*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Underwriting Agreement for 2,125,000 Common Shares with Leerink Partners LLC, dated March 14, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.78**#</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Employment Agreement Elizabeth Howard, dated March 7, 2016 </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.79**&#8224;&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Option Agreement by and among Arbutus Biopharma Corporation, Protiva Biotherapeutics Inc., Protiva Agricultural Development Company Inc. and Monsanto Canada Inc., dated March 4, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112</font></div></div><hr style="page-break-after:always"><a name="s34E8DB1CFF9CDD2FFEBDEF6379A589F5"></a><div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="11%"></td><td width="1%"></td><td width="88%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.80**&#8224;&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amended and Restated License and Services Agreement by and among Protiva Biotherapeutics Inc., Protiva Agricultural Development Company Inc. and Arbutus Biopharma Corporation, dated March 4, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.81**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Amendment to the Protiva-Monsanto Services Agreement by and among  Protiva Biotherapeutics Inc., Protiva Agricultural Development Company Inc. and Monsanto Company, dated March 4, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.1**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">List of Subsidiaries</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.1**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consent of KPMG LLP, an Independent Registered Public Accounting Firm</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Executive Officer pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Financial Officer pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.2**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE**</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:17.578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">* </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Previously filed </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">**</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed herewith</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8224; </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential treatment granted as to portions of this exhibit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8224;&#8224;  </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential treatment has been requested as to portions of this exhibit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">#</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management Contract</font></div></td></tr></table><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.78
<SEQUENCE>2
<FILENAME>exhibit1078lizhowardea.htm
<DESCRIPTION>EXHIBIT 10.78
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s088E920CB1F3C0B9C4C85A2CD73C0F6D"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.78</font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Executive Employment Agreement (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;) is made effective as of February 25, 2016 by and between Arbutus Biopharma, Inc., a Delaware corporation (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:11pt;">&#8221;), and Elizabeth A. Howard, Ph.D. (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Executive</font><font style="font-family:inherit;font-size:11pt;">&#8221;) (together the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Parties</font><font style="font-family:inherit;font-size:11pt;">&#8221;), and shall become effective upon Executive&#8217;s commencement of employment, which is expected to commence on March 7, 2016 (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:11pt;">&#8221;).  The Company and Executive agree that in the event the Executive has not commenced employment with the Company as of April 1, 2016 (or such later date as agreed by each of the Company and Executive in writing) then this Agreement shall be void and of no further effect. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:72px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">WHEREAS, the Company and Executive desire to enter into this Agreement to set forth the terms of Executive&#8217;s employment with the Company, as of the Effective Date. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">THEREFORE, the Parties agree and intend to be bound as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:58px;">Section 1.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:11pt;">. </font><font style="font-family:inherit;font-size:12pt;">The Company shall employ Executive, and Executive hereby accepts employment with the Company, upon the terms and conditions set forth in this Agreement for the period beginning on the Effective Date and ending as provided in Section 5 hereof.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:58px;">Section 2.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Position and Duties</font><font style="font-family:inherit;font-size:11pt;">.  The Executive will serve as Executive Vice-President and General Counsel of the Company, and will have powers and duties consistent with Executive&#8217;s position and as outlined on </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:11pt;">&#32;attached hereto and such other powers and duties consistent with such position as may from time to time be prescribed by the President and Chief Executive Officer of the Company, </font><font style="font-family:inherit;font-size:12pt;">subject to the power and authority of the Company&#8217;s </font><font style="font-family:inherit;font-size:11pt;">President and Chief Executive Officer </font><font style="font-family:inherit;font-size:12pt;">to expand or limit such duties, responsibilities, functions and powers</font><font style="font-family:inherit;font-size:11pt;">.  Any increase or reduction in the Executive&#8217;s duties, </font><font style="font-family:inherit;font-size:12pt;">responsibilities, functions</font><font style="font-family:inherit;font-size:11pt;">&#32;or powers hereunder shall not operate to change or modify the compensation or severance, if applicable, to be paid by the Company to the Executive.  As the Executive Vice President and General Counsel of the Company, the Executive shall devote her full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may manage her personal investments or engage charitable or other community activities as long as those services and activities do not interfere with the Executive&#8217;s performance of her duties to the Company. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:58px;">Section 3.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Compensation and Related Matters</font><font style="font-family:inherit;font-size:11pt;">.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:11pt;">. The Executive&#8217;s base salary will be $330,000 per year, less withholdings and payable in accordance with the Company&#8217;s normal payroll practices. The Executive&#8217;s base salary will be reviewed annually by the Chief Executive Officer of the Company and is subject to increase but not decrease except for an across-the-board salary reduction affecting all or substantially all senior executives of the Company. The base salary in effect at any given time is referred to as &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:11pt;">&#8221; and this Agreement need not be modified to reflect a change in Base Salary. The Base Salary is subject to withholding and payable in a manner that is consistent with the Company&#8217;s usual payroll practices for senior executives.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Bonus</font><font style="font-family:inherit;font-size:11pt;">.  The Executive is eligible to be considered for an annual discretionary target bonus of up to 40% of Base Salary, which will be subject to the terms of the bonus plan and the approval of the Company&#8217;s Board of Directors (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:11pt;">&#8221;), in its sole discretion, on an annual basis.</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">114848-5509-3806\1</font></div></div><hr style="page-break-after:always"><a name="s088E920CB1F3C0B9C4C85A2CD73C0F6D"></a><div></div><br><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Expenses</font><font style="font-family:inherit;font-size:11pt;">.  The Executive is entitled to receive prompt reimbursement for all reasonable expenses incurred by her in performing services under this Agreement, in accordance with the policies and procedures then in effect and established by the Company for its senior executives.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Other Benefits</font><font style="font-family:inherit;font-size:11pt;">.  The Executive is entitled to participate in or receive benefits under the Company&#8217;s employee benefit plans as they may be adopted and amended from time to time, subject to the terms and conditions of those employee benefit plans. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Equity Compensation</font><font style="font-family:inherit;font-size:11pt;">.  Subject to the discretionary approval of the board of directors of Arbutus Biopharma Corporation, the parent of the Company (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Parent</font><font style="font-family:inherit;font-size:11pt;">&#8221;) and in accordance with the Company and the Parent&#8217;s annual performance and compensation review process in effect from time to time, the Company&#8217;s President and CEO will promptly recommend to the Parent&#8217;s board of directors that Executive receive an option grant in the amount of 120,000 of shares of the Parent, subject to the terms of the Arbutus Biopharma Corporation Share Incentive Plan, or any other similar equity incentive plan in effect from time to time, the terms of a notice of grant and any such other terms as may be required by the Parent&#8217;s board of directors.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(e)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Vacations</font><font style="font-family:inherit;font-size:11pt;">.  The Executive is entitled to paid holidays and vacation days each year, in an amount determined in accordance with and subject to the Company&#8217;s applicable policies in effect, and as may be amended from time to time. Unless a different number is established by the Board in its sole discretion, the Executive will be entitled to four weeks (20 business days) of vacation per calendar year, which will be pro-rated for any year in which the Executive is only employed with the Company for a portion of the year or for any period in which the Executive is not a full-time employee.  Executive may carry over unused and accrued vacation days from year to year, but total vacation accrual will be capped at 34 days.  Any accrued but unused vacation days will be paid upon termination.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(f)</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Paid Sick Time</font><font style="font-family:inherit;font-size:12pt;">.  The Executive will be awarded paid sick days in accordance with Company policy</font><font style="font-family:inherit;font-size:11pt;">.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:147px;">Section 4.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Non-Competition and Non-Solicitation.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:11pt;">The Executive acknowledges that the Company&#8217;s industry is highly competitive and employees leaving the employ of the Company have the ability to cause significant damage to the Company&#8217;s interests if they join a competing business immediately upon leaving the Company.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Definitions:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:144px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:11pt;">&#8220;Affiliate&#8221; means any person or entity directly or indirectly controlling, controlled by or under common control with the Company, where control may be by either management authority or equity interest.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:144px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:11pt;">&#8220;Business&#8221; or &#8220;Business of the Company&#8221; means (a) researching, developing, producing and marketing any treatment for hepatitis B virus infection in humans or (b) any other treatment area in which the Company has as active research and development program on the date this Agreement terminates and in connection with which the Executive directly provided service or had direct supervisory responsibilities.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:144px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(iii)</font><font style="font-family:inherit;font-size:11pt;">&#8220;Competing Business&#8221; means any endeavor, activity or business which is competitive in any material way with the Business of the Company worldwide.</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s088E920CB1F3C0B9C4C85A2CD73C0F6D"></a><div></div><br><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:144px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(iv)</font><font style="font-family:inherit;font-size:11pt;">&#8220;Contact&#8221; means any person, firm, corporation or other entity that was a client, customer, supplier, principal, shareholder, investor, collaborator, strategic partner, licensee, contact or prospect of the Company (or of its partners, funders or Affiliates) with whom the Executive dealt or otherwise became aware of during the term of her employment in any capacity with the Company.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Reasonableness</font><font style="font-family:inherit;font-size:11pt;">.  The Executive hereby acknowledges and agrees that:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">both before and since the Effective Date the Company has operated and competed and will operate and compete worldwide, with respect to the Business of the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">competitors of the Company and the Business are located worldwide; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">in order to protect the Company adequately, any enjoinder of competition would have to apply to any country in which the Company, during the term of the Executive&#8217;s employment, had material business relationships; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">during the course of the Executive&#8217;s employment with the Company, on behalf of the Company, the Executive will acquire knowledge of, and will come into contact with, initiate and establish relationships with, both existing and new clients, customers, suppliers, principals, contacts and prospects of the Company, and that in some circumstances the Executive may become the senior or sole representative of the Company dealing with such persons; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">in light of the foregoing, the provisions of this Section 4 are reasonable and necessary for the proper protection of the Business of the Company.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Restrictive Covenant</font><font style="font-family:inherit;font-size:11pt;">.  The Executive hereby acknowledges and agrees that:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">During the term of the Executive&#8217;s employment, the Executive shall not, without the advance written consent of the Board, such consent to be granted or withheld in the Board&#8217;s sole discretion, within the geographic scope of any country in which the Company, during the term of the Executive&#8217;s employment, had material business relationships, carry on or be employed by or engaged in or have any financial or other interest in or be otherwise commercially involved in a Competing Business, directly or indirectly, either individually or in partnership or jointly or in conjunction with any person, firm, corporation or other entity, as principal, agent, consultant, advisor, employee, shareholder or in any manner whatsoever; and </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">In the event that Executive relocates to Pennsylvania, Canada, or any other jurisdiction permitting a post-employment restrictive covenant, and Executive&#8217;s employment is terminated for any reason while employee resides in such jurisdiction, for a period of eighteen (18) months after Executive&#8217;s termination, Executive shall not, without the advance written consent of the Board, such consent to be granted or withheld in the Board&#8217;s sole discretion, within the geographic scope of any country in which the Company, during the term of the Executive&#8217;s employment, had material business relationships, carry on or be employed by or engaged in or have any financial or other interest in or be otherwise commercially involved in a Competing Business, directly or indirectly, either individually or in partnership or jointly or in conjunction with any person, firm, corporation or other entity, as principal, agent, consultant, advisor, employee, shareholder or in any manner whatsoever.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(e)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exception</font><font style="font-family:inherit;font-size:11pt;">.  The Executive shall not be in default of Section 4(d) by virtue of the Executive:</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s088E920CB1F3C0B9C4C85A2CD73C0F6D"></a><div></div><br><div style="line-height:120%;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(viii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">In the event Section 3(d)(ii) applies, following the termination of employment, holding, strictly for portfolio purposes and as a passive investor, no more than five percent (5%) of the issued and outstanding shares of, or any other interest in, any corporation or other entity which is listed on any recognized stock exchange, that is a Competing Business.  In the event Section 3(d)(ii) is inapplicable, this Agreement shall not be deemed to restrict Executive&#8217;s post-termination investments; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ix)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">during the term of Executive&#8217;s employment, holding, strictly for portfolio purposes and as a passive investor, issued and outstanding shares of, or any other interest in, any corporation or other entity, the business of which corporation or other entity is in the </font><font style="font-family:inherit;font-size:12pt;">same Business or Competitive Business as the Company</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If the Executive holds issued and outstanding shares or any other interest in a corporation or other entity pursuant to Section 4(e)(ii) above, and following the acquisition of such shares or other interest the business of the corporation or other entity becomes a Competing Business, the Executive will promptly dispose of the Executive&#8217;s shares or other interest in such corporation or other entity.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(f)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Non-Solicitation</font><font style="font-family:inherit;font-size:11pt;">.  The Executive shall not, during the term of Executive&#8217;s employment and after Executive&#8217;s termination thereof for any reason, whether legal or illegal, either individually or in partnership or jointly or in conjunction with any person, firm, corporation or other entity, as principal, agent, consultant, advisor, employee, shareholder or in any manner whatsoever, without the prior written and informed consent of the Company, directly or indirectly:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(x)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">use any trade secret information of the Company to solicit, induce or encourage any Contact to curtail or cease its relationship with the Company, for any purpose which is competitive with the Business; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">use any trade secret information of the Company to procure or assist the acceptance of any business from any Contact if such business is competitive with the Business.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(g)</font><font style="font-family:inherit;font-size:11pt;">The Executive shall not, during the term of Executive&#8217;s employment and for the a period of eighteen (18) months after the termination thereof for any reason, offer employment or engagement to or solicit the employment or engagement of or otherwise entice away from or solicit, induce or encourage to leave the employment or engagement of the Company, any individual who is employed or engaged by the Company at the time of any such offer, solicitation or enticement whether or not such individual would commit any breach of his or her contract or terms of employment or engagement by leaving the employ or the engagement of the Company, provided that the Executive shall be permitted, solely in a personal capacity, to provide letters of reference for individuals who are employed by the Company.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(h)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Validity</font><font style="font-family:inherit;font-size:11pt;">.  The Executive expressly recognizes and acknowledges that it is the intent of the parties that the Executive&#8217;s activities following the termination of the Executive&#8217;s employment with the Company be restricted in the manner described in this Section 4, and acknowledges that good, valuable, and sufficient consideration has been provided in exchange for such restrictions.  The Executive agrees that should any of the restrictions contained in this Section 4 be found to be unreasonable to any extent by a court of competent jurisdiction adjudicating upon the validity of the restriction, whether as to the scope of the restriction, the area of the restriction or the duration of the restriction, then such restriction shall be reduced to that which is in fact declared reasonable by such court, or a subsequent court of competent jurisdiction, requested to make such a declaration, in order to ensure that the intention of the parties is given the greatest possible effect.</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s088E920CB1F3C0B9C4C85A2CD73C0F6D"></a><div></div><br><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:58px;">Section 5.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination</font><font style="font-family:inherit;font-size:11pt;">.  Executive will continue to be employed by the Company as Executive Vice-President and General Counsel until termination pursuant to this Section 5 of this Agreement. Executive&#8217;s employment by the Company may be terminated without any breach of this Agreement under the following circumstances:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Death</font><font style="font-family:inherit;font-size:11pt;">.  The Executive&#8217;s employment hereunder terminates upon her death.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Disability</font><font style="font-family:inherit;font-size:11pt;">.  The Company may terminate the Executive&#8217;s employment if she is disabled (as determined by the Chief Executive Officer) in a manner that renders the Executive unable to perform the essential functions of her then existing position or positions under this Agreement with or without reasonable accommodation for a period of six months or more. Nothing in this Section 1(b) is to be construed to waive the Executive&#8217;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601 et seq., and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 et seq., and the California Fair Employment and Housing Act.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination by Company for Cause</font><font style="font-family:inherit;font-size:11pt;">.  For purposes of this Agreement, &#8220;For Cause&#8221; shall mean: (i) Employee commits a felony , or any crime involving dishonesty, breach of trust, or physical harm to any person; (ii) Employee willfully engages in conduct that is in bad faith and materially injurious to the Company, including but not limited to, misappropriation of trade secrets, fraud or embezzlement; (iii) Employee commits a material breach of this Agreement; (iv) Employee willfully refuses to implement or follow a lawful policy or directive of the Company; or (v) Employee engages in misfeasance or malfeasance demonstrated by a pattern of failure to perform job duties diligently and professionally. The Company may terminate Employee&#8217;s employment For Cause at any time, without any advance notice. The Company shall pay Employee all compensation to which Employee is entitled up through the date of termination, subject to any other rights or remedies of the Company under law; and thereafter all obligations of the Company under this Agreement shall cease.    </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination by the Company Without Cause or by the Executive for Good Reason</font><font style="font-family:inherit;font-size:11pt;">.  The Company may terminate the Executive&#8217;s employment under this Agreement at any time without Cause and for any reason, and the Executive may terminate her employment with Good Reason.  For purposes of this Agreement, &#8220;Good Reason&#8221; means</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;">the occurrence of any of the following events without the Executive's prior written consent: (i) the failure of the Executive to be appointed to the position set forth in Section 2, if not promptly cured after written notice; or (ii) a reduction by the Company of the Executive's Base Salary or Target Bonus percentage, except for an across-the-board salary reduction affecting all or substantially all senior executives of the Company.  For purposes of this Agreement, termination for Good Reason requires Executive to comply with the &#8220;Good Reason Process,&#8221; which means that (i) the Executive reasonably determines in good faith that a Good Reason condition has occurred; (ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 30 days of the first occurrence of such condition (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Good Reason Notice</font><font style="font-family:inherit;font-size:11pt;">&#8221;); (iii) the Executive cooperates in good faith with the Company&#8217;s efforts, for a period of not less than 30 days following that notice (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Cure Period</font><font style="font-family:inherit;font-size:11pt;">&#8221;) to remedy the condition; (iv) notwithstanding the Company&#8217;s efforts, the Good Reason condition continues to exist; and (v) the Executive gives a Notice of Termination effective within 10 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason is deemed not to have occurred.  Notwithstanding the foregoing, upon the Company&#8217;s receipt of the Good Reason Notice, the Company may, in its sole discretion, elect to immediately accept a termination by the Executive for Good Reason, waive the requirement for a Cure Period and such termination will not be deemed a termination by the Company for purposes of this Agreement.    </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s088E920CB1F3C0B9C4C85A2CD73C0F6D"></a><div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any termination by the Company of the Executive&#8217;s employment under this Agreement that does not constitute a termination for Cause under Section 5(c) and does not result from the death or disability of the Executive under Section 5(a) or (b) is a termination without Cause. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:12pt;padding-right:48px;">(e)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination by the Executive</font><font style="font-family:inherit;font-size:11pt;">.  Executive may terminate employment with the Company without Good Reason at any time for any reason or no reason at all, upon thirty (30) days&#8217; advance written notice.  The Company shall have the option, in its sole discretion, to make Executive&#8217;s termination effective or to direct the Executive to perform no work and/or remain off premises at any time prior to the end of such notice period as long as the Company pays Executive all compensation to which Executive is entitled up through the last day of the 30 day notice period.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(f)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Notice of Termination</font><font style="font-family:inherit;font-size:11pt;">.  Except for termination as specified in Section 5(a) any termination of the Executive&#8217;s employment by the Company or any termination of her employment by the Executive must be communicated by written Notice of Termination to the other party. For purposes of this Agreement, a &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Notice of Termination</font><font style="font-family:inherit;font-size:11pt;">&#8221; means a notice that indicates the specific termination provision in this Agreement that the termination is based upon.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(g)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Date of Termination</font><font style="font-family:inherit;font-size:11pt;">.  &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Date of Termination</font><font style="font-family:inherit;font-size:11pt;">&#8221; means: (i) if the Executive&#8217;s employment is terminated by her death, the date of her death; (ii) if the Executive&#8217;s employment is terminated on account of disability under Section 5(b)  or by the Company for Cause under Section 5(c), or by the Company without Cause under Section 5(d) on the date the Notice of Termination is given; (iii) if the Executive terminates  her employment under Section 5(e) Good Reason, on the date specified by the Executive in the notice (which shall be at least 30 days after the date of the Notice of Termination); and (iv) if the Executive terminates her employment under Section 5(d) with Good Reason, the date of the effectiveness of the Notice of Termination, which shall be during the ten day period following the Cure Period, or, if the Company elects to immediately accept the termination by the Executive for Good Reason, on such date of the Company&#8217;s acceptance. Notwithstanding the foregoing, if the Executive gives a Good Reason Notice or a Notice of Termination to the Company that takes effect at a future date, the Company may unilaterally accelerate the Date of Termination and that acceleration will not be deemed a termination by the Company for purposes of this Agreement. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:164px;">Section 6.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Compensation Upon Termination</font><font style="font-family:inherit;font-size:11pt;">.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination Generally</font><font style="font-family:inherit;font-size:11pt;">.  If the Executive&#8217;s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to her authorized representative or estate), (i) unpaid expense reimbursements; (ii) accrued but unused vacation to the extent payment is required by law or Company policy; (iii) any vested benefits the Executive may have under any employee benefit plan of the Company; (iv) any earned but unpaid base salary and (v) any earned but unpaid annual bonus for the prior fiscal year (collectively the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Accrued Benefit</font><font style="font-family:inherit;font-size:11pt;">&#8221;) on or before the time required by law, but in no event more than 30 days after the Executive&#8217;s Date of Termination.  The Executive shall not be entitled to any other salary, compensation, bonus (or pro rata share thereof) or benefits from the Company thereafter, except as otherwise specifically provided hereunder, under the Company&#8217;s employee benefit plans or as expressly required by applicable law. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination by the Company Without Cause or by the Executive for Good Reason</font><font style="font-family:inherit;font-size:11pt;">. If the Executive&#8217;s employment is terminated by the Company without Cause or by the Executive for Good Reason, then the Company shall pay the Executive her Accrued Benefit as of the Date of Termination.  In addition, subject to the Executive providing the Company with a fully effective general release of claims in a form and manner satisfactory to the Company that includes but is not limited to the </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s088E920CB1F3C0B9C4C85A2CD73C0F6D"></a><div></div><br><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;"><font style="font-family:inherit;font-size:11pt;">terms set forth in the attached Exhibit A (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Release</font><font style="font-family:inherit;font-size:11pt;">&#8221;) within the 60-day period following the Date of Termination, the Company shall pay the Executive (i)  severance pay in a lump sum in cash in an amount equal to one and one-half times the Executive&#8217;s Base Salary (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Severance Amount</font><font style="font-family:inherit;font-size:11pt;">&#8221;), less withholding, payable within 60 days after the Date of Termination, but if that 60-day period extends over two calendar years, the Company shall make the payment in the second calendar year, (ii) a bonus payment equal to  the Target Bonus pro-rated for the portion of the year the Executive was employed by the Company prior to the termination, and (iii) provided that the Executive timely elects COBRA coverage, reimburse the Executive for the COBRA premiums paid by the Executive, if any, for the continuation of coverage under the Executive&#8217;s then-existing group company health plan that the Executive and her dependents are eligible to receive for the earlier of (x) a period of up to 24 months from the date of the Executive&#8217;s termination of employment, or (y) until the Executive becomes eligible to receive health insurance benefits under any other employer&#8217;s group health plan.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:58px;">Section 7.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Change of Control Provisions</font><font style="font-family:inherit;font-size:11pt;">.  The provisions of this Section 7 set forth the Executive&#8217;s rights and obligations upon the occurrence of a Change of Control of the Company. These provisions are intended to assure and encourage in advance the Executive&#8217;s continued attention and dedication to her assigned duties and her objectivity during the pendency and after the occurrence of any Change of Control. The provisions of this Section 7 apply in addition to, and/or modify, the provisions of Section 6 regarding severance pay and benefits upon a termination of employment, if applicable, if the termination of employment occurs within 12 months after the occurrence of a Change of Control.  These provisions are subject to the Executive providing (and not revoking) the Company with a fully effective Release.  These provisions terminate and are of no further force or effect beginning 12 months after the occurrence of such a Change of Control.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Severance following Change of Control</font><font style="font-family:inherit;font-size:11pt;">.  If within 12 months following a Change of Control (i) the Company terminates the Executive&#8217;s employment with the Company other than for Cause, or (ii) the Executive resigns from her employment with the Company for Good Reason, within the 60-day period following the Date of Termination, then, in lieu of paying the Executive the Severance Amount and in addition to paying the Accrued Benefit, Company shall: (i) pay the Executive severance pay in a lump sum in cash (less applicable withholdings) in an amount equal to two times the Executive&#8217;s Base Salary (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Change in Control Severance Amount</font><font style="font-family:inherit;font-size:11pt;">&#8221;), payable within 60 days after the Date of Termination, but if that 60-day period extends over two calendar years, the Company shall make the payment in the second calendar year; (ii) pay the Executive a bonus payment equal to the Target Bonus pro-rated for that portion of the year that Executive is employed (iii) provided that the Executive timely elects COBRA coverage, reimburse the Executive for the COBRA premiums paid by the Executive, if any, for the continuation of coverage under the Executive&#8217;s then-existing group company health plan that the Executive and her dependents are eligible to receive for the earlier of (x) a period of up to 24 months from the date of the Executive&#8217;s termination of employment, or (y) until the Executive becomes eligible to receive health insurance benefits under any other employer&#8217;s group health plan; and (iv) cause all stock options and other stock-based awards granted after the Effective Date and held by the Executive to immediately accelerate, vest, and become fully exercisable or nonforfeitable.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Additional Limitation.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:144px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:11pt;">Anything in this Agreement to the contrary notwithstanding, if the amount of any compensation, payment, acceleration, benefit, or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Code</font><font style="font-family:inherit;font-size:11pt;">&#8221;) and the applicable regulations thereunder (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Severance </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s088E920CB1F3C0B9C4C85A2CD73C0F6D"></a><div></div><br><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Payments</font><font style="font-family:inherit;font-size:11pt;">&#8221;), would be subject to the excise tax imposed by Section 4999 of the Code, then the Severance Payments will be reduced (but not below zero) to the extent necessary so that the sum of all Severance Payments does not exceed the Threshold Amount (defined below), but if the after-tax amount the Executive would receive if there were no reduction pursuant to this section (including any federal, state, and local taxes) exceeds the after-tax amount the Executive would receive if the Severance Payments were reduced below the Threshold Amount, the Severance Payments will no longer be so reduced. If Severance Payments are required to be reduced, the Severance Payments will be reduced in the following order: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:144px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:11pt;">For the purposes of this Section 7(b), &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Threshold Amount</font><font style="font-family:inherit;font-size:11pt;">&#8221; means three times the Executive&#8217;s &#8220;base amount&#8221; within the meaning of Section 280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00).</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:144px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(iii)</font><font style="font-family:inherit;font-size:11pt;">The determinations under this Section 7(b) will be made by a nationally recognized accounting firm selected by the Company (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Accounting Firm</font><font style="font-family:inherit;font-size:11pt;">&#8221;), which must provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Change of Control Definition</font><font style="font-family:inherit;font-size:11pt;">.  For purposes of this Section 7, &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Change of Control</font><font style="font-family:inherit;font-size:11pt;">&#8221; means the consummation of any of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">the sale of all or substantially all of the assets of the Company or the Parent to an unrelated person or entity;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">a merger, reorganization, or consolidation involving the Company or the Parent in which the shares of voting stock outstanding immediately prior to the transaction represent or are converted into or exchanged for securities of the surviving or resulting entity that, immediately upon completion of the transaction, represent less than 50% of the outstanding voting power of the surviving or resulting entity;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">the acquisition of all or a majority of the outstanding voting stock of the Company or the Parent in a single transaction or a series of related transactions by a person or group of persons; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">any other acquisition of the business of the Company or the Parent, as determined by the Board; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">but the Company&#8217;s initial public offering, any subsequent public offering, or another capital raising event, or a merger effected solely to change the Company&#8217;s domicile does not constitute a Change of Control.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:58px;">Section 8.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 409A Compliance</font><font style="font-family:inherit;font-size:11pt;">.  The following rules shall apply, to the extent necessary, with respect to distribution of the payments and benefits, if any, to be provided to the Executive under this Agreement.  Subject to the provisions in this Section, the severance payments pursuant to this Agreement shall begin only upon the date of the Executive's &#8220;separation from service&#8221; (determined as set forth below) which occurs on or after the date of the Executive's termination of employment.</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s088E920CB1F3C0B9C4C85A2CD73C0F6D"></a><div></div><br><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:11pt;">This Agreement is intended to comply with Code Section 409A (to the extent applicable) and the parties hereto agree to interpret, apply and administer this Agreement in the least restrictive manner necessary to comply therewith and without resulting in any increase in the amounts owed hereunder by the Company.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:11pt;">It is intended that each installment of the severance payments and benefits provided under this Agreement shall be treated as a separate &#8220;payment&#8221; for purposes of Section 409 A of the Internal Revenue Code of 1986, as amended, and the guidance issued thereunder (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Section 409A</font><font style="font-family:inherit;font-size:11pt;">&#8221;).  Neither the Executive nor the Company shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:11pt;">If, as of the date of the Executive's &#8220;separation from service&#8221; from the Company, the Executive is not a &#8220;specified employee&#8221; (within the meaning of Section 409 A), then each installment of the severance payments and benefits shall be made on the dates and terms set forth in this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:11pt;">If, as of the date of the Executive's &#8220;separation from service&#8221; from the Company, the Executive is a &#8220;specified employee&#8221; (within the meaning of Section 409A), then:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:144px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:11pt;">Each installment of the severance payments and benefits due under this Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the separation from service occurs, be paid within the short-term deferral period (as defined in Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-l(b)(4) to the maximum extent permissible under Section 409A; and</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:144px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:11pt;">Each installment of the severance payments and benefits due under this Agreement that is not described in Section 7(d)(i) above and that would, absent this subsection, be paid within the six-month period following the Executive's &#8220;separation from service&#8221; from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, the Executive's death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following the Executive's separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of severance payments and benefits if and to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1 (b)(9)(iii) (relating to separation pay upon an involuntary separation from service).  Any installments that qualify for the exception under Treasury Regulation Section 1.409A-l(b)(9)(iii) must be paid no later than the last day of the second taxable year following the taxable year in which the separation from service occurs.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(e)</font><font style="font-family:inherit;font-size:11pt;">The determination of whether and when the Executive's separation from service from the Company has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-l(h). Solely for purposes of this Section, &#8220;Company&#8221; shall include all persons with whom the Company would be considered a single employer as determined under Treasury Regulation Section 1.409A-l(h)(3).</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(f)</font><font style="font-family:inherit;font-size:11pt;">All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during the Executive's lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s088E920CB1F3C0B9C4C85A2CD73C0F6D"></a><div></div><br><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;"><font style="font-family:inherit;font-size:11pt;">reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(g)</font><font style="font-family:inherit;font-size:11pt;">Notwithstanding anything herein to the contrary, the Company shall have no liability to the Executive or to any other person if the payments and benefits provided in this Agreement that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:58px;">Section 9.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Confidential Information</font><font style="font-family:inherit;font-size:11pt;">.  Employee agrees to enter into the Company&#8217;s standard Employee Confidentiality and Proprietary Rights Agreement (the &#8220;Confidential Information Agreement&#8221;).  Employee&#8217;s receipt of any benefits in connection with or following Employee&#8217;s termination will be subject to Employee continuing to comply with the terms of Confidential Information Agreement. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:119px;">Section 10.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Cooperation; Other Documents; Non-Disclosure</font><font style="font-family:inherit;font-size:11pt;">.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Litigation and Regulatory Cooperation</font><font style="font-family:inherit;font-size:11pt;">.  During and after the Executive&#8217;s employment, the Executive shall reasonably cooperate with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that took place while the Executive was employed by the Company. The Executive&#8217;s reasonable cooperation in connection with such claims or actions includes, but is not limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive&#8217;s employment, the Executive also shall reasonably cooperate with the Company in connection with any investigation or review of any federal, state, or local regulatory authority as any such investigation or review relates to events or occurrences that took place while the Executive was employed by the Company. The Company shall compensate Executive for her time spent, and reimburse the Executive for any reasonable out-of-pocket expenses incurred, in connection with the Executive&#8217;s performance of obligations pursuant to this Section 10. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Non-Disclosure</font><font style="font-family:inherit;font-size:11pt;">.  The Executive shall use her reasonable efforts to maintain the confidentiality of the terms of this Agreement to the extent permitted by law, but the Executive may disclose the terms to her immediate family members and to her legal, tax, and other advisors.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:194px;">Section 11.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Arbitration of Disputes</font><font style="font-family:inherit;font-size:11pt;">. </font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Scope of Arbitration Requirement</font><font style="font-family:inherit;font-size:11pt;">. The Executive hereby waives her right to a trial before a judge or jury and agrees to arbitrate before a neutral arbitrator skilled in hearing similar disputes any and all claims or disputes arising out of this Agreement and any and all claims arising from or relating to her employment, including but not limited to claims against any current or former employee, director, or agent of the Company, claims of wrongful termination, retaliation, discrimination, harassment, breach of contract (including but not limited to disputes pertaining to the formation, validity, interpretation or effect of this Agreement), breach of the covenant of good faith and fair dealing, defamation, invasion of privacy, fraud, misrepresentation, constructive discharge or failure to provide a leave of absence, or claims regarding commissions, stock options or bonuses, infliction of emotional distress, or unfair business practices (each an &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Arbitrable Dispute</font><font style="font-family:inherit;font-size:11pt;">&#8221;). Arbitration is the exclusive remedy for any Arbitrable Dispute, instead of any court or administrative action, unless the waiver of a certain court or administrative action is prohibited by law.</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s088E920CB1F3C0B9C4C85A2CD73C0F6D"></a><div></div><br><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Procedure</font><font style="font-family:inherit;font-size:11pt;">. Any arbitration will be administered by the American Arbitration Association (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">AAA</font><font style="font-family:inherit;font-size:11pt;">&#8221;) and the neutral arbitrator will be selected in a manner consistent with AAA&#8217;s National Rules For The Resolution of Employment Disputes (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Applicable Arbitration Rules</font><font style="font-family:inherit;font-size:11pt;">&#8221;). Any arbitration under this Agreement must be conducted in the State of California, and the arbitrator must administer and conduct the arbitration in accordance with the Applicable Arbitration Rules, except that (i) the arbitrator must allow for the discovery authorized by the California Rules of Civil Procedure or the discovery that the arbitrator decides is necessary for the Parties to vindicate their respective claims or defenses, and (ii) presentation of evidence will be governed by the California Rules of Evidence. Within a reasonable time after the conclusion the arbitration proceedings, the arbitrator shall issue a written decision and must include the findings of fact and law that support that decision. The arbitrator has the power to award any remedies available under applicable law, and the arbitrator&#8217;s decision is final and binding on both Parties, except to the extent applicable law allows for judicial review of arbitration awards.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(e)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Costs</font><font style="font-family:inherit;font-size:11pt;">. The Company shall bear all the costs of arbitration, except that the Executive shall pay the first $125.00 of any filing fees associated with any arbitration the Executive initiates. Both Parties are responsible for their own attorneys&#8217; fees, and the arbitrator may not award attorneys&#8217; fees unless a statute or contract at issue specifically authorizes such an award.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(f)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Applicability</font><font style="font-family:inherit;font-size:11pt;">. This Section 11, does not apply to (i) workers&#8217; compensation or unemployment insurance claims or (ii) claims concerning ownership, validity, infringement, misappropriation, disclosure, misuse, or enforceability of any confidential information, patent right, copyright, mask work, trademark, or any other trade secret or intellectual property held or sought by either the Executive or the Company.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(g)</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Remedy</font><font style="font-family:inherit;font-size:11pt;">.  Should any party institute any legal action or administrative proceeding against the other with respect to any claim waived by this Agreement or pursue any Arbitrable Dispute by any method other than as set forth above, except to enforce the arbitration provisions and as expressly provided for in this Section 11, the responding party is entitled to recover from the initiating party all damages, costs, expenses, and attorneys&#8217; fees incurred as a result of that action.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:65px;">Section 12.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Consent to Jurisdiction</font><font style="font-family:inherit;font-size:11pt;">.  To the extent that any court action is initiated to enforce Section 11 of this Agreement, the Parties hereby consent to the jurisdiction of any state court in the State of California and any U.S. District Court sitting in the State of California. Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup>&#160;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:65px;">Section 13.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Integration</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement and the Confidential Information Agreement executed concurrently herewith, constitute the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior agreements between the Parties concerning such subject matter, but any indemnification agreement between the Parties, and all plans and agreements related to stock options and other stock-based awards held by the Executive remain in full force and effect except to the extent specifically modified by this Agreement.  Without limiting the foregoing, the parties agree that any employment agreement, other than this Agreement, existing between the Parties as of the date hereof is hereby terminated and shall be of no force of effect. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:65px;">Section 14.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Withholding</font><font style="font-family:inherit;font-size:11pt;">.  All payments made by the Company to the Executive under this Agreement will be net of any tax or other amounts required to be withheld by the Company under </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s088E920CB1F3C0B9C4C85A2CD73C0F6D"></a><div></div><br><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;"><font style="font-family:inherit;font-size:11pt;">applicable law. Nothing in this Agreement is to be construed to obligate the Company to design or implement any compensation arrangement in a way that minimizes tax consequences for the Executive.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:65px;">Section 15.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Successor to the Executive</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement inures to the benefit of and is enforceable by the Executive&#8217;s personal representatives, executors, administrators, heirs, distributees, devisees, and legatees. If the Executive dies after her termination of employment but prior to the completion by the Company of all payments due her under this Agreement, the Company shall continue the payments to the Executive&#8217;s beneficiary designated in writing to the Company prior to her death (or to her estate, if the Executive fails to make such a designation).</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:65px;">Section 16.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Enforceability</font><font style="font-family:inherit;font-size:11pt;">.  If any portion or provision of this Agreement is declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of that portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, will not be affected by that declaration, and each portion and provision of this Agreement will continue to be valid and enforceable to the fullest extent permitted by law. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:65px;">Section 17.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Survival</font><font style="font-family:inherit;font-size:11pt;">.  The provisions of this Agreement survive the termination of this Agreement and/or the termination of the Executive&#8217;s employment to the extent necessary to effectuate the intent of the Parties as expressed in this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:65px;">Section 18.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Waiver</font><font style="font-family:inherit;font-size:11pt;">.  No waiver of any provision of this Agreement is effective unless made in writing and signed by the waiving party, and, in the case of the Company only after the waiver has been specifically approved by the Board. The failure of either party to require the performance of any term or obligation of this Agreement, or the waiver by either party of any breach of this Agreement, will not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:65px;">Section 19.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:11pt;">.  Any notices, requests, demands, and other communications provided for by this Agreement are sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention to the Corporate Secretary.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:65px;">Section 20.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendment</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:65px;">Section 21.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement is to be construed under and be governed in all respects by the laws of the State of California without giving effect to the conflict of laws principles of that state.</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup>&#160;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:65px;">Section 22.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement may be executed in any number of counterparts, and by each party on separate counterparts, each of which counterparts, when so executed and delivered is to be taken to be an original; but those counterparts together constitute one and the same document. PDF, facsimile, scanned, and electronic signatures have the same legal effect as original ink signatures.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:65px;">Section 23.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Successor to Company</font><font style="font-family:inherit;font-size:11pt;">.  The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation, or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of the Company to </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s088E920CB1F3C0B9C4C85A2CD73C0F6D"></a><div></div><br><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;"><font style="font-family:inherit;font-size:11pt;">obtain an assumption of this Agreement at or prior to the effectiveness of any succession is a material breach of this Agreement.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:65px;">Section 24.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Voluntary Nature of Agreement</font><font style="font-family:inherit;font-size:11pt;">. The Executive acknowledges and agrees that she is executing this Agreement voluntarily and without any duress or undue influence by the Company or anyone else. The Executive further acknowledges and agrees that she has carefully read this Agreement and that she has asked any questions needed for her to fully understand the terms, consequences, and binding effect of this Agreement. The Executive agrees that she has been provided an opportunity to seek the advice of an attorney of her choice before signing this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Parties are executing this Executive Agreement as of the date set forth in the introductory paragraph. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;<br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[Remainder of page left blank intentionally.  Signature page follows.]</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s088E920CB1F3C0B9C4C85A2CD73C0F6D"></a><div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:192px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                                    </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ARBUTUS BIOPHARMA</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">, INC.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;padding-left:336px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/Mark J. Murray&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;padding-left:336px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Printed Name: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Mark J. Murray</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;padding-left:336px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">President and CEO</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:32px;text-align:justify;padding-left:336px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXECUTIVE</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:32px;text-align:justify;padding-left:336px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Elizabeth Howard                                         </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:32px;text-align:justify;padding-left:336px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Printed Name: Elizabeth Howard</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[Signature page to Executive Employment Agreement]</font></div><div style="line-height:120%;text-align:left;padding-left:288px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s787A47747D4E4A09D7CB5A2CD8164FCA"></a><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXHIBIT A</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FORM OF GENERAL RELEASE</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This General Release and Waiver (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Release</font><font style="font-family:inherit;font-size:11pt;">&#8221;) is made and entered into as of ________________________ (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Release Date</font><font style="font-family:inherit;font-size:11pt;">&#8221;), by and between Arbutus Biopharma, Inc. (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:11pt;">&#8221;), and Elizabeth A. Howard, Ph.D. (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Executive</font><font style="font-family:inherit;font-size:11pt;">&#8221;).  The Company and/or Executive may hereinafter be referred to individually as a "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Party</font><font style="font-family:inherit;font-size:11pt;">" or collectively as the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Parties</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:11pt;">"</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In consideration of the mutual covenants hereinafter set forth, the Parties hereby agree as follows:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Separation</font><font style="font-family:inherit;font-size:11pt;">. Executive&#8217;s employment with Employer ended effective ______________________.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Payment and Benefits</font><font style="font-family:inherit;font-size:11pt;">. </font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">In consideration of the promises made in this Release, Employer has agreed to pay Executive the benefits described in the applicable provisions of Sections&#160;5 and 6 (and, in the event of a Change in Control, Section 7) of that certain Executive Employment Agreement made and entered into between the Parties (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Employment Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;).  Executive understands and acknowledges that the benefits described in this Section&#160;2 constitute benefits in excess of those to which Executive would be entitled without entering into this Release.  Executive acknowledges that such benefits are being provided by Employer as consideration for Executive entering into this Release, including the release of claims and waiver of rights provided in Section&#160;3 of this Release.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Release of Claims and Waiver of Rights</font><font style="font-family:inherit;font-size:11pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)&#160;&#160;&#160;&#160;Executive, on Executive&#8217;s own behalf and that of Executive&#8217;s spouse, heirs, executors or administrators, assigns, insurers, attorneys and other persons or entities acting or purporting to act on Executive&#8217;s behalf (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Executive&#8217;s Parties</font><font style="font-family:inherit;font-size:11pt;">&#8221;), hereby irrevocably and unconditionally release, acquit and forever discharge Employer, its affiliates, subsidiaries, directors, officers, employees, shareholders, partners, agents, representatives, predecessors, successors, assigns, insurers, attorneys, benefit plans sponsored by Employer and said plans&#8217; fiduciaries, agents and trustees (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Released Parties</font><font style="font-family:inherit;font-size:11pt;">&#8221;), from any and all actions, cause of action, suits, claims, obligations, liabilities, debts, demands, contentions, damages, judgments, levies and executions of any kind, whether in law or in equity, known or unknown, which the Executive&#8217;s Parties have, have had, or may in the future claim to have against the Released Parties by reason of, arising out of, related to, or resulting from Executive&#8217;s employment with Employer or the termination thereof.  This release specifically includes without limitation any claims arising in tort or contract, any claim based on wrongful discharge, any claim based on breach of contract, any claim arising under federal, state or local law prohibiting race, sex, age, religion, national origin, handicap, disability or other forms of discrimination, any claim arising under federal, state or local law concerning employment practices, and any claim relating to compensation or benefits.  This specifically includes, without limitation, any claim which the Executive has or has had under </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title VII of the Civil Rights Act of 1964; 42 U.S.C. &#167;&#167;  1981-1988; the Americans with Disabilities Act; , the Age Discrimination in Employment Act (and the Older Workers Benefit Protection Act), the Fair Labor Standards Act; the Family and Medical Leave Act; the Workers Adjustment and Retraining Notification Act, as amended; the Occupational Safety and Health Act, as amended, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the California Family Rights Act (Cal. Govt. Code &#167; 12945.2 et seq.), the California Fair Employment and Housing Act (Cal. Govt. </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s787A47747D4E4A09D7CB5A2CD8164FCA"></a><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Code &#167; 12900 et seq.), statutory provision regarding retaliation/discrimination for filing a workers&#8217; compensation claim under Cal. Labor Code &#167; 132a, and/or any other claims of whatever nature arising in connection with Executive&#8217;s employment with the Company or her separation from such employment, and any and all other claims arising under federal, state or local law.  Executive acknowledges she received any and all leaves of absence to which she may have been entitled during employment, and that she suffers from no workplace injuries arising from her employment at the Company, and does not intend to file any claim for workers&#8217; compensation benefits.   It is understood and agreed that the waiver of benefits and claims contained in this section does not include: (i)&#160;a waiver of the right to payment of any vested, nonforfeitable benefits to which the Executive or a beneficiary of the Executive may be entitled under the terms and provisions of any employee benefit plan of Employer which have accrued as of the separation date; (ii)&#160;a waiver of the right to benefits and payment of consideration to which Executive may be entitled under the Employment Agreement or any of the agreements contemplated thereby (including indemnification agreements and the stock option agreements); and (iii)&#160;a waiver of any rights to indemnification under the Certificate of Incorporation or Bylaws of the Employer or an subsidiary of Employer or under applicable law and regulation.  Executive acknowledges that she is only entitled to the severance benefits and compensation set forth in the Employment Agreement, and that all other claims for any other benefits or compensation are hereby waived, except those expressly stated in the preceding sentence.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Nothing in this Release shall be deemed to require the waiver or release of any claim that may not be released or waived under applicable federal or state law.  To the extent required by law, nothing contained in this Agreement shall be construed to prohibit Executive from filing a charge or complaint, including a challenge to the validity of the waiver provision of this Agreement, with the U.S. Equal Employment Opportunity Commission, or participating in any investigation conducted by the U.S. Equal Employment Opportunity Commission; provided, however, that Executive has waived her right to any monetary damages or other individual legal or equitable relief awarded as a result of any such proceeding.  Nothing contained in this Agreement shall bar a claim by either party to enforce the terms of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)&#160;&#160;&#160;&#160;Executive hereby acknowledges that she understands that under this Release she is releasing any known or unknown claims she may have arising out of, related to, or resulting from Executive&#8217;s employment with Employer or the termination thereof (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Released Claims</font><font style="font-family:inherit;font-size:11pt;">").  She therefore acknowledges that she has read and understands Section&#160;1542 of the California Civil Code, which reads as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">&#8220;A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Executive expressly waives and relinquishes all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to the Released Claims. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Acknowledgment of Waiver of Claims under ADEA</font><font style="font-family:inherit;font-size:11pt;">.  Executive acknowledges that Executive is waiving and releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ADEA</font><font style="font-family:inherit;font-size:11pt;">&#8221;) and that this waiver and release is knowing and voluntary.  Executive acknowledges that the consideration given for this Release is in addition to anything of value to which Executive already is entitled.  Executive further acknowledges that Executive has been advised by this writing that:</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)&#160;&#160;&#160;&#160;the release and waiver granted herein does not relate to claims under the ADEA which may arise after this Release is executed;</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)&#160;&#160;&#160;&#160;Executive should consult with an attorney </font><font style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">prior</font><font style="font-family:inherit;font-size:11pt;">&#32;to executing this Release;</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s787A47747D4E4A09D7CB5A2CD8164FCA"></a><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)&#160;&#160;&#160;&#160;Executive has at least twenty-one (21) days within which to consider this Release as it relates to claims under the ADEA, although Executive may accept the terms of this Release at any time within those 21 days and earlier execute this Release;</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)&#160;&#160;&#160;&#160;Executive has seven (7) days following the execution of this Release to revoke this Release as it relates to claims under the ADEA; and</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)&#160;&#160;&#160;&#160;This Release will not be effective as it relates to claims under the ADEA until the revocation period has expired, which will be the eighth (8</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">) day after this Release is executed by both Parties, and the severance payments described in the Employment Agreement will not be paid until this Release has become effective and all statutory revocation periods have expired.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Non-Disparagement</font><font style="font-family:inherit;font-size:11pt;">. The parties agree to treat each other respectfully and professionally and not disparage the other party, and the other party&#8217;s officers, directors, employees, shareholders and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation; provided that both the Executive and Employer will respond accurately and fully to any question, inquiry or request for information when required by the legal process.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">No Admissions</font><font style="font-family:inherit;font-size:11pt;">.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:11pt;">Employer denies that it or any of its employees or agents has taken any improper action against Executive.  Nothing contained herein shall be deemed as an admission by Employer of any liability of any kind to Executive, all such liability being expressly denied.  Further, this Release shall not be admissible in any proceeding as evidence of improper action by Employer or any of its employees or agents. </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Non-Waiver</font><font style="font-family:inherit;font-size:11pt;">. Employer&#8217;s waiver of a breach of this Release by Executive shall not be construed or operate as a waiver of any subsequent breach by Executive of the same or of any other provision of this Release.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Restrictive Covenants</font><font style="font-family:inherit;font-size:11pt;">. Executive understands that the covenants in Section 4 of the Employment Agreement survive the termination of her employment with Employer.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendment, Waiver</font><font style="font-family:inherit;font-size:11pt;">.  No amendment or variation of the terms of this Release shall be valid unless made in writing and signed by Executive and Employer.  A waiver of any term or condition of this Agreement shall not be construed as a general waiver by Employer.  Failure of either Employer or Executive to enforce any provision or provisions of this Agreement shall not waive any enforcement of any continuing breach of the same provision or provisions or any breach of any provision or provisions of this Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[Remainder of page left blank intentionally.  Signature page follows.]</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s787A47747D4E4A09D7CB5A2CD8164FCA"></a><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:144%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the Parties have executed this Release as of dates set forth below their respective signatures below.</font></div><div style="line-height:144%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="46%"></td><td width="54%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EMPLOYER:</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ARBUTUS BIOPHARMA, INC. </font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXECUTIVE:</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:  </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:  </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:  </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date:  </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: </font></div></td></tr></table></div></div><div style="line-height:144%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[Signature page to Executive&#8217;s Release Agreement]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s787A47747D4E4A09D7CB5A2CD8164FCA"></a><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXHIBIT B</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">DUTIES AND RESPONSIBILITIES</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Executive Vice-President and General Counsel</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Reports to: CEO</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Responsibilities: </font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Reporting to the President and Chief Executive Officer, this position is responsible for leading corporate strategic intellectual property, business, licensing and corporate legal initiatives as well as implementation of tactics and practices. Provides senior management with effective advice on company legal strategies and their implementation, manages the legal function, and obtains and oversees the work of outside counsel. Is directly involved in complex business transactions and in negotiating critical contracts.</font></div><div style="padding-bottom:6px;padding-top:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Essential Functions:</font></div><div style="padding-bottom:6px;padding-top:6px;padding-left:24px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Develops the company&#8217;s intellectual property strategy and oversees its execution.</font></div><div style="padding-bottom:6px;padding-top:6px;padding-left:24px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Is responsible for license agreements and contracts into which the company enters.</font></div><div style="padding-bottom:6px;padding-top:6px;padding-left:24px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Participates in the definition and development of corporate policies, procedures and programs and provides continuing counsel and guidance on legal matters and on legal implications of all matters.</font></div><div style="padding-bottom:6px;padding-top:6px;padding-left:24px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Serves as key lawyer/legal advisor on all major business transactions, including acquisitions, licenses, divestitures and joint ventures.</font></div><div style="padding-bottom:6px;padding-top:6px;padding-left:24px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Judges the merits of major court cases filed against or on behalf of the company, works with the appropriate executive(s) to define a strategic defense and approves settlements of disputes where warranted.</font></div><div style="padding-bottom:6px;padding-top:6px;padding-left:24px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">While initially focused on intellectual property and licensing, this role will eventually assume the responsibility for all general corporate legal matters and act as General Counsel.</font></div><div style="padding-bottom:6px;padding-top:6px;padding-left:24px;text-indent:-24px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Structures and manages the company&#8217;s internal legal function and staff. Oversees the selection, retention, management and evaluation of all outside counsel.</font></div><div style="padding-bottom:6px;padding-top:6px;padding-left:37px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.79
<SEQUENCE>3
<FILENAME>exhibit1079monsantoamendme.htm
<DESCRIPTION>EXHIBIT 10.79
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sD7DCBF56AC98F1276F5C5A1C95B53349"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.79</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">AMENDED AND RESTATED</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">PROTIVA AGRICULTURAL DEVELOPMENT COMPANY INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">OPTION AGREEMENT</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><a name="s84CBCBB789AE8BCEB5F25A1C95D73481"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="9%"></td><td width="78%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Page</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">INTRODUCTION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Certain Defined Terms</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Conduct of Research Program.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Rights and Responsibilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">PadCo-Protiva License and Services Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Protiva-Monsanto Services Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Diligence</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Phase A, Phase B and Phase C</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Call Option.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Option Grant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Option Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Exercise of Call Option</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Closing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Payment at Closing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(f)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Right to Setoff</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(g)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Withholding Rights and Tax Treatment of Transactions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(h)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Change of Control of Protiva or Tekmira</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Representations and Warranties Regarding the Company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Representations and Warranties Regarding Protiva and Arbutus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Representations and Warranties of Monsanto Canada</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Covenants and Restrictions.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Acknowledgement of Transfer Restriction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No Assignment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Due Diligence Investigation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Prior to Closing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Payment of Taxes, Etc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(f)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Material Contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(g)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No Shop</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(h)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Disclosure Schedule and Supplement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Third Party Consents and Regulatory Approvals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(j)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Monsanto Canada Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(k)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Grant of Proxy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(l)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Confidential Information</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(m)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Financial Reporting</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(n)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Notification of Certain IP Matters</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(o)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Certain Business Practices Covenant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(p)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Export Controls Covenant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(q)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">PadCo-Protiva License and Services Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(r)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Arbutus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Closing Conditions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">27</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div><div style="line-height:120%;text-align:left;text-indent:305px;font-size:12pt;"><font style="font-family:inherit;font-size:8pt;"></font><font style="font-family:inherit;font-size:12pt;">i</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><a name="s84CBCBB789AE8BCEB5F25A1C95D73481"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><br><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="9%"></td><td width="78%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Conditions of Monsanto Canada</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">27</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Conditions of Protiva</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Termination</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Breach by Company or Protiva</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Breach of This Agreement by Monsanto Canada</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Acquisition of Protiva or Arbutus by a Principal Competitor</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Phase A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Phase B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(f)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Phase C</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(g)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Survival</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(h)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Rights Upon Termination</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Rights and Obligations Upon Termination</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Certain Covenants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Reporting</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Exclusivity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Indemnification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Miscellaneous</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Further Assurances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Notices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Entire Agreement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Amendments, Waivers and Consents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Binding Effect; Assignment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(f)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Public Announcements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(g)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">General</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(h)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Severability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Counterparts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(j)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Governing Law; Jurisdiction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(k)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Joint Research Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(l)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Disclosure of Protiva Project Compounds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(m)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Specific Enforcement</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">36</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(n)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No Finder&#8217;s Fees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">36</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(o)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Titles and Subtitles</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">36</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(p)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Delays or Omissions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">36</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">ii</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><a name="s84CBCBB789AE8BCEB5F25A1C95D73481"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><br><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibits</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit A&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Research Plan</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-1&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Intentionally Omitted</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-2(i)&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Option Plant Phase A Completion Criteria</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-2(ii)&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Option Insect Phase A Completion Criteria</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-3(i)&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Option Plant Phase B Completion Criteria</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-3(ii)&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Option Insect Phase B Completion Criteria</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-4(i)&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Option Plant Phase C Completion Criteria</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-4(ii)&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Option Insect Phase C Completion Criteria</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-5(i)&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Option Set-up Completion Criteria</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-5(ii)&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Option Shipment Completion Criteria</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-6&#160;&#160;&#160;&#160;- &#160;&#160;&#160;&#160;Technology Transfer Completion Criteria</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit C&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;PadCo-Protiva License and Services Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit D&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Protiva-Monsanto Services Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit E&#160;&#160;&#160;&#160;- &#160;&#160;&#160;&#160;Intentionally Omitted </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit F&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Disclosure Schedule</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit G&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Intentionally Omitted</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit H&#160;&#160;&#160;&#160;- &#160;&#160;&#160;&#160;Intentionally Omitted</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit I&#160;&#160;&#160;&#160;- &#160;&#160;&#160;&#160;Intentionally Omitted</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit J&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Certain Knowledge Persons</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit K&#160;&#160;&#160;&#160;- &#160;&#160;&#160;&#160;Intentionally Omitted</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit L&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;PadCo-Protiva License and Services Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit M&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;Protiva-Monsanto Services Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Appendix A</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">iii</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><a name="s74C45C728316236639215A1C961F7179"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">AMENDED AND RESTATED OPTION AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This AMENDED AND RESTATED OPTION AGREEMENT (this &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), made as of March 4, 2016 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;) by and among </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Monsanto Canada, Inc.</font><font style="font-family:inherit;font-size:12pt;">, a Canadian corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Monsanto Canada</font><font style="font-family:inherit;font-size:12pt;">&#8221;), </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Arbutus Biopharma Corporation (formerly known as Tekmira Pharmaceuticals Corporation)</font><font style="font-family:inherit;font-size:12pt;">, a British Columbia corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Arbutus</font><font style="font-family:inherit;font-size:12pt;">&#8221;), </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Protiva Biotherapeutics Inc.</font><font style="font-family:inherit;font-size:12pt;">, a British Columbia corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Protiva</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Protiva Agricultural Development Company Inc.</font><font style="font-family:inherit;font-size:12pt;">, a British Columbia corporation (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:12pt;">&#8221;).   </font></div><br><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.9</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.10A</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><a name="s144A2368A08D862666905A1C96225BA0"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">INTRODUCTION</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">A.</font><font style="font-family:inherit;font-size:12pt;">Protiva previously formed the Company for the purpose of conducting a program to design and synthesize Compounds and/or Formulations and to conduct research and development activities for such Compounds and/or Formulations as described in the Research Plan (as amended and restated the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Research Program</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">B.</font><font style="font-family:inherit;font-size:12pt;">The parties hereto entered into that certain Option Agreement dated January 12, 2014, pursuant to which, among other things, Protiva granted to Monsanto Canada an option for Monsanto Canada to acquire all of the outstanding capital stock of the Company from Protiva (as amended, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Original Option Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;). </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">C.</font><font style="font-family:inherit;font-size:12pt;">Concurrently with the execution of the Original Option Agreement, the Company and Protiva entered into a License and Services Agreement (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Original PadCo-Protiva License and Services Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to which, among other things, (a) the Company allows Protiva to conduct services for the Company to design and synthesize Compounds and/or Formulations according to the Research Program and (b) Protiva granted the Company the Protiva License.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">D.</font><font style="font-family:inherit;font-size:12pt;">Concurrently with the execution of the Original Option Agreement, Protiva and Monsanto Company, a Delaware corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Monsanto</font><font style="font-family:inherit;font-size:12pt;">&#8221;), entered into a Services Agreement (as amended, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Original Protiva-Monsanto Services Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to which, among other things, Monsanto conducts services for Protiva to screen Compounds and/or Formulations according to the Research Program.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">E.</font><font style="font-family:inherit;font-size:12pt;">The parties hereto desire to amend and restate the Original Option Agreement as set forth in this Agreement to facilitate Monsanto Canada&#8217;s exercise of the Call Option and further desire to (i) amend and restate the Original PadCo-Protiva License and Services Agreement in the form attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit L</font><font style="font-family:inherit;font-size:12pt;">&#32;(the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">PadCo-Protiva License and Services Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">)</font><font style="font-family:inherit;font-size:12pt;">&#32;and (ii) amend and restate the Original Protiva-Monsanto Services Agreement in the form attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit M</font><font style="font-family:inherit;font-size:12pt;">&#32;(the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Protiva-Monsanto Services Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">)</font><font style="font-family:inherit;font-size:12pt;">, concurrently with the parties&#8217; execution and delivery of this Agreement.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">F.</font><font style="font-family:inherit;font-size:12pt;">Monsanto Canada desires to exercise the Call Option to acquire from Protiva, and Protiva desires to sell to Monsanto Canada, all of the outstanding capital stock of the Company, subject to terms and condition set forth herein.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">G.</font><font style="font-family:inherit;font-size:12pt;">As of the date hereof, Monsanto Canada has paid, or caused to be paid to Protiva, [***] pursuant to the Original Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In consideration of the foregoing and the agreements set forth below, the parties agree with each other as follows:</font></div><a name="s32538FA0508BB8799A015A1C963657C0"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">2</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Certain Defined Terms</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  As used in this Agreement, the following terms shall have the following respective meanings:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Action</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any pending or threatened claim, demand, notice, action, suit, arbitration, proceeding or investigation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, when used with respect to a specified Person, another Person that either directly or indirectly, now or hereafter, through one or more intermediaries, controls, is controlled by, or is under common control with, the specified Person; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that until Monsanto has acquired all of the outstanding capital stock of the Company from Protiva, the Company shall not be an Affiliate of Monsanto Canada and none of Monsanto Canada or its Affiliates shall be an Affiliate of the Company.  For purposes of this definition, &#8220;control&#8221; (including the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;), with respect to the relationship between or among two or more Persons, shall mean the power to direct or cause the direction of the affairs or management of a Person, whether through the ownership of voting securities, as trustee, personal representative or executor, by contract or otherwise, including, without limitation, the ownership, directly or indirectly, of securities having the power to elect a majority of the board of directors or similar body governing the affairs of such Person.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Agricultural Field</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning in the PadCo-Protiva License and Services Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Board of Directors of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Business Day</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any weekday on which banks are open for general banking business in St. Louis, Missouri and in Vancouver, British Columbia. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Call Period</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the period commencing on the Effective Date of this Agreement and ending on the earliest to occur of (a) the Closing, (b) the expiration of the Option Notice Period without Monsanto Canada having exercised the Call Option, or (c) the termination of this Agreement in accordance with the terms of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 9</font><font style="font-family:inherit;font-size:12pt;">&#32;without a Closing having occurred. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Change of Control</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) the closing of the sale, transfer or other disposition (including by way of exclusive license) of all or substantially all of an entity&#8217;s assets, (b) the consummation of the merger or consolidation of an entity with or into another entity (except a merger or consolidation in which the members or stockholders of such original entity immediately prior to such merger or consolidation continue to hold at least fifty percent (50%) of the voting power of such original entity or the surviving or acquiring entity), or (c) the closing of the transfer (whether by merger, consolidation or otherwise), in one transaction or a series of related transactions, to a Person or group of Affiliated Persons (other than an underwriter of an entity&#8217;s securities), of an entity&#8217;s securities if, after such closing, such Person or group of affiliated Persons would hold fifty percent (50%) or more of the outstanding securities of such entity (or the surviving or acquiring entity).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Code</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Income Tax Act</font><font style="font-family:inherit;font-size:12pt;">&#32;(Canada).</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">3</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Commercial</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Milestone Payment</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning given to such term in the PadCo-Protiva License and Services Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Company Business</font><font style="font-family:inherit;font-size:12pt;">&#8221; means discovering, identifying, characterizing and conducting research and Commercialization activities on Compounds and Formulations intended for the delivery of nucleic acids in the Agricultural Field.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Company Licensed Intellectual Property</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Intellectual Property licensed to the Company by any third party, including the Protiva Intellectual Property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Company Owned Intellectual Property</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all Intellectual Property owned by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Compound</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning given to such term in the PadCo-Protiva License and Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning in the PadCo-Protiva License and Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Continuing JRC Term</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning in the PadCo-Protiva License and Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Controlled by</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning in the PadCo-Protiva License and Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Copyrights</font><font style="font-family:inherit;font-size:12pt;">&#8221; means United States and foreign copyrights, copyrightable works and mask works, whether registered or unregistered, and pending applications to register the same, and moral rights in the foregoing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Damages</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the amount of any liabilities, losses, damages, penalties, fines, charges (including costs of investigation), costs, claims, deficiencies, injuries, settlements, judgments, awards, fees, or expenses (including reasonable attorneys&#8217; fees and expenses and reasonable costs and expenses of other professionals, including consultants and experts), whether or not involving an Action, including any costs of defending any Actions or enforcing an Indemnified Party&#8217;s rights under this Agreement, actually incurred or suffered by a party with respect to or relating to an Action, event, circumstance or state of facts.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Data Package</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all relevant study reports and other previously prepared and reasonably related documents in the possession or control of (i) Protiva to the extent such reports or documents are generated pursuant to the Research Program or (ii) the Company, including existing development plans and regulatory correspondence, that provide evidence that Phase C has been completed. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">4</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Disclosing Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, as applicable, (i) Monsanto, Monsanto Canada and/or their Affiliates to the extent such &#8220;Disclosing Party&#8221; is disclosing Confidential Information to a Receiving Party; (ii) Protiva and/or its Affiliates (other than the Company and any subsidiaries of the Company) to the extent such &#8220;Disclosing Party&#8221; is disclosing Confidential Information to a Receiving Party; or (iii) the Company and/or any subsidiaries of the Company to the extent such &#8220;Disclosing Party&#8221; is disclosing Confidential Information to a Receiving Party.   If the Closing occurs, then from and after the Closing, provisions regarding disclosures of Confidential Information made by the Company and/or any of its subsidiaries as the Disclosing Party to Protiva and/or its Affiliates (other than the Company and any subsidiaries of the Company)  shall inure to the benefit of Monsanto Canada as the successor in interest to the Company (whether as a result of the acquisition of the Company&#8217;s right, title and interest in and to the Protiva License or the outstanding capital stock of the Company). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Exclusivity Period</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the period beginning on the Effective Date and ending on the later of (a) the termination by Monsanto Canada of this Agreement in accordance with the terms of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 9</font><font style="font-family:inherit;font-size:12pt;">, (b) the Failure to Exercise, or (c) [***].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Failure to Exercise</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the expiration of the Call Period without Monsanto Canada exercising the Call Option.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Formulation</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning given to such term in the PadCo-Protiva License and Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">GAAP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means generally accepted accounting principles in the United States, consistently applied.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Governmental Authority</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any United States or supra-national, foreign, federal, state, local, provincial, or municipal government, governmental, regulatory or administrative authority, agency, body, branch, bureau, instrumentality or commission or any court, tribunal, or judicial or arbitral body having relevant jurisdiction over a subject matter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Governmental Order</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any order or injunction issued by or under the authority of any Governmental Authority.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">5</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Indebtedness</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, as applied to any Person, (a) all indebtedness for borrowed money, whether current or funded, or secured or unsecured, (b) all indebtedness for the deferred purchase price of property or services represented by a note or other security (other than  trade payables incurred in the ordinary course of business), (c) all indebtedness created or arising under any conditional sale or other title retention agreement with respect to property acquired (even though the rights and remedies of the seller or lender under such agreement in the event of default are limited to repossession or sale of such property), (d) all indebtedness secured by a purchase money mortgage or other lien to secure all or part of the purchase price of property subject to such mortgage or lien, (e) all obligations under leases which shall have been or must be, in accordance with GAAP, recorded as capital leases in respect of which such Person is liable as lessee, (f) any liability in respect of banker&#8217;s acceptances or letters of credit, (g) all Tax or Taxes payable to a Governmental Authority, and (h) all indebtedness referred to in clauses (a), (b), (c), (d), (e), (f) or (g) above which is directly or indirectly guaranteed by or which such Person has agreed (contingently or otherwise) to purchase or otherwise acquire or in respect of which it has otherwise assured a creditor against loss. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Independent IP Counsel</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an independent, registered, U.S. patent attorney selected (i) by the mutual agreement of the parties hereto or (ii) if they cannot agree, each party hereto shall provide the names of two (2) law firms they find acceptable, excluding those firms the other party found unacceptable, to the third party arbitrator as provided in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 12(k)(iv)</font><font style="font-family:inherit;font-size:12pt;">&#32;below and agree to abide by the decision of the arbitrator.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Intellectual Property</font><font style="font-family:inherit;font-size:12pt;">&#8221; means patents or patent applications and other intellectual property and proprietary rights of any description including (a) Copyrights, (b) Patent Rights, (c) Trademarks, (d) Trade Secrets, (e) related registrations and applications for registration, (f) moral rights or publicity rights, (g) inventions, discoveries, improvements, modifications, techniques, methodologies, writings, works of authorship, designs or data, whether or not patented, patentable, copyrightable or reduced to practice, including as embodied or disclosed in any:  (i) computer source codes (human readable format) and object codes (machine readable format); (ii) specifications; (iii) manufacturing, assembly, test, installation, service and inspection instructions and procedures; (iv) engineering, programming, service and maintenance notes and logs; (v) technical, operating and service and maintenance manuals and data; (vi) hardware reference manuals; and (vii) user documentation, help files or training materials, (h) other protectable intellectual property and proprietary rights of any description, including any know-how, and (i) goodwill related to any of the foregoing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Joint Project Intellectual Property</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;has the meaning set forth in the PadCo-Protiva License and Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Joint Project Inventions</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;has the meaning set forth in the PadCo-Protiva License and Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Joint Project Patents</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;has the meaning set forth in the PadCo-Protiva License and Services Agreement.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">6</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">JRC Joint IP Infringement Matter</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:12pt;">&#32;has the meaning set forth in the Protiva-Monsanto Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Knowledge,</font><font style="font-family:inherit;font-size:12pt;">&#8221; including the phrase &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">to the Company&#8217;s Knowledge</font><font style="font-family:inherit;font-size:12pt;">,&#8221; means with respect to a fact or matter, the knowledge of (i) the most senior employee who is principally responsible for conducting the activities under the Research Plan or overseeing any of the transactions contemplated by the Transaction Agreements, (ii) the person who is a member of the JRC designated by Protiva on the date hereof or the Closing, as applicable or (iii) those persons identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit J</font><font style="font-family:inherit;font-size:12pt;">, in the case of clause (i), (ii), and (iii), following reasonable inquiry; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;that the persons referenced in clauses (i), (ii) and (iii) are current employees or independent contractors of Arbutus, Protiva, the Company or any of their Affiliates.  Each of &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Known</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Knowingly</font><font style="font-family:inherit;font-size:12pt;">&#8221; has a correlative meaning.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Law</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, in each case to the extent applicable, any United States or non-U.S. federal, state, provincial, municipal, or local law, statute, regulation, rule, code, constitution, regulation, rule, notice, court decision, interpretation, agency guidance, order, resolution, stipulation, determination, requirement, edict or ordinance enacted, adopted, issued, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority (including those pertaining to electrical, building, zoning, environmental, animal welfare and occupational safety and health requirements) or common law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Liability</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all debts, liabilities and obligations of any kind or nature, whether accrued or fixed, absolute or contingent, matured or unmatured, or determined or determinable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Lien</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any mortgage, deed of trust, security interest, pledge, hypothecation, assignment in the nature of a security interest, attachment, encumbrance, lien (statutory, judgment or otherwise), or other security agreement of any kind or nature whatsoever (including any conditional sale or other title retention agreement and any lease in the nature of a security interest).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Material Adverse Effect</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any change, event, circumstance, development, occurrence or effect that individually, or taken together with any other change, event, circumstance, development, occurrence or effect is, or would reasonably be expected to have, a materially adverse effect on (i) to the business, assets (including intangible assets), Intellectual Property, liabilities, financial condition, property, or results of operations of the Company or (ii) the ability of the Company, Arbutus or Protiva, as applicable, to consummate the transactions contemplated by this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Milestone Payments</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Option Insect Milestone A Payment, the Option Plant Milestone A Payment, the Option Insect Milestone B Payment, the Option Plant Milestone B Payment, the Option Insect Milestone C Payment, the Option Plant Milestone C Payment, the Option Set-up Milestone Payment and the Option Shipment Milestone Payment; for clarification, &#8220;Milestone Payments&#8221; shall not include any Commercial Milestone Payment or any payment with respect to the Post-Closing Milestones.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">7</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Monsanto Project Intellectual Property</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall have the meaning given to such term in the Protiva-Monsanto Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Insect Milestone A</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean that the JRC has made a determination that the Company has satisfied the Option Insect Phase A Completion Criteria. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Insect Milestone B</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean that the JRC has made a determination that the Company has satisfied the Option Insect Phase B Completion Criteria.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Insect Milestone C</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean that the JRC has made a determination that the Company has satisfied the Option Insect Phase C Completion Criteria. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Insect Phase A Completion Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the criteria outlined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-2(ii)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Insect Phase B Completion Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the criteria outlined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-3(ii)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Insect Phase C Completion Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the criteria outlined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-4(ii)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option Notice Period</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, after the JRC has made a determination in accordance with </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 12(k)</font><font style="font-family:inherit;font-size:12pt;">&#32;that the Company has completed Phase C, the period commencing on the date on which  Monsanto Canada has received both (a) the Data Package from Protiva, and (b) an Amended Disclosure Schedule dated no later than the date of delivery of such Data Package, and ending ninety (90) days after the later of the date of delivery of such Data Package or Amended Disclosure Schedule.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Plant</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Milestone A</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean that the JRC has made a determination that the Company has satisfied the Option Plant Phase A Completion Criteria. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Plant</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Milestone B</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean that the JRC has made a determination that the Company has satisfied the Option Plant Phase B Completion Criteria.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Plant</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Milestone C</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean that the JRC has made a determination that the Company has satisfied the Option Plant Phase C Completion Criteria.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Plant</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Phase A Completion Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the criteria outlined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-2(i)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Plant</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Phase B Completion Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the criteria outlined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-3(i)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Plant</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Phase C Completion Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the criteria outlined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-4(i)</font><font style="font-family:inherit;font-size:12pt;">. </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">8</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option Set-up</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Completion Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the criteria outlined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-5(i)</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option Set-up Milestone</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean that the JRC has made a determination that the Company has satisfied the Option Set-up Completion Criteria.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option Shipment</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Completion Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the criteria outlined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-5(ii)</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option Shipment Milestone</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean that the JRC has made a determination that the Company has satisfied the Option Shipment Completion Criteria.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Order</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any order, stay, writ, judgment, injunction, decree, determination or award from a court or other Governmental Authority of competent jurisdiction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Patent</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning in the PadCo-Protiva License and Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Patent Rights</font><font style="font-family:inherit;font-size:12pt;">&#8221; means rights in or licensed access to a Patent.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Person</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an individual, corporation, limited liability company, syndicate, association, trust, partnership, joint venture, unincorporated organization, government agency or any agency, instrumentality or political subdivision thereof, or other entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Phase A</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the initial development activities outlined in the Research Plan to be commenced pursuant </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 2(e)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Post-Closing Insect Approval Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean Regulatory Approval of the first insect-based Product.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Post-Closing Insect Approval Milestone</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean that the Company has satisfied the Post-Closing Insect Approval Criteria.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Post-Closing Insect Submission Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean Regulatory Submission of the first Insect-based Product.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Post-Closing Insect Submission Milestone</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean that the Company has satisfied the Post-Closing Insect Submission Criteria.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Post-Closing Milestone</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the Post-Closing Plant Submission Milestone, Post-Closing Insect Submission Milestone, Post-Closing Plant Approval Milestone and Post-Closing Insect Approval Milestone.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Post-Closing Plant Approval Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean Regulatory Approval of the first plant-based Product.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Post-Closing Plant Approval Milestone</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean that the Company has satisfied the Post-Closing Plant Approval Criteria.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">9</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Post-Closing Plant Submission Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean Regulatory Submission of the first plant-based Product.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Post-Closing Plant Submission Milestone</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean that the Company has satisfied the Post-Closing Plant Submission Criteria.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Principal Competitor</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) those Persons listed on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit K</font><font style="font-family:inherit;font-size:12pt;">&#32;and, unless otherwise indicated with respect to such Person on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit K</font><font style="font-family:inherit;font-size:12pt;">, any of their Affiliates, and any entity that acquires all or substantially all of any of the foregoing Persons or all or substantially all of such Person&#8217;s agricultural division or the agricultural subsidiary of any of the foregoing Persons; &#160;and (b) any Person and any of their Affiliates (i) now known, or that emerges in the future, which is engaged in the business of developing, marketing or selling agricultural products (including agricultural chemical products and transgenic plants) for applications in the Agricultural Field and (ii) which is one of the top ten businesses in sales world-wide in developing, marketing or selling agricultural products (including agricultural chemical products and transgenic plants) for applications in the Agricultural Field.&#160; Notwithstanding the foregoing, in no event shall Monsanto or any controlled Affiliate thereof be deemed a &#8220;Principal Competitor&#8221; under this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Products</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning in the PadCo-Protiva License and Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Protiva Intellectual Property</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning in the PadCo-Protiva License and Services Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Protiva License</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning in the PadCo-Protiva License and Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Protiva Project Inventions</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning in the PadCo-Protiva License and Services Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Protiva Project Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning in the PadCo-Protiva License and Services Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Receiving Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, as applicable, (i) Monsanto, Monsanto Canada and/or their Affiliates to the extent such &#8220;Receiving Party&#8221; is receiving Confidential Information from a Disclosing Party; (ii) Protiva and/or its Affiliates (other than the Company and any subsidiaries of the Company) to the extent such &#8220;Receiving Party&#8221; is receiving Confidential Information from a Disclosing Party; or (iii) the Company and/or any subsidiaries of the Company to the extent such &#8220;Receiving Party&#8221; is receiving Confidential Information from a Disclosing Party. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Regulatory Approval</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">means the point in time at which Monsanto Canada, or its Affiliate, receives permission from the US governmental regulatory authorities or such comparable authority in countries outside of the U.S., to begin commercialization of a Product in the US or any of such countries.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">10</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Regulatory Submission</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">&#8221;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">means the point in time at which Monsanto Canada, or its Affiliate, completes submission of a dossier to a U.S. regulatory authority, or such comparable authority in countries outside of the U.S., whose purpose is to regulate the production, importation, or commercialization of a Product in the jurisdiction governed by such regulatory authority.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Research Plan</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221; means the written research plan attached hereto as</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">, which describes the activities performed in the course of the Research Program, and subsequent amendments thereto approved by the JRC.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Tax</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Taxes</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all taxes, assessments, levies, tariffs, imposts, duties or other charges or impositions in the nature of a tax (together with any and all interest, penalties, additions to tax and additional amounts imposed with respect thereto) imposed by any Governmental Authority, including income, estimated income, gross receipts, profits, business, license, occupation, franchise, capital stock, real or personal property, sales, use, transfer, value added, employment or unemployment, social security, disability, alternative or add-on minimum, customs, excise, stamp, environmental, commercial rent and withholding taxes. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Tax Return</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any return (including any information return), report, statement, declaration, schedule, notice, form, election or other document (including any attachments thereto and amendments thereof) required to be filed with any Governmental Authority with respect to any Tax.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Technology Transfer</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the transfer by Protiva to Monsanto of the specifications, physical material, protocols, data and other documentation described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-6</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Technology Transfer Completion Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the criteria outlined in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-6</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Trade Secrets</font><font style="font-family:inherit;font-size:12pt;">&#8221; means confidential ideas and information, trade secrets, inventions, concepts, methods, processes, formulae, reports, data, research and development results, customer lists, mailing lists, business plans and other proprietary information.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Trademarks</font><font style="font-family:inherit;font-size:12pt;">&#8221; means United States, state and foreign trademarks, service marks, logos, trade dress, trade names and Internet domain names, whether registered or unregistered, and pending applications to register the foregoing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Transaction Agreements</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall have the meaning given to such term in the PadCo-Protiva License and Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Transactions</font><font style="font-family:inherit;font-size:12pt;">&#8221; means each of the transactions contemplated by this Agreement and each of the other Transaction Agreements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">United States</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the United States of America and its territories and possessions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">As used in this Agreement, the following terms shall have the meanings ascribed thereto in the respective Sections of this Agreement set forth opposite each such term below:   </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">11</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:118px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.15384615384616%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="71%"></td><td width="29%"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition Proposal</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7(g)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquisition Transaction</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7(g)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preamble</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amended Disclosure Schedule</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7(h)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preamble</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Call Option</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3(a)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Closing</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3(d)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Closing Date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3(d)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Company</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preamble</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Company Cure Period</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9(a)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Company Indemnified Parties</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11(b)(ii) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Company Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7(j)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosure Schedule</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7(h)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dispute Negotiation Period</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12(k)(i)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective Date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preamble</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Environmental Laws</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4(w) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercise Date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3(b)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FCPA</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4(i) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial Statements</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4(k) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fundamental Representations</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11(a) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hazardous Substance</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4(w) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indemnified Party</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11(d)(i) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indemnifying Party</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11(d)(i) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Joint Patent Prosecution Matters</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Schedule 12(k)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">JRC</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12(k)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">JRC Party</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12(k)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">JRC Parties</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12(k)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Introduction</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto Canada</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preamble</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto Canada Cure Period</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9(b)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto Canada Director</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7(j)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto Indemnified Parties</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11(b) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Option Phase A-1 Initiation Payment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2(e)(ii)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Option Phase A-2 Initiation Payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2(e)(iii)</font></div></td></tr></table></div></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">12</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:118px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.15384615384616%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="71%"></td><td width="29%"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Organizational Documents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4(v) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Original Option Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Introduction</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Original PadCo-Protiva License and Services Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Introduction</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Original Protiva-Monsanto Services Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Introduction</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PadCo-Protiva License and Services Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Introduction</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PCBs</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4(w) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permits</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4(h)(ii) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permitted Recipients</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12(l)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Project Patent Response Deadline</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Schedule 12(k)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proposed Project Patent Abandonment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Schedule 12(k)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prosecution Matters Resolution Period</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Schedule 12(k)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Protiva</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preamble</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Protiva-Monsanto Services Agreement</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Introduction</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Protiva Patent Prosecution Matters</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Schedule 12(k)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Protiva Project Compound</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12(l)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proxy Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7(k)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regulatory Filings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4(h)(iii) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research Program</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Introduction</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Substantive Action</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7(n)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax Representations</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11(a) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Party Claim</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11(d)(i) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Threshold</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11(c)(i) of Appendix A</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UK Bribery Act</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4(i) of Appendix A</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><a name="s6617BAA5FBC3057047255A1C9668E284"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Conduct of Research Program.</font></div><a name="sDD9A48EE9684CE7AE9845A1C9688951D"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:96px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Rights and Responsibilities</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Subject to Monsanto&#8217;s performance of its obligations herein, the Company shall be responsible for all payments due to Protiva under the PadCo-Protiva License and Services Agreement.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><a name="sB240B4090BA8E63325FE5A1C96D72006"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:96px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">PadCo-Protiva License and Services Agreement</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  The Company previously engaged Protiva to perform certain activities described in the Research Plan pursuant to that certain Original PadCo-Protiva License and Services Agreement attached hereto as Exhibit C.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><a name="s74AC325E444B0E0D3C9C5A1C96EEFC09"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:96px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva-Monsanto Services Agreement</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Protiva previously engaged Monsanto to perform certain activities described in the Research Plan pursuant to that certain Original Protiva-Monsanto Services Agreement attached hereto as Exhibit D.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><a name="sA7CEAB0AB206EBE0B98E5A1C971CE7D1"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:96px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Diligence</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Monsanto, Protiva and the Company shall use reasonable best efforts to (x) pursue the achievement of the Technology Transfer Completion Criteria, and (y) comply with all of its obligations under this Agreement and the other Transaction Agreements.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;&#32;</font></div><a name="s7B7DBB00485D8770EBE95A1C9730720E"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:96px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(e)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Phase A, Phase B and Phase C</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  The parties acknowledge and agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:144px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The Research Plan outlined the following initial development activities:</font></div><div style="line-height:120%;padding-left:54px;padding-bottom:16px;text-align:justify;text-indent:144px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:46px;">(A)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">for Phase A, the Option Insect Phase A Completion Criteria and the Option Plant Phase A Completion Criteria,</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">13</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:54px;padding-bottom:16px;text-align:justify;text-indent:144px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:46px;">(B)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">for Phase B, the Option Insect Phase B Completion Criteria and the Option Plant Phase B Completion Criteria, and</font></div><div style="line-height:120%;padding-left:54px;padding-bottom:16px;text-align:justify;text-indent:144px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:46px;">(C)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">for Phase C, the Option Insect Phase C Completion Criteria and the Option Plant Phase C Completion Criteria. </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:144px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:12pt;">The Company has not achieved any of the Option Insect Phase A Completion Criteria, the Option Plant Phase A Completion Criteria, the Option Insect Phase B Completion Criteria, the Option Plant Phase B Completion Criteria, the Option Insect Phase C Completion Criteria or the Option Plant Phase C Completion Criteria.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:144px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(iii)</font><font style="font-family:inherit;font-size:12pt;">On or about May 22, 2015, Monsanto Canada paid to Protiva [***] (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Phase A-1 Initiation Payment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) by electronic wire as arranged with Protiva to continue Phase A of the Research Program.  </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:144px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">(iv)</font><font style="font-family:inherit;font-size:12pt;">On or about September 1, 2015, Monsanto Canada paid to Protiva [***] (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Option</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Phase A-2 Initiation Payment</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  </font></div><a name="sA5940FB783C5009B11B85A1C977FC78C"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Call Option.</font></div><a name="s922C1E94B3662DB3C1555A1C9792D172"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Option Grant</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Protiva granted Monsanto Canada the option (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Call Option</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;) during the Call Period to require Protiva to sell, convey and transfer to Monsanto Canada all outstanding capital stock of the Company in consideration for the payment by Monsanto Canada to Protiva of the amounts set forth in this</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 3</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><a name="s450F18D5274BE5DA7B725A1C97B5433A"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Option Exercise</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Monsanto Canada hereby exercises the Call Option and Protiva hereby accepts this Agreement as written notice of such exercise as of the date hereof (the</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Exercise Date</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;).</font></div><a name="s47738CE540DBF9ADBEB25A1C97D574AE"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Exercise of Call Option</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Monsanto Canada shall pay to Protiva the following amounts in the manner set forth below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">At the Closing, Monsanto Canada shall pay to Protiva by electronic wire transfer as arranged with Protiva an amount in cash equal to [***]</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-style:italic;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Promptly but no later than thirty (30) days following the date on which each of the Post-Closing Plant Submission Milestone, Post-Closing Insect Submission Milestone, Post-Closing Plant Approval Milestone and Post-Closing Insect Approval Milestone, respectively, has been achieved:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:54px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(A)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Monsanto Canada shall pay or cause to be paid to Protiva, within thirty (30) days after achievement of the Post-Closing Plant Submission Milestone, [***] by electronic wire as arranged with Protiva.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:54px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(B)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Monsanto Canada shall pay or cause to be paid to Protiva, within thirty (30) days after achievement of the Post-Closing Insect Submission Milestone, [***] by electronic wire as arranged with Protiva.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">14</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:54px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(C)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Monsanto Canada shall pay or cause to be paid to Protiva, within thirty (30) days after achievement of the Post-Closing Plant Approval Milestone, [***] by electronic wire as arranged with Protiva.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:54px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(D)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Monsanto Canada shall pay or cause to be paid to Protiva, within thirty (30) days after achievement of the Post-Closing Insect Approval Milestone, [***] by electronic wire as arranged with Protiva.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">In no event shall Monsanto Canada be required to pay to Protiva any of the foregoing milestone payments more than once.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Within one hundred twenty (120) days after Closing, Protiva shall complete the Technology Transfer to Monsanto Canada in accordance with Sections 1, 2, 3 and 5 of the Technology Transfer Completion Criteria.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Monsanto Canada shall provide to Protiva written notice of the achievement of any milestone set forth in this Section 3(c) within ten (10) days of the achievement thereof.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><a name="s11A73082B78A6DA3863E5A1C98147FA0"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Closing</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  The closing of the transactions contemplated by the exercise of the Call Option (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Closing</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;) shall take place at the offices of Bryan Cave LLP, 211 North Broadway, Suite 3600, St. Louis, Missouri 63012, at 10:00 a.m., Central time, on the fifth (5th) calendar day after the satisfaction or waiver of the last of the conditions set forth in Section 8 to be satisfied or waived in accordance with the terms of this Agreement following the exercise of the Call Option (other than those conditions which, by their terms, are to be satisfied at the Closing), or at such other date, time and location as Monsanto Canada and Protiva may agree in writing (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Closing Date</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;).</font></div><a name="sAC1C39AA2E16AF3AF1DE5A1C98293AB4"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Payment at Closing</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  At the Closing, (i) Monsanto Canada shall pay the amounts set forth in</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 3(c)(i)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">, (ii) Protiva, Arbutus and the Company shall execute, acknowledge and deliver such assignments, transfers, consents, assumptions and other documents and instruments and take such other commercially reasonable actions as may reasonably be requested to assign, convey or transfer to or vest in Monsanto Canada all of Protiva&#8217;s right, title and interest in all of the outstanding capital stock of the Company, and (iii) Monsanto Canada&#8217;s obligation to pay Protiva any further Milestone Payments pursuant to this Agreement shall be extinguished.  If the outstanding capital stock of the Company is represented by certificates, Protiva shall deliver to Monsanto Canada such certificates, endorsed or accompanied by appropriate transfer power duly executed.  For the avoidance of doubt, subject to</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 3(h)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">, the sale of all of Protiva&#8217;s right, title and interest in the outstanding capital stock of the Company hereunder shall not extinguish the obligation of the Company to pay the Commercial Milestone Payment to Protiva in accordance with the PadCo-Protiva License and Services Agreement.</font></div><a name="s8C4869E49F73DE28A2B55A1C985CCB93"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">15</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Right to Setoff</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  From and after the Closing, Monsanto Canada shall have the right, but not the obligation, exercisable by delivery of written notice to Protiva by Monsanto Canada, to set off against and reduce the amount of any Commercial Milestone Payment by an amount equal to [***] of any and all royalties, license fees and other consideration payable under licenses obtained from Third Parties deemed reasonably necessary or appropriate by Monsanto Canada in its discretion to avoid any claims that any  Compound, Formulation or Product infringes the intellectual property rights of such Third Parties directed to lipid nano particles or the use or manufacture of lipid nano particles; provided, however, that in no event shall such set off reduce the Commercial Milestone Payment by more than one-third of the amount of such payment (e.g., if a Commercial Milestone Payment is made pursuant to part (i) of Section 3.1(a) of the PadCo-Protiva License and Services Agreement and there has been no Change of Control of Protiva or Arbutus, then in no event shall Protiva receive less than [***] as such Commercial Milestone Payment, or if such Commercial Milestone Payment is made and there has been a Change of Control of Protiva or Arbutus, then in no event shall Protiva receive less than [***]).</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><a name="s9D171634919E5E16E7545A1C988DFF03"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Withholding Rights and Tax Treatment of Transactions</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  If Monsanto Canada is required by any Governmental Authority to deduct and withhold from the consideration otherwise payable pursuant to this Agreement to Protiva or any assignee such amounts as it is required to deduct and withhold with respect to the making of such payment under the Code, or any applicable provision of state, local or foreign Tax Law, Monsanto Canada shall gross up the payments owed to Protiva so that Protiva receives net of withholding taxes the amount Protiva would otherwise have received but for such withholding.  The parties hereto agree to make commercially reasonable efforts to inform one another of potential exceptions to withholding obligations.  To the extent that Protiva, its assignees, or successors are able to obtain a refund of such Tax withheld by Monsanto Canada, Protiva, its assignees, or successors agree to make a good-faith effort to obtain such refund and remit such refund to Monsanto, its assignees, or successors within thirty days of receipt of such refund.  The parties will use their commercially reasonable efforts to mitigate any withholding Tax on any payments hereunder, including providing any appropriate certification or other documentation.</font></div><a name="sECE8AD0826008C505BF35A1C98BDDD4F"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change of Control of Protiva or Tekmira</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  In the event of a Change of Control of Protiva or Tekmira with a Principal Competitor, the Commercial Milestone Payment under the PadCo-Protiva License and Services Agreement (if and when either is paid or payable under the terms of such agreement) shall be reduced by [***].  Such amounts may be further reduced in accordance with</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 3(f)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">above.</font></div><a name="s82FA080890FF35B042BF5A1C98D28546"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Representations and Warranties Regarding the Company</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Each of Protiva and the Company represents and warrants to Monsanto Canada that, except as set forth on the Disclosure Schedule or the Amended Disclosure Schedule, as applicable, which exceptions shall be deemed to be part of the representations and warranties made hereunder, the representations and warranties set forth in Section 4 of </font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Appendix A</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;to this Agreement are true and complete as of the Closing Date.</font></div><a name="s4D596440BF2C9C5FA5145A1C9905CA3D"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">16</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Representations and Warranties Regarding Protiva and Arbutus</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Each of Protiva and Arbutus hereby severally represents and warrants to Monsanto Canada that the representations and warranties set forth in Section 5 of</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Appendix A</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">to this Agreement are true and complete as of the Closing Date.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font></div><a name="sA9C122077FCF9925C3255A1C99335351"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Representations and Warranties of Monsanto Canada</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Monsanto Canada hereby represents and warrants to the Company and Protiva that the representations and warranties set forth in Section 6 of</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Appendix A</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">to this Agreement are true and complete as of the Closing Date.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font></div><a name="s3C7957A343D8868D229F5A1C9956C2B7"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">7.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Covenants and Restrictions.  </font></div><a name="sB4254C0F2EBC5E11FC895A1C9977DA2A"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Acknowledgement of Transfer Restriction</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  During the Call Period, each of Protiva and the Company acknowledges and agrees that the Protiva License may not be transferred or sublicensed to any Person other than Monsanto Canada.</font></div><a name="s11546D00A200C306B9235A1C99A6B823"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Assignment</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  During the Call Period, the Company shall not assign or transfer or sublicense any rights in the PadCo-Protiva License and Services Agreement and the Company Owned Intellectual Property and any other Company Licensed Intellectual Property, if any, to any Person other than Monsanto Canada.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><a name="s270009A197CCB150CCD35A1C99C8DC18"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Due Diligence Investigation</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">During the Call Period, upon Monsanto Canada&#8217;s request, provided that such requests are no more frequent than once (1) per calendar year, or at any other time when Monsanto Canada has a good faith intention to exercise the Call Option, Protiva will furnish to Monsanto Canada all information reasonably requested with respect to the affairs and businesses of Protiva to the extent it relates to the Protiva Intellectual Property and the Company, including the books and records of the Company and a reasonably detailed report on the current and planned development of the Company&#8217;s product candidates, including timelines and budgets, patents, patent applications, and other Intellectual Property, field studies, interactions with regulatory authorities, manufacturing activities, and publication plans; provided that, all reasonable third party out of pocket expenses (other than accounting fees and attorneys fees) incurred by Protiva in providing such information to Monsanto Canada shall be paid by Monsanto Canada.  To the extent any such report contains a significant change in activities and timelines from the report previously furnished to Monsanto Canada, such report will also include explanations for all of such changes.  Representatives of the Company and Protiva shall meet with Monsanto Canada, upon Monsanto Canada&#8217;s reasonable request, regularly during each year at the Company&#8217;s facilities at mutually agreeable times to discuss the matters set forth in this subsection.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">During the Call Period, other than in connection with the matters specified in clause (i) above, Protiva shall permit Monsanto Canada at Monsanto Canada&#8217;s expense, to visit and inspect the Company&#8217;s properties no more than two (2) times per year, or at any other time when Monsanto Canada has a good faith intention to exercise the Call Option, upon at least five (5) Business Days&#8217; advance written notice, to examine the Company&#8217;s books of account and records and discuss the Company&#8217;s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by Monsanto Canada.  </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">17</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><a name="sD0222BCC57C5C7DF380A5A1C99FA6EDD"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Prior to Closing</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  During the period beginning on the Effective Date and ending on the (x) expiration of the Call Period if Monsanto Canada does not exercise the Call Option or (y) Closing if Monsanto Canada exercises the Call Option, and without limiting the covenants set forth in</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 2</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">with respect to the conduct of the Research Program, without the approval of the Board, including the approval of the Representatives in any event, the Company shall use commercially reasonable efforts to:  (A) operate the Company Business in accordance with the Research Plan, (B) preserve intact the business organization of the Company, (C) preserve the current relationships of the Company with customers, suppliers and other Persons with which the Company has significant business relations, and (D) comply with all of the material covenants set forth in the PadCo-Protiva License and Services Agreement.  In addition, during such period the Company shall not and Protiva shall cause the Company to not, without the prior written consent of Monsanto Canada, directly or indirectly do, or propose to do, any of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">waive compliance by Protiva with the PadCo-Protiva License and Services Agreement or the Protiva-Monsanto Services Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">own any stock or other securities of any subsidiary or other corporation, partnership, or other entity;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">create any encumbrance on any material assets or properties of the Company (whether tangible or intangible) or the capital stock of the Company; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">except as approved by the Board or as contemplated by this Agreement, incur any Indebtedness or guarantee, directly or indirectly, any Indebtedness; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">issue, transfer, deliver, sell, authorize, pledge or otherwise encumber or propose the issuance of any units, equity interests or other interests, or create, or authorize the creation of any additional class or series of units, equity interests or other interests;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">increase the authorized number of any class or series of units, equity interests or other interests; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">except as contemplated by this Agreement, distribute any of the Company&#8217;s material assets in the form of a dividend;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(viii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">except for the Transaction Agreements, enter into any transaction or agreement with any Affiliate;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ix)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">engage in any business other than the Company Business;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(x)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">enter into any transaction or agreement with any third party;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">sell, assign, transfer, lease, license, abandon, permit to lapse or otherwise dispose of, or agree to sell, assign, transfer, lease, license, abandon, permit to lapse or otherwise dispose of, any of the material tangible assets of the Company, any material proprietary rights or technology, except as approved by the Board; </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">18</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><a name="sD0222BCC57C5C7DF380A5A1C99FA6EDD"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">sell, assign, transfer, lease, sublicense, abandon, permit to lapse or otherwise dispose of, or agree to sell, assign, transfer, lease, sublicense, abandon, permit to lapse or otherwise dispose of, any of the Company&#8217;s rights in, to, or under the Protiva License or any of Protiva&#8217;s rights in the capital stock of the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xiii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">acquire (by merger, consolidation or combination, or acquisition of stock or assets) any corporation, partnership or other business organization or division or material portion of the assets thereof, except acquisitions of inventory and supplies in the ordinary course of business consistent with past practice; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xiv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">make any change in any method of financial accounting or financial accounting practice used by the Company, other than such changes as are required by GAAP;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">except in accordance with generally accepted accounting principles in Canada, consistently applied, make any change to (1) the Company&#8217;s normal month to month accounting practices and policies, including those relating to the collection of accounts receivable, the payment of accounts payable or other similar Liabilities of the Company or (2) the application of such policies;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xvi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">(1) hire any employee, (2) enter into or amend any employment, deferred compensation, severance or similar contract, (3) incur any obligation to compensate any member of the Board  or officer of the Company, (4) pay or make provision for the payment of any bonus, profit sharing, deferred compensation, pension, retirement, severance or other similar payment or arrangement to any employee, or any member of the Board, officer of the Company or any of its Affiliates, (5) adopt any employee benefit plan, or (6) make any loans to any officer, member of the Board, Affiliate, agent, representative or consultant of the Company (other than advances to cover business expenses in the ordinary course of business) or make any change in any existing borrowing or lending arrangement for or on behalf of any of such Persons;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xvii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">amend the Company&#8217;s organizational documents;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xviii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">make any loans, advances or capital contributions to, or investments in, any other Person, other than advances to cover business expenses in the ordinary course of business;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xix)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">liquidate, dissolve or effect a recapitalization or reorganization in any form of transaction;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xx)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">(1) declare or pay any dividends on, or make any other distributions (whether in cash, stock or property) in respect of, any securities, (2) split, combine or reclassify any of its securities, (3) effect a recapitalization, (4) issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for units, equity interests or similar interests, or (5) except as contemplated by this Agreement, repurchase or otherwise acquire or offer to redeem or otherwise acquire, directly or indirectly, any units, equity interests or similar interests;</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">19</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><a name="sD0222BCC57C5C7DF380A5A1C99FA6EDD"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xxi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">create, incur, assume, suffer to exist or otherwise be liable with respect to any debt other than on terms that allow for prepayment at any time;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xxii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">commence, settle, or offer or propose to settle, any (1) material action, or (2) action that relates to the transactions contemplated by this Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xxiii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">enter into, or allow any Affiliate to enter into any agreement, license or other similar arrangement that restricts the Company&#8217;s performance of its obligations under the Transaction Agreements; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(xxiv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">authorize, commit, enter into or offer to enter into, any contract or agreement to take or cause to be taken any of the actions prohibited by this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7(d)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><a name="sB574EA499FEADF39115D5A1C9A1D1960"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Payment of Taxes, Etc.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The Company shall, and Protiva shall cause the Company and each of its subsidiaries to, and the Company shall cause each of its subsidiaries to:  (i) timely file all required Tax Returns as they become due (taking all timely filed proper extension requests into account); (ii) ensure that all such Tax Returns are true, correct and complete in all material respects; and (iii) timely pay and discharge, as they become due and payable, all Taxes (other than Taxes contested in good faith by the Company or its subsidiaries in appropriate proceedings), assessments and other governmental charges or levies imposed upon the Company or its subsidiaries, their income, or any property of the Company or its subsidiaries as well as all claims of any kind (including claims for labor, materials and supplies) that, if unpaid, may by law become a Lien or charge upon the properties of the Company or its subsidiaries.</font></div><a name="s8F58A120F9FD8DEDEE7B5A1C9A4FB9F9"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Material Contracts</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Protiva shall cause the Company not to and the Company shall not enter into, or extend, any material contract or commitment during the Call Period to the extent that the exercise of the Call Option or the consummation of the Closing could require the consent of the counterparty, result in a breach or violation of such contract, or otherwise require the payment of any fees or expenses in connection therewith, or give the other party the right to accelerate any obligations of the Company or such subsidiary thereunder or to cause the termination of such contract.</font></div><a name="s25CAA6DC792F6F61424B5A1C9A70A73E"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">20</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Shop</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Until this Agreement has been terminated in accordance with its terms:  (i) neither the Company nor Protiva will, nor will the Company or Protiva authorize or permit any of their respective officers, directors, Affiliates or employees, or any investment banker, attorney or other advisor or representative retained by them to directly or indirectly, (A) solicit, initiate or induce the making, submission or announcement of any Acquisition Proposal, (B) participate in any discussions or negotiations regarding, or furnish to any Person any &#8220;non-public&#8221; information with respect to, or take any other action to facilitate any inquiries or the making of any proposal that constitutes, or may reasonably be expected to lead to, any Acquisition Proposal, (C) engage in discussions with any Person with respect to an Acquisition Proposal, except as to disclose the existence of these provisions, including in response to any initial unsolicited expression of an Acquisition Proposal, (D) endorse or recommend any Acquisition Proposal, or (E) enter into any letter of intent or document or any contract, agreement or commitment contemplating or otherwise relating to any Acquisition Proposal; and (ii) the Company and Protiva will promptly notify Monsanto Canada of the receipt after the Effective Date of any proposal relating to an Acquisition Proposal or of any request for information relating to the Company or for access to the properties, books or records of the Company by any Person who has informed the Company or Protiva that such Person is considering making, or has made, an Acquisition Proposal, and the Company and Protiva will promptly provide Monsanto Canada with a summary of any documents received relating to an Acquisition Proposal and will keep Monsanto Canada informed regarding the status and details of any such Acquisition Proposal.  &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Acquisition Proposal</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221; means any offer or proposal relating to any Acquisition Transaction.  &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Acquisition Transaction</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221; means (1) any transaction or series of related transactions, other than the transactions contemplated by this Agreement, involving the purchase of all or a majority of the units or equity interests or assets of the Company or the purchase, acquisition, or sublicense of any right, title or interest of the Company in, to, or under the PadCo-Protiva License and Services Agreement, (2) any agreement to enter into a business combination with the Company, and (3) any agreement made, other than in the ordinary course of business, with regard to the Protiva Intellectual Property that would result in the transfer of the Protiva License from the Company to a third Person.  For the avoidance of doubt, (x) an offer or proposal relating to purchase  or sale of Protiva or Arbutus (including by sale of equity, merger, asset transaction or other business combination) shall not be an Acquisition Proposal or (y) the purchase or sale of Protiva or Arbutus (including by sale of equity, merger, asset transaction or other business combination) shall not be an Acquisition Transaction.</font></div><a name="sE73D26F3E5B38BF405A35A1C9AA08DB7"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">21</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Disclosure Schedule and Supplement</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Attached hereto at</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Exhibit F</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">is a schedule of disclosures and exceptions to the representations and warranties made by the Company and Protiva in</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 4</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">and</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 5</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">hereof as of the Effective Date (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Disclosure Schedule</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;).  As soon as reasonably practicable, and in any event no later than ten (10) Business Days following delivery to the Company by Monsanto Canada from time to time of a request in writing for Amended Disclosure Schedules at any time when Monsanto Canada has a good faith intention to exercise the Call Option, Protiva and the Company shall prepare and deliver to Monsanto Canada an updated schedule of disclosures and exceptions to the representations and warranties of the Company and Protiva contained in</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 4</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">and</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 5</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">hereof (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Amended Disclosure Schedule</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;), as if such representations and warranties were made as of the date of such Amended Disclosure Schedule, except to the extent any such representations and warranties refer expressly to an earlier date.  Protiva shall deliver the Amended Disclosure Schedule to Monsanto Canada as soon as reasonably practicable, and in any event no later than ten (10) Business Days following delivery to the Company by Monsanto Canada from time to time of a request in writing for Amended Disclosure Schedules at any time when Monsanto Canada has a good faith intention to exercise the Call Option.  For the avoidance of doubt, in the Amended Disclosure Schedule, Protiva may schedule disclosures and exceptions to any representation and warranty made herein regardless of whether Protiva or the Company has taken exception to such representation and warranty in this Agreement as of the Effective Date so long as the Amended Disclosure Schedule refer only to disclosures of actual, specific facts or events in existence on the date of such Amended Disclosure Schedule that have occurred or been discovered since the Effective Date.  Notwithstanding the foregoing, no disclosure of a fact or event on the Amended Disclosure Schedule shall be deemed to cure any failure to disclose such fact or event on any previously delivered Disclosure Schedule (or Amended Disclosure Schedule, if any), or otherwise amend any previously delivered Disclosure Schedule (or Amended Disclosure Schedule, if any); provided, however, the exceptions set forth on the Amended Disclosure Schedule shall be deemed to be part of the representations and warranties made as of such date and any item disclosed or otherwise set forth on the Disclosure Schedule or Amended Disclosure Schedule shall qualify such representations and warranties disclosed against in such schedules.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><a name="sF4CB1F19BF3B0D802C875A1C9AC102BA"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party Consents and Regulatory Approvals</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Upon exercise of the Call Option, the parties hereto shall cooperate with each other and use reasonable best efforts to promptly achieve the closing conditions set forth in</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 8</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">, including to (i) prepare and file all necessary documentation, to effect all applications, notices, petitions and filings as soon as reasonably practicable, to obtain as promptly as reasonably practicable all permits, consents, approvals, authorizations and clearances, which are necessary or advisable to consummate the Closing; (ii) defend any lawsuits or other legal proceedings, whether judicial or administrative, challenging this Agreement or the consummation of the transactions contemplated by this Agreement; and (iii) execute and deliver any additional instruments reasonably necessary to consummate the transactions contemplated by this Agreement.</font></div><a name="sCCA5ACE4C036A3AF48965A1C9AF37D93"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">22</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Monsanto Canada Director</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  During the Option Period, Protiva hereby agrees to vote, or cause to be voted, all the shares of capital stock of the Company now owned or which may hereafter be acquired by Protiva (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Company Shares</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;) in whatever manner as shall be necessary to ensure that at each annual or special meeting of stockholders of the Company or pursuant to any written consent of the stockholders of the Company (i) the individual designated by Monsanto Canada (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Monsanto Canada Director</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;) be elected to, and remain a member of, the Board, (ii) the Monsanto Canada Director is not removed from the Board (other than for cause) unless approved by Monsanto Canada, (iii) any vacancy created by the death, resignation, removal or otherwise of a Monsanto Canada Director be filled by an individual designated by Monsanto Canada, (iv) upon the request of Monsanto Canada, the Monsanto Canada Director be removed from the Board and (v) in the absence of a designation by Monsanto Canada of a Monsanto Canada Director, to retain one vacant seat on the Board until such time that Monsanto Canada designates a Monsanto Canada Director and to promptly elect such Monsanto Canada Director to the Board after such designation.</font></div><a name="sE1645B856018C47581B95A1C9B1A1F11"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(k)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Grant of Proxy</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Protiva hereby appoints Monsanto Canada as the true and lawful attorney in fact, agent and proxy of Protiva to (i) represent Protiva, solely with respect to [***] of the Company Shares held by Protiva (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Proxy Shares</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;), at any meeting of the stockholders of the Company, and at any postponements and adjournments of such meeting, (ii) execute on behalf of Protiva any written consent of the stockholders of the Company with respect to the Proxy Shares, and (iii) vote (or execute a written consent on behalf of) the Proxy Shares standing on the books of the Company in the name of Protiva.  Protiva affirms that this irrevocable proxy is coupled with an interest and may not be revoked until this Agreement terminates.   Protiva hereby covenants and agrees that Protiva shall not enter into any voting agreement or grant a proxy or power of attorney with respect to the Company Shares which is inconsistent with this Agreement.  Protiva also hereby agrees that, until the Call Period has expired without the Call Option having been exercised, or this Agreement has been terminated in accordance with its terms, it will not, without the prior written consent of Monsanto Canada (i) grant or enter into any Liens, proxies or powers of attorney (other than as granted herein) with respect to the voting of the Company Shares, or deposit any Company Shares into a voting trust or enter into a voting agreement with respect to any Company Shares, or any interest in any of the Company Shares, except to Monsanto Canada, (ii) sell, assign, transfer, encumber or otherwise dispose of, or enter into any contract, option or other arrangement or understanding with respect to the direct or indirect sale, assignment, transfer, encumbrance or other disposition of any of the Company Shares, or (iii) take any action that would have the effect of limiting, preventing or disabling Protiva from performing its obligations hereunder or the transactions contemplated hereby.</font></div><a name="s65ED23B5307ADA0BB9DE5A1C9B46C120"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(l)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each party agrees that, for itself and its Affiliates, until the first to occur of (a) [***] or (b) [***], a Receiving Party shall maintain all Confidential Information of the Disclosing Party in strict confidence and shall not (x) disclose Confidential Information to any third party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below or (y) use Confidential Information for any purpose except those explicitly licensed or otherwise authorized or permitted by this Agreement or any other Transaction Agreement.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">23</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The obligations in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7(m)</font><font style="font-family:inherit;font-size:12pt;">&#32;will not apply with respect to any portion of the Confidential Information that the Receiving Party can show by competent proof: (a) was known to the Receiving Party or its Affiliates, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party; (b) is subsequently disclosed to the Receiving Party or its Affiliates by a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use; (c) is or otherwise becomes generally available to the public or enters the public domain, either before or after it is disclosed to the Receiving Party and such public availability is not the result, directly or indirectly, of any fault of, or improper taking, use or disclosure by, the Receiving Party or its Affiliates or anyone working in concert or participation with the Receiving Party or its Affiliates; or (d) has been independently developed by employees or contractors of the Receiving Party or its Affiliates without the aid, application or use of Confidential Information of the Disclosing Party.  Specific Confidential Information disclosed by a Disclosing Party will not be deemed to be within any exceptions set forth in (a), (b), or (c) above merely because it is embraced by more general information to which one or more of those exceptions may apply and provided further that no combination of information shall be deemed to be within any such exceptions unless the combination itself and its principle of operation are within the public domain.  Even though Confidential Information may be within one of the exceptions described in the preceding sentence, the Receiving Party shall not disclose to third parties that the excepted Confidential Information was received from the Disclosing Party.   If the Closing occurs, then effective as of the Effective Date, references in (a), (b) and (d) to &#8220;Affiliates&#8221; shall not include the Company or any subsidiaries of the Company with respect to Protiva as the Receiving Party.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Confidential Information of a Disclosing Party may be used by the Receiving Party in the performance of its obligations under any Transaction Agreement, as otherwise expressly authorized in any Transaction Agreement or by the Disclosing Party in writing.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: (a) subject to the proviso below, by any party, in order to comply with applicable non-patent law (including any securities law or regulation or the rules of a securities exchange in a relevant jurisdiction) and with judicial process, if based on the reasonable advice of the Receiving Party&#8217;s counsel, such disclosure is necessary for such compliance; (b) subject to the proviso below, by any party, in connection with prosecuting or defending litigation; (c) by any party in connection with filing and prosecuting Protiva Project Patent or Joint Project Patent, only in a manner that complies with such party&#8217;s rights and obligations in connection with such matters as set out in the Transaction Agreements; (d) subject to the proviso below, by the Company, to its Affiliates, permitted acquirers or assignees under the Transaction Agreements and its or any of their research collaborators, subcontractors, lenders (but, with respect to lenders, only Confidential Information related to the terms and conditions of the Transaction Agreements and financial information related thereto) and each of the Company&#8217;s and its Affiliates&#8217; respective directors, employees, contractors and agents; (e) subject to the proviso below, by Monsanto, to its Affiliates, permitted acquirers or assignees under the Transaction Agreements and its or any of their research collaborators, subcontractors, lenders (but, with respect to lenders, only Confidential Information related to the terms and conditions of the Transaction Agreements and financial </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">24</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">information related thereto) and each of Monsanto&#8217;s and its Affiliates&#8217; respective directors, employees, contractors and agents; and (f) subject to the proviso below, by Protiva, to its Affiliates, permitted acquirers or assignees under the Transaction Agreements and its or any of their research collaborators, subcontractors, lenders (but, with respect to lenders, only Confidential Information related to the terms and conditions of the Transaction Agreements and financial information related thereto) and Protiva&#8217;s and its Affiliates&#8217; respective directors, employees, contractors and agents, provided, that (x) with respect to clause (a) and (b) where reasonably possible, (1) the Receiving Party will notify the Disclosing Party of the Receiving Party&#8217;s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed, and (2) consistent with applicable law or regulation, the Disclosing Party shall have the right to suggest reasonable changes to the disclosure to protect its interests and the Receiving Party shall not unreasonably refuse to include such changes in its disclosure, and (x) with respect to clause (d), (e) and (f), each Person to whom Confidential Information is disclosed must be bound prior to disclosure by confidentiality and non-use restrictions at least as restrictive as those contained in this Agreement (other than investment bankers, investors and lenders, who must be bound prior to disclosure by commercially reasonable obligations of confidentiality).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">No party shall use the name of any other party or of any director, officer, employee, or agent of any other party or any adaptation thereof in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds or financing without the prior written approval of such party or individual whose name is to be used.</font></div><a name="sB46C24AEAB9EF13EF6DF5A1C9B6E1416"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(m)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Financial Reporting</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">With respect to any period that Monsanto Canada determines it is required to consolidate the financial position and results of operations of the Company for financial account purposes or otherwise desires to audit the financial statements provided by the Company pursuant to </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7(m)(ii)</font><font style="font-family:inherit;font-size:12pt;">, Monsanto Canada shall be entitled (at its own expense) to access such books and records of the Company as may be required to perform (or cause to be performed) an audit of the Company&#8217;s financial position and results of operations for such period.  Such access shall be provided on a timely basis at reasonable times, during normal business hours, and shall be made available to Monsanto Canada and any third-party accounting firm or other agent designated by Monsanto Canada.  In connection with such review, Protiva shall cause the Company to make and the Company shall make, and shall cause any officers of the Company to make, such representations regarding the Company&#8217;s financial position, results of operations, books and records and accounting controls as may be reasonably requested by such third-party accounting firm in the performance of any such audit of the Company&#8217;s financial position and results of operations.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In addition to its obligations under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7(m)</font><font style="font-family:inherit;font-size:12pt;">, the Company shall deliver to Monsanto Canada as soon as practicable, but in any event not later than the thirtieth (30</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">) calendar day after each calendar month of the Company (or the sixtieth (60</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">) calendar day following December 31): (i) unaudited financial statements (balance sheet, income statement, statement of members&#8217; equity and statement of cash flows) of the Company as of the end of such calendar month; (ii) copies of all agreements entered during the previous month that would reasonably be considered </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">25</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">material or that required Monsanto Canada&#8217;s consent prior to entry pursuant to this Agreement or the Transaction Agreements; and (iii) copies of all minutes of meetings (or written consents executed in lieu thereof) of the Board held during such calendar quarter.   In addition to its obligations under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7(m)</font><font style="font-family:inherit;font-size:12pt;">, the Company shall deliver to Monsanto Canada as soon as practicable, but in any event not later than the thirtieth (30</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">) calendar day after each calendar quarter of the Company (or the sixtieth (60</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">) calendar day following December 31), unaudited financial statements (balance sheet, income statement, statement of members&#8217; equity and statement of cash flows) of the Company as of the end of such calendar quarter.  In addition to its obligations under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7(m)</font><font style="font-family:inherit;font-size:12pt;">, the Company shall deliver to Monsanto Canada as soon as practicable, but in any event not later than the thirtieth (30</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">) calendar day after each calendar year of the Company (or the sixtieth (60</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">th</sup></font><font style="font-family:inherit;font-size:12pt;">) calendar day following December 31), unaudited financial statements (balance sheet, income statement, statement of members&#8217; equity and statement of cash flows) of the Company as of the end of such calendar year.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Company shall provide Monsanto Canada the opportunity to discuss any financial data delivered pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7(m)</font><font style="font-family:inherit;font-size:12pt;">&#32;with the Company&#8217;s management (including the Board) at such times as may be mutually agreed upon between the Company and Monsanto Canada.  Monsanto Canada acknowledges and agrees that it will keep all information received pursuant to this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section&#160;7(m)</font><font style="font-family:inherit;font-size:12pt;">&#32;confidential in accordance with </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7(m)</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Protiva shall provide to Monsanto Canada copies of all of the Company&#8217;s Tax Returns within thirty (30) calendar days after filing with the relevant Governmental Authority.</font></div><a name="s11D04A4F86DB531F030E5A1C9B9AABE3"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(n)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Notification of Certain IP Matters</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Protiva shall provide to the persons then serving as the Monsanto Canada members of the JRC, not less often than once per quarter, notice and copies (if applicable) of: (1) all office actions, notices of allowance or allowability, or other substantive actions issued in connection with any Protiva Project Patent (each a &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Substantive Action</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;); (2) all correspondence from counsel (including foreign associates) explaining or providing guidance or recommendations regarding a Substantive Action; (3) a pre-filing draft of all Protiva Project Patent applications and responses to Substantive Actions that will or may be filed after the Effective Date as directed by the JRC in its exercise of its authority to oversee the filing, prosecution and maintenance of such Patents, revised drafts as directed by the JRC, and a copy of each Protiva Project Patent application, application and response to Substantive Action as filed; (4) all Protiva Project Inventions and invention disclosures received or prepared by Protiva directed to any Protiva Project Invention; and (5) the due date of any maintenance, annuity, or similar payment required </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">to maintain or otherwise prevent the abandonment, expiration, or cancellation of any Protiva Project Patent, provided that such notice is given to such members of the JRC not less than 30 days prior to such due date; and, further, Protiva shall provide, in a timely manner, any of the foregoing information to the JRC that is required for the JRC to make a decision regarding a Protiva Project Patent application.  For the avoidance of doubt, any Confidential Information of Protiva (as the Disclosing Party) included in such disclosures shall be subject to the provisions of</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 7(m)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">; in addition, prior to Closing the following additional provisions shall apply: (i) the recipients of such information shall use such Confidential Information solely in connection with the performance of their duties as members of the JRC to consult with Protiva regarding whether to file Patents for Protiva Project Inventions and the prosecution, maintenance and/or abandonment of Protiva Project Patents and, for such purposes only, may disclose such Confidential Information only to such representatives of Monsanto or Monsanto Canada who (A) are bound by non-disclosure obligations with respect to such information at least as restrictive as those contained in</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 7(l)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">and this</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 7(m)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">, (B) whose input such members of the JRC deem useful for such purposes (i.e., disclosure to representatives on a need to know basis only), and (C) who are either (i) a senior officer of Monsanto (e.g., the Vice President, Chemistry Technology) or (ii) Monsanto&#8217;s internal legal counsel.</font></div><a name="sC78D5BEB0F7BFF91887D5A1C9BBBC180"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(o)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Certain Business Practices Covenant</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  None of the Company, Arbutus or Protiva, or any of its other Affiliates or any Board Member or officer of the Company or any of its Affiliates, or any consultant, agent, employee or other Person acting for or on behalf of the Company or any of its Affiliates, will (A) use any funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity in respect of the Company Business; (B) directly or indirectly, pay or deliver any fee, commission or other sum of money or item of property, however characterized, to any finder, agent, or other party acting on behalf of or under the auspices of a governmental official or Governmental Authority which is in any manner illegal under any Laws of the United States or any other country having jurisdiction; or (C) make any payment to any customer or supplier of the Company, or given any other consideration to any such customer or supplier in respect of the Company Business that violates applicable Law in any material respect.  Without limiting the foregoing, none of the Company, Protiva, Arbutus or any of its other Affiliates or any Board Member or officer of the Company or any of its Affiliates, or any consultant, agent, employee or other Person acting for or on behalf of the Company or any of its Affiliates, will, directly or indirectly, take any action that would result in a violation by such Persons of the FCPA, UK Bribery Act or the Corruption of Foreign Public Officials Act (Canada), or any rules or regulations thereunder or any other applicable anti-corruption Law, including: (x) by making use of the mails or any means or instrumentality of interstate commerce in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or offer, gift, promise to give, or authorization of the giving of anything of value, directly or indirectly, to any &#8220;foreign official&#8221; (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office to secure official action, or to any Person (whether or not a foreign official) to influence that Person to act in breach of a duty of good faith, impartiality or trust (&#8220;acting improperly&#8221;) or to reward the Person for acting improperly, in contravention of the FCPA, the UK Bribery Act or the Corruption of Foreign Public Officials Act (Canada) or any other applicable anticorruption Law, (y) by requesting, agreeing to receive or accepting a financial or other advantage intending that, as a consequence, anyone&#8217;s work duties will be performed </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">26</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">improperly, or as a reward for anyone&#8217;s past improper performance, or (z) by otherwise offering or conveying, directly or indirectly (such as through an agent), anything of value to obtain or retain business or to obtain any improper advantage, including any bribe, rebate, payoff, influence payment, kickback or other similar unlawful payment to a foreign government official, candidate for office, or political party or official of a political party.  The Company and each of its Affiliates will conduct their respective businesses in compliance with all applicable anti-corruption Laws, including the FCPA, the UK Bribery Act and the Corruption of Foreign Public Officials Act (Canada), and the Company and each of its Affiliates will institute and maintain policies and procedures designed to cause each such Person to comply with all applicable anti-corruption Laws, including the FCPA, the UK Bribery Act and the Corruption of Foreign Public Officials Act (Canada).</font></div><a name="s565A7ACB7E79B67F367C5A1C9BEDD71F"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(p)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Export Controls Covenant</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  The Company will comply in all material respects with the export control Laws and regulations of the United States and Canada, including but not limited to the Export Administration Regulations, and sanctions regimes of the U.S. Department of Treasury, Office of Foreign Asset Controls, and the Area Control List and sanctions regimes of Global Affairs Canada and the Company will not export, reexport, or transfer products, materials, software and/or technology, either directly or indirectly, without prior U.S. or Canadian government authorization (as the case may be), to (i) any country subject to a comprehensive U.S. trade embargo (currently Cuba, Iran, North Korea, Sudan, and Syria) or a comprehensive Canada trade embargo (currently North Korea and Belarus) or to any Person listed on the &#8220;Entity List&#8221; or &#8220;Denied Persons List&#8221; maintained by the U.S. Department of Commerce or the list of &#8220;Specifically Designated Nationals and Blocked Persons&#8221; maintained by the U.S. Department of Treasury, or (ii) any end-user engaged in activities related to weapons of mass destruction.  Such activities include but are not necessarily limited to activities related to: (x) the design, development, production, or use of nuclear materials, nuclear facilities, or nuclear weapons; (y) the design, development, production, or use of missiles or support of missiles projects; and (z) the design, development, production, or use of chemical or biological weapons.</font></div><a name="sE85DF2EB699209B7ACD05A1C9C0F3C5E"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(q)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">PadCo-Protiva License and Services Agreement</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  None of Arbutus, Protiva or the Company shall amend the PadCo-Protiva License and Services Agreement  in any respect without the prior written consent of Monsanto Canada.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;&#32;&#32;&#32;</font></div><a name="s03844E28BC1BDBE792DF5A1C9C40917E"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(r)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Arbutus</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Within five (5) Business Days of execution of the PadCo-Protiva License and Services Agreement, Arbutus shall transfer to the Company the [***] Class A Common Share held by Arbutus.</font></div><a name="sF189AECEBFD946C6D5505A1C9C6254B9"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">8.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Closing Conditions</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><a name="s863ADA8B8968AB5FC4125A1C9C94400F"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Conditions of Monsanto Canada</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Monsanto Canada&#8217;s obligation to consummate the Closing is subject to the satisfaction, at or prior to the Closing, of each of the following conditions (any of which may be waived in writing by Monsanto Canada, in whole or in part, in its sole discretion):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exercise of Call Option</font><font style="font-family:inherit;font-size:12pt;">.  Monsanto Canada shall have exercised the Call Option in accordance with the terms of this Agreement;</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">27</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Representations and Warranties Regarding the Company and Protiva</font><font style="font-family:inherit;font-size:12pt;">.  The representations and warranties set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4</font><font style="font-family:inherit;font-size:12pt;">&#32;that are qualified by materiality or Material Adverse Effect and the Fundamental Representations shall be true and correct in all respects as of the Effective Date and as of the Closing Date as though made on the Closing Date (except that those representations and warranties that are made as of a specific date, which need be true and correct only as of such date).  The representations and warranties set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4</font><font style="font-family:inherit;font-size:12pt;">&#32;(other than the Fundamental Representations) that are not qualified by materiality or Material Adverse Effect shall be true and correct in all material respects as of the Effective Date and as of the Closing Date as though made on the Closing Date (except that those representations and warranties that are made as of a specific date need only be so true and correct as of such date);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Representations and Warranties Regarding Protiva and Arbutus</font><font style="font-family:inherit;font-size:12pt;">.  The representations and warranties set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be true and correct in all respects as of the Closing Date as though made on the Closing Date; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Covenants</font><font style="font-family:inherit;font-size:12pt;">.  The covenants and agreements set forth in this Agreement to be performed or complied with or by the Company and/or Protiva and/or Arbutus at or prior to the Closing shall have been performed or complied with by the Company or Protiva or Arbutus, as applicable, in all material respects.  The covenants and agreements set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7(q)</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 7(r)</font><font style="font-family:inherit;font-size:12pt;">&#32;shall have been performed or complied with by the Company or Protiva or Arbutus, as applicable, in all respects;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Governmental Order</font><font style="font-family:inherit;font-size:12pt;">.  (A) No Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Governmental Order or Law which is in effect or shall have initiated (which is continuing) any action that has the effect of making (or is seeking to make) the transactions contemplated by this Agreement illegal or otherwise has the effect of restraining or prohibiting (or is seeking to restrain or prohibit) the consummation thereof; and (B) all actions by or in respect of or filings with any Governmental Authority required to permit the consummation of the Closing in accordance with the terms hereof shall have been obtained (other than those actions or filings that may, by their terms, be made after such Closing or which, if not obtained or made prior to the consummation of the transactions contemplated hereby, would not have a Material Adverse Effect on the Company or Protiva prior to or after the Closing or a material adverse effect on Monsanto Canada after the Closing or be reasonably likely to subject Monsanto Canada or any of its subsidiaries or any of their respective officers or directors to substantial penalties or criminal liability);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Material Adverse Effect</font><font style="font-family:inherit;font-size:12pt;">.  No change, event, circumstance, development, occurrence or effect shall have occurred or been discovered since the Exercise Date and be continuing as of the Closing Date that, individually or taken together with any other change, event, circumstance, development, occurrence or effect, has had or would reasonably be expected to have a Material Adverse Effect;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Officer&#8217;s Certificates</font><font style="font-family:inherit;font-size:12pt;">.  Monsanto Canada shall have received an officer&#8217;s certificate from each of the Company and Protiva, dated as of the Closing Date, certifying as to the matters set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Sections 8(a)(ii)</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">(iii)</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">(iv)</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">(vi)</font><font style="font-family:inherit;font-size:12pt;">; </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">28</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(viii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Litigation</font><font style="font-family:inherit;font-size:12pt;">.  There shall be no Action pending against Monsanto Canada, Protiva or the Company or any of their respective Affiliates by any Governmental Authority (A) seeking to enjoin or make illegal, delay or otherwise restrain or prohibit the consummation of the Call Option; (B) that would result in the Call Option being rescinded following consummation; (C) seeking material damages in connection with the Call Option; (D)&#160;seeking to compel the Company or Monsanto Canada to dispose of or hold separate any material assets as a result of the Call Option; or (E) seeking to impose any criminal sanctions or liability on Monsanto Canada, Protiva or the Company in connection with the consummation of the Call Option;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ix)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Consents</font><font style="font-family:inherit;font-size:12pt;">.  The Company and Protiva shall have obtained the consent or approval of each Person whose consent or approval shall be required in connection with the consummation of the Closing under all notes, bonds, mortgages, indentures, contracts, agreements, leases, licenses, permits, franchises and other instruments or obligations to which it is a party; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(x)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">PadCo-Protiva License and Services Agreement</font><font style="font-family:inherit;font-size:12pt;">.  The PadCo-Protiva License and Services Agreement shall be in full force and effect and all representations and warranties set forth in the PadCo-Protiva License and Services Agreement shall be true and correct as of the Closing Date as though made on the Closing Date and shall continue to inure to the benefit of the Company, if Monsanto Canada acquires all of the outstanding capital stock of the Company, or Monsanto Canada as assignee of all of the Company&#8217;s right, title, and interest in, to, and under the Protiva License, if Monsanto Canada acquires the PadCo-Protiva License and Services Agreement and the Protiva License.</font></div><a name="s6D35DFFA959BDC3FC8425A1C9CC28921"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Conditions of Protiva</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  The obligation of Protiva to consummate the Closing is subject to the satisfaction, at or prior to the Closing, of each of the following conditions (any of which may be waived in writing by Protiva, in whole or in part, in its sole discretion):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Representations and Warranties</font><font style="font-family:inherit;font-size:12pt;">.  The representations and warranties of Monsanto Canada set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 6</font><font style="font-family:inherit;font-size:12pt;">&#32;shall be true and correct as of the Closing Date as though made on the Closing Date; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Covenants</font><font style="font-family:inherit;font-size:12pt;">.  The covenants and agreements set forth in this Agreement to be performed or complied with Monsanto Canada at or prior to the Closing shall have been performed or complied with in all material respects; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Governmental Order</font><font style="font-family:inherit;font-size:12pt;">.  (A) No Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Governmental Order or Law which is in effect or shall have initiated (which is continuing) any action that has the effect of making (or is seeking to make) the transactions contemplated by this Agreement illegal or otherwise has the effect of restraining or prohibiting (or is seeking to restrain or prohibit) the consummation thereof; and (B) all actions by or in respect of or filings with any Governmental Authority required to permit the consummation of the Closing in accordance with the terms hereof shall have been obtained (other than those actions or filings that may, by their terms, be made after such Closing, or which, if not obtained or made prior to the consummation of the transactions contemplated hereby, would not have a Material Adverse Effect on the Company prior to or after the Closing or a material adverse effect on Protiva after the Closing or be reasonably likely to subject Protiva or any of its subsidiaries </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">29</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or any of their respective officers or member of the Board to substantial penalties or criminal liability); and </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Litigation</font><font style="font-family:inherit;font-size:12pt;">.  There shall be no Action pending against Monsanto Canada, Protiva or the Company or any of their respective Affiliates by any Governmental Authority (A) seeking to enjoin or make illegal, delay or otherwise restrain or prohibit the consummation of the Call Option; (B) that would result in the Call Option being rescinded following consummation; (C) seeking material damages in connection with the Call Option; (D)&#160;seeking to compel the Company or Monsanto Canada to dispose of or hold separate any material assets as a result of the Call Option; or (E) seeking to impose any criminal sanctions or liability on Monsanto Canada, Protiva or the Company in connection with the consummation of the Call Option.</font></div><a name="sE3A62A838750B871F34E5A1C9CE7B42C"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">9.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Termination</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.</font></div><a name="s3730D3FF9804E5B35CCE5A1C9D0BDE0D"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Breach by Company or Protiva</font><font style="font-family:inherit;font-size:12pt;">.  Monsanto Canada may terminate this Agreement within the twenty (20) day period following the Company Cure Period if there is a material breach of any representation, warranty, covenant or obligation of the Company or Protiva that (i) would give rise (in the case of a breach of a representation or warranty) to a failure of the condition set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Sections 8(a)(ii) and 8(a)(iii)</font><font style="font-family:inherit;font-size:12pt;">&#32;to be satisfied, and (ii) if susceptible to cure, has not been cured within thirty (30) days following receipt by Protiva of written notice thereof from Monsanto Canada (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Company Cure Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;); </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, that this Agreement shall in no event terminate under this </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 9(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;if Monsanto Canada is then in material breach of any of its obligations under this Agreement.</font></div><a name="s8F1FF20EA73476AAC9325A1C9D3A53A9"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Breach of This Agreement by Monsanto Canada</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Protiva may terminate this Agreement within the twenty (20) day period following the Monsanto Canada Cure Period if there is a material breach of any representation, warranty, covenant or obligation of Monsanto Canada that (i) would give rise to a failure of the condition set forth in</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 8(b)(i)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">to be satisfied (in the case of a breach of a representation or warranty), and (ii) if susceptible to cure, has not been cured within thirty (30) days following receipt by the Monsanto Canada of written notice thereof from Protiva (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Monsanto Canada Cure Period</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;);</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">, that this Agreement shall in no event terminate under this</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 9(b)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">, if the Company or Protiva is in material breach of any of their obligations under this Agreement.</font></div><a name="s0E34C78CF39B4EE903FF5A1C9D5D7C52"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Acquisition of Protiva or Arbutus by a Principal Competitor</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Monsanto Canada may terminate this Agreement immediately upon written notice to Protiva in the event of a Change of Control of Protiva or Arbutus to a Principal Competitor.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;&#32;</font></div><a name="sA297DAB6AA3E1DE4FFBD5A1C9D90DC3A"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Phase A</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Monsanto Canada may terminate this Agreement upon delivery by Monsanto Canada to Protiva of (i) written notice of termination at any time during Phase&#160;A and (ii) [***] by electronic wire as arranged with Protiva.  Notwithstanding the foregoing, if Phase B is initiated by Monsanto Canada, Monsanto Canada shall not be entitled to terminate this Agreement pursuant to this</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 9(d)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><a name="sD06094E874612AB30BAB5A1C9DB0E1A0"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">30</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Phase B</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Monsanto Canada may terminate this Agreement upon delivery by Monsanto Canada to Protiva of (i) written notice of termination at any time during Phase&#160;B and (ii) [***] by electronic wire as arranged with Protiva.  Notwithstanding the foregoing, if Phase C is initiated by Monsanto Canada, Monsanto Canada shall not be entitled to terminate this Agreement pursuant to this</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 9(e</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">).</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><a name="s863488F1C8CAAFF009E35A1C9DE17A5C"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Phase C</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Monsanto Canada may terminate this Agreement upon delivery by Monsanto Canada to Protiva of (i) written notice of termination at any time during Phase&#160;C and (ii) Protiva [***], by electronic wire as arranged with Protiva.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><a name="s872A87925A7165CFCEC95A1C9E03611E"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Survival</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  The provisions of</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Sections 1</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(Definitions),</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">7(l)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(Confidential Information),</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">9(h)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(Survival),</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">11</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(Indemnification) and</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">12</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(Miscellaneous) shall survive the termination of this Agreement and shall remain in full force and effect.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;&#32;</font></div><a name="s4D155942B9806BF2DDDF5A1C9E34A72C"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Rights Upon Termination</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  For clarity, if this Agreement terminates and the Closing has not occurred prior to such termination: (a) Monsanto will relinquish its seat(s) on the Board, and (b) the Company and Protiva shall have the right to amend or terminate the PadCo-Protiva License and Services Agreement in such manner as they may deem appropriate and Monsanto shall no longer be a third party beneficiary of the PadCo-Protiva License and Services Agreement.</font></div><a name="sF17046C1F5880B341B4A5A1C9E56C011"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Rights and Obligations Upon Termination</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">of the Original Option Agreement</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Notwithstanding anything in this Agreement to the contrary and notwithstanding the replacement of the Original Option Agreement with this Agreement, none of the parties hereto shall be relieved from liability for any breach of the Original Option Agreement prior to the date hereof.</font></div><a name="s6BA3A761EA538F340B3A5A1C9E885DF0"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">10.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Certain Covenants</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.</font></div><a name="s67E6EB04F026A03C17BF5A1C9EA9669C"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Reporting</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  From the Closing Date until the date after which Protiva is not eligible to receive any further Commercial Milestone Payments, upon the written request of Protiva, Monsanto Canada shall provide Protiva by December 31 of each calendar year with an annual summary report of the status of any Commercialization activities of Monsanto Canada or any of its Affiliates or sublicensees with respect to any Product being developed by Monsanto Canada or any of their Affiliates.  For the avoidance of doubt, all reports and other information provided by Monsanto Canada to Protiva pursuant to this</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section&#160;10(a)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">shall constitute &#8220;Confidential Information&#8221; and shall be kept confidential in accordance with the applicable provisions of</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 7(l)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Monsanto Canada shall provide Protiva with written notice of the achievement by Monsanto Canada or the Company of the criteria for which a Commercial Milestone Payment is to be paid to Protiva, no later than five (5) Business Days after the occurrence thereof.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><a name="s7DA1DF31CED51F1CDB845A1C9EDD6F37"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">31</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exclusivity</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  During the Call Period and the Exclusivity Period, other than as specifically contemplated by the Research Plan, none of Arbutus, Protiva (and, during the Call Period, the Company), nor any of their respective Affiliates shall, directly or indirectly, alone or with any third Person, conduct or facilitate the conduct of any research, Development (as defined in the PadCo-Protiva License and Services Agreement) or Commercialization activities with respect to, or undertake to Develop (as defined in the PadCo-Protiva License and Services Agreement), any molecule intended for formulation and delivery of RNAi to plants and insects or other applications for use in the Agricultural Field, including through the license of any Intellectual Property to enable such action.  Notwithstanding the foregoing, if a Person acquires Arbutus or Protiva and such Person (i) has a valuation of greater than [***] and (ii) is not a Principal Competitor, then such Person shall be permitted to continue to operate its existing operations without regard to the restrictions set forth in this</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 10(b)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font></div><a name="sDF5D0B193191D0441BA15A1C9F0B54B0"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">11.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Indemnification</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  The indemnification obligations of the parties hereto are set forth in Section 11 of</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Appendix A</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">to this Agreement.</font></div><a name="s59F55870A862E168460D5A1C9F4542ED"></a><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;font-weight:bold;padding-right:48px;">12.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Miscellaneous</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><a name="s1524842A839BA0463DEE5A1C9F63CA79"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Further Assurances</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  If Monsanto Canada exercises the Call Option in accordance with the terms of this Agreement, from time to time and without additional consideration, but at the requesting party&#8217;s expense, the parties will execute and deliver, or cause to be executed and delivered, such additional or further agreements, transfers, assignments, endorsements, consents and other instruments as may be reasonably request for the purpose of effectively carrying out the transactions contemplated by this Agreement, including the Closing, the transfer of the Protiva License, the Company Owned Intellectual Property and any other Company Licensed Intellectual Property, if any, or the outstanding capital stock of the Company to Monsanto Canada and the release of any and all liens, claims and encumbrances with respect thereto, and will use commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all things necessary so as to permit consummation of the transactions contemplated hereunder prior to the Closing Date.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><a name="s32E46509B87CA37D465D5A1C9F83FF47"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">32</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or:  (i) personal delivery to the party to be notified, (ii) when sent, if sent by facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient&#8217;s next Business Day, (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next Business Day delivery, with written verification of receipt.  All communications shall be sent to the respective parties at their address as set forth on the signature page, or to such facsimile number or address as subsequently modified by written notice given in accordance with this</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 12(b)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  If notice is given to the Company or Protiva, a copy (which shall not constitute notice) shall also be sent to Orrick, Herrington &amp; Sutcliffe LLP, 51 West 52</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;"><sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:8pt">nd</sup></font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Street, New York, NY 10019, Attn: R. King Milling, Jr. (Fax: (212) 506-5151).  If notice is given to Monsanto Canada, a copy (which shall not constitute notice) shall also be sent to Bryan Cave LLP, One Metropolitan Square, 211 North Broadway, Suite 3600, St. Louis, Missouri 63102, Attn:  C. Brendan Johnson (Fax: (314) 552-8438).</font></div><a name="s725F0F655E32E70BABA05A1C9FA50660"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  This Agreement (including the Exhibits hereto) and the other Transaction Agreements constitute the entire agreement of the parties with respect to the matters contemplated herein and therein.  This Agreement and the other Transaction Agreements supersede any and all prior understandings as to the subject matter herein and therein.</font></div><a name="s73CAC77B1416035A6A6E5A1C9FD7718D"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Amendments, Waivers and Consents</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  This Agreement may be amended only by an instrument in writing, signed by each of Monsanto Canada and Protiva.  Any provisions of this Agreement may be waived if the party seeking waiver obtains the written consent of all of the affected parties.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><a name="s68EC9FC67987DE1E6DBF5A1C9FF887D8"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Binding Effect; Assignment</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  This Agreement shall be binding upon and inure to the benefit of the personal representatives and successors of the respective parties hereto and shall not be assignable by Protiva or the Company without the express written consent of the other parties hereto.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;&#32;&#32;&#32;</font></div><a name="s7EED5ADC50CC423C64545A1CA02A4360"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Public Announcements</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Except as required by Law or by a Governmental Authority (including the rules and regulations of any stock exchange or trading market on which a party&#8217;s (or its parent entity&#8217;s) securities are traded) or as permitted by the following sentence, none of the Company, Protiva, or Monsanto Canada, nor any of their respective Affiliates or any of their respective officers, directors, employees, agents, and representatives, as applicable, shall issue or cause the publication of any press release or other public announcement with respect to the transactions contemplated by this Agreement without the prior written consent of the other parties hereto, which consent shall not be unreasonably withheld, conditioned or delayed.  In connection with the execution and delivery of this Agreement, the parties agree to publication of the press release in the form attached hereto as</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Exhibit G</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">and agree that each party shall be permitted to continue to use such press release, including the specific content contained therein, for any purposes without the need to obtain the prior written consent of the other parties hereto.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;&#32;&#32;</font></div><a name="sCE2D575E50D6B136C8F75A1CA04ABF39"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">33</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  The headings contained in this Agreement are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement.  In this Agreement the singular includes the plural, the plural the singular, the masculine gender includes the neuter, masculine and feminine genders.  All dollar amounts are expressed in U.S. dollars.</font></div><a name="sBF2E4F6DB7093C471BDB5A1CA07C41CE"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  If any provision of this Agreement shall be found by any court of competent jurisdiction to be invalid or unenforceable, the parties hereby waive such provision to the extent that it is found to be invalid or unenforceable.  Such provision shall, to the maximum extent allowable by law, be modified by such court so that it becomes enforceable, and, as modified, shall be enforced as any other provision hereof, all the other provisions hereof continuing in full force and effect.</font></div><a name="sD4C72D075B0C5838C1BB5A1CA0B05348"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></div><a name="sF770E5161B3602F3524F5A1CA0DA3D72"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(j)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law; Jurisdiction</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  This Agreement shall be governed and interpreted in accordance with the substantive laws of the State of New York.  In the event any action shall be brought to enforce or interpret the terms of this Agreement, the Parties agree that such action will be brought in the State or Federal courts located in New York, New York.  Each of the Parties hereby irrevocably submits with regard to any action or proceeding for itself and in respect to its property, generally and unconditionally, to the nonexclusive jurisdiction of the aforesaid courts.  Each of the Parties hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in any action or proceeding with respect to this Agreement, (a) any claim that it is not personally subject to the jurisdiction of the above-named courts for any reason other than the failure to lawfully serve process, (b) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise), and (c) to the fullest extent permitted by Applicable Law, that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper, and (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.</font></div><a name="s9113C62CE16B5AE554085A1CA0FA18FE"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(k)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Joint Research Committee</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  As soon as practicable following the Effective Date, the parties will replace the representatives of the Company on the Joint Research Committee (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">JRC</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;), established pursuant to the Original Option Agreement, with representatives of Protiva such that, from and after the Effective Date, the JRC will be comprised of an equal number of representatives of Monsanto Canada and Protiva and will perform the matters expressly contemplated by this</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 12(k)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">to be performed by the JRC following exercise of the Call Option, Monsanto Canada and Protiva).  Each of Monsanto Canada and Protiva, as applicable (each, a &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">JRC Party</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221; and collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">JRC Parties</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;), may replace its representatives on the JRC at any time upon written notice to the other party.  The representatives of each JRC Party shall </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">34</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">collectively have one (1) vote on all matters to be decided by the JRC, and the JRC shall take all actions by unanimous vote.  The JRC will meet at such times as are deemed reasonably necessary by the JRC Parties.  Meetings of the JRC will be effective only if at least one (1) representative of each JRC Party is present or participating.  Each JRC Party will be responsible for all of its own expenses of participating in the JRC meetings.  The JRC Parties will endeavor to schedule meetings of the JRC at least six (6) months in advance;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">provide</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">d, that each JRC Party shall be permitted to call additional special meetings of the JRC on not less than ten (10) business days&#8217; notice.  The JRC Parties will alternate in preparing the meeting agenda, and the JRC Party that was responsible for preparing the meeting agenda will act as facilitator or chair of the meeting, as well as prepare and circulate for review and approval by the other JRC Party written minutes of such meeting within thirty (30) days after such meeting.  The JRC Parties will agree on the minutes of each meeting promptly, but in no event later than the next meeting of the JRC.  The JRC, subject to and in accordance with the provisions of this</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 12(k)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">and Schedule 12(k), will (i) consult and/or make decisions (as provided in Schedule 12(k)) regarding filing of Patent protection in the Territory for Protiva Project Inventions and decisions regarding the prosecution, maintenance and/or abandonment of Protiva Project Patents in the Territory; (ii) make decisions regarding filing of Patent protection in the Territory for Joint Project Inventions and decisions regarding the prosecution, maintenance and/or abandonment of Joint Project Patents in the Territory; (iii) resolve disputes among the parties to the PadCo-Protiva License and Services Agreement or the Protiva-Monsanto Services Agreement regarding the appropriate course of action with respect to any JRC Joint IP Infringement Matter or JRC Protiva Project Infringement Matter; (iv) resolve disputes regarding whether the Post-Closing Milestones have been achieved or the Technology Transfer has been completed (if Monsanto Canada exercises the Call Option); (v) determine, within thirty (30) days following Protiva&#8217;s delivery of the Data Package, whether the Company has met all requirements of Option Insect Phase C Completion Criteria and Option Plant Phase C Completion Criteria; and (vi) attend to such other matters as may be directed to the JRC by the Parties or under the terms of any Transaction Agreement.  Each of the Parties shall provide the JRC with copies of all substantive communications (including a copy of the patent application as filed, and copies of all communications from the relevant patent office, and responses thereto) in connection with each patent application that is a Joint Project Patent and shall provide the JRC with periodic updates in respect of the status of any pending application for a Joint Project Patent; the members of the JRC shall review and comment on all drafts of Joint Project Patents.  In the event there is a dispute among the members of the JRC regarding any matter to be handled by the JRC, e.g., in the event the members of the JRC are unable to reach a unanimous decision regarding such matter within a reasonable time (wherein such reasonable time may be determined by any one member of the JRC), then such member or members may initiate the appropriate dispute resolution process (as described below) by written notice to the other members of the JRC and such other persons who will be involved in such dispute resolution process (as described below).  The processes for resolving such disputes are as follows:</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-style:italic;">Milestone and Technology Transfer Disputes.</font><font style="font-family:inherit;font-size:12pt;font-style:italic;background-color:#ffffff;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">In the event of a dispute relating to whether certain Milestones have been met or whether the Technology Transfer has been completed  in accordance with the Technology Transfer Completion Criteria, the Chief Executive Officer of Protiva and the Vice President of Chemistry of Monsanto shall use commercially reasonable efforts for a period of 20 days (or such longer period as they may mutually agree) to </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">35</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">resolve any such dispute.  If, at the end of such period (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Dispute Negotiation Period</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;), they are unable to resolve such dispute, then the matter shall be resolved in accordance with</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 12(k)(iv)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-style:italic;">Patent Matters Disputes.</font><font style="font-family:inherit;font-size:12pt;font-style:italic;background-color:#ffffff;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Any disputes regarding Patent prosecution matters or patent strategies shall be resolved in the manner set forth on Schedule 12(k).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-style:italic;">Infringement Matter Dispute.</font><font style="font-family:inherit;font-size:12pt;font-style:italic;background-color:#ffffff;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Any dispute relating to a JRC Joint IP Infringement Matter or JRC Protiva Project Infringement Matter shall be referred to Independent IP Counsel for a recommendation, which recommendation shall be delivered to the Chief Executive Officer of Protiva and the Vice President of Chemistry of Monsanto within 10 days following such referral. During the 10 day period immediately following receipt of Independent IP Counsel&#8217;s recommendation, the Chief Executive Officer of Protiva and the Vice President of Chemistry of Monsanto shall use commercially reasonable efforts to resolve such dispute taking into consideration Independent IP Counsel&#8217;s recommendation.  If, at the end of such period, they are unable to resolve such dispute, then the Parties agree to proceed based on Independent IP Counsel&#8217;s recommendation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-style:italic;">Arbitration.</font><font style="font-family:inherit;font-size:12pt;font-style:italic;background-color:#ffffff;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Any dispute relating to (A) whether certain Milestones or Post-Closing Milestones have been met or whether the Technology Transfer has been completed in accordance with the Technology Transfer Completion Criteria that has not been resolved in accordance with</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 12(k)(i)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">, (B) whether the Company has completed Phase C or (C) the designation of the Independent IP Counsel, shall be settled by arbitration in New York, New York in accordance with the Commercial Arbitration Rules of the American Arbitration Association, and judgment on the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-style:italic;">Any Other Dispute.</font><font style="font-family:inherit;font-size:12pt;font-style:italic;background-color:#ffffff;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">In the event of any other dispute relating to the Research Plan, including any dispute relating to prioritization, direction, or other strategic issues regarding services provided by Protiva pursuant to the PadCo-Protiva License and Services Agreement or services provided by Monsanto pursuant to the Protiva-Monsanto Services Agreement, or any other dispute to be resolved pursuant to the provisions of this</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 12(k)(v)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">, the Chief Executive Officer of Protiva and the Vice President of Chemistry of Monsanto shall use commercially reasonable efforts for a period of 20 days (or such longer period as they may mutually agree) to resolve any such dispute.  If, at the end of such period, they are unable to resolve such dispute, then the matter shall be resolved by the Chief Technology Officer of Monsanto; provided, however, that (a) such resolution shall not contravene existing agreements that Protiva is a party to or its business strategies or require the contribution of additional resources of the Company without Protiva&#8217;s prior written consent, which consent shall not be unreasonably withheld, delayed or conditioned and (b) any increase in costs to Protiva as a result of decisions by Monsanto Canada under this</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 12(k)(v)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">shall be borne by Monsanto Canada.</font></div><a name="sF3E897D6DF51F49BDB625A1CA125FDD0"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">36</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(l)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Disclosure of Protiva Project Compounds</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  In the event Monsanto Canada requests disclosure of the chemical composition of any Compounds or Formulations Discovered by, Developed by, that come under the Control of, or that are otherwise used by or on behalf of, Protiva or any of its Affiliates under the Research Program or in connection with the provision of Services provided prior to Closing that are not Joint Project Intellectual Property and that are the Confidential Information of Protiva (each a &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Protiva Project Compound</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;) prior to Closing: (i) Protiva shall disclose the chemical composition of such Protiva Project Compound to the persons then serving as the Monsanto Canada members of the JRC (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">Permitted Recipients</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;); (ii) the Permitted Recipients shall use such chemical composition information solely to evaluate the merits of filing a Patent application that would require disclosure of such chemical composition information and, for such purpose only, may disclose such chemical composition to such representatives of Monsanto or Monsanto Canada who (A) are bound by non-disclosure obligations with respect to such information at least as restrictive as those contained in</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 7(m)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">and this</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 12(l)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">and (B) whose input the Permitted Recipients deem useful for purposes of such evaluation (i.e., disclosure to representatives on a need to know basis only); and (iii) in the event the Permitted Recipients, in their discretion, elect to recommend filing such a Patent application, such recommendation shall be referred to the JRC, to be considered by the JRC in the performance of its duties, as set forth in</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 12(k)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">and</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Schedule 12(k)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  In the event the then Licensee (as defined in the PadCo-Protiva License and Services Agreement) under the PadCo-Protiva License and Services Agreement requests disclosure of the chemical composition of any Protiva Project Compound after Closing including, without limitation, in connection with the performance of Technical Transfer Completion Criteria: (i) Protiva shall disclose the chemical composition of such Protiva Project Compound to the persons designated by the Licensee; (ii) the Licensee may use and disclose such chemical composition information (which chemical composition information is and shall be Protiva Know-How for purposes of the Transaction Agreements) for the purposes set out in and subject to the terms and conditions of the PadCo-Protiva License and Services Agreement; and (iii) in the event the Licensee, in its discretion, elects to recommend filing a Patent application that would require disclosure of such chemical composition information, such recommendation shall be referred to the JRC, to be considered by the JRC in the performance of its duties, as set forth in</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 12(k)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">and Schedule 12(k).  Nothing in this</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 12(l)</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">shall be deemed to limit Protiva&#8217;s rights to make decisions and/or recommendations regarding the filing or prosecution of Protiva Background Patents or Protiva Project Patent so long as such activities are conducted in a manner Protiva reasonably determines will prevent the disclosure to Monsanto Canada of chemical composition information not requested by Monsanto Canada.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font></div><a name="s51A9C515BC374A4E13BD5A1CA14470A2"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(m)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Specific Enforcement</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  The parties hereto agree that if any of the provisions of this Agreement, were not performed in accordance with their specific terms or were otherwise breached, irreparable damage would occur, no adequate remedy at law would exist and damages would be difficult to determine, and that, except as otherwise provided herein, the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy at law or equity, without any requirement to the securing or posting of any bond in connection with such remedy.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><a name="s4DA7E05B6533AF9D03945A1CA1768CD2"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">37</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(n)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Finder&#8217;s Fees</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  Each party represents that it neither is nor will be obligated for any finder&#8217;s fee or commission in connection with this transaction.  Monsanto Canada agrees to indemnify and to hold harmless the Company and Protiva from any liability for any commission or compensation in the nature of a finder&#8217;s or broker&#8217;s fee arising out of this transaction (and&#160;the costs and expenses of defending against such liability or asserted liability) for which Monsanto Canada or any of its officers, employees, or representatives is responsible.  The Company and Protiva agree to indemnify and hold harmless Monsanto Canada from any liability for any commission or compensation in&#160;the nature of a finder&#8217;s or broker&#8217;s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Company or Protiva or any of their respective officers, employees or representatives is&#160;responsible.</font></div><a name="s5CD8516CF91A2EE009F55A1CA19767AA"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(o)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Titles and Subtitles</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.</font></div><a name="s8D3794756F045D9F135C5A1CA1CB455B"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(p)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Delays or Omissions</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.  No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non&#8209;breaching or non&#8209;defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring.  Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing.  All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><a name="s9D72CF9FFD49D0FCF02D5A1CA1EDD68A"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">, the parties have caused this Agreement to be duly executed under seal as of the date first above written.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="49%"></td><td width="51%"></td></tr><tr><td style="vertical-align:top;padding-left:8px;padding-top:2px;padding-bottom:2px;padding-right:8px;"><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PROTIVA BIOTHERAPEUTICS INC.</font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:         </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/Bruce Cousins</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:    Bruce Cousins</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:      Executive Vice President and CFO</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Address: </font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;</font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td><td style="vertical-align:top;padding-left:8px;padding-top:2px;padding-bottom:2px;padding-right:8px;"><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PROTIVA AGRICULTURAL DEVELOPMENT COMPANY, INC.</font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:          </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/Bruce Cousins</font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:     Bruce Cousins</font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:       Executive Vice President and CFO</font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Address: </font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:8px;padding-top:2px;padding-bottom:2px;padding-right:8px;"><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION (formerly known as Tekmira Pharmaceuticals Corporation)</font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:         </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/Bruce Cousins</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:    Bruce Cousins</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:      Executive Vice President and CFO</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Address: </font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;</font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td><td style="vertical-align:top;padding-left:8px;padding-top:2px;padding-bottom:2px;padding-right:8px;"><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MONSANTO CANADA, INC.</font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:           </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/Robert M. McCarroll</font></div><div style="padding-left:65px;text-indent:-66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:      Robert M. McCarroll, Ph. D.</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:        VP, Chemistry Technology</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Address: </font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">38</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><a name="s0D713B51092DDE19F4D25A1CA21FC47F"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Schedule 12(k)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Patent Prosecution and Review Procedures</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[Signature Page to Form of Option Exercise Price Certificate]</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.9</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.10A</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><a name="s0D713B51092DDE19F4D25A1CA21FC47F"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT A</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">RESEARCH PLAN</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><br><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">EXECUTION VERSION</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT B-2(i)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">PLANT PHASE A</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">COMPLETION CRITERIA</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT B-2(ii)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">INSECT PHASE A</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">COMPLETION CRITERIA</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT B-3(i)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">PLANT PHASE B</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">COMPLETION CRITERIA</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT B-3(ii)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">INSECT PHASE B</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">COMPLETION CRITERIA</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT B-4(i)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">PLANT PHASE C</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">COMPLETION CRITERIA</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:29px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT B-4(ii)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">INSECT PHASE C</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">COMPLETION CRITERIA</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT B-5(i)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">OPTION SET-UP COMPLETION CRITERIA</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT B-5(ii)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">OPTION SHIPMENT COMPLETION CRITERIA</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT B-6</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">TECHNOLOGY TRANSFER COMPLETION CRITERIA</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT C</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">PADCO-PROTIVA LICENSE AND SERVICES AGREEMENT </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;background-color:#ffffff;">(not attached &#8211; this is simply the License and Services Agreement previously </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;background-color:#ffffff;">entered into by the parties)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT D</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">PROTIVA-MONSANTO SERVICES AGREEMENT </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;background-color:#ffffff;">&#32;(not attached &#8211; this is simply the Services Agreement previously </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;background-color:#ffffff;">entered into by the parties)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT E</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">INTENTIONALLY OMITTED</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT F</font></div><div style="line-height:120%;text-align:center;text-indent:480px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">DISCLOSURE SCHEDULE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">TO PROTIVA AGRICULTURAL DEVELOPMENT COMPANY INC. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">AMENDED AND RESTATED OPTION AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">BY AND AMONG</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MONSANTO CANADA, INC.,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARBUTUS BIOPHARMA CORPORATION (FORMERLY KNOWN AS TEKMIRA PHARMACEUTICALS CORPORATION),</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">PROTIVA BIOTHERAPEUTICS INC.,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">AND</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PROTIVA AGRICULTURAL DEVELOPMENT COMPANY INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Dated as of March 4, 2016</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:480px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Section 4(f)(iii)(A)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">INTELLECTUAL PROPERTY</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">[***]</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Section 4(f)(iii)(C)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">COVENANTS NOT TO SUE</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">[***]</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Section 4(f)(iii)(D)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">RESEARCH PROGRAM NON-INFRINGEMENT AS OF THE EFFECTIVE DATE</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Section 4(f)(iii)(E)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">RESEARCH PROGRAM IP NON-INFRINGEMENT ON THE CLOSING DATE</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffff00;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Section 4(f)(iii)(F)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">NO ACTIONS PENDING &#8211; PROTIVA IP</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Section 4(f)(x)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">CONFIDENTIAL INFORMATION - EMPLOYEES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Section 4(f)(x)-2</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">CONFIDENTIAL INFORMATION</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Section 4(f)(xi)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">OPTIONS, LICENSES, COVENANTS, SECURITY INTERESTS, LIENS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Section 4(f)(xii)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">USE OF GOVERNMENTAL AUTHORITIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Section 4(h)(ii)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">PERMITS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">[***]</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Section 4(k)(i)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">&#160;</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT G</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">INTENTIONALLY OMITTED </font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT H</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">INTENTIONALLY OMITTED </font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT I</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">INTENTIONALLY OMITTED </font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT J</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">CERTAIN KNOWLEDGE PERSONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT K</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">CERTAIN PRINCIPAL COMPETITORS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s3AEC203240F0FD675B0D5A1CA23FC1E6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT L</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">AMENDED AND RESTATED</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">LICENSE AND SERVICES AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Between</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">PROTIVA AGRICULTURAL DEVELOPMENT COMPANY INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">on the one hand,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">PROTIVA BIOTHERAPEUTICS INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">ARBUTUS BIOPHARMA CORPORATION, </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">on the other hand</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Dated:  March 4, 2016</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s553EF18F60338F5489855A1CA272129C"></a><div><div style="line-height:120%;text-align:center;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:center;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:right;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.50427350427351%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="12%"></td><td width="80%"></td><td width="7%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Page</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE I - DEFINITIONS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">General</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Interpretation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE II - LICENSE GRANTS AND RELATED RIGHTS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">License Grants to Licensee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Sublicensing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Grant Back</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Retained Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Rights in Bankruptcy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Compliance With Applicable Laws</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE III - FINANCIAL PROVISIONS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Payment for License</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Payment for License</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;Protiva Subsection 85(1) Election</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tekmira Subsection 85(1) Election</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE IV - SERVICES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Termination of Services Obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE V - INTELLECTUAL PROPERTY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ownership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prosecution and Maintenance of Patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Third-Party Infringement of Protiva Background Patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Third-Party Infringement of Protive Project Patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Defense of Claims Brought by Third Parties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Disclosures and Opt-In Rights Regarding Protiva Background Patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Joint Research Committee Oversight</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE VI - CONFIDENTIAL INFORMATION AND PUBLICITY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Non-Disclosure of Confidential Information</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exceptions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Permitted Uses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Permitted Disclosures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE VII - INDEMNIFICATION AND INSURANCE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Protiva Indemnification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee Indemnification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tender of Defense; Counsel</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Insurance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE VIII - TERM AND TERMINATION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Material Breach</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Challenges of Protiva&#8217;s Patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Rights in Bankruptcy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Consequences of Termination; Survival</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Remedies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.14529914529915%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="44%"></td><td width="11%"></td><td width="45%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">i</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s553EF18F60338F5489855A1CA272129C"></a><div><div style="line-height:120%;text-align:center;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:center;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(continued)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:right;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.50427350427351%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="12%"></td><td width="80%"></td><td width="7%"></td><td width="1%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE IX - MISCELLANEOUS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Representations and Warranties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Force Majeure</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Consequential Damages</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Assignment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Independent Contractors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Governing Law; Jurisdiction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Severability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">No Implied Waivers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Headings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Entire Agreement; Amendment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Waiver of Rule of Construction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">No Third-Party Beneficiaries</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Further Assurances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Performance by Affiliates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Effect of Amendment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.14529914529915%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="44%"></td><td width="11%"></td><td width="45%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">ii</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s74F7BA7F5714BD04E3775A1CA2ACAD89"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">AMENDED AND RESTATED</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">LICENSE AND SERVICES AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Amended and Restated License and Services Agreement (this &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is entered into as of March 4, 2016 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;), between Protiva Agricultural Development Company Inc., a British Columbia corporation with a principal place of business at 100&#8209;8900&#160;Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">PadCo</font><font style="font-family:inherit;font-size:12pt;">&#8221;), on the one hand, and Protiva Biotherapeutics, Inc., a British Columbia corporation with a principal place of business at 100&#8209;8900&#160;Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and Arbutus Biopharma Corporation (formerly, Tekmira Pharmaceuticals Corporation), a British Columbia corporation with a principal place of business at 100&#8209;8900&#160;Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Arbutus</font><font style="font-family:inherit;font-size:12pt;">&#8221;), on the other hand. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Protiva and Arbutus own or Control Protiva Intellectual Property (as defined below) that is useful for the delivery of a variety of oligonucleotide products, including those that function through RNA interference or the modulation of microRNAs; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, PadCo, Protiva and Tekmira entered into that certain License and Services Agreement on January 12, 2014 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Original License</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and, contemporaneously with the execution of the Original License: (a) as consideration for the Transferred Protiva Rights and in full satisfaction of the Protiva Purchase Price, the Licensee issued the Protiva Note and one Class B Common share in the capital stock of Licensee to Protiva and granted to Protiva the rights set out in Section 3.3 of the Original License; (b) as consideration for the Transferred Tekmira Rights and in full satisfaction of the Protiva Purchase Price, the Licensee issued one Class A Common share in the capital stock of Licensee to Tekmira that was later transferred to Protiva; (c) Protiva, Tekmira, PadCo and Monsanto Canada entered into the Option Agreement and (d) Protiva and Monsanto entered into the Protiva-Monsanto Services Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, contemporaneously with the execution of this Agreement and as of the Effective Date: (a) the parties to the Protiva-Monsanto Services Agreement are amending the Protiva-Monsanto Services Agreement, (b) the parties to the Option Agreement are amending and restating the Option Agreement, (c) Monsanto Canada is exercising the Call Option to acquire all of the outstanding capital stock of PadCo, and (d) Closing is occurring; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Protiva, Arbutus and PadCo desire to amend and restate the Original License, effective as of the Effective Date, upon the terms and subject to the conditions set forth in this Agreement; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, as required by the terms of the Original License, Monsanto Canada has consented to the amendment and restatement of the Original License upon the terms and conditions of this Agreement.</font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s74F7BA7F5714BD04E3775A1CA2ACAD89"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, in consideration of the mutual covenants contained herein, and other good and valuable consideration, the receipt of which is hereby acknowledged, PadCo, Arbutus and Protiva enter into this Agreement to amend and restate the Original License effective as of the Effective Date:</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">2</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s60ADBE533335B628A4D85A1CA2C8446A"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:center;text-indent:0px;"><font style="padding-bottom:16px;text-align:center;font-family:inherit;font-size:12pt;text-decoration:underline;padding-right:0px;">ARTICLE I &#8211; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">DEFINITIONS</font></div><a name="s2D827659ECA87F41B0E95A1CA2E81572"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;">.&#160;&#160;&#160;&#160; When used in this Agreement, each of the following terms, whether used in the singular or plural, shall have the meanings set forth in this Article I.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Person, any corporation, company, partnership, joint venture and/or firm which controls, is controlled by, or is under common control with such Person.  For purposes of the foregoing sentence, &#8220;control&#8221; means (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the right to vote for the election of directors, or (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the introductory paragraph.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agricultural Field</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all applications in agriculture, horticulture, forestry, aquaculture, and/or residential (e.g., lawn and garden) markets relating to, for example, plants, fish, arthropods and/or pests and pathogens thereof.  For the avoidance of doubt, Agricultural Field excludes, for example: (a)&#160;all human and animal (other than fish and arthropods) therapeutic, prophylactic, and diagnostic applications; and (b)&#160;modification of any cells, tissues, or organisms for the purpose of manufacturing heterologous proteins, peptides, or viruses for any purpose, including producing therapeutic products, other than the modification of plants, plant cells, or plant tissues for the purpose of manufacturing heterologous proteins, peptides, or viruses for application to plants, fish, arthropods, and/or pests or pathogens thereof.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Applicable Laws</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all applicable laws, statutes, rules, regulations, guidelines, guidances, ordinances, orders, decrees, writs, judicial or administrative decisions and the like of any nation or government, any state or other political subdivision thereof, any entity exercising executive, judicial, regulatory or administrative functions of or pertaining to government (including any Governmental Authority), any tribunal or arbitrator of competent jurisdiction, and any trade organization whose regulations have the force of law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Arbutus</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the introductory paragraph.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Background Patent Infringement Action</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.3(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">BIA</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 2.5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Call Option</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">CCAA</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 2.5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change of Control</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Channel Costs</font><font style="font-family:inherit;font-size:12pt;">&#8221; means those costs incurred by a Party and its Affiliates in preparing and utilizing distribution channels for a Product (including product returns, customer rebates, dealer incentives, volume discounts, seed service fees, cash discounts (pre-pay discounts), local </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">3</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">competitive response, transportation or cargo insurance, and some of which, by way of example, are currently identified as &#8220;seed service fees,&#8221; &#8220;crop loss and replant,&#8221; &#8220;volume discount,&#8221; and &#8220;seed action pack&#8221;), in all cases allocated to such Products in accordance with GAAP.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Closing</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Code</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 2.4.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Combination Product</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Product that incorporates other technology and/or materials that embody Patents, Know-How, or other intellectual property rights, benefits, and/or value, including for example, seeds, seed treatments (chemicals or biopesticides), or transgenic or non-transgenic components of a plant genome; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that a Product will only be a Combination Product if such other technology and/or materials have been packaged and sold separately at any time. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Commercial Milestone Payment</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 3.1(a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Commercialize</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all activities directed to marketing, promoting, distributing, importing, having imported, exporting, having exported, selling and having sold a Product, in each case for commercial purposes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Commercial Launch</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the first bona fide commercial sale of the Product in an arm&#8217;s length transaction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compound</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any molecule (a) that was Controlled by Protiva as of the Original Effective Date, (b) Discovered by Protiva or any of its Affiliates</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">under the Research Program or in the performance of the Technology Transfer, (c) became (or becomes, as the case may be) under the Control of Protiva or any of its Affiliates during the period in which Protiva provided Services pursuant to the Research Program or conducts activities pursuant to the Technology Transfer.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all proprietary or confidential information and materials, patentable or otherwise, of a Party disclosed by or on behalf of such Party to the other Party before, on or after the Original Effective Date, chemical substances, formulations, techniques, processes, methodology, equipment, data, reports, Know-How, sources of supply, patent positioning, business plans, and also each Party&#8217;s proprietary and confidential information of Third Parties in possession of such Party under an obligation of confidentiality, whether or not related to making, using or selling Products.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Control</font><font style="font-family:inherit;font-size:12pt;">,&#8221; &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Controls</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Controlled by</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to any Compound, Formulation, or Protiva Intellectual Property, the possession of (whether by ownership or license, other than pursuant to this Agreement), or the ability of Protiva or any of its Affiliates to grant access to, or a license or sublicense of, such Compound, Formulation, or Protiva Intellectual Property as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time Protiva would be required hereunder to grant (or cause its Affiliates to grant) Licensee such access or license or sublicense.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">4</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cover</font><font style="font-family:inherit;font-size:12pt;">,&#8221; &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Covers</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Covered by</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Product, that, but for ownership of or a license or sublicense granted under a Valid Claim of a Protiva Background Patent or Protiva Project Patent, the Discovery, Development, Manufacture, and/or Commercialization with respect to such Product would infringe such Patent (or, if such Patent is a patent application, would infringe a patent issued from such patent application if such patent application were to issue with the claims pending in the patent application as of the moment the determination of &#8220;Cover,&#8221; &#8220;Covers,&#8221; or &#8220;Covered by&#8221; is being made).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Develop</font><font style="font-family:inherit;font-size:12pt;">,&#8221; &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Developing</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Development</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all activities, testing and studies required to develop one or more Products for Regulatory Approval and/or commercial sale.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Disclosing Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Discover</font><font style="font-family:inherit;font-size:12pt;">&#8221;, &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Discovering</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Discovery</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all research or discovery activities in respect of a Compound, Formulation, or Product.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the introductory paragraph.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Formulation</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any chemical composition, including lipids, conjugates and polymers formulated with a variety of excipients, that (a) was Controlled by Protiva as of the Original Effective Date; (b) was designed, screened or tested under the Research Program or is designed, screened or tested by Protiva in the performance of the Technology Transfer; or (c) became (or becomes, as the case may be) under the Control of Protiva or any of its Affiliates during the period in which Protiva provided Services pursuant to the Research Program or conducts activities pursuant to the Technology Transfer.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">GAAP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means United States generally accepted accounting principles as in effect from time to time, consistently applied.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governmental Authority</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any United States or supra-national, foreign, federal, state, local, provincial, or municipal government, governmental, regulatory or administrative authority, agency, body, branch, bureau, instrumentality or commission or any court, tribunal, or judicial or arbitral body having relevant jurisdiction over a subject matter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Identified Infringement</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.4(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnified Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnifying Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Infringement Action</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a Background Patent Infringement Action or a Project Patent Infringement Action.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Initiating Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.4(d).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insolvent Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 8.4.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">5</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Joint Project Intellectual Property</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) all inventions that were conceived jointly by: (i) Monsanto, employees of Monsanto, or other Persons owing a duty to assign to Monsanto (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Monsanto Personnel</font><font style="font-family:inherit;font-size:12pt;">&#8221;) </font><font style="font-family:inherit;font-size:12pt;font-style:italic;text-decoration:underline;">and</font><font style="font-family:inherit;font-size:12pt;">&#32;(ii) Protiva, any of its Affiliates, employees of Protiva or any of its Affiliates, or other Persons owing a duty to assign to Protiva or any of its Affiliates (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Personnel</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in the conduct of activities under the Research Program (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Joint Project Inventions</font><font style="font-family:inherit;font-size:12pt;">&#8221;), (b) all Know-How that was developed, created, made, discovered, or produced jointly by Monsanto Personnel and Protiva Personnel in the conduct of activities under the Research Program, (c) all tangible works of expression that was co-authored by Monsanto Personnel and Protiva Personnel in the conduct of activities under the Research Program, (d) all inventions that are conceived jointly by Monsanto Personnel </font><font style="font-family:inherit;font-size:12pt;font-style:italic;text-decoration:underline;">and</font><font style="font-family:inherit;font-size:12pt;">&#32;Protiva Personnel in the conduct of activities under the Technology Transfer (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Joint Technology Transfer Inventions</font><font style="font-family:inherit;font-size:12pt;">&#8221;), (e) all Know-How that is developed, created, made, discovered, or produced jointly by Monsanto Personnel and Protiva Personnel in the conduct of activities under the Technology Transfer, and (f) all tangible works of expression that are co-authored by Monsanto Personnel and Protiva Personnel in the conduct of activities under the Technology Transfer.  In the event the same invention is conceived of independently by both Monsanto Personnel and Protiva Personnel in the conduct of activities under the Research Program or the Technology Transfer, such invention shall be Joint Project Intellectual Property. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Joint Project Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Patents that are directed to</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Joint Project Inventions or to Joint Technology Transfer Inventions. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">JRC</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">JRC Protiva Project Infringement Matter</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Knowingly</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Knowledge</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Know-How</font><font style="font-family:inherit;font-size:12pt;">&#8221; means biological materials and other tangible materials, information, data, inventions, practices, methods, protocols, formulas, formulations, knowledge, know-how, trade secrets, processes, assays, skills, experience, techniques and results of experimentation and testing,  patentable or otherwise (but excluding any marketing, financial, commercial, personnel and other business information and plans).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Licensee</font><font style="font-family:inherit;font-size:12pt;">&#8221; means PadCo or, in the event Monsanto Canada exercises the Call Option and receives from PadCo an assignment of all of PadCo&#8217;s rights and obligations under this Agreement, shall mean Monsanto Canada or any permitted assignee of Monsanto Canada.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Licensee Indemnitees</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Losses</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Manufacturing</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Manufacture</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Product, all activities associated with the production, manufacture, packaging, labeling, releasing or processing of such Product.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Monsanto</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Monsanto Company, a Delaware corporation.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">6</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Monsanto Canada</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Monsanto Canada, Inc., a Canadian corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Monsanto Improvements</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Protiva-Monsanto Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Net Sales</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Value Captured for a Product less Channel Costs.&#160; Net Sales shall also be consistent with GAAP.&#160; For the avoidance of doubt, for a Combination Product, Net Sales shall be equitably apportioned for the contribution of Protiva Background Patents, Protiva Project Patents and/or Joint Project Patents in the Combination Product in a manner generally consistent with the then-current custom and practice</font><font style="font-family:inherit;font-size:12pt;color:#111111;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Non-Initiating Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.4(d).&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Option Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means that certain option agreement by and between Protiva, Arbutus, PadCo and Monsanto Canada dated as of January 12, 2014, pursuant to which Protiva granted Monsanto Canada an exclusive option, as such agreement is amended and restated by the parties thereto effective as of the Effective Date and as such option agreement may be hereafter amended, restated, or otherwise modified from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Original Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means January 12, 2014.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Original License</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Recitals.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">PadCo</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the introductory paragraph.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; means either Licensee or Protiva; &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Parties</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Licensee and Protiva.  References to &#8220;Party&#8221; and &#8220;Parties&#8221;, as applicable, shall also refer to Arbutus with respect to the Tekmira Patents and the rights and obligations related thereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Patent</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any patent (including any reissue, extension, substitution, confirmation, re-registrations, re-examination, revival, supplementary protection certificate, patents of addition, continuation, continuation-in-part, or divisional) or patent application (including any provisional application, non-provisional patent application, continuation, continuation-in-part, divisional, PCT international applications or national phase applications), in each case whether in the U.S. or any foreign country.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Person</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an individual, corporation, limited liability company, syndicate, association, trust, partnership, joint venture, unincorporated organization, government agency or any agency, instrumentality or political subdivision thereof, or other entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Product</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any product or process in the Agricultural Field Covered by a Valid Claim of one or more of the Protiva Background Patents, Protiva Project Patents, or Joint Project Patents.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Project Patent Infringement Action</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.4(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Proposed Abandonment</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.6.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">7</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the introductory paragraph.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Background Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Patents relevant to or useful in the composition, formulation, or manufacture of Compounds and/or Formulations and/or their use in the Agricultural Field that are (i) Controlled by Protiva and that are (1) independent of the activities under the Research Program and (2) exist (whether as pending applications, issued patents, or otherwise) as of the Original Effective Date and/or (ii) Controlled by Protiva or any of its Affiliates and that are (1) independent of the activities under the Research Program and (2) exist (whether as pending applications, issued patents, or otherwise) at any time during the period beginning immediately following the Original Effective Date and ending on the date that is [***].  For purposes of Sections 5.2(a), 5.3, 5.5, and 5.6 references to &#8220;Protiva Background Patents&#8221; shall be deemed to also refer to Tekmira Patents (and, as applicable, references to Protiva shall be deemed to refer to Arbutus). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Indemnitees</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.2.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Intellectual Property</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Protiva Know-How, Protiva Background Patents, Protiva Project Patents, Protiva Research Data and Tekmira Patents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Know-How</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Know-How relevant to or useful in the composition, formulation, or manufacture of Compounds and/or Formulations and/or their use in the Agricultural Field which is Controlled by (a) Protiva on the Original Effective Date and/or (b) Protiva or any of its Affiliates at any time during the period beginning immediately following the Original Effective Date and ending on the date the Technology Transfer is complete in accordance with the Technology Transfer Completion Criteria; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, Protiva Know-How shall exclude Protiva Background Patents, Protiva Project Patents, and Joint Project Intellectual Property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva License</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all rights and licenses in and to the Protiva Intellectual Property, and all other rights, granted to Licensee, or to which Licensee is otherwise entitled, pursuant to this Agreement, together with the benefit of (and subject to) all representations, warranties, covenants, and terms related to the Protiva Intellectual Property as set forth in this Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva-Monsanto Services Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means that certain services agreement by and between Protiva and Monsanto dated as of January 12, 2014, pursuant to which, among other things, Monsanto agreed to conduct services for Protiva to screen Compounds and/or Formulations according to the Research Program, as such services agreement is amended by the amendment thereto effective as of the Effective Date, and as such services agreement may be hereafter amended, restated, or otherwise modified from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Note</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a non-interest-bearing demand promissory note in the principal amount of [***].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Project Inventions</font><font style="font-family:inherit;font-size:12pt;">&#8221; means inventions that are not Joint Project Intellectual Property and that were conceived by Protiva Personnel in the conduct of the Services or other activities under the Research Program pursuant to the Original License or that are conceived by Protiva Personnel in the conduct of activities under the Technology Transfer.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">8</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Project Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Patents that are directed to Protiva Project Inventions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Purchase Price</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean [***].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Research Data</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) </font><font style="font-family:inherit;font-size:12pt;">all information and data provided to Licensee and the JRC pursuant to Section 4.3 of the Original License and (b) all summary reports, data and other information Protiva provides or is required to provide pursuant to the Technology Transfer</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Receiving Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Record Retention Period</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 3.1(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Research</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Researching</font><font style="font-family:inherit;font-size:12pt;">&#8221; means identifying, evaluating, testing, validating and/or optimizing Compounds, Formulations or Products.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Research Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Research Program</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the program to design and synthesize Compounds and/or Formulations and to conduct research and development activities for such Compounds and/or Formulations as described in the Research Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Response Deadline</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.6.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Services</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the research services described in the Research Plan, activities conducted by or on behalf of Protiva or its Affiliates pursuant to the Research Plan or otherwise pursuant to the Original License, and activities conducted by or on behalf of Protiva or its Affiliates in the performance of the Technology Transfer.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Solvent Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 8.4.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Sublicensee</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a Third Party to whom Licensee has granted a sublicense pursuant to the terms hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tax Act</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Income Tax Act (Canada).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tax Value</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, in respect of the rights transferred to the Licensee hereunder, where the respective transferred right is eligible capital property under the Tax Act, the least of the amounts referred to in subparagraphs 85(1)(d)(i), (ii) and (iii) of the Tax Act; where the respective transferred right is capital property under the Tax Act, the least of the amounts referred to in subparagraphs 85(1)(c.1)(i) and (ii) of the Tax Act; and where the respective transferred right is depreciable property under the Tax Act, the least of the amounts referred to in subparagraphs 85(1)(e)(i), (ii) and (iii) of the Tax Act.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Technology Transfer</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Technology Transfer Completion Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the criteria outlined in Exhibit B-6.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">9</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Technology Transfer Compound List</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a complete list of the components (including Compounds, Formulations, and Compound structures) and ratios of each LNP Composition (as such term is defined in the Technology Transfer Compound Criteria) tested during Phase A (as such term is defined in the Research Program) of the Research Plan as to which the representation and warranty in Section 9.1(b)(vi) is true and correct as of the Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tekmira</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Tekmira Pharmaceuticals Corporation, predecessor to Arbutus.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tekmira Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Patents relevant to or useful in the composition, formulation, or manufacture of Compounds and/or Formulations and/or their use in the Agricultural Field that were Controlled by Tekmira as of the Original Effective Date, other than the Patents listed on Exhibit A. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tekmira Purchase Price</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 3.2(b). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the term described in Section 8.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Territory</font><font style="font-family:inherit;font-size:12pt;">&#8221; means worldwide.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Person other than Protiva, Licensee or any of their respective Affiliates.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Transaction Agreements</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean this Agreement, the Protiva-Monsanto Services Agreement, the Option Agreement, and such other documents entered into in connection therewith.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Transferred Protiva Rights</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221; means the licenses granted by Protiva to Licensee set forth in Section 2.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Transferred Tekmira Rights</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the licenses granted by Arbutus to Licensee set forth in Section 2.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">UBC</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the University of British Columbia.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">UBC IP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the patent families set forth in Exhibit A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Valid Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a claim of: (a) an issued and unexpired Protiva Project Patent, Protiva Background Patent, or Joint Project Patent, as applicable, which claim has not been revoked or held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, which is not appealable or has not been appealed within the time allowed for appeal, and which has not been abandoned, disclaimed, denied, or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise, or (b) a patent application that is a Protiva Project Patent, a Protiva Background Patent, or a Joint Project Patent, as applicable, that has not been pending for more than eight years after the original priority date for said application and that has not been cancelled, withdrawn or abandoned, or finally rejected by an administrative agency action, which is not appealable or has not been appealed within the time allowed for appeal; provided, however, that for purposes of defining Products for purposes of Section 3.1(a), a claim </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">10</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">of a pending application shall be a Valid Claim only if such claim has been identified in an office action (or other office communication) issued by the U.S. Patent and Trademark Office in connection with the prosecution of such application (x) as allowable, or (y) allowable but for its dependency on a rejected independent claim (the conditions of (x) and (y) collectively referred to as &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Allowable</font><font style="font-family:inherit;font-size:12pt;">&#8221;) during the 10-year period following the Commercial Launch of the first Product, such claim as Allowable Covers the Product, and, during such period, the designation of such claim as Allowable has not been reversed or otherwise rejected in subsequent prosecution of such application and no substantive amendments have been made to such claim (or any claims from which it depends) during prosecution of such application since its designation as Allowable, wherein the substantive amendment(s) results in the claim no longer Covers the Product.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Value Captured</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the gross amount invoiced on sales of the Products by a Party and its Affiliates and Sublicensees in the Agricultural Field in the Territory.  For a Combination Product, the Value Captured shall be determined in accordance with the foregoing sentence, except that the gross amount invoiced on sales of the Combination Product will be reduced on a per unit basis by the invoice amount of the other technology and/or materials in the Combination Product when sold separately. </font></div><a name="s1AC1CD34FA1BDDC9A2905A1CA3314414"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Interpretation</font><font style="font-family:inherit;font-size:12pt;">.&#160;&#160;&#160;&#160;  Words such as &#8220;herein&#8221;, &#8220;hereinafter&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221; refer to this Agreement as a whole and not merely to a section, paragraph or clause in which such words appear, unless the context otherwise requires.  Enumerative references to sections, paragraphs or clauses, or exhibits, without reference to an explicit agreement, document or exhibit, refer to this Agreement or exhibits attached to this Agreement, as applicable.  The singular shall include the plural, and each masculine, feminine and neuter reference shall include and refer also to the others, unless the context otherwise requires.  The words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; are deemed to be followed by &#8220;without limitation&#8221; or words of similar import.  Except where the context otherwise requires, the word &#8220;or&#8221; is used in the inclusive sense (and/or).  All dollar amounts are expressed in U.S. dollars.</font></div><a name="sC0D764BCDF664C2033B85A1CA34C395D"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE II &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">LICENSE GRANTS AND RELATED RIGHTS</font></div><a name="s1B26B11D97EC2FE11DD95A1CA36D62B6"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">License Grants to Licensee</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  Subject to the terms and conditions of this Agreement, effective as of the Original Effective Date, Protiva (and with respect to the Tekmira Patents only, Arbutus) hereby grants to Licensee an irrevocable, worldwide, perpetual (subject to Article VIII), fully paid-up, transferrable (subject to Section 9.4), sublicensable (subject to Section 2.2), exclusive (even as to Protiva, except as provided in Section 2.3, and even as to Arbutus with respect to the Tekmira Patents) right and license under the Protiva Intellectual Property for all purposes in the Agricultural Field, including to Discover, Develop, Commercialize and Manufacture Products, and to discover, develop, commercialize, and manufacture other products and processes that use or employ Protiva Intellectual Property, in the Agricultural Field.  In the event Licensee reasonably determines that any Patent or Know-How </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">owned or Controlled by Arbutus or its Affiliate (other than Protiva) to which Licensee does not have a license under this Agreement is relevant to or useful in the composition, formulation, or manufacture of Compounds and/or Formulations and/or their use in the Agricultural Field, then upon Licensee&#8217;s request, Protiva shall cause Arbutus or such Affiliate to promptly grant a license in and to such Patent or Know-How to Licensee under </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">11</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">this Agreement, and such Patent or Know-How shall thereafter be included in Protiva Intellectual Property for all purposes of this Agreement.  For the avoidance of doubt, (a) Protiva has not granted to Licensee any right or license to the Protiva Intellectual Property outside of the Agricultural Field, (b) Licensee shall have the right to develop and manufacture Compounds and Formulations in connection with the exercise of its rights to Discover, Develop, Commercialize and Manufacture Products, and to discover, develop, commercialize, and manufacture other products and processes that use or employ Protiva Intellectual Property, in the Agricultural Field, and (c) all UBC IP is expressly excluded from this Agreement, and Licensee is not granted any rights in or to any UBC IP, other than as may be granted pursuant to the second sentence of this Section 2.1.   </font></div><a name="s57077539D192D67450DF5A1CA38D17E0"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Sublicensing</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Licensee may grant sublicenses of any or all of its licensed rights under the Protiva Intellectual Property for any purposes within the Agricultural Field, but solely within the Agricultural Field; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that any sublicense granted by Licensee shall be subject and subordinate to the terms and conditions of this Agreement and shall contain terms and conditions consistent with those in this Agreement.  Licensee shall assume full responsibility for the performance of all obligations and observance of all terms herein under the licenses granted to it.  If Licensee becomes aware of a material breach of any sublicense by a Sublicensee, Licensee shall promptly notify Protiva of the particulars of same and take all reasonable efforts to enforce the terms of such sublicense.  Any agreement between Licensee and the Sublicensee shall provide that such Sublicensee may only use the Confidential Information of Protiva in accordance with terms of this Agreement applicable to Licensee&#8217;s use of such Confidential Information and subject to provisions at least as stringent as those set forth in Article VI, and Protiva shall be an express third party beneficiary of such agreement, including provisions related to use and disclosure of Confidential Information.  Subject to the foregoing provisions of this Section 2.2(a), Sublicensees shall have the right to further sublicense Protiva Intellectual Property in the Agricultural Field to Third Parties.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Unless otherwise provided in this Agreement, Licensee shall notify Protiva within thirty (30) days after execution of a sublicense entered into hereunder and provide a copy of the fully executed sublicense agreement to Protiva within the same time, which shall be treated as Confidential Information of Licensee under Article VI.</font></div><a name="s73FC050D509512BB51D25A1CA3BE6810"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Grant Back</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  Licensee agrees to grant and hereby grants to Protiva a non-exclusive right and license under the Protiva Intellectual Property to Discover and Develop Products in the Agricultural Field for purposes of performing the Technology Transfer.  This right and license shall terminate following completion of all activities pursuant to the Technology Transfer.</font></div><a name="s1936E131CCB98E8206D95A1CA3E07191"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Retained Rights</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  Protiva expressly retains any rights not expressly granted to Licensee under this Article II (or otherwise under this Agreement).  Nothing in Section 2.1 limits Protiva&#8217;s ability to perform its obligations under this Agreement, the Protiva-Monsanto Service Agreement or the Option Agreement.  For purposes of clarity and without limitation, Protiva has exclusively retained (even as to Licensee) the right to use and employ Protiva Intellectual Property (alone or with Third Parties) in connection with any and all activities related to the Discovery, Development, Commercialization and manufacture (including Manufacture) of Compounds, Formulations and products outside the Agricultural Field in the Territory.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">12</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sC34282BFB069AD39883B5A1CA4122E60"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Rights in Bankruptcy</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  All licenses and rights to licenses granted under or pursuant to this Agreement by Protiva to Licensee are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Code</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and Section 65.11(7) of the Bankruptcy and Insolvency Act (Canada) (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">BIA</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and Section 32(6) of the Companies&#8217; Creditors Arrangment Act (Canada) (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">CCAA</font><font style="font-family:inherit;font-size:12pt;">&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined under Section 101(35A) of the Code, and as utilized generally in the BIA and CCAA.  Licensee, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Code, and that upon commencement of a bankruptcy proceeding by or against Protiva (or any Affiliate of Protiva that owns or Controls Protiva Intellectual Property) under the Code, Licensee shall be entitled to a complete duplicate of, or complete access to (as Licensee deems appropriate), any such intellectual property and all embodiments of such intellectual property.  Such intellectual property and all embodiments thereof shall be promptly delivered to Licensee (a) upon any such commencement of a bankruptcy proceeding upon written request therefore by Licensee, unless Protiva (or its Affiliate) elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of Protiva upon written request therefor by Licensee.  The foregoing provisions are without prejudice to any rights Licensee may have arising under the Code or other Applicable Law.</font></div><a name="sCE5624DC76BE45808F265A1CA433F376"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compliance With Applicable Laws</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  Each Party shall conduct its obligations under this Agreement, and conduct the Discovery, Development, Manufacture and Commercialization of the Products, in all material respects in accordance with Applicable Laws.  </font></div><a name="sBD53EB99171783923F1A5A1CA465E82B"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE III &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">FINANCIAL PROVISIONS</font></div><a name="s2E9C4FBAB304867524A55A1CA4861107"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Payment for License</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Licensee shall pay promptly to Protiva: (i) a one-time, non-refundable, non-creditable payment in the amount of [***] upon the first to occur, if either, of (x) the Net Sales in the Territory of Products by Monsanto or its Affiliates equals or exceeds [***] in any single year during the 10-year period following Commercial Launch of the first Product, or (y) the aggregate Net Sales in the Territory of Products by Monsanto or its Affiliates equals or exceeds [***]</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">cumulatively over the 10-year period following the Commercial Launch of the first such Product and (ii) a one-time, non-refundable, non-creditable payment in the amount of [***] if in any single year during the 10-year period following Commercial Launch of the first Product, the Net Sales in the Territory of Products by Monsanto or its Affiliates equals or exceeds [***] (each a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Commercial Milestone Payment</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  The amount of any Commercial Milestone Payment shall be reduced, if applicable, in accordance with Monsanto&#8217;s right of set off and/or any reduction in the amount of the Commercial Milestone Payment as a result of a Change of Control of Protiva or Arbutus, in each case under Section 3(f) or 3(g) of the Option Agreement.</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Any payments due from Licensee to Protiva under Section 3.1 of this Agreement that are not paid by the date such payments are due shall bear interest at LIBOR plus two percent (2%) per month from the date such unpaid payments are due until paid in full.  The foregoing interest shall be in addition to any other remedies that the Protiva may have pursuant to this Agreement.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">13</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">During the period of time beginning upon termination of Protiva&#8217;s obligation to provide the Services, as set forth in the Original License, and ending on expiration of the 10-year period following Commercial Launch of the first Product (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Record Retention Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;), Licensee shall maintain and retain (and shall cause Monsanto and its Affiliates to maintain and retain) complete and accurate books of account and records covering all transactions relating to payment of amounts that may be due under Section 3.1(a) of this Agreement, then until expiration of the two (2) year period following expiration of the Record Retention Period, shall make such books and records available for inspection and audit by Protiva&#8217;s authorized representative (which shall be a national certified public accounting firm), subject to reasonable precautions to protection of confidential information of Licensee, Monsanto, or its Affiliates (including Confidential Information), for the purpose of verifying the accuracy of all payments that may be due under Section 3.1(a) of this Agreement.  Protiva shall pay the cost of such audit unless it discovers that Licensee has underreported aggregate Gross Profits during any year in the Record Retention Period to Protiva by an amount of at least [***], in which case the costs of such audit shall be borne by Licensee.</font></div><a name="s2EFCE01AF6EA15DE21455A1CA4B9AA92"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Payment for License</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">As consideration for the Transferred Protiva Rights, and in full satisfaction of the Protiva Purchase Price, the Licensee (i) issued to Protiva the Protiva Note, (ii) issued to Protiva one Class B Common share without par value in the capital stock of the Licensee as a fully paid and non-assessable share, and (iii) granted to Protiva the rights set out in Section 3.3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">As consideration for the Transferred Tekmira Rights, and in full satisfaction of the Tekmira Purchase Price, the Licensee issued to Tekmira one Class A Common share without par value in the capital stock of the Licensee as a fully paid and non-assessable share.  [***].</font></div><a name="s043CD47248A8C4B89F395A1CA526FC90"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Subsection 85(1) Election</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Protiva and Licensee have jointly made and filed an election under subsection 85(1) of the Tax Act (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Election</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in the prescribed form and within the time required by subsection 85(6) of the Tax Act in respect of the transfer of the Transferred Protiva Rights and have elected therein that the elected amount will be deemed to be Protiva&#8217;s proceeds of disposition and the Licensee&#8217;s cost of the Transferred Protiva Rights (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Elected Amount</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If the Canada Revenue Agency or any other competent authority at any time hereafter proposes to issue or issues any assessment or assessments on the basis that the fair market value of the Transferred Protiva Rights at the time of transfer is greater or less than the Protiva Purchase Price, then:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">upon the fair market value of the Transferred Protiva Rights being finally determined by the agreement of Protiva and the Licensee with the Canada Revenue Agency if they do so agree, or by final determination by a court of competent jurisdiction if they do not, the Protiva Purchase Price will be deemed conclusively to have always been the amount so determined, and this Agreement will be deemed to be amended as of the Effective Date to reflect such Protiva Purchase Price as determined under this Section 3.4(b)(i); and</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">14</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">if permitted under the Tax Act or the administrative discretion of the Canada Revenue Agency, Protiva at its sole discretion may file an amended election under subsection 85(7.1) of the Tax Act along with the appropriate penalty payment reporting a new fair market value of the Transferred Protiva Rights based on the amounts determined pursuant to section 3.4(b)(i) of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If the Canada Revenue Agency or any other competent authority at any time hereafter proposes to issue or issues any assessment or assessments, on the basis that the Protiva Elected Amount set out in the Protiva Election is greater or less than the applicable Tax Values of the Transferred Protiva Rights, then:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">upon the applicable Tax Values being finally determined, by the Agreement of Protiva and the Licensee with the Canada Revenue Agency if they do so agree, or by final determination by a court of competent jurisdiction if they do not, the Protiva Elected Amount will be deemed conclusively to have always been such finally determined Tax Value; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">if permitted under the Tax Act or the administrative discretion of the Canada Revenue Agency, Protiva at its sole discretion may file an amended election under subsection 85(7.1) of the Tax Act along with the appropriate penalty payment electing such amount as is deemed to be the Protiva Elected Amount under Section 3.4(c)(i).</font></div><a name="sBC3EBA8DD27934425CFB5A1CA5411658"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tekmira Subsection 85(1) Election</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Tekmira and Licensee have jointly made and filed an election under subsection 85(1) of the Tax Act (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tekmira Election</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in the prescribed form and within the time required by subsection 85(6) of the Tax Act in respect of the transfer of the Transferred Tekmira Rights and have elected therein that the elected amount will be deemed to be Arbutus&#8217; proceeds of disposition and the Licensee&#8217;s cost of the Transferred Tekmira Rights (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tekmira Elected Amount</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If the Canada Revenue Agency or any other competent authority at any time hereafter proposes to issue or issues any assessment or assessments on the basis that the fair market value of the Transferred Tekmira Rights at the time of transfer is greater or less than the Tekmira Purchase Price, then:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">upon the fair market value of the Transferred Tekmira Rights being finally determined by the agreement of Arbutus and the Licensee with the Canada Revenue Agency if they do so agree, or by final determination by a court of competent jurisdiction if they do not, the Tekmira Purchase Price will be deemed conclusively to have always been the amount so determined, and this Agreement will be deemed to be amended as of the Effective Date to reflect such Tekmira Purchase Price as determined under this Section 3.5(b)(i); and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">if permitted under the Tax Act or the administrative discretion of the Canada Revenue Agency, Arbutus at its sole discretion may file an amended election under subsection 85(7.1) of the Tax Act along with the appropriate penalty payment reporting a new fair market value of the Transferred Tekmira Rights based on the amounts determined pursuant to section 3.5(b)(i) of this Agreement.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">15</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If the Canada Revenue Agency or any other competent authority at any time hereafter proposes to issue or issues any assessment or assessments, on the basis that the Tekmira Elected Amount set out in the Tekmira Election is greater or less than the applicable Tax Values of the Transferred Tekmira Rights, then:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">upon the applicable Tax Values being finally determined, by the agreement of Arbutus and the Licensee with the Canada Revenue Agency if they do so agree, or by final determination by a court of competent jurisdiction if they do not, the Tekmira Elected Amount will be deemed conclusively to have always been such finally determined Tax Value; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">if permitted under the Tax Act or the administrative discretion of the Canada Revenue Agency, Arbutus at its sole discretion may file an amended election under subsection 85(7.1) of the Tax Act along with the appropriate penalty payment electing such amount as is deemed to be the Tekmira Elected Amount under Section 3.5(c)(i).</font></div><a name="s4BDDF247D8A7E0844E2D5A1CA55C3265"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE IV &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">SERVICES</font></div><a name="sB4973EE77D0F727D47CB5A1CA571BEC0"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination of Services Obligations</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:12pt;">The Parties acknowledge and agree that, as of the Effective Date, Monsanto Canada is exercising the Call Option prior to completion of Phase C (as such term is defined in the Research Program).  Monsanto Canada hereby elects to terminate research under the Research Plan as of the Effective Date and, therefore, the Parties acknowledge and agree that, on and as of the Effective Date, Protiva&#8217;s</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">obligation to provide Services under this Agreement terminates; provided, however, that, for the avoidance of doubt, from and after the Effective Date, Protiva remains obligated to provide the Technology Transfer in accordance with the Option Agreement through completion of the Technology Transfer in accordance with the Technology Transfer Completion Criteria.  </font></div><a name="s5B9FB86C9481BC924CA85A1CA5835FC3"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE V &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">INTELLECTUAL PROPERTY</font></div><a name="sDE9601645E3F7A571D195A1CA5B1D432"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Ownership</font><font style="font-family:inherit;font-size:12pt;">.  Subject to the licenses granted by Protiva herein, Protiva is and shall at all times remain the owner of the Protiva Intellectual Property, including, for the avoidance of doubt, Protiva Project Patents.  As more particularly set forth in the Protiva-Monsanto Services Agreement, and subject to the license granted by Monsanto in the Protiva-Monsanto Services Agreement, Monsanto is and shall at all times remain owner of any Joint Project Intellectual Property. </font></div><a name="s0E366B00476D0E0CF6275A1CA5D3E277"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Prosecution and Maintenance of Patents</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Subject to Section 5.6, Protiva shall have the sole right and responsibility, in its sole discretion and at its sole cost and expense, to file, prosecute, maintain and/or abandon patent protection in the Territory for Protiva Background Patents.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">During the Term, decisions regarding the filing of Patent protection in the Territory for Protiva Project Inventions and decisions regarding the prosecution, maintenance and/or abandonment of Protiva Project Patents in the Territory shall be made by Protiva and/or the JRC in accordance with the applicable provisions of the Option Agreement and, subject to and in accordance with such provisions, Protiva shall be responsible for implementing Protiva&#8217;s and/or the JRC&#8217;s </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">16</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">decisions regarding the filing, prosecution, maintenance, and/or abandonment of Protiva Project Patents in the Territory.  Except as otherwise set out in the Option Agreement, all costs and fees incurred in connection with the filing, prosecution, maintenance and/or abandonment of all Protiva Project Patents through the Effective Date shall be the sole responsibility of Protiva; all costs and fees incurred in connection with the filing, prosecution, maintenance and/or abandonment of all Protiva Project Patents after the Effective Date shall be the sole responsibility of Licensee.  </font></div><a name="sCBC5B9A364E869FB90A05A1CA60871BB"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third-Party Infringement of Protiva Background Patents</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each Party shall promptly report in writing to the other Party during the Term known or suspected commercially relevant infringement by a Third Party of any of the Protiva Background Patents in any field and any known or suspected infringement by a Third Party of any of the Protiva Background Patents in the Agricultural Field of which such Party becomes aware and shall provide the other Party with all evidence supporting or relating to such infringement in its possession.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Protiva shall have the sole and exclusive right to initiate an infringement or other appropriate suit with respect to infringements or suspected infringements of any of the Protiva Background Patents, or to take such other actions as Protiva, in its sole discretion, deems appropriate with respect to such infringements or suspected infringements (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Background Patent Infringement Action</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  Protiva shall notify Licensee promptly after initiating any Background Patent Infringement Action.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">With respect to any Background Patent Infringement Action initiated on or after the Effective Date directed to infringement occurring at least in part in the Agricultural Field: (i) Licensee may join such Infringement Action as a party if it has standing to do so (at its own cost and expense), may retain counsel at its own cost and expense to provide advice to Licensee regarding such Infringement Action, and may share all information regarding the Infringement Action provided by Protiva with such counsel, and, if Licensee has joined such Infringement Action, such counsel shall be permitted to attend meetings, discussions, or other activities relating to the Infringement Action on behalf of Licensee; and (ii) Provita agrees to give due consideration to any recommendations or suggestions of Licensee in connection with the Infringement Action, but shall not be obligated to implement or follow any such recommendations or suggestions.  After the Effective Date, Protiva shall not enter into any settlement or compromise in connection with any Background Patent Infringement Action that would eliminate, diminish, or otherwise modify any right, title, or interest of the Licensee in any Protiva Intellectual Property or that would require any payments, concessions, or otherwise bind the Licensee, without the Licensee&#8217;s prior written consent, which consent shall not be unreasonably withheld; for the avoidance of doubt, any settlement or compromise that permits continuation of Licensee&#8217;s rights in and to Protiva Intellectual Property in the same manner and subject to the same terms and conditions as set forth in this Agreement shall not require Licensee&#8217;s prior consent.  Licensee shall provide reasonable cooperation and assistance in connection with a Background Patent Infringement Action initiated by Protiva (including being joined as a party in such Background Patent Infringement Action) at Protiva&#8217;s reasonable request and sole cost. </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">17</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sBE5F5C2EACCD4019312E5A1CA62D1CB6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third-Party Infringement of Protiva Project Patents</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each Party shall promptly report in writing to the other Party during the Term known or suspected commercially relevant infringement by a Third Party of any of the Protiva Project Patents in any field and any known or suspected infringement by a Third Party of any of the Protiva Project Patents in the Agricultural Field of which such Party becomes aware and shall provide the other Party with all evidence supporting or relating to such infringement in its possession.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Protiva shall have the right, but not the obligation, to initiate an infringement or other appropriate suit with respect to infringements or suspected infringements of any of the Protiva Project Patents, or to take such other actions as Protiva, in its sole discretion, deems appropriate with respect to such infringements or suspected infringements (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Project Patent Infringement Action</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  If Protiva declines to commence a Project Patent Infringement Action with respect to a particular actual or threatened infringement of any issued patent within the Protiva Project Patents (an &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Identified Infringement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) within sixty (60) days following its receipt of a written request from Licensee that it initiate a Project Patent Infringement Action with respect to such Identified Infringement, or if Protiva otherwise fails to confirm that it will commence a Project Patent Infringement Action with respect to such Identified Infringement within such sixty (60) day period, then Licensee may thereafter commence a Project Patent Infringement Action with respect to such Identified Infringement.  Licensee shall use reasonable best efforts to notify Protiva prior to initiating any Project Patent Infringement Action and shall continue to inform Protiva of the status of any Project Patent Infringement Action initiated by Licensee, including by responding to Protiva&#8217;s reasonable requests for status reports, providing drafts of substantive filings of Licensee prior to the due date for such filings, and providing copies of substantive filings of any other party to any such Project Patent Infringement Action promptly after receiving such filings.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">If any monetary judgment or settlement is recovered in connection with any Project Patent Infringement Action  initiated by Licensee or Protiva in accordance with this Section 5.4(b), then, after Licensee or Protiva, as applicable, recoups actual costs and reasonable expenses associated with such Project Patent Infringement Action, (i) then if the monetary judgment or settlement is primarily attributable to infringement in the Agricultural Field, Licensee shall be entitled to receive from the remainder an amount equal to all direct damages attributable to infringement in the Agricultural Field</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">awarded in such judgment or payable under such settlement; Protiva shall then be entitled to receive from the remainder after such payment to Licensee, if any, an amount equal to all direct damages attributable to infringement outside of the Agricultural Field</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">awarded in such judgment or payable under such settlement; and the balance, if any, remaining after such payments to Licensee and Protiva shall be allocated and payable [***] to Licensee and [***] to Protiva; or (ii) if the monetary judgment or settlement is primarily attributable to infringement outside of the Agricultural Field, Protiva shall be entitled to receive from the remainder an amount equal to all direct damages attributable to infringement outside of the Agricultural Field</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">awarded in such judgment or payable under such settlement, Licensee shall then be entitled to receive from the remainder after such payment to Protiva, if any, an amount equal to all direct damages attributable to infringement in the Agricultural Field</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">awarded in such judgment or payable under such settlement; and the balance, if any, remaining after such payments to Protiva and Licensee shall be allocated and payable [***] to Licensee and [***] to Protiva. </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">18</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sBE5F5C2EACCD4019312E5A1CA62D1CB6"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Protiva shall use reasonable best efforts to notify Licensee prior to initiating any Project Patent Infringement Action and shall continue to inform Licensee of the status of any Project Patent Infringement Action initiated by Protiva, including by responding to Licensee&#8217;s reasonable requests for status reports, providing drafts of substantive filings of Protiva prior to the due date for such filings, and providing copies of substantive filings of any other party to any such Infringement Action promptly after receiving such filings.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each Party (as a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Non-Initiating Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;), with respect to a Project Patent Infringement Action initiated by the other Party (as an &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Initiating Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;), may join such Infringement Action as a party if it has standing to do so (at its own cost and expense), may retain counsel at its own cost and expense to provide advice to the Non-Initiating Party regarding such Infringement Action, and may share all information regarding the Infringement Action provided by the Initiating Party with such counsel, and, if the Non-Initiating Party has joined such Infringement Action, such counsel shall be permitted to attend meetings, discussions, or other activities relating to the Infringement Action on behalf of the Non-Initiating Party.  The Initiating Party agrees to give due consideration to any recommendations or suggestions of the Non-Initiating Party in connection with a Project Patent Infringement Action, but shall not be obligated to implement or follow any such recommendations or suggestions; provided however, that the Initiating Party shall not enter into any settlement or compromise in connection with a Project Patent Infringement Action that would eliminate, diminish, or otherwise modify any right, title, or interest of the Non-Initiating Party in any Protiva Intellectual Property or that would require any payments, concessions, or otherwise bind the Non-Initiating Party, without the Non-Initiating Party&#8217;s prior written consent, which consent shall not be unreasonably withheld; for the avoidance of doubt, any settlement or compromise that permits continuation of the Non-Initiating Party&#8217;s rights in and to Protiva Intellectual Property in the same manner and subject to the same terms and conditions as set forth in this Agreement shall not require the Non-Initiating Party&#8217;s prior consent.  The Non-Initiating Party shall provide reasonable cooperation and assistance in connection with a Project Patent Infringement Action initiated by the Initiating Party (including being joined as a party in such Project Patent Infringement Action) at the Initiating Party&#8217;s reasonable request and sole cost.    </font></div><a name="s9EEF004E52113BAEAA765A1CA65A777E"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Defense of Claims Brought by Third Parties</font><font style="font-family:inherit;font-size:12pt;">.  Each Party shall promptly notify the other Party if it becomes aware of any claim that Licensee&#8217;s actual use or practice of Compounds or Formulations within the Protiva Intellectual Property, or Licensee&#8217;s methods of creating or using such Formulations or Compounds, in connection with its exercise of its license under Section 2.1 infringes, misappropriates, or otherwise violates the intellectual property rights of any Third Party in the Agricultural Field.  In any such instance, the Parties shall cooperate and shall mutually agree upon an appropriate course of action; provided, however, that in the absence of any such agreement, (i) any such matter relating to Protiva Project Patents (such matter a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">JRC Protiva Project Infringement Matter</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall be referred to the JRC to be addressed in the manner set forth in the Option Agreement, and (ii) Protiva shall have sole right to determine what action, if any, should be taken in respect of Protiva Background Patents.  Each Party shall provide to the other Party copies of any notices it receives from Third Parties regarding any patent nullity actions regarding the Protiva Background Patents or the Protiva Project Patents, any declaratory judgment actions and any alleged infringement or misappropriation of Third Party intellectual property rights arising out of Licensee&#8217;s use or practice of the Protiva Intellectual Property in connection with its exercise of </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">19</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">its license under Section 2.1.  Each Party shall be responsible for its own costs incurred pursuant to this Section 5.5; provided, however, that nothing in this Section 5.5 or elsewhere in this Agreement shall be deemed to eliminate, reduce, or otherwise modify any liability or obligation of Protiva in respect of the Protiva Intellectual Property or Licensee&#8217;s (or its Sublicensees&#8217;) use or practice of the Protiva Intellectual Property in connection with its exercise of its license under Section 2.1, including but not limited to any such liability or obligation that may arise out of any representation, warranty, or covenant made by Protiva under the Option Agreement or any other Transaction Agreement; and provided further, however, that nothing in this Section 5.5 shall be deemed to limit or eliminate a Party&#8217;s right to defend actions initiated by a Third Party against such Party, except to the extent such rights may be limited under any indemnification provisions applicable to such actions.</font></div><a name="sBC75A811527718683E765A1CA67B6F06"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Disclosures and Opt-In Rights Regarding Protiva Background Patents</font><font style="font-family:inherit;font-size:12pt;">.  If, during the Term, Protiva decides not to pay the maintenance fee, annuity fee, or similar fee due on any Protiva Background Patent or decides to abandon or discontinue prosecution of any Protiva Background Patent (each a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Proposed Abandonment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and if (a) such Proposed Abandonment will not be accompanied by the proper filing of a continuation or continuation-in-part application for a Protiva Background Patent and (b) there will be no remaining Protiva Background Patent in the same country or jurisdiction in which the abandoned or discontinued Protiva Background Patent was filed that will substantially</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">maintain the value of Licensee&#8217;s exclusive license under the Protiva Background Patents in the Agricultural Field, Protiva shall notify Licensee at least sixty (60) days in advance of any applicable administrative deadline, maintenance fee due date, or response date after or upon which such Protiva Background Patent will be or become abandoned or trigger a similar loss of rights in jurisdictions other than the United States (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Response Deadline</font><font style="font-family:inherit;font-size:12pt;">&#8221;), such notice to include the Response Deadline.  Upon written request of Licensee, Protiva shall promptly assign to Licensee all of its right, title, and interest in and to such Protiva Background Patent </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">unless</font><font style="font-family:inherit;font-size:12pt;">&#32;(x) such Protiva Background Patent is assigned to a Third Party who takes all steps necessary to prevent the Proposed Abandonment and (y) Licensee retains its license to such Protiva Background Patent on the terms and conditions set forth in this Agreement; Protiva shall thereafter have no further right, title, or interest in or to such Protiva Background Patent, except that Protiva shall thereafter have a perpetual, fully paid-up, non-exclusive right and license under such Protiva Background Patent for all uses in the Protiva Field.  To the extent necessary or appropriate to prevent the abandonment or similar loss of rights of a Protiva Background Patent assigned or to be assigned to Licensee, Protiva shall take such other steps (including submission of filings or payments on behalf of Licensee or Monsanto) that are reasonably requested by Licensee (or Monsanto), at Licensee&#8217;s (or Monsanto&#8217;s) sole cost and expense.</font></div><a name="sCA197052C36E8063E8245A1CA6AD4478"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Joint Research Committee Oversight</font><font style="font-family:inherit;font-size:12pt;">.  From and after termination of the Option Agreement, then until the disbandment of the JRC by unanimous vote of the JRC at any time after expiration of the last to expire Valid Claim of a Protiva Project Patent or a Joint Project Patent, the JRC shall remain in existence and shall perform the functions described in this Agreement and any other Transaction Agreements according to the general processes and procedures set out in the Option Agreement (as such processes and procedures may be modified by the unanimous vote of the JRC).  For the avoidance of doubt, the JRC&#8217;s oversight of Protiva Project Patents shall terminate if this Agreement terminates.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">20</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s642B57727E649D2C042B5A1CA6CF794C"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE VI &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">CONFIDENTIAL INFORMATION AND PUBLICITY</font></div><a name="s3734D09283E99D9E40145A1CA7010AD8"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Non-Disclosure of Confidential Information</font><font style="font-family:inherit;font-size:12pt;">.  Each Party agrees that, for itself and its Affiliates, until the first to occur of (i) [***] or (ii) [***], a Receiving Party shall maintain all Confidential Information of the Disclosing Party in strict confidence and shall not (a) disclose Confidential Information to any third party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below or (b) use Confidential Information for any purpose except those explicitly licensed or otherwise authorized or permitted by this Agreement or any other Transaction Agreement.</font></div><a name="s102BBE148C40E9E0188F5A1CA7223446"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exceptions</font><font style="font-family:inherit;font-size:12pt;">.  The obligations in Section 6.1 will not apply with respect to any portion of the Confidential Information that the Receiving Party can show by competent proof: (i) was known to the Receiving Party or its Affiliates, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party; (ii) is subsequently disclosed to the Receiving Party or its Affiliates by a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use; (iii) is or otherwise becomes generally available to the public or enters the public domain, either before or after it is disclosed to the Receiving Party and such public availability is not the result, directly or indirectly, of any fault of, or improper taking, use or disclosure by, the Receiving Party or its Affiliates or anyone working in concert or participation with the Receiving Party or its Affiliates; or (iv) has been independently developed by employees or contractors of the Receiving Party or its Affiliates without the aid, application or use of Confidential Information of the Disclosing Party.  Specific Confidential Information disclosed by a Disclosing Party will not be deemed to be within any exceptions set forth in (i), (ii), or (iii) above merely because it is embraced by more general information to which one or more of those exceptions may apply and provided further that no combination of information shall be deemed to be within any such exceptions unless the combination itself and its principle of operation are within the public domain.  Even though Confidential Information may be within one of the exceptions described in the preceding sentence, the Receiving Party shall not disclose to third parties that the excepted Confidential Information was received from the Disclosing Party.  </font></div><a name="sA1FAC271CF098CC886805A1CA754D83D"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Permitted Uses</font><font style="font-family:inherit;font-size:12pt;">.  Confidential Information of a Disclosing Party may be used by the Receiving Party in the performance of its obligations under any Transaction Agreement, as otherwise expressly authorized in any Transaction Agreement or as expressly authorized by the Disclosing Party in writing.  Confidential Information that is Protiva Intellectual Property may be used by Licensee subject to and in accordance with the provisions of this Agreement applicable to Licensee&#8217;s license to Protiva Intellectual Property.  Licensee shall take steps to maintain the confidentiality of such Confidential Information that are consistent with the steps it takes to maintain the confidentiality of its own most-valuable confidential information, but in no event less than commercially reasonable steps; provided, however, that nothing in this Agreement shall be deemed to eliminate, restrict, or otherwise limit Licensee&#8217;s license to use such Confidential Information in accordance with the terms and conditions of this Agreement, even if such use may result, directly or indirectly, in the disclosure of such Confidential Information, so long as such disclosures are made in a manner than complies with Section 6.4 below.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">21</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB6C4B77CEF9E7A6E36CD5A1CA7755E76"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Permitted Disclosures</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  The Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: (i) subject to the proviso below, by any Party hereto, in order to comply with applicable non-patent law (including any securities law or regulation or the rules of a securities exchange in a relevant jurisdiction) and with judicial process, if based on the reasonable advice of the Receiving Party&#8217;s counsel, such disclosure is necessary for such compliance; (ii) subject to the proviso below, by any Party hereto, in connection with prosecuting or defending litigation; (iii) by any Party hereto, in connection with filing and prosecuting Protiva Project Patents and Joint Project Patents only in a manner that complies with such Party&#8217;s rights and obligations in connection with such matters as set out in the Transaction Agreements; (iv) subject to the proviso below, by Licensee, its Sublicensees, or their sublicensees in connection with any legal or regulatory requirements related to the development, sale, offer for sale, use or manufacture of commercial products (or potential commercial products) that use or employ Protiva Intellectual Property, such as labeling requirements, disclosures in connection with obtaining regulatory approvals, and the like, so long as the discovery, development, use, manufacture, and commercialization of such products has been and is performed in a manner that complies with the terms and conditions of Licensee&#8217;s license to such Protiva Intellectual Property and reasonable steps shall be taken to maintain the confidentiality of said Confidential Information even when disclosed for legal or regulatory purposes; (v) subject to the proviso below, by the Licensee, to its Affiliates, permitted acquirers or assignees under the Transaction Agreements and its or any of their research collaborators, subcontractors, lenders (but, with respect to lenders, only Confidential Information related to the terms and conditions of the Transaction Agreements and financial information related thereto), and each of the Licensee&#8217;s and its Affiliates&#8217; respective directors, employees, contractors and agents; and (vi) subject to the proviso below, by Protiva, to its Affiliates, permitted acquirers or assignees under the Transaction Agreements and its or any of their research collaborators, subcontractors, lenders (but, with respect to lenders, only Confidential Information related to the terms and conditions of the Transaction Agreements and financial information related thereto), and Protiva&#8217;s and its Affiliates&#8217; respective directors, employees, contractors and agents, provided, that (a) with respect to clause (i), (ii) and (iv) where legally permissible, (1) the Receiving Party shall notify the Disclosing Party of the Receiving Party&#8217;s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed, and (2) consistent with applicable law or regulation, the Disclosing Party shall have the right to suggest reasonable changes to the disclosure to protect its interests and the Receiving Party shall not unreasonably refuse to include such changes in its disclosure, and (b) with respect to clause (v) and (vi), each Person to whom Confidential Information is disclosed must be bound prior to disclosure by confidentiality and non-use restrictions at least as restrictive as those contained in this Agreement (other than investment bankers, investors and lenders, who must be bound prior to disclosure by commercially reasonable obligations of confidentiality).</font></div><a name="s7649BAB43D66987B77175A1CA7A75798"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE VII &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">INDEMNIFICATION AND INSURANCE</font></div><a name="sFA73E8FCFDB2E29ACB535A1CA7C997BB"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Indemnification</font><font style="font-family:inherit;font-size:12pt;">.  Protiva agrees to indemnify Licensee and its Affiliates, and their respective agents, directors, officers, employees, representatives, successors and permitted assigns (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Licensee Indemnitees</font><font style="font-family:inherit;font-size:12pt;">&#8221;) against and to hold each of them harmless from any and all </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">22</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">losses, costs, damages, fees or expenses (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Losses</font><font style="font-family:inherit;font-size:12pt;">&#8221;) actually incurred or suffered by an Licensee Indemnitee to the extent arising out of or in connection with any claim, suit, demand, investigation or proceeding brought by a Third Party based on any breach of any representation, warranty or covenant by Protiva under this Agreement or Protiva&#8217;s gross negligence or willful misconduct.  The foregoing indemnification shall not apply to the extent that any Losses are due to (a) a breach of any of Licensee&#8217;s representations, warranties, covenants and/or obligations under this Agreement or (b) Licensee&#8217;s gross negligence or willful misconduct.</font></div><a name="s4D5D0E63150FFB09B2845A1CA7FA25EB"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Licensee Indemnification</font><font style="font-family:inherit;font-size:12pt;">.  Licensee agrees to indemnify Protiva and its Affiliates, and their respective agents, directors, officers, employees, representatives, successors and permitted assigns (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Indemnitees</font><font style="font-family:inherit;font-size:12pt;">&#8221;) against and to hold each of them harmless from any and all Losses actually incurred or suffered by a Protiva Indemnitee to the extent arising out of or in connection with (a) any claim, suit, demand, investigation or proceeding brought by a Third Party based on (i) any breach of any representation, warranty or covenant by Licensee under this Agreement, or (ii) Licensee&#8217;s gross negligence or willful misconduct, or (b) a Third Party&#8217;s direct damages resulting from any development or Commercialization of any Product or products or processes that use or employ Protiva Intellectual Property.  In addition to the limitations set forth in the preceding sentence, the foregoing indemnification obligations shall not apply to the extent that any Losses are due to (x) a breach of any of Protiva&#8217;s representations, warranties, covenants and/or obligations under this Agreement, (y) Protiva&#8217;s gross negligence or willful misconduct, or (z) any of the following occurring prior to or at Closing: (A) any breach of any representation, warranty or covenant by Licensee under this Agreement; (B) Licensee&#8217;s gross negligence or willful misconduct; or (C) a breach of any of Protiva&#8217;s representations, warranties, or covenants directed to Protiva Intellectual Property or the Protiva License under the Option Agreement.</font></div><a name="s10DE466E56CCC9B2B8115A1CA81CA8F7"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tender of Defense; Counsel</font><font style="font-family:inherit;font-size:12pt;">.  Any Person (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnified Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) seeking indemnification under Article VII agrees to give prompt notice in writing to the other Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnifying Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) of the assertion of any claim or the commencement of any action by any third party (a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in respect of which indemnity may be sought under such section.  Such notice shall set forth in reasonable detail such Third Party Claim and the basis for indemnification (taking into account the information then available to the Indemnified Party).  The failure to so notify the Indemnifying Party shall not relieve the Indemnifying Party of its obligations hereunder, except to the extent such failure shall have materially and adversely prejudiced the Indemnifying Party.  The Indemnifying Party shall be entitled to participate in the defense of any Third Party Claim and shall, upon its written confirmation of its obligation to indemnify the Indemnified Party in accordance with this Article VII, be entitled to control and appoint lead counsel reasonably satisfactory to the Indemnified Party for such defense by written notice to the Indemnified Party within twenty (20) calendar days after the Indemnifying Party has received notice of the Third Party Claim, in each case at its own expense; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that the Indemnifying Party must conduct the defense of the Third Party Claim actively and diligently thereafter in order to preserve its rights in this regard.  The Indemnifying Party shall not be entitled to assume or maintain control of the defense of any Third Party Claim and shall pay the fees and expenses of one counsel retained by the Indemnified Party if:  (a) the Third Party Claim relates to or arises in connection with any criminal proceeding, action, indictment or allegation, (b) the Third Party Claim seeks an injunction or equitable relief against a Indemnified Party or any of its Affiliates, or (c) the Indemnifying Party </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">23</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">has failed or is failing to prosecute or defend vigorously the Third Party Claim.  Each Indemnified Party shall obtain the prior written consent of the Indemnifying Party, such consent not to be unreasonably withheld, delayed or conditioned, before entering into any settlement of a Third Party Claim.  Notwithstanding the foregoing, the Indemnifying Party shall not be entitled to enter into or approve any settlement of a Third Party Claim without the consent of the Indemnified Party (which may be withheld in its sole discretion), if the settlement (a) does not expressly unconditionally release all applicable Indemnified Parties and their Affiliates from all Liabilities with respect to such Third Party Claim or (b) imposes injunctive or other equitable relief against the Indemnified Party or any of its Affiliates, (c) involves any admission of criminal or similar liability, or (d) involves any monetary damages that may not be fully covered by the Indemnifying Party.  In the event that the Indemnifying Party fails to assume the defense of the Third Party Claim in accordance with this Section 7.3, (a) the Indemnified Party may defend against the Third Party Claim in any manner it reasonably may deem appropriate, and (b) the Indemnifying Party will remain responsible for any Losses of the Indemnified Party as a result of such Third Party Claim.  In circumstances where the Indemnifying Party is controlling the defense of a Third Party Claim in accordance with this Section 7.3, the Indemnified Party shall be entitled to participate in the defense of any Third Party Claim and to employ separate counsel of its choice for such purpose, in which case the fees and expenses of such separate counsel shall be borne by such Indemnified Party.   Notwithstanding anything herein to the contrary, in circumstances where there is a conflict of interest that would reasonably make it inappropriate under applicable standards of professional conduct to have common counsel for the Indemnifying Party and the Indemnified Party, the Indemnified Party shall be entitled to employ separate counsel, that is reasonably acceptable to the Indemnifying Party, and the Indemnifying Party shall pay the reasonable fees and expenses of such separate counsel.  Each Party shall cooperate, and cause their respective Affiliates to cooperate in all reasonable respects, in the defense or prosecution of any Third Party Claim and shall furnish or cause to be furnished such records, information and testimony, and attend such conferences, discovery proceedings, hearings, trials or appeals, as may be reasonably requested in connection therewith.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><a name="s6E938B87D4CDFE9BA8255A1CA84DB7F1"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insurance</font><font style="font-family:inherit;font-size:12pt;">.  Each Party shall maintain insurance, including product liability insurance, with respect to its activities under this Agreement regarding Products in such amount as such Party customarily maintains with respect to similar activities for its other products. Each Party shall maintain such insurance for so long as it continues its activities under this Agreement, and thereafter for so long as such Party customarily maintains insurance for itself covering similar activities for its other products.  Notwithstanding the foregoing, the Parties agree that during such time that Licensee is an Affiliate of Protiva, Licensee shall have satisfied its obligations under this Section 7.4 provided it is covered by Protiva&#8217;s existing insurance policies.  </font></div><a name="s5F52397FED896265E00B5A1CA86F593F"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE VIII &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TERM AND TERMINATION</font></div><a name="sFEA1721484E3C9ABD1635A1CA8A138B0"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:12pt;">.  The term of this Agreement (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall begin on the Original Effective Date and, unless terminated earlier as provided herein, shall continue in perpetuity.</font></div><a name="sF7DF8138895B72A6E85C5A1CA8C3708B"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination for Material Breach</font><font style="font-family:inherit;font-size:12pt;">.   In the event of a material breach of this Agreement by Licensee, Protiva may provide notice to Licensee setting forth the nature of the breach and a description of the facts underlying the breach sufficient to identify the breach.  If Licensee has not </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">24</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">cured such breach or proposed a reasonably satisfactory plan to cure or otherwise remedy such breach within ninety (90) days from the date of receipt of such notice of breach, Protiva may provide a notice of termination to Licensee and this Agreement shall terminate ninety (90) days after such notice of termination unless the breach is cured to the reasonable satisfaction of Protiva or unless Licensee has begun to implement a reasonably satisfactory plan to cure or otherwise remedy such breach within ninety (90) days from the receipt of such notice of termination.   Notwithstanding the foregoing, or any termination of Licensee&#8217;s license pursuant to Section 8.4 below, with respect to any sublicense entered into by Licensee for which the Sublicensee is not the cause of the material breach that resulted in the termination of this Agreement, then upon the assignment to Protiva of all rights of Licensee under such sublicense, Protiva shall assume those obligations of Licensee to such Sublicensee under such sublicense that are within the scope of Protiva&#8217;s obligations to Licensee under this Agreement; all other obligations to the Sublicensee under such sublicense, and all liabilities of Licensee to such Sublicensee, shall remain the sole and exclusive obligations and liabilities of Protiva, and nothing in this Section 8.2 shall be deemed to expand, increase, or otherwise modify Protiva&#8217;s obligations or liabilities under this Agreement.</font></div><a name="sA68F671232351C67D5B65A1CA8F4AD1A"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Challenges of Protiva&#8217;s Patents</font><font style="font-family:inherit;font-size:12pt;">.  If Licensee or any of its Affiliates shall (a) commence or participate in any action or proceeding (including any patent opposition or re-examination proceeding), or otherwise assert in writing any claim, challenging or denying the validity of any of the Protiva Background Patents or Protiva Project Patents or any claim thereof or (b) actively assist any other Person in bringing or prosecuting any action or proceeding (including any patent opposition or re-examination proceeding) challenging or denying the validity of such Patents or any claim thereof, Protiva will have the right to give notice to Licensee (which notice must be given, if at all, within ninety (90) days after Arbutus&#8217;s CEO first learns of the foregoing) that the licenses granted by Protiva to such Patent will terminate in ninety (90) days following such notice, and, unless Licensee and/or its Affiliate, as applicable, withdraws or causes to be withdrawn all such challenge(s) within such ninety-day period, such licenses will so terminate.</font></div><a name="s616123D2F65949F690AF5A1CA916CF53"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Rights in Bankruptcy</font><font style="font-family:inherit;font-size:12pt;">.  Each Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insolvent Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall promptly notify the other Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Solvent Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in writing upon the initiation of any proceeding in bankruptcy, reorganization, dissolution, liquidation or arrangement for the appointment of a receiver or trustee to take possession of the assets of the Insolvent Party or similar proceeding under the law for release of creditors by or against the Insolvent Party or if the Insolvent Party shall make a general assignment for the benefit of its creditors.  To the extent permitted by Applicable Law, if the applicable circumstances described above shall have continued for ninety (90) days undismissed, unstayed, unbonded and undischarged, the Solvent Party may terminate this Agreement upon written notice to the Insolvent Party at any time.  If Protiva is the Insolvent Party, the rights and remedies granted to Licensee (as the Solvent Party) pursuant to this Section 8.4 shall be in addition to, and not in lieu of, Licensee&#8217;s rights and remedies under Section 2.4 above.</font></div><a name="sCD37C23995C585439DD45A1CA94765B4"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Consequences of Termination; Survival</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In the event this Agreement is properly terminated in accordance with its terms, then except as provided in the Protiva-Monsanto Services Agreement, Licensee&#8217;s rights and licenses under the Protiva Intellectual Property shall terminate upon the effective date of such termination.  </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">25</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Termination of this Agreement shall not relieve the Parties of any obligation accruing prior to or upon such expiration or termination and the provisions of ARTICLE I &#8211; (Definitions), ARTICLE VI &#8211; (Confidential Information), ARTICLE VII &#8211; (Indemnification), and ARTICLE IX &#8211; (Miscellaneous) shall survive any expiration or termination of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything to the contrary contained in this Agreement, if it is determined that Protiva has breached its representation and warranty in Section 9.1(b)(iii), Licensee&#8217;s sole and exclusive remedy shall be to require Arbutus or its Affiliate, as applicable, to grant to Licensee a license under its Patents or Know-How for all purposes in the Agricultural Field and such Patents and/or Know-How shall thereafter be included within Protiva Intellectual Property for all purpose of this Agreement; provided, however, that the foregoing shall not be deemed to limit, eliminate or otherwise modify Protiva&#8217;s obligations under Section 7.1 to indemnify any Licensee Indemnitee against or hold any Licensee Indemnitee harmless in respect of any </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Losses</font><font style="font-family:inherit;font-size:12pt;">&#32;actually incurred or suffered by a Licensee Indemnitee arising out of or in connection with any claim, suit, demand, investigation or proceeding brought by UBC or any other Third Party based on any breach of any representation, warranty or covenant by Protiva under this Agreement, including Section 9.1(b)(vi), even if or to the extent such Losses may also arise out Protiva&#8217;s breach of Section 9.1(b)(iii).  Furthermore, omission from the Technology Transfer Compound List of any Compound or Formulation that was provided or created by Protiva or its Affiliate in connection with the Research Program shall not be deemed to limit or eliminate Licensee&#8217;s rights under the second sentence of Section 2.1 with respect to such Compound or Formulation.</font></div><a name="sF59F351E1F2AACCFBE205A1CA9694AF0"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Remedies</font><font style="font-family:inherit;font-size:12pt;">. The Parties acknowledge and agree that, in the event of a breach or a threatened breach by either Party of this Agreement for which it will have no adequate remedy at law, the other Party may suffer irreparable damage and, accordingly, shall be entitled to injunctive and other equitable remedies to prevent or restrain such breach or threatened breach, in addition to any other remedy they might have at law or at equity. In the event of a breach or threatened breach by a Party of any such provision, the other Party shall be authorized and entitled to obtain from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which the other Party may be entitled in law or equity. </font></div><a name="sD9BC94484E945CA3F9595A1CA99BCE03"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE IX &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">MISCELLANEOUS</font></div><a name="sD17CCA911BD1B89562445A1CA9BD442F"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Representations and Warranties</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Mutual Representations and Warranties by Protiva and Licensee</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each Party hereby represents and warrants to the other Party as of the Original Effective Date:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">It is duly organized and validly existing under the laws of the jurisdiction of its incorporation or formation, and has all necessary power and authority to conduct its business in the manner in which it is currently being conducted, to own and use its assets in the manner in which its assets are currently owned and used, and to enter into and perform its obligations under this Agreement.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">26</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The execution, delivery and performance of this Agreement has been duly authorized by all necessary action on the part of such Party and its Board of Directors and no consent, approval, order or authorization of, or registration, declaration or filing with any Third Party or Governmental Authority is necessary for the execution, delivery or performance of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement constitutes the legal, valid and binding obligation of such Party, enforceable against it in accordance with its terms, subject to (A)&#160;laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (B) rules of law governing specific performance, injunctive relief and other equitable remedies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">It has never approved or commenced any proceeding, or made any election contemplating, the winding up or cessation of its business or affairs or the assignment of material assets for the benefit of creditors.  To such Party&#8217;s knowledge, no such proceeding is pending or threatened.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each Party acknowledges and agrees that the other Party has not made any representation or warranty under this Agreement that it has or can provide all the rights that are necessary or useful to Research, Develop or Commercialize a Product; provided, however, that nothing in this Section 9.1(a)(ii) or elsewhere in this Agreement shall be deemed to eliminate, reduce, or otherwise modify any liability or obligation of Protiva or Licensee that may arise out of any representation, warranty, or covenant made by Protiva or Licensee under the Option Agreement or any other Transaction Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each Party represents and warrants to the other Party that as of the Original Effective Date and as of Closing it has the right to grant to such other Party, its Affiliates and Sublicensees the licenses granted hereunder and has not granted any conflicting rights to any other Person.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Representations, Warranties, and Covenants</font><font style="font-family:inherit;font-size:12pt;">.  Protiva hereby represents, warrants, and covenants to Licensee that:  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">To Protiva&#8217;s Knowledge, except as set forth on Schedule 9.1(b), the conception, development and reduction to practice of the Protiva Intellectual Property licensed to Licensee under the Original License did not constitute or involve the infringement, misappropriation, or other violation of trade secrets or other rights (including intellectual property rights) or property related to polynucleotide delivery in biological systems of any Person anywhere in the Territory.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If a Compound or Formulation was provided or created by Protiva or its Affiliate in connection with the Research Program, the use and employment of which as contemplated by the Research Program or the Original License (including but not limited to in connection with the development, Manufacture, or Commercialization of any Product or the development, manufacture, or commercialization of any other product or process that uses or employs Protiva Intellectual Property) would, to the Knowledge of Protiva, infringe upon or  misappropriate or otherwise violate the Intellectual Property of any Third Party, then Protiva promptly (and, in any event, prior to or contemporaneously with providing such Compound or </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">27</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Formulation to Monsanto under the Protiva-Monsanto Services Agreement) provided written notice thereof to the JRC; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except for the Tekmira Patents, as of the Original Effective Date, neither Tekmira nor any of its Affiliates (other than Protiva) owned or Controlled (including by joint ownership) any Patents or Know-How relevant to or useful in the composition, formulation, or manufacture of Compounds and/or Formulations and their use in the Agricultural Field; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Neither Protiva nor any of its Affiliates has assigned, transferred, conveyed or otherwise encumbered its right, title and interest in the Protiva Intellectual Property in a manner that conflicts with any rights granted to Licensee hereunder; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In the provision of Services under the Original License, and except as disclosed in accordance with Section 9.1(b)(ii) above, Protiva did not Knowingly infringe, misappropriate, or otherwise violate any trade secrets or other rights (including intellectual property rights) or property of any Person anywhere in the Territory; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">No Compound or Formulation: (i) that was provided or created by Protiva or its Affiliate in connection with the Research Program and that is identified, or required to be identified, on the Technology Transfer Compound List to be provided to Licensee pursuant to the Technology Transfer or (ii) that was or is delivered, disclosed or otherwise provided to Licensee in the performance of the Technology Transfer, or the use and employment any Compound or Formulation described in item (i) or (ii) above as contemplated by the Original License (including but not limited to in connection with the development, Manufacture, or Commercialization of any Product or the development, manufacture, or commercialization of any other product or process that uses or employs Protiva Intellectual Property), will infringe, misappropriate or otherwise violate any UBC IP; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">During the Term, neither Arbutus nor any of its Affiliates will grant a license, sublicense or other right, title, or interest in or to any Patents or Know-How it owns or Controls (including by joint ownership) as of the Original Effective Date to any Third Party for use in the Agricultural Field.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(viii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding Sections 9.1(b)(i) and 9.1(b)(v) above, Licensee agrees and acknowledges that Protiva makes no representation, warranty or covenant regarding whether any nucleic acid molecules provided by Monsanto and used by Protiva in the performance of the Research Plan, or used by Licensee in connection with the development, Manufacture, or Commercialization of any Product or the development, manufacture, or commercialization of any other product or process that uses or employs Protiva Intellectual Property infringe, misappropriate, or otherwise violate the trade secrets or other rights (including intellectual property rights) or property of any Person anywhere in the Territory.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Warranty Disclaimer</font><font style="font-family:inherit;font-size:12pt;">.  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT OR THE ORIGINAL LICENSE, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">28</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">INTELLECTUAL PROPERTY, PRODUCTS, GOODS, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT OR THE ORIGINAL LICENSE AND HEREBY DISCLAIMS ALL IMPLIED CONDITIONS, REPRESENTATIONS, AND WARRANTIES, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT OR VALIDITY OF PATENT RIGHTS WITH RESPECT TO ANY AND ALL OF THE FOREGOING.  EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY PRODUCT PURSUANT TO THIS AGREEMENT SHALL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO ANY SUCH PRODUCT SHALL BE ACHIEVED.  Nothing in this Section 9.1(c) or elsewhere in this Agreement or the Original License shall be deemed to eliminate, reduce, or otherwise modify any liability or obligation of Protiva or Licensee that may arise out of any representation, warranty, or covenant made by Protiva or Licensee under the Option Agreement or any other Transaction Agreement.</font></div><a name="s06EAF0B1B917E32E38975A1CA9EE75A8"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Force Majeure</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  </font><font style="font-family:inherit;font-size:12pt;">Except with respect to payment obligations, a Party shall neither be held liable or responsible to any other Party, nor be deemed to have defaulted under or breached this Agreement, for failure or delay in fulfilling or performing any term of this Agreement to the extent, and for so long as, such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including fire, floods, embargoes, power shortage or failure, acts of war (whether war be declared or not), insurrections, riots, terrorism, civil commotions, strikes, lockouts or other labor disturbances, acts of God or any acts, omissions or delays in acting by any Governmental Authority or any other Party, and such affected Party promptly begins performing under this Agreement once such causes have been removed.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><a name="s80B8F7B6FC89AECFC6655A1CAA0F668E"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Consequential Damages</font><font style="font-family:inherit;font-size:12pt;">.  UNDER NO CIRCUMSTANCES WILL ANY PARTY BE LIABLE TO ANY OTHER PARTY WITH RESPECT TO THE PROVISION OF THE SERVICES HEREUNDER OR UNDER THE ORIGINAL LICENSE FOR ANY CONSEQUENTIAL, INDIRECT, SPECIAL, PUNITIVE, INCIDENTAL OR SIMILAR DAMAGES, WHETHER FORESEEABLE OR UNFORESEEABLE AND REGARDLESS OF THE CAUSE OF ACTION FROM WHICH THEY ARISE, INCLUDING, WITHOUT LIMITATION, CLAIMS FOR LOSS OF GOODWILL OR LOST PROFITS, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OCCURRING.  NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 9.3 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OF A PARTY OR DAMAGES AVAILABLE FOR A PARTY&#8217;S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE VI OR ANY DAMAGES THAT MAY BE AVAILABLE TO A PARTY AS A RESULT OF ANOTHER PARTY&#8217;S BREACH OF ITS OBLIGATIONS UNDER ANY OTHER TRANSACTION AGREEMENT, SUBJECT TO THE LIMITATIONS SET FORTH THEREIN.</font></div><a name="sBE9E026FFF0CB460832C5A1CAA41CF6E"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assignment</font><font style="font-family:inherit;font-size:12pt;">.  Licensee may freely assign its rights and obligations hereunder to Monsanto or Monsanto Canada upon or at any time after the Closing so long as Monsanto or Monsanto Canada, as the case may be, expressly assumes in writing Licensee&#8217;s rights and obligations herein.  Protiva may not assign or otherwise transfer this Agreement or any of its rights and obligations under this Agreement at any time without the prior written consent of Monsanto.  Any </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">29</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">purported transfer or assignment in contravention of this Section 9.4 shall, at the option of the non-assigning Party, be null and void and of no effect.  This Agreement shall be binding upon and inure to the benefit of the Parties and their permitted successors and assigns.   No assignment by Protiva or any of its Affiliates of any right, title, or interest in or to the Protiva Intellectual Property shall extinguish, limit, or otherwise modify any rights granted to Licensee in or to such Protiva Intellectual Property, or the exclusivity of such rights.</font></div><a name="s0BF1A7F74E266DBF55075A1CAA6333EA"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Notices to Licensee shall be addressed to: </font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Protiva Agricultural Development Company Inc.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">c/o Monsanto Company</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">800 North Lindbergh Boulevard</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">St. Louis, Missouri 63167</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention:  Technology Alliances Lead</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With copies to:</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Monsanto Company</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">800 North Lindbergh Boulevard</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">St. Louis, Missouri 63167</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention: Deputy General Counsel, Intellectual Property</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bryan Cave LLP</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">One Metropolitan Square</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">211 North Broadway, Suite 3600</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">St. Louis, Missouri 63102</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn:  C. Brendan Johnson</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Facsimile No.: (314) 552-8438</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Notices to Protiva shall be addressed to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Protiva Pharmaceuticals Corporation <br>100-8900 Glenlyon Parkway <br>Burnaby, B.C. <br>Canada V5J 5J8 <br>Attention: President &amp; CEO <br>Facsimile No.: (604) 630-5103</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">Notices to Arbutus shall be addressed to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Arbutus Biopharma Corporation <br>100-8900 Glenlyon Parkway <br>Burnaby, B.C. <br>Canada V5J 5J8 <br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">30</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention: President &amp; CEO <br>Facsimile No.: (604) 630-5103</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:-24px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">In each case with copy to:</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Orrick, Herrington &amp; Sutcliffe LLP <br>51 West 52</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">nd</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Street <br>New York,  NY  10019</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention:&#160;&#160;&#160;&#160;R. King Milling <br>Facsimile No.: (212) 506-5151</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Either Party may change its address by giving notice to the other Party in the manner provided in this Section 9.5.  Any notice required or provided for by the terms of this Agreement shall be in writing and shall be (a) sent by certified mail, return receipt requested, postage prepaid, (b) sent via a reputable international express courier service, or (c) sent by facsimile transmission, with a copy by regular mail.  The effective date of the notice shall be the actual date of receipt by the Receiving Party.</font></div><a name="sEEAF4E758D4A4162FC715A1CAA94E6CA"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Independent Contractors</font><font style="font-family:inherit;font-size:12pt;">.  It is understood and agreed that the relationship between the Parties is that of independent contractors and that nothing in this Agreement shall be construed as authorization for either Party to act as the agent for the other Party.</font></div><a name="sFB3411C12694257F6A4D5A1CAAB6878F"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law; Jurisdiction</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall be governed and interpreted in accordance with the substantive laws of the State of New York, excluding its conflicts of laws principles.  In the event any action shall be brought to enforce or interpret the terms of this Agreement, the Parties agree that such action will be brought in the State or Federal courts located in New York, New York.  Each of the Parties hereby irrevocably submits with regard to any action or proceeding for itself and in respect to its property, generally and unconditionally, to the nonexclusive jurisdiction of the aforesaid courts.  Each of the Parties hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in any action or proceeding with respect to this Agreement, (a) any claim that it is not personally subject to the jurisdiction of the above-named courts for any reason other than the failure to lawfully serve process, (b) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise), and (c) to the fullest extent permitted by Applicable Law, that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper, and (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.</font></div><a name="s8563FD858D10E4F8783D5A1CAAE8DC3E"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">.  In the event that any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable because it is invalid or in conflict with any law of the relevant jurisdiction, the validity of the remaining provisions shall not be affected and the rights and obligations of the Parties shall be construed and enforced as if the Agreement did not contain the particular provisions held to be unenforceable, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">that</font><font style="font-family:inherit;font-size:12pt;">&#32;the Parties shall negotiate in good faith a modification of this Agreement with a view to revising this Agreement in a manner which </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">31</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">reflects, as closely as is reasonably practicable, the commercial terms of this Agreement as originally signed.</font></div><a name="s76C7A817982D1F6E7E425A1CAB0A3B06"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Implied Waivers</font><font style="font-family:inherit;font-size:12pt;">.  The waiver by either Party of a breach or default of any provision of this Agreement by the other Party shall not be construed as a waiver of any succeeding breach of the same or any other provision, nor shall any delay or omission on the part of either Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such Party.</font></div><a name="s4EA64F40DAAC67E18E7B5A1CAB3B0B47"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Headings</font><font style="font-family:inherit;font-size:12pt;">.  The headings of articles and sections contained this Agreement are intended solely for convenience and ease of reference and do not constitute any part of this Agreement, or have any effect on its interpretation or construction.</font></div><a name="s893D57ED0E0398E25D695A1CAB5EA469"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Entire Agreement; Amendment</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement (along with the attachments) and the other Transaction Agreements (as amended as of the Effective Date) contain the entire understanding of the Parties with respect to the subject matter hereof and thereof and, except as provided in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 9.16</font><font style="font-family:inherit;font-size:12pt;">&#32;below, supersede and replace any and all previous arrangements and understandings, whether oral or written, between the Parties with respect to the subject matter hereof and thereof.  This Agreement (including the attachments hereto) may be amended only by a writing signed by each of the Parties.</font></div><a name="s183054942AD472035C625A1CAB8FF125"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waiver of Rule of Construction</font><font style="font-family:inherit;font-size:12pt;">.  Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement.  Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.</font></div><a name="sE7A9376BFF28FFBD3AB35A1CABB1B033"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Third-Party Beneficiaries</font><font style="font-family:inherit;font-size:12pt;">.  Except as expressly contemplated herein, no Third Party, including any employee of any Party to this Agreement, shall have or acquire any rights by reason of this Agreement.</font></div><a name="sC936BC85B008EFFF5EFC5A1CABE269E0"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Further Assurances</font><font style="font-family:inherit;font-size:12pt;">.  Each Party shall provide such further documents or instruments required by the other Party as may be reasonably necessary or desirable to give effect to the purpose of this Agreement and carry out its provisions.</font></div><a name="s2433283F1D8B27618D6E5A1CAC04437D"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Performance by Affiliates</font><font style="font-family:inherit;font-size:12pt;">.  Either Party may use one or more of its Affiliates to perform its obligations and duties hereunder and Affiliates of a Party are expressly granted certain rights herein; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">that</font><font style="font-family:inherit;font-size:12pt;">&#32;each such Affiliate shall be bound by the corresponding obligations of such Party and the relevant Party shall remain liable hereunder for the prompt payment and performance of all their respective obligations hereunder.</font></div><a name="s3E61D294D86D8188E6955A1CAC36A7F6"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effect of Amendment</font><font style="font-family:inherit;font-size:12pt;">.  Nothing in this Agreement shall be deemed to eliminate or modify any rights or obligations of the Parties under the Original License that had accrued prior to the Effective Date, including any obligations in respect of any election under subsection 85(1) of the Tax Act made pursuant to the Original License, it being understood and agreed by the Parties that the terms and conditions of this Agreement are effective from and after the Effective Date.</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">32</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s15809E04D636DED9A4175A1CAC582A45"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Signature Page Follows</font><font style="font-family:inherit;font-size:12pt;">]</font></div><a name="sDBD1CA52915F0EFFE6EA5A1CAC884727"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, Licensee and Protiva have set their hands to this License and Services Agreement as of the date first written above.</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PROTIVA AGRICULTURAL DEVELOPMENT COMPANY, INC.</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/Bruce Cousins</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">Name: Bruce Cousins  <br>Title: Executive Vice President and CFO</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARBUTUS BIOPHARMA CORPORATION </font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/Bruce Cousins</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">Name: Bruce Cousins  <br>Title: Executive Vice President and CFO</font></div><div style="line-height:120%;padding-bottom:24px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:24px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PROTIVA BIOTHERAPEUTICS INC.</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/Bruce Cousins</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">Name: Bruce Cousins  <br>Title: Executive Vice President and CFO</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">33</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sEDC0218003EE8BB3EC4C5A1CACABF1A5"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">EXHIBIT A to</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">AMENDED AND RESTATED</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">LICENSE AND SERVICES AGREEMENT </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">[***]</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">34</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sEDC0218003EE8BB3EC4C5A1CACABF1A5"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT M</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">FIRST AMENDMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TO</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">PROTIVA-MONSANTO SERVICES AGREEMENT</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">THIS FIRST AMENDMENT TO THE PROTIVA-MONSANTO SERVICES AGREEMENT (this &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Amendment</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;) is made and entered into as of March 4, 2016, (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;) by and among Protiva Biotherapeutics, Inc., a British Columbia corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Protiva</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;) and a wholly-owned subsidiary of Arbutus Biopharma Corporation, formerly Tekmira Pharmaceutcals Corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Arbutus</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;), Protiva Agricultural Development Company Inc. (&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">PadCo</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;), a British Columbia corporation and a wholly-owned subsidiary of Protiva (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;), and Monsanto Company, a Delaware corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Monsanto</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Protiva, the Company and Monsanto entered into that certain Protiva-Monsanto Services Agreement on January 12, 2014 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and, contemporaneously with the execution of the Agreement: (a) Protiva, Arbutus, PadCo  and Monsanto Canada entered into the Option Agreement and (b) PadCo, Protiva and Tekmira entered into the PadCo-Protiva License and Services Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, contemporaneously with the execution of this Amendment and as of the Effective Date: (a) the parties to the PadCo-Protiva License and Services Agreement are amending and restating the PadCo-Protiva License and Services Agreement, (b) the parties to the Option Agreement are amending and restating the Option Agreement, (c) Monsanto is exercising the Call Option to acquire all of the outstanding capital stock of PadCo, and (d) Closing is occurring; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Protiva, the Company and Monsanto desire to amend the Agreement, effective as of the Effective Date, as set forth herein; and</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">NOW THEREFORE, in consideration of the representations, warranties, covenants and agreements contained herein, and for other valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties mutually agree to amend and modify the Agreement as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">All capitalized terms used in this Amendment, unless otherwise defined, shall have the meanings ascribed to such terms in the Agreement.  In addition, the following terms shall have the following meanings for purposes of this Amendment:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(a)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Monsanto New Improvement</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221; means an invention that is (i) Monsanto New Intellectual Property, (ii) claimed in an issued patent owned by Monsanto and having a priority date that is on or after the Effective Date, and (iii) the practice of which, if practiced at the time of said priority date, would be covered by at least one Valid Claim of a Patent that is a Protiva Background Patent or Protiva Project Patent.  </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">35</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sEDC0218003EE8BB3EC4C5A1CACABF1A5"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(b)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Monsanto New Intellectual Property</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221; means all inventions that are conceived by Monsanto Personnel on or after the Effective Date and that are covered by at least one Valid Claim of a Patent.  For the avoidance of doubt inventions that were conceived by Monsanto Personnel in the conduct of activities under the Research Program and that are not Joint Project Intellectual Property are Monsanto Project Intellectual Property and not Monsanto New Intellectual Property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The Parties acknowledge and agree that, as of the Effective Date, Monsanto Canada is exercising the Call Option prior to completion of Phase C (as such term is defined in the Research Program).  Monsanto hereby elects to terminate research under the Research Plan as of the Effective Date and, therefore, the Parties acknowledge and agree that, on and as of the Effective Date, the Term of the Agreement shall be deemed to expire.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The following new subsection (c) is hereby added to Section 4.2 of the Agreement:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">&#8220;(c)&#160;&#160;&#160;&#160;an irrevocable, worldwide, perpetual (subject to Sections 8.3 and 8.4), royalty-free, transferrable (subject to Section 9.1 below) license, with right to sublicense (subject to Section 4.3 below), in and to any Monsanto New Improvements for all purposes in the Protiva Field, which license shall be exclusive, other than in respect of any Monsanto New Improvements that Monsanto is obligated to license to a third party pursuant to any agreement in existence as of the Effective Date, in which case such license shall be non-exclusive. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">References to &#8220;Monsanto Improvements&#8221; in Sections 4.1, 4.3, 4.7, 4.9, 4.10, 6.2, and 8.3(ii) of the Agreement shall be deemed to also refer to and include Monsanto New Improvements.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">References to &#8220;Monsanto Project Intellectual Property&#8221; in Sections 4.1, 4.4, and 4.5 of the Agreement shall be deemed to also refer to and include Monsanto New Intellectual Property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">In all other respects, the terms, conditions, and covenants of the Agreement shall remain unchanged and any rights that either of the Parties may have under the Agreement shall remain in full force and effect.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">This Amendment may be executed in two or more counterparts, each of which will be deemed an original and all of which together will constitute one and the same instrument.  Each shall be considered signed when the signature of a Party is delivered by facsimile, electronic signature or electronic (email) transmission to the other Parties, when it is delivered in a manner that reasonably identifies the signatory as the Party named.  Such electronic signatures shall be treated in all respects as having the same effect as an original signature.  If requested by any Party, documents bearing an original signature may be subsequently and promptly submitted to replace copies bearing electronic signatures.  By signing this Amendment the representatives of each Party thereby represent that such Person is duly authorized by the Party in question to execute this Amendment on behalf of such Party and that each respective Party agrees to be bound by the provisions thereof.  The Parties to this document agree that a copy of the original signature (including </font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">36</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sEDC0218003EE8BB3EC4C5A1CACABF1A5"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">an electronic copy) may be used for any and all purposes for which the original signature may have been used.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">37</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s2C74A749FA81C5414F395A1CACDD72AA"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:32px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">IN WITNESS WHEREOF, the Parties hereto by their duly authorized representatives have caused this Amendment to be executed and delivered as of the date first shown above.</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PROTIVA BIOTHERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: &#160;&#160;&#160;&#160;  </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/Bruce Cousins</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:   Bruce Cousins</font></div><div style="line-height:120%;padding-bottom:48px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:     Executive Vice President and CFO</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PROTIVA AGRICULTURAL DEVELOPMENT COMPANY, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: &#160;&#160;&#160;&#160;  </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/Bruce Cousins</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:   Bruce Cousins</font></div><div style="line-height:120%;padding-bottom:48px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:     Executive Vice President and CFO</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MONSANTO COMPANY</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/Robert M. McCarroll</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:  Robert M. McCarroll, Ph. D.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: &#160;&#160;&#160;&#160; VP, Chemistry Technology</font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">1</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.5</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.10A</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s2C74A749FA81C5414F395A1CACDD72AA"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">APPENDIX A</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;text-decoration:underline;">TO</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;background-color:#ffffff;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">AMENDED AND RESTATED</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">PROTIVA AGRICULTURAL DEVELOPMENT COMPANY INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OPTION AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">2</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;background-color:#ffffff;">6503474.12</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.80
<SEQUENCE>4
<FILENAME>exhibit1080monsantoamendme.htm
<DESCRIPTION>EXHIBIT 10.80
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s237F85026900D0925B305A2713074B4C"></a><div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.80 </font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AMENDED AND RESTATED</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LICENSE AND SERVICES AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Between</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PROTIVA AGRICULTURAL DEVELOPMENT COMPANY INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">on the one hand,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PROTIVA BIOTHERAPEUTICS INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION, </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">on the other hand</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dated:  March 4, 2016</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sEEAE129763CAF33B5D1D5A2713191CBB"></a><div><div style="line-height:120%;text-align:center;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:center;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:right;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.7948717948718%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="12%"></td><td width="75%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Page</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE I - DEFINITIONS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">General</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Interpretation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE II - LICENSE GRANTS AND RELATED RIGHTS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">License Grants to Licensee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Sublicensing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Grant Back</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Retained Rights</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Rights in Bankruptcy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Compliance With Applicable Laws</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE III - FINANCIAL PROVISIONS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Payment for License</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Payment for License</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;Protiva Subsection 85(1) Election</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tekmira Subsection 85(1) Election</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE IV - SERVICES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Termination of Services Obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE V - INTELLECTUAL PROPERTY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ownership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prosecution and Maintenance of Patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Third-Party Infringement of Protiva Background Patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Third-Party Infringement of Protive Project Patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Defense of Claims Brought by Third Parties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Disclosures and Opt-In Rights Regarding Protiva Background Patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Joint Research Committee Oversight</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE VI - CONFIDENTIAL INFORMATION AND PUBLICITY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Non-Disclosure of Confidential Information</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exceptions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Permitted Uses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Permitted Disclosures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE VII - INDEMNIFICATION AND INSURANCE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Protiva Indemnification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensee Indemnification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Tender of Defense; Counsel</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Insurance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE VIII - TERM AND TERMINATION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Material Breach</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">24</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Challenges of Protiva&#8217;s Patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Rights in Bankruptcy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Consequences of Termination; Survival</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Remedies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.14529914529915%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="44%"></td><td width="11%"></td><td width="45%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">i</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sEEAE129763CAF33B5D1D5A2713191CBB"></a><div><div style="line-height:120%;text-align:center;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:center;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(continued)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:right;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.7948717948718%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="12%"></td><td width="75%"></td><td width="12%"></td><td width="1%"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARTICLE IX - MISCELLANEOUS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Representations and Warranties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Force Majeure</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Consequential Damages</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Assignment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Independent Contractors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Governing Law; Jurisdiction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Severability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">No Implied Waivers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Headings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Entire Agreement; Amendment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Waiver of Rule of Construction</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">No Third-Party Beneficiaries</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Further Assurances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Performance by Affiliates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Effect of Amendment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.14529914529915%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="44%"></td><td width="11%"></td><td width="45%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ii</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s376612BC93E9BC2BDB8D5A2713545711"></a><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">AMENDED AND RESTATED</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">LICENSE AND SERVICES AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Amended and Restated License and Services Agreement (this &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is entered into as of March 4, 2016 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;), between Protiva Agricultural Development Company Inc., a British Columbia corporation with a principal place of business at 100&#8209;8900&#160;Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">PadCo</font><font style="font-family:inherit;font-size:12pt;">&#8221;), on the one hand, and Protiva Biotherapeutics, Inc., a British Columbia corporation with a principal place of business at 100&#8209;8900&#160;Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and Arbutus Biopharma Corporation (formerly, Tekmira Pharmaceuticals Corporation), a British Columbia corporation with a principal place of business at 100&#8209;8900&#160;Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Arbutus</font><font style="font-family:inherit;font-size:12pt;">&#8221;), on the other hand. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Protiva and Arbutus own or Control Protiva Intellectual Property (as defined below) that is useful for the delivery of a variety of oligonucleotide products, including those that function through RNA interference or the modulation of microRNAs; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, PadCo, Protiva and Tekmira entered into that certain License and Services Agreement on January 12, 2014 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Original License</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and, contemporaneously with the execution of the Original License: (a) as consideration for the Transferred Protiva Rights and in full satisfaction of the Protiva Purchase Price, the Licensee issued the Protiva Note and one Class B Common share in the capital stock of Licensee to Protiva and granted to Protiva the rights set out in Section 3.3 of the Original License; (b) as consideration for the Transferred Tekmira Rights and in full satisfaction of the Protiva Purchase Price, the Licensee issued one Class A Common share in the capital stock of Licensee to Tekmira that was later transferred to Protiva; (c) Protiva, Tekmira, PadCo and Monsanto Canada entered into the Option Agreement and (d) Protiva and Monsanto entered into the Protiva-Monsanto Services Agreement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, contemporaneously with the execution of this Agreement and as of the Effective Date: (a) the parties to the Protiva-Monsanto Services Agreement are amending the Protiva-Monsanto Services Agreement, (b) the parties to the Option Agreement are amending and restating the Option Agreement, (c) Monsanto Canada is exercising the Call Option to acquire all of the outstanding capital stock of PadCo, and (d) Closing is occurring; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Protiva, Arbutus and PadCo desire to amend and restate the Original License, effective as of the Effective Date, upon the terms and subject to the conditions set forth in this Agreement; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, as required by the terms of the Original License, Monsanto Canada has consented to the amendment and restatement of the Original License upon the terms and conditions of this Agreement.</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s376612BC93E9BC2BDB8D5A2713545711"></a><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">NOW, THEREFORE, in consideration of the mutual covenants contained herein, and other good and valuable consideration, the receipt of which is hereby acknowledged, PadCo, Arbutus and Protiva enter into this Agreement to amend and restate the Original License effective as of the Effective Date:</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sC68568BB83CF9328A4375A271359E0AD"></a><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:center;text-indent:0px;"><font style="padding-bottom:16px;text-align:center;font-family:inherit;font-size:12pt;text-decoration:underline;padding-right:0px;">ARTICLE I &#8211; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">DEFINITIONS</font></div><a name="s3520DC7636BE10ACAE715A271398931B"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.1&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">General</font><font style="font-family:inherit;font-size:12pt;">.&#160;&#160;&#160;&#160; When used in this Agreement, each of the following terms, whether used in the singular or plural, shall have the meanings set forth in this Article I.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Person, any corporation, company, partnership, joint venture and/or firm which controls, is controlled by, or is under common control with such Person.  For purposes of the foregoing sentence, &#8220;control&#8221; means (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the right to vote for the election of directors, or (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the introductory paragraph.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agricultural Field</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all applications in agriculture, horticulture, forestry, aquaculture, and/or residential (e.g., lawn and garden) markets relating to, for example, plants, fish, arthropods and/or pests and pathogens thereof.  For the avoidance of doubt, Agricultural Field excludes, for example: (a)&#160;all human and animal (other than fish and arthropods) therapeutic, prophylactic, and diagnostic applications; and (b)&#160;modification of any cells, tissues, or organisms for the purpose of manufacturing heterologous proteins, peptides, or viruses for any purpose, including producing therapeutic products, other than the modification of plants, plant cells, or plant tissues for the purpose of manufacturing heterologous proteins, peptides, or viruses for application to plants, fish, arthropods, and/or pests or pathogens thereof.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Applicable Laws</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all applicable laws, statutes, rules, regulations, guidelines, guidances, ordinances, orders, decrees, writs, judicial or administrative decisions and the like of any nation or government, any state or other political subdivision thereof, any entity exercising executive, judicial, regulatory or administrative functions of or pertaining to government (including any Governmental Authority), any tribunal or arbitrator of competent jurisdiction, and any trade organization whose regulations have the force of law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Arbutus</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the introductory paragraph.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Background Patent Infringement Action</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.3(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">BIA</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 2.5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Call Option</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">CCAA</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 2.5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Change of Control</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Channel Costs</font><font style="font-family:inherit;font-size:12pt;">&#8221; means those costs incurred by a Party and its Affiliates in preparing and utilizing distribution channels for a Product (including product returns, customer rebates, dealer incentives, volume discounts, seed service fees, cash discounts (pre-pay discounts), local </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">competitive response, transportation or cargo insurance, and some of which, by way of example, are currently identified as &#8220;seed service fees,&#8221; &#8220;crop loss and replant,&#8221; &#8220;volume discount,&#8221; and &#8220;seed action pack&#8221;), in all cases allocated to such Products in accordance with GAAP.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Closing</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Code</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 2.4.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Combination Product</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Product that incorporates other technology and/or materials that embody Patents, Know-How, or other intellectual property rights, benefits, and/or value, including for example, seeds, seed treatments (chemicals or biopesticides), or transgenic or non-transgenic components of a plant genome; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that a Product will only be a Combination Product if such other technology and/or materials have been packaged and sold separately at any time. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Commercial Milestone Payment</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 3.1(a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Commercialize</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all activities directed to marketing, promoting, distributing, importing, having imported, exporting, having exported, selling and having sold a Product, in each case for commercial purposes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Commercial Launch</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the first bona fide commercial sale of the Product in an arm&#8217;s length transaction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Compound</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any molecule (a) that was Controlled by Protiva as of the Original Effective Date, (b) Discovered by Protiva or any of its Affiliates</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">under the Research Program or in the performance of the Technology Transfer, (c) became (or becomes, as the case may be) under the Control of Protiva or any of its Affiliates during the period in which Protiva provided Services pursuant to the Research Program or conducts activities pursuant to the Technology Transfer.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all proprietary or confidential information and materials, patentable or otherwise, of a Party disclosed by or on behalf of such Party to the other Party before, on or after the Original Effective Date, chemical substances, formulations, techniques, processes, methodology, equipment, data, reports, Know-How, sources of supply, patent positioning, business plans, and also each Party&#8217;s proprietary and confidential information of Third Parties in possession of such Party under an obligation of confidentiality, whether or not related to making, using or selling Products.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Control</font><font style="font-family:inherit;font-size:12pt;">,&#8221; &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Controls</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Controlled by</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to any Compound, Formulation, or Protiva Intellectual Property, the possession of (whether by ownership or license, other than pursuant to this Agreement), or the ability of Protiva or any of its Affiliates to grant access to, or a license or sublicense of, such Compound, Formulation, or Protiva Intellectual Property as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time Protiva would be required hereunder to grant (or cause its Affiliates to grant) Licensee such access or license or sublicense.</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Cover</font><font style="font-family:inherit;font-size:12pt;">,&#8221; &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Covers</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Covered by</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Product, that, but for ownership of or a license or sublicense granted under a Valid Claim of a Protiva Background Patent or Protiva Project Patent, the Discovery, Development, Manufacture, and/or Commercialization with respect to such Product would infringe such Patent (or, if such Patent is a patent application, would infringe a patent issued from such patent application if such patent application were to issue with the claims pending in the patent application as of the moment the determination of &#8220;Cover,&#8221; &#8220;Covers,&#8221; or &#8220;Covered by&#8221; is being made).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Develop</font><font style="font-family:inherit;font-size:12pt;">,&#8221; &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Developing</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Development</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all activities, testing and studies required to develop one or more Products for Regulatory Approval and/or commercial sale.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Disclosing Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Discover</font><font style="font-family:inherit;font-size:12pt;">&#8221;, &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Discovering</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Discovery</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all research or discovery activities in respect of a Compound, Formulation, or Product.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the introductory paragraph.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Formulation</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any chemical composition, including lipids, conjugates and polymers formulated with a variety of excipients, that (a) was Controlled by Protiva as of the Original Effective Date; (b) was designed, screened or tested under the Research Program or is designed, screened or tested by Protiva in the performance of the Technology Transfer; or (c) became (or becomes, as the case may be) under the Control of Protiva or any of its Affiliates during the period in which Protiva provided Services pursuant to the Research Program or conducts activities pursuant to the Technology Transfer.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">GAAP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means United States generally accepted accounting principles as in effect from time to time, consistently applied.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governmental Authority</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any United States or supra-national, foreign, federal, state, local, provincial, or municipal government, governmental, regulatory or administrative authority, agency, body, branch, bureau, instrumentality or commission or any court, tribunal, or judicial or arbitral body having relevant jurisdiction over a subject matter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Identified Infringement</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.4(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnified Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnifying Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Infringement Action</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a Background Patent Infringement Action or a Project Patent Infringement Action.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Initiating Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.4(d).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insolvent Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 8.4.</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Joint Project Intellectual Property</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) all inventions that were conceived jointly by: (i) Monsanto, employees of Monsanto, or other Persons owing a duty to assign to Monsanto (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Monsanto Personnel</font><font style="font-family:inherit;font-size:12pt;">&#8221;) </font><font style="font-family:inherit;font-size:12pt;font-style:italic;text-decoration:underline;">and</font><font style="font-family:inherit;font-size:12pt;">&#32;(ii) Protiva, any of its Affiliates, employees of Protiva or any of its Affiliates, or other Persons owing a duty to assign to Protiva or any of its Affiliates (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Personnel</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in the conduct of activities under the Research Program (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Joint Project Inventions</font><font style="font-family:inherit;font-size:12pt;">&#8221;), (b) all Know-How that was developed, created, made, discovered, or produced jointly by Monsanto Personnel and Protiva Personnel in the conduct of activities under the Research Program, (c) all tangible works of expression that was co-authored by Monsanto Personnel and Protiva Personnel in the conduct of activities under the Research Program, (d) all inventions that are conceived jointly by Monsanto Personnel </font><font style="font-family:inherit;font-size:12pt;font-style:italic;text-decoration:underline;">and</font><font style="font-family:inherit;font-size:12pt;">&#32;Protiva Personnel in the conduct of activities under the Technology Transfer (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Joint Technology Transfer Inventions</font><font style="font-family:inherit;font-size:12pt;">&#8221;), (e) all Know-How that is developed, created, made, discovered, or produced jointly by Monsanto Personnel and Protiva Personnel in the conduct of activities under the Technology Transfer, and (f) all tangible works of expression that are co-authored by Monsanto Personnel and Protiva Personnel in the conduct of activities under the Technology Transfer.  In the event the same invention is conceived of independently by both Monsanto Personnel and Protiva Personnel in the conduct of activities under the Research Program or the Technology Transfer, such invention shall be Joint Project Intellectual Property. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Joint Project Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Patents that are directed to</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Joint Project Inventions or to Joint Technology Transfer Inventions. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">JRC</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">JRC Protiva Project Infringement Matter</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Knowingly</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Knowledge</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Know-How</font><font style="font-family:inherit;font-size:12pt;">&#8221; means biological materials and other tangible materials, information, data, inventions, practices, methods, protocols, formulas, formulations, knowledge, know-how, trade secrets, processes, assays, skills, experience, techniques and results of experimentation and testing,  patentable or otherwise (but excluding any marketing, financial, commercial, personnel and other business information and plans).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Licensee</font><font style="font-family:inherit;font-size:12pt;">&#8221; means PadCo or, in the event Monsanto Canada exercises the Call Option and receives from PadCo an assignment of all of PadCo&#8217;s rights and obligations under this Agreement, shall mean Monsanto Canada or any permitted assignee of Monsanto Canada.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Licensee Indemnitees</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Losses</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Manufacturing</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Manufacture</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Product, all activities associated with the production, manufacture, packaging, labeling, releasing or processing of such Product.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Monsanto</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Monsanto Company, a Delaware corporation.</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Monsanto Canada</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Monsanto Canada, Inc., a Canadian corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Monsanto Improvements</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Protiva-Monsanto Services Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Net Sales</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Value Captured for a Product less Channel Costs.&#160; Net Sales shall also be consistent with GAAP.&#160; For the avoidance of doubt, for a Combination Product, Net Sales shall be equitably apportioned for the contribution of Protiva Background Patents, Protiva Project Patents and/or Joint Project Patents in the Combination Product in a manner generally consistent with the then-current custom and practice</font><font style="font-family:inherit;font-size:12pt;color:#111111;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Non-Initiating Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.4(d).&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Option Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means that certain option agreement by and between Protiva, Arbutus, PadCo and Monsanto Canada dated as of January 12, 2014, pursuant to which Protiva granted Monsanto Canada an exclusive option, as such agreement is amended and restated by the parties thereto effective as of the Effective Date and as such option agreement may be hereafter amended, restated, or otherwise modified from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Original Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221; means January 12, 2014.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Original License</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Recitals.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">PadCo</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the introductory paragraph.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; means either Licensee or Protiva; &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Parties</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Licensee and Protiva.  References to &#8220;Party&#8221; and &#8220;Parties&#8221;, as applicable, shall also refer to Arbutus with respect to the Tekmira Patents and the rights and obligations related thereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Patent</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any patent (including any reissue, extension, substitution, confirmation, re-registrations, re-examination, revival, supplementary protection certificate, patents of addition, continuation, continuation-in-part, or divisional) or patent application (including any provisional application, non-provisional patent application, continuation, continuation-in-part, divisional, PCT international applications or national phase applications), in each case whether in the U.S. or any foreign country.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Person</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an individual, corporation, limited liability company, syndicate, association, trust, partnership, joint venture, unincorporated organization, government agency or any agency, instrumentality or political subdivision thereof, or other entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Product</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any product or process in the Agricultural Field Covered by a Valid Claim of one or more of the Protiva Background Patents, Protiva Project Patents, or Joint Project Patents.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Project Patent Infringement Action</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.4(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Proposed Abandonment</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.6.</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the introductory paragraph.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Background Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Patents relevant to or useful in the composition, formulation, or manufacture of Compounds and/or Formulations and/or their use in the Agricultural Field that are (i) Controlled by Protiva and that are (1) independent of the activities under the Research Program and (2) exist (whether as pending applications, issued patents, or otherwise) as of the Original Effective Date and/or (ii) Controlled by Protiva or any of its Affiliates and that are (1) independent of the activities under the Research Program and (2) exist (whether as pending applications, issued patents, or otherwise) at any time during the period beginning immediately following the Original Effective Date and ending on the date that is [***].  For purposes of Sections 5.2(a), 5.3, 5.5, and 5.6 references to &#8220;Protiva Background Patents&#8221; shall be deemed to also refer to Tekmira Patents (and, as applicable, references to Protiva shall be deemed to refer to Arbutus). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Indemnitees</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.2.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Intellectual Property</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Protiva Know-How, Protiva Background Patents, Protiva Project Patents, Protiva Research Data and Tekmira Patents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Know-How</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Know-How relevant to or useful in the composition, formulation, or manufacture of Compounds and/or Formulations and/or their use in the Agricultural Field which is Controlled by (a) Protiva on the Original Effective Date and/or (b) Protiva or any of its Affiliates at any time during the period beginning immediately following the Original Effective Date and ending on the date the Technology Transfer is complete in accordance with the Technology Transfer Completion Criteria; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, Protiva Know-How shall exclude Protiva Background Patents, Protiva Project Patents, and Joint Project Intellectual Property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva License</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all rights and licenses in and to the Protiva Intellectual Property, and all other rights, granted to Licensee, or to which Licensee is otherwise entitled, pursuant to this Agreement, together with the benefit of (and subject to) all representations, warranties, covenants, and terms related to the Protiva Intellectual Property as set forth in this Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva-Monsanto Services Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means that certain services agreement by and between Protiva and Monsanto dated as of January 12, 2014, pursuant to which, among other things, Monsanto agreed to conduct services for Protiva to screen Compounds and/or Formulations according to the Research Program, as such services agreement is amended by the amendment thereto effective as of the Effective Date, and as such services agreement may be hereafter amended, restated, or otherwise modified from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Note</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a non-interest-bearing demand promissory note in the principal amount of [***].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Project Inventions</font><font style="font-family:inherit;font-size:12pt;">&#8221; means inventions that are not Joint Project Intellectual Property and that were conceived by Protiva Personnel in the conduct of the Services or other activities under the Research Program pursuant to the Original License or that are conceived by Protiva Personnel in the conduct of activities under the Technology Transfer.</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Project Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Patents that are directed to Protiva Project Inventions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Purchase Price</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean [***].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Research Data</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) </font><font style="font-family:inherit;font-size:12pt;">all information and data provided to Licensee and the JRC pursuant to Section 4.3 of the Original License and (b) all summary reports, data and other information Protiva provides or is required to provide pursuant to the Technology Transfer</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Receiving Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Record Retention Period</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 3.1(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Research</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Researching</font><font style="font-family:inherit;font-size:12pt;">&#8221; means identifying, evaluating, testing, validating and/or optimizing Compounds, Formulations or Products.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Research Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Research Program</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the program to design and synthesize Compounds and/or Formulations and to conduct research and development activities for such Compounds and/or Formulations as described in the Research Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Response Deadline</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 5.6.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Services</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the research services described in the Research Plan, activities conducted by or on behalf of Protiva or its Affiliates pursuant to the Research Plan or otherwise pursuant to the Original License, and activities conducted by or on behalf of Protiva or its Affiliates in the performance of the Technology Transfer.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Solvent Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 8.4.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Sublicensee</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a Third Party to whom Licensee has granted a sublicense pursuant to the terms hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tax Act</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Income Tax Act (Canada).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tax Value</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, in respect of the rights transferred to the Licensee hereunder, where the respective transferred right is eligible capital property under the Tax Act, the least of the amounts referred to in subparagraphs 85(1)(d)(i), (ii) and (iii) of the Tax Act; where the respective transferred right is capital property under the Tax Act, the least of the amounts referred to in subparagraphs 85(1)(c.1)(i) and (ii) of the Tax Act; and where the respective transferred right is depreciable property under the Tax Act, the least of the amounts referred to in subparagraphs 85(1)(e)(i), (ii) and (iii) of the Tax Act.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Technology Transfer</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Option Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Technology Transfer Completion Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the criteria outlined in Exhibit B-6.</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Technology Transfer Compound List</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a complete list of the components (including Compounds, Formulations, and Compound structures) and ratios of each LNP Composition (as such term is defined in the Technology Transfer Compound Criteria) tested during Phase A (as such term is defined in the Research Program) of the Research Plan as to which the representation and warranty in Section 9.1(b)(vi) is true and correct as of the Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tekmira</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Tekmira Pharmaceuticals Corporation, predecessor to Arbutus.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tekmira Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Patents relevant to or useful in the composition, formulation, or manufacture of Compounds and/or Formulations and/or their use in the Agricultural Field that were Controlled by Tekmira as of the Original Effective Date, other than the Patents listed on Exhibit A. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tekmira Purchase Price</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 3.2(b). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the term described in Section 8.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Territory</font><font style="font-family:inherit;font-size:12pt;">&#8221; means worldwide.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Person other than Protiva, Licensee or any of their respective Affiliates.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in Section 7.3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Transaction Agreements</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean this Agreement, the Protiva-Monsanto Services Agreement, the Option Agreement, and such other documents entered into in connection therewith.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Transferred Protiva Rights</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the licenses granted by Protiva to Licensee set forth in Section 2.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Transferred Tekmira Rights</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the licenses granted by Arbutus to Licensee set forth in Section 2.1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">UBC</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the University of British Columbia.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">UBC IP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the patent families set forth in Exhibit A.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Valid Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a claim of: (a) an issued and unexpired Protiva Project Patent, Protiva Background Patent, or Joint Project Patent, as applicable, which claim has not been revoked or held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, which is not appealable or has not been appealed within the time allowed for appeal, and which has not been abandoned, disclaimed, denied, or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise, or (b) a patent application that is a Protiva Project Patent, a Protiva Background Patent, or a Joint Project Patent, as applicable, that has not been pending for more than eight years after the original priority date for said application and that has not been cancelled, withdrawn or abandoned, or finally rejected by an administrative agency action, which is not appealable or has not been appealed within the time allowed for appeal; provided, however, that for purposes of defining Products for purposes of Section 3.1(a), a claim </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">of a pending application shall be a Valid Claim only if such claim has been identified in an office action (or other office communication) issued by the U.S. Patent and Trademark Office in connection with the prosecution of such application (x) as allowable, or (y) allowable but for its dependency on a rejected independent claim (the conditions of (x) and (y) collectively referred to as &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Allowable</font><font style="font-family:inherit;font-size:12pt;">&#8221;) during the 10-year period following the Commercial Launch of the first Product, such claim as Allowable Covers the Product, and, during such period, the designation of such claim as Allowable has not been reversed or otherwise rejected in subsequent prosecution of such application and no substantive amendments have been made to such claim (or any claims from which it depends) during prosecution of such application since its designation as Allowable, wherein the substantive amendment(s) results in the claim no longer Covers the Product.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Value Captured</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the gross amount invoiced on sales of the Products by a Party and its Affiliates and Sublicensees in the Agricultural Field in the Territory.  For a Combination Product, the Value Captured shall be determined in accordance with the foregoing sentence, except that the gross amount invoiced on sales of the Combination Product will be reduced on a per unit basis by the invoice amount of the other technology and/or materials in the Combination Product when sold separately. </font></div><a name="sF193C4FC50DF9CDCA2255A2713C7196B"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.2&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Interpretation</font><font style="font-family:inherit;font-size:12pt;">.&#160;&#160;&#160;&#160;  Words such as &#8220;herein&#8221;, &#8220;hereinafter&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221; refer to this Agreement as a whole and not merely to a section, paragraph or clause in which such words appear, unless the context otherwise requires.  Enumerative references to sections, paragraphs or clauses, or exhibits, without reference to an explicit agreement, document or exhibit, refer to this Agreement or exhibits attached to this Agreement, as applicable.  The singular shall include the plural, and each masculine, feminine and neuter reference shall include and refer also to the others, unless the context otherwise requires.  The words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; are deemed to be followed by &#8220;without limitation&#8221; or words of similar import.  Except where the context otherwise requires, the word &#8220;or&#8221; is used in the inclusive sense (and/or).  All dollar amounts are expressed in U.S. dollars.</font></div><a name="s21D5F631A4FEDBD3D3E45A2713FAE6D2"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE II &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">LICENSE GRANTS AND RELATED RIGHTS</font></div><a name="s9A45AD5637D71FAC32405A27140CB6AD"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">License Grants to Licensee</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.  </font><font style="font-family:inherit;font-size:12pt;">Subject to the terms and conditions of this Agreement, effective as of the Original Effective Date, Protiva (and with respect to the Tekmira Patents only, Arbutus) hereby grants to Licensee an irrevocable, worldwide, perpetual (subject to Article VIII), fully paid-up, transferrable (subject to Section 9.4), sublicensable (subject to Section 2.2), exclusive (even as to Protiva, except as provided in Section 2.3, and even as to Arbutus with respect to the Tekmira Patents) right and license under the Protiva Intellectual Property for all purposes in the Agricultural Field, including to Discover, Develop, Commercialize and Manufacture Products, and to discover, develop, commercialize, and manufacture other products and processes that use or employ Protiva Intellectual Property, in the Agricultural Field.  In the event Licensee reasonably determines that any Patent or Know-How  owned or Controlled by Arbutus or its Affiliate (other than Protiva) to which Licensee does not have a license under this Agreement is relevant to or useful in the composition, formulation, or manufacture of Compounds and/or Formulations and/or their use in the Agricultural Field, then upon Licensee&#8217;s request, Protiva shall cause Arbutus or such Affiliate to promptly grant a license in and to such Patent or Know-How to Licensee under this </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Agreement, and such Patent or Know-How shall thereafter be included in Protiva Intellectual Property for all purposes of this Agreement.  For the avoidance of doubt, (a) Protiva has not granted to Licensee any right or license to the Protiva Intellectual Property outside of the Agricultural Field, (b) Licensee shall have the right to develop and manufacture Compounds and Formulations in connection with the exercise of its rights to Discover, Develop, Commercialize and Manufacture Products, and to discover, develop, commercialize, and manufacture other products and processes that use or employ Protiva Intellectual Property, in the Agricultural Field, and (c) all UBC IP is expressly excluded from this Agreement, and Licensee is not granted any rights in or to any UBC IP, other than as may be granted pursuant to the second sentence of this Section 2.1.   </font></div><a name="sD53CF7DD895672CEFF645A27144FDB4F"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Sublicensing</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Licensee may grant sublicenses of any or all of its licensed rights under the Protiva Intellectual Property for any purposes within the Agricultural Field, but solely within the Agricultural Field; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that any sublicense granted by Licensee shall be subject and subordinate to the terms and conditions of this Agreement and shall contain terms and conditions consistent with those in this Agreement.  Licensee shall assume full responsibility for the performance of all obligations and observance of all terms herein under the licenses granted to it.  If Licensee becomes aware of a material breach of any sublicense by a Sublicensee, Licensee shall promptly notify Protiva of the particulars of same and take all reasonable efforts to enforce the terms of such sublicense.  Any agreement between Licensee and the Sublicensee shall provide that such Sublicensee may only use the Confidential Information of Protiva in accordance with terms of this Agreement applicable to Licensee&#8217;s use of such Confidential Information and subject to provisions at least as stringent as those set forth in Article VI, and Protiva shall be an express third party beneficiary of such agreement, including provisions related to use and disclosure of Confidential Information.  Subject to the foregoing provisions of this Section 2.2(a), Sublicensees shall have the right to further sublicense Protiva Intellectual Property in the Agricultural Field to Third Parties.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Unless otherwise provided in this Agreement, Licensee shall notify Protiva within thirty (30) days after execution of a sublicense entered into hereunder and provide a copy of the fully executed sublicense agreement to Protiva within the same time, which shall be treated as Confidential Information of Licensee under Article VI.</font></div><a name="s6839288E36C8C81C482A5A2714619912"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4f81bd;font-weight:bold;text-decoration:underline;">Grant Back</font><font style="font-family:inherit;font-size:12pt;color:#4f81bd;font-weight:bold;">&#160;&#160;&#160;&#160;.  Licensee agrees to grant and hereby grants to Protiva a non-exclusive right and license under the Protiva Intellectual Property to Discover and Develop Products in the Agricultural Field for purposes of performing the Technology Transfer.  This right and license shall terminate following completion of all activities pursuant to the Technology Transfer.</font></div><a name="s9A1519E865E40BB52D895A2714A3BFD7"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Retained Rights</font><font style="font-family:inherit;font-size:12pt;">.  Protiva expressly retains any rights not expressly granted to Licensee under this Article II (or otherwise under this Agreement).  Nothing in Section 2.1 limits Protiva&#8217;s ability to perform its obligations under this Agreement, the Protiva-Monsanto Service Agreement or the Option Agreement.  For purposes of clarity and without limitation, Protiva has exclusively retained (even as to Licensee) the right to use and employ Protiva Intellectual Property (alone or with Third Parties) in connection with any and all activities related to the Discovery, Development, Commercialization and manufacture (including Manufacture) of Compounds, Formulations and products outside the Agricultural Field in the Territory.</font></div><a name="s89E1265DE8A93F0E039E5A2714B55CF5"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Rights in Bankruptcy</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;All licenses and rights to licenses granted under or pursuant to this Agreement by Protiva to Licensee are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Code</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and Section 65.11(7) of the Bankruptcy and Insolvency Act (Canada) (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">BIA</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and Section 32(6) of the Companies&#8217; Creditors Arrangment Act (Canada) (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">CCAA</font><font style="font-family:inherit;font-size:12pt;">&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined under Section 101(35A) of the Code, and as utilized generally in the BIA and CCAA.  Licensee, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Code, and that upon commencement of a bankruptcy proceeding by or against Protiva (or any Affiliate of Protiva that owns or Controls Protiva Intellectual Property) under the Code, Licensee shall be entitled to a complete duplicate of, or complete access to (as Licensee deems appropriate), any such intellectual property and all embodiments of such intellectual property.  Such intellectual property and all embodiments thereof shall be promptly delivered to Licensee (a) upon any such commencement of a bankruptcy proceeding upon written request therefore by Licensee, unless Protiva (or its Affiliate) elects to continue to perform all of its obligations under this Agreement or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of Protiva upon written request therefor by Licensee.  The foregoing provisions are without prejudice to any rights Licensee may have arising under the Code or other Applicable Law.</font></div><a name="s5F18B39946299EC9F3EA5A2714DED0D2"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Compliance With Applicable Laws</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;.  </font><font style="font-family:inherit;font-size:12pt;">Each Party shall conduct its obligations under this Agreement, and conduct the Discovery, Development, Manufacture and Commercialization of the Products, in all material respects in accordance with Applicable Laws.  </font></div><a name="s3B3B02EEE53A84BB12DA5A27150ADD0F"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE III &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">FINANCIAL PROVISIONS</font></div><a name="s6B511909FDC8187EACEB5A27152DA6CE"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Payment for License</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Licensee shall pay promptly to Protiva: (i) a one-time, non-refundable, non-creditable payment in the amount of [***] upon the first to occur, if either, of (x) the Net Sales in the Territory of Products by Monsanto or its Affiliates equals or exceeds [***] in any single year during the 10-year period following Commercial Launch of the first Product, or (y) the aggregate Net Sales in the Territory of Products by Monsanto or its Affiliates equals or exceeds [***]</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">cumulatively over the 10-year period following the Commercial Launch of the first such Product and (ii) a one-time, non-refundable, non-creditable payment in the amount of [***] if in any single year during the 10-year period following Commercial Launch of the first Product, the Net Sales in the Territory of Products by Monsanto or its Affiliates equals or exceeds [***] (each a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Commercial Milestone Payment</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  The amount of any Commercial Milestone Payment shall be reduced, if applicable, in accordance with Monsanto&#8217;s right of set off and/or any reduction in the amount of </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Commercial Milestone Payment as a result of a Change of Control of Protiva or Arbutus, in each case under Section 3(f) or 3(g) of the Option Agreement.</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Any payments due from Licensee to Protiva under Section 3.1 of this Agreement that are not paid by the date such payments are due shall bear interest at LIBOR plus two percent (2%) per month from the date such unpaid payments are due until paid in full.  The foregoing interest shall be in addition to any other remedies that the Protiva may have pursuant to this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">During the period of time beginning upon termination of Protiva&#8217;s obligation to provide the Services, as set forth in the Original License, and ending on expiration of the 10-year period following Commercial Launch of the first Product (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Record Retention Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;), Licensee shall maintain and retain (and shall cause Monsanto and its Affiliates to maintain and retain) complete and accurate books of account and records covering all transactions relating to payment of amounts that may be due under Section 3.1(a) of this Agreement, then until expiration of the two (2) year period following expiration of the Record Retention Period, shall make such books and records available for inspection and audit by Protiva&#8217;s authorized representative (which shall be a national certified public accounting firm), subject to reasonable precautions to protection of confidential information of Licensee, Monsanto, or its Affiliates (including Confidential Information), for the purpose of verifying the accuracy of all payments that may be due under Section 3.1(a) of this Agreement.  Protiva shall pay the cost of such audit unless it discovers that Licensee has underreported aggregate Gross Profits during any year in the Record Retention Period to Protiva by an amount of at least [***], in which case the costs of such audit shall be borne by Licensee.</font></div><a name="sEBACAE5970BD67851FDB5A27155EB213"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Payment for License</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">As consideration for the Transferred Protiva Rights, and in full satisfaction of the Protiva Purchase Price, the Licensee (i) issued to Protiva the Protiva Note, (ii) issued to Protiva one Class B Common share without par value in the capital stock of the Licensee as a fully paid and non-assessable share, and (iii) granted to Protiva the rights set out in Section 3.3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">As consideration for the Transferred Tekmira Rights, and in full satisfaction of the Tekmira Purchase Price, the Licensee issued to Tekmira one Class A Common share without par value in the capital stock of the Licensee as a fully paid and non-assessable share.  [***].</font></div><a name="s77E3504539D2493FC3EF5A2715814537"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Protiva Subsection 85(1) Election</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Protiva and Licensee have jointly made and filed an election under subsection 85(1) of the Tax Act (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Election</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in the prescribed form and within the time required by subsection 85(6) of the Tax Act in respect of the transfer of the Transferred Protiva Rights and have elected therein that the elected amount will be deemed to be Protiva&#8217;s proceeds of disposition and the Licensee&#8217;s cost of the Transferred Protiva Rights (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Elected Amount</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If the Canada Revenue Agency or any other competent authority at any time hereafter proposes to issue or issues any assessment or assessments on the basis that the fair market value of </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Transferred Protiva Rights at the time of transfer is greater or less than the Protiva Purchase Price, then:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">upon the fair market value of the Transferred Protiva Rights being finally determined by the agreement of Protiva and the Licensee with the Canada Revenue Agency if they do so agree, or by final determination by a court of competent jurisdiction if they do not, the Protiva Purchase Price will be deemed conclusively to have always been the amount so determined, and this Agreement will be deemed to be amended as of the Effective Date to reflect such Protiva Purchase Price as determined under this Section 3.4(b)(i); and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">if permitted under the Tax Act or the administrative discretion of the Canada Revenue Agency, Protiva at its sole discretion may file an amended election under subsection 85(7.1) of the Tax Act along with the appropriate penalty payment reporting a new fair market value of the Transferred Protiva Rights based on the amounts determined pursuant to section 3.4(b)(i) of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If the Canada Revenue Agency or any other competent authority at any time hereafter proposes to issue or issues any assessment or assessments, on the basis that the Protiva Elected Amount set out in the Protiva Election is greater or less than the applicable Tax Values of the Transferred Protiva Rights, then:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">upon the applicable Tax Values being finally determined, by the Agreement of Protiva and the Licensee with the Canada Revenue Agency if they do so agree, or by final determination by a court of competent jurisdiction if they do not, the Protiva Elected Amount will be deemed conclusively to have always been such finally determined Tax Value; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">if permitted under the Tax Act or the administrative discretion of the Canada Revenue Agency, Protiva at its sole discretion may file an amended election under subsection 85(7.1) of the Tax Act along with the appropriate penalty payment electing such amount as is deemed to be the Protiva Elected Amount under Section 3.4(c)(i).</font></div><a name="sFE4CD0621CFE212F9ADC5A2715A1AD50"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Tekmira Subsection 85(1) Election</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Tekmira and Licensee have jointly made and filed an election under subsection 85(1) of the Tax Act (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tekmira Election</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in the prescribed form and within the time required by subsection 85(6) of the Tax Act in respect of the transfer of the Transferred Tekmira Rights and have elected therein that the elected amount will be deemed to be Arbutus&#8217; proceeds of disposition and the Licensee&#8217;s cost of the Transferred Tekmira Rights (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tekmira Elected Amount</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If the Canada Revenue Agency or any other competent authority at any time hereafter proposes to issue or issues any assessment or assessments on the basis that the fair market value of the Transferred Tekmira Rights at the time of transfer is greater or less than the Tekmira Purchase Price, then:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">upon the fair market value of the Transferred Tekmira Rights being finally determined by the agreement of Arbutus and the Licensee with the Canada Revenue Agency if they </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">do so agree, or by final determination by a court of competent jurisdiction if they do not, the Tekmira Purchase Price will be deemed conclusively to have always been the amount so determined, and this Agreement will be deemed to be amended as of the Effective Date to reflect such Tekmira Purchase Price as determined under this Section 3.5(b)(i); and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">if permitted under the Tax Act or the administrative discretion of the Canada Revenue Agency, Arbutus at its sole discretion may file an amended election under subsection 85(7.1) of the Tax Act along with the appropriate penalty payment reporting a new fair market value of the Transferred Tekmira Rights based on the amounts determined pursuant to section 3.5(b)(i) of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If the Canada Revenue Agency or any other competent authority at any time hereafter proposes to issue or issues any assessment or assessments, on the basis that the Tekmira Elected Amount set out in the Tekmira Election is greater or less than the applicable Tax Values of the Transferred Tekmira Rights, then:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">upon the applicable Tax Values being finally determined, by the agreement of Arbutus and the Licensee with the Canada Revenue Agency if they do so agree, or by final determination by a court of competent jurisdiction if they do not, the Tekmira Elected Amount will be deemed conclusively to have always been such finally determined Tax Value; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">if permitted under the Tax Act or the administrative discretion of the Canada Revenue Agency, Arbutus at its sole discretion may file an amended election under subsection 85(7.1) of the Tax Act along with the appropriate penalty payment electing such amount as is deemed to be the Tekmira Elected Amount under Section 3.5(c)(i).</font></div><a name="sDC08FD9C66752F2840095A2715D4CE82"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE IV &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">SERVICES</font></div><a name="s86D2C7624EA9276601FE5A271602706C"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Termination of Services Obligations</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.  </font><font style="font-family:inherit;font-size:12pt;">The Parties acknowledge and agree that, as of the Effective Date, Monsanto Canada is exercising the Call Option prior to completion of Phase C (as such term is defined in the Research Program).  Monsanto Canada hereby elects to terminate research under the Research Plan as of the Effective Date and, therefore, the Parties acknowledge and agree that, on and as of the Effective Date, Protiva&#8217;s obligation to provide Services under this Agreement terminates; provided, however, that, for the avoidance of doubt, from and after the Effective Date, Protiva remains obligated to provide the Technology Transfer in accordance with the Option Agreement through completion of the Technology Transfer in accordance with the Technology Transfer Completion Criteria. </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><a name="s18C9D58B66A28D2E9DEB5A2716339B4D"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE V &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">INTELLECTUAL PROPERTY</font></div><a name="sBDD4835BCE39834CE3245A27164AC38E"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Ownership</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.  </font><font style="font-family:inherit;font-size:12pt;">Subject to the licenses granted by Protiva herein, Protiva is and shall at all times remain the owner of the Protiva Intellectual Property, including, for the avoidance of doubt, Protiva Project Patents.  As more particularly set forth in the Protiva-Monsanto Services Agreement, and subject to the license granted by Monsanto in the Protiva-Monsanto Services Agreement, Monsanto is and shall at all times remain owner of any Joint Project Intellectual Property. </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s800C21A470E244F5DC5F5A27167DEFEB"></a><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Prosecution and Maintenance of Patents</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Subject to Section 5.6, Protiva shall have the sole right and responsibility, in its sole discretion and at its sole cost and expense, to file, prosecute, maintain and/or abandon patent protection in the Territory for Protiva Background Patents.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">During the Term, decisions regarding the filing of Patent protection in the Territory for Protiva Project Inventions and decisions regarding the prosecution, maintenance and/or abandonment of Protiva Project Patents in the Territory shall be made by Protiva and/or the JRC in accordance with the applicable provisions of the Option Agreement and, subject to and in accordance with such provisions, Protiva shall be responsible for implementing Protiva&#8217;s and/or the JRC&#8217;s decisions regarding the filing, prosecution, maintenance, and/or abandonment of Protiva Project Patents in the Territory.  Except as otherwise set out in the Option Agreement, all costs and fees incurred in connection with the filing, prosecution, maintenance and/or abandonment of all Protiva Project Patents through the Effective Date shall be the sole responsibility of Protiva; all costs and fees incurred in connection with the filing, prosecution, maintenance and/or abandonment of all Protiva Project Patents after the Effective Date shall be the sole responsibility of Licensee.  </font></div><a name="s571229FC8700354770425A2716A9D856"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.3</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Third-Party Infringement of Protiva Background Patents</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each Party shall promptly report in writing to the other Party during the Term known or suspected commercially relevant infringement by a Third Party of any of the Protiva Background Patents in any field and any known or suspected infringement by a Third Party of any of the Protiva Background Patents in the Agricultural Field of which such Party becomes aware and shall provide the other Party with all evidence supporting or relating to such infringement in its possession.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Protiva shall have the sole and exclusive right to initiate an infringement or other appropriate suit with respect to infringements or suspected infringements of any of the Protiva Background Patents, or to take such other actions as Protiva, in its sole discretion, deems appropriate with respect to such infringements or suspected infringements (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Background Patent Infringement Action</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  Protiva shall notify Licensee promptly after initiating any Background Patent Infringement Action.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">With respect to any Background Patent Infringement Action initiated on or after the Effective Date directed to infringement occurring at least in part in the Agricultural Field: (i) Licensee may join such Infringement Action as a party if it has standing to do so (at its own cost and expense), may retain counsel at its own cost and expense to provide advice to Licensee regarding such Infringement Action, and may share all information regarding the Infringement Action provided by Protiva with such counsel, and, if Licensee has joined such Infringement Action, such counsel shall be permitted to attend meetings, discussions, or other activities relating to the Infringement Action on behalf of Licensee; and (ii) Provita agrees to give due consideration to any recommendations or suggestions of Licensee in connection with the Infringement Action, but shall not be obligated to implement or follow any such recommendations or suggestions.  After the Effective Date, Protiva shall not enter into any settlement or compromise in connection with any Background Patent Infringement Action that would eliminate, diminish, or otherwise modify any right, title, or interest of the Licensee in any Protiva Intellectual Property or that would require any payments, concessions, </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">16</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or otherwise bind the Licensee, without the Licensee&#8217;s prior written consent, which consent shall not be unreasonably withheld; for the avoidance of doubt, any settlement or compromise that permits continuation of Licensee&#8217;s rights in and to Protiva Intellectual Property in the same manner and subject to the same terms and conditions as set forth in this Agreement shall not require Licensee&#8217;s prior consent.  Licensee shall provide reasonable cooperation and assistance in connection with a Background Patent Infringement Action initiated by Protiva (including being joined as a party in such Background Patent Infringement Action) at Protiva&#8217;s reasonable request and sole cost. </font></div><a name="sA7D1CB822B00710AAFEF5A2716DF16B0"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third-Party Infringement of Protiva Project Patents</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each Party shall promptly report in writing to the other Party during the Term known or suspected commercially relevant infringement by a Third Party of any of the Protiva Project Patents in any field and any known or suspected infringement by a Third Party of any of the Protiva Project Patents in the Agricultural Field of which such Party becomes aware and shall provide the other Party with all evidence supporting or relating to such infringement in its possession.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Protiva shall have the right, but not the obligation, to initiate an infringement or other appropriate suit with respect to infringements or suspected infringements of any of the Protiva Project Patents, or to take such other actions as Protiva, in its sole discretion, deems appropriate with respect to such infringements or suspected infringements (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Project Patent Infringement Action</font><font style="font-family:inherit;font-size:12pt;">&#8221;).  If Protiva declines to commence a Project Patent Infringement Action with respect to a particular actual or threatened infringement of any issued patent within the Protiva Project Patents (an &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Identified Infringement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) within sixty (60) days following its receipt of a written request from Licensee that it initiate a Project Patent Infringement Action with respect to such Identified Infringement, or if Protiva otherwise fails to confirm that it will commence a Project Patent Infringement Action with respect to such Identified Infringement within such sixty (60) day period, then Licensee may thereafter commence a Project Patent Infringement Action with respect to such Identified Infringement.  Licensee shall use reasonable best efforts to notify Protiva prior to initiating any Project Patent Infringement Action and shall continue to inform Protiva of the status of any Project Patent Infringement Action initiated by Licensee, including by responding to Protiva&#8217;s reasonable requests for status reports, providing drafts of substantive filings of Licensee prior to the due date for such filings, and providing copies of substantive filings of any other party to any such Project Patent Infringement Action promptly after receiving such filings. If any monetary judgment or settlement is recovered in connection with any Project Patent Infringement Action  initiated by Licensee or Protiva in accordance with this Section 5.4(b), then, after Licensee or Protiva, as applicable, recoups actual costs and reasonable expenses associated with such Project Patent Infringement Action, (i) then if the monetary judgment or settlement is primarily attributable to infringement in the Agricultural Field, Licensee shall be entitled to receive from the remainder an amount equal to all direct damages attributable to infringement in the Agricultural Field awarded in such judgment or payable under such settlement; Protiva shall then be entitled to receive from the remainder after such payment to Licensee, if any, an amount equal to all direct damages attributable to infringement outside of the Agricultural Field awarded in such judgment or payable under such settlement; and the balance, if any, remaining after such payments to Licensee and Protiva shall be allocated and payable [***] to Licensee and [***] to Protiva; or (ii) if the monetary judgment or settlement is primarily attributable to infringement outside of the Agricultural Field, </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">17</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Protiva shall be entitled to receive from the remainder an amount equal to all direct damages attributable to infringement outside of the Agricultural Field awarded in such judgment or payable under such settlement, Licensee shall then be entitled to receive from the remainder after such payment to Protiva, if any, an amount equal to all direct damages attributable to infringement in the Agricultural Field awarded in such judgment or payable under such settlement; and the balance, if any, remaining after such payments to Protiva and Licensee shall be allocated and payable [***] to Licensee and [***] to Protiva. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Protiva shall use reasonable best efforts to notify Licensee prior to initiating any Project Patent Infringement Action and shall continue to inform Licensee of the status of any Project Patent Infringement Action initiated by Protiva, including by responding to Licensee&#8217;s reasonable requests for status reports, providing drafts of substantive filings of Protiva prior to the due date for such filings, and providing copies of substantive filings of any other party to any such Infringement Action promptly after receiving such filings.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each Party (as a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Non-Initiating Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;), with respect to a Project Patent Infringement Action initiated by the other Party (as an &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Initiating Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;), may join such Infringement Action as a party if it has standing to do so (at its own cost and expense), may retain counsel at its own cost and expense to provide advice to the Non-Initiating Party regarding such Infringement Action, and may share all information regarding the Infringement Action provided by the Initiating Party with such counsel, and, if the Non-Initiating Party has joined such Infringement Action, such counsel shall be permitted to attend meetings, discussions, or other activities relating to the Infringement Action on behalf of the Non-Initiating Party.  The Initiating Party agrees to give due consideration to any recommendations or suggestions of the Non-Initiating Party in connection with a Project Patent Infringement Action, but shall not be obligated to implement or follow any such recommendations or suggestions; provided however, that the Initiating Party shall not enter into any settlement or compromise in connection with a Project Patent Infringement Action that would eliminate, diminish, or otherwise modify any right, title, or interest of the Non-Initiating Party in any Protiva Intellectual Property or that would require any payments, concessions, or otherwise bind the Non-Initiating Party, without the Non-Initiating Party&#8217;s prior written consent, which consent shall not be unreasonably withheld; for the avoidance of doubt, any settlement or compromise that permits continuation of the Non-Initiating Party&#8217;s rights in and to Protiva Intellectual Property in the same manner and subject to the same terms and conditions as set forth in this Agreement shall not require the Non-Initiating Party&#8217;s prior consent.  The Non-Initiating Party shall provide reasonable cooperation and assistance in connection with a Project Patent Infringement Action initiated by the Initiating Party (including being joined as a party in such Project Patent Infringement Action) at the Initiating Party&#8217;s reasonable request and sole cost.    </font></div><a name="sDC1FA6D90DE47F13DC325A2717018581"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Defense of Claims Brought by Third Parties</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  Each Party shall promptly notify the other Party if it becomes aware of any claim that Licensee&#8217;s actual use or practice of Compounds or Formulations within the Protiva Intellectual Property, or Licensee&#8217;s methods of creating or using such Formulations or Compounds, in connection with its exercise of its license under Section 2.1 infringes, misappropriates, or otherwise violates the intellectual property rights of any Third Party in the Agricultural Field.  In any such instance, the Parties shall cooperate and shall mutually agree upon an appropriate course of action; provided, however, that in the absence of any such agreement, </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">18</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i) any such matter relating to Protiva Project Patents (such matter a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">JRC Protiva Project Infringement Matter</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall be referred to the JRC to be addressed in the manner set forth in the Option Agreement, and (ii) Protiva shall have sole right to determine what action, if any, should be taken in respect of Protiva Background Patents.  Each Party shall provide to the other Party copies of any notices it receives from Third Parties regarding any patent nullity actions regarding the Protiva Background Patents or the Protiva Project Patents, any declaratory judgment actions and any alleged infringement or misappropriation of Third Party intellectual property rights arising out of Licensee&#8217;s use or practice of the Protiva Intellectual Property in connection with its exercise of its license under Section 2.1.  Each Party shall be responsible for its own costs incurred pursuant to this Section 5.5; provided, however, that nothing in this Section 5.5 or elsewhere in this Agreement shall be deemed to eliminate, reduce, or otherwise modify any liability or obligation of Protiva in respect of the Protiva Intellectual Property or Licensee&#8217;s (or its Sublicensees&#8217;) use or practice of the Protiva Intellectual Property in connection with its exercise of its license under Section 2.1, including but not limited to any such liability or obligation that may arise out of any representation, warranty, or covenant made by Protiva under the Option Agreement or any other Transaction Agreement; and provided further, however, that nothing in this Section 5.5 shall be deemed to limit or eliminate a Party&#8217;s right to defend actions initiated by a Third Party against such Party, except to the extent such rights may be limited under any indemnification provisions applicable to such actions.</font></div><a name="sFDBE6F3659E547BEF6EF5A2717212E4F"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Disclosures and Opt-In Rights Regarding Protiva Background Patents</font><font style="font-family:inherit;font-size:12pt;">.  If, during the Term, Protiva decides not to pay the maintenance fee, annuity fee, or similar fee due on any Protiva Background Patent or decides to abandon or discontinue prosecution of any Protiva Background Patent (each a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Proposed Abandonment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and if (a) such Proposed Abandonment will not be accompanied by the proper filing of a continuation or continuation-in-part application for a Protiva Background Patent and (b) there will be no remaining Protiva Background Patent in the same country or jurisdiction in which the abandoned or discontinued Protiva Background Patent was filed that will substantially maintain the value of Licensee&#8217;s exclusive license under the Protiva Background Patents in the Agricultural Field, Protiva shall notify Licensee at least sixty (60) days in advance of any applicable administrative deadline, maintenance fee due date, or response date after or upon which such Protiva Background Patent will be or become abandoned or trigger a similar loss of rights in jurisdictions other than the United States (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Response Deadline</font><font style="font-family:inherit;font-size:12pt;">&#8221;), such notice to include the Response Deadline.  Upon written request of Licensee, Protiva shall promptly assign to Licensee all of its right, title, and interest in and to such Protiva Background Patent </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">unless</font><font style="font-family:inherit;font-size:12pt;">&#32;(x) such Protiva Background Patent is assigned to a Third Party who takes all steps necessary to prevent the Proposed Abandonment and (y) Licensee retains its license to such Protiva Background Patent on the terms and conditions set forth in this Agreement; Protiva shall thereafter have no further right, title, or interest in or to such Protiva Background Patent, except that Protiva shall thereafter have a perpetual, fully paid-up, non-exclusive right and license under such Protiva Background Patent for all uses in the Protiva Field.  To the extent necessary or appropriate to prevent the abandonment or similar loss of rights of a Protiva Background Patent assigned or to be assigned to Licensee, Protiva shall take such other steps (including submission of filings or payments on behalf of Licensee or Monsanto) that are reasonably requested by Licensee (or Monsanto), at Licensee&#8217;s (or Monsanto&#8217;s) sole cost and expense.</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">19</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s1F08B7ED1D28A6CEB66A5A271745988B"></a><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Joint Research Committee Oversight</font><font style="font-family:inherit;font-size:12pt;">.  From and after termination of the Option Agreement, then until the disbandment of the JRC by unanimous vote of the JRC at any time after expiration of the last to expire Valid Claim of a Protiva Project Patent or a Joint Project Patent, the JRC shall remain in existence and shall perform the functions described in this Agreement and any other Transaction Agreements according to the general processes and procedures set out in the Option Agreement (as such processes and procedures may be modified by the unanimous vote of the JRC).  For the avoidance of doubt, the JRC&#8217;s oversight of Protiva Project Patents shall terminate if this Agreement terminates.</font></div><a name="sFA9B1F4127993A6707125A27178FD5C5"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE VI &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">CONFIDENTIAL INFORMATION AND PUBLICITY</font></div><a name="sB8A9A87DEC27E52214D05A2717A10417"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Non-Disclosure of Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  Each Party agrees that, for itself and its Affiliates, until the first to occur of (i) [***] or (ii) [***], a Receiving Party shall maintain all Confidential Information of the Disclosing Party in strict confidence and shall not (a) disclose Confidential Information to any third party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below or (b) use Confidential Information for any purpose except those explicitly licensed or otherwise authorized or permitted by this Agreement or any other Transaction Agreement.</font></div><a name="sEA35259F993ABE2C8D7B5A2717C97186"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exceptions</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  The obligations in Section 6.1 will not apply with respect to any portion of the Confidential Information that the Receiving Party can show by competent proof: (i) was known to the Receiving Party or its Affiliates, without any obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing Party; (ii) is subsequently disclosed to the Receiving Party or its Affiliates by a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any restriction on its use; (iii) is or otherwise becomes generally available to the public or enters the public domain, either before or after it is disclosed to the Receiving Party and such public availability is not the result, directly or indirectly, of any fault of, or improper taking, use or disclosure by, the Receiving Party or its Affiliates or anyone working in concert or participation with the Receiving Party or its Affiliates; or (iv) has been independently developed by employees or contractors of the Receiving Party or its Affiliates without the aid, application or use of Confidential Information of the Disclosing Party.  Specific Confidential Information disclosed by a Disclosing Party will not be deemed to be within any exceptions set forth in (i), (ii), or (iii) above merely because it is embraced by more general information to which one or more of those exceptions may apply and provided further that no combination of information shall be deemed to be within any such exceptions unless the combination itself and its principle of operation are within the public domain.  Even though Confidential Information may be within one of the exceptions described in the preceding sentence, the Receiving Party shall not disclose to third parties that the excepted Confidential Information was received from the Disclosing Party.  </font></div><a name="s5001DD75FDFAF11178B75A2717F7FBC6"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Permitted Uses</font><font style="font-family:inherit;font-size:12pt;">.  Confidential Information of a Disclosing Party may be used by the Receiving Party in the performance of its obligations under any Transaction Agreement, as otherwise expressly authorized in any Transaction Agreement or as expressly authorized by the Disclosing Party in writing.  Confidential Information that is Protiva Intellectual Property may be used by Licensee subject to and in accordance with the provisions of this Agreement applicable to Licensee&#8217;s license to Protiva Intellectual Property.  Licensee shall take steps to maintain the confidentiality of </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">20</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">such Confidential Information that are consistent with the steps it takes to maintain the confidentiality of its own most-valuable confidential information, but in no event less than commercially reasonable steps; provided, however, that nothing in this Agreement shall be deemed to eliminate, restrict, or otherwise limit Licensee&#8217;s license to use such Confidential Information in accordance with the terms and conditions of this Agreement, even if such use may result, directly or indirectly, in the disclosure of such Confidential Information, so long as such disclosures are made in a manner than complies with Section 6.4 below.</font></div><a name="s2C302D1ED7C4FA1D79115A27181D84D6"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4f81bd;font-weight:bold;text-decoration:underline;">P</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ermitted Disclosures</font><font style="font-family:inherit;font-size:12pt;">.  The Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: (i) subject to the proviso below, by any Party hereto, in order to comply with applicable non-patent law (including any securities law or regulation or the rules of a securities exchange in a relevant jurisdiction) and with judicial process, if based on the reasonable advice of the Receiving Party&#8217;s counsel, such disclosure is necessary for such compliance; (ii) subject to the proviso below, by any Party hereto, in connection with prosecuting or defending litigation; (iii) by any Party hereto, in connection with filing and prosecuting Protiva Project Patents and Joint Project Patents only in a manner that complies with such Party&#8217;s rights and obligations in connection with such matters as set out in the Transaction Agreements; (iv) subject to the proviso below, by Licensee, its Sublicensees, or their sublicensees in connection with any legal or regulatory requirements related to the development, sale, offer for sale, use or manufacture of commercial products (or potential commercial products) that use or employ Protiva Intellectual Property, such as labeling requirements, disclosures in connection with obtaining regulatory approvals, and the like, so long as the discovery, development, use, manufacture, and commercialization of such products has been and is performed in a manner that complies with the terms and conditions of Licensee&#8217;s license to such Protiva Intellectual Property and reasonable steps shall be taken to maintain the confidentiality of said Confidential Information even when disclosed for legal or regulatory purposes; (v) subject to the proviso below, by the Licensee, to its Affiliates, permitted acquirers or assignees under the Transaction Agreements and its or any of their research collaborators, subcontractors, lenders (but, with respect to lenders, only Confidential Information related to the terms and conditions of the Transaction Agreements and financial information related thereto), and each of the Licensee&#8217;s and its Affiliates&#8217; respective directors, employees, contractors and agents; and (vi) subject to the proviso below, by Protiva, to its Affiliates, permitted acquirers or assignees under the Transaction Agreements and its or any of their research collaborators, subcontractors, lenders (but, with respect to lenders, only Confidential Information related to the terms and conditions of the Transaction Agreements and financial information related thereto), and Protiva&#8217;s and its Affiliates&#8217; respective directors, employees, contractors and agents, provided, that (a) with respect to clause (i), (ii) and (iv) where legally permissible, (1) the Receiving Party shall notify the Disclosing Party of the Receiving Party&#8217;s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed, and (2) consistent with applicable law or regulation, the Disclosing Party shall have the right to suggest reasonable changes to the disclosure to protect its interests and the Receiving Party shall not unreasonably refuse to include such changes in its disclosure, and (b) with respect to clause (v) and (vi), each Person to whom Confidential Information is disclosed must be bound prior to disclosure by confidentiality and non-use restrictions at least as restrictive as those contained </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">21</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">in this Agreement (other than investment bankers, investors and lenders, who must be bound prior to disclosure by commercially reasonable obligations of confidentiality).</font></div><a name="s236BF552B751442D9D755A27184BE2F6"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE VII &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">INDEMNIFICATION AND INSURANCE</font></div><a name="s5F47B272592214790D005A2718709F51"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Indemnification</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  Protiva agrees to indemnify Licensee and its Affiliates, and their respective agents, directors, officers, employees, representatives, successors and permitted assigns (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Licensee Indemnitees</font><font style="font-family:inherit;font-size:12pt;">&#8221;) against and to hold each of them harmless from any and all losses, costs, damages, fees or expenses (&#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Losses</font><font style="font-family:inherit;font-size:12pt;">&#8221;) actually incurred or suffered by an Licensee Indemnitee to the extent arising out of or in connection with any claim, suit, demand, investigation or proceeding brought by a Third Party based on any breach of any representation, warranty or covenant by Protiva under this Agreement or Protiva&#8217;s gross negligence or willful misconduct.  The foregoing indemnification shall not apply to the extent that any Losses are due to (a) a breach of any of Licensee&#8217;s representations, warranties, covenants and/or obligations under this Agreement or (b) Licensee&#8217;s gross negligence or willful misconduct.</font></div><a name="sF5007C86C0F780D765DC5A27189CA99A"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Licensee Indemnification</font><font style="font-family:inherit;font-size:12pt;">.  Licensee agrees to indemnify Protiva and its Affiliates, and their respective agents, directors, officers, employees, representatives, successors and permitted assigns (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Indemnitees</font><font style="font-family:inherit;font-size:12pt;">&#8221;) against and to hold each of them harmless from any and all Losses actually incurred or suffered by a Protiva Indemnitee to the extent arising out of or in connection with (a) any claim, suit, demand, investigation or proceeding brought by a Third Party based on (i) any breach of any representation, warranty or covenant by Licensee under this Agreement, or (ii) Licensee&#8217;s gross negligence or willful misconduct, or (b) a Third Party&#8217;s direct damages resulting from any development or Commercialization of any Product or products or processes that use or employ Protiva Intellectual Property.  In addition to the limitations set forth in the preceding sentence, the foregoing indemnification obligations shall not apply to the extent that any Losses are due to (x) a breach of any of Protiva&#8217;s representations, warranties, covenants and/or obligations under this Agreement, (y) Protiva&#8217;s gross negligence or willful misconduct, or (z) any of the following occurring prior to or at Closing: (A) any breach of any representation, warranty or covenant by Licensee under this Agreement; (B) Licensee&#8217;s gross negligence or willful misconduct; or (C) a breach of any of Protiva&#8217;s representations, warranties, or covenants directed to Protiva Intellectual Property or the Protiva License under the Option Agreement.</font></div><a name="s806DB3E0B3E12FDFBD405A2718BFED44"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Tender of Defense; Counsel</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  Any Person (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnified Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) seeking indemnification under Article VII agrees to give prompt notice in writing to the other Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Indemnifying Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) of the assertion of any claim or the commencement of any action by any third party (a &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Third Party Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in respect of which indemnity may be sought under such section.  Such notice shall set forth in reasonable detail such Third Party Claim and the basis for indemnification (taking into account the information then available to the Indemnified Party).  The failure to so notify the Indemnifying Party shall not relieve the Indemnifying Party of its obligations hereunder, except to the extent such failure shall have materially and adversely prejudiced the Indemnifying Party.  The Indemnifying Party shall be entitled to participate in the defense of any Third Party Claim and shall, upon its written confirmation of its obligation to indemnify the Indemnified Party in accordance with this Article VII, be entitled to control and appoint lead counsel reasonably satisfactory to the Indemnified Party for such defense by written notice to the Indemnified </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">22</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Party within twenty (20) calendar days after the Indemnifying Party has received notice of the Third Party Claim, in each case at its own expense; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">however</font><font style="font-family:inherit;font-size:12pt;">, that the Indemnifying Party must conduct the defense of the Third Party Claim actively and diligently thereafter in order to preserve its rights in this regard.  The Indemnifying Party shall not be entitled to assume or maintain control of the defense of any Third Party Claim and shall pay the fees and expenses of one counsel retained by the Indemnified Party if:  (a) the Third Party Claim relates to or arises in connection with any criminal proceeding, action, indictment or allegation, (b) the Third Party Claim seeks an injunction or equitable relief against a Indemnified Party or any of its Affiliates, or (c) the Indemnifying Party has failed or is failing to prosecute or defend vigorously the Third Party Claim.  Each Indemnified Party shall obtain the prior written consent of the Indemnifying Party, such consent not to be unreasonably withheld, delayed or conditioned, before entering into any settlement of a Third Party Claim.  Notwithstanding the foregoing, the Indemnifying Party shall not be entitled to enter into or approve any settlement of a Third Party Claim without the consent of the Indemnified Party (which may be withheld in its sole discretion), if the settlement (a) does not expressly unconditionally release all applicable Indemnified Parties and their Affiliates from all Liabilities with respect to such Third Party Claim or (b) imposes injunctive or other equitable relief against the Indemnified Party or any of its Affiliates, (c) involves any admission of criminal or similar liability, or (d) involves any monetary damages that may not be fully covered by the Indemnifying Party.  In the event that the Indemnifying Party fails to assume the defense of the Third Party Claim in accordance with this Section 7.3, (a) the Indemnified Party may defend against the Third Party Claim in any manner it reasonably may deem appropriate, and (b) the Indemnifying Party will remain responsible for any Losses of the Indemnified Party as a result of such Third Party Claim.  In circumstances where the Indemnifying Party is controlling the defense of a Third Party Claim in accordance with this Section 7.3, the Indemnified Party shall be entitled to participate in the defense of any Third Party Claim and to employ separate counsel of its choice for such purpose, in which case the fees and expenses of such separate counsel shall be borne by such Indemnified Party.   Notwithstanding anything herein to the contrary, in circumstances where there is a conflict of interest that would reasonably make it inappropriate under applicable standards of professional conduct to have common counsel for the Indemnifying Party and the Indemnified Party, the Indemnified Party shall be entitled to employ separate counsel, that is reasonably acceptable to the Indemnifying Party, and the Indemnifying Party shall pay the reasonable fees and expenses of such separate counsel.  Each Party shall cooperate, and cause their respective Affiliates to cooperate in all reasonable respects, in the defense or prosecution of any Third Party Claim and shall furnish or cause to be furnished such records, information and testimony, and attend such conferences, discovery proceedings, hearings, trials or appeals, as may be reasonably requested in connection therewith. </font></div><a name="sC965CD364148DF15B95E5A2718E3C8DD"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insurance</font><font style="font-family:inherit;font-size:12pt;">.  Each Party shall maintain insurance, including product liability insurance, with respect to its activities under this Agreement regarding Products in such amount as such Party customarily maintains with respect to similar activities for its other products. Each Party shall maintain such insurance for so long as it continues its activities under this Agreement, and thereafter for so long as such Party customarily maintains insurance for itself covering similar activities for its other products.  Notwithstanding the foregoing, the Parties agree that during such time that Licensee is an Affiliate of Protiva, Licensee shall have satisfied its obligations under this Section 7.4 provided it is covered by Protiva&#8217;s existing insurance policies.  </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">23</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s00119B613F6FA41A08565A271920EABC"></a><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE VIII &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TERM AND TERMINATION</font></div><a name="s7A10F08A36601CAC45D65A271937B8D6"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;color:#4f81bd;font-weight:bold;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:12pt;color:#4f81bd;font-weight:bold;">&#160;&#160;&#160;&#160;.  The term of this Agreement (the &#8220;</font><font style="font-family:inherit;font-size:12pt;color:#4f81bd;font-weight:bold;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:12pt;color:#4f81bd;font-weight:bold;">&#8221;) shall begin on the Original Effective Date and, unless terminated earlier as provided herein, shall continue in perpetuity.</font></div><a name="sBB81532490F9FC0CDA8F5A27196A56E6"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Termination for Material Breach</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.   In the event of a material breach of this Agreement by Licensee, Protiva may provide notice to Licensee setting forth the nature of the breach and a description of the facts underlying the breach sufficient to identify the breach.  If Licensee has not cured such breach or proposed a reasonably satisfactory plan to cure or otherwise remedy such breach within ninety (90) days from the date of receipt of such notice of breach, Protiva may provide a notice of termination to Licensee and this Agreement shall terminate ninety (90) days after such notice of termination unless the breach is cured to the reasonable satisfaction of Protiva or unless Licensee has begun to implement a reasonably satisfactory plan to cure or otherwise remedy such breach within ninety (90) days from the receipt of such notice of termination.   Notwithstanding the foregoing, or any termination of Licensee&#8217;s license pursuant to Section 8.4 below, with respect to any sublicense entered into by Licensee for which the Sublicensee is not the cause of the material breach that resulted in the termination of this Agreement, then upon the assignment to Protiva of all rights of Licensee under such sublicense, Protiva shall assume those obligations of Licensee to such Sublicensee under such sublicense that are within the scope of Protiva&#8217;s obligations to Licensee under this Agreement; all other obligations to the Sublicensee under such sublicense, and all liabilities of Licensee to such Sublicensee, shall remain the sole and exclusive obligations and liabilities of Protiva, and nothing in this Section 8.2 shall be deemed to expand, increase, or otherwise modify Protiva&#8217;s obligations or liabilities under this Agreement.</font></div><a name="s1C356EA122A4153EDACC5A27198EE615"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Challenges of Protiva&#8217;s Patents</font><font style="font-family:inherit;font-size:12pt;">.  If Licensee or any of its Affiliates shall (a) commence or participate in any action or proceeding (including any patent opposition or re-examination proceeding), or otherwise assert in writing any claim, challenging or denying the validity of any of the Protiva Background Patents or Protiva Project Patents or any claim thereof or (b) actively assist any other Person in bringing or prosecuting any action or proceeding (including any patent opposition or re-examination proceeding) challenging or denying the validity of such Patents or any claim thereof, Protiva will have the right to give notice to Licensee (which notice must be given, if at all, within ninety (90) days after Arbutus&#8217;s CEO first learns of the foregoing) that the licenses granted by Protiva to such Patent will terminate in ninety (90) days following such notice, and, unless Licensee and/or its Affiliate, as applicable, withdraws or causes to be withdrawn all such challenge(s) within such ninety-day period, such licenses will so terminate.</font></div><a name="sBA5F440873F5B52476845A2719CCC616"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Rights in Bankruptcy</font><font style="font-family:inherit;font-size:12pt;">.  Each Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Insolvent Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall promptly notify the other Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Solvent Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in writing upon the initiation of any proceeding in bankruptcy, reorganization, dissolution, liquidation or arrangement for the appointment of a receiver or trustee to take possession of the assets of the Insolvent Party or similar proceeding under the law for release of creditors by or against the Insolvent Party or if the Insolvent Party shall make a general assignment for the benefit of its creditors.  To the extent permitted by Applicable Law, if the applicable circumstances described above shall have continued for ninety (90) days undismissed, unstayed, unbonded and undischarged, the Solvent Party may terminate this Agreement upon written notice to the Insolvent Party at any time.  If Protiva is the Insolvent Party, the rights and remedies granted </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">24</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">to Licensee (as the Solvent Party) pursuant to this Section 8.4 shall be in addition to, and not in lieu of, Licensee&#8217;s rights and remedies under Section 2.4 above.</font></div><a name="s9E580B8BC4B1C17EACFE5A2719E340B8"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Consequences of Termination; Survival</font><font style="font-family:inherit;font-size:12pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In the event this Agreement is properly terminated in accordance with its terms, then except as provided in the Protiva-Monsanto Services Agreement, Licensee&#8217;s rights and licenses under the Protiva Intellectual Property shall terminate upon the effective date of such termination.  Termination of this Agreement shall not relieve the Parties of any obligation accruing prior to or upon such expiration or termination and the provisions of ARTICLE I &#8211; (Definitions), ARTICLE VI &#8211; (Confidential Information), ARTICLE VII &#8211; (Indemnification), and ARTICLE IX &#8211; (Miscellaneous) shall survive any expiration or termination of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything to the contrary contained in this Agreement, if it is determined that Protiva has breached its representation and warranty in Section 9.1(b)(iii), Licensee&#8217;s sole and exclusive remedy shall be to require Arbutus or its Affiliate, as applicable, to grant to Licensee a license under its Patents or Know-How for all purposes in the Agricultural Field and such Patents and/or Know-How shall thereafter be included within Protiva Intellectual Property for all purpose of this Agreement; provided, however, that the foregoing shall not be deemed to limit, eliminate or otherwise modify Protiva&#8217;s obligations under Section 7.1 to indemnify any Licensee Indemnitee against or hold any Licensee Indemnitee harmless in respect of any </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Losses</font><font style="font-family:inherit;font-size:12pt;">&#32;actually incurred or suffered by a Licensee Indemnitee arising out of or in connection with any claim, suit, demand, investigation or proceeding brought by UBC or any other Third Party based on any breach of any representation, warranty or covenant by Protiva under this Agreement, including Section 9.1(b)(vi), even if or to the extent such Losses may also arise out Protiva&#8217;s breach of Section 9.1(b)(iii).  Furthermore, omission from the Technology Transfer Compound List of any Compound or Formulation that was provided or created by Protiva or its Affiliate in connection with the Research Program shall not be deemed to limit or eliminate Licensee&#8217;s rights under the second sentence of Section 2.1 with respect to such Compound or Formulation.</font></div><a name="s13D78EE5815BAA0179205A271A112C66"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Remedies</font><font style="font-family:inherit;font-size:12pt;">. The Parties acknowledge and agree that, in the event of a breach or a threatened breach by either Party of this Agreement for which it will have no adequate remedy at law, the other Party may suffer irreparable damage and, accordingly, shall be entitled to injunctive and other equitable remedies to prevent or restrain such breach or threatened breach, in addition to any other remedy they might have at law or at equity. In the event of a breach or threatened breach by a Party of any such provision, the other Party shall be authorized and entitled to obtain from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which the other Party may be entitled in law or equity. </font></div><a name="s79C64A9E0620AA7D07FA5A271A3D2B32"></a><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">ARTICLE IX &#8211;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">MISCELLANEOUS</font></div><a name="sABC98B84C90D975BEFDA5A271A65BC46"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Representations and Warranties</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Mutual Representations and Warranties by Protiva and Licensee</font><font style="font-family:inherit;font-size:12pt;">.</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">25</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each Party hereby represents and warrants to the other Party as of the Original Effective Date:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">It is duly organized and validly existing under the laws of the jurisdiction of its incorporation or formation, and has all necessary power and authority to conduct its business in the manner in which it is currently being conducted, to own and use its assets in the manner in which its assets are currently owned and used, and to enter into and perform its obligations under this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The execution, delivery and performance of this Agreement has been duly authorized by all necessary action on the part of such Party and its Board of Directors and no consent, approval, order or authorization of, or registration, declaration or filing with any Third Party or Governmental Authority is necessary for the execution, delivery or performance of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">This Agreement constitutes the legal, valid and binding obligation of such Party, enforceable against it in accordance with its terms, subject to (A)&#160;laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (B) rules of law governing specific performance, injunctive relief and other equitable remedies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">It has never approved or commenced any proceeding, or made any election contemplating, the winding up or cessation of its business or affairs or the assignment of material assets for the benefit of creditors.  To such Party&#8217;s knowledge, no such proceeding is pending or threatened.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each Party acknowledges and agrees that the other Party has not made any representation or warranty under this Agreement that it has or can provide all the rights that are necessary or useful to Research, Develop or Commercialize a Product; provided, however, that nothing in this Section 9.1(a)(ii) or elsewhere in this Agreement shall be deemed to eliminate, reduce, or otherwise modify any liability or obligation of Protiva or Licensee that may arise out of any representation, warranty, or covenant made by Protiva or Licensee under the Option Agreement or any other Transaction Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Each Party represents and warrants to the other Party that as of the Original Effective Date and as of Closing it has the right to grant to such other Party, its Affiliates and Sublicensees the licenses granted hereunder and has not granted any conflicting rights to any other Person.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Protiva Representations, Warranties, and Covenants</font><font style="font-family:inherit;font-size:12pt;">.  Protiva hereby represents, warrants, and covenants to Licensee that:  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">To Protiva&#8217;s Knowledge, except as set forth on Schedule 9.1(b), the conception, development and reduction to practice of the Protiva Intellectual Property licensed to Licensee under the Original License did not constitute or involve the infringement, misappropriation, </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">26</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or other violation of trade secrets or other rights (including intellectual property rights) or property related to polynucleotide delivery in biological systems of any Person anywhere in the Territory.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">If a Compound or Formulation was provided or created by Protiva or its Affiliate in connection with the Research Program, the use and employment of which as contemplated by the Research Program or the Original License (including but not limited to in connection with the development, Manufacture, or Commercialization of any Product or the development, manufacture, or commercialization of any other product or process that uses or employs Protiva Intellectual Property) would, to the Knowledge of Protiva, infringe upon or  misappropriate or otherwise violate the Intellectual Property of any Third Party, then Protiva promptly (and, in any event, prior to or contemporaneously with providing such Compound or Formulation to Monsanto under the Protiva-Monsanto Services Agreement) provided written notice thereof to the JRC; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Except for the Tekmira Patents, as of the Original Effective Date, neither Tekmira nor any of its Affiliates (other than Protiva) owned or Controlled (including by joint ownership) any Patents or Know-How relevant to or useful in the composition, formulation, or manufacture of Compounds and/or Formulations and their use in the Agricultural Field; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Neither Protiva nor any of its Affiliates has assigned, transferred, conveyed or otherwise encumbered its right, title and interest in the Protiva Intellectual Property in a manner that conflicts with any rights granted to Licensee hereunder; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">In the provision of Services under the Original License, and except as disclosed in accordance with Section 9.1(b)(ii) above, Protiva did not Knowingly infringe, misappropriate, or otherwise violate any trade secrets or other rights (including intellectual property rights) or property of any Person anywhere in the Territory; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vi)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">No Compound or Formulation: (i) that was provided or created by Protiva or its Affiliate in connection with the Research Program and that is identified, or required to be identified, on the Technology Transfer Compound List to be provided to Licensee pursuant to the Technology Transfer or (ii) that was or is delivered, disclosed or otherwise provided to Licensee in the performance of the Technology Transfer, or the use and employment any Compound or Formulation described in item (i) or (ii) above as contemplated by the Original License (including but not limited to in connection with the development, Manufacture, or Commercialization of any Product or the development, manufacture, or commercialization of any other product or process that uses or employs Protiva Intellectual Property), will infringe, misappropriate or otherwise violate any UBC IP; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(vii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">During the Term, neither Arbutus nor any of its Affiliates will grant a license, sublicense or other right, title, or interest in or to any Patents or Know-How it owns or Controls (including by joint ownership) as of the Original Effective Date to any Third Party for use in the Agricultural Field.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(viii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Notwithstanding Sections 9.1(b)(i) and 9.1(b)(v) above, Licensee agrees and acknowledges that Protiva makes no representation, warranty or covenant regarding whether any </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">27</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">nucleic acid molecules provided by Monsanto and used by Protiva in the performance of the Research Plan, or used by Licensee in connection with the development, Manufacture, or Commercialization of any Product or the development, manufacture, or commercialization of any other product or process that uses or employs Protiva Intellectual Property infringe, misappropriate, or otherwise violate the trade secrets or other rights (including intellectual property rights) or property of any Person anywhere in the Territory.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Warranty Disclaimer</font><font style="font-family:inherit;font-size:12pt;">.  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT OR THE ORIGINAL LICENSE, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY INTELLECTUAL PROPERTY, PRODUCTS, GOODS, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT OR THE ORIGINAL LICENSE AND HEREBY DISCLAIMS ALL IMPLIED CONDITIONS, REPRESENTATIONS, AND WARRANTIES, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT OR VALIDITY OF PATENT RIGHTS WITH RESPECT TO ANY AND ALL OF THE FOREGOING.  EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY PRODUCT PURSUANT TO THIS AGREEMENT SHALL BE SUCCESSFUL OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO ANY SUCH PRODUCT SHALL BE ACHIEVED.  Nothing in this Section 9.1(c) or elsewhere in this Agreement or the Original License shall be deemed to eliminate, reduce, or otherwise modify any liability or obligation of Protiva or Licensee that may arise out of any representation, warranty, or covenant made by Protiva or Licensee under the Option Agreement or any other Transaction Agreement.</font></div><a name="sD054D2CD0F252FBF37925A271A9D3B5E"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Force Majeure</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  Except with respect to payment obligations, a Party shall neither be held liable or responsible to any other Party, nor be deemed to have defaulted under or breached this Agreement, for failure or delay in fulfilling or performing any term of this Agreement to the extent, and for so long as, such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including fire, floods, embargoes, power shortage or failure, acts of war (whether war be declared or not), insurrections, riots, terrorism, civil commotions, strikes, lockouts or other labor disturbances, acts of God or any acts, omissions or delays in acting by any Governmental Authority or any other Party, and such affected Party promptly begins performing under this Agreement once such causes have been removed. </font></div><a name="s25A4644138092DF97C5F5A271AB482EA"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Consequential Damages</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  UNDER NO CIRCUMSTANCES WILL ANY PARTY BE LIABLE TO ANY OTHER PARTY WITH RESPECT TO THE PROVISION OF THE SERVICES HEREUNDER OR UNDER THE ORIGINAL LICENSE FOR ANY CONSEQUENTIAL, INDIRECT, SPECIAL, PUNITIVE, INCIDENTAL OR SIMILAR DAMAGES, WHETHER FORESEEABLE OR UNFORESEEABLE AND REGARDLESS OF THE CAUSE OF ACTION FROM WHICH THEY ARISE, INCLUDING, WITHOUT LIMITATION, CLAIMS FOR LOSS OF GOODWILL OR LOST PROFITS, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OCCURRING.  NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 9.3 IS INTENDED TO OR SHALL LIMIT OR </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">28</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">RESTRICT THE INDEMNIFICATION RIGHTS OF A PARTY OR DAMAGES AVAILABLE FOR A PARTY&#8217;S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE VI OR ANY DAMAGES THAT MAY BE AVAILABLE TO A PARTY AS A RESULT OF ANOTHER PARTY&#8217;S BREACH OF ITS OBLIGATIONS UNDER ANY OTHER TRANSACTION AGREEMENT, SUBJECT TO THE LIMITATIONS SET FORTH THEREIN.</font></div><a name="sD1C4F804412C658669725A271AD4E018"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Assignment</font><font style="font-family:inherit;font-size:12pt;">.  Licensee may freely assign its rights and obligations hereunder to Monsanto or Monsanto Canada upon or at any time after the Closing so long as Monsanto or Monsanto Canada, as the case may be, expressly assumes in writing Licensee&#8217;s rights and obligations herein.  Protiva may not assign or otherwise transfer this Agreement or any of its rights and obligations under this Agreement at any time without the prior written consent of Monsanto.  Any purported transfer or assignment in contravention of this Section 9.4 shall, at the option of the non-assigning Party, be null and void and of no effect.  This Agreement shall be binding upon and inure to the benefit of the Parties and their permitted successors and assigns.   No assignment by Protiva or any of its Affiliates of any right, title, or interest in or to the Protiva Intellectual Property shall extinguish, limit, or otherwise modify any rights granted to Licensee in or to such Protiva Intellectual Property, or the exclusivity of such rights.</font></div><a name="s2E9A4BE59C6E2C287D115A271B069FE7"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notices to Licensee shall be addressed to: </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Protiva Agricultural Development Company Inc.</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">c/o Monsanto Company</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">800 North Lindbergh Boulevard</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">St. Louis, Missouri 63167</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention:  Technology Alliances Lead</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With copies to:</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Monsanto Company</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">800 North Lindbergh Boulevard</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">St. Louis, Missouri 63167</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention: Deputy General Counsel, Intellectual Property</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bryan Cave LLP</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">One Metropolitan Square</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">211 North Broadway, Suite 3600</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">St. Louis, Missouri 63102</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attn:  C. Brendan Johnson</font></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Facsimile No.: (314) 552-8438</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notices to Protiva shall be addressed to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Protiva Pharmaceuticals Corporation <br>100-8900 Glenlyon Parkway <br></font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">29</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Burnaby, B.C. <br>Canada V5J 5J8 <br>Attention: President &amp; CEO <br>Facsimile No.: (604) 630-5103</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notices to Arbutus shall be addressed to:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Arbutus Biopharma Corporation <br>100-8900 Glenlyon Parkway <br>Burnaby, B.C. <br>Canada V5J 5J8 <br>Attention: President &amp; CEO <br>Facsimile No.: (604) 630-5103</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In each case with copy to:</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Orrick, Herrington &amp; Sutcliffe LLP <br>51 West 52</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">nd</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;Street <br>New York,  NY  10019</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention:&#160;&#160;&#160;&#160;R. King Milling <br>Facsimile No.: (212) 506-5151</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Either Party may change its address by giving notice to the other Party in the manner provided in this Section 9.5.  Any notice required or provided for by the terms of this Agreement shall be in writing and shall be (a) sent by certified mail, return receipt requested, postage prepaid, (b) sent via a reputable international express courier service, or (c) sent by facsimile transmission, with a copy by regular mail.  The effective date of the notice shall be the actual date of receipt by the Receiving Party.</font></div><a name="sEFC49C8BE23E374622D85A271B2A0BF4"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Independent Contractors</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  It is understood and agreed that the relationship between the Parties is that of independent contractors and that nothing in this Agreement shall be construed as authorization for either Party to act as the agent for the other Party.</font></div><a name="s5E67B6EAB54C96ADB4715A271B5FD77D"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Governing Law; Jurisdiction</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall be governed and interpreted in accordance with the substantive laws of the State of New York, excluding its conflicts of laws principles.  In the event any action shall be brought to enforce or interpret the terms of this Agreement, the Parties agree that such action will be brought in the State or Federal courts located in New York, New York.  Each of the Parties hereby irrevocably submits with regard to any action or proceeding for itself and in respect to its property, generally and unconditionally, to the nonexclusive jurisdiction of the aforesaid courts.  Each of the Parties hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in any action or proceeding with respect to this Agreement, (a) any claim that it is not personally subject to the jurisdiction of the above-named courts for any reason other than the failure to lawfully serve process, (b) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise), and (c) to the fullest extent permitted </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">30</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">by Applicable Law, that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper, and (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.</font></div><a name="sFEB298B8D9A1EB7FA25B5A271B8ACE90"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  In the event that any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable because it is invalid or in conflict with any law of the relevant jurisdiction, the validity of the remaining provisions shall not be affected and the rights and obligations of the Parties shall be construed and enforced as if the Agreement did not contain the particular provisions held to be unenforceable, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">that</font><font style="font-family:inherit;font-size:12pt;">&#32;the Parties shall negotiate in good faith a modification of this Agreement with a view to revising this Agreement in a manner which reflects, as closely as is reasonably practicable, the commercial terms of this Agreement as originally signed.</font></div><a name="s656DC13CC16C607FB3475A271BAD3A63"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Implied Waivers</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  The waiver by either Party of a breach or default of any provision of this Agreement by the other Party shall not be construed as a waiver of any succeeding breach of the same or any other provision, nor shall any delay or omission on the part of either Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such Party.</font></div><a name="sBE69B9C34D90864C6B0D5A271BD0C35D"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Headings</font><font style="font-family:inherit;font-size:12pt;">.  The headings of articles and sections contained this Agreement are intended solely for convenience and ease of reference and do not constitute any part of this Agreement, or have any effect on its interpretation or construction.</font></div><a name="sABB0121EAD2DF29091635A271C029AA7"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Entire Agreement; Amendment</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  This Agreement (along with the attachments) and the other Transaction Agreements (as amended as of the Effective Date) contain the entire understanding of the Parties with respect to the subject matter hereof and thereof and, except as provided in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 9.16</font><font style="font-family:inherit;font-size:12pt;">&#32;below, supersede and replace any and all previous arrangements and understandings, whether oral or written, between the Parties with respect to the subject matter hereof and thereof.  This Agreement (including the attachments hereto) may be amended only by a writing signed by each of the Parties.</font></div><a name="s1843DAB9ADBD6E2E74D95A271C25CCC6"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Waiver of Rule of Construction</font><font style="font-family:inherit;font-size:12pt;">.  Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement.  Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.</font></div><a name="sDF880B954D8F8555F9E65A271C802AFD"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">No Third-Party Beneficiaries</font><font style="font-family:inherit;font-size:12pt;">.  Except as expressly contemplated herein, no Third Party, including any employee of any Party to this Agreement, shall have or acquire any rights by reason of this Agreement.</font></div><a name="sD53D232E402D280EDECD5A271C826E33"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Further Assurances</font><font style="font-family:inherit;font-size:12pt;">.  Each Party shall provide such further documents or instruments required by the other Party as may be reasonably necessary or desirable to give effect to the purpose of this Agreement and carry out its provisions.</font></div><a name="sA6427DB87E747306F7925A271CA8137D"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Performance by Affiliates</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;.  Either Party may use one or more of its Affiliates to perform its obligations and duties hereunder and Affiliates of a Party are expressly granted certain </font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">31</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">rights herein; </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">provided</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">that</font><font style="font-family:inherit;font-size:12pt;">&#32;each such Affiliate shall be bound by the corresponding obligations of such Party and the relevant Party shall remain liable hereunder for the prompt payment and performance of all their respective obligations hereunder.</font></div><a name="sFA242C01CFEB6E2E90955A271CC8E31C"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Effect of Amendment</font><font style="font-family:inherit;font-size:12pt;">.  Nothing in this Agreement shall be deemed to eliminate or modify any rights or obligations of the Parties under the Original License that had accrued prior to the Effective Date, including any obligations in respect of any election under subsection 85(1) of the Tax Act made pursuant to the Original License, it being understood and agreed by the Parties that the terms and conditions of this Agreement are effective from and after the Effective Date.</font></div><a name="s1090535EA0817CB531F55A271D0AE86E"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">Signature Page Follows</font><font style="font-family:inherit;font-size:12pt;">]</font></div><a name="sE20CE820D26172B1A3DF5A271D2C08B7"></a><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, Licensee and Protiva have set their hands to this License and Services Agreement as of the date first written above.</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PROTIVA AGRICULTURAL DEVELOPMENT COMPANY, INC.</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:       </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/Bruce Cousins</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:12pt;">Name:  Bruce Cousins  <br>Title:    Executive Vice President and CFO</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">ARBUTUS BIOPHARMA CORPORATION </font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/Bruce Cousins</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:&#160;&#160;&#160;&#160;Bruce Cousins &#160;&#160;&#160;&#160;  <br>Title:&#160;&#160;&#160;&#160;Executive Vice President and CFO</font></div><div style="line-height:120%;padding-bottom:24px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:24px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PROTIVA BIOTHERAPEUTICS INC.</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/Bruce Cousins</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: &#160;&#160;&#160;&#160;Bruce Cousins <br>Title:&#160;&#160;&#160;&#160;Executive Vice President and CFO</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s7D59CA32112B5D8C6BFE5A271D6B4571"></a><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">EXHIBIT A</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[***]</font></div><br><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.81
<SEQUENCE>5
<FILENAME>exhibit1081monsantoamendme.htm
<DESCRIPTION>EXHIBIT 10.81
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s5B3CEA2301620463F86259FAF1B6B4F7"></a><div><div style="line-height:138%;padding-bottom:13px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Exhibit 10.81</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:138%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">FIRST AMENDMENT</font></div><div style="line-height:138%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">TO</font></div><div style="line-height:138%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">PROTIVA-MONSANTO SERVICES AGREEMENT</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">THIS FIRST AMENDMENT TO THE PROTIVA-MONSANTO SERVICES AGREEMENT (this &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Amendment</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;) is made and entered into as of March 4, 2016, (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Effective Date</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;) by and among Protiva Biotherapeutics, Inc., a British Columbia corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Protiva</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;) and a wholly-owned subsidiary of Arbutus Biopharma Corporation, formerly Tekmira Pharmaceutcals Corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Arbutus</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;), Protiva Agricultural Development Company Inc. (&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">PadCo</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;), a British Columbia corporation and a wholly-owned subsidiary of Protiva (the &#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;), and Monsanto Company, a Delaware corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Monsanto</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Protiva, the Company and Monsanto entered into that certain Protiva-Monsanto Services Agreement on January 12, 2014 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and, contemporaneously with the execution of the Agreement: (a) Protiva, Arbutus, PadCo  and Monsanto Canada entered into the Option Agreement and (b) PadCo, Protiva and Tekmira entered into the PadCo-Protiva License and Services Agreement;</font></div><div style="line-height:138%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, contemporaneously with the execution of this Amendment and as of the Effective Date: (a) the parties to the PadCo-Protiva License and Services Agreement are amending and restating the PadCo-Protiva License and Services Agreement, (b) the parties to the Option Agreement are amending and restating the Option Agreement, (c) Monsanto is exercising the Call Option to acquire all of the outstanding capital stock of PadCo, and (d) Closing is occurring; </font></div><div style="line-height:138%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">WHEREAS, Protiva, the Company and Monsanto desire to amend the Agreement, effective as of the Effective Date, as set forth herein; and</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">NOW THEREFORE, in consideration of the representations, warranties, covenants and agreements contained herein, and for other valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties mutually agree to amend and modify the Agreement as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">All capitalized terms used in this Amendment, unless otherwise defined, shall have the meanings ascribed to such terms in the Agreement.  In addition, the following terms shall have the following meanings for purposes of this Amendment:</font></div><div style="line-height:138%;padding-bottom:16px;text-align:justify;text-indent:64px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(a)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Monsanto New Improvement</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221; means an invention that is (i) Monsanto New Intellectual Property, (ii) claimed in an issued patent owned by Monsanto and having a priority date that is on or after the Effective Date, and (iii) the practice of which, if practiced at the time of said </font></div><br><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">1</font></div></div><hr style="page-break-after:always"><a name="s5B3CEA2301620463F86259FAF1B6B4F7"></a><div><div style="line-height:138%;padding-bottom:13px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Exhibit 10.81</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:138%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">priority date, would be covered by at least one Valid Claim of a Patent that is a Protiva Background Patent or Protiva Project Patent.  </font></div><div style="line-height:138%;padding-bottom:16px;text-align:justify;text-indent:64px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">(b)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Monsanto New Intellectual Property</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221; means all inventions that are conceived by Monsanto Personnel on or after the Effective Date and that are covered by at least one Valid Claim of a Patent.  For the avoidance of doubt inventions that were conceived by Monsanto Personnel in the conduct of activities under the Research Program and that are not Joint Project Intellectual Property are Monsanto Project Intellectual Property and not Monsanto New Intellectual Property.</font></div><div style="line-height:138%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The Parties acknowledge and agree that, as of the Effective Date, Monsanto Canada is exercising the Call Option prior to completion of Phase C (as such term is defined in the Research Program).  Monsanto hereby elects to terminate research under the Research Plan as of the Effective Date and, therefore, the Parties acknowledge and agree that, on and as of the Effective Date, the Term of the Agreement shall be deemed to expire.</font></div><div style="line-height:138%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">3.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">The following new subsection (c) is hereby added to Section 4.2 of the Agreement:</font></div><div style="line-height:138%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8220;(c)&#160;&#160;&#160;&#160;an irrevocable, worldwide, perpetual (subject to </font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Sections 8.3 and 8.4</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">), royalty-free, transferrable (subject to </font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 9.1</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;below) license, with right to sublicense (subject to </font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;text-decoration:underline;">Section 4.3</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;below), in and to any Monsanto New Improvements for all purposes in the Protiva Field, which license shall be exclusive, other than in respect of any Monsanto New Improvements that Monsanto is obligated to license to a third party pursuant to any agreement in existence as of the Effective Date, in which case such license shall be non-exclusive. </font></div><div style="line-height:138%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">4.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">References to &#8220;Monsanto Improvements&#8221; in Sections 4.1, 4.3, 4.7, 4.9, 4.10, 6.2, and 8.3(ii) of the Agreement shall be deemed to also refer to and include Monsanto New Improvements.  </font></div><div style="line-height:138%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">5.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">References to &#8220;Monsanto Project Intellectual Property&#8221; in Sections 4.1, 4.4, and 4.5 of the Agreement shall be deemed to also refer to and include Monsanto New Intellectual Property.</font></div><div style="line-height:138%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">6.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">In all other respects, the terms, conditions, and covenants of the Agreement shall remain unchanged and any rights that either of the Parties may have under the Agreement shall remain in full force and effect.  </font></div><div style="line-height:138%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">7.</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">This Amendment may be executed in two or more counterparts, each of which will be deemed an original and all of which together will constitute one and the same instrument.  Each shall be considered signed when the signature of a Party is delivered by facsimile, electronic signature or electronic (email) transmission to the other Parties, when it is delivered in a manner that reasonably identifies the signatory as the Party named.  Such electronic signatures shall be </font></div><br><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">2</font></div></div><hr style="page-break-after:always"><a name="s5B3CEA2301620463F86259FAF1B6B4F7"></a><div><div style="line-height:138%;padding-bottom:13px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Exhibit 10.81</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:138%;padding-left:0px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">treated in all respects as having the same effect as an original signature.  If requested by any Party, documents bearing an original signature may be subsequently and promptly submitted to replace copies bearing electronic signatures.  By signing this Amendment the representatives of each Party thereby represent that such Person is duly authorized by the Party in question to execute this Amendment on behalf of such Party and that each respective Party agrees to be bound by the provisions thereof.  The Parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used.</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">3</font></div></div><hr style="page-break-after:always"><a name="s9FF8700E97B99197152059FAF1E4BC8B"></a><div><div style="line-height:138%;padding-bottom:13px;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:32px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">IN WITNESS WHEREOF, the Parties hereto by their duly authorized representatives have caused this Amendment to be executed and delivered as of the date first shown above.</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PROTIVA BIOTHERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Bruce Cousins</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: Bruce Cousins</font></div><div style="line-height:120%;padding-bottom:48px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:    Executive Vice President and CFO</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">PROTIVA AGRICULTURAL DEVELOPMENT COMPANY, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/ Bruce Cousins</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: Bruce Cousins</font></div><div style="line-height:120%;padding-bottom:48px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:   Executive Vice President and CFO</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MONSANTO COMPANY</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">/s/Robert M. McCarroll</font></div><div style="line-height:120%;text-align:left;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name: Robert M. McCarroll, Ph. D.&#160;&#160;&#160;&#160;</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:   VP, Chemistry Technology</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:64px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#32;</font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>exhibit211listingofsubsidi.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s8A36FD37EA63A738EC935A145BE96F5A"></a><div></div><br><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 21.1 <br>&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Arbutus Biopharma Corporation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">List of Subsidiaries</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.85974754558204%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="35%"></td><td width="30%"></td><td width="35%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date on which the entity</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">became Arbutus&#8217; wholly</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">owned sub</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Jurisdiction</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Protiva Biotherapeutics Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 30, 2008</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">British Columbia, Canada</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mar. 4, 2015</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware, United&#160;States&#160;of&#160;America</font></div></td></tr></table></div></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><br><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>exhibit231kpmgconsent.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sD508EA516609A865BAEA59F7E28EDA2E"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 23.1</font></div></div><br><div style="line-height:120%;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:32px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED <br>PUBLIC ACCOUNTING FIRM</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Board of Directors</font></div><div style="padding-bottom:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Arbutus Biopharma Corporation</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We consent to the incorporation by reference in the registration statement on Form&#160;S-3MEF (No.&#160;333&#8209;202883), registration statement on Form S-3A (No.&#160;333&#8209;200625), registration statement on Form S-8 (No. 333-202762) and registration statement on Form S-8 (No. 333-186185) of Arbutus Biopharma Corporation of our reports dated March&#160;9, 2016, with respect to the consolidated balance sheets of Arbutus&#160;Biopharma Corporation as of December&#160;31, 2015 and 2014, and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the years in the three-year period ended December&#160;31, 2015, and the effectiveness of internal control over financial reporting as of December&#160;31, 2015, which reports appear in the December&#160;31, 2015 annual report on Form&#160;10&#8209;K of Arbutus Biopharma Corporation.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">/s/  KPMG LLP</font></div><div style="text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chartered Professional Accountants</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">March 9, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Vancouver, Canada</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;padding-left:197px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:68.77637130801688%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:5pt;"><font style="font-family:inherit;font-size:5pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s6F7AD920D9A51D842840EF636F3E2F39"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div></div><br><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE SECURITIES </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Mark J. Murray, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Form 10-K Arbutus Biopharma Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">March&#160;9, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="25%"></td><td width="25%"></td><td width="1%"></td><td width="49%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Mark J. Murray</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark J. Murray</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s734241B9419E4243900EEF636E96FFE9"></a><div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2 </font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE SECURITIES </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Bruce Cousins, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Form 10-K of Arbutus Biopharma Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting</font></div></td></tr></table><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">March&#160;9, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="25%"></td><td width="25%"></td><td width="1%"></td><td width="49%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Bruce Cousins</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bruce Cousins</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President, Finance and </font></div><div style="padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s104277A3FD654E83D02EEF636DEE7CB5"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div></div><br><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AS ADOPTED PURSUANT TO SECTION 906 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Annual Report of Arbutus Biopharma Corporation (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I Mark J. Murray, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">March&#160;9, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="25%"></td><td width="25%"></td><td width="1%"></td><td width="49%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Mark J. Murray</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mark J. Murray</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>exhibit322.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2016 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s462401C09EBC5C8E9CFAEF636B56FFF4"></a><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.2</font></div></div><br><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AS ADOPTED PURSUANT TO SECTION 906 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Annual Report of Arbutus Biopharma Corporation (the &#8220;Company&#8221;) on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I Bruce Cousins, Executive Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">March&#160;9, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td width="25%"></td><td width="25%"></td><td width="1%"></td><td width="49%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Bruce Cousins</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bruce Cousins</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Executive Vice President, Finance and </font></div><div style="padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>12
<FILENAME>abus-20151231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:829adeb9dd5849d0a9e138b1e0b91e2f,x:77598f2e1717423593b47d5e1b171833-->
<xbrli:xbrl xmlns:abus="http://www.tekmirapharm.com/20151231" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="abus-20151231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Feb29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1March04">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Mar05-Dec31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-05</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abus_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abus:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Mar05-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-05</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec31-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-31</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-04</xbrli:startDate>
			<xbrli:endDate>2015-03-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Mar04-Mar04_us-gaap_AwardTypeAxis_abus_SharesIssuedWithoutSubjectsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:SharesIssuedWithoutSubjectsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-04</xbrli:startDate>
			<xbrli:endDate>2015-03-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1March04_us-gaap_AwardTypeAxis_abus_AbutusStockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:AbutusStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Nov30-Nov30_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-11-30</xbrli:startDate>
			<xbrli:endDate>2015-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_abus_AbutusStockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:AbutusStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDCyclophilinsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">abus:IPRDCyclophilinsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Mar04-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-04</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_OtherIPRDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">abus:OtherIPRDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Mar04-Dec31_us-gaap_AwardTypeAxis_abus_AbutusStockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:AbutusStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-04</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Mar04-Mar04_us-gaap_AwardTypeAxis_abus_SharesIssuedSubjectToRepurchaseProvisionMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:SharesIssuedSubjectToRepurchaseProvisionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-04</xbrli:startDate>
			<xbrli:endDate>2015-03-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Oct28-Oct28_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDCyclophilinsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">abus:IPRDCyclophilinsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-28</xbrli:startDate>
			<xbrli:endDate>2015-10-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Oct28-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDCyclophilinsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">abus:IPRDCyclophilinsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-28</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_GoodwillMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1March03_us-gaap_AwardTypeAxis_abus_SharesIssuedWithoutSubjectsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:SharesIssuedWithoutSubjectsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Mar04-Mar04_us-gaap_AwardTypeAxis_abus_AbutusStockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:AbutusStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-04</xbrli:startDate>
			<xbrli:endDate>2015-03-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDCyclophilinsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">abus:IPRDCyclophilinsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2May31-May31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-05-31</xbrli:startDate>
			<xbrli:endDate>2016-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1March04_us-gaap_AwardTypeAxis_abus_SharesIssuedSubjectToRepurchaseProvisionMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:SharesIssuedSubjectToRepurchaseProvisionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Jan11_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDAntigenInhibitorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">abus:IPRDAntigenInhibitorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDcccDNASterilizersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">abus:IPRDcccDNASterilizersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDImmuneModulatorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">abus:IPRDImmuneModulatorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDAntigenInhibitorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">abus:IPRDAntigenInhibitorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDCyclophilinsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">abus:IPRDCyclophilinsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDcccDNASterilizersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">abus:IPRDcccDNASterilizersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDImmuneModulatorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">abus:IPRDImmuneModulatorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:CommonShareIssuableForArbutusInc.StockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_abus_SharesIssuedSubjectToRepurchaseProvisionMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:SharesIssuedSubjectToRepurchaseProvisionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_abus_SharesIssuedWithoutSubjectsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:SharesIssuedWithoutSubjectsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Feb29-Feb29_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-02-29</xbrli:startDate>
			<xbrli:endDate>2016-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_DoDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DoDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_BMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:BMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_MonsantoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:MonsantoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_DicernaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DicernaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_OtherRNAiCollaboratorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:OtherRNAiCollaboratorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_MonsantoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:MonsantoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_DicernaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DicernaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_MonsantoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:MonsantoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_AlnylamLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:AlnylamLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_DicernaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DicernaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_BMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:BMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_BMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:BMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_SpectrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:SpectrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_AlnylamLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:AlnylamLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_OtherRNAiCollaboratorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:OtherRNAiCollaboratorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_DoDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DoDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_OtherRNAiCollaboratorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:OtherRNAiCollaboratorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_SpectrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:SpectrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_DoDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DoDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_SpectrumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:SpectrumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_AlnylamLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:AlnylamLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2006Q2May06">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2006-05-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q2March31_us-gaap_CounterpartyNameAxis_abus_MonsantoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:MonsantoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-05-01</xbrli:startDate>
			<xbrli:endDate>2015-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q1Jan13-Jan13_us-gaap_CounterpartyNameAxis_abus_MonsantoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:MonsantoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-13</xbrli:startDate>
			<xbrli:endDate>2014-01-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q1Mar09_dei_LegalEntityAxis_abus_MonsantoMember_us-gaap_BusinessAcquisitionAxis_abus_PADCo.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:MonsantoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:PADCo.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_MarqiboMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">abus:MarqiboMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CounterpartyNameAxis_abus_DoDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DoDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2April22_abus_ContractModificationsAxis_abus_IncreasedFundingForStageOneMember_us-gaap_CounterpartyNameAxis_abus_DoDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="abus:ContractModificationsAxis">abus:IncreasedFundingForStageOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DoDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-04-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_PADCo.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abus:PADCo.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q1Mar01-Mar31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_AlnylamLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">abus:AlnylamLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-03-01</xbrli:startDate>
			<xbrli:endDate>2014-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2010Q3_us-gaap_CounterpartyNameAxis_abus_DoDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DoDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2010-07-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec31-Dec31_us-gaap_CounterpartyNameAxis_abus_DicernaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DicernaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-31</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_MarqiboCommercialSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">abus:MarqiboCommercialSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_MarqiboMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">abus:MarqiboMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4_us-gaap_CounterpartyNameAxis_abus_DicernaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DicernaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-16</xbrli:startDate>
			<xbrli:endDate>2014-11-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_CounterpartyNameAxis_abus_TalonTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:TalonTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q1March13_us-gaap_CounterpartyNameAxis_abus_MonsantoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:MonsantoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-01-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2010Q2May10-May10_us-gaap_CounterpartyNameAxis_abus_BMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:BMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-05-10</xbrli:startDate>
			<xbrli:endDate>2010-05-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Nov16_us-gaap_CounterpartyNameAxis_abus_DicernaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DicernaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-11-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2010Q3_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_ContractExtensionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">abus:ContractExtensionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2010-07-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q4Nov30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_AlnylamLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">abus:AlnylamLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-11-01</xbrli:startDate>
			<xbrli:endDate>2013-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_MarqiboMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">abus:MarqiboMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2May08_abus_ContractModificationsAxis_abus_IncreaseToSupportDevelopmentPlansMember_us-gaap_CounterpartyNameAxis_abus_DoDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="abus:ContractModificationsAxis">abus:IncreaseToSupportDevelopmentPlansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DoDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q2Jun21-Jun21_us-gaap_LitigationCaseAxis_abus_AlnylamandAscletisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">abus:AlnylamandAscletisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-06-21</xbrli:startDate>
			<xbrli:endDate>2013-06-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_MarqiboMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">abus:MarqiboMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q4Dec01_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_AlnylamLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">abus:AlnylamLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-12-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2010Q2_us-gaap_CounterpartyNameAxis_abus_BMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:BMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2010-05-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2April22_abus_ContractModificationsAxis_abus_StageOneMember_us-gaap_CounterpartyNameAxis_abus_DoDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="abus:ContractModificationsAxis">abus:StageOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DoDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-04-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CounterpartyNameAxis_abus_MonsantoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:MonsantoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CounterpartyNameAxis_abus_DicernaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DicernaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CounterpartyNameAxis_abus_DicernaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DicernaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CounterpartyNameAxis_abus_DoDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:DoDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_CounterpartyNameAxis_abus_MonsantoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:MonsantoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_PADCo.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abus:PADCo.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abus_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abus:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abus_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abus:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EquivalentNumberOfCompanyCommonSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EquivalentNumberOfCompanyCommonSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EquivalentNumberOfCompanyCommonSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EquivalentNumberOfCompanyCommonSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EquivalentNumberOfCompanyCommonSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EquivalentNumberOfCompanyCommonSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EquivalentNumberOfCompanyCommonSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ArbutusPlansMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ArbutusPlansMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ArbutusPlansMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ArbutusPlansMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ArbutusPlansMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ArbutusPlansMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ArbutusPlansMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:OnCoreOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range4Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range4Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range5Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range5Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_TotalRangeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:TotalRangeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range8Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range8Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range6Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range6Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range4Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range4Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range6Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range6Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range8Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range8Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_TotalRangeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:TotalRangeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range7Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range7Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range7Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range7Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range5Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">abus:Range5Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:OnCoreOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Mar05-Dec31_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:OnCoreOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-05</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EquivalentNumberOfCompanyCommonSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:OnCoreOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Mar05-Dec31_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EquivalentNumberOfCompanyCommonSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:OnCoreOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-05</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1March04_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:OnCoreOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1March04_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EquivalentNumberOfCompanyCommonSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:OnCoreOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1March25">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-03-25</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Mar25-Mar25">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-25</xbrli:startDate>
			<xbrli:endDate>2015-03-25</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_abus_CashlessExerciseProvisionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:CashlessExerciseProvisionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q4Oct22">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-22</xbrli:startDate>
			<xbrli:endDate>2013-10-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q1March26">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-03-26</xbrli:startDate>
			<xbrli:endDate>2014-03-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Dec31-Dec31_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:OnCoreOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-12-31</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_abus_CashlessExerciseProvisionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:CashlessExerciseProvisionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q4Nov02">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-11-02</xbrli:startDate>
			<xbrli:endDate>2013-11-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:OnCoreOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-04</xbrli:startDate>
			<xbrli:endDate>2015-03-04</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2008Q2_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2008-05-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q2June22_us-gaap_PlanNameAxis_abus_A2007PlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:A2007PlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-06-22</xbrli:startDate>
			<xbrli:endDate>2011-06-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q4Oct22">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-10-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_abus_ProtivaShareOptionsMember_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q1March26">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-03-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_DesignatedPlansMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:DesignatedPlansMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q4Mar04-Dec31_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:OnCoreOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-04</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2008Q2May30-May30_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2008-05-30</xbrli:startDate>
			<xbrli:endDate>2008-05-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q4Nov02">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-11-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q2June22_us-gaap_PlanNameAxis_abus_A2007PlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:A2007PlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-06-22</xbrli:startDate>
			<xbrli:endDate>2011-06-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q2June22_us-gaap_PlanNameAxis_abus_A2011PlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:A2011PlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-06-22</xbrli:startDate>
			<xbrli:endDate>2011-06-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2008Q2_us-gaap_AwardTypeAxis_abus_RevisedNewCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:RevisedNewCommonSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2008-05-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_abus_ProtivaShareOptionsMember_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_AwardTypeAxis_abus_ProtivaShareOptionsMember_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:ProtivaShareOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q4Oct02">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-02</xbrli:startDate>
			<xbrli:endDate>2013-10-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_AwardTypeAxis_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q2May08">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-05-08</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Jul09">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-07-09</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q2June22_us-gaap_PlanNameAxis_abus_A2011PlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:A2011PlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-06-22</xbrli:startDate>
			<xbrli:endDate>2011-06-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ProtivaOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Jan01-Jan31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_ISARICMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">abus:ISARICMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_InvestmentCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:InvestmentCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_InvestmentCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:InvestmentCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Nov23-Nov23_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-11-23</xbrli:startDate>
			<xbrli:endDate>2011-11-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2011Q4Nov23-Nov23">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-11-23</xbrli:startDate>
			<xbrli:endDate>2011-11-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Oct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:BlumbergMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q1Feb28_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergandDrexelMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:OnCoreBiopharmaInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:BlumbergandDrexelMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2004Q1Nov12-Mar31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>1999-11-12</xbrli:startDate>
			<xbrli:endDate>2004-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Jan16_us-gaap_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">abus:ArbitrationWithTheUniversityOfBritishColumbiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-16</xbrli:startDate>
			<xbrli:endDate>2015-01-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Oct01toOct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:BlumbergMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-10-01</xbrli:startDate>
			<xbrli:endDate>2014-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Nov30_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergandDrexelMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:OnCoreBiopharmaInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:BlumbergandDrexelMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-11-01</xbrli:startDate>
			<xbrli:endDate>2014-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Dec30_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_CounterpartyNameAxis_abus_CytosMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:CytosMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:OnCoreBiopharmaInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:EnantigenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:OnCoreBiopharmaInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:EnantigenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_abus_MarqiboMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">abus:MarqiboMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q1Feb28_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergandDrexelMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:OnCoreBiopharmaInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:BlumbergandDrexelMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-02-01</xbrli:startDate>
			<xbrli:endDate>2014-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Jan01-Jan31_us-gaap_CounterpartyNameAxis_abus_ArcturusMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:ArcturusMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Nov30_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergandDrexelMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:OnCoreBiopharmaInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:BlumbergandDrexelMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-11-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q3Sep30_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_CounterpartyNameAxis_abus_NeuroViveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:NeuroViveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-09-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ProductOrServiceAxis_abus_MarqiboMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">abus:MarqiboMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q4Nov29-Nov29_us-gaap_CounterpartyNameAxis_abus_MarinaBiotechInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:MarinaBiotechInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-11-29</xbrli:startDate>
			<xbrli:endDate>2012-11-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_us-gaap_ProductOrServiceAxis_abus_MarqiboMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">abus:MarqiboMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Oct31_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:OnCoreBiopharmaInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:EnantigenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_MarinaBiotechInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">abus:MarinaBiotechInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Jan11_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:OnCoreBiopharmaInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:EnantigenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ProductOrServiceAxis_abus_MarqiboMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">abus:MarqiboMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ConcentrationRiskByTypeAxis_abus_ForeignCurrencyExposureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">abus:ForeignCurrencyExposureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_ConcentrationRiskByTypeAxis_abus_ForeignCurrencyExposureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">abus:ForeignCurrencyExposureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-04-01</xbrli:startDate>
			<xbrli:endDate>2014-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-07-01</xbrli:startDate>
			<xbrli:endDate>2014-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-10-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-10-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="cadPershares">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:CAD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="subsidiary">
		<xbrli:measure>abus:subsidiary</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="cad">
		<xbrli:measure>iso4217:CAD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="reporting_unit">
		<xbrli:measure>abus:reporting_unit</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="chemotherapy_products">
		<xbrli:measure>abus:chemotherapy_products</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="compensation_plan">
		<xbrli:measure>abus:compensation_plan</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="program">
		<xbrli:measure>abus:program</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="executive_officers">
		<xbrli:measure>abus:executive_officers</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="compound_series">
		<xbrli:measure>abus:compound_series</xbrli:measure>
	</xbrli:unit>
	<abus:AccruedLicenseFeeCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-333FD24B0C169E386E9F33FDA422E13D" unitRef="usd">250000</abus:AccruedLicenseFeeCurrent>
	<abus:AccruedLicenseFeeCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-8EB15E06EC08A74F60D533FCA2C0D520" unitRef="usd">0</abus:AccruedLicenseFeeCurrent>
	<abus:AccruedPayrollCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-C9B45FC1B6EA5F38C1DD3401D2840250" unitRef="usd">2873000</abus:AccruedPayrollCurrent>
	<abus:AccruedPayrollCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-0078A8703E7C7445856A3401D297D712" unitRef="usd">2331000</abus:AccruedPayrollCurrent>
	<abus:AccruedResearchandDevelopmentCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-AF5D0B3F035C275B914233FB70D367F6" unitRef="usd">2391000</abus:AccruedResearchandDevelopmentCurrent>
	<abus:AccruedResearchandDevelopmentCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-1A4AE67171AA27D4533433FB70D52893" unitRef="usd">2358000</abus:AccruedResearchandDevelopmentCurrent>
	<abus:ApproximateOptionPeriod contextRef="D2014Q1Jan13-Jan13_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" id="Fact-61D9CB25597F4BADFD8EEF63647E7764">P4Y</abus:ApproximateOptionPeriod>
	<abus:BalanceWeightedaverageremainingcontractuallife contextRef="FD2013Q4YTD" id="Fact-43B4092B447A65F7ACB1CC458AFDDA0D">P2Y8M12D</abus:BalanceWeightedaverageremainingcontractuallife>
	<abus:BalanceWeightedaverageremainingcontractuallife contextRef="FD2014Q4YTD" id="Fact-0DC82307FD4B91131D7BCC458B2FADFB">P1Y9M18D</abus:BalanceWeightedaverageremainingcontractuallife>
	<abus:BalanceWeightedaverageremainingcontractuallife contextRef="FD2015Q4YTD" id="Fact-CA54E4765C6D7E0B3AF6CC458A9900C5">P9M18D</abus:BalanceWeightedaverageremainingcontractuallife>
	<abus:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice contextRef="I2015Q1March04_us-gaap_AwardTypeAxis_abus_AbutusStockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-76AE985E4C39D087C3FB3950D628BACF" unitRef="usd">2160000</abus:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice>
	<abus:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-A45AE0EE9A43BF4D57B6389DDA9612EB" unitRef="usd">56934000</abus:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice>
	<abus:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice contextRef="I2015Q1March04_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="-3" id="Fact-75C79EB206099002F9D83EFDE3E88B50" unitRef="usd">2160000</abus:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice>
	<abus:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice contextRef="I2015Q1March04_us-gaap_AwardTypeAxis_abus_AbutusStockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-021C52DCD7E022019FF83950AC211E4C" unitRef="usd">1127000</abus:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice>
	<abus:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-9E97DD32C06CDA972EDE38998FCE0529" unitRef="usd">9262000</abus:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice>
	<abus:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice contextRef="I2015Q1March04_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="-3" id="Fact-13E496314DC972CE97003EFD41788F13" unitRef="usd">1127000</abus:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice>
	<abus:BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted contextRef="FD2014Q4YTD" decimals="2" id="Fact-3ED29C0571FF5B457D8639D86BB09F61" unitRef="usdPerShare">-1.24</abus:BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted>
	<abus:BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-F81BA5F196BC1DD2101C39D836314C4E" unitRef="usdPerShare">-1.38</abus:BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted>
	<abus:BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter contextRef="FD2015Q3QTD" decimals="-3" id="Fact-F261B3A03295B60A14FB38AB36F3927B" unitRef="usd">1900000</abus:BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter>
	<abus:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities contextRef="D2015Q4Mar05-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-65A5B3BD2AA6843F224339A91EA04340" unitRef="usd">0</abus:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities>
	<abus:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable contextRef="D2015Q4Mar05-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-4E97FACD54A2135A0AFB39A7F8D5534F" unitRef="usd">0</abus:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable>
	<abus:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash contextRef="D2015Q4Mar05-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-E5811D1991E4462B984939A54781DB0F" unitRef="usd">0</abus:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash>
	<abus:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability contextRef="D2015Q4Mar05-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-B82CA0B8E21648BD4E8C39AA67683FED" unitRef="usd">6644000</abus:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability>
	<abus:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities contextRef="D2015Q4Mar05-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-32B017FF423375AEA97D39A9EED96C6E" unitRef="usd">1991000</abus:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities>
	<abus:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets contextRef="D2015Q4Mar05-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-30EF422ACACFD1A544AA39A65ACEA30F" unitRef="usd">-11000</abus:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets>
	<abus:BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-1073E1FAAEC77662F6E9398CC6C7D2E5" unitRef="usd">3580000</abus:BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities>
	<abus:BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-77C2ED461A31B425CE6B398B5C15BB7B" unitRef="usd">3580000</abus:BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities>
	<abus:ClassOfWarrantOrRightExercisedDuringPeriod contextRef="FD2014Q4YTD" decimals="INF" id="Fact-88F0BC54671BF8CDCD25CC458A8F0A94" unitRef="shares">616478</abus:ClassOfWarrantOrRightExercisedDuringPeriod>
	<abus:ClassOfWarrantOrRightExercisedDuringPeriod contextRef="FD2015Q4YTD" decimals="INF" id="Fact-88375D83E34B72963E2ACC458AB7C6EE" unitRef="shares">18750</abus:ClassOfWarrantOrRightExercisedDuringPeriod>
	<abus:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice contextRef="FD2014Q4YTD" decimals="2" id="Fact-073DD8952586D9163783CC458B6BA3D4" unitRef="cadPershares">3.09</abus:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice>
	<abus:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice contextRef="FD2014Q4YTD" decimals="2" id="Fact-7E57AE7D20209FF49211CC458B25205E" unitRef="usdPerShare">2.80</abus:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice>
	<abus:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice contextRef="FD2015Q4YTD" decimals="2" id="Fact-1A1238EF964FABA45732CC458AE99748" unitRef="usdPerShare">2.25</abus:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice>
	<abus:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice contextRef="FD2015Q4YTD" decimals="2" id="Fact-9872CA9955DCEA34EEFACC458B432294" unitRef="cadPershares">2.88</abus:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice>
	<abus:ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue contextRef="FD2013Q4YTD" decimals="-3" id="Fact-5DFC1E10829C547173ECCC458A8FF6DA" unitRef="usd">5298000</abus:ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue>
	<abus:ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue contextRef="FD2013Q4YTD" decimals="-3" id="Fact-A1A4F1A64B33474AD5A9CC458B073008" unitRef="cad">5635000</abus:ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue>
	<abus:ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1AB5EAD4B9EA58B0E3F2CC458AA36C68" unitRef="usd">5343000</abus:ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue>
	<abus:ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-0084D5E8398644DB8971CC458B1B6262" unitRef="cad">5902000</abus:ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue>
	<abus:ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C8C8CBF263944B19EB70CC458ACB9A61" unitRef="usd">879000</abus:ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue>
	<abus:ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-75D9165C8DD7D8D6CCDBCC458B930BB5" unitRef="cad">1217000</abus:ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue>
	<abus:ClassOfWarrantorRightOutstandExcercisePriceRange contextRef="FD2013Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-E36BA17BDCF4A1D4CDCDEF63645DD14F" unitRef="usdPerShare">3.15</abus:ClassOfWarrantorRightOutstandExcercisePriceRange>
	<abus:ClassOfWarrantorRightOutstandExcercisePriceRange contextRef="FD2013Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-5C8053186CC7CDF149F8EF636454E6AA" unitRef="cadPershares">3.35</abus:ClassOfWarrantorRightOutstandExcercisePriceRange>
	<abus:ClassOfWarrantorRightOutstandExcercisePriceRange contextRef="FD2013Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-C1DCA3A5B9829C0307C4EF63644FA38A" unitRef="usdPerShare">2.44</abus:ClassOfWarrantorRightOutstandExcercisePriceRange>
	<abus:ClassOfWarrantorRightOutstandExcercisePriceRange contextRef="FD2013Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-7DEE2CC1BF3999663E42EF63643C1E80" unitRef="cadPershares">2.60</abus:ClassOfWarrantorRightOutstandExcercisePriceRange>
	<abus:ClassOfWarrantorRightOutstandExcercisePriceRange contextRef="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-84E75A6C38B99A87E616EF636450D119" unitRef="usdPerShare">3.03</abus:ClassOfWarrantorRightOutstandExcercisePriceRange>
	<abus:ClassOfWarrantorRightOutstandExcercisePriceRange contextRef="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-2BA1B2DF982413842909EF63643F8E8A" unitRef="cadPershares">3.35</abus:ClassOfWarrantorRightOutstandExcercisePriceRange>
	<abus:ClassOfWarrantorRightOutstandExcercisePriceRange contextRef="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-DDAD0E1B8C39FD1D438DEF63645EE85C" unitRef="usdPerShare">2.35</abus:ClassOfWarrantorRightOutstandExcercisePriceRange>
	<abus:ClassOfWarrantorRightOutstandExcercisePriceRange contextRef="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-7DAF0F1B43CC8C231E30EF63645D5E2F" unitRef="cadPershares">2.60</abus:ClassOfWarrantorRightOutstandExcercisePriceRange>
	<abus:ClassOfWarrantorRightOutstandExcercisePriceRange contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-5B713CF6533AD88114CCEF6364546CA3" unitRef="cadPershares">3.35</abus:ClassOfWarrantorRightOutstandExcercisePriceRange>
	<abus:ClassOfWarrantorRightOutstandExcercisePriceRange contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-BEDF154554B29B2F46FBEF63645F0E76" unitRef="usdPerShare">2.62</abus:ClassOfWarrantorRightOutstandExcercisePriceRange>
	<abus:ClassOfWarrantorRightOutstandExcercisePriceRange contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-FCF1206C4A2AD817C7ABEF636451CF25" unitRef="usdPerShare">2.03</abus:ClassOfWarrantorRightOutstandExcercisePriceRange>
	<abus:ClassOfWarrantorRightOutstandExcercisePriceRange contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-FE6243414A81E6AE72A7EF636462D2C1" unitRef="cadPershares">2.60</abus:ClassOfWarrantorRightOutstandExcercisePriceRange>
	<abus:ClassOfWarrantsOrRightsExcercisedPriceRange contextRef="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-A1D5BF590C9FDB7A4325EF6364507EF7" unitRef="cadPershares">3.35</abus:ClassOfWarrantsOrRightsExcercisedPriceRange>
	<abus:ClassOfWarrantsOrRightsExcercisedPriceRange contextRef="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-314F5A1EE57D137AF5C5EF63645BC437" unitRef="usdPerShare">3.03</abus:ClassOfWarrantsOrRightsExcercisedPriceRange>
	<abus:ClassOfWarrantsOrRightsExcercisedPriceRange contextRef="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-DEAF2BC18BE6BD0A9AD8EF6364520D7C" unitRef="cadPershares">2.60</abus:ClassOfWarrantsOrRightsExcercisedPriceRange>
	<abus:ClassOfWarrantsOrRightsExcercisedPriceRange contextRef="FD2014Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-F3826D5D4D0A3638E920EF63644FA040" unitRef="usdPerShare">2.35</abus:ClassOfWarrantsOrRightsExcercisedPriceRange>
	<abus:ClassOfWarrantsOrRightsExcercisedPriceRange contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-9966E5BDE43CC1FCCBA4EF63643EDA67" unitRef="usdPerShare">2.62</abus:ClassOfWarrantsOrRightsExcercisedPriceRange>
	<abus:ClassOfWarrantsOrRightsExcercisedPriceRange contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-200E4CBDAFEF57318AC1EF63645E3BED" unitRef="cadPershares">3.35</abus:ClassOfWarrantsOrRightsExcercisedPriceRange>
	<abus:ClassOfWarrantsOrRightsExcercisedPriceRange contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-BD02D1BA8E972AE9140BEF636453BBEC" unitRef="usdPerShare">2.03</abus:ClassOfWarrantsOrRightsExcercisedPriceRange>
	<abus:ClassOfWarrantsOrRightsExcercisedPriceRange contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-9A91291CCEC82D799172EF63643FF635" unitRef="cadPershares">2.60</abus:ClassOfWarrantsOrRightsExcercisedPriceRange>
	<abus:ContractualObligationAmountOfResearchFundingPerYear contextRef="I2014Q4Oct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergMember" decimals="INF" id="Fact-38F6D071187C8A7E2E3F37D04521EBFA" unitRef="usd">1000000</abus:ContractualObligationAmountOfResearchFundingPerYear>
	<abus:CumulativeContributionforProduct contextRef="FD2015Q4YTD" decimals="-3" id="Fact-468B0FE4FD6861160C9F3F8F0C4F74E6" unitRef="cad">3702000</abus:CumulativeContributionforProduct>
	<abus:CumulativeContributionforProduct contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6FD58B99C5CD3E97D22B3500326145ED" unitRef="usd">2675000</abus:CumulativeContributionforProduct>
	<abus:DeferredTaxAssetBookAmortizationInExcessOfTax contextRef="FI2014Q4" decimals="-3" id="Fact-0EF0FAE54334D98D375AEF63644BB80F" unitRef="usd">2745000</abus:DeferredTaxAssetBookAmortizationInExcessOfTax>
	<abus:DeferredTaxAssetBookAmortizationInExcessOfTax contextRef="FI2015Q4" decimals="-3" id="Fact-BEE83C68CD222BC3DBC3EF63649E7FA6" unitRef="usd">2142000</abus:DeferredTaxAssetBookAmortizationInExcessOfTax>
	<abus:DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes contextRef="FI2014Q4" decimals="-3" id="Fact-909022D9CBDA83568591EF636426666E" unitRef="usd">4086000</abus:DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes>
	<abus:DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes contextRef="FI2015Q4" decimals="-3" id="Fact-418695DD7EE47CCEC9A1EF63651FBE7F" unitRef="usd">281000</abus:DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes>
	<abus:DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements contextRef="FI2014Q4" decimals="-3" id="Fact-6BCF33769956AD99BE61EF6363FED07C" unitRef="usd">65000</abus:DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements>
	<abus:DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements contextRef="FI2015Q4" decimals="-3" id="Fact-47C1D9AF086292B13DE2EF6364D214EA" unitRef="usd">77000</abus:DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements>
	<abus:DeferredTaxAssetUpfrontLicenseFees contextRef="FI2014Q4" decimals="-3" id="Fact-F4961C19C99ACF07743C34570E43FAF9" unitRef="usd">0</abus:DeferredTaxAssetUpfrontLicenseFees>
	<abus:DeferredTaxAssetUpfrontLicenseFees contextRef="FI2015Q4" decimals="-3" id="Fact-79ECDAE1D1834148DC2D34570E416F69" unitRef="usd">629000</abus:DeferredTaxAssetUpfrontLicenseFees>
	<abus:ExposureToUSDollar contextRef="FI2014Q4_us-gaap_ConcentrationRiskByTypeAxis_abus_ForeignCurrencyExposureMember" decimals="-3" id="Fact-53DB31339475E70CA23DEF6364E0277D" unitRef="cad">73296000</abus:ExposureToUSDollar>
	<abus:ExposureToUSDollar contextRef="FI2015Q4_us-gaap_ConcentrationRiskByTypeAxis_abus_ForeignCurrencyExposureMember" decimals="-3" id="Fact-9EDDDF42ABAFD439578FEF6364E3576C" unitRef="cad">206607000</abus:ExposureToUSDollar>
	<abus:FairValueOfWarrantsExercisedInThePeriod contextRef="FD2013Q4YTD" decimals="-3" id="Fact-AF7FC6017DF1BDB65E8ACD9A37F22E87" unitRef="usd">1854000</abus:FairValueOfWarrantsExercisedInThePeriod>
	<abus:FairValueOfWarrantsExercisedInThePeriod contextRef="FD2014Q4YTD" decimals="-3" id="Fact-4957922543CD3ED8B751CD9A38039AB6" unitRef="usd">10208000</abus:FairValueOfWarrantsExercisedInThePeriod>
	<abus:FairValueOfWarrantsExercisedInThePeriod contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7F600EEF9EB780CCFA31CD9A3800A9A3" unitRef="usd">334000</abus:FairValueOfWarrantsExercisedInThePeriod>
	<abus:FairValueOfWarrantsExercisedOnACashlessBasis contextRef="FD2013Q4YTD" decimals="-3" id="Fact-3B12FBB9ADF8E0FA2706EF63651D203D" unitRef="usd">1404000</abus:FairValueOfWarrantsExercisedOnACashlessBasis>
	<abus:FairValueOfWarrantsExercisedOnACashlessBasis contextRef="FD2014Q4YTD" decimals="-3" id="Fact-292306D1407A7C227B68EF63649D05D3" unitRef="usd">-116000</abus:FairValueOfWarrantsExercisedOnACashlessBasis>
	<abus:FairValueOfWarrantsExercisedOnACashlessBasis contextRef="FD2015Q4YTD" decimals="-3" id="Fact-125E3DBFDD7B2B8CAC99EF636505C693" unitRef="usd">0</abus:FairValueOfWarrantsExercisedOnACashlessBasis>
	<abus:FairValueOfWarrantsOutstandingPerWarrant contextRef="FI2014Q4" decimals="2" id="Fact-E121DF9F3F2E4606AA9CCC459435602B" unitRef="usdPerShare">12.80</abus:FairValueOfWarrantsOutstandingPerWarrant>
	<abus:FairValueOfWarrantsOutstandingPerWarrant contextRef="FI2015Q4" decimals="2" id="Fact-D96036344491B3FF5352CC45942BCC55" unitRef="usdPerShare">2.33</abus:FairValueOfWarrantsOutstandingPerWarrant>
	<abus:FairValueWarrantsForeignExchangeGainLoss contextRef="FD2013Q4YTD" decimals="-3" id="Fact-ECC32E2F1833C4E2973CCD9A38049105" unitRef="usd">-312000</abus:FairValueWarrantsForeignExchangeGainLoss>
	<abus:FairValueWarrantsForeignExchangeGainLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D7BBD2222403B0CDB522CD9A37F5C779" unitRef="usd">-455000</abus:FairValueWarrantsForeignExchangeGainLoss>
	<abus:FairValueWarrantsForeignExchangeGainLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7C587A6A99C7C9F2FD63CD9A37FB190A" unitRef="usd">-541000</abus:FairValueWarrantsForeignExchangeGainLoss>
	<abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability contextRef="FD2013Q4YTD" decimals="-3" id="Fact-92A2E260EF9C1B4BA27F2F2A2E8FA258" unitRef="usd">0</abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability>
	<abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D44DF48E3C852DDBA26C2F2A2E8BCE0B" unitRef="usd">0</abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability>
	<abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability contextRef="FD2015Q4YTD" decimals="-3" id="Fact-989AAA1B92FD22125E552F2A2E8CCE94" unitRef="usd">770000</abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability>
	<abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability contextRef="FD2015Q4YTD_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember" decimals="-3" id="Fact-4EDD49ECBD73AE80F39F352C5FCACF44" unitRef="usd">770000</abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability>
	<abus:IncreaseDecreaseInValueOfWarrants contextRef="FD2013Q4YTD" decimals="-3" id="Fact-74BAF97B25A37129B273CD9A38023829" unitRef="usd">3530000</abus:IncreaseDecreaseInValueOfWarrants>
	<abus:IncreaseDecreaseInValueOfWarrants contextRef="FD2014Q4YTD" decimals="-3" id="Fact-5DD83FD667F9A3CE9ACCCD9A37FF86BE" unitRef="usd">10383000</abus:IncreaseDecreaseInValueOfWarrants>
	<abus:IncreaseDecreaseInValueOfWarrants contextRef="FD2015Q4YTD" decimals="-3" id="Fact-783DBF53B3CE7E291D04CD9A37F78F9F" unitRef="usd">-3341000</abus:IncreaseDecreaseInValueOfWarrants>
	<abus:IncreaseDecreaseOtherDeferredCostsNet contextRef="FD2013Q4YTD" decimals="-3" id="Fact-372023F21DFD988DF356EF6365181ADD" unitRef="usd">-231000</abus:IncreaseDecreaseOtherDeferredCostsNet>
	<abus:IncreaseDecreaseOtherDeferredCostsNet contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C205AE52362A11392739EF63640BBE3E" unitRef="usd">-167000</abus:IncreaseDecreaseOtherDeferredCostsNet>
	<abus:IncreaseDecreaseOtherDeferredCostsNet contextRef="FD2015Q4YTD" decimals="-3" id="Fact-41DF8F3EAFB8333C46DDEF6364A459A7" unitRef="usd">0</abus:IncreaseDecreaseOtherDeferredCostsNet>
	<abus:LengthOfAgreementWithBristolMyersSquibb contextRef="D2010Q2May10-May10_us-gaap_CounterpartyNameAxis_abus_BMSMember" id="Fact-DB156E3622C86768B403519E60449EDA">P4Y</abus:LengthOfAgreementWithBristolMyersSquibb>
	<abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense contextRef="I2014Q1Feb28_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergandDrexelMember" decimals="INF" id="Fact-F3CD22931937DBB53F0837C2CEF8D023" unitRef="usd">3500000</abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense>
	<abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense contextRef="I2014Q4Dec30_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_CounterpartyNameAxis_abus_CytosMember" decimals="INF" id="Fact-A4AB4D90FA7019458F4B37DF981E6B38" unitRef="usd">67000000</abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense>
	<abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense contextRef="I2014Q4Nov30_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergandDrexelMember" decimals="INF" id="Fact-69C7C9E2161E8A93749E37C814C17C7F" unitRef="usd">1000000</abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense>
	<abus:LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense contextRef="I2014Q1Feb28_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergandDrexelMember" decimals="INF" id="Fact-7EA35720217F5E87C92137C58058B7C9" unitRef="usd">92500000</abus:LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense>
	<abus:LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense contextRef="I2014Q4Dec30_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_CounterpartyNameAxis_abus_CytosMember" decimals="INF" id="Fact-D609882011DCC43E4DBA37E189F8CDAD" unitRef="usd">110000000</abus:LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense>
	<abus:MarketCapitalizationValue contextRef="FI2015Q4" decimals="-3" id="Fact-869D44BFCB6B46012CE139EB07058275" unitRef="usd">242844000</abus:MarketCapitalizationValue>
	<abus:MaximumContributionForProduct contextRef="D2004Q1Nov12-Mar31" decimals="-3" id="Fact-9A2D2A015EDAEDD2081EEF6364A040F0" unitRef="usd">7179000</abus:MaximumContributionForProduct>
	<abus:MaximumContributionForProduct contextRef="D2004Q1Nov12-Mar31" decimals="-3" id="Fact-958C6E383247603E921B3F8E363F05C8" unitRef="cad">9330000</abus:MaximumContributionForProduct>
	<abus:MaximumPotentialTransactionValue contextRef="D2014Q1March13_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" decimals="INF" id="Fact-CC360F3CD6EB3E8CAFE4EF63647C5ACA" unitRef="usd">86200000</abus:MaximumPotentialTransactionValue>
	<abus:MaximumPotentialTransactionValue contextRef="D2015Q2March31_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" decimals="-3" id="Fact-F77448CA53C985CF02D93D2B5D220605" unitRef="usd">2000000</abus:MaximumPotentialTransactionValue>
	<abus:MilestonePayment contextRef="D2012Q4Nov29-Nov29_us-gaap_CounterpartyNameAxis_abus_MarinaBiotechInc.Member" decimals="INF" id="Fact-14911AD7C31574B92987EF636429D40F" unitRef="usd">3250000</abus:MilestonePayment>
	<abus:MilestonePayment contextRef="D2014Q4_us-gaap_CounterpartyNameAxis_abus_DicernaMember" decimals="-3" id="Fact-8A051B28F5F82AB8B09DEF636485C397" unitRef="usd">22000000</abus:MilestonePayment>
	<abus:MilestonePayment contextRef="D2015Q1Jan01-Jan31_us-gaap_CounterpartyNameAxis_abus_ArcturusMember" decimals="INF" id="Fact-A1AB3B22A8581B3C1F9635116A2E566C" unitRef="usd">250000</abus:MilestonePayment>
	<abus:MilestonePayment contextRef="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_MarinaBiotechInc.Member" decimals="-3" id="Fact-9D875A54F3193D6E4D54EF6364A0CF24" unitRef="usd">200000</abus:MilestonePayment>
	<abus:NearTermContractPayments contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" decimals="-3" id="Fact-66D388AC07AD7AA1F5393D237D035E29" unitRef="usd">19300000</abus:NearTermContractPayments>
	<abus:NetLiquidity contextRef="FI2014Q4" decimals="-3" id="Fact-C7D833017396E96E1F403411681A45C5" unitRef="usd">102833000</abus:NetLiquidity>
	<abus:NetLiquidity contextRef="FI2015Q4" decimals="-3" id="Fact-C7D2712835CE88C71DA63411681C2D18" unitRef="usd">172477000</abus:NetLiquidity>
	<abus:NumberOfAdditionalSharesAuthorized contextRef="D2014Q1March26" decimals="INF" id="Fact-B839A6DFA539A8161959EF6364DA69F6" unitRef="shares">318750</abus:NumberOfAdditionalSharesAuthorized>
	<abus:NumberOfChemotherapyProductsWithWorldwideLicenses contextRef="I2006Q2May06" decimals="INF" id="Fact-B25ECF3333505C2817D651A333EEBD42" unitRef="chemotherapy_products">3</abus:NumberOfChemotherapyProductsWithWorldwideLicenses>
	<abus:NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments contextRef="FI2013Q4" decimals="INF" id="Fact-4133382AB08FF5EC840051B41B1F740A" unitRef="executive_officers">2</abus:NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments>
	<abus:NumberofShareBasedCompensationPlans contextRef="FI2015Q4" decimals="INF" id="Fact-62CEB79E85F32A1F25B33E735B36C31A" unitRef="compensation_plan">6</abus:NumberofShareBasedCompensationPlans>
	<abus:Numberofseriesofcompounds contextRef="I2014Q1Feb28_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergandDrexelMember" decimals="INF" id="Fact-48239FB86182FEBE6D8737EE71D93852" unitRef="compound_series">3</abus:Numberofseriesofcompounds>
	<abus:Numberofseriesofcompounds contextRef="I2014Q4Dec30_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_CounterpartyNameAxis_abus_CytosMember" decimals="INF" id="Fact-571FFEB7FD98E09809C337E5213F6E85" unitRef="compound_series">6</abus:Numberofseriesofcompounds>
	<abus:OpeningLiabilityOfWarrantsIssuedInThePeriod contextRef="FD2013Q4YTD" decimals="-3" id="Fact-26EC927E0FA0069BEAF0CD9A37FEE009" unitRef="usd">0</abus:OpeningLiabilityOfWarrantsIssuedInThePeriod>
	<abus:OpeningLiabilityOfWarrantsIssuedInThePeriod contextRef="FD2014Q4YTD" decimals="-3" id="Fact-9290826CBB7BAA9CA53B3839A55116E2" unitRef="usd">0</abus:OpeningLiabilityOfWarrantsIssuedInThePeriod>
	<abus:OpeningLiabilityOfWarrantsIssuedInThePeriod contextRef="FD2015Q4YTD" decimals="-3" id="Fact-AC905389EAB3B1FBF2143839A649291E" unitRef="usd">0</abus:OpeningLiabilityOfWarrantsIssuedInThePeriod>
	<abus:OptionPeriodExtension contextRef="D2015Q2March31_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" id="Fact-210F62D6B07F4657574E3D198DEC65A6">P5M</abus:OptionPeriodExtension>
	<abus:OptionalExcercisedContractualOptionAmount contextRef="FI2014Q4_us-gaap_CounterpartyNameAxis_abus_DoDMember" decimals="-3" id="Fact-31B95F3010BE4A609A80EF6364646384" unitRef="usd">7000000</abus:OptionalExcercisedContractualOptionAmount>
	<abus:OptionalExcercisedContractualOptionAmount contextRef="I2016Q1Mar09_dei_LegalEntityAxis_abus_MonsantoMember_us-gaap_BusinessAcquisitionAxis_abus_PADCo.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-333392058421254EAD9856F4352C6B66" unitRef="usd">1000000</abus:OptionalExcercisedContractualOptionAmount>
	<abus:PatentTaxRefundPercentage contextRef="D2011Q4Nov23-Nov23" decimals="INF" id="Fact-851B0059998A1D9927F0346F60DD8CF3" unitRef="number">0.75</abus:PatentTaxRefundPercentage>
	<abus:PercentOfCostsFundedByTPC contextRef="D2004Q1Nov12-Mar31" decimals="2" id="Fact-F73167875A62C1455EDAEF63649E188A" unitRef="number">0.27</abus:PercentOfCostsFundedByTPC>
	<abus:PerformancePeriodtoRecognizeRevenue contextRef="D2015Q4Dec31-Dec31_us-gaap_CounterpartyNameAxis_abus_DicernaMember" id="Fact-1C5D4D6365358158CBC43D484CB9CD09">P28M</abus:PerformancePeriodtoRecognizeRevenue>
	<abus:PeriodofEstimatedCashFlowsUsedInFairValue contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" id="Fact-2FF6E3C438DA2E5B969839EE6CC1AFC6">P20Y</abus:PeriodofEstimatedCashFlowsUsedInFairValue>
	<abus:PotentialContractFundingAmount contextRef="FI2012Q4_us-gaap_CounterpartyNameAxis_abus_TalonTherapeuticsMember" decimals="INF" id="Fact-5CCDF17751828131C50BEF6364742F40" unitRef="usd">18000000</abus:PotentialContractFundingAmount>
	<abus:PotentialContractFundingAmount contextRef="I2010Q3_us-gaap_CounterpartyNameAxis_abus_DoDMember" decimals="-3" id="Fact-AADEDEC3725335DDE8D9EF63647C450F" unitRef="usd">34700000</abus:PotentialContractFundingAmount>
	<abus:PotentialContractFundingAmount contextRef="I2010Q3_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_ContractExtensionMember" decimals="INF" id="Fact-F2670CD9DCF262EE0BB1EF636480A980" unitRef="usd">140000000</abus:PotentialContractFundingAmount>
	<abus:PotentialContractFundingAmount contextRef="I2013Q2May08_abus_ContractModificationsAxis_abus_IncreaseToSupportDevelopmentPlansMember_us-gaap_CounterpartyNameAxis_abus_DoDMember" decimals="-3" id="Fact-1A4E18EADB12E8F231B7EF636484D12F" unitRef="usd">6970000</abus:PotentialContractFundingAmount>
	<abus:PotentialContractFundingAmount contextRef="I2014Q2April22_abus_ContractModificationsAxis_abus_IncreasedFundingForStageOneMember_us-gaap_CounterpartyNameAxis_abus_DoDMember" decimals="-3" id="Fact-9B53AB9ECE8D9F4AF99FEF63646E668B" unitRef="usd">2100000</abus:PotentialContractFundingAmount>
	<abus:PotentialContractFundingAmount contextRef="I2014Q2April22_abus_ContractModificationsAxis_abus_StageOneMember_us-gaap_CounterpartyNameAxis_abus_DoDMember" decimals="-3" id="Fact-DA360A927DFC671FCD3EEF63647CA822" unitRef="usd">43819000</abus:PotentialContractFundingAmount>
	<abus:PotentialProceedsOfAdditionalSharesAuthorized contextRef="D2014Q1March26" decimals="INF" id="Fact-134E96B63035CC93DF78EF6364C6BE3D" unitRef="usd">9084000</abus:PotentialProceedsOfAdditionalSharesAuthorized>
	<abus:PotentialProceedsOfAdditionalSharesAuthorized contextRef="D2015Q1Mar25-Mar25" decimals="INF" id="Fact-64D15442CEF70FFF776A3DAFA2362E09" unitRef="usd">22781000</abus:PotentialProceedsOfAdditionalSharesAuthorized>
	<abus:ProceedsFromIssuanceOfCommonStockNet contextRef="D2013Q4Nov02" decimals="-3" id="Fact-45D180F3EFC1F3218503EF6364C81A10" unitRef="usd">32038000</abus:ProceedsFromIssuanceOfCommonStockNet>
	<abus:ProceedsFromIssuanceOfCommonStockNet contextRef="D2014Q1March26" decimals="-3" id="Fact-8B20E38C854C61B1DE6AEF6364B04F0A" unitRef="usd">56477000</abus:ProceedsFromIssuanceOfCommonStockNet>
	<abus:ProceedsFromIssuanceOfCommonStockNet contextRef="D2015Q1Mar25-Mar25" decimals="-3" id="Fact-214B963DF584550684883DB0052587BC" unitRef="usd">142177000</abus:ProceedsFromIssuanceOfCommonStockNet>
	<abus:ProgramsInPreClinicalDevelopment contextRef="I2014Q4Oct31_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember" decimals="INF" id="Fact-27F9B825B3775A9F209237F560687038" unitRef="program">2</abus:ProgramsInPreClinicalDevelopment>
	<abus:ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments contextRef="I2014Q4Oct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergMember" decimals="INF" id="Fact-1EEDDC031FFDC79119F637DA5DEF310A" unitRef="usd">92500000</abus:ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments>
	<abus:ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments contextRef="I2014Q4Oct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergMember" decimals="INF" id="Fact-E3A8207905CB430E3C9C37D855B9ADE7" unitRef="usd">8100000</abus:ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments>
	<abus:ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment contextRef="I2014Q4Oct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergMember" decimals="-3" id="Fact-97121475759F31233B1837D64075C2F8" unitRef="usd">100000</abus:ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment>
	<abus:ResearchFundingPeriod contextRef="D2014Q4Oct01toOct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergMember" id="Fact-F9715EB9F476EA730F8737CCBC137DFD">P3Y</abus:ResearchFundingPeriod>
	<abus:ResearchFundingPeriodRenewableOption contextRef="D2014Q4Oct01toOct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergMember" id="Fact-48CE75864D6CC31D58F037F3B13C6216">P3Y</abus:ResearchFundingPeriodRenewableOption>
	<abus:RoyaltiesPaidOrAccrued contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_abus_MarqiboMember" decimals="-3" id="Fact-20895C049382A4E9034A350817952F83" unitRef="usd">12000</abus:RoyaltiesPaidOrAccrued>
	<abus:RoyaltyGuaranteesCommitmentsPercentage contextRef="FD2015Q4YTD" decimals="3" id="Fact-EA4548A0B49BE49423A1EF636515449B" unitRef="number">0.025</abus:RoyaltyGuaranteesCommitmentsPercentage>
	<abus:RoyaltyPayable contextRef="FI2013Q4_us-gaap_ProductOrServiceAxis_abus_MarqiboMember" decimals="-3" id="Fact-CDEBCAD56E0639EB15ED354C0365BA5C" unitRef="usd">1000</abus:RoyaltyPayable>
	<abus:RoyaltyPayable contextRef="FI2014Q4_us-gaap_ProductOrServiceAxis_abus_MarqiboMember" decimals="-3" id="Fact-608CD01E2687E49233533505A308F1CD" unitRef="usd">190000</abus:RoyaltyPayable>
	<abus:RoyaltyPayable contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_abus_MarqiboMember" decimals="-3" id="Fact-577F91D6CE5A0589A4D7350539BC6802" unitRef="usd">6000</abus:RoyaltyPayable>
	<abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue contextRef="FI2014Q4" decimals="2" id="Fact-23DF857FFD264CB536D2CC459B796232" unitRef="cadPershares">9.30</abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue>
	<abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue contextRef="FI2014Q4" decimals="2" id="Fact-8F522F945FD22F2C16E4EF6364EAF2DB" unitRef="usdPerShare">8.42</abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue>
	<abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue contextRef="FI2015Q4" decimals="2" id="Fact-EF846498F00AB6944716CC459A9D42EC" unitRef="usdPerShare">11.34</abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue>
	<abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue contextRef="FI2015Q4" decimals="2" id="Fact-4B4981C67D26E814820BCC459ABBEE2B" unitRef="cadPershares">15.69</abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue>
	<abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="2" id="Fact-875D5DDE68B56BF363293E635278179B" unitRef="usdPerShare">16.42</abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue>
	<abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue contextRef="I2015Q1March04_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="2" id="Fact-3BB8C8E62EDB2793BD523E6346C5C6FF" unitRef="usdPerShare">16.42</abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue>
	<abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue contextRef="D2015Q4Mar05-Dec31_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="2" id="Fact-31343C1457E72FBCA1813E63A01C2194" unitRef="usdPerShare">16.42</abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue>
	<abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue contextRef="FD2015Q4YTD" decimals="2" id="Fact-FAC7B8514746EA26E0C9CC459AB160BD" unitRef="cadPershares">8.77</abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue>
	<abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue contextRef="FD2015Q4YTD" decimals="2" id="Fact-587EF783D1DA28090E64CC459AC5D1E6" unitRef="usdPerShare">6.86</abus:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue>
	<abus:StockRepurchaseRightsExpirationRateShares contextRef="D2015Q3Nov30-Nov30_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="0" id="Fact-E3DA76365B62066A034B39323F18F732" unitRef="shares">302120</abus:StockRepurchaseRightsExpirationRateShares>
	<abus:StockRepurchaseRightsExpirationRateShares contextRef="D2016Q1Feb29-Feb29_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="0" id="Fact-4DBEB21E713613438A9239436BA48788" unitRef="shares">302120</abus:StockRepurchaseRightsExpirationRateShares>
	<abus:StockRepurchaseRightsExpirationRateShares contextRef="D2016Q2May31-May31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember" decimals="0" id="Fact-36B5DCB8F61D8D7C8E27394560225298" unitRef="shares">503552</abus:StockRepurchaseRightsExpirationRateShares>
	<abus:UpfrontFee contextRef="D2012Q4Nov29-Nov29_us-gaap_CounterpartyNameAxis_abus_MarinaBiotechInc.Member" decimals="-3" id="Fact-4FF015B740B59B1B436CEF6365139FE7" unitRef="usd">300000</abus:UpfrontFee>
	<abus:WarrantsExercised contextRef="FD2014Q4YTD" decimals="INF" id="Fact-3029725486530BDE7AC3EF6364E21770" unitRef="shares">610478</abus:WarrantsExercised>
	<abus:WarrantsExercised contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_abus_CashlessExerciseProvisionMember" decimals="INF" id="Fact-EBBBA3F8898FF122F696EF6364E30A1A" unitRef="shares">6000</abus:WarrantsExercised>
	<abus:WarrantsExercised contextRef="FD2015Q4YTD" decimals="INF" id="Fact-87669491AED4E10B5B63EF6364F35386" unitRef="shares">18750</abus:WarrantsExercised>
	<abus:WarrantsExercised contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_abus_CashlessExerciseProvisionMember" decimals="INF" id="Fact-FDC3E694F2DA574E11573DBE03F0E9F8" unitRef="shares">0</abus:WarrantsExercised>
	<abus:WhollyOwnedSubsidiariesIncludedinFinancialStatements contextRef="FI2015Q4" decimals="INF" id="Fact-AFB4C20BE309BF32A8C73F68DECEB136" unitRef="subsidiary">4</abus:WhollyOwnedSubsidiariesIncludedinFinancialStatements>
	<dei:AmendmentFlag contextRef="FD2015Q4YTD" id="Fact-2349AC774902EC0FFBE4EF6364075657">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2015Q4YTD" id="Fact-BA461E5FBCDCDDA95DFAEF63641E8738">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2015Q4YTD" id="Fact-C37D54F156D075C2C3C2EF63641D0D08">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2015Q4YTD" id="Fact-430D1D2F6D4FC73A29F4EF63641F2328">2015</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2015Q4YTD" id="Fact-8CAE18259AE9862F367DEF636410C3DE">2015-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2015Q4YTD" id="Fact-FBBCB4B74A638DE22E962F03C790F2D7">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2015Q4YTD" id="Fact-80A9AE178E5510475574EF6364047E69">0001447028</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2016Q1Feb29" decimals="INF" id="Fact-766F150601DDE2EA0D0942D269AC3664" unitRef="shares">54625703</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2015Q4YTD" id="Fact-BBDFA4F74790EC0CBCEBEF636416860A">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2015Q4YTD" id="Fact-C1297AEDEADF4016FC102F0406EEEB78">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2015Q2" decimals="0" id="Fact-7D1E9347B41013AE52F4EF636403F5D6" unitRef="usd">644038348</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2015Q4YTD" id="Fact-0EF2B1CDD112D55ADD4DEF6364D9DA12">Arbutus Biopharma Corp</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2015Q4YTD" id="Fact-F56C1D06432941CF9B59EF63640A7A6C">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2015Q4YTD" id="Fact-2BBBB22143BE3842A054EF6364183B6C">No</dei:EntityWellKnownSeasonedIssuer>
	<invest:InvestmentOptionsExercisePrice contextRef="D2008Q2May30-May30_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember" decimals="2" id="Fact-6381A21688B29B34731FEF6364B0FA82" unitRef="cadPershares">0.30</invest:InvestmentOptionsExercisePrice>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-592327F09FB5F327DDF6EF6364A01E19" unitRef="usd">9328000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-C90C14ED4D4A42B65585EF6364A6D7A4" unitRef="usd">8827000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-0F16498ABA1E2E3FB44D3411682164FE" unitRef="usd">9328000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="FI2014Q4_us-gaap_ConcentrationRiskByTypeAxis_abus_ForeignCurrencyExposureMember" decimals="-3" id="Fact-20B2908C261712BF84883411674B3A60" unitRef="cad">4494000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-CB0B8144B0F10D4788C7341168181176" unitRef="usd">8827000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="FI2015Q4_us-gaap_ConcentrationRiskByTypeAxis_abus_ForeignCurrencyExposureMember" decimals="-3" id="Fact-8982366657F1DA7D79693411674E50E5" unitRef="cad">8061000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
	<us-gaap:AccountsPayableTradeCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-FC9A346B97A8A10B3D3933F8008190D4" unitRef="usd">2044000</us-gaap:AccountsPayableTradeCurrent>
	<us-gaap:AccountsPayableTradeCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-56F4FF6ED07B8635259A33F8007FCDE4" unitRef="usd">2610000</us-gaap:AccountsPayableTradeCurrent>
	<us-gaap:AccountsReceivableNet contextRef="FI2014Q4" decimals="-3" id="Fact-AA686F5A5212592D0EF7EF6364390B18" unitRef="usd">1903000</us-gaap:AccountsReceivableNet>
	<us-gaap:AccountsReceivableNet contextRef="FI2014Q4_us-gaap_ConcentrationRiskByTypeAxis_abus_ForeignCurrencyExposureMember" decimals="-3" id="Fact-3F9051A79B68109B28AB341167538BD8" unitRef="cad">1942000</us-gaap:AccountsReceivableNet>
	<us-gaap:AccountsReceivableNet contextRef="FI2015Q4" decimals="-3" id="Fact-D62AABC1DA845091F73E340E3CA56CCF" unitRef="usd">1008000</us-gaap:AccountsReceivableNet>
	<us-gaap:AccountsReceivableNet contextRef="FI2015Q4_us-gaap_ConcentrationRiskByTypeAxis_abus_ForeignCurrencyExposureMember" decimals="-3" id="Fact-8135ED0C477A207EB22E3411674D4235" unitRef="cad">1071000</us-gaap:AccountsReceivableNet>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-3BAD724B64DE94CE70FBEF6364AE13F2" unitRef="usd">1903000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-C5AF84110BA7BF80B817EF6364A39F36" unitRef="usd">1008000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-F5A896E811C2F99B9DF833FD0AFEEA7E" unitRef="usd">1294000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-369234ABB665956A823D33FCBAC6CD2B" unitRef="usd">640000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="FI2015Q4_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_MarqiboMember" decimals="-3" id="Fact-22A14CE1114FCA13D12B3D4E1557B1F1" unitRef="usd">6000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2014Q4" decimals="-3" id="Fact-11FA2FE4B8D02659A36DEF63648340DF" unitRef="usd">11199000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abus_LaboratoryEquipmentMember" decimals="-3" id="Fact-9C30498580AAD3B5234DEF6364B64314" unitRef="usd">4451000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-D3EDFFD816BFA5D67713EF6364B1971A" unitRef="usd">1588000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-66F938C8E18A0D8F2658EF6364B2FFD8" unitRef="usd">364000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-5D9178E98EC8626BF94EEF6364C30601" unitRef="usd">4796000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2015Q4" decimals="-3" id="Fact-29FB65ACF708E2ACF0A0EF63645DA90A" unitRef="usd">9729000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abus_LaboratoryEquipmentMember" decimals="-3" id="Fact-7F3B7BD747DA58A79630EF636408D8A5" unitRef="usd">3748000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-6631B3035D9E070ED2B4EF63640A48D7" unitRef="usd">1487000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-9DD61966980EC9682B02EF63640F3A7D" unitRef="usd">305000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-637E1EFF924114962EE0EF63640A3DB9" unitRef="usd">4189000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2014Q4" decimals="-3" id="Fact-8C674D657C2287591BA4EF6364813601" unitRef="usd">-22313000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4" decimals="-3" id="Fact-40657CCDDDFC74B37FA0EF6364B2F6CB" unitRef="usd">-49782000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2014Q4" decimals="-3" id="Fact-425A4CF744C4F41EF9A4EF63649736AA" unitRef="usd">26208000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2015Q4" decimals="-3" id="Fact-3F136658CABE7E703AB3EF6364C2ABA2" unitRef="usd">30206000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2013Q4YTD" decimals="-3" id="Fact-08A2402D286CF0AF96F9EF63648E4981" unitRef="usd">903000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-743F109ED0EEE54B40ECEF6364826C7E" unitRef="usd">903000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-78BEF6CE01640ADBCDD4EF6364852380" unitRef="usd">3283000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-18DD351CABCA3822D1D6EF63649E99A7" unitRef="usd">3283000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E50F778141E8A7916DE633387FEF3A81" unitRef="usd">22093000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5598AD5DF323FC6683C433387BD7949A" unitRef="usd">5406000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-CA0347E484A829DE73DC333A61260B64" unitRef="usd">16687000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="FD2013Q4YTD" decimals="-3" id="Fact-26658B498A78D366F8CCEF6364E4FA40" unitRef="usd">2462000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="FD2014Q4YTD" decimals="-3" id="Fact-618F3CA0F3C64AFC4B1FEF6364B00752" unitRef="usd">4085000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="FD2015Q4YTD" decimals="-3" id="Fact-278F2B676ED008CD0773EF63645B2BCD" unitRef="usd">9700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2015Q4Mar04-Dec31_us-gaap_AwardTypeAxis_abus_AbutusStockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-36AD5C01D42FA35F5A9E3950F9B8EBA2" unitRef="usd">463000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2015Q4Mar04-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-73CD899759BA42E012473925D7F393EA" unitRef="usd">16687000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2015Q4Mar04-Dec31_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="-3" id="Fact-E837629383EE06A720043F001E655165" unitRef="usd">463000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2013Q4YTD" decimals="0" id="Fact-CCCF677B9BD5EFDF346A3864CA725D94" unitRef="shares">3064767</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2014Q4YTD" decimals="0" id="Fact-FE57A5B269ECDA36FEDE3864B53CDB51" unitRef="shares">2221233</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD" decimals="0" id="Fact-75CFDEE145A68FA3F0D3386122F14C9D" unitRef="shares">2899331</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AssetImpairmentCharges contextRef="FD2015Q4YTD" decimals="INF" id="Fact-7CF6C4C14221DD8ABA79EF6364F290C1" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:Assets contextRef="FI2014Q4" decimals="-3" id="Fact-DD81AAD9FE5413F247712ECB67B0560E" unitRef="usd">118178000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2015Q4" decimals="-3" id="Fact-3890C9D43CD10AEBD2402ECB67AE5524" unitRef="usd">712291000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-82FD83434B4FD8A64CFBEF636497D72C" unitRef="usd">116418000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-7F280218F4828827DB10EF6364A60A29" unitRef="usd">183882000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4" decimals="-3" id="Fact-2A19F2E549B018E8A980EF6364902482" unitRef="usd">112161000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-9FE2743F1341C63F6DD4CD9A2FFDE623" unitRef="usd">112161000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4" decimals="-3" id="Fact-845A7CA70C769B2D631DEF6364B782E9" unitRef="usd">191374000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-0F7DB8D998249BBC7B53CD9A10CB5426" unitRef="usd">191374000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="FI2015Q4_us-gaap_AwardTypeAxis_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-A458981A668A5291AC26396968301D15" unitRef="usd">1127000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
	<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="FI2015Q4_us-gaap_AwardTypeAxis_abus_SharesIssuedSubjectToRepurchaseProvisionMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-2F8B4105A3CD4EED058E3969665AF926" unitRef="usd">9262000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
	<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="FI2015Q4_us-gaap_AwardTypeAxis_abus_SharesIssuedWithoutSubjectsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-B2190A1FAACFFA7F8CC039670818C8DB" unitRef="usd">371553000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
	<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="I2015Q1March04_us-gaap_AwardTypeAxis_abus_AbutusStockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-E4F7A57E7D4797C3CDE0394B2C6EB507" unitRef="usd">3287000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
	<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="I2015Q1March04_us-gaap_AwardTypeAxis_abus_SharesIssuedSubjectToRepurchaseProvisionMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-1610529266618D18F2A83891A4583E7F" unitRef="usd">66196000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
	<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-2349DD9FEC5E225808263952D933A925" unitRef="usd">381942000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
	<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned contextRef="I2015Q1March04_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="-3" id="Fact-D2862145DD27E0123D843EF6AD935706" unitRef="usd">3287000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
	<us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="D2015Q1Mar04-Mar04_us-gaap_AwardTypeAxis_abus_SharesIssuedSubjectToRepurchaseProvisionMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="INF" id="Fact-95554424AC5A7439557C392D66DD884F" unitRef="shares">3625412</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
	<us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="I2015Q1Jan11_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="INF" id="Fact-16A2AF2515941CA91AF838840687795D" unitRef="number">1.00</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
	<us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="I2016Q1Mar09_dei_LegalEntityAxis_abus_MonsantoMember_us-gaap_BusinessAcquisitionAxis_abus_PADCo.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-1A97A3D0606E1C34AD7356E58ADBFC9F" unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
	<us-gaap:BusinessAcquisitionSharePrice contextRef="I2015Q1March03_us-gaap_AwardTypeAxis_abus_SharesIssuedWithoutSubjectsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="INF" id="Fact-94081718C6D0197475F3388F527C3FAA" unitRef="usdPerShare">18.26</us-gaap:BusinessAcquisitionSharePrice>
	<us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1EFE0CF1E7D3A29135CF39D8699E30BE" unitRef="usd">-51088000</us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax>
	<us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-DE5EA069CC7775178C8639D70A1A84B1" unitRef="usd">-109387000</us-gaap:BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax>
	<us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="D2015Q4Mar04-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-46399E13DFFEC5DA4FAB39F320B657E0" unitRef="usd">13658000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
	<us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-2DABDA77C01FB75607C739D86A9A61F4" unitRef="usd">-56491000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
	<us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-35219AFD5329DA320B9639D744176F6B" unitRef="usd">-67416000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
	<us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1321933E0EF8B38C4A0C39D8689C10CE" unitRef="usd">14953000</us-gaap:BusinessAcquisitionsProFormaRevenue>
	<us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B64D1E9689D91F8CD58E39D6A42869B6" unitRef="usd">24873000</us-gaap:BusinessAcquisitionsProFormaRevenue>
	<us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="FD2013Q4YTD" decimals="-3" id="Fact-18E122471643BB7690552F125BC1CA8F" unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
	<us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="FD2014Q4YTD" decimals="-3" id="Fact-7931C11B92E24A6975412F1259C3F967" unitRef="usd">462000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
	<us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="FD2014Q4YTD_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-B06CCDBD0DFF414FA250387E7E81BB48" unitRef="usd">462000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
	<us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="FD2015Q4YTD" decimals="-3" id="Fact-FEF97367D783AFFEDF79EF6364097BFE" unitRef="usd">9656000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
	<us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="FD2015Q4YTD_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-89814037678B6D7FC163387E6CB78DD1" unitRef="usd">9656000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
	<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-78451E5F25D06C563C9239947883F849" unitRef="usd">381942000</us-gaap:BusinessCombinationConsiderationTransferred1>
	<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="D2015Q4Dec31-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-E9B80136880C99557F7339949839B25A" unitRef="usd">381942000</us-gaap:BusinessCombinationConsiderationTransferred1>
	<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="D2015Q4Mar04-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-2E94F0C28028F44E940D3966ADA3770E" unitRef="usd">381942000</us-gaap:BusinessCombinationConsiderationTransferred1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="D2015Q4Mar05-Dec31" decimals="-3" id="Fact-6F76E7241EDFFAD96F9D387016CB07A1" unitRef="usd">770000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2013Q4YTD" decimals="-3" id="Fact-165300951EBE475BF2A932CE4C80EFD5" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2014Q4YTD" decimals="-3" id="Fact-DF79933EF81176CCB3D832CE4C823EE6" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2015Q4YTD" decimals="-3" id="Fact-034A146B1A7807F21F0932CE4C7E9C0E" unitRef="usd">770000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="I2014Q4Oct31_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember" decimals="INF" id="Fact-3DD07ACC23CECBF9DFE2351509CEFB1B" unitRef="usd">21000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember" decimals="-3" id="Fact-48FAEE5A649ABB345AE5352B7BE02D33" unitRef="usd">7497000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="I2015Q1Jan11_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember" decimals="-3" id="Fact-A4990ADE917574B7AE5535165C77BF22" unitRef="usd">6727000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-DE1AD7C5E94F7D7697DF2ECE7EAC4AA0" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-EEC361FB8000228035A72ECE7EAF0A7F" unitRef="usd">7497000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-3B45D0DBACF7D81CBFA03A4D66239591" unitRef="usd">7497000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="I2015Q1March04" decimals="-3" id="Fact-80AB2645D50E058D73E4386F88C4262B" unitRef="usd">6727000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred contextRef="D2015Q4Mar05-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-E2D7D39A95E67297320D39AB9B4C7EA2" unitRef="usd">0</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred>
	<us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles contextRef="D2015Q4Mar05-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-08B993BD8C035B315EA7398C9ACF2A88" unitRef="usd">1997000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
	<us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles contextRef="D2015Q4Oct28-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDCyclophilinsMember" decimals="-3" id="Fact-7BC3EFE0D8C42D033C543A00CD1C940B" unitRef="usd">1017000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
	<us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment contextRef="D2015Q4Mar05-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-4D2908674DF5575C6A4F39A878CA2049" unitRef="usd">0</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-F0191646AE00B2B649BC398C5E62737A" unitRef="usd">324000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-1B2A108E5CFC2E805B16398B4B044857" unitRef="usd">324000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-8FD6B0809578C1722375398CBBEAE65B" unitRef="usd">116000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-AC91D640C9513787F69C398B4E33A433" unitRef="usd">127000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-C42931A836BE37844096398CBDB137B5" unitRef="usd">8000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-DDC269BE8527D0E10A13398B51583E43" unitRef="usd">8000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-A0D5D69975AA890DB4C1398CCBE39A3F" unitRef="usd">162509000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-811E9977724BF62B1E68398B6145CFF8" unitRef="usd">155865000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="FI2015Q3_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDCyclophilinsMember" decimals="-3" id="Fact-2E2DBEDBB3D3D5FDD14139FEDCC320E9" unitRef="usd">37990000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDCyclophilinsMember" decimals="-3" id="Fact-2EFFCA10E4E13715F23A39FF5A02F25B" unitRef="usd">39007000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-5AE8A86A5D0D738EE00A3974ABAC06A4" unitRef="usd">391649000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDAntigenInhibitorsMember" decimals="-3" id="Fact-6F494433F813B53CE35B3974ABBAB086" unitRef="usd">36437000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDCyclophilinsMember" decimals="-3" id="Fact-5D949E1C135763A4E3433974ABB28E17" unitRef="usd">39007000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDImmuneModulatorsMember" decimals="-3" id="Fact-A2D3EEE86B507601EB7C3974ABC09D12" unitRef="usd">183103000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDcccDNASterilizersMember" decimals="-3" id="Fact-BDAEB5ACA816C792CCA93974ABB654FC" unitRef="usd">133102000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-DD94CD07EDCECC112D06398CC2A3BE1B" unitRef="usd">391649000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-6F1A2B9695D71594849F398B5748A57A" unitRef="usd">389652000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-3F68E86D8E4419ACBD4A398CC8D7203E" unitRef="usd">6727000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-D2CED4546D3FEDCEFE97398B5EB3FB86" unitRef="usd">4736000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-E0D6E21B1BEAA556B820398CC033D879" unitRef="usd">147000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-4A5D9A6237380E3AF812398B53AC2CE5" unitRef="usd">147000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-9634D55877951F066981398CCDEDFE5B" unitRef="usd">381942000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-FDB6DB877630210C088D398B628BA891" unitRef="usd">381942000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
	<us-gaap:CashAcquiredFromAcquisition contextRef="FD2013Q4YTD" decimals="-3" id="Fact-FDB66414E01F66B52839EF6364A847D6" unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
	<us-gaap:CashAcquiredFromAcquisition contextRef="FD2014Q4YTD" decimals="-3" id="Fact-5B16074C401C5CA99A0432DB1668B8E9" unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
	<us-gaap:CashAcquiredFromAcquisition contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CC13787D8976A9A9C0A9EF6364A4C890" unitRef="usd">324000</us-gaap:CashAcquiredFromAcquisition>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2012Q4" decimals="-3" id="Fact-9E4E03CF0A674621096FEF6365263F5C" unitRef="usd">47024000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2013Q4" decimals="-3" id="Fact-BAD9EB7357B11530682EEF63651E8BFB" unitRef="usd">68717000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-6940E2102AFE6CE47F96EF636495B5E5" unitRef="usd">72187000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-0EDA38CF5253BB59AA03EF636480038F" unitRef="usd">166779000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4" decimals="-3" id="Fact-953D06F7F9299FF49B14383550CDD837" unitRef="usd">72187000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-4D585246727E5123B67638354ADD427D" unitRef="usd">72187000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4" decimals="-3" id="Fact-BDAE8C32AF1B83EF031FEF6364B47C1E" unitRef="usd">166779000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-E05ED210F8337B338EE8CD9A10CAF5B8" unitRef="usd">166779000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2013Q4YTD" decimals="-3" id="Fact-B85F912072013A2ADF44EF63652811A6" unitRef="usd">21693000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F59CEB57589C4ED12A4EEF636400732A" unitRef="usd">3470000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q4YTD" decimals="-3" id="Fact-562E9209362F0614E9CBEF6364E501F6" unitRef="usd">94592000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="FI2014Q4" decimals="-3" id="Fact-D920F52071015AC658643411681F1F9C" unitRef="usd">112161000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
	<us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="FI2014Q4_us-gaap_ConcentrationRiskByTypeAxis_abus_ForeignCurrencyExposureMember" decimals="-3" id="Fact-E3810021DD770705CAC834116756BF57" unitRef="cad">75224000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
	<us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="FI2015Q4" decimals="-3" id="Fact-5F8ACA5EA2D290F3DBF53411681D6131" unitRef="usd">181304000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
	<us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="FI2015Q4_us-gaap_ConcentrationRiskByTypeAxis_abus_ForeignCurrencyExposureMember" decimals="-3" id="Fact-58DB4E8E986019AAF19E341167510357" unitRef="cad">213419000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2013Q4" decimals="2" id="Fact-305925D67B4CA34332CBCC458A71AA0F" unitRef="cadPershares">2.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2013Q4" decimals="2" id="Fact-ACA1E5101B0651D88C8BCC458B573C39" unitRef="usdPerShare">2.72</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2014Q4" decimals="2" id="Fact-13FF55BB8F71861FF87BCC458AAD07A9" unitRef="usdPerShare">2.67</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2014Q4" decimals="2" id="Fact-F01523728F1E44F35B6ACC458AD541AD" unitRef="cadPershares">2.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2015Q4" decimals="2" id="Fact-F015177270F9FD5FC563CC458A7B85FE" unitRef="usdPerShare">2.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2015Q4" decimals="2" id="Fact-27F4A1616EF011B30EABCC458B7FB578" unitRef="cadPershares">2.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2013Q4" decimals="INF" id="Fact-3536573DFCF80207C5EACC458B392F0B" unitRef="shares">1014728</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2014Q4" decimals="INF" id="Fact-F5D1B3E9A6FC20F74734CC458AF30CA3" unitRef="shares">398250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2015Q4" decimals="INF" id="Fact-D7EF49BE98EDB5021941CC458AC1B9C1" unitRef="shares">379500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2014Q4" decimals="INF" id="Fact-A2F77377A14D92292E74CC45940DA41C" unitRef="shares">398250</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2015Q4" decimals="INF" id="Fact-5AD06019E0FB075497BACC4594354C7A" unitRef="shares">379500</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2015Q4_us-gaap_AwardTypeAxis_abus_AbutusStockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="0" id="Fact-880BE561F9C68CC2FB9E394922C24500" unitRef="shares">184332</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2008Q2_us-gaap_AwardTypeAxis_abus_RevisedNewCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember" decimals="INF" id="Fact-597BE7C871353739DBC3EF6364AF5106" unitRef="shares">519073</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2008Q2_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember" decimals="INF" id="Fact-B7FC73462BDAAC6BA042EF6364E27F62" unitRef="shares">350457</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockNoParValue contextRef="FI2014Q4" decimals="INF" id="Fact-9BD858AD66E2F339A322EF63640ECFFA" unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
	<us-gaap:CommonStockNoParValue contextRef="FI2015Q4" decimals="INF" id="Fact-996AC8622E1AECB97D2CEF63640204D5" unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
	<us-gaap:CommonStockSharesIssued contextRef="FI2014Q4" decimals="INF" id="Fact-5C2EF104BBF417211C722ED46A33911F" unitRef="shares">22438169</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2015Q4" decimals="INF" id="Fact-FA1131C3EB1FA59069FB2ED4686EC847" unitRef="shares">54570691</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4" decimals="INF" id="Fact-9C0B506024A07EAEED512ED46CDB3CEA" unitRef="shares">22438169</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4" decimals="INF" id="Fact-F6C2E2DEB860D01B55A82ED46B5E6E3C" unitRef="shares">54570691</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2014Q4" decimals="-3" id="Fact-A832E652E0B9BDD07D2AEF6364A61EA0" unitRef="usd">290004000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2015Q4" decimals="-3" id="Fact-5D7F680BC7BEA4130FF5EF6364848B3D" unitRef="usd">834240000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2013Q4YTD" decimals="-3" id="Fact-7DD9B7CBB9A746D9B533EF6364035A96" unitRef="usd">-17198000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1A85A6F9A40BC1B425E3EF63648FD3A7" unitRef="usd">-45326000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0DA55EEE7EC738006234EF6363F7B2B4" unitRef="usd">-88590000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ContractsRevenue contextRef="D2015Q1Jan01-Jan31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_ISARICMember" decimals="-3" id="Fact-FF7408DA9651FE52E285EF63640125D5" unitRef="usd">1098000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2012Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_MarqiboCommercialSalesMember" decimals="-3" id="Fact-F281EA3223C3FD60431FEF6364720170" unitRef="usd">1000000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2013Q4YTD" decimals="-3" id="Fact-1747FB1E9831C51B07ABEF63647F0A13" unitRef="usd">10425000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_BMSMember" decimals="-3" id="Fact-AE913F28543ED916CD973A5BF8204EAC" unitRef="usd">526000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_DicernaMember" decimals="-3" id="Fact-F65AFDE7726D52F5B2E33A5BF7866D58" unitRef="usd">0</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_DoDMember" decimals="-3" id="Fact-3E78CDD90D1A1C1324843A5BF7D83E3C" unitRef="usd">9806000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" decimals="-3" id="Fact-3193287163708CB73A5F3A5BF7952A1C" unitRef="usd">0</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_OtherRNAiCollaboratorsMember" decimals="-3" id="Fact-0E408CF7C55C70DD3CC93A5BF7E08C0A" unitRef="usd">93000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-746257E587C3C560627EEF63652A1C95" unitRef="usd">11738000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_BMSMember" decimals="-3" id="Fact-841B51C47C820C5B8E3E3A5BF7EEF068" unitRef="usd">1741000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_DicernaMember" decimals="-3" id="Fact-071C90966201334445523A5BF75B5DB7" unitRef="usd">510000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_DoDMember" decimals="-3" id="Fact-667491D41B608563AD4F3A5BF7A81560" unitRef="usd">8407000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" decimals="-3" id="Fact-1684E319590CCEB9C81A3A5BF82E05F3" unitRef="usd">1080000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_OtherRNAiCollaboratorsMember" decimals="-3" id="Fact-63D6A6D6ED4DBB7AF0313A5BF78EB0C3" unitRef="usd">0</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8E513F5746036D3D59CBEF6364006029" unitRef="usd">13309000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_BMSMember" decimals="-3" id="Fact-F87B55631884522552E83A5BF7707A51" unitRef="usd">0</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_DicernaMember" decimals="-3" id="Fact-A42D702CB748C3B2DD253A5BF77821B1" unitRef="usd">1820000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_DoDMember" decimals="-3" id="Fact-929D3C392DD12A087DC73A5BF8368380" unitRef="usd">6764000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" decimals="-3" id="Fact-E7214121144CF7CB0BEC3A5BF811D8EA" unitRef="usd">4725000</us-gaap:ContractsRevenue>
	<us-gaap:ContractsRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_OtherRNAiCollaboratorsMember" decimals="-3" id="Fact-F5B719F6F240D58143803A5BF7A1CCA0" unitRef="usd">0</us-gaap:ContractsRevenue>
	<us-gaap:ContractualObligation contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_abus_MarqiboMember" decimals="-3" id="Fact-0236AC48E8009083BD363508A582C6B6" unitRef="cad">3687000</us-gaap:ContractualObligation>
	<us-gaap:ContractualObligation contextRef="FI2015Q4_us-gaap_ProductOrServiceAxis_abus_MarqiboMember" decimals="-3" id="Fact-9A6C1F76B5B12095661A350841DBBFEB" unitRef="usd">2664000</us-gaap:ContractualObligation>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2008Q2May30-May30_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember" decimals="4" id="Fact-E125F48E059B49570C94EF6364F965B2" unitRef="shares">0.6752</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2013Q4YTD" decimals="-3" id="Fact-807A1588D56D590D97CC2F57BB890E20" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-26218D323B91A5358DEF2F57B9E925C1" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-775464122D73DEDFB298EF6364D7E97F" unitRef="usd">-16185000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2015Q4" decimals="-3" id="Fact-84F0E6ADB4D15D08A7A7EF6364EA3EFD" unitRef="usd">104830000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredRevenue contextRef="FI2014Q4" decimals="-3" id="Fact-75A2F182BA33D6B25D293A5BE8609E88" unitRef="usd">15716000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2015Q4" decimals="-3" id="Fact-ADFA4D1581D9A5CC5F5E3A5BE844A846" unitRef="usd">1081000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="I2010Q2_us-gaap_CounterpartyNameAxis_abus_BMSMember" decimals="-3" id="Fact-F99448C5766D5B94D165EF63647D412C" unitRef="usd">3000000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="I2014Q4Nov16_us-gaap_CounterpartyNameAxis_abus_DicernaMember" decimals="-3" id="Fact-04CA12CEE0FF948054ACEF6364762C51" unitRef="usd">2500000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-2784A4B6BB067B8F75A5EF63646299EC" unitRef="usd">5779000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2014Q4_us-gaap_CounterpartyNameAxis_abus_DicernaMember" decimals="-3" id="Fact-9D606F73764AA3FDCCBD3A5BE874D8B7" unitRef="usd">1221000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2014Q4_us-gaap_CounterpartyNameAxis_abus_DoDMember" decimals="-3" id="Fact-31A2FEA4F941AFE2A7CD3A5BE87BCD84" unitRef="usd">313000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2014Q4_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" decimals="-3" id="Fact-B34D9563DB8F33AE82003A5BE8829951" unitRef="usd">4245000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-317CF61FB0EA29CEF29AEF6364931AFC" unitRef="usd">868000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_abus_DicernaMember" decimals="-3" id="Fact-9F3055D6432CA10DBC3D3A5BE867A562" unitRef="usd">853000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_abus_DoDMember" decimals="-3" id="Fact-DA971C5DB6EEBE0A47973A5BE84B17B7" unitRef="usd">15000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" decimals="-3" id="Fact-6CA0DEB66FFED82B737E3A5BE82EB185" unitRef="usd">0</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-5D3A9E816FC5E550C2FA2ECD3BCFDCB7" unitRef="usd">9937000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2014Q4_us-gaap_CounterpartyNameAxis_abus_DicernaMember" decimals="-3" id="Fact-C6E55EAAF6BDD5A11ED53A5BE83D76FB" unitRef="usd">1271000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2014Q4_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" decimals="-3" id="Fact-5126D2878FBC84B95C273A5BE852C1C2" unitRef="usd">8666000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-C39316E158461AEF8898EF6364A245F8" unitRef="usd">213000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_abus_DicernaMember" decimals="-3" id="Fact-FC9756B6F615AB7173D73A5BE835F494" unitRef="usd">213000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2015Q4_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" decimals="-3" id="Fact-28B4B0C20276C43B78CB3A5BE80F3FCB" unitRef="usd">0</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2014Q4" decimals="-3" id="Fact-9391957CF375BA9BBD03EF6365083165" unitRef="usd">37818000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2014Q4_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-3" id="Fact-E942653DF5D103E293C93479BF5E3BD4" unitRef="usd">8424000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="FI2014Q4" decimals="-3" id="Fact-CDCBF5E5E16746946334EF63650AA2BD" unitRef="usd">14006000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
	<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="FI2015Q4" decimals="-3" id="Fact-54DA4EB4F831AB6A730EEF63641E8DEE" unitRef="usd">13474000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
	<us-gaap:DeferredTaxAssetsInvestments contextRef="FI2014Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-3" id="Fact-9862CCD4D9659E0E99B5EF63641FE327" unitRef="usd">5821000</us-gaap:DeferredTaxAssetsInvestments>
	<us-gaap:DeferredTaxAssetsInvestments contextRef="FI2014Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-3" id="Fact-DF099F2A82DFCECCECAAEF63652A4AA1" unitRef="usd">3322000</us-gaap:DeferredTaxAssetsInvestments>
	<us-gaap:DeferredTaxAssetsInvestments contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-3" id="Fact-5C250AE634A96200AC15EF636442D9ED" unitRef="usd">6303000</us-gaap:DeferredTaxAssetsInvestments>
	<us-gaap:DeferredTaxAssetsInvestments contextRef="FI2015Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-3" id="Fact-1DA2E2860F0CE132C3BFEF6363F6D5C0" unitRef="usd">3879000</us-gaap:DeferredTaxAssetsInvestments>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2014Q4" decimals="-3" id="Fact-87BCDBB71A41EBFE7090EF6364B42B56" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2014Q4" decimals="-3" id="Fact-14C26EAE33925019A06BEF63650BB4F9" unitRef="usd">6578000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2014Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-3" id="Fact-D24FE82EDB1020EC62BB346CD479C9AC" unitRef="usd">49907000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2015Q4" decimals="-3" id="Fact-3E716AFD9B1E57B83977EF6364B3C8D5" unitRef="usd">13932000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2015Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-3" id="Fact-C9A744BD048FF2D8857C346D1E1CC78D" unitRef="usd">51823000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="FI2014Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_InvestmentCreditMember" decimals="-3" id="Fact-E4D1060B395D94BD9D06346715E5E756" unitRef="usd">7866000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="FI2015Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_InvestmentCreditMember" decimals="-3" id="Fact-A14E9D31F68C448A7F3E3F3AC7DF3FE4" unitRef="usd">7969000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2014Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_InvestmentCreditMember" decimals="-3" id="Fact-7F87CE81DCAF646C0E9E3468C0A529CE" unitRef="usd">3401000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2015Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_InvestmentCreditMember" decimals="-3" id="Fact-6BACC79B4BF1FFE31743346836A07C77" unitRef="usd">3869000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="FI2014Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-3" id="Fact-F783B4783D722A6EFCBB3472901B9E2D" unitRef="usd">25301000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="FI2015Q4" decimals="-3" id="Fact-F37643CB416B931DB418346E0F0A538D" unitRef="usd">17235000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="FI2015Q4_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-3" id="Fact-8A83C7EFCBA9E7E7AE9534734327593C" unitRef="usd">24745000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2015Q4" decimals="-3" id="Fact-4F383170656B3CBDEAB9516A86A31535" unitRef="usd">483000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2014Q4" decimals="-3" id="Fact-829A0A3C2D4B7173AF4AEF6364E7313D" unitRef="usd">1195000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2015Q4" decimals="-3" id="Fact-662895651B4B9C085288EF6364A83C75" unitRef="usd">777000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2014Q4" decimals="-3" id="Fact-07377DEDEAF65BE28510EF63642B2492" unitRef="usd">37818000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2014Q4_us-gaap_StatementScenarioAxis_us-gaap_RestatementAdjustmentMember" decimals="-3" id="Fact-211D9D08CB63F3B7A8A334797DD0B80F" unitRef="usd">8424000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2015Q4" decimals="-3" id="Fact-E09446D014DB9005BD7DEF6364955931" unitRef="usd">41494000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2015Q4" decimals="-3" id="Fact-EAD130ABCE790AC0EFF2EF636514A0EF" unitRef="usd">146324000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="FI2014Q4" decimals="-3" id="Fact-707606DD7D37C66272DE34538D69C2DD" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
	<us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="FI2015Q4" decimals="-3" id="Fact-E1000D7B33ABA776E0A134538D4DA56F" unitRef="usd">146324000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2014Q4" decimals="-3" id="Fact-708B0D52750EC9AE29A32ED0407A79A8" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2015Q4" decimals="-3" id="Fact-B168AB06622C36E094C42ED0408115B7" unitRef="usd">146324000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:Depreciation contextRef="FD2013Q4YTD" decimals="-3" id="Fact-6A3001F0456A7E09F258EF6363F9F378" unitRef="usd">613000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2014Q4YTD" decimals="-3" id="Fact-785A6A9C7BF7757EBC83EF6364BE826E" unitRef="usd">529000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-DA737B2BF662B9CB909BEF6364F36B15" unitRef="usd">589000</us-gaap:Depreciation>
	<us-gaap:EarningsPerShareBasic contextRef="FD2013Q4YTD" decimals="2" id="Fact-F682A444C5B252BA2187EF63651ED560" unitRef="usdPerShare">-0.92</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2014Q4YTD" decimals="2" id="Fact-C6724513184F07415D36EF636526C58E" unitRef="usdPerShare">-1.80</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2015Q4YTD" decimals="2" id="Fact-90CE862EA8CEDBFC17CBEF63652DF1D0" unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q1QTD" decimals="2" id="Fact-01EDFB008CC323470EDFEF636416444F" unitRef="usdPerShare">-0.91</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q2QTD" decimals="2" id="Fact-0DD095BA874E1D3E3B8AEF63645EBD99" unitRef="usdPerShare">-0.28</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q3QTD" decimals="2" id="Fact-01F8F2E05A51FFC838FFEF636415601B" unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q4QTD" decimals="2" id="Fact-BC91F321343C9872469AEF636419F09D" unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2014Q4YTD" decimals="2" id="Fact-C4176D42288B299AACFCEF636517D5F4" unitRef="usdPerShare">-1.80</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q1QTD" decimals="2" id="Fact-2CEF504A4C25F677581DEF636496B206" unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q2QTD" decimals="2" id="Fact-7C54947D0BB3DCD87D86EF6364708DD3" unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q3QTD" decimals="2" id="Fact-7015DF0F47A8A686A584EF6364655CFF" unitRef="usdPerShare">-0.57</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q4QTD" decimals="2" id="Fact-6AB98A6FA422B64A66FEEF636491F4E3" unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-89396F804ED822115F06EF636496E8BC" unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2013Q4YTD" decimals="2" id="Fact-290A6BF8F48EE1E77DA0EF6364A6FBE5" unitRef="usdPerShare">-0.92</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2014Q4YTD" decimals="2" id="Fact-7DBC6A3F169E23014AB9EF63641EAE0D" unitRef="usdPerShare">-1.80</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-53D95B202BC94EBA799BEF6363F6372D" unitRef="usdPerShare">-1.34</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2013Q4YTD" decimals="-3" id="Fact-9D039713432EFF7DEE07EF6364B8622C" unitRef="usd">-3561000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2014Q4YTD" decimals="-3" id="Fact-81F4500BC90F66C34CD0EF6364B64417" unitRef="usd">-1827000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2015Q4YTD" decimals="-3" id="Fact-16D446B93F891FFB42F3EF63651729E9" unitRef="usd">-2175000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2013Q4YTD" decimals="2" id="Fact-08E81E718D10BD6D8C8E3426E6ABC7EC" unitRef="number">0.26</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2014Q4YTD" decimals="2" id="Fact-E2AFE7F52728F15716273426D39E6BE5" unitRef="number">0.26</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q4YTD" decimals="2" id="Fact-C02E3BF6DEDB6973234234265C596690" unitRef="number">0.26</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2015Q4" decimals="-3" id="Fact-236AAD23C5981B40640E3F08613472B7" unitRef="usd">11972000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2015Q4_us-gaap_AwardTypeAxis_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member" decimals="-3" id="Fact-13E43DDA852BA7B4A1F53F08FD0CBCAD" unitRef="usd">35967000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2015Q4YTD" id="Fact-006F59ADAE051C5CAA803F08BC5E6E39">P16M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member" id="Fact-BE8C24D163B12C60ED103F095A0F9E75">P12M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="FD2013Q4YTD" decimals="-3" id="Fact-A88321372864FE4DFB773E50D2103793" unitRef="usd">903000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
	<us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-029D9508BD3B7A624F753E50C3E360DB" unitRef="usd">281000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
	<us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-F501E17C38AA9C1B89BC3E50B22D27D8" unitRef="usd">622000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
	<us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-8A8A237D0A3C08EDF3BA3E50D212925C" unitRef="usd">3283000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
	<us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-20F2C6099BC61EBD93AE3E50C3ED82F8" unitRef="usd">940000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
	<us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-9509F23B5F54A1F5191B3E50B2426141" unitRef="usd">2343000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
	<us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5359A910F3498A9120E73E50D20D7E78" unitRef="usd">22093000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
	<us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-04E3C04F1441919621A73E50C3E6C391" unitRef="usd">14225000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
	<us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-8098E6061FEDA225F75D3E50B234ADA4" unitRef="usd">7868000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="D2015Q1Mar04-Mar04_us-gaap_AwardTypeAxis_abus_AbutusStockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="INF" id="Fact-14BFCA60CA1C61227D4B3A169188B21C" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="D2015Q1Mar04-Mar04_us-gaap_AwardTypeAxis_abus_SharesIssuedSubjectToRepurchaseProvisionMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="INF" id="Fact-4A294B6B91C5BEDC2F57389509EFC9AA" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="D2015Q1_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-16099059C37FF20DD3B43EF99D67D9F6" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2014Q4YTD" decimals="INF" id="Fact-AB317D97AE2CCE728B06CC45940DC8BD" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="FD2015Q4YTD" decimals="INF" id="Fact-D868BCDCBFDE324FE9D3CC45943F7F8A" unitRef="number">0</us-gaap:FairValueAssumptionsExpectedDividendRate>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2015Q1Mar04-Mar04_us-gaap_AwardTypeAxis_abus_AbutusStockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" id="Fact-6C97F98CF0A063BC9A6D39502C7EFFCD">P8Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2015Q1Mar04-Mar04_us-gaap_AwardTypeAxis_abus_SharesIssuedSubjectToRepurchaseProvisionMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" id="Fact-0A686FF60EB49279162138968D62210E">P4Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="D2015Q1_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" id="Fact-362E6A618E69DC609C533EF9B444CE7D">P8Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2014Q4YTD" id="Fact-446ACB32AF702CF143A1CC45942188D5">P6M</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2015Q4YTD" id="Fact-EC80C87E9DA6694BB394CC45942B678C">P7M6D</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="D2015Q1Mar04-Mar04_us-gaap_AwardTypeAxis_abus_AbutusStockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="INF" id="Fact-005370AEC8FB9B39CA9B394F73762569" unitRef="number">0.78</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="D2015Q1Mar04-Mar04_us-gaap_AwardTypeAxis_abus_SharesIssuedSubjectToRepurchaseProvisionMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="INF" id="Fact-0740EB5751F4F5DC31343894774DDC9A" unitRef="number">0.81</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="D2015Q1_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="2" id="Fact-2DE86E51504618BCDBA73EF9860E81BA" unitRef="number">0.78</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q4YTD" decimals="INF" id="Fact-1347F7F447E2F3BF720CCC45942BB792" unitRef="number">0.8522</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD" decimals="INF" id="Fact-A10196D6065D55F8050ACC4594216228" unitRef="number">0.4907</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="D2015Q1Mar04-Mar04_us-gaap_AwardTypeAxis_abus_AbutusStockOptionsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="INF" id="Fact-8BF95347288DF3C9D086394F58A80899" unitRef="number">0.0097</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="D2015Q1Mar04-Mar04_us-gaap_AwardTypeAxis_abus_SharesIssuedSubjectToRepurchaseProvisionMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="INF" id="Fact-FAA9A8822D8135324598389310DCA312" unitRef="number">0.0074</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="D2015Q1_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="4" id="Fact-6D90E93F6618964A48093EF8B7FFF3FC" unitRef="number">0.0097</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2014Q4YTD" decimals="INF" id="Fact-DABFC6BE85607852344ECC459417E0EB" unitRef="number">0.01</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD" decimals="INF" id="Fact-413800128F0E33AFE1EECC45943F345C" unitRef="number">0.0048</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-220DEA72BCD988188740EF6364DA04D1" unitRef="number">0</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities contextRef="FI2014Q4" decimals="-3" id="Fact-31583166E306DD21FBE33836275E1229" unitRef="usd">0</us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities>
	<us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-E6E1F70C9424D83991B038362450A490" unitRef="usd">0</us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities>
	<us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities contextRef="FI2015Q4" decimals="-3" id="Fact-9178101A8B9873D0BADA382154550C23" unitRef="usd">0</us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities>
	<us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-9F47C76464B6C452D1363820A00FCB7C" unitRef="usd">0</us-gaap:FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities>
	<us-gaap:FairValueInputsDiscountRate contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="3" id="Fact-3C41A38A7A3B5AC1417A398684F82D4F" unitRef="number">0.137</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="FD2013Q4YTD" decimals="-3" id="Fact-694C559617A31CBAA32BEF63651C34A4" unitRef="usd">-3530000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
	<us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="FD2014Q4YTD" decimals="-3" id="Fact-8ACCD906B9475A920570EF6364E3CE0D" unitRef="usd">-10383000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
	<us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="FD2015Q4YTD" decimals="-3" id="Fact-40535129FED105BCC6F8EF63651B77FF" unitRef="usd">3341000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2013Q4YTD" decimals="-3" id="Fact-1D3937A1D299DE2BC113EF63641F62DD" unitRef="usd">1079000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2014Q4YTD" decimals="-3" id="Fact-CD03565FA56CD24C4C0BEF6363F7A8A1" unitRef="usd">4127000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-31302FCAAF7931119A99EF636515076D" unitRef="usd">21771000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="FD2013Q4YTD" decimals="-3" id="Fact-EB6342C50F33BF867C64EF6364C2D6B7" unitRef="usd">18000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
	<us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="FD2014Q4YTD" decimals="-3" id="Fact-836341E6A38A53DFB61CEF6364E6443F" unitRef="usd">4218000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
	<us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F7917573E57934F4F640EF6364FA4FAF" unitRef="usd">21966000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2013Q4YTD" decimals="-3" id="Fact-93141699694ACDF21B622F5AFABC5103" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2014Q4YTD" decimals="-3" id="Fact-71084E14DE8F1054442A2F5AF8C97BD3" unitRef="usd">80000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-514ED8111AB6D5B24DC8EF6364E781C4" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2013Q4YTD" decimals="-3" id="Fact-99AB505A36832FF2A16DEF636401EE18" unitRef="usd">5546000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-444B3E791377CD31EFC4EF6364E7A1D6" unitRef="usd">8683000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-29259D2999AB816412EDEF636498982D" unitRef="usd">26438000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:Goodwill contextRef="FI2014Q4" decimals="-3" id="Fact-55B0D49DDD7242E6345F2EC8C6FBC8AE" unitRef="usd">0</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2015Q4" decimals="-3" id="Fact-B773CBF6DA5C4CED87232EC8C6FDBAD8" unitRef="usd">162514000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-9D1BE8245A5F3A49EF36398CC4EFC76C" unitRef="usd">162514000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2015Q1March04_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-08879B51CE718366433B398B597DA0D9" unitRef="usd">155865000</us-gaap:Goodwill>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2015Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_GoodwillMember" decimals="INF" id="Fact-1994B0D9D46C25A36E883A22348F1EEB" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="D2015Q4Mar05-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-7269590D7A78BDFB3B8E398C9C82E605" unitRef="usd">6649000</us-gaap:GoodwillPurchaseAccountingAdjustments>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="D2015Q4Oct28-Oct28_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDCyclophilinsMember" decimals="-3" id="Fact-6A619D286A9853D5844939F7B9237510" unitRef="usd">37990000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2013Q4YTD" decimals="-3" id="Fact-0BFA837123EFCBDC4C9C2F137DDDA5D0" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2014Q4YTD" decimals="-3" id="Fact-DCD34FCBA47A2A648E2D2F137DE10070" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2015Q4YTD" decimals="-3" id="Fact-AAB6285463F048C5A2EE2F137DE06640" unitRef="usd">39007000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2015Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_OtherIPRDMember" decimals="INF" id="Fact-E2F35D4B2B0774D653E33A25618CE052" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2013Q4YTD" decimals="-3" id="Fact-C667FF26F4173A7E4D1F2F3FA9CB9394" unitRef="usd">-14063000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2014Q4YTD" decimals="-3" id="Fact-32FBE4C42DD2B7C3F98E2F3FA9C6A702" unitRef="usd">-38837000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A3DEAAA034957F643C1E2F3FA9C88278" unitRef="usd">-77306000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2014Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_PADCo.Member" decimals="INF" id="Fact-C4ECC4C32021463CF7233D33ADD3A685" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2015Q4YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_PADCo.Member" decimals="INF" id="Fact-23416A1AD70C2245E6963D31E806A0E1" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2015Q4Oct28-Dec31_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDCyclophilinsMember" decimals="-3" id="Fact-9671EA498FFF3A37138D3A002C56B248" unitRef="usd">-989000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="D2015Q4Oct28-Oct28_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDCyclophilinsMember" decimals="-3" id="Fact-8CD96A0E1632E1E24AED39FBE5379DE4" unitRef="usd">-15196000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2013Q4YTD" decimals="-3" id="Fact-4C9C36133FD84AC85BE82F3B6576E0FE" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D8269D5171879DF9373E2F3B657D24AC" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-392A1187E17CB101513B2F3B656F16F5" unitRef="usd">-16185000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2013Q4YTD" decimals="-3" id="Fact-C834B27E5B26357ED33FEF6363FEEFE3" unitRef="usd">2407000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2014Q4YTD" decimals="-3" id="Fact-06D3ADDDE221D28CC80BEF6363FD62E7" unitRef="usd">6599000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5526FA66AB9272D16D21EF6363FCA7C0" unitRef="usd">3676000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2013Q4YTD" decimals="-3" id="Fact-6BF0107D619DBD4B4621EF636402C9A7" unitRef="usd">-9000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2014Q4YTD" decimals="-3" id="Fact-D4F2A16DDAFDB3362907EF6364007F9C" unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A339E85021431C4D2437343CCD9BE23F" unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="FD2013Q4YTD" decimals="-3" id="Fact-F0F58B04E2B82DE5AF50343F560751DC" unitRef="usd">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="FD2014Q4YTD" decimals="-3" id="Fact-4D9A3EA65B4EA4455D97343F5609A97C" unitRef="usd">0</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="FD2015Q4YTD" decimals="-3" id="Fact-AB2C3965D43010796EF1343F5605DA61" unitRef="usd">-7874000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2013Q4YTD" decimals="-3" id="Fact-7340A58EC08A0720FB19EF6363FF9B84" unitRef="usd">-3486000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2014Q4YTD" decimals="-3" id="Fact-9C85E7A790D58E4CED2AEF6363FF4A51" unitRef="usd">-10097000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q4YTD" decimals="-3" id="Fact-50F88B762B9054531E59EF6363FFE923" unitRef="usd">-20100000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="FD2013Q4YTD" decimals="-3" id="Fact-0E0E5E2D585ED2D5A4DDEF6363FE136E" unitRef="usd">1088000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="FD2014Q4YTD" decimals="-3" id="Fact-78E79CA8FFA14B2B4329EF6363F9B91F" unitRef="usd">3498000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-00EE33A9CB21BB99DA46EF63640062CD" unitRef="usd">8113000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxesReceivable contextRef="FI2014Q4" decimals="-3" id="Fact-B6C0600F363DF606DB1FEF6364A2D4A4" unitRef="usd">86000</us-gaap:IncomeTaxesReceivable>
	<us-gaap:IncomeTaxesReceivable contextRef="FI2015Q4" decimals="-3" id="Fact-F0B53CEB989A8027E583EF63646C4251" unitRef="usd">246000</us-gaap:IncomeTaxesReceivable>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-A58598F0A91B5720DA96EF6364162E10" unitRef="usd">130000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-0F7425722B53E361C25BEF63645390D9" unitRef="usd">6253000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8EB38261B0D2EC2E524AEF6364E60BC6" unitRef="usd">-2489000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2013Q4YTD" decimals="-3" id="Fact-7B5A31A524DDF717F8BAEF6365273AFE" unitRef="usd">-889000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2014Q4YTD" decimals="-3" id="Fact-EAAE36901F5E83D2E7CEEF63652EC85D" unitRef="usd">1887000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D2CE61B39521CE82CB8AEF6363F81859" unitRef="usd">-628000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2013Q4YTD" decimals="-3" id="Fact-71814D5CDDB38E94899CEF6364C0E643" unitRef="usd">-153000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C7C7FC137F5583F1C51DEF636452BB79" unitRef="usd">13171000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-93AB2DD224FA15739009EF6364E4E9CE" unitRef="usd">-13090000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="FD2013Q4YTD" decimals="-3" id="Fact-41EFE39DD02BC39A8376EF6364B9C60C" unitRef="usd">31000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
	<us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A989B345909A267D06A7EF63651F4B7E" unitRef="usd">52000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
	<us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-61B34E8C942309892759EF6364071989" unitRef="usd">188000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2013Q4YTD" decimals="-3" id="Fact-2CF4B59761642BAA48E7EF63640F2160" unitRef="usd">776000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C04729AF59004DA5D50DEF636509F3E9" unitRef="usd">773000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6AFF88F3754686FCA23DEF63651CA4E6" unitRef="usd">-159000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInUnbilledReceivables contextRef="FD2013Q4YTD" decimals="-3" id="Fact-0E54F04B5C1DB1550CDDEF6364C0CC0F" unitRef="usd">-2008000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
	<us-gaap:IncreaseDecreaseInUnbilledReceivables contextRef="FD2014Q4YTD" decimals="-3" id="Fact-2BD512E6B4537F319641EF636406DC1E" unitRef="usd">360000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
	<us-gaap:IncreaseDecreaseInUnbilledReceivables contextRef="FD2015Q4YTD" decimals="-3" id="Fact-EC08794BF198B7885A5DEF6364099CA5" unitRef="usd">-349000</us-gaap:IncreaseDecreaseInUnbilledReceivables>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2014Q4" decimals="-3" id="Fact-ECB8DD614A1A6047E19E2EC841390F72" unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2015Q4" decimals="-3" id="Fact-C430A4647D7C667B8AA72EC8414CE15D" unitRef="usd">352642000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="-3" id="Fact-E2AC2A3145D9AEE03DCC39E1F687D66F" unitRef="usd">352642000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDAntigenInhibitorsMember" decimals="-3" id="Fact-7A752597E1D5AD8446963A13DE8DF03C" unitRef="usd">36437000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDCyclophilinsMember" decimals="-3" id="Fact-83AAC4491189F5E2379339E23B177E93" unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDImmuneModulatorsMember" decimals="-3" id="Fact-2103AF53488C6B3F45F63A13DE9F80AC" unitRef="usd">183103000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2015Q4_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_IPRDcccDNASterilizersMember" decimals="-3" id="Fact-4761512C5FD8FD473D473A13DE695023" unitRef="usd">133102000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2013Q4YTD" decimals="-3" id="Fact-9FDFAF20D1A80582E495EF6364091B98" unitRef="usd">540000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2014Q4YTD" decimals="-3" id="Fact-76F02A8E65499DBE6A0FEF63640B0C90" unitRef="usd">853000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5C46FB54A1984090CCEAEF63641F7423" unitRef="usd">674000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentTaxCredit contextRef="FD2014Q4YTD" decimals="-3" id="Fact-18CC85B35967412982D2EF6363F78D45" unitRef="usd">52000</us-gaap:InvestmentTaxCredit>
	<us-gaap:InvestmentTaxCredit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-38C9B5ED605B4D558B6C34B3165C0483" unitRef="usd">196000</us-gaap:InvestmentTaxCredit>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2014Q4" decimals="-3" id="Fact-2E5024B6ABACEB3070FC383557A408A6" unitRef="usd">39974000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-44AB6E2BF1D746D122153835521A1A05" unitRef="usd">39974000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4" decimals="-3" id="Fact-D02E26296E201625A57A380F5397194F" unitRef="usd">14525000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-278ECF714D0FC9ED1D0A380F4E177716" unitRef="usd">14525000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:LeaseIncentivePayableCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-F0B011108961DF65106A33FFC302AB77" unitRef="usd">250000</us-gaap:LeaseIncentivePayableCurrent>
	<us-gaap:LeaseIncentivePayableCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-8A772C28945304D8B6DE33FFC30E889E" unitRef="usd">297000</us-gaap:LeaseIncentivePayableCurrent>
	<us-gaap:Liabilities contextRef="FI2014Q4" decimals="-3" id="Fact-33DE71F17B4765858B11EF6364A2DD0D" unitRef="usd">30143000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2015Q4" decimals="-3" id="Fact-8E845F11AA09ADA836B6EF6364757CC5" unitRef="usd">164612000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-58951FCAFE185594B024EF636453BD16" unitRef="usd">118178000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-C4862F5AB1FB7265C939EF6364719E3A" unitRef="usd">712291000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-40EDE50E58BB53F9FF56EF6364A39887" unitRef="usd">20206000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-8745E1EAF3BA1177A355EF6364A13672" unitRef="usd">10578000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2014Q4" decimals="-3" id="Fact-F0D9CAC3DB20E1CEA1CCEF6364905014" unitRef="usd">5099000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-D222C2AEFBF9A8000412CD9A2FF6B1E4" unitRef="usd">5099000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2015Q4" decimals="-3" id="Fact-EB16E004719E19D91E71EF6364B9C7DB" unitRef="usd">8380000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-66ECFDC8CAD43B9C0331CD9A10D20273" unitRef="usd">8380000</us-gaap:LiabilitiesFairValueDisclosureRecurring>
	<us-gaap:LicenseCosts contextRef="D2014Q1Feb28_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergandDrexelMember" decimals="-3" id="Fact-2FB32A200F9C5F8BA31537BB32FCC020" unitRef="usd">150000</us-gaap:LicenseCosts>
	<us-gaap:LicenseCosts contextRef="D2014Q3Sep30_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_CounterpartyNameAxis_abus_NeuroViveMember" decimals="-3" id="Fact-8565252CB3A927CE585237DCCD64A403" unitRef="usd">1000000</us-gaap:LicenseCosts>
	<us-gaap:LicenseCosts contextRef="D2014Q4Nov30_dei_LegalEntityAxis_abus_OnCoreBiopharmaInc.Member_us-gaap_CounterpartyNameAxis_abus_BlumbergandDrexelMember" decimals="-3" id="Fact-D9334B682506A697F4BC37C7BF2C6276" unitRef="usd">50000</us-gaap:LicenseCosts>
	<us-gaap:LicensesRevenue contextRef="D2013Q2Jun21-Jun21_us-gaap_LitigationCaseAxis_abus_AlnylamandAscletisPharmaceuticalsMember" decimals="-3" id="Fact-6EDD17E5DFB0ED0F79F0EF63647370A9" unitRef="usd">5000000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="D2013Q4Dec01_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_AlnylamLicenseAgreementMember" decimals="-3" id="Fact-B3BA2146F866D050BEDBEF636471E5C2" unitRef="usd">5000000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="D2013Q4Nov30_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_AlnylamLicenseAgreementMember" decimals="-3" id="Fact-655CB2AE83C2E506DE3AEF63646FBC54" unitRef="usd">375000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="D2014Q1Mar01-Mar31_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_AlnylamLicenseAgreementMember" decimals="-3" id="Fact-7986604E11426A4227CE3D3A4FABA88D" unitRef="usd">150000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2013Q4YTD" decimals="-3" id="Fact-8BAC7B7695BFBC52CA24EF636484499B" unitRef="usd">5040000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_AlnylamLicenseAgreementMember" decimals="-3" id="Fact-D955BFA37F2D58E02AC33A5BF7FED924" unitRef="usd">5000000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_DicernaMember" decimals="-3" id="Fact-AEA047F6822C9C3471283A5BF7B64478" unitRef="usd">0</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" decimals="-3" id="Fact-194ADDE00722B59F799C3A5BF7D173BB" unitRef="usd">0</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2013Q4YTD_us-gaap_CounterpartyNameAxis_abus_SpectrumMember" decimals="-3" id="Fact-CC64AD5CD1CB6DCB86B73A5BF7E796C7" unitRef="usd">40000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2014Q4YTD" decimals="-3" id="Fact-C5A187545785EC043AB5EF6365042A31" unitRef="usd">3215000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_AlnylamLicenseAgreementMember" decimals="-3" id="Fact-A11179BA3F0CD85A3BD53A5BF7AF4AF8" unitRef="usd">150000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_DicernaMember" decimals="-3" id="Fact-1B5DE71F980BDAA0256D3A5BF7F6BD48" unitRef="usd">131000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" decimals="-3" id="Fact-E1F24971F7CF93153DCE3A5BF827E9F7" unitRef="usd">2744000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_abus_SpectrumMember" decimals="-3" id="Fact-043495D0BCB6BA85EB073A5BF73A0751" unitRef="usd">190000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-440D2CAE716F5DC9C938EF6364F77D0C" unitRef="usd">11564000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_AlnylamLicenseAgreementMember" decimals="-3" id="Fact-EF88B08A902E0C6706F83A5BF7C5826C" unitRef="usd">15000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_DicernaMember" decimals="-3" id="Fact-B82EF74CB868219028DE3A5BF77F9FC9" unitRef="usd">1053000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" decimals="-3" id="Fact-B7CC37C2918DD62670673A5BF7BE7128" unitRef="usd">10256000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_SpectrumMember" decimals="-3" id="Fact-7D51C40DB1F3EE71FC7D3A5BF8188BEE" unitRef="usd">240000</us-gaap:LicensesRevenue>
	<us-gaap:LongTermInvestments contextRef="FI2014Q4" decimals="-3" id="Fact-538B1B03464D1FEC287E2EC6607AB5B4" unitRef="usd">0</us-gaap:LongTermInvestments>
	<us-gaap:LongTermInvestments contextRef="FI2015Q4" decimals="-3" id="Fact-8104A211026513BB455E2EC66078B1A6" unitRef="usd">10070000</us-gaap:LongTermInvestments>
	<us-gaap:LongTermInvestments contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-9B8D898A287E1B2630AECD9A10C25406" unitRef="usd">10070000</us-gaap:LongTermInvestments>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2015Q1Jan16_us-gaap_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" decimals="INF" id="Fact-9187A72910E39DAC0B7EEF6364168FE0" unitRef="usd">3500000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-53A9C6A90B19ADA08C87EF63640A9FA1" unitRef="usd">32716000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-4F942FF27AF0BE1E5432EF63652D6B56" unitRef="usd">60676000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-38A0A8A7C2DF3EC4E02BEF636401D32F" unitRef="usd">143870000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-6C2202DD65EC83073C30EF6364E0B062" unitRef="usd">-725000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-BA76D59D6A3C578770B7EF63648E1F9D" unitRef="usd">-42958000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4C1F7F99DB32EB22BD16EF63651D22E7" unitRef="usd">7682000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2013Q4YTD" decimals="-3" id="Fact-3759F4B94648D3B27E46EF63651A8CE2" unitRef="usd">-6737000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2014Q4YTD" decimals="-3" id="Fact-E5527B154A6ADEFDE87DEF636417F018" unitRef="usd">-12421000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4CD69EA029086EDFD03AEF636525488C" unitRef="usd">-54785000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q4YTD" decimals="-3" id="Fact-8F8E699F98C6B9F7ADD52F32CBBE6CC8" unitRef="usd">-14063000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-51F1C128E89A6AD6F07CEF636491CDC7" unitRef="usd">-14063000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q1QTD" decimals="-3" id="Fact-F645CB630C2250F754FEEF63640C0513" unitRef="usd">-17984000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q2QTD" decimals="-3" id="Fact-287C49CB521165C01E2FEF636443212C" unitRef="usd">-6081000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q3QTD" decimals="-3" id="Fact-98DA5265C9990E6FA4ADEF636519A1FC" unitRef="usd">-8604000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4QTD" decimals="-3" id="Fact-8C4993F22960A3FF6DBBEF63643D7D98" unitRef="usd">-6168000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-FD3E1664B2484CF3337E2F32CA404309" unitRef="usd">-38837000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-1D0AFCA2000698B119E0EF63648DFDD1" unitRef="usd">-38837000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q1QTD" decimals="-3" id="Fact-18BB947CB20376552E13EF63646E7675" unitRef="usd">-11989000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q2QTD" decimals="-3" id="Fact-3DDF686AD1FC4052044DEF6364830C90" unitRef="usd">-14886000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-3B4D8AAFD7EE4FF57B90EF63648EDD95" unitRef="usd">-28982000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4QTD" decimals="-3" id="Fact-C2B939061AEAE75CB8AFEF63648DE01A" unitRef="usd">-5264000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BC57620DF72B7E9E64ED2F32C8D9849B" unitRef="usd">-61121000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-9367303065008BD119E233392BB9A5CB" unitRef="usd">-61121000</us-gaap:NetIncomeLoss>
	<us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="FD2013Q4YTD" decimals="-3" id="Fact-528B0312C60F34CF2D12EF63640F3DC1" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
	<us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="FD2014Q4YTD" decimals="-3" id="Fact-B0A5F245B4A4434E01EC32E2C03A0E02" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
	<us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7D468E17E120EFDB1F8E32E2BF04BC5B" unitRef="usd">381618000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2013Q4YTD" decimals="-3" id="Fact-9C8319C32188105D6681EF63652B47B8" unitRef="usd">-1911000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-4ED14A893F953CAFCD8CEF6365265819" unitRef="usd">-5403000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E5BEAE121E2F95005D26EF63649505FA" unitRef="usd">25016000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NumberOfReportingUnits contextRef="FD2015Q4YTD" decimals="INF" id="Fact-C2B4D268437AB962D2643A24230C4C10" unitRef="reporting_unit">1</us-gaap:NumberOfReportingUnits>
	<us-gaap:OperatingExpenses contextRef="FD2013Q4YTD" decimals="-3" id="Fact-F61BC4A2D2104BB157FEEF636515BA16" unitRef="usd">27617000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2014Q4YTD" decimals="-3" id="Fact-8C08368C822D7353144DEF6364093525" unitRef="usd">48387000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2015Q4YTD" decimals="-3" id="Fact-64A5754AD7DC4C247CE7EF63640695FB" unitRef="usd">127195000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2013Q4YTD" decimals="-3" id="Fact-F0276E8750E9390E5324EF6364D27213" unitRef="usd">-12152000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q1QTD" decimals="-3" id="Fact-A52D526211C7789475E7EF63641AFD70" unitRef="usd">-5958000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q2QTD" decimals="-3" id="Fact-DCBB650FC4A1E11F69EDEF6364185F9A" unitRef="usd">-9423000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q3QTD" decimals="-3" id="Fact-627761AB459FFE1D1AC4EF636515AF26" unitRef="usd">-6844000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q4QTD" decimals="-3" id="Fact-4ECD7E99CBFD60E78628EF63640623CF" unitRef="usd">-10747000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2014Q4YTD" decimals="-3" id="Fact-0C5785E779C5D5EFE045EF6364EB310C" unitRef="usd">-33434000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q1QTD" decimals="-3" id="Fact-99EA4DD790C7D08D76B3EF6364823277" unitRef="usd">-18006000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q2QTD" decimals="-3" id="Fact-FAA529873FAA18C8BC4DEF63647F621B" unitRef="usd">-14420000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q3QTD" decimals="-3" id="Fact-EF3CEB959B159D27C227EF6364656B0A" unitRef="usd">-58138000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4QTD" decimals="-3" id="Fact-DFEA771ECFB3CC578184EF636475F11B" unitRef="usd">-11758000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-71A8A8C0C85DED76B1D2EF6363FA9B16" unitRef="usd">-102322000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2015Q4" decimals="-3" id="Fact-13094CD8B300A5D87E36EF63651DD89F" unitRef="usd">3652000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-9E741D1FD44EA674E3E2EF6365293371" unitRef="usd">1229000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2015Q4" decimals="-3" id="Fact-81AF1E0D4119B67061F8EF6365024A72" unitRef="usd">547000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2015Q4" decimals="-3" id="Fact-7C4F738B2EAC73BB5828EF6365165D60" unitRef="usd">938000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2015Q4" decimals="-3" id="Fact-0B3F7BC82E962F61E543EF63652613FD" unitRef="usd">938000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2013Q4YTD" decimals="-3" id="Fact-CE8F53C96D39F58894B6354A6D26FA6E" unitRef="usd">1225000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2014Q4YTD" decimals="-3" id="Fact-08D4FDFBD678D52AD1E6EF6364296AB1" unitRef="usd">1133000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F116A7B6EBEFD52568DD34C8A5E07BC3" unitRef="usd">1158000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-27816046AB3444F420CD34020EE5D6F9" unitRef="usd">226000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-5E22161580A2917D964D34020EE42E7E" unitRef="usd">591000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2013Q4YTD" decimals="-3" id="Fact-FEA9E5AAA5EF60F77DA5EF636403363C" unitRef="usd">-3135000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-83ED01BB393479FE8354EF6364A6A01A" unitRef="usd">-3135000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2014Q4YTD" decimals="-3" id="Fact-0BD805C41671E0B22FDBEF636497A7DA" unitRef="usd">-6489000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-80797E15E9704A95476E333569001AD5" unitRef="usd">-6489000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-96566E13315ADB83C5B3EF6364FCC601" unitRef="usd">-27469000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-B72697EBB2DE5E96B9083338F479FC3A" unitRef="usd">-27469000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:PaymentsForProceedsFromInvestments contextRef="FD2013Q4YTD" decimals="-3" id="Fact-4A74795371E7C6622B8B32DAF8A061BD" unitRef="usd">0</us-gaap:PaymentsForProceedsFromInvestments>
	<us-gaap:PaymentsForProceedsFromInvestments contextRef="FD2014Q4YTD" decimals="-3" id="Fact-EC60936412FD19F3CB2632DAF73626D7" unitRef="usd">41982000</us-gaap:PaymentsForProceedsFromInvestments>
	<us-gaap:PaymentsForProceedsFromInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B0463BB36B50A9FF973DEF63640DB5B5" unitRef="usd">-9645000</us-gaap:PaymentsForProceedsFromInvestments>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2013Q4Nov02" decimals="-3" id="Fact-E071B395B9A42DC16227EF6365053AF3" unitRef="usd">2462000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2014Q1March26" decimals="-3" id="Fact-51F15F5C941387EC8538EF6364C2918F" unitRef="usd">4085000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2015Q1Mar25-Mar25" decimals="-3" id="Fact-30A2E37C45699442CA253DAFD9ABC685" unitRef="usd">9700000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2013Q4YTD" decimals="-3" id="Fact-262EA92E0F83225D81FEEF6365274B01" unitRef="usd">725000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2014Q4YTD" decimals="-3" id="Fact-842026D85BB9D958AFE7EF6364E59248" unitRef="usd">1056000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-300EA85C6739C7C8746AEF636410E382" unitRef="usd">2287000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-48FF3DD2C2853149F41DEF6364A09A66" unitRef="usd">1730000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-8B4AE24E112F47B25027EF636475DF18" unitRef="usd">1196000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromIncomeTaxRefunds contextRef="D2011Q4Nov23-Nov23_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-2994F798EA2FB2CEDD48347053BB93EB" unitRef="cad">8000000</us-gaap:ProceedsFromIncomeTaxRefunds>
	<us-gaap:ProceedsFromIncomeTaxRefunds contextRef="FD2013Q4YTD" decimals="-3" id="Fact-72DEAD42816A1F1920CAEF6363FC7324" unitRef="usd">10000</us-gaap:ProceedsFromIncomeTaxRefunds>
	<us-gaap:ProceedsFromIncomeTaxRefunds contextRef="FD2014Q4YTD" decimals="-3" id="Fact-18D599E0157D366A949EEF63649EBD1A" unitRef="usd">0</us-gaap:ProceedsFromIncomeTaxRefunds>
	<us-gaap:ProceedsFromIncomeTaxRefunds contextRef="FD2015Q4YTD" decimals="-3" id="Fact-332C90FCE97164CB57AF32E2DA8EA289" unitRef="usd">24000</us-gaap:ProceedsFromIncomeTaxRefunds>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2013Q4Nov02" decimals="INF" id="Fact-EF7830796F990211694BEF6364F73645" unitRef="usd">34500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2013Q4Oct02" decimals="INF" id="Fact-945F11C696D59718FB92EF6364E3F69D" unitRef="usd">30000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2014Q1March26" decimals="INF" id="Fact-9F344E09213ED4849713EF6365078BFA" unitRef="usd">60562000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2015Q1Mar25-Mar25" decimals="INF" id="Fact-067D1D8235213AF6F9743A5320469F90" unitRef="usd">151875000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2013Q4YTD" decimals="-3" id="Fact-8970E32F29DE40B2B22BEF6364E606F4" unitRef="usd">32038000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2014Q4YTD" decimals="-3" id="Fact-A1DA8F40A53F2CF43673EF6364070779" unitRef="usd">56477000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F7A564C4B9ADC541C265EF63646B2690" unitRef="usd">142177000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2013Q4YTD" decimals="-3" id="Fact-A311E8139A8174F55B7132D65A672D32" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2014Q4YTD" decimals="-3" id="Fact-106EE6DD61AFA805DD1E32DB172146C3" unitRef="usd">80000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-268CBDD201F5F594F80532D65A5A784A" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2013Q4YTD" decimals="-3" id="Fact-AA35F2C20E506094F808EF6364C138E3" unitRef="usd">389000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2014Q4YTD" decimals="-3" id="Fact-CBE376EE852739B69D33EF63651936F4" unitRef="usd">2616000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-3" id="Fact-2E966EF8B9CF0666B5CDEF63651E0C90" unitRef="usd">1651000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromWarrantExercises contextRef="FD2013Q4YTD" decimals="-3" id="Fact-9D52A2AE2E8CBE937E7CEF6364BFE640" unitRef="usd">289000</us-gaap:ProceedsFromWarrantExercises>
	<us-gaap:ProceedsFromWarrantExercises contextRef="FD2014Q4YTD" decimals="-3" id="Fact-3E1C2E085A2CD14CB28EEF636463C4F9" unitRef="usd">1583000</us-gaap:ProceedsFromWarrantExercises>
	<us-gaap:ProceedsFromWarrantExercises contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9750F35E10DA89CE2ACFEF6364E7B46C" unitRef="usd">42000</us-gaap:ProceedsFromWarrantExercises>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2014Q4" decimals="-3" id="Fact-F64A5995CB884C19535CEF63649297B1" unitRef="usd">12959000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abus_LaboratoryEquipmentMember" decimals="-3" id="Fact-5E32BA8916D95572AEB9EF6364D3544B" unitRef="usd">5021000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-481004887ACBD85B371FEF6364B86093" unitRef="usd">2293000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-29493B0A0858F28F895AEF6364B31BE6" unitRef="usd">364000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-04EB26026F74059757E0EF6364B18BBA" unitRef="usd">5281000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4" decimals="-3" id="Fact-7D752037481663633026EF6364630919" unitRef="usd">12912000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abus_LaboratoryEquipmentMember" decimals="-3" id="Fact-CBA0BCC7C533DD21F90FEF63640C1895" unitRef="usd">5910000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-89C5DD1198A83D99C228EF63640D7267" unitRef="usd">2014000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-A44C63C40E35337CC91EEF636408BAD6" unitRef="usd">307000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-4997AA79ECA2EDB19659EF6364084832" unitRef="usd">4681000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2014Q4" decimals="-3" id="Fact-79C5AC822345EF80EDA4EF6364AD766A" unitRef="usd">1760000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abus_LaboratoryEquipmentMember" decimals="-3" id="Fact-08D88E52ACB38293F1CBEF6364B62784" unitRef="usd">570000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-F42D6D92A13C324FA279EF6364B52FAC" unitRef="usd">705000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-483C6C55992ADCB870C834BBDA855593" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2014Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-F1B9E800AD6F9CBD95DCEF6364B3DE95" unitRef="usd">485000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4" decimals="-3" id="Fact-36B16078B7AC34F8A7ECEF6364C039A7" unitRef="usd">3183000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abus_LaboratoryEquipmentMember" decimals="-3" id="Fact-4CCE915517138A7CE98FEF63640CAB73" unitRef="usd">2162000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-651ADF59ABAA90834198EF636407E876" unitRef="usd">527000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-436C947C6906834D5F7534BAA9F69C63" unitRef="usd">2000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2015Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-51821CA1186549CA0AD6EF63640EF36C" unitRef="usd">492000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_abus_LaboratoryEquipmentMember" id="Fact-021C4A244ACA9022333FEF636443DEBB">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-DBF2057CF2198B77B587EF636441C660">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-5F4199973E8F7D9C2D19EF63643F3FEA">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2015Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" id="Fact-5C24E82D79C121697CEBEF63643FDED5">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2013Q4YTD" decimals="-3" id="Fact-08B9875F48274B3E2132EF6363FFCC5D" unitRef="usd">21458000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2014Q4YTD" decimals="-3" id="Fact-E2D92DD216E32074B9DAEF63652E58BC" unitRef="usd">38713000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F57E28768B53E9DEE3FAEF6364087231" unitRef="usd">51505000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2014Q4" decimals="-3" id="Fact-8B0E22BB6C342E735857EF63646D5040" unitRef="usd">-205864000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2015Q4" decimals="-3" id="Fact-690E77B6F4D440F9C47EEF636494AC84" unitRef="usd">-266985000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromGrants contextRef="FD2014Q4YTD" decimals="-3" id="Fact-F897D85D9EF81F65D9DBEF6363F8D2B0" unitRef="usd">172000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B19D559A13758C65CF7634B2FBE32DF3" unitRef="usd">1245000</us-gaap:RevenueFromGrants>
	<us-gaap:Revenues contextRef="FD2013Q4YTD" decimals="-3" id="Fact-F2FA9859093C1DDB7EB8EF636401767D" unitRef="usd">15465000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q1QTD" decimals="-3" id="Fact-35DF28C7C4BBBC1747AAEF6364192010" unitRef="usd">4430000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q2QTD" decimals="-3" id="Fact-208D7F11B0173319C6AEEF63640CEAFC" unitRef="usd">1811000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q3QTD" decimals="-3" id="Fact-F37D03AE749595C0CBA9EF6364DA9B7D" unitRef="usd">4362000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q4QTD" decimals="-3" id="Fact-BC3C2A440ED4C92FC0BEEF63644CA856" unitRef="usd">4350000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2014Q4YTD" decimals="-3" id="Fact-5C332F957E8520D3650CEF6365039313" unitRef="usd">14953000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q1QTD" decimals="-3" id="Fact-C199C5B35F5A53404E92EF636490EE11" unitRef="usd">4682000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q2QTD" decimals="-3" id="Fact-0B61AB46A52A478DA396EF6364668B7B" unitRef="usd">3440000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q3QTD" decimals="-3" id="Fact-537A3FB23C7E9C55E4DEEF63648E2E31" unitRef="usd">4065000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q4QTD" decimals="-3" id="Fact-8C6978595EAD3537D7A6EF636464D193" unitRef="usd">12686000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q4YTD" decimals="-3" id="Fact-AC22EDC67BDAF57D14AAEF6363F7EAB6" unitRef="usd">24873000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_abus_MonsantoMember" decimals="-3" id="Fact-90B3A754F23FC0773B143D2D8C00E7F6" unitRef="usd">14981000</us-gaap:Revenues>
	<us-gaap:RoyaltyRevenue contextRef="FD2013Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_MarqiboMember" decimals="-3" id="Fact-5C9BBF216E07C33498FC3D4D0FFA15F7" unitRef="usd">40000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2014Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_MarqiboMember" decimals="-3" id="Fact-2924811E9633AF8428D8EF636474D10E" unitRef="usd">190000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2015Q4YTD_us-gaap_ProductOrServiceAxis_abus_MarqiboMember" decimals="-3" id="Fact-BB9F6D26C09CC45B7CA53503D4E6534A" unitRef="usd">240000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2015Q4YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_abus_MarqiboMember" decimals="-3" id="Fact-A6D63A3DD7B63D8AC10C3D4C56720AF7" unitRef="usd">240000</us-gaap:RoyaltyRevenue>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2013Q4Nov02" decimals="INF" id="Fact-D0CCA4A1ED2AB02E73C8EF6364C678C3" unitRef="usdPerShare">8.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2013Q4Oct22" decimals="INF" id="Fact-C988BF2E7AA53B8A621FEF6364AFA30B" unitRef="usdPerShare">8.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2014Q1March26" decimals="INF" id="Fact-8E059C7A3C1290AFB001EF6364C591E2" unitRef="usdPerShare">28.50</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2015Q1March25" decimals="INF" id="Fact-4B371B0759CD7512F1E73A5175D1F494" unitRef="usdPerShare">20.25</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:ShareBasedCompensation contextRef="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-3B43D7D9FCCD2BA67CCEEF63652A08DA" unitRef="usd">281000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2013Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-4FEEFA3845587B220A5BEF63652DF2B1" unitRef="usd">622000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-FB1A4312CB4BFAEE75ABEF6364E9AE73" unitRef="usd">940000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2014Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-35EB77E61CB9276D6178EF6363FD8708" unitRef="usd">2343000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-72F1DCC3176522EB2103EF6364E5134E" unitRef="usd">14224000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-9AF5C6B4A25C0DBC4332EF63640D3961" unitRef="usd">7869000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2011Q2June22_us-gaap_PlanNameAxis_abus_A2007PlanMember" id="Fact-13281D4507BE98201A32EF6364D8C395">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="D2011Q2June22_us-gaap_PlanNameAxis_abus_A2011PlanMember" id="Fact-A6D94AAB245393E8A111EF636503F4D7">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-6E733047A0BB6393EAAECC45D2C95AE3" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-C6DDA87E10649D053E98CC45D2B5828F" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-277A8C21D2591E8395B7CC45D2A17E1F" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-D48AA3527AA23E7A5F9ACC45D2BF4EC7" unitRef="number">1.1161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-7140D690C0A3F32ED021CC45D2C9B74A" unitRef="number">1.0108</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-5FC1CC5490CB0D960590CC45D2D32B3B" unitRef="number">0.7688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-125CB85AEBB4E9902BBACC45D2B52720" unitRef="number">0.0239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-73C5C45DD6F9CAC8055DCC45D2ABB547" unitRef="number">0.0225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-3FFFC484E6EFFA58B974CC45D2BFAB08" unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2015Q4" decimals="INF" id="Fact-D720EECF3BC00FFE62A13EEDA2215202" unitRef="shares">3135980</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2014Q2May08" decimals="INF" id="Fact-D4CB5145DA1F439A5291EF63650625EE" unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2015Q1March04_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-626A91697DB5B856DE423EF1762569E6" unitRef="shares">184332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2015Q3Jul09" decimals="INF" id="Fact-C0D362F5721B08BD3B753E80DB2E5C0F" unitRef="shares">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2013Q4" decimals="INF" id="Fact-5AABD1A51C366385CA88EF6364C1D5AF" unitRef="shares">1377091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2014Q4" decimals="INF" id="Fact-07238180C2D428035F62EF6364C3CB03" unitRef="shares">1088908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2015Q4" decimals="INF" id="Fact-C99AA7545127514EA5AD3E831130ECE6" unitRef="shares">938730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-2540811AB88940395AB23F02FC48A85C" unitRef="shares">87269</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-45F904423942E8FE245F3F02EF8BB30B" unitRef="shares">86658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="2" id="Fact-EA6AE1BBE333877AA7A03F048A357184" unitRef="usdPerShare">0.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_abus_ProtivaShareOptionsMember_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember" decimals="-3" id="Fact-D3C4100C610AF8A53E153EA00111D3ED" unitRef="usd">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="-3" id="Fact-4D3B34C551EE9FBEE93DCC4565CB9292" unitRef="usd">535000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="-3" id="Fact-9535194F8E7444CC9AE5CC4567536D2A" unitRef="cad">551000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_abus_ProtivaShareOptionsMember_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember" decimals="-3" id="Fact-E0425C5C0AB0340B3757EF6364F52E04" unitRef="usd">378000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="-3" id="Fact-04B3DA459F9EDEF16149CC45663BD80E" unitRef="cad">7650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="-3" id="Fact-F36A6D68AACA5EAD9FE2CC4566153BB7" unitRef="usd">6926000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_abus_ProtivaShareOptionsMember_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember" decimals="-3" id="Fact-FF6ADE96FC14923FE5123EA3A2AD458A" unitRef="usd">1249000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="-3" id="Fact-8E745CC1E160F8050EAECC4567172CD0" unitRef="cad">6887000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="-3" id="Fact-3876DD56C826D9A71BDFCC4566EFE0BD" unitRef="usd">5386000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="D2015Q4Mar05-Dec31_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-E1685BF16EFBF42AC25F3E4A28FA84EC" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="D2015Q4Mar05-Dec31_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-E4BEE445F6ED4BC151133E4A25F7B4FA" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-1D64215ADCBB710D0C143E34FC1E545F" unitRef="shares">675.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-5C96944F61A4B73F73E3CC4567214009" unitRef="shares">64085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-560DD14A85239D28B9923E34F9292677" unitRef="shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-B212A17A123F63734CA0CC45B8B75F94" unitRef="shares">675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-DCA4CC86C0883A5A2C56CC4564E56BB7" unitRef="shares">9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-536195B3F3D4404440B5CC45B7BDD62A" unitRef="shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-55D2FE308B3004F4B3BCCC45B803D69D" unitRef="shares">5445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-3C86E54E19C3B4B35AF9CC45673F85FA" unitRef="shares">151207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-717A05088E77A93A2CA7CC45B79F15D5" unitRef="shares">8065</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-9B7F836C1C4DE308C07FCC456535D8A4" unitRef="usdPerShare">21.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-53A23007B43A1919DEA9CC45658F75D2" unitRef="cadPershares">21.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-6E7DF5186F4ED5B653C23E3502B50BDC" unitRef="usdPerShare">0.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-C733F4FFD50961896DEC3E35001B50F0" unitRef="cadPershares">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-286915A51213C6A8D854CC456567FBD9" unitRef="cadPershares">8.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-63FB47517B50082852CDCC456517E984" unitRef="usdPerShare">7.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-5A2F559402FF4705683ACC45B7C7AD3B" unitRef="usdPerShare">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-753DCC68A7BFF20EA46CCC45B8B7D623" unitRef="cadPershares">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-9F36F2C5893ED481E1CBCC45655D0729" unitRef="cadPershares">19.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-6188610066A2DAD4DAA9CC4566A921E4" unitRef="usdPerShare">15.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-14821EE147874DBA0E1ACC45B7F9C66A" unitRef="usdPerShare">0.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-1851BA06CDD31586680ECC45B795D5B4" unitRef="cadPershares">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="D2015Q1Mar25-Mar25" decimals="INF" id="Fact-99BBE041F4B93885E2813DAF34712EF0" unitRef="shares">1125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-2E29924FB85FE259CEB9CC4567217694" unitRef="shares">270250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_DesignatedPlansMember" decimals="INF" id="Fact-44288E7A7840C1ED0DF8EF6364F83D3B" unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-FDAF3A5DEB4595AB7AF1CC4567496193" unitRef="shares">431125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2015Q4YTD" decimals="INF" id="Fact-C4F586579E2B8A03506DCC459ACFEDE1" unitRef="shares">1309625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-2F79C1B7AF38A404B78DCC4565F33CD8" unitRef="shares">1309625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD" decimals="2" id="Fact-B9C932293AB76FC46C8ACC459AA7BE9D" unitRef="cadPershares">15.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD" decimals="2" id="Fact-AB685FD2B24A8C9DC36ACC459AB1A310" unitRef="usdPerShare">11.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2012Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="-3" id="Fact-2B86F6E6F914019AAC50CC4566E52A55" unitRef="usd">2301000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2012Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="-3" id="Fact-6A87842822180F67110FCC4565499A13" unitRef="cad">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2013Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="-3" id="Fact-85E99A379C6AC7675AFACC456735D715" unitRef="usd">6826000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2013Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="-3" id="Fact-CC0AEA5FD1805FBA849CCC4565D525AE" unitRef="cad">7030000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2014Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="-3" id="Fact-A2FFCA319E7DD3ACDBB7CC45672BF979" unitRef="cad">16573000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2014Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="-3" id="Fact-5DCB41A1DECBC21533D3CC4566636823" unitRef="usd">15004000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="-3" id="Fact-7F9455BB1D48ED28C456CC4567490F2C" unitRef="cad">1376000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="-3" id="Fact-DB466680DD7C1BC89851CC456619B14F" unitRef="usd">994000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2012Q4_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-F21953D8AF2D7650F3E4CC45B7A94222" unitRef="shares">321299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2012Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-2FFE54CC33661FFEB5DBCC45673F9AFD" unitRef="shares">1648846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2012Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-198F868605AB1E7ECE2FCC45B80D91D9" unitRef="shares">475885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2013Q4_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-4C0A0876ED04F282CD0ACC45B7B3536A" unitRef="shares">319274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2013Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-3A9F0FD9981E66D4B6BECC4565C14CEC" unitRef="shares">1730765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2013Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-CDF0BF0CC88D8A7ACF90CC45B817A1DC" unitRef="shares">472885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2014Q4_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-D7DB56E32BB2014AF523CC45B7B355C3" unitRef="shares">292845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2014Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-C908C982B73E4A6F8FCACC45672B0B4D" unitRef="shares">1530138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2014Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-BDDD6832F9D7AA5482FFCC45B79F895F" unitRef="shares">433740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4" decimals="INF" id="Fact-5C6BD6847DB0ECCF7FD33EEB53CFDF5F" unitRef="shares">2519831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-6E5DDD188FE35A5BE1CB3E4A30B8ECC8" unitRef="shares">184332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-FBB39E718E35044C3635CC45B7BDF9F3" unitRef="shares">45236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-6C36666A70D0BA7FDF00EF6364E99F5A" unitRef="shares">2290263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-D038575730938FE308F93E4A2D67A141" unitRef="shares">183040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-F0C1ED54065E0BC10622CC45B7EFDCB3" unitRef="shares">67000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2015Q1March04_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-37021D122B8A2669A5E33E4A1442F3DF" unitRef="shares">184332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2015Q1March04_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-19700BD1E45D059C3D993E4A0FBFA97E" unitRef="shares">183040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2012Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-D5E4A5A7F387CCC47126CC456721B96E" unitRef="cadPershares">4.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2012Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-6F54C579F8D295FBCBD5CC4566C7A80E" unitRef="usdPerShare">4.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2012Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-86F7796C4F99E14EA699CC45B817BBC5" unitRef="cadPershares">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2012Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-6468607EF5F6BDFC66B5CC45B7D1F818" unitRef="usdPerShare">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2013Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-30B31484D5341CA0B4A7CC4567351EC1" unitRef="cadPershares">4.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2013Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-C23CD8ADB971FFA7A769CC45669F5528" unitRef="usdPerShare">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2013Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-D573A66ACC28D7F59A5BCC45B7DB618F" unitRef="cadPershares">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2013Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-07600DB38BF701CFFAA6CC45B7D11715" unitRef="usdPerShare">0.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2014Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-6AE0E6286263365EAD78CC4566770B97" unitRef="usdPerShare">6.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2014Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-981ACEAFEEB5AAE3300BCC45668BA078" unitRef="cadPershares">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2014Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-E63D19841C5028087244CC45B7D1388C" unitRef="usdPerShare">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2014Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-D28F0547542F7FFF05D8CC45B7EFA453" unitRef="cadPershares">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-D9F51A3C011A00594217CC45657B8770" unitRef="usdPerShare">11.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-29C65E2609C61B3E990BCC4565AD52E6" unitRef="cadPershares">15.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="2" id="Fact-D19691676347CE48D5473E4A35ADE43E" unitRef="usdPerShare">0.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-6931FFEEE0A3FE673D67CC45B82164A3" unitRef="usdPerShare">0.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-EDF9F05B56D1525C1A5ACC45B781A54E" unitRef="cadPershares">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range1Member" decimals="2" id="Fact-62023221B1314F9DFFA4CC45780BBB51" unitRef="usdPerShare">1.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range2Member" decimals="2" id="Fact-6D285AD2D81BAAB8C9A7CC457815029A" unitRef="usdPerShare">1.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range3Member" decimals="2" id="Fact-4C7D633006A9CF80487FCC45786F3A59" unitRef="usdPerShare">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range4Member" decimals="2" id="Fact-B527B5EF1A0E0A7051EBCC457833C754" unitRef="usdPerShare">3.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range5Member" decimals="2" id="Fact-E26FCAC4CA684025789FCC4577D928CB" unitRef="usdPerShare">6.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range6Member" decimals="2" id="Fact-46234DB610CF513AC6E8CC4577F7E0D1" unitRef="usdPerShare">9.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range7Member" decimals="2" id="Fact-71C8A8126C8D205AD2BA3DF7E5273488" unitRef="usdPerShare">11.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range8Member" decimals="2" id="Fact-F4A86AD242830874B4A4CC45785BCC00" unitRef="usdPerShare">17.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_TotalRangeMember" decimals="2" id="Fact-3348F6894142EDA56019CC4578016DB5" unitRef="usdPerShare">11.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="I2015Q1March04_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="2" id="Fact-DF6D7462890DAFCD0A853E4A19752BC3" unitRef="usdPerShare">0.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2013Q4" decimals="-3" id="Fact-BCBDA465BB03EE6E6FAB3E951CC02274" unitRef="usd">943000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2014Q4" decimals="-3" id="Fact-7BDEE1A2D2EC003CEA533E9501773544" unitRef="usd">2626000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2015Q4" decimals="-3" id="Fact-FCFCAD517B30DBDEE2EE3E949FC3FA7F" unitRef="usd">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="-3" id="Fact-83B4E5B7B3F48ACAA0013EE822C47C90" unitRef="usd">695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4" decimals="2" id="Fact-A16027DAAB653812B3273E92EA031547" unitRef="usdPerShare">15.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4" decimals="2" id="Fact-AF245FE310BECFD3906B3E932633B2EA" unitRef="cadPershares">21.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="2" id="Fact-3A37B038542E52E767723EE49965F101" unitRef="usdPerShare">0.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-E87ED1F27351EB0E1744CC4566314775" unitRef="usdPerShare">3.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-5570D83C62D9CCB3997ECC45664FBD40" unitRef="cadPershares">3.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-EF3C622F9D7EB5FE814ACC45B7E5CAFF" unitRef="cadPershares">0.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-D09402743584A05495F0CC45B78B0446" unitRef="usdPerShare">0.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-E924B4A28F915FA244FCCC45652B8171" unitRef="cadPershares">4.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-D9E5BED4D2A8D51380AECC4566F94657" unitRef="usdPerShare">4.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-E2C355B0CFB5337D27BFCC45B7C7403D" unitRef="cadPershares">0.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-0A222B8D4B1FAF00E4CFCC45B8039D49" unitRef="usdPerShare">0.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-99AF44E767B45D44F74CCC456753A857" unitRef="cadPershares">5.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-D31A79025821B4269665CC45653FEEF5" unitRef="usdPerShare">3.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-C91929CFE80220652E20CC45B79F3F7A" unitRef="usdPerShare">0.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="2" id="Fact-FA14AA6411CDD498F19ACC45B7E50A12" unitRef="cadPershares">0.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD" decimals="2" id="Fact-1371369CD1A39AA85850CC459ACF2269" unitRef="usdPerShare">11.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD" decimals="2" id="Fact-221C828A581045F780E9CC459ACF210A" unitRef="cadPershares">14.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-36AB683EEB8AD65C553CCC4565DF23A1" unitRef="cadPershares">7.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-F64CC0C3F3B4104C1803CC45661D42BA" unitRef="usdPerShare">7.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-3A2DD91060487D98F186CC4565F3ECB2" unitRef="cadPershares">13.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-C0BF7DC896FDDB0C4CD5CC456553E9ED" unitRef="usdPerShare">12.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="2" id="Fact-59C66D071FADB2484B7ACC4566D1DADF" unitRef="usdPerShare">16.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range1Member" decimals="2" id="Fact-8FBEDEBA8F721EFE0570EF63642807EF" unitRef="usdPerShare">1.08</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range2Member" decimals="2" id="Fact-DF141E8CD4CF1D4EEEBCEF63642CA247" unitRef="usdPerShare">1.52</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range3Member" decimals="2" id="Fact-824B20E89EDB9235F8BEEF63652DCB12" unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range4Member" decimals="2" id="Fact-FE7572592FA1B9EECAAFEF63642B843D" unitRef="usdPerShare">3.24</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range5Member" decimals="2" id="Fact-EE61281CF26C41E57DC3EF636515AC6D" unitRef="usdPerShare">5.10</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range6Member" decimals="2" id="Fact-E4FE84210552F06BBFB7EF6365188D51" unitRef="usdPerShare">8.38</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range7Member" decimals="2" id="Fact-298718ED4EAC986875A33DF7D9847FE5" unitRef="usdPerShare">10.69</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range8Member" decimals="2" id="Fact-3CFCB3663455E82FFD3EEF63651A8968" unitRef="usdPerShare">13.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_TotalRangeMember" decimals="2" id="Fact-93AF5DD87F7B0C28E133EF63651CD078" unitRef="usdPerShare">1.08</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range1Member" decimals="INF" id="Fact-4350F0D3B4024EE73088CC4578796479" unitRef="shares">102800</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range2Member" decimals="INF" id="Fact-C92E5CF6DFF03F4CD0E3CC4577ED1C0C" unitRef="shares">120475</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range3Member" decimals="INF" id="Fact-7A7A0AF5CE478CF32FF6CC45781FD8AE" unitRef="shares">83000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range4Member" decimals="INF" id="Fact-B165A792F81165695D21CC457801A7CA" unitRef="shares">268900</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range5Member" decimals="INF" id="Fact-B52025B0CB6B52226B9DCC45785B4EB2" unitRef="shares">175112</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range6Member" decimals="INF" id="Fact-182F95EFBEEE5B51D400CC45781FF5BD" unitRef="shares">99189</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range7Member" decimals="INF" id="Fact-84658FDA0D25BDC7C76D3DF7E7A1A010" unitRef="shares">79252</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range8Member" decimals="INF" id="Fact-EE39F27361CF0DA69DE3CC457865C25F" unitRef="shares">10002</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_TotalRangeMember" decimals="INF" id="Fact-B48D9F547E0B75863F83EF636427CD34" unitRef="shares">938730</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range1Member" decimals="INF" id="Fact-24BDC66C8168008FFAC1CC45781F7375" unitRef="shares">102800</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range2Member" decimals="INF" id="Fact-5096FDFD331FFECD9979CC457851B8A6" unitRef="shares">120475</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range3Member" decimals="INF" id="Fact-5BDEB33AE3F054D01025CC457829F45D" unitRef="shares">83000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range4Member" decimals="INF" id="Fact-979862C39081C3357324CC457833DF3D" unitRef="shares">288960</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range5Member" decimals="INF" id="Fact-4D9780AFB6FBE721BAD8CC457847CFA9" unitRef="shares">261923</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range6Member" decimals="INF" id="Fact-99A2CEE2186894B92A11CC45780B9CB1" unitRef="shares">176813</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range7Member" decimals="INF" id="Fact-4A296DFD281FCEC7B05B3DF7DF9B07CD" unitRef="shares">129417</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range8Member" decimals="INF" id="Fact-21D10D4D9E11EECBF894CC4577D9F90F" unitRef="shares">1126875</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_TotalRangeMember" decimals="INF" id="Fact-F5030AD06E9B7B7F90DEEF636529530F" unitRef="shares">2290263</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range1Member" decimals="2" id="Fact-1760AC8F2FC5CFEFBA82EF6365187B6D" unitRef="usdPerShare">1.37</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range2Member" decimals="2" id="Fact-3C06C35C071FFFE7D167EF63642A9025" unitRef="usdPerShare">1.88</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range3Member" decimals="2" id="Fact-87784FFAB00C1D19E278EF63650BF620" unitRef="usdPerShare">2.78</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range4Member" decimals="2" id="Fact-07801E3FDA449F151816EF63652BC0BD" unitRef="usdPerShare">4.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range5Member" decimals="2" id="Fact-73A6F0110EC888337150EF63651E6FA7" unitRef="usdPerShare">7.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range6Member" decimals="2" id="Fact-825076E24537905E101FEF63651F59E1" unitRef="usdPerShare">10.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range7Member" decimals="2" id="Fact-658574B1BCC1A0220D043DF7DD400EBA" unitRef="usdPerShare">13.39</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range8Member" decimals="2" id="Fact-CB6F4F1069D7B6CD9FAFEF6365095DBF" unitRef="usdPerShare">17.57</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_TotalRangeMember" decimals="2" id="Fact-6F045216E2FBF87931E7EF63651E0A0F" unitRef="usdPerShare">17.57</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="D2014Q1March26" id="Fact-88A2E5347252D42366BF3DAC1057EA4C">P30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="D2015Q1Mar25-Mar25" id="Fact-D53C9EB882FAC5EB511B3DAE775BEF1B">P30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2011Q2June22_us-gaap_PlanNameAxis_abus_A2007PlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-4323783A500CC5D799A7EF6364D2935D">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2011Q2June22_us-gaap_PlanNameAxis_abus_A2011PlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-044214A0CC893E571EE0EF6364C001F1">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" id="Fact-626AE0C599A4F1D99180CC45D2A145A7">P9Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" id="Fact-12860723A3FF3FEDF509CC45D2BFC5C8">P8Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" id="Fact-C48F936EA24BD0153C62CC45D2AB6A6D">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2015Q4" decimals="-3" id="Fact-41F7A611734B9E7D73D73E858B2970F2" unitRef="usd">994000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="-3" id="Fact-AA8C1C0F6D4A7B6B9BCC3F05C9178AA7" unitRef="usd">337000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember" decimals="-3" id="Fact-E61962231806409BC90B3EA2DABCF8B4" unitRef="usd">187000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="FI2014Q4" decimals="INF" id="Fact-158A2BE7EC248B4E2CD5CC459AA7F794" unitRef="shares">441230</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="FI2015Q4" decimals="INF" id="Fact-99483A8DE7EEA28F3228EF6364F1D16B" unitRef="shares">1351541</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="FI2015Q4_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-CA0E477375B097DF0CDE3E60A4C00D6C" unitRef="shares">97063</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="FI2015Q4_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-ED18D55098F933DE75A93E58F3626E61" unitRef="shares">96382</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="I2015Q1March04_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-21FC6FBDD326C571E25F3E609E94C303" unitRef="shares">129417</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="I2015Q1March04_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-D83EA69502F100755ACD3E58EDDCD4BA" unitRef="shares">128510</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="D2015Q4Mar05-Dec31_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-2D2EA132BBE5B8D365A43E60A2ACE309" unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="D2015Q4Mar05-Dec31_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-1DF6FB1B7EB0D5755BA03E58F0C4B3F6" unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="FD2015Q4YTD" decimals="INF" id="Fact-415E9C71CE09DCE591D4CC459ABBCC7B" unitRef="shares">148853</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range1Member" id="Fact-50E7CBE3CC2BD1E7DBBECC45783DDA76">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range2Member" id="Fact-B5AB6FC901B02F2E1B76CC4578A198D4">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range3Member" id="Fact-3DDC9F9A771084697DC2CC45783D7CDF">P2Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range4Member" id="Fact-C8074B106B79E051F3C9CC4577E39090">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range5Member" id="Fact-12C308C4C00DA12B176CCC45788DF735">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range6Member" id="Fact-4599956A5997A8E4D6DFCC45785175F4">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range7Member" id="Fact-BF33583A2C749D70AED83DF7E222C23C">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range8Member" id="Fact-2DAEA9FBB239C303EAC2CC457883E4BA">P9Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_TotalRangeMember" id="Fact-8FDCB9F340B56961DF57CC45781585FB">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2015Q4YTD" id="Fact-8A82666E7E8DF29D05E13E9232DBA243">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" id="Fact-9E655CB1E26C1D7A18223EE3578DB5CD">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="D2015Q4Mar04-Dec31_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="-3" id="Fact-CF3D000DED589C8064DD3EE893344A7C" unitRef="usd">620000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2013Q4YTD" decimals="-3" id="Fact-41AFF9D47E7FD1B0A91E3E98994934D2" unitRef="usd">955000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2014Q4YTD" decimals="-3" id="Fact-1705ABD76D930EF3B8A23E9877D75C09" unitRef="usd">2505000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BC5FE1179F6424B12BF83E974A184491" unitRef="usd">1718000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="D2015Q4Mar05-Dec31_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-1D3236BD1C1326E482463E60A0FBDFA0" unitRef="shares">32354</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="D2015Q4Mar05-Dec31_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-67276A077D4F73BF0B503E58EF39B221" unitRef="shares">32128</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="FD2015Q4YTD" decimals="INF" id="Fact-AC37233233EEB8629559CC459ABBDC74" unitRef="shares">250461</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range1Member" decimals="2" id="Fact-26C25061BB65145DE54ECC4577EDDF58" unitRef="usdPerShare">1.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range2Member" decimals="2" id="Fact-EFC3DB52BFBBD6D848E0CC457851F858" unitRef="usdPerShare">1.66</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range3Member" decimals="2" id="Fact-C548F9118FC92CC5E155CC45783DFFB7" unitRef="usdPerShare">2.56</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range4Member" decimals="2" id="Fact-26BB3ED414CB5A15591FCC4578791CCC" unitRef="usdPerShare">3.83</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range5Member" decimals="2" id="Fact-756F9A09979E49853939CC457801B55B" unitRef="usdPerShare">6.12</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range6Member" decimals="2" id="Fact-540C329B6F44F5E17281CC4578971D33" unitRef="usdPerShare">9.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range7Member" decimals="2" id="Fact-19C1C2DDA90B044EEABB3DF7EADD11CF" unitRef="usdPerShare">11.90</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_Range8Member" decimals="2" id="Fact-2B8B4E458F14B5815D67CC4577E382B6" unitRef="usdPerShare">17.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2015Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_abus_TotalRangeMember" decimals="2" id="Fact-94A6DD786B070F2B719CCC4577F734A0" unitRef="usdPerShare">4.98</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="D2015Q4Dec31-Dec31_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" id="Fact-F27FB34726C129F0680E3F057FDF703C">P8Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD" id="Fact-2A094B955AB1A6B5DA5F3E83ECBD611A">P6Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_abus_ProtivaShareOptionsMember_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember" id="Fact-2FC890C2D5E40AEDF7073EA10ED6F81B">P1Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharesIssued contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-8B7C40418DDCB5C4C0CFEF63647333BD" unitRef="shares">14305356</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-4107F66F25B47D5BFFE233349C909856" unitRef="shares">19048900</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-BC56702C3D8706C8BE91333596B03F60" unitRef="shares">22438169</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-281DA5AEEC7B32BEF9093335FDF4BF97" unitRef="shares">54570691</us-gaap:SharesIssued>
	<us-gaap:ShortTermInvestments contextRef="FI2014Q4" decimals="-3" id="Fact-75B3C0E39B6D47FA3D772EC20DFB4B90" unitRef="usd">39974000</us-gaap:ShortTermInvestments>
	<us-gaap:ShortTermInvestments contextRef="FI2015Q4" decimals="-3" id="Fact-43250A911C1919E91905EF63645EE8CC" unitRef="usd">14525000</us-gaap:ShortTermInvestments>
	<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="D2015Q1Mar04-Mar04_us-gaap_AwardTypeAxis_abus_SharesIssuedSubjectToRepurchaseProvisionMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="0" id="Fact-D8AD618866919CCD5C73388BDDE8A94A" unitRef="shares">3625412</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
	<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="D2015Q1Mar04-Mar04_us-gaap_AwardTypeAxis_abus_SharesIssuedWithoutSubjectsMember_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="INF" id="Fact-277D70F963A4F1089BB3388BD07F4379" unitRef="shares">20347906</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
	<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_abus_ArbutusInc.Member" decimals="INF" id="Fact-D0A558274078AADD3862388A387415F6" unitRef="shares">23973315</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
	<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D9A853D97231F1B0F8AA33331BE204F1" unitRef="shares">23973315</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2014Q4YTD" decimals="INF" id="Fact-11A5AB3CF0AE1EE5123AEF6365062A58" unitRef="shares">5285</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2013Q4Nov02" decimals="INF" id="Fact-685D9C2D9261E3769BDDEF6364C83DB9" unitRef="shares">562500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2013Q4Oct22" decimals="INF" id="Fact-E6355A4027C0724994A0EF6364D04CDC" unitRef="shares">3750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2014Q1March26" decimals="INF" id="Fact-29ABA5E22F39E40D572FEF6364C2DA76" unitRef="shares">2125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q1Mar25-Mar25" decimals="INF" id="Fact-C1E1C6F26416376CFA133A4F393D0C13" unitRef="shares">7500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D9050AA967AC0FD82CA7EF63644E5382" unitRef="shares">4312500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-0F084CF63BFA9D95BE39EF63642CB22E" unitRef="shares">2125000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-5E506D2ABFA4A996A41E33389009964A" unitRef="shares">7500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-0AF93697BD51F477B3CFEF63649F3936" unitRef="shares">305448</us-gaap:StockIssuedDuringPeriodSharesOther>
	<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-01B5C58BE11D2FE46E97EF63643DB401" unitRef="shares">615763</us-gaap:StockIssuedDuringPeriodSharesOther>
	<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D5C0C27CA8F36DEB61E0333888669FDF" unitRef="shares">18750</us-gaap:StockIssuedDuringPeriodSharesOther>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="D2015Q4Mar05-Dec31_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-E096B202E7FE93F8E6F43E4A22304749" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="D2015Q4Mar05-Dec31_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" decimals="INF" id="Fact-4CD0D810EC8492949D6D3E4A1D4CC9C2" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-C8524245BF12D7F58030CC45B8C1F38E" unitRef="shares">1350</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-6BF0955B7E0F6BDE9529CC456521D4E1" unitRef="shares">124246</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2013Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-05B71E582D0595EC6A65CC45B8C16CC1" unitRef="shares">2000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-CD36E7D3B5B8D848625BEF63648FB4A6" unitRef="shares">125596</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-CFBB7EA8FCCB4FB31803CC45B7A922DF" unitRef="shares">25754</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-C364928F4454315EFE3FCC45670D9A79" unitRef="shares">622752</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-FF53295285F7C3C58C21CC45B78BC717" unitRef="shares">38145</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-831F61CCA7BE7A6B86B33334E673436E" unitRef="shares">648506</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_abus_EquivalentNumberOfCompanyCommonSharesMember_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-02C01D2144ECFB8437D9CC45B80DCBCF" unitRef="shares">242164</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ArbutusPlansMember" decimals="INF" id="Fact-DCCF41D7B8CB12F166D7CC4566817DEC" unitRef="shares">398293</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaShareOptionsMember" decimals="INF" id="Fact-824D8EA65B8E995188E8CC45B7959417" unitRef="shares">358675</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A5776D9F2745C7D239AE3338C0BF8529" unitRef="shares">640457</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9AEBBF0AE9D3258F89163339ECEBE34A" unitRef="usd">381942000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1ED73F420B40C36413E73339E1345A7B" unitRef="usd">1127000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-6B77F022361989F094113332E9F42289" unitRef="usd">380815000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2013Q4YTD" decimals="-3" id="Fact-311623B0E3F6E39A3731EF63640D6D04" unitRef="usd">32038000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-DB48EC9C83B28EBE9C7CEF6364A17CD3" unitRef="usd">32038000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD" decimals="-3" id="Fact-347B04627D36BCE55C64EF63648026E3" unitRef="usd">56477000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-EA48A1F864553B35A12FEF6364204090" unitRef="usd">56477000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD" decimals="-3" id="Fact-8304FD7027E142621385333962F7D6B6" unitRef="usd">142177000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-057995AE3EE95F2AEB99333891834D54" unitRef="usd">142177000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2013Q4YTD" decimals="-3" id="Fact-151A06714422099BF5B4EF6364A0DFAF" unitRef="usd">2143000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-C229C1A9AC9A50646C59EF63645FE7ED" unitRef="usd">2143000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2014Q4YTD" decimals="-3" id="Fact-6E48339CF9FA2E960E71333568F839E9" unitRef="usd">11791000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-66684D28805D19A8E95FEF636427571F" unitRef="usd">11791000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2015Q4YTD" decimals="-3" id="Fact-37D32EA6BC18568BE85B33388F3CF73F" unitRef="usd">371000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueOther contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-C11E531FFFF7A018D3C1333889D5076A" unitRef="usd">371000</us-gaap:StockIssuedDuringPeriodValueOther>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2013Q4YTD" decimals="-3" id="Fact-285BF50BDF7A07DF09A0EF636483F872" unitRef="usd">389000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5AA05AAAF038D3F641D8EF636512174E" unitRef="usd">-346000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2013Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D0E7FD5BC74A64EC22A9EF63647E73F7" unitRef="usd">735000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q4YTD" decimals="-3" id="Fact-8B4FBA48B2239A44CEF6EF63647D451F" unitRef="usd">2616000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D3B6A4B81612999FE26AEF63647D3F74" unitRef="usd">-2418000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2014Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-5CA6923E4AF690594E93EF63652A83A7" unitRef="usd">5034000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-3" id="Fact-FA77DD206A19A4F204193338878E9050" unitRef="usd">1651000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5D25D8399348D28AB6C3333883899B4E" unitRef="usd">-2535000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-FA4EF09CB06072C85161333882069CD0" unitRef="usd">4186000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4" decimals="-3" id="Fact-28B1675F445B53B21D87EF63642D0B14" unitRef="usd">40919000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-111D92BF83CFBCFF0538EF6364AE696D" unitRef="usd">-12689000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5E4341D8CB4626FFA5BFEF636476371B" unitRef="usd">24786000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D7F514AEF59A073A1881EF63648FED41" unitRef="usd">181786000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2012Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-0B2D4A21B2CF9DC7B49EEF63649F9531" unitRef="usd">-152964000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4" decimals="-3" id="Fact-86C7D2222D402E7571403334A4B831B1" unitRef="usd">59194000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-0CC3D51BDC3019121C7F3334A312575F" unitRef="usd">-15824000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-3B272BF030B5045A1FEA33349FD18009" unitRef="usd">25343000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A5424D5FA10DADA9BC9533349E3567D8" unitRef="usd">216702000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2013Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-920BB80467C0D5F99DFD3334A172C052" unitRef="usd">-167027000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-711EF2D5E7929D03A534EF636497E6EB" unitRef="usd">88035000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-08B898B19953B03DF9093335A150DD04" unitRef="usd">-22313000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-CD8F1E944D1F41B108EF3335E162DC64" unitRef="usd">26208000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-FC8889AEC41DDAB4B4F533359852774A" unitRef="usd">290004000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-D2E1F3B32D702A39796D3335E15F4FE1" unitRef="usd">-205864000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-BEBC0007EDEA51391662EF6364727863" unitRef="usd">547679000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-625E4A655D8444CAA3B733360475CC05" unitRef="usd">-49782000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7E5EEA2BE77EDA04C1703336013576A6" unitRef="usd">30206000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-860623DC86BD9D71DC673335FF9911D9" unitRef="usd">834240000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-34EAC10F696DBF64A6D8333602D4B9FC" unitRef="usd">-266985000</us-gaap:StockholdersEquity>
	<us-gaap:UnbilledReceivablesCurrent contextRef="FI2014Q4" decimals="-3" id="Fact-54D8BE5978CF81ED2B70EF63643EFF1C" unitRef="usd">538000</us-gaap:UnbilledReceivablesCurrent>
	<us-gaap:UnbilledReceivablesCurrent contextRef="FI2014Q4_us-gaap_ConcentrationRiskByTypeAxis_abus_ForeignCurrencyExposureMember" decimals="-3" id="Fact-5CB59B0A676889A4851934116754DB93" unitRef="cad">624000</us-gaap:UnbilledReceivablesCurrent>
	<us-gaap:UnbilledReceivablesCurrent contextRef="FI2015Q4" decimals="-3" id="Fact-99DF6A9D3CB979A9EED5EF63649F8711" unitRef="usd">128000</us-gaap:UnbilledReceivablesCurrent>
	<us-gaap:UnbilledReceivablesCurrent contextRef="FI2015Q4_us-gaap_ConcentrationRiskByTypeAxis_abus_ForeignCurrencyExposureMember" decimals="-3" id="Fact-F88D83173D0DCAE0FC6034116745E656" unitRef="cad">178000</us-gaap:UnbilledReceivablesCurrent>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2014Q4" decimals="-3" id="Fact-27634BEC13046AC17DB3EF6364C03253" unitRef="usd">5099000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2015Q4" decimals="-3" id="Fact-FEC622AC3D50C9BEA824EF6364D5036C" unitRef="usd">883000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="FI2012Q4" decimals="-3" id="Fact-CD2F6339BBA933D5D915CD9A37F818EC" unitRef="usd">4015000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
	<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="FI2013Q4" decimals="-3" id="Fact-71C13687F8AB27EEE7BDCD9A37FA00F3" unitRef="usd">5379000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
	<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="FI2014Q4" decimals="-3" id="Fact-E0DC8301FFE40C714E63CD9A37FD4209" unitRef="usd">5099000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
	<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="FI2014Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-6EB6841D2B8A30EB36F2CD9A38017D4F" unitRef="usd">5099000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
	<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="FI2015Q4" decimals="-3" id="Fact-4C258B58041B76E963003810B66EDB9F" unitRef="usd">883000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
	<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="FI2015Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-85302C7EFCBCA72B5D54CD9A10BAF35F" unitRef="usd">883000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2013Q4YTD" decimals="0" id="Fact-D42C0D1D2D3E14EAC361EF636404DC8A" unitRef="shares">15302680</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2014Q4YTD" decimals="0" id="Fact-D85FE66F3357EF896B6EEF6364A2B330" unitRef="shares">21603136</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q4YTD" decimals="0" id="Fact-2FDF01526B9A6781E672EF636528E64B" unitRef="shares">45462324</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2013Q4YTD" decimals="0" id="Fact-EA1B5D7898AE43C2E801EF6364F404BD" unitRef="shares">15302680</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2014Q4YTD" decimals="0" id="Fact-13DFEEAB37B127DFE9E2EF6364EBA0CF" unitRef="shares">21603136</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q4YTD" decimals="0" id="Fact-AD31153A6427F40719F5EF63651C3FED" unitRef="shares">45462324</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<abus:ChangesInFairValueOfWarrantsTableTextBlock contextRef="FD2015Q4YTD" id="Fact-BA9227DFCDED428F651DEF6364423135">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the changes in fair value of the Company&amp;#8217;s warrants:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="23%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability at beginning&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants issued in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;warrants exercised&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;in the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increase (decrease) in fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability at end&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(312&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(541&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</abus:ChangesInFairValueOfWarrantsTableTextBlock>
	<abus:GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-E5D317908549EA27CC06EF63645CE2A0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Government grants and refundable investment tax credits&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government grants and tax credits provided for current expenses is included in the determination of income or loss for the year, as a reduction of the expenses to which it relates. Government grants and tax credits towards the acquisition of property and equipment is deducted from the cost of the related property and equipment.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</abus:GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock>
	<abus:GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock contextRef="FD2015Q4YTD" id="Fact-90192621AF75A973DBD4EF636402FBC8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Government grants and refundable investment tax credits&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government grants and refundable investment tax credits have been recorded as a reduction in research and development expenses. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(a) Government grants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2014, the Company entered into a Manufacturing and Clinical Trial Agreement with the University of Oxford to provide the new TKM-Ebola-Guinea therapeutic product for clinical studies in West Africa. The University of Oxford is the representative of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), who conducted clinical studies of TKM-Ebola-Guinea in Ebola virus infected patients, with funding provided by the Wellcome Trust. In January 2015, the Company received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,098,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from ISARIC for materials manufactured and used in the March 2015 TKM-Ebola-Guinea Phase II single arm trial conducted in Sierra Leone. In June 2015, the Company announced closing of the enrollment for the trial as it reached a futility boundary, which was a predefined statistical endpoint. No further funding is expected under this grant. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government grants for the year ended December 31, 2015 include &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,245,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in funding from the U.S. National Institutes of Health (2014 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$172,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(b) Refundable investment tax credits&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s estimated claim for refundable Scientific Research and Experimental Development investment tax credits for the year ended December 31, 2015 is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$196,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2014 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$52,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</abus:GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock>
	<abus:NetLiquidityDisclosureTableTextBlock contextRef="FD2015Q4YTD" id="Fact-E07C372C8F7B8EB6BADAEF63643AD744">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The net liquidity of the Company is considered to be the cash and cash equivalents and short-term investments less accounts payable and accrued liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents and&amp;#160;short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;181,304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Accounts payable and accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(8,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,328&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;172,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;102,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</abus:NetLiquidityDisclosureTableTextBlock>
	<abus:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock contextRef="FD2015Q4YTD" id="Fact-5FD7C0A339B7091365CAEF6364C12234">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company records depreciation using the straight-line method over the estimated useful lives of the capital assets as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="77%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Useful life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer and office equipment &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</abus:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
	<abus:ReplacementAwardsPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-00489F257073C313DB5233875A327FAD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Replacement awards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Replacement awards are share-based payment awards exchanged for awards held by employees of Arbutus Inc. As part of the Company&amp;#8217;s acquisition of Arbutus Inc., Arbutus shares were exchanged for Arbutus Inc.&amp;#8217;s shares subject to repurchase rights held by Arbutus Inc.&amp;#8217;s employees - see note 3.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at the date of acquisition of Arbutus Inc., the Company determined the total fair value of replacement awards and attributed a portion of the replacement awards to pre-combination service as part of the total acquisition consideration, and a portion to post-combination service, which is recognized as compensation expense over the expiry period of repurchase provision rights subsequent to the acquisition date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The replacement awards consist of common shares that were issued at acquisition. Accordingly, as stock compensation expense related to these awards is recognized, share capital is increased by a corresponding amount. Replacement awards are excluded in the calculation of basic net income (loss) per share until the repurchase rights have expired.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</abus:ReplacementAwardsPolicyTextBlock>
	<abus:SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock contextRef="FD2015Q4YTD" id="Fact-CD088CC052BA774F289F339853384AB0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The following table presents a summary of revisions and adjustments made to the preliminary estimates as previously disclosed to the finalized purchase price allocation:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="46%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="16%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="16%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="16%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Preliminary Amounts Recognized as of Acquisition Date &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Measurement Period Adjustments&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#160;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts Recognized as of Acquisition Date (as adjusted)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Purchase Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Identifiable assets acquired and liabilities assumed:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Prepaid expenses and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;147&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;147&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Acquired intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;389,652&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;391,649&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;155,865&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,649&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,514&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Other non-current liabilities (note 8)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,736&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,991&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Deferred income tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(155,865&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,644&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(162,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total purchase price allocation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preliminary purchase price as of the acquisition date of March 4, 2015 as previously disclosed in the notes to consolidated financial statements included in the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2015.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The measurement period is from the acquisition date of March 4, 2015 to the date the Company finalized the purchase price allocation on December 31, 2015. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</abus:SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock>
	<abus:TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock contextRef="FD2015Q4YTD" id="Fact-C43ABBCCACB7C42F32F0EF6364C0E465">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes information pertaining to stock options outstanding at December 31, 2015 under the Arbutus Plans:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="23" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Options outstanding December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Options exercisable December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Range of&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Exercise prices (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;of options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;price (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;of options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;price (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;102,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;102,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;120,475&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;120,475&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$2.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$2.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;83,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;83,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$3.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$4.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;288,960&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;268,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$5.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$7.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;261,923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;6.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;175,112&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;6.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$8.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$10.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;176,813&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;9.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;99,189&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;9.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$10.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$13.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;129,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;11.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;79,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;11.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$13.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$17.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,126,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;17.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;10,002&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;17.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$17.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,290,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;7.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;11.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;938,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</abus:TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock>
	<abus:WarrantsPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-BA328B1362710A87A134EF63644C1BFB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for the warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company&amp;#8217;s own stock, on the understanding that in compliance with applicable securities laws, the registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies warrants in its consolidated balance sheet as a liability which is revalued at each balance sheet date subsequent to the initial issuance. The Company uses the Black-Scholes pricing model to value the warrants. Determining the appropriate fair-value model and calculating the fair value of registered warrants requires considerable judgment. A small change in the estimates used may cause a relatively large change in the estimated valuation. The estimated volatility of the Company&amp;#8217;s common stock at the date of issuance, and at each subsequent reporting period, is based on historic fluctuations in the Company&amp;#8217;s stock price. The risk-free interest rate is based on the Government of Canada rate for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is based on the historical pattern of exercises of warrants&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</abus:WarrantsPolicyTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-BCF8304D27B4E979D892EF63644DA24F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation) was incorporated on October&amp;#160;6, 2005 as an inactive wholly owned subsidiary of Inex Pharmaceuticals Corporation (Inex). Pursuant to a &amp;#8220;Plan of Arrangement&amp;#8221; effective April&amp;#160;30, 2007, the business and substantially all of the assets and liabilities of Inex were transferred to the Company. The consolidated financial statements for all periods presented herein include the consolidated operations of Inex until April&amp;#160;30, 2007 and the operations of the Company thereafter.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; wholly-owned subsidiaries as at December 31, 2015: Arbutus Biopharma, Inc. (formerly OnCore Biopharma, Inc.) Protiva Biotherapeutics Inc. (Protiva), Protiva Biotherapeutics (USA) Inc. (Protiva USA), and Protiva Agricultural Development Company Inc. (&amp;#8220;PADCo&amp;#8221;). Protiva and Protiva USA were acquired on May 30, 2008. PADCo was incorporated on January 9, 2014. Arbutus Inc. was acquired by way of a Merger Agreement on March 4, 2015, which included Arbutus Inc.'s wholly-owned subsidiary, Enantigen Therapeutics, Inc. (Enantigen) - see note 3. Enantigen was merged with Arbutus Inc. on September 30, 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These consolidated financial statements include the accounts of the Company and three of its wholly-owned subsidiaries, Arbutus Inc., Protiva and Protiva USA. All intercompany transactions and balances have been eliminated on consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company records its investment in PADCo using the equity method. The Company has determined that PADCo is a variable interest entity (&amp;#8220;VIE&amp;#8221;) of which it is not the primary beneficiary. The Company is not the primary beneficiary as it does not have the power to make decisions that most significantly affect the economic performance of the VIE nor does the Company have the right to receive benefits or the obligation to absorb losses that in either case could potentially be significant to the VIE. PADCo is described further in note 4(b).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="FD2015Q4YTD" id="Fact-6DB2603A0500E0C862EC339A9B73CB56">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The pro forma financial information presented includes acquisition costs, amortization charges for acquired tangible assets, impairment charge on acquired intangible assets (as described in note 3b below), but does not include amortization charges for acquired intangible assets as these assets have not yet been put in use.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="47%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="24%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="24%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Pro forma information&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;24,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(109,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(51,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(67,416&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(56,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(1.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-27885BA7477D09399F5B2E8546005CD3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Merger with Arbutus Biopharma, Inc. (formerly OnCore BioPharma, Inc.)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(a)&amp;#160;&amp;#160;&amp;#160; &amp;#160;&amp;#160;Purchase Price Allocation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 11, 2015, the Company entered into a Merger Agreement to acquire &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the outstanding shares of Arbutus Inc. (formerly OnCore Biopharma, Inc.) and its wholly-owned subsidiary, Enantigen (see note 9). Arbutus Inc. was a privately owned U.S. company focused on discovery, development and commercialization of an all-oral cure regimen for patients with HBV. The merger was approved by the Company&amp;#8217;s shareholders on March 3, 2015 and closed on March 4, 2015. Arbutus Inc.&amp;#8217;s results of operations and fair value of assets acquired and liabilities assumed are included in the Company&amp;#8217;s consolidated financial statements from the date of acquisition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The transaction has been accounted for using the acquisition method based on ASC 805, Business Combinations, with Arbutus (formerly Tekmira) identified as the acquirer, based on managements&amp;#8217; analysis and evaluation of the form of the acquisition, the relative contribution and rights of the predecessor groups post-closing, and the relative number of shares issued by the Company on acquisition of Arbutus Inc. Under the acquisition method, the consideration transferred is measured at fair value; common shares as consideration are issued at the market price as at the acquisition date. The excess of the purchase price over the preliminary fair value assigned to the net assets acquired has been recorded as goodwill. Acquisition costs were expensed as incurred. The Company recorded $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,656,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of acquisition costs for the year ended December 31, 2015 (2014 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$462,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company issued consideration with a total fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$381,942,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on acquisition. Of this consideration, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,973,315&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares were issued, which is comprised of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,347,906&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares issued without subjects and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,625,412&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares issued to Arbutus Inc.&amp;#8217;s founding executives and subject to repurchase provisions. The fair value of the common shares issued without subjects has been determined to be the Company&amp;#8217;s NASDAQ closing price of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18.26&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on the date prior to the acquisition&amp;#8217;s consummation, March 4, 2015. The total fair value of the common shares issued subject to repurchase provision has been determined to be $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66,196,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, using the Black-Scholes pricing model with assumed risk-free interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.74%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, volatility of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; dividend yield and an expected life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Of the total fair value, $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,262,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$56,934,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; will be recognized as compensation expense over the period of expiry of repurchase provision rights and is not included in the total acquisition consideration. In July 2015, in conjunction with amendments to the employment contracts of Arbutus Inc.&amp;#8217;s founding executives, the Company amended the repurchase provision rights period of expiry from August 2018 to August 2017. This amendment results in an acceleration of compensation expense recognized in each subsequent period by approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,900,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per quarter, effective in Q3 2015. The Company recorded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$16,687,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in stock-based compensation expense related to services performed during the period of expiration of repurchase provision rights from the acquisition date through to December 31, 2015. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at the acquisition date, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,625,412&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares were issued and outstanding which were and continue to remain subject to a repurchase provision. Subsequent to the acquisition date and the July 2015 amendment to the repurchase provision rights, the rights expire at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;302,120&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on November 30, 2015 and February 29, 2016 and at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;503,552&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares every three months thereafter commencing May 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has further reserved &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;184,332&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares for the future exercise of Arbutus Inc. stock options. The total fair value of Arbutus Inc. stock options at the date of acquisition has been determined to be $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,287,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, using the Black-Scholes pricing model with an assumed risk-free interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.97%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, volatility of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; dividend yield and an expected life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which are consistent with the assumption inputs used by the Company to determine the fair value of its options. Of the total fair value, $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,127,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,160,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; will be recognized as compensation expense over the vesting period of the stock options through to December 2018. The Company has included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$463,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; compensation expense related to the vesting of Arbutus Inc. stock options from the acquisition date through to December 31, 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The aggregate fair value of consideration transferred to acquire Arbutus Inc.&amp;#8217;s outstanding shares has been determined to be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$381,942,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and has been attributed to fair values of assets acquired and liabilities assumed. The Company has refined the preliminary allocation of the purchase price for intangible assets, goodwill, contingent consideration and deferred tax liability from what was disclosed in prior periods. The following table summarizes the Company&amp;#8217;s finalized purchase price allocation as at December 31, 2015:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consideration paid:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Common shares issued without subjects&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;371,553&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Common shares issued subject to repurchase provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,262&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Common shares issuable for Arbutus Inc. stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Identifiable assets acquired and liabilities assumed:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Prepaid expenses and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;147&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Acquired intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;391,649&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,514&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Other non-current liabilities (note 9)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Deferred income tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(162,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total purchase price allocation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of intangible assets is estimated to be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$391,649,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The fair value of each IPR&amp;amp;D asset is estimated using the income approach. The income approach uses valuation techniques to discount future economic benefits attributed to the subject intangible asset to a present value. Present value is based on current market expectations about those future amounts and includes management&amp;#8217;s estimates of risk-adjusted future incremental earnings that may be achieved upon regulatory approval, promotion, and distribution associated with the rights and includes estimated cash flows of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and a discount rate of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.7%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The identifiable intangible assets acquired consist of in-process research and development (IPR&amp;amp;D) HBV assets, as summarized in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; Cyclophilins&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,007&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; Immune Modulators&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; Antigen Inhibitors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; cccDNA Sterilizers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;391,649&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All IPR&amp;amp;D acquired is currently classified as indefinite-lived and is not currently being amortized. IPR&amp;amp;D becomes definite-lived upon the completion or abandonment of the associated research and development efforts, and will be amortized from that time over an estimated useful life based on respective patent terms. The fair value of each IPR&amp;amp;D asset will continue to be evaluated on a quarterly basis for indicators of impairment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Based on the fair values above, an amount of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,514,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been allocated to goodwill, which represents the excess of the purchase price over the fair values assigned to the net assets acquired. Goodwill is attributable to synergies expected to arise after the Company&amp;#8217;s acquisition of Arbutus Inc. The full amount of the value of goodwill has been assigned to the entire Company, since management has determined that the Company has only &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; reporting unit. The goodwill is not deductible for tax purposes, and is not amortized, but will be evaluated for impairment on an annual basis or more often if the Company identifies impairment indicators that would require earlier testing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Reconciliation of preliminary to final purchase price allocation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the year ended December 31, 2015, the Company finalized the purchase price allocation and made revisions to certain preliminary estimated fair values of assets acquired and liabilities assumed. The following table presents a summary of revisions and adjustments made to the preliminary estimates as previously disclosed to the finalized purchase price allocation:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="46%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="16%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="16%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="16%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Preliminary Amounts Recognized as of Acquisition Date &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Measurement Period Adjustments&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#160;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts Recognized as of Acquisition Date (as adjusted)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Purchase Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Identifiable assets acquired and liabilities assumed:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Prepaid expenses and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;147&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;147&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Acquired intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;389,652&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;391,649&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;155,865&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,649&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,514&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Other non-current liabilities (note 8)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,736&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,991&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Deferred income tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(155,865&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,644&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(162,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total purchase price allocation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preliminary purchase price as of the acquisition date of March 4, 2015 as previously disclosed in the notes to consolidated financial statements included in the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2015.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The measurement period is from the acquisition date of March 4, 2015 to the date the Company finalized the purchase price allocation on December 31, 2015. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The measurement period adjustment for intangible assets acquired was made as the Company revised certain royalty rates on future sales of various intangible assets acquired. This resulted in an increase in deferred income tax liability associated with the intangible assets. In addition, the Company revised its preliminary tax rate based on management's revised analysis of a combined federal and state tax rate in the jurisdiction in which the Company expects the deferred tax liability to be settled or realized. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The measurement period adjustment for other non-current liabilities relate to the contingent consideration payable to former Enantigen shareholders upon the achievement of certain regulatory, development and sales milestones, as described in note 9. The adjustment relates to management's revision to the probabilities used in a probability weighted assessment of the likelihood of milestones being met and timing of such payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Based on the above measurement period adjustments, the increase to goodwill of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6,649,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; results in a final goodwill allocation of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$162,514,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As described in note 2 and further below, the Company conducts its annual goodwill impairment test on December 31st.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Pro forma information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The amount of net loss of Arbutus Inc. included in the consolidated statements of operations from the acquisition date, through the period ended December 31, 2015 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13,658,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Arbutus Inc. did not earn any revenues from the acquisition date through the year-ended December 31, 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the unaudited pro forma results for the year ended December 31, 2015 and 2014. The pro forma financial information combines the results of operations of Arbutus, Arbutus Inc., Protiva, Protiva USA, and Enantigen as though the businesses had been combined as of the beginning of fiscal 2014. The pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the merger had taken place at the beginning of fiscal 2014. The pro forma financial information presented includes acquisition costs, amortization charges for acquired tangible assets, impairment charge on acquired intangible assets (as described in note 3b below), but does not include amortization charges for acquired intangible assets as these assets have not yet been put in use.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="47%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="24%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="24%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Pro forma information&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;24,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(109,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(51,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(67,416&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(56,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(1.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(b)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Impairment evaluations for intangible assets and goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates the recoverable amount of intangible assets on an annual basis and performs an annual evaluation of goodwill as of December 31 each year, unless there is an event or change in the business that could indicate impairment and earlier testing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of intangible assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 28, 2015, the Company announced that the development of the cyclophilin drug candidate, OCB-030 has been discontinued. The decision was based on extensive preclinical evaluations performed by the Company of OCB-030 and other competitive cyclophilin inhibitors following the acquisition of Arbutus Inc., which concluded that cyclophilins do not play a meaningful role in HBV biology. Although the final conclusion was made subsequent to the period end, it reflected management&amp;#8217;s best estimate as at September 30, 2015, and as such, the Company recorded an estimated impairment charge of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,990,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and a corresponding income tax benefit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15,196,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;  related to the decrease in deferred tax liability for the discontinuance of OCB-030 in the consolidated statement of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As noted above, the Company finalized its purchase price allocation during the fourth quarter of 2015 by making certain revisions to estimates which included adjustments to the fair value of individual intangible assets acquired. The fair value of cyclophilin inhibitors has been adjusted to be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$39,007,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as compared to management's best estimate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$37,990,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; previously written off in the third quarter. The incremental adjustment to fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,017,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as well as the corresponding incremental adjustment to income tax benefit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$989,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are cumulatively reflected in the Company's consolidated statement of operations and comprehensive loss for the year-ended December 31, 2015. For all other IPR&amp;amp;D, fair values of the intangible assets were calculated to be above the respective carrying values; therefore, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impairment was recorded. The following table summarizes the carrying values, net of impairment of the intangible assets as at December 31, 2015:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; Cyclophilins&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; Immune Modulators&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; Antigen Inhibitors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; cccDNA Sterilizers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;352,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Annual impairment evaluation of goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 31, the Company conducted its annual impairment evaluation of goodwill. Goodwill was recorded as a result of the acquisition of Arbutus Inc. as described in note 3(a), and has a carrying value of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,514,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As part of the evaluation of the recoverability of goodwill, the Company has identified only &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; reporting unit to which the total carrying amount of goodwill has been assigned. The income approach is used to estimate the fair value of the reporting unit, which requires estimating future cash flows and risk-adjusted discount rates. Changes in these estimates and assumptions could materially affect the determination of fair value of the reporting unit and may result in impairment charges in future periods. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2015, the fair value of the reporting unit exceeded the carrying value of the reporting unit, and as such the second step of the impairment test, which measures the amount of impairment charge, was not required. In addition to the income approach, the Company considered the market capitalization of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$242,844,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as at December 31, 2015. Although the Company&amp;#8217;s carrying value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$547,679,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; exceeded the market capitalization, the Company reconciled the income approach determination of fair value with the market capitalization by considering macroeconomic factors, and as such, the Company does not believe that market capitalization appropriately reflected the value of the Company for the purpose of testing goodwill impairment. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impairment charge on goodwill was recorded for the year ended December 31, 2015.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-F8F4874F5AD20913B64CEF63644A1019">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents are all highly liquid instruments with an original maturity of three months or less when purchased. Cash equivalents are recorded at cost plus accrued interest. The carrying value of these cash equivalents approximates their fair value.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-281FF69AF99D19202944EF6364815FB4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Collaborations, contracts and licensing agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following tables set forth revenue recognized under collaborations, contracts and licensing agreements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Collaborations and contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;DoD (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,764&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Monsanto (b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;4,725&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;BMS (d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dicerna (e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,820&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;510&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other RNAi collaborators (g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total research and development collaborations and contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;13,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Licensing fees, milestone and royalty payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Monsanto licensing fees and milestone payments (b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;10,256&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Alnylam and Acuitas licensing fees and milestone payments (c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dicerna licensing fee (e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Spectrum royalty payments (f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;240&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total licensing fees, milestone and royalty payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;11,564&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,215&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;24,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,465&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth deferred collaborations and contracts revenue:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;DoD (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Monsanto current portion (b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dicerna current portion (e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;853&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue, current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;868&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Monsanto long-term portion (b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dicerna long-term portion (e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,271&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,716&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(a)&amp;#160;&amp;#160;&amp;#160; &amp;#160;&amp;#160;Contract with United States Government&amp;#8217;s Department of Defense (&amp;#8220;DoD&amp;#8221;) to develop TKM-Ebola&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On July&amp;#160;14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company&amp;#8217;s lipid nanoparticle technology to treat Ebola virus infection.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company was eligible to receive up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$34,700,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This initial funding was for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle (&amp;#8220;LNP&amp;#8221;) formulation and manufacturing technologies. The contract modification increased the stage one targeted funding by an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6,970,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. On April 22, 2014, the Company and the DoD signed a contract modification to further increase the stage one targeted funding by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,100,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$43,819,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The additional funding was to compensate the Company for unrecovered overheads related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The DoD had the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract&amp;#8217;s budget this would have provided the Company with up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$140,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in funding for the entire program. In December 2014, the DoD exercised an option valued at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to manufacture TKM-Ebola-Guinea, developed by the Company targeting the Ebola-Guinea strain responsible for the current outbreak in West Africa.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year, the Company estimates its labor and overhead rates for the year ahead. At the end of the year the actual labor and overhead rates are calculated and revenue is adjusted accordingly. The Company&amp;#8217;s actual labor and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company&amp;#8217;s efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs.&amp;#160;&amp;#160;During the contractual period, incentive fee revenue and total costs are impacted by management&amp;#8217;s estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method.&amp;#160;&amp;#160;For the years ended December 31, 2014 and 2015, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 1, 2015, the Company received formal notification from the DoD that, due to the unclear development path for TKM-Ebola and TKM-Ebola-Guinea, the Ebola-Guinea Manufacturing and the Ebola-Guinea IND submission statements of work had been terminated, subject to the completion of certain post-termination obligations. &amp;#160;The TKM-Ebola portion of the contract was completed in November 2015. The Company is currently conducting contract close out procedures with the DoD. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(b)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Option and Services Agreements with Monsanto Company (&amp;#8220;Monsanto&amp;#8221;)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the &amp;#8220;Agreements&amp;#8221;). Under the Agreements, Monsanto has an option to obtain a license to use the Company&amp;#8217;s proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, the Company will provide lipid formulations for Monsanto&amp;#8217;s research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$86,200,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; following the successful completion of milestones. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2015, the arrangement was amended to extend the option period by approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months, with payments up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the extension period. From inception of the contract to December 31, 2015, the Company had received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$19,300,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from Monsanto. The amounts received relate to research services and use of the Company&amp;#8217;s technology over the option period, and are recognized as revenue on a straight-line basis over the extended option period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Following the completion of the Phase A extension period in October 2015, no further research activities were conducted under the arrangement, as Monsanto did not elect to proceed to Phase B of the research plan. As such, the Company revised its estimate of the option period, over which payments received from Monsanto is recognized as revenue, to be from inception to December 31, 2015 as the Company believes it no longer has any further obligations to provide future research activities to Monsanto. This resulted in the full release of Monsanto deferred revenue and a recognition of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14,981,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in Monsanto revenue for the year-ended December 31, 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Agreements, the Company has established a wholly-owned subsidiary, PADCo. The Company has determined that PADCo is a variable interest entity (&amp;#8220;VIE&amp;#8221;); however, Monsanto is the primary beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company&amp;#8217;s proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements. The Company&amp;#8217;s initial investment is not significant, and the Company has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The Company has included its investment in PADCo in other assets. There were no significant assets or liabilities for PADCo as at December 31, 2015. There was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; equity income or loss with respect to PADCo recorded for the periods ended December 31, 2014 and December 31, 2015. In March 2016, Monsanto exercised its option to acquire &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the outstanding shares of PADCo and will pay the Company an exercise fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; - refer to note 13 for the subsequent event.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(c)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;License and collaboration with Alnylam Pharmaceuticals, Inc. (Alnylam) and Acuitas Therapeutics Inc. (Acuitas)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Milestone receipts and payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2013, Alnylam initiated a Phase III trial with ALN-TTR02, also known as patisiran, and the associated &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; development milestone was paid to the Company in December 2013. In addition, the Company earned a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$150,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone in March 2014 from Acuitas (formerly AlCana Technologies, Inc.) subsequent to Acuitas receiving a milestone payment from Alnylam with respect to Alnylam initiating a Phase III trial for ALN-TTR02.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2013, the Company initiated Phase I/II clinical trial for TKM-PLK1, resulting in a milestone payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$375,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Alnylam.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Arbitration with Alnylam and Ascletis Pharmaceuticals (Hangzhou) Co. Ltd. (&amp;#8220;Ascletis&amp;#8221;)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 21, 2013, the Company transferred manufacturing process technology to Ascletis to enable them to produce ALN-VSP, a product candidate licensed to them by Alnylam. The Company believed that under its licensing agreement with Alnylam, the technology transfer to Ascletis triggered a $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone obligation from Alnylam to the Company. However, Alnylam demanded a declaration that the Company had not yet met its milestone obligations. The Company disputed Alnylam&amp;#8217;s position. To remedy this dispute, the Company and Alnylam commenced arbitration proceedings as provided for under the agreement.&amp;#160; The hearing date for this arbitration took place in May 2015, and in March 2016, the arbitration proceeding with Alnylam has concluded resulting in no milestone payment to the Company. &amp;#160;The Company has not recorded any revenue in respect of this milestone for the year-ended December 31, 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(d)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Bristol-Myers Squibb (&amp;#8220;BMS&amp;#8221;) collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On May 10, 2010 the Company announced the expansion of its research collaboration with BMS. Under the new agreement, BMS uses small interfering RNA (&amp;#8220;siRNA&amp;#8221;) molecules formulated by the Company in LNP technology to silence target genes of interest.&amp;#160;&amp;#160;BMS is conducting the preclinical work to validate the function of certain genes and share the data with the Company.&amp;#160;&amp;#160;The Company can use the preclinical data to develop RNAi therapeutic drugs against the therapeutic targets of interest.&amp;#160;&amp;#160;The Company received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from BMS concurrent with the signing of the agreement and recorded the amount as deferred revenue. The Company is required to provide a pre-determined number of LNP batches over the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year agreement.&amp;#160;&amp;#160;BMS has a first right to negotiate a licensing agreement on certain RNAi products developed by the Company that evolve from BMS validated gene targets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue from the May 10, 2010 agreement with BMS is being recognized as the Company produces the related LNP batches.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue earned for the year-ended December 31, 2014 relates to batches shipped to BMS during the period. In August 2014, the agreement expired and both companies' obligations under the agreement ended.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(e)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;License and Development and Supply Agreement with Dicerna Pharmaceuticals, Inc. (&amp;#8220;Dicerna&amp;#8221;)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On November 16, 2014, the Company signed a License Agreement and a Development and Supply Agreement (together, the &amp;#8220;Agreements&amp;#8221;) with Dicerna to development, manufacture, and commercialization of products directed to treatment of Primary Hyperoxaluria 1 (&amp;#8220;PH1&amp;#8221;), In consideration for the rights granted under the Agreements, Dicerna paid the Company an upfront cash payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company is also entitled to receive payments from Dicerna on the manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$22,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee has been established to provide guidance and direction on the progression of the collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined the deliverables under the Agreements included the rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed under the joint development committee.  The license and participation in the joint development committee have been determined by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has estimated to be approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months as at December 31, 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has determined that manufacturing services and other services provided have standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures charged at comparable market rates with embedded margins on each work order. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Manufacturing work orders are invoiced at the time of execution of the work order, at the initiation of manufacture, and at the release of materials. The Company has deferred the recognition of revenue on all cash deposit payments received for manufacturing work orders until acceptance of inventory.&amp;#160;&amp;#160;Revenue from service work orders is recognized as the services are performed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company believes the development and regulatory milestones are substantive, due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development and regulatory events are based in part on the Company&amp;#8217;s performance and the occurrence of a specific outcome resulting from performance. The Company has not received any milestone payments to date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(f)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Agreements with Spectrum Pharmaceuticals, Inc. (&amp;#8220;Spectrum&amp;#8221;)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On May 6, 2006, the Company signed a number of agreements with Talon Therapeutics, Inc. (&amp;#8220;Talon&amp;#8221;, formerly Hana Biosciences, Inc.) including the grant of worldwide licenses (the &amp;#8220;Talon License Agreement&amp;#8221;) for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Company&amp;#8217;s chemotherapy products, Marqibo&amp;#174;, Alocrest &amp;#8482; (Optisomal Vinorelbine) and Brakiva &amp;#8482; (Optisomal Topotecan).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On August 9, 2012, the Company announced that Talon had received accelerated approval for Marqibo from the FDA for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Marqibo is a liposomal formulation of the chemotherapy drug vincristine. In the year ended December 31, 2012, the Company received a milestone of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; based on the FDA&amp;#8217;s approval of Marqibo and will receive royalty payments based on Marqibo&amp;#8217;s commercial sales. There are no further milestones related to Marqibo but the Company is eligible to receive total milestone payments of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$18,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on Alocrest and Brakiva.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Talon was acquired by Spectrum in July 2013. The acquisition did not affect the terms of the license between Talon and the Company. On September 3, 2013, Spectrum announced that they had shipped the first commercial orders of Marqibo. In the year ended December 31, 2015, the Company recorded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$240,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in Marqibo royalty revenue (2014 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$190,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, 2013 -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). In the year ended December 31, 2015, the Company accrued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in royalties due to TPC in respect of the Marqibo royalty earned by the Company (see note 9).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(g)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Other RNAi collaborators&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;The Company had active research agreements with a number of other RNAi collaborators.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-21419B1F877E95B2736BEF63649843A2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contingencies and commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Property lease&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The minimum rent and estimated operating cost commitment, net of lease inducements, is as follows:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,229,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;938,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;938,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;547,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,652,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s lease expense, for the year ended December 31, 2015 of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,158,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been recorded in the consolidated statements of operations and comprehensive loss (2014 of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,133,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; 2013 -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,225,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Product development partnership with the Canadian Government&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company entered into a Technology Partnerships Canada (TPC) agreement with the Canadian Federal Government on November 12, 1999.&amp;#160;&amp;#160;Under this agreement, TPC agreed to fund &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the costs incurred by the Company, prior to March 31, 2004, in the development of certain oligonucleotide product candidates up to a maximum contribution from TPC of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7,179,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;C$9,330,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&amp;#160;&amp;#160;As at December 31, 2015, a cumulative contribution of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,675,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;C$3,702,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) had been received and the Company does not expect any further funding under this agreement.&amp;#160;&amp;#160;In return for the funding provided by TPC, the Company agreed to pay royalties on the share of future licensing and product revenue, if any, that is received by the Company on certain non-siRNA oligonucleotide product candidates covered by the funding under the agreement.&amp;#160;&amp;#160;These royalties are payable until a certain cumulative payment amount is achieved or until a pre-specified date.&amp;#160;&amp;#160;In addition, until a cumulative amount equal to the funding actually received under the agreement has been paid to TPC, the Company agreed to pay &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; royalties on any royalties the Company receives for Marqibo. For the year ended December 31, 2015, the Company earned royalties on Marqibo sales in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$240,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (see note 4(f)), resulting in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recorded by the Company as royalty payable to TPC (2014 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$190,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; 2013 -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&amp;#160;The cumulative amount paid or accrued up to December 31, 2015 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, resulting in the contingent amount due to TPC being &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,664,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;C$3,687,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;License agreement with Marina Biotech, Inc. (&amp;#8220;Marina&amp;#8221;)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On November 29, 2012 the Company announced a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleobase Analog (&amp;#8220;UNA&amp;#8221;) from Marina for the development of RNAi therapeutics.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;UNA technology can be used in the development of RNAi therapeutics, which treat disease by silencing specific disease causing genes. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the license agreement the Company paid Marina an upfront fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$300,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. A further license payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$200,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was paid in 2013 and the Company will make milestone payments of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,250,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and royalties on each product developed by the Company that uses Marina&amp;#8217;s UNA technology. The payments to Marina are expensed to research, development, collaborations and contracts expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effective August 9, 2013, Marina&amp;#8217;s UNA technology was acquired by Arcturus Therapeutics, Inc. (&amp;#8220;Arcturus&amp;#8221;) and the UNA license agreement between the Company and Marina was assigned to Arcturus. The terms of the license are otherwise unchanged. On December 22, 2014, the Company received clearance from Health Canada to conduct a Phase I Clinical Study with TKM-HBV, which utilizes Arcturus&amp;#8217; UNA technology. The dosing of first subject in the Phase I clinical trial of TKM-HBV occurred in January 2015, which  resulted in a milestone payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$250,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Arcturus.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Arbitration with the University of British Columbia (&amp;#8220;UBC&amp;#8221;)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain early work on lipid nanoparticle delivery systems and related inventions was undertaken at UBC.&amp;#160;&amp;#160;These inventions are licensed to the Company by UBC under a license agreement, initially entered in 1998 as amended in 2001, 2006 and 2007. The Company has granted sublicenses under the UBC license to Alnylam as well as to Talon.&amp;#160;&amp;#160;Alnylam has in turn sublicensed back to the Company under the licensed UBC patents for discovery, development and commercialization of RNAi products. In 2009, the Company entered into a supplemental agreement with UBC, Alnylam and Acuitas, in relation to a separate research collaboration to be conducted among UBC, Alnylam and Acuitas to which the Company has license rights. The settlement agreement signed in late 2012 to resolve the litigation among the Company, Alnylam, and Acuitas, provided for the effective termination of all obligations under such supplemental agreement as between and among all litigants (see note 4(c)).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On November 10, 2014, UBC filed a notice of arbitration against the Company and on January 16, 2015, filed a Statement of Claim, which alleges entitlement to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in allegedly unpaid royalties based on publicly available information, and an unspecified amount based on non-public information. UBC also seeks interest and costs, including legal fees. The Company is currently disputing UBC&amp;#8217;s allegations, and no dates have been scheduled for this arbitration. However, the Company notes that arbitration is subject to inherent uncertainty and an arbitrator could rule against the Company. The Company has not recorded an estimate of the possible loss associated with this arbitration, due to the uncertainties related to both the likelihood and amount of any possible loss or range of loss. However, the defense of arbitration and related matters are costly and may divert the attention of the Company&amp;#8217;s management and other resources that would otherwise be engaged in other activities. Costs related to the arbitration have been recorded by the Company as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contingent consideration from OnCore acquisition of Enantigen and License Agreements between Enantigen and Blumberg and Drexel&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2014, OnCore acquired all of the outstanding shares of Enantigen pursuant to a stock purchase agreement. Through this transaction, OnCore acquired a HBV surface antigen secretion inhibitor program and a capsid assembly inhibitor program, each of which are now assets of Arbutus, following the Company&amp;#8217;s merger with Arbutus Inc. - see note 3.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the stock purchase agreement, OnCore agreed to pay up to a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$21,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Enantigen&amp;#8217;s selling stockholders upon the achievement of certain triggering events related to Enantigen&amp;#8217;s &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; programs in pre-clinical development related to HBV therapies. The first triggering event is the enrollment of first patient in Phase 1b clinical trial in HBV patients, which the Company does not expect to occur in the next twelve-month period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The regulatory, development and sales milestone payments have an estimated fair value of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6,727,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as at the date of acquisition of Arbutus Inc., and have been treated as contingent consideration payable in the purchase price allocation (note 3), based on information available at the date of acquisition, using a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, time to complete the program development, and overall biotech indices.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration is considered as a financial liability, and measured at its fair value at each reporting period with any changes in fair value from the previous reporting period recorded in the statement of operations and comprehensive loss. For the period ended December 31, 2015, the Company performed an evaluation of the fair value of the contingent consideration using the probability weighted assessment of likelihood of milestone payments as described above. The Company determined the fair value of the contingent consideration has increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$770,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7,497,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the increase in fair value has been recorded in other losses in the statement of operations and comprehensive loss for the year-ended December 31, 2015. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Drexel and Blumberg&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2014, OnCore entered into a license agreement with Blumberg and Drexel that granted an exclusive, worldwide, sub-licensable license to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; different compound series: cccDNA inhibitors, capsid assembly inhibitors and HCC inhibitors.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In partial consideration for this license, OnCore paid a license initiation fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$150,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and issued warrants to Blumberg and Drexel. Under this license agreement, OnCore also agreed to pay up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in development and regulatory milestones per licensed compound series, up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$92,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in sales performance milestones per licensed product, and royalties in the mid-single digits based upon the proportionate net sales of licensed products in any commercialized combination. The Company is obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from the sub-licensees, subject to customary exclusions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2014, OnCore entered into an additional license agreement with Blumberg and Drexel pursuant to which it received an exclusive, worldwide, sub-licensable license under specified patents and know-how controlled by Blumberg and Drexel covering epigenetic modifiers of cccDNA and STING agonists. In consideration for these exclusive licenses, OnCore made an upfront payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Under this agreement, the Company will be required to pay up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each licensed product upon the achievement of a specified regulatory milestone and a low single digit royalty, based upon the proportionate&amp;#160;net sales of compounds covered by this intellectual property&amp;#160;in any commercialized combination. The Company is also obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from its sub-licensees, subject to exclusions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Research Collaboration and Funding Agreement with Blumberg&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2014, Arbutus Inc. entered into a research collaboration and funding agreement with Blumberg under which the Company will provide &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year of research funding for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, renewable at the Company&amp;#8217;s option for an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, for Blumberg to conduct research projects in HBV and liver cancer pursuant to a research plan to be agreed upon by the parties. Blumberg has exclusivity obligations to Arbutus with respect to HBV research funded under the agreement. In addition, the Company has the right to match any third party offer to fund HBV research that falls outside the scope of the research being funded under the agreement. Blumberg has granted the Company the right to obtain an exclusive, royalty bearing, worldwide license to any intellectual property generated by any funded research project. If the Company elects to exercise its right to obtain such a license, the Company will have a specified period of time to negotiate and enter into a mutually agreeable license agreement with Blumberg. This license agreement will include the following pre negotiated upfront, milestone and royalty payments: an upfront payment in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8,100,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of specified development and regulatory milestones; up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$92,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of specified commercialization milestones; and royalties at a low single to mid-single digit rates based upon the proportionate&amp;#160;net sales of licensed&amp;#160;products from any commercialized combination.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;NeuroVive Pharmaceutical AB (&amp;#8220;NeuroVive&amp;#8221;)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In September 2014, Arbutus Inc. entered into a license agreement with NeuroVive that granted them an exclusive, worldwide, sub-licensable license to develop, manufacture and commercialize, for the treatment of HBV, oral dosage form sanglifehrin based cyclophilin inhibitors (including OCB-030). Under this license agreement, the Company has been granted a non-exclusive, royalty free right and license and right of reference to NeuroVive&amp;#8217;s relevant regulatory approvals and filings for the sole purpose of developing, manufacturing and commercializing licensed products for the treatment of HBV. Under this license agreement, the Company has (1)&amp;#160;an option to expand its exclusive license to include treatment of viral diseases other than HBV and (2)&amp;#160;an option, exercisable upon specified conditions, to expand its exclusive license to include development, manufacture and commercialization of non-oral variations of licensed products for treatment of viral diseases other than HBV. NeuroVive retains all rights with respect to development, manufacture and commercialization of licensed products and non-oral variations of licensed products for all indications (other than HBV) for which the Company has not exercised its option.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In partial consideration for this license, Arbutus Inc. paid NeuroVive a license fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As described in note 3 above, Arbutus Inc. became our wholly owned subsidiary by way of a Merger Agreement, which does not trigger any milestone payments. We have conducted significant research and analysis on the NeuroVive Product, OCB-030. Based on this research and analysis, we have decided to discontinue the OCB-030 development program.&amp;#160; Otherwise, the license agreement and ongoing relationship with NeuroVive remains in full effect.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cytos Biotechnology Ltd (&amp;#8220;Cytos&amp;#8221;)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December&amp;#160;30, 2014, Arbutus Inc. entered into an exclusive, worldwide, sub-licensable (subject to certain restrictions with respect to licensed viral infections other than hepatitis) license to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; different series of compounds. The licensed compounds are Qbeta-derived virus-like particles that encapsulate TLR9, TLR7 or RIG-I agonists and may or may not be conjugated with antigens from the hepatitis virus or other licensed viruses.&amp;#160; The Company has an option to expand this license to include additional viral infections other than influenza and Cytos will retain all rights for influenza, all non-viral infections, and all viral infections (other than hepatitis) for which it has not exercised its option.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In partial consideration for this license, the Company is obligated to pay Cytos up to a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$67,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; licensed compound series upon the achievement of specified development and regulatory milestones; for hepatitis and each additional licensed viral infection, up to a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$110,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of specified sales performance milestones; and tiered royalty payments in the high-single to low-double digits, based upon the proportionate&amp;#160;net sales of licensed products in any&amp;#160;commercialized combination.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-F9439F841535B4C3A80DEF63643A9A67">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Concentrations of business risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Credit risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Credit risk is defined by the Company as an unexpected loss in cash and earnings if a collaborative partner is unable to pay its obligations in due time. The Company&amp;#8217;s main source of credit risk is related to its accounts receivable balance which principally represents temporary financing provided to collaborative partners in the normal course of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company does not currently maintain a provision for bad debts as the majority of accounts receivable are from collaborative partners or government agencies and are considered low risk.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at December 31, 2015 was the accounts receivable balance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,008,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2014 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,903,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All accounts receivable balances were current as at December 31, 2015 and December 31, 2014.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Significant collaborators and customers risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We depend on a small number of collaborators and customers for a significant portion of our revenues (see note 4).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liquidity Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liquidity risk results from the Company&amp;#8217;s potential inability to meet its financial liabilities, for example payments to suppliers.&amp;#160;&amp;#160;The Company ensures sufficient liquidity through the management of net working capital and cash balances.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s liquidity risk is primarily attributable to its cash and cash equivalents, and short-term investments. The Company limits exposure to liquidity risk on its liquid assets through maintaining its cash and cash equivalent, and short-term investments with high-credit quality financial institutions. Due to the nature of these investments, the funds are available on demand to provide optimal financial flexibility.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company believes that its current sources of liquidity are sufficient to cover its likely applicable short term cash obligations. The Company&amp;#8217;s financial obligations include accounts payable and accrued liabilities which generally fall due within &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; days. The net liquidity of the Company is considered to be the cash and cash equivalents and short-term investments less accounts payable and accrued liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash, cash equivalents and&amp;#160;short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;181,304&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Accounts payable and accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(8,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,328&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;172,477&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;102,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Foreign currency risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The results of the Company&amp;#8217;s operations are subject to foreign currency transaction and translation risk as the Company&amp;#8217;s revenues and expenses are denominated in both Canadian and US dollars. The fluctuation of the US dollar in relation to the Canadian dollar will consequently have an impact upon the Company&amp;#8217;s reported income or loss and may also affect the value of the Company&amp;#8217;s assets, liabilities, and the amount of shareholders&amp;#8217; equity both as recorded in the Company&amp;#8217;s financial statements, in the Canadian functional currency, and as reported, for presentation purposes, in the US dollar.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company manages its US dollar exchange rate risk by, whenever possible, using cash received from US dollar revenues and financing to pay US dollar expenses. Prior to the financing in October 2013 (note 6(a)), which was denominated in US dollars, the Company&amp;#8217;s policy was to convert all but a working capital level of US dollars into Canadian dollars. Given the Company&amp;#8217;s increasing level of US dollar expenses, its policy is now to maintain US and Canadian dollar cash and investment and short-term investment balances based on long term forecasts of currency needs thereby creating a natural currency hedge.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has not entered into any agreements or purchased any instruments to hedge possible currency risks. The Company&amp;#8217;s exposure to US dollar currency expressed in Canadian dollars was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(in C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents and short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;213,419&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;178&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(8,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;206,607&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;An analysis of the Company&amp;#8217;s sensitivity to foreign currency exchange rate movements is not provided in these financial statements as the Company&amp;#8217;s US dollar cash holdings and expected US dollar revenues are sufficient to cover US dollar expenses for the foreseeable future.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
	<us-gaap:DeferredRevenueByArrangementDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-729E6A88C0568205B020EF636481DADB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth deferred collaborations and contracts revenue:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;DoD (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;313&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Monsanto current portion (b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dicerna current portion (e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;853&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue, current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;868&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Monsanto long-term portion (b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dicerna long-term portion (e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,271&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,716&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-55E6E98C70DCE1796359EF63644C5B47">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income or loss per share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income or loss per share is calculated based on the weighted average number of common shares outstanding. Diluted loss per share does not differ from basic loss per share for the years ended December 31, 2015, 2014 and 2013, since the effect of the Company&amp;#8217;s stock options and warrants is anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="FD2015Q4YTD" id="Fact-C98782DBA889AF8335EFEF63642D6C7B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following tables present information about the Company&amp;#8217;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Guaranteed investment certificate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Term deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;191,374&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;191,374&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,497&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,497&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instrument&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Guaranteed investment certificates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instrument&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-C608DF0215D2405E9208EF63644AD7E4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair value of financial instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We measure certain financial instruments and other items at fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 inputs are quoted market prices for identical instruments available in active markets.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&amp;#8217;s assumptions about market assumptions that would be used to price the asset or liability.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:0px;text-align:justify;padding-left:72px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s financial instruments consist of cash and cash equivalents, short-term and long-term investments, accounts receivable, accounts payable and accrued liabilities, warrants and financial instruments. Long-term investments approximate fair value due to the interest rates being at prevailing market rates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The carrying values of cash and cash equivalents, short-term investments, accounts receivable and accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As quoted prices for the warrants are not readily available, the Company has used a Black-Scholes pricing model, as described in note 6, to estimate fair value. These are level 3 inputs as defined above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company used a discounted cash flow model to determine the fair value of the financial instrument related to Monsanto&amp;#8217;s call option to acquire the equity or all of the assets of PADCo, as described in note 4. The fair value was determined at the date of recognition, and at each reporting date. The initial fair value of the financial instrument was nil, and there has been no change to its fair value as at December 31, 2015. The assumptions used in the discounted cash flow model are level 3 inputs as defined above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To determine the fair value of the contingent consideration, the Company uses a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, time to complete the program development, and overall biotech indices, as in note 9.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-DE61E4A7542AF989CD1FEF6364F1F9ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Foreign currency translation and change in reporting currency&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The functional currency of the Company and two of its integrated subsidiaries (Protiva and Protiva USA), is the Canadian dollar, and the functional currency of Arbutus Inc. is the U.S. dollar. Foreign currency monetary assets and liabilities are translated into the functional currency at the rate of exchange prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month&amp;#8217;s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is using United States dollars as its reporting currency. All assets and liabilities are translated using the exchange rate at the balance sheet date. Revenues, expenses and other income (losses) are translated using the average rate for the period, except for large transactions, for which the exchange rate on the date of the transaction is used. Equity accounts are translated using the historical rate. As the translation differences from the Company&amp;#8217;s functional currency of Canadian dollars to the Company&amp;#8217;s reporting currency of US dollars are unrealized gains and losses, the differences are recorded in other comprehensive income (loss), and do not impact the calculation of Income or Loss per Share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 1, 2016, the Company changed its functional currency from the Canadian dollar to the U.S. dollar based on management's analysis of the changes in the primary economic environment in which the Company operates.  The change in functional currency is accounted for prospectively from January 1, 2016 and financial statements prior to and including the year-ended December 31, 2015 have not been restated for the change in functional currency. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-33750457DCBCD1CCE2CEEF63652C7169">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Goodwill and intangible assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible assets consist of in-process research and development arising from the Company&amp;#8217;s acquisition of Arbutus Inc. - see note 3. In-process research and development (IPR&amp;amp;D) intangible assets are classified as indefinite-lived and are not amortized. IPR&amp;amp;D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives, which are the respective patent terms. Amortization begins when intangible assets with finite lives are put into use. If there is a major event indicating that the carrying value of intangible assets may be impaired, then management will perform an impairment test and if the carrying value exceeds the recoverable value, based on discounted future cash flows, then such assets are written down to their fair values. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets of Arbutus Inc. - see note 3. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is subject to a two-step impairment test on an annual basis, unless the Company identifies impairment indicators that would require earlier testing. The first step compares the fair value of the reporting unit to its carrying amount, which includes the goodwill. When the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not to be impaired, and the second step of the impairment test is unnecessary. If the carrying amount exceeds the implied fair value of the reporting unit, the second step measures the amount of the impairment loss. If the carrying amount exceeds the fair value of the reporting unit, an impairment loss is recognized equal to that excess.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company reviews the recoverable amount of intangible assets on an annual basis, and the annual evaluation for goodwill is performed as of December 31 each year. In addition, the Company evaluates for events or changes in the business that could indicate impairment and earlier testing. Such indicators include, but are not limited to, on an ongoing basis: (a) industry and market considerations such as increased competitive environment or adverse change in legal factors including an adverse assessment by regulators; (b) an accumulation of costs significantly in excess of the amount originally expected for the development of the asset; (c) current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the asset; and (d) if applicable, a sustained decrease in share price. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-9DD10EFABB206D8A5DAFEF63645B060C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If there is a major event indicating that the carrying value of property and equipment may be impaired then management will perform an impairment test and if the carrying value exceeds the recoverable value, based on undiscounted future cash flows, then such assets are written down to their fair values.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-82EA40194DA60DD66876EF636463C373">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax (recovery) expense varies from the amounts that would be computed by applying the combined Canadian federal and provincial income tax rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2014 -  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; 2013 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) to the loss before income taxes as shown in the following tables:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computed taxes (recoveries) at Canadian&amp;#160;federal and provincial tax rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(20,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,097&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,486&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Differences due to change in enacted tax rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Permanent and other differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;8,113&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance - other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,676&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,599&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Difference due to income taxed at foreign rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(7,874&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income tax recovery&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(16,185&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has investment tax credits available to reduce Canadian federal income taxes of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7,969,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (December&amp;#160;31, 2014 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7,866,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) and provincial income taxes of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,869,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (December&amp;#160;31, 2014 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,401,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;), expiring between 2027 and 2035. In addition, the Company has research and development credits of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$483,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; available for indefinite carry-forward, which can be used to reduce future taxable income in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December&amp;#160;31, 2015, the Company has scientific research and experimental development expenditures of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$51,823,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;  (December 31, 2014 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$49,907,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) available for indefinite carry-forward and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24,745,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (December&amp;#160;31, 2014 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25,301,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) of net operating losses due to expire between 2027 and 2035 and which can be used to offset future taxable income in Canada.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2015, the Company has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$17,235,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of net operating losses due to expire between 2030 and 2035, which can be used to offset future taxable income in the U.S. Future use of a portion of the U.S. loss carry-forwards is subject to limitations under the Internal Revenue Code Section 382. As a result of ownership changes occurred on October 1, 2014 and March 4, 2015, the Company's ability to use these losses may be limited. Losses incurred to date may be further limited if a subsequent change in control occurs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On November 23, 2011, the Company was registered as a corporation under the Business Activity Act in the province of British Columbia. Under this program, provincial corporation tax charged on foreign income earned from the Company&amp;#8217;s patents will be eligible for a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; tax refund up to a maximum of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;C$8,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Significant components of the Company&amp;#8217;s deferred tax assets are shown below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-capital loss carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;13,932&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,578&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development deductions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;13,474&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Book amortization in excess of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;777&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue recognized for tax purposes in excess of revenue recognized for accounting purposes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;281&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Tax value in excess of accounting value in lease inducements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal investment tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Provincial investment tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(146,324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upfront license fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;629&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(104,830&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,818&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(41,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37,818&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(146,324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The comparative figures in the above table have been recast to increase the deferred tax assets before valuation allowance by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8,424,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the valuation allowance by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8,424,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as at December 31, 2014 to be consistent with current year's disclosure. The comparative figures in the income tax expense reconciliation table have also been recast to reflect these changes. These adjustments have no impact on the consolidated financial position, consolidated results of operations or the consolidated cash flows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-FD94C1E14A5CC9790B77EF63644CFBE9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Deferred income taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income taxes are accounted for using the asset and liability method of accounting. Deferred income taxes are recognized for the future income tax consequences attributable to differences between the carrying values of assets and liabilities and their respective income tax bases and for loss carry-forwards. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the periods in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax laws or rates is included in earnings in the period that includes the enactment date. When realization of deferred income tax assets does not meet the more-likely-than-not criterion for recognition, a valuation allowance is provided.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-1FC0BA8DDC3A2ACA53AEEF63643C56FB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory includes materials assigned for the manufacture of products for collaborative partners and manufacturing costs for products awaiting acceptance by collaborative partners. Inventory is carried at the lower of cost and net realizable value and measured using first-in-first-out method. The cost of inventories includes all costs of purchase, costs of manufacturing and other costs incurred in bringing the inventories to their present location and condition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Materials purchased for the Company&amp;#8217;s own research and development products are not recorded as inventory but are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:InvestmentPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-E5DDA9CD4F27E9BCCD12EF6363F9727C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Short-term and long-term investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company acquired guaranteed investment certificates and a term deposit during the year, which are classified as short-term and long-term investments on the balance sheet respectively. Short-term investments have original maturities exceeding three months, and have remaining maturities less than one year. Long-term investments have remaining maturities exceeding twelve months. Short-term and long-term investments accrue interest daily based on a fixed interest rate for the term. The carrying value of these investments are recorded at cost plus accrued interest, which approximates their fair value. All investments are governed by the Board approved Investment Policy for the Company.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
	<us-gaap:LeasePolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-25AD8E0C366CDAB0A2E0EF636449AE2C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases and lease inducements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leases entered into are classified as either capital or operating leases. Leases which substantially transfer all benefits and risks of ownership of property to the Company are accounted for as capital leases. At the time a capital lease is entered into, an asset is recorded together with its related long-term obligation to reflect the purchase and financing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All other leases are accounted for as operating leases wherein rental payments are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lease inducements represent leasehold improvement allowances and reduced or free rent periods and are amortized on a straight-line basis over the term of the lease and are recorded as a reduction of rent expense.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeasePolicyTextBlock>
	<us-gaap:NatureOfOperations contextRef="FD2015Q4YTD" id="Fact-082A0802ECA0549FFC51EF63652AC78F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Nature of business and future operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Arbutus Biopharma Corporation (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Arbutus&amp;#8221;) is a Canadian biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (&amp;#8220;HBV&amp;#8221;). The Company is also developing a pipeline focused on advancing novel RNA interference therapeutics (RNAi) leveraging the Company&amp;#8217;s expertise in Lipid Nanoparticle (LNP) technology.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effective July 31, 2015, the corporate name changed from Tekmira Pharmaceuticals Corporation (Tekmira) to Arbutus Biopharma Corporation. Also effective July 31, 2015, the corporate name of the wholly-owned subsidiary, OnCore Biopharma, Inc. (OnCore) changed to Arbutus Biopharma, Inc. (Arbutus Inc.). Including Arbutus Inc., the Company has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; wholly-owned subsidiaries: Protiva Biotherapeutics Inc. (Protiva), Protiva Biotherapeutics (USA) Inc. (Protiva USA), and Protiva Agricultural Development Company Inc. (&amp;#8220;PADCo&amp;#8221;). In March 2016, Monsanto exercised its option to acquire 100% of the outstanding shares in PADCo - refer to note 13 subsequent events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company&amp;#8217;s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company&amp;#8217;s ability to continue to fund these programs in the future.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-3DCFD58D20B17D3DF03CEF63644B8162">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent accounting pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842): Recognition and Measurement of Financial Assets and Financial Liabilities. The update supersedes Topic 840, Leases and requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP.  Topic 842 retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. The amendments in this update are effective for fiscal years beginning after December 15, 2018 for public business entities, which for the Company means January 1, 2019. The Company does not plan to early adopt this update. The extent of the impact of this adoption has not yet been determined.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In September 2015, the FASB issued ASU 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The update eliminates the requirement to retrospectively adjust the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill during the measurement period when new information is obtained about the facts and circumstances that existed as of the acquisition date, that if known, would have affected the measurement of the amounts initially recognized or would have resulted in the recognition of additional assets or liabilities. The amendments in this update are effective for fiscal years beginning after December 15, 2015, which for the Company means January 1, 2016, and should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update. Early application is permitted for financial statements that have not been issued. The Company has adopted this update and applied it to the acquisition of Arbutus Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASC 606). The standard is intended to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS by creating a new Topic 606, Revenue from Contracts with Customers. This guidance supersedes the revenue recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition - Construction-Type and Production-Type Contracts. The core principle of the accounting standard is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1) retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date to defer the effective date of Update 2014-09 for all entities by one year. The new guidance would be effective for fiscal years beginning after December 15, 2017, which for the Company means January 1, 2018. Entities are permitted to adopt in accordance with the original effective date if they choose. The Company has not yet determined the extent of the impact of adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern. The update is intended to provide guidance in GAAP about management&amp;#8217;s responsibility to evaluate whether there is substantial doubt about an entity&amp;#8217;s ability to continue as a going concern and to provide related footnote disclosures. Under amendments to GAAP, the assessment period is within one year after the date that the financial statements are issued (or available to be issued). The amendments are effective for the annual period ending after December 15, 2016, which for the Company means January 1, 2017, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not plan to early adopt this update. The extent of the impact of this adoption has not yet been determined.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-276CACF139B513CE8F8FEF6364C63B77">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;book value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,910&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,748&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,681&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,189&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer hardware and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,487&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;527&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,183&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;book value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,451&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,281&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,796&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;485&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer hardware and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,293&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;705&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,959&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31, 2015, all of the Company&amp;#8217;s property and equipment are currently in use and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impairment has been recorded.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-8608728EFE2E99E96D26EF63644A30B2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment is recorded at cost less impairment losses, accumulated depreciation, related government grants and investment tax credits. The Company records depreciation using the straight-line method over the estimated useful lives of the capital assets as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="77%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Useful life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer and office equipment &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements are depreciated over their estimated useful lives but in no case longer than the lease term, except where lease renewal is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2015Q4YTD" id="Fact-E22D245BFDA462A5C3DDEF6364E63698">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;book value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,910&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,748&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,681&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,189&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer hardware and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,487&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;527&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(305&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,912&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,183&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;book value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,451&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,281&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,796&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;485&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer hardware and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,293&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;705&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(364&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,959&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2015Q4YTD" id="Fact-8C8570B797C3607F7A99EF6364B07475">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Interim financial data (unaudited)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="31%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,440&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,065&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;24,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(58,138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,758&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(102,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,886&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,982&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(61,121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(1.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="31%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,430&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,362&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;14,953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,844&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(33,434&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,604&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(38,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(1.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-A04EEA580F29E25966B1EF636449E087">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and development costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are charged as an expense in the period in which they are incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-A82F40B36FC0B9617649EF636438C967">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company earns revenue from research and development collaboration and contract services, licensing fees, milestone and royalty payments. Revenues associated with multiple element arrangements are attributed to the various elements based on their relative fair values or are recognized as a single unit of accounting when relative fair values are not determinable. Non-refundable payments received under collaborative research and development agreements are recorded as revenue as services are performed and related expenditures are incurred. Non-refundable upfront license fees from collaborative licensing and development arrangements are recognized as the Company fulfills its obligations related to the various elements within the agreements, in accordance with the contractual arrangements with third parties and the term over which the underlying benefit is being conferred. The Company evaluates new arrangements for any substantive milestones by considering: whether substantive uncertainty exists upon execution of the arrangement; if the event can only be achieved based in whole or in part on the Company&amp;#8217;s performance, or occurrence of a specific outcome resulting from the Company&amp;#8217;s performance; any future performance required, and payment is reasonable relative to all deliverables; and, the payment terms in the arrangement. Payments received upon the achievement of substantive milestones are recognized as revenue in their entirety. Payments received upon the occurrence of milestones that are non-substantive are deferred and recognized as revenue over the estimated period of performance applicable to the associated collaborative agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue earned under research and development manufacturing collaborations where the Company bears some or all of the risk of a product manufacturing failure is recognized when the purchaser accepts the product and there are no remaining rights of return.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue earned under research and development collaborations where the Company does not bear any risk of product manufacturing failure is recognized in the period the work is performed. For contracts where the manufacturing amount is specified, revenue is recognized as product is manufactured in proportion to the total amount specified under the contract.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue and expenses under the contract with the United States Government Department of Defense (&amp;#8220;DoD&amp;#8221;) are being recorded using the percentage-of-completion method. Contract progress is based on costs incurred to date. Expenses under the contract are recorded in the Company&amp;#8217;s consolidated statement of operations and comprehensive income (loss) as they are incurred. Government contract revenues related to expenses incurred under the contract are recorded in the same period as those expenses. Expenses accrued under the contract but not yet invoiced are recorded in the Company&amp;#8217;s balance sheet as accrued liabilities and accrued revenues. Equipment purchased under the contract is recorded on the Company&amp;#8217;s balance sheet as deferred expense and deferred revenue and amortized, on a straight-line basis, over the life of the contract.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash or other compensation received in advance of meeting the revenue recognition criteria is recorded on the balance sheet as deferred revenue. Revenue meeting recognition criteria but not yet received or receivable is recorded on the balance sheet as accrued revenue.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="FD2015Q4YTD" id="Fact-B8A1DC4BF8FD0F0EA3E6EF63641BC553">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and accrued liabilities is comprised of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Trade accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2,610&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,044&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2,358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,391&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;License fee accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Professional fee accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred lease inducements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payroll accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;8,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,328&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="FD2015Q4YTD" id="Fact-A8144F424F54B82E9D5F338CBA3A281E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the changes in fair value of the Company&amp;#8217;s contingent consideration:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="26%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="22%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="22%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="22%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability at beginning&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of the period &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increase in fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;value of contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability at end&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,497&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;(1) As at acquisition date of March 4, 2015 - see note 3 below.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
	<us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="FD2015Q4YTD" id="Fact-4D9F75AD4CF6FA9D0A1F33906FB2F3F3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the Company&amp;#8217;s finalized purchase price allocation as at December 31, 2015:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Consideration paid:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Common shares issued without subjects&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;371,553&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Common shares issued subject to repurchase provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,262&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Common shares issuable for Arbutus Inc. stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Identifiable assets acquired and liabilities assumed:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Prepaid expenses and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;147&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Acquired intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;391,649&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,514&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Other non-current liabilities (note 9)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160; &amp;#160; &amp;#160; &amp;#160;Deferred income tax liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(162,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total purchase price allocation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;381,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
	<us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="FD2015Q4YTD" id="Fact-312EC4E254338F681DEAEF6364712947">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following tables set forth revenue recognized under collaborations, contracts and licensing agreements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ended December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Collaborations and contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;DoD (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,764&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,806&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Monsanto (b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;4,725&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;BMS (d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dicerna (e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,820&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;510&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other RNAi collaborators (g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total research and development collaborations and contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;13,309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Licensing fees, milestone and royalty payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Monsanto licensing fees and milestone payments (b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;10,256&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Alnylam and Acuitas licensing fees and milestone payments (c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dicerna licensing fee (e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Spectrum royalty payments (f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;240&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total licensing fees, milestone and royalty payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;11,564&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,215&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;24,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,465&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2015Q4YTD" id="Fact-7999D5729892D795C987EF6364420159">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant components of the Company&amp;#8217;s deferred tax assets are shown below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-capital loss carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;13,932&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,578&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development deductions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;13,474&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Book amortization in excess of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,745&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share issue costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;777&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue recognized for tax purposes in excess of revenue recognized for accounting purposes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;281&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Tax value in excess of accounting value in lease inducements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal investment tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;6,303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Provincial investment tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(146,324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upfront license fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;629&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(104,830&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37,818&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(41,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37,818&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(146,324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2015Q4YTD" id="Fact-BBE3E0427FE0F6E13C7BEF63647F6525">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets out the computation of basic and diluted net income (loss) per common share:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;For the year ended December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(61,121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(38,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,063&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;45,462,324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,603,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,302,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic income (loss) per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(1.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Diluted income (loss) per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(1.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2015Q4YTD" id="Fact-CA5A75B20858AC419AB3EF63644B2B4B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax (recovery) expense varies from the amounts that would be computed by applying the combined Canadian federal and provincial income tax rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2014 -  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; 2013 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) to the loss before income taxes as shown in the following tables:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computed taxes (recoveries) at Canadian&amp;#160;federal and provincial tax rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(20,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,097&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,486&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Differences due to change in enacted tax rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Permanent and other differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;8,113&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,498&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance - other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3,676&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,599&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,407&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Difference due to income taxed at foreign rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(7,874&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income tax recovery&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(16,185&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2015Q4YTD" id="Fact-27038945B79A1083BC90EF6365073223">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The total stock-based compensation has been recorded in the consolidated statement of operations and comprehensive income (loss) as follows:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research, development, collaborations and contracts expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;7,868&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;14,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;940&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;281&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;22,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;903&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2015Q4YTD" id="Fact-A194508DA00A1FAB499BEF6363FF6D98">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The minimum rent and estimated operating cost commitment, net of lease inducements, is as follows:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,229,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;938,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;938,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;547,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,652,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock contextRef="FD2015Q4YTD" id="Fact-133E76C0AD60B38175E6339CC83C7C63">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the carrying values, net of impairment of the intangible assets as at December 31, 2015:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; Cyclophilins&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; Immune Modulators&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; Antigen Inhibitors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; cccDNA Sterilizers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;352,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock>
	<us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock contextRef="FD2015Q4YTD" id="Fact-F8A01A2878B4006678DF339199FA2512">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The identifiable intangible assets acquired consist of in-process research and development (IPR&amp;amp;D) HBV assets, as summarized in the table below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="87%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; Cyclophilins&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,007&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; Immune Modulators&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; Antigen Inhibitors&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,437&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;IPR&amp;amp;D &amp;#8211; cccDNA Sterilizers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;391,649&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
	<us-gaap:ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock contextRef="FD2015Q4YTD" id="Fact-8AE7E7EAD66E501F4E7DEF63643A746F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s exposure to US dollar currency expressed in Canadian dollars was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(in C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents and short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;213,419&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;178&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(8,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;206,607&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock>
	<us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="FD2015Q4YTD" id="Fact-0C2B36C425E4D7375AD9EF6364C2B855">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of the Company&amp;#8217;s non-vested stock option activity and related information for the year ended December 31, 2015 is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;optioned&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;fair value (C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;fair value (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-vested at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;441,230&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,309,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(250,461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-vested options forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(148,853&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-vested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,351,541&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
	<us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" id="Fact-AA0D115934008895F69633B31CD72BCF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of the OnCore Option Plan's non-vested stock option activity and related information for the period from acquisition to December 31, 2015 is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;OnCore Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equivalent number&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of Company&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;fair value (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-vested at March 4, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;128,510&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,354&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-vested options forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-vested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;96,382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;97,063&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="FD2015Q4YTD" id="Fact-64E95939266A890C8C70EF6364AEEEBC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="31%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,682&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,440&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,065&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,686&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;24,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(18,006&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(58,138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,758&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(102,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,886&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,982&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,264&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(61,121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(1.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="31%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Q4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,430&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,362&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;14,953&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,844&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,747&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(33,434&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17,984&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,604&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(38,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(1.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2015Q4YTD" id="Fact-1C7D96A79C60A5872046EF6364D15818">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock option activity for the Arbutus Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="31%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;optioned&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;price (C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;price (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;value (C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;value (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,648,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;270,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(124,246&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited, canceled or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(64,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21.87&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,730,765&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,030&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;431,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(622,752&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,926&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited, canceled or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,530,138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,004&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,309,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(398,293&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,887&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,386&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited, canceled or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(151,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,290,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;994&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2015Q4YTD" id="Fact-38820A545FA99242C7CFEF6364E69260">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average Black-Scholes option-pricing assumptions and the resultant fair values are as follows for warrants outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;49.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;0.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected average term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;0.6 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Aggregate fair value of warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;379,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;398,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="FD2015Q4YTD" id="Fact-8C55E9563754F4ACFB62EF6364FCF139">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the Company&amp;#8217;s warrant activity for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="37" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="3%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="3%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Common shares&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;purchasable upon&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;exercise of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Weighted average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;exercise price (C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;average exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;price (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Range of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;exercise prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Range of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;exercise prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Weighted average remaining contractual life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;intrinsic value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;intrinsic value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Balance, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,014,728&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$2.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(616,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;398,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,902&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(18,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;379,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$2.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,217&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2015Q4YTD" id="Fact-916256C3356670C8D830EF6364608D2A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company operates in a single reporting segment. Substantially all of the Company&amp;#8217;s revenues to date were earned from customers or collaborators based in the United States. Substantially all of the Company&amp;#8217;s premises, property and equipment are located in Canada and the United States.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock contextRef="FD2015Q4YTD" id="Fact-BD289C82EE6B6057DF21EF6364F4181C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average option pricing assumptions and the resultant fair values are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;76.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;101.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;111.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected average option term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;7.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.8 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.6 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_OnCoreOptionPlanMember" id="Fact-35AD623DE6C35121C2C733AD45AB9C1C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth outstanding options under the OnCore Option Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of OnCore&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equivalent number&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of Company&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;price (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, March 4, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;184,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited, canceled or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;184,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_abus_ProtivaOptionPlanMember" id="Fact-C23513E1F01D893B34D0EF6365080428">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth outstanding options under the Protiva Option Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of Protiva&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equivalent number&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of Company&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;price (C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;price (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;475,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;321,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited, canceled or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;472,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;319,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(38,145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,754&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited, canceled or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;433,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;292,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(358,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(242,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited, canceled or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,065&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,445&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2015Q4YTD" id="Fact-2BD6192D71FDEBA1F8F5EF6364500B81">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company grants stock options to employees and directors pursuant to a share incentive plan described in note 6. Compensation expense is recorded for issued stock options using the fair value method with a corresponding increase in additional paid-in capital. Any consideration received on the exercise of stock options is credited to share capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of stock options is measured at the grant date and amortized on a straight-line basis over the vesting period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2015Q4YTD" id="Fact-D277F15D9174A5251C11EF63644C0E6E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant accounting policies&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation) was incorporated on October&amp;#160;6, 2005 as an inactive wholly owned subsidiary of Inex Pharmaceuticals Corporation (Inex). Pursuant to a &amp;#8220;Plan of Arrangement&amp;#8221; effective April&amp;#160;30, 2007, the business and substantially all of the assets and liabilities of Inex were transferred to the Company. The consolidated financial statements for all periods presented herein include the consolidated operations of Inex until April&amp;#160;30, 2007 and the operations of the Company thereafter.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; wholly-owned subsidiaries as at December 31, 2015: Arbutus Biopharma, Inc. (formerly OnCore Biopharma, Inc.) Protiva Biotherapeutics Inc. (Protiva), Protiva Biotherapeutics (USA) Inc. (Protiva USA), and Protiva Agricultural Development Company Inc. (&amp;#8220;PADCo&amp;#8221;). Protiva and Protiva USA were acquired on May 30, 2008. PADCo was incorporated on January 9, 2014. Arbutus Inc. was acquired by way of a Merger Agreement on March 4, 2015, which included Arbutus Inc.'s wholly-owned subsidiary, Enantigen Therapeutics, Inc. (Enantigen) - see note 3. Enantigen was merged with Arbutus Inc. on September 30, 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These consolidated financial statements include the accounts of the Company and three of its wholly-owned subsidiaries, Arbutus Inc., Protiva and Protiva USA. All intercompany transactions and balances have been eliminated on consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company records its investment in PADCo using the equity method. The Company has determined that PADCo is a variable interest entity (&amp;#8220;VIE&amp;#8221;) of which it is not the primary beneficiary. The Company is not the primary beneficiary as it does not have the power to make decisions that most significantly affect the economic performance of the VIE nor does the Company have the right to receive benefits or the obligation to absorb losses that in either case could potentially be significant to the VIE. PADCo is described further in note 4(b). In March 2016, Monsanto exercised its option to acquire PADCo - refer to note 13 subsequent events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring the use of management estimates relate to purchase price allocation, valuation of intangible assets and goodwill, recognition of revenue, stock-based compensation, valuation of warrant liability and financial instrument, and the amounts recorded as accrued liabilities, contingent consideration, and income tax recovery.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents are all highly liquid instruments with an original maturity of three months or less when purchased. Cash equivalents are recorded at cost plus accrued interest. The carrying value of these cash equivalents approximates their fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Short-term and long-term investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company acquired guaranteed investment certificates and a term deposit during the year, which are classified as short-term and long-term investments on the balance sheet respectively. Short-term investments have original maturities exceeding three months, and have remaining maturities less than one year. Long-term investments have remaining maturities exceeding twelve months. Short-term and long-term investments accrue interest daily based on a fixed interest rate for the term. The carrying value of these investments are recorded at cost plus accrued interest, which approximates their fair value. All investments are governed by the Board approved Investment Policy for the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair value of financial instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We measure certain financial instruments and other items at fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 inputs are quoted market prices for identical instruments available in active markets.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&amp;#8217;s assumptions about market assumptions that would be used to price the asset or liability.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:0px;text-align:justify;padding-left:72px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s financial instruments consist of cash and cash equivalents, short-term and long-term investments, accounts receivable, accounts payable and accrued liabilities, warrants and financial instruments. Long-term investments approximate fair value due to the interest rates being at prevailing market rates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The carrying values of cash and cash equivalents, short-term investments, accounts receivable and accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As quoted prices for the warrants are not readily available, the Company has used a Black-Scholes pricing model, as described in note 6, to estimate fair value. These are level 3 inputs as defined above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company used a discounted cash flow model to determine the fair value of the financial instrument related to Monsanto&amp;#8217;s call option to acquire the equity or all of the assets of PADCo, as described in note 4. The fair value was determined at the date of recognition, and at each reporting date. The initial fair value of the financial instrument was nil, and there has been no change to its fair value as at December 31, 2015. The assumptions used in the discounted cash flow model are level 3 inputs as defined above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To determine the fair value of the contingent consideration, the Company uses a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, time to complete the program development, and overall biotech indices, as in note 9. The fair value was determine at the date of recognition to be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6,727,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company determined the fair value of the contingent consideration has increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$770,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7,497,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the increase in fair value has been recorded in other losses in the statement of operations and comprehensive loss for the year-ended December 31, 2015. The assumptions used in the discounted cash flow model are level 3 inputs as defined above.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following tables present information about the Company&amp;#8217;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Guaranteed investment certificate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Term deposit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,070&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;191,374&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;191,374&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,497&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,497&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instrument&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72,187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Guaranteed investment certificates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,974&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instrument&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the changes in fair value of the Company&amp;#8217;s warrants:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="23%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability at beginning&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants issued in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;warrants exercised&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;in the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increase (decrease) in fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign exchange&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability at end&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,530&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(312&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,383&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(334&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(541&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the changes in fair value of the Company&amp;#8217;s contingent consideration:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="26%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="22%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="22%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="22%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability at beginning&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of the period &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increase in fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;value of contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability at end&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,497&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;(1) As at acquisition date of March 4, 2015 - see note 3 below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inventory includes materials assigned for the manufacture of products for collaborative partners and manufacturing costs for products awaiting acceptance by collaborative partners. Inventory is carried at the lower of cost and net realizable value and measured using first-in-first-out method. The cost of inventories includes all costs of purchase, costs of manufacturing and other costs incurred in bringing the inventories to their present location and condition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Materials purchased for the Company&amp;#8217;s own research and development products are not recorded as inventory but are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment is recorded at cost less impairment losses, accumulated depreciation, related government grants and investment tax credits. The Company records depreciation using the straight-line method over the estimated useful lives of the capital assets as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="77%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="7%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Useful life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer and office equipment &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements are depreciated over their estimated useful lives but in no case longer than the lease term, except where lease renewal is reasonably assured. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If there is a major event indicating that the carrying value of property and equipment may be impaired then management will perform an impairment test and if the carrying value exceeds the recoverable value, based on undiscounted future cash flows, then such assets are written down to their fair values.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Goodwill and intangible assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible assets consist of in-process research and development arising from the Company&amp;#8217;s acquisition of Arbutus Inc. - see note 3. In-process research and development (IPR&amp;amp;D) intangible assets are classified as indefinite-lived and are not amortized. IPR&amp;amp;D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives, which are the respective patent terms. Amortization begins when intangible assets with finite lives are put into use. If there is a major event indicating that the carrying value of intangible assets may be impaired, then management will perform an impairment test and if the carrying value exceeds the recoverable value, based on discounted future cash flows, then such assets are written down to their fair values. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets of Arbutus Inc. - see note 3. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is subject to a two-step impairment test on an annual basis, unless the Company identifies impairment indicators that would require earlier testing. The first step compares the fair value of the reporting unit to its carrying amount, which includes the goodwill. When the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not to be impaired, and the second step of the impairment test is unnecessary. If the carrying amount exceeds the implied fair value of the reporting unit, the second step measures the amount of the impairment loss. If the carrying amount exceeds the fair value of the reporting unit, an impairment loss is recognized equal to that excess.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company reviews the recoverable amount of intangible assets on an annual basis, and the annual evaluation for goodwill is performed as of December 31 each year. In addition, the Company evaluates for events or changes in the business that could indicate impairment and earlier testing. Such indicators include, but are not limited to, on an ongoing basis: (a) industry and market considerations such as increased competitive environment or adverse change in legal factors including an adverse assessment by regulators; (b) an accumulation of costs significantly in excess of the amount originally expected for the development of the asset; (c) current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the asset; and (d) if applicable, a sustained decrease in share price. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company earns revenue from research and development collaboration and contract services, licensing fees, milestone and royalty payments. Revenues associated with multiple element arrangements are attributed to the various elements based on their relative fair values or are recognized as a single unit of accounting when relative fair values are not determinable. Non-refundable payments received under collaborative research and development agreements are recorded as revenue as services are performed and related expenditures are incurred. Non-refundable upfront license fees from collaborative licensing and development arrangements are recognized as the Company fulfills its obligations related to the various elements within the agreements, in accordance with the contractual arrangements with third parties and the term over which the underlying benefit is being conferred. The Company evaluates new arrangements for any substantive milestones by considering: whether substantive uncertainty exists upon execution of the arrangement; if the event can only be achieved based in whole or in part on the Company&amp;#8217;s performance, or occurrence of a specific outcome resulting from the Company&amp;#8217;s performance; any future performance required, and payment is reasonable relative to all deliverables; and, the payment terms in the arrangement. Payments received upon the achievement of substantive milestones are recognized as revenue in their entirety. Payments received upon the occurrence of milestones that are non-substantive are deferred and recognized as revenue over the estimated period of performance applicable to the associated collaborative agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue earned under research and development manufacturing collaborations where the Company bears some or all of the risk of a product manufacturing failure is recognized when the purchaser accepts the product and there are no remaining rights of return.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue earned under research and development collaborations where the Company does not bear any risk of product manufacturing failure is recognized in the period the work is performed. For contracts where the manufacturing amount is specified, revenue is recognized as product is manufactured in proportion to the total amount specified under the contract.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue and expenses under the contract with the United States Government Department of Defense (&amp;#8220;DoD&amp;#8221;) are being recorded using the percentage-of-completion method. Contract progress is based on costs incurred to date. Expenses under the contract are recorded in the Company&amp;#8217;s consolidated statement of operations and comprehensive income (loss) as they are incurred. Government contract revenues related to expenses incurred under the contract are recorded in the same period as those expenses. Expenses accrued under the contract but not yet invoiced are recorded in the Company&amp;#8217;s balance sheet as accrued liabilities and accrued revenues. Equipment purchased under the contract is recorded on the Company&amp;#8217;s balance sheet as deferred expense and deferred revenue and amortized, on a straight-line basis, over the life of the contract.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash or other compensation received in advance of meeting the revenue recognition criteria is recorded on the balance sheet as deferred revenue. Revenue meeting recognition criteria but not yet received or receivable is recorded on the balance sheet as accrued revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases and lease inducements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leases entered into are classified as either capital or operating leases. Leases which substantially transfer all benefits and risks of ownership of property to the Company are accounted for as capital leases. At the time a capital lease is entered into, an asset is recorded together with its related long-term obligation to reflect the purchase and financing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All other leases are accounted for as operating leases wherein rental payments are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lease inducements represent leasehold improvement allowances and reduced or free rent periods and are amortized on a straight-line basis over the term of the lease and are recorded as a reduction of rent expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and development costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are charged as an expense in the period in which they are incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income or loss per share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income or loss per share is calculated based on the weighted average number of common shares outstanding. Diluted loss per share does not differ from basic loss per share for the years ended December 31, 2015, 2014 and 2013, since the effect of the Company&amp;#8217;s stock options and warrants is anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets out the computation of basic and diluted net income (loss) per common share:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;For the year ended December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(61,121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(38,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,063&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;45,462,324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,603,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,302,680&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic income (loss) per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(1.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Diluted income (loss) per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(1.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, potential common shares of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,899,331&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were excluded from the calculation of income per common share because their inclusion would be anti-dilutive (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,221,233&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2013&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,064,767&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Government grants and refundable investment tax credits&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government grants and tax credits provided for current expenses is included in the determination of income or loss for the year, as a reduction of the expenses to which it relates. Government grants and tax credits towards the acquisition of property and equipment is deducted from the cost of the related property and equipment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Foreign currency translation and change in reporting currency&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The functional currency of the Company and two of its integrated subsidiaries (Protiva and Protiva USA), is the Canadian dollar, and the functional currency of Arbutus Inc. is the U.S. dollar. Foreign currency monetary assets and liabilities are translated into the functional currency at the rate of exchange prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month&amp;#8217;s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is using United States dollars as its reporting currency. All assets and liabilities are translated using the exchange rate at the balance sheet date. Revenues, expenses and other income (losses) are translated using the average rate for the period, except for large transactions, for which the exchange rate on the date of the transaction is used. Equity accounts are translated using the historical rate. As the translation differences from the Company&amp;#8217;s functional currency of Canadian dollars to the Company&amp;#8217;s reporting currency of US dollars are unrealized gains and losses, the differences are recorded in other comprehensive income (loss), and do not impact the calculation of Income or Loss per Share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On January 1, 2016, the Company changed its functional currency from the Canadian dollar to the U.S. dollar based on management's analysis of the changes in the primary economic environment in which the Company operates.  The change in functional currency is accounted for prospectively from January 1, 2016 and financial statements prior to and including the year-ended December 31, 2015 have not been restated for the change in functional currency. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Deferred income taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income taxes are accounted for using the asset and liability method of accounting. Deferred income taxes are recognized for the future income tax consequences attributable to differences between the carrying values of assets and liabilities and their respective income tax bases and for loss carry-forwards. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the periods in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax laws or rates is included in earnings in the period that includes the enactment date. When realization of deferred income tax assets does not meet the more-likely-than-not criterion for recognition, a valuation allowance is provided.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company grants stock options to employees and directors pursuant to a share incentive plan described in note 6. Compensation expense is recorded for issued stock options using the fair value method with a corresponding increase in additional paid-in capital. Any consideration received on the exercise of stock options is credited to share capital.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of stock options is measured at the grant date and amortized on a straight-line basis over the vesting period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Replacement awards&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Replacement awards are share-based payment awards exchanged for awards held by employees of Arbutus Inc. As part of the Company&amp;#8217;s acquisition of Arbutus Inc., Arbutus shares were exchanged for Arbutus Inc.&amp;#8217;s shares subject to repurchase rights held by Arbutus Inc.&amp;#8217;s employees - see note 3.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at the date of acquisition of Arbutus Inc., the Company determined the total fair value of replacement awards and attributed a portion of the replacement awards to pre-combination service as part of the total acquisition consideration, and a portion to post-combination service, which is recognized as compensation expense over the expiry period of repurchase provision rights subsequent to the acquisition date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The replacement awards consist of common shares that were issued at acquisition. Accordingly, as stock compensation expense related to these awards is recognized, share capital is increased by a corresponding amount. Replacement awards are excluded in the calculation of basic net income (loss) per share until the repurchase rights have expired.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for the warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company&amp;#8217;s own stock, on the understanding that in compliance with applicable securities laws, the registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies warrants in its consolidated balance sheet as a liability which is revalued at each balance sheet date subsequent to the initial issuance. The Company uses the Black-Scholes pricing model to value the warrants. Determining the appropriate fair-value model and calculating the fair value of registered warrants requires considerable judgment. A small change in the estimates used may cause a relatively large change in the estimated valuation. The estimated volatility of the Company&amp;#8217;s common stock at the date of issuance, and at each subsequent reporting period, is based on historic fluctuations in the Company&amp;#8217;s stock price. The risk-free interest rate is based on the Government of Canada rate for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is based on the historical pattern of exercises of warrants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company operates in a single reporting segment. Substantially all of the Company&amp;#8217;s revenues to date were earned from customers or collaborators based in the United States. Substantially all of the Company&amp;#8217;s premises, property and equipment are located in Canada and the United States.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent accounting pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842): Recognition and Measurement of Financial Assets and Financial Liabilities. The update supersedes Topic 840, Leases and requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP.  Topic 842 retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. The amendments in this update are effective for fiscal years beginning after December 15, 2018 for public business entities, which for the Company means January 1, 2019. The Company does not plan to early adopt this update. The extent of the impact of this adoption has not yet been determined.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In September 2015, the FASB issued ASU 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The update eliminates the requirement to retrospectively adjust the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill during the measurement period when new information is obtained about the facts and circumstances that existed as of the acquisition date, that if known, would have affected the measurement of the amounts initially recognized or would have resulted in the recognition of additional assets or liabilities. The amendments in this update are effective for fiscal years beginning after December 15, 2015, which for the Company means January 1, 2016, and should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update. Early application is permitted for financial statements that have not been issued. The Company has adopted this update and applied it to the acquisition of Arbutus Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASC 606). The standard is intended to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS by creating a new Topic 606, Revenue from Contracts with Customers. This guidance supersedes the revenue recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition - Construction-Type and Production-Type Contracts. The core principle of the accounting standard is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1) retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date to defer the effective date of Update 2014-09 for all entities by one year. The new guidance would be effective for fiscal years beginning after December 15, 2017, which for the Company means January 1, 2018. Entities are permitted to adopt in accordance with the original effective date if they choose. The Company has not yet determined the extent of the impact of adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern. The update is intended to provide guidance in GAAP about management&amp;#8217;s responsibility to evaluate whether there is substantial doubt about an entity&amp;#8217;s ability to continue as a going concern and to provide related footnote disclosures. Under amendments to GAAP, the assessment period is within one year after the date that the financial statements are issued (or available to be issued). The amendments are effective for the annual period ending after December 15, 2016, which for the Company means January 1, 2017, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not plan to early adopt this update. The extent of the impact of this adoption has not yet been determined.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2015Q4YTD" id="Fact-28F85C3B0D389BCA6424EF63650696CA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Share capital&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(a)&amp;#160;&amp;#160;&amp;#160; &amp;#160;Financing&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 22, 2013, the Company completed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,750,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares, at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, representing gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. On November 1, 2013, the offering&amp;#8217;s underwriter completed the exercise of its over-allotment option to purchase a further &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;562,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; bringing the aggregate financing gross proceeds to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$34,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The cost of the financing, including commissions and professional fees, was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,462,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, resulting in net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$32,038,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On March 26, 2014, the Company completed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,125,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares, at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$28.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, representing gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$60,562,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company also granted the underwriters a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-day option to purchase an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;318,750&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares for an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9,084,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to cover any over-allotments. The underwriters did not exercise the option. The cost of financing, including commissions and professional fees, was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4,085,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, resulting in net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$56,477,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On March 25, 2015, the Company announced that it had completed an underwritten public offering of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares, at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.25&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, representing gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$151,875,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company also granted the underwriters a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-day option to purchase an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,125,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares for an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$22,781,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to cover any over-allotments. The underwriters did not exercise the option. The cost of financing, including commissions and professional fees, was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9,700,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, resulting in net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$142,177,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(b)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Authorized share capital&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s authorized share capital consists of an unlimited number of common and preferred shares without par value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(c)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Warrants to purchase common shares&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,750&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants exercised for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$42,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;610,478&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,583,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants were exercised using the cashless exercise provision (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,285&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the Company&amp;#8217;s warrant activity for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="37" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="3%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="5%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="4%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="3%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="8%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="6%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Common shares&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;purchasable upon&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;exercise of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Weighted average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;exercise price (C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;average exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;price (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Range of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;exercise prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Range of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;exercise prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Weighted average remaining contractual life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;intrinsic value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;intrinsic value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Balance, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,014,728&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$2.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(616,478&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;398,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.67&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,902&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(18,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;379,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$2.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$2.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1,217&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;879&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The aggregate intrinsic value in the table above is calculated based on the difference between the exercise price of the warrants and the quoted price of the Company&amp;#8217;s common stock as of the reporting date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All of the Company&amp;#8217;s warrants were exercisable as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average Black-Scholes option-pricing assumptions and the resultant fair values are as follows for warrants outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As at December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;49.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;0.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected average term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;0.6 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Aggregate fair value of warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,099&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of warrants outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;379,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;398,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The value of the Company&amp;#8217;s warrants are particularly sensitive to changes in the Company&amp;#8217;s share price and the estimated share price volatility.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(d)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; share-based compensation plans; the &amp;#8220;2007 Plan&amp;#8221;, the &amp;#8220;2011 Plan&amp;#8221;, two &amp;#8220;Designated Plans&amp;#8221; (together, the &amp;#8220;Arbutus Plans&amp;#8221;), the &amp;#8220;Protiva Option Plan&amp;#8221;, and the "OnCore Option Plan" (see note 3 above).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 22, 2011, the shareholders of the Company approved an omnibus stock-based compensation plan (the &amp;#8220;2011 Plan&amp;#8221;). The Company&amp;#8217;s pre-existing 2007 Plan was limited to the granting of stock options as equity incentive awards whereas the 2011 Plan also allows for the issuance of tandem stock appreciation rights, restricted stock units and deferred stock units (collectively, and including options, referred to as &amp;#8220;Awards&amp;#8221;). The 2011 Plan replaces the 2007 Plan. The 2007 Plan will continue to govern the options granted thereunder. No further options will be granted under the Company&amp;#8217;s 2007 Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Company&amp;#8217;s 2007 Plan the Board of Directors granted options to employees, directors and consultants of the Company.&amp;#160;&amp;#160;The exercise price of the options was determined by the Company&amp;#8217;s Board of Directors but was always at least equal to the closing market price of the common shares on the day preceding the date of grant and the term of options granted did not exceed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years.&amp;#160;&amp;#160;The options granted generally vested over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for employees and immediately for directors.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Company&amp;#8217;s 2011 Plan the Board of Directors may grant options, and other types of Awards, to employees, directors and consultants of the Company.&amp;#160;&amp;#160;The exercise price of the options is determined by the Company&amp;#8217;s Board of Directors but will be at least equal to the closing market price of the common shares on the day preceding the date of grant and the term may not exceed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years.&amp;#160;&amp;#160;Options granted generally vest over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for employees and immediately for directors.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additionally, the Company granted a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options in 2013 to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; executive officers in conjunction with their new appointments as executive officers. These options were granted in accordance with the policies of the Toronto Stock Exchange and pursuant to newly designated share compensation plans (the &amp;#8220;Designated Plans&amp;#8221;). The Designated Plans are governed by substantially the same terms as the 2011 Plan. Hereafter, information on options governed by the 2007 Plan, the 2011 Plan, and the Designated Plans is presented on a consolidated basis as the terms of the four plans are similar. Information on the Protiva Option Plan and the OnCore Option Plan is presented separately.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the Company&amp;#8217;s annual general and special meeting of shareholders on May 8, 2014 and July 9, 2015, the shareholders of the Company approved respectively, a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;800,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; increase in the number of stock-based compensation awards that the Company is permitted to issue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock option activity for the Arbutus Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="31%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;optioned&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;price (C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;price (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;value (C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;intrinsic&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;value (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,648,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;270,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(124,246&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited, canceled or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(64,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21.87&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,730,765&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,030&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;431,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(622,752&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,926&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited, canceled or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,530,138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,004&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,309,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(398,293&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,887&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,386&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited, canceled or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(151,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,290,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;994&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options under the Arbutus Plans expire at various dates from March 28, 2016 to December 2, 2025.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes information pertaining to stock options outstanding at December 31, 2015 under the Arbutus Plans:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="23" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="13%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="10%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="9%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Options outstanding December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Options exercisable December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Range of&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Exercise prices (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;of options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;price (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;of options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;price (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;102,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;102,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.52&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;120,475&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;120,475&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1.66&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$2.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$2.78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;83,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;83,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2.56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$3.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$4.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;288,960&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;268,900&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;3.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$5.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$7.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;261,923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;6.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;175,112&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;6.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$8.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$10.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;176,813&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;9.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;99,189&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;9.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$10.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$13.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;129,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;11.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;79,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;11.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$13.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$17.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;1,126,875&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;17.02&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;10,002&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;17.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$1.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;to&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$17.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;2,290,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;7.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;11.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;938,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;4.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December 31, 2015, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;938,730&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options exercisable (December 31, 2014 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,088,908&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; December 31, 2013 &amp;#8211; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,377,091&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) . The weighted average remaining contractual life of exercisable options as at December 31, 2015 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The aggregate intrinsic value of in-the-money options exercisable at December 31, 2015 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$994,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of the Company&amp;#8217;s non-vested stock option activity and related information for the year ended December 31, 2015 is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;optioned&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;fair value (C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;fair value (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-vested at December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;441,230&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,309,625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(250,461&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-vested options forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(148,853&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-vested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,351,541&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average remaining contractual life for options expected to vest at December 31, 2015 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years and the weighted average exercise price for these options was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.54&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;C$21.51&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The aggregate intrinsic value of options expected to vest as at December 31, 2015 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (December 31, 2014 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,626,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; December 31, 2013 -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$943,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The total fair value of options that vested during the year ended December 31, 2015 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,718,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2014 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,505,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; 2013 -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$955,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Valuation assumptions for the Arbutus Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On March 3, 2015, the Company de-listed from the Toronto Stock Exchange. All stock options granted after March 3, 2015 were denominated in US dollars based on the Company's stock price on the NASDAQ. The methodology and assumptions used  to estimate the fair value of stock options at date of grant under the Black-Scholes option-pricing model remain unchanged. Assumptions on the dividend yield are based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. Assumptions about the Company&amp;#8217;s expected stock-price volatility are based on the historical volatility of the Company&amp;#8217;s publicly traded stock. The risk-free interest rate used for each grant is equal to the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; coupon rate for instruments with a similar expected life. Expected life assumptions are based on the Company&amp;#8217;s historical data. Based on an analysis of its historical forfeitures, the Company  has applied a forfeiture rate to all unvested options held as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeitures are higher than estimated. The weighted average option pricing assumptions and the resultant fair values are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;76.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;101.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;111.61&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1.10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected average option term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;7.5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.8 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.6 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Protiva Option Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On May 30, 2008, as a condition of the acquisition of Protiva Biotherapeutics Inc., a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;350,457&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares of the Company were reserved for the exercise of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;519,073&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Protiva share options (&amp;#8220;Protiva Options&amp;#8221;). The Protiva Options have an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;C$0.30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, were fully vested and exercisable as of May 30, 2008. As at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the outstanding options expire at various dates from April 3, 2017 to March 1, 2018 and upon exercise each option will be converted into approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.6752&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company (the same ratio at which Protiva common shares were exchanged for Company common shares at completion of the acquisition of Protiva). The Protiva Options are not part of the Arbutus Plans and the Company is not permitted to grant any further Protiva Options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth outstanding options under the Protiva Option Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="45%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of Protiva&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equivalent number&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of Company&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;price (C$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;price (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;475,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;321,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited, canceled or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;472,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;319,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(38,145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,754&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited, canceled or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;433,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;292,845&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(358,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(242,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited, canceled or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,065&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,445&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average remaining contractual life of exercisable Protiva Options as at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The aggregate intrinsic value of Protiva Options outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$187,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The intrinsic value of Protiva Options exercised in the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,249,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (2014 - &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$378,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; 2013 -&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;OnCore Option Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As described in note 3 above, as at the acquisition date, the Company reserved &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;184,332&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares for the future exercise of OnCore (Arbutus Inc.) stock options. The total fair value of OnCore stock options at the date of acquisition has been determined to be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,287,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, using the Black-Scholes pricing model with an assumed risk-free interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.97%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, volatility of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; dividend yield and an expected life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, which are consistent with the assumption inputs used by the Company to determine the fair value of its options. Of the total fair value, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,127,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,160,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; will be recognized as compensation expense over the vesting period of the stock options through to December 2018. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Following the merger, the Company is not permitted to grant any further options under the OnCore Option Plan. The Company has included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$463,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of compensation expense related to the vesting of Arbutus Inc. stock options from the acquisition date through to December 31, 2015, which includes an estimated forfeiture rate consistent with the Company's forfeiture estimate under the Arbutus Plans.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth outstanding options under the OnCore Option Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of OnCore&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equivalent number&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of Company&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;price (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, March 4, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;184,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited, canceled or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;183,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;184,332&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December 31, 2015, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86,658&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; OnCore options (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87,269&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Arbutus equivalent) exercisable with a weighted average exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.57&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The weighted average remaining contractual life of exercisable options as at December 31, 2015 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.9&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. The aggregate intrinsic value of in-the-money options exercisable at December 31, 2015 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$337,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of the OnCore Option Plan's non-vested stock option activity and related information for the period from acquisition to December 31, 2015 is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="12%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;OnCore Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equivalent number&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;of Company&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;fair value (US$)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-vested at March 4, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;128,510&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,354&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-vested options forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-vested at December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;96,382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;97,063&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16.42&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average remaining contractual life for options expected to vest at December 31, 2015 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.9&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years and the weighted average exercise price for these options was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.57&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The aggregate intrinsic value of options expected to vest as at December 31, 2015 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$695,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The total fair value of options that vested during the period from acquisition on March 4, 2015 to December 31, 2015 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$620,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense is comprised of: (1) the vesting options awarded to employees under the Arbutus and OnCore option plans calculated in accordance with the fair value method as described above; and (2) the expiration of repurchase rights related to the post-combination service portion of the total fair value of shares issued to Arbutus Inc.'s employees as described in note 3 above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The total stock-based compensation has been recorded in the consolidated statement of operations and comprehensive income (loss) as follows:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="59%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ended December 31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research, development, collaborations and contracts expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;7,868&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;622&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;14,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;940&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;281&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;22,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;903&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December 31, 2015, there remains &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11,972,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of unearned compensation expense related to unvested employee stock options to be recognized as expense over a weighted-average period of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months, as well as a remaining &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$35,967,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unearned compensation expense related to unexpired repurchase rights on shares issued to Arbutus Inc. employees to be recognized as expense over a weighted average period of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Awards outstanding and available for issuance&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Combining all of the Company&amp;#8217;s share-based compensation plans, at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,519,831&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options outstanding and a further &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,135,980&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Awards available for issuance.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2015Q4YTD" id="Fact-FB628DF6AF4A374770E3EF6365077CA5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(a) Protiva USA Reorganization&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effective January 1, 2016, the Company undertook a corporate reorganization merging Protiva USA into Arbutus Inc., which acquired Protiva USA's assets and assumed Protiva USA's liabilities in exchange for Arbutus Inc. shares. The reorganization did not result in any adverse Canadian and U.S. tax consequences.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(b) Monsanto Option Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On March 4, 2016, Monsanto exercised its option to acquire &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the outstanding shares of Protiva Agricultural Development Company Inc. (PADCo), pursuant under its Option Agreement with the Company. Monsanto will pay the Company &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in exercise fee, which the Company will record in the statement of operations and comprehensive loss for the period ended March 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="FD2015Q4YTD" id="Fact-C8A56C9EFBA6D1CC4C03EF636494259C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Supplementary information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and accrued liabilities is comprised of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td width="73%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="11%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td width="1%" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Trade accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2,610&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,044&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2,358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,391&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;License fee accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Professional fee accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;640&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred lease inducements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payroll accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;8,827&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,328&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2015Q4YTD" id="Fact-D237E9DE048D78ECF169EF636443CEBF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring the use of management estimates relate to purchase price allocation, valuation of intangible assets and goodwill, recognition of revenue, stock-based compensation, valuation of warrant liability and financial instrument, and the amounts recorded as accrued liabilities, contingent consideration, and income tax recovery.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>abus-20151231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.tekmirapharm.com/20151231" xmlns:abus="http://www.tekmirapharm.com/20151231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-roles-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20151231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20151231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20151231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20151231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CollaborationsContractsAndLicensingAgreements" roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreements">
        <link:definition>2104100 - Disclosure - Collaborations, Contracts and Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails">
        <link:definition>2404404 - Disclosure - Collaborations, Contracts and Licensing Agreements - Deferred Collaborations and Contracts Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsContractsAndLicensingAgreementsDetails" roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDetails">
        <link:definition>2404402 - Disclosure - Collaborations, Contracts and Licensing Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails">
        <link:definition>2404403 - Disclosure - Collaborations, Contracts and Licensing Agreements - Revenue Recognized Under Collaborations, Contracts and Licensing Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsContractsAndLicensingAgreementsTables" roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsTables">
        <link:definition>2304301 - Disclosure - Collaborations, Contracts and Licensing Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConcentrationsOfBusinessRisk" roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRisk">
        <link:definition>2110100 - Disclosure - Concentrations of Business Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConcentrationsOfBusinessRiskDetails" roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskDetails">
        <link:definition>2410402 - Disclosure - Concentrations of Business Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails">
        <link:definition>2410404 - Disclosure - Concentrations of Business Risk - Foreign Currency Exposure (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails">
        <link:definition>2410403 - Disclosure - Concentrations of Business Risk - Net Liquidity of the Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConcentrationsOfBusinessRiskTables" roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskTables">
        <link:definition>2310301 - Disclosure - Concentrations of Business Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementOfStockholdersEquity" roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquity">
        <link:definition>1003000 - Statement - Consolidated Statement of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementOfStockholdersEquityParenthetical" roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical">
        <link:definition>1003501 - Statement - Consolidated Statement of Stockholders Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAndCommitments" roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitments">
        <link:definition>2109100 - Disclosure - Contingencies and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAndCommitmentsDetails" roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsDetails">
        <link:definition>2409403 - Disclosure - Contingencies and Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails">
        <link:definition>2409402 - Disclosure - Contingencies and Commitments - Minimum Rent and Estimated Operating Cost Commitment, Net Lease Inducements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAndCommitmentsTables" roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsTables">
        <link:definition>2309301 - Disclosure - Contingencies and Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.tekmirapharm.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GovernmentGrantsAndRefundableInvestmentTaxCredits" roleURI="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCredits">
        <link:definition>2107100 - Disclosure - Government Grants and Refundable Investment Tax Credits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" roleURI="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails">
        <link:definition>2407401 - Disclosure - Government Grants and Refundable Investment Tax Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.tekmirapharm.com/role/IncomeTaxes">
        <link:definition>2108100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsDetails" roleURI="http://www.tekmirapharm.com/role/IncomeTaxesDeferredTaxAssetsDetails">
        <link:definition>2408404 - Disclosure - Income Taxes - Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.tekmirapharm.com/role/IncomeTaxesDetails">
        <link:definition>2408402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxReconciliationDetails" roleURI="http://www.tekmirapharm.com/role/IncomeTaxesIncomeTaxReconciliationDetails">
        <link:definition>2408403 - Disclosure - Income Taxes - Income Tax Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.tekmirapharm.com/role/IncomeTaxesTables">
        <link:definition>2308301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimFinancialDataUnaudited" roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnaudited">
        <link:definition>2112100 - Disclosure - Interim Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimFinancialDataUnauditedDetails" roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedDetails">
        <link:definition>2412402 - Disclosure - Interim Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterimFinancialDataUnauditedTables" roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedTables">
        <link:definition>2312301 - Disclosure - Interim Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc" roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc">
        <link:definition>2103100 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails" roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails">
        <link:definition>2403407 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Carrying Value of Intangible Assets After Impairment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails">
        <link:definition>2403402 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails" roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails">
        <link:definition>2403406 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails" roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails">
        <link:definition>2403403 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails" roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails">
        <link:definition>2403405 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Reconciliation of Preliminary to Final Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails" roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails">
        <link:definition>2403404 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Summary of Acquired Identifiable Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables" roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables">
        <link:definition>2303301 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureOfBusinessAndFutureOperations" roleURI="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperations">
        <link:definition>2101100 - Disclosure - Nature of Business and Future Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureOfBusinessAndFutureOperationsNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperationsNarrativeDetails">
        <link:definition>2401401 - Disclosure - Nature of Business and Future Operations Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipment">
        <link:definition>2105100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetails" roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentDetails">
        <link:definition>2405402 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentPropertyAndEquipmentSummaryDetails">
        <link:definition>2405403 - Disclosure - Property and Equipment - Property and Equipment Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentTables">
        <link:definition>2305301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapital" roleURI="http://www.tekmirapharm.com/role/ShareCapital">
        <link:definition>2106100 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalBlackScholesOptionPricingAssumptionsDetails" roleURI="http://www.tekmirapharm.com/role/ShareCapitalBlackScholesOptionPricingAssumptionsDetails">
        <link:definition>2406404 - Disclosure - Share Capital - Black-Scholes Option-pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalDetails" roleURI="http://www.tekmirapharm.com/role/ShareCapitalDetails">
        <link:definition>2406402 - Disclosure - Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" roleURI="http://www.tekmirapharm.com/role/ShareCapitalLocationOfExpensesForStockBasedCompensationDetails">
        <link:definition>2406412 - Disclosure - Share Capital - Location Of Expenses for Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalNonVestedStockOptionActivityDetails" roleURI="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityDetails">
        <link:definition>2406407 - Disclosure - Share Capital - Non-vested Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" roleURI="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails">
        <link:definition>2406411 - Disclosure - Share Capital - Non-vested Stock Option Activity OnCore Option Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" roleURI="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails">
        <link:definition>2406410 - Disclosure - Share Capital - Outstanding Options Under the OnCore Option Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" roleURI="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails">
        <link:definition>2406409 - Disclosure - Share Capital - Outstanding Options Under the Protiva Option Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalStockOptionActivityDetails" roleURI="http://www.tekmirapharm.com/role/ShareCapitalStockOptionActivityDetails">
        <link:definition>2406405 - Disclosure - Share Capital - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalStockOptionsOutstandingDetails" roleURI="http://www.tekmirapharm.com/role/ShareCapitalStockOptionsOutstandingDetails">
        <link:definition>2406406 - Disclosure - Share Capital - Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalSummaryOfWarrantActivityDetails" roleURI="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfWarrantActivityDetails">
        <link:definition>2406403 - Disclosure - Share Capital - Summary of Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalTables" roleURI="http://www.tekmirapharm.com/role/ShareCapitalTables">
        <link:definition>2306301 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalWeightedAverageOptionPricingAssumptionsDetails" roleURI="http://www.tekmirapharm.com/role/ShareCapitalWeightedAverageOptionPricingAssumptionsDetails">
        <link:definition>2406408 - Disclosure - Share Capital - Weighted Average Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>2402404 - Disclosure - Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails">
        <link:definition>2402405 - Disclosure - Significant Accounting Policies - Changes in Fair Value of the Company's Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails">
        <link:definition>2402406 - Disclosure - Significant Accounting Policies - Changes in Fair Value of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails">
        <link:definition>2402408 - Disclosure - Significant Accounting Policies - Computation of Basic and Diluted Net Income (Loss) Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesEstimatedUsefulLivesDetails" roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesEstimatedUsefulLivesDetails">
        <link:definition>2402407 - Disclosure - Significant Accounting Policies - Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2402403 - Disclosure - Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesTables" roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.tekmirapharm.com/role/SubsequentEvents">
        <link:definition>2113100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.tekmirapharm.com/role/SubsequentEventsDetails">
        <link:definition>2413401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryInformation" roleURI="http://www.tekmirapharm.com/role/SupplementaryInformation">
        <link:definition>2111100 - Disclosure - Supplementary Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryInformationDetails" roleURI="http://www.tekmirapharm.com/role/SupplementaryInformationDetails">
        <link:definition>2411402 - Disclosure - Supplementary Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryInformationTables" roleURI="http://www.tekmirapharm.com/role/SupplementaryInformationTables">
        <link:definition>2311301 - Disclosure - Supplementary Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="abus_A2007PlanMember" name="A2007PlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_A2011PlanMember" name="A2011PlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_AbutusStockOptionsMember" name="AbutusStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_AccruedLicenseFeeCurrent" name="AccruedLicenseFeeCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_AccruedPayrollCurrent" name="AccruedPayrollCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_AccruedResearchandDevelopmentCurrent" name="AccruedResearchandDevelopmentCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_AlnylamLicenseAgreementMember" name="AlnylamLicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_AlnylamandAscletisPharmaceuticalsMember" name="AlnylamandAscletisPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ApproximateOptionPeriod" name="ApproximateOptionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" name="ArbitrationWithTheUniversityOfBritishColumbiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_ArbutusInc.Member" name="ArbutusInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_ArbutusPlansMember" name="ArbutusPlansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ArcturusMember" name="ArcturusMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_BMSMember" name="BMSMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_BalanceWeightedaverageremainingcontractuallife" name="BalanceWeightedaverageremainingcontractuallife" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_BlumbergMember" name="BlumbergMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_BlumbergandDrexelMember" name="BlumbergandDrexelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice" name="BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" name="BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted" name="BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter" name="BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward" name="BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" name="BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_CashlessExerciseProvisionMember" name="CashlessExerciseProvisionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ChangesInFairValueOfWarrantsTableTextBlock" name="ChangesInFairValueOfWarrantsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" name="ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue" name="ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_ClassOfWarrantorRightOutstandExcercisePriceRange" name="ClassOfWarrantorRightOutstandExcercisePriceRange" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ClassOfWarrantsOrRightsExcercisedPriceRange" name="ClassOfWarrantsOrRightsExcercisedPriceRange" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_CollaborationsAndContractsAbstract" name="CollaborationsAndContractsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_CommonShareIssuableForArbutusInc.StockOptionsMember" name="CommonShareIssuableForArbutusInc.StockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_ComponentsofDeferredTaxAssetsLineItems" name="ComponentsofDeferredTaxAssetsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_ComponentsofDeferredTaxAssetsTable" name="ComponentsofDeferredTaxAssetsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_ContingenciesandCommitmentsLineItems" name="ContingenciesandCommitmentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_ContingenciesandCommitmentsTable" name="ContingenciesandCommitmentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ContractExtensionMember" name="ContractExtensionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_ContractModificationsAxis" name="ContractModificationsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_ContractModificationsDomain" name="ContractModificationsDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ContractualObligationAmountOfResearchFundingPerYear" name="ContractualObligationAmountOfResearchFundingPerYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_CumulativeContributionforProduct" name="CumulativeContributionforProduct" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_CytosMember" name="CytosMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_DeferredTaxAssetBookAmortizationInExcessOfTax" name="DeferredTaxAssetBookAmortizationInExcessOfTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes" name="DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements" name="DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="abus_DeferredTaxAssetUpfrontLicenseFees" name="DeferredTaxAssetUpfrontLicenseFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="abus_DesignatedPlansMember" name="DesignatedPlansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_DicernaMember" name="DicernaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_DoDMember" name="DoDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_EnantigenMember" name="EnantigenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_EquivalentNumberOfCompanyCommonSharesMember" name="EquivalentNumberOfCompanyCommonSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ExposureToUSDollar" name="ExposureToUSDollar" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" name="FairValueLiabilitiesMeasuredonRecurringBasisRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_FairValueOfWarrantsExercisedInThePeriod" name="FairValueOfWarrantsExercisedInThePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_FairValueOfWarrantsExercisedOnACashlessBasis" name="FairValueOfWarrantsExercisedOnACashlessBasis" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_FairValueOfWarrantsOutstandingPerWarrant" name="FairValueOfWarrantsOutstandingPerWarrant" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="abus_FairValueWarrantsForeignExchangeGainLoss" name="FairValueWarrantsForeignExchangeGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_ForeignCurrencyExposureMember" name="ForeignCurrencyExposureMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract" name="GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock" name="GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock" name="GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems" name="GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable" name="GovernmentGrantsandRefundableInvestmentTaxCreditsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_IPRDAntigenInhibitorsMember" name="IPRDAntigenInhibitorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_IPRDCyclophilinsMember" name="IPRDCyclophilinsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_IPRDImmuneModulatorsMember" name="IPRDImmuneModulatorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_IPRDcccDNASterilizersMember" name="IPRDcccDNASterilizersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ISARICMember" name="ISARICMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_IncomeTaxesDetailsLineItems" name="IncomeTaxesDetailsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_IncomeTaxesTable" name="IncomeTaxesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" name="IncreaseDecreaseInFairValueOfContingentConsiderationLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_IncreaseDecreaseInValueOfWarrants" name="IncreaseDecreaseInValueOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_IncreaseDecreaseOtherDeferredCostsNet" name="IncreaseDecreaseOtherDeferredCostsNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_IncreaseToSupportDevelopmentPlansMember" name="IncreaseToSupportDevelopmentPlansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_IncreasedFundingForStageOneMember" name="IncreasedFundingForStageOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_LengthOfAgreementWithBristolMyersSquibb" name="LengthOfAgreementWithBristolMyersSquibb" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" name="LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense" name="LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract" name="LicensingFeesMilestoneAndRoyaltyPaymentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_MarinaBiotechInc.Member" name="MarinaBiotechInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_MarketCapitalizationValue" name="MarketCapitalizationValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_MarqiboCommercialSalesMember" name="MarqiboCommercialSalesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_MarqiboMember" name="MarqiboMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_MaximumContributionForProduct" name="MaximumContributionForProduct" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_MaximumPotentialTransactionValue" name="MaximumPotentialTransactionValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_MilestonePayment" name="MilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_MonsantoMember" name="MonsantoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_NearTermContractPayments" name="NearTermContractPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_NetLiquidity" name="NetLiquidity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="abus_NetLiquidityDisclosureTableTextBlock" name="NetLiquidityDisclosureTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_NeuroViveMember" name="NeuroViveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_NumberOfAdditionalSharesAuthorized" name="NumberOfAdditionalSharesAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_NumberOfChemotherapyProductsWithWorldwideLicenses" name="NumberOfChemotherapyProductsWithWorldwideLicenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments" name="NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="abus_NumberofShareBasedCompensationPlans" name="NumberofShareBasedCompensationPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="abus_Numberofseriesofcompounds" name="Numberofseriesofcompounds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="abus_OnCoreBiopharmaInc.Member" name="OnCoreBiopharmaInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_OnCoreOptionPlanMember" name="OnCoreOptionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_OpeningLiabilityOfWarrantsIssuedInThePeriod" name="OpeningLiabilityOfWarrantsIssuedInThePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_OptionPeriodExtension" name="OptionPeriodExtension" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_OptionalExcercisedContractualOptionAmount" name="OptionalExcercisedContractualOptionAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="abus_OtherIPRDMember" name="OtherIPRDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_OtherRNAiCollaboratorsMember" name="OtherRNAiCollaboratorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_PADCo.Member" name="PADCo.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_PatentTaxRefundPercentage" name="PatentTaxRefundPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_PercentOfCostsFundedByTPC" name="PercentOfCostsFundedByTPC" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_PerformancePeriodtoRecognizeRevenue" name="PerformancePeriodtoRecognizeRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_PeriodofEstimatedCashFlowsUsedInFairValue" name="PeriodofEstimatedCashFlowsUsedInFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_PotentialContractFundingAmount" name="PotentialContractFundingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_PotentialProceedsOfAdditionalSharesAuthorized" name="PotentialProceedsOfAdditionalSharesAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_ProgramsInPreClinicalDevelopment" name="ProgramsInPreClinicalDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_ProtivaOptionPlanMember" name="ProtivaOptionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ProtivaShareOptionsMember" name="ProtivaShareOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_Range1Member" name="Range1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_Range2Member" name="Range2Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_Range3Member" name="Range3Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_Range4Member" name="Range4Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_Range5Member" name="Range5Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_Range6Member" name="Range6Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_Range7Member" name="Range7Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_Range8Member" name="Range8Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ReplacementAwardsPolicyTextBlock" name="ReplacementAwardsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments" name="ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments" name="ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment" name="ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_ResearchFundingPeriod" name="ResearchFundingPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ResearchFundingPeriodRenewableOption" name="ResearchFundingPeriodRenewableOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_RevisedNewCommonSharesMember" name="RevisedNewCommonSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_RoyaltiesPaidOrAccrued" name="RoyaltiesPaidOrAccrued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_RoyaltyGuaranteesCommitmentsPercentage" name="RoyaltyGuaranteesCommitmentsPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_RoyaltyPayable" name="RoyaltyPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_SharesIssuedSubjectToRepurchaseProvisionMember" name="SharesIssuedSubjectToRepurchaseProvisionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_SharesIssuedWithoutSubjectsMember" name="SharesIssuedWithoutSubjectsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_SpectrumMember" name="SpectrumMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_StageOneMember" name="StageOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_StockRepurchaseRightsExpirationRateShares" name="StockRepurchaseRightsExpirationRateShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock" name="SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_TalonTherapeuticsMember" name="TalonTherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" name="TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_TotalRangeMember" name="TotalRangeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member" name="UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_UpfrontFee" name="UpfrontFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_WarrantsExercised" name="WarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements" name="WhollyOwnedSubsidiariesIncludedinFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>abus-20151231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreements" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsTables" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRisk" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRisk" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskDetails" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskTables" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets" xlink:href="abus-20151231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="abus-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="abus-20151231.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:href="abus-20151231.xsd#ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="abus-20151231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="abus-20151231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitments" xlink:href="abus-20151231.xsd#ContingenciesAndCommitments" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsDetails" xlink:href="abus-20151231.xsd#ContingenciesAndCommitmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:href="abus-20151231.xsd#ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsTables" xlink:href="abus-20151231.xsd#ContingenciesAndCommitmentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/DocumentAndEntityInformation" xlink:href="abus-20151231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:href="abus-20151231.xsd#GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:href="abus-20151231.xsd#GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxes" xlink:href="abus-20151231.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:href="abus-20151231.xsd#IncomeTaxesDeferredTaxAssetsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesDetails" xlink:href="abus-20151231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesIncomeTaxReconciliationDetails" xlink:href="abus-20151231.xsd#IncomeTaxesIncomeTaxReconciliationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesTables" xlink:href="abus-20151231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnaudited" xlink:href="abus-20151231.xsd#InterimFinancialDataUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedDetails" xlink:href="abus-20151231.xsd#InterimFinancialDataUnauditedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedTables" xlink:href="abus-20151231.xsd#InterimFinancialDataUnauditedTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperations" xlink:href="abus-20151231.xsd#NatureOfBusinessAndFutureOperations" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperationsNarrativeDetails" xlink:href="abus-20151231.xsd#NatureOfBusinessAndFutureOperationsNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipment" xlink:href="abus-20151231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentDetails" xlink:href="abus-20151231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:href="abus-20151231.xsd#PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentTables" xlink:href="abus-20151231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapital" xlink:href="abus-20151231.xsd#ShareCapital" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalBlackScholesOptionPricingAssumptionsDetails" xlink:href="abus-20151231.xsd#ShareCapitalBlackScholesOptionPricingAssumptionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalDetails" xlink:href="abus-20151231.xsd#ShareCapitalDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:href="abus-20151231.xsd#ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityDetails" xlink:href="abus-20151231.xsd#ShareCapitalNonVestedStockOptionActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:href="abus-20151231.xsd#ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:href="abus-20151231.xsd#ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:href="abus-20151231.xsd#ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalStockOptionActivityDetails" xlink:href="abus-20151231.xsd#ShareCapitalStockOptionActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalStockOptionsOutstandingDetails" xlink:href="abus-20151231.xsd#ShareCapitalStockOptionsOutstandingDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfWarrantActivityDetails" xlink:href="abus-20151231.xsd#ShareCapitalSummaryOfWarrantActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalTables" xlink:href="abus-20151231.xsd#ShareCapitalTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalWeightedAverageOptionPricingAssumptionsDetails" xlink:href="abus-20151231.xsd#ShareCapitalWeightedAverageOptionPricingAssumptionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPolicies" xlink:href="abus-20151231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesPolicies" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesTables" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SubsequentEvents" xlink:href="abus-20151231.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SubsequentEventsDetails" xlink:href="abus-20151231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformation" xlink:href="abus-20151231.xsd#SupplementaryInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformationDetails" xlink:href="abus-20151231.xsd#SupplementaryInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformationTables" xlink:href="abus-20151231.xsd#SupplementaryInformationTables" xlink:type="simple" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreements" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRisk" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:type="extended">
    <loc xlink:href="abus-20151231.xsd#abus_ExposureToUSDollar" xlink:label="loc_abus_ExposureToUSDollar_a6f969da-810c-7e02-672b-ef6337763489" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_99cc497a-24d6-394d-7b8f-e0bd0a50eba0" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_ExposureToUSDollar_a6f969da-810c-7e02-672b-ef6337763489" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_99cc497a-24d6-394d-7b8f-e0bd0a50eba0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_3524be21-eaec-4398-eb0d-fe71dbe67324" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_ExposureToUSDollar_a6f969da-810c-7e02-672b-ef6337763489" xlink:to="loc_us-gaap_AccountsReceivableNet_3524be21-eaec-4398-eb0d-fe71dbe67324" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_01c79cd5-7db4-c322-4828-4ad1d3c115b4" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_ExposureToUSDollar_a6f969da-810c-7e02-672b-ef6337763489" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_01c79cd5-7db4-c322-4828-4ad1d3c115b4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_3185ab5b-1aca-212d-4c91-70e5620fe0fb" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_ExposureToUSDollar_a6f969da-810c-7e02-672b-ef6337763489" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_3185ab5b-1aca-212d-4c91-70e5620fe0fb" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:type="extended">
    <loc xlink:href="abus-20151231.xsd#abus_NetLiquidity" xlink:label="loc_abus_NetLiquidity_3dc9ec35-4578-627a-c6d9-ef633774e06e" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_99cc497a-24d6-394d-7b8f-e0bd0a50eba0" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_NetLiquidity_3dc9ec35-4578-627a-c6d9-ef633774e06e" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_99cc497a-24d6-394d-7b8f-e0bd0a50eba0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_3185ab5b-1aca-212d-4c91-70e5620fe0fb" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_abus_NetLiquidity_3dc9ec35-4578-627a-c6d9-ef633774e06e" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_3185ab5b-1aca-212d-4c91-70e5620fe0fb" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_c952180c-d37a-a6b0-3e18-a18cd8328eee" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_DeferredRevenueCurrent_c952180c-d37a-a6b0-3e18-a18cd8328eee" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_ce979c60-36c9-c8c1-cd3c-341cd1a8c7d0" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1477e02d-b6d8-3df6-e715-8364fedce6d9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_ce979c60-36c9-c8c1-cd3c-341cd1a8c7d0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_e71e7b37-2828-6759-f8ce-a5ac289c852b" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_e71e7b37-2828-6759-f8ce-a5ac289c852b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2f75413a-0715-3e2a-7260-1e1c79d9f7ef" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2f75413a-0715-3e2a-7260-1e1c79d9f7ef" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_43aaac76-959d-69e2-234b-7c7a89d77345" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_16ce0436-3b82-55c5-d896-5cba4c9023bd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_43aaac76-959d-69e2-234b-7c7a89d77345" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae9fd5e7-8741-dfbd-241e-1460ec6c786e" xlink:to="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_ffd09989-75a8-4713-beb0-21bebb3561d6" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_CommonStockValue_ffd09989-75a8-4713-beb0-21bebb3561d6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dcbd5d14-4ec6-06fe-e5c1-a41efced6761" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dcbd5d14-4ec6-06fe-e5c1-a41efced6761" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_440a13e9-e4dc-f397-4d0d-27daacd44483" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_440a13e9-e4dc-f397-4d0d-27daacd44483" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4d60b95b-a2a9-55da-7eaa-2ca718a58484" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_26e56c7a-24ab-e869-809a-0509ccbe86d9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4d60b95b-a2a9-55da-7eaa-2ca718a58484" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c4121e9a-097d-7136-dbac-b93469330286" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c4121e9a-097d-7136-dbac-b93469330286" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2c0591e3-817a-5563-df1e-5c3ede33266d" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a1eaafaf-055b-e423-85ef-4424fb2ef4e4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2c0591e3-817a-5563-df1e-5c3ede33266d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_c62110c4-28c7-e8eb-2a6d-e8964607a348" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_LongTermInvestments_c62110c4-28c7-e8eb-2a6d-e8964607a348" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_32ecd7de-6410-d56f-5547-ab1b682ebbc0" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_32ecd7de-6410-d56f-5547-ab1b682ebbc0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d1288432-0516-3188-e96b-2bc623375a5a" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_Goodwill_d1288432-0516-3188-e96b-2bc623375a5a" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b517a4f1-4597-b094-2608-75af660328e1" xlink:to="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999960f8-6702-f7e9-88df-fcb8021751b2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_999960f8-6702-f7e9-88df-fcb8021751b2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_96e417a6-7446-6031-787d-9a81025423eb" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_ShortTermInvestments_96e417a6-7446-6031-787d-9a81025423eb" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dc301a2a-78b3-2f7c-72b2-6d5ec18f9327" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dc301a2a-78b3-2f7c-72b2-6d5ec18f9327" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_01c79cd5-7db4-c322-4828-4ad1d3c115b4" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_01c79cd5-7db4-c322-4828-4ad1d3c115b4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_b55f8997-2ee7-02b3-cb5b-06e177e6e17d" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_IncomeTaxesReceivable_b55f8997-2ee7-02b3-cb5b-06e177e6e17d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3227d5e9-cb9d-fda7-e599-c6fb89b5e07a" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_67f49e84-05fd-4b0b-ae5a-e9913b97cea2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3227d5e9-cb9d-fda7-e599-c6fb89b5e07a" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6b5c2f7-2ab7-a264-6d06-119dda52768c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_5ad9674a-6203-3e3a-f329-f4cfb3162c67" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_5ad9674a-6203-3e3a-f329-f4cfb3162c67" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_af325b40-4a9e-bc21-ac47-5d226ccd5482" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_af325b40-4a9e-bc21-ac47-5d226ccd5482" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_90abc8df-a70a-7c23-5fff-9b3d9bc98c9b" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_90abc8df-a70a-7c23-5fff-9b3d9bc98c9b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37181af6-e562-cefc-f2b6-8490ea2c3e04" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fb013d5f-7e0c-1a40-5a42-42bd8c3a1d51" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37181af6-e562-cefc-f2b6-8490ea2c3e04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdec3780-88f3-c634-f85d-cb36bba63bd2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdec3780-88f3-c634-f85d-cb36bba63bd2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_29d765d3-9bf3-69a0-f67a-85487c765b79" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_29d765d3-9bf3-69a0-f67a-85487c765b79" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_60196f93-012a-e451-c3d1-1aecefe41f32" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6d7b73b6-0db7-23f7-377e-417fa8fc8e27" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_60196f93-012a-e451-c3d1-1aecefe41f32" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_21149c4c-60e9-1f3a-82d3-665a83a5c4f2" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_46b895b2-8ff5-9e37-d4c3-5b75649cbcba" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_21149c4c-60e9-1f3a-82d3-665a83a5c4f2" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_375e0d17-4818-4239-a370-aada0b6ca8eb" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7fd63b12-05a5-a417-a943-a2dd6e58d717" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_375e0d17-4818-4239-a370-aada0b6ca8eb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7fd63b12-05a5-a417-a943-a2dd6e58d717" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_375e0d17-4818-4239-a370-aada0b6ca8eb" xlink:to="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_10afc0e9-1faa-0be3-fc32-15d128e46f3f" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_10afc0e9-1faa-0be3-fc32-15d128e46f3f" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_10afc0e9-1faa-0be3-fc32-15d128e46f3f" xlink:to="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_467b5ef7-2b02-661a-3e41-f79140739819" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:to="loc_us-gaap_Revenues_467b5ef7-2b02-661a-3e41-f79140739819" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_6e350f7a-ab47-e4cf-c75e-0634d95fc8b2" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_467b5ef7-2b02-661a-3e41-f79140739819" xlink:to="loc_us-gaap_ContractsRevenue_6e350f7a-ab47-e4cf-c75e-0634d95fc8b2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_897c0d66-1163-53d3-0580-29e565de71d0" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_467b5ef7-2b02-661a-3e41-f79140739819" xlink:to="loc_us-gaap_LicensesRevenue_897c0d66-1163-53d3-0580-29e565de71d0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_72b2c986-6e1a-bdde-cc72-888b0df562b9" xlink:to="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7d1bc05d-33ee-c009-4533-b70ee0a74dc9" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7d1bc05d-33ee-c009-4533-b70ee0a74dc9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7c6d12de-ee49-8fea-ba36-2f44ccb8dae4" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7c6d12de-ee49-8fea-ba36-2f44ccb8dae4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_296ac298-3acc-b888-34a0-99e6da446889" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_Depreciation_296ac298-3acc-b888-34a0-99e6da446889" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b4af5cc9-e22d-6655-b850-9e2926452dd4" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_b4af5cc9-e22d-6655-b850-9e2926452dd4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_086246f8-2deb-77e5-5749-2b3fc6e74fb5" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ee2bd36d-150a-7303-38c4-eb755f792210" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_086246f8-2deb-77e5-5749-2b3fc6e74fb5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_89191b30-59c9-0ba0-34ea-6e2a98cbdb1c" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_10afc0e9-1faa-0be3-fc32-15d128e46f3f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_89191b30-59c9-0ba0-34ea-6e2a98cbdb1c" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a24d82ba-62b0-7744-0b3a-f37dbe668bee" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_89191b30-59c9-0ba0-34ea-6e2a98cbdb1c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a24d82ba-62b0-7744-0b3a-f37dbe668bee" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b3399012-62b0-7fc5-0d6c-327b1e46d7be" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_89191b30-59c9-0ba0-34ea-6e2a98cbdb1c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b3399012-62b0-7fc5-0d6c-327b1e46d7be" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_4c6646f7-2200-0f24-ebab-985fcfdd94a1" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_89191b30-59c9-0ba0-34ea-6e2a98cbdb1c" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_4c6646f7-2200-0f24-ebab-985fcfdd94a1" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_9C0FCAE61C37B385D6392F30CEAF7932" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_89191b30-59c9-0ba0-34ea-6e2a98cbdb1c" xlink:to="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_9C0FCAE61C37B385D6392F30CEAF7932" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_faecc408-4bea-6e13-83bd-71b4c2ddf64c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitments" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cc811211-f8d9-2df0-b015-05419b9bfc99" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_a329292c-67ac-0030-2d90-e18d188691fe" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cc811211-f8d9-2df0-b015-05419b9bfc99" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_a329292c-67ac-0030-2d90-e18d188691fe" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_d0d481f0-55e7-c97c-ec8d-df7b34e55256" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cc811211-f8d9-2df0-b015-05419b9bfc99" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_d0d481f0-55e7-c97c-ec8d-df7b34e55256" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b90d3e1a-4d8a-a6c8-154e-2ac9658c1ba3" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cc811211-f8d9-2df0-b015-05419b9bfc99" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b90d3e1a-4d8a-a6c8-154e-2ac9658c1ba3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_50b4cfc1-5417-1ddf-07f2-e739d063c669" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_cc811211-f8d9-2df0-b015-05419b9bfc99" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_50b4cfc1-5417-1ddf-07f2-e739d063c669" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxes" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_4c447841-8fe7-39fb-b3f1-0ad85920e353" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c6255722-3158-aa8e-fb0b-718e4b04bb3b" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4c447841-8fe7-39fb-b3f1-0ad85920e353" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c6255722-3158-aa8e-fb0b-718e4b04bb3b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9afa727c-dfb8-5804-93fa-f0667d5fb87b" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_4c447841-8fe7-39fb-b3f1-0ad85920e353" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9afa727c-dfb8-5804-93fa-f0667d5fb87b" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_c43448c4-6b4c-56ea-f479-78cea348bda4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_576d5a77-ba10-3881-36d9-b5e9bdaefd1b" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_c43448c4-6b4c-56ea-f479-78cea348bda4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_576d5a77-ba10-3881-36d9-b5e9bdaefd1b" xlink:type="arc" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_c43448c4-6b4c-56ea-f479-78cea348bda4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9afa727c-dfb8-5804-93fa-f0667d5fb87b" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesIncomeTaxReconciliationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6ddabc60-b949-830f-ceec-3c3166ee4678" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6ddabc60-b949-830f-ceec-3c3166ee4678" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_5be9418b-d455-e525-e892-c42da5d9af08" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_5be9418b-d455-e525-e892-c42da5d9af08" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_97197894-8a5f-31b0-a37d-05c54140608d" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_97197894-8a5f-31b0-a37d-05c54140608d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_98c96f59-a5e7-5cf9-49f0-76a97dacee60" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_98c96f59-a5e7-5cf9-49f0-76a97dacee60" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1dfd4cb0-12c9-60ef-4e8f-faef112ad93a" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_3a83e980-c99b-5657-79fd-300643b7fa11" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_1dfd4cb0-12c9-60ef-4e8f-faef112ad93a" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnaudited" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_3F925705BFB001150EC239A538441B38" xlink:type="locator" />
    <calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_3F925705BFB001150EC239A538441B38" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_10CA3D1AE18A0F940F0D39A649386A5C" xlink:type="locator" />
    <calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_10CA3D1AE18A0F940F0D39A649386A5C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_CC68B0BCFFD4D3E227BE39A7EACDF399" xlink:type="locator" />
    <calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_CC68B0BCFFD4D3E227BE39A7EACDF399" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_f944ecf8-d194-df76-9d48-a0c103c51480" xlink:type="locator" />
    <calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_f944ecf8-d194-df76-9d48-a0c103c51480" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_439e2522-10d1-8116-e942-1ae9198edc43" xlink:type="locator" />
    <calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_439e2522-10d1-8116-e942-1ae9198edc43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_be65df66-ba7c-f27f-83d4-ab2c1f0859c9" xlink:type="locator" />
    <calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_be65df66-ba7c-f27f-83d4-ab2c1f0859c9" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_7F1CCD8028C526F9E1CD39A9124EB2A0" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_7F1CCD8028C526F9E1CD39A9124EB2A0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_022894920530B847C71639A9E1DAB7FC" xlink:type="locator" />
    <calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_022894920530B847C71639A9E1DAB7FC" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_B80688D3420D8CB473A539AA5ABDCFB4" xlink:type="locator" />
    <calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_037c29de-ccb7-dec0-287b-acc4250657a5" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_B80688D3420D8CB473A539AA5ABDCFB4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ac0c8685-2a5b-4001-4838-de7767c606f3" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ac0c8685-2a5b-4001-4838-de7767c606f3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_33e8fe41-b5e8-bc8e-8934-058be6d022a1" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_33e8fe41-b5e8-bc8e-8934-058be6d022a1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8108f0d4-08a0-ec7c-c765-bac280e911fb" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_8108f0d4-08a0-ec7c-c765-bac280e911fb" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_40b1481f-0626-6aa6-7abd-04c754980b6d" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_40b1481f-0626-6aa6-7abd-04c754980b6d" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_81e8c6d9-1c93-f9e0-90a7-5f22ce1d3593" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_81e8c6d9-1c93-f9e0-90a7-5f22ce1d3593" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d1288432-0516-3188-e96b-2bc623375a5a" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_Goodwill_d1288432-0516-3188-e96b-2bc623375a5a" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:label="loc_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_9d7274dd-da7e-cdcd-cafc-ef6337766903" xlink:type="locator" />
    <calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_9d7274dd-da7e-cdcd-cafc-ef6337766903" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_f7ff0ef9-3907-f619-c985-f9387c2b8b2e" xlink:type="locator" />
    <calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_f7ff0ef9-3907-f619-c985-f9387c2b8b2e" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_e0905149-e955-96b0-6abe-a8cc2f161e28" xlink:type="locator" />
    <calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_5baa6f06-d5c1-e7d5-57ec-bd3b80e4bef6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_e0905149-e955-96b0-6abe-a8cc2f161e28" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperations" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperationsNarrativeDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipment" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapital" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalBlackScholesOptionPricingAssumptionsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalStockOptionActivityDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalStockOptionsOutstandingDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfWarrantActivityDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalWeightedAverageOptionPricingAssumptionsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8b55b75a-d66d-1dbb-a26a-c58c1cb8c8b0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1b16e3b5-4267-805c-bc8d-0fbc8ca9b0da" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8b55b75a-d66d-1dbb-a26a-c58c1cb8c8b0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1b16e3b5-4267-805c-bc8d-0fbc8ca9b0da" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_c834eacb-13fa-94c9-344e-6c3e507eff22" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8b55b75a-d66d-1dbb-a26a-c58c1cb8c8b0" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_c834eacb-13fa-94c9-344e-6c3e507eff22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_c62110c4-28c7-e8eb-2a6d-e8964607a348" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8b55b75a-d66d-1dbb-a26a-c58c1cb8c8b0" xlink:to="loc_us-gaap_LongTermInvestments_c62110c4-28c7-e8eb-2a6d-e8964607a348" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_f80fe47d-2734-e6b6-3064-c1fcdf2dcb97" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_10e4f07a-452f-c83d-9b21-0f27fc5e3c69" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_f80fe47d-2734-e6b6-3064-c1fcdf2dcb97" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_10e4f07a-452f-c83d-9b21-0f27fc5e3c69" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2f75413a-0715-3e2a-7260-1e1c79d9f7ef" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_f80fe47d-2734-e6b6-3064-c1fcdf2dcb97" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2f75413a-0715-3e2a-7260-1e1c79d9f7ef" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_20ad9326-5aff-435e-b0c6-939122f423a7" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_f80fe47d-2734-e6b6-3064-c1fcdf2dcb97" xlink:to="loc_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_20ad9326-5aff-435e-b0c6-939122f423a7" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesTables" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SubsequentEvents" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SubsequentEventsDetails" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformation" xlink:type="extended" />
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_3e363941-50d5-576d-93bf-bcf41fd83617" xlink:type="locator" />
    <calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_3e363941-50d5-576d-93bf-bcf41fd83617" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AccruedResearchandDevelopmentCurrent" xlink:label="loc_abus_AccruedResearchandDevelopmentCurrent_879547B33F4FA2533F0633FB67209E57" xlink:type="locator" />
    <calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:to="loc_abus_AccruedResearchandDevelopmentCurrent_879547B33F4FA2533F0633FB67209E57" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AccruedLicenseFeeCurrent" xlink:label="loc_abus_AccruedLicenseFeeCurrent_912ACD57762A3213D2C033FD9B2EA6E5" xlink:type="locator" />
    <calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:to="loc_abus_AccruedLicenseFeeCurrent_912ACD57762A3213D2C033FD9B2EA6E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_28c626c7-9023-e30f-2e48-0f4dd115d912" xlink:type="locator" />
    <calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_28c626c7-9023-e30f-2e48-0f4dd115d912" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="loc_us-gaap_LeaseIncentivePayableCurrent_7cf1cbd8-570e-ba27-e267-e28a9ead2b2e" xlink:type="locator" />
    <calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:to="loc_us-gaap_LeaseIncentivePayableCurrent_7cf1cbd8-570e-ba27-e267-e28a9ead2b2e" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AccruedPayrollCurrent" xlink:label="loc_abus_AccruedPayrollCurrent_90EC98AAC74548078C6F3401C80755EA" xlink:type="locator" />
    <calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:to="loc_abus_AccruedPayrollCurrent_90EC98AAC74548078C6F3401C80755EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_46c5e103-584b-b600-2852-4201435cc29f" xlink:type="locator" />
    <calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_771fda46-ad18-43f7-74a8-24b4258a1976" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_46c5e103-584b-b600-2852-4201435cc29f" xlink:type="arc" />
  </calculationLink>
  <calculationLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformationTables" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>abus-20151231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreements" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsTables" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRisk" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRisk" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskDetails" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskTables" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets" xlink:href="abus-20151231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="abus-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="abus-20151231.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:href="abus-20151231.xsd#ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="abus-20151231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="abus-20151231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitments" xlink:href="abus-20151231.xsd#ContingenciesAndCommitments" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsDetails" xlink:href="abus-20151231.xsd#ContingenciesAndCommitmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:href="abus-20151231.xsd#ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsTables" xlink:href="abus-20151231.xsd#ContingenciesAndCommitmentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/DocumentAndEntityInformation" xlink:href="abus-20151231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:href="abus-20151231.xsd#GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:href="abus-20151231.xsd#GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxes" xlink:href="abus-20151231.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:href="abus-20151231.xsd#IncomeTaxesDeferredTaxAssetsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesDetails" xlink:href="abus-20151231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesIncomeTaxReconciliationDetails" xlink:href="abus-20151231.xsd#IncomeTaxesIncomeTaxReconciliationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesTables" xlink:href="abus-20151231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnaudited" xlink:href="abus-20151231.xsd#InterimFinancialDataUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedDetails" xlink:href="abus-20151231.xsd#InterimFinancialDataUnauditedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedTables" xlink:href="abus-20151231.xsd#InterimFinancialDataUnauditedTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperations" xlink:href="abus-20151231.xsd#NatureOfBusinessAndFutureOperations" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperationsNarrativeDetails" xlink:href="abus-20151231.xsd#NatureOfBusinessAndFutureOperationsNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipment" xlink:href="abus-20151231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentDetails" xlink:href="abus-20151231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:href="abus-20151231.xsd#PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentTables" xlink:href="abus-20151231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapital" xlink:href="abus-20151231.xsd#ShareCapital" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalBlackScholesOptionPricingAssumptionsDetails" xlink:href="abus-20151231.xsd#ShareCapitalBlackScholesOptionPricingAssumptionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalDetails" xlink:href="abus-20151231.xsd#ShareCapitalDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:href="abus-20151231.xsd#ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityDetails" xlink:href="abus-20151231.xsd#ShareCapitalNonVestedStockOptionActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:href="abus-20151231.xsd#ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:href="abus-20151231.xsd#ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:href="abus-20151231.xsd#ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalStockOptionActivityDetails" xlink:href="abus-20151231.xsd#ShareCapitalStockOptionActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalStockOptionsOutstandingDetails" xlink:href="abus-20151231.xsd#ShareCapitalStockOptionsOutstandingDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfWarrantActivityDetails" xlink:href="abus-20151231.xsd#ShareCapitalSummaryOfWarrantActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalTables" xlink:href="abus-20151231.xsd#ShareCapitalTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalWeightedAverageOptionPricingAssumptionsDetails" xlink:href="abus-20151231.xsd#ShareCapitalWeightedAverageOptionPricingAssumptionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPolicies" xlink:href="abus-20151231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesPolicies" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesTables" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SubsequentEvents" xlink:href="abus-20151231.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SubsequentEventsDetails" xlink:href="abus-20151231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformation" xlink:href="abus-20151231.xsd#SupplementaryInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformationDetails" xlink:href="abus-20151231.xsd#SupplementaryInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformationTables" xlink:href="abus-20151231.xsd#SupplementaryInformationTables" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreements" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_53C1C04652AE1D8BAF403A63730E7E92" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_29237406AF8FCADFB9E03A63730E2BC6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_53C1C04652AE1D8BAF403A63730E7E92" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_29237406AF8FCADFB9E03A63730E2BC6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_730438FA039938FFB7103A63730E2967" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_29237406AF8FCADFB9E03A63730E2BC6" xlink:to="loc_us-gaap_CounterpartyNameAxis_730438FA039938FFB7103A63730E2967" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C2958E9A32146A78A1443A63730EAA96_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_730438FA039938FFB7103A63730E2967" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C2958E9A32146A78A1443A63730EAA96_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C2958E9A32146A78A1443A63730EAA96" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_730438FA039938FFB7103A63730E2967" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C2958E9A32146A78A1443A63730EAA96" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DoDMember" xlink:label="loc_abus_DoDMember_691D241242E145CF5ADF3A63730E70B4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C2958E9A32146A78A1443A63730EAA96" xlink:to="loc_abus_DoDMember_691D241242E145CF5ADF3A63730E70B4" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MonsantoMember" xlink:label="loc_abus_MonsantoMember_03BA9B3460113A8A5E313A63730E58C6" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C2958E9A32146A78A1443A63730EAA96" xlink:to="loc_abus_MonsantoMember_03BA9B3460113A8A5E313A63730E58C6" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BMSMember" xlink:label="loc_abus_BMSMember_C07B03A92985D82FEE8F3A63730E80EB" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C2958E9A32146A78A1443A63730EAA96" xlink:to="loc_abus_BMSMember_C07B03A92985D82FEE8F3A63730E80EB" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DicernaMember" xlink:label="loc_abus_DicernaMember_4D0AFD556C62502EFA8D3A63730E8167" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C2958E9A32146A78A1443A63730EAA96" xlink:to="loc_abus_DicernaMember_4D0AFD556C62502EFA8D3A63730E8167" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_45689432A9AD8AD9643B3A63730EE45F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_53C1C04652AE1D8BAF403A63730E7E92" xlink:to="loc_us-gaap_DeferredRevenueCurrent_45689432A9AD8AD9643B3A63730EE45F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_2D3D95F9895193E55D933A63730EB4D2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_53C1C04652AE1D8BAF403A63730E7E92" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_2D3D95F9895193E55D933A63730EB4D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_382499D07829A6D9238E3A63730E7FB6" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_53C1C04652AE1D8BAF403A63730E7E92" xlink:to="loc_us-gaap_DeferredRevenue_382499D07829A6D9238E3A63730E7FB6" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0B8AFFBA216770A5779B56E9A21688FE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0B8AFFBA216770A5779B56E9A21688FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7C63DEC59FBEB825839356E9A21A6AB3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0B8AFFBA216770A5779B56E9A21688FE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7C63DEC59FBEB825839356E9A21A6AB3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7C63DEC59FBEB825839356E9A21A6AB3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0B8AFFBA216770A5779B56E9A21688FE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7C63DEC59FBEB825839356E9A21A6AB3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_437B1FE2FE92AE1C3EDF56EA0C3E2778" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7C63DEC59FBEB825839356E9A21A6AB3" xlink:to="loc_us-gaap_SubsequentEventMember_437B1FE2FE92AE1C3EDF56EA0C3E2778" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CFB3ADC1B8108FE94AAD56E759A2C44D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_CFB3ADC1B8108FE94AAD56E759A2C44D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19CA19CF66BF2FEE66E256E75BA3F45F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CFB3ADC1B8108FE94AAD56E759A2C44D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19CA19CF66BF2FEE66E256E75BA3F45F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19CA19CF66BF2FEE66E256E75BA3F45F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CFB3ADC1B8108FE94AAD56E759A2C44D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19CA19CF66BF2FEE66E256E75BA3F45F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PADCo.Member" xlink:label="loc_abus_PADCo.Member_104765838A3A2C65158356E759DCDB11" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19CA19CF66BF2FEE66E256E75BA3F45F" xlink:to="loc_abus_PADCo.Member_104765838A3A2C65158356E759DCDB11" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_C0A4072D38520081C14956E6A4A880CF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_dei_LegalEntityAxis_C0A4072D38520081C14956E6A4A880CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A69CF107778E563FEEC956E6A625DEBB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_C0A4072D38520081C14956E6A4A880CF" xlink:to="loc_dei_EntityDomain_A69CF107778E563FEEC956E6A625DEBB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A69CF107778E563FEEC956E6A625DEBB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_C0A4072D38520081C14956E6A4A880CF" xlink:to="loc_dei_EntityDomain_A69CF107778E563FEEC956E6A625DEBB" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MonsantoMember" xlink:label="loc_abus_MonsantoMember_D7F7CA817A0709FF576356E9049BD149" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_A69CF107778E563FEEC956E6A625DEBB" xlink:to="loc_abus_MonsantoMember_D7F7CA817A0709FF576356E9049BD149" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_5D41E86159F961391A7356E5215A7F8D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_LitigationCaseAxis_5D41E86159F961391A7356E5215A7F8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_6C81F462410729FCA31056E5215A3C91_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationCaseAxis_5D41E86159F961391A7356E5215A7F8D" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_6C81F462410729FCA31056E5215A3C91_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_6C81F462410729FCA31056E5215A3C91" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationCaseAxis_5D41E86159F961391A7356E5215A7F8D" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_6C81F462410729FCA31056E5215A3C91" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AlnylamandAscletisPharmaceuticalsMember" xlink:label="loc_abus_AlnylamandAscletisPharmaceuticalsMember_1EB58ADDFBE8ECE13A4056E5215A9EC7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6C81F462410729FCA31056E5215A3C91" xlink:to="loc_abus_AlnylamandAscletisPharmaceuticalsMember_1EB58ADDFBE8ECE13A4056E5215A9EC7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1C76C6D1852D50DAEC4256E5215AA914" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1C76C6D1852D50DAEC4256E5215AA914" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1C76C6D1852D50DAEC4256E5215AA914" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1C76C6D1852D50DAEC4256E5215AA914" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PADCo.Member" xlink:label="loc_abus_PADCo.Member_BF1077866F98656C0ECE56E5215B9F8F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA" xlink:to="loc_abus_PADCo.Member_BF1077866F98656C0ECE56E5215B9F8F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ContractModificationsAxis" xlink:label="loc_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ContractModificationsDomain" xlink:label="loc_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F" xlink:to="loc_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58_default" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ContractModificationsDomain" xlink:label="loc_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F" xlink:to="loc_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IncreaseToSupportDevelopmentPlansMember" xlink:label="loc_abus_IncreaseToSupportDevelopmentPlansMember_F363ECFA8A8BDBB1370F56E5215B11B8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:to="loc_abus_IncreaseToSupportDevelopmentPlansMember_F363ECFA8A8BDBB1370F56E5215B11B8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IncreasedFundingForStageOneMember" xlink:label="loc_abus_IncreasedFundingForStageOneMember_D225727F4C8D6F3A7DA956E5215BCF93" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:to="loc_abus_IncreasedFundingForStageOneMember_D225727F4C8D6F3A7DA956E5215BCF93" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_StageOneMember" xlink:label="loc_abus_StageOneMember_F2E7C00DF6CEDFBBCD8A56E5215BFE43" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:to="loc_abus_StageOneMember_F2E7C00DF6CEDFBBCD8A56E5215BFE43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A1760AD2AFD44B5E855156E5215BA64A" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A1760AD2AFD44B5E855156E5215BA64A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05BDD7E8F476865F75BD56E5215B4331_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A1760AD2AFD44B5E855156E5215BA64A" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05BDD7E8F476865F75BD56E5215B4331_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05BDD7E8F476865F75BD56E5215B4331" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A1760AD2AFD44B5E855156E5215BA64A" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05BDD7E8F476865F75BD56E5215B4331" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ContractExtensionMember" xlink:label="loc_abus_ContractExtensionMember_9060E444E25CA35EBDA056E5215BC22D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05BDD7E8F476865F75BD56E5215B4331" xlink:to="loc_abus_ContractExtensionMember_9060E444E25CA35EBDA056E5215BC22D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AlnylamLicenseAgreementMember" xlink:label="loc_abus_AlnylamLicenseAgreementMember_010368E4BE90C8EFF26056E5215BDF3E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05BDD7E8F476865F75BD56E5215B4331" xlink:to="loc_abus_AlnylamLicenseAgreementMember_010368E4BE90C8EFF26056E5215BDF3E" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MarqiboCommercialSalesMember" xlink:label="loc_abus_MarqiboCommercialSalesMember_6F06915279EDC38A1FBF56E5215C3F94" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05BDD7E8F476865F75BD56E5215B4331" xlink:to="loc_abus_MarqiboCommercialSalesMember_6F06915279EDC38A1FBF56E5215C3F94" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MarqiboMember" xlink:label="loc_abus_MarqiboMember_53F11E5E03EC881B3EA056E5215CD7DC" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05BDD7E8F476865F75BD56E5215B4331" xlink:to="loc_abus_MarqiboMember_53F11E5E03EC881B3EA056E5215CD7DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CF3877822FE05A8AEA3E56E5215C42F7" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_RangeAxis_CF3877822FE05A8AEA3E56E5215C42F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_C263BCF1408F98C6C72D56E5215C4BD9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_CF3877822FE05A8AEA3E56E5215C42F7" xlink:to="loc_us-gaap_RangeMember_C263BCF1408F98C6C72D56E5215C4BD9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_C263BCF1408F98C6C72D56E5215C4BD9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_CF3877822FE05A8AEA3E56E5215C42F7" xlink:to="loc_us-gaap_RangeMember_C263BCF1408F98C6C72D56E5215C4BD9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_17F8CB7173BA030658FC56E5215C2B9D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_C263BCF1408F98C6C72D56E5215C4BD9" xlink:to="loc_us-gaap_MaximumMember_17F8CB7173BA030658FC56E5215C2B9D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_0F10427E6218B30F7A2B56E5215C2552" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_CounterpartyNameAxis_0F10427E6218B30F7A2B56E5215C2552" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_0F10427E6218B30F7A2B56E5215C2552" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_0F10427E6218B30F7A2B56E5215C2552" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DoDMember" xlink:label="loc_abus_DoDMember_513779151BC4CE7FAB9156E5215C323C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC" xlink:to="loc_abus_DoDMember_513779151BC4CE7FAB9156E5215C323C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MonsantoMember" xlink:label="loc_abus_MonsantoMember_B1F6CF8CFA82FFE9634E56E5215C426B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC" xlink:to="loc_abus_MonsantoMember_B1F6CF8CFA82FFE9634E56E5215C426B" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BMSMember" xlink:label="loc_abus_BMSMember_2AACB3F71E6522F6550A56E5215C3AE4" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC" xlink:to="loc_abus_BMSMember_2AACB3F71E6522F6550A56E5215C3AE4" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DicernaMember" xlink:label="loc_abus_DicernaMember_C337071CBF4916E6017356E5215C7900" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC" xlink:to="loc_abus_DicernaMember_C337071CBF4916E6017356E5215C7900" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_TalonTherapeuticsMember" xlink:label="loc_abus_TalonTherapeuticsMember_AC338069851D9FA0044956E5215C4FE4" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC" xlink:to="loc_abus_TalonTherapeuticsMember_AC338069851D9FA0044956E5215C4FE4" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PotentialContractFundingAmount" xlink:label="loc_abus_PotentialContractFundingAmount_5F87F2F4A9E8A20EEC4456E5215C0B42" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_PotentialContractFundingAmount_5F87F2F4A9E8A20EEC4456E5215C0B42" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OptionalExcercisedContractualOptionAmount" xlink:label="loc_abus_OptionalExcercisedContractualOptionAmount_D044486EA1BF69EFBC7756E5215CB0CC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_OptionalExcercisedContractualOptionAmount_D044486EA1BF69EFBC7756E5215CB0CC" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ApproximateOptionPeriod" xlink:label="loc_abus_ApproximateOptionPeriod_003E8B24B0BA92E7CEC256E5215CB8BC" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_ApproximateOptionPeriod_003E8B24B0BA92E7CEC256E5215CB8BC" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MaximumPotentialTransactionValue" xlink:label="loc_abus_MaximumPotentialTransactionValue_6D8475DC05249754BD6456E5215C949B" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_MaximumPotentialTransactionValue_6D8475DC05249754BD6456E5215C949B" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OptionPeriodExtension" xlink:label="loc_abus_OptionPeriodExtension_CA22F52B0DA910F4AD4E56E5215CD99E" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_OptionPeriodExtension_CA22F52B0DA910F4AD4E56E5215CD99E" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_NearTermContractPayments" xlink:label="loc_abus_NearTermContractPayments_6622C7131EB15EEE94A756E5215CDFB9" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_NearTermContractPayments_6622C7131EB15EEE94A756E5215CDFB9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_9D1FA807F31D510DF1EE56E5215DD63B" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_Revenues_9D1FA807F31D510DF1EE56E5215DD63B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_B3A566F08405B6DE8F7156E5215DEAF9" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_LicensesRevenue_B3A566F08405B6DE8F7156E5215DEAF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_32E836AB46F9EC03268B56E5215DE32F" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_32E836AB46F9EC03268B56E5215DE32F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0BB2A9545E013CE6537056E759698CB8" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0BB2A9545E013CE6537056E759698CB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_2B43A033F3525E4084B956E5215DAD8A" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_DeferredRevenue_2B43A033F3525E4084B956E5215DAD8A" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_LengthOfAgreementWithBristolMyersSquibb" xlink:label="loc_abus_LengthOfAgreementWithBristolMyersSquibb_AE262ED6A4E076ACC6D456E5215D2EF7" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_LengthOfAgreementWithBristolMyersSquibb_AE262ED6A4E076ACC6D456E5215D2EF7" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MilestonePayment" xlink:label="loc_abus_MilestonePayment_1FA2582C8A567813931856E5215DE266" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_MilestonePayment_1FA2582C8A567813931856E5215DE266" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PerformancePeriodtoRecognizeRevenue" xlink:label="loc_abus_PerformancePeriodtoRecognizeRevenue_1DCD390936142502430F56E5215D0388" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_PerformancePeriodtoRecognizeRevenue_1DCD390936142502430F56E5215D0388" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_NumberOfChemotherapyProductsWithWorldwideLicenses" xlink:label="loc_abus_NumberOfChemotherapyProductsWithWorldwideLicenses_5C5CC8DC53442392E59B56E5215D5889" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_NumberOfChemotherapyProductsWithWorldwideLicenses_5C5CC8DC53442392E59B56E5215D5889" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_6F6D66C31D7D8DD2275A56E5215DF445" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_ContractsRevenue_6F6D66C31D7D8DD2275A56E5215DF445" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_B59E86EAB8E051411DF656E5215D5975" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_RoyaltyRevenue_B59E86EAB8E051411DF656E5215D5975" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_F93D58BB572AD55D32CD56E5215D7690" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_F93D58BB572AD55D32CD56E5215D7690" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9CF88A80E3B5F08818B3A624D52EFD0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3F4194F76462C4AB1A23A624D523CED" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9CF88A80E3B5F08818B3A624D52EFD0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3F4194F76462C4AB1A23A624D523CED" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_806498FF6AB3E473E54E3A624D523A1D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3F4194F76462C4AB1A23A624D523CED" xlink:to="loc_us-gaap_CounterpartyNameAxis_806498FF6AB3E473E54E3A624D523A1D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_806498FF6AB3E473E54E3A624D523A1D" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_806498FF6AB3E473E54E3A624D523A1D" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DoDMember" xlink:label="loc_abus_DoDMember_4521AF9606A65EF13B0B3A624D5235FF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450" xlink:to="loc_abus_DoDMember_4521AF9606A65EF13B0B3A624D5235FF" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MonsantoMember" xlink:label="loc_abus_MonsantoMember_B66E5CA1FD69649556F23A624D529244" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450" xlink:to="loc_abus_MonsantoMember_B66E5CA1FD69649556F23A624D529244" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BMSMember" xlink:label="loc_abus_BMSMember_B3DF153DDF3249856F333A624D5293B0" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450" xlink:to="loc_abus_BMSMember_B3DF153DDF3249856F333A624D5293B0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AlnylamLicenseAgreementMember" xlink:label="loc_abus_AlnylamLicenseAgreementMember_86428C977DDCCBADAF8B3A624D52DA4A" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450" xlink:to="loc_abus_AlnylamLicenseAgreementMember_86428C977DDCCBADAF8B3A624D52DA4A" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DicernaMember" xlink:label="loc_abus_DicernaMember_051C4C3B4BAC32B77D6B3A624D525079" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450" xlink:to="loc_abus_DicernaMember_051C4C3B4BAC32B77D6B3A624D525079" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OtherRNAiCollaboratorsMember" xlink:label="loc_abus_OtherRNAiCollaboratorsMember_C123DC4F733391E76CF03A624D52FF95" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450" xlink:to="loc_abus_OtherRNAiCollaboratorsMember_C123DC4F733391E76CF03A624D52FF95" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_SpectrumMember" xlink:label="loc_abus_SpectrumMember_A089079545CF9793FCDC3A624D52D09A" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450" xlink:to="loc_abus_SpectrumMember_A089079545CF9793FCDC3A624D52D09A" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_CollaborationsAndContractsAbstract" xlink:label="loc_abus_CollaborationsAndContractsAbstract_85B9207C91C3FA77A2E93A624D526C09" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9CF88A80E3B5F08818B3A624D52EFD0" xlink:to="loc_abus_CollaborationsAndContractsAbstract_85B9207C91C3FA77A2E93A624D526C09" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_1E29C85268EB860801513A624D529EB6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_CollaborationsAndContractsAbstract_85B9207C91C3FA77A2E93A624D526C09" xlink:to="loc_us-gaap_ContractsRevenue_1E29C85268EB860801513A624D529EB6" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract" xlink:label="loc_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_C0738CE99416F8D2422A3A624D532589" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9CF88A80E3B5F08818B3A624D52EFD0" xlink:to="loc_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_C0738CE99416F8D2422A3A624D532589" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_DB372064670D8FE018373A624D53A555" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_C0738CE99416F8D2422A3A624D532589" xlink:to="loc_us-gaap_LicensesRevenue_DB372064670D8FE018373A624D53A555" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E6A6FB24D38115A454753A624D5372CF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_C0738CE99416F8D2422A3A624D532589" xlink:to="loc_us-gaap_Revenues_E6A6FB24D38115A454753A624D5372CF" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRisk" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:label="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable" xlink:label="loc_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable_31B325829B37895EE61751CB6C53753F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:to="loc_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable_31B325829B37895EE61751CB6C53753F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1F168606B6C2466FF2B051CB6C531A99" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable_31B325829B37895EE61751CB6C53753F" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1F168606B6C2466FF2B051CB6C531A99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1F168606B6C2466FF2B051CB6C531A99" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1F168606B6C2466FF2B051CB6C531A99" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ForeignCurrencyExposureMember" xlink:label="loc_abus_ForeignCurrencyExposureMember_8E4F15D5114431BE44DF51CB6C538A3C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5" xlink:to="loc_abus_ForeignCurrencyExposureMember_8E4F15D5114431BE44DF51CB6C538A3C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4B627EDB5D43A0E0DE8751CB6C539D5D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4B627EDB5D43A0E0DE8751CB6C539D5D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_2D48EA515E2F52D757E251CB6C539CDC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:to="loc_us-gaap_AccountsReceivableNet_2D48EA515E2F52D757E251CB6C539CDC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_4A30FB63851D6A1CA4CE51CB6C538753" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_4A30FB63851D6A1CA4CE51CB6C538753" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2647062540676364250051CB6C535D16" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2647062540676364250051CB6C535D16" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ExposureToUSDollar" xlink:label="loc_abus_ExposureToUSDollar_7320640E1C27F02D7D1B51CB6C53669E" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:to="loc_abus_ExposureToUSDollar_7320640E1C27F02D7D1B51CB6C53669E" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8C381D4372010FA43A8E3F2E893F23D8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StatementTable_8C381D4372010FA43A8E3F2E893F23D8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_45275BD4A09E6EBCE3843F2E893FCDFD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8C381D4372010FA43A8E3F2E893F23D8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_45275BD4A09E6EBCE3843F2E893FCDFD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_45275BD4A09E6EBCE3843F2E893FCDFD" xlink:to="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_45275BD4A09E6EBCE3843F2E893FCDFD" xlink:to="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E9B70B7EC457EADB62F43F2E893F5FCB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:to="loc_us-gaap_CommonStockMember_E9B70B7EC457EADB62F43F2E893F5FCB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_781E61B44BFE1B4CBD583F2E893F3FE1" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_781E61B44BFE1B4CBD583F2E893F3FE1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_8339FE1055DB5CA049853F2E893FDF87" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:to="loc_us-gaap_RetainedEarningsMember_8339FE1055DB5CA049853F2E893FDF87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D2318EF639D2050A815B3F2E893FEA1D" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D2318EF639D2050A815B3F2E893FEA1D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_D170B005E4A6343DEFB53F2E893FB227" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_SharesIssued_D170B005E4A6343DEFB53F2E893FB227" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CD94FD6BBFE58714B7F93F2E894008AA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockholdersEquity_CD94FD6BBFE58714B7F93F2E894008AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CDB4135736A8F62162073F2E8940DEA4" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CDB4135736A8F62162073F2E8940DEA4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_199857DB1DB6DCA336AC3F2E8940D434" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_199857DB1DB6DCA336AC3F2E8940D434" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_FDDCACCEA81BC9F59BD63F2E8940929F" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_FDDCACCEA81BC9F59BD63F2E8940929F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_4873560D06A42CF38EED3F2E8940E137" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_4873560D06A42CF38EED3F2E8940E137" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_BB7C80F4DF87E90BE01B3F2E89403534" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_BB7C80F4DF87E90BE01B3F2E89403534" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A30D0598F4F3BA04AF3B3F2E89403608" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A30D0598F4F3BA04AF3B3F2E89403608" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_21FDACA2E22DC4BC41423F2E8940632F" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_21FDACA2E22DC4BC41423F2E8940632F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_04F18B81E44038EE63053F2E8940CBE8" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_04F18B81E44038EE63053F2E8940CBE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_15D39AC604AEC65719633F2E89407C4B" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_15D39AC604AEC65719633F2E89407C4B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6746F2603FC7999B072C3F2E89401EAB" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6746F2603FC7999B072C3F2E89401EAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E2B4C4A855D55FD31E203F2E8940E8F8" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_NetIncomeLoss_E2B4C4A855D55FD31E203F2E8940E8F8" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8C643C9B098E11C59D093F2E89350BE5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_StatementTable_8C643C9B098E11C59D093F2E89350BE5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E4F127FAF9A0BD25436E3F2E8935006F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8C643C9B098E11C59D093F2E89350BE5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E4F127FAF9A0BD25436E3F2E8935006F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_67B7C6D971356AFA84803F2E89352034_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E4F127FAF9A0BD25436E3F2E8935006F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_67B7C6D971356AFA84803F2E89352034_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_67B7C6D971356AFA84803F2E89352034" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E4F127FAF9A0BD25436E3F2E8935006F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_67B7C6D971356AFA84803F2E89352034" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C5C3B691A1937AAC80E63F2E8935A539" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_67B7C6D971356AFA84803F2E89352034" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C5C3B691A1937AAC80E63F2E8935A539" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_35F6AFF588AD408BD2B73F2E8935A6BD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_67B7C6D971356AFA84803F2E89352034" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_35F6AFF588AD408BD2B73F2E8935A6BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_46BE7B5FF7129ECCAE933F2E89356354" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:to="loc_us-gaap_NetIncomeLoss_46BE7B5FF7129ECCAE933F2E89356354" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5DEA17ACE212F7F7163C3F2E89360149" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5DEA17ACE212F7F7163C3F2E89360149" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_107C5FD901B3117D8EFA3F2E89368B11" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_Depreciation_107C5FD901B3117D8EFA3F2E89368B11" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F2522175DC91B335792E3F2E89362DC8" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F2522175DC91B335792E3F2E89362DC8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3EB5CDBEBE5C1C8D04693F2E893620BD" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_ShareBasedCompensation_3EB5CDBEBE5C1C8D04693F2E893620BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_BE9834A2EA04086E44023F2E893668EC" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_BE9834A2EA04086E44023F2E893668EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_26AD38B8FEE2D00E8FB33F2E893655C1" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_26AD38B8FEE2D00E8FB33F2E893655C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7A5439ED3019EBCC2B883F2E89364066" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7A5439ED3019EBCC2B883F2E89364066" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_806B602262D327B967FF3F2E8936814D" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_806B602262D327B967FF3F2E8936814D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5E83D6C4A61F549ECE3D3F2E893656EC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5E83D6C4A61F549ECE3D3F2E893656EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_1575597DDA2991CE338F3F2E89366AA2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_1575597DDA2991CE338F3F2E89366AA2" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IncreaseDecreaseOtherDeferredCostsNet" xlink:label="loc_abus_IncreaseDecreaseOtherDeferredCostsNet_EFD496B4505441B2B28A3F2E89362F37" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="loc_abus_IncreaseDecreaseOtherDeferredCostsNet_EFD496B4505441B2B28A3F2E89362F37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_EBAD1C67389A2E83AC3A3F2E8936173C" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_EBAD1C67389A2E83AC3A3F2E8936173C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08D0255F21E2254A990A3F2E89368DD7" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08D0255F21E2254A990A3F2E89368DD7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76F28B88C2CAF7334D0A3F2E8936EB72" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76F28B88C2CAF7334D0A3F2E8936EB72" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_F9801F6EC4C4950895763F2E89360842" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_F9801F6EC4C4950895763F2E89360842" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_211C716CA1DC14E2D3C73F2E8936936B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_211C716CA1DC14E2D3C73F2E8936936B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_E278D2AE1064B4F268293F2E893794FC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_E278D2AE1064B4F268293F2E893794FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_CE235DA82C0A451089273F2E8937281A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_CE235DA82C0A451089273F2E8937281A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5D93D9FE7E87B696AB53F2E893799F1" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5D93D9FE7E87B696AB53F2E893799F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D7BA07D036F7DAFDC0E73F2E893765DB" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D7BA07D036F7DAFDC0E73F2E893765DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_79DACFCF001CE2904D7D3F2E89376514" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_79DACFCF001CE2904D7D3F2E89376514" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A3A237A5E608B00ABEB03F2E89372377" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A3A237A5E608B00ABEB03F2E89372377" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_E64C2C70DE832995E1AD3F2E89370210" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_E64C2C70DE832995E1AD3F2E89370210" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_4B87A3A2B675F7CC70953F2E8937EB95" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_4B87A3A2B675F7CC70953F2E8937EB95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CF8786EE316E8F910F7E3F2E89373436" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CF8786EE316E8F910F7E3F2E89373436" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_44E530C632DF65908F843F2E89378B21" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_44E530C632DF65908F843F2E89378B21" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B02A593D37BB9424C493F2E89373735" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B02A593D37BB9424C493F2E89373735" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49A11B81911ADC7EE4E73F2E893774A1" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49A11B81911ADC7EE4E73F2E893774A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_FairValueOfWarrantsExercisedOnACashlessBasis" xlink:label="loc_abus_FairValueOfWarrantsExercisedOnACashlessBasis_3D355EA7041F2343E5FD3F2E8937F372" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:to="loc_abus_FairValueOfWarrantsExercisedOnACashlessBasis_3D355EA7041F2343E5FD3F2E8937F372" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_AE17DABF0B938CC635DE3F2E8938057F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_AE17DABF0B938CC635DE3F2E8938057F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3E3A6B63B04A5ABA5E1B3F2E8938C122" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3E3A6B63B04A5ABA5E1B3F2E8938C122" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitments" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsDetails" xlink:type="extended">
    <loc xlink:href="abus-20151231.xsd#abus_ContingenciesandCommitmentsLineItems" xlink:label="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_ContingenciesandCommitmentsTable" xlink:label="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_36D5F6CDC300B8BF83D93F2E8843E1AD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:to="loc_us-gaap_ProductOrServiceAxis_36D5F6CDC300B8BF83D93F2E8843E1AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_36D5F6CDC300B8BF83D93F2E8843E1AD" xlink:to="loc_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_36D5F6CDC300B8BF83D93F2E8843E1AD" xlink:to="loc_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MarqiboMember" xlink:label="loc_abus_MarqiboMember_68AECCEE35A2FEBCCE773F2E884372C6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D" xlink:to="loc_abus_MarqiboMember_68AECCEE35A2FEBCCE773F2E884372C6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_19DCCA34ED6282C62EE43F2E8843A6EC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:to="loc_us-gaap_CounterpartyNameAxis_19DCCA34ED6282C62EE43F2E8843A6EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_19DCCA34ED6282C62EE43F2E8843A6EC" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_19DCCA34ED6282C62EE43F2E8843A6EC" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MarinaBiotechInc.Member" xlink:label="loc_abus_MarinaBiotechInc.Member_8779338F3CC09C2C380B3F2E88446999" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:to="loc_abus_MarinaBiotechInc.Member_8779338F3CC09C2C380B3F2E88446999" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArcturusMember" xlink:label="loc_abus_ArcturusMember_28842033654F77A5FCD43F2E8844D0AE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:to="loc_abus_ArcturusMember_28842033654F77A5FCD43F2E8844D0AE" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BlumbergandDrexelMember" xlink:label="loc_abus_BlumbergandDrexelMember_C773531DDF4447003A893F2E88447020" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:to="loc_abus_BlumbergandDrexelMember_C773531DDF4447003A893F2E88447020" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BlumbergMember" xlink:label="loc_abus_BlumbergMember_6B727FD16B4EB07D58CF3F2E8844DD51" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:to="loc_abus_BlumbergMember_6B727FD16B4EB07D58CF3F2E8844DD51" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_NeuroViveMember" xlink:label="loc_abus_NeuroViveMember_AFA932BF5AA507FAAB403F2E8844EFFF" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:to="loc_abus_NeuroViveMember_AFA932BF5AA507FAAB403F2E8844EFFF" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_CytosMember" xlink:label="loc_abus_CytosMember_0F9A99E52512037C4E1E3F2E88449DF4" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:to="loc_abus_CytosMember_0F9A99E52512037C4E1E3F2E88449DF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_4538E864982D97521C623F2E88446A69" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:to="loc_us-gaap_LitigationCaseAxis_4538E864982D97521C623F2E88446A69" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationCaseAxis_4538E864982D97521C623F2E88446A69" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationCaseAxis_4538E864982D97521C623F2E88446A69" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:label="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_E9244D587690EC77C4DE3F2E8844106F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744" xlink:to="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_E9244D587690EC77C4DE3F2E8844106F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_C0EB6CF52B80DBA3A6913F2E8844CFD8" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:to="loc_dei_LegalEntityAxis_C0EB6CF52B80DBA3A6913F2E8844CFD8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A1E2B4749BC55DCCFC7F3F2E88442DF4_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_C0EB6CF52B80DBA3A6913F2E8844CFD8" xlink:to="loc_dei_EntityDomain_A1E2B4749BC55DCCFC7F3F2E88442DF4_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A1E2B4749BC55DCCFC7F3F2E88442DF4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_C0EB6CF52B80DBA3A6913F2E8844CFD8" xlink:to="loc_dei_EntityDomain_A1E2B4749BC55DCCFC7F3F2E88442DF4" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OnCoreBiopharmaInc.Member" xlink:label="loc_abus_OnCoreBiopharmaInc.Member_F84A424625E7A924B0223F2E884469B0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_A1E2B4749BC55DCCFC7F3F2E88442DF4" xlink:to="loc_abus_OnCoreBiopharmaInc.Member_F84A424625E7A924B0223F2E884469B0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_096A84363C385A1D49A53F2E8844E066" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_A1E2B4749BC55DCCFC7F3F2E88442DF4" xlink:to="loc_abus_ArbutusInc.Member_096A84363C385A1D49A53F2E8844E066" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C1683995FD41CCA55D723F2E8844A549" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_C1683995FD41CCA55D723F2E8844A549" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A3073D84F51DEAF6BDCE3F2E88441A4C_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C1683995FD41CCA55D723F2E8844A549" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A3073D84F51DEAF6BDCE3F2E88441A4C_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A3073D84F51DEAF6BDCE3F2E88441A4C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C1683995FD41CCA55D723F2E8844A549" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A3073D84F51DEAF6BDCE3F2E88441A4C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_EnantigenMember" xlink:label="loc_abus_EnantigenMember_69BA02B156C6D7483E143F2E88457BE8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A3073D84F51DEAF6BDCE3F2E88441A4C" xlink:to="loc_abus_EnantigenMember_69BA02B156C6D7483E143F2E88457BE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_0BAF8946E7FE153454623F2E88457029" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_0BAF8946E7FE153454623F2E88457029" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PercentOfCostsFundedByTPC" xlink:label="loc_abus_PercentOfCostsFundedByTPC_30BE652DEEEE61C6469B3F2E8845C9A5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_PercentOfCostsFundedByTPC_30BE652DEEEE61C6469B3F2E8845C9A5" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MaximumContributionForProduct" xlink:label="loc_abus_MaximumContributionForProduct_08EDEB1FC2419981101C3F2E884560EB" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_MaximumContributionForProduct_08EDEB1FC2419981101C3F2E884560EB" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_CumulativeContributionforProduct" xlink:label="loc_abus_CumulativeContributionforProduct_413443817508A5BA386C3F2E8845A4CB" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_CumulativeContributionforProduct_413443817508A5BA386C3F2E8845A4CB" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_RoyaltyGuaranteesCommitmentsPercentage" xlink:label="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_3E7EF474F13F61DF828D3F2E88453678" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_3E7EF474F13F61DF828D3F2E88453678" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_9DB25B865730B91BB0523F2E88459C71" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_us-gaap_RoyaltyRevenue_9DB25B865730B91BB0523F2E88459C71" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_RoyaltyPayable" xlink:label="loc_abus_RoyaltyPayable_ED22447846626B080EAF3F2E8845898E" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_RoyaltyPayable_ED22447846626B080EAF3F2E8845898E" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_RoyaltiesPaidOrAccrued" xlink:label="loc_abus_RoyaltiesPaidOrAccrued_1CCF7558E0278D1557223F2E88452137" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_RoyaltiesPaidOrAccrued_1CCF7558E0278D1557223F2E88452137" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_FB3DCF960E24A638244C3F2E8845E650" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_us-gaap_ContractualObligation_FB3DCF960E24A638244C3F2E8845E650" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_UpfrontFee" xlink:label="loc_abus_UpfrontFee_FBECB0E9EC4680609BD23F2E8845ED52" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_UpfrontFee_FBECB0E9EC4680609BD23F2E8845ED52" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MilestonePayment" xlink:label="loc_abus_MilestonePayment_63161EF40D0DEACA88263F2E8845E876" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_MilestonePayment_63161EF40D0DEACA88263F2E8845E876" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_D6FF8D790C0E0831A6783F2E8845AB6D" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_D6FF8D790C0E0831A6783F2E8845AB6D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5E85C357880E63D47F543F2E88454D63" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5E85C357880E63D47F543F2E88454D63" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ProgramsInPreClinicalDevelopment" xlink:label="loc_abus_ProgramsInPreClinicalDevelopment_991A24A88986C5CF99173F2E8845746A" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ProgramsInPreClinicalDevelopment_991A24A88986C5CF99173F2E8845746A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9918C010F83B7A6D50B53F2E884586CB" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9918C010F83B7A6D50B53F2E884586CB" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_2AAB54D0C7D6F434200C3F2E88468FFD" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_2AAB54D0C7D6F434200C3F2E88468FFD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_C4DBD086EBAD06A833F43F2E884699A1" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_us-gaap_LicenseCosts_C4DBD086EBAD06A833F43F2E884699A1" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_42666D523B32D70538113F2E8846CAB2" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_42666D523B32D70538113F2E8846CAB2" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense" xlink:label="loc_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense_1D92C7EA24CFC3784E6B3F2E8846670E" xlink:type="locator" />
    <definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense_1D92C7EA24CFC3784E6B3F2E8846670E" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ContractualObligationAmountOfResearchFundingPerYear" xlink:label="loc_abus_ContractualObligationAmountOfResearchFundingPerYear_B30A7BEC2580208F10673F2E8846648C" xlink:type="locator" />
    <definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ContractualObligationAmountOfResearchFundingPerYear_B30A7BEC2580208F10673F2E8846648C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ResearchFundingPeriod" xlink:label="loc_abus_ResearchFundingPeriod_7D424CA92C019B1D84343F2E8846DCC8" xlink:type="locator" />
    <definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ResearchFundingPeriod_7D424CA92C019B1D84343F2E8846DCC8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ResearchFundingPeriodRenewableOption" xlink:label="loc_abus_ResearchFundingPeriodRenewableOption_F9535AF97E2DD69392173F2E8846C0BB" xlink:type="locator" />
    <definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ResearchFundingPeriodRenewableOption_F9535AF97E2DD69392173F2E8846C0BB" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment" xlink:label="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment_59CB66938508F26AFC223F2E8846F2B7" xlink:type="locator" />
    <definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment_59CB66938508F26AFC223F2E8846F2B7" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments" xlink:label="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments_4139AA00D2B8B016AB973F2E88461EFA" xlink:type="locator" />
    <definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments_4139AA00D2B8B016AB973F2E88461EFA" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments" xlink:label="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments_DF56F1752B89A5B7BF463F2E88462870" xlink:type="locator" />
    <definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments_DF56F1752B89A5B7BF463F2E88462870" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Numberofseriesofcompounds" xlink:label="loc_abus_Numberofseriesofcompounds_D61FDD8DB21770EBC0D43F2E88462BFB" xlink:type="locator" />
    <definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_Numberofseriesofcompounds_D61FDD8DB21770EBC0D43F2E88462BFB" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:type="extended">
    <loc xlink:href="abus-20151231.xsd#abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems" xlink:label="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable" xlink:label="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:to="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3A228753E3831C4CCE7334AE80BB95FB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3A228753E3831C4CCE7334AE80BB95FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3A228753E3831C4CCE7334AE80BB95FB" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3A228753E3831C4CCE7334AE80BB95FB" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ISARICMember" xlink:label="loc_abus_ISARICMember_FBAC4BF4A6BFC03A424634AE80BC3C13" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047" xlink:to="loc_abus_ISARICMember_FBAC4BF4A6BFC03A424634AE80BC3C13" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_BD66435FEC77C4FABD7F34AE80BCB4A4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:to="loc_us-gaap_ContractsRevenue_BD66435FEC77C4FABD7F34AE80BCB4A4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_ED5E52E3F31037BB466834AE80BCB30C" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:to="loc_us-gaap_RevenueFromGrants_ED5E52E3F31037BB466834AE80BCB30C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTaxCredit" xlink:label="loc_us-gaap_InvestmentTaxCredit_803FEAD48B90ECE5E4C634AE80BC43EF" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:to="loc_us-gaap_InvestmentTaxCredit_803FEAD48B90ECE5E4C634AE80BC43EF" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxes" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended">
    <loc xlink:href="abus-20151231.xsd#abus_ComponentsofDeferredTaxAssetsLineItems" xlink:label="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_ComponentsofDeferredTaxAssetsTable" xlink:label="loc_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_63DD88CA35D2D9AC95FB344946B13AC1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_63DD88CA35D2D9AC95FB344946B13AC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_63DD88CA35D2D9AC95FB344946B13AC1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_63DD88CA35D2D9AC95FB344946B13AC1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_CBB201378661935F315A344946B2666A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6" xlink:to="loc_us-gaap_DomesticCountryMember_CBB201378661935F315A344946B2666A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5C36A52C597E507DAB56344946B21A76" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5C36A52C597E507DAB56344946B21A76" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_534BD121FF3FD810CB61344946B26D22" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_534BD121FF3FD810CB61344946B26D22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_906D86C7EB62018060FA344946B24DF7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_906D86C7EB62018060FA344946B24DF7" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DeferredTaxAssetBookAmortizationInExcessOfTax" xlink:label="loc_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_CE096A759CFE704BB943344946B22F66" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_CE096A759CFE704BB943344946B22F66" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_EDBDDDE144D84E96A3B5344946B20247" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_EDBDDDE144D84E96A3B5344946B20247" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes" xlink:label="loc_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7546690123BA1955F20D344946B2C460" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7546690123BA1955F20D344946B2C460" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements" xlink:label="loc_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_4F2AD3507162A0E4582C344946B22181" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_4F2AD3507162A0E4582C344946B22181" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_549356D553A093E09CB7344946B394F7" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_549356D553A093E09CB7344946B394F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_684C77D34B808793BD1A3454970A38C5" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_684C77D34B808793BD1A3454970A38C5" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DeferredTaxAssetUpfrontLicenseFees" xlink:label="loc_abus_DeferredTaxAssetUpfrontLicenseFees_11E25EE66346FA645ED034570E2212E8" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_abus_DeferredTaxAssetUpfrontLicenseFees_11E25EE66346FA645ED034570E2212E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_DEFDD4277414129EB097345C47231444" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_DEFDD4277414129EB097345C47231444" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7C7B66985DE1214F5F8A344946B3D69B" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7C7B66985DE1214F5F8A344946B3D69B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5F121E3BAD37379062C6344946B3807D" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5F121E3BAD37379062C6344946B3807D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_5A220A8B32C1E7656D2E345D70982794" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxLiabilities_5A220A8B32C1E7656D2E345D70982794" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2CCC4662B176DA9F458B344946B3CFAF" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_2CCC4662B176DA9F458B344946B3CFAF" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:href="abus-20151231.xsd#abus_IncomeTaxesDetailsLineItems" xlink:label="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_IncomeTaxesTable" xlink:label="loc_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_FD15BE8A00EFA9317E235167E77EC162" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:to="loc_us-gaap_StatementScenarioAxis_FD15BE8A00EFA9317E235167E77EC162" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_FD15BE8A00EFA9317E235167E77EC162" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_FD15BE8A00EFA9317E235167E77EC162" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_6782008242A7346B433C5167E77EFFA0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD" xlink:to="loc_us-gaap_RestatementAdjustmentMember_6782008242A7346B433C5167E77EFFA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_5522F9904F0248045D1D5167E77E20A5" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_5522F9904F0248045D1D5167E77E20A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_5522F9904F0248045D1D5167E77E20A5" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_5522F9904F0248045D1D5167E77E20A5" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentCreditMember" xlink:label="loc_us-gaap_InvestmentCreditMember_008D9669ECA4CA308C195167E77F1BFE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB" xlink:to="loc_us-gaap_InvestmentCreditMember_008D9669ECA4CA308C195167E77F1BFE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_15BCF254A798DBF984475167E77F2908" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB" xlink:to="loc_us-gaap_ResearchMember_15BCF254A798DBF984475167E77F2908" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F8853D65171693D2ED5C5167E77F9D91" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:to="loc_us-gaap_RangeAxis_F8853D65171693D2ED5C5167E77F9D91" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_F8853D65171693D2ED5C5167E77F9D91" xlink:to="loc_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_F8853D65171693D2ED5C5167E77F9D91" xlink:to="loc_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_90DB767E4FE19A6044105167E77F5714" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD" xlink:to="loc_us-gaap_MaximumMember_90DB767E4FE19A6044105167E77F5714" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_58F9AADF11B1F227DC955167E77F0B96" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_58F9AADF11B1F227DC955167E77F0B96" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7B62DD270598CF2212DF5167E77F47DE" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7B62DD270598CF2212DF5167E77F47DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75E9C33BA177B07AD3AB5167E77F7551" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75E9C33BA177B07AD3AB5167E77F7551" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4B5FA2A4B6EA24A9B920516A8684D9BD" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4B5FA2A4B6EA24A9B920516A8684D9BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_51AB23E214FB64351B1C5167E77F7F9B" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_51AB23E214FB64351B1C5167E77F7F9B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_856CE1B6BB49327FDB4E5167E77FAD5E" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_856CE1B6BB49327FDB4E5167E77FAD5E" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PatentTaxRefundPercentage" xlink:label="loc_abus_PatentTaxRefundPercentage_164089C14E76D2E1C4DB5167E77F6527" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_abus_PatentTaxRefundPercentage_164089C14E76D2E1C4DB5167E77F6527" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_E4B2E49E22D7D5B052705167E77FC928" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_E4B2E49E22D7D5B052705167E77FC928" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_BBE3CA45116EED5036325167E77FC3F0" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_BBE3CA45116EED5036325167E77FC3F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_37D2CE24EA3B0C921A475167E77F2BCE" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_37D2CE24EA3B0C921A475167E77F2BCE" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesIncomeTaxReconciliationDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnaudited" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_552AFF5E4B84B767BA953A13C6045A77" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_552AFF5E4B84B767BA953A13C6045A77" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C1D89D513DDD0E1138703A13C6039200" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_C1D89D513DDD0E1138703A13C6039200" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C1D89D513DDD0E1138703A13C6039200" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C1D89D513DDD0E1138703A13C6039200" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_9EBE9A1E2AFA965807FC3A13C6043BCE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D" xlink:to="loc_abus_ArbutusInc.Member_9EBE9A1E2AFA965807FC3A13C6043BCE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7DAEFBE4B6FFC49ECF533A13C604771F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7DAEFBE4B6FFC49ECF533A13C604771F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7DAEFBE4B6FFC49ECF533A13C604771F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7DAEFBE4B6FFC49ECF533A13C604771F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDCyclophilinsMember" xlink:label="loc_abus_IPRDCyclophilinsMember_DB47B65C1986953429563A13C6044BEA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:to="loc_abus_IPRDCyclophilinsMember_DB47B65C1986953429563A13C6044BEA" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDImmuneModulatorsMember" xlink:label="loc_abus_IPRDImmuneModulatorsMember_394330645A4A821AA7E13A13DDF1AAE9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:to="loc_abus_IPRDImmuneModulatorsMember_394330645A4A821AA7E13A13DDF1AAE9" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDAntigenInhibitorsMember" xlink:label="loc_abus_IPRDAntigenInhibitorsMember_C646387965FB4F4D07543A13DF12471D" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:to="loc_abus_IPRDAntigenInhibitorsMember_C646387965FB4F4D07543A13DF12471D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDcccDNASterilizersMember" xlink:label="loc_abus_IPRDcccDNASterilizersMember_27D502512DF3DAF6E18B3A13DFA927ED" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:to="loc_abus_IPRDcccDNASterilizersMember_27D502512DF3DAF6E18B3A13DFA927ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A0F0A4816FF1E52C9AD93A13C604CE8B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_552AFF5E4B84B767BA953A13C6045A77" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A0F0A4816FF1E52C9AD93A13C604CE8B" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_37903BC987CBF4F169035212D70F319B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_37903BC987CBF4F169035212D70F319B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9F222167F3FAE96B4F105212D70F0781_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_37903BC987CBF4F169035212D70F319B" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9F222167F3FAE96B4F105212D70F0781_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9F222167F3FAE96B4F105212D70F0781" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_37903BC987CBF4F169035212D70F319B" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9F222167F3FAE96B4F105212D70F0781" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDCyclophilinsMember" xlink:label="loc_abus_IPRDCyclophilinsMember_EBB0D56E879A49F2776E5212D70F2578" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9F222167F3FAE96B4F105212D70F0781" xlink:to="loc_abus_IPRDCyclophilinsMember_EBB0D56E879A49F2776E5212D70F2578" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OtherIPRDMember" xlink:label="loc_abus_OtherIPRDMember_0C4ADBCBDC3E740E94B15212D70FA751" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9F222167F3FAE96B4F105212D70F0781" xlink:to="loc_abus_OtherIPRDMember_0C4ADBCBDC3E740E94B15212D70FA751" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaap_GoodwillMember_2EBE929CC167E51978245212D70F14FA" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9F222167F3FAE96B4F105212D70F0781" xlink:to="loc_us-gaap_GoodwillMember_2EBE929CC167E51978245212D70F14FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ADA3AE84E6F3DD2F54A85212D70F7048" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ADA3AE84E6F3DD2F54A85212D70F7048" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A74983C38FCE09B15CBB5212D710F2AE_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ADA3AE84E6F3DD2F54A85212D70F7048" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A74983C38FCE09B15CBB5212D710F2AE_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A74983C38FCE09B15CBB5212D710F2AE" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ADA3AE84E6F3DD2F54A85212D70F7048" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A74983C38FCE09B15CBB5212D710F2AE" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_C930ACCB821A3F6CD6995212D71049B1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A74983C38FCE09B15CBB5212D710F2AE" xlink:to="loc_abus_ArbutusInc.Member_C930ACCB821A3F6CD6995212D71049B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F7E3AAD8397EE3274DBF5212D710195B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:to="loc_us-gaap_AwardTypeAxis_F7E3AAD8397EE3274DBF5212D710195B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFC8F8CF87F4BDCD858D5212D7101FDA_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_F7E3AAD8397EE3274DBF5212D710195B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFC8F8CF87F4BDCD858D5212D7101FDA_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFC8F8CF87F4BDCD858D5212D7101FDA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_F7E3AAD8397EE3274DBF5212D710195B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFC8F8CF87F4BDCD858D5212D7101FDA" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_SharesIssuedWithoutSubjectsMember" xlink:label="loc_abus_SharesIssuedWithoutSubjectsMember_A673B4697A8211AA20205212D7101170" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFC8F8CF87F4BDCD858D5212D7101FDA" xlink:to="loc_abus_SharesIssuedWithoutSubjectsMember_A673B4697A8211AA20205212D7101170" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_SharesIssuedSubjectToRepurchaseProvisionMember" xlink:label="loc_abus_SharesIssuedSubjectToRepurchaseProvisionMember_947511718FF725445F6C5212D7106B32" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFC8F8CF87F4BDCD858D5212D7101FDA" xlink:to="loc_abus_SharesIssuedSubjectToRepurchaseProvisionMember_947511718FF725445F6C5212D7106B32" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AbutusStockOptionsMember" xlink:label="loc_abus_AbutusStockOptionsMember_C2B0BFBF587756B584F05212D7102ACA" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFC8F8CF87F4BDCD858D5212D7101FDA" xlink:to="loc_abus_AbutusStockOptionsMember_C2B0BFBF587756B584F05212D7102ACA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5114EA4584A73325BE605212D710F1E1" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5114EA4584A73325BE605212D710F1E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C43457796E06B03FC5EF5212D71066E5_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5114EA4584A73325BE605212D710F1E1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C43457796E06B03FC5EF5212D71066E5_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C43457796E06B03FC5EF5212D71066E5" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5114EA4584A73325BE605212D710F1E1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C43457796E06B03FC5EF5212D71066E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_60E277CB6FFC9AAB99055212D710A6A9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_C43457796E06B03FC5EF5212D71066E5" xlink:to="loc_us-gaap_SubsequentEventMember_60E277CB6FFC9AAB99055212D710A6A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_4A34B47764DEB65297735212D7108185" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:to="loc_us-gaap_StatementScenarioAxis_4A34B47764DEB65297735212D7108185" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_F7BA3F5F7DC5911B22B35212D7102AD2_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_4A34B47764DEB65297735212D7108185" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_F7BA3F5F7DC5911B22B35212D7102AD2_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_F7BA3F5F7DC5911B22B35212D7102AD2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_4A34B47764DEB65297735212D7108185" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_F7BA3F5F7DC5911B22B35212D7102AD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_CD885FBD127974B850C45212D71017CC" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_F7BA3F5F7DC5911B22B35212D7102AD2" xlink:to="loc_us-gaap_ScenarioForecastMember_CD885FBD127974B850C45212D71017CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AB03177D28D1491BA1235212D710F828" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AB03177D28D1491BA1235212D710F828" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1B2533240B72B35B1A175212D7109FE4" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1B2533240B72B35B1A175212D7109FE4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_0618D0C05784024CEC415212D711CF34" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_0618D0C05784024CEC415212D711CF34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0416DA2D675799C2D5045212D7110096" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0416DA2D675799C2D5045212D7110096" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_DE40DC8E8A81531D07D25212D711EF7A" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_DE40DC8E8A81531D07D25212D711EF7A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_62E777FFC7E611CFC8685212D7117B22" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_62E777FFC7E611CFC8685212D7117B22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_33B10726905EC1F00A2F5212D711CE86" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_33B10726905EC1F00A2F5212D711CE86" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_C3B2355E02D05DBF21675212D711660F" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_C3B2355E02D05DBF21675212D711660F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_4A7554225FD727541E7C5212D711A8B7" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_4A7554225FD727541E7C5212D711A8B7" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:label="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_05415629A009C4AA93D75212D711552B" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_05415629A009C4AA93D75212D711552B" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice" xlink:label="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_D04CD03E2C883AAE16665212D711CA43" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_D04CD03E2C883AAE16665212D711CA43" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter" xlink:label="loc_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter_4E8C1CB19ABE3EAAF0DB5212D711701D" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter_4E8C1CB19ABE3EAAF0DB5212D711701D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_B993EE1331A4BCBDFFB55212D711B07B" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_B993EE1331A4BCBDFFB55212D711B07B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_10CA073E7D89A3F91B215212D71128CD" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_10CA073E7D89A3F91B215212D71128CD" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_StockRepurchaseRightsExpirationRateShares" xlink:label="loc_abus_StockRepurchaseRightsExpirationRateShares_EE09A63FE0F3B0466E035212D711C745" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_abus_StockRepurchaseRightsExpirationRateShares_EE09A63FE0F3B0466E035212D711C745" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B69786A3DE65311C4EB45212D711A4AE" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B69786A3DE65311C4EB45212D711A4AE" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PeriodofEstimatedCashFlowsUsedInFairValue" xlink:label="loc_abus_PeriodofEstimatedCashFlowsUsedInFairValue_574514D996C963B16E2C5212D7115A5F" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_abus_PeriodofEstimatedCashFlowsUsedInFairValue_574514D996C963B16E2C5212D7115A5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_5394AD3D3DE09BE7E8DB5212D711D22E" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_5394AD3D3DE09BE7E8DB5212D711D22E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC7C123EDE9FE6BCED2C5212D711A7E8" xlink:type="locator" />
    <definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC7C123EDE9FE6BCED2C5212D711A7E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_D40D8ECC8DE7A90C03675212D7119C57" xlink:type="locator" />
    <definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_D40D8ECC8DE7A90C03675212D7119C57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DAAE12CA70B75B9C5D515212D711DF79" xlink:type="locator" />
    <definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DAAE12CA70B75B9C5D515212D711DF79" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_19030CED2B3257713A1D5212D7111139" xlink:type="locator" />
    <definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_19030CED2B3257713A1D5212D7111139" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_FC7784F0A21EC3393A525212D712E720" xlink:type="locator" />
    <definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_FC7784F0A21EC3393A525212D712E720" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_308CA0BF2732998B0D9D5212D712BC3E" xlink:type="locator" />
    <definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_Goodwill_308CA0BF2732998B0D9D5212D712BC3E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_C320E3E8157BD26670E65212D712DAFE" xlink:type="locator" />
    <definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_NumberOfReportingUnits_C320E3E8157BD26670E65212D712DAFE" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MarketCapitalizationValue" xlink:label="loc_abus_MarketCapitalizationValue_1B8EC0F28BDA116DA9F45212D7127E3A" xlink:type="locator" />
    <definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_abus_MarketCapitalizationValue_1B8EC0F28BDA116DA9F45212D7127E3A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_716C419C27E3E1C5CCB95212D71248DB" xlink:type="locator" />
    <definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_716C419C27E3E1C5CCB95212D71248DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CF5347B547C02E8182EA5212D71249B6" xlink:type="locator" />
    <definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_StockholdersEquity_CF5347B547C02E8182EA5212D71249B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_EBA2FB9C233A9F1A73F05212D71269B4" xlink:type="locator" />
    <definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_EBA2FB9C233A9F1A73F05212D71269B4" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2D27FD6A272C9A5CEE3251CB6D1409B7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C46C711BC116DAF450F251CB6D1460C1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2D27FD6A272C9A5CEE3251CB6D1409B7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C46C711BC116DAF450F251CB6D1460C1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E275D00ADF3F2611127351CB6D14A06D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C46C711BC116DAF450F251CB6D1460C1" xlink:to="loc_us-gaap_AwardTypeAxis_E275D00ADF3F2611127351CB6D14A06D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DCB61D8ACC390A4604BF51CB6D144CF9_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_E275D00ADF3F2611127351CB6D14A06D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DCB61D8ACC390A4604BF51CB6D144CF9_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DCB61D8ACC390A4604BF51CB6D144CF9" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_E275D00ADF3F2611127351CB6D14A06D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DCB61D8ACC390A4604BF51CB6D144CF9" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_SharesIssuedWithoutSubjectsMember" xlink:label="loc_abus_SharesIssuedWithoutSubjectsMember_0F08D792454927DE5DC251CB6D14846C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DCB61D8ACC390A4604BF51CB6D144CF9" xlink:to="loc_abus_SharesIssuedWithoutSubjectsMember_0F08D792454927DE5DC251CB6D14846C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_SharesIssuedSubjectToRepurchaseProvisionMember" xlink:label="loc_abus_SharesIssuedSubjectToRepurchaseProvisionMember_46B8192EA35F480A4F9B51CB6D14EA69" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DCB61D8ACC390A4604BF51CB6D144CF9" xlink:to="loc_abus_SharesIssuedSubjectToRepurchaseProvisionMember_46B8192EA35F480A4F9B51CB6D14EA69" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_CommonShareIssuableForArbutusInc.StockOptionsMember" xlink:label="loc_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_116FC7FE75077C8F9CF651CB6D14116C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DCB61D8ACC390A4604BF51CB6D144CF9" xlink:to="loc_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_116FC7FE75077C8F9CF651CB6D14116C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2F9D421FE3D9CC38D4C251CB6D1429A0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C46C711BC116DAF450F251CB6D1460C1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2F9D421FE3D9CC38D4C251CB6D1429A0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F81E35CE276B9F0068BE51CB6D144985_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2F9D421FE3D9CC38D4C251CB6D1429A0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F81E35CE276B9F0068BE51CB6D144985_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F81E35CE276B9F0068BE51CB6D144985" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2F9D421FE3D9CC38D4C251CB6D1429A0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F81E35CE276B9F0068BE51CB6D144985" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_FB27565DED7184CEFA7551CB6D14345B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F81E35CE276B9F0068BE51CB6D144985" xlink:to="loc_abus_ArbutusInc.Member_FB27565DED7184CEFA7551CB6D14345B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_EDA7D6A4098DD11B12A051CB6D154E4A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2D27FD6A272C9A5CEE3251CB6D1409B7" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_EDA7D6A4098DD11B12A051CB6D154E4A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2D27FD6A272C9A5CEE3251CB6D1409B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0A37BAAD5F7C7F05D24351CB6D156251" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0A37BAAD5F7C7F05D24351CB6D156251" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2F1E2C3FAD6E173FA29951CB6D1522FC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2F1E2C3FAD6E173FA29951CB6D1522FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_AE17E243C5596CC4BBBA51CB6D15097B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_AE17E243C5596CC4BBBA51CB6D15097B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_93FFF539FC1634C07E2451CB6D1592D4" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_93FFF539FC1634C07E2451CB6D1592D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_DCA215A54146F89EEE8B51CB6D157EEE" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_DCA215A54146F89EEE8B51CB6D157EEE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2A4CE65537858CDFF74551CB6D15961A" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_Goodwill_2A4CE65537858CDFF74551CB6D15961A" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:label="loc_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_0282D059BE178527EDF351CB6D1588BF" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_0282D059BE178527EDF351CB6D1588BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_33DD8848FF172016FA3751CB6D1512E9" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_33DD8848FF172016FA3751CB6D1512E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FD8A310688627294E59B51CB6D16C0E2" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FD8A310688627294E59B51CB6D16C0E2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_54DD8297AF47F684CC8651CB6D16494E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2D27FD6A272C9A5CEE3251CB6D1409B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_54DD8297AF47F684CC8651CB6D16494E" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA0EA67F1374786CEC5651CB6D09768F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA0EA67F1374786CEC5651CB6D09768F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_09D32284BB0922B4803151CB6D09EAE8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA0EA67F1374786CEC5651CB6D09768F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_09D32284BB0922B4803151CB6D09EAE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3C528CB91BA6E8F3651251CB6D0AF64B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_09D32284BB0922B4803151CB6D09EAE8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3C528CB91BA6E8F3651251CB6D0AF64B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3C528CB91BA6E8F3651251CB6D0AF64B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_09D32284BB0922B4803151CB6D09EAE8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3C528CB91BA6E8F3651251CB6D0AF64B" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_AEB198D4993F32F4F1E151CB6D0A9F70" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3C528CB91BA6E8F3651251CB6D0AF64B" xlink:to="loc_abus_ArbutusInc.Member_AEB198D4993F32F4F1E151CB6D0A9F70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_5FC343C35067B7DCA00A51CB6D0ABFCF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_5FC343C35067B7DCA00A51CB6D0ABFCF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3052BC75057FDB7E3A0651CB6D0AA0AC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3052BC75057FDB7E3A0651CB6D0AA0AC" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_0ABEF0A5144EECC34B3D51CB6D0AAB13" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_0ABEF0A5144EECC34B3D51CB6D0AAB13" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5112A84A601EB8B5909051CB6D0A193C" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5112A84A601EB8B5909051CB6D0A193C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_D67CD2B1765A5135675E51CB6D0AFF1D" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_D67CD2B1765A5135675E51CB6D0AFF1D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_968FC3F69DD1108AEE2551CB6D0A0881" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_968FC3F69DD1108AEE2551CB6D0A0881" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_F994557C1F2FEC245D7D51CB6D0AC26F" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_F994557C1F2FEC245D7D51CB6D0AC26F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_57CD58632110A0A0273651CB6D0ADF83" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_57CD58632110A0A0273651CB6D0ADF83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_E60F3AC6F63E810C8A1F51CB6D0AF9F5" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_E60F3AC6F63E810C8A1F51CB6D0AF9F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_C42C737C946E035E6D8B51CB6D0AF301" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_C42C737C946E035E6D8B51CB6D0AF301" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1448234CBFAF1CA71EA651CB6D0AC236" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1448234CBFAF1CA71EA651CB6D0AC236" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_9A949442672DDCD4AC4951CB6D0AE1EC" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_Goodwill_9A949442672DDCD4AC4951CB6D0AE1EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_681597C6610D6994F12751CB6D0A7DAC" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_681597C6610D6994F12751CB6D0A7DAC" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:label="loc_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_E1536AE2C98E4366420351CB6D0A0385" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_E1536AE2C98E4366420351CB6D0A0385" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_55F00CCC5E82861C76B751CB6D0BC07C" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_55F00CCC5E82861C76B751CB6D0BC07C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_FB88DFD0B79628BBE26251CB6D0B6100" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_FB88DFD0B79628BBE26251CB6D0B6100" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_89DE3A2DB5DD9CC4A01C51CB6D0B1D89" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_89DE3A2DB5DD9CC4A01C51CB6D0B1D89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FA9EC989581E75524BFF51CB6D0B87E0" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FA9EC989581E75524BFF51CB6D0B87E0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_CAE885E4D45C09D5BD3D51CB6D0B68FE" xlink:type="locator" />
    <definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_CAE885E4D45C09D5BD3D51CB6D0B68FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2537C2E385D844FC9E3B51CB6D0BBCD2" xlink:type="locator" />
    <definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2537C2E385D844FC9E3B51CB6D0BBCD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_F9D57A4DE30FEBCDB81051CB6D0B64C4" xlink:type="locator" />
    <definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_F9D57A4DE30FEBCDB81051CB6D0B64C4" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_337152E809B755596E4C39734BDF0E3E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_FAD630DC7A039D9E155A39734BD37261" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_337152E809B755596E4C39734BDF0E3E" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_FAD630DC7A039D9E155A39734BD37261" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0067213C9E81218D9EF839734BD3E0B1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_FAD630DC7A039D9E155A39734BD37261" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0067213C9E81218D9EF839734BD3E0B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BA031A823CE4C7A4706639734BD3FD8D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0067213C9E81218D9EF839734BD3E0B1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BA031A823CE4C7A4706639734BD3FD8D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BA031A823CE4C7A4706639734BD3FD8D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0067213C9E81218D9EF839734BD3E0B1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BA031A823CE4C7A4706639734BD3FD8D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_90353BBFA04F2CFD431B397917F11D30" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BA031A823CE4C7A4706639734BD3FD8D" xlink:to="loc_abus_ArbutusInc.Member_90353BBFA04F2CFD431B397917F11D30" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6BC5CF12D6CCA485E80D39734BD82B7F" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_FAD630DC7A039D9E155A39734BD37261" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6BC5CF12D6CCA485E80D39734BD82B7F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EF0F05B11A84566279539734BDF385C_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6BC5CF12D6CCA485E80D39734BD82B7F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EF0F05B11A84566279539734BDF385C_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EF0F05B11A84566279539734BDF385C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6BC5CF12D6CCA485E80D39734BD82B7F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EF0F05B11A84566279539734BDF385C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDCyclophilinsMember" xlink:label="loc_abus_IPRDCyclophilinsMember_F9512297E021CFDF585D3979D96A4CC8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EF0F05B11A84566279539734BDF385C" xlink:to="loc_abus_IPRDCyclophilinsMember_F9512297E021CFDF585D3979D96A4CC8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDImmuneModulatorsMember" xlink:label="loc_abus_IPRDImmuneModulatorsMember_F76AB9FCA0201D5733ED397C435FDCF7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EF0F05B11A84566279539734BDF385C" xlink:to="loc_abus_IPRDImmuneModulatorsMember_F76AB9FCA0201D5733ED397C435FDCF7" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDAntigenInhibitorsMember" xlink:label="loc_abus_IPRDAntigenInhibitorsMember_B3084CD478FA3A62BE49397B12B960A5" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EF0F05B11A84566279539734BDF385C" xlink:to="loc_abus_IPRDAntigenInhibitorsMember_B3084CD478FA3A62BE49397B12B960A5" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDcccDNASterilizersMember" xlink:label="loc_abus_IPRDcccDNASterilizersMember_20A58E04C4CD859CCB37397B88921250" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EF0F05B11A84566279539734BDF385C" xlink:to="loc_abus_IPRDcccDNASterilizersMember_20A58E04C4CD859CCB37397B88921250" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BF21C18294ABF21D54A83974AE33AAFB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_337152E809B755596E4C39734BDF0E3E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BF21C18294ABF21D54A83974AE33AAFB" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperations" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperationsNarrativeDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipment" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_43843726237D56A104D43F2E88BC389F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FA276111290DDBECF6733F2E88BC4F0D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_43843726237D56A104D43F2E88BC389F" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FA276111290DDBECF6733F2E88BC4F0D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0386E6281FB6502236143F2E88BC070C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FA276111290DDBECF6733F2E88BC4F0D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0386E6281FB6502236143F2E88BC070C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5DF4DB61BD84B67566CD3F2E88BC32B3_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0386E6281FB6502236143F2E88BC070C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5DF4DB61BD84B67566CD3F2E88BC32B3_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5DF4DB61BD84B67566CD3F2E88BC32B3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0386E6281FB6502236143F2E88BC070C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5DF4DB61BD84B67566CD3F2E88BC32B3" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_LaboratoryEquipmentMember" xlink:label="loc_abus_LaboratoryEquipmentMember_0F7CDB34389790A0D3733F2E88BC478A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5DF4DB61BD84B67566CD3F2E88BC32B3" xlink:to="loc_abus_LaboratoryEquipmentMember_0F7CDB34389790A0D3733F2E88BC478A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3DA5FB6FC85B1DE19F243F2E88BC4561" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5DF4DB61BD84B67566CD3F2E88BC32B3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3DA5FB6FC85B1DE19F243F2E88BC4561" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_331F65307F3885B46FC43F2E88BC5F3F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5DF4DB61BD84B67566CD3F2E88BC32B3" xlink:to="loc_us-gaap_ComputerEquipmentMember_331F65307F3885B46FC43F2E88BC5F3F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_B08F490DDE8E3695B15C3F2E88BC0DED" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5DF4DB61BD84B67566CD3F2E88BC32B3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_B08F490DDE8E3695B15C3F2E88BC0DED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_04131AF8006BA89D74A03F2E88BCE549" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_43843726237D56A104D43F2E88BC389F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_04131AF8006BA89D74A03F2E88BCE549" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3FB953825CDED7ADDBF83F2E88BD96DC" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_43843726237D56A104D43F2E88BC389F" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3FB953825CDED7ADDBF83F2E88BD96DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_65D33A342BD8A089708F3F2E88BDC74E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_43843726237D56A104D43F2E88BC389F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_65D33A342BD8A089708F3F2E88BDC74E" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ShareCapital" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalBlackScholesOptionPricingAssumptionsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F0CC78B92735225F2ED5167E7B69DED" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F0CC78B92735225F2ED5167E7B69DED" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6C145A733D7C1F9DB8C45167E7B68281" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F0CC78B92735225F2ED5167E7B69DED" xlink:to="loc_us-gaap_PlanNameAxis_6C145A733D7C1F9DB8C45167E7B68281" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6C145A733D7C1F9DB8C45167E7B68281" xlink:to="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6C145A733D7C1F9DB8C45167E7B68281" xlink:to="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_A2007PlanMember" xlink:label="loc_abus_A2007PlanMember_DFCFD00E94BC348181415167E7B68362" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:to="loc_abus_A2007PlanMember_DFCFD00E94BC348181415167E7B68362" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_A2011PlanMember" xlink:label="loc_abus_A2011PlanMember_2244ECDAF773052418E05167E7B7F65D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:to="loc_abus_A2011PlanMember_2244ECDAF773052418E05167E7B7F65D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DesignatedPlansMember" xlink:label="loc_abus_DesignatedPlansMember_2A9C5AAD5021B6D0C31C5167E7B7DD11" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:to="loc_abus_DesignatedPlansMember_2A9C5AAD5021B6D0C31C5167E7B7DD11" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusPlansMember" xlink:label="loc_abus_ArbutusPlansMember_01B85777EEBFC08AA6E05167E7B70EB2" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:to="loc_abus_ArbutusPlansMember_01B85777EEBFC08AA6E05167E7B70EB2" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ProtivaOptionPlanMember" xlink:label="loc_abus_ProtivaOptionPlanMember_758A64C37CC4726B1B315167E7B73676" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:to="loc_abus_ProtivaOptionPlanMember_758A64C37CC4726B1B315167E7B73676" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OnCoreOptionPlanMember" xlink:label="loc_abus_OnCoreOptionPlanMember_C77ECD846FA425C42EE15167E7B78972" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:to="loc_abus_OnCoreOptionPlanMember_C77ECD846FA425C42EE15167E7B78972" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_45509FA86F212C6C7B715167E7B7C8CF" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F0CC78B92735225F2ED5167E7B69DED" xlink:to="loc_us-gaap_AwardTypeAxis_45509FA86F212C6C7B715167E7B7C8CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_45509FA86F212C6C7B715167E7B7C8CF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_45509FA86F212C6C7B715167E7B7C8CF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_CashlessExerciseProvisionMember" xlink:label="loc_abus_CashlessExerciseProvisionMember_C445A81D07EDE53799305167E7B7278D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8" xlink:to="loc_abus_CashlessExerciseProvisionMember_C445A81D07EDE53799305167E7B7278D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_RevisedNewCommonSharesMember" xlink:label="loc_abus_RevisedNewCommonSharesMember_5FD7FEFBD20D13E697915167E7B76AE3" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8" xlink:to="loc_abus_RevisedNewCommonSharesMember_5FD7FEFBD20D13E697915167E7B76AE3" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ProtivaShareOptionsMember" xlink:label="loc_abus_ProtivaShareOptionsMember_7C1C1AF21D8842B763D85167E7B768D8" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8" xlink:to="loc_abus_ProtivaShareOptionsMember_7C1C1AF21D8842B763D85167E7B768D8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_EquivalentNumberOfCompanyCommonSharesMember" xlink:label="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_6A0809F109D28550486B5167E7B72CE0" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8" xlink:to="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_6A0809F109D28550486B5167E7B72CE0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member" xlink:label="loc_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member_6D7934BDCFFAA9890BD55167E7B77E97" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8" xlink:to="loc_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member_6D7934BDCFFAA9890BD55167E7B77E97" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_41809F1EE245A892D89D5167E7B72CD6" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F0CC78B92735225F2ED5167E7B69DED" xlink:to="loc_us-gaap_RangeAxis_41809F1EE245A892D89D5167E7B72CD6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6F21AD289056B705EFF65167E7B70146_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_41809F1EE245A892D89D5167E7B72CD6" xlink:to="loc_us-gaap_RangeMember_6F21AD289056B705EFF65167E7B70146_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6F21AD289056B705EFF65167E7B70146" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_41809F1EE245A892D89D5167E7B72CD6" xlink:to="loc_us-gaap_RangeMember_6F21AD289056B705EFF65167E7B70146" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1288729F5D9009761A1F5167E7B71222" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6F21AD289056B705EFF65167E7B70146" xlink:to="loc_us-gaap_MaximumMember_1288729F5D9009761A1F5167E7B71222" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3F4CD740603E50B603DD5167E7B7ED37" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F0CC78B92735225F2ED5167E7B69DED" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3F4CD740603E50B603DD5167E7B7ED37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3F4CD740603E50B603DD5167E7B7ED37" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3F4CD740603E50B603DD5167E7B7ED37" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_CashlessExerciseProvisionMember" xlink:label="loc_abus_CashlessExerciseProvisionMember_BB1292BA68A637694EBB5167E7B81BD4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1" xlink:to="loc_abus_CashlessExerciseProvisionMember_BB1292BA68A637694EBB5167E7B81BD4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A676E5ACF0AC8F1E3A1D5167E7B81F13" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A676E5ACF0AC8F1E3A1D5167E7B81F13" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_78CE8D22830943E6AB0A5167E7B847C7" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_78CE8D22830943E6AB0A5167E7B847C7" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_NumberOfAdditionalSharesAuthorized" xlink:label="loc_abus_NumberOfAdditionalSharesAuthorized_6E1E1C51ACDF1F4E59705167E7B8FB70" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_NumberOfAdditionalSharesAuthorized_6E1E1C51ACDF1F4E59705167E7B8FB70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_33AE50CFAB9459B265D05167E7B8FA43" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_33AE50CFAB9459B265D05167E7B8FA43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_E1943F5AFC38FE4791675167E7B88E4B" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_E1943F5AFC38FE4791675167E7B88E4B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_2751674643DA86C7BF105167E7B8C0CD" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_2751674643DA86C7BF105167E7B8C0CD" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ProceedsFromIssuanceOfCommonStockNet" xlink:label="loc_abus_ProceedsFromIssuanceOfCommonStockNet_410C0FA3800328D69F795167E7B874DA" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_ProceedsFromIssuanceOfCommonStockNet_410C0FA3800328D69F795167E7B874DA" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_WarrantsExercised" xlink:label="loc_abus_WarrantsExercised_1D554D09E69546962A9D5167E7B80AE6" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_WarrantsExercised_1D554D09E69546962A9D5167E7B80AE6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_3135D87AACA36C7FFCA75167E7B8432B" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_3135D87AACA36C7FFCA75167E7B8432B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2E679E32D37A5DB094DD5167E7B8FC0F" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2E679E32D37A5DB094DD5167E7B8FC0F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_NumberofShareBasedCompensationPlans" xlink:label="loc_abus_NumberofShareBasedCompensationPlans_C0140F8F4777E1408F4D5167E7B883E1" xlink:type="locator" />
    <definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_NumberofShareBasedCompensationPlans_C0140F8F4777E1408F4D5167E7B883E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0F8C7D66BA15C2C06AD5167E7B89C13" xlink:type="locator" />
    <definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0F8C7D66BA15C2C06AD5167E7B89C13" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F22CE8E6D1563660D2BB5167E7B810B8" xlink:type="locator" />
    <definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F22CE8E6D1563660D2BB5167E7B810B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0E9277A09195225343E35167E7B87AF0" xlink:type="locator" />
    <definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0E9277A09195225343E35167E7B87AF0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments" xlink:label="loc_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments_AA3FEF8604D953A0C1EC51B41AC4E26F" xlink:type="locator" />
    <definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments_AA3FEF8604D953A0C1EC51B41AC4E26F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF187D84C94A4EE4635A5167E7B83500" xlink:type="locator" />
    <definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF187D84C94A4EE4635A5167E7B83500" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_67E2EABA08433FE9CFDD5167E7B8201C" xlink:type="locator" />
    <definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_67E2EABA08433FE9CFDD5167E7B8201C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A2975673089C1830397E5167E7B81248" xlink:type="locator" />
    <definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A2975673089C1830397E5167E7B81248" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_6F88EFB84EAFF2C0202F5167E7B884C4" xlink:type="locator" />
    <definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_6F88EFB84EAFF2C0202F5167E7B884C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7CCAD9899CBC118CFF085167E7B8E4A8" xlink:type="locator" />
    <definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7CCAD9899CBC118CFF085167E7B8E4A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_87D0F54F8C0FFA70AEF55167E7B9CA75" xlink:type="locator" />
    <definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_87D0F54F8C0FFA70AEF55167E7B9CA75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_BF1FC3AB52D16F55E2765167E7B9FDD0" xlink:type="locator" />
    <definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_BF1FC3AB52D16F55E2765167E7B9FDD0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A1A2CC538DA6508A6DF15167E7B9DA42" xlink:type="locator" />
    <definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A1A2CC538DA6508A6DF15167E7B9DA42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42414AFADED704E3B9DF5167E7B9FFD4" xlink:type="locator" />
    <definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42414AFADED704E3B9DF5167E7B9FFD4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_881EDCEC404BBE5915315167E7B93EB9" xlink:type="locator" />
    <definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_881EDCEC404BBE5915315167E7B93EB9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F8035EA9C1F00EDDA5365167E7B9D606" xlink:type="locator" />
    <definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F8035EA9C1F00EDDA5365167E7B9D606" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_invest_InvestmentOptionsExercisePrice_06829610CAC6DD40F74B5167E7B923A8" xlink:type="locator" />
    <definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_invest_InvestmentOptionsExercisePrice_06829610CAC6DD40F74B5167E7B923A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_D8062F83DF1DC74DD09E5167E7B91060" xlink:type="locator" />
    <definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_D8062F83DF1DC74DD09E5167E7B91060" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6E6AA9825A372588585C5167E7B90099" xlink:type="locator" />
    <definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6E6AA9825A372588585C5167E7B90099" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_BEBA7E5DE9EB15DEF5CB5167E7B99C28" xlink:type="locator" />
    <definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_BEBA7E5DE9EB15DEF5CB5167E7B99C28" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_F52A78DE8DC18C71BB475167E7B984B2" xlink:type="locator" />
    <definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_F52A78DE8DC18C71BB475167E7B984B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_B93B158D0139627058545167E7B9BE16" xlink:type="locator" />
    <definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_B93B158D0139627058545167E7B9BE16" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:label="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_984B266233DF2214CB245167E7B9907B" xlink:type="locator" />
    <definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_984B266233DF2214CB245167E7B9907B" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice" xlink:label="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_CEFA8866135C2E92E2885167E7B9AA47" xlink:type="locator" />
    <definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_CEFA8866135C2E92E2885167E7B9AA47" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_897C057F0043F6910D315167E7B97D71" xlink:type="locator" />
    <definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_897C057F0043F6910D315167E7B97D71" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_006DD2DE990553A515EF5167E7B9842D" xlink:type="locator" />
    <definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_006DD2DE990553A515EF5167E7B9842D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62F439558F49F671D0925167E7B9B9E8" xlink:type="locator" />
    <definitionArc order="37" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62F439558F49F671D0925167E7B9B9E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22AF587E8FDC606E7E975167E7B957B6" xlink:type="locator" />
    <definitionArc order="38" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22AF587E8FDC606E7E975167E7B957B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_175CA4EC8F592EF6F6D75167E7B99023" xlink:type="locator" />
    <definitionArc order="39" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_175CA4EC8F592EF6F6D75167E7B99023" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PotentialProceedsOfAdditionalSharesAuthorized" xlink:label="loc_abus_PotentialProceedsOfAdditionalSharesAuthorized_E19275DA83E233A53C895167E7B97AFA" xlink:type="locator" />
    <definitionArc order="40" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_PotentialProceedsOfAdditionalSharesAuthorized_E19275DA83E233A53C895167E7B97AFA" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8720897B7EFF6039DD443E548BDE5287" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CCF1656A9C1B2842CCC3E548BDDC4D0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8720897B7EFF6039DD443E548BDE5287" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CCF1656A9C1B2842CCC3E548BDDC4D0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_03E2EFD6FB0015B500413E548BDE3E90" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CCF1656A9C1B2842CCC3E548BDDC4D0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_03E2EFD6FB0015B500413E548BDE3E90" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_03E2EFD6FB0015B500413E548BDE3E90" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_03E2EFD6FB0015B500413E548BDE3E90" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E6D0A0D1BBB64034517F3E548BDEE455" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E6D0A0D1BBB64034517F3E548BDEE455" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_CB8462D876406C71ADC23E548BDEF4E9" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_CB8462D876406C71ADC23E548BDEF4E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_8236D70CCCE2C662FC0E3E548BDE7612" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8720897B7EFF6039DD443E548BDE5287" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_8236D70CCCE2C662FC0E3E548BDE7612" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25562F6259A9EB5F01F652F945F84D91" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0E4AF06776F0199DE57552F945F2DADA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25562F6259A9EB5F01F652F945F84D91" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0E4AF06776F0199DE57552F945F2DADA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_18256D8DEC49D6C8260A52F945F3050F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0E4AF06776F0199DE57552F945F2DADA" xlink:to="loc_us-gaap_AwardTypeAxis_18256D8DEC49D6C8260A52F945F3050F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59F7C903575339B5162D52F945F3390F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_18256D8DEC49D6C8260A52F945F3050F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59F7C903575339B5162D52F945F3390F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59F7C903575339B5162D52F945F3390F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_18256D8DEC49D6C8260A52F945F3050F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59F7C903575339B5162D52F945F3390F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_EquivalentNumberOfCompanyCommonSharesMember" xlink:label="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_3A22EA5F409B15A062B252F945F3ADBF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59F7C903575339B5162D52F945F3390F" xlink:to="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_3A22EA5F409B15A062B252F945F3ADBF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_0EFEC391FC83E94B3C8B52F945F33978" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0E4AF06776F0199DE57552F945F2DADA" xlink:to="loc_us-gaap_PlanNameAxis_0EFEC391FC83E94B3C8B52F945F33978" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9D2AFE65E1A49D37F43952F945F8CE57_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0EFEC391FC83E94B3C8B52F945F33978" xlink:to="loc_us-gaap_PlanNameDomain_9D2AFE65E1A49D37F43952F945F8CE57_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9D2AFE65E1A49D37F43952F945F8CE57" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0EFEC391FC83E94B3C8B52F945F33978" xlink:to="loc_us-gaap_PlanNameDomain_9D2AFE65E1A49D37F43952F945F8CE57" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OnCoreOptionPlanMember" xlink:label="loc_abus_OnCoreOptionPlanMember_31A0738B14C0A7E5CA2B52F945F8F1A1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9D2AFE65E1A49D37F43952F945F8CE57" xlink:to="loc_abus_OnCoreOptionPlanMember_31A0738B14C0A7E5CA2B52F945F8F1A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25562F6259A9EB5F01F652F945F84D91" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C6C041D77F36F7AFAB7852F945F80918" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C6C041D77F36F7AFAB7852F945F80918" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue" xlink:label="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F100DBBCA5CBA944BD0552F945F89730" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:to="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F100DBBCA5CBA944BD0552F945F89730" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5813E54093C66FC68C4352F945F878FA" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5813E54093C66FC68C4352F945F878FA" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue" xlink:label="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_C6091C66B92A54C919BE52F945F94275" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:to="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_C6091C66B92A54C919BE52F945F94275" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_B5044E515159DA721D9552F945F9C531" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_B5044E515159DA721D9552F945F9C531" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13C0B169F08E2991C98651CB6C9FA8A1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13C0B169F08E2991C98651CB6C9FA8A1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E4DB1AAB8812BF4283A051CB6C9E2152" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF" xlink:to="loc_us-gaap_AwardTypeAxis_E4DB1AAB8812BF4283A051CB6C9E2152" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_E4DB1AAB8812BF4283A051CB6C9E2152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_E4DB1AAB8812BF4283A051CB6C9E2152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_EquivalentNumberOfCompanyCommonSharesMember" xlink:label="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_146312698EE0506529AA51CB6C9FCB90" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8" xlink:to="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_146312698EE0506529AA51CB6C9FCB90" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_10A136B0606997EDEC6351CB6C9F9A87" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF" xlink:to="loc_us-gaap_PlanNameAxis_10A136B0606997EDEC6351CB6C9F9A87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_10A136B0606997EDEC6351CB6C9F9A87" xlink:to="loc_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_10A136B0606997EDEC6351CB6C9F9A87" xlink:to="loc_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OnCoreOptionPlanMember" xlink:label="loc_abus_OnCoreOptionPlanMember_810B28D2585A8D9639EF51CB6C9F10E7" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D" xlink:to="loc_abus_OnCoreOptionPlanMember_810B28D2585A8D9639EF51CB6C9F10E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13C0B169F08E2991C98651CB6C9FA8A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F82B44D7B8EDE82FCE2251CB6C9F13DD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F82B44D7B8EDE82FCE2251CB6C9F13DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23855B5812957BF382D851CB6C9F7DB0" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23855B5812957BF382D851CB6C9F7DB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E6FC854EAF2E5EE4B68251CB6C9F1869" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E6FC854EAF2E5EE4B68251CB6C9F1869" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9946190883E509433E3351CB6CA02686" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9946190883E509433E3351CB6CA02686" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E4D614193D106D04593852F9462649D0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7D835D6606146ADEB28452F94625D5B3" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E4D614193D106D04593852F9462649D0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7D835D6606146ADEB28452F94625D5B3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4914EDE118BC8715899352F946250808" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7D835D6606146ADEB28452F94625D5B3" xlink:to="loc_us-gaap_AwardTypeAxis_4914EDE118BC8715899352F946250808" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B83D4EAE668187EBB45552F94625D7C0_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4914EDE118BC8715899352F946250808" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B83D4EAE668187EBB45552F94625D7C0_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B83D4EAE668187EBB45552F94625D7C0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4914EDE118BC8715899352F946250808" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B83D4EAE668187EBB45552F94625D7C0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_EquivalentNumberOfCompanyCommonSharesMember" xlink:label="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_189CC06924A5D83B338952F9462537CF" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B83D4EAE668187EBB45552F94625D7C0" xlink:to="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_189CC06924A5D83B338952F9462537CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_8432EDF5A61E802A340952F94626159B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7D835D6606146ADEB28452F94625D5B3" xlink:to="loc_us-gaap_PlanNameAxis_8432EDF5A61E802A340952F94626159B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2EF9691D950C3F0F168052F94626B2B0_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8432EDF5A61E802A340952F94626159B" xlink:to="loc_us-gaap_PlanNameDomain_2EF9691D950C3F0F168052F94626B2B0_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2EF9691D950C3F0F168052F94626B2B0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8432EDF5A61E802A340952F94626159B" xlink:to="loc_us-gaap_PlanNameDomain_2EF9691D950C3F0F168052F94626B2B0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ProtivaShareOptionsMember" xlink:label="loc_abus_ProtivaShareOptionsMember_D852069F7474F2692FEA52F94626C22D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2EF9691D950C3F0F168052F94626B2B0" xlink:to="loc_abus_ProtivaShareOptionsMember_D852069F7474F2692FEA52F94626C22D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E4D614193D106D04593852F9462649D0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7F06266E486AEC7D023E52F94626D3D8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7F06266E486AEC7D023E52F94626D3D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4A2BB3D19B9F9D1E80C452F946262F5B" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4A2BB3D19B9F9D1E80C452F946262F5B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E96FA42D5D464693658852F94626495C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E96FA42D5D464693658852F94626495C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3856F20620A8BFDE93D152F94626F23E" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3856F20620A8BFDE93D152F94626F23E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_D683FE0735DCE072CC7752F946260047" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_D683FE0735DCE072CC7752F946260047" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_A045A92E12595C508D7B52F9462B7EBB" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_A045A92E12595C508D7B52F9462B7EBB" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalStockOptionActivityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98306E7FE35CBEE0989052F59096CA42" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8A588D77608BC0EEF0FE52F59096CFEA" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98306E7FE35CBEE0989052F59096CA42" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8A588D77608BC0EEF0FE52F59096CFEA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_A85D0DBC4C379E5A1A8D52F59096D98C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8A588D77608BC0EEF0FE52F59096CFEA" xlink:to="loc_us-gaap_PlanNameAxis_A85D0DBC4C379E5A1A8D52F59096D98C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1A5D110B164C4260A31C52F59096F88F_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_A85D0DBC4C379E5A1A8D52F59096D98C" xlink:to="loc_us-gaap_PlanNameDomain_1A5D110B164C4260A31C52F59096F88F_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1A5D110B164C4260A31C52F59096F88F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_A85D0DBC4C379E5A1A8D52F59096D98C" xlink:to="loc_us-gaap_PlanNameDomain_1A5D110B164C4260A31C52F59096F88F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusPlansMember" xlink:label="loc_abus_ArbutusPlansMember_EC4C5043F5D3419BA6C252F590963FA0" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1A5D110B164C4260A31C52F59096F88F" xlink:to="loc_abus_ArbutusPlansMember_EC4C5043F5D3419BA6C252F590963FA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98306E7FE35CBEE0989052F59096CA42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_847F293EFE7A9BB6ECF452F590964D8C" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_847F293EFE7A9BB6ECF452F590964D8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FA9F816BF8C3C6B66F0F52F59096949D" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FA9F816BF8C3C6B66F0F52F59096949D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_22626A9A1415DC20F06452F59096D68E" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_22626A9A1415DC20F06452F59096D68E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_567328A91F38F900A87A52F59096B967" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_567328A91F38F900A87A52F59096B967" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_966D094864B752FB019852F59097DE6A" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_966D094864B752FB019852F59097DE6A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7D52E2386CD720A601BD52F5909718CA" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7D52E2386CD720A601BD52F5909718CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B58F8136A367A98124652F5909752E6" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B58F8136A367A98124652F5909752E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6C939EC932A4264F41D852F5909792E1" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6C939EC932A4264F41D852F5909792E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0D951485E91F94E6EACF52F5909753CE" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0D951485E91F94E6EACF52F5909753CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D203477D8EE34579A35A52F59097DB3C" xlink:type="locator" />
    <definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D203477D8EE34579A35A52F59097DB3C" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalStockOptionsOutstandingDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_7B5339E8CB2F369A3CED3DF3E166532B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_7B5339E8CB2F369A3CED3DF3E166532B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3971ADF47DBB2CBF99B93DF14F8466ED" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_7B5339E8CB2F369A3CED3DF3E166532B" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3971ADF47DBB2CBF99B93DF14F8466ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3971ADF47DBB2CBF99B93DF14F8466ED" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3971ADF47DBB2CBF99B93DF14F8466ED" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range1Member" xlink:label="loc_abus_Range1Member_26B0EB4FDEB8E068D81B3DF420B2BC8D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range1Member_26B0EB4FDEB8E068D81B3DF420B2BC8D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range2Member" xlink:label="loc_abus_Range2Member_5A4888246A259B3D4E003DF420CB1702" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range2Member_5A4888246A259B3D4E003DF420CB1702" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range3Member" xlink:label="loc_abus_Range3Member_142834906DBE9088D6A93DF420D9CE1C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range3Member_142834906DBE9088D6A93DF420D9CE1C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range4Member" xlink:label="loc_abus_Range4Member_766136016F9756BD45743DF420E8F7B6" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range4Member_766136016F9756BD45743DF420E8F7B6" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range5Member" xlink:label="loc_abus_Range5Member_BCD96735ACAA264DB5683DF420F76FC0" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range5Member_BCD96735ACAA264DB5683DF420F76FC0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range6Member" xlink:label="loc_abus_Range6Member_8E2EF304880CB625B4B73DF421068E1D" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range6Member_8E2EF304880CB625B4B73DF421068E1D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range7Member" xlink:label="loc_abus_Range7Member_52AF63D2E242282684FA3DF4211540CC" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range7Member_52AF63D2E242282684FA3DF4211540CC" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range8Member" xlink:label="loc_abus_Range8Member_365F3209B6D87E30DF6E3DFD4EE2BDBE" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range8Member_365F3209B6D87E30DF6E3DFD4EE2BDBE" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_TotalRangeMember" xlink:label="loc_abus_TotalRangeMember_10646EF5E42C0901CD643DF421254377" xlink:type="locator" />
    <definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_TotalRangeMember_10646EF5E42C0901CD643DF421254377" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8063E26932D57D998A763DF493AD2630" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8063E26932D57D998A763DF493AD2630" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_156E0A293B5045CA74A53DF493B003FA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_156E0A293B5045CA74A53DF493B003FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_67654481AC6FC62B66293DF493B24EC1" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_67654481AC6FC62B66293DF493B24EC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_461D78239B2DB76FAD6D3DF493B4CBC4" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_461D78239B2DB76FAD6D3DF493B4CBC4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9AA74796458FE0661CC63DF493B71C56" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9AA74796458FE0661CC63DF493B71C56" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2446C2CD512F986FF7DD3DF493B96126" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2446C2CD512F986FF7DD3DF493B96126" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2D04F146AEBCE7C495313DF493BC08FB" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2D04F146AEBCE7C495313DF493BC08FB" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfWarrantActivityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_186B981AB1CFC30C43FD5167E7AD8F7F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_889C610D185CCB2A51C65167E7AC643B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_186B981AB1CFC30C43FD5167E7AD8F7F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_889C610D185CCB2A51C65167E7AC643B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CFE02B3CDA66F65F78055167E7ACD845" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_889C610D185CCB2A51C65167E7AC643B" xlink:to="loc_us-gaap_RangeAxis_CFE02B3CDA66F65F78055167E7ACD845" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2AD1FED5D682D7E7013A5167E7AC0DCB_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_CFE02B3CDA66F65F78055167E7ACD845" xlink:to="loc_us-gaap_RangeMember_2AD1FED5D682D7E7013A5167E7AC0DCB_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2AD1FED5D682D7E7013A5167E7AC0DCB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_CFE02B3CDA66F65F78055167E7ACD845" xlink:to="loc_us-gaap_RangeMember_2AD1FED5D682D7E7013A5167E7AC0DCB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_65491CBBCECF913797E05167E7AD1C3D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_2AD1FED5D682D7E7013A5167E7AC0DCB" xlink:to="loc_us-gaap_MinimumMember_65491CBBCECF913797E05167E7AD1C3D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_2A5AE2C8C835986B54E35167E7AD6BE2" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_2AD1FED5D682D7E7013A5167E7AC0DCB" xlink:to="loc_us-gaap_MaximumMember_2A5AE2C8C835986B54E35167E7AD6BE2" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward" xlink:label="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_186B981AB1CFC30C43FD5167E7AD8F7F" xlink:to="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1DE01F24B41EF4FCEEEE5167E7ADBB6B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1DE01F24B41EF4FCEEEE5167E7ADBB6B" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="loc_abus_ClassOfWarrantOrRightExercisedDuringPeriod_A69ACB80F0072DD481915167E7AD6FED" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_abus_ClassOfWarrantOrRightExercisedDuringPeriod_A69ACB80F0072DD481915167E7AD6FED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CDCADB3AAD3C4E8CFC7D5167E7ADE0CD" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CDCADB3AAD3C4E8CFC7D5167E7ADE0CD" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="loc_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_870A5FA4C1C62D45998C5167E7AD75DD" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_870A5FA4C1C62D45998C5167E7AD75DD" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantorRightOutstandExcercisePriceRange" xlink:label="loc_abus_ClassOfWarrantorRightOutstandExcercisePriceRange_525675FF39318BAA71F05167E7ADB71A" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_abus_ClassOfWarrantorRightOutstandExcercisePriceRange_525675FF39318BAA71F05167E7ADB71A" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantsOrRightsExcercisedPriceRange" xlink:label="loc_abus_ClassOfWarrantsOrRightsExcercisedPriceRange_5FDC9EFA31FD2116448D5167E7AD8FC6" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_abus_ClassOfWarrantsOrRightsExcercisedPriceRange_5FDC9EFA31FD2116448D5167E7AD8FC6" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BalanceWeightedaverageremainingcontractuallife" xlink:label="loc_abus_BalanceWeightedaverageremainingcontractuallife_BF491E2197D8187E33245167E7ADE7D9" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_abus_BalanceWeightedaverageremainingcontractuallife_BF491E2197D8187E33245167E7ADE7D9" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue" xlink:label="loc_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue_635AC93B282659C7B9815167E7AD1176" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue_635AC93B282659C7B9815167E7AD1176" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FB54C428D8E8AAAEDDE733AD1AED3999" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FB54C428D8E8AAAEDDE733AD1AED3999" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4F2D60A9BEEACFBD7FC433AD1AEE7819" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FB54C428D8E8AAAEDDE733AD1AED3999" xlink:to="loc_us-gaap_PlanNameAxis_4F2D60A9BEEACFBD7FC433AD1AEE7819" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_07197E762DF7B56AE4C533AD1AEF9D7B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4F2D60A9BEEACFBD7FC433AD1AEE7819" xlink:to="loc_us-gaap_PlanNameDomain_07197E762DF7B56AE4C533AD1AEF9D7B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_07197E762DF7B56AE4C533AD1AEF9D7B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4F2D60A9BEEACFBD7FC433AD1AEE7819" xlink:to="loc_us-gaap_PlanNameDomain_07197E762DF7B56AE4C533AD1AEF9D7B" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ProtivaOptionPlanMember" xlink:label="loc_abus_ProtivaOptionPlanMember_6FB2EC3A34FE74ACFE1F33AEF39B6614" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_07197E762DF7B56AE4C533AD1AEF9D7B" xlink:to="loc_abus_ProtivaOptionPlanMember_6FB2EC3A34FE74ACFE1F33AEF39B6614" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OnCoreOptionPlanMember" xlink:label="loc_abus_OnCoreOptionPlanMember_0037E5B52F43B99C588033AFD7DE5E87" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_07197E762DF7B56AE4C533AD1AEF9D7B" xlink:to="loc_abus_OnCoreOptionPlanMember_0037E5B52F43B99C588033AFD7DE5E87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9B55D9165AD48D6ABF3333A201FB5A4F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9B55D9165AD48D6ABF3333A201FB5A4F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CB98BB6FD6020DDAD1CB33A201FBDA43" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CB98BB6FD6020DDAD1CB33A201FBDA43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F13BF2A8758FAAE1F68133A201FB04E1" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F13BF2A8758FAAE1F68133A201FB04E1" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:label="loc_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_C523790D434218EDAB8433A201FB17EA" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_C523790D434218EDAB8433A201FB17EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_7D13CCE808523AB5EFA633A201FB48C0" xlink:type="locator" />
    <definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_7D13CCE808523AB5EFA633A201FB48C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C048482A9F67197ADE8533A201FB4A53" xlink:type="locator" />
    <definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C048482A9F67197ADE8533A201FB4A53" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_43A0ED03AB39AE2A50BF33A201FB9C51" xlink:type="locator" />
    <definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_43A0ED03AB39AE2A50BF33A201FB9C51" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B91DD6A242950CA8A34F33A201FB678B" xlink:type="locator" />
    <definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B91DD6A242950CA8A34F33A201FB678B" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalWeightedAverageOptionPricingAssumptionsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AEA9197B1ED3320525413E2DA8D2A9FE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3CA92A2D5BA7163C512E3E2DA8CBC78A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AEA9197B1ED3320525413E2DA8D2A9FE" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3CA92A2D5BA7163C512E3E2DA8CBC78A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1442AB7A67FCD6B114993DF14F7A8AAB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3CA92A2D5BA7163C512E3E2DA8CBC78A" xlink:to="loc_us-gaap_PlanNameAxis_1442AB7A67FCD6B114993DF14F7A8AAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_CFF786F45427EAC8D5EA3DF14F7A2276_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1442AB7A67FCD6B114993DF14F7A8AAB" xlink:to="loc_us-gaap_PlanNameDomain_CFF786F45427EAC8D5EA3DF14F7A2276_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_CFF786F45427EAC8D5EA3DF14F7A2276" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1442AB7A67FCD6B114993DF14F7A8AAB" xlink:to="loc_us-gaap_PlanNameDomain_CFF786F45427EAC8D5EA3DF14F7A2276" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusPlansMember" xlink:label="loc_abus_ArbutusPlansMember_754A6249116D21BC2DF83E306EE37FDB" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_CFF786F45427EAC8D5EA3DF14F7A2276" xlink:to="loc_abus_ArbutusPlansMember_754A6249116D21BC2DF83E306EE37FDB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3D4A027DE56BBAEE0BD53DF14F7AD00D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AEA9197B1ED3320525413E2DA8D2A9FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3D4A027DE56BBAEE0BD53DF14F7AD00D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2F7C87584866FE4826393E31555D6FBD" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AEA9197B1ED3320525413E2DA8D2A9FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2F7C87584866FE4826393E31555D6FBD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8A04889A1F2E07E309003E315C3EF0FE" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AEA9197B1ED3320525413E2DA8D2A9FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8A04889A1F2E07E309003E315C3EF0FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1BA8AEDEC3AC4156C4D33DF14F7AA289" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AEA9197B1ED3320525413E2DA8D2A9FE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1BA8AEDEC3AC4156C4D33DF14F7AA289" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_B8B22FBC3BDD7885FC0A3F2E891A5A54" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_B8B22FBC3BDD7885FC0A3F2E891A5A54" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6E654DBAD3DA175B7B463F2E891A11D8" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_B8B22FBC3BDD7885FC0A3F2E891A5A54" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6E654DBAD3DA175B7B463F2E891A11D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6E654DBAD3DA175B7B463F2E891A11D8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6E654DBAD3DA175B7B463F2E891A11D8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_73D040B56307B9A643B63F2E891A069F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_73D040B56307B9A643B63F2E891A069F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_F608A8BB1D0AF86C687A3F2E891A11CA" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_F608A8BB1D0AF86C687A3F2E891A11CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8989C1DDE9D9D8AE7D253F2E891BBD01" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8989C1DDE9D9D8AE7D253F2E891BBD01" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8435361D25C60E9337F53F2E891B8C57" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8435361D25C60E9337F53F2E891B8C57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_B9FB61C5031C01B1FC3F3F2E891B913F" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:to="loc_us-gaap_LongTermInvestments_B9FB61C5031C01B1FC3F3F2E891B913F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_96B9C0F11CC95876A5713F2E891B6003" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_96B9C0F11CC95876A5713F2E891B6003" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_AF3F9B65892D2E2AE7853F2E891BDC7B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_AF3F9B65892D2E2AE7853F2E891BDC7B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_800B9B96F2CFE844125F3F2E891B068E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_800B9B96F2CFE844125F3F2E891B068E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_684D963462CA5AA804023F2E891BD56C" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:to="loc_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_684D963462CA5AA804023F2E891BD56C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_C893C9BC7C7209F9F6803F2E891BC9CE" xlink:type="locator" />
    <definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_C893C9BC7C7209F9F6803F2E891BC9CE" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25D21BD5B86D44F69F853857C970ADF4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25D21BD5B86D44F69F853857C970ADF4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AFBF244724AF7DF9064A3857C9708BA1" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AFBF244724AF7DF9064A3857C9708BA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AFBF244724AF7DF9064A3857C9708BA1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AFBF244724AF7DF9064A3857C9708BA1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_LaboratoryEquipmentMember" xlink:label="loc_abus_LaboratoryEquipmentMember_96CE844CB157A76D6EA13857C970E45A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:to="loc_abus_LaboratoryEquipmentMember_96CE844CB157A76D6EA13857C970E45A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_41986536DC411D85777C3857C970AA9E" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:to="loc_us-gaap_ComputerEquipmentMember_41986536DC411D85777C3857C970AA9E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3B7093F504EEE7EFFA793857C970DC1B" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3B7093F504EEE7EFFA793857C970DC1B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5E9E9C03C03C093BC4993857C9704C77" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E" xlink:to="loc_us-gaap_RangeAxis_5E9E9C03C03C093BC4993857C9704C77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_B26B10F5C7D18BA6BFC73858271C966B_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5E9E9C03C03C093BC4993857C9704C77" xlink:to="loc_us-gaap_RangeMember_B26B10F5C7D18BA6BFC73858271C966B_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_B26B10F5C7D18BA6BFC73858271C966B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5E9E9C03C03C093BC4993857C9704C77" xlink:to="loc_us-gaap_RangeMember_B26B10F5C7D18BA6BFC73858271C966B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_114C9767A5AEF7F59E1D3857C970ED24" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_B26B10F5C7D18BA6BFC73858271C966B" xlink:to="loc_us-gaap_MinimumMember_114C9767A5AEF7F59E1D3857C970ED24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_3444FCB18BC11576641F3857C9701206" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_B26B10F5C7D18BA6BFC73858271C966B" xlink:to="loc_us-gaap_MaximumMember_3444FCB18BC11576641F3857C9701206" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_911876483CA57560C7C03857C9705C60" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25D21BD5B86D44F69F853857C970ADF4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_911876483CA57560C7C03857C9705C60" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesTables" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/SubsequentEvents" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC" xlink:to="loc_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2C4E901939E0F069F64A56EFD504855F" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:to="loc_dei_LegalEntityAxis_2C4E901939E0F069F64A56EFD504855F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2C4E901939E0F069F64A56EFD504855F" xlink:to="loc_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2C4E901939E0F069F64A56EFD504855F" xlink:to="loc_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MonsantoMember" xlink:label="loc_abus_MonsantoMember_1032A1225017D632340856EFD53ED18B" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E" xlink:to="loc_abus_MonsantoMember_1032A1225017D632340856EFD53ED18B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_E4B553527EFEC435B39B56EFD4EB0D0A" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_E4B553527EFEC435B39B56EFD4EB0D0A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CCC958DECA31BD5C14AF56EFD4EC0F44_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E4B553527EFEC435B39B56EFD4EB0D0A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CCC958DECA31BD5C14AF56EFD4EC0F44_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CCC958DECA31BD5C14AF56EFD4EC0F44" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E4B553527EFEC435B39B56EFD4EB0D0A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CCC958DECA31BD5C14AF56EFD4EC0F44" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PADCo.Member" xlink:label="loc_abus_PADCo.Member_705ED5B67B23D8449AFD56EFD51E537A" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CCC958DECA31BD5C14AF56EFD4EC0F44" xlink:to="loc_abus_PADCo.Member_705ED5B67B23D8449AFD56EFD51E537A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0117269AE8812DEDB26F56EFD4D01690" xlink:type="locator" />
    <definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0117269AE8812DEDB26F56EFD4D01690" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203_default" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0117269AE8812DEDB26F56EFD4D01690" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203_default" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0117269AE8812DEDB26F56EFD4D01690" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_22C488EC3596E1918AD256EFD52D30D4" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203" xlink:to="loc_us-gaap_SubsequentEventMember_22C488EC3596E1918AD256EFD52D30D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4E9DC42AFFD528975A9156EFD4DF44A2" xlink:type="locator" />
    <definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4E9DC42AFFD528975A9156EFD4DF44A2" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OptionalExcercisedContractualOptionAmount" xlink:label="loc_abus_OptionalExcercisedContractualOptionAmount_EC05C1C78D414A920EB156F773173265" xlink:type="locator" />
    <definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC" xlink:to="loc_abus_OptionalExcercisedContractualOptionAmount_EC05C1C78D414A920EB156F773173265" xlink:type="arc" />
  </definitionLink>
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformation" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformationDetails" xlink:type="extended" />
  <definitionLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformationTables" xlink:type="extended" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>abus-20151231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_31F5442E07A07787289C5167E77E04D1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_31F5442E07A07787289C5167E77E04D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_31F5442E07A07787289C5167E77E04D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_31F5442E07A07787289C5167E77E04D1" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_31F5442E07A07787289C5167E77E04D1" xlink:type="arc" />
    <link:label id="lab_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273_terseLabel_en-US" xlink:label="lab_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273_label_en-US" xlink:label="lab_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273_documentation_en-US" xlink:label="lab_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="abus-20151231.xsd#abus_IncomeTaxesTable" xlink:label="loc_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:to="lab_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_FD15BE8A00EFA9317E235167E77EC162_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_FD15BE8A00EFA9317E235167E77EC162" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_FD15BE8A00EFA9317E235167E77EC162_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_FD15BE8A00EFA9317E235167E77EC162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_FD15BE8A00EFA9317E235167E77EC162" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_FD15BE8A00EFA9317E235167E77EC162" xlink:to="lab_us-gaap_StatementScenarioAxis_FD15BE8A00EFA9317E235167E77EC162" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestatementAdjustmentMember_6782008242A7346B433C5167E77EFFA0_terseLabel_en-US" xlink:label="lab_us-gaap_RestatementAdjustmentMember_6782008242A7346B433C5167E77EFFA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recast adjustment</link:label>
    <link:label id="lab_us-gaap_RestatementAdjustmentMember_6782008242A7346B433C5167E77EFFA0_label_en-US" xlink:label="lab_us-gaap_RestatementAdjustmentMember_6782008242A7346B433C5167E77EFFA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Adjustment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_6782008242A7346B433C5167E77EFFA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestatementAdjustmentMember_6782008242A7346B433C5167E77EFFA0" xlink:to="lab_us-gaap_RestatementAdjustmentMember_6782008242A7346B433C5167E77EFFA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_5522F9904F0248045D1D5167E77E20A5_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_5522F9904F0248045D1D5167E77E20A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_5522F9904F0248045D1D5167E77E20A5_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_5522F9904F0248045D1D5167E77E20A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_5522F9904F0248045D1D5167E77E20A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_5522F9904F0248045D1D5167E77E20A5" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_5522F9904F0248045D1D5167E77E20A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentCreditMember_008D9669ECA4CA308C195167E77F1BFE_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCreditMember_008D9669ECA4CA308C195167E77F1BFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_InvestmentCreditMember_008D9669ECA4CA308C195167E77F1BFE_label_en-US" xlink:label="lab_us-gaap_InvestmentCreditMember_008D9669ECA4CA308C195167E77F1BFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentCreditMember" xlink:label="loc_us-gaap_InvestmentCreditMember_008D9669ECA4CA308C195167E77F1BFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCreditMember_008D9669ECA4CA308C195167E77F1BFE" xlink:to="lab_us-gaap_InvestmentCreditMember_008D9669ECA4CA308C195167E77F1BFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_15BCF254A798DBF984475167E77F2908_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_15BCF254A798DBF984475167E77F2908" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_15BCF254A798DBF984475167E77F2908_label_en-US" xlink:label="lab_us-gaap_ResearchMember_15BCF254A798DBF984475167E77F2908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_15BCF254A798DBF984475167E77F2908" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_15BCF254A798DBF984475167E77F2908" xlink:to="lab_us-gaap_ResearchMember_15BCF254A798DBF984475167E77F2908" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_F8853D65171693D2ED5C5167E77F9D91_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_F8853D65171693D2ED5C5167E77F9D91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_F8853D65171693D2ED5C5167E77F9D91_label_en-US" xlink:label="lab_us-gaap_RangeAxis_F8853D65171693D2ED5C5167E77F9D91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F8853D65171693D2ED5C5167E77F9D91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_F8853D65171693D2ED5C5167E77F9D91" xlink:to="lab_us-gaap_RangeAxis_F8853D65171693D2ED5C5167E77F9D91" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD_label_en-US" xlink:label="lab_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD" xlink:to="lab_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_90DB767E4FE19A6044105167E77F5714_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_90DB767E4FE19A6044105167E77F5714" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_90DB767E4FE19A6044105167E77F5714_label_en-US" xlink:label="lab_us-gaap_MaximumMember_90DB767E4FE19A6044105167E77F5714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_90DB767E4FE19A6044105167E77F5714" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_90DB767E4FE19A6044105167E77F5714" xlink:to="lab_us-gaap_MaximumMember_90DB767E4FE19A6044105167E77F5714" xlink:type="arc" />
    <link:label id="lab_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0_terseLabel_en-US" xlink:label="lab_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0_label_en-US" xlink:label="lab_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes (Details) [Line Items]</link:label>
    <link:label id="lab_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0_documentation_en-US" xlink:label="lab_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="abus-20151231.xsd#abus_IncomeTaxesDetailsLineItems" xlink:label="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="lab_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_58F9AADF11B1F227DC955167E77F0B96_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_58F9AADF11B1F227DC955167E77F0B96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canadian federal and provincial income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_58F9AADF11B1F227DC955167E77F0B96_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_58F9AADF11B1F227DC955167E77F0B96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_58F9AADF11B1F227DC955167E77F0B96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_58F9AADF11B1F227DC955167E77F0B96" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_58F9AADF11B1F227DC955167E77F0B96" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7B62DD270598CF2212DF5167E77F47DE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7B62DD270598CF2212DF5167E77F47DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment tax credits available to reduce Canadian federal income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7B62DD270598CF2212DF5167E77F47DE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7B62DD270598CF2212DF5167E77F47DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7B62DD270598CF2212DF5167E77F47DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7B62DD270598CF2212DF5167E77F47DE" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7B62DD270598CF2212DF5167E77F47DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75E9C33BA177B07AD3AB5167E77F7551_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75E9C33BA177B07AD3AB5167E77F7551" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment tax credits available to reduce provincial income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75E9C33BA177B07AD3AB5167E77F7551_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75E9C33BA177B07AD3AB5167E77F7551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75E9C33BA177B07AD3AB5167E77F7551" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75E9C33BA177B07AD3AB5167E77F7551" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75E9C33BA177B07AD3AB5167E77F7551" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4B5FA2A4B6EA24A9B920516A8684D9BD_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4B5FA2A4B6EA24A9B920516A8684D9BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4B5FA2A4B6EA24A9B920516A8684D9BD_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4B5FA2A4B6EA24A9B920516A8684D9BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4B5FA2A4B6EA24A9B920516A8684D9BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4B5FA2A4B6EA24A9B920516A8684D9BD" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4B5FA2A4B6EA24A9B920516A8684D9BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_51AB23E214FB64351B1C5167E77F7F9B_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_51AB23E214FB64351B1C5167E77F7F9B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Scientific research and experimental development expenditures available for indefinite carry-forward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_51AB23E214FB64351B1C5167E77F7F9B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_51AB23E214FB64351B1C5167E77F7F9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_51AB23E214FB64351B1C5167E77F7F9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_51AB23E214FB64351B1C5167E77F7F9B" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_51AB23E214FB64351B1C5167E77F7F9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_856CE1B6BB49327FDB4E5167E77FAD5E_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_856CE1B6BB49327FDB4E5167E77FAD5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, operating loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_856CE1B6BB49327FDB4E5167E77FAD5E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_856CE1B6BB49327FDB4E5167E77FAD5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_856CE1B6BB49327FDB4E5167E77FAD5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_856CE1B6BB49327FDB4E5167E77FAD5E" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_856CE1B6BB49327FDB4E5167E77FAD5E" xlink:type="arc" />
    <link:label id="lab_abus_PatentTaxRefundPercentage_164089C14E76D2E1C4DB5167E77F6527_terseLabel_en-US" xlink:label="lab_abus_PatentTaxRefundPercentage_164089C14E76D2E1C4DB5167E77F6527" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent tax refund percentage</link:label>
    <link:label id="lab_abus_PatentTaxRefundPercentage_164089C14E76D2E1C4DB5167E77F6527_label_en-US" xlink:label="lab_abus_PatentTaxRefundPercentage_164089C14E76D2E1C4DB5167E77F6527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patent Tax Refund Percentage</link:label>
    <link:label id="lab_abus_PatentTaxRefundPercentage_164089C14E76D2E1C4DB5167E77F6527_documentation_en-US" xlink:label="lab_abus_PatentTaxRefundPercentage_164089C14E76D2E1C4DB5167E77F6527" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the patent tax refund percentage.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_PatentTaxRefundPercentage" xlink:label="loc_abus_PatentTaxRefundPercentage_164089C14E76D2E1C4DB5167E77F6527" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_PatentTaxRefundPercentage_164089C14E76D2E1C4DB5167E77F6527" xlink:to="lab_abus_PatentTaxRefundPercentage_164089C14E76D2E1C4DB5167E77F6527" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_E4B2E49E22D7D5B052705167E77FC928_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds_E4B2E49E22D7D5B052705167E77FC928" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax refund maximum from patents</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_E4B2E49E22D7D5B052705167E77FC928_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds_E4B2E49E22D7D5B052705167E77FC928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Income Tax Refunds</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_E4B2E49E22D7D5B052705167E77FC928" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds_E4B2E49E22D7D5B052705167E77FC928" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds_E4B2E49E22D7D5B052705167E77FC928" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_BBE3CA45116EED5036325167E77FC3F0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_BBE3CA45116EED5036325167E77FC3F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_BBE3CA45116EED5036325167E77FC3F0_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_BBE3CA45116EED5036325167E77FC3F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_BBE3CA45116EED5036325167E77FC3F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_BBE3CA45116EED5036325167E77FC3F0" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_BBE3CA45116EED5036325167E77FC3F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_37D2CE24EA3B0C921A475167E77F2BCE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_37D2CE24EA3B0C921A475167E77F2BCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_37D2CE24EA3B0C921A475167E77F2BCE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_37D2CE24EA3B0C921A475167E77F2BCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_37D2CE24EA3B0C921A475167E77F2BCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_37D2CE24EA3B0C921A475167E77F2BCE" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_37D2CE24EA3B0C921A475167E77F2BCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_10219CA78A74A244BA363409FEA3CC11_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_10219CA78A74A244BA363409FEA3CC11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_10219CA78A74A244BA363409FEA3CC11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_10219CA78A74A244BA363409FEA3CC11" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_10219CA78A74A244BA363409FEA3CC11" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_DE5393F29BB34D9A5AEE3409FEA4BD93_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent_DE5393F29BB34D9A5AEE3409FEA4BD93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_DE5393F29BB34D9A5AEE3409FEA4BD93_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent_DE5393F29BB34D9A5AEE3409FEA4BD93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_DE5393F29BB34D9A5AEE3409FEA4BD93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent_DE5393F29BB34D9A5AEE3409FEA4BD93" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent_DE5393F29BB34D9A5AEE3409FEA4BD93" xlink:type="arc" />
    <link:label id="lab_abus_AccruedResearchandDevelopmentCurrent_DEB72D9421B6E0B4A5EC3409FEA43EF1_terseLabel_en-US" xlink:label="lab_abus_AccruedResearchandDevelopmentCurrent_DEB72D9421B6E0B4A5EC3409FEA43EF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development accruals</link:label>
    <link:label id="lab_abus_AccruedResearchandDevelopmentCurrent_DEB72D9421B6E0B4A5EC3409FEA43EF1_label_en-US" xlink:label="lab_abus_AccruedResearchandDevelopmentCurrent_DEB72D9421B6E0B4A5EC3409FEA43EF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research and Development, Current</link:label>
    <link:label id="lab_abus_AccruedResearchandDevelopmentCurrent_DEB72D9421B6E0B4A5EC3409FEA43EF1_documentation_en-US" xlink:label="lab_abus_AccruedResearchandDevelopmentCurrent_DEB72D9421B6E0B4A5EC3409FEA43EF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research and Development, Current</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_AccruedResearchandDevelopmentCurrent" xlink:label="loc_abus_AccruedResearchandDevelopmentCurrent_DEB72D9421B6E0B4A5EC3409FEA43EF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AccruedResearchandDevelopmentCurrent_DEB72D9421B6E0B4A5EC3409FEA43EF1" xlink:to="lab_abus_AccruedResearchandDevelopmentCurrent_DEB72D9421B6E0B4A5EC3409FEA43EF1" xlink:type="arc" />
    <link:label id="lab_abus_AccruedLicenseFeeCurrent_842D5FF8573829AD13883409FEA427C9_terseLabel_en-US" xlink:label="lab_abus_AccruedLicenseFeeCurrent_842D5FF8573829AD13883409FEA427C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fee accruals</link:label>
    <link:label id="lab_abus_AccruedLicenseFeeCurrent_842D5FF8573829AD13883409FEA427C9_label_en-US" xlink:label="lab_abus_AccruedLicenseFeeCurrent_842D5FF8573829AD13883409FEA427C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued License Fee, Current</link:label>
    <link:label id="lab_abus_AccruedLicenseFeeCurrent_842D5FF8573829AD13883409FEA427C9_documentation_en-US" xlink:label="lab_abus_AccruedLicenseFeeCurrent_842D5FF8573829AD13883409FEA427C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued License Fee, Current</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_AccruedLicenseFeeCurrent" xlink:label="loc_abus_AccruedLicenseFeeCurrent_842D5FF8573829AD13883409FEA427C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AccruedLicenseFeeCurrent_842D5FF8573829AD13883409FEA427C9" xlink:to="lab_abus_AccruedLicenseFeeCurrent_842D5FF8573829AD13883409FEA427C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_B037D407E18CC5803CEF3409FEA4C6BC_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_B037D407E18CC5803CEF3409FEA4C6BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fee accruals</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_B037D407E18CC5803CEF3409FEA4C6BC_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_B037D407E18CC5803CEF3409FEA4C6BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_B037D407E18CC5803CEF3409FEA4C6BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_B037D407E18CC5803CEF3409FEA4C6BC" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_B037D407E18CC5803CEF3409FEA4C6BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseIncentivePayableCurrent_250DE92085A5459125B93409FEA49148_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseIncentivePayableCurrent_250DE92085A5459125B93409FEA49148" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred lease inducements</link:label>
    <link:label id="lab_us-gaap_LeaseIncentivePayableCurrent_250DE92085A5459125B93409FEA49148_label_en-US" xlink:label="lab_us-gaap_LeaseIncentivePayableCurrent_250DE92085A5459125B93409FEA49148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Incentive, Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="loc_us-gaap_LeaseIncentivePayableCurrent_250DE92085A5459125B93409FEA49148" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseIncentivePayableCurrent_250DE92085A5459125B93409FEA49148" xlink:to="lab_us-gaap_LeaseIncentivePayableCurrent_250DE92085A5459125B93409FEA49148" xlink:type="arc" />
    <link:label id="lab_abus_AccruedPayrollCurrent_856718137475577EF0CF3409FEA4408E_terseLabel_en-US" xlink:label="lab_abus_AccruedPayrollCurrent_856718137475577EF0CF3409FEA4408E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll accruals</link:label>
    <link:label id="lab_abus_AccruedPayrollCurrent_856718137475577EF0CF3409FEA4408E_label_en-US" xlink:label="lab_abus_AccruedPayrollCurrent_856718137475577EF0CF3409FEA4408E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Payroll, Current</link:label>
    <link:label id="lab_abus_AccruedPayrollCurrent_856718137475577EF0CF3409FEA4408E_documentation_en-US" xlink:label="lab_abus_AccruedPayrollCurrent_856718137475577EF0CF3409FEA4408E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Payroll, Current</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_AccruedPayrollCurrent" xlink:label="loc_abus_AccruedPayrollCurrent_856718137475577EF0CF3409FEA4408E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AccruedPayrollCurrent_856718137475577EF0CF3409FEA4408E" xlink:to="lab_abus_AccruedPayrollCurrent_856718137475577EF0CF3409FEA4408E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D39D12D382E4CF14639D3409FEA433E6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D39D12D382E4CF14639D3409FEA433E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D39D12D382E4CF14639D3409FEA433E6_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D39D12D382E4CF14639D3409FEA433E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_D39D12D382E4CF14639D3409FEA433E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_D39D12D382E4CF14639D3409FEA433E6" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_D39D12D382E4CF14639D3409FEA433E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_339D11B273E287EDD8163409FEA4CCE8_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_339D11B273E287EDD8163409FEA4CCE8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_339D11B273E287EDD8163409FEA4CCE8_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_339D11B273E287EDD8163409FEA4CCE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_339D11B273E287EDD8163409FEA4CCE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_339D11B273E287EDD8163409FEA4CCE8" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_339D11B273E287EDD8163409FEA4CCE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_11348673CEC0A436A1F451CB6C9E4803_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_11348673CEC0A436A1F451CB6C9E4803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_11348673CEC0A436A1F451CB6C9E4803" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_11348673CEC0A436A1F451CB6C9E4803" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_11348673CEC0A436A1F451CB6C9E4803" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_E4DB1AAB8812BF4283A051CB6C9E2152_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_E4DB1AAB8812BF4283A051CB6C9E2152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_E4DB1AAB8812BF4283A051CB6C9E2152_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_E4DB1AAB8812BF4283A051CB6C9E2152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E4DB1AAB8812BF4283A051CB6C9E2152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_E4DB1AAB8812BF4283A051CB6C9E2152" xlink:to="lab_us-gaap_AwardTypeAxis_E4DB1AAB8812BF4283A051CB6C9E2152" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8" xlink:type="arc" />
    <link:label id="lab_abus_EquivalentNumberOfCompanyCommonSharesMember_146312698EE0506529AA51CB6C9FCB90_terseLabel_en-US" xlink:label="lab_abus_EquivalentNumberOfCompanyCommonSharesMember_146312698EE0506529AA51CB6C9FCB90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equivalent number of Company common shares</link:label>
    <link:label id="lab_abus_EquivalentNumberOfCompanyCommonSharesMember_146312698EE0506529AA51CB6C9FCB90_label_en-US" xlink:label="lab_abus_EquivalentNumberOfCompanyCommonSharesMember_146312698EE0506529AA51CB6C9FCB90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equivalent Number Of Company Common Shares [Member]</link:label>
    <link:label id="lab_abus_EquivalentNumberOfCompanyCommonSharesMember_146312698EE0506529AA51CB6C9FCB90_documentation_en-US" xlink:label="lab_abus_EquivalentNumberOfCompanyCommonSharesMember_146312698EE0506529AA51CB6C9FCB90" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the equivalent number of company common shares.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_EquivalentNumberOfCompanyCommonSharesMember" xlink:label="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_146312698EE0506529AA51CB6C9FCB90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_146312698EE0506529AA51CB6C9FCB90" xlink:to="lab_abus_EquivalentNumberOfCompanyCommonSharesMember_146312698EE0506529AA51CB6C9FCB90" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_10A136B0606997EDEC6351CB6C9F9A87_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_10A136B0606997EDEC6351CB6C9F9A87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_10A136B0606997EDEC6351CB6C9F9A87_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_10A136B0606997EDEC6351CB6C9F9A87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_10A136B0606997EDEC6351CB6C9F9A87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_10A136B0606997EDEC6351CB6C9F9A87" xlink:to="lab_us-gaap_PlanNameAxis_10A136B0606997EDEC6351CB6C9F9A87" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D" xlink:to="lab_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D" xlink:type="arc" />
    <link:label id="lab_abus_OnCoreOptionPlanMember_810B28D2585A8D9639EF51CB6C9F10E7_terseLabel_en-US" xlink:label="lab_abus_OnCoreOptionPlanMember_810B28D2585A8D9639EF51CB6C9F10E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OnCore Option Plan</link:label>
    <link:label id="lab_abus_OnCoreOptionPlanMember_810B28D2585A8D9639EF51CB6C9F10E7_label_en-US" xlink:label="lab_abus_OnCoreOptionPlanMember_810B28D2585A8D9639EF51CB6C9F10E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OnCore Option Plan [Member]</link:label>
    <link:label id="lab_abus_OnCoreOptionPlanMember_810B28D2585A8D9639EF51CB6C9F10E7_documentation_en-US" xlink:label="lab_abus_OnCoreOptionPlanMember_810B28D2585A8D9639EF51CB6C9F10E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OnCore Option Plan [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_OnCoreOptionPlanMember" xlink:label="loc_abus_OnCoreOptionPlanMember_810B28D2585A8D9639EF51CB6C9F10E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OnCoreOptionPlanMember_810B28D2585A8D9639EF51CB6C9F10E7" xlink:to="lab_abus_OnCoreOptionPlanMember_810B28D2585A8D9639EF51CB6C9F10E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13C0B169F08E2991C98651CB6C9FA8A1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13C0B169F08E2991C98651CB6C9FA8A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13C0B169F08E2991C98651CB6C9FA8A1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13C0B169F08E2991C98651CB6C9FA8A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13C0B169F08E2991C98651CB6C9FA8A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13C0B169F08E2991C98651CB6C9FA8A1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13C0B169F08E2991C98651CB6C9FA8A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F82B44D7B8EDE82FCE2251CB6C9F13DD_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F82B44D7B8EDE82FCE2251CB6C9F13DD" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance - Number of optioned common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F82B44D7B8EDE82FCE2251CB6C9F13DD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F82B44D7B8EDE82FCE2251CB6C9F13DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F82B44D7B8EDE82FCE2251CB6C9F13DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F82B44D7B8EDE82FCE2251CB6C9F13DD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F82B44D7B8EDE82FCE2251CB6C9F13DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23855B5812957BF382D851CB6C9F7DB0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23855B5812957BF382D851CB6C9F7DB0" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance - Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23855B5812957BF382D851CB6C9F7DB0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23855B5812957BF382D851CB6C9F7DB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23855B5812957BF382D851CB6C9F7DB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23855B5812957BF382D851CB6C9F7DB0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23855B5812957BF382D851CB6C9F7DB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E6FC854EAF2E5EE4B68251CB6C9F1869_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E6FC854EAF2E5EE4B68251CB6C9F1869" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E6FC854EAF2E5EE4B68251CB6C9F1869_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E6FC854EAF2E5EE4B68251CB6C9F1869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E6FC854EAF2E5EE4B68251CB6C9F1869" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E6FC854EAF2E5EE4B68251CB6C9F1869" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E6FC854EAF2E5EE4B68251CB6C9F1869" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9946190883E509433E3351CB6CA02686_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9946190883E509433E3351CB6CA02686" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options forfeited, canceled or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9946190883E509433E3351CB6CA02686_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9946190883E509433E3351CB6CA02686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9946190883E509433E3351CB6CA02686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9946190883E509433E3351CB6CA02686" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9946190883E509433E3351CB6CA02686" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04A57E601EA009AEF0051CB6CA09251_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04A57E601EA009AEF0051CB6CA09251" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance - Number of optioned common shares (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04A57E601EA009AEF0051CB6CA09251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04A57E601EA009AEF0051CB6CA09251" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04A57E601EA009AEF0051CB6CA09251" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3287FD198CF5C1B0EE3E51CB6CA072A0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3287FD198CF5C1B0EE3E51CB6CA072A0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance - Weighted average exercise price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3287FD198CF5C1B0EE3E51CB6CA072A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3287FD198CF5C1B0EE3E51CB6CA072A0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3287FD198CF5C1B0EE3E51CB6CA072A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8C0B13743D098164ABC62EAA60A4E6EB_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8C0B13743D098164ABC62EAA60A4E6EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8C0B13743D098164ABC62EAA60A4E6EB_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8C0B13743D098164ABC62EAA60A4E6EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8C0B13743D098164ABC62EAA60A4E6EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8C0B13743D098164ABC62EAA60A4E6EB" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8C0B13743D098164ABC62EAA60A4E6EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_B76E490037F7015E95AC5167E80F7A2C_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_B76E490037F7015E95AC5167E80F7A2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B76E490037F7015E95AC5167E80F7A2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B76E490037F7015E95AC5167E80F7A2C" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_B76E490037F7015E95AC5167E80F7A2C" xlink:type="arc" />
    <link:label id="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37_terseLabel_en-US" xlink:label="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</link:label>
    <link:label id="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37_label_en-US" xlink:label="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</link:label>
    <link:label id="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37_documentation_en-US" xlink:label="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" xlink:label="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37" xlink:to="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_B332CEA88CE4E2FF81E95167E80F0309_periodStartLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_B332CEA88CE4E2FF81E95167E80F0309" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Liability at beginning of the period</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_B332CEA88CE4E2FF81E95167E80F0309_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_B332CEA88CE4E2FF81E95167E80F0309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_B332CEA88CE4E2FF81E95167E80F0309" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_B332CEA88CE4E2FF81E95167E80F0309" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_B332CEA88CE4E2FF81E95167E80F0309" xlink:type="arc" />
    <link:label id="lab_abus_OpeningLiabilityOfWarrantsIssuedInThePeriod_0CFD902E011BDC2060F85167E80F675D_terseLabel_en-US" xlink:label="lab_abus_OpeningLiabilityOfWarrantsIssuedInThePeriod_0CFD902E011BDC2060F85167E80F675D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued in the period</link:label>
    <link:label id="lab_abus_OpeningLiabilityOfWarrantsIssuedInThePeriod_0CFD902E011BDC2060F85167E80F675D_label_en-US" xlink:label="lab_abus_OpeningLiabilityOfWarrantsIssuedInThePeriod_0CFD902E011BDC2060F85167E80F675D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Opening liability of warrants issued in the period</link:label>
    <link:label id="lab_abus_OpeningLiabilityOfWarrantsIssuedInThePeriod_0CFD902E011BDC2060F85167E80F675D_documentation_en-US" xlink:label="lab_abus_OpeningLiabilityOfWarrantsIssuedInThePeriod_0CFD902E011BDC2060F85167E80F675D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the opening liability of warrants issues in the period.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_OpeningLiabilityOfWarrantsIssuedInThePeriod" xlink:label="loc_abus_OpeningLiabilityOfWarrantsIssuedInThePeriod_0CFD902E011BDC2060F85167E80F675D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OpeningLiabilityOfWarrantsIssuedInThePeriod_0CFD902E011BDC2060F85167E80F675D" xlink:to="lab_abus_OpeningLiabilityOfWarrantsIssuedInThePeriod_0CFD902E011BDC2060F85167E80F675D" xlink:type="arc" />
    <link:label id="lab_abus_FairValueOfWarrantsExercisedInThePeriod_E8D454CC02E7A7E403075167E80FA4D8_negatedTerseLabel_en-US" xlink:label="lab_abus_FairValueOfWarrantsExercisedInThePeriod_E8D454CC02E7A7E403075167E80FA4D8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants exercised in the period</link:label>
    <link:label id="lab_abus_FairValueOfWarrantsExercisedInThePeriod_E8D454CC02E7A7E403075167E80FA4D8_label_en-US" xlink:label="lab_abus_FairValueOfWarrantsExercisedInThePeriod_E8D454CC02E7A7E403075167E80FA4D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FairValueOfWarrantsExercisedInThePeriod</link:label>
    <link:label id="lab_abus_FairValueOfWarrantsExercisedInThePeriod_E8D454CC02E7A7E403075167E80FA4D8_documentation_en-US" xlink:label="lab_abus_FairValueOfWarrantsExercisedInThePeriod_E8D454CC02E7A7E403075167E80FA4D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the fair value of warrants exercised in the period.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_FairValueOfWarrantsExercisedInThePeriod" xlink:label="loc_abus_FairValueOfWarrantsExercisedInThePeriod_E8D454CC02E7A7E403075167E80FA4D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_FairValueOfWarrantsExercisedInThePeriod_E8D454CC02E7A7E403075167E80FA4D8" xlink:to="lab_abus_FairValueOfWarrantsExercisedInThePeriod_E8D454CC02E7A7E403075167E80FA4D8" xlink:type="arc" />
    <link:label id="lab_abus_IncreaseDecreaseInValueOfWarrants_554B3238AF99D7BE1FE65167E80F281C_terseLabel_en-US" xlink:label="lab_abus_IncreaseDecreaseInValueOfWarrants_554B3238AF99D7BE1FE65167E80F281C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value of warrants</link:label>
    <link:label id="lab_abus_IncreaseDecreaseInValueOfWarrants_554B3238AF99D7BE1FE65167E80F281C_label_en-US" xlink:label="lab_abus_IncreaseDecreaseInValueOfWarrants_554B3238AF99D7BE1FE65167E80F281C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in value of warrants</link:label>
    <link:label id="lab_abus_IncreaseDecreaseInValueOfWarrants_554B3238AF99D7BE1FE65167E80F281C_documentation_en-US" xlink:label="lab_abus_IncreaseDecreaseInValueOfWarrants_554B3238AF99D7BE1FE65167E80F281C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the increase decrease in value of warrants.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_IncreaseDecreaseInValueOfWarrants" xlink:label="loc_abus_IncreaseDecreaseInValueOfWarrants_554B3238AF99D7BE1FE65167E80F281C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IncreaseDecreaseInValueOfWarrants_554B3238AF99D7BE1FE65167E80F281C" xlink:to="lab_abus_IncreaseDecreaseInValueOfWarrants_554B3238AF99D7BE1FE65167E80F281C" xlink:type="arc" />
    <link:label id="lab_abus_FairValueWarrantsForeignExchangeGainLoss_E6D050A79E1103DBE9A85167E80F5694_terseLabel_en-US" xlink:label="lab_abus_FairValueWarrantsForeignExchangeGainLoss_E6D050A79E1103DBE9A85167E80F5694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange loss</link:label>
    <link:label id="lab_abus_FairValueWarrantsForeignExchangeGainLoss_E6D050A79E1103DBE9A85167E80F5694_label_en-US" xlink:label="lab_abus_FairValueWarrantsForeignExchangeGainLoss_E6D050A79E1103DBE9A85167E80F5694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FairValueWarrantsForeignExchangeGainLoss</link:label>
    <link:label id="lab_abus_FairValueWarrantsForeignExchangeGainLoss_E6D050A79E1103DBE9A85167E80F5694_documentation_en-US" xlink:label="lab_abus_FairValueWarrantsForeignExchangeGainLoss_E6D050A79E1103DBE9A85167E80F5694" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of gains and losses from changes in foreign exchanges.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_FairValueWarrantsForeignExchangeGainLoss" xlink:label="loc_abus_FairValueWarrantsForeignExchangeGainLoss_E6D050A79E1103DBE9A85167E80F5694" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_FairValueWarrantsForeignExchangeGainLoss_E6D050A79E1103DBE9A85167E80F5694" xlink:to="lab_abus_FairValueWarrantsForeignExchangeGainLoss_E6D050A79E1103DBE9A85167E80F5694" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_BACA4068FC11CD21F1345167E80FFD98_periodEndLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_BACA4068FC11CD21F1345167E80FFD98" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Liability at end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_BACA4068FC11CD21F1345167E80FFD98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_BACA4068FC11CD21F1345167E80FFD98" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_BACA4068FC11CD21F1345167E80FFD98" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_362D3EBE7C78868BF0B433A2017A1ED0_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_362D3EBE7C78868BF0B433A2017A1ED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_362D3EBE7C78868BF0B433A2017A1ED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_362D3EBE7C78868BF0B433A2017A1ED0" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_362D3EBE7C78868BF0B433A2017A1ED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E910DE13C9C2C013263933A2017A7C6C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E910DE13C9C2C013263933A2017A7C6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of interim financial data (unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E910DE13C9C2C013263933A2017A7C6C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E910DE13C9C2C013263933A2017A7C6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E910DE13C9C2C013263933A2017A7C6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E910DE13C9C2C013263933A2017A7C6C" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E910DE13C9C2C013263933A2017A7C6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_99FD32139BABAC9EB2D92EAA60FD725B_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_99FD32139BABAC9EB2D92EAA60FD725B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_99FD32139BABAC9EB2D92EAA60FD725B_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_99FD32139BABAC9EB2D92EAA60FD725B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_99FD32139BABAC9EB2D92EAA60FD725B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_99FD32139BABAC9EB2D92EAA60FD725B" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_99FD32139BABAC9EB2D92EAA60FD725B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueDisclosureAbstract_5F9700007F17A39347503A61681D97AF_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueDisclosureAbstract_5F9700007F17A39347503A61681D97AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_5F9700007F17A39347503A61681D97AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_5F9700007F17A39347503A61681D97AF" xlink:to="lab_us-gaap_DeferredRevenueDisclosureAbstract_5F9700007F17A39347503A61681D97AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_116BE26B05CC972B01903A616823642C_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_116BE26B05CC972B01903A616823642C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborations, contracts and licensing agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_116BE26B05CC972B01903A616823642C_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_116BE26B05CC972B01903A616823642C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_116BE26B05CC972B01903A616823642C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_116BE26B05CC972B01903A616823642C" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_116BE26B05CC972B01903A616823642C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E939593931D164C298065167E77AF01B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E939593931D164C298065167E77AF01B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computed taxes (recoveries) at Canadian federal and provincial tax rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E939593931D164C298065167E77AF01B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E939593931D164C298065167E77AF01B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E939593931D164C298065167E77AF01B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E939593931D164C298065167E77AF01B" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E939593931D164C298065167E77AF01B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2AC82367FEF2C4FA37ED5167E77AB3DD_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2AC82367FEF2C4FA37ED5167E77AB3DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Differences due to change in enacted tax rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2AC82367FEF2C4FA37ED5167E77AB3DD_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2AC82367FEF2C4FA37ED5167E77AB3DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2AC82367FEF2C4FA37ED5167E77AB3DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2AC82367FEF2C4FA37ED5167E77AB3DD" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2AC82367FEF2C4FA37ED5167E77AB3DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_37C1846D313D52E2192C5167E77AF8DE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_37C1846D313D52E2192C5167E77AF8DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent and other differences</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_37C1846D313D52E2192C5167E77AF8DE_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_37C1846D313D52E2192C5167E77AF8DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_37C1846D313D52E2192C5167E77AF8DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_37C1846D313D52E2192C5167E77AF8DE" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_37C1846D313D52E2192C5167E77AF8DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_BA2E14388FF4C2D10B555167E77AE20C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_BA2E14388FF4C2D10B555167E77AE20C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance - other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_BA2E14388FF4C2D10B555167E77AE20C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_BA2E14388FF4C2D10B555167E77AE20C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_BA2E14388FF4C2D10B555167E77AE20C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_BA2E14388FF4C2D10B555167E77AE20C" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_BA2E14388FF4C2D10B555167E77AE20C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8A91EC1BBEFC5134791D5167E77A6345_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8A91EC1BBEFC5134791D5167E77A6345" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference due to income taxed at foreign rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8A91EC1BBEFC5134791D5167E77A6345_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8A91EC1BBEFC5134791D5167E77A6345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8A91EC1BBEFC5134791D5167E77A6345" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8A91EC1BBEFC5134791D5167E77A6345" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8A91EC1BBEFC5134791D5167E77A6345" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_D541F50F9A522C8287C65167E77A7426_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_D541F50F9A522C8287C65167E77A7426" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax recovery</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_D541F50F9A522C8287C65167E77A7426_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_D541F50F9A522C8287C65167E77A7426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_D541F50F9A522C8287C65167E77A7426" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_D541F50F9A522C8287C65167E77A7426" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_D541F50F9A522C8287C65167E77A7426" xlink:type="arc" />
    <link:label id="lab_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward_C26E632073A9A1C689DA5190336EDE70_terseLabel_en-US" xlink:label="lab_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward_C26E632073A9A1C689DA5190336EDE70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration Fair Value, Liability [Roll Forward]</link:label>
    <link:label id="lab_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward_C26E632073A9A1C689DA5190336EDE70_label_en-US" xlink:label="lab_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward_C26E632073A9A1C689DA5190336EDE70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration Fair Value, Liability [Roll Forward]</link:label>
    <link:label id="lab_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward_C26E632073A9A1C689DA5190336EDE70_documentation_en-US" xlink:label="lab_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward_C26E632073A9A1C689DA5190336EDE70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration Fair Value, Liability [Roll Forward]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward" xlink:label="loc_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward_C26E632073A9A1C689DA5190336EDE70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward_C26E632073A9A1C689DA5190336EDE70" xlink:to="lab_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward_C26E632073A9A1C689DA5190336EDE70" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3A25095241C0282A01D35167E80D87A3_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3A25095241C0282A01D35167E80D87A3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Liability at beginning of the period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3A25095241C0282A01D35167E80D87A3_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3A25095241C0282A01D35167E80D87A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3A25095241C0282A01D35167E80D87A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3A25095241C0282A01D35167E80D87A3" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3A25095241C0282A01D35167E80D87A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_45E035B6D900A02700585167E80D2E05_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_45E035B6D900A02700585167E80D2E05" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_45E035B6D900A02700585167E80D2E05_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_45E035B6D900A02700585167E80D2E05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_45E035B6D900A02700585167E80D2E05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_45E035B6D900A02700585167E80D2E05" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_45E035B6D900A02700585167E80D2E05" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3CAA47A99F6E366F5C705167E80D0892_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3CAA47A99F6E366F5C705167E80D0892" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Liability at end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3CAA47A99F6E366F5C705167E80D0892" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3CAA47A99F6E366F5C705167E80D0892" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3CAA47A99F6E366F5C705167E80D0892" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_2B5882A50D609298EA39385C7CBDA8DB_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_2B5882A50D609298EA39385C7CBDA8DB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2B5882A50D609298EA39385C7CBDA8DB_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_2B5882A50D609298EA39385C7CBDA8DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2B5882A50D609298EA39385C7CBDA8DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_2B5882A50D609298EA39385C7CBDA8DB" xlink:to="lab_us-gaap_NetIncomeLoss_2B5882A50D609298EA39385C7CBDA8DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3DCA7E527680B1662DB0385C7CBD4A46_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3DCA7E527680B1662DB0385C7CBD4A46" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3DCA7E527680B1662DB0385C7CBD4A46_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3DCA7E527680B1662DB0385C7CBD4A46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3DCA7E527680B1662DB0385C7CBD4A46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3DCA7E527680B1662DB0385C7CBD4A46" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3DCA7E527680B1662DB0385C7CBD4A46" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_A27204E23F51C7C23571385C7CBDA38D_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_A27204E23F51C7C23571385C7CBDA38D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic income (loss) per common share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_A27204E23F51C7C23571385C7CBDA38D_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_A27204E23F51C7C23571385C7CBDA38D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_A27204E23F51C7C23571385C7CBDA38D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_A27204E23F51C7C23571385C7CBDA38D" xlink:to="lab_us-gaap_EarningsPerShareBasic_A27204E23F51C7C23571385C7CBDA38D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7C435E71536D44B7D13A385C7CBDC6C3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_7C435E71536D44B7D13A385C7CBDC6C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted income (loss) per common share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7C435E71536D44B7D13A385C7CBDC6C3_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_7C435E71536D44B7D13A385C7CBDC6C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7C435E71536D44B7D13A385C7CBDC6C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_7C435E71536D44B7D13A385C7CBDC6C3" xlink:to="lab_us-gaap_EarningsPerShareDiluted_7C435E71536D44B7D13A385C7CBDC6C3" xlink:type="arc" />
    <link:label id="lab_abus_ProtivaOptionPlanMember_6FB2EC3A34FE74ACFE1F33AEF39B6614_terseLabel_en-US" xlink:label="lab_abus_ProtivaOptionPlanMember_6FB2EC3A34FE74ACFE1F33AEF39B6614" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Protiva Option Plan</link:label>
    <link:label id="lab_abus_ProtivaOptionPlanMember_6FB2EC3A34FE74ACFE1F33AEF39B6614_label_en-US" xlink:label="lab_abus_ProtivaOptionPlanMember_6FB2EC3A34FE74ACFE1F33AEF39B6614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Protiva Option Plan [Member]</link:label>
    <link:label id="lab_abus_ProtivaOptionPlanMember_6FB2EC3A34FE74ACFE1F33AEF39B6614_documentation_en-US" xlink:label="lab_abus_ProtivaOptionPlanMember_6FB2EC3A34FE74ACFE1F33AEF39B6614" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Protiva Option Plan [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ProtivaOptionPlanMember" xlink:label="loc_abus_ProtivaOptionPlanMember_6FB2EC3A34FE74ACFE1F33AEF39B6614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ProtivaOptionPlanMember_6FB2EC3A34FE74ACFE1F33AEF39B6614" xlink:to="lab_abus_ProtivaOptionPlanMember_6FB2EC3A34FE74ACFE1F33AEF39B6614" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9B55D9165AD48D6ABF3333A201FB5A4F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9B55D9165AD48D6ABF3333A201FB5A4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of warrant activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9B55D9165AD48D6ABF3333A201FB5A4F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9B55D9165AD48D6ABF3333A201FB5A4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9B55D9165AD48D6ABF3333A201FB5A4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9B55D9165AD48D6ABF3333A201FB5A4F" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9B55D9165AD48D6ABF3333A201FB5A4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CB98BB6FD6020DDAD1CB33A201FBDA43_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CB98BB6FD6020DDAD1CB33A201FBDA43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of weighted average Black-Scholes option-pricing assumptions and resultant fair values</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CB98BB6FD6020DDAD1CB33A201FBDA43_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CB98BB6FD6020DDAD1CB33A201FBDA43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CB98BB6FD6020DDAD1CB33A201FBDA43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CB98BB6FD6020DDAD1CB33A201FBDA43" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CB98BB6FD6020DDAD1CB33A201FBDA43" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F13BF2A8758FAAE1F68133A201FB04E1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F13BF2A8758FAAE1F68133A201FB04E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock option activity for the Arbutus Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F13BF2A8758FAAE1F68133A201FB04E1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F13BF2A8758FAAE1F68133A201FB04E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F13BF2A8758FAAE1F68133A201FB04E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F13BF2A8758FAAE1F68133A201FB04E1" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F13BF2A8758FAAE1F68133A201FB04E1" xlink:type="arc" />
    <link:label id="lab_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_C523790D434218EDAB8433A201FB17EA_terseLabel_en-US" xlink:label="lab_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_C523790D434218EDAB8433A201FB17EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of stock options outstanding by exercise price range</link:label>
    <link:label id="lab_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_C523790D434218EDAB8433A201FB17EA_label_en-US" xlink:label="lab_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_C523790D434218EDAB8433A201FB17EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporal Diagram of Share Based Compensation Shares Authorized Under Stock Option Plans by Exercise Price Range [Table Text Block]</link:label>
    <link:label id="lab_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_C523790D434218EDAB8433A201FB17EA_documentation_en-US" xlink:label="lab_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_C523790D434218EDAB8433A201FB17EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the schedule of share based compensation for the shares authorized under the stock option plan.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:label="loc_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_C523790D434218EDAB8433A201FB17EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_C523790D434218EDAB8433A201FB17EA" xlink:to="lab_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_C523790D434218EDAB8433A201FB17EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_7D13CCE808523AB5EFA633A201FB48C0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_7D13CCE808523AB5EFA633A201FB48C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of non-vested stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_7D13CCE808523AB5EFA633A201FB48C0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_7D13CCE808523AB5EFA633A201FB48C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_7D13CCE808523AB5EFA633A201FB48C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_7D13CCE808523AB5EFA633A201FB48C0" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_7D13CCE808523AB5EFA633A201FB48C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C048482A9F67197ADE8533A201FB4A53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C048482A9F67197ADE8533A201FB4A53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of weighted average option pricing assumptions and the resultant fair values</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C048482A9F67197ADE8533A201FB4A53_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C048482A9F67197ADE8533A201FB4A53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C048482A9F67197ADE8533A201FB4A53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C048482A9F67197ADE8533A201FB4A53" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C048482A9F67197ADE8533A201FB4A53" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_43A0ED03AB39AE2A50BF33A201FB9C51_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_43A0ED03AB39AE2A50BF33A201FB9C51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of option activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_43A0ED03AB39AE2A50BF33A201FB9C51_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_43A0ED03AB39AE2A50BF33A201FB9C51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_43A0ED03AB39AE2A50BF33A201FB9C51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_43A0ED03AB39AE2A50BF33A201FB9C51" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_43A0ED03AB39AE2A50BF33A201FB9C51" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B91DD6A242950CA8A34F33A201FB678B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B91DD6A242950CA8A34F33A201FB678B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of allocation of stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B91DD6A242950CA8A34F33A201FB678B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B91DD6A242950CA8A34F33A201FB678B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B91DD6A242950CA8A34F33A201FB678B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B91DD6A242950CA8A34F33A201FB678B" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B91DD6A242950CA8A34F33A201FB678B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1B869857FD90A656A26E33EB41E2FD95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1B869857FD90A656A26E33EB41E2FD95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1B869857FD90A656A26E33EB41E2FD95_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1B869857FD90A656A26E33EB41E2FD95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1B869857FD90A656A26E33EB41E2FD95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1B869857FD90A656A26E33EB41E2FD95" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1B869857FD90A656A26E33EB41E2FD95" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_A82AC769DA8B12C2257B3A13C6027A0D_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_A82AC769DA8B12C2257B3A13C6027A0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_A82AC769DA8B12C2257B3A13C6027A0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_A82AC769DA8B12C2257B3A13C6027A0D" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_A82AC769DA8B12C2257B3A13C6027A0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_C1D89D513DDD0E1138703A13C6039200_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_C1D89D513DDD0E1138703A13C6039200" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_C1D89D513DDD0E1138703A13C6039200_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_C1D89D513DDD0E1138703A13C6039200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C1D89D513DDD0E1138703A13C6039200" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C1D89D513DDD0E1138703A13C6039200" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_C1D89D513DDD0E1138703A13C6039200" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D" xlink:type="arc" />
    <link:label id="lab_abus_ArbutusInc.Member_9EBE9A1E2AFA965807FC3A13C6043BCE_terseLabel_en-US" xlink:label="lab_abus_ArbutusInc.Member_9EBE9A1E2AFA965807FC3A13C6043BCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arbutus Inc.</link:label>
    <link:label id="lab_abus_ArbutusInc.Member_9EBE9A1E2AFA965807FC3A13C6043BCE_label_en-US" xlink:label="lab_abus_ArbutusInc.Member_9EBE9A1E2AFA965807FC3A13C6043BCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arbutus Inc. [Member]</link:label>
    <link:label id="lab_abus_ArbutusInc.Member_9EBE9A1E2AFA965807FC3A13C6043BCE_documentation_en-US" xlink:label="lab_abus_ArbutusInc.Member_9EBE9A1E2AFA965807FC3A13C6043BCE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Arbutus Inc. [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_9EBE9A1E2AFA965807FC3A13C6043BCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ArbutusInc.Member_9EBE9A1E2AFA965807FC3A13C6043BCE" xlink:to="lab_abus_ArbutusInc.Member_9EBE9A1E2AFA965807FC3A13C6043BCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7DAEFBE4B6FFC49ECF533A13C604771F_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7DAEFBE4B6FFC49ECF533A13C604771F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7DAEFBE4B6FFC49ECF533A13C604771F_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7DAEFBE4B6FFC49ECF533A13C604771F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7DAEFBE4B6FFC49ECF533A13C604771F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7DAEFBE4B6FFC49ECF533A13C604771F" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7DAEFBE4B6FFC49ECF533A13C604771F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:type="arc" />
    <link:label id="lab_abus_IPRDCyclophilinsMember_DB47B65C1986953429563A13C6044BEA_terseLabel_en-US" xlink:label="lab_abus_IPRDCyclophilinsMember_DB47B65C1986953429563A13C6044BEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D Cyclophilins</link:label>
    <link:label id="lab_abus_IPRDCyclophilinsMember_DB47B65C1986953429563A13C6044BEA_label_en-US" xlink:label="lab_abus_IPRDCyclophilinsMember_DB47B65C1986953429563A13C6044BEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPR&amp;D Cyclophilins [Member]</link:label>
    <link:label id="lab_abus_IPRDCyclophilinsMember_DB47B65C1986953429563A13C6044BEA_documentation_en-US" xlink:label="lab_abus_IPRDCyclophilinsMember_DB47B65C1986953429563A13C6044BEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IPR&amp;D Cyclophilins [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_IPRDCyclophilinsMember" xlink:label="loc_abus_IPRDCyclophilinsMember_DB47B65C1986953429563A13C6044BEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IPRDCyclophilinsMember_DB47B65C1986953429563A13C6044BEA" xlink:to="lab_abus_IPRDCyclophilinsMember_DB47B65C1986953429563A13C6044BEA" xlink:type="arc" />
    <link:label id="lab_abus_IPRDImmuneModulatorsMember_394330645A4A821AA7E13A13DDF1AAE9_terseLabel_en-US" xlink:label="lab_abus_IPRDImmuneModulatorsMember_394330645A4A821AA7E13A13DDF1AAE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D Immune Modulators</link:label>
    <link:label id="lab_abus_IPRDImmuneModulatorsMember_394330645A4A821AA7E13A13DDF1AAE9_label_en-US" xlink:label="lab_abus_IPRDImmuneModulatorsMember_394330645A4A821AA7E13A13DDF1AAE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPR&amp;D Immune Modulators [Member]</link:label>
    <link:label id="lab_abus_IPRDImmuneModulatorsMember_394330645A4A821AA7E13A13DDF1AAE9_documentation_en-US" xlink:label="lab_abus_IPRDImmuneModulatorsMember_394330645A4A821AA7E13A13DDF1AAE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IPR&amp;D Immune Modulators [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_IPRDImmuneModulatorsMember" xlink:label="loc_abus_IPRDImmuneModulatorsMember_394330645A4A821AA7E13A13DDF1AAE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IPRDImmuneModulatorsMember_394330645A4A821AA7E13A13DDF1AAE9" xlink:to="lab_abus_IPRDImmuneModulatorsMember_394330645A4A821AA7E13A13DDF1AAE9" xlink:type="arc" />
    <link:label id="lab_abus_IPRDAntigenInhibitorsMember_C646387965FB4F4D07543A13DF12471D_terseLabel_en-US" xlink:label="lab_abus_IPRDAntigenInhibitorsMember_C646387965FB4F4D07543A13DF12471D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D Antigen Inhibitors</link:label>
    <link:label id="lab_abus_IPRDAntigenInhibitorsMember_C646387965FB4F4D07543A13DF12471D_label_en-US" xlink:label="lab_abus_IPRDAntigenInhibitorsMember_C646387965FB4F4D07543A13DF12471D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPR&amp;D Antigen Inhibitors [Member]</link:label>
    <link:label id="lab_abus_IPRDAntigenInhibitorsMember_C646387965FB4F4D07543A13DF12471D_documentation_en-US" xlink:label="lab_abus_IPRDAntigenInhibitorsMember_C646387965FB4F4D07543A13DF12471D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IPR&amp;D Antigen Inhibitors [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_IPRDAntigenInhibitorsMember" xlink:label="loc_abus_IPRDAntigenInhibitorsMember_C646387965FB4F4D07543A13DF12471D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IPRDAntigenInhibitorsMember_C646387965FB4F4D07543A13DF12471D" xlink:to="lab_abus_IPRDAntigenInhibitorsMember_C646387965FB4F4D07543A13DF12471D" xlink:type="arc" />
    <link:label id="lab_abus_IPRDcccDNASterilizersMember_27D502512DF3DAF6E18B3A13DFA927ED_terseLabel_en-US" xlink:label="lab_abus_IPRDcccDNASterilizersMember_27D502512DF3DAF6E18B3A13DFA927ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D cccDNA Sterilizers</link:label>
    <link:label id="lab_abus_IPRDcccDNASterilizersMember_27D502512DF3DAF6E18B3A13DFA927ED_label_en-US" xlink:label="lab_abus_IPRDcccDNASterilizersMember_27D502512DF3DAF6E18B3A13DFA927ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPR&amp;D cccDNA Sterilizers [Member]</link:label>
    <link:label id="lab_abus_IPRDcccDNASterilizersMember_27D502512DF3DAF6E18B3A13DFA927ED_documentation_en-US" xlink:label="lab_abus_IPRDcccDNASterilizersMember_27D502512DF3DAF6E18B3A13DFA927ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IPR&amp;D cccDNA Sterilizers [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_IPRDcccDNASterilizersMember" xlink:label="loc_abus_IPRDcccDNASterilizersMember_27D502512DF3DAF6E18B3A13DFA927ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IPRDcccDNASterilizersMember_27D502512DF3DAF6E18B3A13DFA927ED" xlink:to="lab_abus_IPRDcccDNASterilizersMember_27D502512DF3DAF6E18B3A13DFA927ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_552AFF5E4B84B767BA953A13C6045A77_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_552AFF5E4B84B767BA953A13C6045A77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_552AFF5E4B84B767BA953A13C6045A77_label_en-US" xlink:label="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_552AFF5E4B84B767BA953A13C6045A77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_552AFF5E4B84B767BA953A13C6045A77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_552AFF5E4B84B767BA953A13C6045A77" xlink:to="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_552AFF5E4B84B767BA953A13C6045A77" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_A0F0A4816FF1E52C9AD93A13C604CE8B_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_A0F0A4816FF1E52C9AD93A13C604CE8B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, carrying value after impairments</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_A0F0A4816FF1E52C9AD93A13C604CE8B_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_A0F0A4816FF1E52C9AD93A13C604CE8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A0F0A4816FF1E52C9AD93A13C604CE8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A0F0A4816FF1E52C9AD93A13C604CE8B" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_A0F0A4816FF1E52C9AD93A13C604CE8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3F4194F76462C4AB1A23A624D523CED_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3F4194F76462C4AB1A23A624D523CED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3F4194F76462C4AB1A23A624D523CED_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3F4194F76462C4AB1A23A624D523CED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3F4194F76462C4AB1A23A624D523CED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3F4194F76462C4AB1A23A624D523CED" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3F4194F76462C4AB1A23A624D523CED" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_806498FF6AB3E473E54E3A624D523A1D_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_806498FF6AB3E473E54E3A624D523A1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_806498FF6AB3E473E54E3A624D523A1D_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_806498FF6AB3E473E54E3A624D523A1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_806498FF6AB3E473E54E3A624D523A1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_806498FF6AB3E473E54E3A624D523A1D" xlink:to="lab_us-gaap_CounterpartyNameAxis_806498FF6AB3E473E54E3A624D523A1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_BBAEA845BEDD7E83BF973A624D520450" xlink:type="arc" />
    <link:label id="lab_abus_DoDMember_4521AF9606A65EF13B0B3A624D5235FF_terseLabel_en-US" xlink:label="lab_abus_DoDMember_4521AF9606A65EF13B0B3A624D5235FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DoD</link:label>
    <link:label id="lab_abus_DoDMember_4521AF9606A65EF13B0B3A624D5235FF_label_en-US" xlink:label="lab_abus_DoDMember_4521AF9606A65EF13B0B3A624D5235FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Do D [Member]</link:label>
    <link:label id="lab_abus_DoDMember_4521AF9606A65EF13B0B3A624D5235FF_documentation_en-US" xlink:label="lab_abus_DoDMember_4521AF9606A65EF13B0B3A624D5235FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the department of defense.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_DoDMember" xlink:label="loc_abus_DoDMember_4521AF9606A65EF13B0B3A624D5235FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_DoDMember_4521AF9606A65EF13B0B3A624D5235FF" xlink:to="lab_abus_DoDMember_4521AF9606A65EF13B0B3A624D5235FF" xlink:type="arc" />
    <link:label id="lab_abus_MonsantoMember_B66E5CA1FD69649556F23A624D529244_terseLabel_en-US" xlink:label="lab_abus_MonsantoMember_B66E5CA1FD69649556F23A624D529244" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monsanto</link:label>
    <link:label id="lab_abus_MonsantoMember_B66E5CA1FD69649556F23A624D529244_label_en-US" xlink:label="lab_abus_MonsantoMember_B66E5CA1FD69649556F23A624D529244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monsanto [Member]</link:label>
    <link:label id="lab_abus_MonsantoMember_B66E5CA1FD69649556F23A624D529244_documentation_en-US" xlink:label="lab_abus_MonsantoMember_B66E5CA1FD69649556F23A624D529244" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the company Monsanto.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_MonsantoMember" xlink:label="loc_abus_MonsantoMember_B66E5CA1FD69649556F23A624D529244" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_MonsantoMember_B66E5CA1FD69649556F23A624D529244" xlink:to="lab_abus_MonsantoMember_B66E5CA1FD69649556F23A624D529244" xlink:type="arc" />
    <link:label id="lab_abus_BMSMember_B3DF153DDF3249856F333A624D5293B0_terseLabel_en-US" xlink:label="lab_abus_BMSMember_B3DF153DDF3249856F333A624D5293B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BMS</link:label>
    <link:label id="lab_abus_BMSMember_B3DF153DDF3249856F333A624D5293B0_label_en-US" xlink:label="lab_abus_BMSMember_B3DF153DDF3249856F333A624D5293B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BMS [Member]</link:label>
    <link:label id="lab_abus_BMSMember_B3DF153DDF3249856F333A624D5293B0_documentation_en-US" xlink:label="lab_abus_BMSMember_B3DF153DDF3249856F333A624D5293B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Bristol Myers Squibb.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BMSMember" xlink:label="loc_abus_BMSMember_B3DF153DDF3249856F333A624D5293B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BMSMember_B3DF153DDF3249856F333A624D5293B0" xlink:to="lab_abus_BMSMember_B3DF153DDF3249856F333A624D5293B0" xlink:type="arc" />
    <link:label id="lab_abus_AlnylamLicenseAgreementMember_86428C977DDCCBADAF8B3A624D52DA4A_terseLabel_en-US" xlink:label="lab_abus_AlnylamLicenseAgreementMember_86428C977DDCCBADAF8B3A624D52DA4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alnylam License Agreement</link:label>
    <link:label id="lab_abus_AlnylamLicenseAgreementMember_86428C977DDCCBADAF8B3A624D52DA4A_label_en-US" xlink:label="lab_abus_AlnylamLicenseAgreementMember_86428C977DDCCBADAF8B3A624D52DA4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alnylam License Agreement [Member]</link:label>
    <link:label id="lab_abus_AlnylamLicenseAgreementMember_86428C977DDCCBADAF8B3A624D52DA4A_documentation_en-US" xlink:label="lab_abus_AlnylamLicenseAgreementMember_86428C977DDCCBADAF8B3A624D52DA4A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Alnylam License Agreement.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_AlnylamLicenseAgreementMember" xlink:label="loc_abus_AlnylamLicenseAgreementMember_86428C977DDCCBADAF8B3A624D52DA4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AlnylamLicenseAgreementMember_86428C977DDCCBADAF8B3A624D52DA4A" xlink:to="lab_abus_AlnylamLicenseAgreementMember_86428C977DDCCBADAF8B3A624D52DA4A" xlink:type="arc" />
    <link:label id="lab_abus_DicernaMember_051C4C3B4BAC32B77D6B3A624D525079_terseLabel_en-US" xlink:label="lab_abus_DicernaMember_051C4C3B4BAC32B77D6B3A624D525079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dicerna</link:label>
    <link:label id="lab_abus_DicernaMember_051C4C3B4BAC32B77D6B3A624D525079_label_en-US" xlink:label="lab_abus_DicernaMember_051C4C3B4BAC32B77D6B3A624D525079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dicerna [Member]</link:label>
    <link:label id="lab_abus_DicernaMember_051C4C3B4BAC32B77D6B3A624D525079_documentation_en-US" xlink:label="lab_abus_DicernaMember_051C4C3B4BAC32B77D6B3A624D525079" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Dicerna pharmaceuticals.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_DicernaMember" xlink:label="loc_abus_DicernaMember_051C4C3B4BAC32B77D6B3A624D525079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_DicernaMember_051C4C3B4BAC32B77D6B3A624D525079" xlink:to="lab_abus_DicernaMember_051C4C3B4BAC32B77D6B3A624D525079" xlink:type="arc" />
    <link:label id="lab_abus_OtherRNAiCollaboratorsMember_C123DC4F733391E76CF03A624D52FF95_terseLabel_en-US" xlink:label="lab_abus_OtherRNAiCollaboratorsMember_C123DC4F733391E76CF03A624D52FF95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other RNAi Collaborators</link:label>
    <link:label id="lab_abus_OtherRNAiCollaboratorsMember_C123DC4F733391E76CF03A624D52FF95_label_en-US" xlink:label="lab_abus_OtherRNAiCollaboratorsMember_C123DC4F733391E76CF03A624D52FF95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other RN Ai Collaborators [Member]</link:label>
    <link:label id="lab_abus_OtherRNAiCollaboratorsMember_C123DC4F733391E76CF03A624D52FF95_documentation_en-US" xlink:label="lab_abus_OtherRNAiCollaboratorsMember_C123DC4F733391E76CF03A624D52FF95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the other collaborators working with The Company to develop and implement Ribonucleic acid interference technology.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_OtherRNAiCollaboratorsMember" xlink:label="loc_abus_OtherRNAiCollaboratorsMember_C123DC4F733391E76CF03A624D52FF95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OtherRNAiCollaboratorsMember_C123DC4F733391E76CF03A624D52FF95" xlink:to="lab_abus_OtherRNAiCollaboratorsMember_C123DC4F733391E76CF03A624D52FF95" xlink:type="arc" />
    <link:label id="lab_abus_SpectrumMember_A089079545CF9793FCDC3A624D52D09A_terseLabel_en-US" xlink:label="lab_abus_SpectrumMember_A089079545CF9793FCDC3A624D52D09A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Spectrum</link:label>
    <link:label id="lab_abus_SpectrumMember_A089079545CF9793FCDC3A624D52D09A_label_en-US" xlink:label="lab_abus_SpectrumMember_A089079545CF9793FCDC3A624D52D09A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spectrum [Member]</link:label>
    <link:label id="lab_abus_SpectrumMember_A089079545CF9793FCDC3A624D52D09A_documentation_en-US" xlink:label="lab_abus_SpectrumMember_A089079545CF9793FCDC3A624D52D09A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the company Spectrum.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_SpectrumMember" xlink:label="loc_abus_SpectrumMember_A089079545CF9793FCDC3A624D52D09A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_SpectrumMember_A089079545CF9793FCDC3A624D52D09A" xlink:to="lab_abus_SpectrumMember_A089079545CF9793FCDC3A624D52D09A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9CF88A80E3B5F08818B3A624D52EFD0_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9CF88A80E3B5F08818B3A624D52EFD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9CF88A80E3B5F08818B3A624D52EFD0_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9CF88A80E3B5F08818B3A624D52EFD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9CF88A80E3B5F08818B3A624D52EFD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9CF88A80E3B5F08818B3A624D52EFD0" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9CF88A80E3B5F08818B3A624D52EFD0" xlink:type="arc" />
    <link:label id="lab_abus_CollaborationsAndContractsAbstract_85B9207C91C3FA77A2E93A624D526C09_terseLabel_en-US" xlink:label="lab_abus_CollaborationsAndContractsAbstract_85B9207C91C3FA77A2E93A624D526C09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborations and contracts</link:label>
    <link:label id="lab_abus_CollaborationsAndContractsAbstract_85B9207C91C3FA77A2E93A624D526C09_label_en-US" xlink:label="lab_abus_CollaborationsAndContractsAbstract_85B9207C91C3FA77A2E93A624D526C09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CollaborationsAndContractsAbstract</link:label>
    <link:label id="lab_abus_CollaborationsAndContractsAbstract_85B9207C91C3FA77A2E93A624D526C09_documentation_en-US" xlink:label="lab_abus_CollaborationsAndContractsAbstract_85B9207C91C3FA77A2E93A624D526C09" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="abus-20151231.xsd#abus_CollaborationsAndContractsAbstract" xlink:label="loc_abus_CollaborationsAndContractsAbstract_85B9207C91C3FA77A2E93A624D526C09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_CollaborationsAndContractsAbstract_85B9207C91C3FA77A2E93A624D526C09" xlink:to="lab_abus_CollaborationsAndContractsAbstract_85B9207C91C3FA77A2E93A624D526C09" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractsRevenue_1E29C85268EB860801513A624D529EB6_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractsRevenue_1E29C85268EB860801513A624D529EB6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contracts revenue</link:label>
    <link:label id="lab_us-gaap_ContractsRevenue_1E29C85268EB860801513A624D529EB6_label_en-US" xlink:label="lab_us-gaap_ContractsRevenue_1E29C85268EB860801513A624D529EB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contracts Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_1E29C85268EB860801513A624D529EB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractsRevenue_1E29C85268EB860801513A624D529EB6" xlink:to="lab_us-gaap_ContractsRevenue_1E29C85268EB860801513A624D529EB6" xlink:type="arc" />
    <link:label id="lab_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_C0738CE99416F8D2422A3A624D532589_terseLabel_en-US" xlink:label="lab_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_C0738CE99416F8D2422A3A624D532589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing fees, milestone and royalty payments</link:label>
    <link:label id="lab_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_C0738CE99416F8D2422A3A624D532589_label_en-US" xlink:label="lab_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_C0738CE99416F8D2422A3A624D532589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LicensingFeesMilestoneAndRoyaltyPaymentsAbstract</link:label>
    <link:label id="lab_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_C0738CE99416F8D2422A3A624D532589_documentation_en-US" xlink:label="lab_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_C0738CE99416F8D2422A3A624D532589" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="abus-20151231.xsd#abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract" xlink:label="loc_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_C0738CE99416F8D2422A3A624D532589" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_C0738CE99416F8D2422A3A624D532589" xlink:to="lab_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_C0738CE99416F8D2422A3A624D532589" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensesRevenue_DB372064670D8FE018373A624D53A555_terseLabel_en-US" xlink:label="lab_us-gaap_LicensesRevenue_DB372064670D8FE018373A624D53A555" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing fees, milestone and royalty payments</link:label>
    <link:label id="lab_us-gaap_LicensesRevenue_DB372064670D8FE018373A624D53A555_label_en-US" xlink:label="lab_us-gaap_LicensesRevenue_DB372064670D8FE018373A624D53A555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licenses Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_DB372064670D8FE018373A624D53A555" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensesRevenue_DB372064670D8FE018373A624D53A555" xlink:to="lab_us-gaap_LicensesRevenue_DB372064670D8FE018373A624D53A555" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_E6A6FB24D38115A454753A624D5372CF_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_E6A6FB24D38115A454753A624D5372CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_E6A6FB24D38115A454753A624D5372CF_label_en-US" xlink:label="lab_us-gaap_Revenues_E6A6FB24D38115A454753A624D5372CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E6A6FB24D38115A454753A624D5372CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_E6A6FB24D38115A454753A624D5372CF" xlink:to="lab_us-gaap_Revenues_E6A6FB24D38115A454753A624D5372CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C6C041D77F36F7AFAB7852F945F80918_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C6C041D77F36F7AFAB7852F945F80918" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-vested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C6C041D77F36F7AFAB7852F945F80918_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C6C041D77F36F7AFAB7852F945F80918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C6C041D77F36F7AFAB7852F945F80918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C6C041D77F36F7AFAB7852F945F80918" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C6C041D77F36F7AFAB7852F945F80918" xlink:type="arc" />
    <link:label id="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F100DBBCA5CBA944BD0552F945F89730_periodStartLabel_en-US" xlink:label="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F100DBBCA5CBA944BD0552F945F89730" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-vested, beginning balance, weighted average fair value</link:label>
    <link:label id="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F100DBBCA5CBA944BD0552F945F89730_label_en-US" xlink:label="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F100DBBCA5CBA944BD0552F945F89730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue</link:label>
    <link:label id="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F100DBBCA5CBA944BD0552F945F89730_documentation_en-US" xlink:label="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F100DBBCA5CBA944BD0552F945F89730" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the share based compensation arrangement for the share based payment award for the fair value of equity instruments.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue" xlink:label="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F100DBBCA5CBA944BD0552F945F89730" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F100DBBCA5CBA944BD0552F945F89730" xlink:to="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F100DBBCA5CBA944BD0552F945F89730" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5813E54093C66FC68C4352F945F878FA_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5813E54093C66FC68C4352F945F878FA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5813E54093C66FC68C4352F945F878FA_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5813E54093C66FC68C4352F945F878FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5813E54093C66FC68C4352F945F878FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5813E54093C66FC68C4352F945F878FA" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5813E54093C66FC68C4352F945F878FA" xlink:type="arc" />
    <link:label id="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_C6091C66B92A54C919BE52F945F94275_verboseLabel_en-US" xlink:label="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_C6091C66B92A54C919BE52F945F94275" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options vested</link:label>
    <link:label id="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_C6091C66B92A54C919BE52F945F94275_label_en-US" xlink:label="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_C6091C66B92A54C919BE52F945F94275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue</link:label>
    <link:label id="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_C6091C66B92A54C919BE52F945F94275_documentation_en-US" xlink:label="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_C6091C66B92A54C919BE52F945F94275" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the share based compensation arrangement concerning the fair value of options vested.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue" xlink:label="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_C6091C66B92A54C919BE52F945F94275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_C6091C66B92A54C919BE52F945F94275" xlink:to="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_C6091C66B92A54C919BE52F945F94275" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_B5044E515159DA721D9552F945F9C531_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_B5044E515159DA721D9552F945F9C531" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-vested options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_B5044E515159DA721D9552F945F9C531_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_B5044E515159DA721D9552F945F9C531" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_B5044E515159DA721D9552F945F9C531" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_B5044E515159DA721D9552F945F9C531" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_B5044E515159DA721D9552F945F9C531" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_85F7753C78C472D5958D52F945F97F9F_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_85F7753C78C472D5958D52F945F97F9F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-vested, ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_85F7753C78C472D5958D52F945F97F9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_85F7753C78C472D5958D52F945F97F9F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_85F7753C78C472D5958D52F945F97F9F" xlink:type="arc" />
    <link:label id="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_54B03EDEBFC79C96996E52F945F9B5B6_periodEndLabel_en-US" xlink:label="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_54B03EDEBFC79C96996E52F945F9B5B6" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-vested, ending balance, weighted average fair value</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue" xlink:label="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_54B03EDEBFC79C96996E52F945F9B5B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_54B03EDEBFC79C96996E52F945F9B5B6" xlink:to="lab_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_54B03EDEBFC79C96996E52F945F9B5B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2963F51C63C8A3730BBA2EADBA805024_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2963F51C63C8A3730BBA2EADBA805024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2963F51C63C8A3730BBA2EADBA805024" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2963F51C63C8A3730BBA2EADBA805024" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2963F51C63C8A3730BBA2EADBA805024" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_3D59515E5DACE27BEC262EADBA82A3E4_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_3D59515E5DACE27BEC262EADBA82A3E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of business and future operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_3D59515E5DACE27BEC262EADBA82A3E4_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_3D59515E5DACE27BEC262EADBA82A3E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_3D59515E5DACE27BEC262EADBA82A3E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_3D59515E5DACE27BEC262EADBA82A3E4" xlink:to="lab_us-gaap_NatureOfOperations_3D59515E5DACE27BEC262EADBA82A3E4" xlink:type="arc" />
    <link:label id="lab_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884_label_en-US" xlink:label="lab_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884_documentation_en-US" xlink:label="lab_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="abus-20151231.xsd#abus_DocumentAndEntityInformationAbstract" xlink:label="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="lab_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_4ACCB6A75BDA13E6C6F33F2E895FDCA9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_4ACCB6A75BDA13E6C6F33F2E895FDCA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_4ACCB6A75BDA13E6C6F33F2E895FDCA9_label_en-US" xlink:label="lab_dei_EntityRegistrantName_4ACCB6A75BDA13E6C6F33F2E895FDCA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_4ACCB6A75BDA13E6C6F33F2E895FDCA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_4ACCB6A75BDA13E6C6F33F2E895FDCA9" xlink:to="lab_dei_EntityRegistrantName_4ACCB6A75BDA13E6C6F33F2E895FDCA9" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_02C1DFF68E79655AFEAD3F2E895F796A_terseLabel_en-US" xlink:label="lab_dei_DocumentType_02C1DFF68E79655AFEAD3F2E895F796A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_02C1DFF68E79655AFEAD3F2E895F796A_label_en-US" xlink:label="lab_dei_DocumentType_02C1DFF68E79655AFEAD3F2E895F796A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_02C1DFF68E79655AFEAD3F2E895F796A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_02C1DFF68E79655AFEAD3F2E895F796A" xlink:to="lab_dei_DocumentType_02C1DFF68E79655AFEAD3F2E895F796A" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3A13EFBAF0E65BFC3C173F2E895FB467_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_3A13EFBAF0E65BFC3C173F2E895FB467" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3A13EFBAF0E65BFC3C173F2E895FB467_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_3A13EFBAF0E65BFC3C173F2E895FB467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_3A13EFBAF0E65BFC3C173F2E895FB467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_3A13EFBAF0E65BFC3C173F2E895FB467" xlink:to="lab_dei_CurrentFiscalYearEndDate_3A13EFBAF0E65BFC3C173F2E895FB467" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9434F64DD4FFBC377D3D3F2E895FFFCA_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_9434F64DD4FFBC377D3D3F2E895FFFCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9434F64DD4FFBC377D3D3F2E895FFFCA_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_9434F64DD4FFBC377D3D3F2E895FFFCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9434F64DD4FFBC377D3D3F2E895FFFCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_9434F64DD4FFBC377D3D3F2E895FFFCA" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_9434F64DD4FFBC377D3D3F2E895FFFCA" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_9C84356884CF7C46C7B03F2E895F881B_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_9C84356884CF7C46C7B03F2E895F881B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_9C84356884CF7C46C7B03F2E895F881B_label_en-US" xlink:label="lab_dei_EntityPublicFloat_9C84356884CF7C46C7B03F2E895F881B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_9C84356884CF7C46C7B03F2E895F881B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_9C84356884CF7C46C7B03F2E895F881B" xlink:to="lab_dei_EntityPublicFloat_9C84356884CF7C46C7B03F2E895F881B" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_B345EBAB995472F3D6DB3F2E895F2C97_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_B345EBAB995472F3D6DB3F2E895F2C97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_B345EBAB995472F3D6DB3F2E895F2C97_label_en-US" xlink:label="lab_dei_AmendmentFlag_B345EBAB995472F3D6DB3F2E895F2C97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_B345EBAB995472F3D6DB3F2E895F2C97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_B345EBAB995472F3D6DB3F2E895F2C97" xlink:to="lab_dei_AmendmentFlag_B345EBAB995472F3D6DB3F2E895F2C97" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_7D26BE027E3703A959A13F2E895F69B8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_7D26BE027E3703A959A13F2E895F69B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_7D26BE027E3703A959A13F2E895F69B8_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_7D26BE027E3703A959A13F2E895F69B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7D26BE027E3703A959A13F2E895F69B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_7D26BE027E3703A959A13F2E895F69B8" xlink:to="lab_dei_EntityCentralIndexKey_7D26BE027E3703A959A13F2E895F69B8" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_E76333E7C4B5C5CFBEF73F2E895FE36E_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_E76333E7C4B5C5CFBEF73F2E895FE36E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_E76333E7C4B5C5CFBEF73F2E895FE36E_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_E76333E7C4B5C5CFBEF73F2E895FE36E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E76333E7C4B5C5CFBEF73F2E895FE36E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_E76333E7C4B5C5CFBEF73F2E895FE36E" xlink:to="lab_dei_EntityCurrentReportingStatus_E76333E7C4B5C5CFBEF73F2E895FE36E" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_72A4F09C8F582105CEDE3F2E895FC0A9_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_72A4F09C8F582105CEDE3F2E895FC0A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_72A4F09C8F582105CEDE3F2E895FC0A9_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_72A4F09C8F582105CEDE3F2E895FC0A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_72A4F09C8F582105CEDE3F2E895FC0A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_72A4F09C8F582105CEDE3F2E895FC0A9" xlink:to="lab_dei_EntityVoluntaryFilers_72A4F09C8F582105CEDE3F2E895FC0A9" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_0F3CB65CD31F1851BA5A3F2E895F5C9F_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_0F3CB65CD31F1851BA5A3F2E895F5C9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_0F3CB65CD31F1851BA5A3F2E895F5C9F_label_en-US" xlink:label="lab_dei_EntityFilerCategory_0F3CB65CD31F1851BA5A3F2E895F5C9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_0F3CB65CD31F1851BA5A3F2E895F5C9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_0F3CB65CD31F1851BA5A3F2E895F5C9F" xlink:to="lab_dei_EntityFilerCategory_0F3CB65CD31F1851BA5A3F2E895F5C9F" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_336CD5967AC3C9F0D4003F2E895F0F0D_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_336CD5967AC3C9F0D4003F2E895F0F0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_336CD5967AC3C9F0D4003F2E895F0F0D_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_336CD5967AC3C9F0D4003F2E895F0F0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_336CD5967AC3C9F0D4003F2E895F0F0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_336CD5967AC3C9F0D4003F2E895F0F0D" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_336CD5967AC3C9F0D4003F2E895F0F0D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_B99CEC5D14C37AAAE7023F2E89604B48_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_B99CEC5D14C37AAAE7023F2E89604B48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_B99CEC5D14C37AAAE7023F2E89604B48_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_B99CEC5D14C37AAAE7023F2E89604B48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_B99CEC5D14C37AAAE7023F2E89604B48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_B99CEC5D14C37AAAE7023F2E89604B48" xlink:to="lab_dei_DocumentPeriodEndDate_B99CEC5D14C37AAAE7023F2E89604B48" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_197EAD14C0F589B937FE3F2E89607B35_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_197EAD14C0F589B937FE3F2E89607B35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_197EAD14C0F589B937FE3F2E89607B35_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_197EAD14C0F589B937FE3F2E89607B35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_197EAD14C0F589B937FE3F2E89607B35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_197EAD14C0F589B937FE3F2E89607B35" xlink:to="lab_dei_DocumentFiscalYearFocus_197EAD14C0F589B937FE3F2E89607B35" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A6259FBADE2FAC733A713F2E896068DE_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A6259FBADE2FAC733A713F2E896068DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A6259FBADE2FAC733A713F2E896068DE_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A6259FBADE2FAC733A713F2E896068DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A6259FBADE2FAC733A713F2E896068DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_A6259FBADE2FAC733A713F2E896068DE" xlink:to="lab_dei_DocumentFiscalPeriodFocus_A6259FBADE2FAC733A713F2E896068DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_616C23D8B0A33871950234C3968934F8_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_616C23D8B0A33871950234C3968934F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_616C23D8B0A33871950234C3968934F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_616C23D8B0A33871950234C3968934F8" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_616C23D8B0A33871950234C3968934F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6B01B3DD557951F2C90134C39689D370_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6B01B3DD557951F2C90134C39689D370" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ended December 31, 2016</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6B01B3DD557951F2C90134C39689D370_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6B01B3DD557951F2C90134C39689D370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6B01B3DD557951F2C90134C39689D370" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6B01B3DD557951F2C90134C39689D370" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6B01B3DD557951F2C90134C39689D370" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_16A2F8741F61CB6C9D8734C3968A0C5B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_16A2F8741F61CB6C9D8734C3968A0C5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ended December 31, 2017</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_16A2F8741F61CB6C9D8734C3968A0C5B_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_16A2F8741F61CB6C9D8734C3968A0C5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_16A2F8741F61CB6C9D8734C3968A0C5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_16A2F8741F61CB6C9D8734C3968A0C5B" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_16A2F8741F61CB6C9D8734C3968A0C5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_972A6B2BAA4E7C6BCC8E34C478D432CE_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_972A6B2BAA4E7C6BCC8E34C478D432CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ended December 31, 2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_972A6B2BAA4E7C6BCC8E34C478D432CE_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_972A6B2BAA4E7C6BCC8E34C478D432CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_972A6B2BAA4E7C6BCC8E34C478D432CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_972A6B2BAA4E7C6BCC8E34C478D432CE" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_972A6B2BAA4E7C6BCC8E34C478D432CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD7B2E5A8D7A95B93F4A34C47AEEC8EC_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD7B2E5A8D7A95B93F4A34C47AEEC8EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ended December 31, 2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD7B2E5A8D7A95B93F4A34C47AEEC8EC_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD7B2E5A8D7A95B93F4A34C47AEEC8EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD7B2E5A8D7A95B93F4A34C47AEEC8EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD7B2E5A8D7A95B93F4A34C47AEEC8EC" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD7B2E5A8D7A95B93F4A34C47AEEC8EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24B5E551A808799EEAD334C3968A361E_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24B5E551A808799EEAD334C3968A361E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Future minimum rent and estimated operating cost commitment, net of lease inducements</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24B5E551A808799EEAD334C3968A361E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24B5E551A808799EEAD334C3968A361E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24B5E551A808799EEAD334C3968A361E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24B5E551A808799EEAD334C3968A361E" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24B5E551A808799EEAD334C3968A361E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_2E211E78308A828851A451CB6C5399E4_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract_2E211E78308A828851A451CB6C5399E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_2E211E78308A828851A451CB6C5399E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_2E211E78308A828851A451CB6C5399E4" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract_2E211E78308A828851A451CB6C5399E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable_31B325829B37895EE61751CB6C53753F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable_31B325829B37895EE61751CB6C53753F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intercompany Foreign Currency Balance [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable_31B325829B37895EE61751CB6C53753F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable_31B325829B37895EE61751CB6C53753F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intercompany Foreign Currency Balance [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable" xlink:label="loc_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable_31B325829B37895EE61751CB6C53753F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable_31B325829B37895EE61751CB6C53753F" xlink:to="lab_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable_31B325829B37895EE61751CB6C53753F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_1F168606B6C2466FF2B051CB6C531A99_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_1F168606B6C2466FF2B051CB6C531A99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_1F168606B6C2466FF2B051CB6C531A99_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_1F168606B6C2466FF2B051CB6C531A99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1F168606B6C2466FF2B051CB6C531A99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1F168606B6C2466FF2B051CB6C531A99" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_1F168606B6C2466FF2B051CB6C531A99" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5" xlink:type="arc" />
    <link:label id="lab_abus_ForeignCurrencyExposureMember_8E4F15D5114431BE44DF51CB6C538A3C_terseLabel_en-US" xlink:label="lab_abus_ForeignCurrencyExposureMember_8E4F15D5114431BE44DF51CB6C538A3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency exposure</link:label>
    <link:label id="lab_abus_ForeignCurrencyExposureMember_8E4F15D5114431BE44DF51CB6C538A3C_label_en-US" xlink:label="lab_abus_ForeignCurrencyExposureMember_8E4F15D5114431BE44DF51CB6C538A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Exposure [Member]</link:label>
    <link:label id="lab_abus_ForeignCurrencyExposureMember_8E4F15D5114431BE44DF51CB6C538A3C_documentation_en-US" xlink:label="lab_abus_ForeignCurrencyExposureMember_8E4F15D5114431BE44DF51CB6C538A3C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the foreign currency exposure.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ForeignCurrencyExposureMember" xlink:label="loc_abus_ForeignCurrencyExposureMember_8E4F15D5114431BE44DF51CB6C538A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ForeignCurrencyExposureMember_8E4F15D5114431BE44DF51CB6C538A3C" xlink:to="lab_abus_ForeignCurrencyExposureMember_8E4F15D5114431BE44DF51CB6C538A3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77_terseLabel_en-US" xlink:label="lab_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intercompany Foreign Currency Balance [Line Items]</link:label>
    <link:label id="lab_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77_label_en-US" xlink:label="lab_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intercompany Foreign Currency Balance [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:label="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:to="lab_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_4B627EDB5D43A0E0DE8751CB6C539D5D_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_4B627EDB5D43A0E0DE8751CB6C539D5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_4B627EDB5D43A0E0DE8751CB6C539D5D_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_4B627EDB5D43A0E0DE8751CB6C539D5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4B627EDB5D43A0E0DE8751CB6C539D5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4B627EDB5D43A0E0DE8751CB6C539D5D" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_4B627EDB5D43A0E0DE8751CB6C539D5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNet_2D48EA515E2F52D757E251CB6C539CDC_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet_2D48EA515E2F52D757E251CB6C539CDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_2D48EA515E2F52D757E251CB6C539CDC_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet_2D48EA515E2F52D757E251CB6C539CDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_2D48EA515E2F52D757E251CB6C539CDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet_2D48EA515E2F52D757E251CB6C539CDC" xlink:to="lab_us-gaap_AccountsReceivableNet_2D48EA515E2F52D757E251CB6C539CDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_4A30FB63851D6A1CA4CE51CB6C538753_verboseLabel_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent_4A30FB63851D6A1CA4CE51CB6C538753" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued revenue</link:label>
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_4A30FB63851D6A1CA4CE51CB6C538753_label_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent_4A30FB63851D6A1CA4CE51CB6C538753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Receivables, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_4A30FB63851D6A1CA4CE51CB6C538753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledReceivablesCurrent_4A30FB63851D6A1CA4CE51CB6C538753" xlink:to="lab_us-gaap_UnbilledReceivablesCurrent_4A30FB63851D6A1CA4CE51CB6C538753" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2647062540676364250051CB6C535D16_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2647062540676364250051CB6C535D16" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2647062540676364250051CB6C535D16_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2647062540676364250051CB6C535D16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2647062540676364250051CB6C535D16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2647062540676364250051CB6C535D16" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2647062540676364250051CB6C535D16" xlink:type="arc" />
    <link:label id="lab_abus_ExposureToUSDollar_7320640E1C27F02D7D1B51CB6C53669E_totalLabel_en-US" xlink:label="lab_abus_ExposureToUSDollar_7320640E1C27F02D7D1B51CB6C53669E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Exposure to US dollar</link:label>
    <link:label id="lab_abus_ExposureToUSDollar_7320640E1C27F02D7D1B51CB6C53669E_label_en-US" xlink:label="lab_abus_ExposureToUSDollar_7320640E1C27F02D7D1B51CB6C53669E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exposure To US Dollar</link:label>
    <link:label id="lab_abus_ExposureToUSDollar_7320640E1C27F02D7D1B51CB6C53669E_documentation_en-US" xlink:label="lab_abus_ExposureToUSDollar_7320640E1C27F02D7D1B51CB6C53669E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the exposure to U.S. Dollar.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ExposureToUSDollar" xlink:label="loc_abus_ExposureToUSDollar_7320640E1C27F02D7D1B51CB6C53669E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ExposureToUSDollar_7320640E1C27F02D7D1B51CB6C53669E" xlink:to="lab_abus_ExposureToUSDollar_7320640E1C27F02D7D1B51CB6C53669E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_F54FC064FA5EBDA17FD82EAA60D8E5AE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_F54FC064FA5EBDA17FD82EAA60D8E5AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_F54FC064FA5EBDA17FD82EAA60D8E5AE_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_F54FC064FA5EBDA17FD82EAA60D8E5AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_F54FC064FA5EBDA17FD82EAA60D8E5AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_F54FC064FA5EBDA17FD82EAA60D8E5AE" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_F54FC064FA5EBDA17FD82EAA60D8E5AE" xlink:type="arc" />
    <link:label id="lab_abus_NetLiquidityDisclosureTableTextBlock_83ED1C0B123DD40A487433A2018E4103_terseLabel_en-US" xlink:label="lab_abus_NetLiquidityDisclosureTableTextBlock_83ED1C0B123DD40A487433A2018E4103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net liquidity</link:label>
    <link:label id="lab_abus_NetLiquidityDisclosureTableTextBlock_83ED1C0B123DD40A487433A2018E4103_label_en-US" xlink:label="lab_abus_NetLiquidityDisclosureTableTextBlock_83ED1C0B123DD40A487433A2018E4103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Liquidity Disclosure [Table Text Block]</link:label>
    <link:label id="lab_abus_NetLiquidityDisclosureTableTextBlock_83ED1C0B123DD40A487433A2018E4103_documentation_en-US" xlink:label="lab_abus_NetLiquidityDisclosureTableTextBlock_83ED1C0B123DD40A487433A2018E4103" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the full tabular disclosure for the net liquidity.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_NetLiquidityDisclosureTableTextBlock" xlink:label="loc_abus_NetLiquidityDisclosureTableTextBlock_83ED1C0B123DD40A487433A2018E4103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NetLiquidityDisclosureTableTextBlock_83ED1C0B123DD40A487433A2018E4103" xlink:to="lab_abus_NetLiquidityDisclosureTableTextBlock_83ED1C0B123DD40A487433A2018E4103" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_FEF764539302E88DE3F133A2018ECB02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_FEF764539302E88DE3F133A2018ECB02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of exposure to US dollar currency expressed in Canadian dollars</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_FEF764539302E88DE3F133A2018ECB02_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_FEF764539302E88DE3F133A2018ECB02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intercompany Foreign Currency Balances [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_FEF764539302E88DE3F133A2018ECB02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_FEF764539302E88DE3F133A2018ECB02" xlink:to="lab_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_FEF764539302E88DE3F133A2018ECB02" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA0EA67F1374786CEC5651CB6D09768F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA0EA67F1374786CEC5651CB6D09768F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA0EA67F1374786CEC5651CB6D09768F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA0EA67F1374786CEC5651CB6D09768F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA0EA67F1374786CEC5651CB6D09768F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA0EA67F1374786CEC5651CB6D09768F" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA0EA67F1374786CEC5651CB6D09768F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_5FC343C35067B7DCA00A51CB6D0ABFCF_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_5FC343C35067B7DCA00A51CB6D0ABFCF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchase Price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_5FC343C35067B7DCA00A51CB6D0ABFCF_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_5FC343C35067B7DCA00A51CB6D0ABFCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_5FC343C35067B7DCA00A51CB6D0ABFCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_5FC343C35067B7DCA00A51CB6D0ABFCF" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_5FC343C35067B7DCA00A51CB6D0ABFCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3052BC75057FDB7E3A0651CB6D0AA0AC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3052BC75057FDB7E3A0651CB6D0AA0AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3052BC75057FDB7E3A0651CB6D0AA0AC_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3052BC75057FDB7E3A0651CB6D0AA0AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3052BC75057FDB7E3A0651CB6D0AA0AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3052BC75057FDB7E3A0651CB6D0AA0AC" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3052BC75057FDB7E3A0651CB6D0AA0AC" xlink:type="arc" />
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_0ABEF0A5144EECC34B3D51CB6D0AAB13_terseLabel_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_0ABEF0A5144EECC34B3D51CB6D0AAB13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Period Adjustments, Cash</link:label>
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_0ABEF0A5144EECC34B3D51CB6D0AAB13_label_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_0ABEF0A5144EECC34B3D51CB6D0AAB13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cash</link:label>
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_0ABEF0A5144EECC34B3D51CB6D0AAB13_documentation_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_0ABEF0A5144EECC34B3D51CB6D0AAB13" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cash</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_0ABEF0A5144EECC34B3D51CB6D0AAB13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_0ABEF0A5144EECC34B3D51CB6D0AAB13" xlink:to="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_0ABEF0A5144EECC34B3D51CB6D0AAB13" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5112A84A601EB8B5909051CB6D0A193C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5112A84A601EB8B5909051CB6D0A193C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5112A84A601EB8B5909051CB6D0A193C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5112A84A601EB8B5909051CB6D0A193C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5112A84A601EB8B5909051CB6D0A193C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5112A84A601EB8B5909051CB6D0A193C" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5112A84A601EB8B5909051CB6D0A193C" xlink:type="arc" />
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_D67CD2B1765A5135675E51CB6D0AFF1D_terseLabel_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_D67CD2B1765A5135675E51CB6D0AFF1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Period Adjustments, Prepaid expenses and other assets</link:label>
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_D67CD2B1765A5135675E51CB6D0AFF1D_label_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_D67CD2B1765A5135675E51CB6D0AFF1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses and Other Assets</link:label>
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_D67CD2B1765A5135675E51CB6D0AFF1D_documentation_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_D67CD2B1765A5135675E51CB6D0AFF1D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses and Other Assets</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_D67CD2B1765A5135675E51CB6D0AFF1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_D67CD2B1765A5135675E51CB6D0AFF1D" xlink:to="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_D67CD2B1765A5135675E51CB6D0AFF1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_968FC3F69DD1108AEE2551CB6D0A0881_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_968FC3F69DD1108AEE2551CB6D0A0881" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_968FC3F69DD1108AEE2551CB6D0A0881_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_968FC3F69DD1108AEE2551CB6D0A0881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_968FC3F69DD1108AEE2551CB6D0A0881" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_968FC3F69DD1108AEE2551CB6D0A0881" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_968FC3F69DD1108AEE2551CB6D0A0881" xlink:type="arc" />
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_F994557C1F2FEC245D7D51CB6D0AC26F_terseLabel_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_F994557C1F2FEC245D7D51CB6D0AC26F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Period Adjustments, Accounts receivable</link:label>
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_F994557C1F2FEC245D7D51CB6D0AC26F_label_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_F994557C1F2FEC245D7D51CB6D0AC26F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable</link:label>
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_F994557C1F2FEC245D7D51CB6D0AC26F_documentation_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_F994557C1F2FEC245D7D51CB6D0AC26F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_F994557C1F2FEC245D7D51CB6D0AC26F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_F994557C1F2FEC245D7D51CB6D0AC26F" xlink:to="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_F994557C1F2FEC245D7D51CB6D0AC26F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_57CD58632110A0A0273651CB6D0ADF83_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_57CD58632110A0A0273651CB6D0ADF83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_57CD58632110A0A0273651CB6D0ADF83_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_57CD58632110A0A0273651CB6D0ADF83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_57CD58632110A0A0273651CB6D0ADF83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_57CD58632110A0A0273651CB6D0ADF83" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_57CD58632110A0A0273651CB6D0ADF83" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_E60F3AC6F63E810C8A1F51CB6D0AF9F5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_E60F3AC6F63E810C8A1F51CB6D0AF9F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Period Adjustments, Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_E60F3AC6F63E810C8A1F51CB6D0AF9F5_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_E60F3AC6F63E810C8A1F51CB6D0AF9F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_E60F3AC6F63E810C8A1F51CB6D0AF9F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_E60F3AC6F63E810C8A1F51CB6D0AF9F5" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_E60F3AC6F63E810C8A1F51CB6D0AF9F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_C42C737C946E035E6D8B51CB6D0AF301_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_C42C737C946E035E6D8B51CB6D0AF301" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_C42C737C946E035E6D8B51CB6D0AF301_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_C42C737C946E035E6D8B51CB6D0AF301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_C42C737C946E035E6D8B51CB6D0AF301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_C42C737C946E035E6D8B51CB6D0AF301" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_C42C737C946E035E6D8B51CB6D0AF301" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1448234CBFAF1CA71EA651CB6D0AC236_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1448234CBFAF1CA71EA651CB6D0AC236" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Period Adjustments, Acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1448234CBFAF1CA71EA651CB6D0AC236_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1448234CBFAF1CA71EA651CB6D0AC236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1448234CBFAF1CA71EA651CB6D0AC236" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1448234CBFAF1CA71EA651CB6D0AC236" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1448234CBFAF1CA71EA651CB6D0AC236" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_9A949442672DDCD4AC4951CB6D0AE1EC_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_9A949442672DDCD4AC4951CB6D0AE1EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_9A949442672DDCD4AC4951CB6D0AE1EC_label_en-US" xlink:label="lab_us-gaap_Goodwill_9A949442672DDCD4AC4951CB6D0AE1EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_9A949442672DDCD4AC4951CB6D0AE1EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_9A949442672DDCD4AC4951CB6D0AE1EC" xlink:to="lab_us-gaap_Goodwill_9A949442672DDCD4AC4951CB6D0AE1EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_681597C6610D6994F12751CB6D0A7DAC_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_681597C6610D6994F12751CB6D0A7DAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Period Adjustments, Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_681597C6610D6994F12751CB6D0A7DAC_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_681597C6610D6994F12751CB6D0A7DAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_681597C6610D6994F12751CB6D0A7DAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_681597C6610D6994F12751CB6D0A7DAC" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_681597C6610D6994F12751CB6D0A7DAC" xlink:type="arc" />
    <link:label id="lab_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_E1536AE2C98E4366420351CB6D0A0385_negatedTerseLabel_en-US" xlink:label="lab_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_E1536AE2C98E4366420351CB6D0A0385" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_E1536AE2C98E4366420351CB6D0A0385_label_en-US" xlink:label="lab_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_E1536AE2C98E4366420351CB6D0A0385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Businsess Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accounts Payable And Accrued Liabilities</link:label>
    <link:label id="lab_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_E1536AE2C98E4366420351CB6D0A0385_documentation_en-US" xlink:label="lab_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_E1536AE2C98E4366420351CB6D0A0385" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the accrued liabilities and accounts payable assumed in the business acquisition.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:label="loc_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_E1536AE2C98E4366420351CB6D0A0385" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_E1536AE2C98E4366420351CB6D0A0385" xlink:to="lab_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_E1536AE2C98E4366420351CB6D0A0385" xlink:type="arc" />
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_55F00CCC5E82861C76B751CB6D0BC07C_negatedTerseLabel_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_55F00CCC5E82861C76B751CB6D0BC07C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Measurement Period Adjustments, Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_55F00CCC5E82861C76B751CB6D0BC07C_label_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_55F00CCC5E82861C76B751CB6D0BC07C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_55F00CCC5E82861C76B751CB6D0BC07C_documentation_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_55F00CCC5E82861C76B751CB6D0BC07C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_55F00CCC5E82861C76B751CB6D0BC07C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_55F00CCC5E82861C76B751CB6D0BC07C" xlink:to="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_55F00CCC5E82861C76B751CB6D0BC07C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_FB88DFD0B79628BBE26251CB6D0B6100_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_FB88DFD0B79628BBE26251CB6D0B6100" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_FB88DFD0B79628BBE26251CB6D0B6100_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_FB88DFD0B79628BBE26251CB6D0B6100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_FB88DFD0B79628BBE26251CB6D0B6100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_FB88DFD0B79628BBE26251CB6D0B6100" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_FB88DFD0B79628BBE26251CB6D0B6100" xlink:type="arc" />
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_89DE3A2DB5DD9CC4A01C51CB6D0B1D89_negatedTerseLabel_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_89DE3A2DB5DD9CC4A01C51CB6D0B1D89" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Measurement Period Adjustments, Other non-current liabilities</link:label>
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_89DE3A2DB5DD9CC4A01C51CB6D0B1D89_label_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_89DE3A2DB5DD9CC4A01C51CB6D0B1D89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Non-Current Liabilities</link:label>
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_89DE3A2DB5DD9CC4A01C51CB6D0B1D89_documentation_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_89DE3A2DB5DD9CC4A01C51CB6D0B1D89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Non-Current Liabilities</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_89DE3A2DB5DD9CC4A01C51CB6D0B1D89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_89DE3A2DB5DD9CC4A01C51CB6D0B1D89" xlink:to="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_89DE3A2DB5DD9CC4A01C51CB6D0B1D89" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FA9EC989581E75524BFF51CB6D0B87E0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FA9EC989581E75524BFF51CB6D0B87E0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FA9EC989581E75524BFF51CB6D0B87E0_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FA9EC989581E75524BFF51CB6D0B87E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FA9EC989581E75524BFF51CB6D0B87E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FA9EC989581E75524BFF51CB6D0B87E0" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FA9EC989581E75524BFF51CB6D0B87E0" xlink:type="arc" />
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_CAE885E4D45C09D5BD3D51CB6D0B68FE_negatedTerseLabel_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_CAE885E4D45C09D5BD3D51CB6D0B68FE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Measurement Period Adjustments, Deferred income tax liability</link:label>
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_CAE885E4D45C09D5BD3D51CB6D0B68FE_label_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_CAE885E4D45C09D5BD3D51CB6D0B68FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liability</link:label>
    <link:label id="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_CAE885E4D45C09D5BD3D51CB6D0B68FE_documentation_en-US" xlink:label="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_CAE885E4D45C09D5BD3D51CB6D0B68FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liability</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_CAE885E4D45C09D5BD3D51CB6D0B68FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_CAE885E4D45C09D5BD3D51CB6D0B68FE" xlink:to="lab_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_CAE885E4D45C09D5BD3D51CB6D0B68FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2537C2E385D844FC9E3B51CB6D0BBCD2_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2537C2E385D844FC9E3B51CB6D0BBCD2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total purchase price allocation</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2537C2E385D844FC9E3B51CB6D0BBCD2_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2537C2E385D844FC9E3B51CB6D0BBCD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2537C2E385D844FC9E3B51CB6D0BBCD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2537C2E385D844FC9E3B51CB6D0BBCD2" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2537C2E385D844FC9E3B51CB6D0BBCD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_F9D57A4DE30FEBCDB81051CB6D0B64C4_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_F9D57A4DE30FEBCDB81051CB6D0B64C4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Measurement Period Adjustments, Total</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_F9D57A4DE30FEBCDB81051CB6D0B64C4_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_F9D57A4DE30FEBCDB81051CB6D0B64C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_F9D57A4DE30FEBCDB81051CB6D0B64C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_F9D57A4DE30FEBCDB81051CB6D0B64C4" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_F9D57A4DE30FEBCDB81051CB6D0B64C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_03E2EFD6FB0015B500413E548BDE3E90_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_03E2EFD6FB0015B500413E548BDE3E90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_03E2EFD6FB0015B500413E548BDE3E90_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_03E2EFD6FB0015B500413E548BDE3E90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_03E2EFD6FB0015B500413E548BDE3E90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_03E2EFD6FB0015B500413E548BDE3E90" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_03E2EFD6FB0015B500413E548BDE3E90" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E6D0A0D1BBB64034517F3E548BDEE455_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E6D0A0D1BBB64034517F3E548BDEE455" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research, development, collaborations and contracts expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E6D0A0D1BBB64034517F3E548BDEE455_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E6D0A0D1BBB64034517F3E548BDEE455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E6D0A0D1BBB64034517F3E548BDEE455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E6D0A0D1BBB64034517F3E548BDEE455" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E6D0A0D1BBB64034517F3E548BDEE455" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_CB8462D876406C71ADC23E548BDEF4E9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_CB8462D876406C71ADC23E548BDEF4E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_CB8462D876406C71ADC23E548BDEF4E9_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_CB8462D876406C71ADC23E548BDEF4E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_CB8462D876406C71ADC23E548BDEF4E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_CB8462D876406C71ADC23E548BDEF4E9" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_CB8462D876406C71ADC23E548BDEF4E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_8236D70CCCE2C662FC0E3E548BDE7612_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_8236D70CCCE2C662FC0E3E548BDE7612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_8236D70CCCE2C662FC0E3E548BDE7612_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_8236D70CCCE2C662FC0E3E548BDE7612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_8236D70CCCE2C662FC0E3E548BDE7612" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_8236D70CCCE2C662FC0E3E548BDE7612" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_8236D70CCCE2C662FC0E3E548BDE7612" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract_10D0039C43A0217527F439DA22A634BC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract_10D0039C43A0217527F439DA22A634BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro forma information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract_10D0039C43A0217527F439DA22A634BC_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract_10D0039C43A0217527F439DA22A634BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_10D0039C43A0217527F439DA22A634BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_10D0039C43A0217527F439DA22A634BC" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationAbstract_10D0039C43A0217527F439DA22A634BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_92A0C0EED9C5556D81F139D6A40F02F7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_92A0C0EED9C5556D81F139D6A40F02F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_92A0C0EED9C5556D81F139D6A40F02F7_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_92A0C0EED9C5556D81F139D6A40F02F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_92A0C0EED9C5556D81F139D6A40F02F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_92A0C0EED9C5556D81F139D6A40F02F7" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_92A0C0EED9C5556D81F139D6A40F02F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_D0E4D0B319B22546327F39D70A0BEEBF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_D0E4D0B319B22546327F39D70A0BEEBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_D0E4D0B319B22546327F39D70A0BEEBF_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_D0E4D0B319B22546327F39D70A0BEEBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Income (Loss) from Continuing Operations before Changes in Accounting and Extraordinary Items, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_D0E4D0B319B22546327F39D70A0BEEBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_D0E4D0B319B22546327F39D70A0BEEBF" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_D0E4D0B319B22546327F39D70A0BEEBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_25730E4980C8189DDCCA39D7440982D1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_25730E4980C8189DDCCA39D7440982D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_25730E4980C8189DDCCA39D7440982D1_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_25730E4980C8189DDCCA39D7440982D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_25730E4980C8189DDCCA39D7440982D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_25730E4980C8189DDCCA39D7440982D1" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_25730E4980C8189DDCCA39D7440982D1" xlink:type="arc" />
    <link:label id="lab_abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted_A5B637ACF5C333E3CCBC39D836219E16_terseLabel_en-US" xlink:label="lab_abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted_A5B637ACF5C333E3CCBC39D836219E16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted loss per share (in USD per share)</link:label>
    <link:label id="lab_abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted_A5B637ACF5C333E3CCBC39D836219E16_label_en-US" xlink:label="lab_abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted_A5B637ACF5C333E3CCBC39D836219E16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Pro Forma Earnings (Loss) Per Share Basic And Diluted</link:label>
    <link:label id="lab_abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted_A5B637ACF5C333E3CCBC39D836219E16_documentation_en-US" xlink:label="lab_abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted_A5B637ACF5C333E3CCBC39D836219E16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition Pro Forma Earnings (Loss) Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted" xlink:label="loc_abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted_A5B637ACF5C333E3CCBC39D836219E16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted_A5B637ACF5C333E3CCBC39D836219E16" xlink:to="lab_abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted_A5B637ACF5C333E3CCBC39D836219E16" xlink:type="arc" />
    <link:label id="lab_abus_ProtivaShareOptionsMember_D852069F7474F2692FEA52F94626C22D_terseLabel_en-US" xlink:label="lab_abus_ProtivaShareOptionsMember_D852069F7474F2692FEA52F94626C22D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Protiva Share Options</link:label>
    <link:label id="lab_abus_ProtivaShareOptionsMember_D852069F7474F2692FEA52F94626C22D_label_en-US" xlink:label="lab_abus_ProtivaShareOptionsMember_D852069F7474F2692FEA52F94626C22D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Protiva Share Options [Member]</link:label>
    <link:label id="lab_abus_ProtivaShareOptionsMember_D852069F7474F2692FEA52F94626C22D_documentation_en-US" xlink:label="lab_abus_ProtivaShareOptionsMember_D852069F7474F2692FEA52F94626C22D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Protiva share options.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ProtivaShareOptionsMember" xlink:label="loc_abus_ProtivaShareOptionsMember_D852069F7474F2692FEA52F94626C22D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ProtivaShareOptionsMember_D852069F7474F2692FEA52F94626C22D" xlink:to="lab_abus_ProtivaShareOptionsMember_D852069F7474F2692FEA52F94626C22D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7F06266E486AEC7D023E52F94626D3D8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7F06266E486AEC7D023E52F94626D3D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance - Number of optioned common shares (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7F06266E486AEC7D023E52F94626D3D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7F06266E486AEC7D023E52F94626D3D8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7F06266E486AEC7D023E52F94626D3D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4A2BB3D19B9F9D1E80C452F946262F5B_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4A2BB3D19B9F9D1E80C452F946262F5B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Balance, Weighted average exercise price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4A2BB3D19B9F9D1E80C452F946262F5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4A2BB3D19B9F9D1E80C452F946262F5B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4A2BB3D19B9F9D1E80C452F946262F5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3856F20620A8BFDE93D152F94626F23E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3856F20620A8BFDE93D152F94626F23E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercised - Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3856F20620A8BFDE93D152F94626F23E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3856F20620A8BFDE93D152F94626F23E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3856F20620A8BFDE93D152F94626F23E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3856F20620A8BFDE93D152F94626F23E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3856F20620A8BFDE93D152F94626F23E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_A045A92E12595C508D7B52F9462B7EBB_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_A045A92E12595C508D7B52F9462B7EBB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options forfeited, cancelled or expired - Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_A045A92E12595C508D7B52F9462B7EBB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_A045A92E12595C508D7B52F9462B7EBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_A045A92E12595C508D7B52F9462B7EBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_A045A92E12595C508D7B52F9462B7EBB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_A045A92E12595C508D7B52F9462B7EBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_E6932CF2061907C4602756EFD3AF4C6A_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_E6932CF2061907C4602756EFD3AF4C6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_E6932CF2061907C4602756EFD3AF4C6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_E6932CF2061907C4602756EFD3AF4C6A" xlink:to="lab_us-gaap_SubsequentEventsAbstract_E6932CF2061907C4602756EFD3AF4C6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:to="lab_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_2C4E901939E0F069F64A56EFD504855F_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_2C4E901939E0F069F64A56EFD504855F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_2C4E901939E0F069F64A56EFD504855F_label_en-US" xlink:label="lab_dei_LegalEntityAxis_2C4E901939E0F069F64A56EFD504855F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2C4E901939E0F069F64A56EFD504855F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_2C4E901939E0F069F64A56EFD504855F" xlink:to="lab_dei_LegalEntityAxis_2C4E901939E0F069F64A56EFD504855F" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E_label_en-US" xlink:label="lab_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E" xlink:to="lab_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E" xlink:type="arc" />
    <link:label id="lab_abus_PADCo.Member_705ED5B67B23D8449AFD56EFD51E537A_terseLabel_en-US" xlink:label="lab_abus_PADCo.Member_705ED5B67B23D8449AFD56EFD51E537A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PADCo.</link:label>
    <link:label id="lab_abus_PADCo.Member_705ED5B67B23D8449AFD56EFD51E537A_label_en-US" xlink:label="lab_abus_PADCo.Member_705ED5B67B23D8449AFD56EFD51E537A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PADCo. [Member]</link:label>
    <link:label id="lab_abus_PADCo.Member_705ED5B67B23D8449AFD56EFD51E537A_documentation_en-US" xlink:label="lab_abus_PADCo.Member_705ED5B67B23D8449AFD56EFD51E537A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PADCo. [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_PADCo.Member" xlink:label="loc_abus_PADCo.Member_705ED5B67B23D8449AFD56EFD51E537A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_PADCo.Member_705ED5B67B23D8449AFD56EFD51E537A" xlink:to="lab_abus_PADCo.Member_705ED5B67B23D8449AFD56EFD51E537A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0117269AE8812DEDB26F56EFD4D01690_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0117269AE8812DEDB26F56EFD4D01690" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0117269AE8812DEDB26F56EFD4D01690_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0117269AE8812DEDB26F56EFD4D01690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0117269AE8812DEDB26F56EFD4D01690" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0117269AE8812DEDB26F56EFD4D01690" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0117269AE8812DEDB26F56EFD4D01690" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_22C488EC3596E1918AD256EFD52D30D4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_22C488EC3596E1918AD256EFD52D30D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_22C488EC3596E1918AD256EFD52D30D4_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_22C488EC3596E1918AD256EFD52D30D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_22C488EC3596E1918AD256EFD52D30D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_22C488EC3596E1918AD256EFD52D30D4" xlink:to="lab_us-gaap_SubsequentEventMember_22C488EC3596E1918AD256EFD52D30D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC" xlink:to="lab_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4E9DC42AFFD528975A9156EFD4DF44A2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4E9DC42AFFD528975A9156EFD4DF44A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, percentage of outstanding shares acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4E9DC42AFFD528975A9156EFD4DF44A2_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4E9DC42AFFD528975A9156EFD4DF44A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4E9DC42AFFD528975A9156EFD4DF44A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4E9DC42AFFD528975A9156EFD4DF44A2" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4E9DC42AFFD528975A9156EFD4DF44A2" xlink:type="arc" />
    <link:label id="lab_abus_OptionalExcercisedContractualOptionAmount_EC05C1C78D414A920EB156F773173265_terseLabel_en-US" xlink:label="lab_abus_OptionalExcercisedContractualOptionAmount_EC05C1C78D414A920EB156F773173265" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Optional exercised contractual option, amount</link:label>
    <link:label id="lab_abus_OptionalExcercisedContractualOptionAmount_EC05C1C78D414A920EB156F773173265_label_en-US" xlink:label="lab_abus_OptionalExcercisedContractualOptionAmount_EC05C1C78D414A920EB156F773173265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Optional Excercised Contractual Option, Amount</link:label>
    <link:label id="lab_abus_OptionalExcercisedContractualOptionAmount_EC05C1C78D414A920EB156F773173265_documentation_en-US" xlink:label="lab_abus_OptionalExcercisedContractualOptionAmount_EC05C1C78D414A920EB156F773173265" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of an option exercise that was embedded in a contract.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_OptionalExcercisedContractualOptionAmount" xlink:label="loc_abus_OptionalExcercisedContractualOptionAmount_EC05C1C78D414A920EB156F773173265" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OptionalExcercisedContractualOptionAmount_EC05C1C78D414A920EB156F773173265" xlink:to="lab_abus_OptionalExcercisedContractualOptionAmount_EC05C1C78D414A920EB156F773173265" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_A3F523ADF93F6EB595B133EB0CC2BB92_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_A3F523ADF93F6EB595B133EB0CC2BB92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplementary information</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_A3F523ADF93F6EB595B133EB0CC2BB92_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_A3F523ADF93F6EB595B133EB0CC2BB92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_A3F523ADF93F6EB595B133EB0CC2BB92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_A3F523ADF93F6EB595B133EB0CC2BB92" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_A3F523ADF93F6EB595B133EB0CC2BB92" xlink:type="arc" />
    <link:label id="lab_abus_A2007PlanMember_DFCFD00E94BC348181415167E7B68362_terseLabel_en-US" xlink:label="lab_abus_A2007PlanMember_DFCFD00E94BC348181415167E7B68362" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2007 Plan</link:label>
    <link:label id="lab_abus_A2007PlanMember_DFCFD00E94BC348181415167E7B68362_label_en-US" xlink:label="lab_abus_A2007PlanMember_DFCFD00E94BC348181415167E7B68362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2007 Plan [Member]</link:label>
    <link:label id="lab_abus_A2007PlanMember_DFCFD00E94BC348181415167E7B68362_documentation_en-US" xlink:label="lab_abus_A2007PlanMember_DFCFD00E94BC348181415167E7B68362" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2007 Plan [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_A2007PlanMember" xlink:label="loc_abus_A2007PlanMember_DFCFD00E94BC348181415167E7B68362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_A2007PlanMember_DFCFD00E94BC348181415167E7B68362" xlink:to="lab_abus_A2007PlanMember_DFCFD00E94BC348181415167E7B68362" xlink:type="arc" />
    <link:label id="lab_abus_A2011PlanMember_2244ECDAF773052418E05167E7B7F65D_terseLabel_en-US" xlink:label="lab_abus_A2011PlanMember_2244ECDAF773052418E05167E7B7F65D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2011 Plan</link:label>
    <link:label id="lab_abus_A2011PlanMember_2244ECDAF773052418E05167E7B7F65D_label_en-US" xlink:label="lab_abus_A2011PlanMember_2244ECDAF773052418E05167E7B7F65D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2011 Plan [Member]</link:label>
    <link:label id="lab_abus_A2011PlanMember_2244ECDAF773052418E05167E7B7F65D_documentation_en-US" xlink:label="lab_abus_A2011PlanMember_2244ECDAF773052418E05167E7B7F65D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2011 Plan [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_A2011PlanMember" xlink:label="loc_abus_A2011PlanMember_2244ECDAF773052418E05167E7B7F65D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_A2011PlanMember_2244ECDAF773052418E05167E7B7F65D" xlink:to="lab_abus_A2011PlanMember_2244ECDAF773052418E05167E7B7F65D" xlink:type="arc" />
    <link:label id="lab_abus_DesignatedPlansMember_2A9C5AAD5021B6D0C31C5167E7B7DD11_terseLabel_en-US" xlink:label="lab_abus_DesignatedPlansMember_2A9C5AAD5021B6D0C31C5167E7B7DD11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated Plans</link:label>
    <link:label id="lab_abus_DesignatedPlansMember_2A9C5AAD5021B6D0C31C5167E7B7DD11_label_en-US" xlink:label="lab_abus_DesignatedPlansMember_2A9C5AAD5021B6D0C31C5167E7B7DD11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated Plans [Member]</link:label>
    <link:label id="lab_abus_DesignatedPlansMember_2A9C5AAD5021B6D0C31C5167E7B7DD11_documentation_en-US" xlink:label="lab_abus_DesignatedPlansMember_2A9C5AAD5021B6D0C31C5167E7B7DD11" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Designated Plans.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_DesignatedPlansMember" xlink:label="loc_abus_DesignatedPlansMember_2A9C5AAD5021B6D0C31C5167E7B7DD11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_DesignatedPlansMember_2A9C5AAD5021B6D0C31C5167E7B7DD11" xlink:to="lab_abus_DesignatedPlansMember_2A9C5AAD5021B6D0C31C5167E7B7DD11" xlink:type="arc" />
    <link:label id="lab_abus_ArbutusPlansMember_01B85777EEBFC08AA6E05167E7B70EB2_terseLabel_en-US" xlink:label="lab_abus_ArbutusPlansMember_01B85777EEBFC08AA6E05167E7B70EB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arbutus Plans</link:label>
    <link:label id="lab_abus_ArbutusPlansMember_01B85777EEBFC08AA6E05167E7B70EB2_label_en-US" xlink:label="lab_abus_ArbutusPlansMember_01B85777EEBFC08AA6E05167E7B70EB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arbutus Plans [Member]</link:label>
    <link:label id="lab_abus_ArbutusPlansMember_01B85777EEBFC08AA6E05167E7B70EB2_documentation_en-US" xlink:label="lab_abus_ArbutusPlansMember_01B85777EEBFC08AA6E05167E7B70EB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Arbutus Plans [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ArbutusPlansMember" xlink:label="loc_abus_ArbutusPlansMember_01B85777EEBFC08AA6E05167E7B70EB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ArbutusPlansMember_01B85777EEBFC08AA6E05167E7B70EB2" xlink:to="lab_abus_ArbutusPlansMember_01B85777EEBFC08AA6E05167E7B70EB2" xlink:type="arc" />
    <link:label id="lab_abus_CashlessExerciseProvisionMember_C445A81D07EDE53799305167E7B7278D_terseLabel_en-US" xlink:label="lab_abus_CashlessExerciseProvisionMember_C445A81D07EDE53799305167E7B7278D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cashless Exercise Provision</link:label>
    <link:label id="lab_abus_CashlessExerciseProvisionMember_C445A81D07EDE53799305167E7B7278D_label_en-US" xlink:label="lab_abus_CashlessExerciseProvisionMember_C445A81D07EDE53799305167E7B7278D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cashless Exercise Provision [Member]</link:label>
    <link:label id="lab_abus_CashlessExerciseProvisionMember_C445A81D07EDE53799305167E7B7278D_documentation_en-US" xlink:label="lab_abus_CashlessExerciseProvisionMember_C445A81D07EDE53799305167E7B7278D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the cashless exercise provision.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_CashlessExerciseProvisionMember" xlink:label="loc_abus_CashlessExerciseProvisionMember_C445A81D07EDE53799305167E7B7278D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_CashlessExerciseProvisionMember_C445A81D07EDE53799305167E7B7278D" xlink:to="lab_abus_CashlessExerciseProvisionMember_C445A81D07EDE53799305167E7B7278D" xlink:type="arc" />
    <link:label id="lab_abus_RevisedNewCommonSharesMember_5FD7FEFBD20D13E697915167E7B76AE3_terseLabel_en-US" xlink:label="lab_abus_RevisedNewCommonSharesMember_5FD7FEFBD20D13E697915167E7B76AE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revised new common shares</link:label>
    <link:label id="lab_abus_RevisedNewCommonSharesMember_5FD7FEFBD20D13E697915167E7B76AE3_label_en-US" xlink:label="lab_abus_RevisedNewCommonSharesMember_5FD7FEFBD20D13E697915167E7B76AE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revised New Common Shares [Member]</link:label>
    <link:label id="lab_abus_RevisedNewCommonSharesMember_5FD7FEFBD20D13E697915167E7B76AE3_documentation_en-US" xlink:label="lab_abus_RevisedNewCommonSharesMember_5FD7FEFBD20D13E697915167E7B76AE3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the revised new common shares.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_RevisedNewCommonSharesMember" xlink:label="loc_abus_RevisedNewCommonSharesMember_5FD7FEFBD20D13E697915167E7B76AE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RevisedNewCommonSharesMember_5FD7FEFBD20D13E697915167E7B76AE3" xlink:to="lab_abus_RevisedNewCommonSharesMember_5FD7FEFBD20D13E697915167E7B76AE3" xlink:type="arc" />
    <link:label id="lab_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member_6D7934BDCFFAA9890BD55167E7B77E97_terseLabel_en-US" xlink:label="lab_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member_6D7934BDCFFAA9890BD55167E7B77E97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unexpired repurchase rights on shares issued to Arbutus Inc.</link:label>
    <link:label id="lab_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member_6D7934BDCFFAA9890BD55167E7B77E97_label_en-US" xlink:label="lab_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member_6D7934BDCFFAA9890BD55167E7B77E97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unexpired Repurchase Rights On Shares Issued to Arbutus Inc. [Member]</link:label>
    <link:label id="lab_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member_6D7934BDCFFAA9890BD55167E7B77E97_documentation_en-US" xlink:label="lab_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member_6D7934BDCFFAA9890BD55167E7B77E97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unexpired Repurchase Rights On Shares Issued to Arbutus Inc. [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member" xlink:label="loc_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member_6D7934BDCFFAA9890BD55167E7B77E97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member_6D7934BDCFFAA9890BD55167E7B77E97" xlink:to="lab_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member_6D7934BDCFFAA9890BD55167E7B77E97" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_3F4CD740603E50B603DD5167E7B7ED37_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_3F4CD740603E50B603DD5167E7B7ED37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_3F4CD740603E50B603DD5167E7B7ED37_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_3F4CD740603E50B603DD5167E7B7ED37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3F4CD740603E50B603DD5167E7B7ED37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3F4CD740603E50B603DD5167E7B7ED37" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_3F4CD740603E50B603DD5167E7B7ED37" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A676E5ACF0AC8F1E3A1D5167E7B81F13_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A676E5ACF0AC8F1E3A1D5167E7B81F13" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during underwritten public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A676E5ACF0AC8F1E3A1D5167E7B81F13_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A676E5ACF0AC8F1E3A1D5167E7B81F13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A676E5ACF0AC8F1E3A1D5167E7B81F13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A676E5ACF0AC8F1E3A1D5167E7B81F13" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A676E5ACF0AC8F1E3A1D5167E7B81F13" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_78CE8D22830943E6AB0A5167E7B847C7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_78CE8D22830943E6AB0A5167E7B847C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock price at public offering (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_78CE8D22830943E6AB0A5167E7B847C7_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_78CE8D22830943E6AB0A5167E7B847C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_78CE8D22830943E6AB0A5167E7B847C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_78CE8D22830943E6AB0A5167E7B847C7" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_78CE8D22830943E6AB0A5167E7B847C7" xlink:type="arc" />
    <link:label id="lab_abus_NumberOfAdditionalSharesAuthorized_6E1E1C51ACDF1F4E59705167E7B8FB70_terseLabel_en-US" xlink:label="lab_abus_NumberOfAdditionalSharesAuthorized_6E1E1C51ACDF1F4E59705167E7B8FB70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized (in Shares)</link:label>
    <link:label id="lab_abus_NumberOfAdditionalSharesAuthorized_6E1E1C51ACDF1F4E59705167E7B8FB70_label_en-US" xlink:label="lab_abus_NumberOfAdditionalSharesAuthorized_6E1E1C51ACDF1F4E59705167E7B8FB70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Additional Shares Authorized (in Shares)</link:label>
    <link:label id="lab_abus_NumberOfAdditionalSharesAuthorized_6E1E1C51ACDF1F4E59705167E7B8FB70_documentation_en-US" xlink:label="lab_abus_NumberOfAdditionalSharesAuthorized_6E1E1C51ACDF1F4E59705167E7B8FB70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of additional shares authorized in which underwriters have the option to purchase.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_NumberOfAdditionalSharesAuthorized" xlink:label="loc_abus_NumberOfAdditionalSharesAuthorized_6E1E1C51ACDF1F4E59705167E7B8FB70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NumberOfAdditionalSharesAuthorized_6E1E1C51ACDF1F4E59705167E7B8FB70" xlink:to="lab_abus_NumberOfAdditionalSharesAuthorized_6E1E1C51ACDF1F4E59705167E7B8FB70" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_33AE50CFAB9459B265D05167E7B8FA43_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_33AE50CFAB9459B265D05167E7B8FA43" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from issuance of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_33AE50CFAB9459B265D05167E7B8FA43_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_33AE50CFAB9459B265D05167E7B8FA43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_33AE50CFAB9459B265D05167E7B8FA43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_33AE50CFAB9459B265D05167E7B8FA43" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_33AE50CFAB9459B265D05167E7B8FA43" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_E1943F5AFC38FE4791675167E7B88E4B_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_E1943F5AFC38FE4791675167E7B88E4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period for option to purchase additional shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_E1943F5AFC38FE4791675167E7B88E4B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_E1943F5AFC38FE4791675167E7B88E4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_E1943F5AFC38FE4791675167E7B88E4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_E1943F5AFC38FE4791675167E7B88E4B" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_E1943F5AFC38FE4791675167E7B88E4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_2751674643DA86C7BF105167E7B8C0CD_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_2751674643DA86C7BF105167E7B8C0CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of stock issuance costs, including commissions and professional fees</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_2751674643DA86C7BF105167E7B8C0CD_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_2751674643DA86C7BF105167E7B8C0CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_2751674643DA86C7BF105167E7B8C0CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_2751674643DA86C7BF105167E7B8C0CD" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_2751674643DA86C7BF105167E7B8C0CD" xlink:type="arc" />
    <link:label id="lab_abus_ProceedsFromIssuanceOfCommonStockNet_410C0FA3800328D69F795167E7B874DA_terseLabel_en-US" xlink:label="lab_abus_ProceedsFromIssuanceOfCommonStockNet_410C0FA3800328D69F795167E7B874DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net</link:label>
    <link:label id="lab_abus_ProceedsFromIssuanceOfCommonStockNet_410C0FA3800328D69F795167E7B874DA_label_en-US" xlink:label="lab_abus_ProceedsFromIssuanceOfCommonStockNet_410C0FA3800328D69F795167E7B874DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock Net</link:label>
    <link:label id="lab_abus_ProceedsFromIssuanceOfCommonStockNet_410C0FA3800328D69F795167E7B874DA_documentation_en-US" xlink:label="lab_abus_ProceedsFromIssuanceOfCommonStockNet_410C0FA3800328D69F795167E7B874DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock net.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ProceedsFromIssuanceOfCommonStockNet" xlink:label="loc_abus_ProceedsFromIssuanceOfCommonStockNet_410C0FA3800328D69F795167E7B874DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ProceedsFromIssuanceOfCommonStockNet_410C0FA3800328D69F795167E7B874DA" xlink:to="lab_abus_ProceedsFromIssuanceOfCommonStockNet_410C0FA3800328D69F795167E7B874DA" xlink:type="arc" />
    <link:label id="lab_abus_WarrantsExercised_1D554D09E69546962A9D5167E7B80AE6_terseLabel_en-US" xlink:label="lab_abus_WarrantsExercised_1D554D09E69546962A9D5167E7B80AE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_abus_WarrantsExercised_1D554D09E69546962A9D5167E7B80AE6_label_en-US" xlink:label="lab_abus_WarrantsExercised_1D554D09E69546962A9D5167E7B80AE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Exercised (in Shares)</link:label>
    <link:label id="lab_abus_WarrantsExercised_1D554D09E69546962A9D5167E7B80AE6_documentation_en-US" xlink:label="lab_abus_WarrantsExercised_1D554D09E69546962A9D5167E7B80AE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants exercised.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_WarrantsExercised" xlink:label="loc_abus_WarrantsExercised_1D554D09E69546962A9D5167E7B80AE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_WarrantsExercised_1D554D09E69546962A9D5167E7B80AE6" xlink:to="lab_abus_WarrantsExercised_1D554D09E69546962A9D5167E7B80AE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_3135D87AACA36C7FFCA75167E7B8432B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_3135D87AACA36C7FFCA75167E7B8432B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from warrant exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_3135D87AACA36C7FFCA75167E7B8432B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_3135D87AACA36C7FFCA75167E7B8432B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_3135D87AACA36C7FFCA75167E7B8432B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_3135D87AACA36C7FFCA75167E7B8432B" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_3135D87AACA36C7FFCA75167E7B8432B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2E679E32D37A5DB094DD5167E7B8FC0F_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2E679E32D37A5DB094DD5167E7B8FC0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares issued from warrants exercise</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2E679E32D37A5DB094DD5167E7B8FC0F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2E679E32D37A5DB094DD5167E7B8FC0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2E679E32D37A5DB094DD5167E7B8FC0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2E679E32D37A5DB094DD5167E7B8FC0F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2E679E32D37A5DB094DD5167E7B8FC0F" xlink:type="arc" />
    <link:label id="lab_abus_NumberofShareBasedCompensationPlans_C0140F8F4777E1408F4D5167E7B883E1_terseLabel_en-US" xlink:label="lab_abus_NumberofShareBasedCompensationPlans_C0140F8F4777E1408F4D5167E7B883E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share-based compensation plans</link:label>
    <link:label id="lab_abus_NumberofShareBasedCompensationPlans_C0140F8F4777E1408F4D5167E7B883E1_label_en-US" xlink:label="lab_abus_NumberofShareBasedCompensationPlans_C0140F8F4777E1408F4D5167E7B883E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Share-Based Compensation Plans</link:label>
    <link:label id="lab_abus_NumberofShareBasedCompensationPlans_C0140F8F4777E1408F4D5167E7B883E1_documentation_en-US" xlink:label="lab_abus_NumberofShareBasedCompensationPlans_C0140F8F4777E1408F4D5167E7B883E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Share-Based Compensation Plans</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_NumberofShareBasedCompensationPlans" xlink:label="loc_abus_NumberofShareBasedCompensationPlans_C0140F8F4777E1408F4D5167E7B883E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NumberofShareBasedCompensationPlans_C0140F8F4777E1408F4D5167E7B883E1" xlink:to="lab_abus_NumberofShareBasedCompensationPlans_C0140F8F4777E1408F4D5167E7B883E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0F8C7D66BA15C2C06AD5167E7B89C13_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0F8C7D66BA15C2C06AD5167E7B89C13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected option term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0F8C7D66BA15C2C06AD5167E7B89C13_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0F8C7D66BA15C2C06AD5167E7B89C13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0F8C7D66BA15C2C06AD5167E7B89C13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0F8C7D66BA15C2C06AD5167E7B89C13" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0F8C7D66BA15C2C06AD5167E7B89C13" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F22CE8E6D1563660D2BB5167E7B810B8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F22CE8E6D1563660D2BB5167E7B810B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F22CE8E6D1563660D2BB5167E7B810B8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F22CE8E6D1563660D2BB5167E7B810B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F22CE8E6D1563660D2BB5167E7B810B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F22CE8E6D1563660D2BB5167E7B810B8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F22CE8E6D1563660D2BB5167E7B810B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0E9277A09195225343E35167E7B87AF0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0E9277A09195225343E35167E7B87AF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0E9277A09195225343E35167E7B87AF0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0E9277A09195225343E35167E7B87AF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0E9277A09195225343E35167E7B87AF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0E9277A09195225343E35167E7B87AF0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0E9277A09195225343E35167E7B87AF0" xlink:type="arc" />
    <link:label id="lab_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments_AA3FEF8604D953A0C1EC51B41AC4E26F_terseLabel_en-US" xlink:label="lab_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments_AA3FEF8604D953A0C1EC51B41AC4E26F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of executive officers granted options with new appointments</link:label>
    <link:label id="lab_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments_AA3FEF8604D953A0C1EC51B41AC4E26F_label_en-US" xlink:label="lab_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments_AA3FEF8604D953A0C1EC51B41AC4E26F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Executive Officers Granted Options With New Appointments</link:label>
    <link:label id="lab_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments_AA3FEF8604D953A0C1EC51B41AC4E26F_documentation_en-US" xlink:label="lab_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments_AA3FEF8604D953A0C1EC51B41AC4E26F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Executive Officers Granted Options With New Appointments</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments" xlink:label="loc_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments_AA3FEF8604D953A0C1EC51B41AC4E26F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments_AA3FEF8604D953A0C1EC51B41AC4E26F" xlink:to="lab_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments_AA3FEF8604D953A0C1EC51B41AC4E26F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF187D84C94A4EE4635A5167E7B83500_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF187D84C94A4EE4635A5167E7B83500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of stock-based compensation awards approved to be issued</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF187D84C94A4EE4635A5167E7B83500_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF187D84C94A4EE4635A5167E7B83500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF187D84C94A4EE4635A5167E7B83500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF187D84C94A4EE4635A5167E7B83500" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF187D84C94A4EE4635A5167E7B83500" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_67E2EABA08433FE9CFDD5167E7B8201C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_67E2EABA08433FE9CFDD5167E7B8201C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of consideration issued</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_67E2EABA08433FE9CFDD5167E7B8201C_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_67E2EABA08433FE9CFDD5167E7B8201C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_67E2EABA08433FE9CFDD5167E7B8201C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_67E2EABA08433FE9CFDD5167E7B8201C" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_67E2EABA08433FE9CFDD5167E7B8201C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A2975673089C1830397E5167E7B81248_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A2975673089C1830397E5167E7B81248" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A2975673089C1830397E5167E7B81248_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A2975673089C1830397E5167E7B81248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A2975673089C1830397E5167E7B81248" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A2975673089C1830397E5167E7B81248" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A2975673089C1830397E5167E7B81248" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_6F88EFB84EAFF2C0202F5167E7B884C4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_6F88EFB84EAFF2C0202F5167E7B884C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of exercisable options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_6F88EFB84EAFF2C0202F5167E7B884C4_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_6F88EFB84EAFF2C0202F5167E7B884C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_6F88EFB84EAFF2C0202F5167E7B884C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_6F88EFB84EAFF2C0202F5167E7B884C4" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_6F88EFB84EAFF2C0202F5167E7B884C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7CCAD9899CBC118CFF085167E7B8E4A8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7CCAD9899CBC118CFF085167E7B8E4A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of in-the-money options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7CCAD9899CBC118CFF085167E7B8E4A8_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7CCAD9899CBC118CFF085167E7B8E4A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7CCAD9899CBC118CFF085167E7B8E4A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7CCAD9899CBC118CFF085167E7B8E4A8" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7CCAD9899CBC118CFF085167E7B8E4A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_87D0F54F8C0FFA70AEF55167E7B9CA75_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_87D0F54F8C0FFA70AEF55167E7B9CA75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life for options expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_87D0F54F8C0FFA70AEF55167E7B9CA75_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_87D0F54F8C0FFA70AEF55167E7B9CA75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_87D0F54F8C0FFA70AEF55167E7B9CA75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_87D0F54F8C0FFA70AEF55167E7B9CA75" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_87D0F54F8C0FFA70AEF55167E7B9CA75" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_BF1FC3AB52D16F55E2765167E7B9FDD0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_BF1FC3AB52D16F55E2765167E7B9FDD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average exercise price for options expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_BF1FC3AB52D16F55E2765167E7B9FDD0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_BF1FC3AB52D16F55E2765167E7B9FDD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_BF1FC3AB52D16F55E2765167E7B9FDD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_BF1FC3AB52D16F55E2765167E7B9FDD0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_BF1FC3AB52D16F55E2765167E7B9FDD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A1A2CC538DA6508A6DF15167E7B9DA42_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A1A2CC538DA6508A6DF15167E7B9DA42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of option expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A1A2CC538DA6508A6DF15167E7B9DA42_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A1A2CC538DA6508A6DF15167E7B9DA42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A1A2CC538DA6508A6DF15167E7B9DA42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A1A2CC538DA6508A6DF15167E7B9DA42" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A1A2CC538DA6508A6DF15167E7B9DA42" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42414AFADED704E3B9DF5167E7B9FFD4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42414AFADED704E3B9DF5167E7B9FFD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of options that vested during period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42414AFADED704E3B9DF5167E7B9FFD4_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42414AFADED704E3B9DF5167E7B9FFD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42414AFADED704E3B9DF5167E7B9FFD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42414AFADED704E3B9DF5167E7B9FFD4" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42414AFADED704E3B9DF5167E7B9FFD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_881EDCEC404BBE5915315167E7B93EB9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_881EDCEC404BBE5915315167E7B93EB9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_881EDCEC404BBE5915315167E7B93EB9_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_881EDCEC404BBE5915315167E7B93EB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_881EDCEC404BBE5915315167E7B93EB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_881EDCEC404BBE5915315167E7B93EB9" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_881EDCEC404BBE5915315167E7B93EB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F8035EA9C1F00EDDA5365167E7B9D606_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F8035EA9C1F00EDDA5365167E7B9D606" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for future exercise</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F8035EA9C1F00EDDA5365167E7B9D606_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F8035EA9C1F00EDDA5365167E7B9D606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F8035EA9C1F00EDDA5365167E7B9D606" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F8035EA9C1F00EDDA5365167E7B9D606" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F8035EA9C1F00EDDA5365167E7B9D606" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentOptionsExercisePrice_06829610CAC6DD40F74B5167E7B923A8_terseLabel_en-US" xlink:label="lab_invest_InvestmentOptionsExercisePrice_06829610CAC6DD40F74B5167E7B923A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise price (in CAD per share)</link:label>
    <link:label id="lab_invest_InvestmentOptionsExercisePrice_06829610CAC6DD40F74B5167E7B923A8_label_en-US" xlink:label="lab_invest_InvestmentOptionsExercisePrice_06829610CAC6DD40F74B5167E7B923A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Options, Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_invest_InvestmentOptionsExercisePrice_06829610CAC6DD40F74B5167E7B923A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentOptionsExercisePrice_06829610CAC6DD40F74B5167E7B923A8" xlink:to="lab_invest_InvestmentOptionsExercisePrice_06829610CAC6DD40F74B5167E7B923A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_D8062F83DF1DC74DD09E5167E7B91060_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_D8062F83DF1DC74DD09E5167E7B91060" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_D8062F83DF1DC74DD09E5167E7B91060_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_D8062F83DF1DC74DD09E5167E7B91060" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_D8062F83DF1DC74DD09E5167E7B91060" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1_D8062F83DF1DC74DD09E5167E7B91060" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1_D8062F83DF1DC74DD09E5167E7B91060" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6E6AA9825A372588585C5167E7B90099_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6E6AA9825A372588585C5167E7B90099" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised - Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6E6AA9825A372588585C5167E7B90099_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6E6AA9825A372588585C5167E7B90099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6E6AA9825A372588585C5167E7B90099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6E6AA9825A372588585C5167E7B90099" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6E6AA9825A372588585C5167E7B90099" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_BEBA7E5DE9EB15DEF5CB5167E7B99C28_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_BEBA7E5DE9EB15DEF5CB5167E7B99C28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_BEBA7E5DE9EB15DEF5CB5167E7B99C28_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_BEBA7E5DE9EB15DEF5CB5167E7B99C28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_BEBA7E5DE9EB15DEF5CB5167E7B99C28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_BEBA7E5DE9EB15DEF5CB5167E7B99C28" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_BEBA7E5DE9EB15DEF5CB5167E7B99C28" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_F52A78DE8DC18C71BB475167E7B984B2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_F52A78DE8DC18C71BB475167E7B984B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_F52A78DE8DC18C71BB475167E7B984B2_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_F52A78DE8DC18C71BB475167E7B984B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_F52A78DE8DC18C71BB475167E7B984B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_F52A78DE8DC18C71BB475167E7B984B2" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedDividendRate_F52A78DE8DC18C71BB475167E7B984B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_B93B158D0139627058545167E7B9BE16_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_B93B158D0139627058545167E7B9BE16" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected average term (years)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_B93B158D0139627058545167E7B9BE16_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_B93B158D0139627058545167E7B9BE16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_B93B158D0139627058545167E7B9BE16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm_B93B158D0139627058545167E7B9BE16" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm_B93B158D0139627058545167E7B9BE16" xlink:type="arc" />
    <link:label id="lab_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_984B266233DF2214CB245167E7B9907B_terseLabel_en-US" xlink:label="lab_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_984B266233DF2214CB245167E7B9907B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, fair value amount attributed as pre-combination service and included as part of acquisition consideration</link:label>
    <link:label id="lab_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_984B266233DF2214CB245167E7B9907B_label_en-US" xlink:label="lab_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_984B266233DF2214CB245167E7B9907B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Equity Interest Issued Or Issuable Value Assigned Attributed As Pre Combination Service And Included As Part Of Total Purchase Price</link:label>
    <link:label id="lab_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_984B266233DF2214CB245167E7B9907B_documentation_en-US" xlink:label="lab_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_984B266233DF2214CB245167E7B9907B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition Equity Interest Issued Or Issuable Value Assigned Attributed As Pre Combination Service And Included As Part Of Total Purchase Price</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:label="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_984B266233DF2214CB245167E7B9907B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_984B266233DF2214CB245167E7B9907B" xlink:to="lab_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_984B266233DF2214CB245167E7B9907B" xlink:type="arc" />
    <link:label id="lab_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_CEFA8866135C2E92E2885167E7B9AA47_terseLabel_en-US" xlink:label="lab_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_CEFA8866135C2E92E2885167E7B9AA47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, post-combination attribution recognized as compensation expense</link:label>
    <link:label id="lab_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_CEFA8866135C2E92E2885167E7B9AA47_label_en-US" xlink:label="lab_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_CEFA8866135C2E92E2885167E7B9AA47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Equity Interest Issued Or Issuable Value Assigned Attributed As Post Combination Service And Not Included As Part Of Total Purchase Price</link:label>
    <link:label id="lab_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_CEFA8866135C2E92E2885167E7B9AA47_documentation_en-US" xlink:label="lab_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_CEFA8866135C2E92E2885167E7B9AA47" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition Equity Interest Issued Or Issuable Value Assigned Attributed As Post Combination Service And Not Included As Part Of Total Purchase Price</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice" xlink:label="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_CEFA8866135C2E92E2885167E7B9AA47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_CEFA8866135C2E92E2885167E7B9AA47" xlink:to="lab_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_CEFA8866135C2E92E2885167E7B9AA47" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_897C057F0043F6910D315167E7B97D71_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_897C057F0043F6910D315167E7B97D71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_897C057F0043F6910D315167E7B97D71_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_897C057F0043F6910D315167E7B97D71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_897C057F0043F6910D315167E7B97D71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_897C057F0043F6910D315167E7B97D71" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_897C057F0043F6910D315167E7B97D71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_006DD2DE990553A515EF5167E7B9842D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_006DD2DE990553A515EF5167E7B9842D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_006DD2DE990553A515EF5167E7B9842D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_006DD2DE990553A515EF5167E7B9842D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_006DD2DE990553A515EF5167E7B9842D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_006DD2DE990553A515EF5167E7B9842D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_006DD2DE990553A515EF5167E7B9842D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62F439558F49F671D0925167E7B9B9E8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62F439558F49F671D0925167E7B9B9E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unearned compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62F439558F49F671D0925167E7B9B9E8_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62F439558F49F671D0925167E7B9B9E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62F439558F49F671D0925167E7B9B9E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62F439558F49F671D0925167E7B9B9E8" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62F439558F49F671D0925167E7B9B9E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22AF587E8FDC606E7E975167E7B957B6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22AF587E8FDC606E7E975167E7B957B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unearned compensation expense, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22AF587E8FDC606E7E975167E7B957B6_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22AF587E8FDC606E7E975167E7B957B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22AF587E8FDC606E7E975167E7B957B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22AF587E8FDC606E7E975167E7B957B6" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22AF587E8FDC606E7E975167E7B957B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_175CA4EC8F592EF6F6D75167E7B99023_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_175CA4EC8F592EF6F6D75167E7B99023" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of options outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_175CA4EC8F592EF6F6D75167E7B99023" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_175CA4EC8F592EF6F6D75167E7B99023" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_175CA4EC8F592EF6F6D75167E7B99023" xlink:type="arc" />
    <link:label id="lab_abus_PotentialProceedsOfAdditionalSharesAuthorized_E19275DA83E233A53C895167E7B97AFA_terseLabel_en-US" xlink:label="lab_abus_PotentialProceedsOfAdditionalSharesAuthorized_E19275DA83E233A53C895167E7B97AFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Proceeds of Additional Shares Authorized</link:label>
    <link:label id="lab_abus_PotentialProceedsOfAdditionalSharesAuthorized_E19275DA83E233A53C895167E7B97AFA_label_en-US" xlink:label="lab_abus_PotentialProceedsOfAdditionalSharesAuthorized_E19275DA83E233A53C895167E7B97AFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Proceeds of Additional Shares Authorized</link:label>
    <link:label id="lab_abus_PotentialProceedsOfAdditionalSharesAuthorized_E19275DA83E233A53C895167E7B97AFA_documentation_en-US" xlink:label="lab_abus_PotentialProceedsOfAdditionalSharesAuthorized_E19275DA83E233A53C895167E7B97AFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The potential cash inflow from the additional capital contribution to the entity if an option is exercised.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_PotentialProceedsOfAdditionalSharesAuthorized" xlink:label="loc_abus_PotentialProceedsOfAdditionalSharesAuthorized_E19275DA83E233A53C895167E7B97AFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_PotentialProceedsOfAdditionalSharesAuthorized_E19275DA83E233A53C895167E7B97AFA" xlink:to="lab_abus_PotentialProceedsOfAdditionalSharesAuthorized_E19275DA83E233A53C895167E7B97AFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AFBF244724AF7DF9064A3857C9708BA1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AFBF244724AF7DF9064A3857C9708BA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AFBF244724AF7DF9064A3857C9708BA1_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AFBF244724AF7DF9064A3857C9708BA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AFBF244724AF7DF9064A3857C9708BA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AFBF244724AF7DF9064A3857C9708BA1" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AFBF244724AF7DF9064A3857C9708BA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:type="arc" />
    <link:label id="lab_abus_LaboratoryEquipmentMember_96CE844CB157A76D6EA13857C970E45A_verboseLabel_en-US" xlink:label="lab_abus_LaboratoryEquipmentMember_96CE844CB157A76D6EA13857C970E45A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_abus_LaboratoryEquipmentMember_96CE844CB157A76D6EA13857C970E45A_label_en-US" xlink:label="lab_abus_LaboratoryEquipmentMember_96CE844CB157A76D6EA13857C970E45A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_abus_LaboratoryEquipmentMember_96CE844CB157A76D6EA13857C970E45A_documentation_en-US" xlink:label="lab_abus_LaboratoryEquipmentMember_96CE844CB157A76D6EA13857C970E45A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the laboratory equipment.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_LaboratoryEquipmentMember" xlink:label="loc_abus_LaboratoryEquipmentMember_96CE844CB157A76D6EA13857C970E45A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LaboratoryEquipmentMember_96CE844CB157A76D6EA13857C970E45A" xlink:to="lab_abus_LaboratoryEquipmentMember_96CE844CB157A76D6EA13857C970E45A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_41986536DC411D85777C3857C970AA9E_verboseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_41986536DC411D85777C3857C970AA9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Computer and office equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_41986536DC411D85777C3857C970AA9E_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_41986536DC411D85777C3857C970AA9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_41986536DC411D85777C3857C970AA9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_41986536DC411D85777C3857C970AA9E" xlink:to="lab_us-gaap_ComputerEquipmentMember_41986536DC411D85777C3857C970AA9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_3B7093F504EEE7EFFA793857C970DC1B_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_3B7093F504EEE7EFFA793857C970DC1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_3B7093F504EEE7EFFA793857C970DC1B_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_3B7093F504EEE7EFFA793857C970DC1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3B7093F504EEE7EFFA793857C970DC1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_3B7093F504EEE7EFFA793857C970DC1B" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_3B7093F504EEE7EFFA793857C970DC1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_114C9767A5AEF7F59E1D3857C970ED24_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_114C9767A5AEF7F59E1D3857C970ED24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_114C9767A5AEF7F59E1D3857C970ED24_label_en-US" xlink:label="lab_us-gaap_MinimumMember_114C9767A5AEF7F59E1D3857C970ED24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_114C9767A5AEF7F59E1D3857C970ED24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_114C9767A5AEF7F59E1D3857C970ED24" xlink:to="lab_us-gaap_MinimumMember_114C9767A5AEF7F59E1D3857C970ED24" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_25D21BD5B86D44F69F853857C970ADF4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_25D21BD5B86D44F69F853857C970ADF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_25D21BD5B86D44F69F853857C970ADF4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_25D21BD5B86D44F69F853857C970ADF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25D21BD5B86D44F69F853857C970ADF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25D21BD5B86D44F69F853857C970ADF4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_25D21BD5B86D44F69F853857C970ADF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_911876483CA57560C7C03857C9705C60_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_911876483CA57560C7C03857C9705C60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_911876483CA57560C7C03857C9705C60_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_911876483CA57560C7C03857C9705C60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_911876483CA57560C7C03857C9705C60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_911876483CA57560C7C03857C9705C60" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_911876483CA57560C7C03857C9705C60" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_962FAFFED8F52CA97F6333A2019C63C3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_962FAFFED8F52CA97F6333A2019C63C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of minimum rent and estimated operating cost commitment, net of lease inducements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_962FAFFED8F52CA97F6333A2019C63C3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_962FAFFED8F52CA97F6333A2019C63C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_962FAFFED8F52CA97F6333A2019C63C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_962FAFFED8F52CA97F6333A2019C63C3" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_962FAFFED8F52CA97F6333A2019C63C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_B921FFB9955E4F461D525167E8A714E1_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_B921FFB9955E4F461D525167E8A714E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_B921FFB9955E4F461D525167E8A714E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B921FFB9955E4F461D525167E8A714E1" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_B921FFB9955E4F461D525167E8A714E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:to="lab_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0" xlink:to="lab_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_331C53B71E4F0BFD67AB5167E8A799BE_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_331C53B71E4F0BFD67AB5167E8A799BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_331C53B71E4F0BFD67AB5167E8A799BE_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_331C53B71E4F0BFD67AB5167E8A799BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_331C53B71E4F0BFD67AB5167E8A799BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_331C53B71E4F0BFD67AB5167E8A799BE" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_331C53B71E4F0BFD67AB5167E8A799BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_7DE6689EE1CB2F9061415167E8A75621_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_7DE6689EE1CB2F9061415167E8A75621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_7DE6689EE1CB2F9061415167E8A75621_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_7DE6689EE1CB2F9061415167E8A75621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_7DE6689EE1CB2F9061415167E8A75621" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_7DE6689EE1CB2F9061415167E8A75621" xlink:to="lab_us-gaap_ShortTermInvestments_7DE6689EE1CB2F9061415167E8A75621" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9F87763679550CBA24235167E8A7962C_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_9F87763679550CBA24235167E8A7962C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9F87763679550CBA24235167E8A7962C_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_9F87763679550CBA24235167E8A7962C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9F87763679550CBA24235167E8A7962C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_9F87763679550CBA24235167E8A7962C" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_9F87763679550CBA24235167E8A7962C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnbilledReceivablesCurrent_D4265D2489FF060B71375167E8A7F602_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledReceivablesCurrent_D4265D2489FF060B71375167E8A7F602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_D4265D2489FF060B71375167E8A7F602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledReceivablesCurrent_D4265D2489FF060B71375167E8A7F602" xlink:to="lab_us-gaap_UnbilledReceivablesCurrent_D4265D2489FF060B71375167E8A7F602" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_A18A4FBF01E6E79DE2EB5167E8A758BE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable_A18A4FBF01E6E79DE2EB5167E8A758BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment tax credits receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_A18A4FBF01E6E79DE2EB5167E8A758BE_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable_A18A4FBF01E6E79DE2EB5167E8A758BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_A18A4FBF01E6E79DE2EB5167E8A758BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable_A18A4FBF01E6E79DE2EB5167E8A758BE" xlink:to="lab_us-gaap_IncomeTaxesReceivable_A18A4FBF01E6E79DE2EB5167E8A758BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C62594F90C0F3ADD1BA55167E8A79B55_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C62594F90C0F3ADD1BA55167E8A79B55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C62594F90C0F3ADD1BA55167E8A79B55_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C62594F90C0F3ADD1BA55167E8A79B55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C62594F90C0F3ADD1BA55167E8A79B55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C62594F90C0F3ADD1BA55167E8A79B55" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C62594F90C0F3ADD1BA55167E8A79B55" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_74485D8D2CC0155E68075167E8A788D4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_74485D8D2CC0155E68075167E8A788D4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_74485D8D2CC0155E68075167E8A788D4_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_74485D8D2CC0155E68075167E8A788D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_74485D8D2CC0155E68075167E8A788D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_74485D8D2CC0155E68075167E8A788D4" xlink:to="lab_us-gaap_AssetsCurrent_74485D8D2CC0155E68075167E8A788D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_044839BE2DD85A85E21D5167E8A8E6CB_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_044839BE2DD85A85E21D5167E8A8E6CB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_044839BE2DD85A85E21D5167E8A8E6CB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_044839BE2DD85A85E21D5167E8A8E6CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_044839BE2DD85A85E21D5167E8A8E6CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_044839BE2DD85A85E21D5167E8A8E6CB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_044839BE2DD85A85E21D5167E8A8E6CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0B5B5CB059C9CCE4CB825167E8A84B75_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0B5B5CB059C9CCE4CB825167E8A84B75" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0B5B5CB059C9CCE4CB825167E8A84B75_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0B5B5CB059C9CCE4CB825167E8A84B75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0B5B5CB059C9CCE4CB825167E8A84B75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0B5B5CB059C9CCE4CB825167E8A84B75" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0B5B5CB059C9CCE4CB825167E8A84B75" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_B335C1C6D05266ED3FB15167E8A83E48_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_B335C1C6D05266ED3FB15167E8A83E48" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_B335C1C6D05266ED3FB15167E8A83E48_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_B335C1C6D05266ED3FB15167E8A83E48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_B335C1C6D05266ED3FB15167E8A83E48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_B335C1C6D05266ED3FB15167E8A83E48" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_B335C1C6D05266ED3FB15167E8A83E48" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_65ED581E39E66D9218B15167E8A86EC0_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_65ED581E39E66D9218B15167E8A86EC0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_65ED581E39E66D9218B15167E8A86EC0_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_65ED581E39E66D9218B15167E8A86EC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_65ED581E39E66D9218B15167E8A86EC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_65ED581E39E66D9218B15167E8A86EC0" xlink:to="lab_us-gaap_LongTermInvestments_65ED581E39E66D9218B15167E8A86EC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_B2C61E13DC1438A21EC35167E8A87A2C_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_B2C61E13DC1438A21EC35167E8A87A2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_B2C61E13DC1438A21EC35167E8A87A2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_B2C61E13DC1438A21EC35167E8A87A2C" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_B2C61E13DC1438A21EC35167E8A87A2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_3E94D5202F6E9165F9C55167E8A80021_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_3E94D5202F6E9165F9C55167E8A80021" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_3E94D5202F6E9165F9C55167E8A80021_label_en-US" xlink:label="lab_us-gaap_Assets_3E94D5202F6E9165F9C55167E8A80021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_3E94D5202F6E9165F9C55167E8A80021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_3E94D5202F6E9165F9C55167E8A80021" xlink:to="lab_us-gaap_Assets_3E94D5202F6E9165F9C55167E8A80021" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_C86FE57195E77FF836C55167E8A85210_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_C86FE57195E77FF836C55167E8A85210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_C86FE57195E77FF836C55167E8A85210_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_C86FE57195E77FF836C55167E8A85210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_C86FE57195E77FF836C55167E8A85210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_C86FE57195E77FF836C55167E8A85210" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_C86FE57195E77FF836C55167E8A85210" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E7FCD867A56C0A5DA57E5167E8A8CFE5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E7FCD867A56C0A5DA57E5167E8A8CFE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E7FCD867A56C0A5DA57E5167E8A8CFE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E7FCD867A56C0A5DA57E5167E8A8CFE5" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E7FCD867A56C0A5DA57E5167E8A8CFE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_9A56021D0F1F7E9CE62F5167E8A8BE84_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_9A56021D0F1F7E9CE62F5167E8A8BE84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_9A56021D0F1F7E9CE62F5167E8A8BE84_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_9A56021D0F1F7E9CE62F5167E8A8BE84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_9A56021D0F1F7E9CE62F5167E8A8BE84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_9A56021D0F1F7E9CE62F5167E8A8BE84" xlink:to="lab_us-gaap_DeferredRevenueCurrent_9A56021D0F1F7E9CE62F5167E8A8BE84" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_C9703DBF11010C8689B75167E8A8EED8_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_C9703DBF11010C8689B75167E8A8EED8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_C9703DBF11010C8689B75167E8A8EED8_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_C9703DBF11010C8689B75167E8A8EED8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_C9703DBF11010C8689B75167E8A8EED8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_C9703DBF11010C8689B75167E8A8EED8" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_C9703DBF11010C8689B75167E8A8EED8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_42B9D84C87885E45CDC45167E8A87A84_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_42B9D84C87885E45CDC45167E8A87A84" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_42B9D84C87885E45CDC45167E8A87A84_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_42B9D84C87885E45CDC45167E8A87A84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_42B9D84C87885E45CDC45167E8A87A84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_42B9D84C87885E45CDC45167E8A87A84" xlink:to="lab_us-gaap_LiabilitiesCurrent_42B9D84C87885E45CDC45167E8A87A84" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_3B773E53DA18F9E608875167E8A87576_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_3B773E53DA18F9E608875167E8A87576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_3B773E53DA18F9E608875167E8A87576_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_3B773E53DA18F9E608875167E8A87576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_3B773E53DA18F9E608875167E8A87576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_3B773E53DA18F9E608875167E8A87576" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_3B773E53DA18F9E608875167E8A87576" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A862A7BEC6B992F162685167E8A83348_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A862A7BEC6B992F162685167E8A83348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A862A7BEC6B992F162685167E8A83348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A862A7BEC6B992F162685167E8A83348" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A862A7BEC6B992F162685167E8A83348" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_E99DB6891BA4C6E4BFE55167E8A89A96_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_E99DB6891BA4C6E4BFE55167E8A89A96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_E99DB6891BA4C6E4BFE55167E8A89A96_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_E99DB6891BA4C6E4BFE55167E8A89A96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_E99DB6891BA4C6E4BFE55167E8A89A96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_E99DB6891BA4C6E4BFE55167E8A89A96" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_E99DB6891BA4C6E4BFE55167E8A89A96" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_189FF0C71B1DF2218D3A5167E8A8E85D_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_189FF0C71B1DF2218D3A5167E8A8E85D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_189FF0C71B1DF2218D3A5167E8A8E85D_label_en-US" xlink:label="lab_us-gaap_Liabilities_189FF0C71B1DF2218D3A5167E8A8E85D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_189FF0C71B1DF2218D3A5167E8A8E85D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_189FF0C71B1DF2218D3A5167E8A8E85D" xlink:to="lab_us-gaap_Liabilities_189FF0C71B1DF2218D3A5167E8A8E85D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_E390F09A3018871B58665167E8A8D1D8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_E390F09A3018871B58665167E8A8D1D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_E390F09A3018871B58665167E8A8D1D8_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_E390F09A3018871B58665167E8A8D1D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_E390F09A3018871B58665167E8A8D1D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E390F09A3018871B58665167E8A8D1D8" xlink:to="lab_us-gaap_StockholdersEquityAbstract_E390F09A3018871B58665167E8A8D1D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_5D81C199C7F3D85817E55167E8A8FB34_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_5D81C199C7F3D85817E55167E8A8FB34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares, authorized - unlimited number with no par value, Issued and outstanding: 54,570,691 (December 31, 2014 - 22,438,169)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_5D81C199C7F3D85817E55167E8A8FB34_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_5D81C199C7F3D85817E55167E8A8FB34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_5D81C199C7F3D85817E55167E8A8FB34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_5D81C199C7F3D85817E55167E8A8FB34" xlink:to="lab_us-gaap_CommonStockValue_5D81C199C7F3D85817E55167E8A8FB34" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_6266289F519719D95EDD5167E8A93F56_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_6266289F519719D95EDD5167E8A93F56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_6266289F519719D95EDD5167E8A93F56_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_6266289F519719D95EDD5167E8A93F56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6266289F519719D95EDD5167E8A93F56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_6266289F519719D95EDD5167E8A93F56" xlink:to="lab_us-gaap_AdditionalPaidInCapital_6266289F519719D95EDD5167E8A93F56" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_18EC0F0CAB9B82F607A55167E8A903F0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_18EC0F0CAB9B82F607A55167E8A903F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_18EC0F0CAB9B82F607A55167E8A903F0_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_18EC0F0CAB9B82F607A55167E8A903F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18EC0F0CAB9B82F607A55167E8A903F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18EC0F0CAB9B82F607A55167E8A903F0" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_18EC0F0CAB9B82F607A55167E8A903F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_00B582D010D2CEBDD3F45167E8A96364_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_00B582D010D2CEBDD3F45167E8A96364" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_00B582D010D2CEBDD3F45167E8A96364_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_00B582D010D2CEBDD3F45167E8A96364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_00B582D010D2CEBDD3F45167E8A96364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_00B582D010D2CEBDD3F45167E8A96364" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_00B582D010D2CEBDD3F45167E8A96364" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_E737748C266A051B894A5167E8A90890_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_E737748C266A051B894A5167E8A90890" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_E737748C266A051B894A5167E8A90890_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_E737748C266A051B894A5167E8A90890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E737748C266A051B894A5167E8A90890" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_E737748C266A051B894A5167E8A90890" xlink:to="lab_us-gaap_StockholdersEquity_E737748C266A051B894A5167E8A90890" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_DCE4A6F65FE3FC2ADCEE5167E8A92061_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_DCE4A6F65FE3FC2ADCEE5167E8A92061" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_DCE4A6F65FE3FC2ADCEE5167E8A92061_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_DCE4A6F65FE3FC2ADCEE5167E8A92061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_DCE4A6F65FE3FC2ADCEE5167E8A92061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_DCE4A6F65FE3FC2ADCEE5167E8A92061" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_DCE4A6F65FE3FC2ADCEE5167E8A92061" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8EB1C7860E36339978A352F9486B4AC2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8EB1C7860E36339978A352F9486B4AC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of finalized acquisition purchase price allocation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8EB1C7860E36339978A352F9486B4AC2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8EB1C7860E36339978A352F9486B4AC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8EB1C7860E36339978A352F9486B4AC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8EB1C7860E36339978A352F9486B4AC2" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8EB1C7860E36339978A352F9486B4AC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_F130DFEB3FDF34B4551D52F9486BD2CB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_F130DFEB3FDF34B4551D52F9486BD2CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of identifiable intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_F130DFEB3FDF34B4551D52F9486BD2CB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_F130DFEB3FDF34B4551D52F9486BD2CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_F130DFEB3FDF34B4551D52F9486BD2CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_F130DFEB3FDF34B4551D52F9486BD2CB" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_F130DFEB3FDF34B4551D52F9486BD2CB" xlink:type="arc" />
    <link:label id="lab_abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock_A4BB8FA7DEB2732CF5AC52F9486B7417_terseLabel_en-US" xlink:label="lab_abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock_A4BB8FA7DEB2732CF5AC52F9486B7417" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of revisions and adjustments to business acquisition purchase price allocation</link:label>
    <link:label id="lab_abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock_A4BB8FA7DEB2732CF5AC52F9486B7417_label_en-US" xlink:label="lab_abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock_A4BB8FA7DEB2732CF5AC52F9486B7417" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Revisions and Adjustments To Business Acquisition Purchase Price Allocation [Table Text Block]</link:label>
    <link:label id="lab_abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock_A4BB8FA7DEB2732CF5AC52F9486B7417_documentation_en-US" xlink:label="lab_abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock_A4BB8FA7DEB2732CF5AC52F9486B7417" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of Revisions and Adjustments To Business Acquisition Purchase Price Allocation [Table Text Block]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock" xlink:label="loc_abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock_A4BB8FA7DEB2732CF5AC52F9486B7417" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock_A4BB8FA7DEB2732CF5AC52F9486B7417" xlink:to="lab_abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock_A4BB8FA7DEB2732CF5AC52F9486B7417" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A04A525846EA81D7BA3F52F9486B84EC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A04A525846EA81D7BA3F52F9486B84EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, pro forma financial information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A04A525846EA81D7BA3F52F9486B84EC_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A04A525846EA81D7BA3F52F9486B84EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A04A525846EA81D7BA3F52F9486B84EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A04A525846EA81D7BA3F52F9486B84EC" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A04A525846EA81D7BA3F52F9486B84EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_C7B161B55EE25EE5D7C752F9486B3CE1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_C7B161B55EE25EE5D7C752F9486B3CE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of intangible assets net of impairment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_C7B161B55EE25EE5D7C752F9486B3CE1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_C7B161B55EE25EE5D7C752F9486B3CE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:label="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_C7B161B55EE25EE5D7C752F9486B3CE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_C7B161B55EE25EE5D7C752F9486B3CE1" xlink:to="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_C7B161B55EE25EE5D7C752F9486B3CE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_79107D7CA86C3E78A4FC2EAA60B2CC80_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_79107D7CA86C3E78A4FC2EAA60B2CC80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_79107D7CA86C3E78A4FC2EAA60B2CC80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_79107D7CA86C3E78A4FC2EAA60B2CC80" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_79107D7CA86C3E78A4FC2EAA60B2CC80" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C5F059225498D4EE872C2EAA60B2C477_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C5F059225498D4EE872C2EAA60B2C477" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C5F059225498D4EE872C2EAA60B2C477_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C5F059225498D4EE872C2EAA60B2C477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C5F059225498D4EE872C2EAA60B2C477" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C5F059225498D4EE872C2EAA60B2C477" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C5F059225498D4EE872C2EAA60B2C477" xlink:type="arc" />
    <link:label id="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract_FB01A2821C99474B19D834AE80BB63A6_label_en-US" xlink:label="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract_FB01A2821C99474B19D834AE80BB63A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Grants And Refundable Investment Tax Credits [Abstract]</link:label>
    <link:label id="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract_FB01A2821C99474B19D834AE80BB63A6_documentation_en-US" xlink:label="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract_FB01A2821C99474B19D834AE80BB63A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="abus-20151231.xsd#abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract" xlink:label="loc_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract_FB01A2821C99474B19D834AE80BB63A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract_FB01A2821C99474B19D834AE80BB63A6" xlink:to="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract_FB01A2821C99474B19D834AE80BB63A6" xlink:type="arc" />
    <link:label id="lab_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42_terseLabel_en-US" xlink:label="lab_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Grants and Refundable Investment Tax Credits [Table]</link:label>
    <link:label id="lab_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42_label_en-US" xlink:label="lab_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Grants and Refundable Investment Tax Credits [Table]</link:label>
    <link:label id="lab_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42_documentation_en-US" xlink:label="lab_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="abus-20151231.xsd#abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable" xlink:label="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42" xlink:to="lab_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3A228753E3831C4CCE7334AE80BB95FB_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3A228753E3831C4CCE7334AE80BB95FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3A228753E3831C4CCE7334AE80BB95FB_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3A228753E3831C4CCE7334AE80BB95FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3A228753E3831C4CCE7334AE80BB95FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3A228753E3831C4CCE7334AE80BB95FB" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3A228753E3831C4CCE7334AE80BB95FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047" xlink:type="arc" />
    <link:label id="lab_abus_ISARICMember_FBAC4BF4A6BFC03A424634AE80BC3C13_terseLabel_en-US" xlink:label="lab_abus_ISARICMember_FBAC4BF4A6BFC03A424634AE80BC3C13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ISARIC</link:label>
    <link:label id="lab_abus_ISARICMember_FBAC4BF4A6BFC03A424634AE80BC3C13_label_en-US" xlink:label="lab_abus_ISARICMember_FBAC4BF4A6BFC03A424634AE80BC3C13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ISARIC [Member]</link:label>
    <link:label id="lab_abus_ISARICMember_FBAC4BF4A6BFC03A424634AE80BC3C13_documentation_en-US" xlink:label="lab_abus_ISARICMember_FBAC4BF4A6BFC03A424634AE80BC3C13" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC).</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ISARICMember" xlink:label="loc_abus_ISARICMember_FBAC4BF4A6BFC03A424634AE80BC3C13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ISARICMember_FBAC4BF4A6BFC03A424634AE80BC3C13" xlink:to="lab_abus_ISARICMember_FBAC4BF4A6BFC03A424634AE80BC3C13" xlink:type="arc" />
    <link:label id="lab_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10_terseLabel_en-US" xlink:label="lab_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Grants and Refundable Investment Tax Credits [Line Items]</link:label>
    <link:label id="lab_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10_label_en-US" xlink:label="lab_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Grants and Refundable Investment Tax Credits [Line Items]</link:label>
    <link:label id="lab_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10_documentation_en-US" xlink:label="lab_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="abus-20151231.xsd#abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems" xlink:label="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:to="lab_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromGrants_ED5E52E3F31037BB466834AE80BCB30C_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromGrants_ED5E52E3F31037BB466834AE80BCB30C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from government grants</link:label>
    <link:label id="lab_us-gaap_RevenueFromGrants_ED5E52E3F31037BB466834AE80BCB30C_label_en-US" xlink:label="lab_us-gaap_RevenueFromGrants_ED5E52E3F31037BB466834AE80BCB30C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Grants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_ED5E52E3F31037BB466834AE80BCB30C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromGrants_ED5E52E3F31037BB466834AE80BCB30C" xlink:to="lab_us-gaap_RevenueFromGrants_ED5E52E3F31037BB466834AE80BCB30C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTaxCredit_803FEAD48B90ECE5E4C634AE80BC43EF_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTaxCredit_803FEAD48B90ECE5E4C634AE80BC43EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment tax credit</link:label>
    <link:label id="lab_us-gaap_InvestmentTaxCredit_803FEAD48B90ECE5E4C634AE80BC43EF_label_en-US" xlink:label="lab_us-gaap_InvestmentTaxCredit_803FEAD48B90ECE5E4C634AE80BC43EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Tax Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTaxCredit" xlink:label="loc_us-gaap_InvestmentTaxCredit_803FEAD48B90ECE5E4C634AE80BC43EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTaxCredit_803FEAD48B90ECE5E4C634AE80BC43EF" xlink:to="lab_us-gaap_InvestmentTaxCredit_803FEAD48B90ECE5E4C634AE80BC43EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_DDC97D583ED7F077CE953329B68D3629_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_DDC97D583ED7F077CE953329B68D3629" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_DDC97D583ED7F077CE953329B68D3629_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_DDC97D583ED7F077CE953329B68D3629" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_DDC97D583ED7F077CE953329B68D3629" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_DDC97D583ED7F077CE953329B68D3629" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_DDC97D583ED7F077CE953329B68D3629" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_94BA4D15011CBFD75B4F3F2E89359D8B_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_94BA4D15011CBFD75B4F3F2E89359D8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_94BA4D15011CBFD75B4F3F2E89359D8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_94BA4D15011CBFD75B4F3F2E89359D8B" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_94BA4D15011CBFD75B4F3F2E89359D8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_8C643C9B098E11C59D093F2E89350BE5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_8C643C9B098E11C59D093F2E89350BE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_8C643C9B098E11C59D093F2E89350BE5_label_en-US" xlink:label="lab_us-gaap_StatementTable_8C643C9B098E11C59D093F2E89350BE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8C643C9B098E11C59D093F2E89350BE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_8C643C9B098E11C59D093F2E89350BE5" xlink:to="lab_us-gaap_StatementTable_8C643C9B098E11C59D093F2E89350BE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_C5C3B691A1937AAC80E63F2E8935A539_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_C5C3B691A1937AAC80E63F2E8935A539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research, development, collaborations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C5C3B691A1937AAC80E63F2E8935A539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C5C3B691A1937AAC80E63F2E8935A539" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_C5C3B691A1937AAC80E63F2E8935A539" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="lab_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_46BE7B5FF7129ECCAE933F2E89356354_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_46BE7B5FF7129ECCAE933F2E89356354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss for the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_46BE7B5FF7129ECCAE933F2E89356354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_46BE7B5FF7129ECCAE933F2E89356354" xlink:to="lab_us-gaap_NetIncomeLoss_46BE7B5FF7129ECCAE933F2E89356354" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Items not involving cash:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5DEA17ACE212F7F7163C3F2E89360149_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5DEA17ACE212F7F7163C3F2E89360149" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5DEA17ACE212F7F7163C3F2E89360149_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5DEA17ACE212F7F7163C3F2E89360149" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5DEA17ACE212F7F7163C3F2E89360149" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5DEA17ACE212F7F7163C3F2E89360149" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5DEA17ACE212F7F7163C3F2E89360149" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_107C5FD901B3117D8EFA3F2E89368B11_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_107C5FD901B3117D8EFA3F2E89368B11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation of property and equipment</link:label>
    <link:label id="lab_us-gaap_Depreciation_107C5FD901B3117D8EFA3F2E89368B11_label_en-US" xlink:label="lab_us-gaap_Depreciation_107C5FD901B3117D8EFA3F2E89368B11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_107C5FD901B3117D8EFA3F2E89368B11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_107C5FD901B3117D8EFA3F2E89368B11" xlink:to="lab_us-gaap_Depreciation_107C5FD901B3117D8EFA3F2E89368B11" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F2522175DC91B335792E3F2E89362DC8_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F2522175DC91B335792E3F2E89362DC8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F2522175DC91B335792E3F2E89362DC8_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F2522175DC91B335792E3F2E89362DC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F2522175DC91B335792E3F2E89362DC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F2522175DC91B335792E3F2E89362DC8" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F2522175DC91B335792E3F2E89362DC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_3EB5CDBEBE5C1C8D04693F2E893620BD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_3EB5CDBEBE5C1C8D04693F2E893620BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3EB5CDBEBE5C1C8D04693F2E893620BD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_3EB5CDBEBE5C1C8D04693F2E893620BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3EB5CDBEBE5C1C8D04693F2E893620BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_3EB5CDBEBE5C1C8D04693F2E893620BD" xlink:to="lab_us-gaap_ShareBasedCompensation_3EB5CDBEBE5C1C8D04693F2E893620BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_BE9834A2EA04086E44023F2E893668EC_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_BE9834A2EA04086E44023F2E893668EC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign exchange (gains) losses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_BE9834A2EA04086E44023F2E893668EC_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_BE9834A2EA04086E44023F2E893668EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_BE9834A2EA04086E44023F2E893668EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_BE9834A2EA04086E44023F2E893668EC" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_BE9834A2EA04086E44023F2E893668EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_26AD38B8FEE2D00E8FB33F2E893655C1_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_26AD38B8FEE2D00E8FB33F2E893655C1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_26AD38B8FEE2D00E8FB33F2E893655C1_label_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_26AD38B8FEE2D00E8FB33F2E893655C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_26AD38B8FEE2D00E8FB33F2E893655C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_26AD38B8FEE2D00E8FB33F2E893655C1" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_26AD38B8FEE2D00E8FB33F2E893655C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7A5439ED3019EBCC2B883F2E89364066_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7A5439ED3019EBCC2B883F2E89364066" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7A5439ED3019EBCC2B883F2E89364066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7A5439ED3019EBCC2B883F2E89364066" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7A5439ED3019EBCC2B883F2E89364066" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_806B602262D327B967FF3F2E8936814D_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_806B602262D327B967FF3F2E8936814D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_806B602262D327B967FF3F2E8936814D_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_806B602262D327B967FF3F2E8936814D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_806B602262D327B967FF3F2E8936814D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_806B602262D327B967FF3F2E8936814D" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_806B602262D327B967FF3F2E8936814D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in non-cash operating items:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5E83D6C4A61F549ECE3D3F2E893656EC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5E83D6C4A61F549ECE3D3F2E893656EC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5E83D6C4A61F549ECE3D3F2E893656EC_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5E83D6C4A61F549ECE3D3F2E893656EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5E83D6C4A61F549ECE3D3F2E893656EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5E83D6C4A61F549ECE3D3F2E893656EC" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5E83D6C4A61F549ECE3D3F2E893656EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_1575597DDA2991CE338F3F2E89366AA2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_1575597DDA2991CE338F3F2E89366AA2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_1575597DDA2991CE338F3F2E89366AA2_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_1575597DDA2991CE338F3F2E89366AA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Unbilled Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_1575597DDA2991CE338F3F2E89366AA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_1575597DDA2991CE338F3F2E89366AA2" xlink:to="lab_us-gaap_IncreaseDecreaseInUnbilledReceivables_1575597DDA2991CE338F3F2E89366AA2" xlink:type="arc" />
    <link:label id="lab_abus_IncreaseDecreaseOtherDeferredCostsNet_EFD496B4505441B2B28A3F2E89362F37_negatedTerseLabel_en-US" xlink:label="lab_abus_IncreaseDecreaseOtherDeferredCostsNet_EFD496B4505441B2B28A3F2E89362F37" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred expenses</link:label>
    <link:label id="lab_abus_IncreaseDecreaseOtherDeferredCostsNet_EFD496B4505441B2B28A3F2E89362F37_label_en-US" xlink:label="lab_abus_IncreaseDecreaseOtherDeferredCostsNet_EFD496B4505441B2B28A3F2E89362F37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IncreaseDecreaseOtherDeferredCostsNet</link:label>
    <link:label id="lab_abus_IncreaseDecreaseOtherDeferredCostsNet_EFD496B4505441B2B28A3F2E89362F37_documentation_en-US" xlink:label="lab_abus_IncreaseDecreaseOtherDeferredCostsNet_EFD496B4505441B2B28A3F2E89362F37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in the amount of other deferred costs. Does not include deferred finance costs or deferred acquisition costs of insurance companies.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_IncreaseDecreaseOtherDeferredCostsNet" xlink:label="loc_abus_IncreaseDecreaseOtherDeferredCostsNet_EFD496B4505441B2B28A3F2E89362F37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IncreaseDecreaseOtherDeferredCostsNet_EFD496B4505441B2B28A3F2E89362F37" xlink:to="lab_abus_IncreaseDecreaseOtherDeferredCostsNet_EFD496B4505441B2B28A3F2E89362F37" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_EBAD1C67389A2E83AC3A3F2E8936173C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_EBAD1C67389A2E83AC3A3F2E8936173C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Investment tax credits receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_EBAD1C67389A2E83AC3A3F2E8936173C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_EBAD1C67389A2E83AC3A3F2E8936173C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_EBAD1C67389A2E83AC3A3F2E8936173C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_EBAD1C67389A2E83AC3A3F2E8936173C" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_EBAD1C67389A2E83AC3A3F2E8936173C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08D0255F21E2254A990A3F2E89368DD7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08D0255F21E2254A990A3F2E89368DD7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08D0255F21E2254A990A3F2E89368DD7_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08D0255F21E2254A990A3F2E89368DD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08D0255F21E2254A990A3F2E89368DD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08D0255F21E2254A990A3F2E89368DD7" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08D0255F21E2254A990A3F2E89368DD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76F28B88C2CAF7334D0A3F2E8936EB72_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76F28B88C2CAF7334D0A3F2E8936EB72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76F28B88C2CAF7334D0A3F2E8936EB72_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76F28B88C2CAF7334D0A3F2E8936EB72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76F28B88C2CAF7334D0A3F2E8936EB72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76F28B88C2CAF7334D0A3F2E8936EB72" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76F28B88C2CAF7334D0A3F2E8936EB72" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_F9801F6EC4C4950895763F2E89360842_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_F9801F6EC4C4950895763F2E89360842" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_F9801F6EC4C4950895763F2E89360842_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_F9801F6EC4C4950895763F2E89360842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_F9801F6EC4C4950895763F2E89360842" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_F9801F6EC4C4950895763F2E89360842" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_F9801F6EC4C4950895763F2E89360842" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_211C716CA1DC14E2D3C73F2E8936936B_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_211C716CA1DC14E2D3C73F2E8936936B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_211C716CA1DC14E2D3C73F2E8936936B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_211C716CA1DC14E2D3C73F2E8936936B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_211C716CA1DC14E2D3C73F2E8936936B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_211C716CA1DC14E2D3C73F2E8936936B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_211C716CA1DC14E2D3C73F2E8936936B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromInvestments_E278D2AE1064B4F268293F2E893794FC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromInvestments_E278D2AE1064B4F268293F2E893794FC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposition (acquisition) of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromInvestments_E278D2AE1064B4F268293F2E893794FC_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromInvestments_E278D2AE1064B4F268293F2E893794FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_E278D2AE1064B4F268293F2E893794FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromInvestments_E278D2AE1064B4F268293F2E893794FC" xlink:to="lab_us-gaap_PaymentsForProceedsFromInvestments_E278D2AE1064B4F268293F2E893794FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_CE235DA82C0A451089273F2E8937281A_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition_CE235DA82C0A451089273F2E8937281A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash acquired through acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_CE235DA82C0A451089273F2E8937281A_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition_CE235DA82C0A451089273F2E8937281A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_CE235DA82C0A451089273F2E8937281A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition_CE235DA82C0A451089273F2E8937281A" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition_CE235DA82C0A451089273F2E8937281A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5D93D9FE7E87B696AB53F2E893799F1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5D93D9FE7E87B696AB53F2E893799F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5D93D9FE7E87B696AB53F2E893799F1_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5D93D9FE7E87B696AB53F2E893799F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5D93D9FE7E87B696AB53F2E893799F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5D93D9FE7E87B696AB53F2E893799F1" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5D93D9FE7E87B696AB53F2E893799F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D7BA07D036F7DAFDC0E73F2E893765DB_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D7BA07D036F7DAFDC0E73F2E893765DB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D7BA07D036F7DAFDC0E73F2E893765DB_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D7BA07D036F7DAFDC0E73F2E893765DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D7BA07D036F7DAFDC0E73F2E893765DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D7BA07D036F7DAFDC0E73F2E893765DB" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D7BA07D036F7DAFDC0E73F2E893765DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_79DACFCF001CE2904D7D3F2E89376514_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_79DACFCF001CE2904D7D3F2E89376514" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_79DACFCF001CE2904D7D3F2E89376514_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_79DACFCF001CE2904D7D3F2E89376514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_79DACFCF001CE2904D7D3F2E89376514" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_79DACFCF001CE2904D7D3F2E89376514" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_79DACFCF001CE2904D7D3F2E89376514" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A3A237A5E608B00ABEB03F2E89372377_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A3A237A5E608B00ABEB03F2E89372377" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common shares, net of issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A3A237A5E608B00ABEB03F2E89372377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A3A237A5E608B00ABEB03F2E89372377" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_A3A237A5E608B00ABEB03F2E89372377" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_E64C2C70DE832995E1AD3F2E89370210_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_E64C2C70DE832995E1AD3F2E89370210" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_E64C2C70DE832995E1AD3F2E89370210_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_E64C2C70DE832995E1AD3F2E89370210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_E64C2C70DE832995E1AD3F2E89370210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_E64C2C70DE832995E1AD3F2E89370210" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_E64C2C70DE832995E1AD3F2E89370210" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_4B87A3A2B675F7CC70953F2E8937EB95_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_4B87A3A2B675F7CC70953F2E8937EB95" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to exercise of warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_4B87A3A2B675F7CC70953F2E8937EB95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_4B87A3A2B675F7CC70953F2E8937EB95" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_4B87A3A2B675F7CC70953F2E8937EB95" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CF8786EE316E8F910F7E3F2E89373436_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CF8786EE316E8F910F7E3F2E89373436" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CF8786EE316E8F910F7E3F2E89373436_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CF8786EE316E8F910F7E3F2E89373436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CF8786EE316E8F910F7E3F2E89373436" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CF8786EE316E8F910F7E3F2E89373436" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_CF8786EE316E8F910F7E3F2E89373436" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_44E530C632DF65908F843F2E89378B21_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_44E530C632DF65908F843F2E89378B21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign currency rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_44E530C632DF65908F843F2E89378B21_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_44E530C632DF65908F843F2E89378B21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_44E530C632DF65908F843F2E89378B21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_44E530C632DF65908F843F2E89378B21" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_44E530C632DF65908F843F2E89378B21" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B02A593D37BB9424C493F2E89373735_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B02A593D37BB9424C493F2E89373735" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B02A593D37BB9424C493F2E89373735_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B02A593D37BB9424C493F2E89373735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B02A593D37BB9424C493F2E89373735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B02A593D37BB9424C493F2E89373735" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B02A593D37BB9424C493F2E89373735" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_49A11B81911ADC7EE4E73F2E893774A1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_49A11B81911ADC7EE4E73F2E893774A1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49A11B81911ADC7EE4E73F2E893774A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49A11B81911ADC7EE4E73F2E893774A1" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_49A11B81911ADC7EE4E73F2E893774A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9BE1E26248364CDD75073F2E89370FCD_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9BE1E26248364CDD75073F2E89370FCD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9BE1E26248364CDD75073F2E89370FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9BE1E26248364CDD75073F2E89370FCD" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9BE1E26248364CDD75073F2E89370FCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:type="arc" />
    <link:label id="lab_abus_FairValueOfWarrantsExercisedOnACashlessBasis_3D355EA7041F2343E5FD3F2E8937F372_terseLabel_en-US" xlink:label="lab_abus_FairValueOfWarrantsExercisedOnACashlessBasis_3D355EA7041F2343E5FD3F2E8937F372" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants exercised on a cashless basis</link:label>
    <link:label id="lab_abus_FairValueOfWarrantsExercisedOnACashlessBasis_3D355EA7041F2343E5FD3F2E8937F372_label_en-US" xlink:label="lab_abus_FairValueOfWarrantsExercisedOnACashlessBasis_3D355EA7041F2343E5FD3F2E8937F372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of warrants exercised on a cashless basis</link:label>
    <link:label id="lab_abus_FairValueOfWarrantsExercisedOnACashlessBasis_3D355EA7041F2343E5FD3F2E8937F372_documentation_en-US" xlink:label="lab_abus_FairValueOfWarrantsExercisedOnACashlessBasis_3D355EA7041F2343E5FD3F2E8937F372" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the fair value of warrants exercised on a cashless basis.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_FairValueOfWarrantsExercisedOnACashlessBasis" xlink:label="loc_abus_FairValueOfWarrantsExercisedOnACashlessBasis_3D355EA7041F2343E5FD3F2E8937F372" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_FairValueOfWarrantsExercisedOnACashlessBasis_3D355EA7041F2343E5FD3F2E8937F372" xlink:to="lab_abus_FairValueOfWarrantsExercisedOnACashlessBasis_3D355EA7041F2343E5FD3F2E8937F372" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_AE17DABF0B938CC635DE3F2E8938057F_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds_AE17DABF0B938CC635DE3F2E8938057F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment tax credits received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_AE17DABF0B938CC635DE3F2E8938057F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds_AE17DABF0B938CC635DE3F2E8938057F" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds_AE17DABF0B938CC635DE3F2E8938057F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3E3A6B63B04A5ABA5E1B3F2E8938C122_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3E3A6B63B04A5ABA5E1B3F2E8938C122" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of Arbutus Inc. net of cash acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3E3A6B63B04A5ABA5E1B3F2E8938C122_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3E3A6B63B04A5ABA5E1B3F2E8938C122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3E3A6B63B04A5ABA5E1B3F2E8938C122" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3E3A6B63B04A5ABA5E1B3F2E8938C122" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3E3A6B63B04A5ABA5E1B3F2E8938C122" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_22626A9A1415DC20F06452F59096D68E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_22626A9A1415DC20F06452F59096D68E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance - Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_22626A9A1415DC20F06452F59096D68E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_22626A9A1415DC20F06452F59096D68E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_22626A9A1415DC20F06452F59096D68E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_22626A9A1415DC20F06452F59096D68E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_22626A9A1415DC20F06452F59096D68E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_966D094864B752FB019852F59097DE6A_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_966D094864B752FB019852F59097DE6A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options granted - Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_966D094864B752FB019852F59097DE6A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_966D094864B752FB019852F59097DE6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_966D094864B752FB019852F59097DE6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_966D094864B752FB019852F59097DE6A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_966D094864B752FB019852F59097DE6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0D951485E91F94E6EACF52F5909753CE_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0D951485E91F94E6EACF52F5909753CE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options forfeited, cancelled or expired - Number of optioned common shares (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0D951485E91F94E6EACF52F5909753CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0D951485E91F94E6EACF52F5909753CE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0D951485E91F94E6EACF52F5909753CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B98378924FBF527E375C52F5909794EF_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B98378924FBF527E375C52F5909794EF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance - Aggregate intrinsic value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B98378924FBF527E375C52F5909794EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B98378924FBF527E375C52F5909794EF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B98378924FBF527E375C52F5909794EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3D4A027DE56BBAEE0BD53DF14F7AD00D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3D4A027DE56BBAEE0BD53DF14F7AD00D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3D4A027DE56BBAEE0BD53DF14F7AD00D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3D4A027DE56BBAEE0BD53DF14F7AD00D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3D4A027DE56BBAEE0BD53DF14F7AD00D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3D4A027DE56BBAEE0BD53DF14F7AD00D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3D4A027DE56BBAEE0BD53DF14F7AD00D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2F7C87584866FE4826393E31555D6FBD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2F7C87584866FE4826393E31555D6FBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2F7C87584866FE4826393E31555D6FBD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2F7C87584866FE4826393E31555D6FBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2F7C87584866FE4826393E31555D6FBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2F7C87584866FE4826393E31555D6FBD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2F7C87584866FE4826393E31555D6FBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8A04889A1F2E07E309003E315C3EF0FE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8A04889A1F2E07E309003E315C3EF0FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8A04889A1F2E07E309003E315C3EF0FE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8A04889A1F2E07E309003E315C3EF0FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8A04889A1F2E07E309003E315C3EF0FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8A04889A1F2E07E309003E315C3EF0FE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8A04889A1F2E07E309003E315C3EF0FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1BA8AEDEC3AC4156C4D33DF14F7AA289_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1BA8AEDEC3AC4156C4D33DF14F7AA289" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected average option term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1BA8AEDEC3AC4156C4D33DF14F7AA289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1BA8AEDEC3AC4156C4D33DF14F7AA289" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1BA8AEDEC3AC4156C4D33DF14F7AA289" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_889C610D185CCB2A51C65167E7AC643B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_889C610D185CCB2A51C65167E7AC643B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_889C610D185CCB2A51C65167E7AC643B_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_889C610D185CCB2A51C65167E7AC643B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_889C610D185CCB2A51C65167E7AC643B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_889C610D185CCB2A51C65167E7AC643B" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_889C610D185CCB2A51C65167E7AC643B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_186B981AB1CFC30C43FD5167E7AD8F7F_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_186B981AB1CFC30C43FD5167E7AD8F7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_186B981AB1CFC30C43FD5167E7AD8F7F_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_186B981AB1CFC30C43FD5167E7AD8F7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_186B981AB1CFC30C43FD5167E7AD8F7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_186B981AB1CFC30C43FD5167E7AD8F7F" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_186B981AB1CFC30C43FD5167E7AD8F7F" xlink:type="arc" />
    <link:label id="lab_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6_terseLabel_en-US" xlink:label="lab_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights [Roll Forward]</link:label>
    <link:label id="lab_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6_label_en-US" xlink:label="lab_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights [Roll Forward]</link:label>
    <link:label id="lab_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6_documentation_en-US" xlink:label="lab_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights [Roll Forward]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward" xlink:label="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="lab_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1DE01F24B41EF4FCEEEE5167E7ADBB6B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1DE01F24B41EF4FCEEEE5167E7ADBB6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, Common shares purchasable upon exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1DE01F24B41EF4FCEEEE5167E7ADBB6B_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1DE01F24B41EF4FCEEEE5167E7ADBB6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1DE01F24B41EF4FCEEEE5167E7ADBB6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1DE01F24B41EF4FCEEEE5167E7ADBB6B" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1DE01F24B41EF4FCEEEE5167E7ADBB6B" xlink:type="arc" />
    <link:label id="lab_abus_ClassOfWarrantOrRightExercisedDuringPeriod_A69ACB80F0072DD481915167E7AD6FED_negatedLabel_en-US" xlink:label="lab_abus_ClassOfWarrantOrRightExercisedDuringPeriod_A69ACB80F0072DD481915167E7AD6FED" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised, Common shares purchasable upon exercise of warrants</link:label>
    <link:label id="lab_abus_ClassOfWarrantOrRightExercisedDuringPeriod_A69ACB80F0072DD481915167E7AD6FED_label_en-US" xlink:label="lab_abus_ClassOfWarrantOrRightExercisedDuringPeriod_A69ACB80F0072DD481915167E7AD6FED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercised During Period</link:label>
    <link:label id="lab_abus_ClassOfWarrantOrRightExercisedDuringPeriod_A69ACB80F0072DD481915167E7AD6FED_documentation_en-US" xlink:label="lab_abus_ClassOfWarrantOrRightExercisedDuringPeriod_A69ACB80F0072DD481915167E7AD6FED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the class of warrant or right, exercised during period.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="loc_abus_ClassOfWarrantOrRightExercisedDuringPeriod_A69ACB80F0072DD481915167E7AD6FED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ClassOfWarrantOrRightExercisedDuringPeriod_A69ACB80F0072DD481915167E7AD6FED" xlink:to="lab_abus_ClassOfWarrantOrRightExercisedDuringPeriod_A69ACB80F0072DD481915167E7AD6FED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CDCADB3AAD3C4E8CFC7D5167E7ADE0CD_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CDCADB3AAD3C4E8CFC7D5167E7ADE0CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CDCADB3AAD3C4E8CFC7D5167E7ADE0CD_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CDCADB3AAD3C4E8CFC7D5167E7ADE0CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CDCADB3AAD3C4E8CFC7D5167E7ADE0CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CDCADB3AAD3C4E8CFC7D5167E7ADE0CD" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CDCADB3AAD3C4E8CFC7D5167E7ADE0CD" xlink:type="arc" />
    <link:label id="lab_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_870A5FA4C1C62D45998C5167E7AD75DD_terseLabel_en-US" xlink:label="lab_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_870A5FA4C1C62D45998C5167E7AD75DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised, Weighted average exercise price</link:label>
    <link:label id="lab_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_870A5FA4C1C62D45998C5167E7AD75DD_label_en-US" xlink:label="lab_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_870A5FA4C1C62D45998C5167E7AD75DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Exercised During Period Exercise Price</link:label>
    <link:label id="lab_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_870A5FA4C1C62D45998C5167E7AD75DD_documentation_en-US" xlink:label="lab_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_870A5FA4C1C62D45998C5167E7AD75DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share of warrants or rights exercised during period.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="loc_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_870A5FA4C1C62D45998C5167E7AD75DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_870A5FA4C1C62D45998C5167E7AD75DD" xlink:to="lab_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_870A5FA4C1C62D45998C5167E7AD75DD" xlink:type="arc" />
    <link:label id="lab_abus_ClassOfWarrantorRightOutstandExcercisePriceRange_525675FF39318BAA71F05167E7ADB71A_terseLabel_en-US" xlink:label="lab_abus_ClassOfWarrantorRightOutstandExcercisePriceRange_525675FF39318BAA71F05167E7ADB71A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, Range of exercise prices</link:label>
    <link:label id="lab_abus_ClassOfWarrantorRightOutstandExcercisePriceRange_525675FF39318BAA71F05167E7ADB71A_label_en-US" xlink:label="lab_abus_ClassOfWarrantorRightOutstandExcercisePriceRange_525675FF39318BAA71F05167E7ADB71A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance, Range of exercise prices</link:label>
    <link:label id="lab_abus_ClassOfWarrantorRightOutstandExcercisePriceRange_525675FF39318BAA71F05167E7ADB71A_documentation_en-US" xlink:label="lab_abus_ClassOfWarrantorRightOutstandExcercisePriceRange_525675FF39318BAA71F05167E7ADB71A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the range of prices for outstanding warrants or rights.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantorRightOutstandExcercisePriceRange" xlink:label="loc_abus_ClassOfWarrantorRightOutstandExcercisePriceRange_525675FF39318BAA71F05167E7ADB71A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ClassOfWarrantorRightOutstandExcercisePriceRange_525675FF39318BAA71F05167E7ADB71A" xlink:to="lab_abus_ClassOfWarrantorRightOutstandExcercisePriceRange_525675FF39318BAA71F05167E7ADB71A" xlink:type="arc" />
    <link:label id="lab_abus_ClassOfWarrantsOrRightsExcercisedPriceRange_5FDC9EFA31FD2116448D5167E7AD8FC6_terseLabel_en-US" xlink:label="lab_abus_ClassOfWarrantsOrRightsExcercisedPriceRange_5FDC9EFA31FD2116448D5167E7AD8FC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised, Range of exercise prices</link:label>
    <link:label id="lab_abus_ClassOfWarrantsOrRightsExcercisedPriceRange_5FDC9EFA31FD2116448D5167E7AD8FC6_label_en-US" xlink:label="lab_abus_ClassOfWarrantsOrRightsExcercisedPriceRange_5FDC9EFA31FD2116448D5167E7AD8FC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Excercised Price Range</link:label>
    <link:label id="lab_abus_ClassOfWarrantsOrRightsExcercisedPriceRange_5FDC9EFA31FD2116448D5167E7AD8FC6_documentation_en-US" xlink:label="lab_abus_ClassOfWarrantsOrRightsExcercisedPriceRange_5FDC9EFA31FD2116448D5167E7AD8FC6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the price range for warrants or rights exercised during the period.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantsOrRightsExcercisedPriceRange" xlink:label="loc_abus_ClassOfWarrantsOrRightsExcercisedPriceRange_5FDC9EFA31FD2116448D5167E7AD8FC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ClassOfWarrantsOrRightsExcercisedPriceRange_5FDC9EFA31FD2116448D5167E7AD8FC6" xlink:to="lab_abus_ClassOfWarrantsOrRightsExcercisedPriceRange_5FDC9EFA31FD2116448D5167E7AD8FC6" xlink:type="arc" />
    <link:label id="lab_abus_BalanceWeightedaverageremainingcontractuallife_BF491E2197D8187E33245167E7ADE7D9_terseLabel_en-US" xlink:label="lab_abus_BalanceWeightedaverageremainingcontractuallife_BF491E2197D8187E33245167E7ADE7D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, Weighted average remaining contractual life</link:label>
    <link:label id="lab_abus_BalanceWeightedaverageremainingcontractuallife_BF491E2197D8187E33245167E7ADE7D9_label_en-US" xlink:label="lab_abus_BalanceWeightedaverageremainingcontractuallife_BF491E2197D8187E33245167E7ADE7D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance, Weighted average remaining contractual life</link:label>
    <link:label id="lab_abus_BalanceWeightedaverageremainingcontractuallife_BF491E2197D8187E33245167E7ADE7D9_documentation_en-US" xlink:label="lab_abus_BalanceWeightedaverageremainingcontractuallife_BF491E2197D8187E33245167E7ADE7D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the class of warrant or right price of warrants or rights contractual term.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BalanceWeightedaverageremainingcontractuallife" xlink:label="loc_abus_BalanceWeightedaverageremainingcontractuallife_BF491E2197D8187E33245167E7ADE7D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BalanceWeightedaverageremainingcontractuallife_BF491E2197D8187E33245167E7ADE7D9" xlink:to="lab_abus_BalanceWeightedaverageremainingcontractuallife_BF491E2197D8187E33245167E7ADE7D9" xlink:type="arc" />
    <link:label id="lab_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue_635AC93B282659C7B9815167E7AD1176_verboseLabel_en-US" xlink:label="lab_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue_635AC93B282659C7B9815167E7AD1176" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Balance, Aggregate intrinsic value</link:label>
    <link:label id="lab_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue_635AC93B282659C7B9815167E7AD1176_label_en-US" xlink:label="lab_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue_635AC93B282659C7B9815167E7AD1176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Price Of Warrants Or Rights Intrinsic Value</link:label>
    <link:label id="lab_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue_635AC93B282659C7B9815167E7AD1176_documentation_en-US" xlink:label="lab_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue_635AC93B282659C7B9815167E7AD1176" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the class of warrant or right price of warrants or rights intrinsic value.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue" xlink:label="loc_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue_635AC93B282659C7B9815167E7AD1176" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue_635AC93B282659C7B9815167E7AD1176" xlink:to="lab_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue_635AC93B282659C7B9815167E7AD1176" xlink:type="arc" />
    <link:label id="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_C4567DC976CBBCA95A145167E8162747_terseLabel_en-US" xlink:label="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_C4567DC976CBBCA95A145167E8162747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wholly-owned subsidiaries</link:label>
    <link:label id="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_C4567DC976CBBCA95A145167E8162747_label_en-US" xlink:label="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_C4567DC976CBBCA95A145167E8162747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wholly-Owned Subsidiaries Included in Financial Statements</link:label>
    <link:label id="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_C4567DC976CBBCA95A145167E8162747_documentation_en-US" xlink:label="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_C4567DC976CBBCA95A145167E8162747" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of wholly owned subsidiaries included in the reporting of the financial statements.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements" xlink:label="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_C4567DC976CBBCA95A145167E8162747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_C4567DC976CBBCA95A145167E8162747" xlink:to="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_C4567DC976CBBCA95A145167E8162747" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_CEA852181458FD2EC8C85167E8165454_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_CEA852181458FD2EC8C85167E8165454" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_CEA852181458FD2EC8C85167E8165454" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_CEA852181458FD2EC8C85167E8165454" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_CEA852181458FD2EC8C85167E8165454" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_B259A75509D00CE378445167E816D1EC_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_B259A75509D00CE378445167E816D1EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive common shares excluded from calculation of income per common share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_B259A75509D00CE378445167E816D1EC_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_B259A75509D00CE378445167E816D1EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_B259A75509D00CE378445167E816D1EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_B259A75509D00CE378445167E816D1EC" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_B259A75509D00CE378445167E816D1EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="lab_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_5DDCD5F1990430089F6D5212C54BE13C_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_5DDCD5F1990430089F6D5212C54BE13C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_5DDCD5F1990430089F6D5212C54BE13C_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_5DDCD5F1990430089F6D5212C54BE13C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_5DDCD5F1990430089F6D5212C54BE13C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_5DDCD5F1990430089F6D5212C54BE13C" xlink:to="lab_us-gaap_RevenuesAbstract_5DDCD5F1990430089F6D5212C54BE13C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractsRevenue_504D8F0EF11B117FD4945212C54BB6F6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractsRevenue_504D8F0EF11B117FD4945212C54BB6F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborations and contracts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_504D8F0EF11B117FD4945212C54BB6F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractsRevenue_504D8F0EF11B117FD4945212C54BB6F6" xlink:to="lab_us-gaap_ContractsRevenue_504D8F0EF11B117FD4945212C54BB6F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_0E0CBBA1475FCE97BCE35212C54BDB56_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_0E0CBBA1475FCE97BCE35212C54BDB56" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_0E0CBBA1475FCE97BCE35212C54BDB56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_0E0CBBA1475FCE97BCE35212C54BDB56" xlink:to="lab_us-gaap_Revenues_0E0CBBA1475FCE97BCE35212C54BDB56" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_3B060C0E992CA6F704495212C54BC0B9_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_3B060C0E992CA6F704495212C54BC0B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_3B060C0E992CA6F704495212C54BC0B9_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_3B060C0E992CA6F704495212C54BC0B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3B060C0E992CA6F704495212C54BC0B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3B060C0E992CA6F704495212C54BC0B9" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_3B060C0E992CA6F704495212C54BC0B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_A825BE630738D515E8F35212C54BDC3D_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_A825BE630738D515E8F35212C54BDC3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research, development, collaborations and contracts</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_A825BE630738D515E8F35212C54BDC3D_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_A825BE630738D515E8F35212C54BDC3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_A825BE630738D515E8F35212C54BDC3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_A825BE630738D515E8F35212C54BDC3D" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_A825BE630738D515E8F35212C54BDC3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_E944D4DDB20F662AFBAC5212C54B9191_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_E944D4DDB20F662AFBAC5212C54B9191" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_E944D4DDB20F662AFBAC5212C54B9191_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_E944D4DDB20F662AFBAC5212C54B9191" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_E944D4DDB20F662AFBAC5212C54B9191" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_E944D4DDB20F662AFBAC5212C54B9191" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_E944D4DDB20F662AFBAC5212C54B9191" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_BDA02D54C71C9CF804AF5212C54C2821_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_BDA02D54C71C9CF804AF5212C54C2821" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_BDA02D54C71C9CF804AF5212C54C2821_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_BDA02D54C71C9CF804AF5212C54C2821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_BDA02D54C71C9CF804AF5212C54C2821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_BDA02D54C71C9CF804AF5212C54C2821" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_BDA02D54C71C9CF804AF5212C54C2821" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_202B8FC3A9F14B9BAF915212C54C1B06_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_202B8FC3A9F14B9BAF915212C54C1B06" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_202B8FC3A9F14B9BAF915212C54C1B06_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_202B8FC3A9F14B9BAF915212C54C1B06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_202B8FC3A9F14B9BAF915212C54C1B06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_202B8FC3A9F14B9BAF915212C54C1B06" xlink:to="lab_us-gaap_OperatingExpenses_202B8FC3A9F14B9BAF915212C54C1B06" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5A0A2167D10DB9E6670E5212C54C8E3B_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_5A0A2167D10DB9E6670E5212C54C8E3B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5A0A2167D10DB9E6670E5212C54C8E3B_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_5A0A2167D10DB9E6670E5212C54C8E3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5A0A2167D10DB9E6670E5212C54C8E3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_5A0A2167D10DB9E6670E5212C54C8E3B" xlink:to="lab_us-gaap_OperatingIncomeLoss_5A0A2167D10DB9E6670E5212C54C8E3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_A7ADABD49FCA683BD2075212C54CD2F7_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_A7ADABD49FCA683BD2075212C54CD2F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (losses)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_A7ADABD49FCA683BD2075212C54CD2F7_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_A7ADABD49FCA683BD2075212C54CD2F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_A7ADABD49FCA683BD2075212C54CD2F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_A7ADABD49FCA683BD2075212C54CD2F7" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_A7ADABD49FCA683BD2075212C54CD2F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_260F801C4F40C5950D3F5212C54C44A8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_260F801C4F40C5950D3F5212C54C44A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_260F801C4F40C5950D3F5212C54C44A8_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_260F801C4F40C5950D3F5212C54C44A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_260F801C4F40C5950D3F5212C54C44A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_260F801C4F40C5950D3F5212C54C44A8" xlink:to="lab_us-gaap_InvestmentIncomeInterest_260F801C4F40C5950D3F5212C54C44A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3D136BEE2A6FF39329DB5212C54C20E2_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3D136BEE2A6FF39329DB5212C54C20E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3D136BEE2A6FF39329DB5212C54C20E2_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3D136BEE2A6FF39329DB5212C54C20E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3D136BEE2A6FF39329DB5212C54C20E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3D136BEE2A6FF39329DB5212C54C20E2" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3D136BEE2A6FF39329DB5212C54C20E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_2AB9969C99D8C9F2470A5212C54C8D81_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_2AB9969C99D8C9F2470A5212C54C8D81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease (increase) in fair value of warrant liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_2AB9969C99D8C9F2470A5212C54C8D81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_2AB9969C99D8C9F2470A5212C54C8D81" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_2AB9969C99D8C9F2470A5212C54C8D81" xlink:type="arc" />
    <link:label id="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_987B528A49617CA83B5B5212C54C4B4E_negatedTerseLabel_en-US" xlink:label="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_987B528A49617CA83B5B5212C54C4B4E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of contingent consideration</link:label>
    <link:label id="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_987B528A49617CA83B5B5212C54C4B4E_label_en-US" xlink:label="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_987B528A49617CA83B5B5212C54C4B4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Fair Value Of Contingent Consideration Liability</link:label>
    <link:label id="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_987B528A49617CA83B5B5212C54C4B4E_documentation_en-US" xlink:label="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_987B528A49617CA83B5B5212C54C4B4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Fair Value Of Contingent Consideration Liability</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_987B528A49617CA83B5B5212C54C4B4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_987B528A49617CA83B5B5212C54C4B4E" xlink:to="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_987B528A49617CA83B5B5212C54C4B4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_9F79C62F39217CE0B0C25212C54CDA29_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_9F79C62F39217CE0B0C25212C54CDA29" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (losses)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_9F79C62F39217CE0B0C25212C54CDA29_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_9F79C62F39217CE0B0C25212C54CDA29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9F79C62F39217CE0B0C25212C54CDA29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9F79C62F39217CE0B0C25212C54CDA29" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_9F79C62F39217CE0B0C25212C54CDA29" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330F0B1EE79F8C05FA435212C54C48BC_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330F0B1EE79F8C05FA435212C54C48BC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330F0B1EE79F8C05FA435212C54C48BC_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330F0B1EE79F8C05FA435212C54C48BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330F0B1EE79F8C05FA435212C54C48BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330F0B1EE79F8C05FA435212C54C48BC" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330F0B1EE79F8C05FA435212C54C48BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_CD38B6F964FB5A9D1B5E5212C54CDF7C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_CD38B6F964FB5A9D1B5E5212C54CDF7C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax recovery</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_CD38B6F964FB5A9D1B5E5212C54CDF7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_CD38B6F964FB5A9D1B5E5212C54CDF7C" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_CD38B6F964FB5A9D1B5E5212C54CDF7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_0F25B5C11B341A94A7715212C54C3A22_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0F25B5C11B341A94A7715212C54C3A22" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0F25B5C11B341A94A7715212C54C3A22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_0F25B5C11B341A94A7715212C54C3A22" xlink:to="lab_us-gaap_NetIncomeLoss_0F25B5C11B341A94A7715212C54C3A22" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_B4BC7F81DE8B4323FABA5212C54C80F0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_B4BC7F81DE8B4323FABA5212C54C80F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_B4BC7F81DE8B4323FABA5212C54C80F0_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_B4BC7F81DE8B4323FABA5212C54C80F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_B4BC7F81DE8B4323FABA5212C54C80F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_B4BC7F81DE8B4323FABA5212C54C80F0" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_B4BC7F81DE8B4323FABA5212C54C80F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_025A5D26FAFEA54935585212C54C97B5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_025A5D26FAFEA54935585212C54C97B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic loss per common share (in USD per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_025A5D26FAFEA54935585212C54C97B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_025A5D26FAFEA54935585212C54C97B5" xlink:to="lab_us-gaap_EarningsPerShareBasic_025A5D26FAFEA54935585212C54C97B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_88F53C4578828FE1D9DB5212C54C4927_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_88F53C4578828FE1D9DB5212C54C4927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted loss per common share (in USD per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_88F53C4578828FE1D9DB5212C54C4927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_88F53C4578828FE1D9DB5212C54C4927" xlink:to="lab_us-gaap_EarningsPerShareDiluted_88F53C4578828FE1D9DB5212C54C4927" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7879E80910119C77B7675212C54C0AFF_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7879E80910119C77B7675212C54C0AFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7879E80910119C77B7675212C54C0AFF_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7879E80910119C77B7675212C54C0AFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7879E80910119C77B7675212C54C0AFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7879E80910119C77B7675212C54C0AFF" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7879E80910119C77B7675212C54C0AFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2959B02A86A7B3B982335212C54CA945_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2959B02A86A7B3B982335212C54CA945" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic weighted average number of common shares (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2959B02A86A7B3B982335212C54CA945" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2959B02A86A7B3B982335212C54CA945" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2959B02A86A7B3B982335212C54CA945" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BAA2C853F1F057C4D4495212C54D7CFD_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BAA2C853F1F057C4D4495212C54D7CFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted weighted average number of common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BAA2C853F1F057C4D4495212C54D7CFD_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BAA2C853F1F057C4D4495212C54D7CFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BAA2C853F1F057C4D4495212C54D7CFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BAA2C853F1F057C4D4495212C54D7CFD" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BAA2C853F1F057C4D4495212C54D7CFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5A8555852E269D2C9CA05212C54DA702_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5A8555852E269D2C9CA05212C54DA702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5A8555852E269D2C9CA05212C54DA702_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5A8555852E269D2C9CA05212C54DA702" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5A8555852E269D2C9CA05212C54DA702" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5A8555852E269D2C9CA05212C54DA702" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5A8555852E269D2C9CA05212C54DA702" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6F80F25E8FBCE0E759735212C54DF776_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6F80F25E8FBCE0E759735212C54DF776" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6F80F25E8FBCE0E759735212C54DF776_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6F80F25E8FBCE0E759735212C54DF776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6F80F25E8FBCE0E759735212C54DF776" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6F80F25E8FBCE0E759735212C54DF776" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6F80F25E8FBCE0E759735212C54DF776" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8E3009800242501F82C85212C54D7E5A_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_8E3009800242501F82C85212C54D7E5A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8E3009800242501F82C85212C54D7E5A_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_8E3009800242501F82C85212C54D7E5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8E3009800242501F82C85212C54D7E5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_8E3009800242501F82C85212C54D7E5A" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_8E3009800242501F82C85212C54D7E5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_37BC4FF95509D87A617734C3A8A1D165_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_37BC4FF95509D87A617734C3A8A1D165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_37BC4FF95509D87A617734C3A8A1D165_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_37BC4FF95509D87A617734C3A8A1D165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_37BC4FF95509D87A617734C3A8A1D165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_37BC4FF95509D87A617734C3A8A1D165" xlink:to="lab_us-gaap_AssetImpairmentCharges_37BC4FF95509D87A617734C3A8A1D165" xlink:type="arc" />
    <link:label id="lab_abus_LaboratoryEquipmentMember_0F7CDB34389790A0D3733F2E88BC478A_terseLabel_en-US" xlink:label="lab_abus_LaboratoryEquipmentMember_0F7CDB34389790A0D3733F2E88BC478A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_LaboratoryEquipmentMember" xlink:label="loc_abus_LaboratoryEquipmentMember_0F7CDB34389790A0D3733F2E88BC478A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LaboratoryEquipmentMember_0F7CDB34389790A0D3733F2E88BC478A" xlink:to="lab_abus_LaboratoryEquipmentMember_0F7CDB34389790A0D3733F2E88BC478A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_3DA5FB6FC85B1DE19F243F2E88BC4561_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_3DA5FB6FC85B1DE19F243F2E88BC4561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_3DA5FB6FC85B1DE19F243F2E88BC4561_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_3DA5FB6FC85B1DE19F243F2E88BC4561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3DA5FB6FC85B1DE19F243F2E88BC4561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_3DA5FB6FC85B1DE19F243F2E88BC4561" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_3DA5FB6FC85B1DE19F243F2E88BC4561" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_331F65307F3885B46FC43F2E88BC5F3F_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_331F65307F3885B46FC43F2E88BC5F3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer hardware and software</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_331F65307F3885B46FC43F2E88BC5F3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_331F65307F3885B46FC43F2E88BC5F3F" xlink:to="lab_us-gaap_ComputerEquipmentMember_331F65307F3885B46FC43F2E88BC5F3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_04131AF8006BA89D74A03F2E88BCE549_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_04131AF8006BA89D74A03F2E88BCE549" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_04131AF8006BA89D74A03F2E88BCE549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_04131AF8006BA89D74A03F2E88BCE549" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_04131AF8006BA89D74A03F2E88BCE549" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3FB953825CDED7ADDBF83F2E88BD96DC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3FB953825CDED7ADDBF83F2E88BD96DC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3FB953825CDED7ADDBF83F2E88BD96DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3FB953825CDED7ADDBF83F2E88BD96DC" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3FB953825CDED7ADDBF83F2E88BD96DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_65D33A342BD8A089708F3F2E88BDC74E_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_65D33A342BD8A089708F3F2E88BDC74E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net book value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_65D33A342BD8A089708F3F2E88BDC74E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_65D33A342BD8A089708F3F2E88BDC74E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_65D33A342BD8A089708F3F2E88BDC74E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_F1C31013C1860A16DD6F3F2E893FEEBF_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_F1C31013C1860A16DD6F3F2E893FEEBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_F1C31013C1860A16DD6F3F2E893FEEBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_F1C31013C1860A16DD6F3F2E893FEEBF" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_F1C31013C1860A16DD6F3F2E893FEEBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_45275BD4A09E6EBCE3843F2E893FCDFD_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_45275BD4A09E6EBCE3843F2E893FCDFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_45275BD4A09E6EBCE3843F2E893FCDFD_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_45275BD4A09E6EBCE3843F2E893FCDFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_45275BD4A09E6EBCE3843F2E893FCDFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_45275BD4A09E6EBCE3843F2E893FCDFD" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_45275BD4A09E6EBCE3843F2E893FCDFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:to="lab_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_E9B70B7EC457EADB62F43F2E893F5FCB_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_E9B70B7EC457EADB62F43F2E893F5FCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_E9B70B7EC457EADB62F43F2E893F5FCB_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_E9B70B7EC457EADB62F43F2E893F5FCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E9B70B7EC457EADB62F43F2E893F5FCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_E9B70B7EC457EADB62F43F2E893F5FCB" xlink:to="lab_us-gaap_CommonStockMember_E9B70B7EC457EADB62F43F2E893F5FCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_781E61B44BFE1B4CBD583F2E893F3FE1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_781E61B44BFE1B4CBD583F2E893F3FE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_781E61B44BFE1B4CBD583F2E893F3FE1_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_781E61B44BFE1B4CBD583F2E893F3FE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_781E61B44BFE1B4CBD583F2E893F3FE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_781E61B44BFE1B4CBD583F2E893F3FE1" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_781E61B44BFE1B4CBD583F2E893F3FE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_8339FE1055DB5CA049853F2E893FDF87_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_8339FE1055DB5CA049853F2E893FDF87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8339FE1055DB5CA049853F2E893FDF87_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_8339FE1055DB5CA049853F2E893FDF87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_8339FE1055DB5CA049853F2E893FDF87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_8339FE1055DB5CA049853F2E893FDF87" xlink:to="lab_us-gaap_RetainedEarningsMember_8339FE1055DB5CA049853F2E893FDF87" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D2318EF639D2050A815B3F2E893FEA1D_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D2318EF639D2050A815B3F2E893FEA1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D2318EF639D2050A815B3F2E893FEA1D_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D2318EF639D2050A815B3F2E893FEA1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D2318EF639D2050A815B3F2E893FEA1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D2318EF639D2050A815B3F2E893FEA1D" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D2318EF639D2050A815B3F2E893FEA1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_D170B005E4A6343DEFB53F2E893FB227_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_D170B005E4A6343DEFB53F2E893FB227" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_D170B005E4A6343DEFB53F2E893FB227_label_en-US" xlink:label="lab_us-gaap_SharesIssued_D170B005E4A6343DEFB53F2E893FB227" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_D170B005E4A6343DEFB53F2E893FB227" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_D170B005E4A6343DEFB53F2E893FB227" xlink:to="lab_us-gaap_SharesIssued_D170B005E4A6343DEFB53F2E893FB227" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_CD94FD6BBFE58714B7F93F2E894008AA_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_CD94FD6BBFE58714B7F93F2E894008AA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CD94FD6BBFE58714B7F93F2E894008AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_CD94FD6BBFE58714B7F93F2E894008AA" xlink:to="lab_us-gaap_StockholdersEquity_CD94FD6BBFE58714B7F93F2E894008AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CDB4135736A8F62162073F2E8940DEA4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CDB4135736A8F62162073F2E8940DEA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CDB4135736A8F62162073F2E8940DEA4_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CDB4135736A8F62162073F2E8940DEA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CDB4135736A8F62162073F2E8940DEA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CDB4135736A8F62162073F2E8940DEA4" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CDB4135736A8F62162073F2E8940DEA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_199857DB1DB6DCA336AC3F2E8940D434_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_199857DB1DB6DCA336AC3F2E8940D434" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to exercise of options (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_199857DB1DB6DCA336AC3F2E8940D434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_199857DB1DB6DCA336AC3F2E8940D434" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_199857DB1DB6DCA336AC3F2E8940D434" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_FDDCACCEA81BC9F59BD63F2E8940929F_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_FDDCACCEA81BC9F59BD63F2E8940929F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_FDDCACCEA81BC9F59BD63F2E8940929F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_FDDCACCEA81BC9F59BD63F2E8940929F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_FDDCACCEA81BC9F59BD63F2E8940929F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_FDDCACCEA81BC9F59BD63F2E8940929F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_FDDCACCEA81BC9F59BD63F2E8940929F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_4873560D06A42CF38EED3F2E8940E137_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_4873560D06A42CF38EED3F2E8940E137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to exercise of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_4873560D06A42CF38EED3F2E8940E137_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther_4873560D06A42CF38EED3F2E8940E137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_4873560D06A42CF38EED3F2E8940E137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther_4873560D06A42CF38EED3F2E8940E137" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther_4873560D06A42CF38EED3F2E8940E137" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_BB7C80F4DF87E90BE01B3F2E89403534_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_BB7C80F4DF87E90BE01B3F2E89403534" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to exercise of warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_BB7C80F4DF87E90BE01B3F2E89403534_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther_BB7C80F4DF87E90BE01B3F2E89403534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_BB7C80F4DF87E90BE01B3F2E89403534" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther_BB7C80F4DF87E90BE01B3F2E89403534" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther_BB7C80F4DF87E90BE01B3F2E89403534" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A30D0598F4F3BA04AF3B3F2E89403608_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A30D0598F4F3BA04AF3B3F2E89403608" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares in conjunction with the private (public in 2015) offering, net of issuance costs (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A30D0598F4F3BA04AF3B3F2E89403608" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A30D0598F4F3BA04AF3B3F2E89403608" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A30D0598F4F3BA04AF3B3F2E89403608" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_21FDACA2E22DC4BC41423F2E8940632F_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_21FDACA2E22DC4BC41423F2E8940632F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares in conjunction with the private (public in 2015) offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_21FDACA2E22DC4BC41423F2E8940632F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_21FDACA2E22DC4BC41423F2E8940632F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_21FDACA2E22DC4BC41423F2E8940632F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_21FDACA2E22DC4BC41423F2E8940632F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_21FDACA2E22DC4BC41423F2E8940632F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_04F18B81E44038EE63053F2E8940CBE8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_04F18B81E44038EE63053F2E8940CBE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase of equity instruments in conjunction with the acquisition of Arbutus Inc. (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_04F18B81E44038EE63053F2E8940CBE8_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_04F18B81E44038EE63053F2E8940CBE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_04F18B81E44038EE63053F2E8940CBE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_04F18B81E44038EE63053F2E8940CBE8" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_04F18B81E44038EE63053F2E8940CBE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_15D39AC604AEC65719633F2E89407C4B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_15D39AC604AEC65719633F2E89407C4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase of equity instruments in conjunction with the acquisition of Arbutus Inc.</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_15D39AC604AEC65719633F2E89407C4B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_15D39AC604AEC65719633F2E89407C4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_15D39AC604AEC65719633F2E89407C4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_15D39AC604AEC65719633F2E89407C4B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_15D39AC604AEC65719633F2E89407C4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6746F2603FC7999B072C3F2E89401EAB_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6746F2603FC7999B072C3F2E89401EAB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6746F2603FC7999B072C3F2E89401EAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6746F2603FC7999B072C3F2E89401EAB" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6746F2603FC7999B072C3F2E89401EAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_F11DA1FC57B7F58294ED3F2E89416E3D_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_F11DA1FC57B7F58294ED3F2E89416E3D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_F11DA1FC57B7F58294ED3F2E89416E3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_F11DA1FC57B7F58294ED3F2E89416E3D" xlink:to="lab_us-gaap_SharesIssued_F11DA1FC57B7F58294ED3F2E89416E3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_095CE28C30820B2C5A1D3F2E89411F82_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_095CE28C30820B2C5A1D3F2E89411F82" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_095CE28C30820B2C5A1D3F2E89411F82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_095CE28C30820B2C5A1D3F2E89411F82" xlink:to="lab_us-gaap_StockholdersEquity_095CE28C30820B2C5A1D3F2E89411F82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_1F128D51100F2F4612323A61D703C757_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_1F128D51100F2F4612323A61D703C757" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of revenue recognized under collaborations, contracts and licensing agreements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_1F128D51100F2F4612323A61D703C757_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_1F128D51100F2F4612323A61D703C757" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_1F128D51100F2F4612323A61D703C757" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_1F128D51100F2F4612323A61D703C757" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_1F128D51100F2F4612323A61D703C757" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_14465C61958F64185E303A61D7039F10_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_14465C61958F64185E303A61D7039F10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of deferred collaborations and contracts revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_14465C61958F64185E303A61D7039F10_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_14465C61958F64185E303A61D7039F10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_14465C61958F64185E303A61D7039F10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_14465C61958F64185E303A61D7039F10" xlink:to="lab_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_14465C61958F64185E303A61D7039F10" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_C38E150A1F3F39D734435212D7455AC8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_C38E150A1F3F39D734435212D7455AC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares in conjunction with the private (public in 2015) offering, net of issuance costs of</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_C38E150A1F3F39D734435212D7455AC8_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_C38E150A1F3F39D734435212D7455AC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_C38E150A1F3F39D734435212D7455AC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_C38E150A1F3F39D734435212D7455AC8" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_C38E150A1F3F39D734435212D7455AC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_A13FD23DC9B07DB5744B3F2E882FD529_negatedLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_A13FD23DC9B07DB5744B3F2E882FD529" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Accounts payable and accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_A13FD23DC9B07DB5744B3F2E882FD529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_A13FD23DC9B07DB5744B3F2E882FD529" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_A13FD23DC9B07DB5744B3F2E882FD529" xlink:type="arc" />
    <link:label id="lab_abus_NetLiquidity_697ECD2B4A59C94E38C93F2E882F2A98_totalLabel_en-US" xlink:label="lab_abus_NetLiquidity_697ECD2B4A59C94E38C93F2E882F2A98" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net liquidity</link:label>
    <link:label id="lab_abus_NetLiquidity_697ECD2B4A59C94E38C93F2E882F2A98_label_en-US" xlink:label="lab_abus_NetLiquidity_697ECD2B4A59C94E38C93F2E882F2A98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Liquidity</link:label>
    <link:label id="lab_abus_NetLiquidity_697ECD2B4A59C94E38C93F2E882F2A98_documentation_en-US" xlink:label="lab_abus_NetLiquidity_697ECD2B4A59C94E38C93F2E882F2A98" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net liquidity</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_NetLiquidity" xlink:label="loc_abus_NetLiquidity_697ECD2B4A59C94E38C93F2E882F2A98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NetLiquidity_697ECD2B4A59C94E38C93F2E882F2A98" xlink:to="lab_abus_NetLiquidity_697ECD2B4A59C94E38C93F2E882F2A98" xlink:type="arc" />
    <link:label id="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock_A822FF2943DCCFE96FD42EAA60345AB3_terseLabel_en-US" xlink:label="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock_A822FF2943DCCFE96FD42EAA60345AB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government grants and refundable investment tax credits</link:label>
    <link:label id="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock_A822FF2943DCCFE96FD42EAA60345AB3_label_en-US" xlink:label="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock_A822FF2943DCCFE96FD42EAA60345AB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Grants And Refundable Investment Tax Credits [Text Block]</link:label>
    <link:label id="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock_A822FF2943DCCFE96FD42EAA60345AB3_documentation_en-US" xlink:label="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock_A822FF2943DCCFE96FD42EAA60345AB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for information about government grants and investment tax credits netted against expenses in the statement of operations.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock" xlink:label="loc_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock_A822FF2943DCCFE96FD42EAA60345AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock_A822FF2943DCCFE96FD42EAA60345AB3" xlink:to="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock_A822FF2943DCCFE96FD42EAA60345AB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_BBF23E5E4D478F7C39FC33E8637E0902_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_BBF23E5E4D478F7C39FC33E8637E0902" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BBF23E5E4D478F7C39FC33E8637E0902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_BBF23E5E4D478F7C39FC33E8637E0902" xlink:to="lab_us-gaap_Revenues_BBF23E5E4D478F7C39FC33E8637E0902" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_92D94831F05AB591CBCC33E8637E03F2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_92D94831F05AB591CBCC33E8637E03F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_92D94831F05AB591CBCC33E8637E03F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_92D94831F05AB591CBCC33E8637E03F2" xlink:to="lab_us-gaap_OperatingIncomeLoss_92D94831F05AB591CBCC33E8637E03F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_48E6867A93936F6E96A033E8637E465F_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_48E6867A93936F6E96A033E8637E465F" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_48E6867A93936F6E96A033E8637E465F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_48E6867A93936F6E96A033E8637E465F" xlink:to="lab_us-gaap_NetIncomeLoss_48E6867A93936F6E96A033E8637E465F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_CBE70F4BD5BACE79EE4533E8637EFB4C_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_CBE70F4BD5BACE79EE4533E8637EFB4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_CBE70F4BD5BACE79EE4533E8637EFB4C_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_CBE70F4BD5BACE79EE4533E8637EFB4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_CBE70F4BD5BACE79EE4533E8637EFB4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_CBE70F4BD5BACE79EE4533E8637EFB4C" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_CBE70F4BD5BACE79EE4533E8637EFB4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BF21C18294ABF21D54A83974AE33AAFB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BF21C18294ABF21D54A83974AE33AAFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BF21C18294ABF21D54A83974AE33AAFB_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BF21C18294ABF21D54A83974AE33AAFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BF21C18294ABF21D54A83974AE33AAFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BF21C18294ABF21D54A83974AE33AAFB" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BF21C18294ABF21D54A83974AE33AAFB" xlink:type="arc" />
    <link:label id="lab_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2_terseLabel_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies and Commitments [Table]</link:label>
    <link:label id="lab_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2_label_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies and Commitments [Table]</link:label>
    <link:label id="lab_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2_documentation_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="abus-20151231.xsd#abus_ContingenciesandCommitmentsTable" xlink:label="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:to="lab_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_36D5F6CDC300B8BF83D93F2E8843E1AD_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_36D5F6CDC300B8BF83D93F2E8843E1AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_36D5F6CDC300B8BF83D93F2E8843E1AD_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_36D5F6CDC300B8BF83D93F2E8843E1AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_36D5F6CDC300B8BF83D93F2E8843E1AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_36D5F6CDC300B8BF83D93F2E8843E1AD" xlink:to="lab_us-gaap_ProductOrServiceAxis_36D5F6CDC300B8BF83D93F2E8843E1AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D" xlink:to="lab_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D" xlink:type="arc" />
    <link:label id="lab_abus_MarqiboMember_68AECCEE35A2FEBCCE773F2E884372C6_terseLabel_en-US" xlink:label="lab_abus_MarqiboMember_68AECCEE35A2FEBCCE773F2E884372C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marqibo</link:label>
    <link:label id="lab_abus_MarqiboMember_68AECCEE35A2FEBCCE773F2E884372C6_label_en-US" xlink:label="lab_abus_MarqiboMember_68AECCEE35A2FEBCCE773F2E884372C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marqibo [Member]</link:label>
    <link:label id="lab_abus_MarqiboMember_68AECCEE35A2FEBCCE773F2E884372C6_documentation_en-US" xlink:label="lab_abus_MarqiboMember_68AECCEE35A2FEBCCE773F2E884372C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Marqibo.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_MarqiboMember" xlink:label="loc_abus_MarqiboMember_68AECCEE35A2FEBCCE773F2E884372C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_MarqiboMember_68AECCEE35A2FEBCCE773F2E884372C6" xlink:to="lab_abus_MarqiboMember_68AECCEE35A2FEBCCE773F2E884372C6" xlink:type="arc" />
    <link:label id="lab_abus_MarinaBiotechInc.Member_8779338F3CC09C2C380B3F2E88446999_terseLabel_en-US" xlink:label="lab_abus_MarinaBiotechInc.Member_8779338F3CC09C2C380B3F2E88446999" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marina</link:label>
    <link:label id="lab_abus_MarinaBiotechInc.Member_8779338F3CC09C2C380B3F2E88446999_label_en-US" xlink:label="lab_abus_MarinaBiotechInc.Member_8779338F3CC09C2C380B3F2E88446999" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marina Biotech, Inc. [Member]</link:label>
    <link:label id="lab_abus_MarinaBiotechInc.Member_8779338F3CC09C2C380B3F2E88446999_documentation_en-US" xlink:label="lab_abus_MarinaBiotechInc.Member_8779338F3CC09C2C380B3F2E88446999" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marina Biotech, Inc. [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_MarinaBiotechInc.Member" xlink:label="loc_abus_MarinaBiotechInc.Member_8779338F3CC09C2C380B3F2E88446999" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_MarinaBiotechInc.Member_8779338F3CC09C2C380B3F2E88446999" xlink:to="lab_abus_MarinaBiotechInc.Member_8779338F3CC09C2C380B3F2E88446999" xlink:type="arc" />
    <link:label id="lab_abus_ArcturusMember_28842033654F77A5FCD43F2E8844D0AE_terseLabel_en-US" xlink:label="lab_abus_ArcturusMember_28842033654F77A5FCD43F2E8844D0AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arcturus</link:label>
    <link:label id="lab_abus_ArcturusMember_28842033654F77A5FCD43F2E8844D0AE_label_en-US" xlink:label="lab_abus_ArcturusMember_28842033654F77A5FCD43F2E8844D0AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arcturus [Member]</link:label>
    <link:label id="lab_abus_ArcturusMember_28842033654F77A5FCD43F2E8844D0AE_documentation_en-US" xlink:label="lab_abus_ArcturusMember_28842033654F77A5FCD43F2E8844D0AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Arcturus Therapeutics.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ArcturusMember" xlink:label="loc_abus_ArcturusMember_28842033654F77A5FCD43F2E8844D0AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ArcturusMember_28842033654F77A5FCD43F2E8844D0AE" xlink:to="lab_abus_ArcturusMember_28842033654F77A5FCD43F2E8844D0AE" xlink:type="arc" />
    <link:label id="lab_abus_BlumbergandDrexelMember_C773531DDF4447003A893F2E88447020_terseLabel_en-US" xlink:label="lab_abus_BlumbergandDrexelMember_C773531DDF4447003A893F2E88447020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Blumberg and Drexel</link:label>
    <link:label id="lab_abus_BlumbergandDrexelMember_C773531DDF4447003A893F2E88447020_label_en-US" xlink:label="lab_abus_BlumbergandDrexelMember_C773531DDF4447003A893F2E88447020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Blumberg and Drexel [Member]</link:label>
    <link:label id="lab_abus_BlumbergandDrexelMember_C773531DDF4447003A893F2E88447020_documentation_en-US" xlink:label="lab_abus_BlumbergandDrexelMember_C773531DDF4447003A893F2E88447020" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Blumberg and Drexel [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BlumbergandDrexelMember" xlink:label="loc_abus_BlumbergandDrexelMember_C773531DDF4447003A893F2E88447020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BlumbergandDrexelMember_C773531DDF4447003A893F2E88447020" xlink:to="lab_abus_BlumbergandDrexelMember_C773531DDF4447003A893F2E88447020" xlink:type="arc" />
    <link:label id="lab_abus_BlumbergMember_6B727FD16B4EB07D58CF3F2E8844DD51_terseLabel_en-US" xlink:label="lab_abus_BlumbergMember_6B727FD16B4EB07D58CF3F2E8844DD51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Blumberg</link:label>
    <link:label id="lab_abus_BlumbergMember_6B727FD16B4EB07D58CF3F2E8844DD51_label_en-US" xlink:label="lab_abus_BlumbergMember_6B727FD16B4EB07D58CF3F2E8844DD51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Blumberg [Member]</link:label>
    <link:label id="lab_abus_BlumbergMember_6B727FD16B4EB07D58CF3F2E8844DD51_documentation_en-US" xlink:label="lab_abus_BlumbergMember_6B727FD16B4EB07D58CF3F2E8844DD51" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Blumberg [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BlumbergMember" xlink:label="loc_abus_BlumbergMember_6B727FD16B4EB07D58CF3F2E8844DD51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BlumbergMember_6B727FD16B4EB07D58CF3F2E8844DD51" xlink:to="lab_abus_BlumbergMember_6B727FD16B4EB07D58CF3F2E8844DD51" xlink:type="arc" />
    <link:label id="lab_abus_NeuroViveMember_AFA932BF5AA507FAAB403F2E8844EFFF_terseLabel_en-US" xlink:label="lab_abus_NeuroViveMember_AFA932BF5AA507FAAB403F2E8844EFFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NeuroVive</link:label>
    <link:label id="lab_abus_NeuroViveMember_AFA932BF5AA507FAAB403F2E8844EFFF_label_en-US" xlink:label="lab_abus_NeuroViveMember_AFA932BF5AA507FAAB403F2E8844EFFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NeuroVive [Member]</link:label>
    <link:label id="lab_abus_NeuroViveMember_AFA932BF5AA507FAAB403F2E8844EFFF_documentation_en-US" xlink:label="lab_abus_NeuroViveMember_AFA932BF5AA507FAAB403F2E8844EFFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NeuroVive [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_NeuroViveMember" xlink:label="loc_abus_NeuroViveMember_AFA932BF5AA507FAAB403F2E8844EFFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NeuroViveMember_AFA932BF5AA507FAAB403F2E8844EFFF" xlink:to="lab_abus_NeuroViveMember_AFA932BF5AA507FAAB403F2E8844EFFF" xlink:type="arc" />
    <link:label id="lab_abus_CytosMember_0F9A99E52512037C4E1E3F2E88449DF4_terseLabel_en-US" xlink:label="lab_abus_CytosMember_0F9A99E52512037C4E1E3F2E88449DF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cytos</link:label>
    <link:label id="lab_abus_CytosMember_0F9A99E52512037C4E1E3F2E88449DF4_label_en-US" xlink:label="lab_abus_CytosMember_0F9A99E52512037C4E1E3F2E88449DF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cytos [Member]</link:label>
    <link:label id="lab_abus_CytosMember_0F9A99E52512037C4E1E3F2E88449DF4_documentation_en-US" xlink:label="lab_abus_CytosMember_0F9A99E52512037C4E1E3F2E88449DF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cytos [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_CytosMember" xlink:label="loc_abus_CytosMember_0F9A99E52512037C4E1E3F2E88449DF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_CytosMember_0F9A99E52512037C4E1E3F2E88449DF4" xlink:to="lab_abus_CytosMember_0F9A99E52512037C4E1E3F2E88449DF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationCaseAxis_4538E864982D97521C623F2E88446A69_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationCaseAxis_4538E864982D97521C623F2E88446A69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationCaseAxis_4538E864982D97521C623F2E88446A69_label_en-US" xlink:label="lab_us-gaap_LitigationCaseAxis_4538E864982D97521C623F2E88446A69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_4538E864982D97521C623F2E88446A69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationCaseAxis_4538E864982D97521C623F2E88446A69" xlink:to="lab_us-gaap_LitigationCaseAxis_4538E864982D97521C623F2E88446A69" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744_label_en-US" xlink:label="lab_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744" xlink:to="lab_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744" xlink:type="arc" />
    <link:label id="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_E9244D587690EC77C4DE3F2E8844106F_terseLabel_en-US" xlink:label="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_E9244D587690EC77C4DE3F2E8844106F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arbitration with the University of British Columbia</link:label>
    <link:label id="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_E9244D587690EC77C4DE3F2E8844106F_label_en-US" xlink:label="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_E9244D587690EC77C4DE3F2E8844106F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arbitration With The University Of British Columbia [Member]</link:label>
    <link:label id="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_E9244D587690EC77C4DE3F2E8844106F_documentation_en-US" xlink:label="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_E9244D587690EC77C4DE3F2E8844106F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to arbitration with the University of British Columbia.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:label="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_E9244D587690EC77C4DE3F2E8844106F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_E9244D587690EC77C4DE3F2E8844106F" xlink:to="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_E9244D587690EC77C4DE3F2E8844106F" xlink:type="arc" />
    <link:label id="lab_abus_OnCoreBiopharmaInc.Member_F84A424625E7A924B0223F2E884469B0_terseLabel_en-US" xlink:label="lab_abus_OnCoreBiopharmaInc.Member_F84A424625E7A924B0223F2E884469B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OnCore</link:label>
    <link:label id="lab_abus_OnCoreBiopharmaInc.Member_F84A424625E7A924B0223F2E884469B0_label_en-US" xlink:label="lab_abus_OnCoreBiopharmaInc.Member_F84A424625E7A924B0223F2E884469B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OnCore Biopharma Inc. [Member]</link:label>
    <link:label id="lab_abus_OnCoreBiopharmaInc.Member_F84A424625E7A924B0223F2E884469B0_documentation_en-US" xlink:label="lab_abus_OnCoreBiopharmaInc.Member_F84A424625E7A924B0223F2E884469B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OnCore Biopharma Inc. [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_OnCoreBiopharmaInc.Member" xlink:label="loc_abus_OnCoreBiopharmaInc.Member_F84A424625E7A924B0223F2E884469B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OnCoreBiopharmaInc.Member_F84A424625E7A924B0223F2E884469B0" xlink:to="lab_abus_OnCoreBiopharmaInc.Member_F84A424625E7A924B0223F2E884469B0" xlink:type="arc" />
    <link:label id="lab_abus_EnantigenMember_69BA02B156C6D7483E143F2E88457BE8_terseLabel_en-US" xlink:label="lab_abus_EnantigenMember_69BA02B156C6D7483E143F2E88457BE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enantigen</link:label>
    <link:label id="lab_abus_EnantigenMember_69BA02B156C6D7483E143F2E88457BE8_label_en-US" xlink:label="lab_abus_EnantigenMember_69BA02B156C6D7483E143F2E88457BE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enantigen [Member]</link:label>
    <link:label id="lab_abus_EnantigenMember_69BA02B156C6D7483E143F2E88457BE8_documentation_en-US" xlink:label="lab_abus_EnantigenMember_69BA02B156C6D7483E143F2E88457BE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enantigen [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_EnantigenMember" xlink:label="loc_abus_EnantigenMember_69BA02B156C6D7483E143F2E88457BE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EnantigenMember_69BA02B156C6D7483E143F2E88457BE8" xlink:to="lab_abus_EnantigenMember_69BA02B156C6D7483E143F2E88457BE8" xlink:type="arc" />
    <link:label id="lab_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331_terseLabel_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies and Commitments [Line Items]</link:label>
    <link:label id="lab_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331_label_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies and Commitments [Line Items]</link:label>
    <link:label id="lab_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331_documentation_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="abus-20151231.xsd#abus_ContingenciesandCommitmentsLineItems" xlink:label="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="lab_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_0BAF8946E7FE153454623F2E88457029_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_0BAF8946E7FE153454623F2E88457029" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_0BAF8946E7FE153454623F2E88457029_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_0BAF8946E7FE153454623F2E88457029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_0BAF8946E7FE153454623F2E88457029" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_0BAF8946E7FE153454623F2E88457029" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_0BAF8946E7FE153454623F2E88457029" xlink:type="arc" />
    <link:label id="lab_abus_PercentOfCostsFundedByTPC_30BE652DEEEE61C6469B3F2E8845C9A5_terseLabel_en-US" xlink:label="lab_abus_PercentOfCostsFundedByTPC_30BE652DEEEE61C6469B3F2E8845C9A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of costs funded by TPC</link:label>
    <link:label id="lab_abus_PercentOfCostsFundedByTPC_30BE652DEEEE61C6469B3F2E8845C9A5_label_en-US" xlink:label="lab_abus_PercentOfCostsFundedByTPC_30BE652DEEEE61C6469B3F2E8845C9A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percent of Costs Funded by TPC</link:label>
    <link:label id="lab_abus_PercentOfCostsFundedByTPC_30BE652DEEEE61C6469B3F2E8845C9A5_documentation_en-US" xlink:label="lab_abus_PercentOfCostsFundedByTPC_30BE652DEEEE61C6469B3F2E8845C9A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percent of costs funded by TPC.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_PercentOfCostsFundedByTPC" xlink:label="loc_abus_PercentOfCostsFundedByTPC_30BE652DEEEE61C6469B3F2E8845C9A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_PercentOfCostsFundedByTPC_30BE652DEEEE61C6469B3F2E8845C9A5" xlink:to="lab_abus_PercentOfCostsFundedByTPC_30BE652DEEEE61C6469B3F2E8845C9A5" xlink:type="arc" />
    <link:label id="lab_abus_MaximumContributionForProduct_08EDEB1FC2419981101C3F2E884560EB_terseLabel_en-US" xlink:label="lab_abus_MaximumContributionForProduct_08EDEB1FC2419981101C3F2E884560EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum contribution for product</link:label>
    <link:label id="lab_abus_MaximumContributionForProduct_08EDEB1FC2419981101C3F2E884560EB_label_en-US" xlink:label="lab_abus_MaximumContributionForProduct_08EDEB1FC2419981101C3F2E884560EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Contribution for Product</link:label>
    <link:label id="lab_abus_MaximumContributionForProduct_08EDEB1FC2419981101C3F2E884560EB_documentation_en-US" xlink:label="lab_abus_MaximumContributionForProduct_08EDEB1FC2419981101C3F2E884560EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum contribution for the product.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_MaximumContributionForProduct" xlink:label="loc_abus_MaximumContributionForProduct_08EDEB1FC2419981101C3F2E884560EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_MaximumContributionForProduct_08EDEB1FC2419981101C3F2E884560EB" xlink:to="lab_abus_MaximumContributionForProduct_08EDEB1FC2419981101C3F2E884560EB" xlink:type="arc" />
    <link:label id="lab_abus_CumulativeContributionforProduct_413443817508A5BA386C3F2E8845A4CB_terseLabel_en-US" xlink:label="lab_abus_CumulativeContributionforProduct_413443817508A5BA386C3F2E8845A4CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative contribution for product</link:label>
    <link:label id="lab_abus_CumulativeContributionforProduct_413443817508A5BA386C3F2E8845A4CB_label_en-US" xlink:label="lab_abus_CumulativeContributionforProduct_413443817508A5BA386C3F2E8845A4CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Contribution for Product</link:label>
    <link:label id="lab_abus_CumulativeContributionforProduct_413443817508A5BA386C3F2E8845A4CB_documentation_en-US" xlink:label="lab_abus_CumulativeContributionforProduct_413443817508A5BA386C3F2E8845A4CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the cumulative contribution for a product.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_CumulativeContributionforProduct" xlink:label="loc_abus_CumulativeContributionforProduct_413443817508A5BA386C3F2E8845A4CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_CumulativeContributionforProduct_413443817508A5BA386C3F2E8845A4CB" xlink:to="lab_abus_CumulativeContributionforProduct_413443817508A5BA386C3F2E8845A4CB" xlink:type="arc" />
    <link:label id="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_3E7EF474F13F61DF828D3F2E88453678_terseLabel_en-US" xlink:label="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_3E7EF474F13F61DF828D3F2E88453678" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty guarantees commitments percentage</link:label>
    <link:label id="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_3E7EF474F13F61DF828D3F2E88453678_label_en-US" xlink:label="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_3E7EF474F13F61DF828D3F2E88453678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Guarantees Commitments Percentage</link:label>
    <link:label id="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_3E7EF474F13F61DF828D3F2E88453678_documentation_en-US" xlink:label="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_3E7EF474F13F61DF828D3F2E88453678" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty guarantees commitments percentage.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_RoyaltyGuaranteesCommitmentsPercentage" xlink:label="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_3E7EF474F13F61DF828D3F2E88453678" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_3E7EF474F13F61DF828D3F2E88453678" xlink:to="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_3E7EF474F13F61DF828D3F2E88453678" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyRevenue_9DB25B865730B91BB0523F2E88459C71_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_9DB25B865730B91BB0523F2E88459C71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyRevenue_9DB25B865730B91BB0523F2E88459C71_label_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_9DB25B865730B91BB0523F2E88459C71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_9DB25B865730B91BB0523F2E88459C71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyRevenue_9DB25B865730B91BB0523F2E88459C71" xlink:to="lab_us-gaap_RoyaltyRevenue_9DB25B865730B91BB0523F2E88459C71" xlink:type="arc" />
    <link:label id="lab_abus_RoyaltyPayable_ED22447846626B080EAF3F2E8845898E_verboseLabel_en-US" xlink:label="lab_abus_RoyaltyPayable_ED22447846626B080EAF3F2E8845898E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty payable</link:label>
    <link:label id="lab_abus_RoyaltyPayable_ED22447846626B080EAF3F2E8845898E_label_en-US" xlink:label="lab_abus_RoyaltyPayable_ED22447846626B080EAF3F2E8845898E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Payable</link:label>
    <link:label id="lab_abus_RoyaltyPayable_ED22447846626B080EAF3F2E8845898E_documentation_en-US" xlink:label="lab_abus_RoyaltyPayable_ED22447846626B080EAF3F2E8845898E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty payable.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_RoyaltyPayable" xlink:label="loc_abus_RoyaltyPayable_ED22447846626B080EAF3F2E8845898E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoyaltyPayable_ED22447846626B080EAF3F2E8845898E" xlink:to="lab_abus_RoyaltyPayable_ED22447846626B080EAF3F2E8845898E" xlink:type="arc" />
    <link:label id="lab_abus_RoyaltiesPaidOrAccrued_1CCF7558E0278D1557223F2E88452137_terseLabel_en-US" xlink:label="lab_abus_RoyaltiesPaidOrAccrued_1CCF7558E0278D1557223F2E88452137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties paid or accrued</link:label>
    <link:label id="lab_abus_RoyaltiesPaidOrAccrued_1CCF7558E0278D1557223F2E88452137_label_en-US" xlink:label="lab_abus_RoyaltiesPaidOrAccrued_1CCF7558E0278D1557223F2E88452137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties Paid or Accrued</link:label>
    <link:label id="lab_abus_RoyaltiesPaidOrAccrued_1CCF7558E0278D1557223F2E88452137_documentation_en-US" xlink:label="lab_abus_RoyaltiesPaidOrAccrued_1CCF7558E0278D1557223F2E88452137" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cumulative amount of royalties paid or accrued of an entity.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_RoyaltiesPaidOrAccrued" xlink:label="loc_abus_RoyaltiesPaidOrAccrued_1CCF7558E0278D1557223F2E88452137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoyaltiesPaidOrAccrued_1CCF7558E0278D1557223F2E88452137" xlink:to="lab_abus_RoyaltiesPaidOrAccrued_1CCF7558E0278D1557223F2E88452137" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligation_FB3DCF960E24A638244C3F2E8845E650_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation_FB3DCF960E24A638244C3F2E8845E650" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_FB3DCF960E24A638244C3F2E8845E650_label_en-US" xlink:label="lab_us-gaap_ContractualObligation_FB3DCF960E24A638244C3F2E8845E650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_FB3DCF960E24A638244C3F2E8845E650" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation_FB3DCF960E24A638244C3F2E8845E650" xlink:to="lab_us-gaap_ContractualObligation_FB3DCF960E24A638244C3F2E8845E650" xlink:type="arc" />
    <link:label id="lab_abus_UpfrontFee_FBECB0E9EC4680609BD23F2E8845ED52_terseLabel_en-US" xlink:label="lab_abus_UpfrontFee_FBECB0E9EC4680609BD23F2E8845ED52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront fee</link:label>
    <link:label id="lab_abus_UpfrontFee_FBECB0E9EC4680609BD23F2E8845ED52_label_en-US" xlink:label="lab_abus_UpfrontFee_FBECB0E9EC4680609BD23F2E8845ED52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Fee</link:label>
    <link:label id="lab_abus_UpfrontFee_FBECB0E9EC4680609BD23F2E8845ED52_documentation_en-US" xlink:label="lab_abus_UpfrontFee_FBECB0E9EC4680609BD23F2E8845ED52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the upfront fee.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_UpfrontFee" xlink:label="loc_abus_UpfrontFee_FBECB0E9EC4680609BD23F2E8845ED52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_UpfrontFee_FBECB0E9EC4680609BD23F2E8845ED52" xlink:to="lab_abus_UpfrontFee_FBECB0E9EC4680609BD23F2E8845ED52" xlink:type="arc" />
    <link:label id="lab_abus_MilestonePayment_63161EF40D0DEACA88263F2E8845E876_terseLabel_en-US" xlink:label="lab_abus_MilestonePayment_63161EF40D0DEACA88263F2E8845E876" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_abus_MilestonePayment_63161EF40D0DEACA88263F2E8845E876_label_en-US" xlink:label="lab_abus_MilestonePayment_63161EF40D0DEACA88263F2E8845E876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_abus_MilestonePayment_63161EF40D0DEACA88263F2E8845E876_documentation_en-US" xlink:label="lab_abus_MilestonePayment_63161EF40D0DEACA88263F2E8845E876" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a milestone payment.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_MilestonePayment" xlink:label="loc_abus_MilestonePayment_63161EF40D0DEACA88263F2E8845E876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_MilestonePayment_63161EF40D0DEACA88263F2E8845E876" xlink:to="lab_abus_MilestonePayment_63161EF40D0DEACA88263F2E8845E876" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_D6FF8D790C0E0831A6783F2E8845AB6D_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_D6FF8D790C0E0831A6783F2E8845AB6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, damages sought for allegedly unpaid royalties</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_D6FF8D790C0E0831A6783F2E8845AB6D_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_D6FF8D790C0E0831A6783F2E8845AB6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_D6FF8D790C0E0831A6783F2E8845AB6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue_D6FF8D790C0E0831A6783F2E8845AB6D" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue_D6FF8D790C0E0831A6783F2E8845AB6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5E85C357880E63D47F543F2E88454D63_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5E85C357880E63D47F543F2E88454D63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, high end of payment upon achievement of certain triggering events</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5E85C357880E63D47F543F2E88454D63_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5E85C357880E63D47F543F2E88454D63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5E85C357880E63D47F543F2E88454D63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5E85C357880E63D47F543F2E88454D63" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5E85C357880E63D47F543F2E88454D63" xlink:type="arc" />
    <link:label id="lab_abus_ProgramsInPreClinicalDevelopment_991A24A88986C5CF99173F2E8845746A_terseLabel_en-US" xlink:label="lab_abus_ProgramsInPreClinicalDevelopment_991A24A88986C5CF99173F2E8845746A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Programs in pre-clinical development</link:label>
    <link:label id="lab_abus_ProgramsInPreClinicalDevelopment_991A24A88986C5CF99173F2E8845746A_label_en-US" xlink:label="lab_abus_ProgramsInPreClinicalDevelopment_991A24A88986C5CF99173F2E8845746A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Programs In Pre-Clinical Development</link:label>
    <link:label id="lab_abus_ProgramsInPreClinicalDevelopment_991A24A88986C5CF99173F2E8845746A_documentation_en-US" xlink:label="lab_abus_ProgramsInPreClinicalDevelopment_991A24A88986C5CF99173F2E8845746A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Programs In Pre-Clinical Development</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ProgramsInPreClinicalDevelopment" xlink:label="loc_abus_ProgramsInPreClinicalDevelopment_991A24A88986C5CF99173F2E8845746A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ProgramsInPreClinicalDevelopment_991A24A88986C5CF99173F2E8845746A" xlink:to="lab_abus_ProgramsInPreClinicalDevelopment_991A24A88986C5CF99173F2E8845746A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9918C010F83B7A6D50B53F2E884586CB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9918C010F83B7A6D50B53F2E884586CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combination, regulatory, development and sales milestone payments estimated fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9918C010F83B7A6D50B53F2E884586CB_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9918C010F83B7A6D50B53F2E884586CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9918C010F83B7A6D50B53F2E884586CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9918C010F83B7A6D50B53F2E884586CB" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9918C010F83B7A6D50B53F2E884586CB" xlink:type="arc" />
    <link:label id="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_2AAB54D0C7D6F434200C3F2E88468FFD_terseLabel_en-US" xlink:label="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_2AAB54D0C7D6F434200C3F2E88468FFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of contingent consideration</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_2AAB54D0C7D6F434200C3F2E88468FFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_2AAB54D0C7D6F434200C3F2E88468FFD" xlink:to="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_2AAB54D0C7D6F434200C3F2E88468FFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseCosts_C4DBD086EBAD06A833F43F2E884699A1_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseCosts_C4DBD086EBAD06A833F43F2E884699A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">License fee</link:label>
    <link:label id="lab_us-gaap_LicenseCosts_C4DBD086EBAD06A833F43F2E884699A1_label_en-US" xlink:label="lab_us-gaap_LicenseCosts_C4DBD086EBAD06A833F43F2E884699A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_C4DBD086EBAD06A833F43F2E884699A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseCosts_C4DBD086EBAD06A833F43F2E884699A1" xlink:to="lab_us-gaap_LicenseCosts_C4DBD086EBAD06A833F43F2E884699A1" xlink:type="arc" />
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_42666D523B32D70538113F2E8846CAB2_terseLabel_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_42666D523B32D70538113F2E8846CAB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and regulatory milestones payment per licensed compound series, maximum</link:label>
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_42666D523B32D70538113F2E8846CAB2_label_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_42666D523B32D70538113F2E8846CAB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Maximum Development And Regulatory Milestone Payments Per License</link:label>
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_42666D523B32D70538113F2E8846CAB2_documentation_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_42666D523B32D70538113F2E8846CAB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Maximum Development And Regulatory Milestone Payments Per License</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_42666D523B32D70538113F2E8846CAB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_42666D523B32D70538113F2E8846CAB2" xlink:to="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_42666D523B32D70538113F2E8846CAB2" xlink:type="arc" />
    <link:label id="lab_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense_1D92C7EA24CFC3784E6B3F2E8846670E_terseLabel_en-US" xlink:label="lab_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense_1D92C7EA24CFC3784E6B3F2E8846670E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales performance milestones payment per licensed product, maximum</link:label>
    <link:label id="lab_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense_1D92C7EA24CFC3784E6B3F2E8846670E_label_en-US" xlink:label="lab_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense_1D92C7EA24CFC3784E6B3F2E8846670E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Maximum Sales Performance Milestone Payments Per License</link:label>
    <link:label id="lab_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense_1D92C7EA24CFC3784E6B3F2E8846670E_documentation_en-US" xlink:label="lab_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense_1D92C7EA24CFC3784E6B3F2E8846670E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Maximum Sales Performance Milestone Payments Per License</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense" xlink:label="loc_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense_1D92C7EA24CFC3784E6B3F2E8846670E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense_1D92C7EA24CFC3784E6B3F2E8846670E" xlink:to="lab_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense_1D92C7EA24CFC3784E6B3F2E8846670E" xlink:type="arc" />
    <link:label id="lab_abus_ContractualObligationAmountOfResearchFundingPerYear_B30A7BEC2580208F10673F2E8846648C_terseLabel_en-US" xlink:label="lab_abus_ContractualObligationAmountOfResearchFundingPerYear_B30A7BEC2580208F10673F2E8846648C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research funding per year under research collaboration and funding agreement</link:label>
    <link:label id="lab_abus_ContractualObligationAmountOfResearchFundingPerYear_B30A7BEC2580208F10673F2E8846648C_label_en-US" xlink:label="lab_abus_ContractualObligationAmountOfResearchFundingPerYear_B30A7BEC2580208F10673F2E8846648C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation Amount Of Research Funding Per Year</link:label>
    <link:label id="lab_abus_ContractualObligationAmountOfResearchFundingPerYear_B30A7BEC2580208F10673F2E8846648C_documentation_en-US" xlink:label="lab_abus_ContractualObligationAmountOfResearchFundingPerYear_B30A7BEC2580208F10673F2E8846648C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation Amount Of Research Funding Per Year</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ContractualObligationAmountOfResearchFundingPerYear" xlink:label="loc_abus_ContractualObligationAmountOfResearchFundingPerYear_B30A7BEC2580208F10673F2E8846648C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ContractualObligationAmountOfResearchFundingPerYear_B30A7BEC2580208F10673F2E8846648C" xlink:to="lab_abus_ContractualObligationAmountOfResearchFundingPerYear_B30A7BEC2580208F10673F2E8846648C" xlink:type="arc" />
    <link:label id="lab_abus_ResearchFundingPeriod_7D424CA92C019B1D84343F2E8846DCC8_terseLabel_en-US" xlink:label="lab_abus_ResearchFundingPeriod_7D424CA92C019B1D84343F2E8846DCC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research funding period</link:label>
    <link:label id="lab_abus_ResearchFundingPeriod_7D424CA92C019B1D84343F2E8846DCC8_label_en-US" xlink:label="lab_abus_ResearchFundingPeriod_7D424CA92C019B1D84343F2E8846DCC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Funding Period</link:label>
    <link:label id="lab_abus_ResearchFundingPeriod_7D424CA92C019B1D84343F2E8846DCC8_documentation_en-US" xlink:label="lab_abus_ResearchFundingPeriod_7D424CA92C019B1D84343F2E8846DCC8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Funding Period</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ResearchFundingPeriod" xlink:label="loc_abus_ResearchFundingPeriod_7D424CA92C019B1D84343F2E8846DCC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ResearchFundingPeriod_7D424CA92C019B1D84343F2E8846DCC8" xlink:to="lab_abus_ResearchFundingPeriod_7D424CA92C019B1D84343F2E8846DCC8" xlink:type="arc" />
    <link:label id="lab_abus_ResearchFundingPeriodRenewableOption_F9535AF97E2DD69392173F2E8846C0BB_terseLabel_en-US" xlink:label="lab_abus_ResearchFundingPeriodRenewableOption_F9535AF97E2DD69392173F2E8846C0BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research funding period, renewable option</link:label>
    <link:label id="lab_abus_ResearchFundingPeriodRenewableOption_F9535AF97E2DD69392173F2E8846C0BB_label_en-US" xlink:label="lab_abus_ResearchFundingPeriodRenewableOption_F9535AF97E2DD69392173F2E8846C0BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Funding Period Renewable Option</link:label>
    <link:label id="lab_abus_ResearchFundingPeriodRenewableOption_F9535AF97E2DD69392173F2E8846C0BB_documentation_en-US" xlink:label="lab_abus_ResearchFundingPeriodRenewableOption_F9535AF97E2DD69392173F2E8846C0BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Funding Period Renewable Option</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ResearchFundingPeriodRenewableOption" xlink:label="loc_abus_ResearchFundingPeriodRenewableOption_F9535AF97E2DD69392173F2E8846C0BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ResearchFundingPeriodRenewableOption_F9535AF97E2DD69392173F2E8846C0BB" xlink:to="lab_abus_ResearchFundingPeriodRenewableOption_F9535AF97E2DD69392173F2E8846C0BB" xlink:type="arc" />
    <link:label id="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment_59CB66938508F26AFC223F2E8846F2B7_terseLabel_en-US" xlink:label="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment_59CB66938508F26AFC223F2E8846F2B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research funding agreement exclusive license upfront payment</link:label>
    <link:label id="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment_59CB66938508F26AFC223F2E8846F2B7_label_en-US" xlink:label="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment_59CB66938508F26AFC223F2E8846F2B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Funding Agreement Right To Obtain Exclusive License Upfront Payment</link:label>
    <link:label id="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment_59CB66938508F26AFC223F2E8846F2B7_documentation_en-US" xlink:label="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment_59CB66938508F26AFC223F2E8846F2B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Funding Agreement Right To Obtain Exclusive License Upfront Payment</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment" xlink:label="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment_59CB66938508F26AFC223F2E8846F2B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment_59CB66938508F26AFC223F2E8846F2B7" xlink:to="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment_59CB66938508F26AFC223F2E8846F2B7" xlink:type="arc" />
    <link:label id="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments_4139AA00D2B8B016AB973F2E88461EFA_terseLabel_en-US" xlink:label="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments_4139AA00D2B8B016AB973F2E88461EFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research funding agreement exclusive license maximum development and regulatory milestone payments</link:label>
    <link:label id="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments_4139AA00D2B8B016AB973F2E88461EFA_label_en-US" xlink:label="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments_4139AA00D2B8B016AB973F2E88461EFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Funding Agreement Right To Obtain Exclusive License Maximum Development And Regulatory Milestone Payments</link:label>
    <link:label id="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments_4139AA00D2B8B016AB973F2E88461EFA_documentation_en-US" xlink:label="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments_4139AA00D2B8B016AB973F2E88461EFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Funding Agreement Right To Obtain Exclusive License Maximum Development And Regulatory Milestone Payments</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments" xlink:label="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments_4139AA00D2B8B016AB973F2E88461EFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments_4139AA00D2B8B016AB973F2E88461EFA" xlink:to="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments_4139AA00D2B8B016AB973F2E88461EFA" xlink:type="arc" />
    <link:label id="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments_DF56F1752B89A5B7BF463F2E88462870_terseLabel_en-US" xlink:label="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments_DF56F1752B89A5B7BF463F2E88462870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research funding agreement license maximum commercialization milestone payments</link:label>
    <link:label id="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments_DF56F1752B89A5B7BF463F2E88462870_label_en-US" xlink:label="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments_DF56F1752B89A5B7BF463F2E88462870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Funding Agreement Right To Obtain Exclusive License Maximum Commercialization Milestone Payments</link:label>
    <link:label id="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments_DF56F1752B89A5B7BF463F2E88462870_documentation_en-US" xlink:label="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments_DF56F1752B89A5B7BF463F2E88462870" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Funding Agreement Right To Obtain Exclusive License Maximum Commercialization Milestone Payments</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments" xlink:label="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments_DF56F1752B89A5B7BF463F2E88462870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments_DF56F1752B89A5B7BF463F2E88462870" xlink:to="lab_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments_DF56F1752B89A5B7BF463F2E88462870" xlink:type="arc" />
    <link:label id="lab_abus_Numberofseriesofcompounds_D61FDD8DB21770EBC0D43F2E88462BFB_terseLabel_en-US" xlink:label="lab_abus_Numberofseriesofcompounds_D61FDD8DB21770EBC0D43F2E88462BFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of series of compounds</link:label>
    <link:label id="lab_abus_Numberofseriesofcompounds_D61FDD8DB21770EBC0D43F2E88462BFB_label_en-US" xlink:label="lab_abus_Numberofseriesofcompounds_D61FDD8DB21770EBC0D43F2E88462BFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of series of compounds</link:label>
    <link:label id="lab_abus_Numberofseriesofcompounds_D61FDD8DB21770EBC0D43F2E88462BFB_documentation_en-US" xlink:label="lab_abus_Numberofseriesofcompounds_D61FDD8DB21770EBC0D43F2E88462BFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of series of compounds</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_Numberofseriesofcompounds" xlink:label="loc_abus_Numberofseriesofcompounds_D61FDD8DB21770EBC0D43F2E88462BFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Numberofseriesofcompounds_D61FDD8DB21770EBC0D43F2E88462BFB" xlink:to="lab_abus_Numberofseriesofcompounds_D61FDD8DB21770EBC0D43F2E88462BFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_9021A9CBAF84E68997662EAA5FF83C82_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_9021A9CBAF84E68997662EAA5FF83C82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of business risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_9021A9CBAF84E68997662EAA5FF83C82_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_9021A9CBAF84E68997662EAA5FF83C82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_9021A9CBAF84E68997662EAA5FF83C82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_9021A9CBAF84E68997662EAA5FF83C82" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_9021A9CBAF84E68997662EAA5FF83C82" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_29237406AF8FCADFB9E03A63730E2BC6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable_29237406AF8FCADFB9E03A63730E2BC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_29237406AF8FCADFB9E03A63730E2BC6_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable_29237406AF8FCADFB9E03A63730E2BC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_29237406AF8FCADFB9E03A63730E2BC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_29237406AF8FCADFB9E03A63730E2BC6" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable_29237406AF8FCADFB9E03A63730E2BC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_53C1C04652AE1D8BAF403A63730E7E92_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems_53C1C04652AE1D8BAF403A63730E7E92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_53C1C04652AE1D8BAF403A63730E7E92_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems_53C1C04652AE1D8BAF403A63730E7E92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_53C1C04652AE1D8BAF403A63730E7E92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_53C1C04652AE1D8BAF403A63730E7E92" xlink:to="lab_us-gaap_DeferredRevenueArrangementLineItems_53C1C04652AE1D8BAF403A63730E7E92" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_45689432A9AD8AD9643B3A63730EE45F_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_45689432A9AD8AD9643B3A63730EE45F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_45689432A9AD8AD9643B3A63730EE45F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_45689432A9AD8AD9643B3A63730EE45F" xlink:to="lab_us-gaap_DeferredRevenueCurrent_45689432A9AD8AD9643B3A63730EE45F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_2D3D95F9895193E55D933A63730EB4D2_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_2D3D95F9895193E55D933A63730EB4D2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue long-term portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_2D3D95F9895193E55D933A63730EB4D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_2D3D95F9895193E55D933A63730EB4D2" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_2D3D95F9895193E55D933A63730EB4D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenue_382499D07829A6D9238E3A63730E7FB6_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue_382499D07829A6D9238E3A63730E7FB6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_382499D07829A6D9238E3A63730E7FB6_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue_382499D07829A6D9238E3A63730E7FB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_382499D07829A6D9238E3A63730E7FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_382499D07829A6D9238E3A63730E7FB6" xlink:to="lab_us-gaap_DeferredRevenue_382499D07829A6D9238E3A63730E7FB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_20CB1C697BF52A37F9733329B7BF5E3A_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_20CB1C697BF52A37F9733329B7BF5E3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_20CB1C697BF52A37F9733329B7BF5E3A_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_20CB1C697BF52A37F9733329B7BF5E3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_20CB1C697BF52A37F9733329B7BF5E3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_20CB1C697BF52A37F9733329B7BF5E3A" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_20CB1C697BF52A37F9733329B7BF5E3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_0852DDB16BEC791E77193329B7BF1F5A_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_0852DDB16BEC791E77193329B7BF1F5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_0852DDB16BEC791E77193329B7BF1F5A_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_0852DDB16BEC791E77193329B7BF1F5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_0852DDB16BEC791E77193329B7BF1F5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_0852DDB16BEC791E77193329B7BF1F5A" xlink:to="lab_us-gaap_UseOfEstimates_0852DDB16BEC791E77193329B7BF1F5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C484E7528D3C7DA8C22D3329B7BFF90D_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C484E7528D3C7DA8C22D3329B7BFF90D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C484E7528D3C7DA8C22D3329B7BFF90D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C484E7528D3C7DA8C22D3329B7BFF90D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C484E7528D3C7DA8C22D3329B7BFF90D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C484E7528D3C7DA8C22D3329B7BFF90D" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C484E7528D3C7DA8C22D3329B7BFF90D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_77D30C55E9AC16CECB343329B7BF1320_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_77D30C55E9AC16CECB343329B7BF1320" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term and long-term investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_77D30C55E9AC16CECB343329B7BF1320_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_77D30C55E9AC16CECB343329B7BF1320" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_77D30C55E9AC16CECB343329B7BF1320" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_77D30C55E9AC16CECB343329B7BF1320" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_77D30C55E9AC16CECB343329B7BF1320" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_11093179F9CC3CE26CAB3329B7C060C3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_11093179F9CC3CE26CAB3329B7C060C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_11093179F9CC3CE26CAB3329B7C060C3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_11093179F9CC3CE26CAB3329B7C060C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_11093179F9CC3CE26CAB3329B7C060C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_11093179F9CC3CE26CAB3329B7C060C3" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_11093179F9CC3CE26CAB3329B7C060C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_55988278392A00E7E1453329B7C0D8DE_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_55988278392A00E7E1453329B7C0D8DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_55988278392A00E7E1453329B7C0D8DE_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_55988278392A00E7E1453329B7C0D8DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_55988278392A00E7E1453329B7C0D8DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_55988278392A00E7E1453329B7C0D8DE" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_55988278392A00E7E1453329B7C0D8DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_DB23FAE35A97CA9BDB003329B7C044E3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_DB23FAE35A97CA9BDB003329B7C044E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_DB23FAE35A97CA9BDB003329B7C044E3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_DB23FAE35A97CA9BDB003329B7C044E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_DB23FAE35A97CA9BDB003329B7C044E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_DB23FAE35A97CA9BDB003329B7C044E3" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_DB23FAE35A97CA9BDB003329B7C044E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4D4E51EDCAFC7B92FD233329B7C086F9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4D4E51EDCAFC7B92FD233329B7C086F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of property and equipment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4D4E51EDCAFC7B92FD233329B7C086F9_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4D4E51EDCAFC7B92FD233329B7C086F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4D4E51EDCAFC7B92FD233329B7C086F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4D4E51EDCAFC7B92FD233329B7C086F9" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4D4E51EDCAFC7B92FD233329B7C086F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_C9336B34AD16A304F8CC3380F44550C5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_C9336B34AD16A304F8CC3380F44550C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_C9336B34AD16A304F8CC3380F44550C5_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_C9336B34AD16A304F8CC3380F44550C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_C9336B34AD16A304F8CC3380F44550C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_C9336B34AD16A304F8CC3380F44550C5" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_C9336B34AD16A304F8CC3380F44550C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_052DC48E94D33A7123A73329B7C05B44_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_052DC48E94D33A7123A73329B7C05B44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_052DC48E94D33A7123A73329B7C05B44_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_052DC48E94D33A7123A73329B7C05B44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_052DC48E94D33A7123A73329B7C05B44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_052DC48E94D33A7123A73329B7C05B44" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_052DC48E94D33A7123A73329B7C05B44" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasePolicyTextBlock_D94C317622B2B0F107FF3329B7C07854_terseLabel_en-US" xlink:label="lab_us-gaap_LeasePolicyTextBlock_D94C317622B2B0F107FF3329B7C07854" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases and lease inducements</link:label>
    <link:label id="lab_us-gaap_LeasePolicyTextBlock_D94C317622B2B0F107FF3329B7C07854_label_en-US" xlink:label="lab_us-gaap_LeasePolicyTextBlock_D94C317622B2B0F107FF3329B7C07854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="loc_us-gaap_LeasePolicyTextBlock_D94C317622B2B0F107FF3329B7C07854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasePolicyTextBlock_D94C317622B2B0F107FF3329B7C07854" xlink:to="lab_us-gaap_LeasePolicyTextBlock_D94C317622B2B0F107FF3329B7C07854" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_C6457A6FFEA2DC5426B63329B7C09E45_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_C6457A6FFEA2DC5426B63329B7C09E45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_C6457A6FFEA2DC5426B63329B7C09E45_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_C6457A6FFEA2DC5426B63329B7C09E45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_C6457A6FFEA2DC5426B63329B7C09E45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_C6457A6FFEA2DC5426B63329B7C09E45" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_C6457A6FFEA2DC5426B63329B7C09E45" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_87FADEFD4CFAB1003C873329B7C0032F_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_87FADEFD4CFAB1003C873329B7C0032F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income or loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_87FADEFD4CFAB1003C873329B7C0032F_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_87FADEFD4CFAB1003C873329B7C0032F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_87FADEFD4CFAB1003C873329B7C0032F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_87FADEFD4CFAB1003C873329B7C0032F" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_87FADEFD4CFAB1003C873329B7C0032F" xlink:type="arc" />
    <link:label id="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock_6571FFF4DBE7CD557B973329B7C05AF0_terseLabel_en-US" xlink:label="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock_6571FFF4DBE7CD557B973329B7C05AF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government grants and refundable investment tax credits</link:label>
    <link:label id="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock_6571FFF4DBE7CD557B973329B7C05AF0_label_en-US" xlink:label="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock_6571FFF4DBE7CD557B973329B7C05AF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Grants And Refundable Investment Tax Credits [Policy Text Block]</link:label>
    <link:label id="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock_6571FFF4DBE7CD557B973329B7C05AF0_documentation_en-US" xlink:label="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock_6571FFF4DBE7CD557B973329B7C05AF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the policy for the government grants and refundable investment tax credits.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock" xlink:label="loc_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock_6571FFF4DBE7CD557B973329B7C05AF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock_6571FFF4DBE7CD557B973329B7C05AF0" xlink:to="lab_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock_6571FFF4DBE7CD557B973329B7C05AF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8E4333D019D7FFF1D1E23329B7C0EEAC_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8E4333D019D7FFF1D1E23329B7C0EEAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation and change in reporting currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8E4333D019D7FFF1D1E23329B7C0EEAC_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8E4333D019D7FFF1D1E23329B7C0EEAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8E4333D019D7FFF1D1E23329B7C0EEAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8E4333D019D7FFF1D1E23329B7C0EEAC" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8E4333D019D7FFF1D1E23329B7C0EEAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_696D93DCC5827FF5AB563329B7C09281_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_696D93DCC5827FF5AB563329B7C09281" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_696D93DCC5827FF5AB563329B7C09281_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_696D93DCC5827FF5AB563329B7C09281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_696D93DCC5827FF5AB563329B7C09281" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_696D93DCC5827FF5AB563329B7C09281" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_696D93DCC5827FF5AB563329B7C09281" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_FBF16AA09E31A52764B43329B7C0C809_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_FBF16AA09E31A52764B43329B7C0C809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_FBF16AA09E31A52764B43329B7C0C809_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_FBF16AA09E31A52764B43329B7C0C809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_FBF16AA09E31A52764B43329B7C0C809" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_FBF16AA09E31A52764B43329B7C0C809" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_FBF16AA09E31A52764B43329B7C0C809" xlink:type="arc" />
    <link:label id="lab_abus_ReplacementAwardsPolicyTextBlock_78DCCAD6CF0DBF2E256E338759F481EE_terseLabel_en-US" xlink:label="lab_abus_ReplacementAwardsPolicyTextBlock_78DCCAD6CF0DBF2E256E338759F481EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Replacement awards</link:label>
    <link:label id="lab_abus_ReplacementAwardsPolicyTextBlock_78DCCAD6CF0DBF2E256E338759F481EE_label_en-US" xlink:label="lab_abus_ReplacementAwardsPolicyTextBlock_78DCCAD6CF0DBF2E256E338759F481EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Replacement Awards [Policy Text Block]</link:label>
    <link:label id="lab_abus_ReplacementAwardsPolicyTextBlock_78DCCAD6CF0DBF2E256E338759F481EE_documentation_en-US" xlink:label="lab_abus_ReplacementAwardsPolicyTextBlock_78DCCAD6CF0DBF2E256E338759F481EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Replacement Awards [Policy Text Block]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ReplacementAwardsPolicyTextBlock" xlink:label="loc_abus_ReplacementAwardsPolicyTextBlock_78DCCAD6CF0DBF2E256E338759F481EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ReplacementAwardsPolicyTextBlock_78DCCAD6CF0DBF2E256E338759F481EE" xlink:to="lab_abus_ReplacementAwardsPolicyTextBlock_78DCCAD6CF0DBF2E256E338759F481EE" xlink:type="arc" />
    <link:label id="lab_abus_WarrantsPolicyTextBlock_8423C9E2113C7716D6053329B7C0A061_terseLabel_en-US" xlink:label="lab_abus_WarrantsPolicyTextBlock_8423C9E2113C7716D6053329B7C0A061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_abus_WarrantsPolicyTextBlock_8423C9E2113C7716D6053329B7C0A061_label_en-US" xlink:label="lab_abus_WarrantsPolicyTextBlock_8423C9E2113C7716D6053329B7C0A061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [Policy Text Block]</link:label>
    <link:label id="lab_abus_WarrantsPolicyTextBlock_8423C9E2113C7716D6053329B7C0A061_documentation_en-US" xlink:label="lab_abus_WarrantsPolicyTextBlock_8423C9E2113C7716D6053329B7C0A061" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The accounting policy for the warrants.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_WarrantsPolicyTextBlock" xlink:label="loc_abus_WarrantsPolicyTextBlock_8423C9E2113C7716D6053329B7C0A061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_WarrantsPolicyTextBlock_8423C9E2113C7716D6053329B7C0A061" xlink:to="lab_abus_WarrantsPolicyTextBlock_8423C9E2113C7716D6053329B7C0A061" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_2D42169B053436CA45113329B7C04F19_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_2D42169B053436CA45113329B7C04F19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_2D42169B053436CA45113329B7C04F19_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_2D42169B053436CA45113329B7C04F19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2D42169B053436CA45113329B7C04F19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2D42169B053436CA45113329B7C04F19" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_2D42169B053436CA45113329B7C04F19" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_25B8446A4B1DA37B94F63329B7C07D39_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_25B8446A4B1DA37B94F63329B7C07D39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_25B8446A4B1DA37B94F63329B7C07D39_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_25B8446A4B1DA37B94F63329B7C07D39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_25B8446A4B1DA37B94F63329B7C07D39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_25B8446A4B1DA37B94F63329B7C07D39" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_25B8446A4B1DA37B94F63329B7C07D39" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_12EAFC9CEBD2FF9E92F73329B7A66C89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_12EAFC9CEBD2FF9E92F73329B7A66C89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_12EAFC9CEBD2FF9E92F73329B7A66C89_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_12EAFC9CEBD2FF9E92F73329B7A66C89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_12EAFC9CEBD2FF9E92F73329B7A66C89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_12EAFC9CEBD2FF9E92F73329B7A66C89" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_12EAFC9CEBD2FF9E92F73329B7A66C89" xlink:type="arc" />
    <link:label id="lab_abus_ChangesInFairValueOfWarrantsTableTextBlock_9EF486FEAB15F305D32E3329B7A65C6D_terseLabel_en-US" xlink:label="lab_abus_ChangesInFairValueOfWarrantsTableTextBlock_9EF486FEAB15F305D32E3329B7A65C6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of warrants</link:label>
    <link:label id="lab_abus_ChangesInFairValueOfWarrantsTableTextBlock_9EF486FEAB15F305D32E3329B7A65C6D_label_en-US" xlink:label="lab_abus_ChangesInFairValueOfWarrantsTableTextBlock_9EF486FEAB15F305D32E3329B7A65C6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Fair Value Of Warrants [Table Text Block]</link:label>
    <link:label id="lab_abus_ChangesInFairValueOfWarrantsTableTextBlock_9EF486FEAB15F305D32E3329B7A65C6D_documentation_en-US" xlink:label="lab_abus_ChangesInFairValueOfWarrantsTableTextBlock_9EF486FEAB15F305D32E3329B7A65C6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the tabular disclosure for the change in fair value of warrants.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ChangesInFairValueOfWarrantsTableTextBlock" xlink:label="loc_abus_ChangesInFairValueOfWarrantsTableTextBlock_9EF486FEAB15F305D32E3329B7A65C6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ChangesInFairValueOfWarrantsTableTextBlock_9EF486FEAB15F305D32E3329B7A65C6D" xlink:to="lab_abus_ChangesInFairValueOfWarrantsTableTextBlock_9EF486FEAB15F305D32E3329B7A65C6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_E972539B3C1049141CC5338CBA2E3D41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_E972539B3C1049141CC5338CBA2E3D41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_E972539B3C1049141CC5338CBA2E3D41_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_E972539B3C1049141CC5338CBA2E3D41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_E972539B3C1049141CC5338CBA2E3D41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_E972539B3C1049141CC5338CBA2E3D41" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_E972539B3C1049141CC5338CBA2E3D41" xlink:type="arc" />
    <link:label id="lab_abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_DD6B7EDB2A2922B217B83329B7A6C366_terseLabel_en-US" xlink:label="lab_abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_DD6B7EDB2A2922B217B83329B7A6C366" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment estimated useful lives</link:label>
    <link:label id="lab_abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_DD6B7EDB2A2922B217B83329B7A6C366_label_en-US" xlink:label="lab_abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_DD6B7EDB2A2922B217B83329B7A6C366" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives [Table Text Block]</link:label>
    <link:label id="lab_abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_DD6B7EDB2A2922B217B83329B7A6C366_documentation_en-US" xlink:label="lab_abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_DD6B7EDB2A2922B217B83329B7A6C366" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of property, plant and equipment, estimated useful lives.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="loc_abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_DD6B7EDB2A2922B217B83329B7A6C366" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_DD6B7EDB2A2922B217B83329B7A6C366" xlink:to="lab_abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_DD6B7EDB2A2922B217B83329B7A6C366" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_85DC6C8B4C1C2AEFFB513329B7A6D05A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_85DC6C8B4C1C2AEFFB513329B7A6D05A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of basic and diluted net income (loss) per common share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_85DC6C8B4C1C2AEFFB513329B7A6D05A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_85DC6C8B4C1C2AEFFB513329B7A6D05A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_85DC6C8B4C1C2AEFFB513329B7A6D05A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_85DC6C8B4C1C2AEFFB513329B7A6D05A" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_85DC6C8B4C1C2AEFFB513329B7A6D05A" xlink:type="arc" />
    <link:label id="lab_abus_FairValueOfWarrantsOutstandingPerWarrant_C77ECA9ED9CE65075E2F4DC688B6DB48_terseLabel_en-US" xlink:label="lab_abus_FairValueOfWarrantsOutstandingPerWarrant_C77ECA9ED9CE65075E2F4DC688B6DB48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants outstanding (in USD per share)</link:label>
    <link:label id="lab_abus_FairValueOfWarrantsOutstandingPerWarrant_C77ECA9ED9CE65075E2F4DC688B6DB48_label_en-US" xlink:label="lab_abus_FairValueOfWarrantsOutstandingPerWarrant_C77ECA9ED9CE65075E2F4DC688B6DB48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FairValueOfWarrantsOutstandingPerWarrant</link:label>
    <link:label id="lab_abus_FairValueOfWarrantsOutstandingPerWarrant_C77ECA9ED9CE65075E2F4DC688B6DB48_documentation_en-US" xlink:label="lab_abus_FairValueOfWarrantsOutstandingPerWarrant_C77ECA9ED9CE65075E2F4DC688B6DB48" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the fair value of the warrants outstanding.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_FairValueOfWarrantsOutstandingPerWarrant" xlink:label="loc_abus_FairValueOfWarrantsOutstandingPerWarrant_C77ECA9ED9CE65075E2F4DC688B6DB48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_FairValueOfWarrantsOutstandingPerWarrant_C77ECA9ED9CE65075E2F4DC688B6DB48" xlink:to="lab_abus_FairValueOfWarrantsOutstandingPerWarrant_C77ECA9ED9CE65075E2F4DC688B6DB48" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_7761D40B42AD6866AD324DC688B6C197_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_7761D40B42AD6866AD324DC688B6C197" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate fair value of warrants outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_7761D40B42AD6866AD324DC688B6C197" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_7761D40B42AD6866AD324DC688B6C197" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_7761D40B42AD6866AD324DC688B6C197" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_436FD6508F3EE55472304DC688B6FA57_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_436FD6508F3EE55472304DC688B6FA57" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_436FD6508F3EE55472304DC688B6FA57_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_436FD6508F3EE55472304DC688B6FA57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_436FD6508F3EE55472304DC688B6FA57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_436FD6508F3EE55472304DC688B6FA57" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_436FD6508F3EE55472304DC688B6FA57" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C6B30ED8F5AF519159AB2EAA600FA773_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C6B30ED8F5AF519159AB2EAA600FA773" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies and commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C6B30ED8F5AF519159AB2EAA600FA773_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C6B30ED8F5AF519159AB2EAA600FA773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C6B30ED8F5AF519159AB2EAA600FA773" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C6B30ED8F5AF519159AB2EAA600FA773" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C6B30ED8F5AF519159AB2EAA600FA773" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BC3D59815B4A0AD8B1B052F92C23F3DF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BC3D59815B4A0AD8B1B052F92C23F3DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BC3D59815B4A0AD8B1B052F92C23F3DF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BC3D59815B4A0AD8B1B052F92C23F3DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BC3D59815B4A0AD8B1B052F92C23F3DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BC3D59815B4A0AD8B1B052F92C23F3DF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BC3D59815B4A0AD8B1B052F92C23F3DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_CB4BBD309357BDF8852C52F92C28374F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_CB4BBD309357BDF8852C52F92C28374F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-vested options forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_CB4BBD309357BDF8852C52F92C28374F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_CB4BBD309357BDF8852C52F92C28374F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_CB4BBD309357BDF8852C52F92C28374F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_CB4BBD309357BDF8852C52F92C28374F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_CB4BBD309357BDF8852C52F92C28374F" xlink:type="arc" />
    <link:label id="lab_abus_SharesIssuedWithoutSubjectsMember_0F08D792454927DE5DC251CB6D14846C_terseLabel_en-US" xlink:label="lab_abus_SharesIssuedWithoutSubjectsMember_0F08D792454927DE5DC251CB6D14846C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares issued without subjects</link:label>
    <link:label id="lab_abus_SharesIssuedWithoutSubjectsMember_0F08D792454927DE5DC251CB6D14846C_label_en-US" xlink:label="lab_abus_SharesIssuedWithoutSubjectsMember_0F08D792454927DE5DC251CB6D14846C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Without Subjects [Member]</link:label>
    <link:label id="lab_abus_SharesIssuedWithoutSubjectsMember_0F08D792454927DE5DC251CB6D14846C_documentation_en-US" xlink:label="lab_abus_SharesIssuedWithoutSubjectsMember_0F08D792454927DE5DC251CB6D14846C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the shares issued without subjects.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_SharesIssuedWithoutSubjectsMember" xlink:label="loc_abus_SharesIssuedWithoutSubjectsMember_0F08D792454927DE5DC251CB6D14846C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_SharesIssuedWithoutSubjectsMember_0F08D792454927DE5DC251CB6D14846C" xlink:to="lab_abus_SharesIssuedWithoutSubjectsMember_0F08D792454927DE5DC251CB6D14846C" xlink:type="arc" />
    <link:label id="lab_abus_SharesIssuedSubjectToRepurchaseProvisionMember_46B8192EA35F480A4F9B51CB6D14EA69_terseLabel_en-US" xlink:label="lab_abus_SharesIssuedSubjectToRepurchaseProvisionMember_46B8192EA35F480A4F9B51CB6D14EA69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares issued subject to repurchase provision</link:label>
    <link:label id="lab_abus_SharesIssuedSubjectToRepurchaseProvisionMember_46B8192EA35F480A4F9B51CB6D14EA69_label_en-US" xlink:label="lab_abus_SharesIssuedSubjectToRepurchaseProvisionMember_46B8192EA35F480A4F9B51CB6D14EA69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Subject To Repurchase Provision [Member]</link:label>
    <link:label id="lab_abus_SharesIssuedSubjectToRepurchaseProvisionMember_46B8192EA35F480A4F9B51CB6D14EA69_documentation_en-US" xlink:label="lab_abus_SharesIssuedSubjectToRepurchaseProvisionMember_46B8192EA35F480A4F9B51CB6D14EA69" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the shares issued subject to repurchase provisions</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_SharesIssuedSubjectToRepurchaseProvisionMember" xlink:label="loc_abus_SharesIssuedSubjectToRepurchaseProvisionMember_46B8192EA35F480A4F9B51CB6D14EA69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_SharesIssuedSubjectToRepurchaseProvisionMember_46B8192EA35F480A4F9B51CB6D14EA69" xlink:to="lab_abus_SharesIssuedSubjectToRepurchaseProvisionMember_46B8192EA35F480A4F9B51CB6D14EA69" xlink:type="arc" />
    <link:label id="lab_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_116FC7FE75077C8F9CF651CB6D14116C_terseLabel_en-US" xlink:label="lab_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_116FC7FE75077C8F9CF651CB6D14116C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common share issuable for Arbutus Inc. stock options</link:label>
    <link:label id="lab_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_116FC7FE75077C8F9CF651CB6D14116C_label_en-US" xlink:label="lab_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_116FC7FE75077C8F9CF651CB6D14116C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Share Issuable For Arbutus Inc. Stock Options [Member]</link:label>
    <link:label id="lab_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_116FC7FE75077C8F9CF651CB6D14116C_documentation_en-US" xlink:label="lab_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_116FC7FE75077C8F9CF651CB6D14116C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common share issuable for Arbutus Inc. stock options [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_CommonShareIssuableForArbutusInc.StockOptionsMember" xlink:label="loc_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_116FC7FE75077C8F9CF651CB6D14116C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_116FC7FE75077C8F9CF651CB6D14116C" xlink:to="lab_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_116FC7FE75077C8F9CF651CB6D14116C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_EDA7D6A4098DD11B12A051CB6D154E4A_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_EDA7D6A4098DD11B12A051CB6D154E4A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consideration paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_EDA7D6A4098DD11B12A051CB6D154E4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_EDA7D6A4098DD11B12A051CB6D154E4A" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_EDA7D6A4098DD11B12A051CB6D154E4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Identifiable assets acquired and liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:type="arc" />
    <link:label id="lab_abus_IPRDCyclophilinsMember_EBB0D56E879A49F2776E5212D70F2578_verboseLabel_en-US" xlink:label="lab_abus_IPRDCyclophilinsMember_EBB0D56E879A49F2776E5212D70F2578" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cyclophilin</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_IPRDCyclophilinsMember" xlink:label="loc_abus_IPRDCyclophilinsMember_EBB0D56E879A49F2776E5212D70F2578" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IPRDCyclophilinsMember_EBB0D56E879A49F2776E5212D70F2578" xlink:to="lab_abus_IPRDCyclophilinsMember_EBB0D56E879A49F2776E5212D70F2578" xlink:type="arc" />
    <link:label id="lab_abus_OtherIPRDMember_0C4ADBCBDC3E740E94B15212D70FA751_terseLabel_en-US" xlink:label="lab_abus_OtherIPRDMember_0C4ADBCBDC3E740E94B15212D70FA751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other IPR&amp;D</link:label>
    <link:label id="lab_abus_OtherIPRDMember_0C4ADBCBDC3E740E94B15212D70FA751_label_en-US" xlink:label="lab_abus_OtherIPRDMember_0C4ADBCBDC3E740E94B15212D70FA751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other IPR&amp;D [Member]</link:label>
    <link:label id="lab_abus_OtherIPRDMember_0C4ADBCBDC3E740E94B15212D70FA751_documentation_en-US" xlink:label="lab_abus_OtherIPRDMember_0C4ADBCBDC3E740E94B15212D70FA751" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other IPR&amp;D [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_OtherIPRDMember" xlink:label="loc_abus_OtherIPRDMember_0C4ADBCBDC3E740E94B15212D70FA751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OtherIPRDMember_0C4ADBCBDC3E740E94B15212D70FA751" xlink:to="lab_abus_OtherIPRDMember_0C4ADBCBDC3E740E94B15212D70FA751" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillMember_2EBE929CC167E51978245212D70F14FA_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillMember_2EBE929CC167E51978245212D70F14FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillMember_2EBE929CC167E51978245212D70F14FA_label_en-US" xlink:label="lab_us-gaap_GoodwillMember_2EBE929CC167E51978245212D70F14FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaap_GoodwillMember_2EBE929CC167E51978245212D70F14FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillMember_2EBE929CC167E51978245212D70F14FA" xlink:to="lab_us-gaap_GoodwillMember_2EBE929CC167E51978245212D70F14FA" xlink:type="arc" />
    <link:label id="lab_abus_AbutusStockOptionsMember_C2B0BFBF587756B584F05212D7102ACA_terseLabel_en-US" xlink:label="lab_abus_AbutusStockOptionsMember_C2B0BFBF587756B584F05212D7102ACA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abutus stock options</link:label>
    <link:label id="lab_abus_AbutusStockOptionsMember_C2B0BFBF587756B584F05212D7102ACA_label_en-US" xlink:label="lab_abus_AbutusStockOptionsMember_C2B0BFBF587756B584F05212D7102ACA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abutus Stock Options [Member]</link:label>
    <link:label id="lab_abus_AbutusStockOptionsMember_C2B0BFBF587756B584F05212D7102ACA_documentation_en-US" xlink:label="lab_abus_AbutusStockOptionsMember_C2B0BFBF587756B584F05212D7102ACA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Abutus Stock Options [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_AbutusStockOptionsMember" xlink:label="loc_abus_AbutusStockOptionsMember_C2B0BFBF587756B584F05212D7102ACA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AbutusStockOptionsMember_C2B0BFBF587756B584F05212D7102ACA" xlink:to="lab_abus_AbutusStockOptionsMember_C2B0BFBF587756B584F05212D7102ACA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioForecastMember_CD885FBD127974B850C45212D71017CC_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_CD885FBD127974B850C45212D71017CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, forecast</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_CD885FBD127974B850C45212D71017CC_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_CD885FBD127974B850C45212D71017CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_CD885FBD127974B850C45212D71017CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember_CD885FBD127974B850C45212D71017CC" xlink:to="lab_us-gaap_ScenarioForecastMember_CD885FBD127974B850C45212D71017CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0416DA2D675799C2D5045212D7110096_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0416DA2D675799C2D5045212D7110096" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common shares issued for acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0416DA2D675799C2D5045212D7110096" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0416DA2D675799C2D5045212D7110096" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0416DA2D675799C2D5045212D7110096" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_DE40DC8E8A81531D07D25212D711EF7A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_DE40DC8E8A81531D07D25212D711EF7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_DE40DC8E8A81531D07D25212D711EF7A_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_DE40DC8E8A81531D07D25212D711EF7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_DE40DC8E8A81531D07D25212D711EF7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_DE40DC8E8A81531D07D25212D711EF7A" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_DE40DC8E8A81531D07D25212D711EF7A" xlink:type="arc" />
    <link:label id="lab_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter_4E8C1CB19ABE3EAAF0DB5212D711701D_terseLabel_en-US" xlink:label="lab_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter_4E8C1CB19ABE3EAAF0DB5212D711701D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acceleration of compensation expense</link:label>
    <link:label id="lab_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter_4E8C1CB19ABE3EAAF0DB5212D711701D_label_en-US" xlink:label="lab_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter_4E8C1CB19ABE3EAAF0DB5212D711701D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Acceleration Of Share Based Compensation Expense Per Quarter</link:label>
    <link:label id="lab_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter_4E8C1CB19ABE3EAAF0DB5212D711701D_documentation_en-US" xlink:label="lab_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter_4E8C1CB19ABE3EAAF0DB5212D711701D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination Acceleration Of Share Based Compensation Expense Per Quarter</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter" xlink:label="loc_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter_4E8C1CB19ABE3EAAF0DB5212D711701D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter_4E8C1CB19ABE3EAAF0DB5212D711701D" xlink:to="lab_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter_4E8C1CB19ABE3EAAF0DB5212D711701D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_10CA073E7D89A3F91B215212D71128CD_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_10CA073E7D89A3F91B215212D71128CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued and outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_10CA073E7D89A3F91B215212D71128CD_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_10CA073E7D89A3F91B215212D71128CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_10CA073E7D89A3F91B215212D71128CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_10CA073E7D89A3F91B215212D71128CD" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_10CA073E7D89A3F91B215212D71128CD" xlink:type="arc" />
    <link:label id="lab_abus_StockRepurchaseRightsExpirationRateShares_EE09A63FE0F3B0466E035212D711C745_terseLabel_en-US" xlink:label="lab_abus_StockRepurchaseRightsExpirationRateShares_EE09A63FE0F3B0466E035212D711C745" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase rights expiration rate (in shares)</link:label>
    <link:label id="lab_abus_StockRepurchaseRightsExpirationRateShares_EE09A63FE0F3B0466E035212D711C745_label_en-US" xlink:label="lab_abus_StockRepurchaseRightsExpirationRateShares_EE09A63FE0F3B0466E035212D711C745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Rights Expiration Rate Shares</link:label>
    <link:label id="lab_abus_StockRepurchaseRightsExpirationRateShares_EE09A63FE0F3B0466E035212D711C745_documentation_en-US" xlink:label="lab_abus_StockRepurchaseRightsExpirationRateShares_EE09A63FE0F3B0466E035212D711C745" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Repurchase Rights Expiration Rate Shares</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_StockRepurchaseRightsExpirationRateShares" xlink:label="loc_abus_StockRepurchaseRightsExpirationRateShares_EE09A63FE0F3B0466E035212D711C745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_StockRepurchaseRightsExpirationRateShares_EE09A63FE0F3B0466E035212D711C745" xlink:to="lab_abus_StockRepurchaseRightsExpirationRateShares_EE09A63FE0F3B0466E035212D711C745" xlink:type="arc" />
    <link:label id="lab_abus_PeriodofEstimatedCashFlowsUsedInFairValue_574514D996C963B16E2C5212D7115A5F_terseLabel_en-US" xlink:label="lab_abus_PeriodofEstimatedCashFlowsUsedInFairValue_574514D996C963B16E2C5212D7115A5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of estimated cash flows</link:label>
    <link:label id="lab_abus_PeriodofEstimatedCashFlowsUsedInFairValue_574514D996C963B16E2C5212D7115A5F_label_en-US" xlink:label="lab_abus_PeriodofEstimatedCashFlowsUsedInFairValue_574514D996C963B16E2C5212D7115A5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period of Estimated Cash Flows Used In Fair Value</link:label>
    <link:label id="lab_abus_PeriodofEstimatedCashFlowsUsedInFairValue_574514D996C963B16E2C5212D7115A5F_documentation_en-US" xlink:label="lab_abus_PeriodofEstimatedCashFlowsUsedInFairValue_574514D996C963B16E2C5212D7115A5F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of Estimated Cash Flows Used In Fair Value</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_PeriodofEstimatedCashFlowsUsedInFairValue" xlink:label="loc_abus_PeriodofEstimatedCashFlowsUsedInFairValue_574514D996C963B16E2C5212D7115A5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_PeriodofEstimatedCashFlowsUsedInFairValue_574514D996C963B16E2C5212D7115A5F" xlink:to="lab_abus_PeriodofEstimatedCashFlowsUsedInFairValue_574514D996C963B16E2C5212D7115A5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_5394AD3D3DE09BE7E8DB5212D711D22E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_5394AD3D3DE09BE7E8DB5212D711D22E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_5394AD3D3DE09BE7E8DB5212D711D22E_label_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_5394AD3D3DE09BE7E8DB5212D711D22E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_5394AD3D3DE09BE7E8DB5212D711D22E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsDiscountRate_5394AD3D3DE09BE7E8DB5212D711D22E" xlink:to="lab_us-gaap_FairValueInputsDiscountRate_5394AD3D3DE09BE7E8DB5212D711D22E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC7C123EDE9FE6BCED2C5212D711A7E8_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC7C123EDE9FE6BCED2C5212D711A7E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets acquired, fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC7C123EDE9FE6BCED2C5212D711A7E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC7C123EDE9FE6BCED2C5212D711A7E8" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC7C123EDE9FE6BCED2C5212D711A7E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_D40D8ECC8DE7A90C03675212D7119C57_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_D40D8ECC8DE7A90C03675212D7119C57" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Measurement period adjustments, intangibles</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_D40D8ECC8DE7A90C03675212D7119C57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_D40D8ECC8DE7A90C03675212D7119C57" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_D40D8ECC8DE7A90C03675212D7119C57" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DAAE12CA70B75B9C5D515212D711DF79_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DAAE12CA70B75B9C5D515212D711DF79" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DAAE12CA70B75B9C5D515212D711DF79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DAAE12CA70B75B9C5D515212D711DF79" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DAAE12CA70B75B9C5D515212D711DF79" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_19030CED2B3257713A1D5212D7111139_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_19030CED2B3257713A1D5212D7111139" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit related to impairment charge</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_19030CED2B3257713A1D5212D7111139" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_19030CED2B3257713A1D5212D7111139" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_19030CED2B3257713A1D5212D7111139" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_FC7784F0A21EC3393A525212D712E720_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_FC7784F0A21EC3393A525212D712E720" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Measurement period adjustments, goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_FC7784F0A21EC3393A525212D712E720" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_FC7784F0A21EC3393A525212D712E720" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_FC7784F0A21EC3393A525212D712E720" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportingUnits_C320E3E8157BD26670E65212D712DAFE_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits_C320E3E8157BD26670E65212D712DAFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_C320E3E8157BD26670E65212D712DAFE_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits_C320E3E8157BD26670E65212D712DAFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_C320E3E8157BD26670E65212D712DAFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits_C320E3E8157BD26670E65212D712DAFE" xlink:to="lab_us-gaap_NumberOfReportingUnits_C320E3E8157BD26670E65212D712DAFE" xlink:type="arc" />
    <link:label id="lab_abus_MarketCapitalizationValue_1B8EC0F28BDA116DA9F45212D7127E3A_terseLabel_en-US" xlink:label="lab_abus_MarketCapitalizationValue_1B8EC0F28BDA116DA9F45212D7127E3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market capitalization</link:label>
    <link:label id="lab_abus_MarketCapitalizationValue_1B8EC0F28BDA116DA9F45212D7127E3A_label_en-US" xlink:label="lab_abus_MarketCapitalizationValue_1B8EC0F28BDA116DA9F45212D7127E3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Capitalization Value</link:label>
    <link:label id="lab_abus_MarketCapitalizationValue_1B8EC0F28BDA116DA9F45212D7127E3A_documentation_en-US" xlink:label="lab_abus_MarketCapitalizationValue_1B8EC0F28BDA116DA9F45212D7127E3A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Capitalization Value</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_MarketCapitalizationValue" xlink:label="loc_abus_MarketCapitalizationValue_1B8EC0F28BDA116DA9F45212D7127E3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_MarketCapitalizationValue_1B8EC0F28BDA116DA9F45212D7127E3A" xlink:to="lab_abus_MarketCapitalizationValue_1B8EC0F28BDA116DA9F45212D7127E3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_716C419C27E3E1C5CCB95212D71248DB_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_716C419C27E3E1C5CCB95212D71248DB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_716C419C27E3E1C5CCB95212D71248DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_716C419C27E3E1C5CCB95212D71248DB" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_716C419C27E3E1C5CCB95212D71248DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_CF5347B547C02E8182EA5212D71249B6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_CF5347B547C02E8182EA5212D71249B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company's carrying value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CF5347B547C02E8182EA5212D71249B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_CF5347B547C02E8182EA5212D71249B6" xlink:to="lab_us-gaap_StockholdersEquity_CF5347B547C02E8182EA5212D71249B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_EBA2FB9C233A9F1A73F05212D71269B4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_EBA2FB9C233A9F1A73F05212D71269B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_EBA2FB9C233A9F1A73F05212D71269B4_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_EBA2FB9C233A9F1A73F05212D71269B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_EBA2FB9C233A9F1A73F05212D71269B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_EBA2FB9C233A9F1A73F05212D71269B4" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_EBA2FB9C233A9F1A73F05212D71269B4" xlink:type="arc" />
    <link:label id="lab_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E_terseLabel_en-US" xlink:label="lab_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Table]</link:label>
    <link:label id="lab_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E_label_en-US" xlink:label="lab_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Table]</link:label>
    <link:label id="lab_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E_documentation_en-US" xlink:label="lab_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="abus-20151231.xsd#abus_ComponentsofDeferredTaxAssetsTable" xlink:label="loc_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E" xlink:to="lab_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_63DD88CA35D2D9AC95FB344946B13AC1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_63DD88CA35D2D9AC95FB344946B13AC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_63DD88CA35D2D9AC95FB344946B13AC1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_63DD88CA35D2D9AC95FB344946B13AC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_63DD88CA35D2D9AC95FB344946B13AC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_63DD88CA35D2D9AC95FB344946B13AC1" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_63DD88CA35D2D9AC95FB344946B13AC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_CBB201378661935F315A344946B2666A_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_CBB201378661935F315A344946B2666A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_CBB201378661935F315A344946B2666A_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_CBB201378661935F315A344946B2666A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_CBB201378661935F315A344946B2666A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_CBB201378661935F315A344946B2666A" xlink:to="lab_us-gaap_DomesticCountryMember_CBB201378661935F315A344946B2666A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_5C36A52C597E507DAB56344946B21A76_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_5C36A52C597E507DAB56344946B21A76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provincial</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_5C36A52C597E507DAB56344946B21A76_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_5C36A52C597E507DAB56344946B21A76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5C36A52C597E507DAB56344946B21A76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_5C36A52C597E507DAB56344946B21A76" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_5C36A52C597E507DAB56344946B21A76" xlink:type="arc" />
    <link:label id="lab_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5_terseLabel_en-US" xlink:label="lab_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Line Items]</link:label>
    <link:label id="lab_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5_label_en-US" xlink:label="lab_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Line Items]</link:label>
    <link:label id="lab_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5_documentation_en-US" xlink:label="lab_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="abus-20151231.xsd#abus_ComponentsofDeferredTaxAssetsLineItems" xlink:label="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="lab_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_534BD121FF3FD810CB61344946B26D22_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_534BD121FF3FD810CB61344946B26D22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-capital loss carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_534BD121FF3FD810CB61344946B26D22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_534BD121FF3FD810CB61344946B26D22" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_534BD121FF3FD810CB61344946B26D22" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_906D86C7EB62018060FA344946B24DF7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_906D86C7EB62018060FA344946B24DF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development deductions</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_906D86C7EB62018060FA344946B24DF7_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_906D86C7EB62018060FA344946B24DF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_906D86C7EB62018060FA344946B24DF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_906D86C7EB62018060FA344946B24DF7" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_906D86C7EB62018060FA344946B24DF7" xlink:type="arc" />
    <link:label id="lab_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_CE096A759CFE704BB943344946B22F66_terseLabel_en-US" xlink:label="lab_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_CE096A759CFE704BB943344946B22F66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Book amortization in excess of tax</link:label>
    <link:label id="lab_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_CE096A759CFE704BB943344946B22F66_label_en-US" xlink:label="lab_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_CE096A759CFE704BB943344946B22F66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Book amortization in excess of tax</link:label>
    <link:label id="lab_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_CE096A759CFE704BB943344946B22F66_documentation_en-US" xlink:label="lab_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_CE096A759CFE704BB943344946B22F66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the deferred tax asset book amortization in excess of tax.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_DeferredTaxAssetBookAmortizationInExcessOfTax" xlink:label="loc_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_CE096A759CFE704BB943344946B22F66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_CE096A759CFE704BB943344946B22F66" xlink:to="lab_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_CE096A759CFE704BB943344946B22F66" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_EDBDDDE144D84E96A3B5344946B20247_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_EDBDDDE144D84E96A3B5344946B20247" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_EDBDDDE144D84E96A3B5344946B20247_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_EDBDDDE144D84E96A3B5344946B20247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_EDBDDDE144D84E96A3B5344946B20247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_EDBDDDE144D84E96A3B5344946B20247" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_EDBDDDE144D84E96A3B5344946B20247" xlink:type="arc" />
    <link:label id="lab_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7546690123BA1955F20D344946B2C460_terseLabel_en-US" xlink:label="lab_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7546690123BA1955F20D344946B2C460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized for tax purposes in excess of revenue recognized for accounting purposes</link:label>
    <link:label id="lab_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7546690123BA1955F20D344946B2C460_label_en-US" xlink:label="lab_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7546690123BA1955F20D344946B2C460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue recognized for tax purposes in excess of revenue recognized for accounting purposes</link:label>
    <link:label id="lab_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7546690123BA1955F20D344946B2C460_documentation_en-US" xlink:label="lab_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7546690123BA1955F20D344946B2C460" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the deferred tax asset revenue recognized for tax purpose in excess of revenue recognized for accounting purposes.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes" xlink:label="loc_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7546690123BA1955F20D344946B2C460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7546690123BA1955F20D344946B2C460" xlink:to="lab_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7546690123BA1955F20D344946B2C460" xlink:type="arc" />
    <link:label id="lab_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_4F2AD3507162A0E4582C344946B22181_terseLabel_en-US" xlink:label="lab_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_4F2AD3507162A0E4582C344946B22181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax value in excess of accounting value in lease inducements</link:label>
    <link:label id="lab_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_4F2AD3507162A0E4582C344946B22181_label_en-US" xlink:label="lab_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_4F2AD3507162A0E4582C344946B22181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax value in excess of accounting value in lease inducements</link:label>
    <link:label id="lab_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_4F2AD3507162A0E4582C344946B22181_documentation_en-US" xlink:label="lab_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_4F2AD3507162A0E4582C344946B22181" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the deferred tax asset tax value in excess of accounting value in lease inducements.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements" xlink:label="loc_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_4F2AD3507162A0E4582C344946B22181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_4F2AD3507162A0E4582C344946B22181" xlink:to="lab_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_4F2AD3507162A0E4582C344946B22181" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_549356D553A093E09CB7344946B394F7_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments_549356D553A093E09CB7344946B394F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_549356D553A093E09CB7344946B394F7_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments_549356D553A093E09CB7344946B394F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_549356D553A093E09CB7344946B394F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestments_549356D553A093E09CB7344946B394F7" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestments_549356D553A093E09CB7344946B394F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_684C77D34B808793BD1A3454970A38C5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_684C77D34B808793BD1A3454970A38C5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_684C77D34B808793BD1A3454970A38C5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_684C77D34B808793BD1A3454970A38C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_684C77D34B808793BD1A3454970A38C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_684C77D34B808793BD1A3454970A38C5" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_684C77D34B808793BD1A3454970A38C5" xlink:type="arc" />
    <link:label id="lab_abus_DeferredTaxAssetUpfrontLicenseFees_11E25EE66346FA645ED034570E2212E8_terseLabel_en-US" xlink:label="lab_abus_DeferredTaxAssetUpfrontLicenseFees_11E25EE66346FA645ED034570E2212E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront license fees</link:label>
    <link:label id="lab_abus_DeferredTaxAssetUpfrontLicenseFees_11E25EE66346FA645ED034570E2212E8_label_en-US" xlink:label="lab_abus_DeferredTaxAssetUpfrontLicenseFees_11E25EE66346FA645ED034570E2212E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Upfront License Fees</link:label>
    <link:label id="lab_abus_DeferredTaxAssetUpfrontLicenseFees_11E25EE66346FA645ED034570E2212E8_documentation_en-US" xlink:label="lab_abus_DeferredTaxAssetUpfrontLicenseFees_11E25EE66346FA645ED034570E2212E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Upfront License Fees</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_DeferredTaxAssetUpfrontLicenseFees" xlink:label="loc_abus_DeferredTaxAssetUpfrontLicenseFees_11E25EE66346FA645ED034570E2212E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_DeferredTaxAssetUpfrontLicenseFees_11E25EE66346FA645ED034570E2212E8" xlink:to="lab_abus_DeferredTaxAssetUpfrontLicenseFees_11E25EE66346FA645ED034570E2212E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_DEFDD4277414129EB097345C47231444_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_DEFDD4277414129EB097345C47231444" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_DEFDD4277414129EB097345C47231444_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_DEFDD4277414129EB097345C47231444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_DEFDD4277414129EB097345C47231444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_DEFDD4277414129EB097345C47231444" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_DEFDD4277414129EB097345C47231444" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5F121E3BAD37379062C6344946B3807D_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5F121E3BAD37379062C6344946B3807D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5F121E3BAD37379062C6344946B3807D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5F121E3BAD37379062C6344946B3807D" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5F121E3BAD37379062C6344946B3807D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_5A220A8B32C1E7656D2E345D70982794_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_5A220A8B32C1E7656D2E345D70982794" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_5A220A8B32C1E7656D2E345D70982794_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_5A220A8B32C1E7656D2E345D70982794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_5A220A8B32C1E7656D2E345D70982794" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_5A220A8B32C1E7656D2E345D70982794" xlink:to="lab_us-gaap_DeferredTaxLiabilities_5A220A8B32C1E7656D2E345D70982794" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_2CCC4662B176DA9F458B344946B3CFAF_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_2CCC4662B176DA9F458B344946B3CFAF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_2CCC4662B176DA9F458B344946B3CFAF_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_2CCC4662B176DA9F458B344946B3CFAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2CCC4662B176DA9F458B344946B3CFAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2CCC4662B176DA9F458B344946B3CFAF" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_2CCC4662B176DA9F458B344946B3CFAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_FBACF398AB687FAC26CE2EAA5FD3F5CC_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_FBACF398AB687FAC26CE2EAA5FD3F5CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_FBACF398AB687FAC26CE2EAA5FD3F5CC_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_FBACF398AB687FAC26CE2EAA5FD3F5CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_FBACF398AB687FAC26CE2EAA5FD3F5CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_FBACF398AB687FAC26CE2EAA5FD3F5CC" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_FBACF398AB687FAC26CE2EAA5FD3F5CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:type="arc" />
    <link:label id="lab_abus_AlnylamandAscletisPharmaceuticalsMember_1EB58ADDFBE8ECE13A4056E5215A9EC7_terseLabel_en-US" xlink:label="lab_abus_AlnylamandAscletisPharmaceuticalsMember_1EB58ADDFBE8ECE13A4056E5215A9EC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alnylam and Ascletis Pharmaceuticals</link:label>
    <link:label id="lab_abus_AlnylamandAscletisPharmaceuticalsMember_1EB58ADDFBE8ECE13A4056E5215A9EC7_label_en-US" xlink:label="lab_abus_AlnylamandAscletisPharmaceuticalsMember_1EB58ADDFBE8ECE13A4056E5215A9EC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alnylam and Ascletis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_abus_AlnylamandAscletisPharmaceuticalsMember_1EB58ADDFBE8ECE13A4056E5215A9EC7_documentation_en-US" xlink:label="lab_abus_AlnylamandAscletisPharmaceuticalsMember_1EB58ADDFBE8ECE13A4056E5215A9EC7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alnylam and Ascletis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_AlnylamandAscletisPharmaceuticalsMember" xlink:label="loc_abus_AlnylamandAscletisPharmaceuticalsMember_1EB58ADDFBE8ECE13A4056E5215A9EC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AlnylamandAscletisPharmaceuticalsMember_1EB58ADDFBE8ECE13A4056E5215A9EC7" xlink:to="lab_abus_AlnylamandAscletisPharmaceuticalsMember_1EB58ADDFBE8ECE13A4056E5215A9EC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1C76C6D1852D50DAEC4256E5215AA914_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1C76C6D1852D50DAEC4256E5215AA914" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1C76C6D1852D50DAEC4256E5215AA914_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1C76C6D1852D50DAEC4256E5215AA914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1C76C6D1852D50DAEC4256E5215AA914" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1C76C6D1852D50DAEC4256E5215AA914" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1C76C6D1852D50DAEC4256E5215AA914" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA" xlink:to="lab_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA" xlink:type="arc" />
    <link:label id="lab_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F_terseLabel_en-US" xlink:label="lab_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Modifications [Axis]</link:label>
    <link:label id="lab_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F_label_en-US" xlink:label="lab_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Modifications [Axis]</link:label>
    <link:label id="lab_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F_documentation_en-US" xlink:label="lab_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Modifications [Axis]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ContractModificationsAxis" xlink:label="loc_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F" xlink:to="lab_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F" xlink:type="arc" />
    <link:label id="lab_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58_terseLabel_en-US" xlink:label="lab_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Modifications [Domain]</link:label>
    <link:label id="lab_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58_label_en-US" xlink:label="lab_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Modifications [Domain]</link:label>
    <link:label id="lab_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58_documentation_en-US" xlink:label="lab_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Contract Modifications [Axis]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ContractModificationsDomain" xlink:label="loc_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:to="lab_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:type="arc" />
    <link:label id="lab_abus_IncreaseToSupportDevelopmentPlansMember_F363ECFA8A8BDBB1370F56E5215B11B8_terseLabel_en-US" xlink:label="lab_abus_IncreaseToSupportDevelopmentPlansMember_F363ECFA8A8BDBB1370F56E5215B11B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase to support development plans</link:label>
    <link:label id="lab_abus_IncreaseToSupportDevelopmentPlansMember_F363ECFA8A8BDBB1370F56E5215B11B8_label_en-US" xlink:label="lab_abus_IncreaseToSupportDevelopmentPlansMember_F363ECFA8A8BDBB1370F56E5215B11B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase To Support Development Plans [Member]</link:label>
    <link:label id="lab_abus_IncreaseToSupportDevelopmentPlansMember_F363ECFA8A8BDBB1370F56E5215B11B8_documentation_en-US" xlink:label="lab_abus_IncreaseToSupportDevelopmentPlansMember_F363ECFA8A8BDBB1370F56E5215B11B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the increase funding potential to support development plans that integrate recent advancements in lipid nanoparticle (&#8220;LNP&#8221;) formulation and manufacturing technologies.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_IncreaseToSupportDevelopmentPlansMember" xlink:label="loc_abus_IncreaseToSupportDevelopmentPlansMember_F363ECFA8A8BDBB1370F56E5215B11B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IncreaseToSupportDevelopmentPlansMember_F363ECFA8A8BDBB1370F56E5215B11B8" xlink:to="lab_abus_IncreaseToSupportDevelopmentPlansMember_F363ECFA8A8BDBB1370F56E5215B11B8" xlink:type="arc" />
    <link:label id="lab_abus_IncreasedFundingForStageOneMember_D225727F4C8D6F3A7DA956E5215BCF93_terseLabel_en-US" xlink:label="lab_abus_IncreasedFundingForStageOneMember_D225727F4C8D6F3A7DA956E5215BCF93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increased funding for stage one</link:label>
    <link:label id="lab_abus_IncreasedFundingForStageOneMember_D225727F4C8D6F3A7DA956E5215BCF93_label_en-US" xlink:label="lab_abus_IncreasedFundingForStageOneMember_D225727F4C8D6F3A7DA956E5215BCF93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increased Funding For Stage One [Member]</link:label>
    <link:label id="lab_abus_IncreasedFundingForStageOneMember_D225727F4C8D6F3A7DA956E5215BCF93_documentation_en-US" xlink:label="lab_abus_IncreasedFundingForStageOneMember_D225727F4C8D6F3A7DA956E5215BCF93" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the increased funding for phase one of the clinical trials.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_IncreasedFundingForStageOneMember" xlink:label="loc_abus_IncreasedFundingForStageOneMember_D225727F4C8D6F3A7DA956E5215BCF93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IncreasedFundingForStageOneMember_D225727F4C8D6F3A7DA956E5215BCF93" xlink:to="lab_abus_IncreasedFundingForStageOneMember_D225727F4C8D6F3A7DA956E5215BCF93" xlink:type="arc" />
    <link:label id="lab_abus_StageOneMember_F2E7C00DF6CEDFBBCD8A56E5215BFE43_terseLabel_en-US" xlink:label="lab_abus_StageOneMember_F2E7C00DF6CEDFBBCD8A56E5215BFE43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stage one</link:label>
    <link:label id="lab_abus_StageOneMember_F2E7C00DF6CEDFBBCD8A56E5215BFE43_label_en-US" xlink:label="lab_abus_StageOneMember_F2E7C00DF6CEDFBBCD8A56E5215BFE43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stage One [Member]</link:label>
    <link:label id="lab_abus_StageOneMember_F2E7C00DF6CEDFBBCD8A56E5215BFE43_documentation_en-US" xlink:label="lab_abus_StageOneMember_F2E7C00DF6CEDFBBCD8A56E5215BFE43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the first stage of the contract and is aligned with phase one of the clinical trials.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_StageOneMember" xlink:label="loc_abus_StageOneMember_F2E7C00DF6CEDFBBCD8A56E5215BFE43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_StageOneMember_F2E7C00DF6CEDFBBCD8A56E5215BFE43" xlink:to="lab_abus_StageOneMember_F2E7C00DF6CEDFBBCD8A56E5215BFE43" xlink:type="arc" />
    <link:label id="lab_abus_ContractExtensionMember_9060E444E25CA35EBDA056E5215BC22D_terseLabel_en-US" xlink:label="lab_abus_ContractExtensionMember_9060E444E25CA35EBDA056E5215BC22D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract extension</link:label>
    <link:label id="lab_abus_ContractExtensionMember_9060E444E25CA35EBDA056E5215BC22D_label_en-US" xlink:label="lab_abus_ContractExtensionMember_9060E444E25CA35EBDA056E5215BC22D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Extension [Member]</link:label>
    <link:label id="lab_abus_ContractExtensionMember_9060E444E25CA35EBDA056E5215BC22D_documentation_en-US" xlink:label="lab_abus_ContractExtensionMember_9060E444E25CA35EBDA056E5215BC22D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the contract extension.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ContractExtensionMember" xlink:label="loc_abus_ContractExtensionMember_9060E444E25CA35EBDA056E5215BC22D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ContractExtensionMember_9060E444E25CA35EBDA056E5215BC22D" xlink:to="lab_abus_ContractExtensionMember_9060E444E25CA35EBDA056E5215BC22D" xlink:type="arc" />
    <link:label id="lab_abus_MarqiboCommercialSalesMember_6F06915279EDC38A1FBF56E5215C3F94_terseLabel_en-US" xlink:label="lab_abus_MarqiboCommercialSalesMember_6F06915279EDC38A1FBF56E5215C3F94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marqibo Commercial Sales</link:label>
    <link:label id="lab_abus_MarqiboCommercialSalesMember_6F06915279EDC38A1FBF56E5215C3F94_label_en-US" xlink:label="lab_abus_MarqiboCommercialSalesMember_6F06915279EDC38A1FBF56E5215C3F94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marqibo Commercial Sales [Member]</link:label>
    <link:label id="lab_abus_MarqiboCommercialSalesMember_6F06915279EDC38A1FBF56E5215C3F94_documentation_en-US" xlink:label="lab_abus_MarqiboCommercialSalesMember_6F06915279EDC38A1FBF56E5215C3F94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Marqibo commercial sales.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_MarqiboCommercialSalesMember" xlink:label="loc_abus_MarqiboCommercialSalesMember_6F06915279EDC38A1FBF56E5215C3F94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_MarqiboCommercialSalesMember_6F06915279EDC38A1FBF56E5215C3F94" xlink:to="lab_abus_MarqiboCommercialSalesMember_6F06915279EDC38A1FBF56E5215C3F94" xlink:type="arc" />
    <link:label id="lab_abus_TalonTherapeuticsMember_AC338069851D9FA0044956E5215C4FE4_terseLabel_en-US" xlink:label="lab_abus_TalonTherapeuticsMember_AC338069851D9FA0044956E5215C4FE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Talon Therapeutics</link:label>
    <link:label id="lab_abus_TalonTherapeuticsMember_AC338069851D9FA0044956E5215C4FE4_label_en-US" xlink:label="lab_abus_TalonTherapeuticsMember_AC338069851D9FA0044956E5215C4FE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Talon Therapeutics [Member]</link:label>
    <link:label id="lab_abus_TalonTherapeuticsMember_AC338069851D9FA0044956E5215C4FE4_documentation_en-US" xlink:label="lab_abus_TalonTherapeuticsMember_AC338069851D9FA0044956E5215C4FE4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Talon Therapeutics.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_TalonTherapeuticsMember" xlink:label="loc_abus_TalonTherapeuticsMember_AC338069851D9FA0044956E5215C4FE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_TalonTherapeuticsMember_AC338069851D9FA0044956E5215C4FE4" xlink:to="lab_abus_TalonTherapeuticsMember_AC338069851D9FA0044956E5215C4FE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:type="arc" />
    <link:label id="lab_abus_PotentialContractFundingAmount_5F87F2F4A9E8A20EEC4456E5215C0B42_terseLabel_en-US" xlink:label="lab_abus_PotentialContractFundingAmount_5F87F2F4A9E8A20EEC4456E5215C0B42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential contract funding amount</link:label>
    <link:label id="lab_abus_PotentialContractFundingAmount_5F87F2F4A9E8A20EEC4456E5215C0B42_label_en-US" xlink:label="lab_abus_PotentialContractFundingAmount_5F87F2F4A9E8A20EEC4456E5215C0B42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Contract Funding Amount</link:label>
    <link:label id="lab_abus_PotentialContractFundingAmount_5F87F2F4A9E8A20EEC4456E5215C0B42_documentation_en-US" xlink:label="lab_abus_PotentialContractFundingAmount_5F87F2F4A9E8A20EEC4456E5215C0B42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the potential contract funding amount.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_PotentialContractFundingAmount" xlink:label="loc_abus_PotentialContractFundingAmount_5F87F2F4A9E8A20EEC4456E5215C0B42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_PotentialContractFundingAmount_5F87F2F4A9E8A20EEC4456E5215C0B42" xlink:to="lab_abus_PotentialContractFundingAmount_5F87F2F4A9E8A20EEC4456E5215C0B42" xlink:type="arc" />
    <link:label id="lab_abus_ApproximateOptionPeriod_003E8B24B0BA92E7CEC256E5215CB8BC_terseLabel_en-US" xlink:label="lab_abus_ApproximateOptionPeriod_003E8B24B0BA92E7CEC256E5215CB8BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Approximate option period</link:label>
    <link:label id="lab_abus_ApproximateOptionPeriod_003E8B24B0BA92E7CEC256E5215CB8BC_label_en-US" xlink:label="lab_abus_ApproximateOptionPeriod_003E8B24B0BA92E7CEC256E5215CB8BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Approximate Option Period</link:label>
    <link:label id="lab_abus_ApproximateOptionPeriod_003E8B24B0BA92E7CEC256E5215CB8BC_documentation_en-US" xlink:label="lab_abus_ApproximateOptionPeriod_003E8B24B0BA92E7CEC256E5215CB8BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the approximate period of the option agreement.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_ApproximateOptionPeriod" xlink:label="loc_abus_ApproximateOptionPeriod_003E8B24B0BA92E7CEC256E5215CB8BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ApproximateOptionPeriod_003E8B24B0BA92E7CEC256E5215CB8BC" xlink:to="lab_abus_ApproximateOptionPeriod_003E8B24B0BA92E7CEC256E5215CB8BC" xlink:type="arc" />
    <link:label id="lab_abus_MaximumPotentialTransactionValue_6D8475DC05249754BD6456E5215C949B_terseLabel_en-US" xlink:label="lab_abus_MaximumPotentialTransactionValue_6D8475DC05249754BD6456E5215C949B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum potential transaction value</link:label>
    <link:label id="lab_abus_MaximumPotentialTransactionValue_6D8475DC05249754BD6456E5215C949B_label_en-US" xlink:label="lab_abus_MaximumPotentialTransactionValue_6D8475DC05249754BD6456E5215C949B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Potential Transaction Value</link:label>
    <link:label id="lab_abus_MaximumPotentialTransactionValue_6D8475DC05249754BD6456E5215C949B_documentation_en-US" xlink:label="lab_abus_MaximumPotentialTransactionValue_6D8475DC05249754BD6456E5215C949B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum potential transaction value.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_MaximumPotentialTransactionValue" xlink:label="loc_abus_MaximumPotentialTransactionValue_6D8475DC05249754BD6456E5215C949B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_MaximumPotentialTransactionValue_6D8475DC05249754BD6456E5215C949B" xlink:to="lab_abus_MaximumPotentialTransactionValue_6D8475DC05249754BD6456E5215C949B" xlink:type="arc" />
    <link:label id="lab_abus_OptionPeriodExtension_CA22F52B0DA910F4AD4E56E5215CD99E_terseLabel_en-US" xlink:label="lab_abus_OptionPeriodExtension_CA22F52B0DA910F4AD4E56E5215CD99E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option period extension</link:label>
    <link:label id="lab_abus_OptionPeriodExtension_CA22F52B0DA910F4AD4E56E5215CD99E_label_en-US" xlink:label="lab_abus_OptionPeriodExtension_CA22F52B0DA910F4AD4E56E5215CD99E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Period Extension</link:label>
    <link:label id="lab_abus_OptionPeriodExtension_CA22F52B0DA910F4AD4E56E5215CD99E_documentation_en-US" xlink:label="lab_abus_OptionPeriodExtension_CA22F52B0DA910F4AD4E56E5215CD99E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option period extension</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_OptionPeriodExtension" xlink:label="loc_abus_OptionPeriodExtension_CA22F52B0DA910F4AD4E56E5215CD99E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OptionPeriodExtension_CA22F52B0DA910F4AD4E56E5215CD99E" xlink:to="lab_abus_OptionPeriodExtension_CA22F52B0DA910F4AD4E56E5215CD99E" xlink:type="arc" />
    <link:label id="lab_abus_NearTermContractPayments_6622C7131EB15EEE94A756E5215CDFB9_terseLabel_en-US" xlink:label="lab_abus_NearTermContractPayments_6622C7131EB15EEE94A756E5215CDFB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments from inception of contract</link:label>
    <link:label id="lab_abus_NearTermContractPayments_6622C7131EB15EEE94A756E5215CDFB9_label_en-US" xlink:label="lab_abus_NearTermContractPayments_6622C7131EB15EEE94A756E5215CDFB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Near Term Contract Payments</link:label>
    <link:label id="lab_abus_NearTermContractPayments_6622C7131EB15EEE94A756E5215CDFB9_documentation_en-US" xlink:label="lab_abus_NearTermContractPayments_6622C7131EB15EEE94A756E5215CDFB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the payments for the near term as part of the contract.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_NearTermContractPayments" xlink:label="loc_abus_NearTermContractPayments_6622C7131EB15EEE94A756E5215CDFB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NearTermContractPayments_6622C7131EB15EEE94A756E5215CDFB9" xlink:to="lab_abus_NearTermContractPayments_6622C7131EB15EEE94A756E5215CDFB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_32E836AB46F9EC03268B56E5215DE32F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_32E836AB46F9EC03268B56E5215DE32F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity income (loss)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_32E836AB46F9EC03268B56E5215DE32F_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_32E836AB46F9EC03268B56E5215DE32F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_32E836AB46F9EC03268B56E5215DE32F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_32E836AB46F9EC03268B56E5215DE32F" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_32E836AB46F9EC03268B56E5215DE32F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenue_2B43A033F3525E4084B956E5215DAD8A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue_2B43A033F3525E4084B956E5215DAD8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_2B43A033F3525E4084B956E5215DAD8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_2B43A033F3525E4084B956E5215DAD8A" xlink:to="lab_us-gaap_DeferredRevenue_2B43A033F3525E4084B956E5215DAD8A" xlink:type="arc" />
    <link:label id="lab_abus_LengthOfAgreementWithBristolMyersSquibb_AE262ED6A4E076ACC6D456E5215D2EF7_terseLabel_en-US" xlink:label="lab_abus_LengthOfAgreementWithBristolMyersSquibb_AE262ED6A4E076ACC6D456E5215D2EF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Length of agreement with Bristol-Myers Squibb</link:label>
    <link:label id="lab_abus_LengthOfAgreementWithBristolMyersSquibb_AE262ED6A4E076ACC6D456E5215D2EF7_label_en-US" xlink:label="lab_abus_LengthOfAgreementWithBristolMyersSquibb_AE262ED6A4E076ACC6D456E5215D2EF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Length Of Agreement With Bristol-Myers Squibb</link:label>
    <link:label id="lab_abus_LengthOfAgreementWithBristolMyersSquibb_AE262ED6A4E076ACC6D456E5215D2EF7_documentation_en-US" xlink:label="lab_abus_LengthOfAgreementWithBristolMyersSquibb_AE262ED6A4E076ACC6D456E5215D2EF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Length Of Agreement With Bristol-Myers Squibb</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_LengthOfAgreementWithBristolMyersSquibb" xlink:label="loc_abus_LengthOfAgreementWithBristolMyersSquibb_AE262ED6A4E076ACC6D456E5215D2EF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LengthOfAgreementWithBristolMyersSquibb_AE262ED6A4E076ACC6D456E5215D2EF7" xlink:to="lab_abus_LengthOfAgreementWithBristolMyersSquibb_AE262ED6A4E076ACC6D456E5215D2EF7" xlink:type="arc" />
    <link:label id="lab_abus_PerformancePeriodtoRecognizeRevenue_1DCD390936142502430F56E5215D0388_terseLabel_en-US" xlink:label="lab_abus_PerformancePeriodtoRecognizeRevenue_1DCD390936142502430F56E5215D0388" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance period to recognize revenue</link:label>
    <link:label id="lab_abus_PerformancePeriodtoRecognizeRevenue_1DCD390936142502430F56E5215D0388_label_en-US" xlink:label="lab_abus_PerformancePeriodtoRecognizeRevenue_1DCD390936142502430F56E5215D0388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Period to Recognize Revenue</link:label>
    <link:label id="lab_abus_PerformancePeriodtoRecognizeRevenue_1DCD390936142502430F56E5215D0388_documentation_en-US" xlink:label="lab_abus_PerformancePeriodtoRecognizeRevenue_1DCD390936142502430F56E5215D0388" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Period to Recognize Revenue</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_PerformancePeriodtoRecognizeRevenue" xlink:label="loc_abus_PerformancePeriodtoRecognizeRevenue_1DCD390936142502430F56E5215D0388" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_PerformancePeriodtoRecognizeRevenue_1DCD390936142502430F56E5215D0388" xlink:to="lab_abus_PerformancePeriodtoRecognizeRevenue_1DCD390936142502430F56E5215D0388" xlink:type="arc" />
    <link:label id="lab_abus_NumberOfChemotherapyProductsWithWorldwideLicenses_5C5CC8DC53442392E59B56E5215D5889_terseLabel_en-US" xlink:label="lab_abus_NumberOfChemotherapyProductsWithWorldwideLicenses_5C5CC8DC53442392E59B56E5215D5889" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of chemotherapy products with worldwide licenses</link:label>
    <link:label id="lab_abus_NumberOfChemotherapyProductsWithWorldwideLicenses_5C5CC8DC53442392E59B56E5215D5889_label_en-US" xlink:label="lab_abus_NumberOfChemotherapyProductsWithWorldwideLicenses_5C5CC8DC53442392E59B56E5215D5889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Chemotherapy Products With Worldwide Licenses</link:label>
    <link:label id="lab_abus_NumberOfChemotherapyProductsWithWorldwideLicenses_5C5CC8DC53442392E59B56E5215D5889_documentation_en-US" xlink:label="lab_abus_NumberOfChemotherapyProductsWithWorldwideLicenses_5C5CC8DC53442392E59B56E5215D5889" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Chemotherapy Products With Worldwide Licenses</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_NumberOfChemotherapyProductsWithWorldwideLicenses" xlink:label="loc_abus_NumberOfChemotherapyProductsWithWorldwideLicenses_5C5CC8DC53442392E59B56E5215D5889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NumberOfChemotherapyProductsWithWorldwideLicenses_5C5CC8DC53442392E59B56E5215D5889" xlink:to="lab_abus_NumberOfChemotherapyProductsWithWorldwideLicenses_5C5CC8DC53442392E59B56E5215D5889" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_F93D58BB572AD55D32CD56E5215D7690_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_F93D58BB572AD55D32CD56E5215D7690" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_F93D58BB572AD55D32CD56E5215D7690_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_F93D58BB572AD55D32CD56E5215D7690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_F93D58BB572AD55D32CD56E5215D7690" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_F93D58BB572AD55D32CD56E5215D7690" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_F93D58BB572AD55D32CD56E5215D7690" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_EF136D4356658BEF13752EAA602A2BCC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_EF136D4356658BEF13752EAA602A2BCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_EF136D4356658BEF13752EAA602A2BCC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_EF136D4356658BEF13752EAA602A2BCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_EF136D4356658BEF13752EAA602A2BCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_EF136D4356658BEF13752EAA602A2BCC" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_EF136D4356658BEF13752EAA602A2BCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_7B5339E8CB2F369A3CED3DF3E166532B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_7B5339E8CB2F369A3CED3DF3E166532B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_7B5339E8CB2F369A3CED3DF3E166532B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_7B5339E8CB2F369A3CED3DF3E166532B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_7B5339E8CB2F369A3CED3DF3E166532B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_7B5339E8CB2F369A3CED3DF3E166532B" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_7B5339E8CB2F369A3CED3DF3E166532B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3971ADF47DBB2CBF99B93DF14F8466ED_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3971ADF47DBB2CBF99B93DF14F8466ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3971ADF47DBB2CBF99B93DF14F8466ED_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3971ADF47DBB2CBF99B93DF14F8466ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3971ADF47DBB2CBF99B93DF14F8466ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3971ADF47DBB2CBF99B93DF14F8466ED" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3971ADF47DBB2CBF99B93DF14F8466ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:type="arc" />
    <link:label id="lab_abus_Range1Member_26B0EB4FDEB8E068D81B3DF420B2BC8D_terseLabel_en-US" xlink:label="lab_abus_Range1Member_26B0EB4FDEB8E068D81B3DF420B2BC8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range 1</link:label>
    <link:label id="lab_abus_Range1Member_26B0EB4FDEB8E068D81B3DF420B2BC8D_label_en-US" xlink:label="lab_abus_Range1Member_26B0EB4FDEB8E068D81B3DF420B2BC8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range 1 [Member]</link:label>
    <link:label id="lab_abus_Range1Member_26B0EB4FDEB8E068D81B3DF420B2BC8D_documentation_en-US" xlink:label="lab_abus_Range1Member_26B0EB4FDEB8E068D81B3DF420B2BC8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents range 1.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_Range1Member" xlink:label="loc_abus_Range1Member_26B0EB4FDEB8E068D81B3DF420B2BC8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Range1Member_26B0EB4FDEB8E068D81B3DF420B2BC8D" xlink:to="lab_abus_Range1Member_26B0EB4FDEB8E068D81B3DF420B2BC8D" xlink:type="arc" />
    <link:label id="lab_abus_Range2Member_5A4888246A259B3D4E003DF420CB1702_terseLabel_en-US" xlink:label="lab_abus_Range2Member_5A4888246A259B3D4E003DF420CB1702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range 2</link:label>
    <link:label id="lab_abus_Range2Member_5A4888246A259B3D4E003DF420CB1702_label_en-US" xlink:label="lab_abus_Range2Member_5A4888246A259B3D4E003DF420CB1702" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range 2 [Member]</link:label>
    <link:label id="lab_abus_Range2Member_5A4888246A259B3D4E003DF420CB1702_documentation_en-US" xlink:label="lab_abus_Range2Member_5A4888246A259B3D4E003DF420CB1702" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents range 2.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_Range2Member" xlink:label="loc_abus_Range2Member_5A4888246A259B3D4E003DF420CB1702" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Range2Member_5A4888246A259B3D4E003DF420CB1702" xlink:to="lab_abus_Range2Member_5A4888246A259B3D4E003DF420CB1702" xlink:type="arc" />
    <link:label id="lab_abus_Range3Member_142834906DBE9088D6A93DF420D9CE1C_terseLabel_en-US" xlink:label="lab_abus_Range3Member_142834906DBE9088D6A93DF420D9CE1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range 3</link:label>
    <link:label id="lab_abus_Range3Member_142834906DBE9088D6A93DF420D9CE1C_label_en-US" xlink:label="lab_abus_Range3Member_142834906DBE9088D6A93DF420D9CE1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range 3 [Member]</link:label>
    <link:label id="lab_abus_Range3Member_142834906DBE9088D6A93DF420D9CE1C_documentation_en-US" xlink:label="lab_abus_Range3Member_142834906DBE9088D6A93DF420D9CE1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents range 3.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_Range3Member" xlink:label="loc_abus_Range3Member_142834906DBE9088D6A93DF420D9CE1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Range3Member_142834906DBE9088D6A93DF420D9CE1C" xlink:to="lab_abus_Range3Member_142834906DBE9088D6A93DF420D9CE1C" xlink:type="arc" />
    <link:label id="lab_abus_Range4Member_766136016F9756BD45743DF420E8F7B6_terseLabel_en-US" xlink:label="lab_abus_Range4Member_766136016F9756BD45743DF420E8F7B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range 4</link:label>
    <link:label id="lab_abus_Range4Member_766136016F9756BD45743DF420E8F7B6_label_en-US" xlink:label="lab_abus_Range4Member_766136016F9756BD45743DF420E8F7B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range 4 [Member]</link:label>
    <link:label id="lab_abus_Range4Member_766136016F9756BD45743DF420E8F7B6_documentation_en-US" xlink:label="lab_abus_Range4Member_766136016F9756BD45743DF420E8F7B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents range 4.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_Range4Member" xlink:label="loc_abus_Range4Member_766136016F9756BD45743DF420E8F7B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Range4Member_766136016F9756BD45743DF420E8F7B6" xlink:to="lab_abus_Range4Member_766136016F9756BD45743DF420E8F7B6" xlink:type="arc" />
    <link:label id="lab_abus_Range5Member_BCD96735ACAA264DB5683DF420F76FC0_terseLabel_en-US" xlink:label="lab_abus_Range5Member_BCD96735ACAA264DB5683DF420F76FC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range 5</link:label>
    <link:label id="lab_abus_Range5Member_BCD96735ACAA264DB5683DF420F76FC0_label_en-US" xlink:label="lab_abus_Range5Member_BCD96735ACAA264DB5683DF420F76FC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range 5 [Member]</link:label>
    <link:label id="lab_abus_Range5Member_BCD96735ACAA264DB5683DF420F76FC0_documentation_en-US" xlink:label="lab_abus_Range5Member_BCD96735ACAA264DB5683DF420F76FC0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents range 5.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_Range5Member" xlink:label="loc_abus_Range5Member_BCD96735ACAA264DB5683DF420F76FC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Range5Member_BCD96735ACAA264DB5683DF420F76FC0" xlink:to="lab_abus_Range5Member_BCD96735ACAA264DB5683DF420F76FC0" xlink:type="arc" />
    <link:label id="lab_abus_Range6Member_8E2EF304880CB625B4B73DF421068E1D_terseLabel_en-US" xlink:label="lab_abus_Range6Member_8E2EF304880CB625B4B73DF421068E1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range 6</link:label>
    <link:label id="lab_abus_Range6Member_8E2EF304880CB625B4B73DF421068E1D_label_en-US" xlink:label="lab_abus_Range6Member_8E2EF304880CB625B4B73DF421068E1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range 6 [Member]</link:label>
    <link:label id="lab_abus_Range6Member_8E2EF304880CB625B4B73DF421068E1D_documentation_en-US" xlink:label="lab_abus_Range6Member_8E2EF304880CB625B4B73DF421068E1D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents range 6.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_Range6Member" xlink:label="loc_abus_Range6Member_8E2EF304880CB625B4B73DF421068E1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Range6Member_8E2EF304880CB625B4B73DF421068E1D" xlink:to="lab_abus_Range6Member_8E2EF304880CB625B4B73DF421068E1D" xlink:type="arc" />
    <link:label id="lab_abus_Range7Member_52AF63D2E242282684FA3DF4211540CC_terseLabel_en-US" xlink:label="lab_abus_Range7Member_52AF63D2E242282684FA3DF4211540CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range 7</link:label>
    <link:label id="lab_abus_Range7Member_52AF63D2E242282684FA3DF4211540CC_label_en-US" xlink:label="lab_abus_Range7Member_52AF63D2E242282684FA3DF4211540CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range 7 [Member]</link:label>
    <link:label id="lab_abus_Range7Member_52AF63D2E242282684FA3DF4211540CC_documentation_en-US" xlink:label="lab_abus_Range7Member_52AF63D2E242282684FA3DF4211540CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents range 7.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_Range7Member" xlink:label="loc_abus_Range7Member_52AF63D2E242282684FA3DF4211540CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Range7Member_52AF63D2E242282684FA3DF4211540CC" xlink:to="lab_abus_Range7Member_52AF63D2E242282684FA3DF4211540CC" xlink:type="arc" />
    <link:label id="lab_abus_Range8Member_365F3209B6D87E30DF6E3DFD4EE2BDBE_terseLabel_en-US" xlink:label="lab_abus_Range8Member_365F3209B6D87E30DF6E3DFD4EE2BDBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range 8</link:label>
    <link:label id="lab_abus_Range8Member_365F3209B6D87E30DF6E3DFD4EE2BDBE_label_en-US" xlink:label="lab_abus_Range8Member_365F3209B6D87E30DF6E3DFD4EE2BDBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range 8 [Member]</link:label>
    <link:label id="lab_abus_Range8Member_365F3209B6D87E30DF6E3DFD4EE2BDBE_documentation_en-US" xlink:label="lab_abus_Range8Member_365F3209B6D87E30DF6E3DFD4EE2BDBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range 8 [Member]</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_Range8Member" xlink:label="loc_abus_Range8Member_365F3209B6D87E30DF6E3DFD4EE2BDBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Range8Member_365F3209B6D87E30DF6E3DFD4EE2BDBE" xlink:to="lab_abus_Range8Member_365F3209B6D87E30DF6E3DFD4EE2BDBE" xlink:type="arc" />
    <link:label id="lab_abus_TotalRangeMember_10646EF5E42C0901CD643DF421254377_terseLabel_en-US" xlink:label="lab_abus_TotalRangeMember_10646EF5E42C0901CD643DF421254377" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Range</link:label>
    <link:label id="lab_abus_TotalRangeMember_10646EF5E42C0901CD643DF421254377_label_en-US" xlink:label="lab_abus_TotalRangeMember_10646EF5E42C0901CD643DF421254377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Range [Member]</link:label>
    <link:label id="lab_abus_TotalRangeMember_10646EF5E42C0901CD643DF421254377_documentation_en-US" xlink:label="lab_abus_TotalRangeMember_10646EF5E42C0901CD643DF421254377" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the total range.</link:label>
    <link:loc xlink:href="abus-20151231.xsd#abus_TotalRangeMember" xlink:label="loc_abus_TotalRangeMember_10646EF5E42C0901CD643DF421254377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_TotalRangeMember_10646EF5E42C0901CD643DF421254377" xlink:to="lab_abus_TotalRangeMember_10646EF5E42C0901CD643DF421254377" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8063E26932D57D998A763DF493AD2630_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8063E26932D57D998A763DF493AD2630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of Exercise prices - Low</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8063E26932D57D998A763DF493AD2630_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8063E26932D57D998A763DF493AD2630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8063E26932D57D998A763DF493AD2630" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8063E26932D57D998A763DF493AD2630" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8063E26932D57D998A763DF493AD2630" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_156E0A293B5045CA74A53DF493B003FA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_156E0A293B5045CA74A53DF493B003FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of Exercise prices - High</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_156E0A293B5045CA74A53DF493B003FA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_156E0A293B5045CA74A53DF493B003FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_156E0A293B5045CA74A53DF493B003FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_156E0A293B5045CA74A53DF493B003FA" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_156E0A293B5045CA74A53DF493B003FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_67654481AC6FC62B66293DF493B24EC1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_67654481AC6FC62B66293DF493B24EC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_67654481AC6FC62B66293DF493B24EC1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_67654481AC6FC62B66293DF493B24EC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_67654481AC6FC62B66293DF493B24EC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_67654481AC6FC62B66293DF493B24EC1" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_67654481AC6FC62B66293DF493B24EC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_461D78239B2DB76FAD6D3DF493B4CBC4_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_461D78239B2DB76FAD6D3DF493B4CBC4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_461D78239B2DB76FAD6D3DF493B4CBC4_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_461D78239B2DB76FAD6D3DF493B4CBC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_461D78239B2DB76FAD6D3DF493B4CBC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_461D78239B2DB76FAD6D3DF493B4CBC4" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_461D78239B2DB76FAD6D3DF493B4CBC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2446C2CD512F986FF7DD3DF493B96126_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2446C2CD512F986FF7DD3DF493B96126" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2446C2CD512F986FF7DD3DF493B96126_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2446C2CD512F986FF7DD3DF493B96126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2446C2CD512F986FF7DD3DF493B96126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2446C2CD512F986FF7DD3DF493B96126" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2446C2CD512F986FF7DD3DF493B96126" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2D04F146AEBCE7C495313DF493BC08FB_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2D04F146AEBCE7C495313DF493BC08FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2D04F146AEBCE7C495313DF493BC08FB_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2D04F146AEBCE7C495313DF493BC08FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2D04F146AEBCE7C495313DF493BC08FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2D04F146AEBCE7C495313DF493BC08FB" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2D04F146AEBCE7C495313DF493BC08FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_B8B22FBC3BDD7885FC0A3F2E891A5A54_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_B8B22FBC3BDD7885FC0A3F2E891A5A54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_B8B22FBC3BDD7885FC0A3F2E891A5A54_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_B8B22FBC3BDD7885FC0A3F2E891A5A54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_B8B22FBC3BDD7885FC0A3F2E891A5A54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_B8B22FBC3BDD7885FC0A3F2E891A5A54" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable_B8B22FBC3BDD7885FC0A3F2E891A5A54" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6E654DBAD3DA175B7B463F2E891A11D8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6E654DBAD3DA175B7B463F2E891A11D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6E654DBAD3DA175B7B463F2E891A11D8_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6E654DBAD3DA175B7B463F2E891A11D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6E654DBAD3DA175B7B463F2E891A11D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6E654DBAD3DA175B7B463F2E891A11D8" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6E654DBAD3DA175B7B463F2E891A11D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_73D040B56307B9A643B63F2E891A069F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_73D040B56307B9A643B63F2E891A069F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_73D040B56307B9A643B63F2E891A069F_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_73D040B56307B9A643B63F2E891A069F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_73D040B56307B9A643B63F2E891A069F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_73D040B56307B9A643B63F2E891A069F" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_73D040B56307B9A643B63F2E891A069F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_F608A8BB1D0AF86C687A3F2E891A11CA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_F608A8BB1D0AF86C687A3F2E891A11CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_F608A8BB1D0AF86C687A3F2E891A11CA_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_F608A8BB1D0AF86C687A3F2E891A11CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_F608A8BB1D0AF86C687A3F2E891A11CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_F608A8BB1D0AF86C687A3F2E891A11CA" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_F608A8BB1D0AF86C687A3F2E891A11CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8989C1DDE9D9D8AE7D253F2E891BBD01_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8989C1DDE9D9D8AE7D253F2E891BBD01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8989C1DDE9D9D8AE7D253F2E891BBD01_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8989C1DDE9D9D8AE7D253F2E891BBD01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8989C1DDE9D9D8AE7D253F2E891BBD01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8989C1DDE9D9D8AE7D253F2E891BBD01" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8989C1DDE9D9D8AE7D253F2E891BBD01" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_8435361D25C60E9337F53F2E891B8C57_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_8435361D25C60E9337F53F2E891B8C57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guaranteed investment certificate</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_8435361D25C60E9337F53F2E891B8C57_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_8435361D25C60E9337F53F2E891B8C57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8435361D25C60E9337F53F2E891B8C57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_8435361D25C60E9337F53F2E891B8C57" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_8435361D25C60E9337F53F2E891B8C57" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_B9FB61C5031C01B1FC3F3F2E891B913F_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_B9FB61C5031C01B1FC3F3F2E891B913F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term deposit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_B9FB61C5031C01B1FC3F3F2E891B913F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_B9FB61C5031C01B1FC3F3F2E891B913F" xlink:to="lab_us-gaap_LongTermInvestments_B9FB61C5031C01B1FC3F3F2E891B913F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_96B9C0F11CC95876A5713F2E891B6003_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_96B9C0F11CC95876A5713F2E891B6003" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_96B9C0F11CC95876A5713F2E891B6003_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_96B9C0F11CC95876A5713F2E891B6003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_96B9C0F11CC95876A5713F2E891B6003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_96B9C0F11CC95876A5713F2E891B6003" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_96B9C0F11CC95876A5713F2E891B6003" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_AF3F9B65892D2E2AE7853F2E891BDC7B_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_AF3F9B65892D2E2AE7853F2E891BDC7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_AF3F9B65892D2E2AE7853F2E891BDC7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_AF3F9B65892D2E2AE7853F2E891BDC7B" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_AF3F9B65892D2E2AE7853F2E891BDC7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_684D963462CA5AA804023F2E891BD56C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_684D963462CA5AA804023F2E891BD56C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instrument</link:label>
    <link:label id="lab_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_684D963462CA5AA804023F2E891BD56C_label_en-US" xlink:label="lab_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_684D963462CA5AA804023F2E891BD56C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Concentration of Risk, Derivative Instruments, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_684D963462CA5AA804023F2E891BD56C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_684D963462CA5AA804023F2E891BD56C" xlink:to="lab_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_684D963462CA5AA804023F2E891BD56C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_C893C9BC7C7209F9F6803F2E891BC9CE_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_C893C9BC7C7209F9F6803F2E891BC9CE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_C893C9BC7C7209F9F6803F2E891BC9CE_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_C893C9BC7C7209F9F6803F2E891BC9CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure, Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_C893C9BC7C7209F9F6803F2E891BC9CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_C893C9BC7C7209F9F6803F2E891BC9CE" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureRecurring_C893C9BC7C7209F9F6803F2E891BC9CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNoParValue_21017D9507A772C7853F5167E88AB8C0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue_21017D9507A772C7853F5167E88AB8C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_21017D9507A772C7853F5167E88AB8C0_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue_21017D9507A772C7853F5167E88AB8C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_21017D9507A772C7853F5167E88AB8C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue_21017D9507A772C7853F5167E88AB8C0" xlink:to="lab_us-gaap_CommonStockNoParValue_21017D9507A772C7853F5167E88AB8C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_BE5738E29CCC17D2DB8B5167E88B9E04_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_BE5738E29CCC17D2DB8B5167E88B9E04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_BE5738E29CCC17D2DB8B5167E88B9E04_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_BE5738E29CCC17D2DB8B5167E88B9E04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_BE5738E29CCC17D2DB8B5167E88B9E04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_BE5738E29CCC17D2DB8B5167E88B9E04" xlink:to="lab_us-gaap_CommonStockSharesIssued_BE5738E29CCC17D2DB8B5167E88B9E04" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_AF3E62A98298057FD1645167E88BD708_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_AF3E62A98298057FD1645167E88BD708" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_AF3E62A98298057FD1645167E88BD708_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_AF3E62A98298057FD1645167E88BD708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_AF3E62A98298057FD1645167E88BD708" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_AF3E62A98298057FD1645167E88BD708" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_AF3E62A98298057FD1645167E88BD708" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9069F009E8698408AC9D33A201B30EE5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9069F009E8698408AC9D33A201B30EE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of effective income tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9069F009E8698408AC9D33A201B30EE5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9069F009E8698408AC9D33A201B30EE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9069F009E8698408AC9D33A201B30EE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9069F009E8698408AC9D33A201B30EE5" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9069F009E8698408AC9D33A201B30EE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_EC882315329CCD43DD9333A201B395DA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_EC882315329CCD43DD9333A201B395DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of components of deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_EC882315329CCD43DD9333A201B395DA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_EC882315329CCD43DD9333A201B395DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_EC882315329CCD43DD9333A201B395DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_EC882315329CCD43DD9333A201B395DA" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_EC882315329CCD43DD9333A201B395DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_BF40EF2F8E3065677C4E2EAA5FDAABEA_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_BF40EF2F8E3065677C4E2EAA5FDAABEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interim financial data (unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_BF40EF2F8E3065677C4E2EAA5FDAABEA_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_BF40EF2F8E3065677C4E2EAA5FDAABEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_BF40EF2F8E3065677C4E2EAA5FDAABEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_BF40EF2F8E3065677C4E2EAA5FDAABEA" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_BF40EF2F8E3065677C4E2EAA5FDAABEA" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>abus-20151231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreements" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreements" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsTables" xlink:href="abus-20151231.xsd#CollaborationsContractsAndLicensingAgreementsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRisk" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRisk" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskDetails" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskTables" xlink:href="abus-20151231.xsd#ConcentrationsOfBusinessRiskTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets" xlink:href="abus-20151231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="abus-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:href="abus-20151231.xsd#ConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:href="abus-20151231.xsd#ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="abus-20151231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="abus-20151231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitments" xlink:href="abus-20151231.xsd#ContingenciesAndCommitments" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsDetails" xlink:href="abus-20151231.xsd#ContingenciesAndCommitmentsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:href="abus-20151231.xsd#ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsTables" xlink:href="abus-20151231.xsd#ContingenciesAndCommitmentsTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/DocumentAndEntityInformation" xlink:href="abus-20151231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:href="abus-20151231.xsd#GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:href="abus-20151231.xsd#GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxes" xlink:href="abus-20151231.xsd#IncomeTaxes" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:href="abus-20151231.xsd#IncomeTaxesDeferredTaxAssetsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesDetails" xlink:href="abus-20151231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesIncomeTaxReconciliationDetails" xlink:href="abus-20151231.xsd#IncomeTaxesIncomeTaxReconciliationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/IncomeTaxesTables" xlink:href="abus-20151231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnaudited" xlink:href="abus-20151231.xsd#InterimFinancialDataUnaudited" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedDetails" xlink:href="abus-20151231.xsd#InterimFinancialDataUnauditedDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedTables" xlink:href="abus-20151231.xsd#InterimFinancialDataUnauditedTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables" xlink:href="abus-20151231.xsd#MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperations" xlink:href="abus-20151231.xsd#NatureOfBusinessAndFutureOperations" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperationsNarrativeDetails" xlink:href="abus-20151231.xsd#NatureOfBusinessAndFutureOperationsNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipment" xlink:href="abus-20151231.xsd#PropertyAndEquipment" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentDetails" xlink:href="abus-20151231.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:href="abus-20151231.xsd#PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/PropertyAndEquipmentTables" xlink:href="abus-20151231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapital" xlink:href="abus-20151231.xsd#ShareCapital" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalBlackScholesOptionPricingAssumptionsDetails" xlink:href="abus-20151231.xsd#ShareCapitalBlackScholesOptionPricingAssumptionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalDetails" xlink:href="abus-20151231.xsd#ShareCapitalDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:href="abus-20151231.xsd#ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityDetails" xlink:href="abus-20151231.xsd#ShareCapitalNonVestedStockOptionActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:href="abus-20151231.xsd#ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:href="abus-20151231.xsd#ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:href="abus-20151231.xsd#ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalStockOptionActivityDetails" xlink:href="abus-20151231.xsd#ShareCapitalStockOptionActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalStockOptionsOutstandingDetails" xlink:href="abus-20151231.xsd#ShareCapitalStockOptionsOutstandingDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfWarrantActivityDetails" xlink:href="abus-20151231.xsd#ShareCapitalSummaryOfWarrantActivityDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalTables" xlink:href="abus-20151231.xsd#ShareCapitalTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/ShareCapitalWeightedAverageOptionPricingAssumptionsDetails" xlink:href="abus-20151231.xsd#ShareCapitalWeightedAverageOptionPricingAssumptionsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPolicies" xlink:href="abus-20151231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesPolicies" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesTables" xlink:href="abus-20151231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SubsequentEvents" xlink:href="abus-20151231.xsd#SubsequentEvents" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SubsequentEventsDetails" xlink:href="abus-20151231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformation" xlink:href="abus-20151231.xsd#SupplementaryInformation" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformationDetails" xlink:href="abus-20151231.xsd#SupplementaryInformationDetails" xlink:type="simple" />
  <roleRef roleURI="http://www.tekmirapharm.com/role/SupplementaryInformationTables" xlink:href="abus-20151231.xsd#SupplementaryInformationTables" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreements" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_5F9700007F17A39347503A61681D97AF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_0CC4B6CC1B3FDFAC2E2A3A14D601D1B1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_5F9700007F17A39347503A61681D97AF" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_0CC4B6CC1B3FDFAC2E2A3A14D601D1B1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_619DF27EE14268F5036E3A63730E6697" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_A952C5458D17DD7C06313A14D59AD4F8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_619DF27EE14268F5036E3A63730E6697" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_A952C5458D17DD7C06313A14D59AD4F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_3E60EA6689C64EEFAEA53A14D59ABA28" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_A952C5458D17DD7C06313A14D59AD4F8" xlink:to="loc_us-gaap_CounterpartyNameAxis_3E60EA6689C64EEFAEA53A14D59ABA28" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CE55F58BD1974F627C093A14D59FF330" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_3E60EA6689C64EEFAEA53A14D59ABA28" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CE55F58BD1974F627C093A14D59FF330" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DoDMember" xlink:label="loc_abus_DoDMember_BF5CA83BD08D9BE20E083A14D59FAB43" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CE55F58BD1974F627C093A14D59FF330" xlink:to="loc_abus_DoDMember_BF5CA83BD08D9BE20E083A14D59FAB43" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MonsantoMember" xlink:label="loc_abus_MonsantoMember_700F8BFD97F303A2E77E3A14D59FCF57" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CE55F58BD1974F627C093A14D59FF330" xlink:to="loc_abus_MonsantoMember_700F8BFD97F303A2E77E3A14D59FCF57" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BMSMember" xlink:label="loc_abus_BMSMember_9C2EF50C40F97E37B47D3A14D59F5D0E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CE55F58BD1974F627C093A14D59FF330" xlink:to="loc_abus_BMSMember_9C2EF50C40F97E37B47D3A14D59F5D0E" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DicernaMember" xlink:label="loc_abus_DicernaMember_05B6509DC8CB572C9F1E3A14D59F91A1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CE55F58BD1974F627C093A14D59FF330" xlink:to="loc_abus_DicernaMember_05B6509DC8CB572C9F1E3A14D59F91A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_BBF5453EF91AE64EDC8B3A14D59F4A6B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_A952C5458D17DD7C06313A14D59AD4F8" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_BBF5453EF91AE64EDC8B3A14D59F4A6B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_289D7286404ECAFD92B03A14D59F9998" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_BBF5453EF91AE64EDC8B3A14D59F4A6B" xlink:to="loc_us-gaap_DeferredRevenueCurrent_289D7286404ECAFD92B03A14D59F9998" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_840BBBDD8D517C9678803A14D5A04401" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_BBF5453EF91AE64EDC8B3A14D59F4A6B" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_840BBBDD8D517C9678803A14D5A04401" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_16D5DA1487E8495098CE3A14D5A00765" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_BBF5453EF91AE64EDC8B3A14D59F4A6B" xlink:to="loc_us-gaap_DeferredRevenue_16D5DA1487E8495098CE3A14D5A00765" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_CF7D20D536B42B5A795A56E5215A00B3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_CF7D20D536B42B5A795A56E5215A00B3" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0B8AFFBA216770A5779B56E9A21688FE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0B8AFFBA216770A5779B56E9A21688FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7C63DEC59FBEB825839356E9A21A6AB3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0B8AFFBA216770A5779B56E9A21688FE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7C63DEC59FBEB825839356E9A21A6AB3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_437B1FE2FE92AE1C3EDF56EA0C3E2778" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7C63DEC59FBEB825839356E9A21A6AB3" xlink:to="loc_us-gaap_SubsequentEventMember_437B1FE2FE92AE1C3EDF56EA0C3E2778" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CFB3ADC1B8108FE94AAD56E759A2C44D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_CFB3ADC1B8108FE94AAD56E759A2C44D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19CA19CF66BF2FEE66E256E75BA3F45F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CFB3ADC1B8108FE94AAD56E759A2C44D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19CA19CF66BF2FEE66E256E75BA3F45F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PADCo.Member" xlink:label="loc_abus_PADCo.Member_BF1077866F98656C0ECE56E5215B9F8F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19CA19CF66BF2FEE66E256E75BA3F45F" xlink:to="loc_abus_PADCo.Member_BF1077866F98656C0ECE56E5215B9F8F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_C0A4072D38520081C14956E6A4A880CF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_dei_LegalEntityAxis_C0A4072D38520081C14956E6A4A880CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A69CF107778E563FEEC956E6A625DEBB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_C0A4072D38520081C14956E6A4A880CF" xlink:to="loc_dei_EntityDomain_A69CF107778E563FEEC956E6A625DEBB" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MonsantoMember" xlink:label="loc_abus_MonsantoMember_B1F6CF8CFA82FFE9634E56E5215C426B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_A69CF107778E563FEEC956E6A625DEBB" xlink:to="loc_abus_MonsantoMember_B1F6CF8CFA82FFE9634E56E5215C426B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_5D41E86159F961391A7356E5215A7F8D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_LitigationCaseAxis_5D41E86159F961391A7356E5215A7F8D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_6C81F462410729FCA31056E5215A3C91" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseAxis_5D41E86159F961391A7356E5215A7F8D" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_6C81F462410729FCA31056E5215A3C91" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AlnylamandAscletisPharmaceuticalsMember" xlink:label="loc_abus_AlnylamandAscletisPharmaceuticalsMember_1EB58ADDFBE8ECE13A4056E5215A9EC7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_6C81F462410729FCA31056E5215A3C91" xlink:to="loc_abus_AlnylamandAscletisPharmaceuticalsMember_1EB58ADDFBE8ECE13A4056E5215A9EC7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1C76C6D1852D50DAEC4256E5215AA914" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1C76C6D1852D50DAEC4256E5215AA914" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1C76C6D1852D50DAEC4256E5215AA914" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA" xlink:type="arc" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_401D25F1AF67BAD5A4B656E5215B5EEA" xlink:to="loc_abus_PADCo.Member_BF1077866F98656C0ECE56E5215B9F8F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ContractModificationsAxis" xlink:label="loc_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ContractModificationsDomain" xlink:label="loc_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContractModificationsAxis_8D670B7C8BC08AD52B9B56E5215BA52F" xlink:to="loc_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IncreaseToSupportDevelopmentPlansMember" xlink:label="loc_abus_IncreaseToSupportDevelopmentPlansMember_F363ECFA8A8BDBB1370F56E5215B11B8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:to="loc_abus_IncreaseToSupportDevelopmentPlansMember_F363ECFA8A8BDBB1370F56E5215B11B8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IncreasedFundingForStageOneMember" xlink:label="loc_abus_IncreasedFundingForStageOneMember_D225727F4C8D6F3A7DA956E5215BCF93" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:to="loc_abus_IncreasedFundingForStageOneMember_D225727F4C8D6F3A7DA956E5215BCF93" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_StageOneMember" xlink:label="loc_abus_StageOneMember_F2E7C00DF6CEDFBBCD8A56E5215BFE43" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContractModificationsDomain_845417A05315618351B956E5215BAA58" xlink:to="loc_abus_StageOneMember_F2E7C00DF6CEDFBBCD8A56E5215BFE43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A1760AD2AFD44B5E855156E5215BA64A" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A1760AD2AFD44B5E855156E5215BA64A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05BDD7E8F476865F75BD56E5215B4331" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_A1760AD2AFD44B5E855156E5215BA64A" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05BDD7E8F476865F75BD56E5215B4331" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ContractExtensionMember" xlink:label="loc_abus_ContractExtensionMember_9060E444E25CA35EBDA056E5215BC22D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05BDD7E8F476865F75BD56E5215B4331" xlink:to="loc_abus_ContractExtensionMember_9060E444E25CA35EBDA056E5215BC22D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AlnylamLicenseAgreementMember" xlink:label="loc_abus_AlnylamLicenseAgreementMember_010368E4BE90C8EFF26056E5215BDF3E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05BDD7E8F476865F75BD56E5215B4331" xlink:to="loc_abus_AlnylamLicenseAgreementMember_010368E4BE90C8EFF26056E5215BDF3E" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MarqiboCommercialSalesMember" xlink:label="loc_abus_MarqiboCommercialSalesMember_6F06915279EDC38A1FBF56E5215C3F94" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05BDD7E8F476865F75BD56E5215B4331" xlink:to="loc_abus_MarqiboCommercialSalesMember_6F06915279EDC38A1FBF56E5215C3F94" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MarqiboMember" xlink:label="loc_abus_MarqiboMember_53F11E5E03EC881B3EA056E5215CD7DC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_05BDD7E8F476865F75BD56E5215B4331" xlink:to="loc_abus_MarqiboMember_53F11E5E03EC881B3EA056E5215CD7DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CF3877822FE05A8AEA3E56E5215C42F7" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_RangeAxis_CF3877822FE05A8AEA3E56E5215C42F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_C263BCF1408F98C6C72D56E5215C4BD9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_CF3877822FE05A8AEA3E56E5215C42F7" xlink:to="loc_us-gaap_RangeMember_C263BCF1408F98C6C72D56E5215C4BD9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_17F8CB7173BA030658FC56E5215C2B9D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_C263BCF1408F98C6C72D56E5215C4BD9" xlink:to="loc_us-gaap_MaximumMember_17F8CB7173BA030658FC56E5215C2B9D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_0F10427E6218B30F7A2B56E5215C2552" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_CounterpartyNameAxis_0F10427E6218B30F7A2B56E5215C2552" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_0F10427E6218B30F7A2B56E5215C2552" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DoDMember" xlink:label="loc_abus_DoDMember_513779151BC4CE7FAB9156E5215C323C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC" xlink:to="loc_abus_DoDMember_513779151BC4CE7FAB9156E5215C323C" xlink:type="arc" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC" xlink:to="loc_abus_MonsantoMember_B1F6CF8CFA82FFE9634E56E5215C426B" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BMSMember" xlink:label="loc_abus_BMSMember_2AACB3F71E6522F6550A56E5215C3AE4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC" xlink:to="loc_abus_BMSMember_2AACB3F71E6522F6550A56E5215C3AE4" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DicernaMember" xlink:label="loc_abus_DicernaMember_C337071CBF4916E6017356E5215C7900" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC" xlink:to="loc_abus_DicernaMember_C337071CBF4916E6017356E5215C7900" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_TalonTherapeuticsMember" xlink:label="loc_abus_TalonTherapeuticsMember_AC338069851D9FA0044956E5215C4FE4" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_E139681975AAB1B63ABB56E5215C27DC" xlink:to="loc_abus_TalonTherapeuticsMember_AC338069851D9FA0044956E5215C4FE4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8AE5EF0543D40AEA0B4E56E5215A696C" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PotentialContractFundingAmount" xlink:label="loc_abus_PotentialContractFundingAmount_5F87F2F4A9E8A20EEC4456E5215C0B42" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_PotentialContractFundingAmount_5F87F2F4A9E8A20EEC4456E5215C0B42" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OptionalExcercisedContractualOptionAmount" xlink:label="loc_abus_OptionalExcercisedContractualOptionAmount_D044486EA1BF69EFBC7756E5215CB0CC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_OptionalExcercisedContractualOptionAmount_D044486EA1BF69EFBC7756E5215CB0CC" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ApproximateOptionPeriod" xlink:label="loc_abus_ApproximateOptionPeriod_003E8B24B0BA92E7CEC256E5215CB8BC" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_ApproximateOptionPeriod_003E8B24B0BA92E7CEC256E5215CB8BC" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MaximumPotentialTransactionValue" xlink:label="loc_abus_MaximumPotentialTransactionValue_6D8475DC05249754BD6456E5215C949B" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_MaximumPotentialTransactionValue_6D8475DC05249754BD6456E5215C949B" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OptionPeriodExtension" xlink:label="loc_abus_OptionPeriodExtension_CA22F52B0DA910F4AD4E56E5215CD99E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_OptionPeriodExtension_CA22F52B0DA910F4AD4E56E5215CD99E" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_NearTermContractPayments" xlink:label="loc_abus_NearTermContractPayments_6622C7131EB15EEE94A756E5215CDFB9" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_NearTermContractPayments_6622C7131EB15EEE94A756E5215CDFB9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_9D1FA807F31D510DF1EE56E5215DD63B" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_Revenues_9D1FA807F31D510DF1EE56E5215DD63B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_B3A566F08405B6DE8F7156E5215DEAF9" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_LicensesRevenue_B3A566F08405B6DE8F7156E5215DEAF9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_32E836AB46F9EC03268B56E5215DE32F" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_32E836AB46F9EC03268B56E5215DE32F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0BB2A9545E013CE6537056E759698CB8" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0BB2A9545E013CE6537056E759698CB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_2B43A033F3525E4084B956E5215DAD8A" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_DeferredRevenue_2B43A033F3525E4084B956E5215DAD8A" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_LengthOfAgreementWithBristolMyersSquibb" xlink:label="loc_abus_LengthOfAgreementWithBristolMyersSquibb_AE262ED6A4E076ACC6D456E5215D2EF7" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_LengthOfAgreementWithBristolMyersSquibb_AE262ED6A4E076ACC6D456E5215D2EF7" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MilestonePayment" xlink:label="loc_abus_MilestonePayment_1FA2582C8A567813931856E5215DE266" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_MilestonePayment_1FA2582C8A567813931856E5215DE266" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PerformancePeriodtoRecognizeRevenue" xlink:label="loc_abus_PerformancePeriodtoRecognizeRevenue_1DCD390936142502430F56E5215D0388" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_PerformancePeriodtoRecognizeRevenue_1DCD390936142502430F56E5215D0388" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_NumberOfChemotherapyProductsWithWorldwideLicenses" xlink:label="loc_abus_NumberOfChemotherapyProductsWithWorldwideLicenses_5C5CC8DC53442392E59B56E5215D5889" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_abus_NumberOfChemotherapyProductsWithWorldwideLicenses_5C5CC8DC53442392E59B56E5215D5889" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_6F6D66C31D7D8DD2275A56E5215DF445" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_ContractsRevenue_6F6D66C31D7D8DD2275A56E5215DF445" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_B59E86EAB8E051411DF656E5215D5975" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_RoyaltyRevenue_B59E86EAB8E051411DF656E5215D5975" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_F93D58BB572AD55D32CD56E5215D7690" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4FB87C7623BA7B064BB756E5215CCA04" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_F93D58BB572AD55D32CD56E5215D7690" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_934043CC0D92C55C98633A624D4996B9" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2605AA73E44D90153B583A14D5B3B6A6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_934043CC0D92C55C98633A624D4996B9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2605AA73E44D90153B583A14D5B3B6A6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_7F89FF94282109A46F213A14D5B35C98" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2605AA73E44D90153B583A14D5B3B6A6" xlink:to="loc_us-gaap_CounterpartyNameAxis_7F89FF94282109A46F213A14D5B35C98" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A47958DC80D4145FB1F43A14D5B334E7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_7F89FF94282109A46F213A14D5B35C98" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A47958DC80D4145FB1F43A14D5B334E7" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DoDMember" xlink:label="loc_abus_DoDMember_EED97A3BCCA400049E423A14D5B33D69" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A47958DC80D4145FB1F43A14D5B334E7" xlink:to="loc_abus_DoDMember_EED97A3BCCA400049E423A14D5B33D69" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MonsantoMember" xlink:label="loc_abus_MonsantoMember_7403D6BEE1DEBF20C8F23A14D5B31E5F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A47958DC80D4145FB1F43A14D5B334E7" xlink:to="loc_abus_MonsantoMember_7403D6BEE1DEBF20C8F23A14D5B31E5F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BMSMember" xlink:label="loc_abus_BMSMember_2CD5581C8915823C0A593A14D5B470C2" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A47958DC80D4145FB1F43A14D5B334E7" xlink:to="loc_abus_BMSMember_2CD5581C8915823C0A593A14D5B470C2" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AlnylamLicenseAgreementMember" xlink:label="loc_abus_AlnylamLicenseAgreementMember_72D0FDF24345E076EBEA3A14D5B4C7F2" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A47958DC80D4145FB1F43A14D5B334E7" xlink:to="loc_abus_AlnylamLicenseAgreementMember_72D0FDF24345E076EBEA3A14D5B4C7F2" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DicernaMember" xlink:label="loc_abus_DicernaMember_1C164E01AC97A5B2E4193A14D5B4B035" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A47958DC80D4145FB1F43A14D5B334E7" xlink:to="loc_abus_DicernaMember_1C164E01AC97A5B2E4193A14D5B4B035" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OtherRNAiCollaboratorsMember" xlink:label="loc_abus_OtherRNAiCollaboratorsMember_40F0AD640A410FCFF3443A14D5B49AEE" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A47958DC80D4145FB1F43A14D5B334E7" xlink:to="loc_abus_OtherRNAiCollaboratorsMember_40F0AD640A410FCFF3443A14D5B49AEE" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_SpectrumMember" xlink:label="loc_abus_SpectrumMember_2EBC46A3EB82AC71F8483A14D5B48457" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A47958DC80D4145FB1F43A14D5B334E7" xlink:to="loc_abus_SpectrumMember_2EBC46A3EB82AC71F8483A14D5B48457" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8F575ABDD41C403F11953A14D5B4DAEC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2605AA73E44D90153B583A14D5B3B6A6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8F575ABDD41C403F11953A14D5B4DAEC" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_CollaborationsAndContractsAbstract" xlink:label="loc_abus_CollaborationsAndContractsAbstract_9DD7D738A6CE44F6EF9C3A14D5B99D49" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8F575ABDD41C403F11953A14D5B4DAEC" xlink:to="loc_abus_CollaborationsAndContractsAbstract_9DD7D738A6CE44F6EF9C3A14D5B99D49" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_3BAB26A5FC59A6EA46433A14D5B9B1EF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_CollaborationsAndContractsAbstract_9DD7D738A6CE44F6EF9C3A14D5B99D49" xlink:to="loc_us-gaap_ContractsRevenue_3BAB26A5FC59A6EA46433A14D5B9B1EF" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract" xlink:label="loc_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_CC7F135A0DCEE178A5FE3A14D5B9B4D5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8F575ABDD41C403F11953A14D5B4DAEC" xlink:to="loc_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_CC7F135A0DCEE178A5FE3A14D5B9B4D5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_E74B4FB9F58C2F4F90913A14D5B96729" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_CC7F135A0DCEE178A5FE3A14D5B9B4D5" xlink:to="loc_us-gaap_LicensesRevenue_E74B4FB9F58C2F4F90913A14D5B96729" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C568BDAC629D9221386A3A14D5B915DD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract_CC7F135A0DCEE178A5FE3A14D5B9B4D5" xlink:to="loc_us-gaap_Revenues_C568BDAC629D9221386A3A14D5B915DD" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueDisclosureAbstract" xlink:label="loc_us-gaap_DeferredRevenueDisclosureAbstract_530B8BB4B40B3F3213283A61D6FD5885" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_8FDE697FC696189A860C3A14D5F560B3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_530B8BB4B40B3F3213283A61D6FD5885" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_8FDE697FC696189A860C3A14D5F560B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_7E66BA8BCC1E803E6F193A14D5F54F1D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueDisclosureAbstract_530B8BB4B40B3F3213283A61D6FD5885" xlink:to="loc_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_7E66BA8BCC1E803E6F193A14D5F54F1D" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRisk" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_92FF2EBFF3DCCCB6133D2EAA5FF8BB88" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_9021A9CBAF84E68997662EAA5FF83C82" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_92FF2EBFF3DCCCB6133D2EAA5FF8BB88" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_9021A9CBAF84E68997662EAA5FF83C82" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_BF6CE06CE2A918CE143433F4132FC0D6" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_014BD45F699DC442040333F4132F9F99" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_BF6CE06CE2A918CE143433F4132FC0D6" xlink:to="loc_us-gaap_AccountsReceivableNet_014BD45F699DC442040333F4132F9F99" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_2E211E78308A828851A451CB6C5399E4" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable" xlink:label="loc_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable_31B325829B37895EE61751CB6C53753F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_2E211E78308A828851A451CB6C5399E4" xlink:to="loc_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable_31B325829B37895EE61751CB6C53753F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1F168606B6C2466FF2B051CB6C531A99" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable_31B325829B37895EE61751CB6C53753F" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1F168606B6C2466FF2B051CB6C531A99" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1F168606B6C2466FF2B051CB6C531A99" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ForeignCurrencyExposureMember" xlink:label="loc_abus_ForeignCurrencyExposureMember_8E4F15D5114431BE44DF51CB6C538A3C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0821849605E28D5E39E351CB6C5326B5" xlink:to="loc_abus_ForeignCurrencyExposureMember_8E4F15D5114431BE44DF51CB6C538A3C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:label="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalanceTable_31B325829B37895EE61751CB6C53753F" xlink:to="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4B627EDB5D43A0E0DE8751CB6C539D5D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4B627EDB5D43A0E0DE8751CB6C539D5D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_2D48EA515E2F52D757E251CB6C539CDC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:to="loc_us-gaap_AccountsReceivableNet_2D48EA515E2F52D757E251CB6C539CDC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_4A30FB63851D6A1CA4CE51CB6C538753" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_4A30FB63851D6A1CA4CE51CB6C538753" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2647062540676364250051CB6C535D16" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2647062540676364250051CB6C535D16" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ExposureToUSDollar" xlink:label="loc_abus_ExposureToUSDollar_7320640E1C27F02D7D1B51CB6C53669E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntercompanyForeignCurrencyBalanceLineItems_C7CD64A583896990829351CB6C533B77" xlink:to="loc_abus_ExposureToUSDollar_7320640E1C27F02D7D1B51CB6C53669E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_40DADA631EDEEEE3C1BD3F2E882EBF7A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_86C30869539A641060A93F2E882E7B7E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_40DADA631EDEEEE3C1BD3F2E882EBF7A" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_86C30869539A641060A93F2E882E7B7E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_A13FD23DC9B07DB5744B3F2E882FD529" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_40DADA631EDEEEE3C1BD3F2E882EBF7A" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_A13FD23DC9B07DB5744B3F2E882FD529" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_NetLiquidity" xlink:label="loc_abus_NetLiquidity_697ECD2B4A59C94E38C93F2E882F2A98" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_40DADA631EDEEEE3C1BD3F2E882EBF7A" xlink:to="loc_abus_NetLiquidity_697ECD2B4A59C94E38C93F2E882F2A98" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_AC4BFB8613B66F79D0BF33A2018E1753" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_NetLiquidityDisclosureTableTextBlock" xlink:label="loc_abus_NetLiquidityDisclosureTableTextBlock_83ED1C0B123DD40A487433A2018E4103" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_AC4BFB8613B66F79D0BF33A2018E1753" xlink:to="loc_abus_NetLiquidityDisclosureTableTextBlock_83ED1C0B123DD40A487433A2018E4103" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_FEF764539302E88DE3F133A2018ECB02" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_AC4BFB8613B66F79D0BF33A2018E1753" xlink:to="loc_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock_FEF764539302E88DE3F133A2018ECB02" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_B921FFB9955E4F461D525167E8A714E1" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B921FFB9955E4F461D525167E8A714E1" xlink:to="loc_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_331C53B71E4F0BFD67AB5167E8A799BE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_331C53B71E4F0BFD67AB5167E8A799BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_7DE6689EE1CB2F9061415167E8A75621" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0" xlink:to="loc_us-gaap_ShortTermInvestments_7DE6689EE1CB2F9061415167E8A75621" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9F87763679550CBA24235167E8A7962C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9F87763679550CBA24235167E8A7962C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnbilledReceivablesCurrent" xlink:label="loc_us-gaap_UnbilledReceivablesCurrent_D4265D2489FF060B71375167E8A7F602" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0" xlink:to="loc_us-gaap_UnbilledReceivablesCurrent_D4265D2489FF060B71375167E8A7F602" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_A18A4FBF01E6E79DE2EB5167E8A758BE" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0" xlink:to="loc_us-gaap_IncomeTaxesReceivable_A18A4FBF01E6E79DE2EB5167E8A758BE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C62594F90C0F3ADD1BA55167E8A79B55" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_D2BD27ED05D43536E9845167E8A753C0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C62594F90C0F3ADD1BA55167E8A79B55" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_74485D8D2CC0155E68075167E8A788D4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:to="loc_us-gaap_AssetsCurrent_74485D8D2CC0155E68075167E8A788D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_044839BE2DD85A85E21D5167E8A8E6CB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_044839BE2DD85A85E21D5167E8A8E6CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0B5B5CB059C9CCE4CB825167E8A84B75" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0B5B5CB059C9CCE4CB825167E8A84B75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_B335C1C6D05266ED3FB15167E8A83E48" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_B335C1C6D05266ED3FB15167E8A83E48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_65ED581E39E66D9218B15167E8A86EC0" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:to="loc_us-gaap_LongTermInvestments_65ED581E39E66D9218B15167E8A86EC0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_B2C61E13DC1438A21EC35167E8A87A2C" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_B2C61E13DC1438A21EC35167E8A87A2C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B8082E72E32A5F1E24815167E8A8C452" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:to="loc_us-gaap_Goodwill_B8082E72E32A5F1E24815167E8A8C452" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_3E94D5202F6E9165F9C55167E8A80021" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1CD8145C69EC8BA96BD25167E8A798A7" xlink:to="loc_us-gaap_Assets_3E94D5202F6E9165F9C55167E8A80021" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B921FFB9955E4F461D525167E8A714E1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_C86FE57195E77FF836C55167E8A85210" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_C86FE57195E77FF836C55167E8A85210" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E7FCD867A56C0A5DA57E5167E8A8CFE5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_C86FE57195E77FF836C55167E8A85210" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E7FCD867A56C0A5DA57E5167E8A8CFE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_9A56021D0F1F7E9CE62F5167E8A8BE84" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_C86FE57195E77FF836C55167E8A85210" xlink:to="loc_us-gaap_DeferredRevenueCurrent_9A56021D0F1F7E9CE62F5167E8A8BE84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_C9703DBF11010C8689B75167E8A8EED8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_C86FE57195E77FF836C55167E8A85210" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_C9703DBF11010C8689B75167E8A8EED8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_42B9D84C87885E45CDC45167E8A87A84" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_C86FE57195E77FF836C55167E8A85210" xlink:to="loc_us-gaap_LiabilitiesCurrent_42B9D84C87885E45CDC45167E8A87A84" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_3B773E53DA18F9E608875167E8A87576" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_3B773E53DA18F9E608875167E8A87576" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A862A7BEC6B992F162685167E8A83348" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A862A7BEC6B992F162685167E8A83348" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_E99DB6891BA4C6E4BFE55167E8A89A96" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_E99DB6891BA4C6E4BFE55167E8A89A96" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_189FF0C71B1DF2218D3A5167E8A8E85D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50" xlink:to="loc_us-gaap_Liabilities_189FF0C71B1DF2218D3A5167E8A8E85D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_E390F09A3018871B58665167E8A8D1D8" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0412A7903B4736B0E6C75167E8A8CE50" xlink:to="loc_us-gaap_StockholdersEquityAbstract_E390F09A3018871B58665167E8A8D1D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_5D81C199C7F3D85817E55167E8A8FB34" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E390F09A3018871B58665167E8A8D1D8" xlink:to="loc_us-gaap_CommonStockValue_5D81C199C7F3D85817E55167E8A8FB34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6266289F519719D95EDD5167E8A93F56" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E390F09A3018871B58665167E8A8D1D8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6266289F519719D95EDD5167E8A93F56" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18EC0F0CAB9B82F607A55167E8A903F0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E390F09A3018871B58665167E8A8D1D8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18EC0F0CAB9B82F607A55167E8A903F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_00B582D010D2CEBDD3F45167E8A96364" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E390F09A3018871B58665167E8A8D1D8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_00B582D010D2CEBDD3F45167E8A96364" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E737748C266A051B894A5167E8A90890" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E390F09A3018871B58665167E8A8D1D8" xlink:to="loc_us-gaap_StockholdersEquity_E737748C266A051B894A5167E8A90890" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_DCE4A6F65FE3FC2ADCEE5167E8A92061" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B921FFB9955E4F461D525167E8A714E1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_DCE4A6F65FE3FC2ADCEE5167E8A92061" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_DD2980F8FC8725DF4F695167E88AA428" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_21017D9507A772C7853F5167E88AB8C0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_DD2980F8FC8725DF4F695167E88AA428" xlink:to="loc_us-gaap_CommonStockNoParValue_21017D9507A772C7853F5167E88AB8C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_BE5738E29CCC17D2DB8B5167E88B9E04" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_DD2980F8FC8725DF4F695167E88AA428" xlink:to="loc_us-gaap_CommonStockSharesIssued_BE5738E29CCC17D2DB8B5167E88B9E04" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_AF3E62A98298057FD1645167E88BD708" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_DD2980F8FC8725DF4F695167E88AA428" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_AF3E62A98298057FD1645167E88BD708" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_F1C31013C1860A16DD6F3F2E893FEEBF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8C381D4372010FA43A8E3F2E893F23D8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_F1C31013C1860A16DD6F3F2E893FEEBF" xlink:to="loc_us-gaap_StatementTable_8C381D4372010FA43A8E3F2E893F23D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_45275BD4A09E6EBCE3843F2E893FCDFD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8C381D4372010FA43A8E3F2E893F23D8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_45275BD4A09E6EBCE3843F2E893FCDFD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_45275BD4A09E6EBCE3843F2E893FCDFD" xlink:to="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E9B70B7EC457EADB62F43F2E893F5FCB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:to="loc_us-gaap_CommonStockMember_E9B70B7EC457EADB62F43F2E893F5FCB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_781E61B44BFE1B4CBD583F2E893F3FE1" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_781E61B44BFE1B4CBD583F2E893F3FE1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_8339FE1055DB5CA049853F2E893FDF87" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:to="loc_us-gaap_RetainedEarningsMember_8339FE1055DB5CA049853F2E893FDF87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D2318EF639D2050A815B3F2E893FEA1D" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5E5F157FB5521191C6673F2E893F5901" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_D2318EF639D2050A815B3F2E893FEA1D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8C381D4372010FA43A8E3F2E893F23D8" xlink:to="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_D170B005E4A6343DEFB53F2E893FB227" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_SharesIssued_D170B005E4A6343DEFB53F2E893FB227" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CD94FD6BBFE58714B7F93F2E894008AA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockholdersEquity_CD94FD6BBFE58714B7F93F2E894008AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CDB4135736A8F62162073F2E8940DEA4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CDB4135736A8F62162073F2E8940DEA4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_199857DB1DB6DCA336AC3F2E8940D434" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_199857DB1DB6DCA336AC3F2E8940D434" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_FDDCACCEA81BC9F59BD63F2E8940929F" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_FDDCACCEA81BC9F59BD63F2E8940929F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_4873560D06A42CF38EED3F2E8940E137" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_4873560D06A42CF38EED3F2E8940E137" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_BB7C80F4DF87E90BE01B3F2E89403534" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_BB7C80F4DF87E90BE01B3F2E89403534" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A30D0598F4F3BA04AF3B3F2E89403608" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A30D0598F4F3BA04AF3B3F2E89403608" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_21FDACA2E22DC4BC41423F2E8940632F" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_21FDACA2E22DC4BC41423F2E8940632F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_04F18B81E44038EE63053F2E8940CBE8" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_04F18B81E44038EE63053F2E8940CBE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_15D39AC604AEC65719633F2E89407C4B" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_15D39AC604AEC65719633F2E89407C4B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6746F2603FC7999B072C3F2E89401EAB" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6746F2603FC7999B072C3F2E89401EAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E2B4C4A855D55FD31E203F2E8940E8F8" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_NetIncomeLoss_E2B4C4A855D55FD31E203F2E8940E8F8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_F11DA1FC57B7F58294ED3F2E89416E3D" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_SharesIssued_F11DA1FC57B7F58294ED3F2E89416E3D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_095CE28C30820B2C5A1D3F2E89411F82" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60B8E37CC9D00C4F1CEB3F2E893FF53D" xlink:to="loc_us-gaap_StockholdersEquity_095CE28C30820B2C5A1D3F2E89411F82" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_F7CB1A65DBCE24BFDB115212D745D1D0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_C38E150A1F3F39D734435212D7455AC8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_F7CB1A65DBCE24BFDB115212D745D1D0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_C38E150A1F3F39D734435212D7455AC8" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_94BA4D15011CBFD75B4F3F2E89359D8B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_8C643C9B098E11C59D093F2E89350BE5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_94BA4D15011CBFD75B4F3F2E89359D8B" xlink:to="loc_us-gaap_StatementTable_8C643C9B098E11C59D093F2E89350BE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E4F127FAF9A0BD25436E3F2E8935006F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8C643C9B098E11C59D093F2E89350BE5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E4F127FAF9A0BD25436E3F2E8935006F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_67B7C6D971356AFA84803F2E89352034" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E4F127FAF9A0BD25436E3F2E8935006F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_67B7C6D971356AFA84803F2E89352034" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C5C3B691A1937AAC80E63F2E8935A539" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_67B7C6D971356AFA84803F2E89352034" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C5C3B691A1937AAC80E63F2E8935A539" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_35F6AFF588AD408BD2B73F2E8935A6BD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_67B7C6D971356AFA84803F2E89352034" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_35F6AFF588AD408BD2B73F2E8935A6BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8C643C9B098E11C59D093F2E89350BE5" xlink:to="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_46BE7B5FF7129ECCAE933F2E89356354" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:to="loc_us-gaap_NetIncomeLoss_46BE7B5FF7129ECCAE933F2E89356354" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5DEA17ACE212F7F7163C3F2E89360149" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5DEA17ACE212F7F7163C3F2E89360149" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_107C5FD901B3117D8EFA3F2E89368B11" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_Depreciation_107C5FD901B3117D8EFA3F2E89368B11" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F2522175DC91B335792E3F2E89362DC8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_F2522175DC91B335792E3F2E89362DC8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3EB5CDBEBE5C1C8D04693F2E893620BD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_ShareBasedCompensation_3EB5CDBEBE5C1C8D04693F2E893620BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_BE9834A2EA04086E44023F2E893668EC" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_BE9834A2EA04086E44023F2E893668EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_26AD38B8FEE2D00E8FB33F2E893655C1" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_26AD38B8FEE2D00E8FB33F2E893655C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7A5439ED3019EBCC2B883F2E89364066" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7A5439ED3019EBCC2B883F2E89364066" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_806B602262D327B967FF3F2E8936814D" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_07DF95829CAFCC94AAD83F2E89369177" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_806B602262D327B967FF3F2E8936814D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_36D8DA65865DCCB845113F2E89358E4E" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5E83D6C4A61F549ECE3D3F2E893656EC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5E83D6C4A61F549ECE3D3F2E893656EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_1575597DDA2991CE338F3F2E89366AA2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="loc_us-gaap_IncreaseDecreaseInUnbilledReceivables_1575597DDA2991CE338F3F2E89366AA2" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IncreaseDecreaseOtherDeferredCostsNet" xlink:label="loc_abus_IncreaseDecreaseOtherDeferredCostsNet_EFD496B4505441B2B28A3F2E89362F37" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="loc_abus_IncreaseDecreaseOtherDeferredCostsNet_EFD496B4505441B2B28A3F2E89362F37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_EBAD1C67389A2E83AC3A3F2E8936173C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_EBAD1C67389A2E83AC3A3F2E8936173C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08D0255F21E2254A990A3F2E89368DD7" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08D0255F21E2254A990A3F2E89368DD7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76F28B88C2CAF7334D0A3F2E8936EB72" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76F28B88C2CAF7334D0A3F2E8936EB72" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_F9801F6EC4C4950895763F2E89360842" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_C285017F01232C2DF3503F2E8936A5EF" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_F9801F6EC4C4950895763F2E89360842" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_211C716CA1DC14E2D3C73F2E8936936B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_211C716CA1DC14E2D3C73F2E8936936B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_E278D2AE1064B4F268293F2E893794FC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_E278D2AE1064B4F268293F2E893794FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_CE235DA82C0A451089273F2E8937281A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_CE235DA82C0A451089273F2E8937281A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5D93D9FE7E87B696AB53F2E893799F1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_F5D93D9FE7E87B696AB53F2E893799F1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D7BA07D036F7DAFDC0E73F2E893765DB" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_100821319882127520A63F2E89373E5A" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_D7BA07D036F7DAFDC0E73F2E893765DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_79DACFCF001CE2904D7D3F2E89376514" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_79DACFCF001CE2904D7D3F2E89376514" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A3A237A5E608B00ABEB03F2E89372377" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A3A237A5E608B00ABEB03F2E89372377" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_E64C2C70DE832995E1AD3F2E89370210" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_E64C2C70DE832995E1AD3F2E89370210" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_4B87A3A2B675F7CC70953F2E8937EB95" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B6A7839430BCAD46B3E73F2E89375E8C" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_4B87A3A2B675F7CC70953F2E8937EB95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CF8786EE316E8F910F7E3F2E89373436" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_CF8786EE316E8F910F7E3F2E89373436" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_44E530C632DF65908F843F2E89378B21" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_44E530C632DF65908F843F2E89378B21" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B02A593D37BB9424C493F2E89373735" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_0B02A593D37BB9424C493F2E89373735" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49A11B81911ADC7EE4E73F2E893774A1" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49A11B81911ADC7EE4E73F2E893774A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9BE1E26248364CDD75073F2E89370FCD" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9BE1E26248364CDD75073F2E89370FCD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_209B67230D3F958380B93F2E8935EB68" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_FairValueOfWarrantsExercisedOnACashlessBasis" xlink:label="loc_abus_FairValueOfWarrantsExercisedOnACashlessBasis_3D355EA7041F2343E5FD3F2E8937F372" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:to="loc_abus_FairValueOfWarrantsExercisedOnACashlessBasis_3D355EA7041F2343E5FD3F2E8937F372" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_AE17DABF0B938CC635DE3F2E8938057F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_AE17DABF0B938CC635DE3F2E8938057F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3E3A6B63B04A5ABA5E1B3F2E8938C122" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_072F2B25CAEC2C69AAC83F2E8937F287" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_3E3A6B63B04A5ABA5E1B3F2E8938C122" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_5DDCD5F1990430089F6D5212C54BE13C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="loc_us-gaap_RevenuesAbstract_5DDCD5F1990430089F6D5212C54BE13C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_504D8F0EF11B117FD4945212C54BB6F6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5DDCD5F1990430089F6D5212C54BE13C" xlink:to="loc_us-gaap_ContractsRevenue_504D8F0EF11B117FD4945212C54BB6F6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_0F11D254C8DAE58189F05212C54B670C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5DDCD5F1990430089F6D5212C54BE13C" xlink:to="loc_us-gaap_LicensesRevenue_0F11D254C8DAE58189F05212C54B670C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_0E0CBBA1475FCE97BCE35212C54BDB56" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="loc_us-gaap_Revenues_0E0CBBA1475FCE97BCE35212C54BDB56" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3B060C0E992CA6F704495212C54BC0B9" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_3B060C0E992CA6F704495212C54BC0B9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_A825BE630738D515E8F35212C54BDC3D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3B060C0E992CA6F704495212C54BC0B9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_A825BE630738D515E8F35212C54BDC3D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_E944D4DDB20F662AFBAC5212C54B9191" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3B060C0E992CA6F704495212C54BC0B9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_E944D4DDB20F662AFBAC5212C54B9191" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_5356787B21CD8435C0835212C54BEC2D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3B060C0E992CA6F704495212C54BC0B9" xlink:to="loc_us-gaap_Depreciation_5356787B21CD8435C0835212C54BEC2D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_BDA02D54C71C9CF804AF5212C54C2821" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3B060C0E992CA6F704495212C54BC0B9" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_BDA02D54C71C9CF804AF5212C54C2821" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_8DF304ABD6A2FE3C744D5212C54C2EE5" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3B060C0E992CA6F704495212C54BC0B9" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_8DF304ABD6A2FE3C744D5212C54C2EE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_202B8FC3A9F14B9BAF915212C54C1B06" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="loc_us-gaap_OperatingExpenses_202B8FC3A9F14B9BAF915212C54C1B06" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5A0A2167D10DB9E6670E5212C54C8E3B" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="loc_us-gaap_OperatingIncomeLoss_5A0A2167D10DB9E6670E5212C54C8E3B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_A7ADABD49FCA683BD2075212C54CD2F7" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_A7ADABD49FCA683BD2075212C54CD2F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_260F801C4F40C5950D3F5212C54C44A8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_A7ADABD49FCA683BD2075212C54CD2F7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_260F801C4F40C5950D3F5212C54C44A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3D136BEE2A6FF39329DB5212C54C20E2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_A7ADABD49FCA683BD2075212C54CD2F7" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3D136BEE2A6FF39329DB5212C54C20E2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_2AB9969C99D8C9F2470A5212C54C8D81" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_A7ADABD49FCA683BD2075212C54CD2F7" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_2AB9969C99D8C9F2470A5212C54C8D81" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_987B528A49617CA83B5B5212C54C4B4E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_A7ADABD49FCA683BD2075212C54CD2F7" xlink:to="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_987B528A49617CA83B5B5212C54C4B4E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9F79C62F39217CE0B0C25212C54CDA29" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9F79C62F39217CE0B0C25212C54CDA29" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330F0B1EE79F8C05FA435212C54C48BC" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_330F0B1EE79F8C05FA435212C54C48BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_CD38B6F964FB5A9D1B5E5212C54CDF7C" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_CD38B6F964FB5A9D1B5E5212C54CDF7C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0F25B5C11B341A94A7715212C54C3A22" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="loc_us-gaap_NetIncomeLoss_0F25B5C11B341A94A7715212C54C3A22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_B4BC7F81DE8B4323FABA5212C54C80F0" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_B4BC7F81DE8B4323FABA5212C54C80F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_025A5D26FAFEA54935585212C54C97B5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_B4BC7F81DE8B4323FABA5212C54C80F0" xlink:to="loc_us-gaap_EarningsPerShareBasic_025A5D26FAFEA54935585212C54C97B5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_88F53C4578828FE1D9DB5212C54C4927" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_B4BC7F81DE8B4323FABA5212C54C80F0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_88F53C4578828FE1D9DB5212C54C4927" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7879E80910119C77B7675212C54C0AFF" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7879E80910119C77B7675212C54C0AFF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2959B02A86A7B3B982335212C54CA945" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7879E80910119C77B7675212C54C0AFF" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2959B02A86A7B3B982335212C54CA945" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BAA2C853F1F057C4D4495212C54D7CFD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_7879E80910119C77B7675212C54C0AFF" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_BAA2C853F1F057C4D4495212C54D7CFD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5A8555852E269D2C9CA05212C54DA702" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5A8555852E269D2C9CA05212C54DA702" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6F80F25E8FBCE0E759735212C54DF776" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5A8555852E269D2C9CA05212C54DA702" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6F80F25E8FBCE0E759735212C54DF776" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8E3009800242501F82C85212C54D7E5A" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2FB573B84C9A7C0379E55212C54B8C0D" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_8E3009800242501F82C85212C54D7E5A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitments" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5A5DB1DF3E6F37D8E2D42EAA600F32BF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C6B30ED8F5AF519159AB2EAA600FA773" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5A5DB1DF3E6F37D8E2D42EAA600F32BF" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C6B30ED8F5AF519159AB2EAA600FA773" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A9F8AA6FCD642989233E3F2E88436000" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_ContingenciesandCommitmentsTable" xlink:label="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A9F8AA6FCD642989233E3F2E88436000" xlink:to="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_36D5F6CDC300B8BF83D93F2E8843E1AD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:to="loc_us-gaap_ProductOrServiceAxis_36D5F6CDC300B8BF83D93F2E8843E1AD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_36D5F6CDC300B8BF83D93F2E8843E1AD" xlink:to="loc_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MarqiboMember" xlink:label="loc_abus_MarqiboMember_68AECCEE35A2FEBCCE773F2E884372C6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_DBDEB33A59FE878A98933F2E8843432D" xlink:to="loc_abus_MarqiboMember_68AECCEE35A2FEBCCE773F2E884372C6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_19DCCA34ED6282C62EE43F2E8843A6EC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:to="loc_us-gaap_CounterpartyNameAxis_19DCCA34ED6282C62EE43F2E8843A6EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_19DCCA34ED6282C62EE43F2E8843A6EC" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MarinaBiotechInc.Member" xlink:label="loc_abus_MarinaBiotechInc.Member_8779338F3CC09C2C380B3F2E88446999" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:to="loc_abus_MarinaBiotechInc.Member_8779338F3CC09C2C380B3F2E88446999" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArcturusMember" xlink:label="loc_abus_ArcturusMember_28842033654F77A5FCD43F2E8844D0AE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:to="loc_abus_ArcturusMember_28842033654F77A5FCD43F2E8844D0AE" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BlumbergandDrexelMember" xlink:label="loc_abus_BlumbergandDrexelMember_C773531DDF4447003A893F2E88447020" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:to="loc_abus_BlumbergandDrexelMember_C773531DDF4447003A893F2E88447020" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BlumbergMember" xlink:label="loc_abus_BlumbergMember_6B727FD16B4EB07D58CF3F2E8844DD51" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:to="loc_abus_BlumbergMember_6B727FD16B4EB07D58CF3F2E8844DD51" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_NeuroViveMember" xlink:label="loc_abus_NeuroViveMember_AFA932BF5AA507FAAB403F2E8844EFFF" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:to="loc_abus_NeuroViveMember_AFA932BF5AA507FAAB403F2E8844EFFF" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_CytosMember" xlink:label="loc_abus_CytosMember_0F9A99E52512037C4E1E3F2E88449DF4" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C5435D09B0D5CDBD6613F2E88434643" xlink:to="loc_abus_CytosMember_0F9A99E52512037C4E1E3F2E88449DF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_4538E864982D97521C623F2E88446A69" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:to="loc_us-gaap_LitigationCaseAxis_4538E864982D97521C623F2E88446A69" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseAxis_4538E864982D97521C623F2E88446A69" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:label="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_E9244D587690EC77C4DE3F2E8844106F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_C6362DCA481406C011B73F2E88447744" xlink:to="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_E9244D587690EC77C4DE3F2E8844106F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_C0EB6CF52B80DBA3A6913F2E8844CFD8" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:to="loc_dei_LegalEntityAxis_C0EB6CF52B80DBA3A6913F2E8844CFD8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_A1E2B4749BC55DCCFC7F3F2E88442DF4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_C0EB6CF52B80DBA3A6913F2E8844CFD8" xlink:to="loc_dei_EntityDomain_A1E2B4749BC55DCCFC7F3F2E88442DF4" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OnCoreBiopharmaInc.Member" xlink:label="loc_abus_OnCoreBiopharmaInc.Member_F84A424625E7A924B0223F2E884469B0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_A1E2B4749BC55DCCFC7F3F2E88442DF4" xlink:to="loc_abus_OnCoreBiopharmaInc.Member_F84A424625E7A924B0223F2E884469B0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_096A84363C385A1D49A53F2E8844E066" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_A1E2B4749BC55DCCFC7F3F2E88442DF4" xlink:to="loc_abus_ArbutusInc.Member_096A84363C385A1D49A53F2E8844E066" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C1683995FD41CCA55D723F2E8844A549" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_C1683995FD41CCA55D723F2E8844A549" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A3073D84F51DEAF6BDCE3F2E88441A4C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C1683995FD41CCA55D723F2E8844A549" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A3073D84F51DEAF6BDCE3F2E88441A4C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_EnantigenMember" xlink:label="loc_abus_EnantigenMember_69BA02B156C6D7483E143F2E88457BE8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A3073D84F51DEAF6BDCE3F2E88441A4C" xlink:to="loc_abus_EnantigenMember_69BA02B156C6D7483E143F2E88457BE8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ContingenciesandCommitmentsLineItems" xlink:label="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_4FB5837116691261BEC43F2E884376C2" xlink:to="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_0BAF8946E7FE153454623F2E88457029" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_0BAF8946E7FE153454623F2E88457029" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PercentOfCostsFundedByTPC" xlink:label="loc_abus_PercentOfCostsFundedByTPC_30BE652DEEEE61C6469B3F2E8845C9A5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_PercentOfCostsFundedByTPC_30BE652DEEEE61C6469B3F2E8845C9A5" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MaximumContributionForProduct" xlink:label="loc_abus_MaximumContributionForProduct_08EDEB1FC2419981101C3F2E884560EB" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_MaximumContributionForProduct_08EDEB1FC2419981101C3F2E884560EB" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_CumulativeContributionforProduct" xlink:label="loc_abus_CumulativeContributionforProduct_413443817508A5BA386C3F2E8845A4CB" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_CumulativeContributionforProduct_413443817508A5BA386C3F2E8845A4CB" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_RoyaltyGuaranteesCommitmentsPercentage" xlink:label="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_3E7EF474F13F61DF828D3F2E88453678" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_3E7EF474F13F61DF828D3F2E88453678" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_9DB25B865730B91BB0523F2E88459C71" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_us-gaap_RoyaltyRevenue_9DB25B865730B91BB0523F2E88459C71" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_RoyaltyPayable" xlink:label="loc_abus_RoyaltyPayable_ED22447846626B080EAF3F2E8845898E" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_RoyaltyPayable_ED22447846626B080EAF3F2E8845898E" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_RoyaltiesPaidOrAccrued" xlink:label="loc_abus_RoyaltiesPaidOrAccrued_1CCF7558E0278D1557223F2E88452137" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_RoyaltiesPaidOrAccrued_1CCF7558E0278D1557223F2E88452137" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_FB3DCF960E24A638244C3F2E8845E650" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_us-gaap_ContractualObligation_FB3DCF960E24A638244C3F2E8845E650" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_UpfrontFee" xlink:label="loc_abus_UpfrontFee_FBECB0E9EC4680609BD23F2E8845ED52" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_UpfrontFee_FBECB0E9EC4680609BD23F2E8845ED52" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MilestonePayment" xlink:label="loc_abus_MilestonePayment_63161EF40D0DEACA88263F2E8845E876" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_MilestonePayment_63161EF40D0DEACA88263F2E8845E876" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_D6FF8D790C0E0831A6783F2E8845AB6D" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_D6FF8D790C0E0831A6783F2E8845AB6D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5E85C357880E63D47F543F2E88454D63" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5E85C357880E63D47F543F2E88454D63" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ProgramsInPreClinicalDevelopment" xlink:label="loc_abus_ProgramsInPreClinicalDevelopment_991A24A88986C5CF99173F2E8845746A" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ProgramsInPreClinicalDevelopment_991A24A88986C5CF99173F2E8845746A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9918C010F83B7A6D50B53F2E884586CB" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9918C010F83B7A6D50B53F2E884586CB" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_2AAB54D0C7D6F434200C3F2E88468FFD" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_2AAB54D0C7D6F434200C3F2E88468FFD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_C4DBD086EBAD06A833F43F2E884699A1" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_us-gaap_LicenseCosts_C4DBD086EBAD06A833F43F2E884699A1" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_42666D523B32D70538113F2E8846CAB2" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_42666D523B32D70538113F2E8846CAB2" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense" xlink:label="loc_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense_1D92C7EA24CFC3784E6B3F2E8846670E" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense_1D92C7EA24CFC3784E6B3F2E8846670E" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ContractualObligationAmountOfResearchFundingPerYear" xlink:label="loc_abus_ContractualObligationAmountOfResearchFundingPerYear_B30A7BEC2580208F10673F2E8846648C" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ContractualObligationAmountOfResearchFundingPerYear_B30A7BEC2580208F10673F2E8846648C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ResearchFundingPeriod" xlink:label="loc_abus_ResearchFundingPeriod_7D424CA92C019B1D84343F2E8846DCC8" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ResearchFundingPeriod_7D424CA92C019B1D84343F2E8846DCC8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ResearchFundingPeriodRenewableOption" xlink:label="loc_abus_ResearchFundingPeriodRenewableOption_F9535AF97E2DD69392173F2E8846C0BB" xlink:type="locator" />
    <presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ResearchFundingPeriodRenewableOption_F9535AF97E2DD69392173F2E8846C0BB" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment" xlink:label="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment_59CB66938508F26AFC223F2E8846F2B7" xlink:type="locator" />
    <presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment_59CB66938508F26AFC223F2E8846F2B7" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments" xlink:label="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments_4139AA00D2B8B016AB973F2E88461EFA" xlink:type="locator" />
    <presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments_4139AA00D2B8B016AB973F2E88461EFA" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments" xlink:label="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments_DF56F1752B89A5B7BF463F2E88462870" xlink:type="locator" />
    <presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments_DF56F1752B89A5B7BF463F2E88462870" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Numberofseriesofcompounds" xlink:label="loc_abus_Numberofseriesofcompounds_D61FDD8DB21770EBC0D43F2E88462BFB" xlink:type="locator" />
    <presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_E225CE120396FA28E26A3F2E88452331" xlink:to="loc_abus_Numberofseriesofcompounds_D61FDD8DB21770EBC0D43F2E88462BFB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_616C23D8B0A33871950234C3968934F8" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6B01B3DD557951F2C90134C39689D370" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_616C23D8B0A33871950234C3968934F8" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_6B01B3DD557951F2C90134C39689D370" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_16A2F8741F61CB6C9D8734C3968A0C5B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_616C23D8B0A33871950234C3968934F8" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_16A2F8741F61CB6C9D8734C3968A0C5B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_972A6B2BAA4E7C6BCC8E34C478D432CE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_616C23D8B0A33871950234C3968934F8" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_972A6B2BAA4E7C6BCC8E34C478D432CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD7B2E5A8D7A95B93F4A34C47AEEC8EC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_616C23D8B0A33871950234C3968934F8" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_BD7B2E5A8D7A95B93F4A34C47AEEC8EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24B5E551A808799EEAD334C3968A361E" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_616C23D8B0A33871950234C3968934F8" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_24B5E551A808799EEAD334C3968A361E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_19242D46D76014AF124E33A2019B3429" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_962FAFFED8F52CA97F6333A2019C63C3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_19242D46D76014AF124E33A2019B3429" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_962FAFFED8F52CA97F6333A2019C63C3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:href="abus-20151231.xsd#abus_DocumentAndEntityInformationAbstract" xlink:label="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:type="locator" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_4ACCB6A75BDA13E6C6F33F2E895FDCA9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="loc_dei_EntityRegistrantName_4ACCB6A75BDA13E6C6F33F2E895FDCA9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_02C1DFF68E79655AFEAD3F2E895F796A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="loc_dei_DocumentType_02C1DFF68E79655AFEAD3F2E895F796A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_3A13EFBAF0E65BFC3C173F2E895FB467" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="loc_dei_CurrentFiscalYearEndDate_3A13EFBAF0E65BFC3C173F2E895FB467" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9434F64DD4FFBC377D3D3F2E895FFFCA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9434F64DD4FFBC377D3D3F2E895FFFCA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_9C84356884CF7C46C7B03F2E895F881B" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="loc_dei_EntityPublicFloat_9C84356884CF7C46C7B03F2E895F881B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_B345EBAB995472F3D6DB3F2E895F2C97" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="loc_dei_AmendmentFlag_B345EBAB995472F3D6DB3F2E895F2C97" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7D26BE027E3703A959A13F2E895F69B8" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="loc_dei_EntityCentralIndexKey_7D26BE027E3703A959A13F2E895F69B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E76333E7C4B5C5CFBEF73F2E895FE36E" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="loc_dei_EntityCurrentReportingStatus_E76333E7C4B5C5CFBEF73F2E895FE36E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_72A4F09C8F582105CEDE3F2E895FC0A9" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="loc_dei_EntityVoluntaryFilers_72A4F09C8F582105CEDE3F2E895FC0A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_0F3CB65CD31F1851BA5A3F2E895F5C9F" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="loc_dei_EntityFilerCategory_0F3CB65CD31F1851BA5A3F2E895F5C9F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_336CD5967AC3C9F0D4003F2E895F0F0D" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_336CD5967AC3C9F0D4003F2E895F0F0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_B99CEC5D14C37AAAE7023F2E89604B48" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="loc_dei_DocumentPeriodEndDate_B99CEC5D14C37AAAE7023F2E89604B48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_197EAD14C0F589B937FE3F2E89607B35" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="loc_dei_DocumentFiscalYearFocus_197EAD14C0F589B937FE3F2E89607B35" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A6259FBADE2FAC733A713F2E896068DE" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_B4768E49187C06B711083F2E895FC884" xlink:to="loc_dei_DocumentFiscalPeriodFocus_A6259FBADE2FAC733A713F2E896068DE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCredits" xlink:type="extended">
    <loc xlink:href="abus-20151231.xsd#abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract" xlink:label="loc_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract_2A6FDAB63E72D33939482EAA60345193" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock" xlink:label="loc_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock_A822FF2943DCCFE96FD42EAA60345AB3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract_2A6FDAB63E72D33939482EAA60345193" xlink:to="loc_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock_A822FF2943DCCFE96FD42EAA60345AB3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails" xlink:type="extended">
    <loc xlink:href="abus-20151231.xsd#abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract" xlink:label="loc_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract_FB01A2821C99474B19D834AE80BB63A6" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable" xlink:label="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract_FB01A2821C99474B19D834AE80BB63A6" xlink:to="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3A228753E3831C4CCE7334AE80BB95FB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3A228753E3831C4CCE7334AE80BB95FB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3A228753E3831C4CCE7334AE80BB95FB" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ISARICMember" xlink:label="loc_abus_ISARICMember_FBAC4BF4A6BFC03A424634AE80BC3C13" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0A56E4C7F270C47F630D34AE80BC4047" xlink:to="loc_abus_ISARICMember_FBAC4BF4A6BFC03A424634AE80BC3C13" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems" xlink:label="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsTable_AF9EFAB3F43C77C5D3A034AE80BBCA42" xlink:to="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="loc_us-gaap_ContractsRevenue_BD66435FEC77C4FABD7F34AE80BCB4A4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:to="loc_us-gaap_ContractsRevenue_BD66435FEC77C4FABD7F34AE80BCB4A4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_ED5E52E3F31037BB466834AE80BCB30C" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:to="loc_us-gaap_RevenueFromGrants_ED5E52E3F31037BB466834AE80BCB30C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentTaxCredit" xlink:label="loc_us-gaap_InvestmentTaxCredit_803FEAD48B90ECE5E4C634AE80BC43EF" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems_A69CB4C8B542E345D81A34AE80BCEE10" xlink:to="loc_us-gaap_InvestmentTaxCredit_803FEAD48B90ECE5E4C634AE80BC43EF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_91D4B842E1353E6AEE062EAA602AD316" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_EF136D4356658BEF13752EAA602A2BCC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91D4B842E1353E6AEE062EAA602AD316" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_EF136D4356658BEF13752EAA602A2BCC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_EECFF30A2E752F250F17344946A484A5" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_ComponentsofDeferredTaxAssetsTable" xlink:label="loc_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EECFF30A2E752F250F17344946A484A5" xlink:to="loc_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_63DD88CA35D2D9AC95FB344946B13AC1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_63DD88CA35D2D9AC95FB344946B13AC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_63DD88CA35D2D9AC95FB344946B13AC1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_CBB201378661935F315A344946B2666A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6" xlink:to="loc_us-gaap_DomesticCountryMember_CBB201378661935F315A344946B2666A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5C36A52C597E507DAB56344946B21A76" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3967FB6EC288BA28A167344946B13DE6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5C36A52C597E507DAB56344946B21A76" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ComponentsofDeferredTaxAssetsLineItems" xlink:label="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsTable_791A2F23F965DD0B33BE344946B18B2E" xlink:to="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_534BD121FF3FD810CB61344946B26D22" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_534BD121FF3FD810CB61344946B26D22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_906D86C7EB62018060FA344946B24DF7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_906D86C7EB62018060FA344946B24DF7" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DeferredTaxAssetBookAmortizationInExcessOfTax" xlink:label="loc_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_CE096A759CFE704BB943344946B22F66" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_abus_DeferredTaxAssetBookAmortizationInExcessOfTax_CE096A759CFE704BB943344946B22F66" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_EDBDDDE144D84E96A3B5344946B20247" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_EDBDDDE144D84E96A3B5344946B20247" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes" xlink:label="loc_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7546690123BA1955F20D344946B2C460" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes_7546690123BA1955F20D344946B2C460" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements" xlink:label="loc_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_4F2AD3507162A0E4582C344946B22181" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements_4F2AD3507162A0E4582C344946B22181" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_549356D553A093E09CB7344946B394F7" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_549356D553A093E09CB7344946B394F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_684C77D34B808793BD1A3454970A38C5" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_684C77D34B808793BD1A3454970A38C5" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DeferredTaxAssetUpfrontLicenseFees" xlink:label="loc_abus_DeferredTaxAssetUpfrontLicenseFees_11E25EE66346FA645ED034570E2212E8" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_abus_DeferredTaxAssetUpfrontLicenseFees_11E25EE66346FA645ED034570E2212E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_DEFDD4277414129EB097345C47231444" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_DEFDD4277414129EB097345C47231444" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7C7B66985DE1214F5F8A344946B3D69B" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7C7B66985DE1214F5F8A344946B3D69B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5F121E3BAD37379062C6344946B3807D" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5F121E3BAD37379062C6344946B3807D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_5A220A8B32C1E7656D2E345D70982794" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxLiabilities_5A220A8B32C1E7656D2E345D70982794" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2CCC4662B176DA9F458B344946B3CFAF" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ComponentsofDeferredTaxAssetsLineItems_8C922D08ABDD5AC5C5B3344946B2F9B5" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_2CCC4662B176DA9F458B344946B3CFAF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_31F5442E07A07787289C5167E77E04D1" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_IncomeTaxesTable" xlink:label="loc_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_31F5442E07A07787289C5167E77E04D1" xlink:to="loc_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_FD15BE8A00EFA9317E235167E77EC162" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:to="loc_us-gaap_StatementScenarioAxis_FD15BE8A00EFA9317E235167E77EC162" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_FD15BE8A00EFA9317E235167E77EC162" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="loc_us-gaap_RestatementAdjustmentMember_6782008242A7346B433C5167E77EFFA0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_B9C4CCDDA1EC5897F0115167E77E02DD" xlink:to="loc_us-gaap_RestatementAdjustmentMember_6782008242A7346B433C5167E77EFFA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_5522F9904F0248045D1D5167E77E20A5" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_5522F9904F0248045D1D5167E77E20A5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_5522F9904F0248045D1D5167E77E20A5" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentCreditMember" xlink:label="loc_us-gaap_InvestmentCreditMember_008D9669ECA4CA308C195167E77F1BFE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB" xlink:to="loc_us-gaap_InvestmentCreditMember_008D9669ECA4CA308C195167E77F1BFE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_15BCF254A798DBF984475167E77F2908" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_CB60B9E246688281AD995167E77EFFBB" xlink:to="loc_us-gaap_ResearchMember_15BCF254A798DBF984475167E77F2908" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F8853D65171693D2ED5C5167E77F9D91" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:to="loc_us-gaap_RangeAxis_F8853D65171693D2ED5C5167E77F9D91" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_F8853D65171693D2ED5C5167E77F9D91" xlink:to="loc_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_90DB767E4FE19A6044105167E77F5714" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_AD3A670439AE752D9E3A5167E77F0ECD" xlink:to="loc_us-gaap_MaximumMember_90DB767E4FE19A6044105167E77F5714" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IncomeTaxesDetailsLineItems" xlink:label="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_IncomeTaxesTable_9EDEAE4E1D37747A62DE5167E77E7273" xlink:to="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_58F9AADF11B1F227DC955167E77F0B96" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_58F9AADF11B1F227DC955167E77F0B96" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7B62DD270598CF2212DF5167E77F47DE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_7B62DD270598CF2212DF5167E77F47DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75E9C33BA177B07AD3AB5167E77F7551" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_75E9C33BA177B07AD3AB5167E77F7551" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4B5FA2A4B6EA24A9B920516A8684D9BD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4B5FA2A4B6EA24A9B920516A8684D9BD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_51AB23E214FB64351B1C5167E77F7F9B" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_51AB23E214FB64351B1C5167E77F7F9B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_856CE1B6BB49327FDB4E5167E77FAD5E" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_856CE1B6BB49327FDB4E5167E77FAD5E" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PatentTaxRefundPercentage" xlink:label="loc_abus_PatentTaxRefundPercentage_164089C14E76D2E1C4DB5167E77F6527" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_abus_PatentTaxRefundPercentage_164089C14E76D2E1C4DB5167E77F6527" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_E4B2E49E22D7D5B052705167E77FC928" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_E4B2E49E22D7D5B052705167E77FC928" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_BBE3CA45116EED5036325167E77FC3F0" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_BBE3CA45116EED5036325167E77FC3F0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_37D2CE24EA3B0C921A475167E77F2BCE" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_IncomeTaxesDetailsLineItems_1200ACDC4A92FB6D552F5167E77F67B0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_37D2CE24EA3B0C921A475167E77F2BCE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesIncomeTaxReconciliationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9C65966DE5197BEE932F5167E77A5C32" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E939593931D164C298065167E77AF01B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9C65966DE5197BEE932F5167E77A5C32" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_E939593931D164C298065167E77AF01B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2AC82367FEF2C4FA37ED5167E77AB3DD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9C65966DE5197BEE932F5167E77A5C32" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_2AC82367FEF2C4FA37ED5167E77AB3DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_37C1846D313D52E2192C5167E77AF8DE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9C65966DE5197BEE932F5167E77A5C32" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_37C1846D313D52E2192C5167E77AF8DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_BA2E14388FF4C2D10B555167E77AE20C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9C65966DE5197BEE932F5167E77A5C32" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_BA2E14388FF4C2D10B555167E77AE20C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8A91EC1BBEFC5134791D5167E77A6345" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9C65966DE5197BEE932F5167E77A5C32" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8A91EC1BBEFC5134791D5167E77A6345" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_D541F50F9A522C8287C65167E77A7426" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9C65966DE5197BEE932F5167E77A5C32" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_D541F50F9A522C8287C65167E77A7426" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_FF051512FA4430C0CC5133A201B3FE1B" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9069F009E8698408AC9D33A201B30EE5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FF051512FA4430C0CC5133A201B3FE1B" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9069F009E8698408AC9D33A201B30EE5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_EC882315329CCD43DD9333A201B395DA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_FF051512FA4430C0CC5133A201B3FE1B" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_EC882315329CCD43DD9333A201B395DA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnaudited" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_C1B59CDBF8E9D2F19B6D2EAA5FDA055C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_BF40EF2F8E3065677C4E2EAA5FDAABEA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_C1B59CDBF8E9D2F19B6D2EAA5FDA055C" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_BF40EF2F8E3065677C4E2EAA5FDAABEA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_DE02A6B201E9EA1ABCA133E8637B6FF2" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5BF7F76F95B2C4D9453C33A201780423" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_DE02A6B201E9EA1ABCA133E8637B6FF2" xlink:to="loc_us-gaap_Revenues_5BF7F76F95B2C4D9453C33A201780423" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_95C99CB7AF281E9DB5BB33A20178F0C7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_DE02A6B201E9EA1ABCA133E8637B6FF2" xlink:to="loc_us-gaap_OperatingIncomeLoss_95C99CB7AF281E9DB5BB33A20178F0C7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E84C0C57137249EF115433A20179A5D0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_DE02A6B201E9EA1ABCA133E8637B6FF2" xlink:to="loc_us-gaap_NetIncomeLoss_E84C0C57137249EF115433A20179A5D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_2444F4231CF34194505E33A20179BA25" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_DE02A6B201E9EA1ABCA133E8637B6FF2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_2444F4231CF34194505E33A20179BA25" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_362D3EBE7C78868BF0B433A2017A1ED0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E910DE13C9C2C013263933A2017A7C6C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_362D3EBE7C78868BF0B433A2017A1ED0" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_E910DE13C9C2C013263933A2017A7C6C" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_28111DC59FA0ABED43A92EAA60D8E657" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_F54FC064FA5EBDA17FD82EAA60D8E5AE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_28111DC59FA0ABED43A92EAA60D8E657" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_F54FC064FA5EBDA17FD82EAA60D8E5AE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_A82AC769DA8B12C2257B3A13C6027A0D" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_A82AC769DA8B12C2257B3A13C6027A0D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_C1D89D513DDD0E1138703A13C6039200" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_C1D89D513DDD0E1138703A13C6039200" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_C1D89D513DDD0E1138703A13C6039200" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_9EBE9A1E2AFA965807FC3A13C6043BCE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FC8A35B90EA7DB2AC74A3A13C603489D" xlink:to="loc_abus_ArbutusInc.Member_9EBE9A1E2AFA965807FC3A13C6043BCE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7DAEFBE4B6FFC49ECF533A13C604771F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7DAEFBE4B6FFC49ECF533A13C604771F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7DAEFBE4B6FFC49ECF533A13C604771F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDCyclophilinsMember" xlink:label="loc_abus_IPRDCyclophilinsMember_DB47B65C1986953429563A13C6044BEA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:to="loc_abus_IPRDCyclophilinsMember_DB47B65C1986953429563A13C6044BEA" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDImmuneModulatorsMember" xlink:label="loc_abus_IPRDImmuneModulatorsMember_394330645A4A821AA7E13A13DDF1AAE9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:to="loc_abus_IPRDImmuneModulatorsMember_394330645A4A821AA7E13A13DDF1AAE9" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDAntigenInhibitorsMember" xlink:label="loc_abus_IPRDAntigenInhibitorsMember_C646387965FB4F4D07543A13DF12471D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:to="loc_abus_IPRDAntigenInhibitorsMember_C646387965FB4F4D07543A13DF12471D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDcccDNASterilizersMember" xlink:label="loc_abus_IPRDcccDNASterilizersMember_27D502512DF3DAF6E18B3A13DFA927ED" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2C73D7D4EC7849535FB23A13C6042AA8" xlink:to="loc_abus_IPRDcccDNASterilizersMember_27D502512DF3DAF6E18B3A13DFA927ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_552AFF5E4B84B767BA953A13C6045A77" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_925EA97EADB9A55BF45F3A13C603E14C" xlink:to="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_552AFF5E4B84B767BA953A13C6045A77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A0F0A4816FF1E52C9AD93A13C604CE8B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_552AFF5E4B84B767BA953A13C6045A77" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_A0F0A4816FF1E52C9AD93A13C604CE8B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_45C48AB4171DDAC2F0085212D70F0A12" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_45C48AB4171DDAC2F0085212D70F0A12" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_37903BC987CBF4F169035212D70F319B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_37903BC987CBF4F169035212D70F319B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9F222167F3FAE96B4F105212D70F0781" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_37903BC987CBF4F169035212D70F319B" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9F222167F3FAE96B4F105212D70F0781" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDCyclophilinsMember" xlink:label="loc_abus_IPRDCyclophilinsMember_EBB0D56E879A49F2776E5212D70F2578" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9F222167F3FAE96B4F105212D70F0781" xlink:to="loc_abus_IPRDCyclophilinsMember_EBB0D56E879A49F2776E5212D70F2578" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OtherIPRDMember" xlink:label="loc_abus_OtherIPRDMember_0C4ADBCBDC3E740E94B15212D70FA751" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9F222167F3FAE96B4F105212D70F0781" xlink:to="loc_abus_OtherIPRDMember_0C4ADBCBDC3E740E94B15212D70FA751" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaap_GoodwillMember_2EBE929CC167E51978245212D70F14FA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9F222167F3FAE96B4F105212D70F0781" xlink:to="loc_us-gaap_GoodwillMember_2EBE929CC167E51978245212D70F14FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ADA3AE84E6F3DD2F54A85212D70F7048" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ADA3AE84E6F3DD2F54A85212D70F7048" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A74983C38FCE09B15CBB5212D710F2AE" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ADA3AE84E6F3DD2F54A85212D70F7048" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A74983C38FCE09B15CBB5212D710F2AE" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_C930ACCB821A3F6CD6995212D71049B1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A74983C38FCE09B15CBB5212D710F2AE" xlink:to="loc_abus_ArbutusInc.Member_C930ACCB821A3F6CD6995212D71049B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F7E3AAD8397EE3274DBF5212D710195B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:to="loc_us-gaap_AwardTypeAxis_F7E3AAD8397EE3274DBF5212D710195B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFC8F8CF87F4BDCD858D5212D7101FDA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_F7E3AAD8397EE3274DBF5212D710195B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFC8F8CF87F4BDCD858D5212D7101FDA" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_SharesIssuedWithoutSubjectsMember" xlink:label="loc_abus_SharesIssuedWithoutSubjectsMember_A673B4697A8211AA20205212D7101170" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFC8F8CF87F4BDCD858D5212D7101FDA" xlink:to="loc_abus_SharesIssuedWithoutSubjectsMember_A673B4697A8211AA20205212D7101170" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_SharesIssuedSubjectToRepurchaseProvisionMember" xlink:label="loc_abus_SharesIssuedSubjectToRepurchaseProvisionMember_947511718FF725445F6C5212D7106B32" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFC8F8CF87F4BDCD858D5212D7101FDA" xlink:to="loc_abus_SharesIssuedSubjectToRepurchaseProvisionMember_947511718FF725445F6C5212D7106B32" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AbutusStockOptionsMember" xlink:label="loc_abus_AbutusStockOptionsMember_C2B0BFBF587756B584F05212D7102ACA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFC8F8CF87F4BDCD858D5212D7101FDA" xlink:to="loc_abus_AbutusStockOptionsMember_C2B0BFBF587756B584F05212D7102ACA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5114EA4584A73325BE605212D710F1E1" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5114EA4584A73325BE605212D710F1E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C43457796E06B03FC5EF5212D71066E5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5114EA4584A73325BE605212D710F1E1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C43457796E06B03FC5EF5212D71066E5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_60E277CB6FFC9AAB99055212D710A6A9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_C43457796E06B03FC5EF5212D71066E5" xlink:to="loc_us-gaap_SubsequentEventMember_60E277CB6FFC9AAB99055212D710A6A9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_4A34B47764DEB65297735212D7108185" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:to="loc_us-gaap_StatementScenarioAxis_4A34B47764DEB65297735212D7108185" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_F7BA3F5F7DC5911B22B35212D7102AD2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_4A34B47764DEB65297735212D7108185" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_F7BA3F5F7DC5911B22B35212D7102AD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_CD885FBD127974B850C45212D71017CC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_F7BA3F5F7DC5911B22B35212D7102AD2" xlink:to="loc_us-gaap_ScenarioForecastMember_CD885FBD127974B850C45212D71017CC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_21790E9EB3B802B6AA515212D70FBCAA" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AB03177D28D1491BA1235212D710F828" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_AB03177D28D1491BA1235212D710F828" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1B2533240B72B35B1A175212D7109FE4" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1B2533240B72B35B1A175212D7109FE4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_0618D0C05784024CEC415212D711CF34" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_0618D0C05784024CEC415212D711CF34" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0416DA2D675799C2D5045212D7110096" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_0416DA2D675799C2D5045212D7110096" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_DE40DC8E8A81531D07D25212D711EF7A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_DE40DC8E8A81531D07D25212D711EF7A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_62E777FFC7E611CFC8685212D7117B22" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_62E777FFC7E611CFC8685212D7117B22" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_33B10726905EC1F00A2F5212D711CE86" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_33B10726905EC1F00A2F5212D711CE86" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_C3B2355E02D05DBF21675212D711660F" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_C3B2355E02D05DBF21675212D711660F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_4A7554225FD727541E7C5212D711A8B7" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_4A7554225FD727541E7C5212D711A8B7" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:label="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_05415629A009C4AA93D75212D711552B" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_05415629A009C4AA93D75212D711552B" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice" xlink:label="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_D04CD03E2C883AAE16665212D711CA43" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_D04CD03E2C883AAE16665212D711CA43" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter" xlink:label="loc_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter_4E8C1CB19ABE3EAAF0DB5212D711701D" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter_4E8C1CB19ABE3EAAF0DB5212D711701D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_B993EE1331A4BCBDFFB55212D711B07B" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_B993EE1331A4BCBDFFB55212D711B07B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_10CA073E7D89A3F91B215212D71128CD" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_10CA073E7D89A3F91B215212D71128CD" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_StockRepurchaseRightsExpirationRateShares" xlink:label="loc_abus_StockRepurchaseRightsExpirationRateShares_EE09A63FE0F3B0466E035212D711C745" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_abus_StockRepurchaseRightsExpirationRateShares_EE09A63FE0F3B0466E035212D711C745" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B69786A3DE65311C4EB45212D711A4AE" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_B69786A3DE65311C4EB45212D711A4AE" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PeriodofEstimatedCashFlowsUsedInFairValue" xlink:label="loc_abus_PeriodofEstimatedCashFlowsUsedInFairValue_574514D996C963B16E2C5212D7115A5F" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_abus_PeriodofEstimatedCashFlowsUsedInFairValue_574514D996C963B16E2C5212D7115A5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_5394AD3D3DE09BE7E8DB5212D711D22E" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_5394AD3D3DE09BE7E8DB5212D711D22E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC7C123EDE9FE6BCED2C5212D711A7E8" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BC7C123EDE9FE6BCED2C5212D711A7E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_D40D8ECC8DE7A90C03675212D7119C57" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_D40D8ECC8DE7A90C03675212D7119C57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DAAE12CA70B75B9C5D515212D711DF79" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DAAE12CA70B75B9C5D515212D711DF79" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_19030CED2B3257713A1D5212D7111139" xlink:type="locator" />
    <presentationArc order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_19030CED2B3257713A1D5212D7111139" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_FC7784F0A21EC3393A525212D712E720" xlink:type="locator" />
    <presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_FC7784F0A21EC3393A525212D712E720" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_308CA0BF2732998B0D9D5212D712BC3E" xlink:type="locator" />
    <presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_Goodwill_308CA0BF2732998B0D9D5212D712BC3E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_C320E3E8157BD26670E65212D712DAFE" xlink:type="locator" />
    <presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_NumberOfReportingUnits_C320E3E8157BD26670E65212D712DAFE" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MarketCapitalizationValue" xlink:label="loc_abus_MarketCapitalizationValue_1B8EC0F28BDA116DA9F45212D7127E3A" xlink:type="locator" />
    <presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_abus_MarketCapitalizationValue_1B8EC0F28BDA116DA9F45212D7127E3A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_716C419C27E3E1C5CCB95212D71248DB" xlink:type="locator" />
    <presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_716C419C27E3E1C5CCB95212D71248DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_CF5347B547C02E8182EA5212D71249B6" xlink:type="locator" />
    <presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_StockholdersEquity_CF5347B547C02E8182EA5212D71249B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_EBA2FB9C233A9F1A73F05212D71269B4" xlink:type="locator" />
    <presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_96FFF739145A2397B0DF5212D710D71B" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_EBA2FB9C233A9F1A73F05212D71269B4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3DEC95A8C0BD1352577D39D58A8DC30E" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_10D0039C43A0217527F439DA22A634BC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3DEC95A8C0BD1352577D39D58A8DC30E" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_10D0039C43A0217527F439DA22A634BC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_92A0C0EED9C5556D81F139D6A40F02F7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_10D0039C43A0217527F439DA22A634BC" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_92A0C0EED9C5556D81F139D6A40F02F7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_D0E4D0B319B22546327F39D70A0BEEBF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_10D0039C43A0217527F439DA22A634BC" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax_D0E4D0B319B22546327F39D70A0BEEBF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_25730E4980C8189DDCCA39D7440982D1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_10D0039C43A0217527F439DA22A634BC" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_25730E4980C8189DDCCA39D7440982D1" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted" xlink:label="loc_abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted_A5B637ACF5C333E3CCBC39D836219E16" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationAbstract_10D0039C43A0217527F439DA22A634BC" xlink:to="loc_abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted_A5B637ACF5C333E3CCBC39D836219E16" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_77D142558FF2C7B745B851CB6D1440D0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C46C711BC116DAF450F251CB6D1460C1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_77D142558FF2C7B745B851CB6D1440D0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C46C711BC116DAF450F251CB6D1460C1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E275D00ADF3F2611127351CB6D14A06D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C46C711BC116DAF450F251CB6D1460C1" xlink:to="loc_us-gaap_AwardTypeAxis_E275D00ADF3F2611127351CB6D14A06D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DCB61D8ACC390A4604BF51CB6D144CF9" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_E275D00ADF3F2611127351CB6D14A06D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DCB61D8ACC390A4604BF51CB6D144CF9" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_SharesIssuedWithoutSubjectsMember" xlink:label="loc_abus_SharesIssuedWithoutSubjectsMember_0F08D792454927DE5DC251CB6D14846C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DCB61D8ACC390A4604BF51CB6D144CF9" xlink:to="loc_abus_SharesIssuedWithoutSubjectsMember_0F08D792454927DE5DC251CB6D14846C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_SharesIssuedSubjectToRepurchaseProvisionMember" xlink:label="loc_abus_SharesIssuedSubjectToRepurchaseProvisionMember_46B8192EA35F480A4F9B51CB6D14EA69" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DCB61D8ACC390A4604BF51CB6D144CF9" xlink:to="loc_abus_SharesIssuedSubjectToRepurchaseProvisionMember_46B8192EA35F480A4F9B51CB6D14EA69" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_CommonShareIssuableForArbutusInc.StockOptionsMember" xlink:label="loc_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_116FC7FE75077C8F9CF651CB6D14116C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DCB61D8ACC390A4604BF51CB6D144CF9" xlink:to="loc_abus_CommonShareIssuableForArbutusInc.StockOptionsMember_116FC7FE75077C8F9CF651CB6D14116C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2F9D421FE3D9CC38D4C251CB6D1429A0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C46C711BC116DAF450F251CB6D1460C1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2F9D421FE3D9CC38D4C251CB6D1429A0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F81E35CE276B9F0068BE51CB6D144985" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2F9D421FE3D9CC38D4C251CB6D1429A0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F81E35CE276B9F0068BE51CB6D144985" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_FB27565DED7184CEFA7551CB6D14345B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F81E35CE276B9F0068BE51CB6D144985" xlink:to="loc_abus_ArbutusInc.Member_FB27565DED7184CEFA7551CB6D14345B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2D27FD6A272C9A5CEE3251CB6D1409B7" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C46C711BC116DAF450F251CB6D1460C1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_2D27FD6A272C9A5CEE3251CB6D1409B7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_EDA7D6A4098DD11B12A051CB6D154E4A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2D27FD6A272C9A5CEE3251CB6D1409B7" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_EDA7D6A4098DD11B12A051CB6D154E4A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2D27FD6A272C9A5CEE3251CB6D1409B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0A37BAAD5F7C7F05D24351CB6D156251" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0A37BAAD5F7C7F05D24351CB6D156251" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2F1E2C3FAD6E173FA29951CB6D1522FC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2F1E2C3FAD6E173FA29951CB6D1522FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_AE17E243C5596CC4BBBA51CB6D15097B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_AE17E243C5596CC4BBBA51CB6D15097B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_93FFF539FC1634C07E2451CB6D1592D4" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_93FFF539FC1634C07E2451CB6D1592D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_DCA215A54146F89EEE8B51CB6D157EEE" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_DCA215A54146F89EEE8B51CB6D157EEE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2A4CE65537858CDFF74551CB6D15961A" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_Goodwill_2A4CE65537858CDFF74551CB6D15961A" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:label="loc_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_0282D059BE178527EDF351CB6D1588BF" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_0282D059BE178527EDF351CB6D1588BF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_33DD8848FF172016FA3751CB6D1512E9" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_33DD8848FF172016FA3751CB6D1512E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FD8A310688627294E59B51CB6D16C0E2" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_0FDFA34A5D1D1312790451CB6D15EF95" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FD8A310688627294E59B51CB6D16C0E2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_54DD8297AF47F684CC8651CB6D16494E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2D27FD6A272C9A5CEE3251CB6D1409B7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_54DD8297AF47F684CC8651CB6D16494E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_080CF37FD752582FBE7351CB6D0963C7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA0EA67F1374786CEC5651CB6D09768F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_080CF37FD752582FBE7351CB6D0963C7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA0EA67F1374786CEC5651CB6D09768F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_09D32284BB0922B4803151CB6D09EAE8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA0EA67F1374786CEC5651CB6D09768F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_09D32284BB0922B4803151CB6D09EAE8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3C528CB91BA6E8F3651251CB6D0AF64B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_09D32284BB0922B4803151CB6D09EAE8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3C528CB91BA6E8F3651251CB6D0AF64B" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_AEB198D4993F32F4F1E151CB6D0A9F70" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3C528CB91BA6E8F3651251CB6D0AF64B" xlink:to="loc_abus_ArbutusInc.Member_AEB198D4993F32F4F1E151CB6D0A9F70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_FA0EA67F1374786CEC5651CB6D09768F" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_5FC343C35067B7DCA00A51CB6D0ABFCF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_5FC343C35067B7DCA00A51CB6D0ABFCF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3052BC75057FDB7E3A0651CB6D0AA0AC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3052BC75057FDB7E3A0651CB6D0AA0AC" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_0ABEF0A5144EECC34B3D51CB6D0AAB13" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash_0ABEF0A5144EECC34B3D51CB6D0AAB13" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5112A84A601EB8B5909051CB6D0A193C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_5112A84A601EB8B5909051CB6D0A193C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_D67CD2B1765A5135675E51CB6D0AFF1D" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets_D67CD2B1765A5135675E51CB6D0AFF1D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_968FC3F69DD1108AEE2551CB6D0A0881" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_968FC3F69DD1108AEE2551CB6D0A0881" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_F994557C1F2FEC245D7D51CB6D0AC26F" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable_F994557C1F2FEC245D7D51CB6D0AC26F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_57CD58632110A0A0273651CB6D0ADF83" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_57CD58632110A0A0273651CB6D0ADF83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_E60F3AC6F63E810C8A1F51CB6D0AF9F5" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment_E60F3AC6F63E810C8A1F51CB6D0AF9F5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_C42C737C946E035E6D8B51CB6D0AF301" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_C42C737C946E035E6D8B51CB6D0AF301" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1448234CBFAF1CA71EA651CB6D0AC236" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1448234CBFAF1CA71EA651CB6D0AC236" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_9A949442672DDCD4AC4951CB6D0AE1EC" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_Goodwill_9A949442672DDCD4AC4951CB6D0AE1EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_681597C6610D6994F12751CB6D0A7DAC" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_681597C6610D6994F12751CB6D0A7DAC" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities" xlink:label="loc_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_E1536AE2C98E4366420351CB6D0A0385" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities_E1536AE2C98E4366420351CB6D0A0385" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_55F00CCC5E82861C76B751CB6D0BC07C" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities_55F00CCC5E82861C76B751CB6D0BC07C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_FB88DFD0B79628BBE26251CB6D0B6100" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_FB88DFD0B79628BBE26251CB6D0B6100" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_89DE3A2DB5DD9CC4A01C51CB6D0B1D89" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities_89DE3A2DB5DD9CC4A01C51CB6D0B1D89" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FA9EC989581E75524BFF51CB6D0B87E0" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent_FA9EC989581E75524BFF51CB6D0B87E0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability" xlink:label="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_CAE885E4D45C09D5BD3D51CB6D0B68FE" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability_CAE885E4D45C09D5BD3D51CB6D0B68FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2537C2E385D844FC9E3B51CB6D0BBCD2" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2537C2E385D844FC9E3B51CB6D0BBCD2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_F9D57A4DE30FEBCDB81051CB6D0B64C4" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_B47F34A4906588F4933D51CB6D0A42CB" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred_F9D57A4DE30FEBCDB81051CB6D0B64C4" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_E653712FDF6DF99DCF963973458C34DE" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_FAD630DC7A039D9E155A39734BD37261" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_E653712FDF6DF99DCF963973458C34DE" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_FAD630DC7A039D9E155A39734BD37261" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0067213C9E81218D9EF839734BD3E0B1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_FAD630DC7A039D9E155A39734BD37261" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0067213C9E81218D9EF839734BD3E0B1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BA031A823CE4C7A4706639734BD3FD8D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0067213C9E81218D9EF839734BD3E0B1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BA031A823CE4C7A4706639734BD3FD8D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_90353BBFA04F2CFD431B397917F11D30" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_BA031A823CE4C7A4706639734BD3FD8D" xlink:to="loc_abus_ArbutusInc.Member_90353BBFA04F2CFD431B397917F11D30" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6BC5CF12D6CCA485E80D39734BD82B7F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_FAD630DC7A039D9E155A39734BD37261" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6BC5CF12D6CCA485E80D39734BD82B7F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EF0F05B11A84566279539734BDF385C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6BC5CF12D6CCA485E80D39734BD82B7F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EF0F05B11A84566279539734BDF385C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDCyclophilinsMember" xlink:label="loc_abus_IPRDCyclophilinsMember_F9512297E021CFDF585D3979D96A4CC8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EF0F05B11A84566279539734BDF385C" xlink:to="loc_abus_IPRDCyclophilinsMember_F9512297E021CFDF585D3979D96A4CC8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDImmuneModulatorsMember" xlink:label="loc_abus_IPRDImmuneModulatorsMember_F76AB9FCA0201D5733ED397C435FDCF7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EF0F05B11A84566279539734BDF385C" xlink:to="loc_abus_IPRDImmuneModulatorsMember_F76AB9FCA0201D5733ED397C435FDCF7" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDAntigenInhibitorsMember" xlink:label="loc_abus_IPRDAntigenInhibitorsMember_B3084CD478FA3A62BE49397B12B960A5" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EF0F05B11A84566279539734BDF385C" xlink:to="loc_abus_IPRDAntigenInhibitorsMember_B3084CD478FA3A62BE49397B12B960A5" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IPRDcccDNASterilizersMember" xlink:label="loc_abus_IPRDcccDNASterilizersMember_20A58E04C4CD859CCB37397B88921250" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EF0F05B11A84566279539734BDF385C" xlink:to="loc_abus_IPRDcccDNASterilizersMember_20A58E04C4CD859CCB37397B88921250" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_337152E809B755596E4C39734BDF0E3E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_FAD630DC7A039D9E155A39734BD37261" xlink:to="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_337152E809B755596E4C39734BDF0E3E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BF21C18294ABF21D54A83974AE33AAFB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_337152E809B755596E4C39734BDF0E3E" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_BF21C18294ABF21D54A83974AE33AAFB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_328C2A9ECD361E8519C652F9486ABB95" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8EB1C7860E36339978A352F9486B4AC2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_328C2A9ECD361E8519C652F9486ABB95" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_8EB1C7860E36339978A352F9486B4AC2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_F130DFEB3FDF34B4551D52F9486BD2CB" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_328C2A9ECD361E8519C652F9486ABB95" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_F130DFEB3FDF34B4551D52F9486BD2CB" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock" xlink:label="loc_abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock_A4BB8FA7DEB2732CF5AC52F9486B7417" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_328C2A9ECD361E8519C652F9486ABB95" xlink:to="loc_abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock_A4BB8FA7DEB2732CF5AC52F9486B7417" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A04A525846EA81D7BA3F52F9486B84EC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_328C2A9ECD361E8519C652F9486ABB95" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_A04A525846EA81D7BA3F52F9486B84EC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:label="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_C7B161B55EE25EE5D7C752F9486B3CE1" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_328C2A9ECD361E8519C652F9486ABB95" xlink:to="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_C7B161B55EE25EE5D7C752F9486B3CE1" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperations" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2963F51C63C8A3730BBA2EADBA805024" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_ADDEF7DB119D8EFF19CF2EAA6100B6C5" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2963F51C63C8A3730BBA2EADBA805024" xlink:to="loc_us-gaap_NatureOfOperations_ADDEF7DB119D8EFF19CF2EAA6100B6C5" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperationsNarrativeDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C9F1D8159D2BA4383D15167E8213840" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements" xlink:label="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_DEB18DDF44E93F7E0B935167E8210D41" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8C9F1D8159D2BA4383D15167E8213840" xlink:to="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_DEB18DDF44E93F7E0B935167E8210D41" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipment" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_79107D7CA86C3E78A4FC2EAA60B2CC80" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C5F059225498D4EE872C2EAA60B2C477" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_79107D7CA86C3E78A4FC2EAA60B2CC80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_C5F059225498D4EE872C2EAA60B2C477" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_23F6B5EAB665D5B2F8E734C3A8A1D592" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_37BC4FF95509D87A617734C3A8A1D165" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_23F6B5EAB665D5B2F8E734C3A8A1D592" xlink:to="loc_us-gaap_AssetImpairmentCharges_37BC4FF95509D87A617734C3A8A1D165" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentPropertyAndEquipmentSummaryDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D31E259E37E359B5EB2A3F2E88BCEE99" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FA276111290DDBECF6733F2E88BC4F0D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_D31E259E37E359B5EB2A3F2E88BCEE99" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FA276111290DDBECF6733F2E88BC4F0D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0386E6281FB6502236143F2E88BC070C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FA276111290DDBECF6733F2E88BC4F0D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0386E6281FB6502236143F2E88BC070C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5DF4DB61BD84B67566CD3F2E88BC32B3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0386E6281FB6502236143F2E88BC070C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5DF4DB61BD84B67566CD3F2E88BC32B3" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_LaboratoryEquipmentMember" xlink:label="loc_abus_LaboratoryEquipmentMember_0F7CDB34389790A0D3733F2E88BC478A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5DF4DB61BD84B67566CD3F2E88BC32B3" xlink:to="loc_abus_LaboratoryEquipmentMember_0F7CDB34389790A0D3733F2E88BC478A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3DA5FB6FC85B1DE19F243F2E88BC4561" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5DF4DB61BD84B67566CD3F2E88BC32B3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3DA5FB6FC85B1DE19F243F2E88BC4561" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_331F65307F3885B46FC43F2E88BC5F3F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5DF4DB61BD84B67566CD3F2E88BC32B3" xlink:to="loc_us-gaap_ComputerEquipmentMember_331F65307F3885B46FC43F2E88BC5F3F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_B08F490DDE8E3695B15C3F2E88BC0DED" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5DF4DB61BD84B67566CD3F2E88BC32B3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_B08F490DDE8E3695B15C3F2E88BC0DED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_43843726237D56A104D43F2E88BC389F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_FA276111290DDBECF6733F2E88BC4F0D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_43843726237D56A104D43F2E88BC389F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_04131AF8006BA89D74A03F2E88BCE549" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_43843726237D56A104D43F2E88BC389F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_04131AF8006BA89D74A03F2E88BCE549" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3FB953825CDED7ADDBF83F2E88BD96DC" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_43843726237D56A104D43F2E88BC389F" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3FB953825CDED7ADDBF83F2E88BD96DC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_65D33A342BD8A089708F3F2E88BDC74E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_43843726237D56A104D43F2E88BC389F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_65D33A342BD8A089708F3F2E88BDC74E" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6E8176FE5E3520A2B9733329B68D1741" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_DDC97D583ED7F077CE953329B68D3629" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6E8176FE5E3520A2B9733329B68D1741" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_DDC97D583ED7F077CE953329B68D3629" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapital" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_CA0D0467DDFC585EE7492EAA60A40F09" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8C0B13743D098164ABC62EAA60A4E6EB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_CA0D0467DDFC585EE7492EAA60A40F09" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8C0B13743D098164ABC62EAA60A4E6EB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalBlackScholesOptionPricingAssumptionsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_7504B4C92F97C660C9D84DC688B693E3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_C35E23A523CD8B12C7C04DC688B625AA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7504B4C92F97C660C9D84DC688B693E3" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_C35E23A523CD8B12C7C04DC688B625AA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_E8D6BA1C0D7C959174B54DC688B628AF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7504B4C92F97C660C9D84DC688B693E3" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_E8D6BA1C0D7C959174B54DC688B628AF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_6E03464891E57A65AC7C4DC688B65C5F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7504B4C92F97C660C9D84DC688B693E3" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_6E03464891E57A65AC7C4DC688B65C5F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_3841C9046CFD56FB29ED4DC688B69EF3" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7504B4C92F97C660C9D84DC688B693E3" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_3841C9046CFD56FB29ED4DC688B69EF3" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_FairValueOfWarrantsOutstandingPerWarrant" xlink:label="loc_abus_FairValueOfWarrantsOutstandingPerWarrant_C77ECA9ED9CE65075E2F4DC688B6DB48" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7504B4C92F97C660C9D84DC688B693E3" xlink:to="loc_abus_FairValueOfWarrantsOutstandingPerWarrant_C77ECA9ED9CE65075E2F4DC688B6DB48" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_7761D40B42AD6866AD324DC688B6C197" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7504B4C92F97C660C9D84DC688B693E3" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_7761D40B42AD6866AD324DC688B6C197" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_436FD6508F3EE55472304DC688B6FA57" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7504B4C92F97C660C9D84DC688B693E3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_436FD6508F3EE55472304DC688B6FA57" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_79B33FB8C964EABC8FE55167E7B6C2CB" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F0CC78B92735225F2ED5167E7B69DED" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_79B33FB8C964EABC8FE55167E7B6C2CB" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F0CC78B92735225F2ED5167E7B69DED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6C145A733D7C1F9DB8C45167E7B68281" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F0CC78B92735225F2ED5167E7B69DED" xlink:to="loc_us-gaap_PlanNameAxis_6C145A733D7C1F9DB8C45167E7B68281" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6C145A733D7C1F9DB8C45167E7B68281" xlink:to="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_A2007PlanMember" xlink:label="loc_abus_A2007PlanMember_DFCFD00E94BC348181415167E7B68362" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:to="loc_abus_A2007PlanMember_DFCFD00E94BC348181415167E7B68362" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_A2011PlanMember" xlink:label="loc_abus_A2011PlanMember_2244ECDAF773052418E05167E7B7F65D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:to="loc_abus_A2011PlanMember_2244ECDAF773052418E05167E7B7F65D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_DesignatedPlansMember" xlink:label="loc_abus_DesignatedPlansMember_2A9C5AAD5021B6D0C31C5167E7B7DD11" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:to="loc_abus_DesignatedPlansMember_2A9C5AAD5021B6D0C31C5167E7B7DD11" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusPlansMember" xlink:label="loc_abus_ArbutusPlansMember_01B85777EEBFC08AA6E05167E7B70EB2" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:to="loc_abus_ArbutusPlansMember_01B85777EEBFC08AA6E05167E7B70EB2" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ProtivaOptionPlanMember" xlink:label="loc_abus_ProtivaOptionPlanMember_758A64C37CC4726B1B315167E7B73676" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:to="loc_abus_ProtivaOptionPlanMember_758A64C37CC4726B1B315167E7B73676" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OnCoreOptionPlanMember" xlink:label="loc_abus_OnCoreOptionPlanMember_C77ECD846FA425C42EE15167E7B78972" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_671DE7EFA02CCB49F36F5167E7B61E36" xlink:to="loc_abus_OnCoreOptionPlanMember_C77ECD846FA425C42EE15167E7B78972" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_45509FA86F212C6C7B715167E7B7C8CF" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F0CC78B92735225F2ED5167E7B69DED" xlink:to="loc_us-gaap_AwardTypeAxis_45509FA86F212C6C7B715167E7B7C8CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_45509FA86F212C6C7B715167E7B7C8CF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_CashlessExerciseProvisionMember" xlink:label="loc_abus_CashlessExerciseProvisionMember_C445A81D07EDE53799305167E7B7278D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8" xlink:to="loc_abus_CashlessExerciseProvisionMember_C445A81D07EDE53799305167E7B7278D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_RevisedNewCommonSharesMember" xlink:label="loc_abus_RevisedNewCommonSharesMember_5FD7FEFBD20D13E697915167E7B76AE3" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8" xlink:to="loc_abus_RevisedNewCommonSharesMember_5FD7FEFBD20D13E697915167E7B76AE3" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ProtivaShareOptionsMember" xlink:label="loc_abus_ProtivaShareOptionsMember_7C1C1AF21D8842B763D85167E7B768D8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8" xlink:to="loc_abus_ProtivaShareOptionsMember_7C1C1AF21D8842B763D85167E7B768D8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_EquivalentNumberOfCompanyCommonSharesMember" xlink:label="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_6A0809F109D28550486B5167E7B72CE0" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8" xlink:to="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_6A0809F109D28550486B5167E7B72CE0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member" xlink:label="loc_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member_6D7934BDCFFAA9890BD55167E7B77E97" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F764E4DFD5615D3343D75167E7B7FEA8" xlink:to="loc_abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member_6D7934BDCFFAA9890BD55167E7B77E97" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_41809F1EE245A892D89D5167E7B72CD6" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F0CC78B92735225F2ED5167E7B69DED" xlink:to="loc_us-gaap_RangeAxis_41809F1EE245A892D89D5167E7B72CD6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6F21AD289056B705EFF65167E7B70146" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_41809F1EE245A892D89D5167E7B72CD6" xlink:to="loc_us-gaap_RangeMember_6F21AD289056B705EFF65167E7B70146" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1288729F5D9009761A1F5167E7B71222" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6F21AD289056B705EFF65167E7B70146" xlink:to="loc_us-gaap_MaximumMember_1288729F5D9009761A1F5167E7B71222" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3F4CD740603E50B603DD5167E7B7ED37" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F0CC78B92735225F2ED5167E7B69DED" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3F4CD740603E50B603DD5167E7B7ED37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3F4CD740603E50B603DD5167E7B7ED37" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1" xlink:type="arc" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_F12CC58FEACD6D7C99CB5167E7B7DED1" xlink:to="loc_abus_CashlessExerciseProvisionMember_C445A81D07EDE53799305167E7B7278D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F0CC78B92735225F2ED5167E7B69DED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A676E5ACF0AC8F1E3A1D5167E7B81F13" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A676E5ACF0AC8F1E3A1D5167E7B81F13" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_78CE8D22830943E6AB0A5167E7B847C7" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_78CE8D22830943E6AB0A5167E7B847C7" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_NumberOfAdditionalSharesAuthorized" xlink:label="loc_abus_NumberOfAdditionalSharesAuthorized_6E1E1C51ACDF1F4E59705167E7B8FB70" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_NumberOfAdditionalSharesAuthorized_6E1E1C51ACDF1F4E59705167E7B8FB70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_33AE50CFAB9459B265D05167E7B8FA43" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_33AE50CFAB9459B265D05167E7B8FA43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_E1943F5AFC38FE4791675167E7B88E4B" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_E1943F5AFC38FE4791675167E7B88E4B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_2751674643DA86C7BF105167E7B8C0CD" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_2751674643DA86C7BF105167E7B8C0CD" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ProceedsFromIssuanceOfCommonStockNet" xlink:label="loc_abus_ProceedsFromIssuanceOfCommonStockNet_410C0FA3800328D69F795167E7B874DA" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_ProceedsFromIssuanceOfCommonStockNet_410C0FA3800328D69F795167E7B874DA" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_WarrantsExercised" xlink:label="loc_abus_WarrantsExercised_1D554D09E69546962A9D5167E7B80AE6" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_WarrantsExercised_1D554D09E69546962A9D5167E7B80AE6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_3135D87AACA36C7FFCA75167E7B8432B" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_3135D87AACA36C7FFCA75167E7B8432B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2E679E32D37A5DB094DD5167E7B8FC0F" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2E679E32D37A5DB094DD5167E7B8FC0F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_NumberofShareBasedCompensationPlans" xlink:label="loc_abus_NumberofShareBasedCompensationPlans_C0140F8F4777E1408F4D5167E7B883E1" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_NumberofShareBasedCompensationPlans_C0140F8F4777E1408F4D5167E7B883E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0F8C7D66BA15C2C06AD5167E7B89C13" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0F8C7D66BA15C2C06AD5167E7B89C13" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F22CE8E6D1563660D2BB5167E7B810B8" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F22CE8E6D1563660D2BB5167E7B810B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0E9277A09195225343E35167E7B87AF0" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0E9277A09195225343E35167E7B87AF0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments" xlink:label="loc_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments_AA3FEF8604D953A0C1EC51B41AC4E26F" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments_AA3FEF8604D953A0C1EC51B41AC4E26F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF187D84C94A4EE4635A5167E7B83500" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_DF187D84C94A4EE4635A5167E7B83500" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_67E2EABA08433FE9CFDD5167E7B8201C" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_67E2EABA08433FE9CFDD5167E7B8201C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A2975673089C1830397E5167E7B81248" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_A2975673089C1830397E5167E7B81248" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_6F88EFB84EAFF2C0202F5167E7B884C4" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_6F88EFB84EAFF2C0202F5167E7B884C4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7CCAD9899CBC118CFF085167E7B8E4A8" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7CCAD9899CBC118CFF085167E7B8E4A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_87D0F54F8C0FFA70AEF55167E7B9CA75" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_87D0F54F8C0FFA70AEF55167E7B9CA75" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_BF1FC3AB52D16F55E2765167E7B9FDD0" xlink:type="locator" />
    <presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_BF1FC3AB52D16F55E2765167E7B9FDD0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A1A2CC538DA6508A6DF15167E7B9DA42" xlink:type="locator" />
    <presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_A1A2CC538DA6508A6DF15167E7B9DA42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42414AFADED704E3B9DF5167E7B9FFD4" xlink:type="locator" />
    <presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_42414AFADED704E3B9DF5167E7B9FFD4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_881EDCEC404BBE5915315167E7B93EB9" xlink:type="locator" />
    <presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_881EDCEC404BBE5915315167E7B93EB9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F8035EA9C1F00EDDA5365167E7B9D606" xlink:type="locator" />
    <presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_F8035EA9C1F00EDDA5365167E7B9D606" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_invest_InvestmentOptionsExercisePrice_06829610CAC6DD40F74B5167E7B923A8" xlink:type="locator" />
    <presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_invest_InvestmentOptionsExercisePrice_06829610CAC6DD40F74B5167E7B923A8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_D8062F83DF1DC74DD09E5167E7B91060" xlink:type="locator" />
    <presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_D8062F83DF1DC74DD09E5167E7B91060" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6E6AA9825A372588585C5167E7B90099" xlink:type="locator" />
    <presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6E6AA9825A372588585C5167E7B90099" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_BEBA7E5DE9EB15DEF5CB5167E7B99C28" xlink:type="locator" />
    <presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_BEBA7E5DE9EB15DEF5CB5167E7B99C28" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_F52A78DE8DC18C71BB475167E7B984B2" xlink:type="locator" />
    <presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_F52A78DE8DC18C71BB475167E7B984B2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_B93B158D0139627058545167E7B9BE16" xlink:type="locator" />
    <presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_B93B158D0139627058545167E7B9BE16" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice" xlink:label="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_984B266233DF2214CB245167E7B9907B" xlink:type="locator" />
    <presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice_984B266233DF2214CB245167E7B9907B" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice" xlink:label="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_CEFA8866135C2E92E2885167E7B9AA47" xlink:type="locator" />
    <presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice_CEFA8866135C2E92E2885167E7B9AA47" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_897C057F0043F6910D315167E7B97D71" xlink:type="locator" />
    <presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_897C057F0043F6910D315167E7B97D71" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_006DD2DE990553A515EF5167E7B9842D" xlink:type="locator" />
    <presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_006DD2DE990553A515EF5167E7B9842D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62F439558F49F671D0925167E7B9B9E8" xlink:type="locator" />
    <presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62F439558F49F671D0925167E7B9B9E8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22AF587E8FDC606E7E975167E7B957B6" xlink:type="locator" />
    <presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22AF587E8FDC606E7E975167E7B957B6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_175CA4EC8F592EF6F6D75167E7B99023" xlink:type="locator" />
    <presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_175CA4EC8F592EF6F6D75167E7B99023" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PotentialProceedsOfAdditionalSharesAuthorized" xlink:label="loc_abus_PotentialProceedsOfAdditionalSharesAuthorized_E19275DA83E233A53C895167E7B97AFA" xlink:type="locator" />
    <presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8E5431DD1697617E42975167E7B868D2" xlink:to="loc_abus_PotentialProceedsOfAdditionalSharesAuthorized_E19275DA83E233A53C895167E7B97AFA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalLocationOfExpensesForStockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_DE16DA8B2F5AA3E4BEBB3E548BDD4821" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CCF1656A9C1B2842CCC3E548BDDC4D0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_DE16DA8B2F5AA3E4BEBB3E548BDD4821" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CCF1656A9C1B2842CCC3E548BDDC4D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_03E2EFD6FB0015B500413E548BDE3E90" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CCF1656A9C1B2842CCC3E548BDDC4D0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_03E2EFD6FB0015B500413E548BDE3E90" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_03E2EFD6FB0015B500413E548BDE3E90" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E6D0A0D1BBB64034517F3E548BDEE455" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E6D0A0D1BBB64034517F3E548BDEE455" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_CB8462D876406C71ADC23E548BDEF4E9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CDA4F042573B760410323E548BDE0AC2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_CB8462D876406C71ADC23E548BDEF4E9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8720897B7EFF6039DD443E548BDE5287" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0CCF1656A9C1B2842CCC3E548BDDC4D0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8720897B7EFF6039DD443E548BDE5287" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_8236D70CCCE2C662FC0E3E548BDE7612" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8720897B7EFF6039DD443E548BDE5287" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_8236D70CCCE2C662FC0E3E548BDE7612" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_B79BD04933AB4F49386752F92C23297F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0117766E9E546276930D52F92C23E504" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_B79BD04933AB4F49386752F92C23297F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0117766E9E546276930D52F92C23E504" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_35804D59C34BFDD6B29852F92C2307DD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0117766E9E546276930D52F92C23E504" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_35804D59C34BFDD6B29852F92C2307DD" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue" xlink:label="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F24FDA6FE8B92A144AD252F92C234679" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0117766E9E546276930D52F92C23E504" xlink:to="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F24FDA6FE8B92A144AD252F92C234679" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_505B895710777F28BC9E52F92C23DFC1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0117766E9E546276930D52F92C23E504" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_505B895710777F28BC9E52F92C23DFC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BC3D59815B4A0AD8B1B052F92C23F3DF" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0117766E9E546276930D52F92C23E504" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BC3D59815B4A0AD8B1B052F92C23F3DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_D5C60E4EF3381C66EE7152F92C23C0D8" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0117766E9E546276930D52F92C23E504" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_D5C60E4EF3381C66EE7152F92C23C0D8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue" xlink:label="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_940DCD01C4341D00F42E52F92C233EFB" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0117766E9E546276930D52F92C23E504" xlink:to="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_940DCD01C4341D00F42E52F92C233EFB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_AE782AF04B27CA7818BF52F92C23085C" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0117766E9E546276930D52F92C23E504" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_AE782AF04B27CA7818BF52F92C23085C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_CB4BBD309357BDF8852C52F92C28374F" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0117766E9E546276930D52F92C23E504" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_CB4BBD309357BDF8852C52F92C28374F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C61EE1622F112404C9D452F92C29AD48" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0117766E9E546276930D52F92C23E504" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C61EE1622F112404C9D452F92C29AD48" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue" xlink:label="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_8C40182D8486EA06EEDD52F92C296D91" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_0117766E9E546276930D52F92C23E504" xlink:to="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_8C40182D8486EA06EEDD52F92C296D91" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_9E8FDE585BF1838E161D52F945F256E0" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0E4AF06776F0199DE57552F945F2DADA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9E8FDE585BF1838E161D52F945F256E0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0E4AF06776F0199DE57552F945F2DADA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_18256D8DEC49D6C8260A52F945F3050F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0E4AF06776F0199DE57552F945F2DADA" xlink:to="loc_us-gaap_AwardTypeAxis_18256D8DEC49D6C8260A52F945F3050F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59F7C903575339B5162D52F945F3390F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_18256D8DEC49D6C8260A52F945F3050F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59F7C903575339B5162D52F945F3390F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_EquivalentNumberOfCompanyCommonSharesMember" xlink:label="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_3A22EA5F409B15A062B252F945F3ADBF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59F7C903575339B5162D52F945F3390F" xlink:to="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_3A22EA5F409B15A062B252F945F3ADBF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_0EFEC391FC83E94B3C8B52F945F33978" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0E4AF06776F0199DE57552F945F2DADA" xlink:to="loc_us-gaap_PlanNameAxis_0EFEC391FC83E94B3C8B52F945F33978" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_9D2AFE65E1A49D37F43952F945F8CE57" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0EFEC391FC83E94B3C8B52F945F33978" xlink:to="loc_us-gaap_PlanNameDomain_9D2AFE65E1A49D37F43952F945F8CE57" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OnCoreOptionPlanMember" xlink:label="loc_abus_OnCoreOptionPlanMember_31A0738B14C0A7E5CA2B52F945F8F1A1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9D2AFE65E1A49D37F43952F945F8CE57" xlink:to="loc_abus_OnCoreOptionPlanMember_31A0738B14C0A7E5CA2B52F945F8F1A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25562F6259A9EB5F01F652F945F84D91" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0E4AF06776F0199DE57552F945F2DADA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25562F6259A9EB5F01F652F945F84D91" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25562F6259A9EB5F01F652F945F84D91" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C6C041D77F36F7AFAB7852F945F80918" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_C6C041D77F36F7AFAB7852F945F80918" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue" xlink:label="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F100DBBCA5CBA944BD0552F945F89730" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:to="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_F100DBBCA5CBA944BD0552F945F89730" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5813E54093C66FC68C4352F945F878FA" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_5813E54093C66FC68C4352F945F878FA" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue" xlink:label="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_C6091C66B92A54C919BE52F945F94275" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:to="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue_C6091C66B92A54C919BE52F945F94275" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_B5044E515159DA721D9552F945F9C531" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_B5044E515159DA721D9552F945F9C531" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_85F7753C78C472D5958D52F945F97F9F" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_85F7753C78C472D5958D52F945F97F9F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue" xlink:label="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_54B03EDEBFC79C96996E52F945F9B5B6" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_785D04E46FF7863E1FD652F945F84813" xlink:to="loc_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue_54B03EDEBFC79C96996E52F945F9B5B6" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_11348673CEC0A436A1F451CB6C9E4803" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_11348673CEC0A436A1F451CB6C9E4803" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E4DB1AAB8812BF4283A051CB6C9E2152" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF" xlink:to="loc_us-gaap_AwardTypeAxis_E4DB1AAB8812BF4283A051CB6C9E2152" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_E4DB1AAB8812BF4283A051CB6C9E2152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_EquivalentNumberOfCompanyCommonSharesMember" xlink:label="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_146312698EE0506529AA51CB6C9FCB90" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1FD8BE2304AF1026771751CB6C9EE2F8" xlink:to="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_146312698EE0506529AA51CB6C9FCB90" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_10A136B0606997EDEC6351CB6C9F9A87" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF" xlink:to="loc_us-gaap_PlanNameAxis_10A136B0606997EDEC6351CB6C9F9A87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_10A136B0606997EDEC6351CB6C9F9A87" xlink:to="loc_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OnCoreOptionPlanMember" xlink:label="loc_abus_OnCoreOptionPlanMember_810B28D2585A8D9639EF51CB6C9F10E7" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7B7CE93F9BBD63FE3C0E51CB6C9F501D" xlink:to="loc_abus_OnCoreOptionPlanMember_810B28D2585A8D9639EF51CB6C9F10E7" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13C0B169F08E2991C98651CB6C9FA8A1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31B16BC6B568EFF67D3151CB6C9E87DF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13C0B169F08E2991C98651CB6C9FA8A1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13C0B169F08E2991C98651CB6C9FA8A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F82B44D7B8EDE82FCE2251CB6C9F13DD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F82B44D7B8EDE82FCE2251CB6C9F13DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23855B5812957BF382D851CB6C9F7DB0" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23855B5812957BF382D851CB6C9F7DB0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E6FC854EAF2E5EE4B68251CB6C9F1869" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E6FC854EAF2E5EE4B68251CB6C9F1869" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9946190883E509433E3351CB6CA02686" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9946190883E509433E3351CB6CA02686" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04A57E601EA009AEF0051CB6CA09251" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_D04A57E601EA009AEF0051CB6CA09251" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3287FD198CF5C1B0EE3E51CB6CA072A0" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_AC00F0155DC983A5E73C51CD0449C15F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3287FD198CF5C1B0EE3E51CB6CA072A0" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_19B020D4BC3F037A8CE152F946253E34" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7D835D6606146ADEB28452F94625D5B3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_19B020D4BC3F037A8CE152F946253E34" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7D835D6606146ADEB28452F94625D5B3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4914EDE118BC8715899352F946250808" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7D835D6606146ADEB28452F94625D5B3" xlink:to="loc_us-gaap_AwardTypeAxis_4914EDE118BC8715899352F946250808" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B83D4EAE668187EBB45552F94625D7C0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4914EDE118BC8715899352F946250808" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B83D4EAE668187EBB45552F94625D7C0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_EquivalentNumberOfCompanyCommonSharesMember" xlink:label="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_189CC06924A5D83B338952F9462537CF" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B83D4EAE668187EBB45552F94625D7C0" xlink:to="loc_abus_EquivalentNumberOfCompanyCommonSharesMember_189CC06924A5D83B338952F9462537CF" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_8432EDF5A61E802A340952F94626159B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7D835D6606146ADEB28452F94625D5B3" xlink:to="loc_us-gaap_PlanNameAxis_8432EDF5A61E802A340952F94626159B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2EF9691D950C3F0F168052F94626B2B0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8432EDF5A61E802A340952F94626159B" xlink:to="loc_us-gaap_PlanNameDomain_2EF9691D950C3F0F168052F94626B2B0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ProtivaShareOptionsMember" xlink:label="loc_abus_ProtivaShareOptionsMember_D852069F7474F2692FEA52F94626C22D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2EF9691D950C3F0F168052F94626B2B0" xlink:to="loc_abus_ProtivaShareOptionsMember_D852069F7474F2692FEA52F94626C22D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E4D614193D106D04593852F9462649D0" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7D835D6606146ADEB28452F94625D5B3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E4D614193D106D04593852F9462649D0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E4D614193D106D04593852F9462649D0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7F06266E486AEC7D023E52F94626D3D8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7F06266E486AEC7D023E52F94626D3D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4A2BB3D19B9F9D1E80C452F946262F5B" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4A2BB3D19B9F9D1E80C452F946262F5B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E96FA42D5D464693658852F94626495C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E96FA42D5D464693658852F94626495C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3856F20620A8BFDE93D152F94626F23E" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3856F20620A8BFDE93D152F94626F23E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_D683FE0735DCE072CC7752F946260047" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_D683FE0735DCE072CC7752F946260047" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_A045A92E12595C508D7B52F9462B7EBB" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEE34A42B9FCAFDEC9EF52F94626D296" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_A045A92E12595C508D7B52F9462B7EBB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalStockOptionActivityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_B3C3E66D8419430DAE6D52F59096D960" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8A588D77608BC0EEF0FE52F59096CFEA" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_B3C3E66D8419430DAE6D52F59096D960" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8A588D77608BC0EEF0FE52F59096CFEA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_A85D0DBC4C379E5A1A8D52F59096D98C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8A588D77608BC0EEF0FE52F59096CFEA" xlink:to="loc_us-gaap_PlanNameAxis_A85D0DBC4C379E5A1A8D52F59096D98C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1A5D110B164C4260A31C52F59096F88F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_A85D0DBC4C379E5A1A8D52F59096D98C" xlink:to="loc_us-gaap_PlanNameDomain_1A5D110B164C4260A31C52F59096F88F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusPlansMember" xlink:label="loc_abus_ArbutusPlansMember_EC4C5043F5D3419BA6C252F590963FA0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1A5D110B164C4260A31C52F59096F88F" xlink:to="loc_abus_ArbutusPlansMember_EC4C5043F5D3419BA6C252F590963FA0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98306E7FE35CBEE0989052F59096CA42" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8A588D77608BC0EEF0FE52F59096CFEA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98306E7FE35CBEE0989052F59096CA42" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_98306E7FE35CBEE0989052F59096CA42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_847F293EFE7A9BB6ECF452F590964D8C" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_847F293EFE7A9BB6ECF452F590964D8C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FA9F816BF8C3C6B66F0F52F59096949D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FA9F816BF8C3C6B66F0F52F59096949D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_22626A9A1415DC20F06452F59096D68E" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_22626A9A1415DC20F06452F59096D68E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_567328A91F38F900A87A52F59096B967" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_567328A91F38F900A87A52F59096B967" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_966D094864B752FB019852F59097DE6A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_966D094864B752FB019852F59097DE6A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7D52E2386CD720A601BD52F5909718CA" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7D52E2386CD720A601BD52F5909718CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B58F8136A367A98124652F5909752E6" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0B58F8136A367A98124652F5909752E6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6C939EC932A4264F41D852F5909792E1" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6C939EC932A4264F41D852F5909792E1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0D951485E91F94E6EACF52F5909753CE" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0D951485E91F94E6EACF52F5909753CE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D203477D8EE34579A35A52F59097DB3C" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_D203477D8EE34579A35A52F59097DB3C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EAE095A298BE1A23AB8A52F59097FF07" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_EAE095A298BE1A23AB8A52F59097FF07" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F4DCCD28B960E09897A452F590979E11" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F4DCCD28B960E09897A452F590979E11" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B98378924FBF527E375C52F5909794EF" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3FF3E0009E64CBF19CF152F59096A162" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_B98378924FBF527E375C52F5909794EF" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalStockOptionsOutstandingDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_B3F188CE98FC27191E953DF14F840F65" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_7B5339E8CB2F369A3CED3DF3E166532B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_B3F188CE98FC27191E953DF14F840F65" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_7B5339E8CB2F369A3CED3DF3E166532B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3971ADF47DBB2CBF99B93DF14F8466ED" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_7B5339E8CB2F369A3CED3DF3E166532B" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3971ADF47DBB2CBF99B93DF14F8466ED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_3971ADF47DBB2CBF99B93DF14F8466ED" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range1Member" xlink:label="loc_abus_Range1Member_6CB02505FDAA94AD00313DF14F84C471" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range1Member_6CB02505FDAA94AD00313DF14F84C471" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range2Member" xlink:label="loc_abus_Range2Member_F9364CD619FE2DA06E2F3DF14F84117D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range2Member_F9364CD619FE2DA06E2F3DF14F84117D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range3Member" xlink:label="loc_abus_Range3Member_147A812269400268C1373DF14F84326A" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range3Member_147A812269400268C1373DF14F84326A" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range4Member" xlink:label="loc_abus_Range4Member_CED30D631FA4C32862493DF14F84E67A" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range4Member_CED30D631FA4C32862493DF14F84E67A" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range5Member" xlink:label="loc_abus_Range5Member_FFACBA7359491087A9D43DF14F8404DD" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range5Member_FFACBA7359491087A9D43DF14F8404DD" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range6Member" xlink:label="loc_abus_Range6Member_C235B12D0426EC6C253B3DF14F858420" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range6Member_C235B12D0426EC6C253B3DF14F858420" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range7Member" xlink:label="loc_abus_Range7Member_250539FEABEE7D547C6F3DF14F856911" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range7Member_250539FEABEE7D547C6F3DF14F856911" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_Range8Member" xlink:label="loc_abus_Range8Member_365F3209B6D87E30DF6E3DFD4EE2BDBE" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_Range8Member_365F3209B6D87E30DF6E3DFD4EE2BDBE" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_TotalRangeMember" xlink:label="loc_abus_TotalRangeMember_C6872B9ED39FA8C5EDC03DF14F854A83" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_57F14213CD9DF99606583DF6A77EDC55" xlink:to="loc_abus_TotalRangeMember_C6872B9ED39FA8C5EDC03DF14F854A83" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_7B5339E8CB2F369A3CED3DF3E166532B" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8063E26932D57D998A763DF493AD2630" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_8063E26932D57D998A763DF493AD2630" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_156E0A293B5045CA74A53DF493B003FA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_156E0A293B5045CA74A53DF493B003FA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_67654481AC6FC62B66293DF493B24EC1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_67654481AC6FC62B66293DF493B24EC1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_461D78239B2DB76FAD6D3DF493B4CBC4" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_461D78239B2DB76FAD6D3DF493B4CBC4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9AA74796458FE0661CC63DF493B71C56" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9AA74796458FE0661CC63DF493B71C56" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2446C2CD512F986FF7DD3DF493B96126" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2446C2CD512F986FF7DD3DF493B96126" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2D04F146AEBCE7C495313DF493BC08FB" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0C26998978B1510C44F93DF3E1752EF2" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_2D04F146AEBCE7C495313DF493BC08FB" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalSummaryOfWarrantActivityDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_2F33B5AB0C46B99A51625167E7ACA4A7" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_889C610D185CCB2A51C65167E7AC643B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_2F33B5AB0C46B99A51625167E7ACA4A7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_889C610D185CCB2A51C65167E7AC643B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CFE02B3CDA66F65F78055167E7ACD845" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_889C610D185CCB2A51C65167E7AC643B" xlink:to="loc_us-gaap_RangeAxis_CFE02B3CDA66F65F78055167E7ACD845" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2AD1FED5D682D7E7013A5167E7AC0DCB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_CFE02B3CDA66F65F78055167E7ACD845" xlink:to="loc_us-gaap_RangeMember_2AD1FED5D682D7E7013A5167E7AC0DCB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_65491CBBCECF913797E05167E7AD1C3D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_2AD1FED5D682D7E7013A5167E7AC0DCB" xlink:to="loc_us-gaap_MinimumMember_65491CBBCECF913797E05167E7AD1C3D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_2A5AE2C8C835986B54E35167E7AD6BE2" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_2AD1FED5D682D7E7013A5167E7AC0DCB" xlink:to="loc_us-gaap_MaximumMember_2A5AE2C8C835986B54E35167E7AD6BE2" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_186B981AB1CFC30C43FD5167E7AD8F7F" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_889C610D185CCB2A51C65167E7AC643B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_186B981AB1CFC30C43FD5167E7AD8F7F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward" xlink:label="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_186B981AB1CFC30C43FD5167E7AD8F7F" xlink:to="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1DE01F24B41EF4FCEEEE5167E7ADBB6B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1DE01F24B41EF4FCEEEE5167E7ADBB6B" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="loc_abus_ClassOfWarrantOrRightExercisedDuringPeriod_A69ACB80F0072DD481915167E7AD6FED" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_abus_ClassOfWarrantOrRightExercisedDuringPeriod_A69ACB80F0072DD481915167E7AD6FED" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CDCADB3AAD3C4E8CFC7D5167E7ADE0CD" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_CDCADB3AAD3C4E8CFC7D5167E7ADE0CD" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="loc_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_870A5FA4C1C62D45998C5167E7AD75DD" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice_870A5FA4C1C62D45998C5167E7AD75DD" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantorRightOutstandExcercisePriceRange" xlink:label="loc_abus_ClassOfWarrantorRightOutstandExcercisePriceRange_525675FF39318BAA71F05167E7ADB71A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_abus_ClassOfWarrantorRightOutstandExcercisePriceRange_525675FF39318BAA71F05167E7ADB71A" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantsOrRightsExcercisedPriceRange" xlink:label="loc_abus_ClassOfWarrantsOrRightsExcercisedPriceRange_5FDC9EFA31FD2116448D5167E7AD8FC6" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_abus_ClassOfWarrantsOrRightsExcercisedPriceRange_5FDC9EFA31FD2116448D5167E7AD8FC6" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_BalanceWeightedaverageremainingcontractuallife" xlink:label="loc_abus_BalanceWeightedaverageremainingcontractuallife_BF491E2197D8187E33245167E7ADE7D9" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_abus_BalanceWeightedaverageremainingcontractuallife_BF491E2197D8187E33245167E7ADE7D9" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue" xlink:label="loc_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue_635AC93B282659C7B9815167E7AD1176" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward_D3D33B60F5D1C4D16F3451C38EF58DA6" xlink:to="loc_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue_635AC93B282659C7B9815167E7AD1176" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_23847CC3433586033D5C33A201FA1D95" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FB54C428D8E8AAAEDDE733AD1AED3999" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_23847CC3433586033D5C33A201FA1D95" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FB54C428D8E8AAAEDDE733AD1AED3999" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4F2D60A9BEEACFBD7FC433AD1AEE7819" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FB54C428D8E8AAAEDDE733AD1AED3999" xlink:to="loc_us-gaap_PlanNameAxis_4F2D60A9BEEACFBD7FC433AD1AEE7819" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_07197E762DF7B56AE4C533AD1AEF9D7B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4F2D60A9BEEACFBD7FC433AD1AEE7819" xlink:to="loc_us-gaap_PlanNameDomain_07197E762DF7B56AE4C533AD1AEF9D7B" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ProtivaOptionPlanMember" xlink:label="loc_abus_ProtivaOptionPlanMember_6FB2EC3A34FE74ACFE1F33AEF39B6614" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_07197E762DF7B56AE4C533AD1AEF9D7B" xlink:to="loc_abus_ProtivaOptionPlanMember_6FB2EC3A34FE74ACFE1F33AEF39B6614" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OnCoreOptionPlanMember" xlink:label="loc_abus_OnCoreOptionPlanMember_0037E5B52F43B99C588033AFD7DE5E87" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_07197E762DF7B56AE4C533AD1AEF9D7B" xlink:to="loc_abus_OnCoreOptionPlanMember_0037E5B52F43B99C588033AFD7DE5E87" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FB54C428D8E8AAAEDDE733AD1AED3999" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9B55D9165AD48D6ABF3333A201FB5A4F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9B55D9165AD48D6ABF3333A201FB5A4F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CB98BB6FD6020DDAD1CB33A201FBDA43" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_CB98BB6FD6020DDAD1CB33A201FBDA43" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F13BF2A8758FAAE1F68133A201FB04E1" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F13BF2A8758FAAE1F68133A201FB04E1" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:label="loc_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_C523790D434218EDAB8433A201FB17EA" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock_C523790D434218EDAB8433A201FB17EA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_7D13CCE808523AB5EFA633A201FB48C0" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_7D13CCE808523AB5EFA633A201FB48C0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C048482A9F67197ADE8533A201FB4A53" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_C048482A9F67197ADE8533A201FB4A53" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_43A0ED03AB39AE2A50BF33A201FB9C51" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_43A0ED03AB39AE2A50BF33A201FB9C51" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B91DD6A242950CA8A34F33A201FB678B" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_67F39F8DE3542630D06333AD1AF4EFC9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_B91DD6A242950CA8A34F33A201FB678B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/ShareCapitalWeightedAverageOptionPricingAssumptionsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_120BAE69CDF7D32ACE013DF14F7A565F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3CA92A2D5BA7163C512E3E2DA8CBC78A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_120BAE69CDF7D32ACE013DF14F7A565F" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3CA92A2D5BA7163C512E3E2DA8CBC78A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1442AB7A67FCD6B114993DF14F7A8AAB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3CA92A2D5BA7163C512E3E2DA8CBC78A" xlink:to="loc_us-gaap_PlanNameAxis_1442AB7A67FCD6B114993DF14F7A8AAB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_CFF786F45427EAC8D5EA3DF14F7A2276" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1442AB7A67FCD6B114993DF14F7A8AAB" xlink:to="loc_us-gaap_PlanNameDomain_CFF786F45427EAC8D5EA3DF14F7A2276" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ArbutusPlansMember" xlink:label="loc_abus_ArbutusPlansMember_754A6249116D21BC2DF83E306EE37FDB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_CFF786F45427EAC8D5EA3DF14F7A2276" xlink:to="loc_abus_ArbutusPlansMember_754A6249116D21BC2DF83E306EE37FDB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AEA9197B1ED3320525413E2DA8D2A9FE" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3CA92A2D5BA7163C512E3E2DA8CBC78A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AEA9197B1ED3320525413E2DA8D2A9FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3D4A027DE56BBAEE0BD53DF14F7AD00D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AEA9197B1ED3320525413E2DA8D2A9FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3D4A027DE56BBAEE0BD53DF14F7AD00D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2F7C87584866FE4826393E31555D6FBD" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AEA9197B1ED3320525413E2DA8D2A9FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2F7C87584866FE4826393E31555D6FBD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8A04889A1F2E07E309003E315C3EF0FE" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AEA9197B1ED3320525413E2DA8D2A9FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8A04889A1F2E07E309003E315C3EF0FE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1BA8AEDEC3AC4156C4D33DF14F7AA289" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AEA9197B1ED3320525413E2DA8D2A9FE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1BA8AEDEC3AC4156C4D33DF14F7AA289" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9AE73758E7A3D4DE42A42EAA60FDBB15" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_99FD32139BABAC9EB2D92EAA60FD725B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9AE73758E7A3D4DE42A42EAA60FDBB15" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_99FD32139BABAC9EB2D92EAA60FD725B" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_77FBAC2F268181FDD6F13F2E891ACD12" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_B8B22FBC3BDD7885FC0A3F2E891A5A54" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_77FBAC2F268181FDD6F13F2E891ACD12" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_B8B22FBC3BDD7885FC0A3F2E891A5A54" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6E654DBAD3DA175B7B463F2E891A11D8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_B8B22FBC3BDD7885FC0A3F2E891A5A54" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6E654DBAD3DA175B7B463F2E891A11D8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6E654DBAD3DA175B7B463F2E891A11D8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_73D040B56307B9A643B63F2E891A069F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_73D040B56307B9A643B63F2E891A069F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_F608A8BB1D0AF86C687A3F2E891A11CA" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2C0F1EE39B0D253E733E3F2E891AA6DD" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_F608A8BB1D0AF86C687A3F2E891A11CA" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_B8B22FBC3BDD7885FC0A3F2E891A5A54" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8989C1DDE9D9D8AE7D253F2E891BBD01" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8989C1DDE9D9D8AE7D253F2E891BBD01" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_8435361D25C60E9337F53F2E891B8C57" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_8435361D25C60E9337F53F2E891B8C57" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_B9FB61C5031C01B1FC3F3F2E891B913F" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:to="loc_us-gaap_LongTermInvestments_B9FB61C5031C01B1FC3F3F2E891B913F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_96B9C0F11CC95876A5713F2E891B6003" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1F8196F0344C675727D63F2E891A4F7D" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_96B9C0F11CC95876A5713F2E891B6003" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2188F5B305F5B83BEFFD3F2E891A399E" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_AF3F9B65892D2E2AE7853F2E891BDC7B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_AF3F9B65892D2E2AE7853F2E891BDC7B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_800B9B96F2CFE844125F3F2E891B068E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_800B9B96F2CFE844125F3F2E891B068E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_684D963462CA5AA804023F2E891BD56C" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:to="loc_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities_684D963462CA5AA804023F2E891BD56C" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_C893C9BC7C7209F9F6803F2E891BC9CE" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_32CC2C70C1D2DEB449A93F2E891B8A50" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureRecurring_C893C9BC7C7209F9F6803F2E891BC9CE" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B76E490037F7015E95AC5167E80F7A2C" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" xlink:label="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B76E490037F7015E95AC5167E80F7A2C" xlink:to="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_B332CEA88CE4E2FF81E95167E80F0309" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_B332CEA88CE4E2FF81E95167E80F0309" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OpeningLiabilityOfWarrantsIssuedInThePeriod" xlink:label="loc_abus_OpeningLiabilityOfWarrantsIssuedInThePeriod_0CFD902E011BDC2060F85167E80F675D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37" xlink:to="loc_abus_OpeningLiabilityOfWarrantsIssuedInThePeriod_0CFD902E011BDC2060F85167E80F675D" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_FairValueOfWarrantsExercisedInThePeriod" xlink:label="loc_abus_FairValueOfWarrantsExercisedInThePeriod_E8D454CC02E7A7E403075167E80FA4D8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37" xlink:to="loc_abus_FairValueOfWarrantsExercisedInThePeriod_E8D454CC02E7A7E403075167E80FA4D8" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_IncreaseDecreaseInValueOfWarrants" xlink:label="loc_abus_IncreaseDecreaseInValueOfWarrants_554B3238AF99D7BE1FE65167E80F281C" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37" xlink:to="loc_abus_IncreaseDecreaseInValueOfWarrants_554B3238AF99D7BE1FE65167E80F281C" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_FairValueWarrantsForeignExchangeGainLoss" xlink:label="loc_abus_FairValueWarrantsForeignExchangeGainLoss_E6D050A79E1103DBE9A85167E80F5694" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37" xlink:to="loc_abus_FairValueWarrantsForeignExchangeGainLoss_E6D050A79E1103DBE9A85167E80F5694" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_BACA4068FC11CD21F1345167E80FFD98" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_97365774413BB6644A6F517E54646A37" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_BACA4068FC11CD21F1345167E80FFD98" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CF42CA30E8436B54B8385167E80D62CB" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward" xlink:label="loc_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward_C26E632073A9A1C689DA5190336EDE70" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CF42CA30E8436B54B8385167E80D62CB" xlink:to="loc_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward_C26E632073A9A1C689DA5190336EDE70" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3A25095241C0282A01D35167E80D87A3" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward_C26E632073A9A1C689DA5190336EDE70" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3A25095241C0282A01D35167E80D87A3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_45E035B6D900A02700585167E80D2E05" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward_C26E632073A9A1C689DA5190336EDE70" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_45E035B6D900A02700585167E80D2E05" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3CAA47A99F6E366F5C705167E80D0892" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward_C26E632073A9A1C689DA5190336EDE70" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3CAA47A99F6E366F5C705167E80D0892" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_A37C48784BD40AB25754385C7CB4BD9C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2B5882A50D609298EA39385C7CBDA8DB" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A37C48784BD40AB25754385C7CB4BD9C" xlink:to="loc_us-gaap_NetIncomeLoss_2B5882A50D609298EA39385C7CBDA8DB" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3DCA7E527680B1662DB0385C7CBD4A46" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A37C48784BD40AB25754385C7CB4BD9C" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3DCA7E527680B1662DB0385C7CBD4A46" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_A27204E23F51C7C23571385C7CBDA38D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A37C48784BD40AB25754385C7CB4BD9C" xlink:to="loc_us-gaap_EarningsPerShareBasic_A27204E23F51C7C23571385C7CBDA38D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7C435E71536D44B7D13A385C7CBDC6C3" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A37C48784BD40AB25754385C7CB4BD9C" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7C435E71536D44B7D13A385C7CBDC6C3" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_873937A26C4CE935961C3857C970F09C" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_873937A26C4CE935961C3857C970F09C" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AFBF244724AF7DF9064A3857C9708BA1" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AFBF244724AF7DF9064A3857C9708BA1" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_AFBF244724AF7DF9064A3857C9708BA1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_LaboratoryEquipmentMember" xlink:label="loc_abus_LaboratoryEquipmentMember_96CE844CB157A76D6EA13857C970E45A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:to="loc_abus_LaboratoryEquipmentMember_96CE844CB157A76D6EA13857C970E45A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_41986536DC411D85777C3857C970AA9E" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:to="loc_us-gaap_ComputerEquipmentMember_41986536DC411D85777C3857C970AA9E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3B7093F504EEE7EFFA793857C970DC1B" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_C574366999651F4701183857C97009D6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3B7093F504EEE7EFFA793857C970DC1B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5E9E9C03C03C093BC4993857C9704C77" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E" xlink:to="loc_us-gaap_RangeAxis_5E9E9C03C03C093BC4993857C9704C77" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_B26B10F5C7D18BA6BFC73858271C966B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5E9E9C03C03C093BC4993857C9704C77" xlink:to="loc_us-gaap_RangeMember_B26B10F5C7D18BA6BFC73858271C966B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_114C9767A5AEF7F59E1D3857C970ED24" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_B26B10F5C7D18BA6BFC73858271C966B" xlink:to="loc_us-gaap_MinimumMember_114C9767A5AEF7F59E1D3857C970ED24" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_3444FCB18BC11576641F3857C9701206" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_B26B10F5C7D18BA6BFC73858271C966B" xlink:to="loc_us-gaap_MaximumMember_3444FCB18BC11576641F3857C9701206" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25D21BD5B86D44F69F853857C970ADF4" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0C080774E183F501B9663857C970C42E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25D21BD5B86D44F69F853857C970ADF4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_911876483CA57560C7C03857C9705C60" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_25D21BD5B86D44F69F853857C970ADF4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_911876483CA57560C7C03857C9705C60" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_F6A75C9E8B24DB0BD4D85167E816E3D8" xlink:type="locator" />
    <loc xlink:href="abus-20151231.xsd#abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements" xlink:label="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_C4567DC976CBBCA95A145167E8162747" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F6A75C9E8B24DB0BD4D85167E816E3D8" xlink:to="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_C4567DC976CBBCA95A145167E8162747" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_CEA852181458FD2EC8C85167E8165454" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F6A75C9E8B24DB0BD4D85167E816E3D8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_CEA852181458FD2EC8C85167E8165454" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_DA4A4FD4ACD85D8171555167E816E1B8" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F6A75C9E8B24DB0BD4D85167E816E3D8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_DA4A4FD4ACD85D8171555167E816E1B8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_B259A75509D00CE378445167E816D1EC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_F6A75C9E8B24DB0BD4D85167E816E3D8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_B259A75509D00CE378445167E816D1EC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_20CB1C697BF52A37F9733329B7BF5E3A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_20CB1C697BF52A37F9733329B7BF5E3A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_0852DDB16BEC791E77193329B7BF1F5A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_UseOfEstimates_0852DDB16BEC791E77193329B7BF1F5A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C484E7528D3C7DA8C22D3329B7BFF90D" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_C484E7528D3C7DA8C22D3329B7BFF90D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_77D30C55E9AC16CECB343329B7BF1320" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_77D30C55E9AC16CECB343329B7BF1320" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_11093179F9CC3CE26CAB3329B7C060C3" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_11093179F9CC3CE26CAB3329B7C060C3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_55988278392A00E7E1453329B7C0D8DE" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_55988278392A00E7E1453329B7C0D8DE" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_DB23FAE35A97CA9BDB003329B7C044E3" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_DB23FAE35A97CA9BDB003329B7C044E3" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4D4E51EDCAFC7B92FD233329B7C086F9" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4D4E51EDCAFC7B92FD233329B7C086F9" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_C9336B34AD16A304F8CC3380F44550C5" xlink:type="locator" />
    <presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_C9336B34AD16A304F8CC3380F44550C5" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_052DC48E94D33A7123A73329B7C05B44" xlink:type="locator" />
    <presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_052DC48E94D33A7123A73329B7C05B44" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="loc_us-gaap_LeasePolicyTextBlock_D94C317622B2B0F107FF3329B7C07854" xlink:type="locator" />
    <presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_LeasePolicyTextBlock_D94C317622B2B0F107FF3329B7C07854" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_C6457A6FFEA2DC5426B63329B7C09E45" xlink:type="locator" />
    <presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_C6457A6FFEA2DC5426B63329B7C09E45" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_87FADEFD4CFAB1003C873329B7C0032F" xlink:type="locator" />
    <presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_87FADEFD4CFAB1003C873329B7C0032F" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock" xlink:label="loc_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock_6571FFF4DBE7CD557B973329B7C05AF0" xlink:type="locator" />
    <presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock_6571FFF4DBE7CD557B973329B7C05AF0" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8E4333D019D7FFF1D1E23329B7C0EEAC" xlink:type="locator" />
    <presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8E4333D019D7FFF1D1E23329B7C0EEAC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_696D93DCC5827FF5AB563329B7C09281" xlink:type="locator" />
    <presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_696D93DCC5827FF5AB563329B7C09281" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_FBF16AA09E31A52764B43329B7C0C809" xlink:type="locator" />
    <presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_FBF16AA09E31A52764B43329B7C0C809" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ReplacementAwardsPolicyTextBlock" xlink:label="loc_abus_ReplacementAwardsPolicyTextBlock_78DCCAD6CF0DBF2E256E338759F481EE" xlink:type="locator" />
    <presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_abus_ReplacementAwardsPolicyTextBlock_78DCCAD6CF0DBF2E256E338759F481EE" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_WarrantsPolicyTextBlock" xlink:label="loc_abus_WarrantsPolicyTextBlock_8423C9E2113C7716D6053329B7C0A061" xlink:type="locator" />
    <presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_abus_WarrantsPolicyTextBlock_8423C9E2113C7716D6053329B7C0A061" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2D42169B053436CA45113329B7C04F19" xlink:type="locator" />
    <presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2D42169B053436CA45113329B7C04F19" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_25B8446A4B1DA37B94F63329B7C07D39" xlink:type="locator" />
    <presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_582DBE74620027C86EC93329B7BAABC3" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_25B8446A4B1DA37B94F63329B7C07D39" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_A27BC4264F1E23F374ED3329B7A5F528" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_12EAFC9CEBD2FF9E92F73329B7A66C89" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A27BC4264F1E23F374ED3329B7A5F528" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_12EAFC9CEBD2FF9E92F73329B7A66C89" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_ChangesInFairValueOfWarrantsTableTextBlock" xlink:label="loc_abus_ChangesInFairValueOfWarrantsTableTextBlock_9EF486FEAB15F305D32E3329B7A65C6D" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A27BC4264F1E23F374ED3329B7A5F528" xlink:to="loc_abus_ChangesInFairValueOfWarrantsTableTextBlock_9EF486FEAB15F305D32E3329B7A65C6D" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_E972539B3C1049141CC5338CBA2E3D41" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A27BC4264F1E23F374ED3329B7A5F528" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_E972539B3C1049141CC5338CBA2E3D41" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="loc_abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_DD6B7EDB2A2922B217B83329B7A6C366" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A27BC4264F1E23F374ED3329B7A5F528" xlink:to="loc_abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_DD6B7EDB2A2922B217B83329B7A6C366" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_85DC6C8B4C1C2AEFFB513329B7A6D05A" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A27BC4264F1E23F374ED3329B7A5F528" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_85DC6C8B4C1C2AEFFB513329B7A6D05A" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_A0DB644756300C6F85662EAA5FD36ACF" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_FBACF398AB687FAC26CE2EAA5FD3F5CC" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_A0DB644756300C6F85662EAA5FD36ACF" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_FBACF398AB687FAC26CE2EAA5FD3F5CC" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_E6932CF2061907C4602756EFD3AF4C6A" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_E6932CF2061907C4602756EFD3AF4C6A" xlink:to="loc_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2C4E901939E0F069F64A56EFD504855F" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:to="loc_dei_LegalEntityAxis_2C4E901939E0F069F64A56EFD504855F" xlink:type="arc" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2C4E901939E0F069F64A56EFD504855F" xlink:to="loc_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_MonsantoMember" xlink:label="loc_abus_MonsantoMember_1032A1225017D632340856EFD53ED18B" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7E5D0A850D8CD59FE77656EFD505BE3E" xlink:to="loc_abus_MonsantoMember_1032A1225017D632340856EFD53ED18B" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_E4B553527EFEC435B39B56EFD4EB0D0A" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_E4B553527EFEC435B39B56EFD4EB0D0A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CCC958DECA31BD5C14AF56EFD4EC0F44" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_E4B553527EFEC435B39B56EFD4EB0D0A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CCC958DECA31BD5C14AF56EFD4EC0F44" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_PADCo.Member" xlink:label="loc_abus_PADCo.Member_705ED5B67B23D8449AFD56EFD51E537A" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_CCC958DECA31BD5C14AF56EFD4EC0F44" xlink:to="loc_abus_PADCo.Member_705ED5B67B23D8449AFD56EFD51E537A" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0117269AE8812DEDB26F56EFD4D01690" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0117269AE8812DEDB26F56EFD4D01690" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0117269AE8812DEDB26F56EFD4D01690" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_22C488EC3596E1918AD256EFD52D30D4" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9C6257450897FDC5B0D956EFD4D09203" xlink:to="loc_us-gaap_SubsequentEventMember_22C488EC3596E1918AD256EFD52D30D4" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_63C385B40B31576B055C56EFD4CFC96A" xlink:to="loc_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4E9DC42AFFD528975A9156EFD4DF44A2" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_4E9DC42AFFD528975A9156EFD4DF44A2" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_OptionalExcercisedContractualOptionAmount" xlink:label="loc_abus_OptionalExcercisedContractualOptionAmount_EC05C1C78D414A920EB156F773173265" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3A54464542EEB4D8ABCD56EFD4D166FC" xlink:to="loc_abus_OptionalExcercisedContractualOptionAmount_EC05C1C78D414A920EB156F773173265" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformation" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3647C75436BE2BE51B6E33EB0CBF0C5F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_BB875E4AFF85533F092033A20184A907" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3647C75436BE2BE51B6E33EB0CBF0C5F" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_BB875E4AFF85533F092033A20184A907" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformationDetails" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_10219CA78A74A244BA363409FEA3CC11" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_14F98EBC77E102899BE833F8006C7BE0" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_10219CA78A74A244BA363409FEA3CC11" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_14F98EBC77E102899BE833F8006C7BE0" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AccruedResearchandDevelopmentCurrent" xlink:label="loc_abus_AccruedResearchandDevelopmentCurrent_13B8B4FDFDDD115CC0A733FB70C3C0D6" xlink:type="locator" />
    <presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_10219CA78A74A244BA363409FEA3CC11" xlink:to="loc_abus_AccruedResearchandDevelopmentCurrent_13B8B4FDFDDD115CC0A733FB70C3C0D6" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AccruedLicenseFeeCurrent" xlink:label="loc_abus_AccruedLicenseFeeCurrent_9F82127A94FFE882D81F33FDA40B0B28" xlink:type="locator" />
    <presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_10219CA78A74A244BA363409FEA3CC11" xlink:to="loc_abus_AccruedLicenseFeeCurrent_9F82127A94FFE882D81F33FDA40B0B28" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_E0D2A11004851D5A858C33FCA2AF8AB8" xlink:type="locator" />
    <presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_10219CA78A74A244BA363409FEA3CC11" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_E0D2A11004851D5A858C33FCA2AF8AB8" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseIncentivePayableCurrent" xlink:label="loc_us-gaap_LeaseIncentivePayableCurrent_55E159DA2DDA5E058EE933FFC2E7E005" xlink:type="locator" />
    <presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_10219CA78A74A244BA363409FEA3CC11" xlink:to="loc_us-gaap_LeaseIncentivePayableCurrent_55E159DA2DDA5E058EE933FFC2E7E005" xlink:type="arc" />
    <loc xlink:href="abus-20151231.xsd#abus_AccruedPayrollCurrent" xlink:label="loc_abus_AccruedPayrollCurrent_860E221D35D75834B5313401D24DCD14" xlink:type="locator" />
    <presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_10219CA78A74A244BA363409FEA3CC11" xlink:to="loc_abus_AccruedPayrollCurrent_860E221D35D75834B5313401D24DCD14" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ABF012AF71D87674E72234020ED6C88E" xlink:type="locator" />
    <presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_10219CA78A74A244BA363409FEA3CC11" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ABF012AF71D87674E72234020ED6C88E" xlink:type="arc" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5C1193A779A9666CB5F233F79ACC00CA" xlink:type="locator" />
    <presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_10219CA78A74A244BA363409FEA3CC11" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5C1193A779A9666CB5F233F79ACC00CA" xlink:type="arc" />
  </presentationLink>
  <presentationLink xlink:role="http://www.tekmirapharm.com/role/SupplementaryInformationTables" xlink:type="extended">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_C653C581A19CA7D5A28633EB41DD2F6F" xlink:type="locator" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_B34C6E2A4B14C02ABC4733A2018270C8" xlink:type="locator" />
    <presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_C653C581A19CA7D5A28633EB41DD2F6F" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_B34C6E2A4B14C02ABC4733A2018270C8" xlink:type="arc" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>arb1467phase2design.jpg
<TEXT>
begin 644 arb1467phase2design.jpg
MB5!.1PT*&@H    -24A$4@  !RX   +9" 8   #AB@8\     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  #L,   [# <=OJ&0  /^E241!
M5'A>[/W;SR77_:>'R7$0 [:!&# 0Q!XX0 !?Y2; !+[UA0/$2/(/Y,;PC7,1
MP,:,/;^Q$WLP=CPS/XD'B:+8,RWQ)/'<[&XVNYLZD!(E41)%B:3(YED\2"+[
M0+*;[*9$BC^)I^ZRGN+^MA:+:ZVJVKOV?O?A>8 /WO?=NVJ=UZIZOY^]:G^A
M$1$1$1$1$1$1$1$1$1'98S0N141$1$1$1$1$1$1$1&3/T;@4$1$1$1$1$1$1
M$1$1D3U'XU)$1$1$1$1$1$1$1$1$]AR-2Q$1$1$1$1$1$1$1$1'9<S0N141$
M1$1$1$1$1$1$1&3/T;@4$1$1$1$1$1$1$1$1D3U'XU)$1$1$1$1$1$1$1$1$
M]AR-2Q$1$1$1$1$1$1$1$1'9<S0N141$1$1$1$1$1$1$1&3/T;@4$1$1$1$1
M$1$1$1$1D3U'XU)$1$1$1$1$1$1$1$1$]AR-2Q$1$1$1$1$1$1$1$1'9<S0N
M141$1$1$1$1$1$1$1&3/T;@4$1$1$1$1$1$1$1$1D3U'XU)$1$1$1$1$1$1$
M1$1$]AR-2Q$1$1$1$1$1$1$1$1'9<S0N141$1$1$1$1$1$1$1&3/T;@4$1$1
M$1$1$1$1$1$1D3U'XU)$1$1$1$1$1$1$1$1$]AR-2Q$1$1$1$1$1$1$1$1'9
M<S0N141$1$1$1$1$1$1$1&3/T;@4$1$1$1$1$1$1$1$1D3U'XU)$1$1$1$1$
M1$1$1$1$]AR-2Q$1$1$1D1WBGW[_=/,?7G&B^<)_^XO+^M__LU\U_Z\[7IX=
M(2(B(B(B(K(W:%R*B(B(B(CL$'__VF<^8UJF$A$1$1$1$=E+-"Y%1$1$1&0M
MN.?9"\U_<?BWK;'&#L"NJ<;K__'^YYM_>/RUYB>_>W=VEHQ%XU)DLV&M9"U,
MYRZ[J*_^R1NS(T1$1$1$-A>-2Q$1$9$=YI7S?_Y<\#/55(^/)(U<^C7]V__D
ML=9@^7_>_.OVT9:4=2SSY$OPEWPQT&YX]-PLI?6"<G4?]8GH+P+:4Q-!<OJD
MFR>B+/33O%"?FIE64BE(3]_ECE]4U',9,+Y+;9M3.C?F,7$U+K>/6,N[XX@Q
MR_@J,>]Y\S+/FLRZEH[W9:QQFT;N@QTA/]0A(B(B(IN.QJ6(B(C(#D-@.A?X
M[&J10#'GYM*<1P2NAP9EI\J7 /$R OCS0-UK1C.:VFS%V*@%R5.-S9NTZ=-<
M6D.$09EC'A-TJ*8V!4@OE\]84>>A[:]QN7W0][G^1/1WB7G/FX<IKP6L2<S_
M>3[0LNGTK1GK<KT2$1$1$9D7C4L1$1&1'2:W:R^G179=U@+C\XB=04,"LU/G
M2UOM59"<? G2#]F5-]2\&LJ8W8MC\J9.0\=?27MA7$[=OE./TR%S5>-R^ZB-
MHW4Q+J<>ZX@UL;0.;"M][;AK[2$B(B(BVX?&I8B(B,B.,F:G%[M;YF49P6K4
M9UXN(U^,ME7#XU"'[GA$U'LJ,!>'F*6A,7DO:EJBO3 NIWY,Y3+&:=]C>S4N
MMX_:.-IFXS*TEQ\L637NN!01$1&1;4?C4D1$1&1'X;O"<D'/DN8U;)85K,90
MJSVV<UGYKFHW"W6;QX"CWE,Q]C&N0_.F#7/GA\@7PS8U(OB=]#DW3$_&<(Z^
M]!?1U.S%.-6XW#YJXV@7C$NT2^9E[<,LM>NBB(B(B,@FH'$I(B(BLJ.,W?'6
MMXNKQ#R!<<[AD9=]N_UJ9:KE6S)U.*?/K*-,JV#,3L=4U&$*2KMZ:M^Q.23O
MVFXAZCQ5^>>EUO_SSH$:M7&:FQ^T'Z9NS7P,E0R,VKFRF8P=1\&\Y\W#/'G%
M>!]R/4"[8E[R0:+N6DS=:2L1$1$1D4U'XU)$1$1D!R'HF08\0^SB*.WDF->P
M6R0P3CEKP>I:F6KYUG:C0=]N5-)>-KE\J6^ZXS"GJ<J6,[<P[FJ[&8?D73(&
MJ=O4CV$=2\U41<OH]]HX[9L??29[Z?LN<WT;DLUDWG&TR/@;RZ)Y84C6UI_0
M(M_)+"(B(B(B>X_&I8B(B,@.0F"W%/ MO8?FV<VQ:+":[^O*G1LJF5VU?/N,
M2ZB9@ZOX#K%NGO1+["2J&4_4>U%*;8>QMXAQ2?ESYZ$A?;)L:F.?\; ,%IT?
MM4=&ELI<&S^RF<P[CA8=?V.8*B_2J7V@!95V&XN(B(B(R/JC<2DB(B*R@Y3,
M#DS TFY,-,^C,J<(5N?.#9%^CEJ^0TRRFHFU"I,M\J+-NT'XFO%4:H\QY$S;
MZ/M%C,O23E9,B+U^O"/YU\R099G5B\Z/OMW!.6KC)X6U@'G0'0^<3[Z+F$/4
MF[%$6KGQQAK%>QRSR$Y<^I6^X[&:W7S(@]>IRR+C+QYEFFM77F/N+/L1GO..
MHT7'WQBFS*OO RWS7*N6W8^K&(MCB/E-W=*UC[)05_IKF;!^E-87YKWFLXB(
MB,CNHG$I(B(BLF.4C$F"E0&_YXY!8X.J4P2K<^>&2L'56KY#C,>:04=P>=G0
M3Z7 ;2ZP'EHTV%PR!*(LM7;IR[M4[GE,AJFI&2'+-%87G1^U\U&.VO@!ZMK]
M_KR<:)<Q<X$Q1%_7#.*2*/-8 Y.Q.B:O(>M""B96;:WLBF.796#..XX6'7]C
MF#JOOC$Z=,ZNHA^G'HNL5SGS$R.P#^9A;0T8H]R<I&S=]DS+1;_P=_I^3F/7
M%Q$1$1'9'C0N141$1'8,C(-<D# -+-:"B@0EQS!%L#IW;HCT<]3R'6)0E-H)
ME?)<%;6@\R)E(Z"<"^"G[<7OW?=#?7GGSD%CQ]0RJ!D70\R >:F-TR'SHW8^
MRE$;/Q@18XW%(>V#T9,[=XPHUQ##B'$\KS$S="S6UH<^+<.HGW<<+3K^QC!U
M7AAPN;1"0_IRV?VXK+%82[/&//.[IMRUM%0VH#UR.ZQK6N;Z*R(B(B+KB<:E
MB(B(R(Y1"EJF.R?X/7<,8I?+&!8-5A/HS)T;*NU*K.4[Q+@L&5FTWUY3"UI3
M[WG)F9+4ESX(YC4N:_VQ2)FGH,]4*XVQ*:BURY#Y43L?Y:B-GWE-C;X^K.4Y
M1I2OKS\6,:.&K V+I!^:VKR<=QPM.O[&L(R\:B987QNOHA\7R:,V%FOSJ<34
MIB7*E;%4MGE,RU#?^B(B(B(BVX7&I8B(B,@.43)H,.FZU':@I496'XL&JVM&
M6:[<02W?/G.B%FP>8FPLFUK0>MX +WV:"VIWZUOKCUK>[![*G8,"SF=W#?7K
MEH77>&_>^M6HM>=8HWXLM7$Z9'[TF:XY:O6=5WUEG3+/FEE4:\\AZIO?M?$_
M5D-VCPYEWG&TZ/@;PS+RJO5'+<U5].,RQV)M/I6HG3.O<F4LY3.O:8DX5T1$
M1$1V!XU+$1$1D1VB9,CE'L7&:[ECT9COG5HD6%TSNU"M'+5\2P%A M"U[TWK
M*^^JJ 6@J?<\Y,8&YF'7I*X%_&MYU\ZCW6M&>5?4?ZI=D+7=Q6A*<RG'(O,#
M:B9[Z?S:^ G1]\ROZ'_:J>^\=-=VE^ZY]#=K#.W;[4O:I#8/*5N)4GM$?=*\
M*"^OI6.O9A9Q;IIF*M+GW&[ZM7%?^^#%6.8=1XN.OS$L(R_&3RZ]4(Y5]>,R
MQV)M+N8@_=RQB+G&^P&_U]:5$/5(ZQ#4RA:*-IAJ?1$1$1&1[4+C4D1$1&1'
M*.VH0SESIA;H'+/[86RPFG)2GK[ :5\9:OG.(X*[71-OKZ@%>*GW6$J!_%S@
MO!; K^5=.V\>,9:G"&37QMF4QE*)1<R<VIQ&& ,Y^@P"YE;.D(#:KJE2?A &
M$^T]=(S6S,M2WY?*5RL;\"$)VK+VO8(U(ZK47E#[ $9N[9V'><?1(N-O+,O(
MJY8FRK&J?ESF6*S-X1RE]9<Y5J+TX:6^=7<OUA<1$1$1V2XT+D5$1$1VA%+0
ME0!IB73W1U>U &]*7V!Y'E'FON#I5/F2U[H%3&N!8>H]EEQZ)=-N7N.R+Y@]
MCRCC(F8R8SB7;F@5_5X;I[19">I="_*CTARM]45?FX8!F1.&T)34VJ8TUG+'
MHGGF10IMDDL7U0RFH-3FN=WN\S#O.)KWO'E85EZY]$)=5MF/N>/0HF,12N5
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M'O:I5G_RC?5L[(<#$,=S_6 \Y]J6?N8#++4ZD0;OT\:DD:Y50\5YM!]UY/I
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M<R5=M^ECRD-_\3Y]RAB)7>3 ^&&L8SKS/OEA2&(*QOC@=Q[#F=8M-2X#CL=
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MDX!Z.LXYCKYE_##/^#WR"_%HTC"2R(\=<)$&[].>C/?4N&0LI&E$?AS+F(_
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MW3/2I@2Q8^<1 77:(MXG\!K&)4%7S+JNN</O[ HA\!OF#8'HOOX,T6ZI:4'
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M\GHZCVB'H<9E]Q'6E#G6DDB'=2/F%[!V\AIK%G7 L([W:6_:ES&4YL58H2V
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M?3!MBA$0@63,+X+N4QF7J2%(0+I6QS@GQAGM7#,N48P)@MF84F'>Y:!/29-
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M1)HAVH4U G.&?H[S*"-M33FH,[MXXS%(M$WT#3^I$V.#N<2\C4?*TGZ<&VW
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M1;0I>5./]%BEE%)**36_N'?C_Q;^=TJ?<"2?1^-2*:644FJDXF9S4>,2,X!
M+0'#^!Z\+@19"? 3D,1DRQDMBQB7'$O0G* J04Z.R8%Y0/"5X"KE"'..MGCP
MP0?;P#7PDR L]X51!O+ <,/4# BL8FAT@ZGL@B&/@"#[F'M,CJ,^Z:-."1YC
MA'7;CKPI*P'>@.]RC#)Q/$9$[)C#1"!@3H \]S@7 N,$GMFM2#G2,M-/M$$*
MYDMJ\@Q1M"MEI.T1^1'LABF,2_H6$RD>/PN4-<R#W#DY,1_H/\"L)@!.^^0^
M5<H8QW2@_3'("9KG(*".49[+CS9A;#,'Z-.8FUTPDQA_Y(,9D(X+TF".Q#S
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MQ/J>SN6N<<FQK-NQJY?T6"M9#UD;:6/2XF_,YICSC'/JG8Y_ZLRXI2S,0<8
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M[=%FG8Y@4^V#N8O]/)$&U8VC?<,Z$E+O'^>-%@K1N$14*?9@A)F%O>&^OZ%
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M3IQPSZ1'2"2@<1F+FN^1\Z]+D;BGPQ=Q.3!\4B[;>9I$7/IJ;J*\Y]8,;73
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M8ER"NPXUR.N7I,B,>.X11E$4-6'!4,,^DU<<DB^MR94Y3U7*]2_6RK(##?+
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MEKZ@\PGO(:TUC/+_JGL1(LZU<6PR!2=+:EQ@8"]/:+!;Z8^GJEM=J\O\4'V
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M,CWHCT^2'VPHU'O0H7Y]K>J\QF/'M3'XE7OS7.O79:+OU+4A73%,.^QA",,
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M15$415%46$3CDA!"""&$Q  T+@DAA) (0N.2HBB*HBB*"HMH7!)"""&$D!B
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MES G,]R,RTT^QB6^#*+JQGZBC<?,>S^.AW\]7BZOO=9GWU)<GQHK1&0Z@7$
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M=U#="*%C)^\[I%[(^'7\1O^.!      X?L&X!   .,:LVI'E]AXC2@4AA$I
M;X06\+5G8TDAPU.FW7D_S X9<Z]/M M^SK#YF_;'&9=*N=IF^I;<"*C -I:5
MWI[DTMM.6K7'#@>%3183G>F.-HOX'$.HK%1O@MLK><4VTL0"    P/$/QB4
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M_AZG[W3>CZCM @      (!J,2P                 H<S N 0
M     *#,P;@$                @#('XQ(                 RAR,2P
M               H<S N 0               *#,P;@$
M@#('XQ(                 RAR,2P                 H<S N 0
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MLS)P\0LAA!!""*6\9&0V][[W*:6L#,P^=SUNLQJT<%L% $#R@W$)
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M#++VU6N[Q2CVLT0((8000H'ROB?J^^+D+WZTW6O6^]\F 2!9P+@$      "
ME&=+QGSK>O5=H11@F)8((8000B@?*3M'V_.OMHRF;?UODP"0+&!< @
M0$JS=\,FF_+ES];TU"I$6B*$$$((H4*I\1_/M0%UG[6-4V?ZWRH!(!G N 0
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MF8VQZ"4%I8MM[^Z7Z#FK\GJ91FFB@]#GA*(R2^*^1D<OC0/&)4!R@'$)
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MF23S3B]VE)ABVJ8^T0LQ0YY\-93&-H#]F=O<9]24KW]Q$;5*-7YX?^*YH_3
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MO9_JRZ Y*V2**M5UY%R7-'?&O?.YVW<UB"%/O>:>YRW+YY5!92/-1XQ+@.0
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M]5S7"Q;NN1E@6BIZ79'W.Y>M]$M%,^Z]+]T+%<=R_%'AI?F(<0F0'&!< @
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M ]N^>)E_-=%H'((B+O4\T%Z]"SOU\H^,1I&8VM\X:(ZHGS4O$J7*EJ'IC,N
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MTR:H+"J\FIUQH76Y\@Z;T[R]W[-Y9&<=M(4=>UJC4RH%ED5E*XQ+@.0!XQ(
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M"<8E0@@AA! J"6%< B0/&)<       "0DF!<(H000@BADA#&)4#R@'$)
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M01&?Z-A):7I[W/2@K1DUP1^-:&;^TLS:5;TNE,[7+X-QB1 *"^,2('G N 0
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M7-3BYEES0IHYQ_O=RM#^B3DY_I%Y;)@ZTT5IMJYT6:#I5=+&I=JO_1-=FM*
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MFRI-;$']GI]Q*<-Q:OW?;$ZS=OYOHM%<&?O.YZ%HR8!SAXU+1=U&DG,DQQG
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M=+[B-F=ZKADY/MXX]ED[=I+UNOT1U_:H=B&$BBWW[//NV4&/O619.W;Z=QL
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MA,P!I1'6SP7MNKG4L;'H=\ZXU!Z1,A,J7VECW_F7_]=H,N<MLCYW/9Z_65V
M\JXUNI_4=PD->.]:FI]5/53N+Q%]I'__I;(K-_RYM_Q61J.]21O_\3QWK#.]
M(\ZK<5$D:^,_54X8A;PE?2[&)4(E+#T']-R9W[:K'3X0_UP"@-(%XQ(
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MR>N?Z=\WM D??F-CW_K,F;2=+KO5*W^A2YL;=&Z$4/&E^TI1T0L[]?*_30)
MLH!Q"0       "E/]L&#MG+H*!>5$HX""EJD0@@A=&P4,AFK^";CN6[_R48G
M5XR7]WO]76:E3+D3(HJP?$UK=L9%[IIS^^?DX/[1WW2,CG41J$19(E3BTHL2
M:96O="\,[-NTV?\V"0#) L8E        '#=D-$US$2K:LXB4>@@AA!!"*%+Z
M?MBJ0BT;^]:GMGO-NM 7R)S0#P!(#C N 0      X+ABXJ??6?MJR;WW&4((
M(800*F65JV&M*UUN_>L^:[M6K?&_.0) LH%Q"0       ,<51[*S;7Z[;M;M
MVGNLR:E5@A>N$$(((830"2.E:VYSWI4VYLU/;<_ZC9:30Y@E0+*"<0D
M  #''8?W'[#5(\;9D"=>,>TCQCYA""&$$$(GGIJ?7=T:GU+).M:L8[-^;6;[
M-F_QORT"0+*"<0D       #')4<.'[;-,S-L6OW?K$?M!ZS9Z56MZ6D76(MS
M2"&+$$(((73<JEP-]]):XS^=9^TNNMY&OOR^+>L[&-,2($7 N 0      (#C
MFH.[]]B2'@-L=+V/K/L-]UGKBI<Y U-&9O,SJUF+LZL[,[,%$9D((8000JDC
M[[N;^P[G?9=K?E8U:W;&A>X[GO[=J=8M-NC1%RV]04O;OGB9_ZT0 %(!C$L
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M=W/?X?1=[G"VY60?\;[@Y?C?]  @5<&X!                ( R!^,2
M             ,H<C$L                 *',P+@$               "@
MS,&X!                ( R!^,2                 ,H<C$L
M        *',P+@$               "@S,&X!                ( R!^,2
M                 ,H<C$L                 *',P+@$
M  "@S,&X!                ( R!^,2                 ,H<C$L
M            *',P+@$               "@S,&X!                ( R
8QNS_!YB<WBJH-:1*     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>arb1467triggers.jpg
<TEXT>
begin 644 arb1467triggers.jpg
MB5!.1PT*&@H    -24A$4@  !_@   %L" 8   #(:F%I     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  #L,   [# <=OJ&0  /^E241!
M5'A>[-T%=!S7V<;QI)QBVB]IVJ3!MF%F3L.)[<3,S,S,S,S,C'$<.S'$CB%F
M9F9F9GB^>:]V95G>78%E:27]?^>\1_;NS)V9G5DY[7/A#@$
M@+!'P \             0#) P \             0#) P \
M0#) P \             0#) P \             0#) P \
M0#) P \             0#) P \             0#) P \
M0#) P \             0#) P \             0#) P \
M0#) P \             0#) P \             0#) P \
M0#) P \             0#) P \             0#) P \
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M^;$]MGV&@?;WEQW7.C9$G3'!_FSMV[[^S@'! NR8VK^52@BLP0\  ,(9 3\
M       0AN(Z@MI"U_@(%;1;@!V([6/+ L0T>CS4.84Z;K"0WO:)*=2V<TH,
M<1DY'[7L&A)"L!';H4:?Q^;8P=JULFM.J/./KU#W/[[?@?@(]?Q:)07KY!/]
M_MOO$>NP    4@X"?@       "#,6% 7-:3SEXW0#39*-[[!=JB@,EC [V?G
M&2KH#G5.H8X;TRC\F&8W2(P0.M!Q[7JCCF /5 EU;H%F#[" .]3H^-@<.UB
M;M>6$-/?WXI0G0^L$N.^^X5Z?JT   !N%P)^        (,S8Z/A H:&]'NP]
MJ_B,U T55,84\!M;VSO0OOX*%@J'.FY, ;\)%:(GQGKCT8]I]\4_97VHJ?L3
M(H0.]ME9 'XK ;^=?Z#]K&)S3VZW4,^^/0^)*=3S:P4  '"[$/ #
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M_!7]>Q+JN0O%@O*XA,LQ5;#O;V(=QX3Z_1!3Q:9#2T+=-_M.A[IOH2H<OI<
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M5C&+:\!OYVGG$U,(%],YQ!20QK4L*(S+S 6W4ZCP+SX!?[#@,E# %RJPC&_
M'Y^R9SEJ<!M?H9ZS4 'L[9:8 ;]]EO[UUOW?/[M?T9_WN ;\P>YYJ%D1@G4L
M"G6O$^LXH0+SZ)T!H@K542G0[UZ3$/?-?D<&VB^F#EK69M2V 0"I#P$_
M    $ :"A4P6Y 03:E1UJ$ KJH0.VJWLG&,*=Q/JN':LN,Q8D!@2.N /U%ZP
M<#M44!_JV+$)+.-:=HZWTNDB6,<&?R7E?4^L@#\VWR6_4&T%$FS[4,])L'L2
M*JQ/C./8<Q9H>ZO8!.'!SC'0["DF(>Y;H/VLXO,[ @"0NA#P P       &'
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MS0 2:@2YO1=HGU"A=F(<)]AZ]@E1@23$?0OU7?6776]<9G$  *0.!/P
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M68[^_ >3$/<MZC[V&=GY1_^.VO<MU+&L\P, (/4AX <        26:AP.%2
M%1,+: .UZ:] 85"HH-*"I=B(J6-!H& YIH TOF4A=&*,]@YT[%LI"Q83PJT$
M_":FD#0N%=OP,50G :O8=!)(;#$]O[&5$$&Q7US;LM\UH3ITQ+7L]T @B74<
M^]XG5&<"?P63T %_?,H^T\3X70< "#\$_        $ B"Q9V!1OM'A>APE(+
MOZ-+B( _II'?@4;4WXZ WT9Z)U;@%>CXMUH)X58#?A-J1H;85FRG1+?P/M#^
M_@KT[(2#E!#PFX3^'@;KH)18QTG(S@363C#A$/ 'Z^@  $CY"/@!      "
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M 0 @M2'@!P         @E0@5O-MR##&QJ>*#C<RW*>;]$NLX  "D-@3\
M      "D$J&"=RM;C[[-K'UN_?JH;+]0(^JM;$I]O\0Z#@  J0T!/P
M    J4BPD?&W4M9F]+ ^L8X# $!J0L /         $ J8E/D!PK/XUL6NMN4
M^M$EUG$  $A-"/@!         $AE;(K\0"%Z7,O6PP\5NB?6<0  2"T(^ $
M        2(5LO?N7.ZX*&*C'5!:XVUKXL9DN/[&. P! :D# #P        !
M*C9KVTDWG?[[W=<&#>(M:+?W+&RWP#X^$NLX  "D9 3\               D
M P3\               D P3\               D P3\               D
M P3\               D P3\               D P3\               D
M P3\               D P3\               D P3\               D
M P3\               D P3\               D P3\               D
M P3\               D P3\               D P3\               D
M P3\               D P3\               D P3\               D
M P3\               D P3\               D P3\               D
M P3\               D P3\               D P3\               D
M P3\               D P3\               D P3\               D
M P3\               D P3\               D P3\               D
M P3\               D P3\               D P3\               D
M P3\               D P3\               D P3\               D
M P3\               D P3\               D P3\               D
M P3\               D P3\               D P3\               D
M P3\          !$<\WW,R6Z=NV:CIXXJVD+-JA^CTFJVVVB&O;\/L9JT.-[
MU>H\04,F+=;N \=UZ?(57XL  ""Q$/ #        0! 68!X]>5:;=A[2ANT'
MM'''P5C5>F_;G?N/Z>SYB[IZ-25'Q2G;E2M7=<R[_SOW'8WU_;?MMNXYK,/'
M3^O"Q<N^EL++%>^9W+[WJ)KWFZH'/J^MOW]4P_U\X+/ =7^4/__M@VK*6V>0
MEJ[;K7,7+OE:!   B86 'P        "".'#DE(9^OU@?%>ND-_.UT0>%.\2J
M7LW=2B6;CM#2];M=R(_DR<+]45.7J6BC87K+N__O%VH?\'Y'K3?SME'F*KW5
M8_0<;=U]V-=2>+%.)SOW'5/;P3/T1(9&>OC+>GHL;7T]DJ:>^[/]]-?#OM<>
M]=[_=[H&>O"+.BK6>+A6;-Q#P \ 0!(@X <       " (/8</*%NH^;HWU\U
MT#W_JZY_?E++C7:^]\,:[J>_[O6]=M_'-77_I[7UU_>K*D/%7IJ[8IM.G[W@
M:PW)C8W"[_/-/*4MV]W=YW]\4M/=8[O7=L\C[[_O>;#GPYZ3U_.T5O-^4]Q,
M#N'(!?S[(P+^)S,VUN,9&NK=@NV4K6I?Y:C>7]FJ]8NL[%[EK-%?GY;HK.>S
M-G.!OS_@/T_ #P! HB/@!P       ( @]ATZZ0+>Y[,U<Z.9G\K86"]D:ZX7
ML[?PRGY&K19Z-DM3-R+:1CGGK-E?"U;OT)ESC.!/KHZ<.*-!$Q<J2Y4^;H2[
MA>'/96D6X-XW=^'WTYF:Z-&T]?2_(AW4;O!T;=QYT-=2>+DAX,_D75/6ILI:
MM8]:])NJMH.FJV7_:9'5>L"/WK7,4/$FP_5FOM9Z-%U]-Z,! 3\  $F#@!\
M        @K" O_>XB(#_B8R-]%G)+JK4=IQJ=9Z@:AW&1U9UKVIW_DX%Z@UV
M(>@C:>LI1PT"_N3.'_!GJM1+3Z2/N/^%&PY5C4[?JGK';R/O?<U.$U2Z^2A]
M7:&GGLW<5.\5:I_L O[,E7NK2>_)+M1OVF=*9#7K.T6MO->*-AJJ-_(2\ ,
MD-0(^ $        @B*@!_].9&RM]A1XN]&P_9(9:#?@QLEH/_%$=AORD\JU&
MZ]V";5T(FKU&/P+^9,X?\&>LU$M/9FBLK\OW5.6VX]PH=[OG_OMO(]SK=IWH
MIK)_P7M6WBO8+ED%_,]F;:I,E7NI4:\?U+S?5!?T^\N>=QO97Z0A 3\  .&
M@!\         @H@:\#^5J;'2E>NN^MTGN< S:@AJ92.?2S4;J7<*6,!?CX _
M!;@QX&_DUN(OUW*T&]5NP;?_WELH;B/ZLU;MZZ;J)^ '  "W"P$_
M  1!P)^Z$? 3\ , $&X(^ $        @" +^U(V GX ? (!P0\ /
M $$0\*=N!/P$_   A!L"?@         (@H _=2/@)^ ' "#<$/ #
M0! $_*D; 3\!/P  X8: 'P        ""(.!/W0CX"?@!  @W!/P
M$ 0!?^I&P$_ #P! N"'@!P       ( @"/A3-P)^ GX  ,(- 3\
M!$' G[H1\!/P P 0;@CX 0       " ( O[4C8"?@!\ @'!#P \
M01#PIVX$_ 3\  "$&P)^          B"@#]U(^ GX < (-P0\ ,       !
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M@_<<3W5!O[^:>]?:RGNVBS:Z/H*_6./A6KUIKRY=NNQK#P  )!8"?@
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MUU@&_/;Y#ALYRAV[<[?N&CYBE+ITZZ'<^0NZ91?V']COKB$Q$/ #
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M[5>M5FVM6K/&]\Z-5JU>H[:^D#WZ*/I0_ &_G=/D  '_EBU;U;MOO^L!_Y0
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M<ZZ=K$,VZ8X*$:/O;?^'FB]ST_$;ZSRP:O]9-9V^1W^JN\@=PP+F5C/WNF4
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MO.?%/A/;WNZ5=9XPME_$>Q'7<O+DJ<BI^T.QY1_\^]E2#T>.'HW5?G%%P \
M        01#PIVX$_ 3\_K)0W07L9>9<+[LWE2,"]QNVM9\6Y)?WWK?M2GME
MT_A7F>=&W[OM[/T*OO=#E>UG[=BQ_6U;>??0O6YM^[>S$?Y5YT<<PP)\^[N]
M;N_;=K[S)=R_S47 GV05UX _H04*ZN,J6!O^UQ/B&/&1'(Y[N[8-1P3\
M     ! $ 7_J1L!/P$]1<2X"_B2KI [X@<1"P \         01#PIVX$_ 3\
M%!7G(N!/LB+@1VI!P \         01#PIVX$_ 3\%!7G(N!/LB+@1VI!P \
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M$? 7;31,*S;NT?D+EWPM @" Q$+ #P        !!$/"G;@3\!/P  (0; GX
M        "(* /W4CX"?@!P @W!#P P       $ 0!/RI&P$_ 3\  .&&@!\
M        @B#@3]T(^ GX 0 (-P3\         ! $ 7_J1L!/P \ 0+@AX <
M      " ( CX4S<"?@)^  #"#0$_          1!P)^Z$? 3\ , $&X(^ $
M       @" +^U(V GX ? (!P0\ /         $$0\*=N!/P$_   A!L"?@
M       (@H _=2/@)^ ' "#<$/ #        0! $_*D; 3\!/P  X8: 'P
M      ""(.!/W0CX"?@!  @W!/P         $ 0!?^I&P$_ #P! N"'@!P
M     ( @"/A3-P)^ GX  ,(- 3\         !$' G[H1\!/P P 0;@CX 0
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M9=?9W+N^P@V&Z(V\K5S ;V'_LO6[=.;<!7=]@8Y#4125E'4[.W\!28V 'P
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M3;+DUN)&;5T;MWO=^L/=(Z;*MVGWZV7(H=__)B+<_\-O?Z>,K[[E9A5HG;.
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MT&TO7;JD8\>/NVT/'#CH/1-G?.\$9ITHSGK'MO-PS\JNW3I^XH1K)S$1\ ,
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M=_A(9)T_8J\=<;,!K.DW7/T>?TL]_OEL9%LIM0CXP[L(^.-?!/P41:7DBDW
M?]G[;R0+?J=-GZ&V[3NZ,+Q0L1+*F3>_<N3)IU+E*JA=QTZ:,7.6]AVXM5'P
M5Z]==1T&QGWSK>HW:JS2Y<JK4=-FFK]@H6^+F]F_:4V:MU2:]!E5J5KU. 7\
M]1HV5EIOOZHU:VGEZN05\-MU3Y@X237KU'/W(W>^ LKEW9-<WL^<WGTI4*28
M:M:MI_X#!VG1DL6Z<.&";\\;V?MY"Q9206_[^HV::.+WWP?<UL+Z/7OW:NB(
MD>YX35NTTJS9<]SKP9PZ=4H+%R]6]5JUE25'+A4M44JCQXQS07]B(N '
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M\7>-2YM+^^8O\5Z/6*_TV(;-&O]U7G6\ZR'7T<!"_D#7E9**@#^\BX __D7
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M/.HIJJN7+[N. [9,Q_"WTZKG_<\'OIX46 3\X5T$_/$O GZ*HE)R)43 ?^#
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M4;:<>5PPO,[[G>F?UOU6Q"_@KZ'E*R.FVK<U]2TLMW#?@G(;"7_J]"FWO;&
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M]._K/,#-6&"=!:Q-UXG N[YPFZ:?@)\*]^IV[U,NT-\S:YY;^_[$MIU:V6V
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MMVWSVMVH-6O7>K5.NW;MUO@)W[G/\W^??*9RWKU:[;UWWC?*_W8@X <
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MUG;6G+G5H7,7K5BYTO?N=:$"?NO,,6K,.)6O5,6UT;I=>S5JUMS=>YN&/VK
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M4:-5LDPY%^1WZ-S5=089^\WX&VK<^&_==MUZ]G)MY<B33VW:== Z[]_:VX6
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MCGG[^I\#^\RM76/[N?>\=MRU>*]'OY9 [/K\^]GG=/KT:5V-Q7YQ1< /
M  @+!/Q40A8!/T7%7!;6]_SG<RXH[?9_3[CO1]2RU^R]'O]X5KT>?$E]4EE
M3< ?WD7 '_\BX*<H*B573 %_;$+:8&+:U__^[3A&0K1]*Y+#<6_7MN&(@!\
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M-6O6N' G(6K;EDU:L'B%6O>=H"]*=HP(^(NV5X':?2/#?0O$K2SP+]%P8&3
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M^PX%"_AO#$&M;@[X^Q'P)W,$_ 3\  "$&P)^          B"@#]U(^ GX <
M(-P0\ ,       ! $ 3\J1L!/P$_  #AAH ?         ((@X$_="/@)^ $
M"#<$_          0! %_ZD; 3\ / $"X(> '        @" (^%,W GX"?@
MP@T!/P         $0<"?NA'P$_ # !!N"/@!        ( @"_M2-@)^ 'P"
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MQ[\(^"F*2JE%P(_4@H ?    0)P1\%,)7<DQX+>1^!:";V[30RUSY-?C_WQ
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MI)(??ZD__/9W;AM;R[YCWJ+:U+J']G;NKSY%RKH. &E??%5#2E;2G+HM7 >
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MF/)[D=+;DXD[9/A(+%VQ E>OJ4H9O8MNW+C!)K#QX*'P\O'#N7,I#?P'#Q[
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M/'W1N6ES?*,V70ODR\_]-9D$:#TOE7G0Q@5<N,8E![[Y2F7PY\N;%Q/Z&^-
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M?>G:J=?QH1&#7_@@B,$O"'JAU/Z1E1MAW9 ).*O\VT/F?5JBNOM7]Q_&/M<
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MZ'7%_PY?N, U\6ES LV#2AAHZMEK=/KT&9X3S7M13(SZJ$HT!FT*F.;A"=^
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M-!<RZLD\+_M;(6W_B>TZX[BS'U_ON),OHH:-Q[ FK5"I<%%D^S_5W#64^+D
M^C=L@ME#Q[)Q3GWTS3\UF@T+FRSL\<<OJA(>N96?Y^#^PW!R6@"BAH]#[9*E
MM=<9T+ IERF@M6@V$= G;2R(-;/&D']:HG2!@MKV:?%UKB^Q=8I3NNZYD'X^
MI,'_>]GJZ#+<&;9SCL!W[0UN2Y'Z+7N/U[;Y,=]O:-K=%!/\-\![S37M3G;:
M%$#]IH3O@GG09I@%;H)9P$;. F 1L@U3(_?!<7X\U\9S5_^''S'X!4$0!$$0
M!$$0,A8R0AT6G(+]_%/\23@N/,V?9-!VLUJJCN"W?H<(?DO4[N^'$;[;.0L
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M"&?<@OA>TO@/0J*P=/0DM*U2 P5^^%';]DU\F_LK;!.#/\/Y> ;_36YK-?,
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M&?DG3L1S!#X]*_-)4WBSQ_/G+]0M7M>6;=LQUFPB)EE.96-_O+D%3(8,XW(
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MYJW;HF6[#NC5MS^&CQK-]>#'F9G#P=D%<^9%X>"A0]P^M5(;_(<.'^;CE%F
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M (.?VI'ACA-G,,?9C6OUTW5RY<S)]?I]+2S9@*<H_]O*-8_%K$2$K2-:U&^
MLLKY7;.5%SCA+!OX6Z;/QA#EAXK2/=,87^;*A;+%BL-R\##LG;M0F?,>W@@0
MOVP-%GOZ<<3_'T5_YXT".'[ZM?E_-,3@_^3AZ'H%,M]G#1F#G]3O,?%%]AQH
M5J$*IX^GR':J77_).P+K)]IA2@=#-"A=GFO'T_>Q$ZS9 -?TI13_PYNT9M.>
MQK_@%8[H$1/0M68];9NB^?)S3?H#MAX\%XJT?YO!?SMP#N(<O.'1<R J%BZJ
M;=M4F6>X\4B<<0OB-G2]O39N7._^KU+E>"X+1YGS&+290+-^@K(+)*OOP6+3
MB2BHCMXG8WYLJP[8,MF!-T%0-@)J1]!&!\I<X&QHA#^+%M?.HT?=!MAAZ<R;
M$$P:J8S@G[[Y#H.5KRE*7W._-=>FK BT&4"3'4'(>#ZDP?][V>KH,MP9MG./
MP'O--;U]-6@,_F_S_,1]O_SJ6]3XIPL&V\UE8UYC\+LN3<($__7XI\LPG13]
M)6%L-0.NRA_/$L$O"((@"((@"(+P8=&8O&3RMQL_C\W=PBTFL\E9IY^?-I)?
M8^Y2M'^C(:_,?3)"R12EM/P4+4WF;NIK")D?RN10WSB -W=0-+[F^=,[P>;^
M1)7!WUYY_G\/#N5(?]K809'N57MY8."T=9P1@L;*#.:^+F3T6RGO)KVC-?IX
M:2/Y529_.)OX+3@MOP]G,J#WOVPG1W2R6,@U]SW>(VI?%S'X!4'(:-[5X*<(
M<DLK&X[*;M>Q,YN\9 !3&GLK6WNL7;^!S?$7Y&!G@"B]_-[]!^ 7$ 3CP</8
MA*=(]RW;MJE;J*0Q^-MTZ,@&_[*5*Q&[;AVGA^]G; (/;U^</'6:_5E=T?=6
MMG8<94\UZJG>_>,G3]1G7VGUFEB.-N_6RPB1L^>HC[Y=9&131@+:_+!TV7+U
M497(T*;Z^[1!@NZCZ;CQO & 2A'HBN[YY*G6:&O0B=/WZXK63?,9,&@P&_24
MTI_&(NAK.D81^)1)@#86/$VU?HVT!K]? !OX)$K+[^WKS\^9LA?0/26=4N[C
MVR+XSR0F8J8R+WI/*!/#HL4QN'7[-I^C-/]4UY\V'= 8=HY.V+9CQVO/)J.5
MI0W^%X>4_S.P;#4<1HU!N1(EM49,W_8=V;1/K\&_5VG;IF$C?/_-M\B1(P?^
M+%,.$79.>*EK\.\^Q/7\R:RG\:DM78LV!)0I5AQ-:M=E0[]YW?JH_V<UE"I*
M*<RSX8?OOL?62.6')_XLCW-[QSXL\/!!_:K5E+ZJ"&HR;G[_K2#W:U[O+[10
M:%"M!BK^48HW M#Y-4'AVC'^$\3@SS)0#?P#MNX8W]H Q?+_K/VY^?ZKKU"A
M4!'\7;8"6E2JBJ85*J-ZL9+X.<\/R*:\RX,;M\!V2V><=0^!>9M.VKKXQ*\_
MY.6H?HIT;U*^,BH7*88?U3\C!-71I]3Y9)Z3(4\1_Q09KSG?LE(UQ)K9($G'
MX*>VE!6 KDD; #1M*1M ^8)%T+A<1:5?5;Y>G9*E\8LR3TJ1;UBK/F\PH#$T
M8VD@P_V&,NY^9?TNW8RTF0&H7 &5+KCL$X&[P?-P+V0>1_D3E(;_LL]TK!QG
MR9L+-//XJW1Y^/89Q*4%AC=MQ<?H9[5X_@)\'S@#P)\UT?;/&CRG84U:P:EK
M'VQ4UDX;!W3-?R%CR"P&/T7VFP=NXC[9L^?@]^+'_ 71O.=8KM7OKYP/W/P
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M!ULVOND]*-?9B=/6T_=4<[]:+P\,<M\(Y\5G^;\[9&9S7Q=Z5RF2G]Y=RDY
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$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>arbutus10k2_chart-35315.jpg
<TEXT>
begin 644 arbutus10k2_chart-35315.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '@ F4# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BN/\?^._#'PR\%^)O'_C+5
M+71_#/A/1[W6]7O[NZL[2..ULXBPACFO[FSM#=WLYAL=/@EN8?M>H75K:(XD
MG3/@GAC]JJQUCP3X-\2^*?@K\;_A9XO^(WCK4/ 'P^^#'Q"TKX<0_%7QEJVF
M:%J'BF[U#2;/PC\3_%_@FV\.Q>&-%\0:_-KFM>.=*L[33-"O9[XVKW.D1:F
M?5=%?)]S^V7\'1IB:GI'_"6^)5T_P9XL^(?CFPT'PZTVL?"_P9X"\6:WX#\;
MZS\0-(U"]TV_TNY\->-O"WC#PK<^&=*AUSQAJ>L^#/%\'AWP_K,7AO59[?ZA
MTK5--US3=/UG1[ZTU32=5LK34M,U*PN(KJQU#3[^WBN[&^L[J%GAN;2\M9H;
MFVGB=HYH)8Y48HP) +]%%)G/K^1'\Q0 M%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >7?&:*QN?AUX@LM5
M^#][\>-'U%+'3]8^%UC8_#W59O$FE7>H6L5]OTGXH^(/#'@K5;;2X2=6NM.U
M76(9;NWL7CTV"]U,VEG/^;7P\_8S\3_!OQ'\)/BEX \!:WX>\"?"W]H;X[^/
M_!G[*^D>+]!U'_A4GP?^.WP1TGP!K/@[P!%<:_;?#W3GTOXLZ%J'Q;LOASH7
MB5?!G@O1_B7XR\(> =7N(-%T72[_ /7:B@#\;_AY^R=\<O@S?_M(>,M.\(GQ
MEX@_;"^&OQ>T^_\ #UOXVTR;3O@_\0_&7[0_[47QJ\':7KM[K.H:?;2>"(M!
M_::CT3QCKW@F+6[NR\0_#_4[O1_#VN6_B329%_3WX&_#5/@S\%OA'\(8M4FU
MR+X6?##X?_#B+6KD2"YU>/P+X1T;PJFJ7 EDFE\_4%TD7DHEFED#S,'D=@7/
MJ=% ',^,/".B^.O#U_X7\0KJ;Z1J1M3=+I&O^(?"^H$V=W!>P>1K?A;5=%UR
MS N+>(RBRU*W%Q%OMK@2VTTT,GXC_'VTU3X(?\%@/^"3WPB^&7CGXK>'?AC\
M</A?_P %$K_XN> I?C)\6_$/A/XA7?PQ^&?PCU?X?7'B70O%7C?7=/NKCP=J
MFL:KJ.@W,$%K=6=WJ%R_GNKJB?N]7X8_MJ_\IQ?^")7_ &2/_@J9_P"JB^"5
M '[8?\(WI?I??^#C6O\ Y8T?\(WI?I??^#C6O_EC6]10!@_\(WI?I??^#C6O
M_EC1_P (WI?I??\ @XUK_P"6-;U% ' :OHUI;ZOX4MX9-1CAOM5OX+M%UG60
ML\47A_6+J..0?VARJW$$,P'!WQ(<X!!Z'_A&]+]+[_P<:U_\L:IZ[_R'?!/_
M &&M3_\ 47UVNJH P?\ A&]+]+[_ ,'&M?\ RQH_X1O2_2^_\'&M?_+&MZB@
M#!_X1O2_2^_\'&M?_+&C_A&]+]+[_P '&M?_ "QK>HH P?\ A&]+]+[_ ,'&
MM?\ RQH_X1O2_2^_\'&M?_+&MZB@#!_X1O2_2^_\'&M?_+&C_A&]+]+[_P '
M&M?_ "QK>HH X+Q+HMG9Z;#-;/J,,C:WX:MV=-9UH$P7GB/2K2ZB)&H_<GMI
MI89!P3'(P!!((W_^$;TOTOO_  <:U_\ +&JWB[_D$V__ &,/A'_U*]%KIZ ,
M'_A&]+]+[_P<:U_\L:/^$;TOTOO_  <:U_\ +&MZB@#!_P"$;TOTOO\ P<:U
M_P#+&C_A&]+]+[_P<:U_\L:WJ* ,'_A&]+]+[_P<:U_\L:/^$;TOTOO_  <:
MU_\ +&MZB@#!_P"$;TOTOO\ P<:U_P#+&C_A&]+]+[_P<:U_\L:WJ* .'\2:
M)96?A[7;NV?4(;BUT;5+B"9-9UH/%-!87$L4B'^T3ADD164D$ @'%:5GX>TV
M2TM9'^WL\EM [,=8UHDL\2LQ)_M'DDDDGO4OBW_D5O$G_8 UK_TV75:UA_QX
MV7_7I;?^B4H S/\ A&]+]+[_ ,'&M?\ RQH_X1O2_2^_\'&M?_+&MZB@#!_X
M1O2_2^_\'&M?_+&C_A&]+]+[_P '&M?_ "QK>HH P?\ A&]+]+[_ ,'&M?\
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MQC6O_EC7.Z!H]I=W'B1+B3495L_$5S9VP?6=:(AMH].TJ584_P")B,())Y7
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M_P IQ?\ @B5_V2/_ (*F?^JB^"5 '[G4444 %%%% '*Z[_R'?!/_ &&M3_\
M47UVNJKE==_Y#O@G_L-:G_ZB^NUU5 !1110 4444 %%%% !1110!S'B[_D$V
M_P#V,/A'_P!2O1:Z>N8\7?\ ()M_^QA\(_\ J5Z+73T %%%% !1110 4444
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ML?\ D<?$?_8!\*?^EOBN@#J**** "BBB@ HHHH **** "BBB@ HHHH ****
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M/<3_ !E^/$WQ'^(MNTI0/);Z9XATZQ#DM':1@XH \I'_  5"LOBP)+;]B/\
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M'_D<?$?_ & ?"G_I;XKH ZBBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K\,?VU?^4XO_  1*_P"R1_\ !4S_ -5%\$J_<ZOPQ_;5
M_P"4XO\ P1*_[)'_ ,%3/_51?!*@#]SJ*** "BBB@#E==_Y#O@G_ +#6I_\
MJ+Z[755RNN_\AWP3_P!AK4__ %%]=KJJ "BBB@ HHHH **** "BBB@#F/%W_
M "";?_L8?"/_ *E>BUT]<QXN_P"03;_]C#X1_P#4KT6NGH **** "BBB@ HH
MHH **** .>\6_P#(K>)/^P!K7_ILNJUK#_CQLO\ KTMO_1*5D^+?^16\2?\
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M_B71K6T\3K/%;302:#<RWJP:M#-%>V+QSV4DT!6^LCYH^V6PE[L'/3_/^>]
M!7X8_MJ_\IQ?^")7_9(_^"IG_JHO@E7[G5^&/[:O_*<7_@B5_P!DC_X*F?\
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M /@MS_P1AA\;?%?_ (3ZYO/A3_P5 ?2;C_A7?ACPG_8D<'P@^# O5QHUY/\
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MEX,L[76?B1KUC(T8N_#_ (-U&U219KJ /_*3_P &U_[2?QW_ ."EOP9\0?\
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M5]:U*XN=3U>^OM0N;BYD]0H Y_\ L[6_^@]_Y2;+N<G_ ):=R2?K1_9VM_\
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M5^&/[:O_ "G%_P"")7_9(_\ @J9_ZJ+X)4 ?N=1110 4444 <KKO_(=\$_\
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MIY1X5^'FJ>(_B#X6U;QEK$=@ME!XM^)OB/08O$?BW5(ID2XC\-V6A:=9TO\
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M%%=>+?B/XZU99-7\4>(KP!IIWAT_3X+#1-.TO3++Z:HHH 1NA^A_E7)^%_\
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MIZ "BBB@ HHHH **** "BBB@#GO%O_(K>)/^P!K7_ILNJUK#_CQLO^O2V_\
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M>3NS2WNK:UJERTE]KGB'6;O4->U[4II]3UG4;Z^GEN']BHHH 0]/Q7^8KDO
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M3+.V'E;UA5W<M^D] !1110 4444 %%%% !1110 4444 %%%!_J/Y\T ?GO\
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M31=I!2:"#7;'X??%'XJVUM*G"B+XFK>0.6FAO4F$;Q,F_P""3W[)NO75K?\
MQ1\+>,_VBKVV.6E_:H^/W[2G[25C=_-OV7?A7XK?%_7O +6^X!A9P>#[>Q5A
MN%L,+M /Y=/^#Q3]L[QA\/Y/V%/#_P"S#^U;XE\#^)K74/VE4^*&@_ ;X]:I
MX:UV"+[+\#F\*'Q_I'PX\766H11[SKH\.-XEME 9M;72CEM1!_B(A_X*!?MX
MQ-*8_P!M?]KB,S-)-*8_VD_C.AEF,84S2E?&P+R%8XPTCDL410Q*J /]%_\
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M7?\ ()M_^QA\(_\ J5Z+73US'B[_ )!-O_V,/A'_ -2O1:Z>@ HHHH ****
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MUUE7_P"+O^.?",UKXAUG5KK4O"5OXVUWPGI=E->_H=_PZO\ V;_$MJL/QO\
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M/OCQ_P $Z=3F\J'2O ^J17,OBK]H_P#8CMG!@BME^'FHZC>?'#X!Z-%:'?\
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M+S5M6\/Q^([>XTB'PCXV\;6L^GI92"*66ZN[*<7/RI;21$3'_%4D^\/]R/\
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MB_>_N9VU"_&J:7<J=5M[?4[4072*\?H7AW_@DOX]\(O;3>%O"/\ P1DT&ZM
MOV>_L?\ @D!J,FJHRP&U\U]9O_VT[W5YYVMVDBEN+B_EN)_-GDN)99;B>20
M^Z_$?_!43_@G#X6=H-6_;J_9,-ZFP'3-*^/GPU\1ZL2TDL9"Z3X:\0ZQJ3F-
MH9C.$M6-O'%)-.(X4:0<A8?\%8/V*-?81^"?%_QC^*$K8*+\(/V1_P!KWXL1
M2?NS.X%[X!^!.O:<'BM<7DT;WBR1V<MM<LGDWEJ\V-X7_9Y_X*(^!K-+#P5^
MT3_P3V\)6<('DV7AK_@G1\4/#]G&4MX[2,+;Z/\ MWV<486VAAMALC!6WBCA
M7]VB(-=?#?\ P5K7K\8O^"=S-W/_  SA^U$%)QR0C?M6R! 3R$W-MX&XXS0
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M3=6D6D:7KVBZIJ?BBPUJVUQ[K1K5+?\ HO\ ^",G[9/B'_@M'\+M$\(_&O\
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MFCZ%80:5HFF6&C:9:J$MM/TBSMM+L;=%54"PVEA%;6\2A%50J1J JJH   H
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M:A+I6CZIXC\6>-]4\.WNF^(KS2[*70-+T'0=:T*>77K[5+VYTG3.5_X)A?\
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M *A^+O\ D$V__8P^$?\ U*]%KIZ ,;S_ !#_ - O1O\ P>WW_P SE'G^(?\
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M_P"9RMFB@#&\_P 0_P#0+T;_ ,'M]_\ ,Y1Y_B'_ *!>C?\ @]OO_F<K9HH
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MN-437AJ<TMU)_J&_\%2O^">W@7_@IY^QC\3_ -D[QKXBN?!-WXH;1O$WP_\
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MPH^#G@73?$'Q'^(>JM)Y<<Z>&?#E]9Z:)H[G6;[3;+?=( ?4I( ))  Y))P
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M]-EU6M8?\>-E_P!>EM_Z)2@"W1110 4444 %%%% !1110 AZ?BO\Q7)>!?\
MD5=)_P"N=S_Z7W==:>GXK_,5R7@7_D5=)_ZYW/\ Z7W= '74444 %%%% !11
M10 4444 (W0_0_RKD_"__'UXM_[&N\_]->BUUC=#]#_*N3\+_P#'UXM_[&N\
M_P#37HM '6T444 %%%% !1110 4444 %<O8_\CCXC_[ /A3_ -+?%==17+V/
M_(X^(_\ L ^%/_2WQ70!U%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7X8_MJ_\ *<7_ ((E?]DC_P""IG_JHO@E7[G5^&/[:O\
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MQ#:Z"TT,4]OX&\)'PO\ #W2GCC31/"6FP11Q)]I8 Z#'4_B3DG\3R?>B@!
M    !T & /H!2T44 %%%% !1110!SWBW_D5O$G_8 UK_ --EU6M8?\>-E_UZ
M6W_HE*R?%O\ R*WB3_L :U_Z;+JM:P_X\;+_ *]+;_T2E %NBBB@ HHHH **
M** "BBB@!#T_%?YBN2\"_P#(JZ3_ -<[G_TONZZT]/Q7^8KDO O_ "*ND_\
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MT.(W1ET^SM73SKBZM@#]^:*_&O\ X:O_ ."S_P#TB._9U_\ %H^A?_0ET?\
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M%GH9LS(=;_MXZS=!!I_]D,;W[+H **** "BBB@ HHHH **** "BBB@ HHHH
M\G^(_P $OAO\5KFRO/&FAW%[>V>B:]X6:]TS7->\.7FH^#O%;Z;)XI\$ZW=^
M'=3TNXUSP7XEDT?29==\*ZK)=Z)J4^FV,\]F9[:.0>G65E9Z;9VNGZ=:6UA8
M6-M!9V5E9P16MI9VEK$D%M:VMM D<-O;6\$<<,$$*)%#"B11HJ(JBU10 444
M4 %%%% !129 &?Z')^@ZG\J,C&<\<\^F.N?3&.<].E 'E'CSX2:-X_\ '?P3
M\>ZCJFJV.H_ _P :>*/&V@65C]B^PZQ?^*?A;XZ^%-W::U]IM9KG[%;:1X\U
M#4K;^SY[.X_M2RL?.FDLOM-M-ZQ2 @Y]NN00>_.#@XX.#T/:EH **,CGV_SU
M_GZ4@(/_ -<$'\CSC@X/0]J %HHHH **** "BC/^?\]:0$$9'\B#^1Y_3^=
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MO$&K^(9FN_[-M;*RS%<ZQ/!%Y-M$/L\4.\/+YDC^O9'3Z]CV]3T'MG&>U+0
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MX7?&ZP\ ^(]2BETN/QIJ=Q\0M+U#1?B!H?CNRU=O!WB#2_%MAX=T>UF%MN0
M_<3QQ\=O@C\,=8TGP]\2?C#\+OA[K^O65WJ6A:)XX\?^$_">K:UI]@\,5]?:
M1INO:MI]YJ=I8R7-LE[<6,,\-H]Q;K<O$9XM_:>%?%WA3QWH&G>*_!'B?P]X
MQ\+ZNDTND^)/"NM:;XAT#5(K>ZGL;B33M8TBYO-.O8X+VUN;.9[:YE6*ZMY[
M=RLT,B+^.?[<GBR'PS_P4_\ ^"8=W:?$WX5?##5=/_9^_P""C0N/$?Q7L8-8
M\/6-GJZ_L>PVUE/IW_"POAI<6]]K<VGW"Z5<'Q/ D_\ 96HK'8:A]GF:RP_B
M7^T9\2]-\1^$? 'PL_:@\#Z#H9_X)S?ME_'[Q+XN^"W@_P"$,_ACQ/\ M)_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M81""RTO2-*M(;'3=/LX5^6*ULK."&V@C'"11HO:M:B@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#'PNTOXS:E?:1\2?"VIZ?XS^)MA\:?#OB#X@ZJ_@_P %6?P^U&( _HFR/?\
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M[SJO_1+3TSG'?IQG- '\YOQ"_P"#V;_A!/'GC7P3_P .XSJ7_"(>+?$OA?\
MM$_M6"T_M#_A'M;O]'^W?91^S_=?9OM7V+S_ +/]HG\DN8Q-*%$C_K]_P1+_
M .#A ?\ !8;XR_&+X2G]E/\ X9^'PH^&.F_$8:^?C2OQ,&N_VAXOT[PK_9 T
MW_A67@4Z=Y7V\WOV[[;>[_(-N;5!()Q_E2_&O3!I/QA^*NE+J>HZP-,^)/CS
M3_[5UO4$U+6=2^Q>+-8MAJ&K:@$A^W:G?"(7=_>>3%]JNYIKCRT$FT?TR_\
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MSPS^Q7^UO^VU^U]^T5J^K>"_V:OVO/#7['?B;X>?%?Q/X;\36NE?#KQ#\-/
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M-WHU_?6]NS+!,RK-(A9892H(C<K^'OQOT[XV^'/^#;#XM:/^U3<7X^/NF?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>hbvlifecycle.jpg
<TEXT>
begin 644 hbvlifecycle.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,J!=P# 2(  A$! Q$!_\0
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MW1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 'S7'-=VG['?QMT">VGL+?0]<GLK73[BY%PUE%YT#B#S!PP0LPR.*^V/#?\
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M\)/$&BZ+J&F:IJ=_K,$SV,.F0"9YI49%$(7(.YB_!Z#:<D5Z=7S/^T)XRL/
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M,^H96!]P:ZG]H[7+'PE\7_@GX@UFY33M$L]0U!+G4)_EA@+VP5-[=%R?7T-
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M:LN6+2]I\'EK;^KE_4\)'5O;?^O\CZ>OOB+#;PI$D2_VE(Y00-)\H  ._/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /AO]I[XD:KX?^+'BJRL[J2W
MLI[&WMI?<!-Q4>@RU?*^EPV_B+Q B7^JVVD6KD_Z5>']VGH6'4C/6ONW]JC]
ME^\^)UY_PD7AW5+>RU-D"7-K?$B*8*,!E902K8&.>#7S;I_[(OBB2QG75IM.
MM+F$8@\F<R";GN<?+7Z[E./P,<%!*:C*R3[W6GS/BL9A\0Z[;C=7T/1/@O\
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M<GE :TZKV/D+9P"VVBW5%$87H% X _"K%?C$M9-H^Z6P4445(PHHHH ****
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M'(-.I 006-O:K&L-O%$L>0@C0*%SUQCI1=V=OJ$#0W4$=S"W6.9 RG\#4]%
M$4-K#;A!%%'&$0(H10-JCH!Z#VJ*XTNSNKB.>>T@FGC^Y+)&K,OT)&15JB@"
M&2S@EN(IWAC>>+(CD9 63/!P>HS45SI5E>3QSW%G;SS1_<DDB5F7Z$CBK=%
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M1L+9J[?\"/R"DL-0CAT6.WE7S?M,J$ G[HW$D_E_.N*MD5*U24$THR]WYO\
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M5[]^U?X/\9?$R\TOQKX;>^U'0HX%M[G3+8%GLI5SF38.2K ]>Q%>$^$_AO\
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MQX5I-L(;Q4(W)"C3EE!P3D'%332M=,JE29+EPH)^N37L?PY\+Z#J7@^6SU%
M+B6-H[BX\P!H^3ROH16'\._A[IFN7U[]JNWD%I<,ELT:\R#HK^U>G3XFHQO"
MHFN1VD^][K0QEE[DURO?5'FFK7$+7(.]6-NA3Z<8 ^F<FKUO>+I-K#"RKN9=
MYW>__P"JNEC^%EYJ'B_5/#OGHPMW#/< A0R-R&QZX[5S_P 0/"&J>'_$DUO=
MVK/N4/#)"=RO'R%/MT/%>S1SS UG:<K-V:2M>S2UUL<LL+6@N:/4_1&BBBI/
M'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%!)[_4U?AF+"H[B1?,Y':N5Y'6C455TTW:QM_:,7'D<M#[-HHHKZ \L****
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M/<[':-IQUJM:P6NAVHM+*VCMK9>?+C&!GU/J?K6)J&I+),TBRB)8<,Q?)'/
M''?-8>TEB\3[5JRT27DB(Q;DYM6+?AO1=!\2>)8I9=1:*\6='6WC!?SBIY49
M QP/6O8]2O\ 2[B\6.PAD@).&20\UR'P1^&MGJ%Q_;UAJUO=W-O V_3URSP2
M$D+EL#(('IWKLM'^&_B2\U8LUBY)DY<]!SUKZ2A*G=N4K6,ZW-HDKGJ?PITD
M1ZEI]W',!<+(%$0ZD8Y-?38Z#-<!\-?AG!X3MXKJX;[1?,@.2.$XZ"O0*^-S
M#$1Q%:\7=(]K#4W3A9A1117EG6%%%% !1110 445%/<1VL+2RN(XU&69CP*
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M_MR-57)Y(SBO,+SQ/:VNAPV4$91TVJ\C?Q\C+?4G^=6[7Q!#Y4SF52RC:%#
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M?\^E7=+O+>WMYY[@;A(F[;W'/'X\5SRJ9)%.P"1CM!'IZ5=OHPC>4S;UBX(
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M)^(UTNLZMJFH>&]:>)5O(8;/[1#,Z@+O0@C;D =?_KGS35[RRCU&Y73I9YK
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M_>#GM516I7LS]1Z***_&C4**** "BBB@ K.UC6[?18/,F8 G[J]S5]F"J22
M/4UX1\4/&$L'B@(#F*#D+V-=N%P[Q%3E,*U3V4;FQXF^-LFGR-#!:LK9ZL:R
M-%^/TBZE%%?(/*<X)STKR3Q/XH;4KIY#@$^E<S\]S,"'PV<BOKH990]G:4=3
MQ98JIS73/L#Q3X@2ZM8&@DS'( W!KYY^)GP'\-^/O$@U_+Z9J[C;<36XRMQ@
M8!=?[V/XN]=OH5U=G0+07.[(7 )K0AA+8=A\F:\[#N6"=Z4K-'35M75IJZ/S
M\\3>#Y_ GC!8KFU6Z^PW0S#*"$E"L" ?8C^=?0>M^1HWQ(^&?Q/@MO(M=16&
M6Y3.X(R81AGV4C\JT_VDO"MC=7]C=6JPM*1^_9&&[/&-P^E7[/2;GQ%\-]#\
M.WT4$5G8R&>"X0[I2&_A] *^PKX^%>C2K2ZWC+T:U_&S/&I82<9SIQZ6:];G
MV3<7%I-:I+,\9@90P9R "",@UQWB;7O#&LV-QI$6I64ETZG;#'("<@>U?//B
MSXK6VG1:#X1UZ_N)+RXN%6QS&=DT03!#L. 5(X]:9X@BDT?1KJ\L4BAN;13<
M1$KA2R<@'IP<5\%3P/*TW+T/IY5+JUC0O->LYO"L^D>1<3NLK;&1/E//K4'@
M_P 56GA73IE^PO/<2DH(E8*01UR:\\^'?Q,L-?\ !T&HZK>V=E>2R2&6)3M5
M6W9^4')Q6%=>/++3_'LLDVI_\29HR5ZE%<@9/2O=LVI4WL]3BY(IJ1[M<_&
M-8K ^BR(J\F3SE.!]*ROBIXFL=:\"S:!%%(UU=>5<"3^%0#G!^M>67GQ2\*S
M0S+'J\+OL/RX/I]*Y_X=>,CKFBSR:GJK7=W',RAIV^98_P" ?0"II4E"2G%6
M:=RIQ4DXO9GH_P 7)M/\5_#7P7IMAEY-(MC#.",;9#C(KW+]E2]T_1OAM%8R
MW-G!>&X=O+\P"0CC!85\V6^KP:EISI;2)-$+AOWB'(.!CK]:KO,UKF59&B*C
M.Y201CO6U>+Q&%^JWLKM_.[,Z=-4ZOMNMK'UK\?+^%=!6/:K.V<-^%>+^"O#
M*R:??:K<8,$2_=;N:Y/6OBK-XLT_3'L;V2[L(X%4/.I5G8<$D'GK73^%?'\>
MNVMIX<%G]F>9PK21G(?ZUA0I2P^'5/SU]!58^TJ<YQ&K:->7WVBZB@;RPYQ@
M>];/PCM+IO$:S21LJ1=2U>U75CI<=NEI9>5-M&U]F#\W>G0^&X=+MQ+'$L3/
MZ#%;2S#FIN%MSG6&M+FOL5?BE\=M,^#_ (=BUB\1KBXD?RK6RC8*\[XSU[*.
MYKYNNOVUOB-KVJ2W5KJ5II-NV0EC%:HZ1@_[3#+'W-=7^T9\%[_XD+:ZCI\S
M27=G'L2V)X(Z\>YKY@UWPC>>%;N.RN)%6_;@VRMEQQW':O;R? X"I2YJD5*;
M[ZV^3_,X,;B,3&=HMJ/D?1?@WXX_$O7=<MX+?QK(LTS\?:HXVBR>Q!7I7U7\
M._BEJ<VO1>%/&45G:^()(?.M+BR?,-Z@'S$#^%AC.*_,;1?$5QIUT-[-&RGK
MG!%>E:#\1M8LO$6CZ]9WTDM]I\H:,R.3\O0K]",BM\PR2GB8_NXQ2L[65G?I
MJNG>YEA<PG2?O-OY]#]1**Q_"7B*'Q9X;T[5X.([N%9=O]TD<C\#FMBOR*47
M"3C+='VJ:DKH****D84444 %%%% !1110 4444 <!\6O@SH?Q>TR&+4?,M-0
MM=WV34(/]9#G&01T93@?*?TKS"Z_9/GUVPTS2]6U73XK&Q8AKS3;(Q7=RG8.
M2Q /OS7T=17I4,RQ6'@J=.>BV\O0Y:F%HU9<THZLY'X>_"[P[\,-,-GH%B+?
M>!YL\C%Y9<=-S'^72NNHHKAJ5)U9.=1W;ZLZ(QC!<L59!1116904444 %%%%
M !1110 4444 <#\7K:]&AQWMD"SV[$NH&?E(Y-?*MT1>:P/,C\Y6;F,]_:O2
M/VC?VO(?A]>3Z!X8L;+7KU$*W=S<2%H(6.1Y>%QN8=3S@=.M>7?LV0ZO\?-5
MU6[O(K;2SI\D<G^BHP1P2>,$GTK[O 8>OA<$\17CRQZ/K]Q\]B*E.M75.F[L
M;XWM=-T/R+>WT9[&YFC9W,[$XS]T@?7FO!_$VL72ZLMA?(E^(%!$L(V<GU7L
M>E?1G[2VH6:^*+E-'BN-1UJQ\NTEM9G6*$JJ\E7YY'''>OBDZQ>:QXFU.\G#
M6TLEPVZ#?GR\<;<^V*B=5RH*3ZG;&FHZ([OSEFF01P&/W8=*Y#QAISW4UND<
MC?V7J%TTFW&,LJCCW!.6%=%8R37%O-$&W2-$RIGU*G%-M]3TS5/!<T5U%YIA
MB)10Q5TE P,$=#FOA,=-^VC?H>!F%:5+$TWRW5_S+7PY\%VTWAN>:1D$D,G+
M9R"0V,9]Z]G\-^&3K3#.V&P@<0E5(5G_ !ZGG'3UKS+X7^&Y_M4=D96\@QK+
MC^$GUQ]:]E^'.F_VA<7IE_U-O+D-_.OF,R2JXFA1FWRN]UWLNOD?IF3REAL#
MC,722YX\MI=8W=O=\_/=&YJ'CCP]X!M9]+TVWGU/585&;'3H&F<,>@8@'!/O
M3/AQ\.=2URZN?$7C2P1KZ60M9Z?<$2"U0G))'3<>.O(QVJM\#534KGQ5JUE
MT5K<ZK)LF8?-,JY'WNN >>/6O:(+A(8R7(4 <YK[>O.&5*>!PL>5V2<NNR;2
M2TBKZ/=]V>)B*\J<YPNW*7Q2;U?5^A3M[1+63& %-.U6\2&$K$ \[#Y5'\S[
M4D]Y/)+FVVJO=F7.:9:VYDNI7E \R1MQ('%?/GDD%IJ]Q!$$NK;)Z>9%T_$&
ML/QAI&IZYX?U:.SEDCN)[9TBBC; )QP/J?6NOO8(H;9F;A0,DU!8:K9W$80/
MMDQPLB[2?IFM*<W3G&:W3O\ <:1;C)270\5\&ZIJ'Q2^%[6$MQNUS39#;3PS
M'$I:,C!?OG'&?45-'(7MDLM0B>PU9!B2%^/-7IN'8_\ UJE\66+Z/\:O#=_X
M;M8XKF\65M1CB^07"#&9'_#//?%:'Q:C&I+IEU!"T5ZEP(P/XN><9[CC-<_$
M-&.%K+-\)I[17</+F:M]]^5]NA]U@94<P4,LJJT*C<XOK"5M?6+L>$^./#GF
M?VC;Q2FW/WAL XR#SC\*XG1K.*T\0:0\]RWV:-@%9ADE@-JY/UZFO5?B'I\M
MI>3W$2-+)-'M(SV'(Q^=>+R"]O+>"+[/)%/-.5C#=>7PI/I7T6#7M*3BW:Z^
MX_(J\''$S5]/\UN>UPV^(V)D;_=!Q6'?[(99(@IC,H'S %B2#TX_&M@@PJJL
MS-(  =O<]ZY_59C#>PN8I7^;:WRDG!&/ZUZ.!J6Y9'L4GS0C(]F^#>DV&H>'
M+[2_MEOJ&H2+]I2W52)+<8P0WXUO?#OX4ZM=:ZDEX!;01R!B6_BP>E><_L\Z
M7?Z/XLDUJ::WM-)CCDM;B66=4.[ 8#:<$]12?M/^*K/Q-!IL&@>)(I9+)G>Z
MMK.Z*MR!@\$9KZK#1K5JKH4W92ZVO8RQ')!>TDMNA^AVDX73;<!=BJ@ 'TK#
M\2>*H[.&[@LRTU]$C<(A94?&0&/;M7P9^SA^T3KWPWE$.H75WKGAYUV26D]P
MSM;\_P"LBW9QCNO0U[VWQ4:UL[JYT^..\N;YGN8(I)A&K[OF W'Z^E?FO%>'
MQN1RC3I14N=Z/IY^C]7YGTV3SHYC&4F[<JV,V^\:ZE9K/.)9+5KAV,E]-$74
M2$<;NG>N%C\:78N+QKA'CND.Z]LU?S%*MP+B,_Q1L?Q4\&I)O&0NQ>H(9!Y?
M[R[T^X3$UONZG'1TS_$O'TKD[J5H[B.YLKG;Y&YHIQRT:G[T;#^)#W'_ .NO
M%P&6JG*2K05Y==WZI]5W^\]ZOB'*ROHOZ^\=?7;V>H0W=EMDBBW%5S\KQ-]^
M%O0'@@]B!5?4)85B,D3-+:S-^Z:9,>7\O*MZD9P:AO&?5K>YNK&&*%8P'N+5
M267!Q\RG^[GC/.,@'UIGA^:*Z:YTF49^UX-NS]//_A4]@6^[GOD=P*^GITE&
M*BEIT?K_ %_EW.)W>C'6<AOM/GBW[;NTP\*L3AHP &3VV\,#Z$^E&@M'_:RK
M-F"VNE:W=FZ*QY /_ @IS]?6JNBSOH^M;Y(R[1L8WM93C<I!5D8GTYYKM+SX
M7:]X9W:D]H+O1E=9/.60%PC$8++UR,C\:YL1C:.#M=KFO:U]_3UN;4Z3J>]T
M.8M+>2'5HK>%S::A;S_*6&<'(R,=P:]2UCX/SZ7;3Z[:7T+QPE;B3360C"]6
M57S]<5T.N7/A+6O"DX6UMFOV1?L[J@%QO'1BPY_.L&&[U)M/^QS7TCVI'S)@
M9;ZFOBJ^98G,-*7NQ4MG;\'^%EL>BJ=/#*TM^C-W5/&5GKWA.;31;$3NBK$F
MP[8"""&!(ZBL-YKV\L5M+RZ,UJN#Y.P*IQW..M,W+&N !3'9V]JUPN57^%=;
MZG%6QC?D0&W@M\^6BKZX%02W"C@"IY(]QY-12PHN"*^KHY?&*7,>9*NV5))G
MZ '%.%I)( Q/%69<%1@<T+(VW!KT(X>R]U&3JKJQ8]/5AEC2MIZ=FIJLWK3@
MS>M=4,+,RE7B5FM7CY!I%9AUJ]\W0_K2_9PPP!7='!QE\2.:5?L5$5HV+1NT
M3-U*'&:M>'IHM)NKAI./..2^,Y]LTY;4BGK;^U*66QE%JVXHXN47N8VK:9!K
M'B"86B"*.89!)PN<<FJ&J^$YM+CA@?YXGR1)'W-=0MN4D#IPPI=02:_5%D/"
M<C%;T\-4HOE@]+">(4EJ<':::8YV=EYC&0#Z]JAFL7_B4AV/.>M>E+!:&Q:-
MH4SMQ]WG-9MIHD5T^)ALV_W1R:[$^9>]$S]IT3.)O[1S<0@#*P1[<_Y]\THM
M2--V%<[I<X^B_P#UZ[/5-%CCN,*=RMR..1[5,WAB..P++)O=26P5Z\=*<G"U
M[;C51WW.'L;4K<7!QG,+CI["J;6ODS0MC 4@]/0@_P!*]"T/0+::4R2LP/*[
M1Z$8J&;1;:QUA4D7S[92#EOIT-8U*T8R:4;V_P [FD6VE=G!ZII,GVZ]*X8&
M0LH'7US6T/ ^JZEHMM?IIK.D,15\8SL!)5@,Y/!(_"NT\46NGZAIT"VT4:7(
M;&Z)0#MQT/Z5:TOQ'J-C8_9UB5SLV+(6X&!@<5\YB\9B)4?W,>O7?]#T:2@I
M/F9S7PD\,Z!=R7CZFWG%_P!T;:1B%*YW9(SZ]*EUS08-!\;2/X?N7@M8U&Q5
M.X(2/F7)[?XU-9Z+'&WS)SZ]*TS8QQ@;% ^E?)8J-2>)=24W)-6L]CTH5DH+
ME5FA]Q-J6JI UY>-+Y#;X@HV[&]1CG->H>"?C1>Z3'':Z[NO[9?E%TO^N7Z_
MWOY_6O,VD6U@+N0J@9.>F/6O*_'GQ4CLHV2WE:*)N%9/]9+]/[H]ZUR[ U(/
MW=%V.B-&>.?EW/O_ $7Q%I/BFU>33KVWOHA\LB(P)3/\+KU4^Q%<;XV^"NG>
M)+>5]*N6T&_;E988Q)%GWC/'Y$5^;EK\1O$FGZJFHZ-J5SH=Q&<K+9RE7/\
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MF^QZ^/Q6*]M[;F?E\K7-:^TV"UU*=;<;;?=NC4\D*>@IZHJK6:-7M[F:5H9
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M!N/!-7[:LVN5*SDXK?I?7\-OQ-%21Q%[H>KV6L)I-QIMU#J<A"I:/$1(Y/3
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MDZ2FJ7NA:A::<X4BYF@94YZ9],\8SZTFJ>"O%&BZ3_:=_H&HV>GX!-S- RJ
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MJ.UM?M'SLV]CU;K7 8_(B4G4)W!8M$K816&..Q(]:GNM*1H<%14RVOEW";2
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M+#$PL8$N)VCG1E$;$A6!!YS@]*IV^A7EYH][J<48:SM&5)GW %2W"\=378>
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M39<.&!S\RMU_&N@NVBM=L@?9O. HY+'T [FN"M7[:%RM%7D]#._LM;:X(0<
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M0ZUBWJ]0>:X(Q4M#3$8:&(ARS/T.K,TWQ)I&M-)'8:E9WKHQ1XX9U=E(.""
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M6S=1ZR$+_.NJ2]$:X0!!Z*,4[^T">]<<LRE]B)TQP--?$V_Z^9B6W@?4)O\
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M;B.Q1IBP'[TJ0H_/K5GQMX(LM8N['4)(MS6W[M1CABQ!)S_P$5W7@O18;6%
M(PH ^Z*T4+R/3IX25;%6V[_\ \3\3?LQK/KAU#PU?_V5<3DR3VDV3#(Y.2R]
MU^G3Z5=LOAK?^%Q'_:UQ;S2DX$=O*)&/OM'0?6NH^*B+KGCS3[*"<@6-N3*L
M3D89VR <=\#/XUUGA_PI;:?IDMY<;8XHD+LS>@%.=M;]#N>#GF.)^IT(N4D[
M7O\ AM?\2MX5\)V^J1JKQ PL"K(XSD'@@U!KG[+'AB/=>Z=.VE-R\B9S%_\
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MVA2_E81R"OUDOQ,TW18X&6/M2[+B3I$WX\5JJ@7H /H*=6,LR_EB=M/A]?\
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M0>H."".Q%>(IXC+9<LM8?UMV/(_?8*5IZQ/R)AN3QS5R*Y/K7N'[2W[*%_\
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MZB@+#=M&WVIU% 6&;*-E/HH"PW;1MIU% 6&[31M-.HH"PWD=.*>LSKT8TE%
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M\,[^7^1YUX*U=_#0M]0B.V>%@R>N:_0W]G_P]K46BWGB;Q*D::UKACEV)U2
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M:R(]+62!BB\&]5 /J:XI8SGG**T2_P" >U1RQ0I1G-W;?X:E&+9'' \Z81I
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M\4>,+30;>"XNYH8UD )DE8+D^PKQCXA_&K5=1DFMM!GALM/C&'O<!C)QSC/
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MRA/NT9Q_VRKY CEK];_VN/AF?BI\"/$>FP1>;J=E'_:=B!U\Z'+;1[LN]/\
M@5?D/#(&4,.A&17;E5;VN'47O'3_ ".[*JWM,.H]8Z?Y&I#)[U:CDK+CDJW%
M)Q7LGNQ2W-%)*E$AJDDE3))S2L:$[,<53N/FS4^[-1R<U#,I&/<QYS69-":Z
M":'=5*6W]J2.:43":&HC%6Q):>U1&TIF/*9?EFD\LUI?93Z4GV2@7*?2^O\
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MDKWO?OK<KV$^5Q25[WOWUN;/@'_DRWXS8.1_;6D]/]X5[_I+!?VY?@L20O\
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M?CD_E7J8";]I32[F^5RDL=2LKER9NM>L_L@V$=Y^T!H5S,,P:=;W5\Y] D+
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M%@KC#)9JV=__ &T<9^B*>]8/_!2[XKI;Z/H'P[LILSW4@U3454_=B0E84/\
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M]Z]?$5Z="F^65Y/:PXQ>[-'2?@5X/M(A=-8RW;#)"7$[,GY=ZZ#0VM[+5H(
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MY6C4N]?YM+Z^:Z'W4X5,TRYU.5RJ47&-U_(T[72[-6OV=GT/9I)()VC#1)*
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M;U/BJV*J3F^2<N7S9Q\7PW^'W@G3Y[Z/POX=T:SM(VFEN5T^&)8T49+%MO
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MSI\WW+^U?Z3+_C7QG<:E+'G!K/D\07$?0@_A6G]G1Z,OVD.Q]R+*DGW)$?\
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MCO4#W?6JGAJ=:/+5BFO-7*C*47>+L?47AO\ ;+>/9'XAT ..AN--EQ^/EO\
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M#\_NIG3_ -G-:*AF,?AG?Y_YF?U?,8;3O\_\STZ/_@FGX*5AGQ9X@(^D _\
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M2UI*S:M"^ER!I;VV3?:R;MSM&.L?^U@<J>N,J>U'A=9!K5NJS1@7+B&Y@?\
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M]DTU^9Y.89#B:="<L124J<7JTTTNU[/0^8M0\4^-+6Q%M<I:W=O'&(U3RMC
M 8&&!Z_A6YJ.LRZE:Z7?P6\C^:4)''!Z,"?;FO;O%/@&QDLG:()(<?PD&O(O
MLT-EI^I6)7 @G)7C'##M^(-?186I[]CX+'8:E2@JM.%FG^9)\.YI1XX?:&6+
M[,^_/ /(Q^M>L23U\^/KK6\5OJ-K-LN(6.64]U."#]>_UKVQ;SS8HY.@90WY
MC-?HV4NTW%]?T,Z%T[/^K%FXN>O.:R[B<TZ>XXK-N+C.:^PC$[R;[0:5;C\Z
MS&F.3_.C[1[UNH :37'O52:X]ZJM==:JRW/O6T8#+;W!]:KR7 _O52>Y/-02
M7'O71&!5BW)<^]5I)L\'H:K-<'UJ%IOQK;E1<5KH03)L8CMVJI.N<U:ED#<F
MJTW>OS_'X5X6LTOA>W^7R/U_*\;]=PZE+XEH_P#/YF/=IUK$NX^M=!=]\5BW
MG>N.)ZDC%F7!J-9-IXJ:X7YJK&MS(T[6XP16]97F,<UR<,A4BM2UN,8YJ91-
M(L[2UO,X[UI1W&5ZURMG.3C!XK9MINE<LHFZ9J,VX56G0<TY9LBFNV[I46!F
M5=1#G-8MU#G.!71W" ^]9-THYK6)FT<[/#ZU49<&M6Z4<]JS9N*Z$9,C#8J5
M9<=ZJLW- ;WJK"-!9C4\<U9T<AJQ')MI&B9KV[=,UJ6\G2L&";I6I:R5E(VB
MS9CD^6GL]587J1FXK(W(II*H3/UJS,W%49C5(RD5Y3FJ[U.U1,O:K1RR95D6
MJSQ_SJ^R57DCZU1@RILYJQ$O2F[:E1:!%N'M5Y&^450AZ]*O1KQS6;-HB2-U
MJA<*6SVJ_(P450N).M5$IF=)&J^]0Y%23OR:JEJU,SZ-\&P^ _!/[,^G>.M;
M\'VGBCQ/)X@N=-LX;R1UMY!Y:MF<*?G5 &PO'+?E%KWA+PK\9OAMX=\;Z%HE
MGX$U+_A)K?PUK=GIS-]C(G*F.YC5C\A 8 K_ (9K:\)ZIX,L_P!C'2+3QQIV
MIW6D7OBZYCCO-&D1;NQE$.Y945QM<8#*5)&0WJ!7%^*?&WAWQ5X5\+?!WX4Z
M5JKZ9>:W'=W-]K<D<5WJ5Z^(HQ\F5C10>OL#C@D^3'F<VU>ZD];Z6_+_ ()Y
M'O.;:O=-Z]+'I%BO@23]I9?@RWPHT670(=0.F"^8S_VLS)'N^TO,'&5)&XK@
M#:>M6O ?AS2/&G[/?Q?TN^UK0O >F+XP@C%XL;_8(O*\M5"*6+8<KQECRU=+
M\6/BIH-[XZU;PIHOQ97P7KD,<>B23W?AL7+1NJ+&\ U0#SL;@078=23G%>#^
M(M6/P9^%?Q#^"_B"TF/BF37;6\6XM2KVGEHL3 [B0WS* 1\O<9QS7/!2J*-K
MI^[WZ/5ZZ?F<\5*HE:Z?N]^^KUT_,[SQKH6D_LY?L[ZGH=CKP\9W7Q*:&6#5
M;&W*:?%;6[AB58L=TA+8Q[]MO/97_P 3-/\ !_@WX+>'/%(:X\!>*/!XL-8@
M)XARZ>5=+Z-&QSD=L]P*^>/#?Q:TN;X%Z[\.O$]M=W:QW*ZGX<O;958V-SSY
MB/N8$1."<XS@LQP>*3XK?%#3/'WA#X::386]U!<>&=$_LV[:X50LDF5.8\$Y
M7@]0/I6WU>4I)5-=7=_+1_E\T:>Q<G:>NKN_EH_R^9[1=_#G4?A1^S[\;O#F
MHL)C;ZOI4EM>)_J[JW:1#',IZ$,OY$$=JM?!WP7XS\._LSZMXA\&:+?:EXG\
M4ZK#!;R6: O!96SEB^<C :167WR*X!?VEFUK]F74/AEK4%S<ZK'+;QZ;J:A6
M46L<JR".4D[LIA@N >"!QCFC\5OC=_PDTGAC2_!MUJ^@>&M TF'3K>#SS!)+
M(.9)7$;D98X[]O>LU3K2O&2WE=]G9+\V1R59)QDMW?RT2_,ZC]LSPC<Z+\1M
M.\42:=+I<?BO3HM0EM)5VM!=JJK/&WN#L)]V->$V[%J].U3XJ6_BWX%VOA#7
MO[0O_$6EZLU[IFI2OYJB"08EA=F;=U)(X/11QBO2_@)^Q7KWQ!%OJ_BGS_#?
MAUL.L++MO+I>ORJ1^[4_WF&?0=ZZ(UHX:C:L[6T]>UOD:QJ+#TK57:VAXEX$
M^&_B/XH:XFD>&=+EU*[.#(R_+%"O]Z1SP@^O7MFOL?PW^RWX:_9T^&GB#QQX
MB>'Q%XKTW39KF&65,VMK*$.P1(?O-NP-[<^@6OIGP/X!T#X<:#%H_AS3(=,L
M8^2L0^:1O[SL>68^I)-;LT*3QE)$61#U5AD&OG<1F,ZKM'2/XL\BMF$ZCM'2
M/YGXP:'\/?%GBEE&E>&M9U5VZM:V$L@)]<A<5WFC?L>_&#Q" 8?!-U:*?XM0
MGAM_T9\_I7ZGZSXOT#PVA.K:WIVEJ/\ G\NXX0/^^B*\ZUS]K3X1>'F9;GQU
MIDSK_!9%[D_^0U:NS^T\14_A4_S9V?VE7G_"I_FSXITG_@G)\4=4P;V^\/Z0
MIZB2[DE8?@D9'ZUVNB_\$O=0DVMJ_P 0;>+U6QTQG_5I!_*O8-:_X*(?"G3=
MZVBZYJS#I]EL-BG\9&7^5<%K/_!3K1H=PTOP'J-S_=:\OXX?T57K3ZQFE3X8
MV^2_47M,QGM&WR7ZFGI/_!,KP7!M_M+Q;K]]ZB!8( ?_ !QOYUU^E?\ !/+X
M0:;@RVFL:@?^GG46&?\ O@+7@FJ?\%._%LK$:=X*T6T7M]JN9IR/^^=E85S_
M ,%#OB?J2DQ?V'I^?^>-BS8_[[<U4<-FE9_';Y_Y"]CCY;RM\_\ (^P;/]BG
MX+V:@?\ "$6\Y'>XNKB3^<E;5G^RK\(+''E?#K0"1_SULUD_]"S7P)JG[;WQ
M=O5('BM;8>EO86Z_^R&N'UC]K#XN7A.?B%K,?_7&1(O_ $%16O\ 96/E\=;\
M9"^HXI_%4_%GZFVOP%^&MECR?A_X83Z:1;__ !%:,/PG\#V^/*\&^'X\=-FE
MP#_V2OR F_:(^*-YGSOB+XG?_N*3*/T85;T3XR>/+JX G\;^(Y >N[5IS_[/
M67]D5V[.K^8?V=6>]3\S[._;X^&?@K1?!NB:OIVFV&C^(I+X6Z)8Q+";F#8Q
M?<J@9VD)\W;..]>4_L@>#[&Z76+ZX.Z5)1&%8\(N <@=B<G\J\<UKQ%?:Y(+
MC5-1NM3N NT37D[3.!Z L2<5L?"7XG'P!XED#S+%87RB&9V!(C;/ROCV/7VK
MV:N"JTL Z*ES26O_  "\9A:GU"5*+YFM?7R/K3XH7FF:9I+BVGAB?!S(5SL7
MUKXP\66=MJ7B1Q \@BF'WG4 LV>7P.F?>O0OC;XLDCDM)-1N-\#*LL+64_$@
M_@"8Y.3@DM@<UX-IL]_JVJ3M:V8-Q/-Y?F>89&4*>YSR23]*^+VT/SI7FW/8
M[N^\&V@T^,94M&NR(8X ]0/6L@?#EM+ACNA#M+G*L5%>Q^!? C+;V\^N;B>/
MW:_,>F>:]3D;P+KGAV:SN(KC;#QYT2?,K8_A]:ZL+6I4*\9U%=(WHT:D]>A\
MP6L.JV>H6K7%U,@4AAA0#CU%?4'PI^'OA3[&-6U"::2>8;BTJ;FZ].G4^@KR
MG4K[P]8Z@KV\EUJ%PHVI]J0*%'88K%U7Q)?V<ER?-5I6.(]DC 1KC@ ?XUZ&
M99A]::IX=NW6W4].GA^;1JYV/Q\\3:*MU'I/AV.2UVN1+)DQR)Z9 P37S->6
M,LTC%B6+')8G)/O7;2;I9GN)Y#/=-G,A.>O?W-9EQ H[5Z&4PJT*<O::7/M\
MIPLJ%)\RM=['5^"OV4?B7XZ\.6.O:%X>6]TN]5G@F^W6\9<!BI^5G##E3U':
MH/B!^S?\0_A;X=?7/$N@KIVF)*D)F6]@E(=CA1M1R>OM6Q^S;(Z_M!> 5#L%
M_M1/EW''W6[5J^#?AWIWQ@_:5\<^&]8O+FVM/.UBZ2:%S^[ECE8HQ'.5!.2H
MZUV3K5:=1\[7*E?9WM?U_KL>@ZLZ=1J37*E?9WM]_P#78\!FD9AC-4)F*U['
M&WP@D\56<%EI7C'6](AL2GEQ/%%=ZK?;QA@HW>5%LR=JY;H/>MOXV?!C0-&\
M"^#O&F@Z!XA\(VVKZD^EWNA>(2QFB<?,LD;,H8HRAN2/3WKI6(C&48R35SJ]
MK3BU'E:N?.5Q-UJ!,LU?5GQ,\ _ 7X/_ !4O_!.K:/XQUORYHEN-3CU&.%;%
M9%5@(T"YEVJP)+8SR .*CT']E'2]'^*GQ2T/5$U3Q;;^#;**_L=&T>18;W5D
MF :/G!P%5ANVC))&.P,?7J;CS--)JZ\UI_FM['.L3"W,TTK77FM/\UN>#?#/
MP!??%#QWHWA33)[>UO\ 5)C##-=%A$I",^6V@G&%/05@:I8OI>I7EE(RM+:S
MR0.R?=+(Q4D>V17T;\"W\+-^UA\-U\,^'-8\*&.ZE6^TS6+O[0\<OE2XV,45
ML;>H89S7 ^%+?P5<^./%D?B;PSXG\8:F^IS#3](\.RB(.OFR>8\C!6?CY<!1
MW.:GVSYWII9.VE]WYVZ=RW6?,[K2R=NN[_K<\A;.>.36IX:\'ZSXP\5:?X;T
MFQ>?6]0F$%O:2$1,[D$@$N0%X!/)%>[_ !.^%/@WX3?$?X;ZO)H?B6+PIXEM
M$O3H%_,+;4;&Y60(8V=E/RJ[(W(R1D9Y!KO?CAX?\#?$7]MJ#PF=,UVPUN_U
MRW@U758M458Y(C9@@0($W1M_J_FR?NMZ\8RQ2=N5:--W]#FEB4[<JT:;OZ'Q
MMJ>GW&D:E=V%VGDW=I,]O-'D';(C%6&1P<$&H%;FO?\ 1OA'X(\)^&?%GCWQ
M\^KZAX?M?$=SX?T71-,G6.YU":-F+/+,P^5%4<D#)(/L#F>./AOX'\3_  H?
MXD?#A-6TJSTW4HM,USP_K$ZW#VK2_P"JFBF &Y"<+AN<GVJUB(MV^5^EP]O&
M]OE?I<\I\-^)-4\(ZW:ZOHFHW.E:I:MOAO+20I(A]B.Q[@\'O7Z#_LW_ /!0
MNP\1?9?#_P 3S#I.IG$<6OQ+MM9SV\Y1_JF/]X?)_NUX7\6/ _P"^!GQ0O/!
MVKZ)XRUYE\B2XO(M2BA2P26-' C 4&8@-N);'7 '%>0_'?X7I\&OBOK7A6"]
M;4;&W\J>TNG #202QK)&6QQN ;!QU(SWKDJ0H8]*,HM75T_Z_4YYQHXQ*,D]
M5=,^P=6_;0\3? [XZ>*O"_B>+_A*O"*7_G64T147=O;3*)8_+?[LJA9!@-S@
M<-7U[X"^(GA7XQ>%1JGA[4+;6=*N%\N:,CYD)'S1RQMRIQU5AS[BOQ2CN'FV
M>8[OL4(NXD[5'11[#TKN_A;\5/$OPA\30Z[X9U!K.Z7"S0MEH;E,_P"KE3HR
M_J.H(-<V(RJ%2"=/22^Y_P"1G6RN%2"=/22^YGV)^TA^Q2+!;KQ1\.+5C&N9
M;OP]'SCN7MO_ (W_ -\_W:^4-,NBC@'((."",$'N#7Z8?L]_M%:#\?/#C3V>
M-/UZT4?VAI,CY>(GC>A_CC)Z-VZ'!KR?]J[]EE/$"W?CCP=:;-90&74M,A7
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MLK"VGOKR8[8[>VC:21SZ!5!)KZ0^%O[!GCWQIY-WXC>'P=IKX8K<CS;QA[1
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MN5?^6<"X+GV)X4>["OL'XM?"_P"'[?!S7=+U?0--MM M;&1E$<"QF!@ORLC
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M].KOIL[WWU'[&+W_ %-%OB-H/A'X@>&_$O@#PS/H']BR><8]2OVNWO&SSO.
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MF,U-/)WK,N)JZHQ*'23<U]!?L3>%1K7Q$U+794W0Z/:;(V[>=*2H_P#'%?\
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M)-<"CS/FD>["*@K(=<719B2<FL^:;WYI)INN3BNE\,_#Z[U[9<79:TL3R/\
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MUPV.RJ.K'T KGK/PO<^))Q>:HOV>TZI!_$1[^E=+#HJPW7]H:FZ7-Z/N*O\
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M<L8TYVU3//\ 5OM*VL,#1%IV5(L)R"Q &!^->ES1FSM+>!C\T<:H><\@ &N
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MD![$-R#_ +)%9<.I-H\QBN)FGTN4_-GK Q/WDS]WW0_*>V#7Z+",8I)I)O\
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M93'MUS7R.?4N:$9'D8^G[1*/?0\4\0^)G7XN:E(TA$<C+;HS$C&U0 !^9KZ
MT.U4Z79S+TC95;Z''/Y_SKY7DTVY\<>(C'"RO<SL78[MN,=\]NU?2G@1M<TV
MWATV^EM)7*8+09;*].=PX-?'U$DDCU,#.G1<:%[2LOP1Z-=6P\+7<6LQH7MG
M(BGC]CW'XCI74_$+['??"G5M1AGCACCMUN(;AN K*P*G..">GXU#=62WG@NZ
MBEP76(L#TY R#2R>"+GQE\";G1+9UCO+F 20ACA2P;>%)YP#T_&O#RFV!SF%
M%/EI-J7I[RN?J%:K#,,MH8VO+][3FH-]X[J_H=)\.VU"U\#Z/<7I$EU+:K+(
MH/'S<J,^RD?E6^P>^PT@P!T4=*\T^&7CPZ1X7M_#GBB.33->TU1;>5,A_>1C
MA'W=",<9SCCK7I^GWT$C*OS(3T##K^-?29E0J4,3/G6C;::V:ONNEO0^-Q-.
M<*LN9:-OT^0?V>NW[M2G4#;JD9!DD_IZFM&0+MK#O+E5O,!&95&"RXKS#GM8
M<UJ;J0R2<M_+V%/6U^SL'3CU'K5^Q:.9-RG(]ZDN%55)SCB@5G8D@E 0<5QG
MQ:\26OA[P/K5Q<%6'V9TVL,@EAM _6N@N=3M)['9;EH[DE5S@CC/)]*\>^'N
MBWWQ"\?:]K&M*9]&TZZDM;6VF&8Y)%8@':>"% _[Z->K@*$)N5>K*T*=F^[U
MT2]>_0[:%-.]2;TCKZ^1?_9]DUO1/AG9#4K>1_.E>:-)F(E6,XP>>QQD#WJ;
MXD:@MKKFB7UNI61Y,%ER&VG YQZ$UZ)XCU2R\-Z>]W?2K%$O'/?T '<UYE:Z
M/-\0->BU5U:'1[<[H$<8:0YR21V&1^E?*<0XUXZM*--+VLY<UETUO?T\S[#(
M8/ZQ4S/%KEH)23?1MJW*N[_X<W?$%K]JTU92/G*Y/U%>"_%K;I^GSW)'W<=O
M4U]#:NRRV#QPMNVY4GT->,^.K$75G*)0')RK#'%>W1ER2C)ZVL?"3BIJ45L[
MGRXVIS:IK"_9QNCB!,C=AD$ ?6M?P;9RW7B1Y6&$MH6DZ]2>!C\S5F33[71X
M'M;9!'&K'ZDYZGUKG+C4)+&Z2>!RDL;;E.?T/M7ZM1INM1M3TNM#P_9N2<(:
M=#J-4D*S-FLF27KS6GJ5Q'?VD%[$,1S)O ]/4?G6%))UYK[W U/;4(L[:#YH
M(9-)UYJA-)WZ"IIFJC,V>:]*QUHCD?KS41:D=JBW4&R1UGPU\::G\/?'&C^)
MM&E\K4=+G$\>20KCHT;?[+*2I'H:_9'X:_$#1_B]X!TWQ'I96:PU&']Y!)AC
M$_22)QZJ<@^O7H:_$>WNC;R;ASV-?1W['G[4#_!7QM_9>MS$>"]8D5;O.2+.
M;@+< >G0/CJ,'^&OCN(\IECZ/MJ2]^'XKM_E_P $[:;2C;J6/VP/@Q=?!#QV
MTT(ED\*:L[2Z;)R1$W5[=CZKGCU7'<&OFK4-3ENSM)V1?W5_SS7[8?%/X9^'
M_C=\/K[PYK*K<Z=?1B2"ZA(+0R8S'-&W]X9R#T()'0FORIOO@'JGPE^-UEHG
MCFP^TZ'I^H0SW$L8/EZC9"0$M%ZAE!!'8Y4\UQY'FT,50<*W\6"^]=UY]_O/
M2ISE)<J.U^'/P2^%'QL&I>'O!UG\0+?6(K":XLO$^J11?V=/-&N[9(B+^[5B
M" -V??/%=!\(O@7X#\._!]/'/BB;6)[P:L^G-;Z=Y8,W[I7559A^[ )8EN<@
M 8KWS0?'VD:'\5&UN]^*=K/X0F,L&F:#IJS"&UB="L8EA"JD2QC'/))P>.<>
M7:OJVD:;\#9_"5OJ]KJ.K6_BE[A5M=Q6: 0;!,I(Y4G\?:N+ZQB*SY+R46X]
M_.^K2\K]%T.BG%I_<7M2\ _#+3/!]IX_>]U[_A&+B4V*:&OEF^^V#)*^;C;Y
M>T%LXSR/6N?\3?!CPQXI_P"%?:[H=UJT'A3Q%J(TZZTF_9/M%O,) K R+PP*
MDD#V&<YP(]=\5Z39_L_Z1H4EY&^N1>()KQK+!WK$T14/TQC/'7O5SPY\0M(D
M\%_";08[Z)]=A\9+--9+G?'$\JA6/&,'/K1^^IKG4G?F:^5G;]-=S7WNCN;^
ML^$_@Y\/?&4G@>[U/7FOVN?LIU6V$2V]DSG$:,F,MMRH9AWST[9_]F3_  W^
M$O[0>CZU*JOH\NF123J#MD7SR5<#K\P*G'OBLOXLZ#\+[[]H#Q!JU]\4M.T:
MSL]99]8T2^M9CJ F1@9([=5!$H<CAATW="13]!\=:1\4+KX[R^(-2M_#K>-9
M;"XTF'5\^4D-HYV)(5!VNRJIV^I/7%81YY4XR;DU[K=T]^:+TT[7;MI9(S3N
MERZ[7^]%CP+H>D6.K_ O6[R\UN:RUV&.[CMUG3=%<BZC6)5#C"0]2RCYCD8(
MK<UK2?"'Q _:N/A?3I?$6CZC=:KJ"ZG>QW<299(W<&W*KN0%E(.[/!Q7$^(/
MBEX=%W\ U358<:"8AJPPW^AXNHW._CLH)XSTKG?!_P :?".A_MQ77BN]UN"'
MPP^KZA<'5&#&)8WAE$9X&?F+*.G>J=.M+GJ13NHSM][L;-.*<Y;V?YF'H/@W
MPAI/P]U/XC?$>]U9]#&JOH^EZ1HI07=_<*"SL7?A$4#D^Q]@?.+N#X1^,/B3
MH0TF#QO8^&YH)&U2UG>VN;T3#/EI PPH1OE!9_NY)KL_ASJ7AOXU?!V^^%NN
M>(4\*ZYIFO3Z]HFLWL+RV4Z2@K+!,5&8SR6#'U'I@^Q? 7X?^"O@?XLGC;Q;
MI&KZM=:3.EIX@AMWDMM.OB0(V)9>1C.& P,\]:]"55T/:.;ESZV2O:W1[6\^
MKO\ <9MRK-MWL4(_V>O >D_#W_A-/"NE>)M'-M?PVE_:^("DDCPOTD@D"@=>
M/3)]N?1_C=?>"]-^&_@=8++6DN&T1CI3-/#L1=X_X^,+ECG^[BI]:\3:<OPG
M\6^'-9^)D&O^(IFAOXIKB2>6W(C.3#%*X^9VQT  R5]\>4_%SQ#H?CGX/>#[
MO3?%>DVVK>'=*>RO-#O'=+R63S!CR1M*OD<]1Q^5>1&52K.#J-Z2??9K3IWT
MN;4XMN-]D_T.H\:?"737^*WB.PU'Q!J-MX4\.Z)!K&JZE<,+BZV/&"L4>0 6
M8Y"YZ =Z\NN/"7PX^+FB^*(?AK+XBTKQEH6G2ZLNF^(98IXM0MHL>8$:/[DH
M!SMZ<@>I'9>.?V@O .M?&3QUH=YKK_\ "&>,?#EGI$WB"QB:0:?=11C9(4QN
M95;<& ]O>O/_  6O@?\ 9HT_Q5XD@^(ND>/_ !;J.D7&D:-IWA^*4QQ&< /<
M7$C@!=H'W.IR1SVTI1K\B<N;GM'E5G9[7OI;>][[(EU9I))N^AFGX9_";P7\
M)OAUXX\;7'BW6=0\66=Q+_9&CR01IOBF*-(97'RKM* (,DDDYQQ7+?';X2^'
M?!FE^"_%O@J^U"\\&^+K.6XLX]6"_:K66)PDL+E>&P2,$>_7@FS\6/%VAZ]\
M#?@CH>FZC%=ZGH.GW\&HVJ [K9GG5D#9&.5!/!/2NWUVVTOX@_L]_!71;?4%
M>ZT(:H=2M5#!XO-N%:,'(Q\R@G@FO3A*K3<*DI/64DUTM[UM/DK,F$)-I^9X
M-X3\&WGBF["0KY=LIQ+.1POT]37M&EZ78>$]/%K9H%./GE/WG/J34_\ HGA^
MP6UM46*-!C"BN2UG73)N ; ]:NI6=1VZ'JTZ98UG7B<K&U<5J.K%F*QMN;H7
M]/I4&H:HUPQ5"0G=NYKIO!_P[FU;9=ZB&M[/J$Z,_P#@*TC"--<]0W;ML8?A
MWPK>^);C$*E8 ?GG;I^'J:]:T7P[I_A.UPBAIB.6(^9OK5A[JVT>U$-JB0QH
M,?*, 5R6L>(FE9EC;.>K5QU:\JNG02BY&IK?B0*S<Y;LHZ"N&UKQ (\M.Y9S
M]V,'DUDZOXD"LR0'S)<\N>@^GK7-23-*Y=V+LW4FB%+K(F=:,-(EN_U2:_8E
MVVIV1>@JGNIO6E[5TW2T1Q.3EJQ<TX4T4_&*S;)%6G+3?:G5-RAWI3A2*I8@
M <UIV>DL^&FX'91UIQA*H[1+C%O8J6]N]PV$&??M75>%?!%[XBODMK* SS,?
MO$<"N@\*_#N\UF+S_),5HO\ %C&:]5\&>7X9F6&*,)SRV.375R0I>;-=(^IU
MOPU^ &E>'(X[O5 NHWW7:P!1?\:]?CCBLX0%"0Q*.P  %<1=_$;2_#.D?:M0
MG"\?*@Y8UX!\1/CUJWBR22VL6-C8= $)#,/<UM1P]7$._0+.6K/H;Q)\;=!\
M)LT0N5N)U_@0UYSKG[0VJZ\YATVWVQGC*DU\XM-)-)O=V<DY.XYK>M?%=U:6
MXB@58\#&X#FO1^HTJ>MKLKE6YZ'>&^U-FN=9OS;P]=@;DUF_:GUF0:?HEOLA
MSAIL<FN.MM0.I70.H7$ACZX!ZUU*^.HM)M?L^EVXCX^^PYJ)WCHO^ ,[S1=&
MTCP)9_:+MTDNR,EFZYKE?%7Q.GU)GALOW<1XW_X5U_P=\.^&O&'@SXA>*?&U
MGJ.KQ>'8;6:*VL;PV[-YC.K#/0]%Z^AJ];^ ?AM\4/ _BO4?!5GKGAS7O#ED
M=2DL]3N5N8+F!<[\-U#  _CC@]O#J8R%.I)33=FDWT5[>=^JZ'-*LDVFMCPM
MC)<2%Y&+L3DECG-2I#[5L1^$=:5;IFTB^5;6!;JX9K9P(86&5D?(^53V)Z]J
MU;'X=>*+_13K%MX;U:XTH#<;V*RD:''KN QCWJ:F*CW%*HCFXX/:K"0>U=_\
M+?@_JOQ0&LR60GAM]-L)KOSTM7F2:1 "+=2.-[9&!U]C6#'X1UK^VET<Z/?C
M5VQC3S;/]HY&1^[QNZ'/2O-EB8MM7U1BZBO8Q8[?/:K*6^.U;FJ>$]5\,:A!
M::WI%]IDSD,(;N!HG=<C.W<!G\/6MKQ=X?AD\6:K%X?T#5]/T^V5'^PW\3/<
MVZ[5!,G!P"QXS_>%<<JUWH9\QR"6]3I#TKH=6\"^(/#EG#=:MH6I:9;2G"37
M=J\:,3T&2,9K,6'VK'VE]4R>:^Q"D%3+#7LGP4\$I<^%_%_B:Z\*MXEET^VB
M73;2X@D>">1I"KX"_?*@#@=,FN"U+0=4O]8G>/P_<6+7-X\,=C;VT@6.7[WD
M(",Y4'[O4"L?:J4G'L1S7;1SRPCBIEB[5MZ3X-US7+VXL].T:^O[JW8K/#;6
M[R-$0<$, .#D'K5:XTVXT^[DM;JWEMKJ-MKPS1E'4^A4\@U7,NY6Y4CAQ4JQ
MUN:AX*U[1K".^U#0]0L;*3&RXN+5T0YZ<D8K/2.FI7U0T0K%4JQU.L=/6.J*
M(TBJ=(P.E/2/VJPD?XTQD<<568XO:GQQU8CCH*&QQU9CAIT<7M5J.+I0,2.*
MK<</2ECBJU'#[4 )'%5N.*ECAJU'#2 SM8UBS\.Z=)>WTHBA3VR6/8 =S7B&
MN>-M?^)C-I\*M8:7(^W[-: M-<+\W#'(V=%R/]JN@^+U\FI:XMEN22*Q3!3.
M1YC<G(SG(&/SKN_A-X832]!2]E7==70#;FY*IV4'TZU\M_;5?%XJ>"RI)./Q
M5)*_+T]V.EY7V;TT>CW/KZ6 H9?A(XW&J[E\,=K]=7VMKH<9\+_@C/H>I6>H
M7Y6*WMG\^*W;F4N5P-YZ +D\ =:]O6.GI'4JQU]3[2K.$(UIN3BDKNUW;J[:
M7>Y\O7J^VJ.=K7Z=ABQU(L=2*E/VU!@1A:-IJ0+2XIE6(64E2 <''!]*^7/B
M5X+U[P7<7>K7<'VV.:[$HU9)]S.P;=&DJ'[J9 7@X'7%?4["N4^*'V3_ (03
M6$O1F&2$QA00"6/"X)Z<XKKH8^.7*5:JTH):M]%W.K#*<JD:<%=R=K%#X;?$
M:Q^(FBBXAVPWT/R75J&W>6XX.#W&0>:ZIEKY@^ MY<^&/B%'I9N&F2\4H\?F
M@G !(^0\J =W.>2:^H6JJGL*G+6PTN:G-*47W3+Q.'EAJKIR5FBO)5:3BK,E
M5Y/6I2.<JR55DJW(*JR5NAE22JLE6I.]5I%K>*+*LE0/5EQ5>0=:U2*2(& J
M)OSJ9JCQ6B11%BDVU)MHVU=@(]M.48IVWMC%*%I6"Q);P^:W7 QG-.48XJ2U
M4[9 .N*:JE3@CFH[DM$JU,HJ)/SJ9:AHFQ-""K9 SCM7(?&?3XM6^']\[1'S
MK/%S"T9PRL.,@]NM=K;#;&['IBJ.K:7_ &UI-[88S]IA>(8]2,"HCI)/L0>8
M?LUZL=0T6^T^SNEN;#39<,]PN)GDD^8D8XV#!QWYKV>*UDN)P6*X7YCNY&!7
MSM\![J?3?&]E8ZO>V-L]Q926]O8VP(*;3D,0/EW':P/>OIF'37@RX*LV?O9Z
M#%17M&3)*-]9",*8D&T\[AU/X566W2,9DY/]VKS;I+@B,-)SUV]J?+9M#ES&
MN.OS'G\JYUIHP,Z\<_89+DH\GDYRL2EF(QP .YKYPU!FTGXTZ7#]C.G6MS/&
MUMI,\:B2,, &E8CU).,D]:^F+JXEAM9DMI(X)G7 DD0,J^Y&:^=O'MQ;3>-]
M*U.UU>X\0RVMS&MQ?8.R+YP @*@)MQZ9-=6'O=I=A6/>+Q=TQ Z#BF)8>9 S
ML-G<,3V[\5,Z9<@=S5BZ3R82 "74;"S#''M7.]+)",/YK>7<C<J>#ZTV^CAF
MC$\;*K?QQD\Y]JFD0U6:%GX49J^7J%C-D&*P/&/A2S\7:%/IFH1DPR?,C#@H
MPY##\:[);*."%YK@Y"\!5]:R;RX>Y;+< <!1T%..KT"QY]\*_".K^%]+O8=8
M6#RED MA"^XE ,<^GK^-='=-YC%L;1Z5M738MXF3MP:S+V)63S5X]:N[D[L+
M&1-WJE-5^9>:J,N]@HZDXJ[ 9\HJJZUI7UO]GD*9SQ5"1:D15DJ!JL2"H&I,
M"%JB-2M435C(EC.*C:I#435C(D:U9U\?WP^E7VK/OL^</I_4UB(_9FBBBOB#
MP0HHHH **** "BBB@ HHHH ***:S;10 R:41J37DFN>)$O/%6J6VH.%@LV40
MQER@VE0=W!Y.2>?:MSXD^(GT^72[;S/*M;J5DF;.,X7A<]@>?RKQ/XG26=QJ
M$(TR*.5TA,<T:R_*O<9YX'6OBLXQ$L34^HTHR[MK^MOU/H,OPZ@O;U-GH<EX
MJM8;BZO!%;M-I_FL\;*^3C.05.>37$C5'M?]%NTEU#33GRVC/[Z,YXVY/(]4
M/_ 2.E2R37.CS%[)3".!-9S$M&_/H.WH1R/<<4^W^S:A.LUJLUM<R,5^PS8R
MYQD%6'#@X.",'VKZS*\'"A#]W)N+W4OZ_%?AURQ-:4W>P-&/L<C0W#7UKN7]
MX%*/%D9 /&?P/H>M8UGJ4%BQL+B3?HTC') S]G8_QJ/X>>J_=// /-1W%S)I
M5[]JM"UK=;3$\<A!+)GE"#]]3_=/X$5I6GAT>)[N.[\.Q?:9V(6;3T)\V'/K
MGJN>A[?K7JU:JI4W5OI%:K^OZ7EI?GIPYG9=2YHO@'6M0G:/3M/_ +7MP/.A
MN;?#1,.V&['(^[U%>Q+\0;B?P_/I4FG203F+[.XEQM3 P<^_7BLWPAJ6N?#6
M!=-U'1VC:1O-C*.I## 'TQ5#5M4::ZNKN50LMQ(9653P">U?EN(;S7%.\?<W
M5G?_ ('W'MN2P]-*+3,_4;Y84\L'VK#6SDNI=P&15R2U;4),J:UM/M39J-PK
M]$P=*.$IV7Q,^<JRYW=DFEVJ0H!(O-:"JH.5&!4.\.>!BIMP"UZ5/#RJRYI'
M#4J\JL@DD %9MS-U%3W$G45G3,6KZ[!82,%<\6M5<F023$FA6J-EI5KW+)'$
MRPK4I:HP=M(S9J0'-)3&EIA.:A=J8#YICM.*\?\ &5U#J7C5K>YCCFCM8%"K
M(H(&_)/7UX_*O5I&W UX_P#&#3;C2[B+Q#:J&BC7RKM00#MS\K>_7%?)<01D
MZ<;;'D8^+G%)/<\ONK'2?!OQ.$-@K10O:K(RN^X!F)R!Z#&.*]@\%Z@+K6Y9
M"<YV@?3 KYE\8:I/JWB1[ZUXE;:J<9S@8YKJ/ _Q*N_#>OVL=PC7$$C+"8AP
MP)( ()_K7QTJ;:3ZG3@Z3IU(59N[<;/\#[CFT^35/"UU;VY'G/$0OY50\">.
MO^$?TS^RM61[.XA.V)K@%59<]-WJ!4G@O6_M%N@ /([UUFK^'[77=)EBN47D
M9#=-I]17S6+P=5UUB\/*TDK6>S7Z'Z1EV9X:&%EEN.IWIRE?F6\7M?S]#F_B
MGH-GXL\'W>KRO*UWI=O)<VTUI@N %RR8Z%3CD>U7/@[XFL/&O@/39K:X2>YM
MX5AN8\_.CCCD>F,<UG_#>WD\+^(+[0[MU>VE7S(5?HX.0V!],9%.'[-7A"RU
M:?4=,N-6TAIMVZ&QO"D?/4#()Q[9KZ;*LRH9AESP^-<H2C*ZLN9)[-6NM'N5
MF.#HX*3PLJCE#24));IKM_6IZ)YLW$6X;0,;N]21V0V\+7B36NK? NZFUJ74
M)O$7A7=Y=Q#%&1/"#G;(PY4@' +9'6NBM_VB=+\26<D'A#2]0U[5]F_[-'#Q
M&O=F.>>W'>O0GD]:=JF$?M*?\VR7E*_PV\SQG@IR]ZD^:/?;[[['I7_'CND"
MY&.0.]9GB'Q-9Z+I[7>I3K:VHX]68^@'>O-9OC!XMT'3+B?Q'X"U66/&8Y+.
M-=R_[Z@G ]\5A^#YM4^/_BH76OZ ]AX0L8F5+><R1F21NF#P6/'/8#BM:>3S
MIN57%27LH[N,HN_E'7=^94<%*+<JK7(MVFG\EYFCXX^-GVGP^8O NG7FMZQ<
M,8D>.V9T@_VCCJ?05V'P*\)ZCX%\!P66L/G5+B9[N==V[:SX.W/J._N37>0P
MZ=X9T=+>UAAL+"W3"Q1@(BJ*X.Z^+&D37+)9I<7S@?*+>%FR<]J\C'9S@\/0
M^J4XJG%N]V[RE;;HM%?9'=0P>)QU)T\!0;BG=O?TN]D1_&")-5DT:U,H7S+E
M5QGU!R?\^M;^GQ"QC6T"K';B,>6H'IV-<'I>F:QXO\5PZKJ=LUG9VYW11/[=
M./7U-=CK6J1V[*=V-I]?:OD<M2KXBMC.6W,TE?LCU\^;PF$PN6>T4G!-R2U2
M;>U^K14U:X2W,R] PS^(KP3XH>/-+T2.>.2YC>Z9MJVZ,"Y/N.U9?QX_:";P
M_??V/HDT<M^5/VB9<-Y&>BC_ &OKTKYCN-0N]:U!IY'9YV+2%F.23W)/K7Z5
MEN32Q*56MI'\6?"MM;'5WVL-<.[LW+DL:P+RZW9YJUI?A[6=:L_M-M;AX-Q0
MR,X49'45M:7X1CTN1;K4Y8YY%^9+>,Y4-ZL>_P!*_1J,J5/W(.[6EE_6AQJ=
M*DWK=]EN7</9^']/@E&V18OF4]LY./UK&DDJ]JE^;J5F;GFLF:3\:^KP%&5&
MBE+=Z_>:48N,==V1RR53DDJ222JSMFO2.R*(W;FHV:G-4;+4MFT4*&IVXL0
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MD$35&U2-43'BL9$C&K/O3B8?2M!JS[W_ %HQZ?U-<[W)/V9HHHKXD\,****
M"BBB@ HHHH **** $K#\6:M)I>A:A<6XW3Q0.Z#K\P4D5KW$PC4G->1:OXB@
MOM<UF+4V4PVKF-8G<A1'M&#C/<'.?>O%S3'?4J/,DVWIH=V$P\L1.RZ:G*>,
MM4TW4O">YY5GOYBKPLTWSR./J>N,UX?X@MGMYC=&.2PN]WRSQO@ANF'QRI]#
M^!K5\46JR7'EI:/-IZRL4F1@2L?.'7U[9 KF?[0FM/\ 0[N)]4TZ1MJLI_>H
MO^SG[P_V&P1V/:N#(\O<'SRE*-2[W_JZ\[GLXNM%>Y"U@75!J"E-0B>UN8DR
M+R%,QN1S\R_P,?;*GVJIXFA3RHGN(CM95DBF!W*P_A?C]&7IZU-<1I;Z;,UJ
M)-0LHI0LK[MLD61E?EZC@]ZS--U""Q9[6Z,DFD2<E(0"8&/_ "T5?X3Z@<-Z
M9YK[K3X=G^O]=OP/'^)W_K^OZU+-K)#XFCCM[RX$6M(W[BYFY6Y]%9AQN]&/
M4=>F:](\'^&?%7@>,:[-HZ"';M??*N] 3U('2L'PC\+]>UIC<Z0MK>6 /F0W
M32;%DYZ!3R&]0?SKT6X\8ZQ?:;<:;>6L=L2?+G^8DC!^Z!]17Y[GF.EB*OU>
ME%.SM+7I\K6/<P\51ASMV9!K_B:Y\0&WEN8%@6W0JB[MQYQDG\A7+SM]NDVY
MJY>7)9MG;UJ%;=%^8-AJ]+*<!&C!-(\K$5^=MLDALS9X(.:E:X+=ZKO*XXSD
M4D+;FY%?:X?"/XIGBU:U]$:-NW&2*=(U1[@J\5$\E>]AJ7,SRZTALS9JLRYY
MJ1FW&DKZ&,>56//>I59*;MJRRU"XK2Y(QCVIAIU--(8UJKR-4LC>E0/WJD21
MR-M4UXU\443Q3K0TF>::*SM5#ND9P'=N03]!_.O89?ND"O'?B-;2:+XF_M!@
M?LUZH&[L'48(_+%?(\0<_)&VQY..Y[)Q/,-%\-IX9\<-#/+'=*L0>)L= 2<9
M'8\5>^*FFZ=&^E:[& E_]J2.0+]V0 $@GW&!S6'XDU@P^*'O%8^7M5"?0 ?R
MJCXOU@ZUI]O'C/EL7W ^W:OCU%N2DSFA"I*K3JM]-3ZF^%?C"&^LH)$D!XY&
M>0?2O65U[^U;A+2-OW46"Y!^\WI^']:_.O0O'FHZ,I^S7DEI<8QN1L ^]?0G
M[-GQ(O=1CU"RUF[FN;^.;S5DGZM&WI]"/UK*I2<5<^II5N=VDK,^A?%WA6_U
M46=[I<WE7MJ24YZ].,UT.DW^JW5K#!J""WG5,2*C9#^^??THT77(I(ERP)JS
M<7:_V@D@/RLFTGT()_QKQZ>#A2KRKQ;7-NNGJ?05<TJXC!T\'4BFH;/[27:_
M8TH[-)(F1D#HR[65AD$'J".XK">/2O <,YLK.TTBR"AW6SMUC+L2<#Y1R2>E
M=):W2[:Y+XC:;<:IIJR6<?GRP.LIB'\07/'UY-=5:K5IT9^SU?;N<.'C&=10
MF[)_+^O4T%N/$QT6#6_[&AM]-N#B*2>?,A^H'2LZ'XBVD<QCNY(["6,$R)+(
M-I'JIKR37OC7>+"NE6T5S),IVI:@-D-_N]JE^''@77_$FKW>J>)K0V]B8ML5
MN[9=R3UXZ8KPJ%'-'%XB4DDUI%M:ORLD['KX/!2E.53,J7LJ*6ZOS7[*^]^W
MXG=^(?%R>/ID\/Z4S,DW^ON5&%5 ><9ZYZ>G-=%I?A6P\+V86"(>;C+2-RS'
MW-+H.AZ7X9C9K.%49OO-U;\ZQ?'GCS3_  SI-SJ&HW26MI"N6D8_H!W/M73@
M\#4E4^L8I*55Z*W1=D=>99K2]DL#ECE&@M7?>3[NWX(OZUXFCT^V>1V$<:J6
M)ST &37R#\</CQ>>)8C::!>W&FVL;9:XC;:]P",8]0.M<M\0OVC=<\<17%E;
MV\>FZ:[$#RV)DD3G&X]@1C(%>9*L^H2'<<D#//05^JY7DK@_:8A:]$?)RYF]
M]"NJO-*7=FDD<Y9F.2Q]2>YK4M5^RH H+RR8&T<GZ"MKP/X3M_$5S>K=SRVR
M6T8;,0&22<8YKKK+1-*\-L9+=6N+CM//@LOT'05]G3?ONE3BW)?=]YRU,1&,
MG32NU_6XEJKZ#X?M[/.)<>9*/]MN2/PZ5A75T\AY-7]0NS.Q)-8T[>]?48'!
MQPU/WE[SU9%&GRZO=D$KGO561C4LC5 V:],[8HA<YJ(K5AE/:I+73YKR39"A
M8^O85$I6.F,6RCMK9T7PG<:DRO*###]/F;_"NDT/PC%;L))1YTO7D<#Z5U]M
M8K&HXKSZN(M\)ZE'#]9&;I.AP:?"$BB"+[#K_C6U'$L:\]*<[) N3U':LG5-
M:2SA,C')/W5]:\F=1L]:%.Q<OK]+>,LSB-/4UQ>N>*HH8V;(2+IN;JWL*Q/$
M7BHQL3*WF2]5A!X'UKA[Z_EOY3),V3V'8?040IN>KV-)3C3TW9]P_LJ?\%!G
M\+W5KX1^(\TDOA[(BL=>D)>6R'0)/W:/T;JO?(Y'WCX\^'_A'XX>!WTC7K.U
MU_0;^,2PRQN&QD92:&1?NL <AE/Z&OQ2\%^ ;CQ(RW5P&@TX'[W>3GH/;WKZ
MT^!O[26K? -;?2HXCJOA%3AM+9\&#GEH&/W3U)4_*?8\U\GFF4Q<_;X)\LUT
M_P NS.%X>51<ZW'_ !E_93U+]GRREO-'@DU?PFIW?;T3,L'I]H _]#'R_P"[
MTKYZUS7(;>$SW3[4[+GEJ_7WX>_$WPO\8/#?]I>'K^'4K-UV3V[@"6$D<QRQ
MGE3UZ\'MD5\J?M0?\$\;/QS)<>(OAO/%H^LX+2:#<-MLI^Y\H_\ +%CZ?<.?
MX>M8X#.??]CC_=??_/MZFM/%.*Y)K4_.77/$$^M2;3^ZME/RPCI]3ZFK'A3P
MC=^*;P1P@I;J?WL^.%'H/4UO)\'?$NF^*;G1/$6E7F@7-FV+F.[CV./]WLP/
M9AD>]>QZ%H-KHUE'!;Q+%$G10.3[GU-?93K1C%*F=5.FZCYI$7AOPS:Z#8QV
M]M$$C7J>[GU/K6Q/.(4P.N*=)((AC//\JXSQ1XD\K=;P-\_=O2O-;<F=R71#
M?$?B(0*\4<F9#U(/2O*]9UEKQFBA8^7GYG_O?_6I^M:PUU(T43$IGYG[L?3Z
M5E+'7?2I<OO2(E+[,2-8ZMZ?I\^H74=M;1---(<*JU/I6D7.L7B6UK'OD;J>
MRCU->R^#_!]MX9MQ*V'G(R\S#D^P]J*U94UYD1AU*GA3P3;^%85EFVS:@PRT
MN/\ 5\?=7_&K>IZLL"E5/-)K6M!I'"&N#US7MC&.-MTG<]E_^O7D>]6EYG;&
M*BM2QK.N>62,[I#_  Y_4U#X9\)7WBZZ\YRT-F#\]PPX/LM:?A#X>S:LRWVJ
M[XK0_,L9^_+]?05Z'/=0Z?;B*%4AAC& BC %5*K&BN6&_<-9;#+.SLO#MB+:
MSC6*,#D_Q.?4FL'6O$.W*1MN;UJAK'B!I-R1M\O=B:X'6?$AD9H;9O9I>_X5
MRQC*HRVXTU=E_6_$0@9E5O-G^O"_6N1GG>XD,DC%W/4FFLQ/)YIG-=48J"T.
M"I5=07TI:*4"BY@&*?24H%9MC%%/&*116A9Z89,-)D#LO<U=.G.L^6"+BF]B
MO;VKW+8487NW:N\\!?#?4/%MZMO80,5S^\N&'RK77?"[X)7WBYXKJ[1K/2U.
M=V.7'H!7U)X;\*V'AFPCL["W6&-0 2 ,M[FN^U/#:+67Y&ZM'U.6\ _"?2?!
M=O&RPK<WV/FN'7G/M7>OJ5MH=NUS=SI;PH,EG.!7,>._B-I/P_L&DNI%>Z8?
MN[=>IKY6\=?%#6?'5X[W$[0VN?DMT8A0*JCA*F*?-/8.7FW/?O&_[5RV>[3_
M  U%]IF;Y/M&?Y#%<GHW@GQ'\2YO[6\6ZE+;V/W_ "I&ZBO)?!^N:;X?D:[N
M+;[5=K]Q6'RCWK2\2?%C6_$2F$3&UMN@CB)'%=WU-4?=P\4N\GN+D4?A/7->
M^(7AOX=61T[P_#'-= ;=\?7/UKC]'\+:O\1-0&HZU*\=H3N$;=Q6%X/T73[*
M)=4UB=68_,L;G-:?B#XL2/$;32D\J(#'F=*S:]G[M/5]6R]CT'5?$NB> M.^
MSVPC5U'"KU->,>)O&%[XGN&:1V2'/$8/%8\UQ/?3&2>5I7/)+'-2QP=.*YO=
MIZO5DMC(H<XKH],\/;E66Y.Q.NWN?K6?9K]GF1]H8J<X:MG-Q?8WLV#R$2O$
MS#,Z&!I.MB9J,5U9IA\/6Q=14J$7*3Z(;>20;?(MXU"=V J"*WW8P*OV^EJ[
MX+;3_=88-:L-BD(& N?6O&I9O@\53]K1JIQ]1U\#BJ$_9U:;3]#)BLWZ[#6C
MI-G;W&HVD-Y,UK:R3(DTZIO,2%@&;;D9P,G&>U2O(BL5&9&'54YQ]3TI$59B
MP (/=6%>/_;V7U<1]4A63GVN74RG'T\/]9E2:AW.]U;X,WVE_&"'P''<BYEN
M+F*."]"85X74-YNW)X"[B1G^$\UKZMX,GT'X?^.1IOB::\T+2=;ALI+06X2.
M]D  \XG<=NT@@#G( ->D>&?&6D?\*]T_XAW%_ /%_A_19]!BM&D42RS%E6"8
M+G) 1VR<=SZ5YWH=U G[//C"TDN8_MLVL6LBPM(/,<!1E@O4^YK7VLY;]++Y
MW/GN9O<=XV^#NE^ ;.9]1\60/?S6D%SIVG1V[&:?>%+&3!(C126P2<MM/ JW
MI?PF\)^)EO\ 3_#OCAM6\1VMK)=+;-ISPV]QL&76-R<Y]"1SZ5J_&";1-:^+
M7A3[;>QR:*=/T^&]GMI P1 Q$@RN<$#KW%>I>%Y[_P -_$:>&?4/"V@^"IA-
M;:7;V4EL&N@R$1'<H,F<<LSD#/'.16,JD^1.^N_]:$.4K+74\<E7=^S%I_OX
MHD/_ )+U#^SJN/C1X8/3]]+_ .B9*V6T:1O@'J&ABXLSJNA>()+F]M?M2;A$
M(MF].?G&[CY<YK'^ =S;V'Q<\.7%S-';P1RR%Y9G"(O[EQR3P*TO[D_F5O&7
MS'7?QF\=Z7XDO9(/%&H$0W<H2*:3S(\!R I4\$8KO]2TFQOOB%\)O&=A:1Z=
M_P )%<PR7=K",1BX21 [*.P.[],]S7-W_P #[J;5[R[O/%?A>PL)+B25IVU)
M7*H6)^Z!R<'IFM>Z\::-J'Q*^'>D:+,1X;\-W$%O%>7'R"9MZF24YZ [1U]S
M4/E?P=G?[A:/X2W\;M+M?B!)X@\0:9"L6M^';V2PU:V3K+;JY6*X ]@-K?3T
M KG?C.N=!^&Q/0>'8_YBH[[QM)X/^-?B#6K39?64FHW$=Q I#1W5N[G<OH01
MR/<"N\\:Z;X:\5>/_AO8:=J%M_PCD%@K/)+.H$<"-O\ +<D\,0 N#SS2C>FX
MWV6OX#7NV[&GX<M;+2_#>C_"JZ2-+O7M(FO;F1C@QW<F'A4^X"'_ +Y6OG22
MUDMIY()D,<T3%'4]58'!'YBO8M:_:$N9?%5SJ-KX;\/W'E7!^S7<]F6N?+4X
M0^9NR#M ^E<]\9+&P_X3B;5-+FBFL-8B34$$3AO+9Q\ZMCH=V3@_WJUH\T96
MDM]?F53NGKU. 6.IEBJ9(O:I5CKLN=2(DBJ:.'%2+'4Z1T[E#$CJQ''3HX35
ME(^U,!L<=6(X^<TY8PO7BK,:"G<8D<=6HXZ(X^E6HX_;-*X!''[59C2B..K,
M:4 +''R!7I^@Z;I=KH<DEPZ(RH22U><1KM8''(KG?BGK.L_V!/#IJ3*K(0TD
M?1!ZDUC6DHTI2<K6U^XYJU.=24815[GSA\?O$D/B#QUJ<-FHGLH$<93:0Q[=
M>.O8U[)^S,97^'K^9NV+=.$^\ .!GAN1SG@UX!XHTF/3=)N8OENKRYE02RMA
MQCDD-CUX'7/-?6OPO\.+X9\#Z39;2LGDK))N.6W,,G)[FM,LQE+%93[6G/G4
MYO7IIH['MU\+5P--4*T>5[VZZ]SJ%6I%6E"T_;[TSS1FVC;3]M&*8R/:::RU
M)5/4]1M=)LY+J\F6WMXQEI'.!6D4V[(9P'QZ%H?AS>)<MB5Y(Q;[3AO,SQBJ
MGP-:)_"]T5"^9Y^'QZ8X%>2_$+X@R_$SQ$IMLIH5C\T"M_RT/3S"#VZC@Y'6
MO:?@[I,NF^#UDE#JUS*T@5R#QG ((KP:^(IO.Z6$CK*%.;?ES.&GX+[SZKZM
M.AD\JD].>4;?*YV<E0,K.Q"@L?\ 9&:L2=#7TEX;ATV'1;0Z8(A9^6NQH\<\
M=SZ^N>]>SB,3]62?+>Y\A6K>Q2=KW/F9=+O9O]797,G^["Q_I3QX2UR?_5Z/
M?O\ 2V?_  KZEFU"U@_UES#'_OR 53D\4:-#_K-6L4_WKE!_6N)9G4?PTSE^
MN2>T3YG_ .%?>)I/NZ#??C$1_.D_X5=XLDZ:%<C_ 'BH_F:^CI/'WAN'[^N6
M _[>%/\ (U5D^*/A./[VO6?X/G^0K19CBOLTOP92Q5;I#\SYZ_X5#XPDY&AR
M_C+'_P#%5&_P7\9M_P P5O\ O_%_\57T$WQ=\'KUUVW/T5C_ $J,_&3P:/\
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M8_>3/XCWJA8W$>NK;V=Y<2PZBI5;6_V[XY%'1)&'.?1CSZYKU'P]X&\5^ [
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MX5*L>>HR*D5*E5*:*&)'C@# J180>-HJ6..IUCJRD,CAZ5,D6.@J18ZF6/\
M&BY0Q8ZE5/QIZI4BQTQC4CJ9(Z<L?>M72= U'6I!'I]A<WK?],(F?\R.E%TM
M6/U*$<=6$CZ<5Z-H?P#\4ZEM:YBM]+C/.;B3+?\ ?*Y_4BN_T7]G/2[7:^IZ
MC<7S=TA B3^I_45SRQ5*/4QE7IQZGA^B:G+H>I6]["L;O$V?+F4,CCNK ]01
M7TIH?AOPCXYT2VU-= M8Q,OS)Y/ELC=QQCOW[ULZ+\/_  [X?P;+2+:-Q_RT
M=-[_ /?39-;@N(O.\D2)YH7=Y>X;L>N/2O,KXE5-8)IG#5K*?PZ'#7?P1\*W
M!)CMKBU/_3&X;_V;-9%U\ =/8DVNJW4/H)45_P"6*]-OKZ#3;62YNID@@C&Y
MY)#@ 5XIXZ^*UQKY>QTDO:Z>?E>7I),/_95_4_I11EB*CM&6@4G6F[19R7B/
M0[30=2-I;:G'J93B1XHRJH?3.3D_2J$:]*2./MBNXT/P.+W3VN'.2!GK7M7Y
M8WDST)5%22YM3D8XRQ '4G JUXT^',NL>"KS>6V-$Q(5L \5YFOCHZ'\8CH<
M]ZHL)HV^65AA)!RN">F>17KWBWXBQV?@V>..:-E>$[65@01CM1*,I0]U7O\
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M[!FD X(/& .F*N:EX?\ !/A+P[X:U#5+;4M6O=6L8[@V,%P(D0_QR%\9P20
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MSOF_::^(^B,#9^-]:A Y6)KMI5_)\BNH\"_MC_'/4[Y;>W\2V][ AS))?:;
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MY'3#&0^TF?&/PF^ EGX3BBU#5T6ZU(C(C8 K'_\ 7KUV6:.UA+N5CC09)/
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M-NI+*[B^Y-$<$9X(]P?0UTNH?%3QCJV1<>(KX*1RL+B$?^. 5[TZ4Y62EH?
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MQCLCJC%1V0Q4_"IDCIZH?3%2K'6ERQ$CJ>..KYT.YAT6'5&"?9)IF@0[QNW
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M1 #X(#=..M:<VI5S':U99@CC SS^=7I+.(R?.&=2V *N^2K1R#8KN#PS'/\
M^JJ4\\D=Q(KX^4<*.&/XTG)RV%<9=V,:J"4#;1\J9^7_ /769J%Z;7'EQ_>7
M"LK9''M5Z;4HW5HY=Z/M#=,X]JK0S1S0,T#[=O\ L]*E77Q <Y/=.TC,6PS=
M<<53DD]#@UM:II?RW$R;MRL"5QP<^E8LT8\@2+VX85T<RDM!7+FH>7-IYN4
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M37,GE0+V)Y8^U<52HZCLMCJIP4%=C-7UA65Y))/+@7J3U/L/\*X'5]6?5)<
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MNK_<_P SRL30>'YZ3UY96.JA%6XU/%5X!5V/TKR&SS&2HO85,BTV-<U81<U
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M^RWEB\ID\ML9#(QYP1Z^M='I?A'2_$>FWJ6_A;4=(6.V>:VU.>9V$C*,@,"
M.?:J2^(M"\.V>DZ5I[2ZO9PZ@M_?7$D/EB4KP%53V YY]*UK'Q%H-GXJN]4N
M?$%[J(OEEB5?L[@6RN/XLGG'  4>]#E*VE_Q_K[QMRMI?\?Z^\Y:#P_9/X.T
M;4?+;[5=:D;:5MYP8_3';ZU>\<:7H7AV_OM*L+:X>\296-Q,_P D:D9V*,\\
M$?,?>F'5K"W\+Z7I<<[3R6>J-.7\LJ&BSPP^OI4/C34K?7O%6H7]HS/;S,I1
MF4J>%4=#[@UK%MRUVU-(\SEKMJ8,<=3K'3EC-3(E;W-PCCKR+Q5\4KZ#Q)<I
M9LATFV5H9(91\LQ&=S"1<XXZ ^E>O7-S#I]K+<W,BQ01*6=VZ #O7RGJEG<^
M*-5ET_1H/MLEU<E5V0K#O1FR<X&57!^]^E?'\0?7ZM;!X;"3=.-2HE*6UOGZ
M7=NMC[#A^EA9+$5L3'FY(Z)_C^GI<V/V:-9M[/QM/">FHV[11?[+(Y;:1C@E
M6'7DXKZG5*\F^%?P-;P7J$.I:G>174]N&^RVMO'MC@9N&8MU=L<9/Y5Z\J^U
M?HV9UJ5:OS4G=66I\O6E&4[Q!5J15I56I OM7DW.<:J_C3PM*%IV*JXQNVH[
MJ$S6LT8ZLC+TSU%3[:KZEJ-MH^GSWUY,L%M A>21NB@42J1IQ<Y.R6MRXQE*
M2C%7;/@W0[4V7BK4K6XC*O;;XW$B^8%VNWIAE'&<=1U'%?8GP?6=?AUI/VG>
M7*L5,C!CMW';@CMCI7B4FE^'K[X_13M<1W.BZU!YFZ3@,S?[74'<HP#^=?3T
M-O':PI#$BQQ1C:J*,  =JX<5@98C//[;A43ISI1C&WK=^73IW^_Z;&8U++X8
M!P:DI<SOZ6MW]1K5&U3-4;5ZR/FB%JB:I6Z5$U;Q+(6J!Q5AOSJ%ZVB6BN]0
M-5AAUJ%AZUO$M%:05 WZ5:9:@85T1-45VJ)A^-6&6H6%=$2A1;AH2"1ZYJK/
M"(\<Y!J=6,>2.1Z5+N\Q5^4=,&K5XC,PKMIDA+').:M30E&/RD#-0LOYUT)F
M@DFV6+)X=?UJLRU/L)Y IK(1VK6.@$(!Z"IEM';D<'TJ2*'#;G&%%7%;<?E'
MRXZTI2ML)E1HSYB)@[5J)47S&9LJ!VJYN^;YQM[9J&3=&V#\RTD!/N^T6&SH
M=X*_K3=OD@ _* *L6,2S1,@^5FY7ZBJ5Q(68*1RO!S4K5M$=;#XV\Z-E;KU%
M26EF['?TP< >M5D8JP(K6:<Q:<"JXW,0&^M*5XZ+J)F:V&D8X[TJQ[C@<FIX
M?)9=D@V'LX'\ZN6=O'','697P"?I[U,I6)91$)$FUAM/2O,/C?XN_P"$8T4I
M=6$5V;AO)TVX63+1S8SN('.%Y/![ =Z]/\5^*M/\"^&[K5]4NK>&&+YA]HD"
M;CGH#W/L.M?'^GZE)\</BTD>EI);Z8O[Q(\'9;Q$_O'_ -X\C\14TY<SU,92
MZ'T?\#]%AT3P;'<M([37[-*K.<DKD\D]RQR2??Z5W@D%SYJ,#O R":I_9[?3
MMMO!&$MX45(HUZ*H P*L+?I-(&.4DVD$8X/'6HE&_O)%<MEH5%D6.3#+D'BE
MCMQ'(/-VY)^0>H]:C-]!%C):9A_#C I\%[_:#'S$ >,[EV\<>F:&GN45=<7R
MU3'S*QR&/;CI7B'Q"\/W_@^\D\1V2;]&<@SPQN8W5@PX!'0'G^7I7N.K2))L
MC8XDQ]WL*HW-FC6#+=C?#*I1X>H=2.<CTK6G)PBK"MH<CX,\96/B+0EFTJ2<
MQQXRL\F]TYSACG/K^5=!>:A]E59E0&64<<=/4UXGXT\ ZMX#U1O$?@F5IH%&
M)M- )(0=>/XU_45Z5X-\2'QEX1L+Z\LCI4DR?ZN9QDXXWK_LGGKS3DHWV)6]
MF;<.LHJN[QK&K'E@,_-3&NA=*;CY><[LCD@=Q[53NK.6.T^5?,&<[DYR*R9/
M.AC$OS(A.T'.*?LHRU1=B\T=HIDD8*NXY1BW#Y['V_PK&LYC#J8B'*,Y!P<\
M5)YD$WRO'L;^\*GTRQ2'4$=V\P8(5?PH?N)W$7?LS74<J0W.(\@@,3NCQZ>M
M<]<6QL[>1IT?!;[Q'WC6C9PSW5YLC;RHV;]XN<# .>:L7H74K2>+:SQ^:/E#
M=L=?85RM\CL9F5H^H<.T:8CA7 W<#)[^]4?$5V\EDB2-O9GW*<8R,=AV%)]G
M_LO[1#='%K(VU>N6P>OT]:R=465;C,C*X(^1D/R[?:ERISNB&),KR::"?X:Q
MVXK;DG$*Q*>4*X(K,NK4QY=1F,]_2HN9LH2>M36< .9GXC3I[FHFZU)>7*M&
MD,7"*.?<UA4OLC)E*[F,\A;M55JF:H6KEEV,60MQFLV__P!</]W_ !K38$GC
MO3I=-1]AD7:VWGGWKEE)(S/V(HHHKX\\@**** &LVU:X3Q=XG>/68M(@?R)&
MB\YYMH8@;L  'OP>:Z+Q5KT7A_1[J^E!985SM7J23@#\R*\4^)EQ=&QMM>6\
M2*ZA;81'&5_=L>G)YP<5\OG6.5&G["$N6<MOZZ'K8##^TGSS7NHX+XA>?I&J
M7^EVU[<?99?WZK;94KGDX ]\\5YQ=:Y<1*Z79?5]/F;:)E(65?7&>I]5;\".
ME:>K:QJD5U+<I>O=[F+-;70W<$=N^/IR/>L*ZO[/4,R03?8+QTS/:7'*R?[C
M#Y7_ $;VKT\CP;ITDU/F4K735M>NGZI_<=6,JMNUMB*Z@6\$O]FS'4(%BWF/
M:RO&,X.X'E<<?XUDV-Y-H\Q:!?/M9&W7%H?N2_[R\9/HPPP]:34(9K2Z$C"2
MQO(SE&W%2A]58<J2*UM/>'Q(\41D^Q:]P%/E;8KGW++PK^IX!ZX%?3SERQ;@
M_AO\_P"OZ3."FKOS9M^$_ ;^+K]3X?N5%LQW3K=J8WMS[C^/TR*]/,WB3P>S
M:+<7<!V1#9-$I^X<X(_(CGTK,T'P;XK\ Z6=4+V:Q/M66%6+,F2,9_\ K9ZU
M/J6HW6I7#75XZO.RA?E& JCH!^9_.ORC%UWFF+<DDX?J>]=8>ERQ>IG3?* @
MX5:JRS+'QGFI+BXV9]:R+FXWYP:_0LIRYR2;1\SBL1;1$LMP>N>*=;OYQP36
M:LA:3%:MO&JID&OOHTXT8J*/ DW)W98/[L<&J\KTKO4#-FO2P\-+G%4D(S5$
MS4K-4#MBO02,17?BHZ;NHS5 +2CFF9IRL!2$2;<"FFD:05'YG>I0$ZG'UI2^
M*K^;[U')-Q180Z:?WK/FN^O--N;CKS69-.<G%;QB!/)<[N]59)=V:A:4GBF/
M)Q6RB,222J[-1))4+2=:V2 ;(W%4YFZU/(U4YFZUM%#*TQZUG7#5=F:J%P>M
M=,8C,ZX;TJE)(15JX/4UG3-MKHBBQLDF,U!)+ZTR23')-5I)?>NB*'8E>;BJ
MDTWO39)*JR29KHB4D+))D\5 S'Z4C/4>:<C:"+^GVK74P4#I78Z;IY@AWD#(
M]:YW0;B*U?<_3%6]6\2+L\N+BO'Q$V]$>U0IR;21=U+6%MPV6YKC=8UKJ\K<
M?PIW-5]2U0KEF.Z3LO:N:NIVFD+.<FN"-+F=WL?01:@K(9?7DEY)N<\=E["J
M+U*[5-I>EW&LWJVUNN6/+,>BCU-;.T5Y&>LF-T?1[C7+U;>W7/=W[(OJ:]2T
M_3[7PSIX@AQG&7D(Y<^IHTW3;;PW8""#ENKR$?,Y]367K&KQ6<+2S'..BUY\
MZCJ.RV.J,5!78:MJ\=K;FXG.%_A7UKSW5=5FU:X+R$A1]U,\#_Z]+JNJS:M<
M>9(<(.$0=%%5%7GCD]*Z:=/DU>YC.3EHA N37>>$?!XA"7VH)\_6.%A]WW/O
M3O"?A%;-5O;Y<S=4B;D+[GWK>U#4A$NU>M95*M_=B:0A;5DNHZD(5*J<MV%<
MGJFJF-BH.Z9NO^S3=4U0QDJIW3'K_LUB\L2<DL>YJ:5&_O2.E:#LEF))R3U)
MI]-44ZNPM'5>#;A+3>[<;CU^E=ZOC:2UBPLIQC&,UY7I=ZMNK*_ Z@U:FUE%
M \M=Y]3P*\BM1E*;:1K:,MSI=6\137A9Y)-B=R37*7VJ-,"D653NW<U3N+N2
MX;+MD>G:I]'T>XUZ^6VMQSU9CT4>IJH4HTUS2&Y=$2Z#H=QX@OEMX 0HYDD[
M*/\ &O:]$T>U\+Z6%C0* .IZL?4U'X9\/VGA^P"1KA$&6<]6/J:P_$WB-IG:
M.,\=/I7GUZSJ.RV",;NQ#XA\0&1F1&Y/6O-M>UXRL\$#<='D'?V%+KVO&8O!
M Q(Z/)Z^PKGJ*=.VLC.M5M[L1*3;3J2MKG$ %+2XI:FX@ HI<5+%"68 #+'H
M*6XQL<?J*]#^&OP=UOXBWL:VL#16I(W7##@#-=-\+_@=/J[1:AK2-#:?>2'N
M_P!?:OI_POY'A^WC@LXD@B08"J,5T>SGR7B=4:,I*XWX?_L]:%\/M/21D6\U
M#;\TSJ.#[5L:M'!I\;R3.L42COQ6;XH^+UGHL7D(WVB[(P(UYYKS'6/%3ZH'
MO=>N_LUJ/F6U0\M]:QHX?$<W--Z$QC.F]2IXNU#_ (2*XD:(^1ID7WIO[U>*
M>,->34+G[/;?+;1\#'?WK8\=?$1]=8VEBOV:P3@*O&:YKP_X=N?$%ZL,*G;G
MYF]*^LHP5*/-/0V<N8K:3HUUK5TL-M&6)/)["O6?#OA:V\(VIGGVO/C+,1TK
M9TG0['PCIH"JOF 99SUKS?QMXRDU*=[:W<B('#,.]<M2LZKLM@=H*[+?BWXA
M-<%[:R;CH9 >E<&JS7EPJJ&FGE8*JCDLQ. ![DFF[<^]:'AW4ET+Q%I.IO'Y
MJ65Y#=-'_>"2*Q'Y"N6<^5>Z<DYMZGOOB_0?AW^S2++P[K?A./XB^/WMH[G5
M&O[MX;'3RXW+"B)]]L=SVP<\X'FGC'5-"^*6K:'9^!/AV_AS6IB\5Q8:;=27
M:7CG!0Q(PRF 'S]<]J[O]LKPK>-\5+CQO9H^H>%/%%O;WNGZK""\+?N41HRP
MX5AMS@]B/>N(^"7PUU?QQXRB6#4;OPQ:6ME<ZE-K$43B1+>)0)3#C&]\.%P#
M_%S7SM*<?8K$3DW*UWJ[7[6VT[6_$X8M<O.WJ9WCGX*^.OAGI]O?^*/#%[H]
ME<,(X[B;8R;R"0I9&(4X!X..AJ_X;^ _Q(\5>2-*\'ZG=I-:1WL<H14C:"0$
MQN'8A?F .!G/'2O7M%O/"6L?LJ_&&/PNGB>?3K.739S=>([B*17E,X&Z)(QB
M,[<;AN8\K6;^TYJWB2S^&/P3@CN+RV\,-X7MG4PNR1/=A1NW$=6";,9]6QWK
M!8JK.2AHG=K\$]K_ *D>TDW8\4;P/XDB\7#PO)H=^OB3S!"-+,#?:"Q&0 OI
MCG/3'.<5T'B;X0^,_AO<:5-XH\+W=E;75TD,2R.C+.^<F'<C'#$ C!YKW?Q-
M\1]0^&&H_!/Q?K^DW.M>)CX4N8=:@)9+MK)V"12L^,JX5C\S>I!(SFO/]<^&
M_ABX\'Z+X_\  &N:S/X:'B.VL+S1]>4":VN&92&5U.V08.,]>>O4#-8B<K.2
MLGIWN[M;]-M+[BYV<OXH\'ZIXB^+.IZ#X=\$7VB7S2#RO#,;&XEM0$4D,Q[?
MQ;CP-U>I>$_A'K_@+X7?%T^+_"\FFW2:3:R64]Y"CX/G$,8I!D \C.#GD9KN
M?'T]W9ZM^T[=>'VD3Q1')IJ&2V)%PE@53SRF.0,9W8[ 5YS\&=6\1WG[.7QD
M@N)KJX\,Q6,#6[3LS1I<F4;Q&3ZKM+ ?[/K7#*I.I335DER][ZV?ZF?,VON/
M&+>2KWF8MW^F*R;=N16G;X9=IY!K/,*,JV'J4X;M-'I8.K&CB*=2>R:;-:PD
M2>U08!4KM92,^Q!JFVC_ /".;[S2XI&@/^NM(V/ _O)[CTY'M2V]O+: O;ON
M'4QL,BM?2;\7RLC*4<#G!SQTR*\'+,WE@90PE>/++:S^&5OP_5'MXS!RDZF-
MPDN>G>[[J_=?J:'A[5%U:Q$JG=@[2<8)],CL:WH5_&O&]&\1:C\/=:N;#4[6
M>XL))-R7"HSDCLP(Z\8R*[_3?B#I=Y(%!DC7UD&UA[[3S7UF-RJO[5SPT.:F
M]5;73_@'@U,//FO!71V$:U9C7T%1PKN (QCJ*LJT<;!&=5<]%9@":^9U.0EC
MCJPJ4BKM4LWRJHR2>@K@;_Q%XA\2ZAY/AR!OL@D*?;'.R( '!);J?P'^-=F%
MPL\4W:2BENV[)&U.FZG6QK_$[Q19>%O"-\US(HGN8FA@AS\TC$8_(9J_\-M*
MATWP7I@AA\CSXEGD#'+%V ))-<Y=?!2'Q)K46I^(]5GU.1 N;=%V18'\/))Q
M^6:].AA2&)410B(H55 P !T KLQ-7#T<+'#4)\S;O)ZI;625^QM+D4%"#N^I
MS7C"^N;2"&&V=HGE;!=?O?0?6M7P[H::?:JS#=<-R\C<L3[DUC:MJ"7WB:QL
MHE#^2^YSUP<=/RYKMXH_E48P*_+\OIPQV:8C%SESJ#48]EIK;S/L<PJSP&58
M;"1CR.:<I=WKI?R!8ZE5*<B>U2JGK7W%SXE#53\*F5*<J5,L=5<H8J^U3I'T
MXIRQU,L=/F 18ZVFUR>3PU!HIBC^SQ7#70D&=Y8C&/3%9BI[5,B4]Q[C42ID
M2E6.ITCHN4(J5,L=.2.ID2BX"*F*GC2A5J=%IW&>0?M):Q<:=X/M;2 L@N[C
M$C*C2955+;2B\D'&#[&O#_AKKEYX5FL=0M)&65)"/+8,0RD_<.[YL>@-?1OQ
MY\(_\)3X!N/+7=<V;B>-0<,^.J9!SR/2O)_V79-(N]0GTK5;&W>ZC+364TD>
MT,5;#A0WIQUY[T\YR^KG&02PV"FHU(3C)OJK/=6U]/1^9]1D^,HX%NK6@Y1L
MTUWN?3.BWCZII=K=O UL\T:N8GZID=#6@JT*N.V*E5:SI\T81C-W:6K[^9\U
M-J4FXJR?3L"K3U6E5:>%K6YF)MI=M+BEIW*&[:\\^/$<S?#NZ\I68">(R!0?
MN[N22.@]Z]&Q7G_QOU:QL?A_J$%R\#S3[4B@D?!9MP.1SVZUXV=P=7*\3!?R
M2_)GKY1+ES"@[?:C^9\DZCK+:=XXT%K9O+DA97R,*<[@>!]U^.PZYR*^[8V\
MR)&Z[E!Z8[5\/_#/P#J7Q%^)8"QR+86TJO/.0 %5#GD'C=G&TCL:^Y-H50HZ
M 8%?24,+3R[*\%@X.[A35_5I-_C<Z,XK?6,9.?=LB:HVJ8_2HFIH\5$+"HFJ
M=A43"M8LM%=A43>U6'%0M6Z+1785"RU99:A9:WB:(K,M0L*M,!2-Y97&"*W3
M+*#K43+5Z:WPNY>155EKHB[EHKLM(C;6YZ5,R5&RULM2R9K*6:$;%+!CD'%0
MFWBM"#.=\G_/-?ZU/#(VP'<RCH,&J<T960Y.>]5&[=FQ(LM>(B@^7&!V7&:;
M'J@&?W<:GL=M4R*8RUJJ<>I7*B653,Q)<'-6;:T7R\%\,#ROMZYJC'&9& JS
M]K$+E-N^/&TU4HNUD#3Z$;(IW@Y /2HMA5MC'<G8UJ3I'DB-&)7 '<'Z52F8
M[6.-A6B+N(<BF&,[3R.0:KW4B7$@D7AV'SKCOZU:60&'<?F%,6S$J;@IC]"W
M IJU[L17AA:;IP!U;TK2N9$_L^3^&*--V3SC'>J\FU((8S($3&3MY)-65FA:
M%$4X'_33HWL:F6MF3(^??$OQX\3>&]8N;2/PM'J]NK$17%KYG/&0" "1D?UK
MFM3_ &IO%KPXTCPM]DN6 0QW5G.[H6XR!P&&?3\J^H/^$=L9% CL8&0-O\M%
M PW^33[73Q#*9C JRCA%11D#V_3\JB4E+8YW&7\Q\7K\.?B[\< DOB&WOHHV
ME!66_/V>VACZ_+'QD_0'ZU]0_"OX+Z-\*_#X@M7^T7LPW7=_(@$C\YV@9X4'
MH*[74KDHKJ@P6PS$G./:LL7/RE')*U$:<FKW"-/EUZD\RVVW;$3U^^W^%4F8
M6UQ&=V58D9].*?MC8_>]ZK>8)+L8'R*,#WK?ETLC:PQ;)ESD\9SN--CNQ9R#
M;\^3@CU'I1J$I60 ' Q6<TFU@?0YK50YEJ5RFS):^9LEF8[$.YF;[WTIFK7L
M*Q^:B>8K# ;/ ]L4+J"WEFZB/!+!2@/./4FL2>:2UF<.&,;9'S#J/I6,8.3U
MZ$69&VI*H)6VC#]FY./>JMQJ$<S8>!3'M &W@KZD5;2SMKK9Y<S*Q/*-S^1J
MM<Z?#;[WF:0)N(4(,\>YK;W+CT**ZA]F\R--QCZIS@K5J%EOH5EF5"N#\I7^
M+./\*IJUN)/DB:5LX"N<BK)8W5PT)P8(U&YEXP1UX[]<?A45$N@F8&K;3=OA
MMQ'!.W;S]*SC<21MD.01TYK7UJV/VAY@0R-R-OIT_I65'9S79/E)D#JQX K1
M6Y=1%]M446))7R[B;Y2Z_J?Y?G5:%@MPIW%@O5<XS3+^W9;>Q7C<V[ISZ4U;
MA?,*!06QU]:Y915M#,NWS+J%L1=*6\H&3IA@".GTQS6&;0W-J9?LJPP*< C.
M3GI780JTVDA77ECR6PORCM[UR6K7%YY3.6\N!6 2-3G'U/K7%&5WRHS,^XA3
M8J2-M;' -0VZ20OL8>9$U5)&+-ECDTZU;;+N9N%&<9ZTYQ=C-E2\@,<S@*=H
M-4GK0:^E5R<[AGH:JW=P+A@?+5"/3O6$K]3&13:HFJ5JFAL7D9&8?(3ZUR5'
M8Q9!:V_F-O9MJJ?2HM6,<=T 2W*@]/K6G,RV]O(?+5<'@>M<UJMP\UT&/'RX
M ].37$_>=S-G[+T445\H>0%,D;:I-.KG?%GB*+0[>+.&FN'\J*,MC<V,GGT
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MMT%%U9SR6TP1MRAT8JV#W&0>:ZC2_!6J7O@O4/%421'2+"[CLIV,@$@D< J
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MHH8ZN1I65QCHUJ1K..XQYB!]O3(Z4^-*L(@K.48S7+)71I"<J;YH.S$AA"#
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MS%Z<UQSCU1C(IW5N;>3:3N'4&JK5JZA<1,@4(K-CJ.U935S-Z:F+(6K/O/\
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L,D7E,2+_ +)K"U %+@*1@@?UK9M9&6088C\:SM;YO,GKM'\S7.V[V9B?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>hbvpipeline.jpg
<TEXT>
begin 644 hbvpipeline.jpg
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MF3/_#1U^!#@B6*0>8I(!:(:!U$.T#4 S#*0>HFT FF$@]1!M ] , ZF':!N
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M#NL0VP:'G2XJ@Z1J*/#N>^\[Q=?2-2>NL^44!72XKLM7H; 3<^^RP,807:8
M@X30)FE"'E(Y@2KLB=M3>1H2;5.+C($-@.6YWF2VW&M#)0N7NQ*9,9W(X<JB
M.*P,,CD*Y*XL4 %;"%,=G@8IY5VV9RY39+JP05(@749M?0KO4E@'RF?:R[UP
M[S*;4S*P,427*< @(;09XAE2#VN<Q(<]M6QG^G,;0W29 KYE![ 9Q)!>-],R
M2#!EHLL  (P#!@E:B2X# # .&"1H);H, , X8)"@E>@R  #C@$&"5J++  ",
MPYGXC@4  ,!:P4."5F(- P P#A@D:"6Z# # .&"0H)7H,@  XX!!@E:BRP
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M8)"@E>@R  #C@$&"5J++  ", P8)6HDN P P#OS\!   3 (\)&@EUC   ..
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M&"1H);H, , X8)"@E>@R  #C@$&"5J++  ",PYF' &W\'P# F. A02NQA@$
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MI2E;YA%E];:'Z#(%&"2$VH4U.I0)/4.RQ8K(T*AD6SL%2LMT/ 8I9'9$ERG
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M!PP2M!)=!@!@',[\"-#&?P  Q@0/"5J)-0P P#A@D*"5Z#(  .. 08)6HLL
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M'#!(T$IT&0" << @02O190  Q@&#!*U$EP$ & <,$K02708 8!S./ $  )@
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M;:[\,9?,TM2LD21+6?IA:!M5QQ%""*&UJ(XCA!!":U$=1P@AA-:B)P   !,
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M)QJ%/7N:<I=P5%NI])S4 ;15XK+Q-G&50TG1<EK1+E^=<32'<XXO)68C..J
MME7F.4J5UX5GM&H?+V*,TK,Q-8V4N^0<9 F*NHEF*M7?+6#YDA4H6R9QQQ#J
M">6NLC\HZA96(!.'5QU?A[Q JQ);Y*;)8880.H8T?.P;*3#K61C-7G5\'<KQ
M<"252YM>IQLAU*(810NJ70B=JNHX0@@AM!;5<8000F@M^LN_'B&$!M3_]^/_
M52G;+%ICA6B<2F?^&Z"-'P$ QN3,5P!M_ \ P)A@D*"5Z#(  .. 08)6HLL
M (P#!@E:B2X# # .&"1H);H, , X8)"@E>@R  #C@$&"5J++  ", P8)6HDN
M P P#A@D:"6Z3$&\CQ, YLRC1X]B2*\;#!*T$EVF0%WYF6??0 C-6M.Q21@D
M:"6Z3 $&":'-T$1L$@8)6HDN4X!!0FAC- 6;-"&#=/N##R^\^%)$YLQG]S]_
M[OD7(K)!1)<IP" AM$E:NTTZ8) TC98SJ:.9^/(KKV;THX\_<1Z3NR+^U5=O
MO?V.HDI7^,'NKO<Z0X8=312]L[-3GL49O'4AVE;GDADKHT9152##VKH^EL(W
M;MYRNM!),YQD9N_2]2IP]MSYW.N R[EZ[;JC"ON\F6&3B"Y3@$%":,.T7IOT
MU"#=O7=/$ZYF4DW03LE9U0%; D>OO/;Z8L]3/.-'9)%'^6V05*RGZ1)/\1%9
M4!V>-L_IVLKV*.!B,[/3,VH4S3-Z5U9/Q]JNY"%RR]*B)-KK"CC@VN8A9:#7
M'U+*N^^]'Y%-(;I, 08)H<V3QG6,\%/GJ4'2O*R9O70='-#$ZH#-@+78?X#2
M(%V\=%E%V7(HJG3O+>=]176NB"PHBU6X-$@J1V4ZZF)E5#SC.V=YK%"TE%)<
M@8PZ3Y;@E!(EJE@;&[EE/H4ORGLSF[?*XX -H2NYEV.#B"Y3@$%":,,T%0^I
MFF0=L#S;:H;U+@?D47GO(N\!@Y39/"DKZFE: 1VE@#]_4R"IC(K"I4%*HRA<
MK#]GDTF3H<ICM<V S^BPMEF]M+@.=&MBE&C9+2M/D5O95WN*LHX.*-WGS=-M
M$M%E"C!("&V2UFN-1!@DS^\IS\*>4G-NM1U2H#(>IIR"%4C9;OEC0 5L9N2-
M5=]?<+:(%#D=]M9.4FGGI'1?]K+NHZ@-@\/:5M7+@ Q)]_,ZH5TJ-LU5GD+E
MI'74MI13?%Y9.W\PN$E$ERG ("&T,5J[-1)AD#1[Y@=HFJ-S>G6* I_=_]P&
MR<K,)M.E2"HLAXU!N5<!>UTEY;$*5P;)ML'5<+&JLW>U&R0K/_US-,-YB%#4
M%5! %JL\A0(.9XI0V#5T(3I%KYV;-=%E"C!("&V&IF"-Q-./[-:.Y_2(G#K#
MGEVE^</)32*Z3 $&":$-T$2LD9B009+?LRZO0H[7L*>608K0!A%=ID#]& #F
MSD2LD9B008*)$UT& & <,$C02G09 (!QP"!!*]%E  #& 8,$K427 0 8!PP2
MM!)=!@!@'#!(T$IT&0" << @02O190  Q@&#!*U$EP$ & <,$K02708 8!PP
M2-!*=!D @'' ($$KT64  ,;A3+S,"   8*W@(4$KL88! !@'#!*T$ET& & <
M,$C02G09 (!QP"!!*]%E  #& 8,$K427 0 8!PP2M!)=!@!@'#!(T$IT&0"
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MH)7H,@  XX!!@E:BRP  C ,&"5J)+@, , X8)&@EN@P P#A@D*"5Z#(  ..
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M!PP2M!)=!@!@'#!(T$IT&0" << @02O190  Q@&#!*U$EP$ & <,$K02708
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M3(,$8Q!=!@!@'#!(T$IT&0" << @02O190  Q@&#!*U$EP$ & <,$K02708
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M P8)6HDN P P#A@D:"6Z# # .&"0H)7H,@  XX!!@E:BRP  C ,&"5J)+@,
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M,_$E5@  @+5RYEN -GX  !@3/K*#5L*I!@ 8!PP2M!)=!@!@'#!(T$IT&0"
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M%7#*,H-4;77("@<H<\H#4T"9%;:<7D9UBLS@:CC=*=+=>_<<4#:EPRD37:8
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M:U7'$4(((8000FAK%4_3 0      MIXS7P$ #,K_     ,P6'"0 &)B870
M  !F" X2  Q,S"X     ,P0'"0 &)F87    @!F"@P0  Q.S"P   , ,P4$"
M@(&)V04   !@AN @ <# Q.P"    ,$-PD !@8&)V 0   )@A.$@ ,# QNP
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M8G8!    F"$X2  P,#&[     ,P0'"0 &)B870    !F" X2  Q,S"X
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M < V@&L$ #,"!PD !B9F%P   ( 9@H,$  ,3LPL   # #,%! H"!B=D%
M8(;@( ' P,3L @   #!#<)  8&!B=@$   "8(3A( # P,;L     S! <)  8
MF)A=     &;(F?B% @      @*WGS#\!  ;E>P   (#9PE?L &!@XODT
MP S!00* @8G9!0   &"&X" !P,#$[ (    P0W"0 &!@8G8!    F"$X2  P
M,#&[     ,P0'"0 &)B870    !F" X2  Q,S"X     ,P0'"0 &)F87
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MP+'!-0( &!P<)  8F)A=     &8(#A( #$S,+@     S! <)  8F9A<   "
M&8*#!  #$[,+    P S!00* @8G9!0   &"&X" !P,#$[ (    P0W"0 &!@
M8G8!    F"%GXI<4        MAZ>( ' P,3'+P     S! <)  8F9A<   "
M&8*#!  #$[,+    P S!00* @8G9!0   &"&X" !P,#$[ (    P0W"0 &!@
M8G8!    F"$X2  P,#&[     ,P0'"0 &)B870    !F" X2  Q,S"[+B9]A
M X 3\.C1HQA1   P*#A( # P,;LLQ\N[9YY] R%T/+UY^U./(]PD (#!P4$"
M@(&)V64Y7MA5"SZ$T%&%FP0 , 8X2,-S]]Z]YYY_0;JSLQ-)T^;=]]Y7;<^>
M.Q_QN7'EM==5?VTCWD&7I@RZS(B/QJ$UJ3AJ_KD0L\MRO*2KEGH(H>,)-PD
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M%=]S\X'N8T(E^%BGI[+FRVKB&Y09LL CU;Q[WF7=6%I19R7VWJ\!B=EE.5[
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M++DZKZA.W:V)\^>I#\V_NN;+*M#B('EO2>_]&H2879;C95RUO$,('4^X1@
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M<)  8&!B=@$   "8(3A( # P,;L     S! <)  8F)A=     &;(F?A%;@
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M#-L&KA$  $P6'"0 &)B870    !F" X2  Q,S"X     ,P0'"0 &)F87
M@!F"@P0  Q.S"P   , ,P4$"@(&)V04   !@AN @ <# Q.P"    ,$-PD !@
M8&)V 0   )@A.$@ ,# QNP    #,D#/QHWT       !;#T^0 &!@XN,7
M@!F"@P0  Q.S"P   , ,P4$"@(&)V04   !@AN @ <# Q.P"    ,$-PD !@
M8&)V 0   )@A.$@ ,# QNP    #,$!PD !B8F%T     9@@.$@ ,3,PN
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M_&#=7'A9-U$VH#(KJG#6S;LRZKU*=%1TV^=(C0D3)&:7E7@I7"V1T78*UP@
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M  8F9A<   " &8*#!  #$[,+    P S!00* @8G9!0   &"&X" !P,#$[ (
M   P0W"0 &!@8G8!    F"$X2  P,#&[     ,P0'"0 &)B870    !FR)F_
C 0 ,RD,   " F?+PX?\/\5;-PA<7Y8H     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>lnptechnology.jpg
<TEXT>
begin 644 lnptechnology.jpg
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MQ#T5Z,G-"1 9SF)A80E+2ROP^8(X#D>UW<.A4\1C:>2R916*^1"B5GVCKWR
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M*^N;[>'6HTM]W=;#NF0=\J#Y7 G[>WX,#TWBP8.7^.Z[A_CA^Q<8'%K$ZGH
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M-&2;E$HE-4?8/T,N5U2!?6QL!L]?=.'9\RXI^P1&1Q?0WS^%[MY)]?P=&%K
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M*9*^LLW8=AQXYO-9)!(QV3<A[571=9S0CB(Q0W4<'AQK[./!@6GUD-W;"ZM
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MYQ"'@3!")U'$XFED<R6U>#P+W]$)IJ:6,3_OQ(!-9Q@N(Z6B*<,PE,M%#<'
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MUATI%R<OW%C?5H]7"M$4A@<')Z5_+:E7.$.(%(L7TH9E:;>T$U)!S@,.8OE
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M.$F1F#"?[D,0QL0].8GB8-^O<:WG9I;0USNL'K"]4GY.4A>+,>8T^TA9REN
MEV$3=GVRG->!:4'*QEC)SN1V16E3R'X;Z.D9TXGE*%[/BC$$".-#!T)9'/A2
MV/%&,"WK*0Z_[AY#O[3GTLH^$JD+;.]&T#<PCUYII\'A18Q/KF-V?E?R-8V'
M#[KQ[&D_.EZ/2!XGM)]M;AZH-[WCR9[7MF'_/PY'4"J442E549"R\D%%,I'%
M:20)_U$$6YL^3$]M8F1X!4.#RY+^K.1S6_O3U,P&7G4.X^&33@P,S6)(^ON
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MX67'(%Z^'E)!_M$3>GT_U_:;7?!BW2/;;Q]C:>50^M(".KK&I"VG,+>PHW&
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M$O&IY 5-ON O*C(8*<OWQIE\$TBZ5U(QQ=XW5Y-CJ7>BV(5LRY_RXXT,-E'
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MGZ 7-#V*>9WB+Q!XG3H.)S0LQ=CHM$YXU]LSJ-<LWOMKWY)DM)_Q]:U=I^W
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MB<88A0M1)@B<:GD0M#_#_NSK.!Q_!8F=S]%*:3EYC4E27-2;1@3H*'V*3YN
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M)D_<2T[>$]:+REOV08]EU*7T!'::\I?'*<N$-H'QHA50KXT5JWXT(DL([][
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M@67?C97E/9:[ &8;[ ZG\4*5MWJ3^5:[:W8N$$GDL&TYA-?O0ZF<I_%'XUP
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MG-="O)%I -.EZS@G,/, O131Q)=QR9M>.E/=1EWH&B2^#O]KAFN0^#I<AW]
MX45E?\6C)7EQ 'CQG(R;*^YA <02@<7R0A,(K W)) )_]2GN38'$ HLES4;?
MLTT L3X%(E8J#0.J:9F^J"$"P80!F-;7#S$VMH1G3Z<Q.;5A^'SG%PYAV?/#
MZ\L:P'5V?@]W[HU21K"T<FB\;^5I_'1@'H^?S/#\#M;6#W!TI$VR4HA&Q86:
MI>1XS(.M+:OQ'LWE6C@^CF/@V8RALDBD:_ 'TUA9.S+T#^]_\!BW[XP9<'IR
M:@=#(ZNX?7\"-VZ/\1E6C$WLXNZ#&>,=O+YQ#+<W:T#?M0V' 8MG9O?@\Q<0
MBE0,J#VWL&N>$XZ6L+'E,!S$6K(N3M.-+1LR^3I*U3;J+98K1^ZN# 13&V(I
M.$<BR?1;748.M>3^P &[S8UX+(5JI8YL5AN!]7F'S7+Y2X]B@<+RD$PFTP9H
MTW=]FJ7G6E*?8OF$HHS/9@!GGS> 4KE&(XEM@,^6Z&6!-J:K\/I2)H=R)F\^
M2UE^\ICBR>9$-9%%*!B#WQN!WQ,VH%\DG$0V4V;ZJO!ZHX;.8&9^ PLKNUC9
M.#  \>:N'8=V/[;VG'!Z(O!%TCAR!;&Z8Z4<PNH.P.X)PG[,3Y?/< B+6_C8
M+>_I I_?8-[K<+C"V+8XL;9CP_+6 64?FWM6N )A1.(I)-G>,JD<<EEY"I<,
MY[$XD#<W[-@1#[+%@UU^+LG#>6$'\\L6+#&-<VL6S*_O8>O !<O^,0[VW;#;
M/7 =>W#L<\,=]"!3*J#1[:+!LBK1\#UF.<_O;, =]:+,2:1\8^0=TS/35QIG
M%)IL!HRG37AYC!,%?FO0:"[6:02V:H8S-YE(HUEKHR)N9=:WQQ]$.)E JEQ
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M[,=Y <2A+)S.$.SB\7;'>'T,.]OLIX$$FC5.3II:%LE&S$G/"=MF.9]')I%
M-IDT0'$RH9<4;'=L>WI))._X8VU6%TJ@D"L;_:"737KII.N43KV<NFJWHD X
MM#EA.;3!Z?'CT.&&TQM B&TDF<G#$PB9S?Z"H8@!@^6=0?5F1!,VE4<FDV-^
M8Z:?B&=78*<\>?/,9R93-%[$^4+% .?/GT\;&I1,MH6] Y_9M.[IP)QY$30Q
MN8UG XNX_V"2>F<%XUK5,+F"U=4]+"QN8')J'LLKZX;:HU*I,6Y1DV0-^"V
M^,KS7ISLZLN]2T!;$\8N]:Q9+LJZJ3=.C)Y<6MK"R,@LYN<W,3>W:9XU.KK
MX[MLPU[X? G#Z[ZTM(V!@0EL;]O8)]6^/=2';N9#?--M0R_1J/?XO=/GT [E
MJ">*!OSO \5L=R&V$>H(T0351"_4XD3/<!++VUE+64^-;M!* XT'JC/E19S(
M6KYL &(IM>MP':[#=?@B2#'(TI&\J"#T7><H4H)7/_5Y)9?GY8TK_2(Q@(KY
MH][A.*@7K0*(SW3#%=I"$4C<Y_^7;85+D%CGFH@'#W"T-0SG[@!RH16<5 .\
MH,D+NQS+]/)5R_FU$7+=>#'V^5ZI ZD'&3$NNF74$M2U*P^P_/PUS#]]"4N#
M/\7VY&MP;7R.E&\:[<HEL"00\[P/9@K0$XV *0HA-M2;$,!Y6D ]O86X]18\
MBR_#,_5->"?_&MZY'R%I?XAZSH:+TXH!1N5=JJ7[!B0^D]=NAI\"B/UH)F;@
MG/\>=I__,]BG_A2AS9=1BPP 76TV5Z#-WKD$B:G'#4AZPGA8CC0(M,F76:I^
M7D8C[\#1VATL/?\U9A_^#"L#KR%NF\!9C>4DST7QXK*<Y'VLNA$0KDW5SN6A
MC0K+,(&,?Q''JQ_#-OYS^!=>1]D]!F@C,@/(TV[16,+G&N[]BY;Q)%;YG(JZ
MKB<J#&:)Y20Q%&@"7CD&?2$F_5^"Q!<"B"GZ+GYB\<?*KNZJ_BG&8Y/E9[R-
M^9PK7N(7@=Y_7_D2(.Z#Q)HC":?KRQ4@K.,OBO+ M)^V>8VDQ?8E3VS1%W3X
MR?;7H7 ,/M?]G'MU.:=BMG%"6T'>[J<]T7L(B*7=IT\:#]J'0?,(43R8#>DZ
M+9RU63<"BD]H6\6W$-ZY@;V)7V!M["7LK_X.J= P:H5MM.M>=%L)=+I9QE=@
M? 7: W'$HEM8F;^!@;L_P?#=[V-A\&4\_>QO,/[XI[!;'J%1];*?58P'<IW/
M:73E14S;T' ;]S??/:.=($_BTW:%A9*"U_8<PW>^A7NO_9=8N/'/X!S["[BF
M_ASNQ>\@9OL8[:J5\64-2*Q-XCJ])LLC3P,Z@&Y^!87 +80/7X;_X"7XCGZ+
MD/L!:N5=YCW*-E[D\T6;0=M%;5Y>URR;4Y;;.1O6!6W""Y;+A3RL3XI,4P29
M^"H"CH?P'WV"3. N]M=_B^697\'O'J*=ZV.[9]VTJ[RG@#.64;-\C+AO&4?K
M][$X_%O,//LA1N_]!9Y]]$_Q],W_#Y[\]K_!\_?_->QKMU 1Q0K[U9E :]EY
M;-M21>8%%MO"&?6?OLNVZF]$Q_3Q>7I6KQ1$SKL,R]C;6'KP8\S=_AZF;_\0
M>S,?4\^LLAT7J?TT)Q!(S/Q11&EA%![C-GJ0:D;J1J(YGM&G7T@? W@1![@.
MU^&/%:Y!XNMP'?X(0>K[Z^3?%:3X7P2&?]^XZ0._$@U8 BCZGFP<3&F47(T9
M^NPOV1;G9L-XP D$EM>P/  +^8H145 (%-:Y*[H)XVG<D&=:%ZWVB=D@2]Z@
MX7 6'F\"Q\<Q1,)%N#TIXY4KB@:'*XH6[=6] S\&GR_AL\^?X]//!O'!AX_Q
M_@>/\,FGS_GY!)_?&,'<_ &"O#]7:!FJ )LSB+W#8VSNV(R'\?+2+I:7=^'W
MB[=7X&L#FYLV'![Z4"J>(!:OX= :-K01LW/[>/IT@?$/X,;-83YWB,\=PIV[
M\AR<QI.G2UA<LF%D;,ULLI?*M&%S1/D<!R+1.G8M?LPO[N'@R(_=_6,LK5HP
M,KZ IX/3F)[=@L>70KE*PXUC-__UYPB7HJ)NMGN(Q^4![6;ZCN%T^AGW+M;7
M=XP7L3QBR^6: 8@3"5%.) W5A(#B/MU$DN>RQF-1 )6\ K/%$E*% I+9 L05
M7"[64"W48-^W86]S%[E$AO:R)CXT'FA0Z%/+*MN=IC$\3VGE:F,5>19&XTE8
M#JQ887JV+4?,3P3)1 [I9)\J0)08\5@&3H<7?E\,U8K:2YOEOP7+OA,N;P13
MLRMPND/(Y&HXL'K@9ASBPMT[LF/?ZH#-Q6/^ "*)!.*YM %,MQT'6-G?PH[S
M$!OV?2Q;=[!PM(T-+^O89\6L<QM3MG4L>79A2WM0/*L9\)4F,[HTMG/%/,O2
MC>65#2PL;F)I:0^34^+C/<#>OA='MB 6ERUX/CJ'D>EE3,UO,)UK&!R>P?34
M*N:FUS T-([9U7DL["]B='L"8X>S&+4O8- VC^?V)=S=&<?;,W=P:WT GRX]
MQ&O#'^#]Q3NXN3N(1[8IC!PO8[_@0XZI$LQ;1PL-?N=T#(<Y%YX?\AKK/.8\
MF]B)V>'*!Q"J)1"HLFR2-FS'#V$KN)%!$35S)_L@Y823JRXG$O5B&=6< /TJ
MZM4&4JS7:#B*=#S6!XA9!O5&@V4=1BPEWC88+NF(/(0/_=BWN(W8K $$@VG#
M\WS$=KRWYS:?'D\<T6@>[F-YH7O@<8>139?0H@[HM3C9ZK"=R -5_+YL@X5,
M&J5<%JDX)QB1OF=[.E,P +4\5QT.#]M(&%7J#TU\)(U:T[S$*,N;]9(?-YW)
M&? W'(LCDF2;SS#N2ATE ;SEBMDHKU87-]P9\UBF]#=PO#)Z-3&0-Z]H6=1?
M8K'$I:=RR7A4Q^)I0^^2+U39?ZUF8\N%Y1VV]3+\P2S[.=O!T#QF%RS4*Q%L
M;+H-%8VH)A87]PW']L3$$LM(&_ %(4[D(ZL=-KOCDL]9WOI!HQ_UTDQZ45S
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M]/-'>/!H',-\]IW[(W@^O&QXD;6177\SNST$@C5$8RU8;0E,3F]AQ^+&P5'
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MJ5_]UJM, ;X"@Z_ C*^"Q'W;4V#QEP"Q0&D]D=]X3@"Q/C5VX(QZJE="+7T
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MWK2\1$70.65<BE< IKQZ3^I -XEF>@YQVWNP+?X(^[,O(6R]!70<3"OU:U=
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MQ1:!R1+&)O'CM0T.8D>_,0P%\22EUB8L[O'B'>\J<7E2-$?XB7]K!3Z]O*J
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M\")V5FZ@FC(+\ M'.3<05J,A>XCTG=<1?NV/$'KFW\+]U&]AY_N_B>#U'^!
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M,3+Y#BY>_2X>#G]$,M@\RM4H\:JJH*L<$E_9;Z71;OC1HGZV5U6BD%R$U_8
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M?&4#,1/C,++';F<+.<-(=#P#CP/0=3XSO^XD_KS'RLI^QPOX^%I.S.<# 3:
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M="4G##EJCW($_G8:SGH,VKP;JI(-,@YFE]W!7&X;XUD)1G,B+#2VL+ZG@.Q
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M3$]W&W4U^13F19.5<9.J\A0&^YOP^69$5XDSO+,B[4\Y6=(O_;-,SH_2-SM
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M4L9R#4W4_F\%B5="ZYH#7E1:H\UHO^!:Q3&_2D_O!/D%S63GU5-8TJIE!:N
M<'%9AY8I7%K126?/&+W&::KK^L3(56F3W!66M)&0+, S,EN,7KD<9Z2UW2*
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M!\Y%#_9Y%TZYIL?G); <9,YAIZ_?B$E E&UFBB6/&W_0)X!40.;ZBNSC)R@
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MX1Q)?(,3$2\1>?MEJJ(/HSOW"&W/?YNQI[Z([?%/8_W-%QEZ^1Z<,6=8K2_
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MKJZ3EI8^;5VG,]#0T$.#U'53@]QS8R\=[29&1QQR#7&LAB;ID7L=L=B8F5[
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M+Y;[R"(Q/8&8Y"C"8JYR/?PTD=&G"8\\PJVP%TD1OR0G\QAEA><Q=*8Q/=Z
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M Y2]\3T*GO@JA0_]$]4/?P7'RS^B;\=M>%[\ :YGOT?WSKN83]K'9GNY&.&
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M!S6!=AI&[%0.MI'7U4A2>P5I[744N<W4#WBI\-DH=!G)=<IU^IK0=#>2U]U
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M.OM":8_42)5<396(*G[:*,_5'(I"5H[C OE=72L$MZDCY%@>%L(Y'%P0\KO
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MP%3P/*;\Y['DOX0I[Q6ZLEXDY.R?<VCKO^;&I:>)C]I-AO2ZH==SA-Y\F(2
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MZS)>H"?W=9S%'S)4L@-SYG::(S^DU/]]"D,^IRCV,/GQIRD0_K>JR!-=1Y;
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MTUIZF.K4SVC(/(15&<#J6 6;\TINS[>P/%[+J"6-,5,B$Z8$>EK\J,TZ16+
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M &G%[G1H"QD>ZL8Q:,1DU&(R2P\3^QD8&F5Z?H'1B0FYQ(/)8D:O-]'9(67
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M>)L+QQ_!X\HS1/N_147VEW36'B+"XS=D1[^)4W^#VNR=A%Q]F"M[_CV!9W]
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MCT6?+WA+.5WJ3!IKPJDO]:*SRA5#U1FTA;LP%GR(-DM@T80G:4U^X?_'WG^
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MQM28B@57)2.MB9@*/#$4WA+7-H(V0P;UUBS*;9GDV=))LZ20W)U(HL *L;H
MPFNN$%9RDKCBTY14>]&B3:"G>V<L@+'Q#G%]30RZVH3/5=-O5P@=RF+2$,2
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M@N>IG^!Q\L=XGGT$?X_G16QS#%-;&IL+5M@4MO>.?'MZ26"616''EX6QEV^
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MX5'9U-5+@G28\HIVRLJTE)4V4E6IH:]OG(4%$6PO;8E^0\R/( ?F<3C&&1%
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MBNLC7]V5K[7"RMI=!H>G:&DWNU_)E0/\5%1JJ:UIH[A(159F&8HR%6VM1A$
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M#'!OU<S"4#6:JAL4)NTF*^H=LB+?)3WD+1)]7R7"XUF"KS\KL,U+P@>\@V_
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MQ%CS)?KJHW14GT5?[\V ,9.Y45E?LY_UE3&6E\:9GQ]E9F:8U959@9?%?2W
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M(;=;!/#C5JI'3*0:5$1H2HAI5Y#E:*)HK(W"41VY@PT4N324#;50UJ<CW]Q
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M/T-)^!XJ?-ZF\M;K%(L^)V 76<$?D>[_'O$W7B'R\K-4IQW 6'<#2Z,O1E4
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MKO(",<$O<^K@W^%^^4%4V2?9&,E@W!Q/><8E/*\^@[_KKPCQ>8V(P%^3F7B
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M9A?LT;H+PG^-3<V(<S/2.S#(_(I8MK+.[.(JHQ.S6+K$N1M[Z;(,,CH\Q\"
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MMNDE- .SZ*7@:UO&(J.#AU?H&UNS1Q$/3V\S/+G!H"Q4-['*@)A:1U;H'%C
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ME%8-4U8]0D7-J+!!:AM&:-?.TF_>(#6D@I-O7B/P8A097MDTIC>QT;])7\,
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MA<8&D_@.]=@$=YZQF5B?Z6%WL9^[2S;N+0S#T@2LBO%S;8[U^0G&90T?38/
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M[I;R"T@>QC,.S"-Y17YE))8FTK.61/HH+FUW)*N=F'48L<?'IASY""0O9LE
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M5'F 7O,)++7O4%_T(N5IKY 7_1XQ7F^0%25Y&3M3FGZ O(17*4I\A*KL!P6
M?(IQ[2N"!#U-??Y!ZLHBJ*HH0B8K)#HNE\0T)?%IE<2D5A(EIB'Q<@*C<@E-
M2"&C* YY=1!J]67D.>^1&_40&<%W85"^REC[(:9Z#C%AEPS$'[/>^2E+^C=9
MJ'F>Q<JG6% ^QE;SZ]#S.;N*1UE*_P4]4?>0<N3O"#_^*V+=]G/]L@OG3P=Q
MZF0T3E=2N7HUG3/GD]EW));/#L=P^$P<3NXIQ"=F4U*02$GF.2JS/T(>]QC1
MY_^*Z./_B=S+?X0Q\MN,Y]_#3/'=#&9]E_6ZQUC2O8Q=_2S#+9\S;C[&0,-^
MAFJ_8*3N,\8:/V)2\RX]Y8_0G/Y=N@I_@C[^'U#[_BFSBB<9*W@"3>!/J/"\
MFV+O)R@)_P1UEB=R612Y&:GBV>6CJM;1H.N@0*XC-*84U^OIN'NGBKJ334Q<
M(AX>E[AZZ4-B0KZ@W1C(B-V;$9L3P]:KW%[*9'DL$WG^9<Z<?95++H?)4^23
MFE](6J&2DAJ3(-NC5!L$02G4X1%>SAF/+"YZIA&?7$:I(/:JHG#RH]^E.>]-
MIAH_8%3](LVI]R /_P&*M,>HE[]/N_X"L]W!%,2^CO?I'Y#N]QM2?7Y)DN<]
MI'G=2V'X0]3)GL5>^P9CEO>9MK_'A.5U9MH^I%__&76%'Q#M\RA!'@^3'/D:
MN6D?$>KS#,<__QZ7C]Z#T[%[.?_%7>Q[XV_X_/4_X^+!;Y.?^JZXKX/$A/^6
MSS[Y$4\__4T>>N2[//'$SWCZB7MX[LE[>/G97^)T_C-1OP.I$B2PKB:/^H82
M='H5&HV*AMIRJE2%*$HR*<Y-("<]5+1'9^+"+I(6>X4PWR_P=7L;/\^W\/=Z
MF[BH0Y27^-#=7L+4A)ZYF38V-\8%(%\6"D8R>JZQ=W.=&U*"$0'*;PJ0OKZV
MY@A[U-2HH;BPF*3$9/S\_+GFXHR'ERMZBY9=\;?%-BMLBKYQA:'M&1H'S.0T
MR(G.3\,_(4ST(ZZ<N'B2,Y=.$QD3B4X0^=8VB8R:4%;64E.O<21>S9(5"]V=
M0V!P'#Y^D>3D*RDJJR,K3T%">@'A<1F$1J42FR2C0MV(R=PI=)Z1)DT+>KV%
MYF8S>B%2O&+IP_+VSI<)4F[<%GA#].-"QTI81!()BTAQB"4O7\GX*AF%)<]A
MZ>.U9+"5PD-(R](V21=+'VTE([+D,;P@\(N4[&Y]8\MA()9"(TD?:H>&)QS>
MRST]@PYC[YS0U7U"-P\.C#(SO> (.R49BG<$%I 2X4GX1PIS,3 @"-^DE,!N
M@;'1:8:'Q@46F'+\QN'Q+)8EH_'(\-B7USK#U-2,N/;9?PT_(7F(W8G?=\=
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MJ7M:X-,[GL#F[B7:^E>Q2X;BP2\-Q2.BSY0,Q8)K](UNT#.Z[@@U(>W3VK.
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M91QFT2;LVA2!03)H;1+/6YN'55>(J;&05EVQN(]\6FI2T:OCA21BJI5A:2S
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M:/4VM+HV>OHDSY]50=(6D9?6$Q<K(S-#3H%D@"[14%*J)2U=27QB":D9%0*
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M)2_C++;F" IEY_#U^IA+E]_'X_HQKGN=P>NZM.XL_MXG\/,\@)?KAW@[OTF
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MN';A;D8[ YCH"B8O]3/<7-[DFOM!(A*"**M4D9!1P&7W<)P]$PB**B$NLYK
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MGWX*I<\CZ,,?I;?P(WHJSI(;_#9I ?O(C78E/RF2I(@8POP%T R)(R30C["
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M]=_>R^$#SW#VZ$L<^_Q)]G_P,/L^>(B#GS[,AV_]F-^^\@]\\NYWQ/,]PO1
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MX>4=).@[!?_N(]W1@[M6QX6*4BY5EN!2F<]E;287E/&<+ KD<,8U#L2=X;/
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M/^%.QTYFE;]@./L[="=^A:Z4OV%6]P@K32\+8O$LR>[_C:@K_X/BA(<Q51S
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MN"4B)@G+4C7NFU)1MX5E^@=&Z!0$:'!HG E!<.;$=LE:VKLP6.LPV9IH;AU
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M6S-=422<(2WJ,%$Q1PA-/DMP]G6""KT(+_4GIB*8V(H0$A1A@E-&$)D728#
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ML=C:G,7M##6-U)I;Q4#>[ 2;M;9V6ML'F)Y9XH:XQL;&#D$TK=34-M#0.R
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M4!=V4*T=H:IZ I5^#+E^DASU*(GR/F*+NXDH:"<DIXW0K$Y",KH)3A>6T4M
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MKK3A:!^ANV.,]J8!6NP]6&K$=>OKG=7/I4A@38T52V,;O8+L=8U.4F:TD"R
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MWHQLO8&\%2N)LSJ"Q3/T:$OD>D,H5ZT^7)9$8N5%SA0=YWRFP/B)'Q&2_+[
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M_$JR<]1.TU>WXNB81"?F4BJ*XI(J;-8.^KHFZ>^8P"B.4:.Q8:JZEX*B3"-
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MC3K[-;2%QY!E7B$UWI/L[$224M,)BTXE/"Z7J.128C($D,\Q$)2LP35,QL6
M3"[YQ>,?&4.)Z)=)T6?QO/@,GF<?0);PBGAVE[@]E<Q"1QB]U5=IJCB'N?02
MZ3%'.7'T70+" @B,R>3@I6CV7TSBA&LV5_WR</--QM<WE/! +]*B/(GW/XWK
M\3?XZ-EO\.L'_@LO//)?N73H)^(Y':;;YDU>_!L4IKPJR.D.C.J==+6<I\E^
M&B^W[Q(6\#!%66]2DOD2]=KW&;!^3%?5:P+$?\"0<0?VPC=IEA^D776-^C)W
M8GT^PN?*ZZ3$'B8_]21^5U_E@U?_GNC@ Y06!9&;'2+&^73*%&5H]568+)(
MIR(K-YWRBD+R<J.("CY.M,\')/N^A#S\65KS7L4:]P@UX0\P5;F+SI*=% 6_
MC->)7Y(1>0EE42[1X>EXB3X3%%&*3-U,:54'67([?E&"D+JEB?8=PSFW.*)3
M<HE/"L/]V@=X7WF.&']QCO2==)BO8"[YC*BK/R;FV@,HDE[!6KH;UZ-_Q6=O
M_0$7/OM3%&DO4Q;W&*G7OX8V\4DZ-,>8; YGO#6&S)@W.'_B*Z3$_Y*R@K=)
MCWZ.O>_^#TY]\DUB/=Y"E769BT>>X<E'_I0'O__?^?X__%\\])T_XI6'_EZ0
MGQ_@]MQ#^+[P4\[]XIL<_ME7./C85WG[@3_FA0?^+YY__+_PU#-_P"G7[Z%L
M.8!V^ S:F2MHYKU0S090,1M)V6P\>9,)) U$$]X13$BK/P%-?GC7^>%:X\M%
MA3LGLB^R/^HHGP8?XD+B%;*E"NS=!CHF.YD68]N:E)M>2C/D3#4D@+T8$V]_
MOLF=NV),75VFMW] /"^;P "EQ,?'XQ?D*W[7DWQZZ3#ECDI,TX( .4K)ZR@E
MIT5&JB6#@+)0+N5X<33Y&GLCSK'#\QC' Z\B-VOI'Q]A>FJ6^KHF=#KA*Q4:
M"@I+2$Y((<0O"(^KUPD/#2$C*YU<T?]B4Q/P#O7GHJ<+^XX=X,.].SE\\JCP
M]0:GD+V\<).5^46VEC>XM7:;WLX!9XJ'Z9D%)F<7Z1F:P-K4CEI?@\5:1V_?
M@+!!NKH'Z.P:H+]_C+:V?J= W-S<YRQ(I]/9G'A!JH=0H3(+G&!SBL12)+$D
M%$NI)R2QN,G1YRQLZV@?9&AH3AQGR&G#P[/._,92E'*=O=4I2+<ZNISG'!N_
ME^9B9'2*X9')>WF1>P:9G5MTYDR6TF&,C$YR0WJS2O@UX>8$7L.9>F)D9(R%
MA47G^OU)(EM2)/'\_+S3I CKS<U-I()C$L:[C_VD^>^2LR^G?Y^3]&S^M7;_
M^7[1[DBIQ#Z7ZDY(*=ON")-(_I;X;(.[MT5[$ECM[MH GR\ZV)@P,-Z436=5
M*(UB_&@LO29\JJ<P+VQ%EX7?/X.]U(V%[ERVIC7<6JAA^Z:1VXNU8KF6]6DC
M<WU*IMKES+:7,MM1PDR'C"EAD]URYD<UK"^865NVL+8J;,7,BCC&\DP5:U-&
M[LXU"5]N9[U)3D^Z"RT!G]!R[34:CS^!?=]/J?ODI]3O?0+%NS]%MOL);+''
MJ<N\0&WR,:PA'U-]Y7ETIWZ)Z>RS-'E\0%?D*7HS_6G/BZ))EB*P03Y6E5)@
M=A,J33,EJFX*5'WD",M2#0JL/B*61\E4#)%6VD=*<1?)11W$YTO%K!R$9303
MF"J)M"T$ICL(S^LDH:2/W(HA*JNG:;#<H*5J$D6,B7RW<DSA#60=D>'_2@1^
MKX3C]E(0?CMBR?'4T*J;8[@+FAK7,)@74.JFD2G'R2@>)+EP@+B"(:<8[!'?
MBD>< \^X9CQB&W"/J<<K0:PGMN.1V(97<N=O!>*KL<U<CF[@0K2=2S%B'F47
MR_5<%_NY)K4[S3VQ$]?X=J[&M'(QHHFSP?=%8I-3)#[F:>:$9RUG?>RX!#7@
M(?;Q$^</3>\B6EQ7;.D(4?(A@HIZ\"_H($#\/B&EG82HNP@S=1-J%\<WU7+)
M7,.ENFHNU>NYWEB%9Z,>U]IRKM44<T6;R]6R)-R*0\1W \BIBD-AS$9;(Z-2
M6X16D4-E6;8SW41E>0':,F$J\9GTEI:JF(J* A3"E,HBU.IB-$IA*CD:C1R%
M0BJ27$RE3HFV4HE**W'!<F%EXO,R=)*0+#"Q7I&+4> _HRH;@UJ<2YV'7BLP
MBMA?$I@5JE+*Q?G*Q3&56O%]C61E]X1?58FX!AGJ<G%-Y27H)&RC4*!25(CM
M"O&]<LK%=Q25<BHJBU"H<\4U98KK3!?G24>O2D93$2NN/5)\'DIY33":IAA*
MF\+)L/D1;_,AJMZ?R-8PHKKBB1O*)F%,1LR0G,01%6EC>F'5I(P:Q;J%A&$K
MX;T6_%N-^-B,A-4V$FOL(%K327!Q!WXY[?AEM!$H3,JC+14W]$T6;2'6P>7P
M1LX&25&X%@Y[6SCH5LMG5RSLN6QBUT4C.R\:V'&QFAV7*MEQ6<-.%RV[+FO9
MZ;1*/KZLX^-+.G8*VWU1SZ&K-5SPM1(HVFA!V>3_B[V_ (\L.\]]<2<Y)^?D
MG!L'3N(D#H/M&,<>L,<>PXS''N8>:F9&M9B9F55BQI(*)958*D&55((2,ZLE
MM=1B:C7][MK5[L3)=>X]D'.2__.?]?3;:]>FVMI[K?6][U??_A8%60,XGXC%
MX5U_0@_'HG 4.L99+;B=GKF:VVSV[+$SO,_ZT#;;(V),&GW(7=,N<6?C.?7L
M)6Z\X2EXY@*#8F@H4DT1D6G&-:8%JX Z+GA6<5:*"A9M]JR7N';/9BZ(ZS_G
MKN><Y!QVJ>>,N)[3SK6<E.!:RVGW.K%_ Q?]])9H9ZL@/;8A>AS#&G&+:L$K
MK@W?A&X"D@<(2ALB.&/ \B--2'8?<27COW 2]Y-;/X*J?93RWC[*^HWHQIJI
MNF40NKL=W58GFJT.5%MM*+=;D6\9R+Q32^1X$=YFP6G,T3BW^&%3Y8RMS@F;
MDAO89IW&1?8)H<D'R,KYF!KM$;IJ3S#0<)R^VD\9;CK,2+/@ZO4'&6DYPVR7
M(VLC,6Q.9+(UHV![L9I[FUT\V)\48_VRQ5&\(W3SGJ2=]]:XM[?"P[O+0C2O
M"9ZW\0N'\;: ]";2X\"KAX)S/)(FS!7\09K([M$O',66".-_XB06Z_^)<UB"
MY""6?MC^EQW#OXQ?9</^-?!9^;<IGSF)_W^L_//.\J0#/>F@_]B9'W%W_X'E
M==.5U2TA-+986MKBUJTUYN;6A*#;8.GV)CW=8YC:AIF9WF!N=@M3ZS IR45"
M.!907%)/1^>4$$3C*%7-1$7G$Q]?0EI:&?GY-<+HMXMCI2B;"7*RR\A(UU"A
M:Q/GG+(X?T=&%A@:E+#(\-!MQD97:#6.4%79ALDT1&OK@#B'@;348K(RU2@5
M->C*&X68:Z&L7$]!43E*=1WE%2T62,).FMRN;V"6CJXQR^1V\I(JB^,X-[\,
MA:K6XM26\@Z7ZXP61[%2U6CY.R1GL;RXGOR"&@J+)*>R-'%>LZ@;Q/HZL;U!
M7+N1NFHA%&LDF# V]6 T]%%=;T)3UX*\3D]>33VIFE*2%2JRRG5D5U>2JZ^E
MH+6)'&,#J?H*8BM+B*LM(:&VF*2:8A1M>C1M!O(;ZLBNJR:UMH+XFE+":Q5X
MZ#*Q*TO MRV7,$&VXZ9*R1'D7'VO@VH&J'DT:$$M@]0S1#/CZ/>&44TT$ZA.
MQB$EF-CR'#(%22OJKD8[WH)NNI7J6^)O6#9;TD0T+@G<-J.?:Z=N5!@\<PVE
MS5JJ6JMH&^Z@9ZJ?L=O3W%J_PZR4QW)EF?7M37:E5U<D9X,0'M($*-OW-KFS
MM\K$R@R&D0Y*3>)Y=31@'.QD]-8D=RR1P]N6:*B]G;N67S&EUUFVMJ4?*[99
MN+U$_Y 0U:.#3,U/L;:U)@3SKL5 24YA"8\G57P\L_WNWCZ;NWNL;FZQO";:
M[&W1ID9'J:ZJ)C<[A[;6-GI[>NGLZJ1GH)_IN1G1WM?%.?:$$7QL"$7GL/2/
M!Z)OW!-BZJXPB%N;:RS-3C#>:V#0H&&X(8>A\CCJHV\0]<G3!+[SIV3<_#)=
MI:\SVOXN\R.?L#1^G*J2E_!Q^CH?O_>W_.S%/\/IQDN8JQV9;G6B2W.4O*!G
M<3G[1UP__55<G ^1E!%+6$(:-A[QV'AEXQPDGG=$*2ZA*AQ\"W#RSB$PHI#L
MO#**BXN)"7,CQ/$0 9=_B.^YOR<W2(BBHO<QE7_$A/$DXZUGT&L/DQSW"6'A
M%Y&EA1*3FD)H0@[>$?E8>Z9SP3Z)"]9)V#AFX^:6B[]W!G%1J83ZNN!G_S%E
M2<?I49]EL.PLU9D?,:AWAI42V-8S8\ZBL<B-MB)'!LJ#Z:U*HS0_EXRT8J)E
M)01$Y>'@D\)UUV1N>N1QU3F+<]8)G+D>C+=?!$DQWF1''*<P\F?49/R8T8:W
MN3=W#C9NL+ETA<692\Q-V+ XZ</F0A0;<Z'<'G9FRG2!H>H#]*E>8DCY(T84
M+S"N^0FWZ]YD4?\64PVO,EKW&O/F(ZR-7Q;"]#BC^I_36?(M&M*_0F_9>W24
MGB/!_RWDZ6Y4E^:@+,ZC0?0W4T<7#2V=I(KQ*2 \![_P-$)B922DA5-0Z$9%
M\3':2M^F6_<JJH1OB?O]-LM#@4RTQU"<YHRGXQDQKL62F9M-:&P*CEXQW'2/
MQ]Y?G$M6A5U@,6?L$[CDEHB=?P)^D=$D)@<2Z'."<+\#M#=XL3Z3Q-:TC/YZ
M%X;KW3 IKY#N\R."K+^#TZ5GN'GY%60R/Y*SI!\4XKGF%(-;0!H)*85X>GIS
M]=QAKAS].:G!ETCQ.X'KF1_B<>X%+A[X&][\_J_S\M.?(\CQ^XP871EHLF.V
MSXOEZ1!&>CWH[G"G5'L9*ZNO<_/:-_%Q^Q'!GM\G)?S[*%-_2%7>C\F-^#(9
M@5^B1DK+H+E.J\*)@NCS>-N]C9/U&T2&GJ0HQYK"K.M$AQTC+LZ&I+1 4C(3
MB$U,)3U'1;DT7G8,HZLUB':?9UF?D!A'2F(PZ3'V!-J\AM.1OR+%[BL4>WX%
M7= W,*7^E,[< ^(9'B4G] 1%R;[DI6?@ZY.,G7,ZSCY%1*14DY#;1&1:'4[^
M<LY:QW/D4@AG;T82F5Q,9EX6T9'6Q 0?)C7R0Q09AS&47:*S\A)-Q0>11_^8
MZFS1/G3G\+CZ9[A?^4LRPE\FP?N[Y(4\3V72BU3(?DISX0FZJ]TPUTEI2 Z2
M'/4#E+EO4)3Q"DGA/R# Z2FRHCY$FV5%>N1YG*W>YI-WO\V/O_O'?..O?Y-O
M_.FO\>+?_1<NOO"W^+SQ#(%O/8/]2U_BW _^A$/?^UU>^LKG>.6YW^#\B;\B
M)N$5E+5'T'6?03EX@>+Q:Q3/VE,RYT'1+3]R9P-)FPPAJM\?/Y,'OD8W?%K<
M\1)MR;W"&]L"%\[%7N5CUR-81]N3J$U!UZZC=<A ]U@7?:.]#(T.,3X^)FS]
M++N[FX(IW.<1@O +;(K/$S/3Z)M:*)8K2$Y*PC_0CZL.USAA=X;PDEAR.A7D
M#*A(ZRU$UI%!=$LB(?6QN.O"L"KVY4R* Y\$7.1*E#-ML_VL"5&RL;G!].0T
M!D,K*F$C"XN*24M*)2HD##]/+YQ=G/ .\B6U,)O8[&3\$D)Q"O'DG/T5CETY
MQ?F;%T4?#:"^L4[P%W&]#Q[;!,D>3$W.T=LW3+= 1\\@INY!40_1U3?$T,BX
MQ=$JY20>&Y\1-F+*DC*KNWN$C@YI\KH!BY-8FJ!.^K%9^M%92F>EEWX<%QRB
M7M]E>5.JU32(OME,34,;=8WMM+3VTM4U2E-3ET G9K-TO@%Z>H8MCN#E.QL6
M;K5X>]7B()Z>6; XB4?'IO\!0\.3ELGTIF?FA6W:$S;MGL6N28X]J=P5XFUZ
M>I;U]77+YR>3USWA=))36(HDWMK:LNPC119+SF*)XSTIO\S_/BO__LH3COX_
MBR?/]@DD+B.U']$]GF2:X*[X($W4>^_!KN@O:VQO3+,R;V9AK):IKB)&FQ(9
MJHU@L#* 09TW0Q5>#)9["BX@[+W<B3:%&_W5H2SVYK$]5\G^:@OWMCJXM]G-
M_:T^'FX/<G]]@'NK_=Q?[6-?<,O]Y2[NWNEB]TXW.RL"ZP);9M%6.]G<,+&Y
MUL;.6CM[JV;VEOIYL-C/H^DVMCOD+.LBF,ZPH=_W('7G7T#QR3=0G_PAA>=>
M)M7J+6)\CQ 1>HJX\%/DA@ANY?4!!2[OH/+XF)J0"W2D^S*IRV.L6D-/11G-
MVG*J-364:0VHRGLH+!TB1SM"9JGD))X@6S=-5L4,&653I*G'2"X90B;O)SZ_
MUY+7-2*CBQ IQ42ZF=",;N(+AL@OG::J?IE.PP9=58\=Q+%7T_#_-)SHHTF$
M'8C'Y]5PG%\.Q//]2++=2AG3;S#<=0^C<1-MU1QYZG'+Y%ZRO"&BLOK%=_01
MD-R+9T(W;O$"<69<(DRX1;3A$=-AR9WJ+K9Y)$II),S_ "F]Q,WP%JZ%Z+&*
M:+8XBQWB.W!.$,?+)(AS)?1:TDXXQ9BQBY"<Q$:N!4A.XB:+D_B*5Q-6OJW8
M^+7B&&3"*ZJ3D.1^8G+'2%!,$:><(%P^A'^>&;\",T'%W82I>PFO["6RJ9_(
MCGX"VMOQ-AOQ[&O!8Z 1'X&  3T!/=4$F"OQ;]?BVR3X:$4D@1I?DBI#**Q)
MI*PF1^B^?*K*,JG2I%)3FB&00Z4FCU)U#J6:?,K+BH3.DU->7F"9VZ%<;-=I
M<JG02L<56"*,RTL+*"LM$MJN6.A!I8 :3:GDW-4(S5AJB?;5:=14:97B_"6"
M"Q:)[RBD7%,BCI4BA1\[E]7E2I1E"HO35U.N$9#.HQ#G43Q.(Z%5B.M44*E6
M4JX2YQ=0BW.HQ36J=?D"F:C*DL6Z.+$MBG)%.*5%_F@+/"DM]J2I(9S6]FB:
MNL*%;0Z@P.A)LL&5J!87<1]]B1V,(F$\A82I;!)F"DB:%WIRJ8J"E48*[K20
M=Z>5S,56XB:;B!AN)*2_D6!S,]'M'<0+71JE$\]'WH5_KIF [![\4SOQ2Y;R
M2G=:?FAPC>G"-M1DF:!0FMCM@F<C9UR;..G8R'$[/8=M]1RT;1"HY:"=Y S6
M<="AG$-V.@[9"HCZ4_M*"P[957+2OIK++G4X^C<3)LZOTBQ253Q#LJ.*F+.I
MQ)Q(0'8VD=1KZ60[Y5$8H$ 56T99:B7EZ57H4G54Q.G0^*KP/N#-R><N</:G
M=C263-'3_I!<Q01AZ>*ZHPW<"*SGG%>5)77$6>FZ/9LYZR[@VL@IIWJ!.DZ+
M^J1CG4"M93*]DRZ2D[C!$GE\V:_Q<:H)*>>VQ4FLQRVR">\8([ZB+P6F#!*6
M-498[K EBEA*\Q)?,D*2>H0431\E34.4M?<(;=M,G;F"EI%R3/,U&%<;J5]O
MHGQ%Z',)F\VH]XP4;361NEA&^$@67N88G S^V-:Y8:MSP$YY \><L[@D",V6
M_ D960<IR?T(3=9;5.6_(;3= 7IJ/F2PX6-&&C^U3*C<5W6$/L%7.]47:)9?
M1%]R@]&.!#87ZWAT=Y2'^S,\O#O'H[UI[F^.B7%YB$<;@\((3 J#,"=(Q&U1
MWQ%8%1"\8G]#;!/8$SQP;TLL[XAU4A"5X!%")TL1Q9\YB3\K_U+YS$G\;US^
M>>/_YQU"6G[2\9Y\_M7[/,:3Y0>"-.[=W;=$8B[?66-]8Y>=W0=(Z1WNW?O%
M@:+,S:TR.'B+I:5](5;6:6[N(R-#28FBCJIJ*8=?A\79*J5J2) 5HU0:4*M;
M*9+7,32TR,;Z0]96]S%WC:/1-%HB@F>F5[F[AR"KCR'I&3'.L"G&J/[^.?$=
MW4Q,2 Z_63H[!VEN,ELFB6EO[Z>AH56<IQ*5JM(2X2--+M/6/BQJ*1?AL 72
M9')2%)!274N)LL92J[4-EM='I<GPJFK:Q;*X3DV3)1>QA,>1Q29*R]J0%S>0
MDR>EOM"1FU=)<7&]97M553L5Y2U4E#73TMQC^9Z:Q@Y4U4T45C>055F#3(C?
M1*V6] IQ;%VM0 UYDI.X14]64RVRVE*B*N7(FM2DM):2WEJ&JM> MKM-[%-/
M1D,E:<W5I+35$*(OQJ4R#9N*!#S:LO#O+2!TI%@0ADKRA#%2[W50^:"?FH<#
M%M0_$K@_0)4@[HJ9)H*JTW H#".Z.9_,01WRV4:4B^+O7C92NM)*A2#HE:N/
MH5MI0[=HI&Q<&+?.<E3B^FK$-?2.]C(R-<*MI056A1A=7+G#'2%$=\4#VY<,
MA"36I4C<^WOLWY<<Q5LL[]QA<&Z$IMY6ZCJ:,/5W,38[R=+J$ML[V^R+=B>E
MC) FX+DGL+MWE]7U#:9F9NCLZF)@:- 2%;RSNV,Q3I(PEARX^_<></>>^-Y?
MU'O2:\=28GXAJM<V-IF?%P)\>)36%B,U%55TMIGH-+5C-!A$NS#1/]C/S-PT
MRY*3>V--")8M80OW+3F.]W9$^Q=]87UUE<5;TXSU=])CK*:SKICNZFSZRQ*I
MC;Q)\+O?(.3=/Z?4ZWNLF\\R;_Z 6]UOLSIRB";5BP2Y?(6/WODBK_WL3PGP
M_(#YX426AB(PZRZ3$_A#K __(1XW7B CR9F(:%]\0R-P\4O@JE,<5AX9. 45
MXQ @Q]8[!R>_;*(25<3*<@D."<'9_C(>-D?PNO$&3F>>(L'G1]3*/V:L]3)3
MIHL8- >0!7Z' -<?X.'R%AY>0D0EAR++RL0O.I7+SA$<NQ;,B6OA7+H1BXMS
M,N&!:40'A1'B?IT@NP\I"CM(=>)A])G',2INT*_W9W$H"S::N-4OQU01SG1'
M*LO#)0RUEY"2$$5\8B:QJ4I<@S(X:Q?%,:LHKGGF<M,[#SO?3#P"4Y#)DE#F
MAE%;:$-=EI3?]25J,W\@1-,';(Q=X.Z2/?<VO 5?">?NBHP'&YFB3F1UVI]I
MLQ6S[>=8,!UCK/)-)LI>8U+S*J:49S&F?9^NXM<9K/J$K0EG'J[X,]#X,<.-
M;S'1]!HFQ0LTYK^.,OX#@AU>)SW&#651GNC7<A0J04I+1=^45R%+*2,@M!!'
MCW@</$((CA+B11Y"N?PR-07O4Y/["MK45\2Y;=B;SR)%"%2["Z_B>O,#XJ+L
M24X-(3P^BIMN(5QPB.:R>P;6@2I.V*5QX$((%UWC<8]()C(IED29&Q%!Q\A.
M.L?R7)$0V#H&VL)QO_9]PAQ_0G;(ZZ*M_(ATWQ<L.9K3HHZC4X:2GQ.#C8T-
M1PX?Q\G.&E5^/ DAUPEV.D"DTUMD^A\@1R#;]P 52>=1)APAUOLGN%[Y>Q+]
M?DBKYA031D>V9^/87<D4_<.'2ITSA45VQ"=<(#;V$BF)-RG(LB<W54H%\39Q
M@3\@R.E+Q/L^)<BH:!-::XH3S^-PZ<<<__C;?/+A4YP^]0.BPH^3D7R9R+#3
MI&7ZDUN226:1G-"X'-$VM)24=U&E'Z)$VT),4B%!D:F$1,G$]\:2G1*&\Y5W
M^?C'OXO3IU\@_/P?DV;]%R@\OXDN["6TD>^3YG^8G'A/TA*3L7>.XY)U,E<<
MLK'W+<8S2B<(?C4._J6<O)',1Z>#.78EA*#8?+(*"\C.#B$OTQYUP76JU9?(
MC'V9U+#G4"3]B"KQ7&L+WJ),D/+$@.^1&?%S2I(_PNOJ5TCP>(:J]+?)\'V.
MG-!7T6:>H:;D&J5Y1Y&GO$9)VL\I2/H)A2D_HT)^5(BB*R@RKA$7=!S;*Z_P
MR3M?X^7O_3=>_O;O\,[3O\^)'_PQSJ]]A9#WOTWH@6_A]LZ7./?B[_/^LY_C
MPH$_)-3C><I4QQD><:-KR);"VD](UQ\BN?4$*=T7R1JU(V/,B<0A1R)[' DP
MV>'1:(U+C17NU?9X5KCB7.S"Y80;7(JX04!>* 4-Q33TB3%XJ(V>T2YZAKIH
M[S+2VM8B[*R>^@8A;MJ:F9P6XH)["'; G<T5S/V]5-;44%!0)-IK(EY^7ERT
MN\P1VU,XIG@1VRC$WJB:Q,%\8OHRB.A.(;@C$1]#+$XU8=PH\>%(]'4NQ3EA
M7.AEE2WV'D@IKC;I[^NCM+R<PL(BTI)3B0H+Q\O#@ZO6U[%R=R"V,)U8128A
M!>)[T\*QB_3DBH\MYYRN<-;Z(J$)$?2-]K.]+\2,*)+K<VUKAXE9:>X!80.;
MVFAH,M%A'F!B^I:P*[>8F)QA8?$.\PO+%N=L6UNW)1>QY-R5)HQM:C2CUW=9
M?F1N:)3R#P_0:1X7-K[/XC#N&YC!W#-AR4U<7M5$K=YD2;<EI:G0Z]LM:&[N
MLD012ZDLI+S'XQ.S%N>P9:*\\1GZ!T8MZZ7(8BF*6/HL11I+3NN5U4V$*13V
M\)'%2?Q <#2I[-^];W$2KZT]=A(_X6X2)(HG?99LI.0L_I<<Q1(_?"+@?ID7
M?E;^?90G?/U_%D_$]Q-8VL=]L2SQ:JE-_0,DOK7+W=UE-NZ,LCAE9+JOC*&6
M3'JK8^BOBF"X.H*IAA@6VI)9-*5QJS6-\984QELSF.K*9WZHE,T% _N;_>SO
MC+"_/<']G1D>[MWBT=Z\!0]W;W%_>X;[6].BGA7[S+&[-</FQKC@^&-L;(Z(
M-CIHP=;&$#OK8VS=F6)W:9I[MT=Y<*N3_>$J-@S9+"A#Z(B^@M+I V377B7*
M[AU"O _B+.RG0^09/.,N$)-PF:2X2\)>72)-C#G9<8Z4Y<70W5!%OZ$-4X/@
M[662'C B5W=0H.DE1S-(EF988(3LTG&RRJ?(U$V3+NI4[3A)BF$2Y /$%?0]
M3C61WDE81A>1.;W$Y_:3IYRBK'R1&NTMU,GM9+HKB;Z0C.]'(;B\[HW+JSX$
M?A!%T(=Q.+T9A,RFB*:"8>8'H:M]!TW%#.E% \2*<X8E=Q"<W(E_4@<^LG8\
MX]MQ$W!-Z,0UKM/B)'8--^$6V8%35#M.,9TXQTJ3T74(M%M@&]G*C9 FK@36
M<SVD$>L( _8Q)AQB.W&,Z\(IWHQS7#>.DH,XLA/KL':N!QNYXB_E)/Z%DUC4
M-WR,V :TX1S:CE=T%Z&I@\07BGM2.D^B9IIX]031ZE$"Y=V$*+N)K1HB3C](
M;&L_45T]A/=T$C)H(FC42.!8"R$3!L(G#82,Z(5VT1,V5$-@5S'>HHUYEWL3
M6>E+9DTDA;HXLO*"R,WVIR0_D+*22*HT251IT]%ITL3SRQ1<)9L*71;EI<F4
M:Q*HT,13H8JC4AE/E3J1ZM)T*K29E*HRT:CRA$Z4"]VF1*-5HBZ5G+RE:+5E
ME J-5J:6G,62HU>*!BZA0JF@7*44YU6C*]6(_=2HM"J4HI8F'U:4JE")_:5S
M:05*U25B_Q)T*H4XC\KR6:/)%]^1CJ8L0;2U$(H*W"C*L4>9;8<NWPE#J3>=
M-?Z8FP(8[8MF8"""YDX?U,V.PL[;$-MD1W2[.]%]@<2/Q9(RFTG*K3Q2Y@O)
M6%93N%F+<L] R4ZK0">%ZUVDSK>2,-5*S' KX=TMQ'9TD"!L5'2E:*_*3H+R
M.O!/-^&;9, GH07OA%8\8CMPCI*<Q!U<#S!P24K9X-[ &1>])=7$,=L&#MDT
M\*E-G4 -!VTJ!70<M"T7ZW4<%I#J3^TJ+3@L<-J^FNMN];@'&XA-[A7W\;;@
MBW/D>U20;5U$L7,)==%UM.>VTZ4PTUK<3JNBDW9M-]V5/4(?F>G1=-.>92+X
M> B7?GH3^T-!U!8+&]RT*?K*",&I7;A$&[ *EB97K.>\3P/GO)HXXR5-IB<Y
MN:6)]NHM#F()DL/XI%.=@)1+69JT3L]%WV:N!QJQ"6W%+LR(0U@+3N&-CYW$
ML:WX)G01F#) >/88X;E# KV$YW614-)/FJ:?7'&=%<9>])UMZ-O*,1IS!'>(
MH;8I'--$(6U+9=3?T5&Q7H-ZJXYB@3RQG'Z[C)C) CR[!#\R!.+0X(&]SA[[
MDBLX99W"0VBNI+P+Z"H<:&_QHK+DC."8;Z')?H/RG)]35_0*;9IWZ"Q]#[/Z
M/3KE[]*6]PY-6>_0D/T!)O4%1EH"6!DMY-%:(X]6]$(/J5CIER8436&V+8'E
M_FRV9\JX=Z>%>RL=W%OMMOR@Q_HP;$\BA(W $MQ=%=CDD>!7#_9W+>F)_C'5
MA.0D?N(H?IQ>XHF#^ G^N3WZ5?A5=NQ? Y^5__/E,R?QOV&1&OV3#O6K/DO+
M4J>41(*T_*1(R__T.&G=XUJ"Y'23\MMM"E&QNKXF!,JZ19A(ND2")%3V]Q]Q
M[]Y#YA?7&1I9H']P#FE"M:*22DM$;O_0'+W]TV3EJ(F(2B<\(IW4-!4MAA$:
M] /D%U0R.;DDKNTQ496*%'63GEYD26FQOBZ]'OG8*?VXWK<XI'M[)X20&K5$
M.-_=?RBNZX'8_@NR>P]+5$Y%92WYA4I+=,_8Q+(0N*N6:Y0@1?O(Q346%5=8
MG,.28[BQN1N#(#'2*Z/2)'JEY<V/G<3:1HNS6XH4EIS M74]0C3W/W82YU:2
MEU=E24,A11E75+8+@=@O]I%>EVVEM6.(2B$R\W6U@F!6DB2(1X)&2U*YCIQ&
M/45M!@H,36375I-=74&!OH[LIEKB:[0$:G*(KBLFO;."HJ$F-"/M*'H,9#95
MDEA72G9G/<43'82WJG"J2L&J,@Y'0=3=.S/Q%8-^Y*0&V5R%,#RUE&RUHMGM
MH&ROBXJ[W6@W313?UI,[54V(,1O/.ADQ@\5D+=92M&&@:+T%A2 9ZCV3.,Z$
M=KL-C8!J6YQGS8AFKA%-?S5E'974=]33U=_)].RD)3W$SMU[W%Y;XXYH-[N(
M-B3DN?3*\B,IIZ^4]/ZA>&:/[K)V=]V2+L+8:Z+>U$A;3SLCDZ/<6IAC>T>:
M'.X7:4^DQ/H"^\+X2.UP?'*"]O9V!@>'65Q<9G?W<425^&>9F'M/J&@)^^+X
MNP+[0@S=$V)(BK9:7]MD;N86 ]W]=!A,M#8:,!F,-#<V45];)P1\(Z;V5KK[
MNND?'69T9LJ2@D*:*?_.;8&%16[/SC(S/LI(7Q<]K?48:Y4TE^?05IY&AR*6
MTL#+^+WQ960'OXPA_&7VS.>XT_&!$%*OL&!Z@W;-CXCS_0I'/OP##G[XUV2G
M7Q$=KI[%T7@Z=%:4)7U$B-73J)(N,=I50DB@+6Z>+@1&R+CI&L9-#YD0/P6X
MA1;CX)^#<T Z4<DE>/B%<^GJ52Y=/(ZS_1G\W$_A[? 6R9'OHB\]S>*0&Q-M
MURE.>)$+'_\&UJ>_B*O5,SC9ODQ2B@M9A3)"93%<]_#GE(TW9VP"N' ]  ?[
M4(*\P_"RO8Z?]7&BG Z2Z'J #*\/4$2?H*\NC,[:<%JKPP69:&)N2(&I/H8[
MMS3L;34R-*C"Q]>:T.@(9-G%V/HF<OQF&"?L8G&.%ML2-(0D%2-+SZ.X*(,&
M;0SF2G?,FO/H,]]&$?$]JE)>I$?W"2N#-CQ8"^/N2CPKD[&"P.3!5@%W[R0R
M-^#&K5Y;[@S<9*+Q*-TE;Z"/_RYY3G]%L<\SU*=\2)L@5;?[_=F9#Z>CYB"C
MK9^P-'",X:8/J,UYBZS MPAW^IB$4'?24S-)3E.0))"0)"<ZMHB8N%("@HNY
M:1>#E;T_ 6$A8AR)%P+$F:J"$U3D?(2YUHZ5B60AE%-XY\=?Y)7O_AYA'F\3
M%2!-8'>)R!AWG'R#L?*2<=4SF[/.V7QX.9KWSP5@Y2T3]R*-]+QX<C.=*4B[
M1+7:B=LS*J;'BDA/O,*S7_T-WGCAO^!G]1T:<@_24W:>ODHKNJK<Z1-$5)WI
MQ?43;_/Z][_$M<,_I";7GHKTLS07B/W*K,CU_0DY7B_1DGF>R3HO01##61T/
M9;K'!5/Y":HSWQ5M]!QC[?Z,],:A+'$D.\>1$E481I,20ULI+<9R^OH:T>OS
MR4QWQL/Y;8*\7J4@]1#MM<Y4*ZR)\'V?C]_Y*W[X_'_CVT_]-L\^^WM<O?0B
MGJ[O8VO]+@7R1"KU]>2+\3<\24-X<B5IA:UDYAN0I5:*]E*(?T0VOJ%)!(7'
MD)&>B,WE3WCEV=_EXEM?P.W3/R3DY!^1=/5OR+!]BD2[[^-W[242@JQ(C!/M
MV#:,4]=B.7X]F=,VZ5SW+,$QN J'P%I.W\SFT[,1G+H>@D>PC-3L#(MPJZJ(
MPM@83$>+*_YN7^7:J5\GP/'W:%2_3KWR#=(CGJ8B_P 5>8=)#WV=&T?^!.^K
M7R$K]"5\K_\M[E>^2HCKB^3)/D6=<1!E\IMDB_9;)/LA=<H/&6JW1YM_FIC
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MO:/;$K4L%6GRC)G9!;&NA]:V3B%@=BWK'SZ28DK%0"']+SF+!;F5](P$*>6
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MME$3_PY^QW^,\X&?4:HX1'N1!]59OBAE]J0IPX2H4*+3)Y.J2T6N4!$6%DN
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MG/][U-Z_IUVSB3BS7V&[^0&49WY.>]0F1M+W4:/<RFR'*_6%EJ)-_9!G?O,
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M^G0Q#I32T-)-?=L@R9FUV'BK."+B_ZQE)!Z>2<3*XDB1.:#UWXG>_1UR7=Y
M?_X9'#?\%[X2,;_MT;_$\\ /*8]ZF='"C71GO4)_T6O4ISU#E-L_<7CW QP]
M]"!1LCULW_P@[[_TUSB<>(4XUP_(D7U*1>(7E$5O)2_D4Q$#&TD/_QR/"\^S
M^0_?XZ-7_X[W7OHG7GOV1SS]Q(_X_4/_P!./?9\OMPCQ'7&:B4$U\S,9-#7*
M2$PTP\/]* $!%L1$>Q(1XD*HOP.!WC;XN5GAZ7@>1ZLCF)_=SMEC'V)RXGUL
MS+=@8?H)ITZ\Q][=K_#-SI?9OO59/OK@(=YYY]>\(?#6ID?XXNC;'/;Z"O/4
ML_@T>B,;B"5B1$G8D((0@:!!*8LXD0"!P)Y$O)MB\*Z,Q:L@'E<A6FWB_'&(
M]B<N1TU!0SGU'<U4U==2655%66D9>3GYJ)-UA 9%8V7IQ)%CISERYJP0J.Z$
M%RE1=&41TZDEN$F\=V4X+H5!V.A]N)#HBDFX(]8R=V2I"<:Q.T:;+/J7,!S]
M/#AM?9Y#)L<X87Y&]"W>9!7GTC<F!-_8B-$0GEM8,IK$\_-2/>$K7%R89WYI
M@<LK5[EY6\K(%#Q+0+I=7S*.KUV72DZL<FGYBN CTH7K!>/%ZW5(I1_6ZQ)+
M-8D'!P>9G)PRFL029Y,,N+756T9(=89O"Y'UK5$\/#0E>,TD@P,3QHO:@P(3
M$W-<G%]F]J(T'\0,@T/CQK5D%'\[@=[*ZDUC*8PIJ6;RE56N7;UAS$B^OG;3
MR,/$H0O.N Y)?$G+K5NWC27(I"QBXP1C*ROB&&^OO_C=\I^V_+G@_(_BSPWA
M?XMO;^/]<QC+2Q@A8E?P_#N242QE$4L98;>O"W$OF<0"M]:$V+\N8O&&,<M8
MFM1Z3<2.M+XC8OW>FN#S-Q:YOS+$RE0Y0XU1=)>XT)%K3GNV*88B1T:;(UB9
MS.7R>"F7QJI8F6GDSB6#0!.K4_E<'8CC6F\0B^WN%$AUV8,^11?Q%>DQ>]!&
M[D$=OH_T^!,4IEK04.K+Y*B.^M9P$K-,D>6>(JCT-/XU%PAHLB&XQQ/9F(S(
M:3E)L\ED3<JIZP^GN<&+IGP[ZC1FM.JLZ,YUHJ_4C=9T*[I2S)E1V=,O,V%2
M80NM<I@I$>*IE17!C1O*RU%K"@F3E^ =5XEK;!TN\<VX)TK9B08"!6)4?6C3
MQT0_-46N?AA5=#WQ@45D)C0R6+?,5,LU=*$%Y$:78LCN9;9B 9UM&LZ?N./[
M302I?M44I4V2E35#K&(8M^!VSKM5<\2Q@OT.Y>RWK^2070W'[&HY[E3+,2F[
MV*6"0\[E'+07L)7,X2JC.7Q0,H<M*XS8;RE>LY%NP:_CE$>#L6R%-*G7!;]Z
M+ +JL0UNPC%,RA+NP$V:#"^V&\_X'CS_F GJ'B.^8U0;/K$=!"1V$I+<3;1N
M@,1T,1:F]9-;.DUZP3#A\G+<0S5X1ZF)4*<3$AM%A,P35:@-A5$65,E.TABP
MA^'@;YAT_) QP6F&CS])R=>_1GOT:<;S[.AK\:.HP05=E1U958[D%MF1K#Q)
M:/"7^/ML(2IL-Y&A>XB1'2$EP9PTA3/I2D]T21YHDES0*!S1*07D5F0J+$2\
M6)*??)HBY5$J4HY2I3E*M?:($35BNT)]E*+D(Q0H16S)CU*>L ^#<B>#BL\8
MEV_D8O(FEE,_Y8I^&TN9NYE.^YH!]0XZDCZC(6$[97&'R(ZU(STQ2!Q#-"E)
MD8*71:)*BD&C3"(Y(1YY? SRI%A4*7&H4\))57J1H78E3^= 2;J-X(5VM)0X
M8"AUHK_&D^XJ#UK+7.EK\&&Z.XC+PR%<'?3ESE@ =_J]&-)^0U?(!_2XOTJW
M[3/TF#U%[]EGZ#_Y#&-'GF%"JCM\^$6R3[Q.O.5F$D-.HU*ZB]B,(#U'3G&!
MFKK23-JJBVFL*J.^II:6YG9:FWL$-^VDI+B%RIH!*NHG**B<0)TW0I16,E0-
MN$:W&3-N):/8S*<.4^]:+'P;L MNPT76:9Q,T3VZ"\_8+KSBN@5$#,5TXQC>
M@:E_D[&DB93E*QFY1VW*.&Y;SAD1QV9>M3@%-Q 4UXI2/T1&]B29NE%T(@;5
MH:TDBW@-L\XGS+6$)!&#<G4_LJ0>7,-:L/2MP\1UW7@^:E<F4,$QARK11M8G
MV#/QJ<(B6"HYT81+9-OZL8D8]XH1QRD=JUB[1QMP#F_%(42TA>!&H76:\1?M
M-U)>2VI:(YF"\Q7EU=!0T4Q'73N#;;U,#XPQ/33&PN0LUR^),7)^D96+\UP3
MZXMCHW2W-E-67$1A<1D9>?FH=*DH1 S$10K>Y7J"B+.?D'#\#9)/OB+6SU+H
M)-I$W%%(LV5%=H 1T]<9.O(;!H\]R+#-8XQ&?\AH^DX&\O?1EK6+&OU62M6;
M*$IZC]R$=RE,^8*FXO/TU3L:RU",5QQF,.<+6I+>ICCD.4HCWJ0F^4O!]4\+
MWGY(]*O[28LZB#[\$)KPPZ1$'"8Y\HC09H=1Q4@X14UA!/.CS=Q=F>?^]6O<
M7EWCUHV;1C-8NN"]=E-*,I3*E$IWFD@&\BT!,:;\T2#^5R;Q'3&.W%WE]MWU
M.U>D^O?&"Y.23R4>&TUB@?6Q28PM]Z2:^3?%^/7G)K$$::P37.5?3&*)MXC7
M_V@22_O\:5S\?S")N2VP?G?4_UM\M_SW+=^9Q/^+ES\%J 2I 4AU7Z0K->MF
MJ=0HUDW4>\:9KQ?F+QLSB:5LE,%!J>[>J%A/,CTMU:>[+H3,"G-BGSGI-L=K
MJT(87:1+FIBE;YB6=BG3MH.ZABX:FONI;QJDHKJ7]*P&DI2E)"G*4:76HDEK
M$F*Z@:CX7(%L-.G5A(9K\?"*Q\<O"3>/>'S]520F%5)1V4%K6S^-8E"2C.>L
MO%HB8W6$A*>0JBL5SPU25=-#N=BOH$A\3E(ZZ>E%Q@S?&]?7A8KT]:7.0"J4
MOK)R67R/)2'BYH1H&J>WMY=.@X'N3@,C_;T,]G31W]W)@'A^<&" P9%A^H4
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M[U=HPA6X.)IAH'<0&_.CV!COQM%L)S*WXU1D^3'5F\'*5#$CK9$,-X<S.Y!
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M*L\^1[7SAU2$[20[= LYZJV4QNRF/N4(.<JM9 9OI3'Q% ,%^DQ4&3%5:\A
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MG9IAI&^8QMHFVEJ[Z.SIIZFWEX*&:D)38[!3>.*9I,0XTHV]P0:<B'=$+S\
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M\X_2E[R7SNBOZ-1NIUV]C=YX<;S@$LNM'MP:B^7.]3+$"VZO#+"^/"ZX^9S
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M*JF+J 0I2*B!Y.0Z\K*;*"]JI;JDF<K".JJ*ZZBK;*6IOINVEEXZVWO$V#7
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M!<;C[1N#KW^L<&P9 DCDDYI90D9.!4FIQ>+\<O*+6HE+*!.?KQ+?/TQ+^[0
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M5QN8:8^E-<N6,NU1NC+/,%6ASWRC*?,M-BSWNK(^ZL/JF!<KXSZL# >PU!'
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MH]@]LA&7T 9<0IJP\Z_'W*L&4\\Z3#SJM7E_KZF4_+]*>H<Z;>2PXB0V<6_
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M2GIK,8Z901@FN&&2[HU%7B VI:$X5$;B4A.+6UT<*A%W1>KC437$XR[BW9!
M0%,R3MF!F(<YXQ3BB5>0GUR#FM# 8,("@X@)CR M-5V>5S(1,9'XJGUQ='?
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MO=]Q;-?W./WI_03;'R#8;C_>QN_BKO<,+KI/X&_[+JE1.D2&Z>#H^ 4Z5][
MQ>T<P9'>^(<G86@9Q!F] ,X9AG+THC]?G//BT"4O+IL'X>*?2'A<"AX>ML2&
M7*4NVY!. ;6%/N\0=^UWE+J]SGCZ"99+=:D)W8/GY<<YL_,G'-WU$(Z69PB1
M9VOM8(>ULS>V[N%8JF(PM OCDJD_%TT\,+7SQM7+ W6P-<$!1\A-.<A(LPXU
MJ1]1'/X6]8E[Z2^YQG*W!]NC[K3E?D!C^O,,EW_&1J^MM*,G.;%7^?C=7V%A
M?(2Z2NDO:BL"O$VD/SG@'^(M(- =6P\/?$.5%!-!^ ;XD! ?0%J2.UG)=I1H
M+"E)UB$W<A\I_DHADM=HS/R(D9ICM!?ND[]]3%;<;H;;[9D?\*&[THKV8FL:
M<NPH3;(EV=\0HZ.O\]'3W\=3_V,2G Z3Y+B;\K"3I'M\@H?.DU@>_37.YQY%
M=5':Y_UO:QW2R1&G\/4\B<K# B?W0"P<H[AF+>UC&<=5ZR1,G=(P=DKEBF6T
M/(MP+INIT37UP,K6!2=[,QPL3F*F\QHJ\U?)C3I$1[X <:^/.//.W_+Y4SNP
M./!O9/OLQEM^Z^K!'V-Z[,<T:H[27G""DJ0]C'?9LSX3R.*H*TU%!QBO.\!&
MTVX:?+Y-B_M?,Q[YCZSG_I0;=8^S5OLT TD/4.WS+Q0[_CVU3O_(:,BOF(U]
MBLZ 1P@_^T^$7?PN;7'/DN7R0\(N?9V($W]'T;7O4V+X;3+/_@V#/H^REK.3
MS>;# L+UQ" 8P,)%6+P"8Y>9JSU.7L ;!%B\B+OY+N)#3$B-]20K-8:FQD:J
M&SI)$7WN%9Z#H74(YW15F)A["E'R)B; GDBWLS1G&-&1?IH W9^B.OF/^)S[
M#L'Z]^%X\CMXZ_^<LIB=C-49,=IH3U6.&069*@KRHB@OSZ&AKHK*\@K1.YEX
M^(1@X^@EX\5#B),?L2H78FVO$*'[%GGV;]&3=("QVLNTE9ZB*.T ^:GG\',_
M@+7Y88*#10_Y16#I&(Z^910732,Y9QS&>>- 3NF[<>J*/;I7G7&7\Z:EA-)8
M'4Q?JS=-TL_3@S\ET7>7 .J3M%?84)QVF8*D4]1DG*(T?A]YH1^3%_*9C E]
MLD(^POK2C^3:'J<V[F4&-2_3$_,$61;_AO?!?\+ST+=)M7V&\H@]Q+F^Q:<O
M?(??_7 '1J=_0W'B04:;#.@L/<)(PP7F>TV8Z[4D-_X@+N8O<.7DKWGC]W_%
M[Q_<P6=O?0.':[\70O@1:2$?TUIPA-:\W>1'/DM^U--4I;Y*<^8'9/G^GOS
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M*A\_K%5!7+,/XHI% )=-?="W],36Q0.5AQV>7I=)BC]-;>DY!IHO4Y=U@(S
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M!R>.$)(X2EC2*%&IX\1I)DG(G! 9)2YCB!A-/V')/00G=!(DWPU(ZL OL96
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M2F_%7R0THX-$.2:G:HS2QAEJVN9H[)JGI6^1KN$5AB;6F)I6 I VM-RQOV>
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MO^BV\%PI@+:]CXG1&<;%9F:4W-1*_N U%N9765Y:$S*@$#S!FVOKU-;7Z:*
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MD:N-(ST]1OBKAOR<%%VZELZ&:H8ZFQGH:*2GO8Z.EFI:FRJHJ\RC3)LH&"2
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M">C7$84K7%7R!&U?TPTG7%F0.C$Q165UE1R;1*0FDI3T1 H+M=16EM+17,]
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M0.U/;$(4Z1F)Y&:G45%20&-=#:UM+31UM5+3UTB.D&S/PA#LI4-7-0;BU!*
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MQ//"RR3YF%*4+/5;-Y%@/?4=?31V#Y&L+9.RCD?E%BH6+-?DA9&A#2=.7\+
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MVT:PIAJ/P +L5(G8RF^Z^X02K0DG.- ,,_W7\7?[A.B0O80&'A9R=AP?*<?
MD%"</2)T0_7MO;*Q=$G!W"$*.Z= U(%2)]T-"3+YF.#+SQ%K\DNRG)ZC+/ -
M&A-WT%UX@I&:2W3E'$;K\PKV1_Z:(.,?4!+Q:_H*]C)0<(**J$,$F7U&LI\=
M.7%)Q$>GDZ&MH$CZI]*&'A(RRPD(3<7-*QJ5JQI/KW!=*@%#$ULI"WM<W=1"
M)-186(1B:1&)@UT<5N91Z.L%<^EBL*S]L#5W)]+/%7_[PZ@NOTBXS:]H3?N,
M[>YS;/5?X.J(,5M#5LRT6M.08TBLW[>8ZWV-WODC7+QDS#D]-PZ><&/O47>.
MGO'EK'XHEXRCN&@8R9E+@6+>Z!MY2+VP(\Q1GQS5/D*./TS\V?NI5CU'AMD#
MQ)O]C-S #P6\!0N92&>PPP7SBP\2[_<2J]UGF*S<293E?=CL_P<!C-]0H3F*
MVO9=]';^"/<3]Y-L_CB)Q@\2?/I^0B_^G&+?U^A*_I"&J)>)-/X>\58/41/Z
M$=,%>A1Z[B#*^ WB+-\@T>%%:C6?LMBH1WO&(?+57Q.M^AB3;Y_APU__$X_^
MY"Z>?^S/^/2-O\'H6RF;V%<8+7V7V<JWF2U]4XC81XQ7[*$I_SB)X?L(\-A/
MG-I<GJ<U84)R$L.]B!70'ZOV$2*O$=*22'%.'$6Y:E(U=EPZ]@%W_^U=O/G8
MW^!XZDE*PSXGU/PI+(__$N,S.P@/$:(2&HN5@]37N!P*JCJH:1U DU&$*B .
M(X<0:>/^0FP#"/;TPL/LG)SG0QP//87OMX\3>?Y18BX^BM_)1XB3YYX:Z2S$
MRE'*S):#IYTX8QS*.:-P3ET(YN!Q;_8=]N+@,6].G??"5GY3F3W=7@B5J]U^
MS"^\P;Z/[V'7.W=S]+.?8_;M*P3:?"KV/EZFKU&:>%:>@S$E"4>)<GX5M?4O
MB+9_C!C;GQ)N]@.BK7Y$>>0+: .>),+V7B(='B!+_1*Y,>\1(/7 ^/S/V/?5
MW;SSRK_RXB^_SU./?I_''OX>#S_XSSSPP/>X_Z?_RH_O_@=^],,_X^'[[^+H
MWH=)B=S'4+,01?-G^?B5O^0IV?[<0__(2S_[,2\]="^O/O03/GS\'H[\^J<X
M['N>'-<]C.6:,EEF)>W/$JT0.3O+3Z6][R$DWIRL6B&6K:GDMV92T):#MB&3
MI-)X0C)#<(UWQS+2#H-0<TX%ZG'$[PR' LYP)/@<IR+U,4BRPE[K@7>)FA#Q
MVQ&UB<0TII#4I:5<"$OU:BN%4X*1QLO)'B@BK2.']-9<4INR2:Q-1U.50E1Y
M AHA"Z7#-51--%$V4J<3B?.Z2\ELS9?]LHBOSB"Y7O!4>S&%W964]-10TE5+
M;J/@EZH"<BJ+R"DOHJ"B5"<2%Q:7DI&A%?^43D-CF^"CVWF$%=^LI(!0HGJ5
MD5K#\O>8;.\?'&-@2#Z/3NF$X>&Q:2;$?P_)ND?P7H_@+&54D2(TS\TL,2+'
MCX_/Z 1B94(Z182>F1/,,*-,:#>JF\1XH']4?/^8;G*ZK<UKN@EME0AB)=A
M23$Q/[\@&$$PG3*,3!:%$-W&I,)W;MS4X4]%2.[O'V1J:I:UM4W=T/0[BX)7
M;\^7\1^)Q,IWMY<[6/?_].7.??Q7V!UA^ _M]Q'$=P1B8:#R[&]=^Y]%XFM"
M7J_>W.+J+2'80H05H?CJ=<6$+%^7S]<WQ>1[)978U=\*Q;JHJRMBPC.N"+E6
M1.-M(=-"T!5RK@P!WMQ6;$N7BWA]<YEM92CPMM2?C46=;0B!WU323ZS+]O5Y
MKJQ/<VUCELW5!=:69;_55587YUF=GV9]?H8MP;!;<W.LS<ZR/"]U63Y/ST\)
MSIUB0FQ\;H+IV4EFID:8'.UB?*"1N=$65J9[F!GM8WILB)GQ$2:&>ID:;F=F
MN(KQKB16QU*Y-J=E;B"5]HH \N*,B7+=C9_Y>X0[?TUUIBT=%8%4YGH2XGT6
M)XO=A'@<HZW,D^7A9#9F<^7WLNCI2J&A1OR$-IRH(!5^;C;XN-OC[""XT\E:
M_+R*H&!?(L-"2(R*)B<YG=*<(FI+!7\+AN]NZ6!B<)CK6UM2[:_+?]=TPH4B
M'MR2\MI>W6)J=)*NUC;J*LLIR<\F)R&25%];JKSU:'7XANK3+])QXE=T?/M+
MRL\\3UG0<>%%_M3.%%*VU4SNC6Y2;_:2?*.7A&O=:+8ZB5AI(7BV'M_1"EQZ
M\[!K2L&B. *]>$^L$OT)%-^75)!!846)\+XFZ1<&F!@;9W9FFN6E!2EK9:BU
MDE)&B=Y;9659RF5Z5+A#-UUM#314%5.0E8@V*9S"Q!#2_"Q)M#E,EO$GM-I]
MQJ3=^RP8OL3$R<?H._PS6K]]DF;#UQB+/L:53G<6>SRHUEXBT/D#K/1>P-WF
M8Z("3^+A> B5W1E<G)3T$-:_%8GMY'F;RW>"X5PN$NMUBK*X\PP4&S!79\9"
MO15C)<:"-[^E.O(HI8)G<P*_(</G*U*]OR;1]S#^3L=QL3V/FYS'U=Y&_K;%
MV=H.1QM['.T<<7!PQ,Y>^=L,3_LSQ+CNHBQ\#SUI4B?B#Y'GLY-0ZQUXV9W'
MV<X2>SM[7>2QDE_8P<$&6WOQ.4Y6.*GD_"Y&!'I>0!MU@8E28V8K#.G,-B15
M;8J_JSDJ>R5'LC5.BDD=<G:VPMG^LF 5$QJSW9BH\F.VQI>A? <* PZ3I/J4
M+/\OZ"\T8+'!GJ4:.]WDCR.YEQG*$2NRHBK9@M@ 0WS=#7!ST\=%2=GA<8G@
M$!-RA-,.]B:POI#+S<TB;F[DL3@116NU+2DQA\E+.T]UD0V512YDIK@0KG;$
MT]-:,(<][A["D[QL")9KTX0:D9=JS7AO# OC*70VA*$)L\7=T0@G6R,<; WD
MWDV%2\K^@8[$1'F0F1I(67Z8M)] ,I(]B8MU(S+42=J<!3Y69PC6WT_:N<]I
M._TVO0>?H>.;QV@X\DMJ3-ZD1,HQO=J>R!ZIKR,1!(]K")U-)6(QDXCE=-3S
M*01,)>,]FH*'M%F7P40<Y-ILVM28";?4SS7G0L)Y3*2NN*?*]0M_BY-GH8ZT
MP2_ E#B-&V6E<;2UY-/>4D1-9289J6'$1$J?$.Q,0*#"$6WD&9C+,S4@R-^8
MZ'!CXJ(ODY-I1F6Q)8UE)O15&DB976:\^!S%@9^0Y?(NU<'[Z(P\QV"<!<,I
M;G1K0VC,BZ0J/X::\D2:ZM-I%VS3V9Q*5V,BG75QM%1%TUX324N9#YGJHZ3Y
M?$E>P.>4!7]%2=!N:N(-F>HMEOZBG;'A#ND'VYCN+F*P,ICFI/.T)7W+0(X^
MTS6>S#<%,UGM3;=<9WWT*8K]=Y+M^CZ%?I]1%/05N<$[*-.<H#G7EN&F:!;'
MRUA>[&)^:82YY4D6%\99G^GGQFP#B_4>=,=]3F?LA_([^VDO=6)SL4I\PC"K
MJU,LK\ZQO++ ZK+X@.45UE;6=+:Y*OYA7?KWE5Y6QO,9J;:B-64GM5$?4QZ^
MGP:E+LG];\UU2?^HX)$E-K=6=$*Q(@XK+Z:N*"\<-\5G;8@OVA2?I(C$6ZM<
MOS;/S:T^%ON3&:[VHEEK0U:8(;UU*>(3Y[EU94W\F>+7Q*Z)#[RNC*#>8$OZ
MM*UK5]F^MLT-\7_<7&5[H9.>BC"JT^RI3'>DK2):_$N+]-&*2*SD:+_&=?&W
MBL:EV W%%]^X*MOD'$K>XEOR-[*/^&?936?_HTBL;%!&7=T1B6]CH_]=^V-8
M_B02_R>7.Y7A=X!0_E: ]^VW_+>'A"D ;G/SJBX"9%@(A#+Y2'M;MTXHKJEN
M("^WB,R,?%U4;FIR*9K80B(B<XB,RB4SJXZ:VD'R\IMH;AEA=1UIZ+<8&EG0
M3587&IY,4$@BX9$9>/E$X^*FEL]) B:$F/1.T=(R0$U-FQ 9 8%78'5- *2
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M'>9&<I >R<Z?D6;_.M&&3Q!A\'.* ]YCHE*?]5YGVO.^9:9>G\F*4X28_(1
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MH\TNH+"XDKJ6+CJ5EP!3<PQ-SC(TIN0B')>.>86!H5&R<G-Q='7!VL$.G\
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M"O]9V==$26<M^<WEY-:74MA83E%#.?G5I90T5%+5VDA]9QM538U4--13V=!
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M$*B698=ZH1.:Q8YHE;I@7.V-35,P-F* =VB585<7P948"X[87.:0]FFNF]S
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M&.OK1 M"&F"@A_7ER]CI:!$3[L_^K]_AS5>^AXWVD[04'&9CX J+;0=9:CO
M8NMAYAJ.TY>]A[ZD+QF-VTNIY6OX'_XM>F]_'\-M/\?S[',D6&T3Y_,<'FI_
MP5=<7_>3CY!F]A:-H7O)$.M[BCYJN%.LO_V'Z'_T,\P_?X3@R^]3%7")\L"S
MJ._Z 2=?WX+FKG_!]]I3R!T^(-M]&U%F+^*E_@B^-QXEV>%54AV>(\WV*=*L
MGR-<^QF<SSV!P8%'4/OL]YS=^3O.??)[SNWZ!4$FVQE4F@OR>X9HMP]P-WF>
MA( ]Q/GMQ</R;=3/_HJ$D,^9ZK D-_QS@LVW8J?V.#>^^2-!%E]0(]>C.4^7
M.OEE*F-.4!U^A$*OO83IOHW6Y[]!=^]C7-O].%^\^"]L?V(+:I_\DASG[2A<
MWJ?8\AV*];>1K[Z-C(L[B#ZZ#?VW'N?+QW[,UH?^D2<>^K]X[JD?L..C1U!7
M^QRY&./GAVI8G6IG9K2%_MXZAOI;&.WO8KR_GXF!8::$'QX;'*:]M8/JVEI*
M*LHH%'TPIZB ].PLD@7!D_I<8E(*J6GIU-<WJ=(K2!&I*@PEX2D!X"7 (KT.
M*!5#F9F:I;>GC[HZ222N(J^XB-1L.;+D&)+RTRAL+"&K0?BN*CGQRB022I)0
MM"CH&&VG?:B#]H$.6KI;J&NNI:RZC*)R!065)90V5E/67D]12S6%PHI:JREN
MK2*_44E>O1)%<S757<W4];11U=E">4L#%<V-5+>V4%1905Z)\%?*"I55US72
MTS.H$H0G)F89&9UD=&Q*%47<UMY-8Y/ 4FV=]/4/BN_&F9R:9GIVAHFI2:;^
M*@Y+$<2228+Q@SS :RPOKZJBC+\KA"Q%]*HJ=@LL)T7[]O<-T=XF8<DI5E?6
MA?^_P_^'O;^ LB0[[GWAL:^?[2O#,\FR-,*11K*DT8PT&M0P4P_W-#-S5W<Q
M,S,S<YVJ4\S,S,S,S(WS>Y&G-?9</W_OZKW[^:[EM9RU8F6><Q)V[KTSXO^/
MBHS8VE1(T /R<5=PWU=.8F6M.(B5-]L43*JLE>)YBCS(E;S*W.PBPT/CC(]-
MRW=K<JU_)3'"B3375C"M@G.5]BEI*)1(54WJJ-\3J*^(SU<DZ*O/7Q&K_\CE
MZ]?\CY"O[N$/%R4-XGUVA(0JM7-V9:VDH;NED-;[MV7&WQ8BNRWX;)N[(G?N
M;'!W9XZ=A5:6^E-9&TAB>SB3V^-5L#+ W4T9YZUEUH7P;MZYS;9@J*\[B'=N
M;[!U:T-3%'AM2PD,D#FC5)G?7./6RA*WYR>Y,]G*8)$+%>&':%2=8[PYF(WY
M)C96QT3F6%]9U!2Q6]U88TE(_\+RC,R1:2'B0^Q,5K)0[\%4WE6F<RZR7FW'
MW>YP$#S(A)KECF"Z\RWHRC"@,>XJI2%G*0Z_0G&,+B5Q2O%;<TH3G6C,"V>H
MLY3Q@3K&^RJ8[LVA(<>9DMB;3"E1Q,-1L)#)/<'";%2+SLFAN<2>[-AKJ,.N
MDI]H2W-1. .U:0S59S-8GTE_HYJ^U@3ZVA+I:$RFOE)-0V4*S=71=#<&LC*=
M*'V0RNI4'$UE]M3DV5&3ZTJ8A]B;($N*<J(IR(ZA.">&TMP(2K+]Z&F-87DV
M4R25'<&^D]W)1+E?(<S^(AG>HG=#C9F-,6#)[SCMUW]-^X5':+_\(^KU?D&U
MS[L4"4Y399PB-/L8WCF'\<@[3'#Q&:(J+A)3=0E5@]Q/\S52&B^16'L.5>T%
M4N3[L-2CA"0<)2KQ+ EQ5PCR.H:]Z0>8Z[V!H_F'!+@=)\K_*LUE <P-9=%1
M&X(Z1@]?YT/XNQV1WP6;^1Q!%7&&M.@+I$9<)B[@"B'N2B[A8YIZ&"V5WC*F
M&=S:R&1U+DK.X\E8DR5EJM-$>^_#P^$ +O:G<;"[BJW-#6PLKV%C>AQ/V_V4
M9YC2K13YRC8AQ?<X(78'\;<Z0J#-$>+=#E,<<9+>/&V:TA3'G=R'QT$\[8_A
M8'T>5_OKN%N>)L+Q#%4))K1GF-.?:\Y(D3GCY5:,5MK0461-0O!U7&Q.RS5/
MXF!V$F>SX[B9'R?:ZR:1GCJX6UW&P5(P@KD!MF9:>%F=)C?B&J.EQLR5G&.U
MXB0+2E'AC#.H@H_)]8]@:W$1<S,=3,U-L+"TQ,S"5+8-,;?4Q=KB/-[V1\D(
M/D)SRDFZ!-?617]&8_PQBD-/$R3W%N9^DU O4[P<]'&S-\#)U@ [&VF#K2$6
M-D:86AEA*6L;:UWA%#?$CIM0$F-&7;R^/ L7R/8]1:KO:3(#SU,5=X/N#$,&
ML_7I3KU"=<01D@4S1CE]2JS/63)BC5&%ZI$>:4Q7J3_C=8&,UGC35J 46]27
M\;F*J^,-/-VT\72_@9OS%<(#C8@/,2':5XM$_XNH@\Z2&7F1^@)+J@KL2(XU
M)5 I=N=DCKNS)5XN9H3XFJ"*,:>BT%&>QW#N;&1Q?RN7W>4TX3/Q3/6'TR*\
M.3?!G"0_,V+=+(ARL2+2Q8)X'W,2@VX2%;B/E.B/J,O;QUS'1;H*]U&NVDM1
MRF54D5K$2)L2(CU(B XF+C*4F%!_$B,]28FQ(#/Q$E4Y9^FO/<U"UQGFNR[0
M5GZ%3)4N:6IGU*F!@E6C1.))2TTA.RV5G-1$"C,C*<[R(2?1E-SXZ^3'GI'Q
M%_P3=93\L"/$N'R$O\T'1'F?HCK?BZKB&,J*U5269U%?DT9%40"9,BX])69L
M][AJG,3;(^'T5KJB#KZ D_Y;V-Y\#3_;?81[7B$WQ8WVQC2ZV@KH;2]DJ#V;
MN4X5\\U!S%0Y,%5D0%_J11KB3E 1?XZ*E.NBTXSI*[=GL,*>_F(S>K.O,U5N
MR'J;([N] 6QU![/>&2(2RDBY$\VB-VN2M2A)N$Y3D3L+DS7,3G4R.=XK-KF/
MB8DA)J8$0TP-"]888'ZF5\:HE8F.5,H391RLGR?)\3GJU&=9Z T2?9W QF @
MBRUV(L[,M(<PW:?HLT;6E@=86QEE9:F7C<5:5L?5C#:ZTEVH1T>.%KTEEJP,
M9W![O9?-M7%VMF8%C\VQNC0M,L.Z8BLV%L3&K+ N_'Y=L3D;ZX)#UMF1]>[6
MFL@<:PN=M%<$TY1O)[K:76R;FNV57!9G"P1CM+"Z-L+FUB*WM]<UD<1WQ%XI
MHA1M_?*NK!7G[ZUI-F;JJ<UQ)2?Z)AGAE\F)N2GC;DQ]82!+8TW<7IWD_LZJ
MX,8ME"*NMQ4?@P ?Y2V>NTI4\?T=[K&K276I.)"5*&/E31_NW^'^K36XLR@R
MI<F3O#K3RM;2@"9?\OT[BN_B02V&_PA'\7^6Y;^<Q/_3Y=\ZA+\2Y?-7W_V/
MBQ+=L;NCY 2[R_;6;7EXE/S$6P+J^^EHEP=O0XFL_/W.7UN4,\W,;5/?,"2*
ML830B#2"P]1$QF21H"H@(;F(Q%0A.35]Y!>WD9!41E9.(]%Q^?CXQVL<Q*V=
MPRP)$5"HU]>7U94=6IH'B8E.)S1$14)\+H4%#61E5I IQY65-E-06*M)%Z$X
MA N+ZZFH:J.I98".KG':.T>IK>_6Y"I.2LZGM+Q%R%XIJ=).Y3P59:VTR?D'
M>J=IKN^EKJ:#ZJI6<O/**2ZMI::^C>)R(7K%%4(>:VCJZB%="*13J!]7'$TY
MYVS,U6![C-(#L:].P+4E&8?Z*+P$^'E416,2[815B M>D8$DJ=64E57*M88$
MW&X*0+[#W.X:%1,=W BWXQ/G"QP,T^%DLAGGLZRXDFO-S6)'=,M<T:]TQZC&
M%[.Z(,RJ@S#*\>*<MSXGS"[A&.!&4'08<4F*L[)$#$H+K4U=5%<V2'^4DY:;
M2U1&,M;AGAA'NN)5F8!OBQK?KE3\!S((&LTB;#J?J*42HM?*B%HM)6*QB/C%
M4J(F<_'NC,>N)@B;Z@!<6B+Q&U 1/I5%[&(!\4M%)*R4DKA60?QZI4@5B:M5
M)"]4H9ZJ)+6_F.2:=-+*,BBL*M*\@CLZ.J8ADDJ^PKN:A.R[PN8V95INR&3:
M%$4FQ));;,GV].XLS7/MI'1FX%KJBV=C,($#\41JG,1"Y+=*R=LJ(U^D8+N"
M@IUJ^2QS8?.!Y&R6:=)-1(XD$=F?0&1'+*'5X7BF>1">'8:Z1(TJ)XF,P@Q*
MI'WU3=7T];<S-3G W,PHBT)2%A>FA/A/,C<]P<3H,#U='=365LJ\RR0M(X[T
MS!BR!:RG)06A<_$(^]YYEH/O/L[1CW[ ]5./X&;U/.4Y5TB)/(#1Y4?1.?4C
MG/6>)L'[79("GR4EY#'RXI^DKV8OC3D?D.#Y)'97OH_*[0/Z\TT8+[6C+=6
MLJBK% E04P5>(29(7P!($ DI<?A'QN+@%4E4<@7Y%0,45P^1E%&/7T@.]JX)
M6-F%X^0<2DA &/%1/F2H;2@KTF:P1UL,]GG6Q_>SV/L9H0X_Y^W?/L1'+S^$
MO_-OZ&\]1G;R"P*6WB0^^@Q)2?8$107BX!^+K5\F]@%%. >5XQ)4B;%#)M<,
MH[BF[X^YK;\\UWY$1[H0['&*8/O72/9\ALK(I^G/>(&YTC?I3WV>+M5+M"2^
MA<[G?\'US[XI8.X37(P^$.![D<08?US= S"R#D;'*@IS-S767IE8N*5C8!V/
MCDDXAI9AN/FG$)6@)B,CC,(,8QJ+;M!8<%[Z]&-<C'^#T<5'L==]ENK4F\PT
M.M&B.DE;TGX:8]XAW_LQFA)>H2SL=_AJ?UN3BS8O_#">IF]Q_(-OHWWT4?)"
M]Y/E^R;9'D]1%?P4,Z4?LM'R.8N-[PM(>H.N_-=H3'^'XH1]I,;I$A7M@X?T
MLYU;%'8N"7@%%&#GD(:^?A1Z!I'H2[M-;4)P\0B0\7 B0L"<C\$KQ.H]1IKV
M]TFY]K?4^3Q%3\K'M*8>8K'+@XY2&^RU?H/9\;\FQN3[]"6^0X;)3_ ^\E?X
MGOI'AG//T9)Z#*>KC^!\Y3'9[^><?.N?>.J'?\3[SS\L]_\9=:E.)+B<PNSD
MKTGS/4*(Y3O87GZ*!(^3)+B=(-7K* ,YNC1%'R;7\14RK5X@V^85\MR4R-$#
MI'CN)=1Z#^[:KV-\\K=H'7X,[1-/8'SA.8S./HW6@7_FQOX?87W^IP1;/"GG
M_R6IWL]1'O,N?OK?X]I'#W'BE8=PO?+/% 8=H"3B')_^[B_X^7<?XG?/_@Q]
M P&,T3$4YA53++JW1LD+7U1/2*#TH4\</L&IA,6)#L\0G:,2/>MD2*BG$%7?
M0\1(>^/LGR36^A<$Z/V$2^__GYQZ^X<X:!\B,M";L-!X')Q#" U+%?N13W1T
M#GX!J3BY)<A<C>2F4;#,I5!<W$,)\W/&47\_NH=^3K3IJX3<_"TN9WY"@L-S
M-*0=IJ_LJLR)3X6$':#0]P"!%YXAXN)K1%UY'\>#+V%U^'4\](^2%&W'G@\>
MYX<//\2IC[XA(/@CF+C*;M\^%AI>9ZKR168KWV2Q<@^SN1_0&?0R?H>^P\7'
M'^+D+Q\B4?]MZD*/418D^L#F<>+,?D&2$CE\^EN:-" JDR=(M7J&H*N/8OGY
MWV&\YQ^X^/PWN/[JMT@RW4>.VUDB3#^2?G^8<V_]/9??^Y8\9P\39/PB*:)7
M0DR?PU?W"=RO_@27"]\FV>XQ2OV>(<_EUZA,?XV;Z*TK;_X55_=\APL?/,S1
MU_Z6_2_\*>XZSS-09DE=AA;1'A_B9/@\R:$G"?/<C]G-9S#5?ISTN,,,-9F3
M'?(A?@:/87OV1SA=^C7!\EPEN7VJB?PN#/]4YM6'!,K^'A=^@<V11[GV[K=Q
M.OLBSA=?Y=@K?\]GHHMT/OL[<CU?H<#M.1+E7-[R3%J\^SWT7_TA-U]^5.,@
M?O(?'^+Q'_\?'#OT/$Y"Y-5)UM15A#$Y6,SV8B?3@W6,]-8RV-M(=UL=W2WU
M]+<U,]K3PVAO'WWM7336-&C^@:NDE\C*S2-3;&9F;@ZI6>FHT]-)3DT7G)))
M:UN'V*X53;3E@T5PEN(D5@"XX*?-]0UFE$C<WD&:&ENIK%+25Y60GI-)7$H\
MJNQD<JKSR&[,([TAF^2J5.(+$REH+*1SK)/!J4&&)H;I&^JEJ:V1NB8E?9#8
MM/)B"FK**6VIH:2]CHKN)BI[6RCK:B"WJ9SL.L$SS=54=3=3WR_VJ;>=FJY6
MJCM:J&YKI:I%GJ>Z>HV#N$S:5"Y24]O(V/@T\PLK&F>QXB!6(HS;.WHTN8G[
M^H?HZNZEI[>?L8D)YI<6F%V88W9^3N,<5AS#RC]ZEY>5PG0;FLCAY64E)[%2
MR.Z!DUA)]: XAY6T#TI!.R4GLO(VEN(HGIM9TCA\YV:7Y'Q*OL!M;M^1?I2N
M?1 QP^\QZ*9&9F<6-<[A6[OWN'WKON:WF>D%>KH'&.@?U6ROK*S_2SH+95'>
MDE,<Q<JBI%)[T";%H;VA<1;_6]+S%8E2EO\=I.BK:_Q'R=?)X;\G7R>1REKA
M $IU]MO29TH*:,7I?N?V/>[>OBW;0CSO[W+[RQUNW9>Q$KDGV_=O+W%[I8L-
MP9&+G5$LM$:PVIW*O84FV)V4<ZVQ<5OZ79-_>)=M)4^Q$'3E'_$[M]?9OO4@
MFGA#"+<B2I7YK4TA[.NKW%V90\ )8Q4^5$<=IS;^-'V5GLR/5; N9'UC;88U
MV6=E98&%E7GF97MQ=5;FR2R;BV/<GFEALMJ+P:QK3!=<8;G<D(TZ.S:;G9FO
ML66XR(3.#!W!!=>ICKQ 4= 9"D,OD15TF8R@&U2GN-)=&L=(<R%#/:)'!D1O
M]-6(?DNE,MF.HL@;S-9Z<'<D!N8RV9TI8FN^0G1.&I79UJ(;+Q(?<)F\1$>:
M2^+HK\]GH*Z8GNI<!IJR9+]LN9=<1GJR::A6TU2CIK,Q@='.<(US>&D\@H%F
M=ZIRS2A,,2(KUI@@ETO$AUI3FA=/078<A8(_BS+#*<KPI:\MFJW53.YL9,KD
M+V=M,HUX[[.$6AP@R_DL0S&&3 :<8\3F/;IT?D.W_J\8L'V.4<%+O>EGJ<J[
M@BK])"'J_?BG?4%P[B%",X\0GG&4F*SC9%9<HKCQ.N6M6E2U:]'8JT]+CQ&Y
MQ1=1I9P@*>$462E:!+KMQ_#RLQA>%9ULOH<@]^,$N9VB0&W-0&LXX]T1-)7;
M49!Z@Y)T'0K5U\F(/4VTW^>"B3XATFL_T3ZG"'4_B:_#47P<3E"6X\3TB(K=
MC1R9&RG,#7O35G*3@L03)(8>)=CO-,Z.)["V.H6UQ3D<;"YB;W%$\/=GY,9?
MHRW?B*Y</2IBSJ'R.$J0U4&"K ^1Z'Z8 K&UE7$G*(T^1E;H$1+]C^)I=P@K
MDR,X6EW T?04GN8G!*->(,O_(I51E^F0MH^5&#)=8\5@I3UIT49X.&EA97X5
M*[,K6!I?Q,+@+$Z65T6N865\%0MC?2Q-C; UT\'5["S1+J<ICSK+:,XI5LM/
ML59SGHEJ+2K3+A'E>PI'Z_.8F6AA;&* B;D)9I8FF%L:8&%V#2?K,\3(/BV9
M%^F1L>E,$5P;>Y "_WW$.1[$V_PT;A9:V,NUS RTY+IZTB]&6%D:8J5Q#IMB
M86N!N94QME:Z^#GK4:IRI3W;E>8D(_*\CY/F(O/&YR2U<=ITI9LRF&O.4*XQ
M=3%G2'7=0[#9:WB;O4> TQ$20K5)#M?31$MV%'LP),]I1YZ-].=50J7??)RO
M$>1K1("/-CZ"W;Q<SQ#L?9F8@.LD!5\C.> ,&2%G!$MKR;-B1T6^O? 50_R]
M37!W-I']38D*LB8VV$B3AF*X,Y3MI33N;69Q9SV=]=D$I@;#Z6\/HB##AH@
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M13Y[B#!_CBC;-W&Y_CN,CSV#S94/.//9T^Q]^W'T+N_'Z,8I+ RN:)[_N.A
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MZ("]Q(<<(2GD-(D!2E3R<7SMCN%C>T+PZ!$R_,[0IKI.7]IUNE*UJ(N_1';
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MI7BRDGMX>6E#$T&\MJJDHMC0.+252&+%2:Q$+BL.8J7(W?3TK*9=#Z*(O\+
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M[!.[/L["["1+\],BDZ+KAT7'=[ ]5\R\</S&0EUZ&\T9ZG*FK<%%KIDK-F&
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M5TO=,:CVPKC1#\O.8.QZP[#K"\=6Q*8O NO^2"SEV*Q;"'^S'U?*G;FB<\!
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M'A]0-=K%S7AOC%.],,[QPBC? U-93,W+_;"N"L*E.0;?MB2"6E6$-J7B7Y&
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M)?^<4<T[U">_3HJG ''W3RG*$D6=KB8F*9_(Y%)BU55$IDC9X04X!N;CX%^
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M#I4S/YC.?&\D\YV^S+5[,-7FPTA[).W5H51D.9(=>5QX82\YJH,T95C1FN5
M0YHU-2G&M!?:TUON0T=Q()WZ( 9D.57NSTR)!V/Y=O2DF]"9<H7ZZ%,4^']!
MAO<7Y(2>I2S)F9I\-97Z!(KRDJ6M2J8X)Y:*'!4->3X,EKFQ4.? 0J4Y,_G&
M3&>9L5SBSDYS!%N=<0R7JBA+]B-5XT>2+HQXG9J86+7XIC T6K'(4,/P>4VX
M+]'AKB1$6E*<=)7FK#/2_A]@L?P0,P6?4!_Y*B7APCNJ<\0'7";2^PH1XH-2
MP\\Q76_%G4$[5MJOT9AYAM30?6@]=I/L^R')7F^C<WE%&.T5X:E/R8B\0&2
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M&KM?^'."G0Z0+^U^9HI:_*B/U&,OW#R\L;&QQ-[Z'+XNA]#ZBV"7,LL/>YO
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M L25N1$4IJO(5BPGBLP<#5G29N5D15.0'4M>6C29<1%DQH20%>5#L<:-\:Q
MEC063)B_2^/^GU!QZ&=46KQ-0\PERLI]2._1H9O,1JMT=ILO)'JIA(35:I(W
MZTG<J"%BJ1#?\51<^V)Q:M/@U*C&L284VPHOK/)ML(Z_2)#N,H6IUM*>^3 I
M[<NHYPD&K^ZB[_#3].[["9U'?DW.OM]1;'60@?10NHN3J"U*HR WF=R<5')R
MTDC/3$(3HR)4[4-8I _)*>%D9(BE!Y*9ZD%6JIM<MY=PH8I!\1F;6]>%>6ZR
MMK["[=NWV%K?8$M9WIYC8U4969-'>W.$6!"][?[T-7O14>E :XD]]7HG*@O<
MY=D*H*,AF86))N[>'C?\./M@>X3Y\7)JBH+1R7,9$WR!G$1GFBIU]#2GT]^2
M3&]#)&T5/A0E7B8M=!]ZS5%*M*<HC;YDZ*W>51;!XD@U#[;F^/+1%@^^5.8C
M4$8HW7\<5Q'&48;V*YBA]*I\S"K"+L)X B%R'K+QGL#)G^*[@B>/F4_9I(1E
ME&UB!DQ2_O!?O0R?%%-V?F+*^S_9DX/]-_O]O__Z_Y,@\5=+YG]<0O]W >(G
MX/GPX2-#@%B9C5D9)J=,%K*VMLWFYGT6%F\)& ML=P\P/:,,^WL\2[4R^[/2
MJT,!ZJ;F/GD_SI  ?%MG/]U]PPP,3S,P-$=WSRSEY;V&('%V3A-%11VDI5:0
M&%],<F()V9DU5)1UTM8Z+H)MGMJ:/A(3] 3XQ9*374-]71\-];WRT)61DI(G
M#YD(GY)J*BOKJ:BH%U%4+<=OD/4FLK.+#!/-C8[.&(8H*D%B)1"L]!)N;>ZD
MN:E=OJ>;T9%)0U!X>FH!)>_=^NT=0V"\IV?($"AN:>V2ZY:']?86B]=OLKJ^
MQ<+234.0O*6^C9KR>@KSR@C7Z/!11^"AC< LS!=SK3_V(FSMTD/PTFN(J$LG
MM;V(Y+H\5.DQF+DY8>KDA&M $-K$-&*5"?+B14"E%U!3V22"KX_FY@Y\Y>\7
M34QQ\/+"6QU&4&PTH?$QJ)/CB$I/$$LD0)R'7VP$(8DQJ%+B2-#G4=+61/U
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MA#KL%R@^3XSO8=+#3E&@.8>/Z>N$N^XC/]F%_%1Q.CDJ2O(BR$D.)"?6AY1
M&SPN?TJ< %QVA #_I>?P,/HE_F8_P^7B/V)__N=<./ 3WGOU&P);5ZBN3R([
M7T."+@AU@#/^CD8X&GU,F.LQJG("T$6X$Q+D0;@ZA&"!,/\@-X)"'*1]\<39
MYB![=OV *X>>X^SN'W+ZK:^3X?8.->J]9'F\@O.Q;TDY_U"$QMOD1%_ V_I=
MSGWZ0\P/_IAPJU>)=WD7]],_(^#2TT08_PK5F>^2;/YSDJ0,_$Y_DVBKIXBS
M>X;@BS]";?QS,IS_0%WH.V39_X84\U^0;?L<.N-G4%UY@2#S]T58GB=-&9X9
M[4Y)9A0U)5G2EA23EYE!068Z^O1X$52VQ'J?(2/X$,7:?018/H7MA7^@(N,+
MYKNM6>QQ% @\(=N>Q?SLF[14)) 2XX:/B"6-2@1'H@M5^7ZTE 4)B/FC"SK&
M\=U_C_4QJ7,FOR71YG<TA[U)O=\SI!K_':5N/Z;:_U?HO7XNU_(=0JY]G2"S
M;Y#@]0MR0N5Z$C_D[J"+H;=/O/-SM.6<9[A<Q)?4TWTO?PV[D_^)S""IF[*/
M_Z6_)<SDVZ0X/X/_N>]SYJU_SSN_^AJ.9_X@^WY!B+*\]B89CN^2[/(Z*1XO
M41#TDL#=*]1$_9KVQ-\Q7_86:_7O\J#K<[:;OR#6Z,\)/O(UBAR^2W/(RQ1Z
MO$F4Q3MD!AJ3K_$B+S:<_,0$DK2Q(EXUI*:D$!T33KC*A42-$TDB>N-=/D?G
M^!YA=J_(/7B?5KT) \77!,Q/DN7Y'K'6KQ%B\AKN1N_B[VZ$7Y 7CEX!F#NI
M,+&)XJIU#.?--)PT5G/T4@C[3KIS])RTY59.! <[$NQ] C>3Y_"[_'UT%C\F
MR>876._]*ZY\^)^Y^OG/.;/O61$]YXB(4&'O&(R1:0C&9E&X>>7@Z)&)M7LZ
M]OX%F#@G<LDJ'&L'E=3W=-+EVAPO?X#=J6>P/_93;/;_$S:??PO--2FKV$^(
MO/1M(BY\ES+?=W'\[)M\^,NO\=*/O\;I/3\FRGT_#1GV GOGR5'MHRQV/XMM
MMHQ7GJ<^[AVZ,SYAIDP1Z&>H"WN91FE?1C7/L9:[B^&$EVF)?8'9ZD^XT764
ME:%+W!RUI3KOK(BSC[ Z]QJV)U]";?4^=7$7:-0=)LWE][B=^'-:TC^B7$2/
MT2=?(]7Q*<I]7R35[)?D.;]"I<!G1[H%U[L3V5ZL86NYA>6I:CJJXBA*\J6_
M+)&F=+6(.B?2U.ZD:3S)3?2EMB"4WAH-P[71=.:$T)4K[TNCZ&],H%[@M;HD
MDOZV/!$?1?35Y]!4D$!C?BR-A2*"BK4"SA'4EL305I5!:U4FI7D:$F/=R4SS
MIZDAE;FY9N:G6YD>:6*\MX[1SG)Z&E)H*@VA0:!;Z9F7J?5 XVLASY,U6?*\
M%:8$B(A0DY,0*?4L"(W:@[!P1U1J>XKU,72WBHBJR:(T/X'L%*F7B9$BG*+)
M2(DE/26&K/18LC.4]V%BP62G!5&<&TYG8P:CO26,]U<R-E@O/K"3V>EA9F8G
MF9Z;%5M@8EK)NSM"9V>W"(8V6AN:::BIH[RD%'VAGMS\/-+SLL@JR:.HOHS:
M[B8J.FLI:JV@L+V"O)92LIN%O5K+*1EHI&:\@^J1=LK[FBCN$M_=64U><SFY
M(@ +JHMI[&JELZ^;YO86:AIJJ:JOH;JIGG+QN14MM51W/9ZTKD2.7])21F%C
M$?GU>O)$2.96%Y!354!V5:$AEW'?Q" [#W8>]R1^)#Y8$1&*]Q?_?%=)=;9S
MU]"#6+$[=^^S<^>>(?"J]"8>GY@7OSYAF%2NM;V/KMX1AI6481,+],CVND8I
MC\X1P\1T3P+!"H..CB\9<A4K[Y7>PTKO8J6G\:#\30D23T[>9$C6.SJ&A&F%
M8X>4%&1#A@#QX."4(3#\.#W9XV"QDK-X9F;),-I,&;'V0-!""6K?N?M01-XV
MBXM+PB0;<CV/Y^\P#,'\$V__RTM95[9]U?YU</B)/=[WL<F>7S%%5!F"P K:
M**\GVY4)YNX_Y.$#^6ZE%X]2SE\*9SW<X,'=5=EVY_&V!\)16].L3M8P5!--
M1XXGS2FV-"9:41=O36>N%]--T88?=5:G2MF\W@3;,[+?JB#4.O?OW.;!/66N
M$F5DF A'N5_;HB.4'__OWM^1,M@0;;$J'#;)S)">JG0[>DN<F6[T9:+>E]&&
M8.8'LKBW/L;=;27EA'Q>F.W>QCIW-Y?9V9AD^W8W"V-9=%5[T%QL17.I#9VU
MG@QV:+@^72$B>IS;:THNZ&7A^&765ZYS9WF*AXN]/)JI@.DT'HRK6.FP9K;5
MF.EN<Y9&7)GK\:2[S)[\&*4GXV7A%!^FQRI8G.MC<7:8Q>DN;BI!XO$$ICN]
M:2D49HGZ$(WG2\3ZOT^>M'VMY8%,=.E9'&QB::"9M<$&UOM*6.]*8:<GG,WN
M &YV!#'1J&&T)96QCGR&V_,8:LN@NS:"RG13<J,.D!W^&:7Q9VC)LZ&[V$.6
M'K06A8IPCZ>U.INVFFRZJ^,9K@AFMLJ'N5)7P^1J]6$G*?/?3U7X,;JS[>@L
M#J:R4$MQ81SZ@EB*<B,HRPJB)LV#1KF?#5$7Z-*=82+K(HM%IDSF&-,2<\Z0
MFB'1^P@IJJOD)7N1DB0:)5:%5J<1?QI#C$9#C/BO6+4OB9$NT@;:R/E>IC;A
M& T)!Y@HN<)4J1&-<9^2Y_\BZ=Y_(#MT-ZDA9PQ!XE!O<X)\K0CP-D$E?).G
M.4E[^DG&\T\PDW^,I>(3+)<<9RCM(QJBWT(?OHN<B/UH??83Z+@/M9?X3Q]C
M0MROXFYY&@^KT_C9GT'E=)*T4",:TAV8KO7CSI"&!Z-:EEO]F:ARIRW7CL)8
M$T.ZB#"7PZB=#@OO'2+"^7.TKGNI236F.<N80O5^,I5)CSV%TUP_)-'C$TK#
MC]*?:<ITF3N-Z4YH_:_B;'T"JVN'L3$_@I/-4?S=3A'I=XXHOY-$!YZ4>G2!
MZ@);YD<BN+^>P<:M#%J:0XG46& F?&YB?A(S)>V$V6F<A?_#_4S$A[B1$FV+
M3FU&7(09*;%65!7XR+.AI3W%F3J?,S2:[V;\RBO,GGV6D=//TGAI%YG"!F&7
MW\?7ZB/44:=)*K,@HOP<P=5G"*R[3$"#'4%-'JA:_8AH]R>JS9^(%E]"&SP(
MK'7&M](&[W(S@JNLT-6[D].D0I-@C;_K<4+-/B/;:A^M%GN8O/0Z,V>>9_3T
M[^DV>IEQ_X,L9%FST!!(?XT?Y5FV)$6<)TY]7GC\,IHP([RD7!QL3V%K=0$[
MZRM86ES UNX2&F&R_NY4UF\4TU#N29K.A,C@BP3[7L##\0R.5F>D7)4>R%>Q
MM3;"V?X"R5&6U&0Y49UN2V&<);K "WC9?D&0]U%R,FP9'=*QL9+#PZUB=E9+
MI)W)%;X.(MCY/$&VQ\A2F=*1YR5UU1A]Q"G2@DX0[GD./]<K>+D8X>EX'DW
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MJ-A+KW&+8--UY,=O11_OA"K*B\0(7Y(C/>4>G"A*V4M'[CY.V5VXVNG%Z=8
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MV_(?*/3^)4W)+PK(>8L.[6O84A12\ %&43C6@GBJRW*H$06I>.\/#$UC;QY
MDU5.9**1B.0<Z0O2G[,S*,R)I-$<S$"M*XOM^[DZYL:E@4.<Z3K$<H<'?>5[
M'/&1HCS>X,.7?L&CO_PV?WSD5_@)\,P5L%148*"A5@GD/R#CL@^3I8T4N4YP
MG(:$=+W,.QHR5%%$"5 TJ5T8K0NG+7<+I=%/41#R"X;+7J8MYU'J- ^PTKV%
MV9K/:<E\D>;4%QDO7,-DZ08J$YZC,.)IU)X/X[_Q^VB]G\$<_Q$%H6^A<GT*
MU:$G*0QZBZ+0]] >?H&@];_"^],?X_;^=W#]X#LDN;XH];('4U8T):9L\O/S
MR9%^7&_OIJ-SAH:F:;+S[<1K2HC1Y))58"17'T%!BM2E^@LL:6]2$/L8:=X_
MI"#FM[3DOL18U7JN2U]CV<1) ?H# @9+(M\B9.//\?O\%VB]WF9("*\2C]9F
M]&"A4]K5N)OBL!<Q>#Q YL'O4>CU QH2?D=3RH/T&YYFNNQ5VM1_P!KY"TK\
MOTNVRS<I#_XI0\:7! QMYZA] \W9;U&:\ ;YT:]3FO(6;45"\)JW,=^ZE7K#
M<\PT;N7"6 @C-5X4)6\G+7@K>:DA]-2;F>MO8[#!0D=E/BUEV;26&^BJS)1[
M]$;E\2()!W]-EN=/J(GY*=:P;]*1\3V6FO[(S8F/N3#P*=U%KQ!]Z.?$^;Q#
M458"JH1$1_)$:V438Q,GZ.E?Q%3:2DA4-N[^:KR"9-R&IPL)B";%TQF_#:_R
MR1^^P1=__"L*H]XA._@-?#8_P)KG_HZ]'_V$!,^W*-&XXKSM5=:\]XP0N.V$
M!@81$99 0$ 2H2%Z0D.-!(5F$1:I)28VB>2X "E_@SSG:V3X/4[B_I^0O.L'
M:/?_@KS#CY&XXWZ\/OTI_CN>8?NG3_+9>R_AYQE,<(@63Q\=>_8GL<<IC?UN
M>O8H'L4^V;@%Z? -2\'+SY^MFS_F3X]\AT=_]A_XTV__BK6O? ]MX//27U_#
M'/L[C+[?Q>#V'?(/_X)LYU^C/O@[$O8]3-C6!P@04N?UV8_8]=H_L.G5;['E
MG1^Q^^-?D.;[&IWYN^@KW$)_X1?8U:\1L^N_$+'E7XC<_#T.O?[O<'WM/A(W
M_S.=ZE>9*'V;/M.SE"?_DF2/?Y'S?TYS[CL4QS^%/N!^2J(?HU'F@(&B-4Q5
M[^1HIR<]ECWDQBA]T)^%IE0&K<D,-&0S.6#ER&R[D( Z&NW%5)3J*,]-I3P[
M 5M^$L--!324I9"O]J>^6/JLD(FFLDPL.8G4%*AI*\^EL[R0SHH2!IOJ63HR
MP[FSISASY@Q'YD_0W2D8H*F;X8$QQD='Z>MI$S)D$N*23U]OI6" 5DI*TX6X
M*09B+Q)BO,DS*$E RJ@N-Y*CCB,UPH?BS$BZJU(YTJWC:(^6Q<XLYEIRF;1G
M,]68R52+FA$AHVWF)+EOF>],*50)66YNUC-_1,G58!:BE(XF-1BU])&,F"#4
M44'H1+=GQH:3'A5 OB:6GL9BKI\;Y]ZU26Y=[.?"L09F>O,9;-32WZ"CKS&'
MWI8B>A0C=J]=]&4C#>UV:EOJJ1'=6&NO<WPU4VNS?26U=53)NKRJDF);)996
M.S5]K0X#<97B(=S30$57/9;N>BI[Z['V-U _VD[C1!?U(VW4#;<Z#,BE;3:'
MU[%B)#8)D:MHJ*6EN^M?C<2=73TT-C4*GJNFW%+J2$K7V-E(DUQ'\22VM%92
MVFBFI%'.;:^AJKN!:KEW2UL=)FLII7)._W ?I\XL"ZZZSF7%2+QZW6$<OG)U
MU6$4OGSEAB.4@R,6\?'3#JRIA'E0$L:-C\\SJB2PFSW.TO)Y5DY?9F%Q6>YM
MRA%Z8DK)C2$X2#$6*XX*W;T3#J]A)=R$(MT]RG/,.0S$0T.S#N>#@8%IN<8*
M2TL7.';LK%Q#\1@^XPBYIC@O*'DY',9IP;934TI<XN..D&;+I\XY1/G*[-QY
M)>',#4=X#.59KJW>X/+EJT+>%$.OX.8_ V<%>W]M''9XX_P9S'Z%TY7M_Y%\
MA>&_DJ_PK^P6D;(4X[-B%%8^__SS%U-?A9(0(B8D3A'%8_C+6ZLH<8BYIW@!
MW>'V[3O<$DQ_5SD.1:X) 5WBPO(PQR;KF.@RTET=2TNQ-UUE;@Q;O1BM]J>E
MX#"U1B\:R^,$5U4Y#+1??GE)".)E[LDUOA2 ?NO**G>5),0WKW']QFG.G1.,
M-VBB+,>9/-4ZS)D;Z+8<DG'FP4AK',L+5=RX/,F]&RO<N7J1U0M*LI[+4G^*
M=_D9SI^9XOA</0,=&70U1,FXB*2O/9Z1/H/@W7HNG)GDVL5C7%V9Y=)8,XN&
M8(;<WV+PX).T.C]$9_3SG&T[Q-$^=P:[W>CN\Z6IQ5=(O)M@RYUD9.P2S!@B
MG,?&\95.CJWT<&*E3<9SH6#%) :Z RDMV$Q!UB;LE;[,CA9Q:KZ94^.M7!SM
MY(J,K0O5.2PD[F',YPT&/)ZCW?<EIO6[N-"FXF2WB:,#E<SVE3'<D$I=WF%,
M*9M$-E"5O5_T8BAC'7K&NW(8E/FEHSJ,QC)OZ@K=J,L]+'7NSG"%%R>;_#G?
M&L!,R7XL$>]AB?J,%MU!QFVQ#->ETV[38[,HQI\<JLUIU)>%TUL=RK@UD.D2
M3T8,>UDH=F59VG'8>)#*Z"_(\OV4PIB]E&O\,!NC*33$8=0G8\A,<QB(LS2R
MG1E&17Z8M%D$$U7^3)3L8KEJ(Q<$,RV9/Z%'_XG@P#54)*_%%/T6!8(13(F?
MD9>\!VV"*W&1AXF,\B,R)I#8&!\20@^@#=V$)?8S9HV?<*G\ RZ4O,I \H-T
M)#]!F_9=BE7K20E91WS@%U0*EAFT1C+;F,AX=;CH(%?*4G=*^3O1Q&R18]82
M<OA#HGT^=7@I-TF?71K2</UX*>?G33*?QF-0[<?WT <$N7].F/=:(GT_PYBZ
M6^9P)QI,>Z5/KJ,@?1U9J9M)#O^$C(A/,26MISAI$V;M04KU'G+?N_#WV(&G
MVSX\W9WP<#\@LD=D)^Z'=^+EM8NPL /4UZHXNU+#K>LM7#AOH[<_ [5Z/Q%1
M.PD(4HX3?!'D1$R$.W%1[J2I?-'K0L@53%QB4F$KU=!A3F?:FL!DCBL]0>_3
MM^=IAC?\GK'U#S,BZYYMC],H6+]2^D"1M&N.S0=-3Q0IDRH2%_6D+!60LER$
M:KF0M),YI)\TD';"0/)"-C%3.D)'U/CU)N/?$4M(8RC153ZDEWB@4^\3#+F&
MXGUOT[+U3TQ_<3_S:W_!D?U/<2QN$T?S_!@IB\=>K,)<DD%1L1J3Z,""@D0,
MV5%HU(&DI?@2'>&"K_<./-PV$.B[&7V&![.3)0SUJ:DH<Z>X2,9 82!:;:#4
MAU*'!_'Q]L#;RP-?7R_\_-P)\#U(3/ NM'&[*%:2V^GW8"\[S-Q $N>/Z+ET
M/(?E63U#W<G8K!%R?5^"@_;AX[F',/^#1/OM(CEH*YK0C:C]/R3=]QW4?K(.
MW$B:[->&;Q,LNY,F@Y(CQ9GY:A<F*PX(+]A!7MQ&M#&[2(UU(S;2A]BH0!)C
M DB+=2<[?C]U^KT<M[MRJ=N'4VV!=)D#*5![RM]]2(V/)#DA7K!& DDI\:2D
M"F95)3J\B3.30RA(/D1=^F9FS?N9+]O!H&$=O?D[J,ES%6X3Z# >:G3)9.D5
M3_XLC%EZ\K*UF SIE AF,>?$4)47AMT40$]E($?:H@2C!S!7<8C)XCTL5A^2
M>W-GKM9=N%4X*V.97#A23G^K\A(IC1J;,D?D4FTIH-:19%='K;1I97X@=44!
M-!3[4EOHCB7[  89 ]E)7S#2ELBYH^5<7*YE8;92=&89K>TE-#6;:6VSTMEA
MH;-%>&1%(J:\  IS_3'E!V NC7 8BEN;!,_5&ZBI,&"O*I)CZQ@;&6!Z8D+*
MFV?I^#%.GCC*T849)D<'9,YMHZ/93DN=C0[!(7URKR/Y*OKC7!GR_, 1'[M_
MVV_I<'Z*EKAU]%A#J>O64S!A)N]D*Z57!K#<&*;DJG##U6X*;W21ORIRK9N<
MRYUH3C63,%='Q+"%L)YBPEJRB;(ED6KR%TQZ@);XS^AR>X;QS;]E8>VO.;KC
M:2XF'>)VG9%[DQU<GA$,,SW$\9EQSBP>X<KR"I=.G7$8O.WU=9C-%9276:6/
MEY.=G8M:FT%<4C01L4'$J\+0&A*QUA6R<&R4\Y>/<?K"+%,SS30([K-4I A&
MUC$V7,J)12MG3I9R^;R9U2M57+M4Q_G3-I86*SDR8^'ZY0%NKHYQ\F0[QQ>;
M.39C9W'8RD1K#@T%_A3$R?RIV4QOY6&FV\*H+W*F5/2P6<9><VTZ'75J^J1]
MCO07<7JRFK.S]1P?M[$\U\RETR."&Y8$3UP4C'%5,(,26DIYR7Q=<(/R1;;(
ME\J+\%L.'*(XGGYE'%9"B"FBY&107I +AE&,PHJ1]TO!(W+N5[$I%" CNV3W
M7QJ)_[S[SZ+\4["3(LI!_]=(_+^P*%7WEY7TM2C[__OEO_96D*,$82I>!$KV
M1 7$*G&(%8/Q^?.7'.$95E?OLK)RQ>&=J_Q6/JV;F)A'B;&F+-+VCD7)-CTP
M,,O9\\JG^P*D5RY26]^%P6@F-3V79)61Y)1<3$5V)B97&!X]3GOG&&UM XXL
MT,JB)"I1$IC=$=!Z1<A"C9)\I;8!)7/TI4NW!)@?<82:J*QL<@#ZTZ>O<FKE
M,A<N"!B_>%W*7:"^OIV*BGI'ANK!H4GZ!T8<82/Z^H<9&9L4,'^,N?DC+"P<
MD>=:D?M>9&1D7":U7L<@KK34.!+;32NQBN6ZBA=U6U<O36V='%\^Q;E+%SE_
MY1)'3IZ@H*24R-A$0J/C2,O.(2HM'6?_ -P"@PB-CR,]6T=N48$\1[60CT[&
M1H=9G%M@8GB"'%TNN[?MY[67WV'-)QOP..Q'?'PJB8DJ,K.S'8947R&0_DDA
MA.>G$&//(ZK51'RO&<U$/1G#-62-U&,:;R*B*(- =:S<@Q!M<R4M#>WT=PXS
M/;S \=F3K"R=X<S*.2%?JUQ8O41E9RTQ96J\2N((J$\CI%U+9'<6<8.YI$X6
MDW742M'9!BQ7VZF^V8WU5C?JHR5XM,6QN=2#'68?#MB".50?CE]'"B%]&H+[
M,@@9SB1\0B;7*2,10WHB>W4D]!C0]A4359[&GG 7O*(#B4Y)("U30Y;R1M14
M(H#<2H75BDV(;F-',\U=S;)NI$X41Y7-0G5-)25E)L*CP@B+""<Q68GKHY=Z
MRB>OL$S.KQ92+"2XII8B4Y'TLQ2B8J)1I:6BU6>25U! >44EE=9J48BU#D^K
MUL8F.EK;Z.[LDK;O$)+03+5=SK>5DU&F)2(W G]1:EYE EIJP_!K$?#4D4QT
M5SJ)?>FHAM)(&TDA=32)M E93Z:2-)9,RD0:*I'X@4CB>GR(;S](@FT+P2FO
M$![P%+E1;V*/_81J]U=(>^>[&#[Z#A7;?T&=U^.4!/V1SI+-W#V3QNWE<,Y-
M'6*T;AUQAW[.WG?^&L^U_\!@Q1IF&]91K7F<@IC[B3SP3?RV_P?L!<\RT[:&
MB9J/*(]XD#RO!S!Z/TV:]ZM\\>8O>..EA]%D&2FO[<7:-"9$?IRV[G&J:KM(
M59N(B,XD196#U5R+N:C(\?ES<7$T=;6A3 V%<&,YF-6%@UP<V<:B_5,TA_Z)
MB'7_$8/KKVE)?HO&Q-?D_A^C/NTC;/H#F+)"R<]))R\W3\JQ2OT.T]HQ357-
M *G:"B*2BPA5%1*;82 ](XE28SC#]FB.=/BPU+6/Y?:MS%H^%S*SGN,US@R8
M]I,3]A'[/GF ]Y__):\_^S"???P6F?HT*JIE3&1ERSAKHZU]G-J&84S6;N(S
MS;@'J_ -21+B)\JVN)BT2"^RXPY2D^U"G6XCYO@7J8A[E*FJMVG.>I#BZ/_"
M:,5K-.N>IC#XEYA#'V:A8@M7!P0,6[:2%_TL$4Z_)MSY0?21;PEX_(S$PZ\0
MY_0"L?N>(6;7XR0[/4/8UD?8]>IWV?[J=]CXPC^Q_L5_(-KC34PZ(5_%>C0:
M+4FJ+-(TQ>2;&BDJZ9"YLIE$51F!L3GXQ<G?Y9B\[#@J].Y4I'U!=O ?B3[P
M?;S7_T<27;Z--?4/C%9^QM'60RQU!'"TP9<NPWHJ(EX@U_M) M?^F/!MCU";
MZ8PMYS!6HYL0)D\F[/Y,U;K2FO,I>2$/D1/X*RJ3'Z,LZ1%:<E]FN/Q#XK9_
MD\C/_SUY3M\F>]<W,#E_BX:(7TM[O$:C^G$2G;Z+]\8?L.6-?V3-<W_#W@^^
M09GJ%8YV.C%LV\CQ7G=.C<;06QN.-3\42T$*/4TVI@8'1(;H;K)3;-"CD[&:
MI\NFSEQ.678RX:X?$+CG430^#]&D?@);W ^I2_DN_:;[.=[Z*B?:WF.P_ WR
M8_]$;O(V2HQI1(7%$!^K)=]8+6!7YBMKG\P+S43&YW/8/P,GKQ1\_).%U,F\
MX^=-X)9WV?J<M,WS?T>:ZV.HO5XD=,\?V?'^3_G\I7_">_OCM)0%HXO=A>>>
MMW':^A9Q0N(T26&DQ$60EJ B(T7:,#6+A-@D0@,]"?380&KH^Q0EO4UEZNOD
M!3U)].;O<?B-OR+LD^_B\^Z_<.C-?R%LQY/L?/]^/GSI07S=#A,1JB(H* ,W
MMT0.N2;CY);&/I=4O((-!,?H\0P*8.W&]WC_O3^P?<.3;/S@)SBO_RF&J!<9
MM^UBS+)6KO53"@)_0J'_+\CU^#4&M]_)^'\:D_^K9$A?3-K]!Z*W/8C[)S]E
M\VO?X^VGO\63O_IW;'W_5QCC-M!9ZLYDO3?-.>O9]]XW>>^1^WC[P?MXZ[?W
ML>.YOR5YQ\]H3WN+KLPW:58_3XON&2&&;]-?]#J%8;\@=,M?$;O['VG5OR;D
MZC..MSMQ^V@R<UW!=%5YTUT5RF2SFM%Z+2WEJ;35Y0HA:.+XTH3@@%Y:6NJ%
MU)4),1%=:=(+,='069=#35DR)GTPUKP$J@N$+!>HJ2LQT&@VB9104UQ(?TL+
M"Q/3S,\>X=2I<YP]=Y5CBV?ID?FMMK83>V,?/?T3@A=&9%\S@[T-3(ZU,#/5
MBM6B1:<)=1AP-:H02O+50D+*I3^J4,>%HDL(I;Y$[KM)^3P\F[EV#9,-&8Q4
M:QBMR62J*5/F7(W,6\DTET9BS5'B$\?1I<0+G; R-5%-=64&F6G!Z*5\?;RL
MA5QF1PAI$N*HB"'*GP93!O/]-JZ=[./:2C<7EYJ%[%H9;-;289-QTZ"ENR&;
M-KM1"$<^M8VE5#=58&FP4%I;3G%5&:65Y5BJK%155U%5586ELHHRBX7B2C/%
MM568V^JQ]C11V67_*L9P5QVE;=64ME=1T6W#-M1$PT2[2 >UPTW4#"D>QG;*
MVK\R$I>WUE!H,U/95$=K;S>#HV/T]@_2(?JS1=J@QE9-67D)1>4FZMOM-/>W
M4-=CIU*N4=942:E(19N-ZDX[M=U-U'8V8JF3>Y3[KA)\-+>XP"UA!]=OW^*&
MDNSL^BU'+.)SYZ^P<OJ"X+P+*+& E21R1XXL<^;,%<&BYZ5=IQ@<F!#,-L_Q
M8Z?EO'N<.W=-,-T,)TY>D')7Z.B6MI<^,#PVS]CD(IW=8_3T33L\B_OZIAS.
M#<-#<W1UC=#:VB_[)AR8]^3)2TQ/'W=<0S%&GSA^AILW[K"\=%:PZ"SC$XI7
M\AQ3TPL.IP(E<9UBT%;"32BB>!,KL8F5K^,40_'%BY<=QEC%J/LU!%?P]W\;
M>N+?#,#_'T0*5+R''>Q*(5P*45.\>1WQAD5N"Q$34G=/Y,O;JW*\8@C^*N.X
M$DOPCMR7D@!823RG$+Y[]V0M1/#.'24Q\#*KEZ:8'Z^DL2*<"MTNZK)WT%YP
M0'#(-HI3ME*4X42])86C\^UR_@IW;Y_CSLV+W+U^#6X(85R]Q:W5*U(?IZ4^
MCG+J9 NM];%8\IVP&'?05+:?]JK##+1$,CN:R^D335R],,G-*R?EVF>X++C[
MDO"3RU<O<^7R"F>71^EN-5)OC:'1%DYG<P)]G7K!UE8NG9G@UL4CW#@^RI6>
M2A83G1G=]B0S.W]/SX'?T17U/*?;W9CL.2QC:0\%5=LQ6O9B*#](IN",-,-N
M"BM]&3U2Q,QR';,KC<R<LM$SF4[[0"B=_8$4E^^AI-B)KI9$%J>LK,RV<&:X
MD>M##=QH+N*<,8QIK[>8//@XDZY/4KO_,4;5V[G:J^5D?Q[S@X6,=&12:W*G
M,&TCQL2UE&0J1J] >AO3&.W(8ZRS@ &9 ]JJPF@V>U.EWTE6T%M8$CYCL$ P
M4H,?2S8O1HR[L$5_0I7,Y8V9KO288^FL3*?1HL.FQ/FLS!']FD)#:2 #58',
M5 <(IO%B+&<OLR87CIC]:%?OQ9:PF\JD0U@S BC71F+2QI&O2\:H32<G0XU1
MHY*Y,8J*PC#Z&N(X/ZKC:G\"$WGK.2VX](9]'9=LZY@IVD";?@-6U><41+Q!
M;H3HB83/,23M)37.C:@(#\(C_05S!A$3[4]\Z"%TD;NQI6YA-N]S+@K^N%C\
M*CW1OZ4N]'ZL@KD*$S]#%;:.:)\U9(1NHM8@]U\3P[@\SXC%B]YR=UJ+#PM6
M.H ^;IL<MY9PK[5$^:Y%%;Z>@<9X+ATKY<R"2>I61:'>#2^W3_#Q6$> UWJ"
MY5A=\C[1-0I&<L:BVT1A^A=DI6XB-6H-J9&?DAFS!FWTYS*/;T&?M(^4F/V$
M!.S'W>T KFX'<3V\#[?#.T5VX.&Y#R^O WAZ;*>H((+%F6)N7K5S_6H=2R=*
MA'>D"O=1\ABX$A7EC"XS7/I3&J5E:104Q9%GBL94FDAYN8X:2QZM57ET6U,%
MFT8QE>=)A\][-&Q^E+;/?L7,EM\QN_,A>O8^3+'+$Q2F?$9IG2_&H42T\WK2
M3Q:B/6=!>]Z*]JR9S)4B]*=-:%=,))_((^Y(#I$S682-:0GHC"?0'D9,31 9
MEF#4F>[$>FXDU^T+:G>]3N>'OV1F[6\8V_@ S3L>8RIY-Q.F&*DS#992@]RO
M4?A8-J7E&N'J*HH*DZBV"@?+C2(Z:C\!OAM(B3\@_3*&A4D3=FL0:8F?DZN$
M6BD)=G@A^WKOP<O#"7_!:OY^/GA[N>/C=8C0(&<2(O>2K=HG.,&-T=90CH_&
M<VHR@96)!([T1=-;%R"XTIGTE'W"IP_@[[\''RDOR'^_(PE>4L@.M%';R/#_
MF"275TAP>HF\R"W"I7;(6OILRD;:#-L%W^QGKM:#<:L[=N,!U%%;B O;0W2D
M.Q&BLV,$'R3$AY 8[4E&G!/6K(,L-GIPMMN'(RU^V(M\R4[S)"763YXWFJ3$
M1)*2DX2[)HC$DY222$J*<,?D2'1)GA2G[F6@]#!3Y@.,%&YFL&0W=06'R,GV
M)D,7*I* 3I].5I;PYLQT#)FI%!FECG/4TI<%)V7%4BIU5UL<SE!MK-Q+."N-
M?JS8W5EN=.%8DS,+S:Y<G$[FSNDB5E<LC/5G8Z]5._(F*#%_:ZWE(A4TU)11
M+_W-9M;09%4[OBC(23E >N0F&4OKR$[>+G-2)"MS9;#:R=7++:+_R@4+&.GH
M,-,I.K];I*?=+'./FGQ#()IT)S(S#@I&]\9:$>^(?]S26$"=K9#FQDH&^MI9
MF)]F\<@"IT^MB+JZP9T;-UB]?)&5DT<9'^ZCM[V5GN86NFIJZ*DH$TZ0Q8@N
MDO$8P<&>K]'O]#A=[L_2&;N&P3(_X9P9E R6472T#<NE$6PW)BBYT$_)ZA"E
MMT<H6.TG]THWV1<ZT*RTD'3$3O2HE; NX</->N)MB:B+_"G1[:,Y:2T#P6_1
M)V-M^//[.7KH+:X51,*H'<[,<N?",6Y>7.:ZZ*H;Y\]R\]QYKIX^(^-^FO;6
M5LK**B@ML8I446BJD'%E("XY13A*%#$ID50VE+)X:HI+UTYR\>IQYH_U4=^8
MBS$OD@R--WJ]+[6V9$8&#,Q/&5@Z5LC*LEGJRL;YL\U<O=0K^G64ZU>&1 =7
M.1(%UE=%4%WBCUE_2/K7#HP1'Y$;^J;4C3/'.B*8:8_"9G*ESA(N>+R"RQ>G
M9'Z:X]KY";Z\>D3:]KCH[F6X<U:@PGGNW;HDN$(QZ"KY%>YP2S#%K5L*1K@B
M6&)5,,TUP1*K@AMN<E>.N2M81%")(]_4'?FMY)Q0;'O*^JZ2>^J>X!*D/(<H
M>.0K@Z_RLMMA)%;@C")_AD;*2OXB_Y12'26+_%\C\?_"HE3=7U;2U_)OH//K
MY7\$+A4#\?7KUSE_7D#8I2L. [$2<N+4\FF'L?3*U9L.T#VG&!L%.!\]>L81
M]U?).JT8B+\V$BL O;]_AJF94[2VCU)<6B<=O)),?0D&HV*@ZR(KNU(Z?#$E
M94(>JEKH[AUWE'WKMO*608DW=]N1#&]F;LY!/OH'AAV?%EZ[)AU,^L+BD15L
M-B$?=1W4U+1BL=0+,1&B(5)AJ:':UD!3<S?=7:/T]BI&8B&'PQ-T]PPXRAH9
M'1=@/R7 ?T84]=*?GUOQ%CGA\"SN[1FDN:F#MM9NA[>TDK%Z;OXH0Z.3C,_,
MLGSF-,=/+=$]U$=^61':O!P2,M()3THD/3>/E&PA]O$)N <$$1831W9N+E8A
M;%V='4P(J9J=GI4)[S1G5\[+8!_'SRN(MUY[#P\W'[)UN=BJZZFLKJ:VQ4Y5
MF]2?391XN9:(<C5A=0;B^\I1C563(D!8/6(C>ZP>XW M0;G)^"9'D*K74EIJ
MQE[3+$2UGYGA(RPOG.'<J4N<.W.!\Y<N</S\$I8.&_%"D'W-B?C7IQ/0F$ZP
MD/BH+CV)0WFDCA>*%) V92)]KIBT^6(BQ_2X-$?Q>:$SFTK=V5L=B%-]&![-
M<?BV)>/3(=*3BM^ FL!A+6'#>J+ZLXB6,I,Z#004Q[$MW(F#81[X18<0+8HR
M-5U-9F86.<8\ 4="0.79J^JD'>U"3&N$ %M**"XKQ%24)_TH ]]@ 0R!/@1'
M1\CYR:1J=>AS<LG-SY<^4"X Q>P(T9&2DDQT3!11<=$DIB:3GJDA4_$J+BFF
MHM+J^"R]OJY>I$X49!75U4)@+644%.>39=*18(C!-]V=P^H#',YQQMOLA9_-
MCY"Z8*+M$22UQY#2%45R=QBJ@7"2AR*('XP@IB^,"-D7WA5*3+> " $,L8U[
M"2G\B%C]VY05;^"$D(Q3S0'TIGZ.;N-/R%W_72Q[?D*3WR,LE&_FRG@0MXY'
M<7[2E6,]VP34?TJ"^Z_9_M9_9/W+]Y'L^6MJ]*_04O@6^K#?$KKO[XD[_"V6
M!K<PW?HQ5=I'&2__A):,-S'Z_1%-X!MD1&W&(*"_LK:)_(H.C.6=-'5/,S!^
MG+;>&;(+ZPF+-1 6F4FVOI3"O&(!)TKX$W]1^BJ.S:LX,>G.B:'M'&W_@N'2
M]XG>_O=XOO?_D++S)YA#GZ<D\"DR77Y#=<K'5!L\,.IB!$C%$A&;3G*:B;RB
M%JG?#G2&!N)59H+B3/C&Y1*FRB)=G>SP&"Q*W4E3_D:FZK=RON\@YYKW<:1T
M*ST9:ZA-7$-VX(<$['Z%?>M?8=>FCSCL>A!]GD&>J8)DG9&"4CLEY>UDY36@
MRJHA4E5.0+21H# M6JV)<E,)/@>V$N/Q!=6B.%N$7)7%OH I['Y.MJ^EU_04
MA1'_3%?>G["I'J$L2@!!P8=<Z#S,I8$ ^LJV4YKV 9K(UTD)>UL Y_LD^'](
MK/M'4L\;T?BO)7+OBX3N^".NG][/QA>_@_^V/Y+D]3Y)?A\2'[B&3)4GI<4&
MTC)T1"?HB4XJ)$U72U)Z-:&1)OS#<G$/SN1P:"I1R6GH,B(ISG#!G+(>0]"S
MZ/U_3TO.6W07O467Z36Z"E_'&/H@6I\'Z1:RUJ7_A,K(YU [W4_HAI\1ONT/
MZ(,^)57J+L3U!;SW/DJ99AU#-F?Z*W:@#WF$X-W?(NS =Z@RO(-)I20B^R?B
M]OR A"W_3,QG?X-^^S]3[/1#; &_$4+Z,A71OR-RY[>)=OH]'S_S?7[YG^_C
MZ9_>1Z+[XTPW[!'RMHM!ZWXJ==OP<WJ=N)!]%!K2J1*@U&+O$! Y0(O,LSG9
MA23$9I 49T"M,I*ESA!2%D"\U)4N^#F:M2]0D_!SFC4_%S+X#//-KS-:]3(-
MNF?(C7K6X3E4E)5*=%@\$:%JDA,*4*7(')EFD?JT$*,JPS?2B'N@AO H':$^
M,E]MV\2>MY\D:L>?R/-_1<;(<U)_[Z /E7'F]2[>VY\@S.D%*G2'A"@?ID#E
M0G:\$XE!6XGTWD#HX0WL7/,F6SY^DWT;/^6#UY[F[1?O9\>:WU.J_IR*]#=0
M>_V2&M5K:-P>P.VMOR%][R.$??Y+]K_\3X1M>PRGCQ_@\Y=^S>YU'Q'B$T!B
M;)J0H# "_.,("9$YU%^9OS2$AD6Q:<M'?/S1X^S9_AQ9JCT4:7:2G_P11B'.
M_67K!/!]1$GT W3GOL:0Z4-J$E\@=OL/\/GP'PG\Y(>$KOTEGN]_CSVO_&<\
MU_R"7>_^C%?_\(\\^(/[>/'W_X#3AL<QQ&Z@)F</U5D;R0AYB3T??]>1].[^
M?[J/=7_\)EJW1^G*^HP (:1;__CWU*8\RV#A&[1F/D->P(^IB'F$;N.['*G;
MR4SM3@&@[EQ;4#%H#Z"_(9;S1VP<&ZY@N+F0KOH"9J:Z.'YRAL432AS9<29%
M)\]-3M';TD2UR>C(7MW1D$M#E9I*4QP#307TU.;3:LEE2/1B>YW,V4J"Q[(R
MVIM;&18]/S@TP_C4<<$.IYB:/$EGYP2U];VB2_IH[E 2ETTP.CS*Z$ 7(WT-
MC [6,#_=)("ZE;F))H9[A-BT5-(D!$F7%D]BA/+I>01C794<':EBM%E'2VD4
M]7GA-!7$TVO1,%RG9;!.Y4@@TU0:34=5.J.=1<R/VX346*@H2Y$^'8(V(8!<
M*:LL/0YK>@+6I&C,T:'8DJ+HR=<P5&E@NJ68DZ,UK,S6L3QG8VZLE$9K I:B
M<"%:B;0U9=/1+H2JO9B:UA(JFDLH:2C!5%=&?E6)S('%F*M%M]76.,),F"U6
M2BRB0VU56-L:L?6T4MG=2)$2YJ&Y"G-'#15*PKK.KXS$=:/-U(PT4#58A[6_
M!NN LJ[#TE,KYRE&8ANFVG)'7.*6WD[ZAQ4\I237[14\5B<Z5,H4XE9L+J*J
MJ1I[3Q/V_A:L@C7,K?*WUFHL+39J.QIIZFFCH>.KE[+E2F*]\C+&IB:YJ1@K
M!9,J(745AX%KJ[<Y<_:2XVNN_OXQ1PS@HT=7!*^=YL2)LPZC<4_/"%U=0]+>
M@RCQB:]<N24X]@9**(@SYU8YL7R1@6'!I7+LD6-G1,XR,7W"$6*B;V!6RC[M
M^"JMMW=2RAAV?(6F&(M[!9OV]T\Z#,9*^4KBNNGIH]+7)AD>G&1(UH-#XYQ:
M4<))K#H\B2]=7I7[ON?P?CZR>(*CQ_X-)]^\=8<+@FV59&Z*@5@>\\_R%0[_
MR^4OO8K_U^3/WL-"P!P9Q+^\)2*D2R%T7RK>PHHHY.[:5R+[;@N9NR5_OW-7
M\1Z6>W1X]XC<$0)W^X9P@%5NW!%L+L?>O7=%MD]S^\8"%Y=;::\(<L0XK]%L
MP292&+\6??1Z3%F^3(W52%G+0AZ5^,07Y!PAD==N\^7UN]P5TG]-2<2S>I2K
M5\8XL]Q(6WT,%?D':;*XTFWWH:<QB-;:,%KK$AGJ,7%RL8<K0L"O7CG+^8OG
M1"YP]>IYKEP\QDB_#9LEB=)"/QIL,72V9#(V(&1W>9@OSTP)*>F'\3K.I;DR
ML_%1IC?\EF&7QQE*^Y#Y1C?J;;O(*%Q#?.%:XHJVD%BRAY2R@V18#F.L#\3<
M$X]M.)/:T2P9%VF4"ZZS=/M3UQ\LX^T@AKR]F,M\&>W.967,QI4!*W=:3=PJ
M3^1\RCYFG)YA9*OHS/V/,A;U*?.%7AQO43'7K9/G3,%6IA@@=I&7NIY"]59J
MBOSH:DAEN"N7@?8\*;>0D2Z#U$LL=45N%"9]3IK'<U3$?\)H\2%.-86Q: M@
M1(A^1^8>ZE)W4Z_SH*TL@49S.K7"':K*,JDJ3:>A/(X^:RC'VZ-9;@YEP7R8
M(?TVI@7/'S'["[[:1D7<;JK3O;$HR>@RXS#I5!0*#LS-S, H/"=?FT1CI9K9
M@6PNSN5)_19P>S2)Q9(M+!:\QTKY^URJ6<\Q\V;ZLM=3E?@!><$OD1/ZAMS[
M1K(2#Y 2XTYDA#<1D4&$1P83$>%/3(@K.8DNM.>Z<*QL"U<K/^5"T6NTA_R2
M*M]?8PE_CJ*D=0X<&^._GABO+\@(VTZ%QI4A:[#@Q1!&;;[TE+O17G*8^@+!
M6)E><OQ>HGS6$NW[,<V64(>!^.K)4N8&-5A,?H0';1$.MA%O]PT$>FT@,^40
MM<6!]-F":2@X@%F_G4+-=G1)&TB-_(B4T'?1)ZU'E[B9E(B-A/FLP]=C&QX>
M!W%S=\;=RPDO[_VX>^[!W4.X@_L!7%VVHM?Z,#:8S9W5)N[<:)1^7\[(D Y[
M73+EI?'";Y(H+DJEK#2#\@H-)16IE%:F8;%)VRG&NLI":BMRL9O5M)7&TI\?
MR)!J'P-^'S"PYRGFM_V.^>V_87#/ Y2[/BXX9)W,^:$43@J>DC;*/&,A]VH#
M^:O-%%QKQ'2EAH)+5K+/FTE=*2%YN9B$XX7$S!H)Z541W"#\RA9$>F4PJ1HW
MHMS6T1#KQGS4/N9V/L/BYH>8VO0[.G<\1HO[>PQH YF3^;VKH9HF>Z5PZ KL
M=A/6RBR'X;NH,(4B4Z)(+*:"<"RE,;34I3'1GT-C53!&S39R];LIR/%$K_$7
M'+3/$6["V\L57U]W?+P/.4)-1(<=$!SI2U=C/,?&M9R>RQ!]F2SZ.8HQX53-
MI:XRGO:0JW4A+=F%\+#]A 0[$11XD$#_O80';",I= L9$1M(=G^31*?G4;F]
M3&[8&LH3ME*=NHV:]+4. ^V)%G].M(<Q6.F#.?,@R5%[" ]U(BS"B\@8Z;?1
M041&^1,7XXL^U9N&(E^6.@,YT^//9+T79H,;FF0WP79^)"I&XJ0DDH2S)B3%
M$Y\82T)R BFI*E*28\A("B _]3 ->9[TRS.,ENUG6.:7NGQGL@6#:G6A:/4)
MZ'3"!W1J])EJLG3IY!@RR#-H*#!H*<K34)2;0GE>+/4ED4S417)<YM*Y2F<F
M*O8P8=O'0KL'JXMJ[ITOX=I**2O'S8P.%5!;K:':DB-S:0DUE1545Y9ALQ93
M5U4H&,P@.$0C?2\9:V$8YGQ_K*8 6JS1@L7269PJY.KE1I:7JQ@9*:2WTTQ'
M<R7M358Z6\V"]W.ID#Z>EKR?I/@=:-,/45H4355E!C8IN]J:3X_@DJFI88[,
M3W'YPEE17Z*[E$2ORI<M-ZYSX^I%3I\\)CAM7.;&7L&#+?1:K?04Y3*2G\JT
MSH]%X8X7]+M8UFYE5+6)1MFN*8^D:J",HLEZ2H]W4G%ND/*+(Q1='"3_T@"%
MUT;(O=2/_FP'&2=;29JM)V;82G17,3'-V2394M"5AE);XLV8R87CTD=/A7_,
MHNNK3+J^S<6R1+Z<:>/NV7GN7#[%+=%1-R^=Y\MKE[EW]3(WSI_CU-&C#/4-
M4&.S8[$(/RVM(S>_DHS, F(2TPB-E;X@_+>MKX5+-\]RZ?HIIA?ZJ6LL(B<O
M@>14'^DS;L)?_:1=DNAHU0@63)2Z36"@5\/LM)ES9SJY>6V,U4LC#/>:*"D(
M("5A$\DQ:U!%?8PZ_$/T$>]CBOX0N_H+3C0'<6DLE9/#Z736A#,^6"BX:9IK
MUY>X>?,T7][^RBC,G8LBET0NBUQS>/S>OJW(39%;@G4$/\A^)>S$G;N797U-
M=/\-AY'XCF"0._=N<_O>'9&[\EN),* 8C947TXI!6'E1+67?D[)17EQ?EG:_
MRKV[\C?%E5C!2,K[;L64^>=%04E?B?+O_QJ)_S\L2K7]925]+?\U\/QO@:4"
M0A4#\0T!;E>O7N7BQ4L.+V+%%5R)37SB^$D&!T<=<=563E]T>&8HG]X=65AA
M8>&DC&'%U/]OBQ([N+EE$&MU!Z;B>@Q&*SJ]F4Q]N?RNHJBXF=R\&HI*ZFGK
M&'9DHSXFY]Q2\*S<ZL6+JXR-3]/:UN5(J-76WL.QXRL"LJ5SR:6N7KWK^.Q/
M,0XKG_J-C\_2V=4GQ[=C;VRBSMY 2VN'D(8A!@3$]_0.TS\P)D1F4F1* /VH
M; \Q-#PFQ&"!\S* E>>_=FV54Z=.,S]_1,CE'/U]HS3:6QWE*(9B)1[QY.P"
M,PN++!P[ZHB=:ZVOQB\\D)0L-0DR<?O%1I"8G4FT.@V/T&#< P.(C$^009Z'
MU5I%;T^OPW/YU*DS7+ZZRM75FXX,W9F9!@X>="4]52;IJAIYGBXAM"VT#W92
MW5-/4JF&R+)TPJNTA-FS2>@K(VVLBHS1*G*F&C#--%$P5$-D@8J0M!C4^DP*
M"HJH--?06-\ID],4\T* EHZ>9F7E+"LR <^N'*&HU4)$:2J'3=%X527A6Y]*
M8*.:L/9,(KOU1/4J7L#R/$/91(_F$#:L(W X ^?V&#XQ.;.NQ(WM57[LJ0WF
M8%TX+O8H#K?$X=F9@G=/*CZ]:00.9!#4JR:@3458FQIO<PP[9;+;%>;"@4 W
M/(-]B(J)D6=78\C*H5#NNZR\PN$-55%526%Q(?H<'5G96C)%,2:I$O )]<4C
MQ ?OB$#\(D.(4@S-FC0T F(-ABSR\XSDY1I(2TV6LB,(BPDC+"Z<F-1XU(9,
ML@MSR2TVD5]43'&9$O:D7"9NQ;ALPF0R8C1JR!!E')7JAW?<?ESCM^&>L1V_
M@KT$E1\DPN)"?)4'JGI?4NS>)-K=26CV(*[-@\@V=X*;7*0N#^%3YT)0@RO!
MM7OQ+UV+E^9EHC->I+SH4Q9[/;G8'\18[@;2-WX'W;IO8=[S$]J"G^!(V0;.
M]1SF[+ [Q[MV,=N\B<[2CSGP^;^P\:UOXK_OM_CL^!%A!WY&LO?]1!WZ 6D!
M/Z/&\"?.3^YEM/X=3(F_IBWW=1IT[U 4]SKJH#<IR_*@J39?R'@UZAP;J89:
MBJNZJ6D>IZIA3.JEE9B44H(CLHB)T:/7Y0L022,^UH6.MF26CJ1S=,R#V<XM
M CX^9Z#D4R$JSZ'U>(@TY]]AB7T3JUPK/_ IBJ+?)3=Y'ZE)87C[A^+F$T=@
M>);T33OIF0W$)DG?BRTC(*8(W[@\PE.RR=2JR4GQ)]KM70H2/F&\QHE;DY',
MEVZE/>Y-NI,_P^3_-AJ?C\B-=R(A8"_!W@>(# ]&G9U->EXQD>EYJ'164C-K
MB555$A8OUX@LQ#?$0%"H#EUF*66%)3AM_0RWS2^C"?Z(\J0/R U^%(/?3QBO
M?(N.O*<HC_LY;=G/8XG_ Y4)3W&VVY7K$Z$<;?,2\K2.E*#720C]4 "9)_D"
M6)7D(MD)?I1KHJG01I(3XRIMLQZ_[2]S\)-'2'#_ &/<#B%!NT@.WT)JO!N&
M;!5JK8[8E!P"8_+QBRK&/:B @UY9'/#,Q,DO$^\H'2IMMA T(6O)3N2&?D!9
MW-NT&85L-FYGIF&=D*+7L64^0?".;^"Y]N^H27L;>_H[&'W_@.^:;Y/F]B?R
MPM>0ZO,^$:ZOL'_#;_CT]6]0F+:&V8X@IIH\*$E]0TC KPC<_Q.*U1^3X/LG
MOGCEK] %O(3&_2D.O?IW['OZ;_%^]9MD[/P)G=HW* K[/=%[?T1#SF[V??(4
M/_SK^WCOB7]'9O"3#%NWT&Q48BAO(CWP$]:^\WM\W7<[$MYDZ0L=+PSS379,
M9<TDIQ43')I%4%".$$<C*8G23JDQ#F*G#7Y-VN$MJJ4_UZ;^G'[SGU@9W,"8
M[3WRPNXGR?UA$GT_%1 43%A '*%!&B+"<O$/,LK<(A(I]9I0C&=4+C[2KU/2
M"O%V]6+CNR^S\97["=[T" ;O9\GS5XC",X3M>YK@O7_";^?3A!U\B=2 -3+>
MWL!]^RN$'/J &,\/Y'H?$.?Q#J[KGF#SZ[_FL^=_S$L/?8.7'_D;MGWX ^QY
M7TB;K*4TZ4E'. Z][^]P^^@_D;#W(8+7_X8#KW\'GT]_A><G#^#RR6,<WO(N
M06Z["?%VQ6GW5MR=]^'GX8*GDQ 2WT,$N6]EPX>/LOF3W^&\]7%"7%XBQOT%
M@O?]'K=U/Z P[GGJ]*^0'_T ;?FOTUWT$9;D5]%X/8K*^1$T;L^B\WR1A/V/
MX;/NIWA^\0N</OT-ZU[Y*8_\\-_Q\ _NX\W'OXWKIL>(]WX%3<0;I(>_3*#3
MP^SZ[,=L>N>G!.WZ _D1KU&5^C[^TG\.OO,];*FOTZI_BX;TEZE-?E[6;S!<
MLH4+@R&<'0QFJ3>(Q9X(QEMCF1,B>'ZQB>E>"P,M90QWUPF&&&7YS'%.G3W%
M[-P19B;GF1N?9ZBKG]::6NK,)EKJ"Z@VIV(NB&' ;F2BK93Q]DK&^YJPV\P4
M%0CY*#?3V"!8H6. AI8!6KLGZ!F<%_V_2$?G)/:F(6H:!VEH56+G3C V,LU(
M7Q\CO4U,#M<R,U;-PG0MQ^:;6)AJHK.YG/SL-!)C0E EA&(V:3@^T\&1\7H:
M*E049OB1I_*C1!-!19:0,5,2;14IM%0(:*].I[\QA^&.(OK;BZFW90GA#44=
M[T=67##EJ7$T:E5T:%2TI\31HXIE)#.9N>),ILJU3%3K9#SF,MFAQ%K-$9*E
MQ6J.PVI)%%R517=_*3TC5CI&;32/2QV-UE Y8*.\LYJ">C-&2S%%5K,C!K'5
M5HU9<$>YB+FVAJI6);R#G=+F:HH:*F4M^]OEW Y9=UFQ]-JH'K%C':ZCHK^*
MTFX+I3T6^6W#-MB I;.&DD8+1;7EV*2<SL$>1L:5$%Z#='1TTMC82+6MBK**
M4HHJBC#;+=BZ[-0/ME+9)64JWLAM<K_--AHZFNCHZ:*UO96&ID:YUQK1]27T
M#@YRZ=HU!^17D.NM._<X>_Z*XT7]J&#%H:%I(9)''0X*"OY<7%QQ;'=WCS P
M,.G(:Z$DLE-"4,S-'I?M28Z>$+QZ[(Q@S3EFY+S9(\M,SRXQ,WM2<."<X"W%
M\'Q<L.V\/,<P[>V##D/QUQ[%BJ%X>'A6RI]@<F+!$8=86<_+6LG!,3 XYHA#
MK!BSE3 32NQDY=YOWOI2ML]R8DGY$NT:ERY?X]RYB[+OM,,)8G7UA@-C"PQW
M+,KZJT\S_VN,_K\N7QN(A50+27/$%?ZS<?CNS0O<7CW+'5G?4PC?O:^\?N[(
MWQU&8L6K1S"_$D/PGF!Z):GOES?E_F[=D#:XR4TA?+>58Q7"B!#'F_-,M6EI
MR3],C78'MHPM%,1^2F;$YQ3JO)D>JY7[.<WJ+<'N=RYP\_8J-Z_*?:T*G;LN
M>/OJ):Y?/\OM6Z>X>7U>QEXM0]T:^MHB'+&%^UM"::D.I-C@0E&.-TTU:J;&
MZ@4[3W'Q\@H7+IV1^CSMB#E\XM@0W>TFRHLCJ*F,H\6N9;"[E+-S0MQ/]L&1
M9F[*OI6(+<QL>)31+^[G:,RGG*SQDSG%E[SRW43FK26T9!.1E?N(K7$CIL:=
MI 8?5,T!I+8$HNF((*,MG-3& #*:_<CI"*2D-YPR^5N1Q9WB@D/TU$1SK#&-
M<U7QG%:[L!*^GI->;S&^[6%Z-_^6/N<_,:7>QUAQ$+V62+KKE3!< >3I]I.7
MOH-BW5ZJ33ZTU:70VY;-8%<^(]T%3/:;&.W2TV@)$0RWEVRI9TW &]1IMCM"
M1AQIC&>Z+H;^T@":,IVI43M1GQU >WDZ+18]=67"*XI3Z*C1,-:4)M41PW)K
M**>;_5FN]6#:M(<CY:[,F;TI"OV4O-#U5*2Y.Y)REF8EDJ]/PZA7DZO+H%"?
MCMF8S+#,11?GB_GR1!%W9C(YW>3/H/83!C)>9R;O'4Y7;>1,U786BC;3D?81
M)6$ODQ_^-L6J'>@3#I$4[45TA/"CB!#"PX()%SP?%>R"(=F5M@)7CI1NY*+Y
M(\X5OD9GZ -4"LXM"WZ.TI3-:**W$^&]D7"O;43[[B M?"\E&:XT%_LR4!W$
M:(T_(]72MI4!=)1)G64<0AVRG@2?#ZC-]V!I5,>=TZ6<6\BEJRX6=<)!0GRV
M"B[8('IW,\E12ASF,*8[U(P*I^FV^M%2+MBY_##V$F?J2P[06NE!7?%A"M1[
MB0W\ E^/C;@)OCGDOA\7][T<]MB#I]<^AY'8W?T@_K[[10]XT]:0P.*,D97C
MI1R;$QW1HZ/)GD&U58/9K,3D59+NYE)39Z*VH1![<Q$M2IS7)@NM]14T*TF[
M*K*P2WNVYT4RGN7/7-(>YOW>Y<B>/S"S_;?T[GT0H^L3TFZ;L0XD8IHWDG6R
M'-W9&O(N-U-RO1/+K6ZJ;W=2>;.%HM5Z=)>K2;]H(?ET&?&+!42.: AOCR6F
M-I"T"E_A\"X80Z2_I7EQ+F$_)P4CG=C\(+.;?T??CB>HW?LR/<G>K/0T,]W3
M(3J\E8&N!GI%9[0TE0NOS:6\-)-2)1] F0J+.87:*C7-=5K:[.E4%'J2E;Z)
M;.G361E.I":ZXN^WV^&)[>'EA(^O,X&!!X1/N%-7E<AXOYZ5(R96SY1S<2E7
M=',2W8W^U$L[%>D.DBY8.SW)E808=X+\#Q 2Y$2(G!\6M)OTQ ,8T_=3H-I&
M3MB'TM_?Q1S_*7;=+NQ9NZC-W"2_US!DWLV)M@!.=L4Q6!5&F=:3^#!GPH(/
M$Q[N2W1,$%'1 41%^CI"3V0F^U!?X,?Q]B#.]@4SU2 80>HM79XE/M:7^/A(
M$A/C24Q*)#XQCKCX&!)D.T653$IRG-QO.-FJ ,HR?6@J\&# [$9_A2O5N:[H
MTSV%'T4*?TE!K\V0WUKYK9%VR4!OT)"=I9$QJJ4@5X\I3TMQ7BIE>3&"2Y28
MW:%T%;G2:-Q-O7$''<)A3XTF<7NED!MG2KEQN8Z3QZUTMF=)W>JPF970@":J
M*PNE7Q926UU ?961)IN!IFKIHT61F(Q^%.9X2;L%4%L13GMCDN"H7(XME+,P
M8Z&_JY1.Z;<=;=)O6\MH:RO!7I=%@3$(C>J0B!NFW!A*3:E4RO6:&ZT,#7:Q
M,#?!F:4CW+EQ6727Z* ;UQPQ[451<._&=:Y?O,"9$R>8&YM@N+V#WAH;/>8B
M1LJR.695<[5!Q;WV9&[5AG(BUXG&N W8Y#[K.HQ4C%HI$XQ7NM1%T9E^"L\-
MD7]^A/R+HQC.]I-YLA/UT382)^N(&; 0UU-*7),!574:>=9X!CMD;N]+8[4Y
MBELR1YV)6L>(Y_LLE\1R8[R1+T_-<N_B:;Z\?(D[(O>N710YS^U+9[ET^A0S
M$U,T-[0[<N68BNHQY%:1H2MQ),3VCX@E+C65]OXNKMZZS"71U0/#'1259)&9
M%4^:.HS4M" R,D(HS(^CHBP1L^B[\J(0JBIBI:YS.+W<Q>WK,UQ8Z:-![CDE
M=H=PKM>$([\B<]1;I$=\3$'2.LJ3UU&?OI%3[9&BQK.X+//@=+^6I46[8( 5
MT?&7'(;>>U]>%SQPC;NWKXI<D]]7!3LH!EPE^>Z?OS(2['#[CN +1TX#)=2$
MLE;"3-P1'*-@BMO<ENU;TI:W%%NC@E,<X2$$GW!9RK@@OQ5,H1B)KTC9E^4Z
M2HX$Y66VH$#EA;62K$ZPT;^*'*DLROK?C,1*F7]I]_S?O_P?823^2T#Y];;R
MB=O-FTH,XNL"6E<=!F+E4SAE44#C\>-+ K2''0!WZ>1I^@=&'2$GIJ:.R?JH
MP^-8*>VV-.0M.7Y*]IDM36@RBRF4@5!5W>,P#)N*&AU)ZE+3BLC+MSG(VN5K
M=QQ-JWB,R"W(M>\)Z%ZBO+P&M3J;HJ)*IJ=/<.7*5Q[$UZ[>EFLNR:0S*(2D
MB_/GI?/*N4JBDPN7SG'RU!)'CB[(/<PP.O:5AX<BHV/3<MX"1X\M,3XQ39^0
MFM&Q<7FV$X[X9K=OWY9GO^XP$D].3LLUYQD?FZ&]K8>FI@ZZNON9DGW3<XM,
MS,XQ.CG!S.(<A3(Y;7?:26*VBD1C.FY1?D1H$O&*#F:+$/W# 3Y$)R6@SS%0
M4E[J($5'3RYQ\?HJ5V3PG+UVE>DCQS!7U9"1F27/7>&(Z]?9TTY;;RMM(QV8
MA+ Z)?OB;HPBU)9)>*.!^.XBTD<JR5'>C"VT8IEOHW2HEIA\%6&I4:0+F,O.
M-E)D,F.M:J*IN=?A4:TD>5E8/,[BRA(C2],8FTOQ+XAG?W8P+N4Q>-F2\1>%
M'=BB(;!5,>S*[VXU8<-9A(_GX#^8@<^(&N>>!#XSN_-9F1OK*SS94N7+=JL_
M>VPA'&J,QKTM"8^.9 ZW)^#1F8"[@ W7QDB\6^1W511[=%YLC7)BF^\^#G@[
M$QH13)I*A4'J0*_+PIB;)Y-C,06F0C)U2ESA>%&F,<3&11(6%8)7J#<>X3YX
M1?GB&>9-:'P("4*^54HB@-1$-!FI&'-T*,D!PN7XL+A0_"+]"4D,(UT4:$9!
M%FE&'2J]!K4H5T->-B6E!1049,MYRMO91#DW@+!H9WS"MN$6O@[WA#7X:3\G
M-&\]L<5;22G;)>!I/RKS?A+*]Q!EWD6X=1=!U3OPK-C$8?-FD2T<+MN$<^Y'
M'%"_S*'X)_$-?Y"4Z-]3I7^5R<I-]&=]B'K;=U!]^O<4[O@Q'9'/TZU^D][<
M#Q@H^8R!TD_H+_N4>L-[K'W]'SBXZ7?4E>PEU.4Q-K[Q=WSR['TXK_M;F?S_
MP&S;>HYT?L%@]5O8LIX@+^Y!3"G/493V'BD!KY&?[DQEB3RS-IOHE (B4DJ(
MSS"39J@EP]A$JKZ1N+0J0J/S\0],0YV>@U:=3%3H+AIKPCDQI^+T7 BSG;L9
MJ]W$5.T>3K1[TUNRD[S(5VG(VD!'_F9JTC\DS>=Y0ES>Q5M LZM' $X>TB_\
M,DA*KR4^I8:@L&+\0POQCS))NQ02FYI#=K08,@<  /_T241!5*:6[,0 _':]
M@2YB'<.V0*Y/J&E-_AB3\Z/TJ]:3MN\Y8@^^+80@D;S4(.)"W(D*#R0^54V,
M.I>@Q%R"$TH)CBTG(*(4O] B//P,N'I*?P[.=!B)B_--[-_\$5O>>QBOS0^1
MX?TXF5Z_0N?] ^S:)VC(?()JU6/8U2]AB7^.)MV[HDRC.#\1+@!KK]3EVW@?
M>(G(D,TT-!AHZZB@H<Y,34FI@'<S367EV$OS*=+$D!:\CPBG#U#YKB$S?!/:
MJ"VD1>TD)<8)55(@NBPMR1EY>$?DL-LCDVVN.G8>-K#338=S0#:A27GHC?D4
M:&(QANTDP_T56O0;6&IW9[)FDQ"B3^@VOTJ)Z@$"MOT=7NO^GHJDURB/?Y68
MO;]BPY_NHS#Z<_HJ0LF*7$^,]QLX;?X-:]_^S]CR=[$RD2KM&4J;>1^%J1^2
M'/ "JL!W\=KQ-)O>^BG9T9O1A:YEW[N_YOGO_BUO_^RO\?WX)S0(\<L->I+(
M/3]G2,9^R+[7>>:7]Q&R]WM4:5^@HU#(9O@K&$,_)MGS,S9]\">"?=T$U.80
MDZ G)#J;D+A\HE,K"(@T21OEXNF;3W!H 3%1.@'CH00>6H-:R'![]KN41_T"
M4\3W:# \SNJ\&S--&TET_1'>FW[$H?5/X[IS"P&>$80&:85,2'M[Z=GME<EV
MOTSVAQEPB<@F*"Y' '49WFXNK'GS"3:_]6OVO?-=@C?\Q.%)'+[K=^Q^_WML
M?^?['%[_$/X[G\'EBR?XTV^_P0/?OX]W_O1] O8]2V;H.V2%OD&FS\N$;7N0
M':]\DR^>^T]L>.7O<-OX?1KS/V6^;0\3]HU2#W)L\/WX;/I' K;^#(]UOV3_
M.S]BU_/?POV=7Q"Y[3GB7#\FTNUSW'>]R[KW'F/;9W_">>NK'-KX++Z[7\1_
MU[,<_/37^.WX ][;'N:+E_^1CY[^][SUR'V\\9!2Y[_"&/,X^H@'J- ^2UGZ
MBVB"GL(0^3+FU,]D7.ZB6KV)@JCW23[\-&YK?X+[%_?CM>E)7G_X[WGL!_?Q
M],_NXZW'_YXMRK-O_17^3@\0Z_\DVMA7R9?YHT*W#HOF"W*BWY)R7Z$P_C4L
MZ@^I2'Z7.O6GC)8=H$:NU23$].ID.K<6,CG9%T.GZ(G9[@R.C90RWEE,;U,Q
M ^W53(_V,C,]RHF3QT5W7^+(_'&&^R?H;AV@MW5("*9(=Q=-]24"AE,HS8VD
M2XCT0K>9XZ-V>MLJ*2LU8# *:;&8J5,2SS9U8:YIH[JISQ%&I[UKFK;V29I:
MQJAO&1'"/2S;8PPJL6@[>QGI;V5^LI&.1CU-M:GT=1D9'2RGH=:()BV&I/@P
MC(84(3KEG#C:RW"?E8+LZ*\RE<?ZH4\*0Q,?2)XZ FM^,HT5&734ZNFHSZ*A
M4D-YH1+#,QI-2HC48Q#Y<>$T9*30HTEC,"V9H:18%O5IG"K0L)B;PK0</UR<
M1%=QO,PA<527Q6 NCZ6Z5DU;CXGAF1I&CC0QL-A"SV(;/4(*VD]V83_21M58
M"\7M-1BKR\BM**&PHHPRJX5*6PW6VCJL]?54MS12T51'66,UE6VU6#OJL,@Y
MI2UFS)V55/;9J.BOIF+01EF_E<+.,@J[RBB7YZX9:L#<7D5Q?3FEM5+?[8WT
M#@\P+EBHK:V=YJ86.CL[J:FU42+7SZ\P45)?@;6[GMJA5BI[[')^+14M-BKE
M^DWMS8Z7YEWMG;2UME-7WT"1S)MM7=TLK9QV$(K;@NTN7KW!_*)@4,5C=V"2
MN;F3@M&.,C:V(.MC* F+%2RJA!53MI6_CXXNT-4E;=W6Y\AC,3*^()AMT6$D
MGI@^YDAD-S@\XTA$-S(\*\>,.LY7#,-*V#-%E-]?[QL>F1/\>-P1RF)ZZ@B+
M1Y99.761\^<$$R^==6!,Q8BM>#LK(3$4APK%0'QM]98CU,29LQ<=82<48[&2
M$V+IY"F6EE<X>_:\PU"L?+$GC^L@0%\[9R@Q^[Y>E/W_<_DW3/]50CO%&_@F
M=VX+6;NC> M?%;G"Y?/'A%Q/<5Z([/6+Q[A[X[20+R&Q]X3\W;LA.%I)."/W
M(?=]]_IM(><WN2>@_)Z0\[M"]A2BYS#TWE1(W$7NKA[C^% Y ]9H&G-<J,W<
M+G/"&K)BOL!L#&1AJE%XP5FNW%KAJESG^IT;7+]VFUN"\6^+K$J[*DEN[MZY
MSLWKY[ASXP17S_=R9,K Y$ BHUW1]#5'D*?=27+D6C*2]E!K369NIDGJ=XG+
M5T])W2X)!SC*U:O'F)]MPUZCQ69)H;Y:0T]+(4<'*EB5,7-[T,2)U/W,'WJ=
MJ8V/T;_^82X8W;@UD4M370@994Z$E>TFI.8@4:V^Q':%$M$>3'A[$!$=041V
M!A$E$M[B1U"]!]'- :@ZPLGNCJ9F5(5=[M5:YDI[D2OC><XLIFYC_, S3&]Z
MD"-;'V%HPX/T['J*'K\/Z<_TH#DOV)$0V%+D3[[!A<RT7>2J]U-M"J)+\'=?
M9S[=[7GTM!N9["]D?L3$:*<&:Z$7>>D[R8K_@KR$+V@U>3)6E\"P/8TANYJ.
M,KF/#%?1OQXTY$726:&CHRJ'Y@H-3>8D%OISN3B9RZ4A%4MV7T[4N+!<Y\K)
M&E>6:KT8+W5#[_,F&;X?4J1RQFJ,H#0G&:,NE:S,5')T*DJ,\KQEJ<QU&[@V
M5\CMV1Q66B,8S-F)+?(-ZD4O]&5]P-&*+5RHV<UYRPYF<M92$_LV1=$?49:V
M'VV<&PF12C*S4*+#PP1'2=T&>1,9Y((F[B V_1ZF"C[G=,E[K!2\3F_,$UC]
M_X I\"5'K-CTB%T$>VPAS/< 87[.LMY/J,\V,A.<J"OP8[@ZA G!CF-6/P;,
M?C0:G"E)W(PA3'!TCA,+'7'<.);#S9-2M_T:2O0^Q ;LQ-=E(SYN2KD[R<_P
M9[A1RTQ[!K/MR<QVQ'!L(('E\216)I,X,9+ 7$^<(XQ6H<99,/(.#GMNQ=E]
M)P=<MN-\:#N>GOMQ=U="31PD,OPP65H?*DH"J+$$T-621%]')HUU:=1496 Q
M:RDV21M;\FELJ*2CPR[S4@/]?4T,#[8RVM?,2*>=P68;;34E-)5G"]9.9M(0
MQK$T%Y;"US*__RDF=CU$A_,39/J]3);I(.63.@J.%F-8L6$XUT3!A5;,UWJH
MO3U($X,TW.NC\FXG^;>;T5ZK(>6LF81C)F(G]<3V)I'0$(2Z_# FPP':5/LX
MFKB7LP&?L;3]498V/<#<YH?I%YS4>/ =AM*"N""\=7ETB(61 :;[.YD8:!<]
MWDAK2Q7UM:64E^G)STO"5)!$I3F#VBHMY44Q9&7L)S7^<W3I6\E(V4M<U'Y\
MO;?CH<0E]MF/E^\>XN.<L%5&<^E,+7>NV+ESJ88;%RI96LBAJRV*PEPGLG4N
MI*<<(BIL+Y%A+H('W0CP/DB0SUXB@O:BBCV(I="?^A)OJK+W8E5OH$&WD5[3
M'D:K/&4,[Z<J<RT-.>OH%8XW5>_-0DL\/14Q%*L#B MVEW*DKX8'$*T8AZ/]
MY%Y%PGQ(C_:D4N_%?$,@Y_HBF&L*I3S+0^8N=Q(<1N)PD1B1.)%8XN)B2$B(
M(SDYD92D.-*2HLE,#L>H"J RV\>1;+&UU),*@Q?ZU !TZCCTZG2I*QVZC"PR
M,_5HA3]H#5J'L3A;\?3/SJ0@+PM3OJQSDZDHC*.F*$*POC^EF2X4I.VE5+.'
MH?I0SLWHN76V7.;Y1JY<M@L>*Z:C*9-Z2SJUTA_KJ@S45N=(G6=3+_.(O=H@
M?5<MY<J<F>9,2N(NN8]#%.1X82D.PBYM,R+SPOQXA6/^ZFPWT=E53E-;"2T=
M98*]BF6^U5.:'XTQ,X1BN3]3;CJ6\CSZNEL9&^[CZ-PDU\XNB?ZY)+KG*K=7
M+XI.6@4EJ9F2\/7J-:Z>/<=))3QH;S<]];7T5ID9L9HXW6V!13LL5,"@CJO6
M8-H3-E*C/41]O1J;8#OS=#VFA59RCW62=VJ(_#/C9)\<0BOX3CW?2=I,"PG#
MM<3T6HCO+"&V+AN554UIO8:CLV8X50-S!= 8P_F,O0P&?,I"?AB7^JNXMS0-
M9T\KH 4NB_Z]<HZ[5U:X??DTURZ>X<CL/*U-W9C+FLC+KR<KQT9Z9AGA\5I\
M0F,)BT_"WM;&V4OG63FS3$=G*_D%"L;58#1FD).33H8FGDQM' 9=++GZ<,&7
M01BS0C&7I'#L2#NW5F<Y?;Q+VB^)N-!-N!]\@9B@#\A)VRXZQY7:?%?,:5LH
MCOZ$N?H0X5(R#YXJX^A4/J>66@6+G.9+Q8"KA(D0G7U;ZO[FC:O<NGE%<(G(
M[;/<NK$L<LJ1//;JY9.R[XK@E1N"'VX+(!$@HV"9NXI\Z3 6*U\I*2^:;]^Y
M*UA",>I*6]Z[(#ABB=LWCG#GU@EI7A'! />^5 S&RI=.RLMMQ7-4,(V4\S4.
M4G#27RY?&8F_$L>%_U7^]R__QQF)OQ;%2'SKE@!  82*1ZT"4F6W8U' ZK*
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MK(GM'.DII+]#P_AP(1,CI<Q,UC,_VTUGNTGP2!63DV;! FVTM^K)4T>C28E
MG2Q$214MI"Z.O/18<M.CT*:%4I(CQ%"?($0T68AU(OF:&'*2PN7YAF)*C&$P
M+YO1K$S&TU.84Z>RIDWG1)&:4\9LE@T9].5'4Y'F0:':$WUQ* UFV7:AGN53
MO2R<'F#FS""39X88$>D_-TC[Z3Z:#G=3-]=-Y; %?7L]A765%%578*BOH=%B
MH;6SDW8A'[WC8XPNSC&^,D?/Y !M(UV8!RS4RS.ILZ:;:*1&I**OFO+>*HR#
M-58'<>U((U6]2B[A)FJ5Z&-+/6U]70R-C3(^/DE/5Z_52=S7UT]+:RN5M2:*
MJ\LQ=332--))RU0/#2/MF&3_RO8Z:ML;:._ID.<P).1P1,BD7$M[)]4-#73T
M]K&\?I3;]Q]RZ>I-5M:/,SFU*%AS57#HVI]2/RAI'E:M 02*8UB)\E6B?17G
ML2)*:HCQ<27'\()U^:A,QZ:6K4[BN<6C+*Z>8&GUI/5XRO9*8()RW"$E1_'P
MG#6"6'$0*_LJ:2>4^7%9/S(\S>3X/+,S*U997#@L^Z];G<3*6VH+BVLLKQRQ
MXD[%::RDQU#FCQP]:<6ACW,3/["FG#A_X1(G3YZV!B8HZ2>40M'?.8J_D^\^
M_V[9GV#]_[5,P?$*9E<<Q(^C:11'L4+PE$@@)5KXX?U+'%Y6<CDV,"[/^;#T
ME8LG)KAY:85OE3R#**^)7A=2+MO?%V+V0,B>D+MO']SCX5TE4D@(GA"]^P_O
M"ME3\AO?X.'-DQR=DN,UI](C=J6GW$/TW!X*DW92KP^3<=4J^YWF]L/SW'AP
MA1OW;G+GCG -.<6=F]]R\]I=JZ/XCN(D5XK:W3K/K2MS7#IEYLA"'HOC*4SW
MQU.K=T*=N!55S#<TU<:SNM3"C>MKW)3SW[AY1N0TUV^<X/BQ"48':FBJR:*I
M+IO>]F*F.PHYUBICJSR(*<%P<S8OL[3[.49%KU_0N7)]3,G5&T2VX-CX1D\B
M._P)[PTC<BB6F/$D8J>3B9M3D;"00M*"3*<3B!Z.)GH@AL2!.+*'DVA:R*%_
M-HN^KD@Z2NSI2]O*3.1&ENV?X_C>WW'ZX',LVK["0L"7S*>YT"6XI28_''U!
M" 4Z;_*TKNBRW2C7^='5F,;,L(&QD4K1>P:&!O3,C!2S.E7&PHCRPU.,X MW
M2C0V5.78TU49S+ YE8&67/K-.KIJ,FC51XJ>CJ*S0G2N24-G93I#31I61;==
M6ZODT<DJOCU<R)7!:.8K#M&7LYGCK=X<MP0Q)&VM#?Q(=/IF*M3NU!6)+BI*
MH5B705%^)GE9<>ASHQAH5G-L5(XQ4\"YH33&RCPQI^ZB)6T'#:E?TI&SA95:
M6\XUV'"Q]@#'RO<)IMU*5?)N*C2>J..]28@.)"$NBOCH:.(B(XF+""8NW(N4
M"!OT"=N8+]W&^>I-G"K[B-'TMS''O4MEW.>4J6P$QSH2&>A F+\KH?Z*$]"#
M8%\'POT/D!*^GXH,>P:,?DS5!=&G=Z$SWY[V/%N9VC%F\F;.',BLQ8_S\VK.
MS.OHJX^7:W(@V&L7@9[["/(Y0(2?'"OTD-@[?X8;XED;3./X1#K')I)8&8ID
MLC.8M=$4SBV5L#"42Z7T^4BY=F_9ST.PCJ>7+9Z>=C)UM!:R4_+AI@MF+,GW
MHC#7V9I2H;(\DBI#/-65&9@JM50:=6+[JL4.=C(Y-L3TQ ASTV,LSXVS.CO"
MRD0_"\.*L[B=J8X&9FJ*6-9%LA1S@#FW]YG;]WMF;)]F+/1#6DN=,?4E4;9<
M@OY$#<:K7=3<&Z/^[@3-]Z:Q/)BAXZ%,'TW0]'"4JH>#Z*Y;R#A;2\8)$ZE+
M1:2.I:/ICB2_VIW:W/V,QFUCR6<CZS:OL+KCMQS9\PSS^U^BS_9=)F/L.5V7
MSX/E::ZN+W-F>9%CLU,L3PXQ,];'B&#D#KGFVIIBRDLS,91G4F/2BFC(SPTF
M*\V>K-1]%&H=R,ET(2G.B:" @_A+N_GZV^+MLXLR?;"T11&WKYI%B;3QZ&8+
M5\[6R+A/%UOI16S,'L+"]A(JSRTTQ)X@/T>"I.U#O)5GNX>,>">:*V,8Z5#1
M4Q>(2;N;&LTV6O/W"&^RH[7H$/5Y^ZC+W8VEY !]52Z,-L@8JT^P\HW,*'=4
M48'6OAH3'D2,<,NX:'^28@-)B0LA+=I;^K<OZYWQG!;=-2\<N+$T4CA7"*G"
M/55B_Y,2$TA*4IS$R:B2DTA)22(M-9F,U"0R4Q/)2A$\D1J.01M*4VD(YO(0
MJ@K"*= (QLA0H<O,DOE\\K,+R<G5D:7+$=&25Y!#45$>)<4ZF>8+-I+Y4JVT
M6;KTLV0:JI)I-";16!8KUQ1&B\%?^G <UT]5BNZUB&[NXLHEP4.S90RUBAXQ
MQHM.R:'7G$]+=39M#05T-)?0T5J$Q:*EO#R<]%1[N6Y[M!G2G_-\Z:A-IKLQ
MG;;Z#-J:L@0_%=+=:Z"CI\(JW=T5#,JTTUR$N4:'N;:$FLI"ZJK+!$.T,3LU
M;G42GSNRQ)W+I^'N-;%)-\4&W;!&%'/WCM51?/O*%4Z>.";;3S#8V4Y_0QU3
ME@;.3+3S[?$!.-L+RS7<LJCH4^W'G.5!:V,6M=WE& 7/Z&<[*%H>(G]EE%RQ
MBYJ%8=*G^D@9ZR1UO /56!M)8B?C+ :BJW-)DWY:)_;D^&H+7.B!D]+_1O*X
M4"P<+'P'<R4Q7!AMYM&9-1Z>/<NC"]?%I-X5TWN-!]?/BYT]S873)YF?6:!-
M\&E559<\FW9R"\PD9QJ%X^FLA:G](P0WMK1S^/A)!H>&:1 \5%Y>)J+'8-#+
MM(3BD@)*]064%&6+/DX0SAQ)5F:8C*%8T146;EY=XN*I4>&>*F*#O\'?Y7WJ
M]'X<F2WA\K%J>NM#*4K<@C;X?3J+'3@QH>;&Z5K!!=FLK5AX^.@R=Q\H..6&
MU3FLU"UXI$02*RFC[I[C]HUU3I\8%OM426-#/GW==6+3+PDFN,>#>_=Y_":2
M !-%E/E'2D3Q71X*=E#PA#5"^.%E&;_K/+H^R<WS?1R>KV=RL(*ID3IN7EX7
M"'/U<<2RDBK+BFG^/WW^!(C^G2A Z7_\YW\2)_'_._GWG^^<P\I'236A.(>_
M<Q _=AI_*\N5;>0YWW]D?3UN52FRMB!*_]A)SIZ]; 74P\IKF[-'.7SD/ M+
MQ^CI'\=0*03#U$QC2Z^0LS%&QM:86S@K<H[^P55,-7UHLI1<Q.U,SQ[F]KW'
MUZ$XB<]?N(G9/"@DO@Z#L9F,S&+K=&GIM,A)IB:%1 [,,] _R]+B2:Y>O<^5
MJTJ>Y.M",N4<<T(<IJ:M^?$4I_:1(\<%?-^P@N\'<A]W;]_GK #RXT)*CQXY
M:DV,?ECDQ(GCUI03Y\[)NN,G6%\_PK(2-?RG(B3CD[-T]P\+>1E@<FZ>^?55
M1A9GJ!"R%"@$<)O/(3*;B\@74A6F3\$G.YI]H:YL<MR)78 +?G%!1&GB21,0
M4-!9@6E22-O2$-5"FG)KRDG,TI"IS:/<:**MK9/AL3%F15$NGEZE9;J+M,9\
MW NC\#0D$B1@+Z(]']60$?5D+=G3]>3-B-*;:Z%TK)E#$1[L<K,A1DF(KQ1K
MRRM$7V82Y5(CQKB)%G,[K4+&6H3@-0IY*^MO)+X^#U=1<JX5\3A5Q>%4'8=G
MBPK?KG1\>])P;8O'I2,.][Y$O$=3<1]1X=@?QX&.,'8V^K.UVHNM51YL-WFR
MM\X/F^80#C6%L+\QD#T-?NQK])-Y7ZOLK?-E=Z4/>XIDVW1G;!*<<4OR(ER4
M7%1Z.*$)@02&^Q 8XH5_D"<>WJZXN#G@X'2(_;:[V+YO"UMV?\;6?1_CZ+V#
MX'@7PI-]2-"$DY(32X(ZBHBD8 (B?? .=L?)VQX77T?\H_SPB?+!*\87OY00
M(G,2B,M3$:V.(RPYG)#8 $+%P(='>1(1X4)DB TA?CL%@&XE,G0+49&?$Q;Q
M'@&A+^$3]'O9]@42T]XF(?U=.><&XK(^)4S],3XR[Z+Y$$?M!ART'V*3^0Z[
M$_[(SK"7V.[U-%L/_H0O/O[?.?#9?R33\V<DVOP=:J=_IEWU/H5NOZ<RX(\<
MK7-AOEJ 2NKKQ#M\GS37'Z&2;>(<?TRU]@MF>@(X/IO,0),+FJC7\=KS?30!
M/Z8B\1<T9/P+35F_8[E],Q=FG6DL>HVB].<HSGP#H_9+LN._(C'B -G9TH_B
MLW'V3\,E.!O/J"+IIP8"8HSXANGQ"RDF-+*4^(0" 5Q!.-IM)"=]+Z.=05Q8
M2>3$5# 3S0XTY>^@N6"OD!$WQBW!=)E<,:1O(M7W11*]7L-E]PMLW_0:"0F1
M)&=H"8K)(B"Z -_0(KP#"O .S)6V+R QHPBU-H?TI#!4P;:D!>Q$&[F'K/!M
MQ#J_0:F0KJ:4+\@/>)WMKWZ/SU[\6^)]OR(F8"MN#A^S8_O[A(:'RCD*"8DK
MQ#4H%WN?')Q\"_ )+L,KH!!W'PW1<?FB5PI(2HACTT>OLO'5GV#WY6]0^[Q&
M:?AK5,>]QFCYUS1FO$VVSZ_)]7V648,-%\;CF# [";G;2G+8!S@?> MU:K#H
M*Q,UYCKZQL<9G5ZAU3)*09Z [-02<O,,5%9449:?04K0?F)</R)=B&I5QGX!
MH?:4J6V$F.Q'G>9#4DJLM$TZ[B$:/,,*"8PU$I:@1%>7D:'-%3(EA,I_-^GN
M'U/D]R'UB5_0JMF$*>D-1BHWL]"R@ZK4Y\D/>X*"T&<P)+Q#=>87Y,5LP&__
M4_0)F3PYJJ,Q5P!XQ/MD!+],B6H# PT>K K169_*9F4\C\Z&!')274B)<B0]
MUAM-<JB, 6<KH2O.32,[(0RMC*.26!<:4_:B<7D>]T_^&H^M/R7<Z0\D^[Q"
MQ(%?H/5YEM*0/Q*SX^>RS5L4!.\@RFF;]+\(<C-S\?))Q,9%Q4$W#7;RC.S]
M]3@'&?$*K;+VB^# 9!)"_4GT^X:L@+<I#W^:+-?_1HK#?R4WZ,<L6?;17;:%
M"/M?DNCY&C9?_(XWGOPA![_>C(^SZ _?.$)",PF*UN(;I<8Y(!;?$"&D\3$"
MJF(H$0"N%R*BC=Q"6>+7U"F5]5,WTY)_"&/Z3@(._)X$EY>(LW^>@^__=[:_
M^4-VOO]+#DE?<?KF%X38/8%&:<-8&5<);V&0:5'$JV0'/(_&]RG*XE^E2_\E
M"VTV+';8TU>Q'4/J!C3A[Q/I_!(N6W[!-R__.8X;_IXXFZ=)\WR#"M5VRA.W
MX_3Y3W#[ZF=$V3Y'FL=+Y$B?S_+](_%VOT<7_!YEL3*._=\CV>T5D3^0Y?^B
M$/L_D!_^ F4)KV'*_(#LB%?D.G_ IZ_^![:\\U=X[WZ*H'W/X;/UUSA^]'WL
MW_MK0K?]C"SWETAQ?(:H [_&??,/^/P/_XF-S_T9^S_^"]2BZXJ2WD0;+>?Q
M>YXXKS=(#OB2W"1;:HJ#J2L/1:LZ2&;D3LJ2[1DUQ=.K#Y3^&,K%L4).#^0Q
M7AN/2>-%178(I3EQ0I#3&1KH$MPPR\CH)$JM .7MEOGYP]8?@#N5M! M(S2W
MC-'9,\GPZ+A@C7:&^BH8Z2[AU)R%U2$E2E]-=H802VTTI<8<ZIIKL/3TT-8W
M2IUE4$2FK>/4-H_2V"K';)NV3AO,0UC:1ZP_<G=W=-#76<_T:)T 5#U30P5,
MCP@1,JL8ZLWGZ.$NEA?;Z!>2TUBO%=PA]ME<2HDNA>RT6+)ES.:E)PH!3$:3
M%D]*4@3)2G&:)'_RT@(HRXE GR4$6Q5*7G0 QI@PVE(2&<O-9DRK82@SC8$T
M^2[[S^G2639D,UB01$UF$'E)KN1I?:BL2Z)_JH+ET[T<N3+!\J5Q9B^,,'Y>
M0+I(S_E!VL[TTW2TC]J%'JJ$X)3WFBDRUY!?4T%9@Y""L5$FYN>9$OPV*3*[
MNLKL^@K#L^/TC@_0+N2]2?:IZVFDNEM)05%+56<-5=VUF/KJJ>RIQ=A1C<%2
M3;ULU]S71E-'"YU]/?0/#$G[#-)AZ13IH*NS1W2@!5-]#7J3@?HN,V;!&4VC
M'=0-M6+J:;!&(ILLM;3V6.@?'F!X9)C>@0%:N[JH-;=@Z>YE8F:>8X+I5@\?
M%SRWQ/C8'#/3<MTSZXR.S#,BHCB)E;?*%%GZDRCI(V;GCL@QYQD;E_U$%*PZ
M);IY>G;-*G,+1UA</FZ5R<G'T<2'#Y\5O'?,V@]G9E9E'VFOJ65K/N/AX1GK
MO+).N0XEW[$R5=)8S,JVBJ-X<4DI@'Q2L.1Y:R2QDD),R4VL.(P5Y["R3(DD
M5B*-;]Q4JGXK^8IO6B.)SY^_: W$4.J *)C[NW03RN?_2CVAX'9EP;^1/RW[
M=TYB:PX_62CR\+X0MF^%9"F%9!Y>$6(WS<1P/5W-.GJ;M$QT%K$^6<?9(_U<
MNS@OY.^8 '$A;TH$CU)T1DC: Y&'2D[BN[>Y<T^)!'I@=18_?'"3^S=/<7:M
ME\F.7"QE@;3JW3%F["$O7G1=CC=S8R;!W$>X^_ \=X3TW1*BJ;RM>/?6/9'[
M<KZ[W+I^F]O7[\BQ[G'O^A7N7%GGUOE^3BV7L3*9P<)((MU-OI3D'B C>;?H
M@3S.GAK@RJ5YP?8KG#V_S+'CLZRM33 A>J+=7$93;2Y-];DRG\]PBY;EFD36
MLUT9$3LTM_\YUO<^S<0WOV$U\@O6RCTQESA3*-@U3?!+?'\,D8,)1(I-C%_(
M)GD]EY1C.M)/Z$@[DD/*BIK$N72BQU3$#2>3,9)"^7@ZYM$TNKMC:2RTQRSV
M9#CL$^8=7F95].[ZWN=9]_J8PPDV+.0$TR)ZP9 ?3W%Q$KK<<'*R@P0S!%-K
MB&.H*Y_Y29/T[PH&!>,/#Y<S,U[.[*B2FSB/;DL&S;5Q5)<&4)'G3'-Y %WU
MR72UY--I+J9=L'Q;51J=)A6]U:+'ZM($MXANZ<OB[%PACTY7P2D#UZ;3F:IP
MI"]W%Z-Z6\[VQ7&D+8:N E>*8W>0'[.7TC0W*G+#*-<I$6M*-'$J!=D15!2&
M,M6MX<*<GEN+>DX/JNF3YU^3X42#M'-%ZA[J-;N8J7;A@L6#JRVN'#;:T99Y
MD-)D1_)3_5'%!1 3%4Q43"31,3$R'TUL9"AQ8;XD!]F*+=O*5,$VSE9OY4S5
M9B;ROJ(Y91/ZN*_)B3N(*M*!R"!G0GQ="?7U)LS?CV!?3X)\' GW/4!2T!X,
M8M^[I'V&*WP9J_!@6DFGT>+'L2XEQVP8QP<CN;:<S=E9+?T-$92H78@/.T"
M]U[\E()SKC)UVHDJS('23&_,<H\]=:'TU@?15JGDO#W(6'LT-T_5<>5X _.C
MQ314B3W("B(B3,E!O!]/#\51[(B7EXBWC>!.=W0Y?FBSW,C+]:$P/X3BPF@J
ME%?N:XMI:ZEFL+>#J;$1%F=F6%M<Y.C*,L=7ESBV-,W1A7&.SHVR-CG,^F 7
MQ\U&UM-]6?;]@@7;EU@6W++D]A+3R9OI,8=3,YE+R:H1O5RCZ7HW30_':7XX
MC?G!+"WW9[$\G*/MT1QF659S=QC]E4YR3C>A/ER->D%/]JB:_(X(X:9.M*1O
M8<;_'=;M7V)M]S/,[7B&L[Y?<B')B>,Y85QH*N3.7#]</,7]2^>Y>?8T%X^N
M<7A^DKF)04;%SO3T--/84(ZQ/(NRTG3*RU+1ER2BR?0E+<E>QK@-^=F>9*K<
MB ZS)]C_$ $^!P0/'I2V<V"@5\V-RTW<N]G,[:L-G#E:SDA?&J5%?B3&V1$L
M.-O??S\! 8<(#K CQ,>.Z  G4B-=20K=1VFV.Z/M,BY:(VDL=:0X_6NJ<O<*
M3[*CH<"!LHP#%*<<0)]FBT%MCS'+&8-<CUX=@";6BWCAE E*>L3($*(C0@@/
M#2 J(M":-B4Y3OB'<,C"5!^&JJ.957*C5\=2K@U'(QA )=A7);PC*3&)Q"05
M"4G))*F4-V2%JPLN2$M)($.FZI0DJZ-8ER'81AN%(3>:DIQX\C0J<@0SY*1K
MR,W((4>=1W9.'IK\7-2Z;++SL\DOS+4Z$?.+"L@MS*>@1$=1B892?3I5%1G4
M&C-I,&;06*&BV1A-3V,<B^.Y7#C7P*W;7=RZT<[U\XV<F"EDHC&6L?I$1D2'
M]-=FT5&GP])01%MS$9WM^=35)),O&"4]W@95Q%ZRXNUI,2;27IU.HS&%&H.*
MNFHU34TZ6EI+:%(<PRW%\@Q-TL>KZ6JKH+%63Z6A@*I*/19+DV#  9;FICB^
MML#-2V?X]NYU$/OS\([8H=MB'Y7I+>6MF(L</7I,,,$<@ST#])HMC+:UL#K0
MRL5I"S<66[DT6,)JA>BT#$]:\Z.P-!4+SFG"--Q-Z=@@)3,3%,]-4S@[1>[D
M.)J1(=('^DCI[R&QIYVX]B;BFJJ(J2A$5::EO$8G8[R6Z\NMW)ZKXYHEF^4<
M?RP1AY@H3>6$X)MK1Y:X??8\]Z_<YN&-^]R_)C;TQG7N7+W*D=4C#/9/4-_0
M39FQ@[RB5M*S&XA),1(L'-A'^(J3=S3IVE*:++U453=@-%9AK*BDIJ:6NKH&
M:FKKJ*@TR7(CI:7%%.C48C^2T*B%UV3%TMJB9VVEA_-GQJBK3"(F>#L1/I_3
MTQ#/V95*3B^7TE+A)3;Z"W*C/J*_VHO3\P5</=4LXTAGQ;OW'E[@SH.K8N^5
M-^RO"1ZX+FU_FLMGICF\8&%JQ$A7NQ939;S862VS$TI^=<$-2@V#NX)!E*C/
M>P)0[LJ,DI% ^;'YT3T1!5=<E>4G>7AYDBNK)LY,:3DRDLIP<S2ME9%TU&=P
M^=34X^VL!>WN"=11\A=;X<[_TT=9\IU\!XJL>0G^)/^O>_S?_?Q/X"3^__[S
MG:/X<9J%6]9(6L5AK'R45]^4"&+EZWUYV->N*J_4G69Q<9G5U<,</W:&I<7C
M0NZ.LS!_REJ@KG]H'E--&[I"(_5-78Q.KC N@'YJ[@2C$T=I;9]";VA#DUU)
MIKJ<RJHV:\&0*]?O<T?.=^'R#:9FCE*L;R(]HQ1=00V9&B%DI0UT=D]0:;+(
M .D4)2)&\^A%SIZ]*8#\"BM""I37!4<$R(\,">D<GV5N=DFN;XUS9R]9KU_Y
M/)!S7+MRG9/'3W!<E,OQ(T=975D28+_"L6-'.'7Z!&?.G+9&%2N _>2),W*>
M4ZRM'^.8@/SYY34L7;T,34XPMB3&=:*?\,)4]L2XLSO1@Y2.$C0#E814I>.F
MC6!;L!T;[+:PR_<0CI'N>*8&$% 22VAU"E&-:E0MA03D)<@Z/\*3D\C,SL-0
M;J*SHY>9N0763Q]G^>(Q*H>:""I.9'^&/TZR?V"CAH@.'7%])<0/E!([4$**
M#%K==",E$V9L8GW8Z65/6&HBL:DJTM19Y!?HQ4A4"! Q45TERJ:AB1ISDY"^
M>DHZ:TFJS\>K- $70RP.AFCLJZ)Q-R?AW9F"9V<2#N8H;)I"L6T)Q;D[&J?>
M&.R[HSC4'LK!UA#V-P>RL]:;;16N?&-T94^-M_7[-S6>?&UR96N5"]LJG=EJ
M=.2K4GN^UCNQN\2=_1IG#B38<S#*%N<$9SP3W?&*=<,MR!Y']WT<M-O.GOU;
MV;;]2[[8O)&-7[['AB_?XJ--K_'I5R_AX/H98;&'"(RT)23.A7"5-Z$J/[SD
MF=@'VK/?8S^[G7:QUWDW=@+0G 54.H>YXACA)N?R(R@M5-HIC( 8'[Q#Y?S!
M-G@%',#'=[< Q6^(\-].7,A6DB*_(C5.E&KZ)G29GQ#B]UL"??^%Z,AGB8EY
M@<B8EPB-?EF.\RIN(K8Q?^10W!_9&_T"VT.?XFO_)W&,?D?._S8??_YW;%32
M0VSZ:^H5!XS[ST@^\'U* YZG*>D3%FK<^78YB_,C0?27;Z(H]FFJ4UY#X_UK
M7#;]9_+CWJ*_SI&YW@#ZF@YATKU/>=HSK+1^QGCY2QBCOD]CQA-,-WS*2L].
MRM*>Q)3W$D/-VX3,V0O8V42D_Q=H,A*)CLO$(R@=U]!L7"/R<8\LQCNB%*_@
M8GR"2ZRI(#Q\5.S9LY<O/WV6V)#/L<CS7!X,X^AX!#5Y7V/_]0^(='N12NT^
MALUAM!O=20M^&_>=/Z8J>X^ +'N2PG8+F(@B.U<M?3*+P)AL?,-R\ _567,4
MQR;K2$H3\I4824JT.ZJ@W40Y?T2XPWL$''P5%R%T6>'O49'Q&8E>3_/5ZW_!
MQA>^1Z##ZV0((8T,_8H=V_](9(0?&0*<(N)R< L4@QN0C6=8$=XA<C]!^02$
MY)"4DD]2<AJ^WJZ\^_K3O/'<#]FYX=?$.[U)<>A'-*B^8*C\ +K0EPC9\P-,
MB?),A*0>[@FC3K<9G6HC21&?X>>VA>2$,(K+]!CJZ^D8F:)_8I5&\QA9.;7$
M)!81GUZ"MK ,K1*M'K"/)#'6)4)R>DKLZ2JQPYC^#<G!'Q$=M)FH2&=BDY)D
M'VF/U!*B$O,)C]&0G5>(L4I BI"+U)!=:/V_)-WQ59)LGB')_BFTODI:C(UT
MY7]!:=0?* Y_GJ*P%] &_(%&W0Z&&GWHJ_7EXFPA)_HSR9/SY06]BC[V=2K2
M/A!R?X#)SF@AY/E8ZI,$B :0FN1+O4E'?U<CW1UF#(9R :,Z-%DYE!;KJ2\O
MIKE0A2EV#VJ[YU$=^BV=)0[4Y>PCPOYY/GGBS_#]Y(<4N+Y(Z&?_2)'GVU1%
M[<#[ZU=)]+9%$Y^(M[OH%/LX]CNF8^>3CZU?$8X!I7B&EN,?DDM84 P)@8ZH
MI6WR_%]%Y_ES<ES^AG2[OR#=]>\9,6RF+G,#00=^1D7F;F+=-_#A<W_/)R_+
M.-FS3?I1#-'AT41&QA,6%HVSDQ.>+C9$!-B2%F-'77$@ _616$H]Z:\44%_E
M34N^C;29'05"\OT/_)94SQ?)#WZ3#(\7R?)_CW2_#=(O7R= VC[(X??$>C]'
MDN_39 0\36[8\Y3%OT5!V"NR_9.4QKQ!==H&FG.^8*K)B?%Z9]KU!VD38J+D
M!%-^0 G<^PN27)\60OPV&K\_RCC?3$O67M3NKY+J]"*9;B^C5O(*1K]/4<0[
MA.S^!>'[?TN4S=,$[7F".,?GR0M]EX:,+ZE1?80^ZG5R E] %_8:*;XOX;;[
M5WSV^I_SZ:M_C>VF)XF2\93H\"[AVY_"\Z-_(&KK/Y/G]A1JEW\AS^\I"D*?
M)];A1P3L^5NB[']"K>93S'E"S./?(<SN26R^_ UV6]\@1>Q9=7D&K0+^C65)
M%&>'8]"$82E.H*,HDHGJ!,X)0%]J4M-9("0G10A6M ^9B4+$BW1T=_<S.*)$
M]X[0W:.\UC_-D."'SJYI6MJF:!)I[I#U_3,,C(XS/M[.Q&@-LZ-5G%YL9]12
M+&0OG"RQJ3I=+!4F)9*XBM;N#MKZAFAH&Z*Z:9"J!F4Z2FWS./7F"1I;QJEK
M[I=S*.FC1NE2')T6);*EC+DQ(RO31N;'"FFI%K#:%,_RK('CZ\T,=!=0E!=.
MNY"C;HO@FZI\\M6)Y&<D49*=+H1-B0**)UD50W**DL,XF/RT("&?D9A$[QG3
MI'WB@F@3XC>F1!!KU0QEJ^G(2*$N(0IS2BR=6<ETZ5(Q94:(CO$E*]V'THHX
MVD>*63C3Q=KE$=:O3;(J,G=YG(F+HPR)]%T<H?/<,"TGAJA;[J=JJAO#H(7B
MMGKRZBK0-]8POK3 D=-G.';Z',N"9^97UIA97!1\)NT^.4;/2#_F'HLU!42U
MI0Y32RU-W2U8!CLP#[13W=% 16L-IO8&FOK:L/1W"1;JI*.KF_;V;EJ;VS$W
MF(6$M=+1UDE+2RO5=364FXR8>RVT#'50W]]";7^3U0%=T5I%18N)QFXS74I*
M+3E_YU _K;V]-'5TT=;33]_P&",3TX()%P1GK@BF6V56B22>6F5:L*7BW%6B
M@)>6CK.Z=I;#1R]Q3/#@PO(IQJ?6&!I=9'A8B2*>MSJ)E1H6WZ6HF)=YY;LR
MKT0G*U,E?9I2"._(D3,R?\Q:=V-Q\0AK:R?D7(N">T]8"^0I1>NFII:LZQ4G
M\=S<FF#0XX(C3W/^W'7!T@\%/\/5:[>MN8E/G#S'M>MWK*DGE")VRIMXY\]?
MMJ:84.3&C5M<N7+-&DU\]:J2DT^PJC75Q..W^92I-6A#YI6W.*W%6_XDUN_*
M<BN6_Y.36'FMSAK)(YLH;^DIN8FY*:)$*A\5W-M'?UL>3:41-!<%TR=C=<22
MQ<)H!6>.]'+[VHKL>U;DHG""<]Q[<(F'CVYR^^XM;M^Y:ZT_<N_!/9G>X-[M
ML]RZ-,_L8"G5A;Y4ZYPI2=M#CMCD_'1[QGH+N7EU3LY[G+OWA7C>N\SM6Y>Y
M<_,J]V[)_DI^2;G_V])6]Z[?X^[5Z]R[<I)[%R<XOU[/X=E<%L>3&!';6UOA
MCD[K*'J@C)/'^CB\UB?/?4"P<C>#@]*/.NMHK"^ERIA#8VT^30T%-#?FT2-X
M>;XFF?5<'T;=WV?VP'.L[7F2R:]_RLBAW],;^ Z-JLV4ESN3VQY)NA#6A#$U
M<=-:DM>*R3QC).=2%;F7*M&<+B7C2"&IJWFR7D/<6#HIHZEHNF,IMD12TQ2&
M4>=$?<H^^F.V,^'\#A,[GF5\V[,L> @>2W1@7A=)6T&2Z,]L*JH**--G4U20
MBKXH"7.=AJ'N0B:&RT4GEM$_:&!TM)+9*1.C \7T=N30UYU/;W<>+0V)E.8Z
M4U7DA=DD>J(YGS:SGK;&(MKKM'379S+2G,9\1QHG1K,Y)VUY<2F'.\<*N3R;
MSDR=-Y7Q7]"<L9L5<PQGAW)8;%71FN^-(=6>$I4#I>GNHM<#,>3&4JY3429\
MI2POE$9#*$M#&FX>J>#AL6I.C^738XK'J VF7*0PQ8$JC2V3=0%<[@WG>G<P
MB\(+&C)=R$WP(CTAF/C84,'-881%APO.B2%"['549+C@[0!4 4[H0G:*CMS&
MB<J=G*G?SX38SMKTW61%?D-2^#ZB0^P(#W0FU,>-,!]OPGW]"1$)]?<EU,^5
M(,_]@CMM,&1Y,E87R9)@TV.=(5P<C>"R8->;"\EPJIA'I\LYOY#+2$LX#67>
MY*0Y$AYT '^?@_AZV.#O;D.PYR&B_)3C[2,K\1!YJ;;DJ Z2'+X%4[$GZS/%
M7#UEYMHI"\<7:AALSR%'^)JOUWZ\/6WP]+#'P\/!&ED<&^=%=G8(V=H@X;AA
M%!9%D9\O-LR8C:6EFK&A'N8F1UF9G^/8ZCIGCY_BDO#1RZ=/<?[X.N>/+7/Q
M^#(G%V8X/=[/Q?8*CB4XLN[R-H<%EQRU?X;U@+>8U>RDHS66RJE"BM=,E)UN
MP'2U@\9[0S0_G*3IP;3,S]+R8(&VATNTWI^G]L8(QHL]%)UH)7NY!NU,*05#
M692U1E!7:D=/PB<L.C_+:<$?1_9(O][S*M<%+])= 0O]<'P>KIP"T0TH;S'<
MN<'M2V=%KZRP-#O&V$@7 _VMF,T*%]6B+TFE6+AM@6"$C P?4I)=!'LZDYGJ
M19S@X1"?0U8)]-I#7(0MU171'%DQRJ';18<T<_)(*0,]R>@+O8F/MB'([P#!
M 8X$!C@0%&!'F&"]Y' 7M/$>%*>Z6VN!6 R^+ RHL%2X49ZSF^*LG506.V+(
M=T$G.DL=8TM&I(.(,QE1SK*_(['!]D0%.Q,5Y"Y3;Q%?8L(#A?^%$!8:3$1$
M*#'2CQ5'<4*T+^I$;RKD^3871U&=%X4Z+H"4F%"28Z-)CD\@.2F9A"05L8F"
M]U4JP0Q)I*CB2!/\D"$8(3,U2:9)J%.40G;Q:-,2T&:JR-:DDZW.)#LC4_"!
MFJS,++*T6C0Z+9DZ-6I=)CGY&@J*\\@KS$=;4("NN(""DER*]1K*RM082S68
MRC34&M2"<]2TU:5B:4P2VRCCX**9&]?,<+>=NR?*.6*)8++4F[&28*9,J?0J
MZ2=$MS;7"5=HSL4L.J:R)(K4B(-$>WTMO&TO-04QM)DTF"NS,!8F4U:4;/T!
MI*XVCRJ3EJIJ+9;64NO;62TMY>A%_^7I,B@NR:.AJ9;.SC9&1X986U[D\OFS
MW+UYG0>W;UCEX>UK/+QYA3O7Q(:>.<WB\F'&)Q;I[YN@N[V?WI8VT7EUS)J-
M'.XP,%>CH3<_FBZYCL[* MHM3;0-#E,_/(-A: []Z +E@B4,4RL4C<ZC&YY&
M.S!!1O<("98>8IO;2#:WD%QM(DTX3T%I'@.M1H[UU7*ZO9Q50P;#ZG LR<&,
M5A:R++CHZ-P<%TY?X.KEVU:Y=/8:UR_<%+G%S.0JK99AC*8.\O6M9.0T$I]6
M35AB!;[A1;CX9'+(.0;_L$PRLLO(+ZJ@W*#42ZJWOLFNI%,SMPB6:FC!5%UO
M=1Z7R77E%VC0YJC0YJID/*71WE8J&*8=@SZ:&.&,"2';Z*R)87%8RV1/$LT&
M%ZKR]M!<8L.JV+L+ZV+[UQI9F*KA^+%A[HC]O_OP$O=%% QPZ]HZ9P[W,R,V
MJ;4R3IZK'Z5%_C34)K$XV\*MJ\?X]IZ,>26*6/&W*1&?,B\&7N2651?(@Q.]
M< %NK7/O;#^79HM9L00R47F08<->>HV.=)N"&&[+XNJ9:=E>P4(/4/(,/)(_
M94Z!/8K;5Y'''V5. 4'*[)_FK7D)Y-Q6$4QD_?L?]_E?PDFL $K%&:RDF%!^
MU;]Y4P"@3+^+(OZNDO+CC:7)!6A>NZH4=+M@!;+'Q6BMKRFYB$\P,WU8!O0R
MHV,"WN>4*M'KE%4T4U[53'OW&/,"V&L;^\C,,E)<VD)N?CWYA4TT-HV(PNBD
MM7W$6G%Z=&)>!L  EO8Q<O.JI>.W,CUS4D!4._JR1EHL0Z+D:F4P5%%9:::^
MOH.&ADYKA<CJZA:J368!A1V,*\5*5H];G=@KRT<X)R#]WIW[W+EUETL7+UL=
MP)<O7^;2^?,"-(^RN# G][$@0/X(UVY<YKZ 7Z4MSIPY8\V_K*304*I2G[UP
MA1-GSS,^.T?7\"!U72WDU.G9'>G&QH"][%7[$M==1.I(!6'-V7CJX]D2;L^K
M!S[A"_<=[(]TQ"G3'Y>2,'SJ$@EKTX@2TN&EC>10L ?A26(0LH1P&VKH[1D2
MY;?&T7.G6;IPE.SF$NQ2_#BD#L:[*M7J)':K2"!&P&2"@'._YDRBNO))'S:2
M/5!%4)$*^Q@_[ (]"8J+(3$M@PR-EKR\(B'H9927&:1=JS#65E-25T66J9A8
MHP;_TD0\2F-Q*HO$SAB!4UTT#O4RWQ".O3G2ZB3>7Q_ [EH?]C?Z<] <Q,'F
M0&QD>J@ID'UU/NP0(/A-F1,[Q !_;71AD\&)+\L=^%)_B,\+]_&9;@]?%NQG
M<]X!OE$?P"[# =<4)UP3''"*M<,F=#][O;YAG]M6MN[[A$^_>H<OMWS(1Q^_
MQ9OOOLR['[_&!Y^_QH>?O\2&3WZ/K<,'Q,8?(EWC0TR2*[Z1MGA$.6 ;>) =
MTNY?V6UFB]T6=CKOY)" /L<@!QR"'3@0>$C$QCKO&>:*>Z =;@$'\0PZB$_0
M?OS\=Q/D^PWQ87M("-M*I/^'A+J_0F7>#A8'@P4,?T)*Q'/$ASXCAOPM4I)>
M)SSL.3Q]?XNMY[^PQ^-7[/#X)=N]?L$NOU]A*]M56/PP=T2Q?]<OV+/QOQ)U
MX)_HR/R0AOA7T+K^A-A=?TM?[G:NCZNXMY3)<JLC[04?T:!Y@_FF [3E?4;0
MWG\@V.;G:&/>HZY@!T&N/\?']K^AC?H5:VV;F2Q_C?+0_TYS^E/,UGW.:OLV
MRI-_24O1RZST[V%]T!Y3[J?$!GZ )C6$U%0U$?$Y>(A1<@[1X!J:AT^X'K]0
MO;1GK0",7KS]57S\\:>\\<=?4B8$XNA" 4LCR1R>3*:N>#_.>W])L.L+) 6]
M3W;T%[3J76B0YUN4\!E#=;YBM 5\E_@*L'8C,RV8-$T*$8FIA,>IB8K+)C)6
M35)*)LFJ6&O$0)J O;RX7?CM?1JW;4^0ZK^1I=XDYH1HU!=N)L;K">PV_SV^
M!YZ6-G!AI#.>NDI? GP_%7#E1[XV4\"FFIC$'$)B<_$+SR8P7$MX="YQLDQQ
M$,?&1.+E;L\[;SS'"T_],QM?^R6!!]\E)V0KAH2=%,5M(NC ;P@Y\&LNCJ5Q
MM"N2QNRO,61L0!/W#JG1F\A3AY*K50LHTY-?7D-I72?%U=UB^.NMA?\BDLL(
M22HD75=&6D82X3X[R4_<CUEG1[MN+[G!K^*_YZ<<^NJ?\'-^G:C0O=(&X1@J
M#>3H"@@-BR R(H*BPBPKX57%.1'E\251MN\1NNL%PO:\0(SMJZ2ZO46RTXLD
M.SZ-UO=%2B/?I#C\-9*<?TM)_(>,-GAR;3F/HWU)M&8?)-/]9?JD[TS7',"4
M]CX5Z9LH4&T7(+$5^P,?X^=C+X2Y@)J:2B'? T+$C]#>,2KZR8"/?SR^ ;&H
MT]0"!@60^GR-VO85C$$;.-6OHE:]BSUO_0VO_<V?X?SJ/Z&S>1;5UI_0D? E
MH[EV1&Q_@?!]'Q$KI"G(+1 GNS .V<;BX)')09<T;-S3\0[.)2$AEY3H".*]
MME(<]25U\>]3'?8467;?(]?E[VA(>L'J)*Y*>9MPNY]1EOP%FJ"/</KRUVQ_
M^\>$V'].?DHP;@>WLO/+#]CQQ7L<W+:! *>O2 W?C2YIOX!W)ZJUMJ0&;"#.
M[4TTP9]8HZPCG5]CUT=_C^V7_T2"TS,8HCZPOCZKC_J8=.^WB'5^E=R8K]!$
M?4J@X^\)=_D-F:%_D';\D$K5AVA\GB5T]S_)]#DT?B^0YO6LM//GM.3OHD.(
MUDQ[!%T5'A0E;D(3\B99(:]*OWN5#.\_4)/R!5UY>RD,>)?$0T^1:/,495'O
MD^CX6X)W_YATCY<)V/4K[#_[!YPV_8B#'_\=KIO_B207T4->+Z!R>8K(@_]"
M2>RGE"1]3;"3Z,J7_XJ7G_@_^/S-GQ)HLY$8AXWX;Y&QM>&?B!%=I ]\D0+_
MWU$4^A0FU6OTEGU-A4K.[_9;4GW^0$',N]*^GUES5"<'[R(K(8C&RE*&^]N9
MFNJ5/M)"7T<=?<V5]-658"E,I+M8 &FSE@%] DV:<*K2(\F)#R$S*8;\/!VU
M]1;:NL?IZ)T6HC!$1]N8 /UYFBV3U)DGJ+-,4],Z84T9T34PS-AH&Y/#U4P-
M&)@7&S?5:10P*=?08Z2[LUR <QGU34;JS74T6-IH:.NGNG& JKH!JAN$%)C'
M:6@9HZYI@-:.8;IZA^CIZ<3<5$%K4Q'#?64L3IM8GZUB94+/\E@!JY,%')XK
MX=BB@>4I Z.]);0WY8H4TME<BK$HG7)=NI!+-9G)T6(#1-+B2$X.PU"4Q$!S
M'M-M^4PWY3%>J66T1,UBF8ZUTD*KD[A%%4]%7 1E\>&4QX=1*NU3(&VK2PXD
M*\6?#+4?-18-0ZMU+%SI9>W6N,@4R]>G6+F]P,*M!2:OS3!Z;9J^BQ-83LI]
MK@Y@FNVE?+B-O)8JLFO**&HPT34^ROSZ88Z>/,NQ4^<X>N(4J^M'F)J;9VQZ
MBB%9WS78A[F[C?JV9AI%!B>&F5F>8V)^BI'9"?JG1N@<%8PVT(.EMPM+9Q<-
MC69,E76/?WPVUF 6\M+9WB6$L YCI9%*P1=M_1VT#752W]U$35<]E>TU&/_D
M)*[M:,#<WT;G2"^=PP-T# W2-:)<BSRC_B%Z!T996#S,J5,7.77R(DL+1YD:
M7V9N9IVYV75FE3S#\X>9GI-[F5%R#*_1-S!#3]\4 T("E3?=AF0Z.*@4UENP
MID93G,/?.8B5Z=J:\I::4K!.B69?MSI\%8>P4A!Y:4DICG?2Z@@^=NR<X,(K
M5@>QXDP^=>H2 T(HAX58*@YCQ7FL.)@O7A1">.V>X.2S@AV5- A*].UCHJ(X
M>I54$PJV5"*(%>?P1<&E2E#"]>LW46I[* $:CW&XT*,'C^>_V_<[1_&_!LHH
M_$C95K:P_O^3D_C;>_+]WN/U2M3OK0?71,X+\9/KN;;(X<46!LT:6DM":2KP
M$SOJ2Y,AG/Z63.9&39P[/L2CN\?DX&?DG.?E^B_S\-%M'BK.X7N*H_B.+!/B
M_O"B7,=QYB<J,.B\J2WRP9CM0&'J/O0:1T:ZLKAPLIL+9\>X?'&1&]>/<O_N
M6>[</,OMZ^>X?^>:3*]R4]KA]K6[W!6\??_J>1Y<6>'VA4%.KU<R-9Q =WL(
M==5^E @Y+<@/P5">3'-C@?"($IJ:RL0^EE%AS*.VNIA6<P4U)K%?IGP:ZG0T
M&%2,"VX^6A['1-@.1@Z^PNB67S*Z^<?T;OL)#7M^28']TQ2K=Z-OCR5K6$W&
M;#XI2WJ2U\K07FJ@^$XK13>:R;M82_:I"M1'RTA>S"=^*IO$D714LE]:C8S;
M$G>*M8ZB\QP93K5EU.U#AK<_1\\73U#WR6_H]]C$$=&)4_5%]+76T-;60$MS
M+;55I525YM!DRJ:Y.L/J?.GH**)_P"C\JHJ)D4I&A: /B0X:["NAOR=?]%:R
MX#$W# 7NU!HB:*G/H4W:PZJ?FC2B']4L#61S=B:/"W,Y7%[*X=)2-G.=H8('
M#U&:\!7EB=]@SG%EM#J>6;.:X9HD&I7T%S&[*4VQI;G0G\;\8!H*H@5[)5!7
M%"MV/X"VB@ .CVJX=ZJ6AV>;.3RLHTZX@R95VB MB.QD5VKD.&L]*5SLB^.<
M)8CY2F],Z1YDQ/J2)#HO-C:"*)'PN"C"8J()BXXF(C*"F+!@$@-=R0K:2WOJ
M#I;+#W"LT87!<A?*TPZ2%+*3</^]!/O;$A+@2D2 -Z'>7@2X>Q+@Y8>?MX]@
M& ^" ]P(\;,A-=*.MI)@YIMC.*%<RW TYT8BN;Z0!I=KX'HS#Z_4<^UX*2,=
MT506>9*5ZDJ(_S[\//83XN,HQSY$H,<>F=]!L/=6POR^(5IL86+4?N+"=XG^
MMV%AJIP+)UHXM5+#XGBI/$L5J8D^^'@<PMWE(!YNPC'<; 37N:.2=E)GA0H7
MCJ.H)!E=?B*F*IVU<->$Z-BEN6E.'CW,]8L7N:-$(MZZPZ,[(@]N\^C>=6M^
MT\O'UCDW/<RY5@/'$ATY[/XNA^V?9<WQ69:#WF4J:Q_FQF@,HP64K(G./=5,
MU>4.:F[UTW1?22\Q0^.#.9KO+=!R?PGSW07JKH]C/-M#\9$6\E?KT4WJ*>[+
M%%L<25NY$R.)G[+B^#O..3S#^L$_T+/O32Y59,#Z&%PX##?.\>UMT15*P;$'
M=T4>%QV[J3B*CXL^G1=].=0A8[9">*B6LC(-%959E!O32!=^G)4=3+8FQ)J'
MV-=C+P&>!PCR.D"HWWZRTWV8&BWER&HE9T]5<^.JF=&A="K*_44O!!$;Y8*?
MEQU^GD[X>-H1X&U#;*@#-871TG^#R8_;C2GK &/-P1R?2*.IU)XZO0/=YG J
MRWQ(E_X>'KB;J  [HOV=B9:^%2/</"K8G0B1L!!O0H)%@KP(#WDL$:%^5BX1
M%QM%3$PXT='!Q$3YD13CBR;1#W6<#QG1OJ1&!9,>'TU:@N #A9/'QQ G\[&)
MB21^YR!."A<N*9(:2;HJVOJC<[HJ@?3D!)E7D9&>2F9&FK40NU:3@2Y;35YV
M)EIM.IH<6:=-)EN72FY^.MFY:<(AM.B*BB@L5=)8%J,OST=?EH/1H*.R7$>%
M/HOJ<C7UE1G6'.Z=7:(;YLNDSS7!I5IN3*4Q5V3#:.HNAI(/,)SMP[!LV]-0
M*+JF (O@&DM#%C6E<<0%["+"?0MI83:498=37YXA&#%'=)J:4L%)^N)TC,8<
M#$8MI65JBN5[44D&N3JE>%\D,8)_4C.2J315TFQN$6S6Q]3D%&NK:YPY)3;K
MTF7NWU;232A1N5>X=>6B]6WPD?$%P0BS=/9,T=8^(GJS7>Q8%2WZ0@:K2QFO
M+V>\H4*>>1V#;>URCT,T=4]AZEF@K&\5??]A2@</HQ]8HZ!OD8+^)9%E<GOF
M47=-D]DU@59$US%(<4L'E8W-]+6U,M?1PH+BC*XU,E-M%*Y=QYBYC?&>868G
MEEE<.L72Z@665LX+9CG#PO1Q&==K] K&;6@>H=C0@3K?3)*FGBA5-4&Q1MP#
M"K!W%Q[ND494?!$Y!;44Z:NIKFG"TM9)3Z]@H^X!X6*]8C?ZL%BZ:6QND3:K
ML/XHD*M36YW%N7FI%!6GRKA*1YWN373(;N("MU&1Y\E$5RJGEXH%XZ9S?#Z+
M&Z<,7#E1R?)D(2,].JZ<G^#APU,\$)NOR/T'I[AT7K"4V*):O9)WW0=]ECOZ
M/"_!>LF</M7+G1MK/+Q]7H#&+<$<,MY%4(H,/KPA<EF6*^O.P=T3<&V>6X?-
M'.M/9[3"F0G#7H:+-M.5^Z78'U_.+I5Q[\8TWSXX(SCFAES+7<$U@FFL?U9W
MY+^3?_W\ZT+Y9PUC5AS$RO3_[R3^_^GSG8-8<0K_6R?QG3M*X;H[\ETI3*'D
M)Q9P>>LVMV_=X_K5VUR\<)7+EQ^#VC.GSUM!L%)=>G'AN #Y4\PMG+*FEJAO
M$K+1-LS B)(#;HV*ZG8T6@&159UH\VK)5%=2JN1BD?ER8XN ^W4!^8>MH+ZQ
MN5^41[V0R![K\6KKNVEHZI7CGV!H>(YN(99=7:-B9!0'<2N-C1WT]2GYBP=H
M;!#2.KG X?43G#A^AI-*_K?+ D!OW.+\N0O6-!,7+UWB]MT[<B_G65]9$J(Q
MS=KZ,A<NGN;> Z7*\P-NW+K%Z;-GN'7[G@#ZAYR2>SU[_A*GSIYC<765@?$1
M2IM,!&7%LSG$EH_##K(SQQ_WAA3\VC1X-Z7A;4KFJVA[GMGU#A^Y;V57K",.
MN8&XF*+QL:00W*DF2H"<:WHP^_V<"8Z)(2^WA(::5MI:>Z0=IUDY?HQ3MR]B
M&C836)" DS82Y\)8W,H2<!% %M:B)::[@."6+.)ZBT@;-)#674J428-G9H35
M^>P9'4*D2HR0.HM,C5;:/EO(IQ*=F"M**!]-81Y)>1E$Y"02J(LA4([M;8C#
MN3P2.T,H-E4A'*@.9J_)GSTF/Q$?=E2XL]ODR;YJ;_96>K"OPH,#E5[8R#I;
MD8,5GNS0.[&YV)[/"FWXN& _'^7N8J/V&S[7[N ;W7YL\NUPU3K@%+&'0VZ;
MV&/S,?N<O\+&>SMVOKO8[[:5K_=_S"=;WN'SS>_SY98-,OV0#S]_D\T[-G#(
M\2M<W#>Q;?N+;-OV!U3)+F)LW F)<< WQ@F'T$/L\=G%=K=OK,[B_3[[< RV
MQS/*#7<1VQ [#@4>PC'0%J]@1]S]#N'I=X" 4 $*T8Y$1]D)6-U/8L1>HH.^
M(M#]+;SMGL&0]36G)J.9[W!GJ-Z.WEI[1MM]Z#4[8RC:1)#_$]@[_E"N[T?8
M>OR,0Y[_C&O(OY":MX')^416%C4"6M\EW/YG:#Q_27?V>[2EO4*Q[T^)V_7G
MU,6]S72%'7.U#G3F;:0C[UWFZK=R>LB#A38GC&D;\=WW"URV_XPPE^<)]7B:
MY- 7,&2^RTS=#H8+/Z ^]K<,Y[_#6OUFUALW8<Z0[^6ORC%V<G[,AB[#%VAB
MWD<598,F,Y&LW")KTGR_<+4UNC<ZJ0I51J.,58L8&PO.+L'LW"X@(,2-+HN.
MQ1DC ]VI3 ZGT5#E+F#Y#3)C-Y 5M8$,_W>I3/D&2]X!NH2(#!B=:9=^4):R
MG7#7=TA4''2Y$41&*6D]@DE(BD<E($F5'$5LM(< PLTD!W^"+NI]M,$ODQ_Q
M-LVYNSD^'"OM?9#RS#?)B?T#.=%O4Y>WGZ4^%3.]"0Q8PF@5DJ:\2J9+\2$_
M/9J8\#!"0Y17&9,)CQ0B$A$B)"20N!A_(@6H>[D?8,?V+]BS:S.^[C9D)010
MK8NEL3B:XC0G8KPV$._U-O--H?3K;2F->P=#QGOD);Y#3O)6 4=IY&9ER3UH
M2<DRH"XTDZYK)2K%1$1R)<&)Y?C%%9*D+24S.X.T>%<,&J4]G.@HW$NRZ^_8
M_]&?\]7;?RF@]!,R$NV%5'C0(N379,A %>-&6JQ".B,HTXG>D#[O8_LI"5[;
M2?7;C3;2@>)D;XRI_A1%VZ'VV83*Y1TRO%XG3YY):<P[=.JV,5_KR$JC.^V:
M'32KMC)5[LQHR6XZM)]1D_(AAI2O2 _;A)?M!CR<]TE[Q5*LKZ+,4(NYI8_A
MD64AY.-DJ^OQ]\WDH&V($)TD2G.RR LZ0*[K1U2'?\79O@SJTW>S_[7_QNO?
M^S/<7_DGRNR>)W?'3VD->)W.J(](^N97Q.Q\GNA#GQ!X: ^1WL'2?U((]$O&
MTS,.+^\80H-BB \+0A6PGU3W=S!&O$5]]$L8?7].^K[_3+'7#Q@MWL!JRV[:
M\C\@U>NGY(<]AR[H!5*<?D_@-S\CT>5-BA,/DA6]#U703E*%T)6FN])3'<ET
M>P(]HLLZC=)VF0?PVO4T>S?\"/]]+PF9]"?4[E4^>?$_L^W-[^&U^2>H[)\A
MU_LU\@+>(M[Q>1R__!'>NW^/ZXXGV?GQ/^*RX\>D!+Q(3=8F*E(^EFV>X-#[
M_P>^W_RCS#^))D#&=^P'5&5^)81[-^826^G'V]%&;:0D\3/R(]\GW>L%8@[]
MBJ+0MZA*_(+( [_'Y?-_(FC7+ZE+^Y(,[^>(E/6%D1OQW_T$>S_\[SAN_CF[
M-GR?71_\+<Z;?HS7ME_BO^LWA!YZEI*D'12I]N-M^RXO__ZO>?I7?\GG[SV#
M_:X-'/SJCVQY_<>X?/4$"<XO2=N]09;_TZ1[_X:<L.?IK=A#0>Q[^.W_#;J$
MKV@H=L92%4"],8S&*@V=+?5"UL9965YB=7V1^?E)9J?'F![I9[1# &U9%I;"
M!$:5*!7IMTW9$;06J"A019 6%R$Z)Y/*ZF9:N\1N]\W1VC:!I76"-LLT=8T3
M5#=.4M,\157S.'6M([0+,)Y4"O8,UC+27LQ 4S[#YB)&VTKI:RFAPUQ,4WT1
MY>6Y@AUTE!J--)@[:6CIIZYYD$;S,*WMX[1UC-'2VD=M7;-@AUHZ6FMIJA/P
M6YE)@RF5$;&E"Z/E+ L1/3YKY.AD,8L#&E9'<UF3^:6Q,B$:N?2UZAAJ+Z&K
M28A2;3YU0G[RE;QP&?%DJ472PVDUI;,^K.?TF)Y3?24<:RWB:%T!QZI+6"D7
M J/-H#8YFJ*8(/)B M#%!9(KHHGU)S/!CU25#VG9_I@'"Y@^:V'Y9C^KMT=8
MOS/!X;MS'+V_RM$'AUF[?YC9FTL,7YJA\^0H#2O]5,YT43;<2D%[-=EU9>16
MEU/;T<K4TA)G+UWAK(+?! \=/R%$9F6-R=E9!D='Z.SMP=S91EU+$Z;Z6GH&
M^YA;6F!Y?969I7E&IB?H'1VB:VB KH%^NOKZ:;5T8&ZVT-+<AL7<05=[#]U=
MO=36U IYJ:+>W&!-*6'I;Z.IMX6:CGHJ+=48S548FV5]5S-MPUU8E%R5PP-T
MCXZ*C-$]/$K/P A]@]*OII>MCEM%YF;76)@]S(ECBM/X"L>.7Q!,=I+9^:-6
M![$2/=S;/VT5!4\J4<1*[F(EY802U*"DE%"<PHIS6$DQH<PK=2U6Y1B* UEQ
M #^.'G[L&%8<OPL+2MV*,YP[=XW3IR];MU$BC95ME()XRC;6:Y/ME6VM4<6'
M3PIF76=U[9A@SNM<OR&X^M9=D3M<O79+,/15.=Z%?TTUH<S?N:.\R:>D>E.<
MO0I.5YS$BD?X,?]Y^)TSV+I2 ?+*O+)$>17SL?QK)/%]6:>D%;[WR!KU>_?1
M39$KW'MT@;OW3W+CZA*G5[J9Z]'3515O+:QDS',3(NA/=X.*J?YBCBPT<?G\
M*/?OK<O)SO/M?:5XT./4$_?OWN3^_>M\^^B2K#O#D>5F&BNC:#9&T*0/H+;0
M@TJ=$]V-42R,Y;,X96!ML9%31WNY>7F.ZQ<7A/BO<O^.W/>M2]RX=E6N2=I(
MY([,W[]Q4J;SG#G1POB8Z)&V2(P5@61I_4A)\T.=%4F)/A.#,0^3J9CZFE+J
MJDNE+U;1V=E(L[F2NOI2Z8<%U%=H1=_G")G/9K4XGI-J+XZ'?LW8KJ?HV?Q3
MS%M^2LG.7U,4]27%@G4+1C1HYXO(6J\@]VP3^MM=&!_V8[C?2_GM3O1796R=
MJT=]M!S58CY)XQJ2NI)(J!(\D^U,3H8C]9DNC*0Z,.ZUD='=S]'_Y;_0]JG@
MO7VO,Q%CSXKHJT49$^,#/0SW=-'7UB+ZI(:.>CVMU;FT*$7F+$4,]!H9&ZJQ
MYFD<ZZ]DJ*=$L%<>[685M<8@]+F.U);Y"O9)P%*GI:TNCYYF+>,]:E8GLCFW
MDL^-X\5<6,T5/::D)PO$I+.A)&TW^K0#5&L]:"R,H*5,1;LQG=:R..H*?"A-
M.TA-MBWM1>Z8<UWH*0MF5*F>7Q5-2X$';<6N'!Y(X_J:@>N'JUD>+J"F/)&,
M]! R%4EVHTKGPUI?)A?ZDSC7%L&B*8BJ=&]2HWR)BPHC)CI,L$8XD;&1A$1%
M$!P904A$&)'A@@F"W%$%[J<J80_CI:ZLMX;371DHN$Z)\MU-@/]!_/P=" QT
M(RS(EV _;_R]O01'^.'KXXV/CP>! =X$^#@1X6=+=K0#M5HO!H7/S+5$,=$8
MR&Q[!&>7"KEWN0GN6KAW5>YC*I7^5FF/JG"R!8_%!@D>\C^$O]M.O)V_QLMU
M,^[.@I6$GP3Z["4T4*[#>Y=<SR[R=4'T]6A97ZYD9<[ V$ QM15IPB/<\/>R
MQ\_3 4]W.WR][067NI"8Z(].EXC1F$6%V) 6Z;-#@^W,3(VPNCS+J1.'98R<
MY[[P<^NK"8]DC#^\:QU_C^Y<X^J9XYR;'^-L9Q47BL*L1>L6W5]CTND/C >^
MQZAF/^U-T52/Z"A?JJ+BN!GC^4XJKPW0<'^2YF_G,7^[2//=>:LTWIFE]L8X
M96>[*#S<1-%J';KQ0HJ[5&)'P^DJ<V9$\,J,PY,<L7^:HY[OL11GRZV^2E$/
M2W#K# _O7A*=<XT']V]:KU462-L*K[YQA8NGC[&D_. XW$-+2ZV,W2+!F3GH
MR[/1&Y0(V%C2,H.(B?,@(-"&\#!G$F.]28SQ1),>2)4AD:&!(B;&"IF=*F1U
MJ9SVUF0*\GQ)37*7?N D?<"9('GV_E[.1 M?R4L/P)3KASYI-ZD^;U*MWL9,
M6R!G9M+I;?"EN<*;ALI@,M.<Y7PV^/O;$N3G)L]6^H^O!V'!OO*L? @.D;X5
MZF.5H% OJZ,_+-25L!!WX44^1(4%$!T13%2$7']T\..(XM@08B("A(?XDQ"E
MI*((1Q4?)M/'1>X29#X^,8:$Q&C!_6%HI#]H$KQ0)WJ1D2PX(#64]%19EYI
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M*4[>NW$3D. 9ZBCBA)NO/9Y^CKAXR3&V?<2VW1_CX;M'#(P_NW>_P1MO_$B
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M:,ZS(\'C;5R^>9) ^U<)=W^?0*=WL-OV/!M?^7L^?^N?\;'[@$B?;X@*/"@
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M\P M9B]L6B<B/5\7 KV5HAP7"K(\.+SK5;9\^B*! 2?(%5TI*R\3_]@LH'J
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M]Q97KEW_CS)<"JY;/W/!(:,CDW1V](HOZ:2U17!:;3-5MGKQ)XT,]8TQ,[7
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MXK7*WYV[@C65\A0;EQS9=DJ06*E-_$T=8@6C*_)-*3A'T%<^=S1J$?F/(+&
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M2O+$/?G\GA"H^T+(E80'D2_DNXK(%QU!805+"6.Z+^_ORGLEDUA9KD2=OQ2
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M&<9')^B2.5%?VT)%>37IRLW'B&C"$F))S<M$6ZS%5)R/R92+R9A+L5DKW,N
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M^.IQ\<S%/SB/^*0<,C/BQ&FX$Q+X&=LV_YH=FW](@,<OJ"IYB\FN'2SV[&/
M^CGFA!=)//5+0@_^G)#COR/,^T,B8TZ2FIM,2IZ>D'@]?A&%!$:;B4RI)#RY
M$O^82ER#*CCB7L I'P-AD4:BHM3X>'C@=F(;E>9XNINS::J.%S =2%]K)K.#
M1@$OKJ1%[20S;C=Y&<ZDQ+D2&^E/GCJ' H.9<FLSO8.KV!OGR=2VXQ]9C'M
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M$[G=!@+4,00E1Y&O+:%<IZ>VQDQ[>P\+"J$Z<Y8+ER]Q4\D.D;_CUT^@::W
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MC;JR!)KTR;16)M)3G<20*8-ABYK!AESLYCSLS3K:&RHQ&XJH*<^D-"^*0G4
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MW*MB]P&US,MS"2YR!*Z2,LO(*]!249Q'<H@S.S]^@==^\)\(W/XT0_4'.2<
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M ';#N"8.X1SWQT!Q1!<[0]O9'B(2U,Z.P#9VAW2Q/Z+7D4'LR"*.&\0[=82
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M(_Y [/[T%!/2)GM::F@QEV"K*Z#+4B0VNYI5L>G+PE7ZA;?8C*$T5(7*\XC
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M]]O_0/SNYU&[_8)\GV?)]?D)2<[21CR>DNMXCY(H 2K2MO9\]@)>NS\D,SZ
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MTH*=_CZCZ(12[B0:34DX=:9,QB::N'KCA"-#Z-:M->[>&./^A1;N+I9PS1S
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M8>S9_AL\G-_#9?>[[-WX#FF1'C08"VFU5A$4> "G_9^S>_O;O/3\7_/.[WZ
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M'CO)V7,7!82+HQ;0?OKT!5973W#]VAW'CP_*1PF4*Z-CV_L&,;=8"4J)84N
M"_M3@O#2)N"M3V)?40CKHO?P8=A6ODDYP":5&]ORO=A3&H";*0Z_YG0"3:FX
M9 4(Z/,A6,AN:F$F6J..IDX;TXNSS!]9Q#K6*=L$\[48^2V%_NRJ"N6 .1K7
MEB1\N]*)F2@F?J8,KZY,UA6Y\4;B%C[/.L!VK1][JD/97AO*CH9(]K7%X]Z=
M)OMD$"2$--"8R!?^6_A@YZ=L=]Z.FY<+(2$!),;'D9V515YA'GE*EFY%L8#F
M8K)U^0(0,O NBF!KKB=?YAUDO<:=S6+H]UC"V&T.9J<I@'U-83A9PSE@#6-/
M<PB[6^2[MG!V26/>TAC 5^)H/JLXP'J]"UMJO=C=&,A6LR^;Z[W9WN@CXB77
MZ\D.BR=[&_S8K60=E[BQ*\N5/0FN.$5[X!T72&1F',GY:0+:(XG(B"0N+YZ8
MO#@BLZ,(S0@A+#6 H&1O_%,]",B7:9D?7A4^["]S8W>%&WMJO'!J#,*I.5BN
M5<06*!(@XL>!9A\.-'AQP.(MS]H7IVHO7+5>^&;[$9#J2W"B/Z'QP80GA!.7
M$D=6MCC'TB(AR"44E!4*2=904JI%4RC/+3-+G',:F5EIY.1FDJ-.1I4:169B
M$,DQ;H0';,%MUUOX[?P=<0?>),OM3>(V_X2X#?],F=^+U"2\3KWJ7>IRWZ,T
M[?=49/X!FV8#*N>G"?G@?Q+UX=^3\<U/T+J\1GW49[3E[Z9#YTQ=X38\=_V(
MY/!W&.Q*)5?MB;_O5ISVK6??MG6X[_X*[[U?L^GCW^"R^5U2_#=3$+&5PM O
MT81_@CE["T4Q[Y$;_0<&Q3#7E>PA(_Q-LD-_(]]]P)CA<P[5O\>JY2T6:UYG
MI.Q5[$6_P:Y]FV'#%]B*/\=2L!6KUI>:/"^,1=X",D*9',S!; @ET.MC@GV^
M)CW>BXJB+"JU132:S0+JNB@I+R4[-YW8&#\^_N!EG':O0U<81Z^UF*7A"B8[
M5>0D["0A8C]Q,:&$1\;A$QB'AW\B05'9!(6FLG^_#Q^\_P7^ 9%B*TK)RBFD
MJ*R*LDHC964EZ$I2J=-%8:L*1I^UF63W7Q#XU=^B#WR1EKC?TAS]6WKS-V)*
M_)A,IV?(VO,C6A,_Y)C9AQ'-7K2!;Q&^[4?$NSY#8=P[6*L.L#2NQB"Z&NCZ
M-F%"$+:\]V.^?/WOB'-[C::B[?16[* TY$52]GZ7-.>GT"=]@T'M06U)"I9:
M(SI=#5J=!:/%3M?089J[ILDM,CE*@B0F%5$H]K*B5$=60A"^>]XA:,_+1#L_
M1Z;H2672.[26;*&GRAFC>C.-Q4XT%+D0ZO0K\N+6R3.+Y/8I/5UU[J0&_X["
MY"^)#U1JJ@FARPO!6E= >U,EYAH-+4U5--674)H;1G[\#C1Q7U"=^3GYT;^B
M/.-UVFLVH8I\#;?-3[+CDW\BTNL=<L7N:#*V49;QM0#CS;25[:0\[GVB]OP,
MIP_^"F?1U8#U_TKBSN?(VO<K8C<^PY[?_CW/__43>&U\@XI49YP_^ZFCWN_N
M+WY-4D0@99HRFIHZ&!B<8')F&7O_+*6E-HJ+S!1FZ\B,32)H_RY</O\=!]__
M&5$;GR-]Y_-D;/\9V7M_3KJ<.W[74V1ZOTVR[Q=$^^^DM#!+"$(%125&:@5L
MMO<>IL5^F,RB)@+CRAP#'GJ&Y1&75H8J6TM8:!3K/_^$%Y]^DJ?^]<]YZ^F_
M9,.K?\>VW_XMI5$;:2[T(>3 .T3Z;2))P'E4E#<??/0F[_[A#8*"/4D6H)Z2
M[$)"M( MU7:*XC_$9\OW>.V'_XGO_;<G>/GOGZ#8^P5J0IXB9OW_"]^/_S.%
M 2_07;:)#-^?D^#Q([*C7Z4T^W/B0M_!==_KTFYVD9.9@JFF5OQLN_BN&4Z>
M/L75JY>YI]0,?71+O)22F713_/3CH(Y2=]51*NK1?0%"]U%&]G5TLWJH=,52
MMGF<3>SXQ5W!3K*W PTX9I2(EY(]*$C[P7F^O7O:,1#6S0L+K,YV,M19Q7!'
M!?-#-1P:,=*OE(MI56H$Y\E\.NVU2E?#!%J,:>AR@RC)\L56G<APLXH!<RKF
MHB!JB\+$1D1351A+16X,==HTNBTE=)ORZ:Q5.[*,[8W%3/>:6)WN8JS;0EU9
M-ODI89A*,[&(;S(6Q%$C^[<:5&*S9-_Z7(9;M4QT5])>IZ;3DD]7LP9SM4K(
MCH8A(>FKRU.,CPW0WFJEN:$>H[Z,LB(U);E)6*KSZ&DNI5^.,=Y3R6A7.5V-
MRC&*Z6XIH[>CFM'!9A;GASA^_) CRW%Z8IAA>SMC]E9&.LT,M.IE/P-M=?GH
MY?H,17%4Y4=2E1M"37&$8X"H.ET, ^V%S/:5L=1;RGRG@&NK/!M+"CWF9";Z
M-2S-F5B<:Z#+IL&@24*KBJ(B/XG*HG1*\E+(S4DE/5/(6%(TJ:DQI*=$"T&,
M$KN?3'-C+2LK2QP]<8SCHB>GSY_CLNC*[3NW1"?N\T" W)U[=[E^\R97KMQP
MU-,=5@:&ZQT2_>JBP6*EKL9$9;F>,FTYE95B)QRVNIW>_E[ZA_OI%>F1^?;N
M#JP=+32U66GJL&)I;Z3&5H>^R4"5U8"AM8;"6@WJREQRJ_(I,9516J>CK%8G
M6,I"2V<K+1UM6-ML-+78L#0W4R/OQ=!@HKI1KL%BP-A23WV7K.^08W<V8>Z3
M?29ZL8YVTS3<2>MD+[:Q'IH&.['86^3<-1B;Z^@;'^#"=66\"6D'HOL/E8"9
MZ/9#T?O[#^YS7YZ#(\-8%/_!'W]0^2/4_?^P]Y=1DJU)>BY8&FGI:FY++;6D
M[M)TE[JZBT_1J3H%A^HP0S)'9@93!C,S,S.'!WF$![A[,#,S8T8D,S.</,_8
M]JS2E6;-GUFK?UV-9UIL9OO,WM>V;?L,]^?2E:M<O'0%I5/C<^<O&<9OWKIC
MR 16RD4HV<1*.0DEZUCY*36,;]]Y9 @$*UG#*ZM;+"RN&8+ ?PD:*_.53&.E
M)(4R5.H2*\%C96B0<Y?_W-'>#</7;5>OWF1]?5/V<48PZGU#FU9^2K#;D!DM
MY_]<+D"I3?RMTF85HO3T,H]O+G%SNYL+\T+:>D2G&MP94]N(OS:F._^HX(8C
MC)9;,ZUQ,@2.IS1FS.HL6>[TX,J:BB=W)L4V7!2YQS?/'O/DL=+S^,O/XPT=
MY(EMN'_WM.#B 1KJ$LG)<A-_Y46'D,65I6:N7AKBVJ4>[EUHX?Y, 1LI1BQZ
MO,.\W1\8M7B-0;OWZ?,]1GN<#[J,6)J*LQ@4O1AI5#/=K6=[88R[5W=X\?@F
MWSRYR_/']WGZX!Z/[MSAVH7+;*YL,C4^*[QAE(:F'O(K]$2DE.,;62IV74U(
M8A,1:>U$9W:26#! =L6,Z-T&ZI9SJ)JVR:Q=(K%\EH32.1*5+#+E<^.<&2+2
MIXC*F" \>9B@N%Z\HSMQB>G"+K87FU@A[G&#G(H;EN$H=O'C."1.XI BDCHF
MN'WX92 YM1_'E %<4X;P31D5?#I"4,H@01E]A.3T$UXP1'#N$"%YXT04S1D^
M;8XL7B"V?)E4S1KI=2NDU,JT>HK HCY<DQNP$C_E&%9$0'*U8%\M^37]-'3.
MTCFX).UPD>F9=2Z=O\XCT4>>/!5Y*'KP@!?/9*C4KG[V2);=XL;%'3:7IIB?
M&&1V;("YL5X9[V)VO)ENL:%-FC1T%4G4%L=3F1M+26:LX()80["X(B>8FCQO
M=(6.Z/--J4H1G):TC\I4(ZHS32E/.TE)LA&EJ<>IS#HAMMD8?9$)G:5FC%99
ML*JWXGS322YK][.C_HS9_ ^85^WA4J<SE_J#V>D-9[$EB'[!Z_T5+C(>R=5I
M%=>FU:QVY3)0'84NQQ.U8(?JA%/4)=O3+EA_7A_%F;X4D42F:GT9D>W'A6\L
M-C@R7VO*=.5>9LL_9+GF4Y8T>Q@J.80N5<X]?A>5V<?HU+DS.QS+QG0:6Y.I
MS/='T:/UI+'"D:(T$\)]!+NZ"7;R/41JG)7,4S"7%<VIQVB-.T!]X"Y4#I]3
M8?DAD[X'N)=BSAFWCU@T^2V+9G_D<M@)[I5'\V2PGN?KX[RXJG1@=UKT^1S/
M']WDQ2.QRP^?<$-LP];J-@MSZXR.+@J_G:2J;@!MQZ*A3$3'Q!4:1RY0/[A#
MW< .#0-GT Z>E7GGZ)F]QL#"#?J4\A(+UQA:E*$B,MT_=9GNL8NT#5^D<> \
M]3WGJ.S<IK1]BZ+6#?+U:^34KY*M629#O4A:U2*I%<LDJE:(+UTENF3%4+<U
M.'^!@)PY?#)>!H@]DJ;PB!O#(W84]YA17*-'<8X9P3%^"/OD09Q$Y]W31_#+
MFB0P:XJ0K!G"LN9?2N:\<+=Y@C/F"$R?Q3]M&K^4*8)2I0UFBN[G+9*B6B*W
M=I6JMM,T]>\(1MYF>'*3R>D-Y@0?KJYO,[>\RLCT-#TC@^)'Q(<TUZ,7'U-;
MD2&^,I+B#&\RXVW)CK= E6I+<;#HJN]!!@(/,N?P-EM6O^*\[2]8M_TY<S8_
M8<KFA\P[_)AE[U\S'_(Z.L]?,55\A,=+L=R8"6&MVXYAS6%ZRO?04?(5C?GR
MW),_H"SI(VD'GXA\1$GB1Q3&?TU1LIDA.SW4WT)PI2/^_BX$^+D2XN=&:( K
MH4'NA(9XR="5J& E*]B:BI13Z+)M:,DRHUTX64^.,6.EUJQI/3C3XL-.HS?K
M>G]Z2MPIBK4E(\J.E,A3)(NDQ-B3%'.*Q!A;4A/L295VDI%L2VF6+6UE-HQK
M+*1M'*6_[ @=I4?0%^Y'7WP ?>DAM"5'J"\RHJ[H) V"Y1O5%C3*^MH:<QKK
M; 1[VE(IHNT/I&$Z&M54%.GCT21.Q9,TET;2="KQH\E$]R<2V9-"9%<*$>V)
MA.HB":L.($;E26:1"S7EWG1K@ABH\J>OU)>>PD#Z2Q/D?N;16E$AR^LH5>DH
M*FM&5=-%0_LD':,;],Z<HU6>OVYP$^W0%HVC9V3Z#%WC.XS.7V#E] TN77_(
MO<<ON/<,+@D<GCI]GR;1^](VT7'=.EEUZZ15KY)D> $B^E6V1+)J\:4HTY5B
M?ZO62%,KP>1U4I1@L;2!V))EPA7=SYS%2VR]LV+[(P>Q">W'*F0 R^ !+((&
ML Z6>2&#V(8-XBAMP35A K?D23Q%M[W21=*F\!0==T^:E&5*J8EQ[,-'L)'M
MS?Q[,?;IXJ1W%Z;>/5CX]6$1T(]I@(S+<4[%#N.2/()7QB0!V;.$2CN,R%T@
M*F^)Z()E\6,+Y-7,T=@^RQG!"]_>V(#+_7P[F<N5,@=& SYA*F*OH>S'6G,\
M"[TY3 P5T3]21'-O!M6-D914>Z/2!Y#?%DJ"B&^].ZY5UKB4',<A<S_^.2<I
MU85S6;#!"RX+#KK&XX=7! ?L<.?F"C>O+'+OQA:/[U[B^<.KO!#>P+-M\44+
MW#PK>'8XCH%Z)^KSQ#^D[!,NO)_&W -T2?L:JCS)5(,-\\V.++4YL2D^8:W)
MFJF*0PSF?4:;\%!]PGNB,R9,Z/R8;(\5CA#._' 9]Z[-"TZX+-CGG@ CX3>&
M3NH4SO,R4*Q\+?:7I("_B/(5EO)/I@QXZE_B][]-D%CY*?,?"RA\\."1H=,,
MI3[QTR?/>2C ^,[MAP)>[W#YT@VN"A@^?_XJ"V*P:ZI;J:WMHJUCG((BC:',
MQ 5IJ5<N/V9J8A.];H"V]C%#!G&-K-?3-TN-IM/0$9VFMH?:NCXJU5T4E;10
M4=5M*"^1D:4QU"M6E7>@KATBIZ"%C&P=):I.&G3C-+5,H=0OKJSNEFT[#9W;
MU=0JI2;Z:)5CC4^M&]X\SLUNB6PR.C+'X."D@.X= S W=#(BP/SVW0="$ 3X
M/WK&^8O7V#E[D8=RO0KV?_ST&3>$&"RMK!MZS:YJTN*?&8=EK"]VN1&X:U+P
M;$S#3@#,KE@;/@XXSIXH<PXGVF*2Y<(IE3]NNE@"VC,(D?6L(AVQ];<3 !I,
M<FXJ)6J5D*MVUL\)B;AX&NUX)Q8)GNR+/L6Q7 ].JKPQKPW"IBD"^[9H//J3
M\1W)Q',P@WUB=-^--F)WLA5'<IPX7NK)L6H?3N@#,6T+P[I#R2B.PZLC"1]M
M/ >#3?G<>@^'K8]@86^*A[<+D5%A)"3$$I^20$QZ(O&Y*23DIXJ33I+K#,=9
MR*U5@3?'\UTP*G;!N-(3\SI?CJO=.%+NA$F=-V9:;TRT7IS4>7&LP8.C(B>;
M?#!N]L5(P-;^2CN.J!TY7N/"<8T+!\I/L;_"EF/UCB)V'*VUYDB-)48:&XY7
MV&!48(E9IBU6XN1LHNQQC'+%.]Z/@)0@W)5:Q1$NN$6[XA+M@G.$(RYA=OA$
M.>$=Y8!'C)T88GN\\ESP4'G@5.&.=84SYE5.6-2Z8EKK@DF]"^8Z-RR;W;%J
M$6F2<9VL(P;,HLX9JRIG'$O=\2GPPSO%"Y]83_QB?/ *\R0@TI_8U!C2\M-)
ME'L5GAI-=&H<"4GB+&-BQ-D'$1+@0W"(+[%QH41%>!,1X$ABA!N![J98&7W"
MH4]_R:'WOX_E%_]$L #))+O72;7_'7'6KU 9\R4=*DMQF);BL(UH$.DJMZ#4
M[WW"=OT]CJ]]A[ /_X:$K[]'S-Y_I,CM3>H3OJ8A8R_Q;K^D).$SIGM"T(O!
MCX\\@8W9NQCM_@WF!]_ \>2'F.SY'28R[7SB'3("3I ;>I+\"&.T15ZHTD]1
MD&1!6UTPM:6.,KZ7_)AW:<AZGX&R]Y@H_QTSY:\R7O(JO;F_I[]0C';A!P)F
MWJ(SYU.TR5]2$/ 9Y=''J$XS0Y-OR6!K" T57D0%'2<CT1.=IICQ(>63YI<U
MP^L;!ZAM[$&C;4%55DIHL#<Y:5$,ME>S/=?&Y85:ECKC*8PY0GS $=F/+>$A
MG@0%^>/IXX^=DSN.3IYX>OC+O$C2LXJIJ&FFKKF/&GT?5?4=8AOJ*2W((#_)
MAW2YWD2OCTAR^2TY;C^G+?9MNF+?I#7BCVPWNS!9846)UQN4N?R:EN!WF<@\
MPJ3H8U/\43(\WB?0ZE5\;'Y';-!N&NMC*"\-)RG>@\SD0#P=CN!@]CY%*<?%
M"8<*X?8AV_TW^!W\6^)M?\N VH^Z/#]4.3'HZG3D%6A(S=904-E%8\\RM:W3
M),ET>$P!(1$Y1,<54EQ41;;H5YC'<6*\=N-G^1N<COP]J;YO4)-^@)822[1R
M?A6I)J0$[L'NZ,_)CSO*^G@:EU:+Z:KS(#7\:Z+]O\+;^2L"?<TH+4FEL;&.
M]HY.FEL[J:_34UM=@[ZFE'(!U7GR_'*COR8QZ'4R8]^ENN@(V;$'"'3ZA%,G
M_X2?QTG1:V>Y;C=*<Y4.O)Q0)1M3'GN(!,<_XK3[OV#YR;_%[]CWR/5\AYKP
M?<28_Y%#O_MK?O-WW\'?>A>UN7Z8[?XY^S[X9^S-=E-57DFUIEV : ^MW5,,
M39T6 KQ*5F$[D?$51,<4DY-22DZL % ':QP^?XUXT_=(-7V#X"_^D>B#/R#6
MZ(>$'O\!7D=_@H?IVP1[F%&<ET5A026)J95DR[Y*JD9$1HG/;,0OJ@JWX!(\
M0PN)B"\E);6$N)@4C X?YK5?_(@__.R[?/"+O^;X.W]'F/D?J$LRHSG'@12?
M7>3&6E"1+\^R( @3HW<YM.\/),?;4YSO2GF1'15Y)ZG)WD>U$(>\T->QW?=]
M]KWY78P_^._D>_Z&FN!72;/Y!\S?^0Y)SK^FK](*YZ-_B^W!OR'&YX]4YA^F
M)->(+*7W[,)PVAK5S,],&FK+_J7&JB&<I=3:4CIB4(+#*$-!R-\(^#'$@+\1
M&/181 DB/Q"1X0M!SR^48++2D8.L:\A%?)F1J+P,-<R2;17G]^USI7[7(UGW
MS]M]>X>'=\YP^>P<EW<FN7AZA(V%5OI:\QCNS&.JKTC:>P9M-4J0.(Z1MGS:
M&]+15L717!/'TF 1I\=+&6U,H$L39RA'T5"62$UA(IJB%+3E&6@*8J@OB:&]
M-HVFZF2Q15GT-I?2VE!,8TV![*> OI8*NG5%LGTJ^K(X^K19C+45";F)I;DZ
MC9ZF8IIJ,FBHDF/7Y-+:6,[T9"\[.ZM<O'C>$'!;6=E@?FZ)\9%QNMI:J*LL
MHDM?P7BWALE>-=-]:D8[RN4XQ7*\*@:[ZAD=;&5]=9J+EW:X<OT*VV?.&.J
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M$4R@=)BK\ OE!?9M0Q+*R\[G9-ZSJS)8X?ZU;G;FLQAN<A+>MU?:RX=D!G^
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MG@1YN^'O[8*/KY.(/&=_6Z*#;$D(L<71]'/VO/]3=K_]C^Q]X[]P_-V_P?W
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M)!21%)>.DY78T@_?YLLW?\I'O_H/6'S^WVD2>]2:8TUKG@TSC2%,M4;3KX]
M6^9)M/]NXH+WT-G@SV1?)-/]P8PT.="J$L"=\B>*(G^'*O$3:4=[:<C<3Y.0
MCC9IIS41?\+ZLW]+E.A(>ZDM42ZO<_##?\\7;_\[TF)WT]\1SNG56NY<F^>;
MQ]?%22L!H)>?FC]]JM3=>FH 109P]/S>2WEV'Y0:HN*_E<" H8?@YP*@E'(4
MSR[(]C*N?)KU3/D\2PGT*)U$W'X)ZI1@@A* 4CK.4MZ0OA!X)<=\\4) EY)]
M; @8*T#L98#HF\<7N79QCN'^:L:':IB;T#+2K6*PK9#13A7+8PV<7>_A]$H[
M8]U%+ X5LC-=RMF9,F:Z\\3FY#+<7BI217-U/@4I8>3$^U&>'2[3Z>@J1!?S
MH\A)"2([-8Q67;G<CW'6%_I9G&AELE=#9VT6+16)-)1$BV[XH%$ETMU2;@@.
M:]1Y-#=5LS _R<[.%A<N*!V+7>72U9N<O7"-Y94SK*^=96YF@19=O>$E28NF
MD&ZMV$&=(J5B#]6,];4R.SDDV&&6]<UUSEV\Q-6;=UD7[# SM\K$^)(L7V)I
M:H[%\1&&._4LC7=Q=GF(@98R^G1%]-874)869/B$N[LQEZF!2IHJHE%G>#&N
M3Z=/G4!K:32]#9D,=JEH:2DB)R^"[*Q(<C.BR4J.I#@[@1*1[.0(LE)CR,M*
M%+N60;N^G-FQ5LYO37'SRB;7KVYS]OPZ&V?66#N[:7@!O277?^;,-A>4[.)S
M.YP^O<GJZBH+"TM,3BE]08S0UMXM]K<3?6,KU35*IUTE(L72QAN8FYN5^W?.
ML(]MV79S<X/5M36FYV<8&A^F9["7QO9&ZIKKJ&MOH,O0"6\7E9VU5'1IJ!W4
MTC+=3OML)VU3@M5&6M#VZJAIT5 NQ+Y(74)!53'%-2K*=6JJFC54M]=3VZVC
MMD=OD/J^1G1#[6A%*KL:T/0WH1^3_<WTRWX':)GJE65M-/0W4]U61UE#!5/+
MT]QZ<,L0)%9*3CS[1BF_\C(0K(@R_N290BZ5X+$T"R5X_(W,DW:@!(C/7[C$
MXR?/9/H9-V[>,>#%A<550X*!DD6L!(F5C.#;=QX8,I(?/GIJ*">AE))0Z@\K
M^'%Z>L$0)%;J#Z]O[!B"Q(\>*\=!<.A5PS)%E'W=NOW 4#9@:_,L5R[?%*S]
MPA PWMD^_^>D#"78?T>!["]_RDDK3?6YX';ERS?E))X_E?_WQ03<E,7*9^U;
M/#C7S+#:@XX<8Z9J''FR6@#7FN%V#UQO9KW-F_Z" TRJC5EL<>?28AX\FA03
MLL&SIY=E/P^%$#Z0^W!/]GN7Y\]N\XW8D.=/+O#X_BK+<PW4E(>@RO.B(,-%
M]-6>I&@+LJ+-J8LS8SKA!!MAN]ET>X\UB]^Q:O8&*XY?LB2X;CDM@,7L"&:D
M?2P5QW&VN8S;"X,\O[(%#ZX;@L3?/GLD\L00)/[FT6,>W+YG^(IQ9&P.;6L_
MI?5=Y%9U$I?3(G:] 9]('0'QK43G#@FQW::XX2SI)6LD%:X0E;\@)'N.T()Y
M@G->!JC\A,3[)(WCE3"&:_0@KI$#.(?V<BJ@ PO?-DQ\VC -Z,0DL /CP'8A
M[QTRWHM9T*#($.8A0YB%#AH(O6EX'^8BEF%]G KNPSED (^H(?Q31PG,&L,_
M:Q3OM#'<D\=P44I7I$_AD3.'=]X"WMDS^.?-$%PBYU>V0*1ZB83Z%3(;UTBO
MG25!-4!T7CNII3V4:95R$^L,CVV+CIUA9>$<MZ[<%Q<@W.WF+9[>N25F77S"
M$[';3Q_RX-8EMM<GF!AMI;NCCA9]-4VZ*O1U16(OTVD5+-BBBD&?&4AK1B#M
MZ<&">X)H2?"D,]F9P4Q[QO*LZ4X1/Q;Q-G61;Z%-^IS&K*/BUX[3HW9AL2>*
MLU/I7)S+X.IB&O<W,[BS%,7U"2^N#-ISM=><K?K]]*:]C3Y&).%S^@I,6&X*
MX.)P"E<F,D7_ IAM]&&E,YK1^ABJ,WV(\[<BPL^6<#][@T3Y.A+M([C2TY08
MMX.4B)[UEGLSHQ4=:@EAK3V,[;XX%AI]&:FR8$I]C%6=$><Z3+C:;<&57FLN
M#SMS=3:8F^N)7%B(9ZS%@Y*4W=3D'>;2<B+WSA=P[X**RYNE#'9$D95AB9O7
MYP1%'B$F^20):2=(S[:@J,0=I:1:5IP5Y9%&],8>9L#[ ^9<WN2TTUNLV;_-
M.6D#UVOC.-.8P9E^%1?FM%Q8[>;LRB@[2_.<6Q6[NG*6U84=9J8VZ.M?H+-O
MB:&I\_1/_;F>\-@Y&D=VT Z?ID'D+YUV=<]?HV_A.H-+-QE9N<WHTBU&%V5\
MX08#<]?IF;I*Q^@56@8OH^V[2$V7$B0^0V'K%GF-ZQ3JE-(K*^36+I%5LTQ&
MS2H9ZC52*]9(*9<V4[9JJ-4:731/1-XL(9DS!*;/X)<\A5?<*!XQ?PX21PT;
MZJ>ZQ+TL.>&6.HQOQABA.5-$RG;1A0O$%"MU8%>)4XG(,#)_T; _PXL9:7^^
MB=(.$\9EW^,$9TT24SI+5NTRY:V;U'9L4*F?ID+X?[5N %W'$-H.I39W*_6-
M]334EZ&KRJ:E)([.+'^ZXH5_A!^G+>JP8'PCY@LMV2JT8EO&5_T_9LKX1TP=
M^1Y+MK]B*>13%E(.L)1_E!M:<Y[V.7"GQYY.P6F5D>]3&OT)*7YO$./Q&C%>
M?R U^'VR([\@+_IK\B*_IC3Q )6IARB.^X*2I-T4)!XB,>2@X.=CP@&-"1#.
M&A1H0TB0$R%*%G&@FV$8XN= A*\9F:%'T:8=8KKB.*?KC3E7>X*K6F-NZ<VX
MK3?G<HT1YRL.<+9L+Z=5!Y@I.B+\ZRB%D5]1FG"0QB(;>C7N3+:&L-@;RWQ?
M@N"80*H*'2A),Q.N9TQSG@7C=<Y,Z!T8K#>CK5*V*]TM6/PK*K,^I]P0(#Z)
MKM:.9JVSV 5[JBLMJ%9;"3>SIJ3N%.J!(,HF8D@?BR)Q/IGX]6SB3Q<2LYY/
MPF8):3M5)"Q7$+]02<)\!9'CA40,Y1+5G4F4/H&(LA!"T]T)B[$C.<%#N% D
M%7GI5!454:E24U&FI;:AG[:>!88G=Q@2N]8]ODW3T"9-HOM-X^=$+M R?IZ>
MF8M,K]W@S)5'W'GPC>$+'W&#W'_R+>>N/F-LZ0:-0V>IZ%@GOW&%[/HE,FN6
M2%<OB&[/DUHV3W*YB(PG5\H\I19WS1J9FDUI!UO2!C9D/27S>-GPDB0X9QY?
MT7M7T5&[F"%L(ONQCE!D -N(0>PCE0SB09QCAW"1Y2ZQP[C&2WM(',59Q$E\
MBV/\&/:Q8YR*'L4F? 1K\1M607V8^HMO\1>?XM_%">\NC'U[, WJYZ3X#Y/P
M 2QCAK%-E/:5/H9/SC2!^;.$ERP2(^>7(.<97[$HUS)!0?403:TC3/7WL]FK
M946714^.)R7!Q^BL#&%\I)S>Q38Z=H9HN3*.[MHP)5M-9,R7D3R90[+PQNC)
M3'P&XG!N#<*AP1VG:GN<2ZSP*[*7>QC%ZOEA[@LF>"J\X\DSP3K".1X_N\NC
MIW<$]PA.>/R8%X\$HPC?>'IO4FR<BI6Q2'KK+(3#OD&$VVM$NKU!6M"'E,1\
M0'W*^[1E?4AK^I]H37V3KO0W&2]\GYG23Y@J^9SQTCT,%!VD+>\H^EQSM 5.
MM&O".;/4Q.-;R^+;_IQ%K'PE^5SI*/C_"A(K 6(E%4"!1@I4^A\_9>+;/X.G
M?Z'?_^V#Q,KO?PX2*Y^R*9UE*(3TR9.GACK%RE I/_&-W/'GTAJ?/E4^W7M9
MHVU<B%*= #5U31O=?1.</G.5*]<>"/$8969V0]9YV3''Q4MWZ>J9)C6CB*J:
M)EK:1LC)KS-D$.L:IQ@:/D=%U1!9V8U4JGL-=8GKM(,TZ(=HZYAA=&R+Q:4K
MC(QNR/HCE*J:J:SJH*M[EKF%L^CT [)--^V=$W*<22:FA"QM7F%CZPJS\ULR
MO<R9<U?9%B"^M++)]-P2,PO++"FUB<]>8-U03TY(U/8%%A<W!'PML2CK;5ZX
MR,3&"GEZ-<&EJ7@*F/6I2B% FT5$9S$Q_158%06S.]J*KR),.9QDBT6!-+ :
MI3.T!/Q:T_#1)& >:H>-EZTA.!N;'$MF7C85-6IZA_H8GAT7XM.,>;P'7X>9
MLT?V<23/A>.E[IQ4>V&N#<"J.13[SBA<^Q,QKO7CZRP;OD@TXXL$,W9GV'"H
MU(43-9X<JW%G?YD3)O5^G-*'<JHZ&,L\#TP3[,3P6&+B:X%-@!U.H6Y8>-A@
M[&R!B8L5%IYVV/D[XQCL@KF?-4>]3W(H\#BFR3:<*G;'7NV+:;DK!XM.\56N
M!9_GF_%ED26[2FW96V;'GI)3["FT97_^*0[GV6%9[HE?6QSNNC"LRMTYDFO-
MH0(K#L@V>XM,9'TC=A4>8%?>+DZH#F%=9H1]X0E<L\P%8-@)@' F(,D&CPAC
M' *.8N-S&%/7O1QS^)KCCOLY[K"?DS*T=#V*DSABCU ;W,)LL0^Q%.-MB8,0
M%K=R7]PU_MA5N6%68<_)2EM,JQTPKW7"LMX%6YT[-G6NV(F3=:_W):PIBM#J
M, 'PLCS(##.?$UCZFV+A8XQ]Z"DA$[[X)OL;Q#O11\B$$\X^IW!WM<'5T0P7
M)U-<W$QQ<S^!OY>1 %HCDH).X'C\#?:\]5V.OO==G/;\DR&8FN/Z)C$6OR#*
MZE5JDHZRW!_/S>TJ+FTHA=USV)F*%\#L1K[''X@\\'=DGO@GRNU^09W[:V@#
M7F<PYVLA=U]1E_@FQ<&_I#3\MS1D?<I @R7]C?8T5EJBSC;%R_IU/GG]/['K
MHQ]C:_HYR5'N=-87,2M$>W:@G9ZF.K1J%?7J4GH[&@0DY%*<XT9\\"?DQ[Q'
M3]G77.XW9;KL770Q/Z,V^G="_MZD,>%MNI+>9BS[<^H"?X?OUW]E*-=0%2WG
M),0A._H V:+'ZLI4&IOJZ>CJHZ=_BHF9;=IZ!9B6]1"=JB$RJ8RTG"IIZZVH
M2HI)B/ 5$F!BR-HL"OJ8FKC/J<\\1JF G6"/+TB)MB9=VHF3K1&!GAZD)V90
M5JQ!K^^A;VB!B=FS5&M'R2QH(J=0*T"G20!0">F12KF #PD_]2JJL#<9+/R<
MH?P/:!/GM-AD0TO.0<)-?TC8@7\@]M _DV[R&[).?4BZTRZB[??@*O?.Q_D$
M2?%!5&LJJ-5IJ:K74ZEII;J^F8KJ,C*S FE2@NP5'K@:_1B;K_XK<<ZO,]84
M2'&*I=Q[1VJJJDE,*24PLIB(9 TQV4U$9&CQCRLC($Y%<'R)W)-B2E0:"G/2
MB/ 6_=OS2QP._)@0RU_+/O\S09:_0!5WD(H4(U(#/\??YC6\+5^E6MKEK(#$
M^E(W 6"N<O^=\!-=S$B+0*VIHK!<3:<\@X5E 5FSYR@O%W(=4T1*0IXA(%U6
M$$=<Q"G\/0\3Z'64Y%@G])H\!KJ;Z.EJ1].@)[NH@MB4'))2LB@N*$1;58*V
M*(XD[T,X'_@1T;:O$F?_2WQ/_(AC[WV/W__C_\&O_O[?8G7H;?+BW2@7$FIU
M\#U<S \1'1),3'P^@=%E^$77$)/>2D*NZ$5&AY#]6AR]"G%TSL#7(TN(6"E9
MD3'X6>[!<?^O<?CJ^[A]]3U<O_QO^!WX9\*,?\4IF>=PX+>$.QTG-R&6Q/@<
MW'RSL';+Q=(E'VN7 H/8^Y7B%E&!5Z2*L-@R(L*S<;%QQVS? 8Y\\ 8'WOXA
M5KM_2JS[!W2H3K'0%LCYL03NKN9R8SF;E?YP6E46=)0+X%:=0).YB^S0-\F+
M> M=_B[Z:@ZAS?V8!*\?$^KX$T(=?DF\M./RV(_I*SW.<IL[6T.1M"@!8K?W
M"'%X%\L#/\?JV._I;\_B^J51X?:G^?;%37'.#P7//!,@))!'?+/2=X A0*QD
M^')71$"9$@!^<($7-\[!U3-P>1W.3_%THYN[:RW<VFGC[N4^[EX9XJ8 O8=7
M9WAV?9X7U^;AMJS[Z)+LXX&"!$24R)-2VTL)KCT1?Z^\H5?2C!61\>=W43J)
M>/;T&C=N;G']QB;7KZUS_LP<2[/BRWKJZ&Q4.GW3L+70S.G9>K9GJMB95K$U
M6<)$9P9#+9E,]*KH:RY$4Y) >JP/29'NY*<$42<^5E.4BKH@A0J1DKQD:3/Y
M=+1IZ.VJ9:BWGI'N6CIK\V@N2T%;'&\HRU!?F4:CV+6&A@JQ,UU,S<Z)CB^Q
ML*1\GGI&<,!9@X^?7]IB8'B>X=%%)B87F9Z88'*XE_ZV6AJK<QGMUC#>JZ=%
M6\-07[?@@"EFYA>875QA:6V;]<V+AA?A(Z-+]/3.,M WP\3H'//3<\R,C;(X
M.<3R9 _#736TU>:B+TNE19W&>'<Y\Z-RWOIT&LI":2@.H+LVBK:*2&D_8=06
M15)7E2:8)H-T(5#)J6$D)X>1FA1&3FH4!2+%&='TM%2Q/*T$X$<XMSG!Q>TI
M+IZ9YLS6%*<W9]C<FF=Y;5[.=9G5C7565E;86%ME9W.#31FNKRRSLKC(_-PL
M$^/C]/</T-K1*02C UV3V+(Z+>5BHRJKJVEJ:1;,M<"UJY>Y=?T:ER]>X.R9
M';:WMUE87&!R:IRQ\1%:VYMI:&Y W]U"RV 'C8-MU/3H*6U34]573\M\)^V+
M7;3.=] T+7AO3$]M?QT5LKQ(6XJJJ9*:K@9J>W34=#=0)<^Y2IYQ98>&*GGN
M-5WUZ 9;:1SN,"RO[6]$/]9.B]R'QHE.&D9:J1ML1M.GIZJCEO+&*IIZFUE8
M7^#1\X>BT?]7N0E#+%4 J?*EV,-'C[G_\!$/1!XK&%?F*UG!ERY?Y\S9BX;.
MCA51QD]O*YGHYPTE)>[=?\R3IR\,0R4PK 1]E6"QTB&=,JT$?)4@\=3D/'.S
MRX(GE2_;5@Q9P\J^E&"Q$CB>7UAC:5G))+[$]>OW>/CP.;=N/N3FC0?<N?V8
M*Y=O<_'B=2Y=4C*_+W'KUFT#/C?\#!>BM%4%O\M KDUIJ\^$+#U_\4#FR;H/
M-KFRHJ>UT(VF#'.&2NQ9;PWCZG0^3\XW27,>XOF9,B[T^3-19<)<@Q4[@X'<
MVBSFX?5^GC_>E)U?EWW?%/-S@V^>7^?YLZLB5_CFJ=B,Y^>Y=67&4)NP39N#
MKCI5_$4Z]=4I5.8%HHZW92#!F(7( ZQ[?\R:^6]8/_Y+UDW_P(K3%\RX[&;$
M_BMZK3ZF\]173,6Z\6BR4\C".B_N7.'9 R4@_9!OGPGY?'"?9W?O<_OJ;38V
M+M [,(^F>8B2AA[2R]N(R6DA+*6-Z*Q!X@LG22Z;)TV]2K)J19;-$9$Y2Y 0
M?=^T:7P429W"-VD"K_AA/!12'S6(0V@OMH$]6/EW8Z%D=WFT8.36Q G/9HR\
MFS#R:>2X;[.0^7:,O7LP\1G U+<?4S\A] %]& ?(O,!NS()[97XGEGY=. C1
M=XT9Q#UA"'<A^\[Q0SC&R;%DZ)0TBDOJ!&Y*L%CI!"QS$K^\&?R+Y%SE_,.K
ME-(3"Z34+)!5MT!^PQPENEFJ6Q9H[5D7OK7&T, :L\*-KN[<YNGMISR]=5^>
MW0WN7;G,G8L7N7%NA_.GEZ3-#TE;U]+47"$VL@QMG0I=31Z-PF4&-*D,%X?3
M'^](?[ )@P%&C 49L1AEPF+X46:#=[$8_35CX>_2%_%'IO.^X$RK+3<F0SD_
M&L+UN3CNKZ5Q=R6%1YNI/#V=RJ.-1.XL1G-U(HB=7C<F:X[0GOTQ]0GO&4H^
MZ#.,T:9;T29<:: ZE,FF> 9J@^FN#J2C*A15BB?)(8Y$^-D1YN]$6("+B#,1
MO@Z$>UH1YG:"4.=#Q'@=)B/T),6)MA0EV) ;94Z.2%;X"7+"#E$2N8>>XI.L
M-MERNMF4G393MCIM6>SRH*_!A>H"2S(B]Q/F\8%@K?<H3-W'<(<7:]-Q+$_$
ML;&8P=1T,MJ.(+%3/F37N9%89D]XOBWA>0[$%KJ3E.U(8;H%#4E': [YE$'O
M=YAS>YLIAS=9CCC,A:H@[@T4<'.\C'-C9:R-J%F;:&-M:E2>W2138_.,BC_I
M&UR@;V25@?'3]$^>H6?B AUC%VD=N4#3\'D:1\[2.':&MJD+=,]=86#Q!D-*
M8'CY#N/+=QE;O,W(PDV&YF_0-W.=SHFKM Q?0M=_46SK>:HZSU#:NDUATR;Y
MN@T*M.L4U*^15[=*;NV*H?.Z;(U(]1I9Z@TRJM9(J5PB425Z6#1'I.AF:.84
M@2F3TG;&\5 R)F.'<!/]5MJ09_PH7HEC^*:.$ZB4;LF9)#I_EO@2V4?9.G&J
M-6)$(E6KA.3/$Y0Y36#:I"%0K&RG9%]Z2CL(R)DBJGA&VN^2X?PJY'SK.K8H
MKY^@H*R-DJHFRC6"OS75U*@+:"A/I:D@E(X49R;BK%@(/<J4YZ<,N;W#F.][
MK$5^P4;@^VQXO,ZZTV^8-_\Q\S:_9-'_?7KC]]"JE$VKL6"JU9*E7FNFVLU1
M9WU-0=R7HE/[R8O92T;XER0&?41LP'LDA7PD.O8E*MFV)NTP]=G'T&0=1I6\
MF]SH+TB7=5/"]Y 0NI=(OZ\(]]\KNFM$2( 50<*M@_VL"/<S(];O,*71^QDI
M.<2*^B!G:H]RL<Z4\QI3+M:;<[G1BO,-RO0Q+M4<Y&K#$2XT'&=%8T1?_M?T
M%NUE0F/"4JL]*\IG^CWNG)L,$>X8R>)0*/U*7>$",]2IQVDL%(Y39D.S\$)]
MA;G<,TMJRZRI+CU%9:DCY27.J(I=J2CU0%WAC;K&!Y7:E4*-,P7-'N3W!I$]
M&DG:3 )I&SFDGU.1?K&*E OE))\O(_EL):EG:D@]74?R>BUQ<]5$3U02/:0B
MIC>?<%T2 <6A^"5YXQON3G"X'RDI261GYU%<HD93WR'<9)ZAZ1WZ)G;H'!6>
M.+)#^]AYVB<OT2;2*N-MXV<97+C"ZMF'7+WW#0_$]SX1'_A(X.FU6\]8V[K/
MQ/PMVD<N4=VY17&3Z'7] ADU<Z)/2F!XCJ3R&9(J9DFLDO%JF:=9)%WT/U.C
ME)P0GU&Q3$*9TGGC,A&%"X:.YWS29G!+FA2[/8I=W#"G8@>Q$W&,&\$M812/
M1!F*+W&796[2%EQBE/K$(]A%R_HBMM%CV$2.8A4VA&6H4JJB#TOQ->;^G2]%
M?(>IO^)'^L6'#' R6'Q+^" 6AB#Q&(ZID[AGS>"3/T>(4B]<VF94]2HQU8LD
M5$V17C&,JG80G;:';N&EO;65@B\+Z=#GBZ^LHG>AA8[30S1?G$!_;9+Z:V-4
M7>FE\$PC&2N5)"V6$#&9C?= (BX=$3CJ_7"L<<&AQ :W'"OBR_V8VNSDQL.S
M/'Y^3_"3TM_7 QX('WCP[#:/9?RYXJN%%_!B4WQU-YLS2<)'?>FH%7L<^Q&)
M89\2&_0%X5X?$NOU%NG^;U(2_@Y5D>]2&RU^(>%#NG*^8+C\$-/UELSI/5AJ
MBV"M+U-TNHI+J^W"7R9Y<O^<\)"7"2[??J,DLCP5?**4%7M9:D()#RM_E=?_
M+[\?>QG;-& F)6JLB *C9/)?XO>_79!8N7,O@\4"JI7/\$1>UD%3YOU%7FZG
M!(S/GKU&:YN M;)Z9A<VN"# =N/T)6IJVYB3:>6GK/[XZ;><OWB+CNYAFMOZ
MJ==UDYZEIJ*JA[;V)9%5BHM[R,P2H%_=)\N':- K0>(!)J<5('V;K=,WZ>B<
M%"+5AKJZ@^Z>62&".T($SQLRF3NZ)FEI&Z5!UT-O_PR+R^<,F8L#0[.,3BRQ
M??8J%Z_<YNR%JRRN;@B17&1N:94+5ZYS]OQ5UE8%N,^O,SVUS.SL"FL;9U@]
M=XZ^Q6G2!51%5&815)F*?V4*H?4YQ+>7D=I?@W]#!J99/GP=8<ZQ5 >LBKUQ
MU(3@T9*(3TLJ'E4QG RPQM39' \_=T(C0TE*32:_L "U1DUC9S,5[758Q7OR
M=:@Y7\58L#_#CJ.%SIRL\,"DSA>+QB!LV\(,@6(+71"'2UWY,M62+Y(MV)5N
MS?Z\4QPJMN=@J1U[2^PX7.'"<=GV9(D'YH6>6&2Y8A9OAUF$+:9!UISP,N>@
MPW%VF1_DRQ-[V66\GP.6AS%R,.*8LQ%['?;QI0#X?7Z',$FVYI0X#XLR5XZ5
M.K"GR)I/\TSXM,"<+V3\ZR(;]A38<JC 'I-B-]PU823UYZ'9D.M:K2=U-!_?
M1C$\<AV6-6X8J^TQJC(3.8YQY5$L50>Q+=R/4\Y!_',L",NT(R+=CMAL.T*3
M37$+/8B]_WZLO/9@[KX'6U\C[/R-L?,3\3V):[ E7A'VN(?8R7K66 588AEA
MPZET9QR*W+$K<<&N4@Q>K3LNC7ZX-0?BV1J,3WLH'KH .5\_O 6<!JA#<,_Q
MQ#C0A*.>1SCL>H"#+GLYZ+J/(YZ'.2''M RSQ2'&$>=8)^Q"K;'S,L5>[J.=
M[1%L; ]@8[\/)^>]!'CL(]9G'\E^N_$T^0V67_T]?L:OD&SW&H5N;U#L_@:A
M1C_$W^@G5,8?H4?CR6B'./867[H;G.FIMJ&_S)3RP#?(L?TA9<X_H\+MI_0D
MOLN%5@NN#CHPK=F/*NQGY/G\$X4!/Z8Z_H_T51]B0&M"1XV) 03GQAW!ZOCO
M.+CW#WAY6%)36<!P;SMK<[.LSRW1T]I+27X%&:EY5*OKJ-544) 72H" K*R8
MSYG46<%F)&NU!VB(^!55H;\38_X^[<D?T1'U%F.IGZ#U^PW!N_\=!:Z_HE:V
M*8_91:+?%X8@I5Y?276]EAIM)TWMXW3V+:,5DI-3VD=03!5>(?F$Q!915-9
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MZF>,N_R!D:BOJ,\Y3JGH0HG.!DVK&?H.$W3-)I2*/<Q-/4).PC'A04=)BSA
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M!95&%+7;D]$EY]SM3F2O'W%CL<1/IA(SEDID?SR) _'D#B>BZI?[VQ:.OB&
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M0'R:H_%HB\*])P;/X00"IS,(GLDB8#0-SXY8_)IB"-7'$Z-/(JTY@_SV/"&
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M\ =$F?P"]UW_B/T7_X#+@7_&T_B?R(Y\A^51'P&7)L0'_AKK _^:6/OO&>H
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MIX_LP/74)N*##U&:XTE';2SUI4$4:!U11Q\BQ&,],?Y;2(W<39C;I_B<?)V
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MUC\A[?0O,+J_(/8&SI__&RD.ZSG?5\:C6POB0&_P\)&2^U?)[WM?YJ5\^+4
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MN,8N4O6=).<(T2T>1U,T39PRT%"B$O'5QJF 1DL>8!NQ([Z-6'G7<=B["NN
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M/\E]A1N* U.$XMFS2Q:AN*I&&0%;B2SNE/E^FIKZJ!3"5E9FIKBX@<*B.FG
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M)@7Y&NI-Z?*NW4CPWDS$F?=(=?L(8[ </WHKJ1Z?$'C\=?R.O86'U=MX6G]
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MD?7C$=7+MJANMD1VLB7<Q=:P=K:&NMCT5]L:T<'.Z&[V)?;BG=9/@/3Z<=X
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MC0C=WCDDR'@WXY,+ OB/T=XQ["X](8G%DC!\<.$L)T]?9_'8);'-(J[.,;=
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MR; 5D5MIP#Y03]-<)XT'.JB=;:)ZNHZJZ1HJ)BHQ#UC=Y28JAFMIGNF@^]
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M$2/WS]GYXK29NR>,W#ENX,9Q+2/MX1CSUS/5E\.A,2/=C=G8#!'"PFFO3>?
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M5@J+^6X@WNX5#KSX;Z;T J_\]B%V;_@N^9J/Z9:QH%<KRQT=:3&$DJ?QP>7
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MZ&#![3:90H"GZ&V^3'WC1?05)]$4+!&NI,W(F"8T=9K@I"E\X\9PCY%[CQ[
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M0$!#%X;)DU1-7Z9VZ)(I!VM=SR7J^R[3,'"1QN&+M(Q>I'WR$MVS5^A;N,[
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M?KIPM 22TF/1)D>B4OO@Z6N#J_M1?#P>_!CB:K<%5X>M^'CN)EQXA3;T*-K
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M^0 ?YU>$R&XB(L(!;4(D4?&)J*+3"(HV$*PIQ3^J#%NO3!P]4PD,2"8N-(9
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MS,9_S#<S67"E&<1^?GNUGNNK!E9'-4SU!C/8XDUOO3?]#2H&&\(8K ]EJ"Z
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M<4*2-:.FO+[.ZA$<(H:P"1O"*G2(8[*UC1R4:PSB'C=L*H*G4I;S9LT2F;M
M=/XB\<5+I)0NDEVQ0$G-$BUMI^AI/TUCZ12>1R/QW*MBM>4T]\\+"5)6NIZ%
M7GT_R2X9)+IE,5:QPFKO35HKCPL'.8->VA&9,X5_JE*0: @7):5$Q"!.H8,X
MJ :QEWNR5YS942,F9[&+W)M'W!"^2<,$I(T1F#Z%7]H,GHG3TMX'>5MMI4U6
MJEXL SNQ#.KDF*H3V] N:6LW[II!0N3\R.Q9XO+GR:I:15^]2$[5)(;:$9ID
M+%6)CM3IM23E1Y%9%D-N=2R&BE *2_PIS_>BQ.A.8K(]OA&6@O,L"//:2XKC
M%AI]=S/DL9E)Q]>9=OXK,T$?,JK>34/05JI#=U,1>5BP@.+8M4<;X4%TI"]1
MD7ZH(_R(#/,G*BR0F+ @8F6K#O$D7+!*>) =$4&61 0<(<+[(&J?HT1X'B+"
M?3=)_KMIRG3@5%<,E_NCN#80P<6^4.;JO1D2/-]B<"0Y:"?ASIM0.7Y$J,-.
M FUWXV>SGQ!7*X+=K%!YFA,;:DEXP!Y4WEL$N^\@-\$:?8*,5^</<+5]#W>[
MC_"TWX&;_2[<G?;CXVE!>+C2!^$8\E,HJS2*KBZFJ+:$[+("X8F%I-2(_FNJ
M);FI@?B&1F+K&@@I+\<U-X<C&AV.J05HJD8H[#U/>=]5RCHN4=EQE<JVRU2U
M7J2FXR+UW1=H'KA Q]@ENJ>NT#<C,GN9WNG+=$]<HE..MPY=I$&N4=UYAI+6
M4^0UKJ.O.4Y&Y0IIE<NDR?--JUPC3<9=2L42:37R6B2E:HED>9U8LD2\C.NX
M/"47\;R,BQE"TY2"=9-$Y<X05[R ONX$==V7Q<Y]P6#3&8HU;00?T)!LJZ<L
MH!ZC6R4I-D9B#B>B/AC%0%8_*Q7+Y+L5D^M82*:\%[U/A^<'01Q\P9JMSQRF
M-*F#N9&;]/1=H:SQ!*FE"T099@G)FB$@=1J_!)FW\1.F_.*.RNJ J %L%9'Y
MH12L<Y?C?O'C!"5.$B[C.4:_(.U0'(@GR"X_A;%2<1"?D6N?I*A:*30Y04E)
M'Q5E3?*]@WQV?D[FYX+)2?SM:@6?UZE8"=G*M,,KK+IL8$[&</^19VC<^EL&
M]SW._-'G.&[^/*<//\/JGC\S=_!9KD29<RG9F16M%8MQ1UA*/,2B3N9 \.MT
M"6<82]@AO",7;K3"9VUPJX';YXQ<6HSGS'0X)\>".3T>P96Y)#Y9SN+3$WE\
M>:Z8+\[D<?>L 2[E\>E\/-='U5P;4M.4N =C\/N4:_>1I]Y)H68/M>EFU&=9
M4IURF)*8G>2%;2$G\"-R [=1%G-0YH<U_67NS'6$,=D2S&"M#V/-04RTAC#=
MKF9Y0,$%4:*_ BC)\2(]P8&X*&NTD38D:YQ(BW<E2;:Z>&?B$UQ)3O:FI5[/
M2$\-W4K:K,%&%N=Z.;XZQIF3\YQ97^+,B14^OWF33\5VG1+;M[*XRO34K"F=
MTN#('!W]LU2W3))?,4Y\9@\1B9UDE2Y1T'B>@J;+9%6<D>=XBH3BDVA*U]&4
MGT1;MDYLX1)Q(CH1K7&!V!S1R=F+1.F74><<%Q%=FK5&2/HB <G3HO,5_:_D
MKAXRY:)WB1:)&9'72IJ>";R3E+R^\Z@RY@B5<:?63Y&0/TM.V3)5M6?H;KW.
M1-=G3#1=HS%]F@270KP^#L?SHV ,WL5T)/9B]"F@*+B,H?Q1OCKQ%9\M?<%H
MU;1P^4S*PJIHTK93'%;-A(SQE>G;@@LO4"IS5(G,C\J>DS$\@5O4*$X1H]B$
M#&(5TH]56#_6D;TRUL6.B5WS299QGB[S,FN>"+VRXF2%<-F&9LX3+,<#4Q1G
M]SC^2EJ)E E\Q6YYZQ3G\)BT?_Q!?GZ-V! E'5.2V+^,"3P-D_@7SQ!>,4=\
MS3SZQF5*6DY0VW**EM83C Z>XNS:%;ZX?INO/[O-O9O7^>;V#;Z]_2G??"HV
M_\9G?'G]%M?/7V1J6.Q&72U%A7D8\O1DZM-(3->A28PB(D:%*M0+?W\[G(3+
M.EB^2XCW+J)4!XD)/23;?<0$[4(3N)VXP*W$^GY E.?;Q'J_38V,ZQ/#<7Q]
MN9*U82UM)8Z4I1VB)/D@Q4D'*4PXB%%S@)R8 QCCCU(KN**K5BT8/YW![B).
MKT^( ?Z<;[Z]RU>";11<\]772C3QWYR0LE%VE:!6Q66I)+93*L5\HZ2D,,G?
M')G_#7__QSF)_^X<5D191O:U=-S77]\WR3??*,7H_G^=^+>H7\4YK,C7 HAO
M?B(@^>HM/KWQ!>O'SYC212@5E>\K#F7YC!)-H128&QN?HJ.SC^)"(3?-O2PO
MGC YA)>73S(V-DMZNI&BHAH3^#YSYAJ3DRNTM S2W3W!0/\, P.S=/5,TBO
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M"0I)P#\BEZ"84I%RG.2ZYBYI'')(X9A'.LX!:01$)*+5Q:()/T:8VP:";)[
MQ^)QW(4PN!QZ#4_S-_ ^]CJN9B]R:.OOV;OY=SB:O4&(BX ?+R&XWAX4&'.9
MGI_EKN+D-!G4>V)'E0C96UQ>[Z96[T1.R"N4BIYH2G\#E>UO"')^G#3-AT2'
MO,<QLV?8LND/.#CLP$MTOG> -WZA$83'I1&74H NL0A_3S6V>X]@O^E-'-_Y
M,W9O_!SS%[^#:M>O!<2^0DW,%NS?_X6\_U],U)I1$/L7M%Z_H3#^-?)U;PGI
M_@MF.W\KWVE.?J8K$?[;B K8A:?UN^R69_/.<S_"U^HUFO/M";!^C$"K/Y =
M_C9Z]3MD1[U+8?)VQEN\:<@\0(R,!]]=#[/KV>^S^?&?$6:Y$[.WGN'PAB?H
M+M*R-%!(<:8/KSWW/5RMWZ<J/Y+ZPF@LMC_#FT_^.]:[7^"59W[,H?WO"E88
MY-Y=Q=,B6.7^EWSSU6WXZB;W;IUAH;^*P:ID1BMUC)9IF*E-8+$IE;["" ;+
MM S5I$G;@M#'AU*:FT)393'#W9TL3LZP,KO$ROP:"[."!<;G&1I1<M1.,#HQ
MS=34#'U=G1C3$BG-2J8N-XVJM'B*XL*IRHAEN+F V:$&9L;Z&1V:9G!@@=&1
M%;G6"4ZLG&=A_C3]0XNT"8;IZ)ND3\[I[!Z@H;:.BGPCE7DYE.5D2A^D49"9
M14U9-1T=RH_42J[$">I:QZEI':.Z27$0#U+3V$-%=0,5%:74U10),2NCKZF0
MEM(DAANSF>HTR#UE,-"@%.]+H[TBA?:R#-H%BW16Z.FJU,M[>8QWE##4FD>'
M]$MUH8:BK @,*2%D)08)"?0C/L:'^%AO='&>Q DQ3$CWH*@AEK8I(P.GJND^
M4TW[6<%Q9^MH/]]$Q_EFVL\UT7JJCL;CU=0N5E,Y74_9> -%@W48NRK)D+[2
M5680+1@FJ]5(PUP;HQ>G&3H_3L_Z *W+G=3/-E,U(9\;J:&PKYR<]@(R!%]E
MUN92WE-+]\P@G6.]-'6WFHK6U4@_UE7)MJR&(F,Q[4U=3 E^'!Z:HK]OC*ZN
M(=K:>VAH;*6NH86VSAY3%/'(Z#A=W;V"\7KI;/][GN(!.MK[J*MKH:&^E;:6
M!\=Z!#=V]PS1*?M*$;LA>8;CXTO,S*S)F#S%VMHY4]3NJ5,748HJW[SU!;<^
MNV.*^%4<Q4KT\*7+#W(2FYS$JR>9G5LQ!2$HJ2I.G[YBNL[DY#*SL\JQ<R:L
MJ3B)KUR^R>E3YV4<SLHYRYP]>T'P]FW!U[=-^8GG%U:9F)B5]LPQ/KG&Z;,W
M.'?^)BO+ITV8>G)R0?9/<4)Q"J^?9O7X.FNR/7'J+.<N7.'.%\H\^HJ[=S[G
M\H6S?";D#R%0 NP%_RL.8A%Y???^/;Z\?Y_[ NCOWO^:NW>5E89?\=5=)2W%
M;;Y1TD[(]NN[G_'5EX+][WXN[PN9O*=$%U_@VM5IF0N-]/46T=B<35E#,CFU
M\3(>HE&5AN!2X(VUB%6I"EN9NPXREEW;\O'O+R-PJ K_H3I\AYIQ::O'MJH*
MAY(:_"N[B:V?(;'N.''%JZBS%PA*FL13HS@!^G"-[<,IML<DKIH!/'6C^"AI
M&Y+F\4]>$)G%-VD"+R6?K^(H5AROD</8A@\+EAW".GP(._4PSC$C>,:-"0Z<
M)"Q]5KYGCBBC4CU^T>0T2RP6[E(Z0T'- BV=IQD4XM_;LB8Z,D:PD3-E434T
M9;33:>QEJ&"4O,!"U!8:U'9)])8LL#3X&5VM%RFN51PA2P1G2QN2E$AA)=JW
M#_N0/FP#^[ )Z.=8\"#'0H>PD7M3(H&=HP;PT [BDS"(?\HH <J2Y=1I4\H)
M9^TD#M'C<JZTYV].8JN@=FQ#.G *[\)%W8.7?#8T8X;HG'F2BY?);UBGN&&9
MPIH)"BIZ3*F=VMH:J2Q+E_D53EZV-_GI+I2DV5&=8$Y#]#[*5=LIBCQ$48(S
MI0EN-,8ZT1]BSJC[-N;L7F?-^AG6[9]F2>S\I/=;C*JV,!B^AXZ(@U2$'28C
MQ((8E2UA(0Y$A+NACO @,M0=39@WVE!O8H)=B UU(%GC0GZ&+U7&(!H*@FDT
M!E"9YF'*%5\NF*L]RX'92F\N=(5PJ<./4_7.S)68,YASD,$\"X:+[&A(,Z<V
M]1B-6:XTZ7UIR@FB/,4/78 5,<)C4B.E77D!-)4%BFX,9K);;-1H"HLCJ0RW
MQ]%9JZ:Q/(*:(C6EQ@B*C6K*Q(Z5ER5359E%76T^C4WEHFLJ**LNI;BZ@M*F
M!BJ[NT1_]5(HNBBWL8L<X;^I]>U$E=?@EUU(=&D'1B6'</=%2CHN4=PBXZ'Q
M/*4BY<T7J&R[2&WG!1I[+] Z?)'.\4OT3(G,7*)[4GE]D;;1"S0-G*>V^QP5
M;6<H;#Q%;NTZ694G2"M?);ELF<12D9(E4Q$XG8Q=7=F2B/)CQP+Q10O$Y2^8
M(LIC9#Q$9<\2D3E-F(RIB*QI-/)>>K52 .\L#6WGZ6DX1;-^%&- N>#E&#1[
MM.38&*D):*'8LP:]4SZY[CE4"EZO#*L@V]E >UP?+;'=1.R+Q?9-5XZ\;HOC
M+NGOH@FFQV[1U'$!0]4JVKQ95!E3IOGI&3^.NV;<]$..4_0P]DH$L8Q[N^@!
M[/]6<%+YL<=7-TF@S._0U!G467-H#(LD%JR17K*.OFR=@NIUBJI7R"N=I+A\
M7)[7$ W5'8QV=7!NKI=[9X?Y]G0[MT?UG#2Z,1.ZB]7P?=S*\>2&WI.+V5Z<
M$CYY3HZ==MG(BL5+K!U]@<F]3]-_\"4NIOMQIB"*L30?1M)=&<MR9#;7CA/Y
MQUC(/LA8YD'!)=Y,MX<RVQ?)R2D-JR,AS/=ZL=+GR7&14P-^G!\+Y^9B$E^=
MS8,;E0(-J^'3*MF6\=E2$NN=@3*6[2D4+I;A_R[&R!T8HW8*!MM&ANHC*A(/
M4Y%PD-R0S:1XO4V\RYO$N[Y#DO"3W/!=5"0=,3F2>TN=&:_W9KC6@X$J+WHK
M?&@7[EAM<*<P0^9:NCNYJ1[DI'IA3/='G^A%9KR[8 1/TE.\R,CPQVB(I$7P
M1%][#9W-2G[B5I:7ACA[>HZ;U\_P^:W+W/[D*O=N?\Z]S[_D]JW/N'KI,J=.
MGF1A89G1L7FZ^V9H:)VBN'*<9'T?L6D]&*O6*&PXCZ'FO.C64R05K1-7N(ZZ
M\#B1BA2L$IZK%&*;)5*)=L^:,HW5\,PYPK,731&VX=EKA&6N$)RZ@*^,"R5Z
MUDFC_.@W8/J!S4$M$B5Z5BG\J5%RND_BDSR#?]H,0:(3%4>Q4K0Q,6^!K*(5
MRJO/T-7^">.]MQEMO49MY@1903+._2M)<<Y#8YE"Q"$M96$US%0L<;KG @,E
M8S0)EQLMFZ8W8T!T937)3MD4QS?17KO @))[O/TL&>4K1&8K/X:,XR;WXQ@Q
M(OI]!)L(L4,1 ]A$B0V([L$^IA>OA-$'1>HR9DUMC<R5SXJ$Z1=12?L#T^0Z
M2A&\9+%W2:-BWT;%?HV:?DAQT2HK:D9EWBBY^:4_$L=P2Q_',V>"@"+IQXIY
MXFL7R6Q:I:!YG?*F4]0U':>WYR0K"Y>X>?DS[GTJS_*SFWS[N?"6VY_Q]:U/
M^5:.?77K-C<O7F9J9)26QD;**LHH*"DDRY!-8GHBL0E11,:H4$<'D)@02*SH
MVE"_/83[[D =L$?T_2&28RP%:SM2(6.P-L^#TG0;#''[R8K:3H[F8^H,%DRT
M!=!<8$UIRGXJTH_05N1$7Y4O@W4JICOB61K*YOA4(6>6*KEXLH4KYP>X=&Y"
MQMXIX0ZW45).?*.DG/A&^9'[;\&O2FX)Q<UI\G%^:W(>*WF*']1 443.-47&
M_O?\_1_E)/Z[@UAQ#G\E8/&^ $'%26S*2:QTXK</HHC_?J[2@:;7RJ&_.8F5
M".(;US_EQK7/.+YZBG,"7N42I@ABI7C&TO()AH:%(/6/TM,[3$5Y(PUU70P-
MS)BB,I1<:FUM \3'9U)6UL3DQ*J ]S$:&GJIK>F2;8^\/\CHZ(() %^\=)MI
M(6&%Q?6T=XX*X!;0/7]"CJVRL'12P/,U >2?<EGDS)FKICS(S2T]3,VN</7Z
MYWSV^5=<N'23X8DYN@?&&)]9XI+<_]4;GW/RS&56CI\5(C%-O1CQ^KHVN9=A
MT_+"4P+<Q^4[BH5 A*>FB2)*):HXG0!##)ZY8?@6JXEJ3B.B/H7(ZC02Z_-)
M+,M'G9:&IRH,_^!(5"H!Q4&1^'D'X^L52%!@*%%Q<23J,T09YI'=6$IBC1%5
M7@+^.5I\]#&X9T9@%>^+7:H*K[Q8/.3[;)(#.!3NR/X 6RR"G; )<N:PPU'V
MF.UFV]Z/>'?SV[S]X08V;'Z3US]ZFW=V?\A6\QT<<#F$F\:+$%'N(85R/V51
M^)5%X%+HCVVN!Q;I3AQ)M.=0K#7N&0%DMQ8P>FJ:DY^<9>WL&CV#W=0V5E%6
M6TQ^>0[9A2DD&C2$I\N]Z;QPB'/%(<D=]YQ  DKD^N6Q1-<GD=R93>Y((<;Q
M0M+ZT@BI#""XR(7P8CMB*ZS0EN\5T+T)5?8&G'4O81/W&HYIF_$L.(Q/F2V>
MI?:XE]CC5FB#J\$<S\P]N,5_B)WJ#6Q\7L<MZ$-"M0?0IE@0$7<(]Y"=V(4<
MQBS(G,/!%MA&.8AR=!(#(1+I@%VH+5:!EASP.LC1('D_6M[7N>*=Z8>?WA^7
M1"<!V38XAIMA[;D36Z>/<+!Y%V?+UU$YOTV^=@_CM:[4IVZA(WL[UT?\N;^D
MAG4MWZS'\^5"!#.E>\GQ^AV%@7^B+74CXY4':#=N)=G_,;P._2LI08]3G;Y)
MC+,%HRTN+(^%,3^LHB!YJP#9;?3E[J,ZYCTQ\G\AQ.994H/?(\;S:51V/R?:
MY>=D!_R!O.!'2'/_*3K''Y*K^A,]94>8[-<*0<ZEJ#25&&T,ZI@$TK*+2,HL
M("Y%CR8IG=RB8GS\/-CP\J.8;_HCR:YOT25*MSMM&\U)[U&F>8O<Z/?QL7F"
M_9M_C,OAQ_$R>XI0^Q<IB]]-7Y$#77D"W/TV<?"MG_'Q"S\B4?JR(CF(S"@/
M#N]\$VOSCW%WM<#=Q8IH=2#QL2I"?.T)#[ C*R6(UL9,\O4JM!&6!+MOQ<M&
MGOV19W W?PICXD$FNM7,CB3AX?@V]N;;B8^()T%31) J'ROG5 X[)F$?K,<W
MO@BOV%Q\14+B<M#HTG"Q/X+%CK\0;K^!3)^WR'![EM#]_T%AT&,,&C8RE/\^
MB4Z_Q>SE?V#3+Q_"\[5_1[?CQR(_(=7L]T3N^SG.[_P_Z([]A(',C5SOL:%7
M]RIZ^_\B[NB/R0MXE4S_MPBU?0E?\Y>(=-M&3KP0I-)X"K(BB%(YF/+CN9I_
M@(_9:[0D'B#?]S7<MOR8[:_\ )M];Z-6!9"<8"0YI9:4C#8R\_K0IC43IJLE
M/+&9($TM ='EA,>6D)E=27I" B'.^XEV>A=]P ;J8M^@)OP9*@.?H,S[*?(<
M'R7?Z8^4>CQ#@<<+!.][E#VO_9C=;_^:5/4AVJH#>>_U_^# SJ=-Z3L:&HII
M;&FFL7V @<GC= T?IZAFF%"-D=#8##(,!:+[&LD579,0L%.(V 'BG)_&=\_W
M\9>^C+3]+V)<?DN4_:\$^/R1-+O'2;3X(_&63Y%H_S):A]?8]_H/V?CX0^Q\
M_7^A<7^:+-5S)'C_@:S0YT@.?)8X[[^0'[L=HWH'^9&[&2WQ)S_L( [;GF;/
M.W_&]LA6PH/]T6G3B=7F$15?ABZKQ>3,=?#)Q-8M#4>/5+S\TE&%9I 4)WHW
MS!/5L=?("7J',O4F4CS^RK%W?\369QYBZU_^!V__\2$^>N[[V&U_@4@/*Q*B
MH]#J](1I"_ *,V+CE<X!VSAV6VG89Z/#VBL5[[ ,PF(2"0WS11-A06S ^S@>
M^ W: )DKF8YDQ1Q%I]IC*KC@8_T:1S?]DL/O_10_\U<(LG@/E?5NM+Y.#$A_
M?G+CDD".NV)"[XL=_5*,Z$VX?XZIGFPB7%XE-_0E6C/?ICO_ U)43Y(0\C)%
MV0=H%8*1%'> 8Q8O$RIZS=_7&CO[H]@[VTO[?0F/C")!FXBGK2U'/G@=URW/
MX?/1(ZBV_XJX0[^APO]5FB+>(=WV20X\^>]8O?XSAHL/"M'[@'S-"Q3$O41)
MRD9B?9_#;,O/J<QQI:,ZC+B0'<2'2=M\MN-EN1%OB]=)"MI"7=81<M1O4:!Y
MFYJ,+1AB-Y :]AK&^"VL#L4P5"U$(O!]PBU?Q/K=1]@ONL9UVT;,-CR/Y;LO
MD:MV95CL9;F0\@TO_P@WV_=I*(EFI#43]Z.OL&O#CXGUV<;!CY_!V7X[4Q.M
MW+ES78"'8)6[GPO&^%SV97OW&HNCK?369-%9DB#W%4:;D/?QFB2FZA*9D^^8
M:$BG-"V4HHQ8ZLORZ!3B/CD\QK)@@JGA&>8FEE@4##$SM4QOWQ@M[?UT]X\S
M-;/"Q-@TM>7E5.;E4I6;14U..F7I\53G)OV_Y+UG>!MWDN[K,WMV=O?LSL[L
MI)WD&6>/9\8YYYQE2[)D2[)RCI1(BD',.9-@!@B2 ',$,PD2!#.8<\X4@ZB<
M<[ D_VXUY#GGW/L\]]M^N.>YM$L--#IW_:O>M[JZ"DME-AV6<FN]X<;&;AJ:
MAK&TC-'>-D9WUR3M[1/4-8U8:PP;:SJIJFFCT=)!K=E,14$NIJ(<BC.3R)3M
MI6FBR,M($VQD%%QCP6BV6(/"Y8*-2BH;*"@U45A<1EYN)OG921B5@*\IF_;*
M#$Q9D307J^FJ3**M0D-+>0)5.2K28]W)U092H(N@0*^B*D]+:U4.W8V%5!@T
MI";X$1MQ"%6P$W$J+Y+5H3(-)"+$E[!@;R(CQ#ZK7(F,=T%O"*"\+1'+=#YU
MAPV81:IG"ZE=J+!F$-?,E6.:+J%\M)"B_@+RNTO([2@EJZ6$M/H"$I4@<9&6
M4+E'^KHL*H9K:#[21>-<.^;))HS#U90-5%+<6V$-$F=:\DBIS4)GRB"E*H/<
MND+*6ZNI;JVU!HE+*P5'&L5^E5=17E1!7J8<4V4]W3]D$2L!W8:&=L&<;9B4
MVL1&6;>ND>;6#FLF<7V#A=K:1JHJ:R@IKJ#:5&]M7J<$B$N*C8(]*^6W6L&/
M%KFOK=;MM+1T6X/$'1W## \?MF;_*EG%O;VCUB9V$Q/S')X]:@W@*N75E #Q
M\1/G_K?/9ZW!9"6#>'3D7OW@R<FCLNX,W3VCUFT-#DTS/C[/],Q1P:]"J.<6
M9=EQ^:U/YD]SZ>(-KE^[:RU)H33*4QKP#0Q-,C5S@I.GKW/FW'6.+)ZFMT^.
M<63*6LKBU*D+G#ZCR#E.G3[#Z=.GN'3AC(!T&4/?7>3FQ6.<.SK!C4O'Q29=
ML\Z__=TU;BE!8N$!-^[<XMKM6S*5STK3:J4$Q:WON'7M*M]=5S*(;W#GQF7Y
M?)'O;E[AUDVE]-Q5KEZ[R VE!,7=,\('3G#^G%+ZHH_1Z1:Z1^7:]I>3W9R!
M5XX/VQ,.\&W\ 3:F^K$M+YK=)8G85Z7B8,[D8$T>MC7%["HUL$VPRZZT GQ+
M6X@UCZ,JFB X?12?!"'X,3W6[-@#(18.*$'B\"8AQA8<(]MPC>W&4SU@S2SS
MU8[CHQVU9EZYQ?7<RS(+Z[ VLMNK=))7:OD&M+,G2.:%=5FS&#UBE69' P0E
M#Q*2.DQ8Y@BJK&&BA%RKE2!Q^1BF^GFZVD\RT'J"J$,I[/GX(-ZK W'[RAN_
M=2&DN@EN]LY#([\%VR9@S.RCH^$TQJI%DO(GK=F3[HF]'(QNPT;.88]?$[N]
MFMCEWL0.-PM;/5H$[[>PW;=%?FMA?Y#2?*[5>G[.,9T<DG-QC.G#+K)/\&ZO
M''\/.WS;V>9I89M'O6#>6G9[UW$@L G[8 N'5&W6IDUAJ2,DY$^06S5#D6F,
MPO(N"@IJ,!M-=-17T-^81VMQ!-5)=I2&K*72;SGUX@,M#N]0O><5ZIP^HR-\
M.X.Q!YB)/L""_Q;&]W[(Y-876=C^-(M[GV9BUU,,['F!2?=/&??]BCZ_;V@(
M6$-)V!8RHO>2'&]+?(PMJO!]!/OO)-QO'RK!46&>VTF2;9;F>-)N#F>B5<UB
M5R)'.Q(8KPJFO]"#@0(7IBK<.5PITY(#C.;MH"/I&\RJ3S!%",;6K*(G<P=]
M^?L9*7-APN3'J"F(B;I(NLM#T 5N0A^RE<H,-X9;XICH4C/1'<_\< IG9@U<
M/5')S5-UG#E<SNRP@?'^0OHZ\^EHS:&U*9O&NFS,)K%II5F4E>8*;RR@TEA"
M=4TUM98FP58=U+1U4=FH-.UJI[BNAUSQ!_K*)F*+:DDU#U/<?I:,ZJ.D&8^0
M7B%2-D]6^3RYE8ODFXY25'.4LH:C&%N.4MUQC-KNX]3U'K=.S1U'J6I3&M8=
MH;!V@9RJ>5E_%EW1#-J"&>+S)HG)&4>I,ZS*'"8B0]'?8>%<PX1D#A&:/DAH
MVKTF=4JS+R6#V#]1]%W;B[](:(I29F**C'(Y!O-I3!6+%,2WB2Z7H+,7WKI7
M1_+.)%+VII+C5$"*73:YGH7T9/=@UE13$"S70V5B,'N,IKAV?%8&L/F5G6Q]
MSX9 .S46D_#W_FL4FXZ@S1NS9G&ZR7AU5%Z+#^VP-I94'N#L"VQC;Y"22:R4
M@5&:3\KOLHP22':)ZL<]IM]:P]LWH4_&Z0 1UD#Q! DY$^AR1TG)&4"?V4E.
M?I?8]TY,91;9=S4CS56<&3!SKCV7(Q61UL9T$UH'3AM"H-L O44P5BW\KH&[
ME3$L!F^F1;A@UZX/:-_S"2T'OV$V4\5H@88Z72"F1'<9*XZT93IQU.S'3(D#
MEF0E>/LUV3&K!#.NI2)C Q7IWV),7TU]SGI:#5OH*-A&:]Y6^LKW,]W@SO'N
M8$X/17)V-(:SPRHF:EUH3-]"?MA2*_^(/_0.25Z?D!.^DO3@Y23(F"R,7D=A
MU+<D>7Q*Q($W"-O_%BK[#PG>]S;13A^1[/,%L2[ODA6Z%%/R)HKCA6>J-U*D
MV4Y&U$9T$9O0AF\A0<9E2IP-AE0WC/F!Y":ZD*PZ0'*T'0DQ=N@2W2C,CQ(;
MD45#=0GUYC)ZNQJ8FNCAV.*X^ ;E@:/@6^6M].O7K?[B^[MWQ2]<X<R9T\S.
M+HBO'J&AKA]C91^YA=UH,UJ)36TCJTRI([U(<L$\\=G31&5,$Y8^C5_*.-XI
M8WCK1_%.&L1+;)=G0@]>:N4MCUYK#5ZE#(-/DA(P%?NN&1$]&A3]Z!%=$;T)
M;69/L$B@4DJH3:;W]&E?D/)0KA/[J&Z<XWMQU?3CJ;W7 "Y$/T2$?I#X]&$R
M\Z<Q&H_3:KF(I?HDM0;A33*V]/Y&_'<*1]F73(9/,171]91%U9 96"#7N)XK
MPS>IBC03N"Z,X"TQ!.U7DQI716?'&<$RQ] 53,A^^O"([\)!J9EOK3O?*3Z@
M4XY7CC&D5<0BTL3!B'9KZ15WT7-O:\F),0+DNOC+=?'5C5C+(;G)]3@4VX&3
M^!''R'8<(CJPE[&B^+)]LMV]XNOVRKS]XC/L-+)/G?BW+/%MA3)>E&:1X@=2
MJV;),<Y3:)S&7#=-7]\1CB^>Y]HE\?G7+G-7Y,[EB]R^<(&[ERYSX]QY3B[(
M/15;9S*9*"@N(LN03W)Z*C$)L02K O +=B4DU)GD)&^2U >)#MY$L,<*HL7^
MIFN=J"P,H[-1QUA?#M.#N0RU:6D3.VTN<!8<NXG$\&6H@S\G*6R9X/"=]->'
M,#>HY\1D/J</EW'K7 ?<FA!>,/^#'!6YU[1.>97G[MW+HH.">;Y72OPI;R,J
M51&^%RYQ+[9I#1++/"7+^*[RL%Q9QCI3B8,JF;'_-7__QP6)_QX<5N36K5O6
MJ3)/"1S_SU(3_UL@69E: \4__-V2P7_IXA5KJ8EC1T\)$!3ED6M[\^9=:^.-
MW+PB9N:.<?GZ'<X)P)U7LB2.7^3R9?E^[AJ7+MT24'V:Q*1LFAI[.;IXB?2T
M$FN]H-:6(0R&2FLC.SDL;LB]O2%VY_#AD]: \OCX$3$Z<.S8!08&)@7\#]#;
M/\T) <NGSURW9GN4E)BIJFIBYO!QZ[)S<Z<H+Z^COJF+ 2&&BP*BKXL^7+A\
MDZ&Q.6N'^X(2$PV63AJ;NVCO&J2C>YC*VA9RRJJ)S\K#-28*S\08O%*CV1/M
MBE-& /[EL008XU#5ZHD7$J2NRB;-7$)281Z!,3&H=:DDIPA1BE(3%!A.2'"$
MM:E=J"J:L+@X8M*2B4@7$I6E)3!;C7V,'_LB/+"-]>&@$#U'?2BV24%L#'5B
MM:\-:[SV\*W['C9YV+#=S89M]CMQ\G'&V><0RU<OX_W/W^.=S]_E_64?\]FJ
M+]FP;S/^4?YDE&90V6[$U%]->5\EI8-&RL>%@(Y4H&U(Q4WGP\Y &S%&+B08
MDBD1D-C<TTK_R("0D7ZY9GT,C/8S,C7,X%0_;4/-E%E*4*6KQ)G;B2&S(R [
M@LQ6A2Q6437>0./A=CJ.]=$ITG&DD[9Y"QUSM32.&LBK#R4J<RN>L9\)*'B?
M97:/\:7S4[CD;"&RV8?XOD@B>Z+0#">0/*%#-Y9(<D\$4=7.>*9NPCEV+79!
MWV#GO9*0Z!V$J';@XKT16_?M;#VXF55[UK!BQ]>L/[ !IR!G4HM2R:_,)R%#
MP]Y#>UFS<S7?[/B&#;;KV>2P260CZ^W6L=E^/=MENF//-]CL_8:#>[_">?>G
MA#I_267*'LX-1-)3N-5:W_-H_6[.MN[G4J>=R$%.RO?1[)74!+U"TJ[?DW[P
M">K57]"1L9:"T/<(W'X_7IM^C<[S>1K25E"3NAQS^M<4:I;@O_LA*N.7,5EN
M2Y+#BS@M_QT'EOZ!"-M7<)%U_&Q^06_E5YP?V<NEX=U,52T70/8 R?;WTY+Q
M+9?F<YF;*B$NWH& @#U$JIQ)2U41'.)"6+@[61G1%&7'X+[O*SY^^E_1NWQ&
M>](6VK3?4J'ZG)+H910GK",E>A-;UCS-TX_=QT>O_(2UG_X.YRU/"9A>1G.1
M X.U09@RG/#?_Q'V:YXGU7\]Q@0[##%[\;7[F'T;7V3[FF?8M_EU MQ6$QFP
M#5_GU;C:?X.O^PYBHGP(#7'#T7XKF]9\POYMR]B\\C56??(XY9E> M+3:*@(
M8H^LOV_+4C2J*/3:?#R\DUFW(P1;KW0<@[)Q"$G!.301__@T(K2I! 8'LF/#
M$E9__!B'-CU/K/-[I/I^3)+[Z^*TWQ5YAQB'IW#\YC_Y]N7_SF=_N@^;E_X)
M_X]^0N!G_X[>Y@DB=SS G@_O0V/_2UI27F2\; F%_D\0N^NW\MO#I H8BW'X
M#+=M[Q'JLH'RG%@A#A:Z6AL$+%5375XIX+,.@U8K0&XONH-+B=WQ"H[+'N;C
MYW_.FN5OXNKB1$14"O':2J(T-=:R(%[AY7B$E>$<6(QK2"DN@09<O%*(C<DF
M66R(RG4+GAN?)W3+(Q1Z/D5C^ N4NCV,=O-/,?N\2%W06Q2XOD"^Y[NXKOHS
M2Y[_#^PVO4=!JBNU9?Y\_MYOV+'I W(R$\C,S""_N%) 2B\M_4<QM\^17MR)
M7U0>[@$ZL4LIY&;EB ,_0)##A^C\/R!@Y_T$[O@%1;+?.MW[-"IE4Q+>(S?@
M%>)L_BI$^&&Y9N^2YK.:F$/?L.35^_G;_?^-UY_\9UQV/$V,Y^O$>KY$8M"[
M^-L^S;ZO?X?KAK_@N_5Y&0M+.=.3Q**0OW*='7X.7^*J='CVM"-*I<;31XV=
M2SRNP5GL]4AFDWTL6VWCV+$_FOWVT;A[JM$EI),1$TC4@<]HUNZ@/GHUWBOO
MQW');]G^[L_Y_&\_YLF?W\=3O_H'/GOV%VQ9^@I^KO9HDS-P]8MGMU,D6^RB
M6+4SF*^W![-F=Q@;]P7AYA=+G$9#=)0G(7YK18_?QNO@RZ3%;2$OT0G;S>_R
MSK._Y.7'_YFM7_Z9;1_])[9+?H?:[@-TKJN(ME]+@,T&QKL;%(\I_O,J=^Y>
M$_AQ39SP6<XNM)(9LXMO/_@7RA(^8ZQV*_792_#>^T>"')^E-',[-:5.9.IV
M$QZP%EW<(=0J-]P==[-R^4=\\.Y++/WT+5SV;\1^\^?L6_$<P=N59I<ODF;W
MK/4A@M'C14H<GD7S[9^(7?,@<9L?0WW@+Y3$?$R9]E,2?)_"H/D(7?![N&Q^
M G.&'<TE7FA#UUAM06+H.N)\OJ$VYQ"FM+WH S\B6_61D,4/R5>_35+(\P0Z
M/$&PX\MT5'C15QU(2<(N_':\R_XE+[#CO9?8]L[KK'SI63YZ^E$^?.%!?$1'
M GS6\-A#/^+@GD]I-D8ST)!(O/<RW+<_37+0"L*\5I*A]^#XT5[! .>MU^_.
MW7M!]KO<X-KU,\R,=]-:5TQIC@9UJ*L 24<*D_P8,B<R:(JG(2^8^L(XFJMR
M:*NOHJZJFL::9CJ;^QGN'N?(] E."@">%/_?W3E,8U,W-0U=-#3W6!]P=W=V
M8:DQ4U]10FMU!9;*(NJ->;*=/"R-1L$2#5286ZBHZ:&J;I#:IE%9?YBJVD&9
M/R#SE2!Q-^;Z#CJ[^@7GU%%:F(&Q*)W"S'@R$D/(%2R1G19/=F8RI:6%Y!?D
MD9.72Y793&%Q,1D"MG.S=)3D:JDR:*@M5--9F4J7,97:[&AJ,B.H$;];DZ,T
MH4L48!V#+MJ9[,0 ,A.#B!=]24D(Q*#49<Y-0*<-M=I@)1 <%>%/?&P$V@3!
M+^$1A(6$$Q$F^"0B7+X'H(KV(C'3C\+Z.&J',ZB9R,8TF4/E1([X]WQ,8T*&
M1@HQ#A10TF/ T)%/;EL!68(!TBT%Z.IR41O3B"Q))*)8@ZXAAX(^(Q5C=;*-
M!HPR+1LR4RQXH;#G7I XVV(@LR&/3%DWLR:7[&H#!36EF-OJJ&MKQ-Q83W5-
M+37F>FJK91ME@MGJ6JVE)MI:E29U<L\$P[6T=E%;UT1E50WFF@8:&IJI5X+P
M%=44%Y538"BQ3FO,#=35-E%66DEQ<3F%1644EU18UU/6KV]0:A@KV^RV-K'K
MZAJQ9O\J@=V^OGNB!(M[>D:L)2 44;[_O3ZP\H;;^?/7.77JDK6&<&-CES5)
MHJ5%J54MZ_6."=8<$JPY(#)HQ9U=,AT:&F=F6O12]&:@?XRSIZ]Q4W#LZ9.7
MK=NW9@M/'N'(L?/T"@9N:>^CM4-L>D</(^/3@H,OR1A1 KLR8FXK.%[LSYW+
MPG].BQSCSL4)KAWMX<)<&S?/C0NI/R5#[(R0^DO<O'V#F]_?X=KWMT2N<U/Y
M[^YW,O^'A!+A"[=O7./6526#6 D07Q#<?X'K\OG:]4LRO<S-[T1N7Q2,?8YK
MLMW+UT]PX<I1SE]>X/SU(QP^-TJ**8F]JOU\Z;:6K\/L6)_DR_9L%;OR8]E3
MJ&5GD8Y->3JVYF6P(SN'';I<@BH[26R:)=0PC&^*\EIZ+X>$/"L98P>4C+'P
M9O9'- OQ;\/EAU=TE69SP<GCA.JG"%$RL'3#^&C[A7 K@6*E],2]0/&^0"63
M2\AT<!?[P[NM-2O=8GJMC8$"$_N$T \0EC:,*G.$Z-P1$HK&R!%B75E[F+[.
M4YR;!I.ZF:!O57A]X8_[$B_B=B?0EM;+D9:S#%;/D1III*9\DB;+&?+*#A.=
MH00W>G%-Z+%VK]\?9&&O$B3V;&2G6P,[7!O8ZFYAJU<S._YGD+@-.R50%M%N
M#9;9J;KEW'O9%]K+GL!>=OIUL\VK4]9K8ZM;$]O<&]GEU81-0"OVP6T<4G5:
MFQI%R+DD&4;)JQRGS#R$T=2.J=Q,1YV)F1XSY\>KN"!X;*' G?Z@K^AU?(.A
M?<\QN?L9)L6O]ZQ_ LNW?V'\P+M,[7F;L74O,+WA1>:VOL3\KA>9V?4<TSM%
ME,_[7V?.^0/FO)<P'OH5AW-M.-(<R&QO%$W57F2F[1%_OPY5P :B?#>C"=I&
M78D?DSUJC@S%<VDBD5L32=P:47.E,X(S];X<,1YBML*1L4(;NM(V4Q/S%<4!
M'U+@]0YUD5_1KEU/7^HV)@MM&3'L%QR^G7K=9IHR=U.?N9?,T!749MHPVQ7%
MV6D] \U!%*3M)B%\/4W&4!9&"ICLS*2K)H&FJC@L#7KJZ_545FHIR(^FK$@P
MB^AH89Y>['HV#68C ]WM# _V"@?ME7$L]J*G3\;Y,.WM8UC:QZEN&::PH0]]
M10>9M5,8FL^)'LVB*9A&+_J07CE/9L7? \5'*# O4ERW2&G3HC50K 2%34IP
MN/U>X+C,<H3BA@7RS(+CR@^C*YXA4;:E-DP1FS-!9.:].L-A2C X=9! $?]4
M&1,I_?CI^_#3]>&;U(-W8K=5O+0RU7;A+SH9E3%&BF&!PM)3--5>H:7\%.G>
M)F)VZHG=IB734?Q 6#4E017XKP_!_5M?,@+SN#8MI%W,#,>_Y^[\78;S1TFW
MS^+0QZYL?E[XV3LV@G%B:#0=%MMUW=I<+C9[&#]M#RZ1'3B&MF$;U,H^T5<E
ML+=7Q":PS3I&K:4"PCID;';A'-F+6V0?[C$B<4HMUFY\Y?BMS?92!HE*&R V
MK0=-6@>ZS ZR<CO%[G?(O6JBV=S$4',]XTUEPN<T#.1&<+Q:QXV^"IAIA85>
M.#D,BFT\,P*'FYC*#"1EVT>4.:VA-\:%.8.:\=)T.H1;5HD_SX[S(2OV$"5)
MSC3GN%"KVTE!Y$JR(Y93H%Y#0<)J-/YO$^_[!HD![PJ6^E"PU!=DAW^.QNTU
MX2POHC[TDF#BU]%[O2'\Y1TR@SXDT>-U$H7'9 1\1*+;&\)!7B3.Z27Y_B%E
ML2L%DV^B(64[1O4&F;<4E=U;LJT/T?LN(\Q&MNOT#BF^GQ&V3[#:SJ<(V?,L
MH?MD&X<$I_JO0!^\!EWHMZB%3X=Y+"$^>!4YR7LQ%7I0H#](4OAV&9/K"71?
M153(#@ISPS ;,P1+E='2:&9\J(LCLR,</S+)K<OGQ)<H0>(;W+WSG?B>6]RX
M=9T;WUWGPJ6+S,\=H[=CG'I3'V4E/6(#>X6;]Z(K'"#/-$^&Z'U"[C31Z1-$
MI$X0K!\7&SZ(NXB'5@D0#^*I46RWV,S8'NO44S,@\X>LRWFHE8>&2IF);NPC
MQ*:'B<T,;F978+/818NU5OMNL:&[_'_X'M!L??!@+S[$*4ZI[]YG#43[)O7C
M*S8Y(*&+2!DC25FC9!?-4%*Q@,ETC(::DS16'\=<,D.AK@O?70G8?N%%S+XD
MX4F5=!D&F)$Q&2#C8OWSVPC;KI;[HB,KKI;^S@N8&XX*[U(>9BBEC)0,8+'I
MD2W8JMJQ#>^TE@RR"^L6Z11IQUY$"?HZRW&ZQ2OG*_Y/R9Y.&9-QK 3/A^3<
ME3(3'3B)'U%J+RN!9<5/*$%BF]!..<\.;)0@<70GMDII(UTW'EF#!!=-$%<U
M1T+5+'J99ID6,<AG8]TT;3US'%XX8VW">_/&56Y>.<^M2V>Y=>$<5T^=Y/21
M><'A([2V6"@WEI-CR"<M)X>DM%2B-7'XAGCCZ6>'K_].X?UR'0+7$N[W-7$A
M:S'F^S,Y4,JET_U<OS3.S:M3W+T]R]U;HUR_V,KIHV6<.5) 9V.0^(4E)$>M
MI:M>!3>[X,X0W]\>%1&G^_U1[GY_DMMW3\M4"0Q?$?DAF40PSZU;%[@K>$0)
M%'___0V9WK(&@)4X\)WO[HB>_E B07G34W".\D:5\E7Y_7_*?\'?_S%!XK\'
M?_^?06+E^[V@\+T2%,IR_T_Y^]^]]>]RY<HU3AQ7FGB<M0:)SY^[(LY1R<KI
M%,<XQ*4K DQE^5MW1)3K_D-07BESIO3%4^JZY>968#9WT-]W&+VNF-R<*FN9
M"26KXL*%ZT(,$=!YAXN7KEM?TRLKJQ?P?8*KH@-'%LX*F)ZV@O>*2HLXY$G&
MQH\*J)X6T*_4.FX2L#Y'?_^4%9 KI2R.""D\=OP2TS/'&9?M]0U-T=HY1*,0
MC 8A W66#B%\%FHM[;3U#M(_,4M27A$'_ /QT27BJ8_'.3$,^Z0 W'+#\2^/
M(] H!D <3(PIG9BR--*JB\DVE:/+RR.[N)1L0Q&:1#W!H2H"@L()BXK%+S0<
MO_!P@N-C"$F.PSLA7,"JEQ@Q)YEZ6TM0>*=%XZ5D%Z>JL(WW9WOH(;8$'.2
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MB S>SL9U;_/V:W]@PXIGV/WML]AO?HY@IW?)46^D)M^9BG0G,B)VD.B]BNR
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MR!(MT15)9+054#)<3?EX'66C-10/F2CLJZ2@5_QQ3P4%767DM0D&M!22TU!
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M2@+>H-#]95*4>J@?_0=^K_X3KL__".>7_Y&@);_!__/_Q/7]GQ*TXG=$;WN
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MF,3<-I)R.XE.;L GM!A7GQQ\_&7,Q>C(2/ E.W8CJ4KP//8-JM0O8PA^G-S
MQTAR?1#_;;_&<<WO<-_R'#&NJU![[4 ?ZDJ6)HJ8B @2- D4Y&>0EQI,E-]Z
MG':\@H_M.Z(37U.5O)?N="?*?%<1MOYIO+Y]4'3Z%3+#EEN!=8##$CQL5Z,*
M\"'8+P(WMTAL#T6QY4 0Z_?ZL?U ,+OM V5>(!Z^P42K0HGTL,%YQ8OX+'^"
MJ-5/D+#NKP1]\2<.O/EK5C_W<[YXZJ=\_LS/^.;-^_$]\!6AGGOP=+4C1&QQ
M0$0L;H$Q>(0F6,7%/QI;%R^V[]C*]DW+\'%93ZCWU[C9OLZR#W[&YZ__@EU?
MOTIJN"/.VS]CRY>B\RXKB=K^*D%?/4S0\L?Y\J$?\\IO?LSF+]YF0.RCU8=R
M740!)0)<KDU3F&A'I-/;I :^3W;XVY0D?$1][FH&:AT8M?C27N5!9OQFO&P_
M9,_:U_ [N$ZNX48.K/^2]5^\RLKW_\K*=QYB_0</L.,S1>YG]1L_X]O7?\KV
M=WZ&P\<_PTWTUO?3GQ*^]#\)7_8;?)?^$N=E/R?-YSWRHY<3?N@E<M7?"(E9
M3YS;YY0GVV#.<B0K3LDB_II8GR_QV_\V'SSU8Q[[^7T\IV3@?_L(<;ZODAG[
M-KJ(5^38_L [S_XKVU8]2Z3_-NL]3X[V)D\3394^C6)U,A[[[/AV^7)VBUWU
M]['AT,%O>.;Q'_.'?[V/-Q_[9U0.GU 4LXX$SP]8]=Y/>.;A^WCV;[]DX\;E
MXH=J!;/=X(ZU*_$MP6WWY-*5<RP<F;5F;34UUE.4GT56<@0-)5&,6!*9ZDRC
MO2:)DMPHLM/C:6AHHLG2)WB@E^;Z/GK;)ACJG:6[<X+F%B$M#3T8:[NI;.BF
MQM)%HZ6%\K(B2@NS9+P742U^V"A^V&PRR+:JJ&MLQ%C32G%5&X;R5O&W+124
M*W6$?V@^5]&.T=1!?4,7];4-5)84"-A-PEB43$E>'-DIP>@UWJ3K@R@RJ*FN
M$C)1F45)<0J%AD0*<N)DN7CJ*E*H*]%BRE51DAI$54Z,2#R&I&"JLV-I*TNF
MPYA,:[F:CJH$!IK2::Q(H*X\B8[&?/K:*U :W:7*M4E/CD2O51I#!A ;'4*B
M-H[4% 'TD9&$A82(!!,9&H0JQ%M\P2%B- ?)+/:GHD5#>7L2I1UZ2N2ZEG1D
M4-PN&*0UFX+F;'(;,\BL2T5OUI,H>$AC3"2N-)&H(@U1I5JT->GD]U9@G&RP
M2LF(&4._D;SN,O*Z2LGO*J.@4SZW%I/;5$A.70&9E;D8S,546LR8F^LP-S50
M72]24T]E5:VU.5U]73--36V"^3IH;;D7(&YJ;+76%59*1BC9P$J@6,D6KJFN
MMV8,*V4FE(SB!O$_2H"XM%0I82%XL;Q*Q$BYL5*PI.Q3"2XWMEB#Q(U-7:(C
MHC?-O71VC0@FFK&6FE"2%)0WWI3,825PJP2)E6SBSLXA6EO[L(@>*0WE:I22
M(XU*0[Q>.MH%3XT>L=:N[NF9H$7PLE+B9&)JD<-SISEYZC(G3EYD<FI>]C5$
M6_L0 _VSC(X<97S\F/5-NM'166O9BKG9$T+2^I@<'^?6]8O<O':6"Z=G.;TX
MPG=7CPG1.2]RX5Z6\-EQSDZ:Q;8DTE,53H\QE$%SE-B;6,;:4CD[5\_M*U-"
M L[PG5)7^/9E;MV]RBTA4]_)YYLWSG+ITA&N7ICEQL49;EV>YMJE"2'_8UR]
MK$SE^Y5Y;MPXQM5KBYR[,,_QTS,LGA+<>&*"Z2-#C$]VR342O%^<3ISH87AB
M**'IT7BFQ^"0%LU^O8C@WSV)L6Q/B&.C1L/:."V;U&DXI!L)*^\GMFH:_XP!
MW)6ZBD)X#PCQW2=D>&]X.WO"6H4(MUO)OI)9%J@;(SQ-"1!/$9L]34SV%*J,
M<8+U0_@F*@&&/ER$E#L*D;8+Z<0V1 AU<#<'0GJLGYV$7'M$=^*GZ29 VT-P
M<I^0^B'B<X=)*9Z@O.8(+0UR3YI/<KSU#)5!9E3?Q!+Q532QZQ)(WIM.CD\I
MLRVGN"1<>'C@"M4-BV273Z$M&$>5/8:O?IA#\7W6S#>;H!;V^%BL0>+M;O5L
M=:MCJWS>I@0W?LA^V^5O8;<21 M4FNPI]2N5AGL=;//N8*MG!UO<VMCBTLJ6
M0RUL=6EFFUL3.SV5#&6E*5ZG-0/36SU >,H0"=F#9!;V4E8A>FIJH:VFEIG.
M>BZ/-\*<^*V!#&X4>W T^&MF'-YAVN9U9FW>XO#NUYC<_!PC:YY@8NW?F%[W
M#%/KGJ=_S?,<=EG!^40'3B<Z<EICQ^G8/9R,WL)"Z&KF(U=S-F\/-]I]N3,3
MQ\W%).'N!?"=2<B>B>_/BYR6S^=,W#R1Q]5%'=<6$C@W%,2I-G=.-3ISLOH@
M)XSV'"FU92!M*PVQJR@/^8)\KP_)]?B  M]/J0I?3EW,*AKCOQ5<O8Y6_68Z
MLK;3EK.+ILRM-&=O8[+Z$,?: EEL#Y;QX")8=0W^SA_CY[J2(*\-1/AM)=IG
M(X'.7^.R_PML]W[!0;NOB0@_2)4QA8JR5(RE&5AJRQCHM# QT,7,4"^+TR.<
M.3K'I;.GN"C\^)SPX)-'SG%T_BPSA\\P,':2FK99:QWA//-I$@QSQ&5/H,D9
M1U<X14K)#&EELV+_%L@Q'2&O^@BYYGGR:^:L0>'\NK\'AV?)JIHAO6*&E-)I
M$HLF41N4^L/C1.5,$)$Y2DC:"(&B7_[)@_@D]EF#PJX)?1P2O7>.[[%FV[O&
M=8ETX!K?*=*!>WP[?HD]1&>,BNU?$-MYGJ+T,32>%43O32/=R2#\P4R5RDQS
M2CLC%5.<[#S+T8Z3#-:,4Y7=0'EJK6#H-OIR1^C6]Y/GG,^!MVRQ?=^!D%UJ
M"O4=XD?G*:TY2E+A)"$I,A:55^5E_-H'-[,_0 D0-[%']%W)GM_KKSQ D?$9
M?&^<*C5<'<.[.:3JQ26ZSYI5:CU^=3ON(EXB/II6@K065,D6U*DM:-.:2<EL
MIJ"@C=IJ\16US>(G*QAKJN%$3S/G!MNY-C7([6,S<$%LYY73HI-*T%/DMO+Z
MNDSOGN;ZXC#'!UN8:*^CUU)KY0)E1;EDIJE)2O 7_'L /Y>E>!]\1[B(8*2P
M):1'?2[X^'UB/%XDRNUYXKQ?1Z_,CUQ.>O@7) >\BUKX8YS3LR0X/R><0WG+
M3C!6T(<8HD2W1;+"/Z%,^PWFM$W4I&W!K-^"*7DKIB3A?+I=6 I<&6F*9JPY
MCM[J$)H,;K06NM)J<)1[L8><\*]1N\HQ.+V+(7H]QJ0]5*?:RW(>-!=[4R?K
M%Z?L(S]I.SG:S8(]UZ$-62%CX$NBA#<&.GV*RDLXJ-Z=\OQH:BLR!5]4,MK?
MQI')0<[-3_'=^1.@E)Q0KMWED_>F5\]R^[S8O^/'6)R:8[!MF(ZZ?BSF/O&_
M[1B$.^7D-X@/[J>@I%\X71?J]'Y4>K'?2O:P\@ @1O14[+12@]I))?9:Q#FZ
M7_1W0.Z[,NVUEMY1&G_:*:6'E!K$(4JC0[&7@19VBLW<X6L1.]K$5N]&D0:V
M>HE]E>DVY:&<-:.XU1HH/J067=0.X:74^DWHE?'0@4=<&]Z:=@*2NE"E]:,U
M3*(O.4RV\0A5]6+W2^:H2!^D(KD#KRUAK'M]"[O?/T"231HUH<W4178P47:2
MD]VW.#IPG=&N2U@:3PI6G$9?-$I4KIRK;-<GJ1\O\5N>ZD'<Y%R=([IQB+@7
M)+95 MG60+&,DZAN7&)E/%NSJ >L 6TOY8&/TLA4W86;C&N7F"[KFS).43T<
M5'5CIY+QHSQ0%7]F+V/%*>E>D#BH<(+H\GGB*X^@K5HDM>JHU?84B+VI;INC
M=6">OO$%AN7>#0PK#[B'F1@=HZ^SFV;!P&:S":.QG/P" _J,--3)6F*U:B+C
MH@D,\<+-<[?PRBWD9'M1*[ACH$/'V:.UW+TQ(F-J0?#)41'1%:LL\OWM<6Y<
M:1$,4\C$8"(=#2'4E+I0F+J;]+@-I DO;:L,9G&TD"MG.KES>U[XP%F^^_ZB
M\(-KW+U[@^^5A^+6@+#HHFS_FH)/S@]QX\(P=X1[<>.P5;[_;I8[M^:X<_.(
M+">Z>E>PTIVK,MZ_$_G_:9!8^5."O?>:U=V3OV<.W_OMWN_W L)*9O'_:FBG
MU.RX=>L&UZY=X?+E2P(8+UNSB6_<O,/Y"U>8FS_&Q8NWF)X^;JTI7%K>8"T#
M<?S456LPMD$ <^_ .)>O?<>UF]\S.W^2\O)&DI,*B(O-LDJ-N8O%(Q>X?.6F
M-4!\]=IUV?8E)B9G:&WKM@)M)4A\YLQU%A?/<4H M9*1D6<P8:H5QU/727:N
M$;U>"%EA#=U=$XR/+C(S=4*F1ZBL:!+GWF"MBW-DX307+MZTEL0X<^$J<\=.
M,31UF(ZA87HG)NF;FJ*B61R,(1?_M"3"BS-Q28UFG]H7I_1P_(MD(%2F"&A-
M)R17(X OD6R3D)WJ*DK-M50W-=/0T45#5Q?FMA:,E@8! ;EX1 3C&1F"=W08
MWI&A>(4'$QRK0BW[2,D3XF6JH+:]"9,0H]J.)AK[VJGK:17 4"Q 0D=6F0&#
M4<BKJ52N:3V=W6U"6GH9'QMA9F:*OOX>LG(R2<].)Z_(0*FQ@GHYCRXATX/C
MPXS/3C"U,,7$_ 23"Y/TC_8)^3*)<4XE.4UG?2+4W-(JQF!4MC?+PL(B1X\>
MY_CQDT)>! R?.L%1,?BS0M";.IH%9.:249A#?EFA &"S@*!!YH\M<N+,*186
MC_RP_DG.G#W/R3-GA# (03HJA&JV$4-/.L$EG@17!Q#>K"*D547DD);XZ30T
MLYEH#F>3.)>'?K$ _7P.^KD,]+/IZ";E6(=TQ#?%BD%WP,YW!R[^=J094JEN
MKJ6UKY/N(:5$QA!CDY/,+=P[#D6.*^=P\CCSBW.,38\R?GB,9KG.X:I@;/;M
M9-NF;['9L8'=FU:Q9_-*'/>O)=1G%\DQ=N0DVJ%3K2?.]W-4A][$=<.#.*W\
M+5ZK'L!KV?WX??0'@M[X/?[/_A*OO_T[[D_]&_ZO_H+ M_^3\$_^2/JVYRAV
M?YN2H'=(=7L.SY6_9/=K/\+WJS^0Y_8NI8&?</"+G[/ZU1^S]=/[B?-<CMI[
M*2JGMU Y/H_>]R72?9\DSNY7%/@_2*/Z>2PI[])<N);N>D<F>@)I*=U%8\XZ
M>LIVT6.RIR9O-\DA2W%8_SC>6Y\A-^!K2@)7D^VVC!B;C_#<^1%A'MM(2PHF
M-2V.@N(L\@TI.-MO9.OJMSFT^U,:RD(8;%;34A8HH&8K.[YXB*^>_Q&AF_],
M_,X_D[#[45(<_TKHCM_BO_TW:.3<,L(_)T'VY;E_)0D1OA3GY6(RU=':/DA;
MSSBU0HYSBHTR7HLHS#(0[>N%Y]XUN.WZD"@/.3:?I0*R/L/;Z0M" _:@C@LA
M0A5$2+ G@7YV>'OL(#\[3 !:--]^_0KKOGY= /XVBK)B,!>E8<K/H"@CA=R,
M=,)#@EGUU1<L>?M9]JYZ@WPA+H<;0YEK<,,8_P$&U3,"QOY,<?PC9$7^G'+]
MGX1$OT-=A@*JGF2?4N/590,Y"1&4Y&1CR"F@M*(6LY!^8Z. ANQJO$(S\ G.
M(SJVE.C09'8L7\+>96_BOO53?.Q7X>F\&6^O X3).<1JDXE*R,(S)(5]A^+8
M;A>%S:%X7/R2" A/(B(V'G5\*+[.&UC_\0/8+?\#JNT/DG'P(:+6_YB$'3^A
MQ/=O&/Q>)-[Y!0ZL>X+G'_\G'OS/^_CPU4>HS(^GMC@6E>\&7.V_(L#O(%&Q
M:IP\PZW["(XK)3Z]A5!U#2Z^>=@<3&*?G187MV3B(I-)"'5$'[R"@L@/K4'A
M!,=?D1_X&&D>CZ)Q>L+ZREO@@7<)<5Z#+L*=RKPTJHN+R<_(1ZO-)DZ=25)B
M.N6&+))4[CAL_1B//1^+'G]!JM<*BCR^)F'#BWA^]&M"-CPDVW^!9,]W"-SW
M,GY[WR7@P$H"#\H]#PI%K9+C.A3(;AM/MMEX8./HPT%W/SS\ P@.\\75>2=;
M5KS!DK_\.^N>_%>\/_H3F9M?PO65G_+-'^[CLS_^")M/_\S!KY]C^Y(GV+?Z
M%6PW?8S#GM6B1XX$A?@0$!9,4J8<<T8&H5$J#CK:LF?GM^S<\#&;OWJ!O>M?
MX.#VE]F]YDD.;G@#V]7O\-6K#V.W]EVB7=<0Y[B,7.>EI&Q] YL7?\Y+_^,^
M7OO#;P18VS$[-6SUK=_=O2J80\DDOLC=RZ,4)NPA8,^3!.UYA C[QTD)>IW*
MU*]I,.R@N=2>ZNP#J%P_9_D;O^/)W_XCV[]ZGP#[[<1XV0K)V$GHP16X;'B-
MG1__D=4O_SL?_?D?>>(7_XT'_NT^GOKU/[#\J7_GFR=_S+=/WL?N5W^$W7L_
MQOVK7Q&V]TGB7=\FVNT#O/>_+O?F17QM/Q+"LI,4U39TD9M(BEB-R][GV;7J
M(39]_D=>>^S'//+S^WCH%_?QW"/WR37Y+7%^;Y <]IZ<XVOLV_@"^[9^B"XQ
MF.;6&O2IR:0DZBE(RZ<DJYA4;28):AVYN;E$1P:Q8^.7//O(O_+77]['5\_]
MAQ"CSXBQ?XL#*Q[DO:?_.T_\\1]Y\(^_X)777J*@T"!XXP+?W;ZN7,5[HKP*
M?TWI/[! ;V^_^*HQ>CH[:#05TEBF%A 925]#/,,=&4+BQ*<5)=/48J&^I5=P
M0@]U=7TT-XW2T39%1^<TC2TC5-;V4BBDI:RVD]KF3BRMS1@K#)04IE)ORJ5!
MQ%R>*=]%UZM*J*NO$[S10D5UFZS70EY9$_GE+=: <6%9*\8J)4 L0-K2256Y
MD2+QQ[FI<=;2#U4EB9@KDDA6NY,4[TZ>4C*B.IT:4[JU<WBM2?99G4)]92*F
MHEA,!;&49$:@B_8@32,V."&41)4W91G1=%:E,=B827]=LNA-!!497C2(3>QO
MRF.RMXJJ0BUY>K%;F7&8BW7R/0E#>@PIVG"Y1U&DZN*(B@@@3 !]1)@G,2H/
M(;K.:&(=,13XR;5)$'^:3J$YGMQJ#?GU>HJ:,S%8,LEI2">[+I7,6CT9(NFU
M*>C-R6@KM<25QA,EQQXOYZF4H"@=-E,YV4C%1#U%0R9KT%@)$F>W%Y'54DAV
M<R%92JF)&B'<U;FR+\$YU444F\NHK#-AENM=V]!$G> J)7A;KS2=J[7(?;!8
M,WXMS>TTR50)")NJE)(4#=9ZPTK6L=*DKE:^5\M\)5!<46ZR9A>7EU=: \-*
M0[OR"OE<8:2V4=9K;)+]-=ZK9]RF=&0?$/WII;&YQXIEAT>53.!9E/K$2N\*
MI01%9^<P2J9Q2TO?#R4E^@2OWLL>MEB4@'&?[+-+CJM#CK$+2U._Z,8 C0T]
M#/0?9F+\&$.#<QP[>HECQR[2US=!3Z^2S# AZPI>:I^DI7442\N X+ KG#IQ
MD?Z>8;K;.I@:[N7BB0ENG!WC]&$+,WW%7%IHY*Z2J7-3B-CE&4Z-5-)5$4%#
MOB<M13YTB2^W%'A2GW>(A@(W.DVAG#U<";=FA" =ER%VGN]_R H3EF\- L\=
M;F!NLHJC,Y6<F)?I82,+4^7,356P.%O#Z:,MG#O9S?RLA>$1,VUR?ROJ%$R;
M3I'@Y*P\#2F"H9.2(E&K(]#HXM'FI!%?E$-,J8'(DB+""PH)R2_"3W"!<X:!
M+=$Z-JM2\<UK(;)T!%71./ZI2@W&'AR$U.\/[V)/:">[0CO8':9D2PDQ%@*M
MO((<E#)&1(:0X*P)8G.4&JT31&:-65^]]T^^5]M2"9(Y*5W@P[JP5U[S#>G&
M5N1 <#L.H>VXR3Y\U4J0N)=0?3_JW%%2BR<IJIZ7^W&6\LQ^]-Y%:&S2T&Y+
M0?UM$F%?1!&_-A&#2QGM:2,<[16^,G7'VK2HO&Z!]/(I8O*&"4X?P3MY!%?-
M$/9R#/N4!EV^S>SV:F2G1ST[/$7D^R[_>Z_>[_&3WT24UZ5W*PV._%K9YM/,
M%N]F-GNTL-FME<TN\OF0S!/9YMK,=G=9WJN5??Y*K==NG"/[\%8/$:8;09.I
MU-SLHZ2DB^IR&4<550S7&CG360%#Q=":Q(5<-PZ';>1,S!Y.1.]C-F(O5_4>
M7-78<]1S)7U;7Z%SW7-T;WZ-UAWO,QOKP.6:5&8*8Y@V1+!8$L'YZDBN-D1R
M4_#]S=XHSO>%<W(HD@MS>JZ=RN?6^1*^.UO*]Z?+X$PYG%/$(!P_BSNG4KDX
M'L'I;E_.MGMSSN+%"9,+T_D':$O8B"EL!87>GZ*W?8/XW2\0M_LY$NU>)MGQ
M570N;Y+J^3%%$:NH3]E)>[XM?:6.C%6Y<:3!G[DZ/SKS[4GV%XSM]KE@4,$S
M@O,-Z7Y4Y(7*O?4E*7P7?DXK<=Z_#!_WS6CCO:@H3:6X, 5C60Y=;75,C_8P
M/S'(W$@?I^8FN'[^I(R;&]P6_OK=U9O<OGZ7:U=O<_KT52:F3]'2/4=I[6$R
M2N9(R)U%G35-8LX,Z<6+I)<ND%8^2V;5@K5AG"*9RFO@/XCR6<D<M@:'RR9)
M+KZ7A1R?/TYL[CB1V:.$90P3E#J$O_(P1#=D#2*Y)_3B'-^-8UP/!V.ZK:_8
M.RI!)-%OI\@.:]F60]&=N,9VX)/0C2IMT-I,K+;Q-)5%$Z2&51*\(PZM;:JH
M10>W)V]SM.4DE>HZU$Y)5&EK6>@\P<T3WW-U\2YCM7-D>.01M246KZ4^V+Y[
MD/#M\91KV\0O7Z:AZ32Y%7.H\\8)TLGQQ7;B&-8FX^]>)O$^)9/X?PL2[PM0
MRL(H 6)EK';B$-Z-DZJ70U'*@YY>7&0<'XI3RLRTXB;B$6O!3]U$:&(34;IF
M$M+:2,YH(S5+['Y%!PVU@A>J&QD6KCO7W<F1GD[."'>]MCC#W?,G!*.=YOL;
MRD.VRX@A%1%[>/TXIV8'Q*\VT]<JW+NE"4M#K?B1(L&]*N+B?8B-ML?5X5/<
M[-\DR.,=HOS>)3;@3:(\GQ=<^PA:OU?)C?V<Y- /28OZG*RXI63&?$:>S#-$
M?TINZ <41'Q,2<P2RM3+J4A<14F"DHF\E$+M&LKT6X6?[)+EMY 3O16#9A^%
M.CM*TITIS?*@/,>3BFPWJG/=&:Q5,=T6QTA#*%5I>]$%+B<Y8#F]5?[TFT-I
M*?:CK2Q(.&. 8 9OJ@UN=-<%,]8>2;O)BVS-1L'@R\F(W4AF[&9RU;LI2W/#
M4AY/5UT.W0TEC/0T<GBXDV.CW=P\.2MC=@[F!F&T#<8[Y/,0UR;$9_7W,"F^
M:M#206==*XV5XH\+C91E%PDV*:*VI):*@CJR,NI(E'L5I>LF6&RN3[Q2&[X7
M5R5H*O=<>3C@$-$K.MN/4W0_CG+O#T:);8ML%5_0S-Y@"WN5-S)$=@6VL%/)
M(A9[N<._A6V^%K&5C?]+Q,YN%=GNTV2UJ?M"VL5W]..F&<9#;+*;N@\WV;][
MO%+FH0./^'L/('P3NPA-'Y(Q-R6^8(;"BEF:&DXPW7^=AKQ^P;-IN*_PQO^K
M4,*_CB=TA9HT.\% 88(IDGL8;3S+6-=EP2?SE)CG2)5QK,H>D&W*N-6/X*<=
MQD<S(&-">=/E7F:TK9(='=Z!K5)N)4+&;%2WC%6ES$HO7C*V?>1:^24JTB?C
M5WR;1LF\5DJQ#%B;^#E%=]\;]S+.#JIE_>1NW#/Z"2P8)\JX@+KZ*,GFXZ2:
M3I)1=93\VD6,K8N8V@]3TSE!7><(9HO@EX8VP5ZM<NQ-5%::Q7>4"KXN(D>P
M?7):"K$)\43&11(>'4:HRA</G[V$A-G0W9W'^=,=,J9&!6.,"[Z8X.[-29$I
MOO^?V<1S7#_7Q+&I5 9:12]%!XVY=F2IUY.C_I8\]2KRXKZF(&8-QJ1==)8'
M<^E$J_"!HWQ_]Y1,9;Q: [UGA2?(]KZ;XOK)9H:;M?361C+5H>7L1#[?G3#Q
M_;DZKAZMX/Q"&1>/UPK6&9?UCLKZYV0["L=0@J&RF?^BO__/!XG_'OC]WP/
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M79IQCM3R672EBL[,D%0\35*14JI$J3U\+W-8"5)%9X]:ZUM'9(T2FC%,0,H
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MCAO +E()=+>S)[@%F^ F#H18L ]K1>G4KYR+FRSC%-4KYZ>4P^AD7T K.Y5
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MH*3AD)SODIS'G.O8XW*4YEO3,O]F7/63(S+'"<N0>6T<$7T?QL<5&!YDIVJ
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M*5_?<,4J[]R]QUW!.7?O"4:X=YF[\MTW]TZ+'.;\T5;F>HUTE08P5.4GXL-
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M-P9]>AA)N@#QN3Y$Q/L2DQ2,.C6!S#PS%L&,3J>3NJHJ>@5;+4V.<?W<<9G
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M=^ ,9\]?Y\K5.US^ZC;'3EQA='ROK">@NV.*CLX9^@<6.7ST/(M[CM(_.,O
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M_OIQ I7'A96ZDDI]2Z7A3^8DB7ES\OL%$2'0\CJ^8 9U\2P998LX&_934[F
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M/\"N_HBB9*4WQZ?8=%^0E[R2Y-#/B/'_C/B@+U"'?4IFTI>4FK;07N1%7TD
M Y4AC#1$,=82RU!3-!T5?C04[Z R=R,VPZ=BHS_#GK$&NWD+SOQ=V'-WD).V
M&GO6)EK*O)GLB&&H,9+V\G#J[3%4%"90;4NGJ][)9&L=!]JJ.=-HXV29B6-V
M \?+LKDVT,@=\4TW%J<Y/37!\D _X^T=#'=TT2/VI*6IA_KZ7FKK!JFI':.T
M:HSBJBD*JN;(*IO#Y)PCHV2>#,>BZ,W2_QTD-MKWDF;;2XIER14D5AHQ)N1.
MBHZ,$Y$Q2I#A?C#+7ZGGFS+BJD7LE3+*[I1QO-,F7.(E<T-Y;'VW9O"^: ?8
MI>F590]!&0/$YH]B*)O%V7Z(OK&++$U?XT#?67IS1W&$5F$/+*-%+?8PN8W(
MM2IBMNI("\K''.VD(D_L9OU!VMI/XZP]2+82Z';,DUZR2*I-R=B7.9 _04*A
MZ+=%"1KO06_?)^=Y0&2?G-^RJ^ZRDB6=J)24,4^YFMGYZH;8K5:"Q$HVL1RS
M>E@^&R5 /T:P:<)5:S4N7^9ST2(ILLT,YU[,94J3/Z51Y*1P]TFT)=,8JF=(
MJQHEWMI*;$$=B875:&W5I#@J,)8)!ZNI(J^^FD+Q&]:&"AP-93AJ[127%9!?
M:,)LUF'*2,9F2:?2::9.\$%KG8F.!B-=C2GTMVK%!XN>. ,8Z1#<,9S.]$ :
MG37A-#J\1(>\F.\.9[8SA*[R712DK,.8\"7)D9\2Z?^6JUE=L7Z58' WQIS;
MF'%N9\;FSEC!!OJS5]!I_I#>O$\8=ZQA3[4[B]7;F*O>R4R--S/U 4S6^C-6
M[<=L4P1'AO6<6[)R?-9"7X-&?/\N$J+6$1NQGO@8-V*B-A$?NX6D.'<2HMV$
MA[F1FN1!OCG E35?[4R@SAE';4$HM1F^-*8*-]#N8BAY!Y/QFYD.^9!)KY<8
MV"Z8<./35.U\AX;XK3C2?,@W!9)G\L.B<<,6^R6VR,^QQZRB6#B*)6X#14GN
MY DG-4=OP13F3KDQD<[R<FK*NK'81S!9QETUNW46Y9J*WN3/$Y<[YPJ,!FK'
M\%&-X!FO-/#LQBVRDPV17:R+Z&%M>"_KE5(28<J-LR[<0GO8$M;O$K?0/C:'
M]+(QN)MU@9VL]F]GI6\K*_U:6170QIH@)5#<+K_MP"VZRU7K>)>J'V^QF<I\
M4O0P5.:84KY(\1]*B1=-T83,UWGJ6L7O#U]GKN$4Q:$UU$0TTQ;?24UD+;:H
M$JK3&YAO7^;ZWEO,UNTA8HT*WT_"\5\93=RN=#JJEUR9R%5U!\DOV8=&J4DL
M]MY?(WJOE%E)ZL-3J2TO>J\\31*4-BY^3*FW+^-3,$^*]7ZY"263.*OLH,@A
MP5E'Q(8<(LTJVQ,?EY MZXNM5V[0J(OG2"E9PEB^G\R:0V37'R"[<9FBOD/D
M#LC\ZQQ U=-%;$\+H=VU!'0X\6[*Q[/2P#9; FY9@6S+\":A+)&"CBQJ!NVT
MB%0W9E!0(+Y/M54XQWH2XT1BUZ&.VTBZ=B<EA7&,#55R[NPB=^^>Y^N[XO]O
M?\6].TH]X"LBEP7GWQ#:=#](?%N S-VO[_&U\*B[PJ,44;#,':7,$4HYOPLB
M)[EQ99)KYP:X)4LX(7)%1/B7<KM<<-"]KY7_7&_OR]]BHG==H>)[W'(MOY'_
M93U%E!\I+_\G_/W_?9!8^?L? \6*_#]J$M^^Q<V;U[EZ]0JG3I\6("K S;6>
MC*4,YEU!FGOWG:!O8)[.KAF7M+5/T=(ZSL#@'KJZ9ZBHZJ2\LN-^L+BLB>[>
M22%OAUP9PD,"<I7:P\KOZQM&Q"$.N#**VSO&Z.@:%QFCO6N8VH;[3>[,F67T
M#RCE(RY27J%\UD!-71?CXXL</WZ!\^>O<^C0.7H5 #VZP.V;WW#C^M></?.5
M*Y!]\>(MCAP][VHRLGS@)'-+AVENZZ>\O!&'O8;*\B9&1V:8F=[#Y,2"@/H#
M3$\OR'G(.A4U9.7DD2)D-R,OCX*R$DJ5C*/A;C(JK0(XXP64!;,]W!_?J##B
M=5I4*6DDZ=)(3-6C-IM096<0E95"DC@0)8LXJLQ 1(61A+IL4NH+B,Q2XQ\?
MAE]8("'AX:Z:PVJ5AK0T WEY!3B=97*,5>@T*7ALVX'/+A\"?/P)#@PB(BR<
MN-A8-!H-YJQ,"HH*R,O/0:U6L77K)C[_]$-V;-F"C^=.@OQ]B8H,)R$A_F^E
M)W+)RLIQB3DSBZ#@4#9N<F/-VO5L<7?'V\^'L(A0D1"2DN/)E/,P9QK)S$HG
M.\>$*=- FEY'?'PL'A[;V+!Q'5NVN.'CZT-(J)Q'7!*I!C/9>58A!B7D%EK)
M*Y#C*Q125Y2%/M] ?'82?NG!;#)L8Z5I(ZL*MK+&OINUI?ZLKQ"CTQ"!9W,T
MNYJC\&^/)J@CFH"V2+P:PM@EXBV.SZLA!)^J8/RM07AK??&-5/8?2$Q,))ID
M->D&$SG9A4*.[=B*A20ZRBDKK:*B7*Y]59U<8^51V!(YOVS,.9F8<\WHS7HR
ME.QI2P%EY954UM32UMW-PKYE#I\\PNGS)[ATZ13GSQ[AI(#A \L'&!V:H+&Q
M%;O#29$UGQ*;F?K2-)K%J;8[_040;Z.KQ(V,T!?8]-J_L_:%?R5DY6\Q^CQ#
MU,:'^>RY[_'"GW^$S[8-:!)32-45$Q&13Y*J G-V#Q;'!.;\?I(-C<1HRXC1
M.5 ;+61GRG6)$>?J\S+6@$=I3GJ:(?/+C.:\1$/B@]3&/TB7\04Z,]XER>UA
M7OJ5$OCZ*;X;7B!HYVK\?;P)"=,0&6<A(*($#[]B-N[*Q\VG@"U^>7@$Y1$4
M;2,T,H^$.#/%>3*6)@U)H6YL^NP1_+8\16;BYS1;=M%M]Z.UR)NJK!V4I&_'
M:5(>X?.A+-<?L\9+0(\'&:EI9&5:1:=RB4DJ(#@Z&Z_@-"&4V:)/^609TE&%
M>I/HMXK4X ](\W\9U?9'4&W[,U4IG](AA*+"_!DA[K]BTX?_.[O6?I?RO%4"
MPKPIS/&6\?)"G:I#9RHA1E-.9'(UX:IJ@N-+"8PL(CPF7[ZWHDO-)2(\$K<-
M*\A,BQ"PEDI;03#E49]2$_HF/=H/R0W\$W';?D2\QT\HT[Q*7>H'%(:_1IK7
MZWA^^&<^^>LO"%G_(<E>[JA]=J'Q]2?1<S=!ZU:QYN5'\?WR)6*VO\G'S_T+
M1>J5G!P1\)BQG8JX+S%XO8S;^]\C:.L#Z*.>$G#T*/GQ2G#V<0(^?X#5S_\'
M&U_[$;';_TJDQ[.D1*RBQI)&76D1#0)<.SJ[7=EK/<-"'"S51"6;,)@+7#<I
M#.HX5!%"W&/=L.BW49FWE1;[9@9JW.@H_HR*U)<HB'R*>+<_L.7U'_+N@_^%
M-4]^EUUO_A+W5WZ _Z<_)V[K']'Z/B-D;2>3#6IZK:$8MCZ/[_/_CO_S_XQZ
MY<_(\WZ4XLB7,86^CLKO'6+\5F#41+L:; :%J?$-3Y/YF(Y_E('P*#7AH2&$
M!;B3%+Z.:*_7\/CD5[SQ^_^"]P>_(-__.?S>^&?BO_@)F@T/\=[O_I'-+_T[
M*3L?QA+Q'%F^?R'-_0$RMCV$UZO_SEN__!9/_^A;^*_X R6J]ZG6?4+(IS\@
MY.-_HD?T?;K@3=HU3Y&^Y2>$?O#/."+?Y.:<A2,]*?06;*8T[FF<\7_!IGJ8
MG.2'28MYF"+]NP+(U_#!4__. __^+1[XSC_PZA_^&^M?_ F>;S_ IN=_Q*IG
MOL^&UW].\(:G2/)\CG3_%RB,>AN#[\L$K7J8E2]\CS<?_2?6?? @V6F>A/I]
MB%Z[@^M7]XKGO2GRM3C16^),KW+YZ#3]3O$7JYYC]Q/?(>39?R?ULU^1L_41
MS#N>(7SU$X2YO4M*5""67#M5E8,T-RW1W78 9_$PR<F5,F\J\(^V$Q1?C#&W
MEB2M"1\?+[9O^AC/#:_CY_8:(1YOR?EM(,^PF_14#W*S@X781!$9'HI&UD_4
MY+/=5X=?1 'A"4XBXAQ$Q#H(BRHF.+Q ?$ 6ZD2QY>+7M+Y;T6YYC>QMCU$;
M^B1]NA?ISWB)DNB'T>UZ@."-#^&]_DE4X1LHR$QRE2$)BU6S(SB9;4'),@\-
M:/39&/1F-J_>Q-,/_IDG?O93WO_C+_CL3__)LS_X!W[_[6_Q\ _^4:[#?Q"\
MZE'2=KZ!8?>':+W6T63/ER&\+2!&&4=9*D%B 8QW[MP0FWQ2_'@W'>UVFFHS
M::\RT56FIZ\LA:D&,]/U!B:K54S6Q#'3E,Q,1SI#';F,]#D9ZJV0WQ307"-2
MD4M-81H5.1K*LY72$ADTE1305F.AN3:7YOIL6AM$ZK)P6I*PYL919M526JBF
MIEA'1X529L)(HT5+F2E&="H">WJL;$='D\/,>$<%"\/-..5]ABH$DRJ,,ME/
M39Z!FIPT:G/U5&7*]M*3[I>",,5CR8QS9:1WM60QUE](6VT*K>7)M#E5M)>H
MZ*LQT%DIQYP?1;>\7A@JX?!<'>.=A=39DRDPA5!2E$1/6S'[%KJ8'6^FOBP3
MDSH0FR&"#EN:S/-\NIWI8LM3J,M1X]1&4ZZ.$3*HHL.02GN*EF95(DV)"3*W
M5/3J-?0)01[-2V%<;--0H5:(;)J04Q/S'3F,MLBXR3$6YH2)S1?)BB4O1RM+
M'49S,MKT!.+3(DDITF+O<E(Y6D?M; OUBQTT+'6ZEC5SK51.->$<KL':74I^
M:_']QG9]U11WE(J44=I;2_U$&RVSG33/M%$Y7$MY7PTE'944U#N$W)=2UJ:4
MCFBC8[R?SDF91R-=M([WT#S62=6 8$JY'K4C+53*Z\J!)DJ[Z["W5M(XU$'[
M>!^MP[UTC0[1,RHX=6"8BCI91_!#0TL'TW-[.'3T%,=/GA=,>EXPY$$FQA?8
MN^<8^T3F9P\R/K8D&'62OKXIE@0'S\TJ20K[7>77E-X< V+')V</,#BV0*^2
M*#&\2'?W-!UM8W0)-N[KGF1T>$&V=8@#!TYP]/A)3IXYQ?4[UX38*/DORO_W
M7*(0G*MB8RX+EK]R^RXW!+/?$KE]1\G 4;**[XC<OU'%-]>Y<O$((_WU#+27
M,M1FITWF35-I"DU.#6V56CIJM/0TI,AW1O9..#A_H)FOCG:R-&"ER19'OLZ3
M3.TN<@S^%&2'BWV)P&0*(\40A-88@B8]BE1S$N:\=/*+<K';K-1558@N-C,]
MU,_AI2FNGE<>*[TDIO&B8/C+W+IY598WN7;U%F?/76??H2L,3IR@KF,O)0U+
M%"M!XJ;#V%I/4=1T@NSJ0QB=>X0@"_'-5+K-CQ":-DR@;OA^D%B(M%_*&+ZI
M8X+;E2#QY/T@<;J2@:4\FC]#?.[?,]2FB,Z>)$ZVI7/,D5^[CYJF0S0X9S&'
MVDG;EDF&FYDLMTQRMF61[9F-R4=>1Q50H+:1K[%1F&@C-[1 UA6\_T$,_F^$
M$[4ZA>:2>89&+V.I741G'2/*W$]02B_^R?WXJ^X'BD/E&"/2QUW9S4H&L2M
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MC-=F,EQIHL>62EM>,EVY6GIS4NC/3J57['9'FH8F=0+U20DT)"?2+GY\.-?
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M%#M%?D<4JX>P5PW@J.['(W((OUB))!Y#F31!F'Z*J*Q9,\&NR5\PEYN(*UE
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M,20D:DA)3B0U)9FX>*T8$QF*4"6JR%#S^"BE3.0HJ?1'DI@4TS"D98H),E.
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MSR1C8OW2XG&.'1&@_MA%YN?6&!8 _.3YR\RM'::HKA:?,#4>X4H!WA($8,O
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M+=;K^.C FQP(^A2O-'O\B\2$6.*+>ZD?CB7>6!6(\\BWQ:+(@;TECNRM<.%
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M%+O_RN:7?H3*[2,2E%O9_O:_$FC]1XIBM])J%-<IU8$,]5XQ)IOPM=M!D&^
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MA=YD=<>0/Y>!<3F'I(4LM(NYQ*V5HCM1C_YT&YGG^\C^;(2TLX.DG!H@]<0
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M/M:.>[!WM\)# #UWE3<.P1["^3MC*W?!)<0=[S!W/,5QN<IL<?*UP=7/#N]
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MI3)!K126M*#/*"4KKXR\8A/*,"5.+E;BW)TXMMB#*4W.KG=_CMSF)8+M7B#
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MN(#L)OGNKU'%2HH*)1I9.8>R+.RMH+BOFH+N"HQ=911V/7$6E_;64#782.U
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MYQ\]Q;IW_S<>ZW]&G,5O23![!I?/_H$=+SW%UI?^$<^USQ E-B/.^DVB=KU
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MY=AP*D='4KA\M)#'M]KE^VF1P_*;+DY,IHL=\Z"WQ(*!0E.&\XP9DKG9GVE
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M[!7!R??O/^+^@T=<$SQR\9)@YN/'&9^:XNC)4YR_<IVKM^YS[<Y#;@J^O?,
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MU!0*\O(I+RN7>UM#;4,U!77%!&JCV:DR9TVH >OCC=F99<.^? ?TBEPP*/7
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M_HJUJQ:R<L5BUJQ?A9V]-3&1*O9L7\6A_4N(E+%/"ME,D/,"T=N/R(S>0GS
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MLTW1%!.5;K$3QN4>&*G$]2EWPJS&&<LZ5_3+;#B0K<L1032.YINB)<9AJ'3
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MD)/=4"#V)P6%2REJ*J.XN8S\AI^"Q%(FL50ON:JSEOJ>)AJEXW0W4]?9^-=
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MZ^/F= PGJ]WX.>TGQ'DO80* 9H=ID1NE2YS??CRL5I,4NI?V2D?*L[4%(-A
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M=XD1^W31^YS#W_^.P]N^(#HLC)"0)+S]4HB*+T%5.T%-ZS()V>T$QM5B[Z]
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M:LH;Z6UL8ZJUB;E:)7.*5):$?SLK?-&I<!-..^WBO-$JSIM^QK#Q!RB,WJ'
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M A31 KS""4F)T1>L"XP.PRG(&PLA0S;17M@F^N&H",$K+X[ PF1\LF,PC_+
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M'_P4@QT?L7O-VY@;;B(MVH6)_DKN7)_AV5-=SN5OY7KN\O3I+<$AND#Q4[G
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M8NM7;^)P9CWU^9Y\NZ@ASGTC9W<\C^6^ESFS[8^L?_,?6/''Y\B-.D1KD:4
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M\E2)LCR1Y/A0\5'^LLQ7_*0OH0%>A 3Z$!*B"PQ[X2<^PT_^]@\*)# HA,#
M8/S\ _#W]2,Z,A)-02X5E<54UVBIK"JBKK%,2$\U=<TU5#=44U9=25%).<4B
M&DT):G4!ZMQ\<G+5J'*59!?FH"K))JM<24:EDLRZ;)2Z$<2"L;+^.I)8U51
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M$E&BSDHC)2F&\(A PN1Y^D>XXA)@BIWG":R=CHAN'2'(WXBD2"/RDD_17>G
M>(L3XVWV@BG<N3R=R:-;?7S_>%D,UDV^?W27[YX\X+MG.KG'D\?B8_2%JA^)
MW!?\?U/D"GQW6;:[K@\H?Z_#'[I1_[H7.\\N\^Q&)[>GLUAJ]V>^R8N%9C\6
M.\,X-Y#*E6D-=Y:KN;-4QI5AW1?5W@P6G*8W2_Q.VG9:X[?2%+^/OCQ''BRW
M"G'2%;6[PW??/^ I3^3?,_GWUP#Q_Q$DU@6&_S8@1Y=QXJ]TZ__Z]U\V2*S_
M;/69KOJQKJKR#\MTHXJ?/'FJS]^[+$#USNT',KW&W-PR5Z_IB*GN%OUPLV[?
MN<?DU*P TGK**QH%S->0F:%EH'])0.DUZFN':&\;9VST/#/3EZFJ:J>NKHO^
M_FD!_0+:BVH9'M;E-K[-K5M/N';M 8-#\Y24-9.E*J6LLA-U?AVI"BT%12WD
M%C3JI^U=L](AV_3+=:.,%5FZ:;6^(-[0Z#S]@U.,C<WI@]K#0U,LSEUD6):U
M"3AN;.NA9VB"@6%=_N1^ZFH:&>P?X=:=N]QX<)?\IG(.NYEA&>>#IS*:D/QD
MDLNS"4R-Q-;'"1_I)/X)D0(@(P0D^F 9Z8UC2@@AVG2<Q2A:A'OBE1&-=W8<
MGGGQ>!<GZT<2^U=E$M:40T!5&LZY81@GNF*<YHFE.A"GTBB\&V6;E@P"ZM,)
MJTDC4!.+ASBF@.1HHM.2461G4UE=(X"_AY&A8?IZ>L4HC')N?H'%V3G*!%#H
M1NE$Q423FI&.1JNEI:.3[OY^>@?ZY9X,,C(^PMCL!"/GIFB9[44AI-8BTQ6C
M'"?.:#TY6^6'54L8CIU1N'5%X]D3BU=O'-Y]\00/2;OZ,@EMS2"R/D,,FX+$
MHG24Y3EHZK4"2H3<=8I1&NQD9'*4B8DQ)J;$>$^-R?WNH[.O4Z1#UK?1.MY*
M^6 Y$251^ A!\2T/(+@QG/"V:"*[8HF4<X8/Q1(Z$D/P<#11DRE$3RH([(K#
M/,.9 YXGV6%^D)VG]K'WU 'VGSG$5J-=;#BSE8TF6]EBNI5]#OLX(\[<7>F!
M=[XOCEG.G(XS99OG7E:8?<T79]>P^LPZUIU:R^K#7[!FWPH.&VTA(<V=AL9D
M(11I A("J"LTI2)CMP#W#4R7[>=VMS&/1VQY.&C+8N4Q 8 ?X;'[W[!>_1SA
MAW])HX#@ N]-'%[U,]:\]:]L^N37&&Q_BZ-;WV#OVA?9MN(_V/KQOW/DZU]B
MO?<O.!UXB4CC#\D5QZ]RV4&HV3:<3A\@V-,?=]=XS*Q2L'#4<-(JFR.FJ9RT
M4W'*+I.SC@K11R6./BFX>$7AZ1V HZTQ[G9'20H]2VKP(1*\-Q+INH(@V_<)
M<?B4& &H(1Y["/0\1:B_BY#Z"+P\X[&U3<#=IQ![=PUG+-.P<- 5>,O$TS\9
M&T=7K&R,!&SLQ]5JC0!S ;E1^U$'[D3AO)I$\_=),7F9'+M7:(I=P;7.TS1G
M?T6JWRL4QFT@W/$SG,]\CK_+40+=+?!Q$<!B9XVYT1G.&ASG[.'#;%OY*5^\
M_2*;5OX!#ZL-5*D=F6R-)-!Z%4?7_ ?[/_\17_SIO[/BA><XL.J?T"8=$Y)A
M1(SO.L*\-I$2:T9!;@S*K%2BX])P]TO Q"X<4[MX[-R4N/GDX1^D(3P\G]BH
M+"S/G.'(SB]P-ME(M.MV$ES6XW?Z;?R-WL/7Z$-<CKZ%Y;Y7L3SP!A[2]H+(
MDV3Y[<=BYU^PVO,Z)]:_P+8/?HS)SG<PW_,Q!NO>Y/BF3T168K9WG0 X"W(B
M;4D/.$6\UWYRHDZ0'6Z X<;?\/4KS['YK;_'_? ;!)[^$+\3[^%]_%WL][[*
M63FNP:>_Q6#%*S@<.X@Z/8_(R%QYOIEX!&AP\=<5_=-@ZU6(@W<!SE[9N'ND
M$.@;(_?7&<<S^[ \O H[P\]Q-_D"BX.O8[KGCS@;ODJ*YWJR@K>1ZK\11>@F
MHMT_P=/T+W@8OX[EGE<Y^/F?6/OJ[W$\94AQ=@Z5V@I:FKII:1U"4]I$@J(8
M_TC1B=!D(E.RB4_+P,_?#;-CZS#>_29>9S^3XWV)IY!S5].-;/[PMWSZPC^Q
M5:8N9P08N^\AR&437KJ7!JYKB?+<@IV02/-]K^!\\F/B_0X2Z+*=XW)_/WOC
M[S':^PY1'H<XM.Y%]G[U/,>VO,7^#1]P>,L*3N[\4N[S*JSWK\!,GH'!ZO_D
M]*;?87_H=?Q-/B?$^BMISR>8[/HCIMM>Y.Q7O\;PM7_ XH-?8/+I[]GWP6_9
MO^H5]JU]EYUKWV/3JC=8]]%+TE]?X(N7_Y--'[W,H0V?L.6C%SGXR1\P6_4"
M^__R=QQY_7]BM>8W! @Q=MKU,D<^_0GK_B0Z^<&_8[[^17W*BFWOO,"^+[X@
MQC\&-_<XCEM$8.R2B:F'6J8J#"U3.'@R"H-3T5C;I^+IH\#"TH.OO_R*-U_Z
M#S:M^"T^IFLPW_07#KSS8_:\\PN<CV\CP,D"/Q<7HH+C2(K+(2^OEG,7;O-
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M#AP5,&6:YH&]D$R'XG#LBR.PTT3@69%(2+6*\-(,;(5863I8"Q!QQ\?'AX#
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M8>62AD]@ =X>R1S>9<C.CS]D_X8WL-R[0=KK^Q@?VD9H@)NTQQB"_/TQ,C#
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M!OUBLT9[XI@=R10IH%(31FYJ",79F?2W=#'6)WBD?Y3QL2G&IF88G)BDK7>
M^F8EJET9 CM!7\> +K*LN""'8DTF5=7Y-#0)+JFOHKFI67#!,",C$TQ.SK&P
MM"YR1NS_,JVM(W*-0<%F(W1WCE*BJ2 K+5WNGR3W3Z"E0L5(NYJNZF2Z:Y/H
M:TR3-N=&2H0M6?&N%*3Z4YH;25E>#.EQ/F0F!U"0%4&JD(?D6&_R,L)I;]0R
MW-?(Z$ ; [TM<L]JP05%E)>I:&M1]E4ST%5"<W6F$,5HT4V!Q(9Y$!GL25QD
M$*E)L4( 4\C)3D=3)/U1FT]140Y:;9XL<RD0#%9<7$!>02;):?$DJQ))STTC
M5R/'U!13VUY+2U\KC;VMM QUTB$DK&VD3[9UT=S53GMW-^V=7;1W=-+5U2/8
M=HB)\7'!LA.,CH[2/]!/9X\<V]:BPWC5#754UM?2-=#+R7/KS"[,"B[MI;FU
MB0;95U55CK:DD-SB/#*+<\A4TE_4%E/86/:MU)6@KM927%=&QV WW?(L33WM
ME#74D"F$,*]4P_3" F<N7N*B@I.N?2.8Z;I@:"5PX9+.,7SJ]#E63Y[BU*DS
M@JF4^4 4(H7LNT)[UX@NFEB))%8FKNOJF=1AZ.[>&8;'5EA<NL2Y\[=9/W5-
MEWJB30AQ1\<0O3UC#/9-T=T^2G?'!+W=,X*3I:VUCPDFGF)Q]3PS"Z?H&YZC
MJV^2T9$%5DZ<X^H9T1."[V^</\NED[-<.3G,K=.]/#K7ROG1)-8Z?;@R&L;E
MD5BNC6=P9T'#_5,UW+_0PKW+G<++AGE\:YJ'=Q9X>.\4C^Y?$+DHZN$B*'+W
M##>OS+ R4<EP:3"CR2:,!>UDQ&TC?7:?TF/]&>UFGU*E_RXYN]XD_> G%'N9
M41X?()@FC:KB4AIJ6FEOZ6=(L/_ZXAJWKMZ0>]WF@>C"^W?O<N_F0ZY<N,O2
MT@TAVY>I[SJ+MNXDV26KI!>MD%JX0G+1&HF%RR05+<OZ,K%Y<X1G3Q&:.2'+
M2:)SIXC/FR8I?YK4HEDR2N?)JEH1626C0LXI7B"N<(Y(.48Y+RIKBNBL2:(R
M1XG*&24Z;X2H_"&BU:/$:R9(+ITAN6R6U,IY,NN6R:Q?056S1'K%O.[::9I9
M$A3G<.XDX3D3\AQCA*0-$98Z0'3&L#SWC&YB+V5&?G7U(L4-RU2VKE+3MD)+
MUQ)]/=.B\[KH46?0F^;+Q<I@[@GFOI%OS8G 7:S'FW!1$\1ZK8K5C@K6ACLX
M/3O"R?EQT>F+8B*N2-U(V[MVD?,G3[(Z?X(3$\-,]#717IU+76&<Z#K1BRH?
M.M0^3%7Z,IXC=1?Z)3.N;W Z\$.FO#^DP?E#:OQW4A5M3%FJL^AS'](3?02G
M>)*<X$U*O(O8<QM28\U)CC8B-=J0K-CC%"684)YXG K!JR5A?Z8L]$6:XEZB
M/_-=!E4?T!;[CLB'=*=\R6C>'L8+#S*B,:!7;4AURE&R0@\1Y:5'N+<1P9[F
M!+B;R=*4$,%?,9Z[*8W=35OZ#OISMC.NV<UDR1Z1O8P7[V.BXBCC-=;T5[N0
MEV2,O_L!7)V/X^UE2V2X"YDISN0DVY*39$UNBCV9B?:DQCF0&.U$D)^9+EHX
MT%/PMYN<XW(,+V<#/)P/X^*HAY>[ 85BPP;ZU<R?J&9L1"T8)QYM@2_9Z1YD
MB0W,$QV7EY-)15F9]%_AR'W2MH=&&!<=/S,YP^*)15:75EE96F-.^:@S.B<Z
M8)J6SFFJFZ;05HV15S)&9M$H&=+>"DIF**M9IJ;U- V=9ZGM.$5IRQ+:UD6*
M6J3]-,ZC;90V5+\D>DNV*U*_*G(:;>TY-%5G*:I81UUZ@ISB"5(UPT07#A!9
M/$)DQ21A%;,$5\X1)!)2-4]8]0*1-0O$U,R+S!%=,TM,G?!/68^IG2>U^209
MK2+M*V1T+E$PL$;)T#H5?:N4=\Q1UC1.>?VPZ.(!T7=C.A_$[/0<2PN+G!;^
M>^G"&<ZLSK,TVB/8O)Z3'7F<K8OF2J4_%U.-673]@H[#?V3(=3>SZ7[TJ4)H
M*8BFL2R5YGHU;8WE8K=J1.K%1C72TM) 0V,E%<H'O^(TLL3F)29Y$R/UF1!K
MCRK9D7R5 X4YMA3GV]#1Z,WZ?"IW+Q; U2+NKHD=K7$G)W0_/J*K7(TWX6*Z
M&V<EU83I0:Q-#F%A? 0SHZ.8FRA.8Q.LS(RQ,C^.M<5Q;*V,L38_*MOUL+'8
MB[/-3GR<-A/A\3F%<;NIRSI,=>H!"D._(M/S ]*=WR+9[G52[=\BSWLC;1E&
MS%9[<JHSE#-]T9SL36"N+9&.XC R(VP(=CY$3;8_P^7!#!?:TA&WB\[PC0S'
M?LU"WE$:8P\2YR8<R?L803[6^/LZ"9_T$'$GP,^%0%\70OQ]" L*)CPDC)"0
M$$)"@XF(#",T+%@D@.@H?]W\!5GI@>0*MLK/]B)'Y41FJ@V:;,%;FF#!&Z'4
M:%THSC6A,.,PY;G&=-5Z"09*H*DA!DUQ!+GY$12JD] *)BPN$M$F4R*B+9(^
MD1TMUXZ5>\23%!<M.D0D-IK8N$CA+A%$Q$01$A%+0&@\7OXQ.+F%8N\<C)>O
M<(:T4BHKN\3>"1;J&65V9HD+9\YS]_HUW:B3^R)WO[DN\@TWQ.:>7CW+R."<
MX(9)ZEK&*:WL0:MIHB*_@K;\?)8K,KC7$L?C>C_N:AU9BS>DW&XC]4D.]'86
M4M]?A7:DCJSQ!M*F6TF8:25&)'*F0R>A$VWX#C3BV%*&>64!1MHL##*3.)(8
MPW%Y)[>T-&*+-((G&JENZZ)[<)2Y^66NB"V^?U,P_>W[8C_OB0B6O_T-=V]<
MYM:U\UPZM\;4Z  ="K\MS*0I/8;^I" F@JT9-OB SJ^?HFWSLPQ;?<UXD!'=
MD=84>!J2[&U"8J@3&:FAJ')B2,L,)3[.E?!0T7%904Q--0E&F>;.7245[05N
MW3C)Y7,SP@&&1/JYN#XH6&&(BZMM#+8DDI]TG/P$/8K3]*C.T1?^;$!KF2,S
M ZG<%TS H]-"!Z[RX,$WW+M_@WL/KO- F3SNL7"%1X]TOL6'#Q[)?B7:6'XK
MOEIA+KID#\(A'H@H03"/'MT5N25R6T3A&K)-]BG74$1)$Z%+XJY+$2'EI40#
MRW&/Y3Z/Y8I*%+'R[[_6%'ZB^'X542B3(KKH&R43L>*F5N2O_.K_3YW$_V>J
M"<5!?/OV7:Y<N<;9L^>9%F4\.2%@\/(WK"R?9FE1R?4A>.'.0]UP."6Z97!P
MG.D94=BG+R$8C+6U"]*Q:R@M;A%RT"&=J9GFEC$&!I<95B:,:)L4)3Q"3<T
MZ1D5Q,:J24DMUA'S\<DU3IWY1A=!7-\X0'%IJP#V,9I:QVCKG&)^Z0IKIVXQ
M/G6:_()Z"M3U.@=SNJJ$U R-+L=QNP#FH:%9,28+3$W.ZR:F:VGNU,GDQ!PG
M3YYC_?1EG9.XK7- )TI$\>3LH@#B86*2TPB.C2,Y-T< 6"HQZ2DD9ZG(*<@7
M0E!,>46Y+AJEM+I2#&D5V94:0G(2<4H,PD4ZE7VB'V:1KN@'VJ 79,W!,%OT
MHQS0CW% +\J&72&F' BWQ##!&>ML/^R+0G'01.!0&(YK40P^A0GX9<5AZ>&(
MN;4ESLXN.+NZXN;I@5^ /S&QL61D9*#1:,1H=E+;4$]<8B+'C8PX>NP8=O;V
M>'IZ$21*/"8F1HY-I[:NFJ'Q02:6II@\/4?M= =V.<%L"S7EBZ"C[$NTY$"Z
M%8=R[# L]L2J+@17(=,!@VF$C641,99#^& 6T;U9^ H9-@MRP-K'":\ 'S$(
MD:2EB.+6:FB5YYE0\AZ?.:,C.S>NW^3FC9M<$^5[^N)I1I;&*>PJQR'%DZ/Q
MEAQ566.L<<12C)IS>PB!XRF$3V82/95#_&P^R8N%)"^IB3N13=)R+O&+F02-
MQ8E"C<*K*P+GND!VA.GSE==N4:CF6!0Z8U_CC4M+(/YB("-&DXF=4!$]*M<<
MS9)UN>Y,#DDG<DF<RR9B*)[0[D@B.J)(Z$P@IR\355,2+N'F[#_^!5_M?).=
M>G]FE]Z;[-[W(OOW_9:C^K_!RNA)W"Q_BY_UT_@:_1JG'=_'Y:OOX?[1O^'U
MVK\2]-J/"'OS/PE[Z]<$O/$+W%[Y"?8O_Q"_3Y_&?]NS^.Q_FL+@+P50'Q+C
M?8",D'>(<'T3/\MW./CY+]G^UD_9\^X3'/SD9;Y\\WD^>?./6!\WQL_=%U_/
M(&RMG:6>W;"V=>&0OB$[=^W#QL9! (X0X:YN,6*5I&=^"RRK2[4"N(-ULSO[
M.>XCR'DS:2';4,=M%]F**F03078?8*/_&F&>^W"QV,2.3W_'\1UOX'QT(UYF
MNS#>]R4.9OK$A/N0D1Y)66D.#4)\-6HU,:$1^#@X$.QD0X*G!4E.^_#9_3P1
M^L^2:?L2>9XOD^GU/ 5A;]"FWD&[1H^FW$-4)>J1(/?UV_\[ O8\2;+9F_@?
M^@-;7O\^?_[]W_+>2W_'Y@]_@L/Q=PFP_0)?<V48XB:2O/>2&K0?-]-W<;-X
M1Y[W'=YX_G^P\9WOXF/U!ED1VTCP^1@?BY<)LO\SQGM>XJMW?\.F#U[ :-]&
M?.V.R7O:$N!A1WQT*+U='?1U*\-O.RDK:R4J0<E;E4- 1#XJ51D)$3&8'MS*
M_B^?P<_V;?IJ[<B,^8JX@ _)BMY,@,7K..U[!N==TA;T?H_7WJ=QV/)+;#?]
M!I]#;Q!H_ EZGSW-MH^?9N?7K[%]TSO8V1PF-LJ#"#]+[(VWL?GC%WCZYW_/
M+W_X'3YYZQG2PYW0I@7@97. YW_SS[SWUI,</[Z=@!!7@L*]"0GS(BS8%2/]
M'6S?^ ';/_^$#>_\B2/[=Q,;$XJCLS4>WJYDYJA$!VO)2HG'50#HKH_?8,-+
M/^73%_Z976]_GV-?_@R;?4JJA)<XOO,%=GWQ,@=V;<3=34!Q0B$N/DH.Y Q,
MW3(Q]<S!PCL;*R\5UNXI^(?DX^$6R];/=K/Q3^]RX+,/\3(UP-U<VJFK&RE)
MJ:BR"XE-S!)@%DYX4 PA7OZX69D1Z&:*C?%FMG[Q/ 9Z[[-_U]N\_]9O>>(G
MW^6G__+W_.</9/G]?V#KUQ^1G!@A=2/Z:W"0WMXQ2BHZB8K7X.Z3A(]_ G%Q
M*M(2DPGU<,#RP!<<^O1Y#F_X#=M?^SX?_.9O>%7*]/.G?\C!/_P,HS_\.TY2
M#ZY;W\7AX$Y"/*0.Y+E\O6()"E2&LM<)<)Q$K6DE/%:+DU<F]JZI^/FF$.83
MAL'6+>QY_Q7T/WH&TTW/82=MRU_:H29F+^5)F\B3-A[G]A2AUK\EP.QY_,U?
MQ\?TS](6/R?8?A_>%@=P-SZ$OZ4QB9ZN)+@ZX"IU:/C%'['<^D>BK;>2Z7J(
M&-.MTH9>)^#XIR2X[R$E^"B1_H;86^]#7W^;V ,7W+W#L'8.Q] ^DD-641PR
MC\30+ I+2^F/\CXE:@U=+;7,CO=P\[HRK$IQ&/\%(.FBB!6 I#AP%9"C@"9%
ME/U_Q03*4MEW78Y3AAV?EI^G>71KG8<W!0?H4D=<%5%F(?Y+"@F=*.>(/)9M
M.L>P NP>Z "> KH$=>B6RE"RVS>O<_G\*5;F)^59*]'F)0CI#B KV9>*PFC&
M^XMIJ15B4!!"15$T);E1:%21:#(C*<Y1TA8$4U,>P4BWDB<XDY*L #)CW5$G
M!]"B3:*W)(&1BG@F:^*9;DYFJ"Z&#B%'@PW1]-=&T5(<1'F&)Q6J .J%.#;+
M.1T5F4)6<FFKRJ:C/H^^=@W#?154E::@2O(C,]Y?KA]"?5X<H[4Y]!4GTI87
M0:?8[IZR9'HJ,^DLSZ&U-(N64A7M51D,M>4RU*6BNS6:CJ8P!KH2F1C,I[DV
M1=XKE6JMEO&^,2:'9QGH&V=B4K#+B16&!5<U=0U14=<MI+57L,TD_3V3]'3T
M4U-9)?JJ4/I#/F55130T-](C^&542/3@R)1.9DZL,3M_EN&Q-=D_3E7-('4-
M0W*=<>KK.X1X%9.;GDQ%02J=U9D,M\H[5T;34Q<KSYR".MV-M&@[LA/=T62$
M4"+EKLD0\I8<C%H5+O4E1$U(=XZ(1AU+2U,^?3V5#/;5T=U536M+J=RGD-J:
M'-I;M72V:BC72!TG^9,8YDY"B#M10CK#1%>%!W@3'1%$4D(4JO1$<K-3R,]+
MI4"D4)U!7FZ*V)Y8,K,221"=$!3B2UAD$/%),>3D9]'0VJ";&'=P;(B!T2$&
ME0B:R3'Z)\;H'1FF9W" WL$ANGK[Z.SJ$5W23[_B<!&],OX71_'(R @]O3V"
M4=NDG.HIKZI$+;BFLJ::8;F>,J]#O^(D;FJ@L;Z6FJH*BDN*R-/DD:7)(:LD
MC]S*(IVC6%U?2G%#.>5-5=2T-] ^T*V+(JYN$<Q:74YJ?K9.FKN[.+&\PH7+
M5[ER];H.>Y^_<!$E_<3RRAKSB\O,+RPQ/[_(RLI)W<BWF[?N<^["5;JEK72)
M3FSO')'G[=%%$[>TC=#1)?VI9YH1Q5&\<HG5DU?_RTG<W3TF^'B&\=%YAOIG
M&.D_P=C @I#9*3KDW*X>P?,GUG71B+T#<U)6DXP/*;G,+W)Y[2I73UWDRNEU
M+J_/<?W4*-=7V[DTK>5D=SAK[5Y<'HG@QFP>=]>:>7QI%+Z9%W5P4O3'65$Y
MYWEX[Y(0/B'C]X4(WK_&O;N7N'YIF0LGQUD[T<GX8 G-Y8(QDJQIC#Q*1Z@>
M'?Z[J7;\BAKG;=2[[:7$=@?99MM)M]:C(,@936(XQ=DJRDK*A5>T"M;OI5_Z
MS=K"&M<N7N'Z966BK_/<OG%-GN4Q]VX\XL*Y>\PMWJ1O] KU[>?15ITFNV2-
M=,TJJ=HUDK4KI!2OD%J\2I)FB?BB>6(+YXC7S,GO.=*T<ZB*3Y!3MD!^U0KJ
MVI,4U)TDKW:-["JY3MDRB9IYHG-GB,Z9)BI[4A=Q&:CJQS^KC\"\ 8+RA@@I
M&"6\:()P[201I3/$5LX35[5 3/D<D=HI$DOG2-#.$ID[3GC>),%9H_BG]1.:
M/D!,U@BIZDERR^8HE'.TM8N4-Z](>UNEOF.5AK9%FEMG:!<NU5511V-: LWA
MSLS%6;$>=9@UG\U,FK_#2>^=7$AQ8$D=Q6)C$0M*SM;^#B8'.EF<&N;ZF65N
M7CC)Q;4E%B<GF9-^,#DB?:VK1I>_O$831W-)'.WET<QVI7%5L/O9O@@6\H\Q
M%?@>)P+?9<3G79H]WJ?6YRM* W=3&'Z4HD0GLA(\28KQ)CD^0/J^+TGQ'B3&
MN9*<X$)JHC/I<?9DQ]N1'V]!0:P^ZL@OT$:\157T*_2DOL%$UCO,9+W-?,[[
MK!5^SH7*[5RJW<.EQD.<:S1BILR45M5Q"I4(Y3!CD@*,B?$Z2KS705)]=U,4
MMI7^+&6X_A=,J3]EKFPS8]K-=.=MH2U[+XW91ZG.MJ PW9:H8!/<G0UP=3(A
MT,^!)+$U^>FN9,2:DA1N2'JL+?'AMH0%*!/EV>+D8(R]K9&<8XFKHRG.ML=P
ML3V"G^=QXJ)LT18$<&*JA#-K=<Q/%M'?GDA7H]B(N@B*\Y34/+YDI462I4JB
M2),O/*Y2^'"3],E.G>X:&1YC8GQ2>.TT4\+3)\9GI6]/2_\?HZYYE++J80JT
M_21EM FN;2(VN97L_$'9/D=#^TE:ND5Z5VGJ$]TPMD[[^"F:A]9HZ5L5O:1,
M#+="G?*QH76=FK9S5+=>HJKY E6-IZEN6*"L=ARUV)3,VB'2&D=):9'VVGR"
MF(831-2?(+)1VG'S(O$MBR2WSI/:+M(Q3TKG$@EM\R2*I,EZ6N<"*>TS\GN4
M](XQ<CO&*6H;1],P2'%M+Y5U?;K)DR?'YCFY>)+3*ZM</'V*&Y<O<E\PQ#<7
MSW!N?H)SXQVL->>P6.#%6K(9RUZ;F3%Z@\']+S!A\P4SPNNZHQVH3?006Q9,
MJ29).%(V515JJH7'5]<44UFMI:0\C_S")-+$KL5)>XR.=B0ZTE8PNS7)<;8D
MQE@0$7*$(+\]LGZ$NBHWUN=3>'A5 ]<T7%E*I[/,@3COS82Y;,/?;@?>UKOP
MMCN M\,1/!V.XVQS'#O+X]B8&\G2#&MS$UV4L96%*9:"H2W,#;&R.H:-M3YV
MUGMPL-J$G]M.(GSV$^:Q1[CG%P18?D22\P9R?3<)Q]I$M.WG9/KNI3+1C,Y"
M%\$_GO25!])5$B9MV(_4$&OA?T=0)[I1E^E&0[(I]5'[Z$_<QY+TU=,5CG0+
M)T\+,"+4VU+:L!.!_E[X!_B**(%JWH*3A7\$!A :&$)(4!C!P:$$AX42'J5,
MAAM,9&0@B?%!I"7YDIOA(]C-C^("P0^Y]A1E6U&1[TR]QH.F4@_J2QW0YAPC
M(WX/11G'18^XTE@=2F%1*%F"J3+SX\D3;%)8J!))(R<[@L*"*$JU2JJK</)5
MH60DR3U#O0D,\,#/WT,XDJR'^Q$2&4Q$=!11,0D$AD1AY^2-BT>08(8T\O-K
M!)-TT:'XB@;'.;U^ACLWO^'1_5L\NO<-#^[<X,'M&SR\?9L'-VYSX_PUZ9_+
M]'9/B8T=H:JZAZJ29L&,I;0)?II.\^-\JC478@ZR%KB34?<M8J\VTY+M*9BD
MA,:91BJ7VM&N=I*]VD'*<BNQB\U$+;00L=!*Z%P+ 1,-N/578M=>C%6]&I/B
M# ZG17% WL4R-HS0W$R*&@1SM+;0U=?'[,P,%\^>X^[U&SR^=5N@_"V!W+<$
MBLOR]C7N?G.!"V>7&!8]WE1=3&U^.LURO8Y(3WK<#.C1>XO>+<_2O^/W#!W_
MD.5@ T[$6U'FO(<TA]W$>QX3O>Q!FN"^],Q 4I-=2$EPH*$VE9LWEKAW[QSW
M[E\6'']3UL66BZ!,.*T;,:A$Z@HW>'B>2VL]]#4E4%W@1$F&(649^M1+6ZO+
M-Z2]U)[S)PIX>&-$^,(9'CV\(%SA(DH>X8>/KXO<DG4EJ.2ACC]\ZR06'O%(
MB1S^UCFL+!_J',1*Y+#PC<=*)/%M.>[;R&2%QBAYC'4I*^18Q='YK>]365=R
M"W_+291_.O?P8\4!K(L]UNV7E?^OR/^^W:^DKY#[Z7B3;L?_]=]_*R?Q_^D@
M5O[^^E,!J2L"3I=%$2\L+.N<P<JH4,5)/#VU*(WAVX)7REB9&V=EY11]_2-T
M=@[*^@6FIP4HY59(ARZGJ+"!JLIN >0GZ.Z9$R,WH',0=W;-R>]Y5)E5Q,85
MZI;UC8/T]L_2/SA'8_.@$)IN ;QCG#I[5^<4;NV8Y.3IVZRNWV1@>!EM<:O.
MB5Q:T:9+6Y&=6TYE51LS,ZM<N* ,,9-*ESH^M7Z>L=%I,:HC.B?QW.RR$()Y
M </#.@=Q=]\HW0-C0BS$N,HQ;KZ!.'AZ$Z_*)#PQ@9BD)#*R<N1^I:C51:A4
M*K*RL\DK4@LP*Z-$B'A^<SD)57GXBU)S3@W"/-J-0P'6' BT1"_,6N<DUHNP
M87>P*9M]#-CF<Y1]@28<%0)FF>F+?7X(]GFAN*IC\,R+Q2TI#$MW1TPL+;&T
MLL'2Q@9[9R<\?41)!XOR"X\@-C86558F\?*,[IX>Z!\VX.!!?4Q,3+!W<,+#
MRTLWJ[CB*$Y7I9-;E*<;%IE;5T1$22H[_$W8Z'N436%&[(PUX4":%?HY]A@4
MN&!0Y(Y1F3>V=<$X-(;A6!^*0V4([D+([5*].>)L@IF3-1X^7D+LHHB/C2-#
MRD69%*:^HU4(VCB+2VN</GV.LZ+(5DZNTC\I==I73V)M%B;Q#NR/,>9 NIG<
MRP;3:C=L6P-P[XLB="*#A!.%I"P6D[8LLJ(1*21I*9>PZ43<>@+EN& \>D-Q
M; G@2)85!Q*-.29+4ZT3UC4>.#;YXMD91F!_/)&CZ<2.Y9(P64#"3#[QLSG$
MS"B.Z QB)],(Z8W"J]$?KQI_?,K]<<UUQ\#O,)M,-K+1X",..>W&S.\@MD$'
ML//;@K'#.QPT?(K=^W_(X8,_XOC>'V*P\9\Q_O"[V+S]/3S^^",\?R_R[(_Q
M$'%X\M^P^^V_XOKRCPC;^!0JP]<I\]U :\HV.O-V4IGZ&2X&/\+=Z&D2O;_"
MV^@]]#]^@J]>^#>.?O8B^SY^B2WOO8+Q_BU8'=7C^($];/GL$W9MV83>OCWL
MV+8-PV-&TB9B=:E@AL>FZ>P;IJRFB4)-M1#M4O)R"LA*3R+4SQ83_0]P-/H3
MX:[OH0KYG*R@KPBR? OSW4\3[[^7W 1+$H,-\;;<A-V1#=@>W82ODSGI0L9K
M:ROIZ&EG8&R8OI$QJNLZY?I5LB^?C+A4DH,#B'4Q)LSH,\(,7B7:Z%G2[9^C
M._MK1LOV41#Z-L6QGU.?OH^&-'VR?3828?0R?GM^@=_>7V/TR8]Y\U??X<VG
M_XZM'SV!S=&/,-S[)OK;_LCAK6^@O_EU#+:]@>'N-SBRXV6<3#_"W^E+/G[C
M'S'=_PS:9#TR0KXBV.Z/.!YY KM#OV7'!S_DDU>EGG9_3)BG!?$A;E@=/TAL
M9(@8^VK1&4J*@1Y:6D:H%K ;EU*#JU\N3M[2#I-+B8M.P<I8'R^[K41Y?TE\
MP 8"W=XF)7(3C5H+4OTWXWU4[K?C*7SV/X?WWJ=PW/X$]CN>Q_7@NU*W&S@D
MS[WM\U?9N^-C7)U-24V-I* @C? 03PX?V,*?7GV*IW_]/5Y[\1<<W/DAJ>%V
MI(5;2=EOX(UG_I;]FU_ R7HK%J9;A7CHX>FJCXO-#@YL>Y.]F][%\K@^IH9'
M\?'VHDA;1%%9,9K*2LKJ&JEM:J=86TE$0#@[-WS*1R\^P=>O_PR3S<]Q_*N?
ML__#?^+HUS_%ZN#+V!M]BK'^5P(.O4A.*<#1+0%3AT1,G-,P\\C$PCL=:^]D
M[+T2\/!-Q-+"B\_>_XK-'WZ*G8$!A:(KRW,+R<M0$QV307"TBM#X?.(R1'<6
M-0CY4V%M9HZ5R2',#+=BJ/\I5F:;.;3_ ]Y]_3?\XOM_QR_^]1_Y_2]^Q@M/
M_IHC>OM)3T\3.U),?4,G[4I>L*9)XE)K<)%G\?#+Q,L_A8B(% JSLO"R,L!H
MZYMX'WL/RRW/L.=//^"SY_Z9=W[Z-WSXX^^P]ZF_Y;B\N^F&/V*\<PM>CN[X
M>$5A;Q^!A]1W5'P9F7E*[N5BO((*</+*Q\HA5<!G%G$"+@WW[F/OAC<YNO$E
MW/3>)-Q,0+KCYZ1[;$ =]C'EB1]2EO01VIA/R OYE R_STGT_(Q(IT_QM_@8
M9_WWL=WS/@Y[/R7PV Y"CF['>>=[V&][E3#3#53'FI/M<1"776^Q7?2(_J=/
M8BSMW&#[RWSP^D_X_,-G,3F^$UMK$TQ-+3ETU ICNV L71.P<4W&S34%1ZL0
MS UL.+Y_'V;ZBB/<DOZV"JZ<7Q30=DUPC^+T54#<3;'Y J840/5(<?)^ZR36
M#=%Z<$\'SI0A6$I>+YTC6,YY=$^ WV,!@<HPJT?*$&X!U ^4=0$(RNRV#P0T
M/5 <STK$L@ ZN<Y]W003W\Y<\$ ,LC*#\>V[-[AP<9W%A7$&^AJH+A42D!U%
M068HY451-)0GT-.4R=1@B9#F#/D=3UN]2A=]FI,2@EH508$JD((L'[3Y?O2U
MI3'<GDE=43@Y"1YHA=P-U.<RU93'9%TZ_271-.;XHTUTHB#.CE9-*-V5,;24
M1%"9$TR)*IARN7]G919M92H:-*FT5>;07)%-<W4NO1VE0@H4)W$ :=$^I(9Z
MH(X+H$N _$!Y%CTE:;06)=%7D\=H:P6C[76,=3?3W51!95&:O%^J+K=Q>W.B
M$-)@*LN"::I+H*,IEY::(NK*2NEJZ:&S=8 VD<F9->97+S&U>$[(^H20\F$J
M:T4_U0S)_G'Z>B?H[NH3W56&*B>%^)08(?[5] Q-T-8W06O7B.CI409&3@BN
M61%[L"1Z8$+(]JA<9YCJ^B':.T9HJF^F*"^3RL)4.JK2&6E5T5L?2V]##/W-
M"5+N$51IPZDIC:.].I,:=2+JU!!JY%WK2]-DNTA9&B5%"61+W27$>1(OQ"(A
MUDOTJ[*4LI(R2T\))$,D)<Z;J$ AW'X.) 2XDA[L0UJ@#XD!@B-$(H3H*9-'
M*CFHDV+DO,00\E31J'/C4*6'$Q/E16BHFV @-\$V'@0&>0J^":- G</@\  S
M<S-,3D\Q/3O#V.2DO+N"Z\;H&1RDK:N;QM8VZIN:1=\WT]K:3I.L-S4U"G;M
MU#F()R<F&91CVSO:=4YB)2V%DK^X0,D%K=70UM9"=W<GC0UUU%574B7U5E*L
M(;\HGQP%7Y7DDU]12'Z5!G5M"55MM33WM=,^V$-M6R/E#=64U%:@J:D@KTR+
M2LY3J0OH'QWEZC?*QW1E?HS+NAS$RD1VDS.S@GVG!:\JN4@G192)GT_H4E&L
MK9^C?VA2\.N8X.0!79JVAJ8^G9.XM7V,YE;%63S!P)#RT6"!GMXI.J3.AX;F
M&!Z:9;!_BLGQ968GUY@:7J)?=&MG^[ NTEAQ%/</GF!H9(FA_GGFQM98FUYG
M17#SVLPDITX,<7:AFTM"<D^-%C)<Z<-TM3.K+>Z<&PCCWLE:N#$GA/4LW+O,
MXWM7A'A?Y=Z=;X10"O%^J$Q(<YN[=Z]P^>(2T\/-M-5D4UX03EZZ)WG)3A0E
MV* -.4IMA"$M@A6+??90XJ='5:@Q%>&6E$4Z4ASM27YLH&["QWS!PH6"T4O$
MGM<VM-'=T<_R_!KG3IUE_L0,RXMS.L?2_>MRW^OWN73^#B<6K](W?)ZFSG-4
M-5V@N/8<!55GR*Y8)[/B)!EEJZ25+*,J7T-5L8JJ:IF,ZB6RJI2)P)8H$"F4
M;875*Q36K%)0O:S+!5S4>(;<FG72BA>)RY\A-F^:F-PIPK)'"<CJQS>[#_^"
M(0+58P04C.&3-XQ?T3@!Q5,$B@2731.B2+'8.L5I7':"</4D8043!&8/X9?>
M353.,&F::6EK\Q35+E#:N$AUVPJ-O>LT]:S2U+$@]G*!UJ8QFBK;1==5T9:3
M17ML -U>1^BSWLBHT5LL''^#D]8?L^RYC_$81Z9*DID1>S'>V<A87P=30[TL
MC VP,C7,TL0PL]+/)@=[&1MH8["[FJ::#.I*8VFOC&>B4\7%A5*XU@S?U'-]
M))39M*WT!;Y#;_ ']$5OH25\.X4^7Y/BMIDLX1Y9<2[2S_U)30PE.2&8I/@
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MA2%KY8;RVYPK;4Y<ZW+G8ILKI^H<6*NV9[G,BOG"XTPF[V0^=3MK63N83OB
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M[ OD\HR*&\O%?+-6S9VSK=*_I^0>)X4X7):EPE44Q^\#[DG]W']P7ZKG+U'
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M_DO_QFM/_RN?O?T[MFY\!T.#?41'1Y.B1-@F:0F**- YA/U""O#TSR$PO(3
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M0;+I\QQ[]W^RZ:6_)SOD.!VETAYM/\'^V$O$>W_"4*4-29X;.++Y:;Z4]U+
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MK,(3RQI?+*H]L:CQP$K:LZB1OJYRPKC< =U"6S3S'-B7[XI:D0\[\GW95A"
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M,%]!E-F'N&J]CZ?Y=C'\X<3%9!(6E4=@9![AB36$Q-;A'5PIX[%6%<VK8Y6
ME7,ROG[Q!'MZHK-U#>K?O\>^[]YB[5O_SJX5O\3LBS]C]OGS:'[X*[0^?PYO
MS<_P5/L$ZW5_P>S+/^+\S1\)WO@*47M6X+[E;:RVR)C1WH*WJSL!P2EX^&?A
MYI.-J[< 'L\"S.RR5 YB4YM, =2IHHO2A##%H_:#.FO>_9 -*UY'_YME[/OX
MMZQ_[2>H?_VO6&N\CIO19QAL6H[>IL^QTM3 W=$79Y=HK)2(8KMX3.V3L'!,
MQLXY2>XG&3]/?\RTMK)OXS*,MK]$E.W'1%B^@X?F:QAO?(DM[_V,U<__A U_
M^ E&[\M]K/T0AXVKV/[!<K9]M0HK8R%T7K$X>25A9!N.H4T$9O;1V#I%BN[T
MP<'6%CNS_6C*'-3^81GVNSX@P7(3P1I?2Y^]C,8[_X[%NC_B8RCSQ^@UW+1?
MQ&'7<UAN^#=LMOP45[5?$&3X//X&+^"J\1Q6FWZ&Q7?_AMWJ7^,FU[?CC9^R
M^H6_9_='OV;WY[]![9O?H[WV98PWKV#/ER_QQ4O_Q,;W?\VF#W_-M\M^RBKY
MO:_?_26KWOLC/WSY/M]]] X?OOQ[EOW\O['^K5]@]L-?T/W^)?9\^AQ;5_R"
MG6\_QU?/_1,K?_7?V"O/UV+GNSAH?8;%WD_8\/'O^/S5?V'+QR_(;[V&_H8/
M<-7?0)B+)@D!IB2'6)(;YTQEEA\=Y3',]N1SL+^0X994^NL3&:Y/8;(QBP$!
MX+594>0F*I&HF72WUC$Q,BB >YZEPT<X='")@],+S([/,38P0F=#@X#_ FH+
MTF2;0D]M-J.M2K[3/(::LNFI2Z=9]'"3D(CZBG3*"E)IK*]F8&B4N7DELN\@
M@^-3#$W,,'5@03Y;9&IJFI[69AI*A2!D)Y&7%$I2F!MQP0[4%<;369--:U4.
M337EM+6VT-<_K"*?8]-SJK;ZA(SVC4PP/#&K<J!-3!^@?["7%B'&S759-%:E
M4)X?16J,-YGQX70UMC#0/<Q OY+/]8!<QTFF#YU6%?5LZAZGNFF(VJ91P3?C
M<HQ<Y\@L586EY*4D4IP9+^WX4Y051U=S-6W-2J'?5EHZ^ZD5[%/9.$A%_1"E
MU0.45/124=5#<_, +4T=--56TUA90%-Y.FW5:?2VYM-2ET=#33&=G:V"C?IH
ME&/+JI7E]+*M&:&\=D2N99RZYB&J:I5BOR745!;2+O=6FA,K]^-+>KP7>6E!
M\OP2Y5ZS2(SR(R%*2%]!O!"E'$9[Y?ETY]'=F"9D,)R4:$\2(CV(C_0D/<&?
MFJ($>JHSF:C+X6!5.@<+XSB0%<E\9C2S*1&,)T8PF!A+74@P1=Z^%/L%4!H8
M0EUX)-T)\0RE)S.<E41O1C1-2?ZT9 327Q%#;TT,;9415!4$D)[H3*'B).XJ
M$BS:*,^\BYD#0QP[M<#5Z\IRQSLB][AU^Q:7+EUB:7%12.&X]$NWJA!=O:I8
M70.E917DY1>J(HCS99N=G2O[BF-1*50LY+&]714=K(HFKJQ411(K4<2%A86J
M8RJ%@"F1Q(J#N*^GETXA9G5U=;2TM]'>W45'3S>]_7UTRGYC<Q-52I1W2[/J
MLX[>'NI:FBBI$A)77$1I13D=79T<73K"V=-G!)LJCN$+G#]_GG/GSJNBB<^<
M.:=*.Z$XB94BTLKJ/B62^/#B,4[(^W/G?F3VP!'Z!J=44<63TX>97SBE2C&Q
ML'1&OCLJ8WV!0XNG5?O]0],J'-W3/RK[2@2QC.&9.8:5W(LSDTR.]3+34\-$
M0RJ35?Y,5M@S66[)H69?SHQF<&.IB1^/]G'UQ#2WKISDZL53G#M[G#-G3W#C
MUH_<?W27>P]$E'RAJORA2A&@FR(W5"EJ'C]4N(>R=/0>#^[+,[M[DP=WKW#O
MSDFN_SC-Q?-=7#G?S-5S]=R\T,+3FU-"3N:X=:J;T>88*C/L*4JVIJTBG/[F
M=%IK4DB+]28YVE=L:029&4G"-0I4J>%R"LO(+ZFFI+R!\HIF(=CU\KQK2$JM
MP-,O"0>W<#S\8@0?%9!9T$A190\U+6.JXEZ3XX?EN9Q1!<3<NZNDXGO$O8=/
MN?,0+EU_R,ES=YA?^I'AR=/T#!^C<_ (G0/"47IG&.R;9&)8=,GXK'"0.16'
M&I5MMW"HEI$9:D</4CFQ2-7<<2J$,Y7/'Z-T_B@EPEL*1*?ER+$9HU,D= T0
M5M-"5&DCT?FUQ.764%3=14/+,%T]$XQ+.T<63G+YW!7N*+57[CW@Z</'*F?Q
MHWMRH;)__^HUKBXM<7ZDGRMM51Q/#>:@RWX6=#_AF-Z''#9=19_M=FH<]E/N
M8RGS+XCF[%AJLN,I2HVF)"N>_(QPT5FN1(>(78BQH*) L&.Q%[5%/E3G^) ;
M8TMZA#%9L8:4"+:N*;2BN\&9<T=2>*0XBF_D<^]L(M,M9I1$?4-AR!?4Q*^A
M*W<G \7[:<O1H"9%G9IT72J2=2E+TJ,\S4CLCPZ9,;H4I-J0E>1!<I0'B4$V
MY(<;T)RJSUBI!1/"!]IS],D,WD-RL#GQBB-$61H?X$V 2'"PC^R[$1;@K"JH
M&1=H2XQPD:R@?2RVN'%K.I1+8Z'T57J3(??A[V$F',9>M4+2V],'=U<OE:/8
M4XDJ%NSH[.Z(HYL][CZ"]SQ=Y#M'/%T=\79S$I%]%UO!1=;XN)KA[ZY/<K@9
ME9DV]%<[<W(BBKEN7TI2-$F+VB-]JB.XV8( 'VW<Q.ZZNNKCZF&"DYQK[V2.
MB[L5X1'.E)6&,3==SH&I<OJ[,D7?QY$D.MO7VU[NT8OD5*785[F,]3+!XBGX
M!8<1$!).=D$1-6*KJNH::>OL9&1T6#CZG'#A12Z=.<7M*U=Y?%M9[JLX!F2J
MWK[-HYO757+C_#G.+QSBF+*JH+..A9I,T>O!S*?;<3K/CLMESAS)LV8XVY+F
M,G<:)L2FG^ZB3N9KRX-#-#U:H%:DXO$A*I[*]NEA2A\LD'=]FHQ+(Z2>'R3Z
M2)OPK"H\!_*QJTW$J2Q!QGL>V:WU5(NN[!@>971R6G#$8:Z>/\/#6S=0%:Z[
M>YNG2IJKV]>Y<_T2%T\O<>KP+,<FASC<7,Y"BA>'W7:R:/(Y"SHK6#!ZGY,>
M:SD0L)GNP&U4!>PASGX'7L9;\;+<0U*H&=4%'G35!\JX]1%<8D-._#[5,\I,
MT"(_RU*X[E[,S+9A9:.!I8TF5K:Z@A&5]!-&V%GI86<NG,Q\ZS-'<;8%2T,A
M7%]*YNZI3.Z=*6"N-X#\A'V$N_U 4L!>BN+,R LW)L%3FP ;-9Q--7"R,L3)
MUAQK"R,LS8VQM#"1?5/LK2T%B]IA:VV/G:41 :YJE"1L9ZI.DZ46;<8+=M.7
ML8^BT'WX2EON=J8X.PD_=!;>+V/2S=,=;R_ECQW.>+C8$.!F1EJP,7U*NHDV
M&\[*O)RNM'@631]@2(2/-1'^S])-! 1ZXQOJ18#@@8!HQ5GL3G"X"[F"%SHK
MDYGNS&.J*X.!IDB:2CUH$.[=7.Q(9ZFCS&]SNK-,Z,NW9% XTD"#O_1Q. V5
M<906)I(K6"TS*X6<O$Q5C862HA3*BF)4A>^:RD(8;(YF<2R-'T\6<NEH)B=F
MXS@YE\C\:#S#7?&T-Z70VIQ+2W,1C77Y-#7D45820V28*9FI3J2GNN#IJ4]M
M?0:S<YV"Q01K-16+_2ZDN;&<SHX&P8)M# UU,3S8S4B_V)C>;FF[F[[6-CKJ
MZ^FJ+&>X()OQV!!J#'93M?T+6K:^3]N6M^C5>(\>T\^IM/R"'%_A[-E6%/;'
MD7.P@+1C5:2+_<J[WDO1[0'R;_63=W>0C-N]Q%YL)/A(&3ZS.;B/)^,R%(=]
M3P16S0%8U_I@5NB,=JP):L+']UIM1]MJ#^Z^ML0EA)"3G2R21DEQ@>#B6EJ;
MZFD3:6FH%7Q;0YU@BK+B0C*R!<>EIQ"?FD!"8HQP7G]"@ET("74DU%_&G;<&
M]0&[.2OZ^D&R'HM:RYA7?Y,S 5H\.=0#UX[!W=,\OGN,V]<G69HMH*700G"9
M&9/U5HS76%"?JDYIPEZJLXQ%!SC3UQ3*]% V%TYTR;R<Y\&]TS)=S_'P_B55
M=#%/+L'3L]+N/->.-')R-)5#78',M;H*=K1AL-R$K@(=JI-V41"YE8*8O306
MV'%@.(N'-^?D_ MR_@T5=E *V(G*XL[3)]Q!;+,H,>7?P\</>/18*:RM.(%5
MKMV_N7C_R^MOGRI)*?[34?Q?Y=E+V7MVW']U%/_/Q_SOO_X_$TFL1! KCN';
M8@BN7[\NG2B=(W>JI)A01,E%K$0MJ(Y]]%2 WV695".J]!)W!1E=OW:'Z:EY
M:FM:*<ROHE) 5W-S'UV=SZ)EE!00ERXI16ON<N/&/=G>$6(WJW(0IZ:7D9I6
M3G)*.2FIE924=E!=VR< NEOE2&YLZ65TXH"0F';R"BO)+9"!7M8HP*Z1JJIF
MFII[!>AW45G51%&1$LW1Q.# &&=.7Q( I^13DL$BQN[LV0LL"C%=.+0H@/HL
MAP1TM;?UR#V<YN[M1P)&GZB*V%VY<I.9V455X8_^T3EZ1^8HJ&@B.;-$ &0A
MB4EYA(<F$2@ ,C.C6)18&4GI.80G)A.:DD*P3#Z/Q$@\TB()*$HDMJF Q)92
M4MLJR>]M(K.IAM0J :FU->165I%?445);3V5+2V4-#607%Z$3WH,-G'^F,9X
ML5^ RPXW(S;::_*#E1J;+-38;:V-D8LEYJ+4S>TML7.QP]S&#"T]3?9IJK%O
MOQJ:FNIHB9@8B[&RL<1"C(J;APO^ I+LG&TQMS7%U-H0$VM]#*QTV&^YC^T6
M>S&/=L NVYN=(09L"=-C5[PIFAD.[$ZR9%.<(>L2]%F?K(@>:Q-T6!^ES4X!
M@7KA-N@(B-&VU<-(VO7R<R<D/)# 4#\\!#1Y>KKAY^,MH"R T+!@ B,"< IR
M1L?5D.T.&FB(8=H3:<#6:$TV)VJAGF^&3KD=ZH7F:)?9HU_I@F:1'?O$J"C?
M[2TT0:/,%(T*4_:6&8O(9V46["TR8UN*-EOC]K$K49O=Z?JHYYJB562-9KXU
M!J5.6-9[85+EA%Z9%3K%INB76Z"GI+:0W]HB '1#F@7KTAWX*M&)CZ*=^2C&
M@S69D1BTEN(]VT'H?!O1AYM(/%I']ME:2J[*\[O90,6U&C)/9! U(_<]:$](
MMPEAM>I$Y6R0\:LIQ-]0"(PVPXV6]%8H^=,$Z/KOQE?_/4S6_1O1ELM)=_F8
M:*LW\=%_GA3OE33G"VA(V$*R_UH2W7^@-$R'"./O,5O]!O9;/T+[^[?8M_$=
M0KQU<;';C9[V.DR4I4Y./EB[)J%GG82Y:RZVWD68N>5A[5N!?4 5SD%%).34
MB*%(P=Y>CT W=7+"M6A*-:(E3I\BCVV$ZJ[$<=<R'#7>Q\W@&_1WK,10;3W.
M5E;X^B3B&U2*>V UCGY56'N68>92C(EC"18N)3CZ%A$8F4]B2@XIL=$$R3A+
ML-,DU68K/CO>Q$')L?SUK]C^T3-'U_IW_H/O7_E'C+__ \&&[Y/D_#VAMNN(
M\3&G)+>8^-AB&3?%1"=('Q?VDUPP2$!B*TYA-9C*O1EYY!*8TH1;< I&EE:$
M"GA)CG438F!"@-,VXH-T*,]QH[9,B$NF%5'A:H0$;!/ O@Y'BV\QT?H&#T=3
M(L-C"(G(Q"TP&RNO#.FS-+F?9.S=$W'WCA/@YXZY@3[&6IM1W[J,_=O^A)/!
MZY3';J,[5YN&Y#U4).ZF.EV;YB(K>FL]20R5\2Q]MVWK!@Q,'7$/RL+6(PLK
M-R5"N0Q+EW),[>4>;+(QM<W RCX9'^\4 5OYV!OM1VWMZP19?D"B[9N4N+S-
M8,BWI*K]FHAM_TI3T!<4>;Y/JOTR4NT^($AW!0Y[/\5F_QYB@J*)CRO$S3\-
MUZ "7 ++</(NP]ZM!'.G' SMD[!RCB,P,)[4J$BB/.UPUM^*YMJWV;#B/]B]
M_#\P^O#W(K_%[.L_X;CM+4*-5N&I_A'FJU_"Z-/?XO[]B\3N6DZRYH?X[7H+
MBTVOH[_]0\R--;%U\<;:(QH+UV3,G3.Q<,[#U#$/ YMT=,QBL+")Q,4I'!=K
M3S9\]C7?+7L3M2_?QVS#2O9\] *?_.XGK%GQ#WSWP3^R_K.?XVGR-2YZJ]CS
M_7(^>^]U]+1TB(Y,P]\_&2^?9+S]D@D*320\/!(OT8^[-[S+QL]_R;ZUO\#/
M_"V2/#_#W_QMMGWVC^AO>@'M;U_@TU_^A%U_^05&G[R,X<K7T5KY%_9^NH(=
MWWR!^K9M L9M1(?%$AZ3+N3,5Y[A7K[_9A6:NS?A9+:7]9_(\]=:14."$VF.
M>['_805:[_T.UZWO$6+P.:%FG^"N]3INZB_BH?8GO-2?PU_[-WAK_@?6F_X>
M@V__#JW/_CO[/_YOZ'W\$^Q7_XP0C658??\\NU;\&^O?^ >V?O@?[/KB.79]
M_@=V?/!'?GCC5WSS_+_PPYO_P9HW_H5/G_\)[[_P$]:N_!TF^U>K@+ZCF1:;
MO_Z U_[M[_CBQ7]%=\WK:,LXVOKI[]GXX>\PW?(Q7[_\6_[\]S]AH[1IM><S
MG+57H[5Z.:O?^ 6?_N[O6?ORS]FQ_/?H?/$:UEL^D/OXBECG750G.]!9XD=?
M31 #=4&J@AQ3W?',]*4PTA;+=$\Z2R.E]%8E49,;34U1!N,#71P^>("EA2-"
M[$ZR,'^"F>DCC X?8*A_FI&!26;&IQE5\O VU3+05DU/0X$0C'P!_@T,MA51
M6:"D$/$G)RV<G(Q8TE+B:&OO9$KL]?C4(E,'CS$^=T2U JBU=YSVODD&Q89/
MC\\PUM=+>VVYD+P,2C/#R1(BG9/H345N%.WUA?3W=#$X-,[ \#2#8R)RSH!(
MGUQ3U^@D'4,3= XI#N@#0JC':*@OIJDVF\;*5 K30D@*]R0K,9K^CCX&>R;H
MZ9FBJW^.OM%%^L>.T#4X3V/G)$I>8,5)W- X1&_7&%,CD[36" ;(B!?R&4!!
M2A#5^?&T5.:*KLJEO*10L$XUK>V]=/2,JM)4M+2/H10?:VSL)CDYG=24!(H+
M4JFKS*!2B%1)3C"5A5'45Z127Y4C;>105UVE<B:WMO;3TBKMM$W2WCY)7GZM
M$(5,4@2[9&0D4%F:(7:JB)+L2+DG5^*#'41O"GDK52((8TB,]"$JR%45N5>8
MX4=]22AME5$TE412GN%/5HPK:1$N<@\Q#+06TUV?0W5.%(6Q?M0D!E,6[D55
MN#<C.2F,YJ;2G1Y/77P$N8)+DGP\B?/S(U8D,R2$^L0$VM.3:4R*HB#,DQ1_
M6S(B'"G)\B,OPY.<3$\*\OVIJHZAOC&-QM8\NOJJY?FWR'/J8>;0)$=.+G'Z
MW&E.GSW-R1,G9?PM,27/<[!O0!7IJSA]FP5[U=<WJ!R]^7GYY.7D"HXM)%>V
MV5G9Y.7F4258K:FQ4:2>AH8Z&AOJ:1:\5E960F%1 >7EI8(]GQW3WM8N?=V,
M4EBUM[=?2.A!9@X<9&!$*2K7+?W?HG(ZM\COMK6UR1A6(L8[J)$VB\I**2HM
MD?MI8&1$,/:1HYP^>>J9G#ZM<A)?OGR9JU>OJ0(WKEZ]KLI1K.#SPS*WAF4,
M'SY\C'/GKXA<Y?B)\RS(?#MP\*A\?HHYF1\#@]-T=X^HBB(.R7CO[1UC>&1&
M%?G>+V.\3[X?'I]G:OXH$X>.,G-$VKMZB3,G#G-XI)UI(=\S#7$L=<1R93*/
MVT=;>'!ADL?7CG+OZ@GN_'B&![>O<OO696[>O,0MV;__4"E><U?E*'[\Y"%/
MGPBY>OB )_?N/I,']U1%@NZ(W)7W#Y75C/=E_[;<[X4I3AUOX_B1*LZ=K.'F
ME4Z>WIN"!TM</SG$=*?,E6QWBA,L*4ZRH3+7FY1H6\*$\"8)?HN+<B$VVH.4
MM#!2,F)(R4PB+3N3S-Q\TK+RB$U()3(ZA=#(5/S"4S%W#!#QQS<DD<B$/#)R
M:E5_D&EI&:&_=XK9\4-<.'-9R.X=[M]Y5LSK[OV'W'[PB)OW'G/MSE/.7WW(
MW.$+](TMT=0E\[Z^B_(BT3_%1<STMG/AT 0W3\]SY=0!%@X,,S362\_D,"VS
M4]0=.D#UD<-4'U^BXOAABH[,D;4P2<K<,/$3?40.=N!95XYYJN"2Q!1\4K*)
MR96Q6]5"35,OK1U## U.JOX(=_'<9>$V#WDLU_90KO/)8X7G"(F6Z[Y_[3IW
M3IWDULPX-]NK6 AU8-S@.TX*ACBO\R:G#=YCWFHMLYZ:3(7:,!KGP61>#$,E
M2=0I>KTX@?ST ")\]0GWT52MU*K(\91[#*"Y)$Q5>+ DT8.L"$O2!=L7IYA3
MG65)2Y$M$ZT^7%Y*@WM5<+N8^^>50G;.E,5\0V'8)S2DK*,K7YWZ+%V*4HS(
M2S(G/]F:PF1;"D2*,Y0"8\X4YWB0FN!!G.BJE @'"B/T:4[29+S8@ -5)@SF
MZU(:OI>,0&,2 EV)"?$7W"<\)-!+5;@J+,2;B"!W(OV=B/&S)<Y'?BM<C\,M
M;EP;#^3<4!!]E3ZJ/*J^+B8$^K@(]_/!W\</+S<OO-Q]\/+TQL/+#6</!QP]
M['#U<L#=4\3-%E<G2]Q$/)PL5,OY/1P,B JPIBHO@-(T!TJ2C&C(-N)P;R!3
M;5X4)6F3':M+8K@A(;[&>+@8X.)LA*N;.0[.)CBXF./D;HFCJS'>2M&[; _.
MG&SBQI4NSAZO87Y6[&1I*)%A3D1%^)"6GDA&=@:!8:'"R7QQ]_'"V]^?XHI*
MVKM[1'>*+FMNI:]_0.SQ- ?GYJ2]DSR\?9>[5V_QX-K]9XYB&3NW+UW@U.$%
MCAXXP)'I*8X,]W.HJ90C5<F<*O+G2/A^)IU6T6/U$=T^/]"39DQO:Q@=BY74
MGN^F_.H(U;<F:7@X3S-':!"I?;I$]>,%JN2SLKNSY%\;(_EL+]%+303-5. U
MD(MU=31VQ5$$5V62UEA&:4<3C?V"$T:&F)^?X^*9$UPXL<15V=ZY(OKFXGDN
MGCC"\?DI3AZ:XNCT" M][1QM*.)@M!U3@O>/&7_,:;T5G-)9SE&]Y1RV^)@I
MAZ]IMUU-D=468LUVX6NT'4_S'43ZZLA8]V"PU9_);F\&6^QEW.TG(TU#[(0E
MWIX[!>]NP-I\%[:6:MC;:.)@HX>5N1[6%@8XVAKB8JLI.'>[\*SMM%:X<&HF
MD?MG"GDH<NE  C-MKC1D:=)18,!XC1W#)98T)1N0X:>&I]EF'$QWXV"MB[VM
M$38V)EA9FV(EG-]&N+V=C:U\YX"#A1$>5CN)]_B>H5)MCK>9,%>FQGBA)I4Q
MFOC9:>!F9XJ3@PT.3C:XN"LYLV7<.BLI4=Q4*?W\W6T(<]>E/MF($RW6G&TS
MYU27(Q-USJ0$J<MW.H1Y.Q#J[TU@D!]^,H<"(OT(C?45C.Q!>)@=-87!'.K/
MY<>%:L[-Y##1(C8Z39_J#&/:BNT9KG6G+]^<GDP#V5K05^%.>Y4_U25!E.1%
MDI\50W9F''G9213D)5)<%$]M50)-]3%T-$<PUAW#L>ET;IPJYLF5"NY?*.'2
M8BX+8QD,MB?26I= <WTFC?6YM F6&>PKIT[.3TMR(3S$F)!@ T)"C B/L**]
M(Y?IJ6::&Y25X4GDY\935)1*L>"@JII"L<WU8BM;Z>YHH;VQC@ZQ_8JTU];0
M45S(@&#045\G6C0WTKKE$WJWO$_GMG=HT/R$8M&=J1X[B$\V(:[>E_C1>.+G
MLTDX5D+BN6K2KS:2>ZN#_'N]9-_K(^E:!Z&GJO ]5(C'9 8N0_$X]4=BWQF$
M58,G]O6>V)8Z811OP'Z/W:A9;D;;8CMNOA9$1'D3'R\X5+"2XBBN*"VBJJ)4
M<(N(;&MD6UY:('@O@[3<9&+3HPA+""(\SI>(6-&%D<YX!9B*;M.3YZQ%<]1^
MEE+UN!*]FQ/&*UC4EGGBO)5+E0EB=L=%9U]"% 2/[U[DSM4#G#]4Q4"-)XW9
M^K3EZ]":KT5GJ1']M79T5MK17NE,9YV/8,)(YL;R.7>J1VS\,5$L2OJ)Z_#X
MEBI'L9*V[O&MDSRZ?I!;YWI$S^0SVAY.2[$C10G:%,=IBNPG.VPG^5$:U&59
M,]D1S\TS _#HG,B//'ETF\>/[_-0,,9]45[WGM[CKF /)0CVR:.G?_7G/E']
M^Y]CA14'L>+T526L^.M6L I*BHK_X0I6G?',>:R<KSB3GSF4_]=C_D^\_J\X
MB?]KY+#R4O:5SKMUZQ8W;MQ0.8K_]KWB(%9V%2>Q4B3C[MU[J@CCZ]=NJ:*'
MCQT])<#NH:I7+E^ZQH&Y10;[)^D5DM35/4Y'QZA,L G&Q@ZQN*@4WU! [6W9
M7A-P>H#*ZD[R"NK(S:LG-;V"N(0B5?&ZNOI^E (;/=+6(0&X%Z_<9&[^F(#7
M"0% ?0+6! BU]M+9-<"@@*'!H4EZ>H=I;>FFIWM0E1]9*41W\X: SCOWN73Q
MJES_.56%Z$,+AU7[RK6/#$^J4F></WN%B^=_E.UE =K'56T."[D<&C\@1'-<
M)E4Y\:D%I&>5DY1<(. B$5^?2&+C,DG-*"(ENY#(Y#3"4E,)R4C#.R46O[PD
MPI2<Q(V%)#25D-I43FYK'6D59207%))=6DY><07%Y374-@NIZ!'R-CA(W4 O
M64U5A!5GX"IDV##$F=T""#:)X=GII(>ZJR&:KB:8>MEAX^.$K9<CUJZV&%H9
MH::MQM9=F]FP>1WK-WS/NG7?H:&^2PR)N:JRKJ>?.UY!7MBXV6!H(XK&>!][
M='>R??]F?E!?QRJUU6RS56-_@#&[ _79%VN)=JH#FJGV;(LV87V$+NOC=%D;
MI\T:F:QKHO>S5H#!ME ]M$(M,0VUP]3;$B,G$]P"W0B*"2(H-@A[3WOL7.UP
M]W;#V\\+WT!O/ /<L/.R1=-6BVT6N]$20+\_PI@]T7KLC-=!*T\I..?(_D(+
M- NMT"JT03W7G#W9QNS*,6!GGCZ["PW84VS(WA*YWD*1/%/V*L>D&;([49?=
MHE1VI>BAEFTB;5BC562#;HD=!N4.Z)5:HU-L)I\9B1BRK\"07=F&K$O4X]L$
M8[Y*L.(C 13OA#OR3H0[7R:%LKL\"\ON2CS&J@F:K2+Z< 7IIZO)O5!%_H5R
MLD\7$#47C<^ .VY=5GBTZN)?NYNHX@WD5FREN'@3.:FK*4G?1&WN?IKR32E/
MTB7+?PN)CE^0[?D517Z?4Q+T,17AGU"7O(J:M-7$^[Q'A.O'Q+NO(=UK&^YJ
M'[!_Y7.8K'D#.[5/"';:3EFN.PE19@)(=F%FO@\G-Q_<_-(Q<TS%V"D-8Y=T
MC%S3L?8KQCFT'*^(?!(S\XF)#<3><COI(9J4")A.<?R*7.>U))M]38#Z>V2Y
M;2/%?3L>!E]AJ_D%1GN^QE!C&P&^$81%%.,34B'/NDK&83FF3D48V15BZ5J"
M>V IX?&%^ 8$86NJ@]F.;['=]@E>>S\A5.<S@K0^P&';Z^SY[-=L>O]?V;+B
MG]%X[]_QV/8:L2:?$&WY#2%6FXCSLZ<@NY2(R")\ @L(#*\@(KF5H*0VG,-K
ML0PH1\\E%VW[=#RCJG'V2\+,TIY@&>=!7J8XFVW$P>A;,J*,Q4#%TM<626:*
M(>Y.7PMP_P)O96OS#98Z7V)CN!U7.RM\O8/P](_#T3<1:_<8G#UE/OO%$NP?
M@96A,?I[-F.IN083M66X&+U)>N WM&3NI2%Y!VE>7Q+G\35I(5LH3M85TFJ(
ME_4Z-JU>QH;UWZ-GXH!K8"9FRC-QR,7,N00C^V+TK'(QL,K$VCE7P)N >O\D
MTN,2L=+9AL::%XFP>8]<C_<H]UA!E=-[Q.][CEBMYZ@-7DF^Y]MD.;])L?M*
MH@7PVFY\"^W5GQ'LZ$YT6#JNWDG8>*9A[9&+G7LQMBZ%6#EGB]X04AR2)< I
MC@@O=T(<C+#=_SUJW[W"E@]_SKX/?X7IRC]B\.XOL?GN1;S5WB50]Q-<=[^#
MY=J7L%[] I%J[Y%M^#FQZLL)4'L3UWUO8ZOS*29Z6S Q-Q5=$X2%2ZR,C13,
M73*Q]RF0L9*%N4,T;AY1N-I[8;)?YNFW7['[RP_06_L)!FL_X(>W?\^R__@)
M7_[EG_CLK;_CRW?^ 7OM=W$U^!B=S:_SQ?*?H[M[#6$^[CB8V<@8L\?)QED5
M$6%CJ8.!/!_=G>^AL>Z/:&_X%4XZTH>.[Q%B_SYF>U_ Q^(3W T^8>?'OV73
MFS]EC[1G^OE+6*U^"],U*]#Z_CWVKOT(?8U-.-F;82N 7%MS+QO7?L6:+]]E
M]P\KT=_Y!=^^\PNTU[Y%F-D6'+>O1&OE"VB\_SOIJ\])MM]*BO,&7/:^CMVV
MW^.ZZ_<$:/^)!-M727)X&2_-GV.]\:<8??-/&'SY#QA]\7?8K_DY_GO>P'SU
M[U'[Z.?L_.B7:*SZ$WN^^B/K5_P'JU[\9[[]TT_9\-JOV/GN<^S[_'EYUJ^@
M_OTK:&Y9@;'F-U@8;,/94A-'HSU\O^(%UBS_#1K?OH+.IN5L^_HEUGST>_9O
M>)>U'[S,RI=_S;8O7\-R[U?8:7S'CH]?X>L7?\:GO_D'OOF=S,O7?H/Z>R^@
M(WUC+/K&6>TCHATV4QRC3V>)DY!](4X=@4SWA#'3'TM_<XA(%.-=&?0UIM-1
MFTU7<Y60UTF.+1WER-)ICARYP,&#9Q@97:*G9Y8N)2=H[P23XW/,34PS.=!/
M9T,E-45IJLC8A8EV(9O%E.7'45:01%IR!(GQD>3EY=$N&&!L:I'1J:/,'[G(
M@:7S](\MT- YH<JSVR+;D>$YID<G&>WMI%EQOA8E4%<<0V5>&-5%L337%C X
M,$#_\#2=_=,J)_/8["+3AT\P<G"13L$Z#3W#U'>,R/=3] ^,TM18(>?ETER5
M+J0HCL+4,(HSD^AL;*-'.:YSDM:N&5I[#M#2?9#&]EGJ6R>I;1JCIF&(AL8!
M(1Z#C,KO=C?54%^<2EE&,"6I_I2E!U.>*6 _,8S<U'C*"O-53L?65B4G;@NU
MM<W4U35345Y)?%P,:2E10@"2:*I+I[HLAH),?[*3O2G.#J>J.(7JTBR1?&K+
M2ZE7G )U;334=E)=T2+G9A,='4-B8@R9Z3&J*)[&RC3*<B+(BO4D-=R9ZMQP
MFLL2J,J/)B7:A\@ 1Q%;DL-M*4WWI*T\G*Z*6)H*0JE,]Z4BW9^&@BA:RQ*I
M$M*7*20D7LY)#?8@T=>%-'\/JA.BQ;[%4A$?3EZX'XF![D3XNQ$:).33WY.H
M0!]RH\(HB@HE1[Y/"%1R(5H0%69#>J87>45!E%9%"79*HJ._@(Z!4IJZ2VCM
MKZ%ML$&DA>ZQ'@:FAN593C UIQ1?.\#<S!P3PV,J)W%/5S==G9VT*='!]?72
MG^5"^@LHR,T3PEA"85X!N=DYY.?E4BG?-=37J9S$=;75U-?5"-YLHK*RG)*2
M(LJ%B"E275-%8V,#S<KS:FE312N/C$TP-#I.9V^?*CJXH_-9ZHJ.]@Y:FINI
ME]]N:&JBMJ&>\JI*5;5U):W%Y,2$S)DCG#YQDE,BS_(2G^*L*JKX$A<O7E;)
MI4N7.7?^@F#:$\S.S#.OK)9;/*Z**%Y<.OE,%D]R6,;S@0-+C(\?9'1TAI&1
M:89ES \,C*OVIZ8.,3IV@.FYHQP\?);1Z45&9@]S\/@I;C^XSZT?+W)V?IS%
M_GI5 <$K!QMY?'E2".,)X517A%,).;MWBX<BCQ\),;M[0^4@OGOO.@\>W58M
M!U5%^CQ^(-\_Y/']^W\5>?] R-R]>]P1N7O_GBK=G1)9K$0;G3W9QXDCM9P]
M4<V5LPT\O#$H!'6&:R<'F>DIH2$_E,($>QE[+C(6@^EN3**B,)CL- _*BX+)
M2'$G)MJ!^"0O$E(#24R/("D]3B1)WB<1DYA >&P\ 1%Q> 3'8.<=AH-/!/X1
MR40GYI*=)QB]1DE=,\)0WZ3HJ(-<.7^%^[?N\.C>757JC <B=Q[<DWYZP*T'
M3[AR\Q&'1,_UC\W3V-8O9+V6TLQ4FG,3.#58Q_V3P_#C#(\OCG/B0*OHJ%IZ
M)]MHG1^D_M@DU:?GJ+UXB*J+\Q2?G2+[Y"C)2_W$'.@D?*(9]Y9B3#)CL1 ]
MZ)&<1&Q!,3D5M534M]'<WB?/=)2YV7G.G#K'_;L/Y!H?\4#Z6B&V2M\_N"O7
MKJP:O721APNSW.VNYT"0#3W[/^6PEI*'\B5.*KDH=3YDWG(]L\YJ#+OK,)OH
MP8SHSM[R>%HJ1._)_ _STB# 91M1ONKD)]G04.A+>UD$K4715*?[41!G3U:4
M$?EQAI0GF]"<8\-$@S>G)V.Y<R8';A3+\RSAX;D$AJKW4YWX#94QJVC/VDV]
M8/*B-"LR$ZS)BE>B.&U%;,A/MI/?=B0OW4U5&"LVPI74*"<*(_5I2M!@-%^;
M ^4Z3!5ITY:L26Z0$?%^CL0&^Q$>[$.((B&^1(3Z$2E8,=+/F1C!FBE!EE0F
M6G*\RYN;T\&<&PR@(<M6]),I0>X6A B'"O3UQL_3&U\/'[S=O?%P]\!-<;AY
M"K;SL%'E#/;T,,-?N%"(GQVA/M:$>%L(5C$CRL^4PF17AIKB:"OQH#;33,:$
M,0<Z_3C4%TIWE2?9L::$>NGAY:0XB2UQ<['&5;:N;I8XNYC*;Y@1$>5,04$0
M _WI7+O2P=,'_=S^L9'IL60:JD/)SPHB0VQ2@NC7D-! 5?H+%P\7/ 0O^0;Z
M4B9ZJZNG1Y5+75E-T=7=P\3D!-/3,RPM+G'YPD4NG;K(CV>N<D\X^_T?KW'U
MU$F69J:9'QOGT,@P2_V='&[(9ZDHC&.)5AQU7\>TR=OT&?Z%/O\?&"ZRDW&=
M3-O1&FHN]5!Q0VS?W6D:'Q^BA24:GRS2(%(G[ZONSU!\<Y2L2[TDG&PC\G M
M0=,E> UF85TMN#LO$(_\*.*KLLEM+*>TI9:6WG;&)^0ZYF<X<D!Q",]QX>@2
MYT6.R?NYT5[F1WHXT-_.7%LM2W5YS BG&S);Q:36V\QKO,Y1C3<XMO\-CNLN
M8]'H/<9-/Z7!Y'O2C#83J+\)%_W-N%OO)"9$EWKAC@<&_3FW&"W][",VV8:B
M?$/\/3?C8+$>=[M=>-CMP<MA']Z..MB;*WF)M7&TT<?13EMPZ4[LA=,D1>HR
MU!S ]:4\'AS/X^%1>8:SX<PVF'&HV9S3/4X<;;%A5'AI58PZ,6Y;\;+9AI/5
M'N%W.H)%#;"V,<+*SA0K);K86BE<9RN8SP1W\UT$67]%7Z$.I[NM.5*GS421
M!N71:@0Z[<?=P>R9D]C!2L:IDXPII8B=*VZN[GBZN>'K;D> LPXE@N\.UEAP
MJL6<,UVV++0ZT"+\.CO2E&@_&R("/0F6N100ZB^<S)>P:"^B9?[%AEG07Q_%
MM84*'IVJY>92/G,=OA3%[!:NJT5SG@6]I3(N2BP9+31311*W%KI27>!'46ZP
MC-LH\D2OY67%49P71U5I/(VU"72W)S/0F\CX8!R')Q.Y<#B#VZ?SN"=R^T0!
MYP_F,]:51GM]JAR?29-2CZ(VCY;&/(;[%.P82)B_/FY.>P@*U"=5R8^L1"0/
M%3$V6DU3;19E14GD9$63G!)&2EH$V;E)E)47"-:JH$&DOJJ$^LIB:LJ+!%?E
MTYB705=L,+TN)K2HKZ9K\P<,;7J'SJW+J=/]F@*7W40':1.28T>0X&2_X4B"
M9I.)6,PFXE@>,:>*2;Q02=J-)A)_;"+\3#5>"_FX3V?@.IJ(4W\4CMW!V+5Z
M857CB$V%'5:Y9IC&:F,5KHM#L(%P;Q/\P^R)C/$B,2E$<%R8W$,B%65Y%!?E
M4%B80Y%(?FXJZ6FQ8@-#B4\-(3HED- $3WS#[? -M1(>:(%?L#'1$<84QAO3
MDZ;'T1P#+B7LX;C5ARP:?\""TR:6TKRY-=L'-W]$*13V6.S(D[M7>'QCGA,S
M98RV!-%5:4UCOBX-N3J""8VHSS.D)L>0ZAQCP9(6@L'=&>Y-X.A2(S>O+\"3
M&SQ]).W<O\/3>[=!]GERC2</3G/M\C1GCW=Q:+)4^(2"*7VHR10;$+&/[-#=
M%$7OHS[3@H7>%!D'/3RYOBA8Y*+*Z?SDZ7T>/KW+_2=WN/_XKMB]Q_([\/3A
M$U7*"25+L>+@_4^WKK)58I 5!_&]OXIB,Y5,QL^.5)S RI'/G,3//E7D6<;C
M__F8_Q.O_RM.8E6H]7]Q$BOO%7!VY<H5;MZ\*0!.;E6^5P[YVV$W;MQ4.8F5
MI6V*H_CQHR>JE!.+BT<%N)[FJ9*3XJ\O);7#K9OR_5DEQ<1)E8-X<'!&E2=X
M<G)!C) 0NM$#=/=,J*)A.KK&:1'P55S:0E)*$:D9932V#')XZ1RGSUWE^DT!
M8-+KR@JI:[)_2GYW5@C<[.R""@B?.GU!)<>.G>;PPC$.'CBL D=*GF3%&7SE
MRE75LCRER(>R75P\PO'C)SEQXC0+<OSXV RC(TIEUWE1%D(0^T:$M XQ*H1U
M:&R.AO9^4K)+!5 6D9U?37)J$;%Q641$I! 8'$]4?"9IN:6DY!62(*0U(C<+
MO_1$0H28Q306$UF;3WQ=,2DUI226%) DQZ3E%I!=H$2@5%)5U21$MY_NH5'Z
MIJ88/#A+^_0HI;TMQ%;DX"H3WR3("3T?&^QC?7!+#L8YUA^G"!\\HP,)B _#
MV=\=4P=S]AMKLG/_3I6C>.N.C>S:O14M;74LK$QP\Q5CX.>*M:<=9JX6Z-CH
ML<=@+ULT-K%VYVJ^V[Z*[W:O9HWV!K;9J:,?88UYFK2;Z8%VDCU;0@U9'ZS-
MYEA]UD5K\GV$.FO#U=D0NH_M\OF^0&,L(QVQ"G' V--<%)@3OK%^!"8$8^UE
M@ZFS.5:NMMBZV6'M;(69O3%&M@:HFZBQW7@7.EZ&Z(>;HR, :5^\(3K9EA@4
MVZ%=:(E&CBE[,HW8E6G CBP]MN?JLK- MODZ[,R7^Q!%I'(>IQBQ(TZ??4DF
M: D8W9=DP)YD?=0RC*4=:W3%..TOLE(=N[_ %.UBD2(C:5^776F:;$K:SW=R
M;U]$ZO&Q*,OEH18L$P6\(MJ3S^0^5J=%LKTP#J/F=.QZ,_ :SR+Z< $QAV4\
MS"40.!:.1Y\7]FVV6#4:8=>@A7OU3@(*UA&:_A41\9\2%KH2'Z?E^-B]3[C[
MMT2[?R]$>3_3U4ZTIZI1$_$M=9&?TI>UAH[,[\@+?0]7_5_B:_8:B1[?X6?\
M,59;7T?SR]^S:^6O\3-?*Z#<G8[&,*I+?4B,ML1% (J/MQ<A86EX!V1AZ9*
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M^+'B3%8=IG(,*PY6)?_P^7,759\IQQT[?ISYA4/R )2N>_9Z*%A13I<V'PF
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M-1R::V)FJI*>SB2*LFTI3-:C.5N7P_46G*@Q8BEW'U/1VQB.W<^AVE">7CX
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M7_\+\_[Z*V;^^Z_XX?U_8-'D?V/+DH_QL=L@LIZ=J[YDV]+/1+Z0[<DX&&_
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M*R0T."X -W\G3)7(8A,M-/=L9?/N]:S17<XFJW7L]-R*=O!.''-M\*\30";
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MWI;G)\@Y8\7>BETIRB(O-YDD=0&R$%*3_4A/\!1;XR6VWIZ\3'/::UTYUAW
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MT?\'E_\M.8E_611GL!)5^XO\#R?R&X?R+T[B7W8K@/'1HR=<NR8@]-IM=72
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M2@O+:&UH8]_0& >E[PX?.,G^T2.TUK>+@<\E(C2:F.AX4C.R**JHH$7 8+^
MU)']2J7:,8X=/LB)HX<9'QL1Q5E/=EX.R1FIY!3E4UE737-S$[T]/>P;&>'
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MW?PN_J;?R?C]3L;>^^@M_1NZ"_^*\;*_XK3E _P%8$48?4NL]1P"I.^MUWR
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MY P24S.(B4O SR\ &QL[W-P\" L+)RTEC<*\(K63^-#8$8X=/LVQ(V<8&3I
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M)_'I_0WT5H?17N!">XX=!VH"N#6:Q[6Q0@9KPLF)-"4OVAI5NCO=,M<>7AF
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MK&\AY]?#W6XMCI:"2RTWX&FWA21_/1(\MQ)AOX)D]S6H8F7.R%A)"]<F*=*
MV% 3W*PU!1ONP,].F[0@$\KBK6C.=F)OI1\'6J-I5P43+N/1QW$7T5X[*(_9
M3EG0(@H]OT7E.X73]3H\/N3&W<->W#P:24>E-]Z.>_!PLL/+W54=$>_I:D"R
MG*]=9<Z1=@N&2C92&S.+CNRUE"5J$!>D*;;9[(V3.,A-QKT[1=G!#'9F<O-"
M&P^N=7-.;'"=V.JT!#?BHEU(2_$E.<&=[!0W&DL#.2QZ^.K>2)$H]M;Y4%_@
M2F6>%^4YP91EA:#*]*>]-(#><F\ZBQW$/EA3EV%$:?(>:DO=:*D)%.P5S,'&
M0([4^;*_RI>AZ@C!1U%4%X61DR[8(\F=]#1/RDM"J56%"48)HZ8RDMK*".&C
M@527N<F8]I*Q',5(7Q'[!BK9.U!+WV =7;WE5%7&DAQE2I"'AMI17*,*Y8"2
MENA@ 4>'HSD^X,>%'D^N-3AR.&$;8UY+..BX@$..RSCDO9-3R6X\ZU/QXD0_
M=\_MY?*Y+CK;0\5.Z-+69B\XREUL>A3G+K5PY>80EZ_OX^KU UR_<8 ;-T:Y
M<4U^=ZN3T\=S!)N94%ZZG?J:K72U:C/88<KQ\2#NWZCFP9WQ_W02W[M]GX>W
M'O#D]EV>W;_)@]NGN'BZ@_[V*#IJ7.FLM$65HD5:R%KB ]>1DV+,\& 6#Q\<
MX<63&R(/>?;H$<\>W^?G5W=X\>@HIP_DBNUT%;QJ2&NQ$2V%QN1';L%);)>+
MX0S"W3=2EN'*N6,M_/3RFECVYSP1K/!8P, +P14_*0Y;);+W^57194<Y,9A#
M28P^Q2&;J(Y:3V>:!L/%2IYL/1HSM2B(WD)&Z!:*DTPXV)O!O<M[Q;Y?@Y^4
M-!%/4.<C_NF9X!#%02P811$E X&"/P2'*'Y>-9[Y6;#+ST_E."62^1&OU<7J
M!'O(@3\K;T8I:2;4$<3_WWV@_R<M_]MR$BO+_Z_.^667LE:<JDJD[X,'CU!R
MD"D.XENW[G+W_B,N7+S!X</G&-M_FL&]1VEI'Z*TO('6CD$&AP\Q/'J4>P^?
M\NSE:\[)L6?/7^'&S7L\?_&:![+_\I4;G#YS0>TP?O/JFO+7@C>.:67[S;G>
M@.*+%R]S_KSB_%722;QQ!BM1LHKS]\*%"VJGL5+(3HFD>/#@OKJZ\R_1QHJC
M6/FL@&2E^-YMF4SGSU]B_X$CU-6WH"JO%8 NX'#X"$<.7^#0P?/J@GM)R7EB
M0*,(#(\A*BF5Y+P",E0J4DI5Q!66D5A:29*JFN3R&I(KJTFIEG55%9'%^425
MY1-344A$438^\3%"M(/Q#Q60%QY+5$0BL5')HD#324_-)BTM&[_ 8.R<G+!W
M=L++UX>@D& A3:%$14:3DIA*7F8^^=F%0JP2<;)WP\38 @MS:UR=W?#P\" X
M.%B=GB([.YO*RDHZ.SO5J224XBCQL7%J![&-I2T^7KX$!X40%R>$NK"(+B$A
MI\Z<5D<=/WWRF =/[G/I_E7V7CR$2V80*]QVLB':B*U95FB5.+.GVAO'[FC\
MAM,('<DF?#2;D-%, D8S"-F?1=2!/&+VY1-0%XMW5C !L8%$QT>0F9M!54,-
MO4-]0C['.7+D$$>/'>3XF:.<NGB*,Y?.JJMV7[QPD0.'QND<;J>\5T5J>SHN
MI5X8Y]MB*X#?J24 S^Y(@O>E$CR62M!H,H'#240*:(J3:XGOSR*SIY 2(?_5
M?0TT=+?0UMM%W_ 08X<.<N#H(<8.C\MZG(,GQME_;!]]0Z+(>UHIKR[%RL&:
MS9I;6*6QDN4:BUFY?1[KM6>QU>![=@JPUS:=Q![KKS&R^0H3VR\PM_L*(XM/
MT35^CYT&;[-1\_=LW/$7=NE_R;8='V"\YQ,Q-K/)C5] 0=Q,,H,GD!4XD0B[
M#[#9]EMLM_T9?[.OB?=:C(W.1.P,Y@AX,1"09D=&:@(-C:VT]XS2VK4?576O
M]&4AH3%9Q*7EDU=604AD,#8V>GB[ZE&9[<9(C0]5L=M(MI]*J,%[1!C^G5BS
M]RCPGDI/YDYB'!:BL_I+5LV;@)>=/9D)>:0F*/F;!AD?/\F^L1-4U_41%5>
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MJ!#[5(OM.D$("W*C!;:)(BDEDJBX2&(28DA(3" E(8'TI 32DJ-)2 X@)2<
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MQ_,G=WAT^P@'QM7TU/C3J+*B76/%D,&)9L4V8ET_(USPN:SP]4*O)W+M[)C
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M-H8862S)\2GD9>0)L*<D.3853Q=O'&R<<+9SQL?#FZ" (&31T:2EII*;FRL
MK)+2TE)3!6TI%W%X6#B.]DZXN7H0$AQ&5%2,*7(G7VRK$,_3VMG!R,XQ]DY/
ML>_P/H;VCU'2785=NA^+PK:R-L>)C2H/S"L#L&N(PK,SB="!'!+&BDG;I2%M
MJI2D:0TI0I&F36I([E$0H);AFQI,1$($Z1DI%*F45#<8&9X88__!&=$W1SE[
MYC3G+I[EW)7S7+@F]><-H2@OLV_?%!W#[:C;-<16)>-5'HJS/@BOYAA">M.0
MC<A)$(0Q<5>1R5F<*I99NTN03Y92.%)*4;?&] JIL;N.SN$>TS5W3>WAX.$C
M'#YZE!EQ_0.'I>)^DNP39%AZM7:,GKXN5*4E!$4$8V:]D14;Y[-L_6S6;?T4
M6\?/<?/X!#_?642$?$QLY,?$1\TB)O0#@KQ>Q<OI9;R<_X27ZRMX.+^!H\V[
MK%_Q$NN7_@IWZS\3[_\.A3&S*$O\"&/&%U2GSJ8D^C,4X;/1Q"]!F[X1GQV?
M8+/I4W&>C<+(IE"JU:&M;*9SX  ](R>H:9HB+<=(1)R*Z"0Q%DO$N%.HB8F/
MQM?+"EG@%I0)9E1GF]&FV$QGX6J:,KZG,?5+VK*^H[-@+>&VLUC]W2NL6O E
M\1'Q:)1UY&5545/52T?'."UM8X*8]I">6T50M!S_F#PQ]DLH4I<(8&.+^=RW
MV/S)/Z,+6TIYZ#R2[-^C.L>*WJH(&C5!!-M^2[3'"E2Y0>BK"E#I2\A0J4G(
M+R>]N)E,50^QF<U$IS2)9Q#+A!:"(PP$AY42FU JQFX9&GD2.<$;R/;YFC27
M=XFR_!.^&_Z9*-L_HHKY$FWR]Y0F+B8_;!%>F]_%;,'?6/O]VZSY838>3O9B
M3A6+9VBAIJ'?Y-CH&SY(4_MNU.5=9!?44J!JIKRZE[J6;LIT2K(R?(D)VTR(
MVR(\MG^.]0K1G]L^PL_Z8W:L^BM^EA^2&KB,(@%&@]VW$A[D1Z6AD>1L/:$)
M.J*S&HC*;B LO8; 1 -A24UBW#<2%6<@,ZM, /DX/!TL<;=<B<QS$T6)SNBR
M?0FP6\RR.7_&:MT</*V7XKKU>Q9_\%N6OO=KS+]]%??U<\3U9V.]]GM"O9P$
M:,BDNE)/M= Y=34UPM"K4>3+!(CV)MQ[(Q;+9[%]H6B/;_[.V@]_PY8O7L)^
M\2OX;GV'$-N/\-[V)E;+?\^Z;_\9ZY5_)=3Y6T+=EA+J8TFL+(+R\BI:.OKI
M'9Y@;/<AZEMWDB6O(S)617RR!GE!I2#&Y7C:6F"VZ%-R(FPHC+,EVGTQF^;_
M@56S?XGYO)?P-7N?3-_YIOZ)=Y]MRJL;8/\I@6*9$K* U."Y1#B]3XKG)X)0
MS";#[7-"MWV ZZK7A;R!W'<)J4[?LF/>RRS[X%]8\.ZOF??^[_CD;_\DY!^8
M^^XOV?+-GW%;]3Z!YI_C;2[UU2>B/3_'Q_)C+);]2=S/;W#=_ :1+E^2Z#.?
M*.>O";'YC*!M[Q.TZ37LYOT2BZ__ >?E+^&V]F_8KGB--=_]C7F?_IEY7[[%
MFN7?XN:P%0?+5:R<]QY;%KZ'S9)W<5KV%IZKW\/R>^G>_@?K/_]G<8Y7B+3\
ME!C+V;@O_!N;/_P56[^4KNU,078I$;(B_"*5^,>7(,NM)4%>3TQF-8$Q&MR"
MB_$,U2!+-@@=GHVKK2W+O_V00#$VT@/7$&X_&R^S=[!?_0;F2]YGP>>SV+K.
MFL1X+?[!:IQ\U+@$5N G:\0_KAF?F 9\XQKPB*K$-:Q(S%\%,6F%)*6E$N C
MB%F4JR!*7@2ZK&#!['_C]7_[!;,__)^L6_$.-E9+V6ZYE:#P>&1"OSAY9V+K
MF8>];S&.05HL/91L=<C&TB&=@& %41&Y^+K[B_;YCA]FO<[ZV6^PY+T_LNC#
MW['JNS^Q?<V[6&_Z"/.U[['VA[^S8LY?6/GI*VR:_29F7[_+YJ_%G/WB%99^
M]#L6OO._^.&M_X[;RG<H\%^'+F$'C04!=%;$TU.7S4"GFO[><MK;U%1HXB@K
M#*-9GR'(2P0%65$T5JOH:2X7!%A+5[V26DTJ58*P-)6G,]%9RFBKDOK2.-JJ
M,J@O3Q8Z)AQ-8;PI$KG.H*2A1DV'='Q'I2FE0V.5G+K*/"%*02S*Z&DUT-E4
MP5"7@8D^/</-"L9:"NFOS4&?'X4RQ9^2S#!:*W/HJ,ZC39]%<UD:O48Y0TU*
M!IH*Z6LHH*TZAVIM*N7%26(^RP39"A4D-PJ])H>^MG)J2M.HUZ;15UM O2H!
M?5XDE3F1U!3&4%,41TU)/ V&#&H-F515I*.OR,)0F4^5OI@J@_2:?#7M[6WT
M]0\*7+:;R3W[3=AK9&0OHT-30O8P)#!:5UN728>4:564: K1592:\CH/CTW0
M/S3!T.A^=N\]PZ%CUYG8<X;NP1D:VB>H;=E)<_NXL)43@A0."%*N%_>526-)
M.O6BO6L*HJE7)V(HCD,MCT*>*>4E3*!2*_81S]Y0)>Y;ET*9)IGBHD1R\N+$
MV(PB*36&E.18TN)EI,9%"+(60D96$(J22,KKDJGNSL78GT?M2 %UDT743*@P
M[M)2NT?HPUU5&,9KJ!R5HGFKT?144])EI*3#*#"$D>*V:A3-!A0M>E3=1JHG
MI301[>BEB..]+52+I4'*8=QOH*BCE/Q6-4KI!XD1(U63C52,U:$;$FW59Q"X
MJ$*<1V"-AB+RFU1HQ3&28[ITP""N6X&F4Q#EMC)*Q%A1U96C-I93V]E$?7N3
M"?\T-#?1W-9*F^BC[LX>4R2QE*=?RDG<TM)"<W,SC<U2;N(J4^J/8I6*J:DI
MT]MU/PIB=/_>/9.3^&?GKD1LI*7TOQ0E+!6XD["OE')"PL%2 ;J?HXRE^AS2
M?I(C6/I.^E]R(/_L;)88EXDL2><5WYD<Q/^>JT]R&O_O]!,O4E \%_)$[/M8
MR"-)Q#%2%)'D)'[R[$4>8BFRV)1FPI03\!X_/;C$_F$#K9IPZO,\Z58$T%\4
M(K!*L, M 5052,[%',9%NYXZ.BSXP'%!/"_Q2!#-!X_/"Q)[49SJ%$_N[N?I
M[9T\N-QFRM5Z<#2.Z8$(=K8%4Z=TI#C)$D-!(*?W=_/XY@E!-J_R],$5'MV_
M(MKP*O?NW^#.[<O<N77>E)OQP<VCW!>D_>[% 6Z=[^32J08.3I?16!=+7HX;
M4>&6^'EM(2K,B8+<&-3*5$J42:@+8M$6)8OU5)0%*13DQ%.8%49)AC>-*0X,
M^B]GRN93CMI\R+2PP:.>7S&4N)J&PNTHM+;$5M@2T>!!6'L@P9U!1/6'D3 2
M2<I8)*EC422+]<3!,)*'Q/<] 435NQ!ML".URH'B>@^J:CW0:QVI+')F:JB8
MO:,5M-?+J1&ZH48G]$1E%A6J>,H4T4)7!@G,9T-X@!FR4 OR4CPIE0=1H1"Z
M*\N:W+B5%&6N8[0G@AL7RN!)"]RJYM)4&@<[0SC<%<[ASBB&*[Q01Z\EUW\1
MJM!E-*5MIE=NP:C&B<D:?R8:(AFJ3Z*])HN6FAS:C5+AT62ZJD)I43G0F+>)
M0<TVJA*_)=/]KY1&?TZC?"W=XCEZM$Y,-?ARJC><HUV1C-3'4*>+HUP=@U89
MA4X93G51,,TJ7_HT'NRJ\.1,?0 WV\.XUAK*E-:5GGPK,:XLZ%=O85>5.<?:
M=W"Z?3LG6BW94^>$-L>9C*0 TM.D"&(AB4+O)(:2D>!,>;X3@T8W#K38,%VU
ME,'"6;2EORDP] <T9/U @](9=;HK.7'.E.4',]FCXN:)-AZ?:>+*/BW3/=ET
M5,53G.E!ILP:1;(#[961C#7'T5?I0V^Y&[5Y5N2'KZ$D02K>M5W@RHV49ILS
MU!C,C:,EW#Y9QLFI/ ::PS H=]"M\^#L< ;W9[0\/]/(U0-"QV5[D!1I2U*L
M%PGQ 8(O!A 6*3F+O<08]28^W(N42%<*,]R%+0OCT)Y"(7)&NV(QEH@QH_(1
M-BA8<,I08J(#" ST)R@HD-!@'\)#Q!B+L"4UT8H&8S#G3Y5Q^U8#C^XT\O",
MAA-5KAQ,7L[)D&^YZ/HAE^S?Y;C=!_39?HK._@L*_>:*,6=%39LOE3U^@B-;
MD*3>2+QB/7'R3:05B[&G<Z# */!1@PL%34XH6^TH:K&BI,62RC9K&GL<:6VW
MQUAA+L;D"N0IZU'FN!(3;DNPCSUA?H+W>KH*[F4IQK09'?7AS$PD,C4<2(UZ
M+:JL9:BR-U*<L0%M]@8J<]>A3EE!8?)ZLA/-B M=2Z3_,K+B-C'>&LVU_;D\
M.U7(C\>SV-/@A"YC&9KTE6*LF%%1:$^EPI6"5"M2HS:1'+Y!+#>0(<V!R.5H
MHQ;2G;6.(]5N'&D*IK?$B>+HI51EK*6U>!L].EN&C!XT%%M3$+L<><P:Y++U
M%,HVH8[=ACQ(^L%E*:T%]DS6A;*[+5[@B"CR4CT(];<FT-,1?W=7@;7<\7%S
MQ=_#F1!?9S&'G4F.]20QQHNP "?"?*U)"[.@*MV2FN255,5]1T/R-YSO=>?9
ML11N'4KCP%"LP!!^Q(8Z$"G&2EB$&#,1;F+<B..T7IR>C&5GE1FM>=]C%+RQ
M*NT[]+DK*2_8CC+7@1RA,S+B T4;AJ/*CZ6Z(H4F@8'JQ3S7:=/)SXTE-SN1
MW)P4P6&34<@3*!881IOK)]H@BM,CZ=S8E\^E_4JF^E.I+?6F/-=%7,.#IF)_
MNDI\Z-%XTB7F=K/*@SJU%\92/^KTD0(_R.BLBF*B.ISIFC#VU8:SNR&&3ET(
M)=G.Q(8);A:RG>1D+PS5^8++ZFCOU-/5K6>P7R]P3S%=C;$"'X;3UQHG\$LA
MDV-E3 CI[<H3NMN%R( 51/LL1B=W9;0MAT.[C.P?KV1F7,F1W>D<VQ7'R8EX
M+HRG<V>/DAL#^9QKR."RP)?7AXS<V-O'I8,[.7-T-R=/[>;LA6&FQ+SK;1?G
MZW&CK\6'D>X485^ZN79Q+Q<O'!%RBLOGSW#]_"EN7SK(\7UUM!D#2(F>0T+D
M6V@47S(Q9,74J#,'=X5S0<I-?GF"VS<N<//Z;>[<O"-$*EQWE9MWKW+[P05N
MW-K'GEU2_8HP.FI<Z38X4)&]FK30K\5Y%Z,J=*"_IY [UX_R_/%=G@@\\/"^
MP N/!+ZX<I#)O@*AM[QI*;&FOVP'.PV.=!:;DQOT#9$.'Y,;M9Z]_2H>7)V&
MY]>$?;_-LZ?WA<U_():/>/)8PAH/7SAGGPN[_^PJ/SX\P?W+PT+'57%E=P[G
MAJ*X-A[+[5T)'&CT8*14TMO;!!:P8;C<EYF.#"[.U O[O4]@D6L"G=SEV8_B
MW,^E2.(7#F&3D_CGW[+_PTDL_9 M_5C]R.0L_O%GX8F0%X[B%VDF_I\=Q)+\
M5_O\EW 2_[\WE.0@EB)YI>B$QR:1TCU(2ZEHG>0TECZ24_?FC?L<.7*6P9'=
MIHK@/?WCC.Z<YNJ->]RY_Y1]!TZ8BMH-C^T1(E5DO&<Z]M&3YTSM/<CTOL/<
MO2<5M/A1 -Q'7+IXC;-G+G+MZFTQR*0\Q$]-:2$N7+CTPK%[XK1I*4452ZDC
MI/S"DN-7 L12.@K)>2Q%44A5H"6@+#F-)2?QGCU[3(YB*;+XT*$C)CE^_)3)
M47WPT'&&AL8%&.P4BF074[N/L'?J&*-C^ZFI[R2SH)@,11%I2B4I14HRR[3"
MZ.G)U5>165Y)1GD%F94&Y,9:"NIJ43;54=[726EOAR <38*<U*&L,Z*HU).M
M+"$I)8_XV Q2DK+)RBP@/3V/R*A8? ("<?+TP,[%"4]_7P)#0P@6$AH:ABPR
MAM2$-/(RY*;\IFYV;MANM\/.T@X7!Q=\O'S$?J'$QL61EIY&5G86N7FY@F 4
MDY2<A+LP+M96-MC;.^+MXTM0<*BIX%U*1@;9\CSRQ7.I2C545E4*$EB'IE%'
MB"(.LSA'ED5O9VVV(^N5KFPI\\7:&(9M703N37&$=6<3.UA(_)@2V;B"&&G9
M(R>L.@6')"\<P]P(C@XA)2V9_,)\M 8=G8-][)F>YL3Q$UR[<LT4P7S]S@VN
MWA+K-ZYS\=PYQB='J>FN(<V8C6NA'SN*O+"K","E,8K@_DQB=BJ($TH[::*(
M=*$(<_9HR!U7DR= <GZWD(9"BHQ%Z)LJZ>SO8F+W) <."N5[_"3'CYW@R.'#
M'#LFI2@1R^.'V#\SQ=C8"#W=W73W]J(N4Q,0ZLFFK0M9L6H66[=^3%3H(F$<
M%Y&?.A]MWD)J5<L$,5Y.=?X"E/&?DA8DY5A]E93 #Y!Y?8RSV9NLF?L;%G_Q
M/]@T[W\29/4*.0'O4QKY(57QGV!,^A)#TEPT,=^C25@A ,P6@ISFX6CQ ][N
MMBB4Q8(@5Y&>;Z"Z;8J6_I-4-<V0FM-$4&0)?J&%Q"274J@VDJ<HQLIJ$UO6
M?(:__1R:5 )LU+LS66LK@/)J^A0_T)$]%UW,-_AM>YN-B]_&?-U2$F)24134
MDI:B1ZELIJ2TC0)E(UGY#21D5!$:K\%7)OHWIY0BM99 !PLLYKZ%]5>_1>T]
MCWR73XDV_SMM"GNZR_TI3=]!A-.W*)-VT&Q()C75G[AT&?%Y>41D%!.5745D
M5@/^L57X1E<3%-L@GJ&-<)F!T @5L?%*\N4*069D9(4)0.DRBQC[5TER?IWP
M[;\ES?/OU&3/1QTWAW3?CPFQ?I>MW[_$^J__Q+8EG[!]Q7QB0\(P5K6;"F\I
M-2U4U W1V+T/?>,$<E6'>"X#\>D&L@H;*#6TDY.?2WB8(YXN*[ SFXW-V@]P
M-9LE^G !41[?8;GB91S6OD*H:-?LR&TD1SB3EB03[5%.<G8%$<EZ0E-K\4VH
MQB5*AUVP!K_8.L(3&XE)-)"374ID<# VFY;AL'$>(79+2?1<C>_6.:R=_1(+
MWOMG?&T6$^&V$3>S>2SZX \LG_5GS.=]A,62.5BO682?LSV:(@W5U<WHJULI
MK1#WKC.B%;I'6Z;":%"3'AO TCGOLNG[C[!:] G;OGN+;=^^AL_FV60&K<7?
MZE,<UKR*];*_L."#_R;:ZQ62@M<0Z;..F#!74Z',O,(R*FH[Z1S9R\[]9ZEM
MGR(YIYX0F8:0&#5)65)D6Q-A0C^Y;EN!/B^<)/_-;%WT*O/>^^\L^NB_L67N
MO^*Q\34R ^>1&[&00-OWQ+B91937=Z1'K$2=88XR<1WQGG-(=/Z,6"F=PM9W
MR/!:3+3#]SBO?HLXQZ\)M_@8J_G_QH:O7V;))W_@^P]^QP^?_)&EL__"AKEO
MX+SV"]PW?(GK1K'</@=WJZ]P,O^,K<M?8]E7OV;I%_^$Y=(_X&_Y/M%.7Q*Z
M0XQ5![&T_ B'Q;_'XKM_QF+>K[!?\6=L5[Z&S>H/L%[_#;9;E^)J+Q46\1)@
M-XU860C;MBS';,UW;%[T$5OGOT7@]N]P6?D>:S[^9\R__BV>:]XDTO)S_-:^
MB_OBU["?^RKF<]XAW,65O&PQ;\(+< F6XR3FK'MT"9Y1&CS"U28'L;V/$@??
M8OPB2DA,51$2&,SJ'V;C9;6(2)?%N&]Z'X=5KV*S3)QSX=M\^]YKK%^XAMAP
M.?X!A=B[%[#=I9#M;D('>&FP]2_#/=R 3[2>H#@ML1DE8KQG(8L-(<3/BIC@
M;:3'6) :O05GT<;+Y_X+*X38;OT01^OOF3?W(UP%$4E.+20@*!LG]PSLW'-P
M#5*+>U6(]5Q</;/$G,DGT%?&U@T;F?O9>WSW_LNL^.1/?/F7?^"#EW[!9Z__
M0NB9U[ U^PS+]9^P\+,_B+'^6Y:_]T>^?_F?F/>G?V3AJ__,O%?^&PM?^S]8
M^>Y_9_VL_X[+HC\09?X>\;:?4RB(7&66BR!I?M16Q-/94L!(7QE==5FTBO^[
M:M*I5,52J4EAL*N2@7:=(  J6JOD-):EF_+_MI8G,]E1Q'2_AM'V0AIT290I
MHRC)CZ2D,)&*DFQJ*@K%,H<6HYJ1GFHZ&HJIJ\S&4)I.3;D@&[7BFJW5M-;I
M&.RH8;RGBEYC'OTUV?1695(O.6&R0\78#A3D(I+V*LDIDBML1!R=ADQ&6XN8
MZ"YE0"P[I()RU7)Q/:%[<Z2<Q() %6:8BLGU-&D%:<JBI3R'P3H5#45)5.5$
M"XG!* A954$,U<4)M->)>Q)2H\^F2I\CI)!J@_3:>SEM[>V,C>]A[_ZC3,T<
M8]>^(TQ,'69@:"]=G1-"QAD<V,WPX"1=';U451F$'M%055,E\-L0@Z.[Z.B6
ML-PTPSN/,[[G'/TC1VGOW4]3YQ[JVB9H;!NCHW-$D*Y>4P&LIM)\VK39U"OC
M,.2&TUR:+/I'2A$BVD:7*^Y7+=I-QTAGB7A&.6UU.70T*VBJ5V#02S@EA;R\
M.++3H\A-CD"1%8U&G*NR(IF&UEP:NN14MF12T9*!OCN'FA$E52/%&$;4Z$<T
M:/O5E _JT(_64M)=B:JC$DUG-25"BELK*6PN0RD(8VFO$</.5AJF>ZF?Z<$X
MTXGQ0 ?54RU42NDB!)$LZM22UUQ,9ET!15UE)L>S%%5<,5Q+67\5I3V5%+=+
M$<D*4D3;%W66H1VJ1MU;(:ZM,SF)I4CBTE8]&H$_2ALJJ6YOH%K@0'UME:EX
M75MGA\DAW]O3)\AI+YWMG2;GL!1=+$FSV,=85T.YKHSBXF)!]G;S3.#N'Y\]
MY\'=^]R[<^<_.8A?X';I?RE*6'(&2XYB"1-+^%AR'$MR]ZX41?S$Y!26(HJE
MP H)*TN.XA?I)EZ<Q_21>("47\+D)'[!P"1'KY074"H@([VR*:XHQ>.8*HP_
M%O)('/-8R#-QQ#-!#AZ9\A#?%\?<%Z>X T^N\^.=,]P^,\E8<S[UA0'4YWG1
MGN]'5V$0'4I!9LM2Z6]4,S76S+5+,X(#7.3I\^OB_+=X\%3@^D<7>?[T'$_N
MSG#O\B /+[?S\%*C.&<EI_;E<7PJE[T#*53ENZ),L*6J,)+C>P>X=^TL3QZ(
M<]R[P?U[-\7SW^;>_=O<OG79E(?X_JTCW+N^A_M71WET;5!(+Q>.&AGI%6.Z
M)AIEOB>QPO9[NZPD)MP.O3:-IEHQYRI242F"T*K"T6GBT!;'(T\/%+K5D?0P
M<\HCMS L=-A1[Q\XM.-C=EN_SZB'(/QIZVDJVHZ\U)*H,@N!EQT(J74AH-J1
M\ 97XMN]2._S):W?CZ1>+_&_"_&MSL0UV!-KL"%)9XNJP4?8Z41V[TJGORV,
MFA(7=@_D,C5<+'1,&GIU!,;26#IJ,H4^3*.C.I6&LFA2(K<2X;>2J,"U)$=N
MI[(XF$YC''J%$ZGA"TD(_I8ZK3T7CBC@:3O<;^#JL0(.#D>SNSV0 SU1C-4&
M4):TF>+(56@B5U 5NXJV],V,%-NQM]J7/;6AC-8FT&T4.K5&S'>CG!ZALWMK
MXVDJ=J4Z?3TC958T9BP@W^]U*N*^I*5P(UU:1^KDVVG,V4B/PHS):@^Z*X.I
MTD2C$SI%4YR,NC !36$,5<41-)<$T:GV8E+GP\F&,*[U)'&T*4:<VY\6N2UU
MF>OH+]G,Z1Y7KO39<KG7CB/M[N@+W<F0WE)(B14B>%!B).D)WBC3[6@M<V2Z
MU95IXQ;V5"QF5/4E36GO8DS^F-JLI=0I75 D.2!/<&2@*8.S,]7</]_&[1.U
M'!Y5T%$51U%V(,DQ+B1'.5"4[DF/4?135SHC=2$,&'QH$GA9';,13?Q6U(EF
M*.+7H4G;Q$"U%U?VY7#]@)R)UB"*T]:A2%A%BVC7XSWQW-A=R,/#E5S8K4&3
M[D!&E 5YR:[D9XDQE^)/5)0'H6'.Q$9[DBD5%DOR0*?P%3HZFIF=V0RV2N/$
M@;(\6W2%/BBS_8D.=B(LV(>0D""3HS@BS(\XF;? N.[D9CG0V1;%W9NU@O!W
MBO'0#.=5W*ISXWS*,DX'S.:D\RQ.NGS& ?=O:;+]&K7#MR@"%Z-76M#:YD5+
MKS?RDK6DR9>2EKN2M.P-9.28DUU@0Y[&F5RM,W*= VJC'56MCG3TN[%SPHN#
M^X/8-^%-EW$KI;E+R$M<07:2-5'!U@3[.!+F)WBLIQN!'A;(0C917>;)_IUQ
MG#N00*-V/>JLA4)6D9^P%%7*"LK25Y$KU3>1+4.1NI5<R5$<LE*(&+_%#NSO
M#N?6OB3NB.,GZJ44=JLI%>-'D;0!1?(V<0^.Y,6;DQ H.1$7DA&[D9R$320%
MS"?#\S,,T?.8*MO!@5HOADKM,:2LHDI<LR%_(QWJ[29ID&^B/'D5)?&K1=^O
M1QN_"57$6N3^2U"%+6>BTIOQ*A\Z2MUHUT<+;" YA<WQ]W# S\,=7P\O?+V\
M"?#UQ=_' T\W6U.>9']?)X("W CRWB'FKP45:594I:RA.G$!+9D_<&' FQ]/
M9G'W6!XCS4&B79Q($)PG)MR+R$A?PL2X"0JQ0*?VY/C.6*::[.E2+,.0\"5E
ML5]0GKH 0_YFT4[.J+*\R8X/("\EFMS4"+)3@\A("B0C)92L=/%=5H+@/*GD
MYD@.8X%QA%V7L)91Z*.#0W+NGZKDQTM5/#I?Q?[!5#2"#Q3*U@M]8DYS@1,M
M^?:T*YWI*?6FLRR0-ET8K?I(6JNC::D*IZTBF*'*0":J@I@TAC)L#!/?"1U<
MX$%\M 7QL0X4%$;3W":P4+=4*-] IU@.]%4QW*MAL$W*TQM.9WVDP"^Y3.Y4
M,3:83Z,^C S91N)$7Q2)_AYNC.?HA)8CDU7L'5*S;T38E]WIG-B5Q$FA<\_N
M47)Y6L_M_4T\V-_-@YEA;A^<Y/*1/9PZO(?CQZ<Y>68O9\\/,;T[F^%.1_8,
MN#+4[,%0:QP7CK5Q^=P4%\X?X\KE\UR]<)X;YT]RZ]RTV)Z-(FT#\4$?D!;]
M#E7JN>P=W<'TJ!,')H(X>UC)S<L[N7-3<A+?$G;L-G=NW1 V7]CT.U>X]> B
MM^X=X?3)%L;Z4P4.<Z6SPI&JO UB_"\@)W$Y.F$O=@XKA>T[R$_"MCY]=)?'
M#Q_R]/$];EP^P&B7P%T:5QJ4V]BI=V"O4<H';TU-^DI2?;ZD6,R?L_OJ>7KK
MD##XUP1$N"MLO90B]K&I!L&3QU)V "GME%3G0$J-)?G^K@LL<59@@7UBM9L;
M^XNY,IG%Q=$49L2X'-,YTUML0[=R!QT%UG07.[&[,8;+!VMY?O^ ./:B.,==
M(0*#2#]<2SA%8(__>.GI/YS$T@_8STV.8BE_\0LG\</_Y"26,,S_WTG\_]7G
MYX8QO4+V7'HU3,I/]J)B\9,GSTSRPDDL%;7X.=I =(3HC(</GIHBB0\>/$E_
M_TZFI@XQ/7V$KJXA9@Z>XN;=ISQX_!-]@Q.T=XUP^=I] ?C@\;.?N'3U#@/B
M^[U[#YK.=>?.(XX<.<WHV"2[]^SCY*GSW+K]0 #>^UR[>LM4X.[4R7.<.'[&
MM+QP_HH PG=,4<U2E+$4;2REICAZ]#@G3ISBTJ7+)B>Q%#U\X, !)B8FV+U[
M-_OWSW#X\-'_<!1+ZT>/GF3OG@/T= XST#O.L"!0_;T3U-9U4%)>0T&I#F6%
MGL)*/3DZ'<DE*E)+2\BNU)&EJR"C3$=V127JYB9*!+@O;FI U=J(JJV1DO9F
M]#U=5 KB5M[0B+:ZGB*-GCQY"1D9^>3D*,G**B Z+A&_X!!<O+T$"7<12T\\
M_7SP]O<C2A9#LBE'7P:9R=G$A,;B:N>&U59KK+?;X.3@C)N;&WZ! 43*HHE-
MC",])X."HD+R"^7(8J)P<G%D^_;M6-O8X.+FBK<PL(%AH43&B7-GII.5GT=^
ML1)E23%R32%QA2DX)GFS46;-BIAMK$[;P88"9S9KO##3!9C$JC($5Z,,[_IX
M/(6XU,IPKXW%6Q^+5U$4UE$N. 2[$AH;1G)&BKA&C@ +2BKJ:^@9'&!FYB!7
M+ETUD9<[]^YRZ<HE3IP\QNZI<1HZ:REL4!!9&8=-OAN6:G=V&'RQJ0G IS<9
MV2XE*5,:TB=5Y(RK4$QJ*1A2D=F<2X(NB8S2-(HJ"ZEIJ:*KKY-=NR=-4>7'
MQ/@X*OK\R*'#G#QQ7(RCLZ8\S/NFIQD='J&OIY?6UC9!M)O152JQLUW%\L5O
M8K7E/0P"J/54"6!8;<ETAQUGQ]RYNMM;*#A7]C>:";+SO0!';Y'J_!HAYG_'
M:N&?6/GY;UCUZ:^Q7?@RA0$+J(Y;3)[;ZR19_9:(+?^,_X9?XK'F-P1:O$.<
M]V(\;182'^$EB+,!N4)'?)86658E&>HN5,9=E!JGB,MHP"]"BU>PBN"H$DHJ
MNJDTMF*SPP(7^U449SIP?#R;%K4%&0$?H@B?A3;J(\HB/T81]!G1SI_C;3L?
M7S=+DA/224LK(SQ*35I6G0!P]6),B/_C*@B(+L,SK!B?:#4I\AI4:CVVZY?@
ML.1]4NR^I=!S+F'K_XK=M_] H?]\\@(6DN:[@(&J8(Q%[D0'K,3.9AX^?M;$
MIB40F:XD(%F+=WPE?@E&_!,:"$EJ(BZ]A>C$2F0)Q:2G%Y"9FD!,R X\K#XA
MQ.%=8MW>(LG]=?("WZ4D]E/*4^:0'_XQT0[OX+CJ%9;/^A=3_E?/30L(L;,@
M,SH1=4$-R:D5)&95DZUJ1:'O)UO327Q.'=&I!B*2*XE.UY.1KR<B*AH'VW5L
M7OTIZQ:]Q=9E[^"^[0O"7+XGU.4;7,S>P7+)GW%<_8YHNY4X;5F(Y>95>'AX
M$Q5?0'QV+1$9C;A$&; ,+,<Z2(>7K);0^!ID\5KR<E2$>KNS\8?/L5_U!3X;
MO\!WW4=8?OT2EE^]A/O*=TEP6TVRSV:"K)>PX>LWV;'L*[RWK<%BE50 T(&D
MF&3R"[3H#.U4-PY24=M#2643><IR\9QRRK5Z =C2V;CX![8LG(O-BOFX;Q)C
M31 &;;(OV2$V^)A_*\XKGF7A:ZR?\Q*N&V>1)L!UL-,J 1B]41=IR,PM%?JN
M 5W3,&5-.RG0]9.8VTQX<C6^LE+\8HM)S"LG)C:>^#!/2K/#\+1<P+?O_Y+/
M_O8+MLQ_&>=U?V?3W'\DPOECLB(6$B*6[MO?)LSM:S29-F1%KB'1[P<2O>83
ML/$=/);\%=]5;Y+LNH@4GY5$.LX5?3N'4,M9^)I]0(C]/%RVS&'+#^+>EWV,
MXUK1)QOF8;'D"S;-GR7:]1.VK?F&#<L_8_7B]]FZYA/LS69CM_X]UGSYC[BO
M_SMQSE\2ON,3G,5XL5[X$HXK_B+:X0]LGO\'<;R4._A-S%9^@:/E6O+2XZG1
M5V"L-E)=74MI63GR_%P*\S,)\+!EQ3<?8+7T,^S$M6P7O$KPEL]$?[Z/\_+7
MD-E^2Z+30L*WSQ/7^9P05\GYKL8G7(Y+:"&.8C[9!A?C$*+&,4C%#L\"K-P+
M</0O)B2^G'0I#WAL'-9FHD\";)"YK1'/\%LQ]M[$R^P3\<QO,^?5W[/PX\_P
MLO41A"$5)\\<S!TS,7?)9[N'$BNO8G9X*7#PSL4[.(O4[$)B$R((\!, .LR<
M".]%A'A\+4C2.M396\A+6(:?[>N$NXOGL)_#5Q__'MMMZP1I3A&23T1(-MY>
M&7CXY> 37$!XM(J$>!7^7M%8;-G.L@5?B6->8?&7?V/'REFL^.SWS'GM_V#V
MZ_^-3:)='3;/$7IC-C]\^!)+W_T#%K/?9ONLOV/YR:OLF/,&ME^_@LO\O^*W
MXA7"-[U*W+;7B+=XC<@M?T.VXR-3!+C?CCFD19EC4(717IW"5'<1>SL+346M
M.FI2Z>]0,MA32E--(;JB5*$#HU"EAPH"$H1!'LI(8PY[>XL9:953K8E!D14L
M^CF4LN)T*DKS*"W*%(0Y'F.9G,&.2AKT<NKT>;0W:!CM;V*DOY7.5B,U.C45
MQ3F"+*7149%!GR&#H>I,1FKS&1+2KDM#EQ=*FSZ-@88\6LJ3Z*K*9+2EB-U]
MY?2W%='>*.Z[7MC!TG2AI^(I*TBD1:^@NUXCGJT(HRJ#^N(,013S:"Y*I[4H
M@TYU+NV:'&H5*50IDAAH*:6K48VQ,A>C(9^V)AV]74UT=K0(7#5J>K-K>/P
M>P^=X>B9:QP^=86=4\?IZI^FO7.2CJYQ^@9VL7-LFK:V;G05!M0E9>+[009'
MIFCK'*>E8S>M7?MHZSE <^<^(=.T=N^C47Q?US),0U,7O>T==-493$[BCO)<
MT1ZY#-<6,-HL^J>_@B,3C1S=U2&(31O[QAJ8&:L29$O'M"0[JYG::10$32_N
M7TFI2HK #$:;%T:?:*-]XS5,3]6R:\I(UV I9<9T-,8TRIJS!:924-DGVK!?
MB:Z_B/*^8K2" &IZRE&TEJ 4[:-J%>LM&I,S-ZLF'V5[B<F)+.41;C[82_.1
M/AJ.]&#<UTK-5!/5D_7HA@QH>@7>:]>075= KL @JJXRJL<;,(S4F2*)-=T5
M%#:KR1%]F%VO(+NIB(*.4DH&#&)?'26=.LI[JBCO%-)6A:ZYFHKF&BH:JM$+
M[-/4WD97;P^]_7WT]PGIZ:.GJ_L_G,32LKFYD?KZ6O3Z2C3J$@X=.&C"W?=N
MW^&!D"</'PGP+N'W%UC\YX^4&N[GM'#2\N;-VZ8@"^F-O"=/I,AC0;'$MC-G
MI!H=%[E\62J =^O?L?V+X)#_S FDRM]27N$?I1S#SQ[RS/0*J9074'IU\[D0
M<4UQW"-QW,.G4MH)"=\_%SA?(G%26HL'X@9O"E)X7ESX"+=.#+"W1T5W12S-
MQ4&TJ8+H+@FEOSR:T=HL0<+;N'GQD""K5WCZ[ ;/Q+%/?KS%W<<W>/#TEOCN
M"O=N[.'>Y3X>7N[@Z=46GEQIXM'E9AY>ZQ32R[F#1AJ$GM"D>9K2GIPZ,,:]
M6Y=X_$BTB^0@?G"'^P_NBO5;@L-<X^&]4]R]OHM[UP>Y?ZV'>Q<[.7^HFLE^
MH0,J(BG.\T*>X4).B@,A/JO)37-CYX".8P=;V36AI;%11F-#!!VM";36)9 1
M:T5,P :2 C=0X+^&J2QG[A5Z,>WX-4.;WV3(^CVF8I;0J]A">;DE:>7;B"G;
M1GCI-D(U6XG2FA-?N9V46DM26VU(;;,BJ<F,A.J-)%9L)+W"G-(&+[I&!+$^
MK.'HH6*&NZ,PE#@PWI_,S(28?YU"#^6[4EODSVAC)H/UJ4QTY##6*G1CZC8R
M(E>2';.>@M0=8OXFL'^LF,'F>"KR[<F+684J>1W')C-%YW;#_2;NG"OAU%0R
M>_M".#@4S62;P'CYENC3MZ*5K:+(?R[-2>L8+;1D4FW#5(4[NVHB&*[+I+<N
MCTZCD.HL!NK3A5[SIS''G,E*.SIREU,<] &5<=_0+-](3ZDC':H=-&:OIS%]
M!;TJ*UI*/#&H(ZC4IE->*A=Z(A^5(@ME?HS0GR%4JT)H4?DQ6!; OH8XS@XK
M.=(C%SK3%WW*1CJ59IP?"N#:D M7!IPXWNU-C<J'K+0@DE-D@E?)2$\,(C_%
ME6:U Z-5UNRI-6>J:A-[#>N9T*Z@(6TV-2G?4)VYBM(,2W+C+"C)=N7H'C77
M3]=P]60U)V9TM!CCR4WW$K@Z@/AH?Q*CO<E*\*#%D,A47RY[NQ.9; ZCN]0=
M??)V--&;44:NHT"VEE)QK]VE KOW1G!]=PJ'>\)I5%M3EKF!ZIPM#%6X<F$T
MC8>'-()W%%*7;T=)DAGE6;94%GJ0G^Y"G,Q.V&87LC/\4.0&4I#I0;G"6[1_
M!/M&,]G5*T5B>E"6:TUAJB-I,6Y$"HX6&1Y 1(04E.1ORD^;E19"F3H:;8D?
MPX/)/'W0).:PD!OEL"^)&T6;.1?R%2?=/^& RQ?,!"QE=]16*CS7D>6ZDLS
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MMWD@SO7@T0T>2 [=*T,\N-3*T\N-/+_2)*2%9]>Z^>G>!,_O3@DRV26P6KS
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M>C6&XFST!4FF_+O]E8)TU^4S7),K"$4J[;H403[RQ#GR:*[*0JK:K<X.I:)
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MOS@]R,/SK3R_6,=/E^L$M^R"^Q/B'(>%G.+QC?T<G:BF-,N1G)@M5!0%<.Q
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M@_QQ]O'"WLV5'4Y..+BYF<3>U15W'Z'L(\.)3HC!)\0/5W]WW +=<0_TQ"W
M R<?9RP=K3"W,<?*SA(??R]BXJ))EIS#L9&$QX03'!6"5[ O'A&^.,=X81'C
MP%H!&I9&;&%)K#E+4ZU9FF//T@)G5@DPN$XH[@T:#S:J7-A8Y,0FH>#-%*YL
MR_-@>[([*[W,6>MHS@Y7!]P]/(0Q\R,R-(3$.!E9&>D4%!2B$@2HJ$BT54$!
M^8H",A4YQ.8GX9L5@G6Z"QO2K%B3O9U-"ANV:>S95N:(I=X-ZVIO; 48=C0$
MX"D ?;!.AD]F$%[1OOB'!Q(5%T-J>@;Y\D)*5*48*JL%^6VAIZ>/X;%1=DY.
M,# R1/_0('T# [0)@M;4T$!-M2"(RESR<Y-0Y,>A+T\A(]$15^NOV;;B[VQ;
M_'N<U_R!6/O7R/-[#TWX+/2RC]&%OD^ATRO$K?H7(N;]DN"O?HWO9[_']Z.7
M"7COKP2]\3?\7WT9W]=^@]\'_TSLPM]3[/@V+<G?4I?Z-:J(KXASG,V.Y>_@
M8KZ*Q,A$8F4*@D+5N/J5X!YDP-G/@(-7!6[^!MQ\RO'R42.+TN#C&<D."W/<
M[-<2'[:1/&$\4R+GDR9;2%+$ H)</\7?[A-"G;XBWG<QH<[?X6O_'8&>:XB2
M^1 KVDF664)$:A5^T7H<_=4X^1?A$:(D.%9)9KZ.N,1D/%RW$>FW&G6J, XY
MUN)>7V'-I_^$_;S?D;;]-88RUW#8X$R>[QRV+_@U2S_Y![RW?H;SQB]9M^!3
MYG_U+>9F#H2$99&6(:5:J28IHXQ061;!X;'X>;OAM&TYGN;?$N,RER+94M*\
M/B31\16R/%ZG0+1WKN>[Q-N\1M#&OY#M_2UM8LRIHM>*]?EDNLTEVNIK,OVL
M!$G,(#U>3FA$$9XA97A&&?&)K<4_1H]W6#&1B67($E78[/!@U0\_L.;;3_'>
M+L">^Q9Q[74XK_^"P!T+\=@^E^\_^C7?OO=KOI/D@U\2Y#R?# $L@SV^Q]]I
M'I$^&\B,$R0AP@M9H ?AOHYBFYG)H1X=*-HX8#&!KI\3[C:+/IT=S;D;B+=Z
MDX!%?\+O^[\2LO0M9%MG$;/C"Y*]%J'-<#,YF\I46?@&!!,BRR8N6XJ\UA&=
M74]L7AL1&4TD%?:3(._#-ZH:O[!RPL58B(W,8\/R=<S]]"W6S'\=7YLYR)SG
M$F[^.<&;/R;"ZC/BW+XFRF4V/MO?$\_Y)I%NBPEP6H?+#D$24O.(3];B(?K?
MP;O$Y"CVCJS&)[*"T,0*PI.4N/@$X>WM1$2 %;&!9B1'F(MG7HG9JK>P6/T.
MEJO>8\V\U[#8^!W^GE:DQ8>2FQA#?F(\A2E)%.5D(<]()2X\"!>KK5BN78SU
MF@4X;%F(Q:HOV++H+1)]EXM[G,O&[_[()W_][[SW\C_SP^Q/Q;R(HU11@;ZD
MGLZZ?OI;=]):/T*!HI'8%!TA,2K"8I0D)!:\<.2:K6;;_'?9]LT?<5WZ9_S7
MOX;G^E?9NNC?6+?P%9;,?X=Y"^;@Y.%%?)J"C/PJ,N1UY"A;*"SI(BFK5LP!
M'>YB'CH%%. =6H@L3BF ="HR'U?\S!?@NN(M''YX"><EOR%\^UL$F+W-CB6O
ML/*+WS/W@]\S[],WV+A<M+%G,(GQ"D+#Y02'%1 I[C4EHUS,K1S\_/PQW[R6
M;SY]DR_>_@/+9K_!K'_[)[Y[_27\MRXAU&HQKJL_8?WG?V#MYR^)9WH=Q[6?
ML7'!6VQ8]"'6&Q>RPVPC-EN$?E^W%9O5F]DR=R&+WGV/+U_Z#4O>^ -.B]\A
MV>5+--'?4YDX%T7(1Z0Z_HW(3;\G4-R[]4?_C:T?_ +?M2\3M/550K>]3:S%
M)P2L>1N/96(LK?\(CS4?8/O#:YA](9YWZ;N$68GQ[[2,[S_X#6_\[A=\_?X?
M"7819"K.E>P("S)"-Y(5N4D06'-R8K=1DN%)<9(_&[__A/=?_B6O_.H7O/'[
M7[#HT]_BO.X-?,W?$CKC;[AO_C<\M[Z,S&L6F5%S20S^@@#;O^!M_J_(7/Y.
MC-OKQ'J\;7(6YP5_CSIR%?H$2]IR ^A3Q@J)9U"52%]Q/*WYT>@S@C$6QM-3
MHZ*MII3VADIZ.^L8ZFUBJ*>1GK8:&JJT5)86H2DJ0*G,1R[ET!>V7U.8@T&5
M1YTFCT8I+[ R&4->%)7980(D"]!=+*YCBJ!5F@KF592EH%8G4*1*1E.20X.Q
MC"YQO4Y]$6WE>715%3+<*CF!"^FIRZ&_/HN&\GAJA:UI%N=H-&H8Z&KBP)XQ
MID:'F1H>$<MQ)H?'&!X8IJV]2V"*<JKJJNGH:::F5DMQ418*>3JUPGYU=_;3
M*W!48\LPC6VCM'2-"]E%0_ODBZ)S'6*;6&]JWTE+^PBUQA;T%57H=7J,54;J
MC4TTUG<(6SE.=Z_8MW68IK81<:XA&@2>Z^CNH[.S@];F.EJ,.NK+%=2HLVBI
ME--FD-.@RQ!S- J]:(?V%C5#?;5,CG6(MJX7A#&52E6F*6);D9E*848*!5(.
MPZP4TJ5T,2F1I":'DIH48DH=DQ0GEO%1I K=D9*02D)L\HL421(QS4@2\S6-
M0JV<DIHBRAHT0LK0UDNB0]>LIZJKEMJ!1AI&FVF>:*=]JI>NF2&Z#P[3>7"
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MFQVK/\)\VT=XFWQ&K.O7)'E\26OF6LX-.5(:^ WQ5F]0Z#N+#/>/2??ZE,R
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MIU5X:WR4!1X>9GCZ.(HXR_NS$;YK0E*,!=6%ME1D:%,:KTP:N8YS$_Y</9#
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M8C0_(,7@4]),/R'+YBNR[&>39/T-/AKO8K3L#^Q8^)]$.,\E+7"=E"MP-EB
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M;/)@7Y,/!QO\.53O)^+#H3I/#M:X<+C&D>E:!PY4V[*SPI+N/ -*8C;*.UE
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MHD.-:<FW9K+:A9DZJ>M2:UJ3=<@.VT)GI1LCK?[T5#K05F*CBAI."M40S&E
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MDJR*)BTJ+J2YI9&)R5%I;P<X=&@W1P[OYO@1D>E):3.#'-K5R\G]PXRU5PF
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M&J+E9X*VP@AM-SVL@FSP2)#CEQZ(5ZP")U]GS!TLT#?65:9Q<)8YX.SNB*,
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M0C0F@0CQ^5>'L%2<3HBTKMPFM2/0RR^O1$IT];_E[_^:DUCZ>]5AXJ$H 9H
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M$_JKOL=^^QS\=9<1:K657:N^8M>65;C(W 1)BB(H(I^DS";R2[HIJ>RCM&:
MDH9Q2IHF*6^>H*E-Z/>>*7H[!P5Q*J$X*XG2[#@:*S.I*DNCK"R7^I9VZCL&
MJ&[MIZR^D^J6?NI:AZFL&U2FB*BH':2\5FQK&J)#X)O>CCXJ"PLI2$NB)#N%
MDMQ4RHKR!"FK$^?KI:%MB*I&<;Z6,2H:1R@1QU8V#E$C1'H+J[:VG>*"0D&V
MXBC,BJ6Y.H/.QBQ!T *4!>C2$P*H*\VD,C^9PM1(\E.D:.- LI-\R$KQ)C]#
MD+F,(*%#_<A-"Z&\()Z&R@SRTT+)2?2G+#.<O#@%N3%RBA/]A/A2G1E,N^0@
MKHRCNS:>[CI!$"H"Z&X,8[0GB8'61/I;4AAH26.@*55\GTA'30*]#5*NTAP&
MVO(9Z"RDHC2>Q'A?(L,5Y.6E4%%1(/1>-&%AO@0$>! 4Y$50L+=8"MSC[T6
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ME@Q+"F,-B?7;1UVA+3.3,3R[5<++V\6<' XB)T&=@G134N/-\)%KX^5IIG0
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MKW00/Q,;A2@=Q1)(D;Y_U>ZOCN+_+7__5YW$O_Y)_:5\_4L*[1:=*"WOW7_
MPX=2LFEI!]'=3U]R7\H[_."I4A[<>\(]*5?PI9M*Y_#X^#$F)HX+(#*C+-PB
MY>63G+Y2CKV^@6G&)\]R_.15 =HGJ:[M4HKD))X\?(XC1R\P.GY*&44L.99'
M)TYQZLPU;MZ1*B.B=.J>OW!%&24L13O<O'U?Z2260*Z4;D+*2SPP.*9T%DO
M6$H[(8%>J8B=].K<H\?/E.!:<B)+CF(I$N/^@\>\D.Y7W)OD@!X>G*2KI8LC
MXY.T-[<0&AB"FZNK,C5!4$@H,?'Q)&>DD9R=1GA*#/ZIX?CFA.-7&HNO($T^
ME?%BF8!;>C V@6Z8NSM@[FB'G:M,$-@0 F(C<8\(0-_#EH/N9NSU,$;%0Q_U
M,!L,$F08Q+E@$.F(690+#G%>F,AM,7*RP$X #S<OJ2A"(+&Q\904E]'>WBU
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MI#>+:@&JZW/L*<GV)#M#@)6,#!(2BE'X9.'MEX=70('HMVSLO?*P]R[$7E&
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M.H_.I# DGG&0\W)ED<"D:'-\/ X)C&>.E[OD#+8DV,>*F&!;$B,<B MW)"S
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MQHVKY[EU?88[-Z>Y?:6;LQ,9'&GU8KK!CFN#GEP?=&.X6)V"H,7$NWY'JJ_
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MD9C3A%=$"2Y!V7B&9A">F$E<4IP8?XYHJB[!3'>9 +(J!#NKH;;^2W8O?U^
M;PV<C%>BO>MK]/?/8\VB]UF\X'/VJQW RR^"A-0*DI+KR,GI)BNWA[BT%@*C
MQ3CQRL'*+@DWSVQBXRK)3"O#VMB<W1N7LFW%YVCM^ XWL[7XVFUBQ](W6/OM
M[]DV[RUV_O@ANQ9]S.YEGW-@_7P,U'?C+G,6NBB+DK(ZRBI;R2N2\AYWD%G:
M26Q6/3X1V1C:>+-FBP:K-AQ@\W8-]N[78=>NO6Q8MY*52^=@=D@%3UMU[/2W
MLGW)1ZR<]3J;YKW/WE5ST=ZT&/-=2PFV6(]"]P=,-KV-[IKWV#[W;RSYZ'<L
M^O1W+/[J#VQ:^$\LU'Y 9K ,\WUS6/7Y?[)&R,X?_LJ!A7]$?^V;F&QY'[T-
M'[)I]I_9.N]M'#378[EW.;IK9W%PP5ML^?S?V3'K=QBL_T0\.W%=^[]%>\='
M'-KU 8=VO(V!D #+Y<3*]A!FNQ\7S748J\Q#8]TG[/CQ=?8M>Q.#31]CN>53
MW'9\B?=6,09^_#,62][ <MV[&*Y]6XSO?V?%5[_!:,\WZ&T5<V_5/]!?_S[:
MR]]&=?[?V3/[=;9^\0=4OODK6DL^1'/Q>ZC,^C-KWGT-0W$.^;:/\=O_)7YZ
M<_ PG(.-UE?H[OR0'4O^RHHO?LO&;]]A[1?OLO3]O[+JL]^S?\D[Z&_\@DU?
M_I[%_WR-E1_\&X?6?(#":"FAMJLQVO:FN-?W\3+\'H7Q0M'?[[#H\]?X^!^O
M,?>K_V#'ZG]@L?]S/ WF8;#M"S[YTVM\]OIK+/S\=^Q8_A;66O/$-<Q%==T_
M,!77)3=;1HC3%ASTEJ"ZZ1NV+I\CB*"K(-8)N'K$().GXJ808]PG%U?O'.P\
MLC!U2<? /@$+IP3L'",PU+7CT-Y]Z*NLP5IM+5I;YK)Y\4>L6_@9ED;:A(:$
MXQ<8*^9_!B$1I40G-A(<68,\0-AK>386LE0L79.5/TIXRR.PUC=A\X]S6/+)
MG]B^X)]8:BQ#3WT->_:L9\O.7>B;>V/ND(B);2H6MNF86"8+FQNO++)HY""N
MRSF.(*'[W-V"<+*P(3/,GZ:L&#H+XZG."B<WR5_H:S]AE\-(2DJEJ+B&SJYQ
M@6LFJ&T<H;Q62AMPA/;N"8%WZ@4Q2B ARE^0X0!!S$-IR(FD,2>"@CAO4L,\
M2(\*H+Z\@(::2F%32ZD0>*:HM);<PDH:FKLH+Z\6<S:-VK(B2K(328]1D)^D
MH"C5AX)D;S*CW40;GN3$!U":'O/*21P71GR0)REAGF3&R)6.Y/Q4?_(S@LE,
M"B K)93,Y#!2XX,IR(BB*"."W(0 BL1W92D!5*3X49,12+D@@ 6Q[E1E!=!9
M$\] :RHU^0JJ\KQI+ ^ANCB4FM)(Z@2AJR@*I;DN@8[F- JS Y1.XOZ./$IS
M0\@1[64D^I$<ZT]<N"^105*%=&^"%7*"?12$2P[BP$ "_ ((\)?$3QE)[./C
M1GBXC[##L=14%PB<5TY+2PVM+?5T=+30U=U.5T\['=UMM'6VT-S62&U#-175
M990(0EE244991;E2"LJ+R*TI)+>IF/RN,O+Z*\@9J""SMT20Y")!D@O):<U7
MIIHH:LBCK*F0O)HL<FJS*.T4Y'2B2>DH+AZLI&RDEM+A6@IZR\D4QZ369Y-2
MG4U:>0[9Y84455=0W=A 4T<[[5T]-#5+CN'.5SF(6P4&;N\6U]LKKK>+NJ8V
M:AI;E#F(I8CB+B$-C:TTBV-Z>X<X=O04UZ[<YLKEVTI'KX2U3YZ\Q,# I/@L
M<); S)*3>&SL&",CT\I]SI^_R<6+MY78_.S9Z\IC^OHFZ.H:IK-S2.#G48:'
MISE\>(;IZ;.B+8&I>\?HZ9^@KW]2''=.&;4LD3OEGT2P!%=0!OM(Y$O\DYS$
MEV_<Y-3Y\]QZ^$AZT9/[3U]P7<J7_&NA/.G-/L$AE.DI7@BB*44"":+WD^ ;
M4O&ZGWX61[U\P(L'EWAP]3"/KX[R_-8$/S\Z(<CE-5[^?(\7/SU2DLV7SY_Q
M\ID@@(*?_"R]42K:E"JQ2\5V7HKOI4CBER_O\^S)):Y=[&6\-XT.@2][BEQI
M23:F/DJ+IEA=:J-T* O3)B]$AZQ0 RHS/9GL*>+FA1&>/SC#RR=GQ?((3V]U
M\.1*,2^NYO#T8@97IJ+%W#4F-UJ#7-%.5I0>\0'J8@X;<'0HE_O71GEZ[QSW
M;U[D[@VI4OUU;EV[PLWK%[AU\S3W;DUQ_U(;5R92&:^RY5R;/9?:+>C+V$*^
M8@Z)+M^0$[B>T7I_;AVOY/&Y"NY,^'&CWXR;@V9<&91Q<TJ*_"SDSIE*KIVL
MX/28E"]<1FK0'@(<EI/HOUO,57N&6I,X/M[&*<E!/#7.Z:DA3D]T<'RHG+'F
M:%KR'2E/U*<ZP9 LOSW$.Z\GU6TS56&J="7KTB/P4D/8+O*\-A+GO$[@)Q,&
MQ7GZ\RP9E'+9%IISO-R6DV5V=,9IDV2WAD2GS>0&Z5"?X4)SGCOM!3(&BITY
MT^[#K>$ (0I.-#O2)MHH2K*EJC"$BM($H3]3!(Y((;<@26#M6(KSPJG-]Z4Y
MUYGZ-'&N1D\N#H=SNMV?B2(W>F,LZ!18:-1I)X<%UARVVT&+ER$E(7;BN=C0
MU^S!N>.^7+_@S=7S#IP\8B#TD"KU%:I4%.I2E&M)5(0YP4%VA(:Y$Q3J)FR+
M+:'A1A05F#$YXLVELQ$TUUM26V$I=)P#B2%&9 194A/J0*>_*;W>.G1YJ]$:
MK,J9>G>>'$ODSG0,Y\1]#M;;4IZF2G'R/LK2#E*3I4=SB3VE&8Z$*LP(]+(F
MP,M&F6(@W-^,TBP9$UVA]-7):,RWH#S%A*)$4S)CC82NU!?7J8>OOY' >.9X
M>IGBXVY K(^1Z!L94Q6>S-2Z*)W$C;%B/'OO)U&VC<KPO0P7Z'&TSI:)6C<:
MLAV)\-;&Q\,0;T]S KQ-E3^.2 ZO^Y-1W!D*8J;1C9X<2XJCC8CWTR/(\Y"P
MY;KXR+0(5VC37>7)^;%8+A])9:(O0=@2=[S<]/%VM\''S09_-T."W7>1&;J5
MEK0M3!6L83IO.:-9:VG/4",M2!6%3!UW=RMD[G:XNIJB<%.C(,F(R69G[D[(
M>3#FPLDJ;2K]EU+@M9A\OU5BGFXAR6\+T3XJ) 1K4BLX;D>YE[#)EE2(\9OL
MJXZ/[2Z\;/;A;KT;;\?=Y,>;49LFYGRB&LW)^RD.V4J<;"4!-HL)D:TG.F ?
M,8)3A@;JX^6NC9.-"L4IYHPWN-*8ID5^T"ZEDU@J5M<4K\N@&+.C90ZBO[RH
M3G/$UU$5F8T.#K8FV-B:8FUOA(V3$?8NYM@[6 C.98ZSHXFX1VTQOA5<N=8@
M]& G3Q]V,G.RA/ ((VP=]F)CKXZ]G3[V-D8XV1GA(3,BTL^,XDA+!N),.!ZA
MR3GO+9RWF,^,\0],6JZB2?#:!#LM/"UU<+83O,O9!AN9+=8R*\%=]'&/MB2S
M(Y"L 06I \[$#UB1-&Y'XI2,N"DO$H\%DW(\@M3I")(FPX@58S:JQYOX3E=2
MF\TIK->AI\6 \ZUFW"G3YZC/2@[;SV/*>AX])@MHM-M*N:<NN7Z60M]8DQ'O
M07=[)M-3Q9PZ4<+Q8_F,#J715!]!5H8GB4G>)*4&DY,;1UE9&J4E261EAI,E
ML%165K"8<X$<F\SA_O4:;EVNH*4NF.("/RK*A2XH3162HXPDKA;<N[ZRA*;J
M4IIJQ+(FGZZF'$Z.%G/S5 5/+M7P\FHUHPWB&:4:<JPSF&M3:3P\4\BS:Y4\
MNES%U>.E'.G)8ZJKD,GN D;:TZD3G+LATX7Q"C^:4ZS)#]8B+5"#^AQG1ANC
M.-&1P61M-,-E"@:%+N@KLF&@TIF)]D!F)G*X=*J5:^?&N75ADNLGFSC=&TE;
MN@9M"6OI3UY"5_R/]&9L$VW8<?U()@\N]?#PYBEA#RYQ\^85;MRZPNT[EWAT
M_P+WKHPR,Y1)?XX!'9&KQ!A8RECV6D:+M]%7JLI0@XQSAXOX^>%)7CZ\QK/[
M]WAZ_R%/[M_ER<.[/'WR@">/I1]*I=2P3Y3.XA=/;_#\_C0WCA<('97$DQ,)
MW)^(YF2S)_TEM@S5>'!I.H\7#T=Y\>("SW^^P[-?'O+B9ZFP[=/_2NLD;+>4
M6_BG6_#B%->/EW!,]/-XM@'C8KX,)6O0D:@EYILADZUQ_"3L]R\O;_*SE)M8
MLO<_O?(S*K- "%$ZB:6WB)2HX9E $Z\<Q3_S0HCDX'WUQK]2_LM/*>&.7W'(
MKR)M$WOS\K_<Q*^<Q%)""ZD5L<NOQ_PJ_TO^_H<XB:5H@%]%>@CB$3U_P>/'
MSUY%#M]_JG00/WWRDUB^Y/:MAUR^=%, SJM*!['TNMK1Z7-*D'GDR!E.G;S,
MS-EK3)^XP.#(46;.W12?;RBCAAN:^ZEOZA> 6,JMUT.'(%3'3ESA^LW'2B?Q
MU)%S7+U^7QQSC5X!4%O;!IB<.LW-6X^Y=^\)YR]<5WZ6P*P4=3PP?(3&IFZ:
M6KMI:>\11*Q)M-LBSB6 T)F+3$P=8WAD4ND@EB**I;S&4NJ*2U>N<^'R=4Z>
MN<#1DS.<.'V6BY>O"K#[E!MW;M,]V(?,RP-C:W,\!(GQCPM5.HC=8_R1)P?C
MG1.&=W$D7N71^#4D$M"2C$MQ"(YY <@*0L1WT?@7Q>.3%8UCE *'""^<(KVP
M"Q=M^CMP2&&%;I M1M$N&,:ZHAUFSZ%0>_0$6#GD9<ENXX/LTMK'(2,]K*RL
M<+)WQ,51AI]/H  ST43&)9">GTU$>BP6_D[L<=9GN[LN>X+-V!]MA5JR'3K9
M+I@*8&Q5XZ^,*)8<OXJ!))S;PMD3;\(JWP.L\-W/UAA]]J99HEW@C%FE J?6
M,-R[8_#LCL5W*)G L50"1Y()&DDEH#<)K]H(G#,4N,8*8A<;0G)*HK(@3%M[
M.T-#(TR.3S$]>9@3T\>$$3S%V3-G.'UVAN&I,>JZFBEIJR*C)8^(^@3<2_RP
M+_'&KLH/YZ9@Y.WA^'5'$C000]!0-,&C,<0<3B9Z/)'XT40R)]/Q+'3$,' _
M1KY[,/+>S7[+-<S?^BD+MW_'*M7E;-;?RD[K_>QR4F>7,**: 4:8)SG@E.^)
MJ5#\NC&&:(7JL%]^@!UV*NPP5T%?IH^ILRDF-B98V%KBZ.R(AZ< /MYR@D("
MB(Z)4CJ I3S%R2G)I&6FDIZ51FIV&DEBF2(MTZ7<O.&$!OL2ZN=.L-P>S3VK
M6+/\$U1V?"N>G18YJ0)D!NIALG\>2V?]F2_>_3=V;9F'GP"VQ0(,1P0;$B:^
M3T^T$63:#@>3E>Q8_CH1;CN(D^]&9K 8O=US\70\)(QN"JD9Q01%%.'LE8>=
M1Q%VGJ_$VJ, $Y=L3&69./IDXQ&8C*N7+^:FNNQ<.Y?-"_Z&YOJ_H;KZ-]BI
M_X&2\.\8S5])?\HBLF2?X*__*<Y:\W VWBN :1B!487( J2(VGR<O/.PE>=A
MZIJ#L1 SCSRLA 1$5A$9G8?N036T=Z_$[.!BS Y\B];&]]!8^S><-=\BSW\E
MY<$;<-CZ9TQ6_">V6][!Z] "U%=)N6;_R;9E"P48]28GHYS$Y$KBDQO(S.FE
MLO(PZ>G= L17XNJ=BW=P(6'QI40E9&-I98+>@678'_R:'/EJ\MT6$JW_'I':
M;Q%UZ'T23+XFR_E'BGW%N<,V4A:UBUC7;5BJ+F/=O&\P.F0BB$$F-BY)F#JD
M8N:8@[5;,<9.!9BZ%"#SKT#N7X"?;PJ!BE"<I>A7]4V8JRTAQ4^')(4J5JJS
M\#!>BJW&7%17_1VKW5\0Z[2#TBAK9*8" )H>$F/)#W??>!R\4G'PSB8\H9ZH
MQ ;\(BIP]BO"7I&#2T"&F%,9Q(DY%1#HS!Z5N:(_Y^%FM1$/BZVH;_J*_6L^
MQL=F&^[F:S'7F(^VRK=L7/JA&&??H:I^$.^@6.+2JPF/EUZ=KR<HNA:OT#)<
M PNQ<<O Q"H>)[=, 4[+24XHQ=;,#NU]6]$7_2&WVXZ/XQ8<#!:ANNE],4[>
M8-VW;[!I]CMLD0H)SO^,5=]_B=Y!52)"HZBJ:E7FFV_KGJ*UZQB%E4/$9[80
MEEA#5$HU]N[AS%^RB:^^G<_<'^:S=LURMFU:QI9U<]FP[&.TQ/TY&ZY5WH^^
MRM?L7?D.NY:]R^JO_\:ZK]YD_X\?8+/]2]SV?XW3[L\P6/LV>^;_E0U?_9Y5
MG_T[Z[_Y/:HKWE$ZYYTTYZ*S[CW6?_%[MLUZG7WS_LZ.6?_&WKG_@<:2OZ*[
M^EW6?O[OK/[LMYALFX/]OL78J<S#=.7'J'[W)]2^_PL66[_$77>I>);+L-69
MC8GJ)^AN?Q/]36^@,)A/K.-VXET.$F:W#Q^+[=AH+F;-G-^R^KM_0V/=N[BH
M_X"?^CP4*I]CN^QU;-?^$]MM'V*PX6U4?OPS:^?\CNW+WD!KTWL8;/X0M:5_
M9\O7OV?M)[]CRU=_8\L7;[#MRS=0^>[O[)K[!CMG_QF567] 9]Y?<-KX 4%:
M/^"N,P<7P_DXF2QA^ZJW6/+M'UG^[9NL__Y3-LSYC(VS/^+ BL_0%6-%9^UG
M;/KRCZS\X#_8_-5?,-ST*7*A0Q3B6/4U?\5(Y0/<#!;B:K@4PSW?LGGIN\S]
M\F\LF/,/MJ[Y$,.]LW#47831OKDLF?TWUBY\3^B/3]F_\5-,5>=BNG\6!]?]
M$_WM'^*@/0>%Y0ILA-XXL.$+-B_^&EL#?13N@<CE"3B[IV(O2\/6)14K)VF>
MI6$LQ,0^46Q+P,X^B/T[U='9JX*%QA8.[5C WM5?"IWP!7O6+\#:2%OH206^
MBC#</&)%>RFX^^3CXIV/HSQ7Z+TLH>^2,7=+PL4G%9EK$-K[#[+@\_=9\.'O
M.+CF4_SM]F!KN)7-&^;S[>QOV+E/'P/S(*'W$] SCD)3+PQ-@W",I***CG&8
M.X3CY!**IJHN>]>O(]36B))00>"3?:E-#Z(X-8CT.'^B0GP("_(G-26%CG8I
MI4 [):4-%)6T4E'9045% P52P;3D2')30P6YC:,V)YRZK! :,T,HB?=2.HI+
MTL.H*4D7MB"5E.0X\O-SR<[))2T]0Y"C<HKR\\A)2Z1>D*6J_'@*DGTH35=0
MF>E+1:8?1<G>@FC[49@22DE:%$5IT>0DAI(0)B<EPI,L<8[<9/&].&=>>@@I
ML;YDBGUSTB/)3HVD."N6BIPX*K-B1)N1E E"5Y3D0UF:KR#.WA0FR6DJB:*S
M+HF6*G%]R>X4ILJI*0RC+#^,DCPA!1%4B'WJ:Q)HJDVB+"^4ILI$VNO2*1+G
MS4D))"W!G\A0#T(#W CS]R0JR)MP7SG!"D^"?!4$22F? OP(]/,AP,]+B#M!
M06["_@926)! K52LIJ9 2#%UM16BOZMI:*RAKJ%*X+]*@0/+J:@JI520R2)!
M*O-+B\@KD6HC2)^+R:\HH*!1K'=54#)81?%(-85"<@?+R>XK5::<2&\1_5Z;
M049UAK+.0E:%6"]-([LZFY+V,BKZ:R@;J*%BN%ZT44UV1Q%IS3FDU&61*CF)
M*W+(*A?GJ13745U!77,3;9U= O^VT""DI;V3SIY^VGOZ:.[JIK&CD_JV#NI;
MVY5.XI8.@6O%LJ*R5HR?.EJ:NIB:/,&Y,U>9.7V9P<'#'!$X6'(22]' TN?!
MP2-B_00# X?I[9U0?CYUZC)GSEP7V/Q5-/'$Q"FED[BO;U*Y3T_/N/+X4Z>N
M<.'"+:5CN5=\WZMT$D\P/GY<''^9AP^?*@-(I/024L7QGR21U@7ANG7W+F<O
M7.3<I<O<>_Q$&=PCU;.3TE5<N7Y+8/='W+W[4/ )012E-O[+22R%*$N?I>@D
MZ;727UX\XN>GMWGY^)IHX*H@H6(I".9//]T31/4Q+\4^TFNO4N[A%\]>\-,S
MJ2W!6<2UO'SVC)]>"/E)(K.BG9?2Z[6"?%_J9;13C-<B=WH*7!C(%^0^RXK6
M1 .:X@VI%UBX.MZ2N@PW!AJ2N7*REX>W3O#BT7E>/)[AX>T1[E^IX^'Y+)Y?
M2N?^J21.](10FF1(6H@F:6&ZQ/IK$.:MJGP%_O3A<A[=GN+QO7/<NWV)NS>N
M<>?Z#6[?N,E-L7[CYGGNW#K.,ZG=TZ5,5#MPO,J(,]6:3.9MH\1W-AF><VC.
MU.+*5!XOKP_PZ%P]]R9"N3-@S]TA6ZX/R;EU.(Y'9\MX<*Z1^^=:!/&O9+C.
MAZR0/7B;?X^_PU+2([7IJ E7.HEGCDYP\O XIPX/<6JR@Z.#I0S4!M-;[D9?
MN8S!"D\*P[4(MEJ!GY0.S'4CM6$':(W81T/H;@I])-NWF?I4*\9K_1BOD=.7
M;\E@CA''2BVY4./(0+(."=9+2'3:1%&$,1VEP?0WQ#)0'\%@C2_'.P*Y-AS$
MG5$_SG;(:,DV)"-,B[(L#RJ*(R@J32"W*(ELZ2V#_"0*\V*I*@BG(=^'VDP'
MANJ]F!D(YDRG:*O8F;$(?;H==S!NO9%)@8>Z!)9H<C<4.,^%G%@G&JI=&1N7
M<_J<@I,SCAP^:L;0F"$M7894-9E17&U+2HX="9FN).8HB,KP($3@[HAT,XIJ
M[!B9"A#<-8:V5D=:ZQQHKY2B1XVI#C>A*\2(4?E^)MU5&'+?0H-\HS)5!^?2
M>7PJD:.=[C05'*(T=0]%*7LHR]06>M^&Z@)7,N*=\9:B;3UL\/>V$[C2 F]7
M#6%+S!@6?=11XTQ=OC6E:3:D1YD1%6PD=* AGH(GN,G-</>V%>MV^,DMB5:8
M41!IS: 8VV?KW#A:8OVJN)K?0>*=-U,1L9?1$B-.-#IQM-67E@(/@MVU\'(U
MQELNSN]E16J0"<VIEIQN\.1RNX(+K5X<KI)1G6A,6K"V,O5=C+\N:1$FU.4Z
M<78HC,=GT[A_)HN)GGAAT]Q1N!D*6V^)CYL)@6X:Q"FV4A&_E>&B[9PH7\^1
M_.5T)Z^D,GHW\8H#>+MHX>INA:N'/1[NYOBY'Z0\U9AC+8[<'96*)UISOD:-
MQN"%E"E^I"1P/471!XA5["1(]'FTF'.U!6X,UGHS4F;/0($Y#8FZ9 >HD>2U
MGQ#'K02+<=B<8TU_B9COJ6J4AVXBUW<]:5Z;B/7<0I1B%Y&!&L2(YQGD;X*'
MZR&<[?:2(YYQ?[D]G;F&E(8?($V^@PRO792%JM.6:LIPB3.3XKR=A:ZD!@J,
M8Z^-HZ4>#K9FV-@98^U@C*V3.?9.5M@[6N#H)/I:(=HJ\^'LN7+NWVGBZ8,V
M+HGU5,%)Y7)U@5<T<;#3Q,Y:"WLA#C8:^#IJDNVEK1SGI_WV<L9^)1<,YG+9
M;!$7Y7LYD>)&@;\57K:'<+(Q%.>RQ,[%&FMG"\Q<Q7A)<"!K,(;X 3_"^UP)
M'Y81?<2+F&,"LQP/(6XFAL29>!)/QA%_/(;(PV&$CO@3TR\GL]5:V!TM6C-5
M.)Z\@^L16SAN^SV3)G,8-%Y O> (%?:[*?(Q$3S(BJ1P)_*S NCJR&:@/Y?!
M@6R&A\1Z;P9M30F4%@63E15(5G8H1<7Q5%=E4%&62DY6I)!HI;.XL"",:Y>:
MA%[OY?+Y,F'G@\G+]1?]%D])63JEI;F4E^93)?!/?64>S;7Y--7DB+F9Q6!'
M+I>.5G#_?!4/SY5P8SJ=H5I7>L1S?' FEY]NUO#R5B-/;K=Q\T(#,X<KF.HM
MXL10.4>Z11M%"O+"=2D(U:)-S+MB,>Y3O?:1&J I<)HS7<4^8CS(Z<IV$^)
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MF3A)6]<P'3V2PV*:$S.7N??H!?<>/A,3]Q*M;=TT-KW*[];>T:-\?:^AOD4
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MR7B\.@]&8N!F):^N%G-:\)2V2@N*,Y0IR],E/\N$J#!CPD-L"0YTP=?7A:
M=X(#[ D),"8GPX&NUF".C,=04VHC=+(Y>9G.1(2:X^MGB4^ $SZ!'O@&^,AR
MM/OYN!#@:46LOSE-N5Y,-05SLRN("XTN#!58T)AJ3%N.!6>Z WAT7,QQ<=X3
M'1$TYGL1(ZX7++A.@*\C >X69(=8TI1@27>J*=W)^G0DZ]"<J$&FWS:R@G?3
M7FC&&='?#XYGB+'+YX<;^=P]F<!(DS>%*4Y$!UH3[&E*J)<^24':E,:KT9=_
M@,.EVSE9L8ESM=L9S%Q#2= *$MWE"'=5%]<UQ\O3"0\O9[P]K AQT21/S*V!
M0CUN]QKS9%"'1UU*W*C=QU3A7MJ3]I,6($^0VT$\G11E036!;DH4Q1@P6>G$
ML0I+CI08<TC,P<DR8\%EU&A)/,#I1AMN]KIRJ]N)&QW.'"NWH"U)M#%"0[9^
MP[T$)G#5PM51%P<[/<'=-$F-,**UP(;^,EO1AR:41:F3YK6'1->=9/D*["UX
MYU"1%<?J7#A:[TMQM!5!COJX6>F+[YOB[&0I.)<5=DZFV#H:X.YM1&5U&"TM
M8;0V^O+P=IW03;V\?-3&S:OU3!TKI:\KE>)\'XJD@HREPG861=)1$LEPAA>#
M+@<Y8K:!\X;+N:J[@.O&R[D?H,R[QF@NU B,$.<J2PWH8JV+HX.1+-U%H, 1
M"8VQ)(TF$3D10^BQ6"(OI)-PHY"T>^5D/:@BZ[XDU62*;<*U0F*NYA)W)9.T
M4[&4=KO1E*U!J\=JQHQG<5YS.I<U9W/2<#6#-O(TN^M3'&!%4;(O':T%]/16
MB'521D=G&6T"G[0T%=#4D$-G:S[=;7DTUTM.X4A*BZ-HJ$NGINKG)P4DC).=
M(16G2Q=VOD+HQP$N7*J@LL:3\NI0RH5.**M(H:HJE]J: NIKQ+GJ,FFH2A0X
M()KVAGB&.I,Y?2B'IS=JA<JOXMFE7.Z(^[UW,EZ\SN;M@UH>7*_B_*DRCAZI
M%G:NCB.'ZC@^*G!'52150I>71:K0GJ)%9[(VE4$'277:3JZ_,BUYSA3'&I(I
M7N?Y*]&68L: T%?#Y:Z<&TSFRJE&87\GN'CU%!>O7."JD/LWIK@Y5<_EP7!N
M#WB(N6S/@TY3CA2I<7LL%AZ.\O3.<1[=$S;BP74>W+\M<Q)+J8D>W[O%\\>W
M>7;_ K=/=S(H=%Z5O]"G'M_1$3Z/GMA%-$8MHR9A'Y,=8?#T&#\^N\[;IX]D
M.8F?OWC!\U<O>2%LK^0D?O'BN2R?L)2"Z=6KQ[Q\>8>W;Z[QH\Q1/"CN(4:L
M52/:$@XPF:,A1(O#Q99<ZHWGQ?4^>"?._>X1;W]ZPSNI<-U+85M?/N>GM\^$
MD7\BC/D=>':2EQ<;.-X40+?0<UT9AO3D6W.\,XZ'E_MX]_(J/_)"%B/\GTYB
M632P% +\3KR1<D:]02H\)T7]"FCQ/SB)_]?+_RE__ULZB5^_EH#6S[F(I3QB
MDJ/XR>-7 NR]%2#GF<Q)?/7J RY>O,V)XY>8G#C+$0% )P])A30NB_U/N7'K
MB2PG<>_ )&,34YP4P//<A3L<$<=+4<2C0HX<N\SAH^+]V&D&AD[0UC%&0U._
M+&I8BA26(HFK:CJH;^RALV>,FOHNVCM'&11@MJ&EGX;6 ?J&CG+JW"V&)T[1
MV#I(:\<P@Z/'Q;6O<_/.4Z[>N"^N>8;FYBZ:6SKI[.JC5P#O/B']O4-"*8TP
MV#?*V,@DQXZ=XLSYRURY=8?K=^\R>F22C$*ID)4K+L$^>,0$X2X(CJ<@5!XY
MD;CFA..4$XJE(%#&":[89/OC4!2"2T4DO@U)A+:F$]V634)['O'U&<0+<I9<
M)8A*=1:)%>F$Y0N"+(B358(45>R.IK\U2BY&'+331\%$ T5=5=2TU3'0U\?"
MU!0'&P$N B0B&XE7H!^>H3Y8^MBB:*_)'F<-=OOHLB?4B-UA!NR+,4(^R8Q]
M"2;(IUJB(L"26JX#!].MV!FESWIO1=9['F1S@!H[(G78FV",0KJES%&L(H[3
M%$#:J-);EG["LCH \Q(_K K\,$MP0<O5"%T[0ZQ=;60.U)BX6++S\ZEK;6-H
M8I*I4V>Y=N$*#V_>YNX-Z5''\TR=GZ+G\ "Y;65XY4>@G^" 4IP):CEV,J>T
M69T_;KTQ!(Z(?AM-)FA(RJ&<2OCA+((/IQ-Z,IN@J4P\QZ/P& C&MS>0P*Y
M3%*,V6JSC;D'%[+.; ?J$:8XE@?@7!^"<TL('IUA^/5)T<G)1$RD$3:12-BA
M1%D:"_^!<'P[0_!K"<6_-ASW7']L(ITQ\[#&S-$*6Q<'O*0\LE'AQ,9%BWX/
M(CC$GZ @?P+\_/#V],39V1%+:PO,K4RPLC;$WD87.TLU7.U5"/+6P-%J*UJ*
MLSFP_6/\A-&1<M=EAVMAI[M"5G3,V_$ ML:;.;CM"];.^07Z^[_$Q7@1O@ZK
M! G?)XBY*4WE;I2D6Y,4K$6D^T%2Q!A'^AG@X:2-O1@'OX 0(F(+<??/QLXM
M TN'9"QL8_'P$?<;D4E$>"PVYOIH*VW"4&T]BG)SV;7V$Q0V_ U/O>ED>,RG
M/&010X5R].1N)]-W :&V<_$T7XJ']0ZBP^R)C@[&+S"<P)!T? /S</,MP"VP
M EOO?$Q=$G'TDQP^7FAHJ"._8PT*ZV>CMVT& =I+B3-=29SY,D)-%Q(F0+6_
M\3S,]KZ/H_H,?,V_Q]=F*VE1)L0$FZ"IN %/%RMB8A((",G"(Z 0)]\R['S*
ML?0LQ=:G%+?@,CQ""@F.+24T)I?]^^39O.0;]#9.(]-A V5>:\FP^99,FV](
M-/F<"-V/"!72$+N%R6H]4ER6X+3O$XQ6?XC9YGGH[5B+N:8VB='IA(=F"0">
M061,);ZAXC[]D_ -BL79UA&= [O9MF0&!GM7$&:O2$&D&>'."KB9;,'9: .F
MJHLP/C@?.[45!!G+D>*D28:G,2ZZ!U#>N9&]<KO$F,01$%F.LV\QCIY%V+CD
M8V:?BY%#+I8>^;B'%!"9D(NOCR]VIIK8Z\AA>7"9Z*_96!V8@[7"'#QTEY'J
M*4]#F@!H,?I8:R[&45S?S5H!&TLM')WM19O#"8_/$==)P=0I 6,Q)XSM4K!R
MRL#5,P=__UR<',)04]1A]>*%8C[,PDYG)>&.&XERV4"(($"A#NOP,EZ!I\%:
ML@*-L5'?SL8ELS@@MQT?ST!R\NJ(2ZXB,K&&L,0&0A*;\(UJPLFO4JP?*15
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M6=8B)<:)O(P04A)"B GU(2G<B]*T8-I*XZ@O#",SSHF23%^:R^(9;,ACJ+&
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MF0>GDKAW+)1+@YZR*O]=I79"?WE17Q)-8U4FU8(7E1:G"5T@11\F4EX8*W1
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M&LEAI;T:4Z4YV&K.)=1Q&Y9JRU#:_ V*&[["8.?7N&I\1[CU2L*=5A'LM))
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MK,$R,GN*26_-)ZTAA[R&(LJ;*JEIJZ6XMI2"FA)*FJO(K9>BB05>JRT@K::
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MQT?A&QLJ2SL15B3>%Z?BEA6)98(?ULG^V"0'8)?@CWVL+S:!KMAZ.N#NYTE
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M?HYX>9KBZR;.[ZE,5:(.HWGJ',_:Q&3**H8S]M!98$N4ORXNSCJX^]C@XNV
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M-WC^_!XOGS\4^O0)LO0#0B8>W.7<Z4%.='>).=]$;5TU%55%Y.0G$9L00*S
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M(3;XR+/&YS!K/0ZSW>4HA^U4.*RGP#$U!?2T-'"U<1!$TH\0SP!\7'P$@/#
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MULS]&RNFO<7AC9.P4ELNYL%"#.1_PD 0#S^]-=B+>^IO_0IK\=YDUY=H;OP
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M+/_^W]DT]VV4=GV%ON(4](Y.X[@X3WW_- SDYV,JOQ2UK7.07S,#^<U+L!*
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M/V(HUI[)OAD8[YO%\4W?<VSS9)1W2O-V"<?E=PLB88B/5R@1D6*.)Y>2E-U
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M<VQ")JD9>514UU/3T$S?J1&NWKS-4RFQMOC:MP5 /=$CP&^G +OM)VAH;!.
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MXAI8B']8!@9&YJ@IR7-DQQ)V+OP4M?5?8WMH%H[*L[ \, 7#79/0D[+@=BY
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M<6R)P*$E#+N64*Q;A;2$8%D?@'FE#S9EWK@5^Q!<&$A:I0"$PGD656<)HE-
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M_,B.17]!<=5?,-_[-;Y'IA.@/ -7^1\PWOR):+^OL%&:C9?A%L*=U0EV,\%
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M[]#<_36'MWS.WM4?"9OP.3O7?L>.E=^S=L[GK)[Q"7(+OY8%UO<N^(!MT_[
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M,5;!T%"=O?MWL'7+*N0V+F7OIB4H;%[(D>V+T3NT$3<+#>+#/(2#BR(S-4Z
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MXCO1[^]?.\?$0#<]':VTMYR@L>$$I96-I.24$123(7A8-"8VWF@;.6-JXT]
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M'<<6=!U/H._<CI''28Q]3V,:U(=%V("P_6&<XL[@&C^&0\P(EF%]& ><Q%3
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MLLK)*FX@JZ"6U,PR,G,K2,LL(2XQFZ#(.+Q"0O$,"R$H+0[WA%#,0MPP"'!
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ME M.TE(=0U-Y# 5) :2%^Q ?Y$6DOP=A4H!8/ X+\R4PV L_\5IP@'CLXT6
MAPLAGHZDAOE0G!A!65(,&6%^1/LX$.II19"[.<$>EH1[VQ'IYR2K<1P7ZD6H
MORO^/N(Z IR)B/$E)C6$N)P(DHIB2"Z+);$TAMBB"!**HTDM%YRA,I64DD22
M"A+(+,\@-C^1H,P8HDO22*LK)*>EG(R&8I*D0'%9&DEEZ204I@CQ&D=07 B!
M44&$B+X2%1=%8DHBN;DY5%=5O<D@;FNCKK&!ZOH:2BK+R"LNHK):FK%V0K8.
M0TM+J^"?=8)S5@A^649M4P.MW>U4MS90<:*6,H'"YBKR&BO(:ZZDM+.!DK8Z
MLJM+B$I/$D*YB8G+%[EVZR9/!!>6U@)Y)#BR-)/OWOW'C)Z9D&4/W[QU3[8_
M.W9>QK/OW7\B>Y^4R#$\/"Y+T!#:4/#K;P4G'Z"W[RP/'K_FR?/ON'3E#ATG
MA\3WZ*2QY22G>H>9N'"-QT]?"QV .,X+61:QM'B=-)U5"A#+@L0_2%I!)AED
MF[3(ULN7KX4(EH+$;Z;_27]_BS?/_V<!^?\6_RA<_W?X.4$LX:?B^2U^3F1_
M)TWA_==ZC]]^]YK7 J^^?25$^DN>"[R0]J]?".WR@A<"TF)VKZ4@\7-I9?YG
MO'KVE!=/'_-<X)G XZ=/>"A$_X,G+\6]>,7#QT+O/'K*XX?W>''_&J_NC//R
M1@\OKK;RZ%PYUWN3&:SVXG2A#?W%YHR4F-"?HT97DISPWQLXD[N5B=+=U$4N
MHRY^.X.UEMR;+.#1S1/<NMC(A>%"KIPIYM:%6JZ=;^+2^1.</]_*V/D.)LYW
M<7&L@^O]37P_V, /%=&<,]C()96Y7%.;RSGU!9Q57\*0RE).*2ZF^? RJE0V
M4V&I0F><#P-E60PUU7%Q>)A[UZ[S\N%#OA/?60H.?RLMP'1/?-?K][EQX1;G
MQZ[*2IS4M?235M!(7&8MT>GUA"14DYQWDM+&2:K;KU-W\AZUW0^HZKQ%3?<M
M&GINT]QWAQ,#=VD;O$O'X!TZ)0S<IKWO%LVGKE/;>9GRUHL4-5\@I_X"Z347
MW@2)2R:(+)P@5"HUD7L&_ZQA?-.&\$D=DF7]NB3UX1C7@WUT#S92'=7@;LS\
MNC#V[L#0HPU]]U;TW=K0<VU%Q_4$VNXGT/5NP\"_0Q8DM@@7GXOIQSYN$*?$
M8=Q3S^"7-4%@SCA!.:,$9 _BFWZ:@(Q>(O)&"<OH(SYGD*+J\S2T7*2C[3RG
M.\XP=/HL5\Y?X^'=)UR^>%7V ]#9<Y<9G;C,T.@D/;VCM'?T4%7;3&Y!,6EI
MR>2F1U.1%4Y-5@@E,5YD^]N2+BT&YZM'68@N-6%:5/HI4>IUD$+?@^2&'R,I
M0I5@_R.$!B@3&:))7*0N13D.M-8','0JBC.G@SG?&\"UH2#NCD7PZ'PT3R<C
M>3KFR[,SGMP?=*.OW(C*)'4RP]5(#-<G+L*"^$A;DB-M2(FV)SG&61S776@_
M=Z'7W 3<"0SP%.._-\%^ K[_"C\O@GP]A-9S%=?D(D.0KS.!PC>$>#L2Y>]
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MRY:@N/1KC#;.1V_9%]AMFX7GD858R<]$9^<G'-_\$9;;9V"V?CK'EXES+?@
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MH=9$"L$>X&U$H(\1^6G>U!2&"<$43EZL'VEA/L0'2T%B-R("W8D(]28LU(>
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MX:^_D%BKY50&[Z(U]@!EP=N(=UA"J/D2(0NKL5?;@.;V%6Q:-(?-*U?B9..
MNZ,'KK:N!'GZX^7D@KZ&*FOGST!EZV(<-#?CKK5._)XE>(G?'V&VAB3';>3Y
M'Z1$V*@@RXTXZ:["W6PO-B::F)J88VSNC*EC(,:.P1@[!.(;'(^MO1,J2ONP
M,S],B(<1$9ZZV C=:Z2R"!/E^=@+F7$S7(>[^4XQKQ78LF4N'W_^%E]\\R5S
MEBQAU:9M;-^]'RU=8?^T3=B\9BNK%RYGV>QYS)L^C2_?^RW+9_X>"\VY>%LN
M)\IM.^F!FL2[J1 LCNFNL0PGI?GH;?J,W;-_Q[Y%;Z$I9--8=2Y:!V>@O&<:
M\ML_9?/:/[-FZ9]9-.M]/OW3?V+II_^*TI)/.22P9^:[;)W^1_8M^ 3C70NQ
M/K $Q97O<7#EV^Q?]19;%_Y:W+=_0G[#!]CHKT=SUQRA>]\1Q_AG%GST*[8N
M^@#30^O0/["2_6N_8KW0H3MF_Q&3G;.(LI 3X[T$#XTEQ C;4!YM3DNN-RT%
M@91G^9"9Z$Q*K -EV4$T%,=27Q!'7FP@N3'!Y"5&D!$;+&16V)*X(*(C?0F7
M90![":?.DZ@0+])B L1Q(JF6D!9&=4*H#.4Q@4)W>)(?YD-VJ \I 9YDA :0
M%18LG+,@<B/"Q78(<;Y>1/NY$Q7L0724-W$I_B2(WY)2&"X<3/%;JH0>+HTC
M.4ML%R207YQ*6&P WI'>>,3XXA'GCW=B$$'I$407)I):*1S]QA)J>NKI&.VB
M9[2'ENYFVKI:Z1_H%;QRG+.G3G'Q[#DNG#DKUD]S_-AQ^OK[:6IMH;JA3G#$
M&DK+*RDKJZ"JJD;HC';!485=&QX5NJ-/%BR6[5,K>$A#C; +]33U"STRV$5]
M7SM5G4V4B_>*&JO(*BND<[B?R[=O\/#I$\&-I>S@G\M-2 'A"Q>O<G3\I*R9
MG!0DEIZBDP+'4Z?.<>GR]9]+0PCZ_^KUCUR^<D.\?X'3IW^N47QRXCR7KMYA
MZHS8/G::\1/G>/SL!Z[=?,CPV$DFSUQB8O*";-_AX>.RVL92P%DJ$2>]_DN
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MDX+&4T3F'"<P1:I3/(1C:#]6@;V8^/6@X]&-EGLWVAZ]Z'GVH^_1AZ& L=<
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M6K)+I&[4PLD0Y#Z_1J"JBNSR<F*SL@A*2" D+AY/_T \O/V(B8F3.?129FM
M3*@@$LXHNQ@C[ZS#7B]#E((M.1SM@&:X+3I1#I@D>6"<[(E.H@M*D9:L<E!D
MB<U>69!8/L)0%B162;9$)\\%DU)OK&L"<6J)Q*LS@8"N5(+;TG$K#,=<&&T3
M7SML_%WPC@P@)BV.XJIBVKO;Q/WI%X[ $28F3C!Y:H+)LQ.,GSXFB%@?93U5
MI#9F$EDC%&Q%*$XEOE@6N6-9[H%UI3>VU?[8UP;A*)2;<V,$?AU)^#3%X5(<
MC%.V/W;BMUM'.PDC8X^1KQZ:3@<Q\CF$19 &I@&J:#C+H>VB(,B5)NYQEH1D
M"F<Q)YC@U$#B\N*(RXG'(\0+&P\[S.S-,+(P0$M?$Q-+(P)"_?$+"2(R/I["
MTC)R\_.)B8_%W=<#)V\7K-UL,;4WQ]K9"AMG:RQLS3 VU47?0 ,#(PUL; W1
MU55DE]Q*MF^;SY8-T]F^\1-4]TS'5F<1?I:K\#"<C;7J)^CN?@>5;>\@M^H/
M;!1.].IIOV/+5V^S^YL/4/CZ Y1F?XK^^ODXJ>U$9\=BY!9\P);IO^;0RH]P
M55M+O+,:-H>$\[Y_)C;Z2_"P7(VUVDP.KWL+KT/SB31>0Z#>4LQV?LJ^N;]E
MXR?_#SO%\=66"B=]VW*,=JQ!?^=&-+=M1&']*C0.[,)0^R#*^]8CM_%;]FW\
M$FOUY?A(C\P?6H:MW SA^.\@T_L@;OJ+L=.>AZ7F+,Q5O\'/;!5^1JLPWOD%
MRLO>1GOC--PTMV"IM [EK?/9N78N=M8&8@YXX^7K@YN'%ZZN[GAY"#(4Z4-<
MA#,!3IKH[YZ/[<%%!!EMPEYU(2;[OD57?CH:XK@F*O-P,5R#MR"P879;B++;
M3)#!<L*%L??4WX:R_"IL;<SP#XO&V2\.SXA\7$.+,'7.D&40NP26XQY82G!4
M!<[N42@I'D)NZQH.;%^,P<&E6"K.Q5%Q!GYJ,\BT6T^B^4I<#WR.]IK_C.'&
MW^"A_ D)5HLH]ME!OL=.;!4^QU#^<RS4%^%HNA,S'3DL])2(]',C.2R , ][
MC-7VH+QC";O73F?7ZD\Q5UN'@]86#JW_DGT+_L2!N?^*^I)W4%_^9S&NGZ"Y
M<3K!5GL(L3N D?):%'>M1^^P-M[>$3A[QF'OD8B#5PINOFGX^*<3$)A*0% B
M]K:.&&HH8*VQG"37;=1''23/<36N.]]#?]Y_PFOKAT0>_)8H0?P]%?Y,I,[7
M9-LNH,AI+F7N"ZCR74-MR&ZRG-8383B/@,-?$6(T3QQKBR JAXD7\RO"4X>4
M*$_:Z\LY>624J9.3C P=H:=[@.[.7H9[!QAL;:<R/1U3E7WL6[^ @UOFH"ON
MK97.&EPMMQ#@+$]BL!8Y<6:D1^@3YK8/3XN->%ELP$V,;9#U#DH2S&@L=:>^
MPE,X$3:$!FCAYZ%%0I0+C34%# YT,C#8P\F)8\(&G!3Z?Y3>KC:ZFAOH:VYD
MN*F9W+!P3.5VH"5D77_Q)]AO_9I8TZUX:2Y&<\-;Z._X *L#G^&H^B5V!S_&
M]L"'8OTCO(R^PM/X:USTIF&G*<G_5]@>GH.SL9AG*G/045F,AXL&'NX&.#L:
MXFAI0+"[ \&N-EAK[V??NF_9LO ME#9_1)R/(D7)9L0&:N+MM ]'\]V8B#FQ
M:L$G+)_W!7NVKT5NVP:V;][,QC6;6#QW(1M6KD1%02I[L1M3]6U8:6[ RV0;
MA=&&@GB;8G?H6VP4IQ-AL9:Z6&W*0Y7)<M]&MOL6<CTWD^.Q@0SG%>2XK"3#
M?AGQIO,I<-]$KL=VPLW6$>VH0H*OE1@##Z*#?8D,"Q'V(Y:X^&2!%*)C$HB*
MBA+79H^&Z@$TE>50DEO%GK4SV+_R<U2%#.NL^PSC]9_B>6 >T?KKB!3ZP6;G
MYVBL_!>,=KZ#D=!K-BI?$NFXG41O1:+<#N!JO!GM_0M0WCD7?:6-N%MJ49 <
MSJDQJ5'2>4%@I8[U8QSM'Z2QO(R8 "_<S'0P5]R!]H:%')CW$?(SI#]5_L#A
MM7_&\> <_+668KKC8[0WOXV>W =8'IJ.S>%O<-"9B8_92OP,5^,F-:/;\37.
MRO/Q,UB-A_9*+/<MQ5AN#0YJ!\5^9@0YNN)KYX*^HC([ERUEY9?36#_M2Z&+
MOV3S](]8]>F_LFWV6QC(SQ!CL8PH%W'-CJN$[GP'Q>7_@O'N+RB.T2?:ZP '
MMW^$EM A>S=_P(9%O\%,=2G*&SYG[;1?H;_U,]S4I6SB%4(OSD-MD[ +Z_Z,
MB_HR$ASWDN:Y#W_CI028+R'$>@F!%O-(]MI 3H@<J?X[J4W7I2'3@*R O60&
M[B$[7)[TR&WX.<S!PV(F(?8K";=9A9?&+,PVO8OAFC]@L>%MG'9^A//NCPG6
MGDN:ZR92W#:1+.0AQ4^!G"CAU(<K$^RQ%4M]89?T9N%MN9P8SZUX&,_#2=S+
MW @5LD+5B'#:BYO>!NP4%Z.W]C-V?_R?,)W_%D';OB!&_DO\M_Z>>+6/Z([<
MP5B6"GE>JU'?^"M6?/,K=F_\#&<;>0X=F,W.->]P<-T[0K^L(--A*[$FJ[&4
MGR;&Y"MLE!=CK[8&U4U?LV[6']F]^DL<C>3)CG6A(B>,NN(X@02J\F,I2 LA
M+=97V YOHD)]"0OR)\C/G^" 8$*"0@@.\A,.O0^1 @F!_J2&!A$O]@GV\I#5
M(H\*"B JP)^$X "R(T(IBXNB3/"GX@A?"B,\J4X+H"$OC.:2*%JJXF@0J"R/
MH:@DF@K!7QK[*JCMKZ1NK):Z$PW43=13+5 I4#Y11]&Q&O*.5)(S5DY&7S&I
M[84D-Q<05Y%%6F4^U9U-U+4U4]_23(O0FYU=/71U=M/6TDY71[?0<T.R(+%4
M@UC*%FX0>JVZIH[*JAKJ&YH8D6H2"W2([TA!Y*[N7L%%AQ@8&:6SKY_6SBYZ
M!X=DRZK:.DI*RV7[39TZPZU;=[E[[[[@M+=EI26D;-Z+%V_*LE[;JBH  /_T
M241!5(FE +"422QKWBP@90Y+S>ND<A-28H24U"%QZ?,7I(;3MV3?FYJZQ.CH
MI.#A4NF+$XP>.4O?P F&QZ8X,7E1AF,GS@E.>(83)\YS_?H#P;%?R;Y[^]9#
M'CU\QI7+-SES^B*G3YT7O/RRX-^/94%BJ7F=E%$LE9GX_OL?94\B2N]+6<52
M;>*_O?Y;#N4OW_\?Q3]R<O\M_".'6<(O'>M?!HG_UE1;6I>:V'W_1GPN?)SO
MW_S$=Z]_$'@M?!CAL,OP2I;Y]>;9,WY\^1Q>/>;[AY<X-U))?V4(8X(W3S;Z
M<J'-G\N=05SKC^36D63N3>9Q]W0E#R^W\_K^$5[=/\[KAY-\]^0,+^Z/\^SN
M",_N'>'Y@PD>WYWB]HU)@7/<NWV9AW>O\.#F&1Y=&^?&5"-MQ2X4QJJ1%;*?
M#/_]I/KL(]EW/RE!2N0GZE)7Z$!O0S UI:ZDYQB36*9/5+4.88T&A'99$C'D
M2M2HF'M#P21V^5/4Y$%7N1T=0L=T.6QDQ'PY)ZS6<#U2@Q\ZH^!L)3]=:N'1
ML5J&J].HSDZ@(#V-])0L4C/+R"IJH[!ZA(:.\_2-WJ-7H&ODMBQ(W#UZ@\$3
M=SEVX2GG[WS'E8<_<?'N=YRX](@QJ0ZQ5(-X\CY]$P_H.?% ]BA^R^AM&@9O
M4M-SG;+VJQ0V7R:WX3)IU1=(JC@GKN><+&LXID J*7%:EBT<G2]M2T'C\[*
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M2HM1WOE;]J_^6XYN_#LL%#\2.K>=QBQEZM(5B7!:CJ/V%^+]3[$3=LQ=G%>
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M"(V,%_,CA>BH..2/'D'QZ%XB NW)$H U5HR=H]XZ+$_,Q4=_.:DNNXBV6D^
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M9A,VA%7( *9^4FF)+G3=I$SA3G2<N]%R[$7#OAMUVTXA':C;M+]OYN78+&N
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M7?T9#O([,13W06O_=I*#?,E+BB<K/IZBU$R*TG/(3<X@-3(!&VT#E+=MP_3
M#IR4]F&MM)/CNY=CI'<()R=-S"T4.'AD%4>.KL;)41T79RWL;36P$'JKI7H
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M<%'\#!^MV4*GEA!CMTS,_R7XFR_ 6]@ +^MMN)ENQ\=\+Q$.1TGUU2#>3YU
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MV#] >TLSM64%U!=E4!8?1*B1$KXJ>_!6$';@\'(,UOT.O56_Q&7_;-P/S2)
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MG18'#)0XJ'8<-6UU='5U,#$VP<'1$3__0,+"(@@)"B8D.)B@H""\ GRP]'!
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MNS%1W$N8H[*XIN.$6&_$1>L+BD+WD>>W!X,=/\-T_Z=8'5N,L=PR- XL1>W
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M$H[G 3'&VFG$ZB01;YG&#3%/'US^/<.#CRBN/DM,QBC>D7W8^W=CY=V+N?<
MIKYBK@0.8QHVC%74" YQ8[@FC..1-(%[HMB.'\$Y9AA[,:>LI/G@V8>N2Z_0
M]2Z4[5HY8=> HGT=)^SK475H0=.I'3W7#LP\.[#U;<,UL(6@\ 8BH^K$_:TG
M.;F=U+0NTK)[R:D<)5_PRZSN"4);V@5.$#9GHI>84[TDG.TC^?( J=<'2;C8
M1=395B+.MQ(X78OWN."[(WDX#TB9Q%&8-P5B6.F"?I$-AOE6F.5;8IMO@6N^
M&7X%9L056U)4;D=%F8V8$U;4"-M8)>9&6TLH4Q-57+LTR-V;I[EW^Q)W;U\6
MZZL\N'V=>[>N<?_N+>X_E +$#[C[Z#YWGMSG_K.'/'SRF,>/G\K\L10@EN2Y
ML/\O7CWAY:O'?R+BM10D?BU\QYO?"U_Q'5)/KS=_]"%2D/B=V'XG_+SD8]X)
MG_+NVV^%?/\_Y5M9@/B_@\3_7U[^2X/$_[I(-U@*$DN9!Q)H>P^:I)LN*<BK
M5V]DX/+NW?NR1Z@>2R4G;CW@T:-7LNP#*4@L-9@[?_XF,S-7.'OVJJR#\N,G
M+P5H^H,L4"PUV9#55^L1!*NUEY*2&L8GS_'XV6O9$9^_^DX ^3/D%E3*:J#=
MOO=4]HB6E*T\.#0IRUR0NCJ^^_8MCYX\Y-JMFPR,C-#:V<UE :"GSTB9Q#.,
MCE\2X/<&)T]=D37=Z!T89_SD^\9YT],7!)B^R-4KC[AS]PT7+S^B=W":Z;,W
MF3I]C=;V85DF<6MK/[T]X^3E51 1F8Q_< PAD?%$_3&3.#8Q@^34;-+2\F2U
MAD-#8@@+BR4KJYC,[%)9W>)(X?C"HH6CB4U\'_A-SQ..M)#<G')*BP61J6RC
MMK:3PI(ZDE+S"(U(%,XSB]R\4HHK:JAI%F2FJT,X@'::3O;3<+J?DLEVL@0X
MB&C*Q:DX"M-<?S337#@>;XU<E"D*L>8H)UIQ.-R0@R'Z' C68XN7&IM=E=GI
MHL81)VT.F:IR6%L1=7TM] T-L+"PP,W#G;"(2&+C$@@)"L'/VQ</=W<<7)W0
MMS-%WEJ+/78J;'-59:NO.MM#M=@9I</>&%T.Q^JAD&B(4JH)RAEFJ&9:H99C
MBVJN+4?33#F48L)!(;OB==@4KL*&X!/LCM-%+MT"Q5Q[3N0ZHEGDB4EU,(YM
M<;AW)>+5G8AO;Q*^/?&XM85A4>V!8;$3NOGVZ(G]FF8[(>^KP4=[9_/I@7FL
M,]J!6H01!FFV&.<Y85+NADUK *X#47B-Q./2'8I[9PC^_=$$#,3@UQN%=VL8
MSF4^.&2)ZXQSQE:0?"<7*WP\7(@("B(U/H&2_'Q9]MWH^#"7+IT5SN *]V]>
MX\J%L_3T=5-07$!T3"3!0;Z$2EG(P2[$!EKA9Z^"A=I60:SGL7/Q;]@P]U_8
M_/5/4=RW!!WE_>AJ:N'E$X%_9 [.(5GX)501D=9"9'(KOF%5V'H68NB8@Z5'
M+AX!V82')1(9Y$%<@!Y)?@>(]5A#@/4"G/2_Q%;K<ZR5OL3RV!Q,Y1:@<V N
M"COGL'?S0FPL34E(R24INYJP)"D07$Q\GCA.2@O^X76X^I7AZ%>,@W\^+H$Y
MQ*:4RYHR:JFKLFW-0C8L^H#]*S]&9?,L%-?\CD-+_Q&]?1_*:OT616N3XJ6.
MB_9^](_NQMO9E="P>*'SF43'%9.86DMB9A/A*0WXQ57C%EZ"0U >/I%% OSF
M$QH4B86.)D8*NPFUDS(Y]Q%JMIY(BU7D>NTFP7H3QCL_Q$EA!?8G-J"Z<R$G
M=BY!<==*3NQ>@_+>M6@<7(7ND25H[9N#R>&O<57:B)OR)O+\C>@K"2/,7AZ#
M PM0W_@1;JIK<%!8A.WQ6:2['R3&=AL>6HOQU5V.]>'/T-WX4PPW_0*;71]B
MN^L3=-;\"NUMLS&6 G4Z)[#7U\7>P!1;0VOTU/505CB!PM$CR!W8B?RA;:@J
M;.?8@>48:VTA*52'EA)G&G),R0J6$^!>D_)(-5*<]^.EO@IWE96X*J] 8?5/
M,).;0YCM/ASU-F"LM PS<9ZASLKD1MF1%FB)P>'UV*CNP<=2#2=C)?Q<30@-
M<,3'TQX_3P=BA<Z5)7M1$6]+58P!C7$:5$<<)=M["Y&V2TGVW$9IC!:MV9XT
MI'B2'V!&F.DAS _.1WO'1^CO_QP+Q84XZV[ S6B7+/ NOWL)>DK[*,Q(8*"S
MG:FQ"2Z<N<3IJ7/T=0U17%A#3F$MQ37MM'3U4UU62(27!<J[YZ"\\U<8RW^
MJ^XLG#1GXVZPG$CWPX1ZR^/A= 13@^VHRZ_AJ+B?!]9_@=;!9=BH;<)#?SN^
MAINIC-;C?&LHT8Z[L3@Q1^QK-@;'YF&LN!A[W8U$>:G@97T(7?D50@<6XF>C
M2&ZDF+M:ZW%26R+NZ2+L%3["09R#P[$/L=K_$3:'OL1:C+/IL5G8JB[!17T-
M+@JKL=JS ./-GV.V]7/B#'<19[(+L]V?<'S)WZ*P_.\QV_<Y_KKKA5XM06/#
MS]'>^EO"K?=3G^&,O<8FE#9_@=*ZSU#=\!DF0L_<=-8+73Z G=B_^MZY6&GO
M(CW!FZ:F$E(SA7U/3R$Y,Y/$C$QB4S.(3DPC.B&%Q)1T,M+2R4U+HB0UCNQ0
M+_R-E##;OP+C[;-QE?L:[Z.+<=L["\OUOT!WZ=]AN/:?<3C\,9XZ"XETVD1F
MR$'2_'>1[+6%!/?U1-@MP]]B&2&.>ZC*#Z6T4!P[-9[LO%QR"XO)*2@A,[>8
MY)1L0:Q2!:E+(SLU6=SS6(K3 @AUU\3.8"=V)KN)#36D*,>#O Q70>2LB0DQ
M$;;(F%@??<)<E&5-X$)=Y7 VV83"G@]1VO\)ZD=FH79X%CO6_ P-Q66"#-K2
MTI#.Q' K9TZ.,CT^P=# $&WM76)\VNAI[Z:UNA8?1SM4#NU@SYJY0C_FL&?5
M9^Q8]CMVK_R0XSOFHB6W' /%E=AJ;L9692VZN[[ 9/?GV!_X"G>YV?C+SR%4
M:2YA*G,)4/P*IX,?8[SEU^AO_PSC@XLQ4UB+PJ[9Z,@OQ]M.#@^K?<3YJ5*6
M:DFB_PD<#,0^3PB[X*Y%7FX4S:U5E->64E9?37EC$X45=4+W*\D28Y>3FR?&
M-4>,;S)%L3YXZQ\6^O IFS[Y,>M^\R-V?OS7J'[]S^^#Q,H+<3K^*>[JG\M*
M.42[;<!4Z6/VK/U[ELW^:U;.^6NV+_A'Y)<*N[/N VP/?460\2IR HX1[W(8
M![7UF!Q;CKFP&YZ6VTB/TB8WT9342$,B_34I2G>F4MPC!^-M^-KM)M%73O:G
MFZO:?*P.?(CI[M_@H;P =^5%:&[XJ7C]$3X:2TFPV8*OYAPL#_X$@YU_@X.J
ML)5Z<[%7FXV5TCQ,CB^0_?ES;.N7[%WW.5M6?L;\SW_!YQ_^A/E?_9K=6Q=B
MK'=0S&T]]-6/H22WGV/[=G%H^WIVK5G$MF5?LF_ME\*N+$=7<2DK%_XMAP_]
M D>OI43D'2"B\CAA#6I$=ED1TNF(;ZL+;DTN6%?98U(J?'V9(Q["5X?UIA#=
MD49D=3)Y[>6,7CK%]0=WN'3].H.C8W1V]<B"Q+52EG!5):7E D>5%9-75$BU
M>*^[OT]@SSY:! :MDQIGUC1245%%44DQ!:7YY%46DEU30&IU#BGUN:0TYI+8
MD$6*P%II3?FD->:1VUI"47L%12U"&DJI;*T61%WLK[.1FO9ZZGO;:![KI7E"
MX+61;NH&VJCI;::JNY'RC@8JI._UMM(TW$OC4"\-_3VT2:4R1D9EF<1]XY/T
MC4S2.S0AKDG*\IV0!7#OWGW*G3M/9#TRSIR^S.F9RTR=/$=__R@GITX+W'V9
M<V<OR1K3236")9&RAB42*CT!*&4BO7DM91-+3>RD(/%]@=_O<>:LU%/D(J?%
M/GM[I:9UTUR^?)<;-R1\_%R0V]<\>?Z.2Y=OR\Y#"A2?/'F&87&.4L+'N7/O
MCWOURDWNW7T@RR3^@2?^P!TD'B&1TO=D4R*C[Y-0_I2<_M\N?TI*_R/R_MC_
M<?GAW'Z0/R77_S:36%I_+\LF_O9;*8/K[1\SB?^83?Q'^49Z_QN)W+]O!"YE
M&+^6'B%^]5S(,YF\>BD%C%_Q1G"MUR]>\OJ9>/_Y$UX\><3+)_=Y\_P.WSR_
MRKO'4SRYULIT=Q2=Q;8T9!K3E&7%R:90'I\MX<'I(L[VQM);Z41?I27CC1:<
MZ;848LB%?D,N#IMP:L"$J2%+)H=LZ&^SH*Q4F]B,$_BDJ^":KX=SE0T.+=XX
M=H?@,AB)UU@T$>?22;E=0NZ3!@I?M%+THHN"%WT4OAP6VV,4/!DC\_8@21?[
MB)WJ(:*OD]2!8:I/7:+YU&TZ)N\)/;]/^^!=(=+V _I//I8U[AJ:OL?)<P\Y
M?^TY5^^\YLKM-YR^]%36W$ZJ72S58.T:O4?SH!0@ODUM[RVJNFZ(^71-S*MK
ME,J"Q-?%O+Q.?N-5LNNND%Y]B:3R"\04G"4B9X8P(2&9IPE*/XU_ZFE\4F;P
M2)K")6X"^^A1K*0 <<@@IL'#& <.8>0_*&0 L\ !K,3[4F,Z.ZDF<40_3E$#
MN,8,X18[C$OD$ YA@U@'2TV\^C&7LBS%[RU"1K ,&\,J5.P[> A+L1]S*6#L
MU8^>2P_:CIUH.+2C8M/\Q\9=4J"X 7WW1BP#6K /;L0WLE%PS6;2DNHHRJBC
MMJB5=L%-:_IZR!QL)794?#[51N*Y7E*N]9-S?YRB9Z?$_3E)R<LIBIZ.DW:K
MB\3K;<1=;23R0@5AYZ4@<38AIY+PZ G$K<6=X XOXML\2*YS(*G82-A,0WH[
MW'EP/5-(&C?.Q7!FS(_A+CL:*W0%1E"F-,>8\@(G2@I\2$WU(BDY0."+*!*2
M8F7!WX3$>)*2XDA)CB,M.596YBL],9K4Q%CQF?A.LL!#*:GB=1HI4H!8\.B4
M>/$Z2>KWDT)4=!RQ\?%B7[&"EX:3("0Q)H*$R B2(J-)C(HA-C**Z.A(HF,C
MB(D/%_P\D,A8#\')[(B+,24MWH""%&W*L]2H+U2EITZ3,R.F7)DVYM*,GK"C
M!K0-_?_8^POHN+(LSQ?N]6"PIZ>ZN[HXJ[.JDC.=G.FTG7::F4FR9#$S,S-+
M(84PI! S,[-D6VA99F;+S)A0^?OV#5=VU]34]'3/Z_7>?&MUK/5?Y\:-RV>?
ML_=_Q[Y[6Y+7;D)8Q1Z\2\SQ%IT3TAM#Y)APQ8.91!W6$'>J@,0+I21=KD!]
MM8&,*\VDGF\D];3@>!-ILRWDS/10?G2<]K-GZ#IV@9Z#E^B>N$S[_HMT[+\D
M\_P5!J8NLT_D>>KP#6:/W^'HJ?L<._- )^O'SCW@Z-D'NC]*9D[<XN#Q6]+>
M8?+8;0X<OBFXH7,0C\A8&):QT#]^G>[]UVD=G:-Q>$[&P%5*6B^0WW &3<T)
M,I5"C46'2"R<)K%D&G7%8;1U)ZAM/<OHR&VNGH)[I[XCWCX=N\5N!*^-)&9S
M$K$[4LAQ+N3V[&T>7X%#XP]I:CE#7LD,"9D'\(OIQRV\'Z?P$1Q$GAU$MIV4
M/TED#/ED3A.0,T.(1L'TRR*0ZDD9'_)[]!CVX2+[@:.8^ YAX-6+OE<'>MYM
M[/'NP-A72<TRB$WP,(YA([A'CP@W'B8T99 H]0"QF4/$ILN\DCM&=MD,^76S
M%+8?(:=GA@CA(>$]_<0>&"7J0!^)AX9(/3%"\M$^$F8[B)UI(_I0&V%3#02-
M51*POPCOX2S<>A-Q; G#LM(3BV)G[(K=<"_SQ+?,@Z 2%V(KW$@I<B(]RX;R
M4@_JA-,UU 5Q8+^&LV>ZN3%WF"N7CW'ETFFN7;W(W+6+7)?VQM7+W+TYQZV;
MU[EV0W#S!M?NW.;Z_;O<$-RZ>Y<[=Y0_51_PX.$#[@L>/O[!07R'1X_EV3^Y
MS1/Y_C+=A%(,]EO1'TI=L.]T3N/GHL]?B%[_!RB.8IV36'X3/?5<])*"K[\3
MG:7@O]%A_ZV3^,_IP#_%G].K?P[_]OG7__QOXB16/B\[61$(17!^Z' EKYGR
M"IEB "I&YJU;=[AW5ZFXJ(3 ?R<#XZX8EG/<N/%(C,T+C(Y.,SP\P359+X?A
M6[$!E4-]\PW<O?M$YR!N:.C0&:2W;C_2;:,87'-S]\7X/$K3'Z)X%8/TQ8OO
M&1P<8__^:5W$Q'TQHNX]$D/BRF7ZAH;8-S[)X>.G=)''+6V#@B%=-/&APQ>D
M/49C4X^@B^Z>8<;'#C$Q?EAPE(-3BK/X(B=.7./4F1N,31ZC?UB(AJ"M?9!]
MHS.<.7U52&(]\0GI)*<*P<XK0UM415Y1!7F%93K'KUH(?F**FL2D-%%66:(D
MB\DKJ$235RF_*;\7D*DIUD469^<4DZD42,JMH*! B=RJ)5>)),LI$0673YI:
M*\JQD(+\,ET%]_:N/@;V'Z!_0DC$[ 1#IZ89.#M-U70OB4)<7$KC,2T*P; D
M$,/R /84^F"0[\G>? \,\CS8G&K'L@A#O@S>S>(@/58$&++1SX@=7J;L<37'
MQ,$"%T]7@D*#"8^)(C@RG,#04$)#P_'W\\?=W0U'5P=LO.PQ\K-ADZ\Q2[WE
M6 &[6!EGQ!J5.>O3+-B8:LZ.;!OT\AS8HW5D3Y[B*';&L,B%#1GFK$HU866:
M&5\J#N+8W2Q1G,0J4S;FV+)-MMM9XH%^N3_&5:&8UT9ATQ"+8Y,2.1R-8WV8
M$$5_K&42-RMUPZ38%1,QB"WE/C>'&_'++?/XU'XUFV/,V"WWNS?7$;,25VSJ
M?''KCL)O-(60,341X^J74<0C*J)'1?D+(ON3\:^+Q+,@2!2<#PZ!#KAX.^+O
M[TUD>#@),?&DBC&2K\W7120U-M31T]I,?ULSG<WU5%4+<2P0XIJ:1%18,*%^
M'D3X.Y,8YH"GS08L=WV&K?[G!#HIA8_6LG?3!^Q<\R%ZFU=B96I#4$@:D8FB
ML.)K\$]LP">V#O?0<IP#B['U+L3"K1 [WWP"HPM)2\\70S&9Y AS@AP_)]KC
M8YR,7V'[ZO_$CM5_A<7F7^*I]S8!1D+$U_V&]?.%O"]Z#2=[&^)56J)3*_"/
M*\0WMI"(M 8BDML(C&C"Q;<,1^\"7/SR\ W-(SFMC!15-KX^GFS?]!4;EKZ-
ML5RWJ_Y\? P^QVWG.YBL_#&>>]]$$[F-NDP'U,'&N)IO)<C7C]!P%2%1N81$
MEQ*M:B(^LU.4?".!R?7X)E3C$5&"O]Q/3%(!Z6H-@9XNN)AL)MQQ,YE^.\D/
MV$ZZ\PKBS.;CNWT>5BO?Q$YQ!*__@EW+/\%.?Q,V^EO8NGPAZ[YXGXT+WL)P
MU;OXF2[';^\BG:/.9_=\<@*,:<H)0A5HC+/^%YBN>8U@JR7DA&RE(<V8@4([
M6M/WDN7]%>[;?H7C^I_@L?57^.]^@^ ][^*S_1W,E_X&@Z_>8=?2S]BV= DF
MVW;C8>=&1& T=C9.;-VZDY4K5[%JY7+6K5["EG4+,=FYA!#7K92DV=*89T])
MPDZ2W;] [?4%U7%;Z$PW(<KX0WRWOD[@KG=PW?A+,KR6TYQE0;CK$NR-/\#*
MX!-<+-<0'R3[B]%;FY/&4'TEX]W-=#66T]%224MS-97E942$B.S:F1+H;$B
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M<W\/C3U== S)M>U7',;#= X,,3!Z@(-*ON&SE[A\Y0;7KM[FY/'S'#UR6E=
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MR,F+#SAQ_A['%"?QF;NZE"M*\<9Q)?_PX9N,S-QD<.J&Z(<Y&3/7Z!F[2I=
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M^5]BN>,-_&P7RKRQ#!?CSS#>^ 8[EOZ2G8M_SIKW_SU;/_\/!)J^B=I/YL6
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M5<(/[" MY!"%<8;XF2Q']^O_C,N1CXFR6T^2^S;"K(4]&WZ&J]$G!#I^14S
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MCS%[>8B*G@("TOTXYF. CI\ANA$VZ LL8YPB,'MF!):YL9AGQPONH< F-XW
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MY%)&L_;2%K.!0L=/4.K^!L7!7Y,L).W(:V0:O$VRZ3L$ZOT6W37_!J-=?TN
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M.TC=P30SK>ADFK,OW91=:D-V)NNS5V' 04&4=65&'/<W8./QC7R^[A,.ZQ_
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MU&GM Q+_E&FM^$@M)Q3C!*5,(,N:0EETDO*&R_3TWJ6E^@PE<9THK++QW!9
MOD\9MT>_Y?[<$QZ=^H''\T]YMO"2/UR&Y^=_Y'3]5>V#DLAC\;CL\"<WI)ZQ
MEMMTM]VELOXZR86+^">-8A_>BWE #Z8!_1CY#V 4,("I-DG<CW-X/^Y"Q[WB
MAO!.'!%V.HJ']/ F=AR7F#$<(T=PEHV*OR=PB1O#-7Y8V&P/7M$-)*:UB/LS
MRK.;U^'F/"_'JKE?%,F<[U$&])>S(/3ZHM$R+AFOY)SI!OH.+J'OQ%J>IOKR
M,B>8>Y&63.FO8E+W"^;T/F?.\%-.&GW**9//6;1<P5G'32QX[F4\Z"BC"5:T
MI]A3JK*CLM27UM9H1H7NG#M;)'QI!3>OEPO?6\2-B]E<.J5DMB^0T287A@7V
M&JRV9D1,9UK<.2?T[]'95'A0"0]KX&FSD!9^N%?)MU>+N3JM%GH=P)FA9.Z=
M*>7&J7SF^Q6,MT4QVZO@NZMM(G:<@9?BG'^\(^0!?W@I88$'/!?RXT]2D>83
M7OST T]?/!'R3"P7,4C[QLL_CUW_5/Y<O/M%_ES,_)?D7S__<S[_2Y/$?WJ#
M?U$,:6"Z9U(?K1<OM54!O[26D%ZO>OKTA39A?.?./6V%L23???>] )&/Q;J/
M>?+D!VT%LK2NE!R6 )34CUA*$M^[_T@ SRF&1R8Y=>HL5Z[<86!HFB$!3,^<
MNTU/G_3= O.G;Y)?6*^5EK81BHN%X^X>$_N51F66>GT)9R6 F-1NXLKU^P*4
M3U&A::>ZKD<0FQ'JFX:IJ1\4,B#F!P7IZ:&TO(.RB@Y!<+NHK1L68'F>JJI!
MRLL$>&\:IZ:ZF^Z>":[>^(8+5VYR^NP%YA<6F9T[)62>Z=EY03:&*=4TD)29
M3TQJ)C'2@#=%1225EQ!?6D!L40[*BB)2R@I)RL\A/B.-!'4JR6+=K#Q!K"MK
M:&QLI[V]C^8FL=^6?H:&9JAOZ!;DK)2H&!51L2H4*5FDYQ2A3,\F/#X!=P'"
M?.)EN">$8R'SPCC:$]-$7ZQ3@[%)#<1:Y8]YBA^FR3[H)[AQ*,J6W:%F; DP
M8&/@"79$F;,_T8;#*0X<%X%?3^7,B517C++$=G)],!&BG^:.0;(;AE$.Z+F;
M8.%IA6N@&_ZR(&*2X\DO+6)@8("3<^)>G5X4Q&*1\Q?/<^'R>18O+#!U>E($
M.N' 2Y2$%\?B)?4LR_/'LM 7J[( [*M#<:J/P%4X68_N>-Q[$O >4.([I,*C
M3X%]1S26+:'8M(;@V.2/B\8-^R(KS#/U,$D[@E76<<PSCF&6IH=5FC''9+KL
M]-S#!I>=@DSN95. +GOE9ICDN.-4&81+30AFQ1[HY3AP+,N.HQFVZ*9;<R3-
M AVU&8=49NBFF*,C-T _WAS36&LVFVSARZV?\?'*=_ETV?MLW[U)D%\;$A6Q
MI*5+_:132!62E9E&;DX&.=EII*D%>8[QP<=3CU!_/=QLMK'Q\__(SF7_!<,=
M;^%T['.,=[_)X<V_XOB>-PGSV8\LX##6^LL(<-XFR/I1\I+TD'FOP<'H78P.
MOHZCR5+LC59@K/,%ACI+"/ X0FJ*.^[N^SER^"/V[?P-W@YKM%7#ON8?$VJ_
M%,.]O^;PMK\G57Z,E(B=1'M\24K(:B$;2 G:0FK@=F)L5Q J J+,; 4A9JL)
MM]U"HOL!DNQW(--;@<O6MS'?\@[Z6]]#?^<G>%ONQM=F#[9Z*_&V7JE-SL3[
M;23.?ROM)>Y<&U:3X;(5_[WOX'O@ P)-5Q-@NXT EX-$!IF3H0JFHD1-:6$&
M)869E!5E4E.2145. KG)OB3+C%!''2(E=!.Q+A^0&[J$XLAEJ#W?)3]L)44Q
MV\B4[20S2H=<^0F*Q'W*B38F-]:$XA1K\I/MB XRQLGZ*#&1 6+[!0+8=3$Z
M-,I@WS!=[3V"# _0V=U/:X>P[]YN6EJKR$H/Q4S_:RR.?8*OY5*"K3\G,W0'
M[3E63&M\2'=?C\/F_R( T&^PWOX:9N(^6NW["'O=95@?7H'A[B7X6!VE,#F6
MF8%N)@?[&16V,3(\3%-;&^5U&HIJ*JBHKZ%.D/QZ*;&0'$1*L D)0F>C;9>2
M%[2.MM2#5$1O(C?H:U3>RY"[?$FXPY<$B>]]+);@:;8$?[LU) ;I$.USD&!Q
M74,]3"G)EEZ5JZ6TM)SLW"+RBLJI:6BAK$H0DN(*LL3?^:55PN=54EU61%UI
M.J5I_J@C="E*.(@F>1>:A#5D^;Z%VO6W% 9\P%2^#L/*'50X?DB5]8<4Z[]!
MYL&_)UWG5RB/_H8$DS=1.GU!@;@?)0IQO?UV49H=1%]'%34UY6AJ:\6YMM/8
M(7QN2R^5-6T4E#0(:::XK)6*BA;JJFHHSD@FUL^2!)_#J/QWDA&TB33_511'
M;Z8[_S@GF^P8UYA1I]I'0?@6<H*W4A2]G]8\<UIRQ7+U"?IR+6@4-I/ANYUP
MJ[7X6VXAV.TH\7(/BDL%21EHY<R9&:Y=/<-E08)/SD\R.MY'7X\ E])@4,H(
M9!XG"+1<383-%\0Y?TJRU^<TI^]C0F/.:*69T+\U*,2U4#E]0JS%VP3K2^U
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M%M$&GY/ML8U<_[WXZ"_%QVHWH;YVA(?Y$!D=C$S8361T )%AWL1%^I&9'"F
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MP']EN_Y9_IR=^Z/\J6W\[Y5___SK?/Y-%*[[X^?9C7YVLY_=>,NJ*,X_B^(
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M/Q3[]!%65FO8OFL#:S=]SJ:MF]BQ<SM[]NSB@.  1:RL=G/@X#Z<7>SP\?7
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M+".GNYKRD38JA]LH[6NF<;R7MJDAVB8$3TZ,TCDQ1O?D.'U34W2.CM(V-,3
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MW,-*P6;%8=P_."?8^(@EHGA^\:PE5W%O_Y3@X7%+BHH;-Y0B:W#[]GU.G;K
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M]<)9%F<G!6/TT]TO<_?P,7I&+UF<Q/6]EZCH.&]Q$A<VG*6HX0+%39<H:KI
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MPXR,+%AD>OH8\_.GF)L[R;@0XF?.8<59/,>L;)]?/"?;CUNV*]N4Y9#\KW]
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MLQPZ=DKP[FGF%T]8',0CP[.6_,/#0W,6Y[#B&%8<QJ.CBTP)GCYR[+*EUL?
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MFD_)52GY9=_%&/(:!I^7T+G] 8W=\VC=WR5'B2A-M<$4MPUUV KTB>LQ)6W
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M*C+G(EFV>5+-<R09YTB4LNCU\\3K%H2^+XKU)>*T2T+_%XDN6B12/4^H8I;
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M*\S*7^/0ODI5R09<FK=1)_\<5?2/R OX<Q1!XKQ+_)BI2Z3?%4)IS@<8$U]
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M/TM1UHLXM6_CL;Z/Q_@N%5HAF@\Q9KQ.0>1+Y(;]%F7\>UCR=U)M#\-I.B
M]5XQIX-I[(ZD>3B&^N$H2EK]!%C9CZ795X#Z_=CJ]N&LVTMI^58<MH^Q:=_!
MIGJ'*L,FVAT[:39NIE&_D7KMAU2JQ/&U']#DW,YH1RQ]S;%T"' LU:U:'#4Q
M,U!,9TTBK66AM+H/TEZQE_[:_8PW^3'9(-Y;M])LWNTM-=+B"/<VOZHI_DS(
M!S3JWJ&KY'V6VWR8J-Y#><$[V//>HT3Y$0[3IY15[,;3$DQ5=PS.M@A!2O:3
M*<XK1?D6<LT[&,2YN]V?8-*]BBSMKTD,^=_("/DS"B/_BJ+H'V$3]]><^G/2
M_?XWDGS^-4E^?^:MTZM*>(82^8M"7L*0]CS%B<^C3G@)6<1OR(E^&VW.3EK*
MLQCOMC ]5,K$D)VQ02M#/09::F78#6$4Y>ZATAI)4YFX]O($.H0MJ#8$8,K>
M3&',6Z0'ODB*_PO(HM[!)+:M+4FDJU[-2)=+Z(#0J<%F^KMKZ6QQT]9@I;E*
M1[6PU_:B9*%/P1BS=PG]D8+LG]%AWDA#T9M4%;Y(C?(Y6O6_IK?D-_24O$B3
M_I>4YTO7^N<8D_\"<_:SV(K%_13WRU3EBZXQE.*.:-2]"2@&D\D;2B5G,(64
M[FAB6H*(%/,KH=:/M$H?X3-V(K?O1VGU$?9W._F%N] 4^>.P).(IRZ?"7835
MJ,(F[)#;646UIQ6G6)HM#B$VX=MJA%1AL0I?49!%?DXBJMP$-/FQY*<=("GD
M':+W/T-F\#/HDI_'DOQS] D_H3#V1V3$B<]EKY%CWD)6E3^9K5'(!]/0+:HQ
M'S%B/E8BI!3MFA/EDIV\.2MQ/7D$U,1RL#2 $/L>HG4;B9>]2&K"7Z!/_4]T
M:YYEWO8"1]R_8:WT17H4/Z(L^4>8XJ7YN0.[*@*+1LSA$JT VZ7"?S<P/#+"
MY-0$H^.#]/9U>+N<NUU.+"8S.HT!E4*#+"??6ULV(RN=U*Q4DM*2B8Z)X:!_
M@#<H*/V99]+I<9>642W\;(V4^5E=@T?8[.IJC[#Q5LQZJ3&<2NAY+N76#&I*
M$J@Q"+M5\#'65*GF]E^A"?^/*"/_(QEA_X&$J+\@.NFG!&<\2XCR#2)L6XBL
M#""L*IR RG .E(6QVQG&5HNP[9H(WA'$\N7L('Z5ZL,S\;MY)GHGS\?LXMU$
M'S9$[^6]O1_QV?Y/V..[ ]^#!P@+#R4F-H;HN!C\@PZRSV\/^P-VXQ^VGZ H
M/\+B_4G*"B5?'8[>%$2Q=BL:[?L8S6]@=[Z+HWPCAM+/2"_ZD!UAS_/&]F?8
M%ODQN^.WLB=!'"/-1Q"N&!1"AYK&.QA<&&5T?IRAZ1$Z>CO$.'FPE9@%1E B
MS\T28YM,KM AG4%)J4M@ (>)<H>%^JH*%J:F.7_FG,!P5SEU]CS'UJ4&:$?I
M[N[#4UF%S5HBSD_XQKQ\$M-3B$V))2(UG*"L$/R4(6Q3'&"C8H<W4+S9O)<M
MEKWXN(,(J C%SQW,KA(_MEE]Q>>^?&[R88O1EYW60/Q*!99PQ!&BCR9 'HIO
MO!^^43X$1 ?@$^S#_H/[\#DHW@>)^Q(>[BTAD9&1*7"5$8?+18@8XPV;-_+N
MIO?9=F '/B$^'(PXR(%07WS$TB]68):D4,+E<<2HDPE7Q@NB'4^R.8^*P19&
M5V=8/K(JL*K B0V-Z'4Z\G)S*50HR%<4DI*51E1R++'9260:"X@SRPDVIG-0
MET2(,8UP<SHAAF1O<'B?,@+?HFCVY8437)3D+4M6UBWTM*,1MU0#MJ.+@>%Q
M;PDQ*5#<-S).KY"QZ056UDYP?/T\1XZ<X?#A,QP]>H$3)Z^*^W"%Y4-GO$%?
M*9M8"A8/C2QX \*K:V>]Y22.'+OTAR#Q<6^06)+O2TXLB[FWR.3D(8Y)P>3C
ME_^S(/'"PC&!*Z3ZQ*<X=?("=Z4F9;?N<?'"5=9/G/66E_BAU\B=V_>Y^L4-
ML<U#;Z+(G3MW!=:_*Y;WN'=/POR/O 'BQX\?_V=!XA]XQ3_DZX?C_'WEOR30
M?[>(;;\3VPJ1 L._^X-\YPT0/_V#?/VW0>)OOI6:?$N!<BDX?$^0^+OPS3U^
M+S4;^EJJ,WR-;QY<X>F]B]Z&=$_O7>$;J;S$73'^7ZQQ^?@@QV<\G%IT<O&P
MDVLGRKB\5L:5M4JN'J]F?='"H6F-P#HZ5F8LK,XZ.31?QO'Y<DXM57+ND(?+
M1ZNY?K*.2\>KF!HNIJ$F':,^2LR;  H*4X1?*<)L+J;$HL7C,-+IL=-=8:6W
MTLIPHYNQMBK&NNH9[FYFL*==^-0N.EL[J15\IJ:ZA?:N8?J%'G:/KE';N4Q%
MR[+ /BM8*U:$O5I&4[J"NGP-9<5A%)5KJ#R'!7Z4LHA/8ZDYAU6(I?HL)L]I
M=!4G43H.(S<O"S^U3+)NGFCU-!%>F22F:((DW93PH0L8JH_@:3]+6]=%>MK/
MTRG>F]/K2-HJP_\U,<??C:?@@(;JG$:L":5TFX:XM?2 ,_T7&;*/"TS<SL.C
M7W.B5QPS1$W&SEQR]JBP)'J8[SS#F;6'@@L^8GSN*EUC%V@:.$MUQRG*FT_B
MJ%O'6'X$E50:PS)/FF&*)/T$"3I))L7ZC+=41H9AF0S]*FG:59**5XA5+A!1
M,$UP[C@!LC'\L\<YF/5_!(FC"N>(4\][,Z@+'8?05QW%UGA28+,SE'6=IZSS
M/ XI:[+V"+:&8V)=C&/=(KDE/:3IZRATMJ&O[J:DL0]72Q^E+3VX6[NH;.\4
MY]Y)56L;I36UE%9Y<%>645KFH+34@LNA%3Y:19U4D[BEA(%N@<G&J@4G%KA\
MNIJYF2J6%VI879 :):H8ZBT0ZV9N7FGC[-%*!CIRJ1$XK;HLF9::3+J:LFCT
MQ-)8%LFLP!#'QG2<&#&PTJ9FOKZ F9H<IFM2F:D7TI3*9&,R<^V"0W3*Q?LL
MQCR)C)9',U43R6)3#(<[$CC>F\:ID3S.S!HY<ZB""R<:.7>\GO5E-T>G]9P:
M*^3JF)R[4[E\NUC([U<+N3V9SI71)"Y.I'%]+H]+ UF<\$2SK/5E-OUS)B(^
M9"CD??H3MC)0$,BP,8%QAYQQM[C&4A7]Y4H&JM5B'A@9:;'34^^@1OA*J7FJ
MW5U/Y_!ANL8OTC1TF?+V<Y34G\ D]-!0=1A=]2&O&&L/>[.^G:VG*!7;.)O/
M4](@=-Y;I_N$-XNXP+5"3LDBZ98YDJ0 L7:&J.)9I :'$8HYP@MG"1,2(06(
M%9.$%(P3E#]!4-XD@;))P<4GO"5+?(7X9(UQ(&M$+(<YF#U,L'R$&,6$T(]Y
M<FV+:,M6*6\X0<_P9>:6;W/JU&,>WT2,[55JDMLQ[W.B^+P86XB+ZZ-W.3=V
MBX':-<8'+M/1(\Z_3LQEYQR9DLX739&HGB%>-4>\T-OXX@7BB\12/2N6,^*X
MDT3DC1,FGR D9XH@H>>!.3/BG*4@\90W2!PIMHF7@L3:.;*,2\BM*]X2,E+M
M<JU'RM _@52N1EM]%'6E5+M\C5SG*GE"5&(;2^,Y7%V7L7:<IJA!_+YBA(RR
M'I(<S<18JH@TN(DRNH@Q.8DVVH28B!+8,**H@(C";&+RTDG.324[/YTB3:[
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M"4EQ^(?[XQOK3V!.!!$:<8WN/-+JU<15Y1+J3L//%L=N?3B;E8%\+!?8(OT
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M""'.$TE4:2@'-?O8%/>!((G[*1 VK-A>B$U@DLK*,AKK&Y@8'^/$^C$N7K[
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MR7V/<>K8&<Z=/,N)PT=8F)UAJ+]7OKM<Y+()O5Y#<G(D"=%>I$7MP*S:2E;
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M[<8OA%Z)W,X[49M9F["%G:KU^,2L(C3D/1+"WR,CZCT,JA4T%_G0+++-JO%
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M:[,P5F=CMJ=+7U1D9423F1(I,B"#\I)<FNHK&!\=8'EICN/'#G'TZ"$.'#S
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M5+S\*-CAAZ6N_R.!Y0] ]O\?^@'G_&%ZB2%>TLMS7^8D?B;TU$DOOA'P_[6
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M1,[G8C :G!'2^05Y(FO,J"UBU]C4!!OBV:$.8EM6$%O4_FQ3!^">$XZW-8;
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M-8/NVD@ZJT/I;8Q@=X^*J0$5^X83V+\WC4-3&2Q/I3.]-Y61O<ET3"12.9Y
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M<;\A*^SGA'G]-3MV_@4N(:\2:MQ&5'D(894Q^)?%$]J036BK#:\&&Y^8D_G
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M+N.:T92"ND5B7KDO?JFO<"[T5YSR_37G_%_&+^(T(=&7"8_Q(3(F@+@-#SP
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M^3$'D[T6)KM,(D8F.G1,]QJ9&[0P-U3)TIB3E<EJEL=MK$Q861TWLSIL9'5
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MPIR+U9)#B2:)U/00@L3G^<9<Q"OI"E<RO#B?<0EO30"QM:GD]I=2-&XB;]Q
MZF ^R8/98J/9Q/>G$-.31$RWLDTGLBV9L+IHPFK""+1<Q;_D%!&%IT@H.$VZ
M^BPY^9>P52;3TFR@MM9*8Z/;LWB<DA2^<>.&Q,.;[&SO<;A_(/%PE^6E!28G
M1VEK:_/,JM3IR]%('"Q09U)2G")V&(ZAZ J&PO,8BRY3)G&AO#2*"J,*1X52
M-UVNT>2FIZ^#H?%!YI;FV=S:9'U]T[-N0&=;'[4U35C--HP2ARR6"JS62LK-
M%9Y9Q84%Q>3EJRG0%Q)?',?5K,L<23W"Z_G'.&H\SUF'#UZU(82V2HSI315)
M([HKE?"V)*(Z4@AICL?'%8YO=20!-3&$U,<1UA!/;%,"*>(+4BO\,=3%XVZ7
MV*2/)3T[3'14;%:718FY&$M-);TC_0R/CS(P-.A)$+>V-HD_=M-04X=9+Z0R
MKTBD$+U@ V511K/=@+/93&6S1DA2!+X9K_-6["]X+?G7O*+Z Z_F'>&MDO.<
M$7)]0:Y_R>;'96G')8<WY^U>G+5?\;3K7%4@YVT!Q$@;<CHE-AI.<UKT[]C%
M?T-B\C^0F_,B>5FOH$I]B92DE\5_'!$].D]A4;2,L8;VEEH&NGL8'1AC<F2*
ML:%1!OO[Z>[J\(Q[79U3_%\5!KU&QC-+,$"F^*H<,LJD_\37A3JC"6^))Z9/
M8O>$4MJIA-SQ8I$BD4+2AW():4O JR&<BS(&YUVA'#?[<D3\]K$\B66Y_OCE
M1Q"E3B!=DT6QH82*B@JQIWI:&EJH<=5ZQMN@,WJ>-#&4:"G3Z\4FR@435: 3
MK)"2E<+50"].73[#.>\+7 ZXRM4@;[Q#? F+"R<J.89XP4DE=B,E;A/)EES.
M9?A[%MY])>T"KZ5?%OP41;PMC\PJ#>DFL9WB3-(+<\@K+I#KV#W)X=45!4_.
M4>M6ZIPWX*RII\+NPFQS4B(ZK\I6>V866ZU.#(9**FQNW/5MGAK%S<V]U-=W
M4E.CM*E)[*J9IN8.VGL':!\8$MWJ)-=01FEE%<V]PTS,;S UO^5)"D],K8M>
MS=/9/4%7WQ3]PW-,3*ZRNKC/UMIU]G=N"3Y^Q,-'[_'X[?=Y\/ =S^QA)4F\
MNK;-W7N/!4._*_CUID=NWKCK6<#YG7?>Y].GGWE*PRFEXI0%Z9X^?>IY*O#Y
MTX'*PG7/D\3_OPCA7RI9_(F[_+?(/Y'L_[HDL:><Q)\EB96$\0\BSQ/'0O*5
MVI(BRBKURGMEI?KOO_U$R,T'?//Y;9[<F>9@H9:U?ATK'?DLMF8PUY3(9%T,
M S7A=%4%T6;WHZ7*EPYW('T-$7371-'A"*/3'LA0C1^+W1%<7\CFW>N5O'/+
MQ=V#*JYOVME<,#,_861ZK%PX414+ZS4,+%O1=B026^U#8D\T<:,2.V9S25PU
MDK)90>Z^&]/];JK>'<'UT03.3R:I^DCDW4FJ'TWCOC=/W;5E&K<WZ3N\3^?Z
M?1R#NY1W;&%HWD+7J"2!MG&V7Z>C]Q[M38=H,]J(.)E+PKE",JYHT48ZZ#)-
ML-1QR,'DV]R<?Y_5WAOTV6=P%PCVKIBBSS*).LQ,0_DX2Y-/6%EYRO#T>S0/
MW,?5>P=;QW7,+0<8F@[0U.R2;U=F:FZ0:E@B23M/HFZ!)-TJ*4I"5R12LT!D
MR2*Q^E4B-'//RTAHYHDN7B):F3DL$E.\3$+INGQFDQ2EWG#9.HE*60G3.@FF
M->*,J\09UD@TRG5,RO64ZQY07'T-;:V2L+Z.L>D&QM;;T@\W*'5?H]BQ3V'E
M#H456Q2+:*MV!(/N27PXD#[:I:5OEY&)?>&M!US;WN;!P3)O7YOBDX=3?/[>
M)(]N=["T8*5GJ)B^11LM6_547^O ]D"XZ=O]Z!]U47*OA=*[C93><I._5T'V
MCI'L[5)R-\5OSV>0,QR+NC,$?5LPU9WA= _%,SZ=SN)2-AO+V>PN9G-[-9=W
M]@OYY%8A'][(YL%."O<V5=S9R.?F>@F'JR9V%BRL39E9&#$RWEU(C^#!9D<@
MM>9+U)DOT.WR9Z0I@E'A$CW5$?0+1QNLC:;+&2@Z[$VKS8M.FS^]E;[TF\_1
M;WR5M=J3W.V^PN,^+^ZVGF:OYA66K+]DMOSOF3#\9P9+_X[NDI_38_@]PX)I
MIQLNLBBX;*G]$I,-9YAI]V%M+(&UZ5R69PS,33J8&G<S/M[ V$2#]&T]PV/U
M#(U*/!QWTC*BP]J;3FY+!*K!1#+F<TE>5).Q(O%M38]ZW8AZLXPBZ4?C#3?&
MPP;*]X6;[_5@6^ND<JX+^]0(;>O[=&T\H''F'E7]M["T7:.L09E)O"5ZL(U)
M=+.B\R;FCIOHFJ]1Y-XCQ[9%FNA1HE;1M>=E3L+S%@C+D6WN M'J)>)$!Y5%
M$5,L:YYR$]G5N^15'Y+G5$I-*#6)M\FQ;E)0N8F^>@='PS4Z.^\SWO6(\LQ>
M<@.MZ"+MN%0--*@;J2^NI<?:1;^]CVYK+SV67IJ+VZA,<J$.*A/,6TM+]3QC
MH_<%ZSS"V78=C5-)ZJZ2;EXA49E];U)F%*^2(?>?5;5-OE*ZI?Z \J:;V%KN
M4BE2T7I'[/&6)TE<6O.\YG=NQ3:9EDU4(LI]%U8IM8SW/+/^'>T'- [<I&?Z
M 1,;[[%T[2-V[GS(M7MO<^O6-1[=6.;;!PMPHY_OYRKXN#:.O;SCS"2_S&J9
M/U.5$?34)-$UK*-QH1+[:A6Z-2?JC6I4LDV<KR1JPD#X2!$1PK/#>P0;-X41
MXKA"<-EI(HUG2;7XD&[PHM060;M@[ >/)GCGR10KBP[&AC7T"-]MK0O'9;E(
MG?6,Z/0Y1NHO,-MRD97.RZQW7^7&1 SOK!7PP;:!CPXJ^51L\)O'K7Q^Q\4[
M6SINSF2PT1?-[D@*GXEO_O'S.?CN@!^>;O/#E[+]^AK??[;/LT_V^>;I#;[[
MZC'??_.1YX?$[[_[BA^_^\8C/WPO\47BS3.1;WZ0[8_?\IW\DVCTSV+33_(O
MQ;;_(_*OK_^^K[_HF<3_J#2*"%A2$L:>Z>U_-HOXJR^^\"2)O_I"68A!WG_Y
M#9]__C6??O*%)UG\[CL?<;!_F\W-Z^*\%^GI&>/6[7>Y__ C ;P//'6'WWWO
M([:V]^78$\\*S7(9/I/O>/SV>Y[%.=YYYP.>//F ^_??YO#:;0$-6\S,+'EJ
M&&]M'@K)?<#-FX_8V[O-TM(V(Z.+S"]L"RF]*=][BX7%'7F_)81@E^'A*08'
M)IB?V^#F]8?L[=QF8GQ9@-0VN[MW/ N([!_>86)FT5-7KLKEIJS<XEEEN[VC
MA[;6+D^IB=J&5FRU]>@<=O(M9935N:CNEH#2V8BVOHI\5P6%M3;4C@J*;#;*
MJFLIKVK 8F^BTM&"S2&?%[':&X44B9.S.C!65Y-46DA(03H!FE0N%,=P2A/)
M:7T4Y\OB"'!F$=NB):%)1U*CGE0157T9J78-\?H<XH3L992JA>0:L+F<M'6T
M,S(RRLSTK/35/'/SR@RQ-:9G%^CL&\#JK*&TW$RA7DN104.)18NNVHBNP41.
MC88D9S[1KER"JE1<LB9R3!_!47T8;^F".*+QX;7"J[PJ\EJA#V_F^W)9'49X
M?ASA:5%$)463DJ'48S50;K-BM)JEG4(*3=)71B-:C<:3((M+C)=S8_&/#>9<
M^%6.A)SC3*:0Y)((WBCRYU6]OR?A^Z8MC!/V4"'0X5P6TG_)%<_EVF2\F]*Y
M[$[T+&QW28X?=X3PNM6/5TW>O*)3[N\*Q_)]""F-(RPWAJ"$,.+3$DG+2"<K
M.YO"DA*Y1Q,6JQ6[W&=#70W='6T,]/?1UMXNI%'(H:64/%TV<>IXKJ3YXUT0
MAJ\ADLO& .F7 "Y7!W.U,8*KS5%<;8J5>THFN".;> %WF=,&L@7 Y(CDRG[&
MA(;8@1P"VI+D,]&<=?IQW'2>D]JS7"J^1&1IJ(Q!,69'&99R$RY'-9WM'4(@
MQUE8F6=M1TD2;[*ZN<Z. ,O#W0,.]PY97!#;ZNW&Z;)AK= **2^DVE5$1Y>>
MX4D+PP+RK!T9I$G_A%J]\7<&X%,7BF]S-)&]<ER9,3971N:8SI,@5D^6H9XR
MD#=12N:PFJ2N#!):$TD1$)A3&TY);2B66@&> @[S52\2$_@S<E*.XBB/HZFF
MB IC-C93(59C,9J\; IRLE'GYI O^WI=B9!M*U4UU3BJ'4*N'1*4JQGM<S+<
M9:2]+ITZ>S15IA J]2$X1/=MQC3*2[/0%^506I1+06$6:9F))*BBB5:%X9?L
MC5]6(($ET?AK(XBPQ8N-9*#JR"*O2T5Q=SKZWE1*VR(HKO,1,'.),A%;K1>N
M)G\!XBDT=26057J*Y-)SA&LN<"GG-!<+KG"Y-) +AG#>T@3S>E$P;VK".5$<
MQ4EU.">S@CBO"B(H/XI48SHE,G;6!B/.1A/5M08<8IOFLCQ*"^5OA<KB@MGD
MJU7D%V21DY])2FH\B:+_B4GQGG(3Z2+9&:D4Y:LHR(VG6*Y1K@^GLBP(N\E7
MQ)MJLP\-,HYM[EBLNDOHU$<QE1S%:CJ!PWF.RMH+)!;^$9_TWW,A\RW.Y5_D
MA%(ON=!7[#98;"*$%W."^6-.""_+]LV\8$X5A'(Z6W19^C#1D"PZ6$!=2QG=
MW58&NLH9;-<SU%9"=WT.;HM2;N DE;JW:'0<%P)[AEK+,70Y+Y,8]BO"_%XB
MU/\4T1%^I*;&DIF;1GI^.M$9T82DAA*4%H)7<B"74@*XDA&(K[0Q6!M-E#F!
M-%<:JNHD5/8H<NP1%#C"*:@((;/4B\2LLX3%'L7+_W6\_(X1&'R)J*@0(B+#
M"0L/)RHRFBS1,T.YXO_L-+<WTM?7S7!WO]Q_)[TM]70V5](J?K/&D8FA2+XW
M_DV2@W]!1M!?HXG[.\SI_X"K\+="<$[3UW0.I^,(V86_(BGO=R04'"%$^C,\
M[PH)VAC239GD.TJ%%%31-BW76!YC8FV2^>UYIA<G&1T;8G"PEXZV%AIJ7;BK
M*["8BC";<JFN*J;"G$EQ410I6;Z>Q'B2*9HP0R@!QF BQ+]E#A2AF2ZG:-)$
M]E ).2/%9(\5DCF:1TI_.BD#8K=#623V9A+5FD)P70Q^U6%X5_KA9;R(M_HX
MD45G4>E]Q,>'8#(G87<44%U=3D-#C:?6]]+B/-</#[A_YPYW;MWAWIU[7#LX
ME'@Q0W]_/_4-391+;-(H"X>I"\G/5Q8:3,4@_K3"%$&-V*FM/(R2 C^TA>'H
M-$D8]'GB@XRXQ9>V2@QJZ^ZFLT<I.3# ]-2,@/ )>COZ:&]NI[FQ6>ZED1IW
MK?@N%W:G ZNMPB.F"A.%905DE*415!3(:_&O\6+:Z[Q:=()CY1>YX/ CL#&*
MV)XTHCJ2"1?_%-:22'B[^-^6>+QK([@BA/5251B7Q5Z\JD*(K(\AHR4!E<V/
MHLH RD3/2LOB2<\,(2;>GYR")+2F APU5KI[.NCNZJ2UI9FFQGJQY0K*)7Y9
M397H2X1,YFDHR%:3K\QX+LZ7V*ZC1FRFOKN$JI9D5(8S>&7\AM?C?\8?DW[.
MBUE_Y'7-28X:+W'"[,5)ZU5.55[AM,@9D;-"I,_9?#WE&[QE'..E'=G2MAAE
M=G'\+WGIW+_EZ,7_D2M^_X[(Z)^1G?42N=FOD9=[7'RJ'U6.=-I:S P/M$H?
M#S [-<O&ZC;S$O?')L89'!FDK:L5=[U+,(C$9*,6C::  J66LC%/^CF=2$,T
M 95A^-2$X-\<25Q_)NFB<UGC11('\DGMRR*F(X6 )HEU$C\NND.XX KEC"V8
MXT8_WE1+.PH#\2J,P%L52DQ>$KFE^>CU.LQ&$^4&$UJMCL)BI0Y[H?BX G(S
M)2[DJ]$:]93+?2D_6)^^<H8CY][B];-'.'+^34[YG.:<_WG.!5S@7- E?&(#
MB5&G"('6DE21S]4BB:6B?\<*@SQ/=KR0<A[_LB2*VBQHFZWD68M)$1^D+ *;
MGIZ.IE!#@[N)@>XA^D7J:EM$7UNHJ6^ERMV(T6*C6%M&<8D!O<$LXZLG,T/:
M8;#@JFFBM:V7]O9!6EK$1NJZ<%6WT%C?24MKKV"=*@H-Y12;*R3&U%$A6+&F
MO9?!J65&IE89FUYG:_<NJQLW&)U<E3$9H[MOZGF2>&F/Y?DM&;L5P:7B1Z:7
M!+>MRA@*;I/]D5%EP<<)#PY^\N1#'CU\5S#V!WSXP2<\_529)?R=ITR%<,5_
M3!(K"]0IY%%Y_?"#LK;(\]E)/\J)BCR?^:'(3P13.?,Y!_A+>_TY;_D_*O\E
MV?XG^2<R_CQ)_%P\]8@54>H1_U23^$_E)[[]5JD'_37/OOU*SA'QO%>2QA_Q
MY/X*>TM-K SJF)08/EL5Q$YC&!NUWLS:).[H7Z,V]S<X,G]%5=X?J-&^1K7N
M=2J+7L&2]QK6O#>H*3W&6+TWF\/1W%I1\]&#5CY]=Y0/GTSPP=L3/+DWRH/;
M8SR\O\##MU>Y^V2)[7O#U"BESMQAQ+5*O.R+)6HL@_B98A+G#:A6*RG>:Z#T
M6C/E#WIQ/9W&\=$$%6^/8+X]A/5@!/O6!+5K\PP<WJ1?6<!K>!=[QR;ES9N4
M-3Y_E-S=>4/PU$/QG3>IMDQCRNN@M6*6+L<\S98)W+H!:G1]-)E'&'(OL3OZ
M@/L+'[+5<XTNW3!ET57D!1CHL,^QOO@A\TL?,C#]-HU#=ZCJOBXX]H"RMCVT
M37L45&^37;F%RKQ%JEY9,&[)LVA<LG:=%/TF*<8MXG6KQ.J6B1.)+5T@3CLO
MQQ9)*%TAL4215>%=:Y[STTT[I)LW235OD**(98.D\G5/'>)X_9HGZ9Q>MDFV
M98<"^QZEKGT,=0?2[D/,+=<QM]^BK/FF'+LF&&H?K6.'4ONV)T%L=.]B;=K'
MV7F-NKY]NL?VF5G89VMCFQL;<SS>'.+9_7%X?Q+>&^*+?1>[/5D,.:*8[BNB
M;]J">\6)3<;(>*V!XL,:LK?MY.[8R-NI('/=2.:&5K;%9"V+/Q]+(J,[G-S6
M8(RM850VA6%S!^)N"I=XG,#X:"9KLT5<6]9R9UW#[545=]:2>;"5(I+&P^TL
M'NT4<&^CA+OK9=Q9M7)]WLJN<(.UH4+FNI.8Z8ADOC."M?X8MH:3V!Y1L3ZH
M9F-8R]JPGIG>(B9["ICJD?/[-"SW%;#1E<)N2R!/AL/X?"Z:SV;#>3+DQ;7F
MHRP[?LMLY2^8L_V"1>=O6';_D;7&-]EH/\=VG^C[@ ]+/9<9:SK+7$\@.],9
MK(PIB^6JF1S2,C)0SM!@A?A))S-S#>(S:QD>M-+2EN^)R8;F"+(; DCOBB!M
M+(7TN5Q4"T7D+)52N&80T5,L6]V&&=-Z)>95!Y8E%];Y.BQ335C&NFA<6J-C
M[3;-<W>I'KB)I>W ,T-66[N)L5'&N.,&ULZ;F-IOBHY>I\B]3ZY]APS1IR1%
M#XL7B5)FL.?.$YX]1X1(3,X"\>HECSXF*;.)*];)<&R16;5'INB0RE/7>-U3
MPB&[?!6U=16S?&]C^SWZ>Q[C-,[CR!NBK6B,JH0&7&GU#%J'V1X0W9J]SL'4
M(=?&K['>OD6/?I34RT64I+H9[KW&R,1#V@;N2YRZ1J%<1[F&,NLY4;]$O&&9
M1-,J:14;@LF5.LE;%-7N891SK4TWJ1"Q2!O+F@[1U^]3XMH5N]@FQY,D5GY,
MV?:47BFN/D!?=XBE^1!W]PW:1NXRM/B$Y9M?L?WP&[;O?,CJ[G66%Z?9G&CC
MP;B+CP8-?-R0RL/"\RP'_!VC9_\].[$OLIEQC(G<,S257)7XFT;#E)[2"2TY
MLR92Y\J)F= 1,5I,V& >H=VIA+0*[Z\.(,!PEM#2T\)O+I%O#21?[TNQWI_*
MRBCZNPH9[%+34!U-364(;EL(M?90*HU7,)><IK+D.+6FTW2(?QZM.\=6?R!W
M9F)X=S6=S_;4?'%0RI>'1I[=M/#9KH9WYE.X.13&<L-%YFHO<3"8P+UE/1_?
M:84O%B74;DNPVH7O1'Z\*9'KH<@[_/CMAWS_[#-/DAB)&7B2Q,_X3IE%+/*-
M$K]%OOOQ.WZ0V/W/X]2_)HC_$E]_$4GB_ST%\1Q3,K9_EAS^*4&LS")^GB3^
MTC.;^-G7WWB.?R7'/O_\*T]MX@\_^)3'C][CQO7[K*X^7[1N;&R!W;U[[![<
M9WOOEN=1NB<"<M?6MSV/T'TFGU5JK[WS[H=<OW'74W?MN^]_%+#U ^_+]]V[
M_S8[N]=8$?*SN7GH6>3NV3/DFC_P^/''\K<[$ARVF!0@_KSNFY#U\1665P[8
MVKXI 'N:KJYA)L86N7O['?;W[@IYG69N;IL]N:][]][CB7SGSOY->OJ'J*UK
MH-+FP%Y5+:1Q@*:F=AR.&AK;NBAW29 N,Y!C*</<7$_]4!_NP2Y*ZJI(M^A1
M"5'.M@K)M]DQ*36,72U45(DH,XBKVD1:L=@:4)>4H]:9/$GB?+N9&$,>5_)C
M.5L0R8FB,$YHA.2:$PAPJ BMSB.JNH"XZB(2[(5R;A9AZB2",V((2XTC/2\+
M@\E C1#NGJYNIB8F69Q;9'UMPU,+<F?W4 C* 6,S\YA=;B'AY>1KM11I-5BJ
MK%0W5^-H$R#2586^HX*L9AWI[7HB&PJX:$WTE)TX8X[B:*D_1[7^O%GBSY%B
M?\YHPPC0Q1-?DD:R.HT459*0UTQ:FQIH;I*V5U@IU99Z'K,WF4QDY^20D)Q$
M1%P,H?%17 GWY7C >5X/.L/9C #/ZN1OE03QABF$URI#>54<]S%[&.><<FY-
M/%?<B4)24_!I3.52=0SGY6]G[4&\5>'#J^67>,EP@9=+1=3G.))]B<#26$)R
M8_"+"R-&6>@L,Y.,G%RR"PO1&/28K&8J;&9/\J2GIX/^01GKCG8JJNT4&PM(
MSD\B(#68D_%7N%P@)-H4S04AQ4KMR(O.("[71W*I(9J+]0E<JDWC:KV*H+9<
MX@>+2!LO0359(J"MB#@AV8$MTH_N2"[4AG/<YLOKNK,<+3G/)8TOD=I8<LOS
MT.@UZ$MT.,PV6AH:16\'F%\1T+PC!'-_AZV]?1G/0_:VKW,HNCHS.T]K1ROV
MZ@K,%5J,)C7&\BS1]7*F9IU"4,LIJTL@S>I/8I40[+IPHMOBB.E-)WX@F_0Q
M#;G3960*N,L9%: T4T[)7!E%LUK/[+'D7A5Q[<G$-<<15Q-&LMV?[ IO#!57
M24O^'1'^?T5AUG$J],'8C'&4J",P:%(IU^5C*"E"J]&BUY5AM5;0W-KJ>81[
M;FF1F?E9(<<CC YU,372QMQ$(U.C=AIJTBC3^%"<?1:S-E D"JW8A"8W$8TZ
ME:+B='(+4TC.C2)<%8!?AI< @$@2:G)(:2T@K4?Z77D\7X""LIA59G\FA:.Y
MJ(?24+6'DU!]F73G5?*J?07H!] I?^L=E7NM\$-C\29-=QZ?M-?P4AW%MT#T
MQQ#,%7T(%_3A7);V!9:G$JQ/(;@XD9B2='3N<CHG>AB9'V9D9I#^X4YZ.IMH
M<MNQE952FB_WJXI%E1%-9I:2E(HE.4WN-RF4Y)0(5*I$C[VHTI+)3$M 6ZRB
MM"@>DSZ6IMH,ZJJBJ3+[82^[0FVE'_6V8&JLP30X(FBIB:*M-H*V^E ZA0RT
M"2DHUA\5?_ "YV/_R/FTDQS//,NKJM.\GG.1-_.\.)[OSTEU$*?S@KB@#B%
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M\<%>$9\<ZOAX5\?[ZUK>7]7SP:J6=Q=R>6<^G2=S23R<BN'.6!2W1A.Y.U7
M_3D3]Q:KN+G2P.%R$P=+S=Q8;I'OJ^6Q_.V#\0P^&HWEPXE8WIU)9*<G@(6F
M2RPV7V&Y_0IK'1=9;SO%4N.;+#<?9;/K')M]EUGLN<1(RUGZ&L[16'$*1^E)
MZLP^-#O":77%TER32)TS"9<]D6I[ DYIJ]WL1[G$38/Y+%K'64K<ERAL]B&O
M/9BL+L'<W4GD#V2C'2_ .)Z#>52%?32+ALD"NA>,C&Q4,;951\]B'>[!&FH&
MNFD<7:!S^CK-P[>IZ;Y%9<LU#.XM=.Y-X?R[(GOHZO?0B&X45.^18]_U_/CP
M3TGB^>=)XLQ9(C)FB$B?(BISAIB\.6**%XC5+1)O6B;1LDJ">8F$L@42= LD
MEBZ05#(O,HM*OX"F<@-[PPWZ!L2V!C]BRGV;X@ 'N5=TU.6V,^&:9[UKBXWN
M399:5NC0]6).<%%3T,](^R'+JY_0.7P?NY+0=NR1I_Q(8M@0/5\E7K-$7(G<
MAVZ)Q+(5DLTKI%6([E>M"\_?1B^Z;5!J%+NW*:W90E/]O%YR?L4&.=+63+'+
M+-LN^<X#M/77/3^>.#INT3!TCS:Q__;)N]0-[4E\7L'5.45K]RB#/=U,M[E9
MJ"IB61?'<J87<^%'6 W\ P=^O^+>E;_A_I6_XL#W9TQ'_)KAO)-TV$*H$/Q3
MV*XBO4-%8FL*X8)+@FO""!5N'F3W)<ATB2C!PR4U,?1,F=B_T<?"G(O.QCQL
M@AUTV><I4U^@OB*4B6YE$5 KFXK>[O2PM]W-PHQ3]"J>2OUEFH23*"5^WM]1
M\\%&.N\OQ_/Q4@)/EY/X="F1#V>CN=OGS6SE*PSI_D!_R1\9T+W"9,4)EFHO
ML][JQV9G,#N]41R,IG)C7L.CO1J>/A[GQR^OP??OP+,/13Z7H/(,)0&F+%[G
MF4FL)(R5.*3DX/Z4%/XOY5^*:___Y%]?_]>]_F+*3?Q+BJ.()TFL;'X0 *4H
MYD\*ZMDJP$EYO.U[$5'.?U32Y]^IO)2GV90%.)Z\K92=N"/D98O9Z34F!5PL
M+&SRSCM//8G>PVMW&9^89VQ<J5UXR">??"%@3+DOL1'Y#F41NX\__9KWY-Q;
MMY]P</B ^P\^X)-/G_'5U\C?GK&R?LCXE)#T@P<LK5YC=GZ7Y;5K DQD*\![
M1ZX_-;,B@&6+F[<?,S,C]S&YPL;&#=;D?$7V=N\*\/Y2KO\E^T+\#64F<@O4
MF"JLU+8T8Z^IE4!;@;'207EM+9;6)LRMC90UUF*HJ\'46(=1Q-321%5?+];6
M=@$-+3C:NK&Z6RAW-&*K;O4DAYTU(K6MV-U-GD7K"LK+!:SH""]2<28EE+.9
M87B5)A!BR\3'G(IW60J!%M7S6<3B1"-T*B[%!W$Y0IQ@;"AQ*0EDY611HM%@
M*;=X%H89'1EC<V-;2,4^6SN[;&QN,S8QA=-=3UI.+@GI*C)R<]%HM9X2 /7-
M=70/=3.Q/,GT]AS#FU-T+ [2O#A X_(@NMYJLNITI"J):FL6,6:Y'TN6!+-<
M"ET&;*U.;'5VRBM-GD=SZVMJ:*RMHTKZJZB@6$B:G)^41&1"'*%Q47+?803$
MA^(=%\CI\$O\T>]-7HXXR5NJJYPL#>9-8S!O6$(X5A7%I;HDO.M3A) F>&83
M7W1&<LH:*.=<Y8CQ$D=,EWG)<);?E9S@UP5'^5W>,?Z8+41< D" D-;PPEA"
M55%$9<21D)6"JC 7?469 "8KE8Y*:JH=0@8MF,KTGGJQ!=HB,HMS2,Q)(CP]
M N]D?TXE7^5<81 7RD(Y5>[G24"<<05S4N242\;,)02Y6DE@)W/5G8Q/72+^
M#0D$-<43VAQ/F!!MO[I(SE7Z>V:WO6Z\R(LEIW@I[P3>VA !$KFHBC/)$>)>
ME%M >:D1F]F*RU,^I$7 0#_3LW,>W;Q^<(N-E6V&^H9IK&N4<US4-=5366.3
M=FDI,>5CMJLQ6%-)U_B3:@XD0>XWW.%'2'4P0>YP@AJBB>O)(FNBE,*%<C3S
MY6@7+>B7K90NFBB:UY,]62R@4T502SR^M1'XR6>#[?Y$2."-S'^#;,T)\M5'
M\;OR'SESY'_FZJF_]21T*XW9-+LKZ>EL$P(\PI3<]\KZ&AL[6ZSO;+*\L2+O
ME\7>UX4(;PMY&*>_OX6V]BKJ&W34UZIIKLVBM3:31F<J#E,,Q;D^9*5>(EOE
MB\&2(J DA:0* <2N1&(;TDCHS"5[7$_^=!GY4WIRQTO)F]#*OB(EY$RI21O-
M(+8KCO"&*,*K(X@7@*FI3Z*J)1VW@ UG50B5YBN8C.?0Z$^C-IXGW^)/054R
MQ;6%Z%O,N(:;Z%\>9?%@C34E(;FY*B1(*7.SP,KJJOB254:'^FD3>ZJM%MVR
MFP2PZG!8B[!;<S$;$BDM"/8DO_/3SU&0<1%M7@ F330V4P:U#@TM=65TM5D8
MZ+$R/&!E8L3&[%@5@YUE=#24T%9?2D];&9TM6NI=F;@<\?1U9+ VJZ&K*5*N
M<Q6M_@*9ZA,DY1XC-N<H02FO$IYU4D"@/^EED>14IE-26XJ]NYJ^^1$6=M>9
MD[;,K2TSNS#/Y)22Z)QF>FJ*H<$^NKI::&RTX[ 54UF>2H4Q2H!3$#6F8#K%
M+J?ZBACK-]#39<#5J"%#&TV,)ISDRF1B[?$D""G)[%%3-*9',VFB8,Q(SK".
M;&4&^XB6O*$25#UYQ+<D$U8;1G"5+R'6BX1JCQ)?>H)L 6F&\C#<U5FB6Z54
M6TNHMI73TEC/Q/@DZ^+K]@\.19]V/;.(5^8DGBRNLK4@XS,YRT!O'PWU;AQ5
MRI,#I909593K$G 8(G$9_6BR7*%=B+BRH*$F^7\A/?1_("OFWY.5\'<49+V)
MJRJ)AD;I[T8;3:T-C$Y.LKFSS\&U6UR[=LTS(_=@;XM]D0WIQ['),1I;V\0.
MJR@Q&,3/"KG3%J K47EFVY<6!Z(UAP@0OTR X0+^-A_\7$&$-,42VZ,B;2"/
MW-$2"B?U9 ZJ2>W-(JD[@[C6!&+%G\0T)1(NI#^X.I: JFA\Q$]>%M"L)(DO
M&*]PL>0B_B5>I)CB2"J,)C$KBORB;"S6,FIKJVBLKZ;6[:"AP4U/?P\] P-T
M]"@+="FSGQMP.FO$'FH\"YXV-C;(,>5'M$KL]A*,NF0*<X+(3KE,:MQ9HL-/
M$!EQ@?BD,'(+LZET.NCJ&4!9*%998&MZ:HZVE@Z:&YIIJ*W'7%:.0:L749XR
M*$5=F$=>88[$5RT:0S%EE48:N^L)2/#F-Z=_SFNA+_''R!=Y,?D-CFK.<:["
MFZLU0>)C0_ 2G^1=%8R/4RDK$<H5L>&+CF"/?SY;%< 59R"AM:$DNH485GL+
M63Q/A>,<3OM%JBR^XE?.D1I_G.P,+QF3.,R*[S1K/75R3483ZKP"LC*R24M)
M)SY6^EVI(1X;35AL.%&ID61JTS#6%Y.J#^=<Y!_X_9G_)Q%YKZ-MBD#;(;$J
M\R7>C/L%5PM>YWS!:YPN?I.3AM.<LESD3)4W%]S^7&T0O]H>2T*_"M5H 1E#
M:I)[LTGLRB"^/84X\;_QXK,B;%Z$F<Z2:+TD,>GW!":\2$UK#FV=1MK;*NGO
M:61]=8$[=V[SX.%#'KW]-O<>/N#@QG7/C.*V[B[!,Q7B&\HH+"H1S)!#0FHB
MT>GB#]7A7-7X<E9_A=.F*YPU>W/)%H"W*XQ T<G0=HF%'<F$2!P+:HS%KS::
MR]5A(N%<J1;=<\3@[U1P2C)>6:'X)H<0$A].;)SH7ER<9\9_>&2$IW9X3&(<
M48(!0F,C2"W,Q-+NI+3%0J0AA3>BS_!JS"G>2KK N2Q??$KD^D8A?N5Q1%0)
M":Q))4#B[,6*2+G/4([K@WFMR)=7\KQY,>,ROPP_CG=^C)!T,Y8&!P;!(P7%
M!61G9Y&;G4.)M-MFL:.7^%JBT6&S58D-M-+<W.%9G+A.XFE#O?@Z.59EJ\%>
MX1+;K\>H-<MG#:+[5AQVT6%+#<4:"W;!=36U'2)=-+8-TM@^B+NEE^KF7FI;
M^VGN&J&K?\I3?[BK=Y+^H3G/8G7*#.+FMB&&QY8$KPHV&UT4WW&/QX\^YL;U
M!ZRO[3,_O^Y9;^/]]S_CPP^_D/BRQ=+R!@<2_Y69Q!]_]#F??Z;4Q'V.MY5$
ML5)V0EFT3DD4/Z]'_!S(*TEB)3G\S3=?RSE*DOAY@EC^_^-+P?T_D<V?WO^T
M_Y?P^NE^_UOD!Y'OI1.%BLN_;_GNQW]*$O^H<!TEV2Z$Y =%OE4FRCQ/&@LE
MXIG\[1LA]=]X9A$KBPT]7W#(,Y/XV==\_?7G?/OENWSZSB;O7>_FW543=WK#
MN=URCL?=Y]FM/<:\[0UF*HXP5W62E?J+;'?XL-_KSVZ?/ZM=/HS7763(?8FQ
MY@#F^Q*XM5'.%^^-\,-7AWS\_@[[.\/,3CH8&3 PV&>@O\]"7U\%0X(;%C?;
M:!PH(4_\8V*U+S%U/D3)]T2V1Q WD$+R>#ZITR4DS>A)F#.1N%A)QJ:;W-UZ
M"G?J,&S64[%0AWO<S<!<-[/+$RPLSC$X.$9+ZQ U#2,X&Z:H:E[$U;%)8_]U
MVD?OT#-QG\'I1PQ,/J1__ $C4X^9F'J;B;%'#'7?I-6U@KMLG#KM*):D9HH#
M[10$.VBK7&%F[!VZ!^]3UW>+RJY#]&W[:%IV43=NDUVSZ:G=JI2%2#"L$E^R
M1'SQ(@F:19)*5TG1KY-6MHG*_+PNJC*;,Z]JFSQE4;"J37DO8ML4#+1%CI+8
MLFZ0;=D@4Q'Y3M6?)*ULG62=DH!>)+EDD339SRY?1UVQ18E\GUY) C?L86[:
MI[SI0'C@+GKW[O,$FFL'7<TVIOIM[.W[U/0>T#B\3\_L=7HF-VGO'Z>WMX?Q
MKEKFFO3,5R:R90KBAO8B.VDOL1K\,Y9]_XK=^#^PE/8J ]E':3)<P2Y\0CNJ
M)G.R2,:MD(0Q-0DR?K%CF40.)1#>*7RP,8#\EDBJA[)I%7S5T6N@J:E(_%R.
MQ'5E$D(@%H./8*@@FFNB<(BOK[)<I4UBY&A[''.]2:P,)K,[I>+!6@$?[VOY
M=*>$IYM%?+J:RT?S*7RTD,CCB0B6W2=9K#G)5LM5;O:$\6 DF<?3^3Q:-')O
MT<R]A0H>+]EX(ASCG8E\WNZ-X$E_"/?Z0MGIBF)G*(7MT6PVAW/9FRA@?R*'
M[<$$ECM#F&OQ85J^=[K=BRFQ@9'6J]24O4F%YBC593[T-&0PTJ5AN%O'8)>.
MCL8"P<^I5)9%8#7X"]:^+'[^E/CX2[@;?*AT7\!0<]Z3+-;4^U(D,5K3FH2A
M0_!L9P*N[EA:^I,9',]C;4/N^Z'8ZI,!KE]K8VS,24=7(YV]8_+W?;J&;]'8
M<Q=GVVTJ&P^Q*C/*FPXI;U1*4.Q1(F.OKE86.=SV_."0I%_UU!Z.RE_TE)F(
MR)PC4B1"-4-$UC01N2(%,T1J9HG6SA%C6!"9)T8G^Z6R+9XEIG"&N,)9$@JG
MR= OH*W:I;'CD=C\!XRU/J TO@E-I)/>\DENC3YBLVV/]N(NUIJWZ2L;HS2R
MDD;#.#/]]UA=_HS.@?M8:P\HL&R39=SRS*Q/TJZ)/2T+=E^4ZRX0I]3[-JV0
M9ETCR[;NJ0->Y-A&(_I?+#98++94++:4;UDCURQ_K]A^;E=5.Q35'F)HNDY%
MQRU<<LW6V7>I';N#J76%JNX-W-VKU';,""X1_M<SQ*3@D[DF%TO59:Q9U*R6
M)+%7$,DMU56N!?Z&Z]Y_P[;/7S/L]5>,I+Y&G\$;2WD !16A9%2*;ROW)ZDR
MD'C!+>'E7@0K/ZSKSY%8=HGFR1+V'PSRWD>;/+J_R,ZJV%YO);TMI8SWF=A=
M:>3^]4'>>;C(N^_L\OY[AWSTT34>/EB@O5E-A<&7&N$(<^)[W]XS\NWC:C[;
M+^7MV52N]8:PUG2%C39O#@;"N#>5),>SN#68Q%C%.7IUK]&C?9$!PXM,6%YG
MWGE"?/P%3])XIR^.&Y-J[J[8^/#6('QV [[]V#.3^$>EE)'$DF<_/*])_,./
MSW-NGOS;GW)N?R[_4ES[KY%_??U?\_J+JTG\OZ<XRKZB@/]4DTM9O.$Y@'K^
MF-I/\OQS'E"J_!?P],W7/PB8?<J=VX\\-83G9]>9F1+2OK@MQ/H!MVZ]+:3^
M#M/3:\S,;'CV/Q/0*[8A0/9'G@GH_4*^XY//ON6#C[_AYIUWV=R^[:GK]N#1
M1W+L*QX\_HB1B24Z^R99W[[#[,*^R!Z[^P\\Y2>65@^X_^A#YA8WF)I=87OO
M)I-3RT)@E07O]EF8WQ%B=8W;-Y_P].FWGNN^\][[ N*[T)G**-9K);BX**]R
M4EQF)E]OQ%Q7A[.G$TVU#:VK"FMS$]4]73@Z.W!V=],R/DEE:R>FNB9QA ,X
M&CNIJ&G!4=N&T]U&=6TKU74MV&H:T54XR!*RG%UN(%ZKQDL5BW=>'&%E2E*X
M +^R5"Z7QN.E2R+2ED=L93XAQ2F<"+G,29_S7 WR(20JC/2,=(J5F<&E.BS6
M2D]-R<&A$89&Q^@?'F%@<(CJZAIR\^3S8>%$1,>0DIY.06$A%3:E%$ S@Z-#
M+&XLLW5]A\T;.RSM"TFYMLG*K1V:QKH%!%6@KA1R:5*3;2ZDT":DWF&@O+82
M=WL=K3U"MMI;/(\0U]<WT%3?2&UU+;H2'=DYN21GI!&5G$!(7 0!L2'X)X9R
M.<Z7HV%G^)WO:_S2[V5>2CC%Y?(H3IO#.5$1SJ7Z9/R;5?@UI'/1&<M%(:3G
M',\7S'E5?X%7#!=X74CM'[1G^'71<7ZM/LH?\D_P<LXICF5?(*@TG&A-+#%Y
M0L+S$L@HS)!Q+,;NMLDX.'%4V:@TEU.FE-Y0YY.9K2(M)YVDG&0BA3P'I 1Q
M,>$J;\6=X72>#^?+@CE9$< QNS]'G0&<4!+%U2&<<89SL2I:"',</K6)GIG$
M 8V)!#4E>!Z%#FV2XTH-1PE>Q\NN\(KV-+\O/,KKA6<(,$:0I22)"S+)RE)Y
M:EUJA<P:=7K,9A,.IYWJ&A?M'5V>%<QWMW98G)FGMZ.'>K> ]QHW36VMV*4]
M)992LDLR*32JR-/'$ZOV)ESO34B%+X%5_@3(/00HL^_JHPEM22)I,)?\.0/%
M(AJ/&&6_C*SQ$N+ZL@EN3\*G*1JOVC"\I+U>YBL$Z,X2;SB-P16 KOP*IX[]
M3[SYPK_![\S?4YH33HVUF.9:.RW-]?0-]C,Y-\/*YBKK.QNL;:^QM+; ROHB
MVSN;7+M^R/+* @/#/32TN,0^RG"Y-+0VE# U7,',<)D$\BSJG3&8M/X4%?AB
MJU6A;\HBK2Z)^.84HMI2B>G*1#51@GI:VC)I\"0C"\9TJ,?U%,T8*)S7DCF1
M2T1[K"<1%^R.(= :0JPID")[)'6MZ70T)]#I#J')?A6W0\0=1'UK,G4=)=1V
MVFCH:V1H<9R%G176#S;%EVRQL2[^;$%Y2F&1+1F7_?U]SPS<UM8ZJEU6JNQE
M."OUU#EU]+:9:'%E8=<'45YP'FW66VASCE%9ZD6]/9ZNIF*&>YR,RG4FAMN8
MG>H2?]G)S&0G<U/=GF,C?4T,R]]'!IOH;+=3Y5!3595)5WL>TR.%U E LLKX
M6/5G*%6_26G!6^C$+K(R7A%;/XO%$8NS*0]W9[D0QUIZIOJ965]B;7]7R.0F
MBVMK+"PO,3,_Q_S"$O/S2XR/3] AOJVFMHI*FP&[^( :AXQQ32'-51FT.5/I
M;<R2]A70UEZ,4T!5KBV)9'LBZ<V9I+1ED-&?@WJJQ*-?A5-Z<D8TY(R6BFC)
M'2ZE<$A+3D\AB2T9A-;%X%\=C$^%%[ZZ4WAEO49@VAOD%/GB=N7)=<1?N972
M$=5T=;0Q/C'%ZOJF]/TA^[N'[*YOL;VZSL[:NFQ769B9IJ>[AQJW&ZO=BJG2
MB$:7C;8T&;LIB?::%/H;HNAPRIAD_ UI(?\C";[_AJ3 ?X<JYA<499\6'Y%
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M J\TA:9P3Y[ )7X4EYAA_)*G",N8(RI[GK3"54HLYVALO4I'ZSX+([?9GWN
M,:Z>\&-)A'P81\))B7V.:XASR&&FXQ(;<T\8'+@M<?!E"BKV2"W<%)Y?41L]
M^F7-X2<RY)\]0X "?2$4(CRO-+13JNP3E(1PZ;KPN (WL4..R%:VTIQ.@98H
MW22]1)&%#7)JMLBKWZ)0=$#5@,CY] W2JB=)- ]3V+E$=;?(>-\ZW0.K# XN
M,]@_PT#/**-"T[W#S/?VL]#9S7R]A45C)ELY?BR%'V3 5N3@@_],Q^D_8<C_
M#;KB#E,3=PACY(>4A$N,$W& G+B/Q:X?(T[F-R;W&"G%5M3UQK*R5<N=V_,\
MOK?+DR\N\/#S/;[\XCR/[EU0Z<M[^SRX=X4']Z^++;W%\Z?7>71_FTOG>FEO
MC$.;<EBM)IX6G^S69@7W=JNXMI#/<F<$'25VU!?84B\^:%VA*U4Y#I@SK:G7
MV5*5<81&W6%F&T5VNOW8Z_1EO<&5S087-H06:UP9+G=BOCV.+R[T\/+^)7C^
M6+4SKQ38HJ^?\>S5$[%'S\56?<4W:M[M?TP0*_2/V;5_"OWK\L^S_(M*$BN+
MPDP*(WZ;)%8<SG^8*%:<)J5Q@Y(D5C")7U<V?*-"3MR_]YBK5VZQ),[N[/0J
M*\L[[.U]ROS"I@3PD\S/;7/^W"UNWW[,@P?/^/+A"^[>?<:5:Y^S?_DFYR_>
M9._\#0EHM^GJF52=;+.E34T6+Z[L,3RV0'NGDC2>87)ZD\F937I%Z0P.SZIX
MQ MROO&I929FEEE:W65Y[1PSLYN,C"RJU<3K:Q?9V[G&I?T;7+MVFSM?/%3O
M>65#%%U1,<5F,SD2Z*9*H*$KJ\!@J:9(:<I64T-)?8,X/<V4UC=14M,HU$19
M79M0.Q6-W=1W#-$S,D?OT"P-3;U45[=15=5"E:69PI(JTG(,Q*1EDIQ?@*:D
MF$1C <%Y*7AD1^.2&X5G80+NAGCLM&$<B?'@:(0KI\+<U$KBHXYGL':QQ]7#
MC;"P,+53>*($X$JB.#M'IR8G,G)R2=)HB(Z.QLW5C;-69W&P<\#;RX>PT'#B
MXN+(S,RDM+14QK"#J=D9EM?76-Y88^O<+G,KB[1TME)85HPF.X.$M"05CB%#
MEX6N*!]#>1&EEC*JFVOH'QUD9&J<X8EQ1B>G&!X9HZNS"XNYBJ*B(@F@=.KO
M$K42^"4$<\++BK<=/^8WKA_Q?LA)WA<'Z6B&,YYU<3C71.%0$XE':R)N#7$X
M5$5@518@@:H7AXK<^%B4\7OY=KRCL^%MG35OB*'_=<9)WM"<X.,L6]Z+.L;?
MV/^&[Q_X"^P"["BI+B);GZ'B#G=TME%154&QL81\)4&?HB$^-H'(J!@"0\+Q
M"0G"/=@')W]GCKH=YUV']WG+Y1V.)\AXYTMP6N# X1)G#I=)D%JJ='KWP:8J
M /LJY57<4)QK0[&U!'#:Y,D9DP<VE5Y8*57$18Y\F&O%FYJC_"+A0WX1]P$'
MDH_CH0L@J3"=R$0)F*-C)&A-)"4E10Q=*EJE\J^J#$MCG1CU%NH:6VAI::.S
MO8/.MG:A-AKJ:R1HS2<S)Y7HI% \0ESP"'/"(\89MU09SP(/W.0Z[8W.V$FP
M[RC7XUH7A&-M $YU@;@V!.,FGSV5U]B;PO!KC<6W+1ZOUAA<FT*QJ_91.^\?
MR;?A<.8QK-(_)CC_$"F&(Z1I/R(R^->$>OZ:Q" %_#\>DR&'TH(""5)*U&KR
M@;X!MH2?SN]ML7]^AXL7SK$O='YOE\WU=88'AT2FZRFM+*6P5"]\FTQ&9C!%
MAE"JRH.HK_*AOL:;NOI *ANCT#=$$FL)E"#'6ZX[$#<);KPZ(@GN3U1QB-/&
M<\F<S"-M2D_R9#ZQ8UF$B[/KWR4RT!2,?;4O9TK=."F\<S93P6X]29S^#'ER
M/V7Z#S'E'J XZV.Y#WL)MF*I,F=29BK 5&6FLW^ R?E%5C:W.*?<@\C(SM86
MYW?W97V!Q845NGM[J&NJH=Q22GYA#NF9\:1K0BG1AY.=8D]*Q(?D)A]$$_T6
M:?$?82D/IJDNE98F/1UM%L;'!EB8GV%A=IKE^3F6%^;D_VD6YJ:8GYE2*V,[
M.UJIKJF@O** $E,F)67QE!MEO,H"J3<%T%SA3TNYC%FA'179QRC5GJ2B4(('
ML^QG2A/]::"^J9J6]A857F)S=Y=MH3WEGO;/LR?WM;FYS<ST(FUMW=34U,D8
ME,G]Y)&5FXXF(PY-:@"9R0[H4DY3(.-8(O*8)Q2?8T5HL:N:Q/>I#<9;>"A(
M'*N8D302AK-)&56:(RJP)GI2%#S$_F0BNU]7S+K6!& G\WU:9.N$P8;3.:<X
MDW($5SE'1DD8NL)H.4<<Q259E%<68JZM$+FHHZNOE[&)"='KTRPMS<MXS3(V
M/"KCJ21UZC&;JS$(/RK)VDQMALA])GI=$KK,($KU/IB+;+ 4'J R]V?DQWZ7
M-/\_H"CA5UA$M]3*N!H+HBDIS*"\O 1+3960F:H:$]5UE<*[U;2V-=(M^E.I
MFJT3&U!558^IHIJR<J5Q73EE0J5E1@PE.M&AP?A%6^,8?IC#H>_R4>P!CF:?
MY%2QHUJUZ=*@O-H?C4]++#ZR5N316P)UY8&.L_"O<U,0S@V!N%A\<1/=XVKR
MP<'HKE87.Y=[X6+RPE;O@%7J:>QC3V'M?Q0'W].$Q@>AT:92:38Q)3RT-#?+
MZ/"0W(L%DUGT85D)N?FYHJ=SR,A((SXNEI3D)-+3-61FI<F895"8GT2!-HB<
M) <,*;:49]J3'7.<*/]#!/J<0I,41E%!+N;R<DSE)K5QJ38GBPQMNHJW'IL0
M3UQ" B%B>_S] @A1\&E#1.\$>N/EYT)<8@A9V7)>C>A/ZS=YX_T_X<.3/\8Q
M^ B>2?;8B0X^F72"X^DR7CKYK#O%J3SA$;T59PVV0G:<U=OC6.*.GSF0J)IP
MPHN\B<AQ)";C+)JL4V1E'"<[[1CYZ59HDTX3%WH$;]'OONX?$^)W1L@>/T][
M/%S%MKHZX>PA>M/;@5,^5MA%.^*>X86_/H#8ZCA26E-):$XBIB&6J,9H(EMB
M\*\+QEUTK)/1"5?AJ\"2,\27GR:MRE9^>X"W OX*IU)[T;%!:@58V+C8[3G1
M$_,%I$SEDZ0TDAK/(G8B@]#!!+S;0W"H\\2NQD/XPYV3$HQ8Y=KBG.M$@,Z7
MV-QPL:L)Z UB*TS%U#36T-[;R>C,F-CC$;'?S;2)#6]I;18Y5B 5JD5^RL1'
MR"-/+WHR)X70E"""=<'8I3GP=L0'_#;N(][2'.)=K=)L[Q0'\ZTYHC8!M.6X
M7M;YMGR<?9I/<JRQ*O+ KS9&A8,X'&'%?W_K^WSOC1_QLP]^S6\^>8L/SGS,
M&?%7W$/<L/6QYK2G\&68(Z'Z*"(J$O$TALE8!<IQO#F4Y\*!+#L^TBK)9Q]"
MV].([<LFI#V%P+9$7.O#./6WN/Z'Q0<XI'<5>^_$>PDVO!MNS:$(9P)S$]$I
MNM=D)$]\*IVA4/BZ@/P"!5^[$%V>7G1REOI65614%+X^OOAX>A$1$DI\=!PY
M6;E45E@PEE:@TQ>+SC"(#(O,5S>I9"@L$QU40H&AG%R=48YI$E_"0DYNJ?A2
M16BU)?*=Z(6&'J:FUSE_X1:KJQ<8GUAF;7U?_*(YVMJ'Q/\56WCI<VY__HP[
M=UYP^<H7[%_\C,\^^Y)//_V<*U>4SP]47.)5\5LW-LZQLKHMQQ ]?>X2%R]>
MX^;-.Q+4/N;A@R?<$[_U[MU[:N,Z)?G[;9+WVTKBUWZ[XJLK_TL<^OPK[MU[
M*#[O33G/;1X]>MWH[EM?_]O \W=E^3;H_=\E!7+BY=>OZ95Z_TJUUNM _=77
M+WCY2L95@9.0,7PAX_3\I9#2N$[V53"(7[UZQC>O'JN=ZGE^'5Y<Y:LO5GGT
MZ0@/+W9R9\7(I:$$%NN]&*]R9*+.@[6!!.Y?[80G*WS]<(EO'LSQXK,A[N\W
M<&O;R)7%+,Y/)G%^/H-+&X7<NE3/\P=3?/5HF=M7ANEKRJ2Z)(+6ZA0V%IJX
MN#? _FX_NQL=3$^4T]B80':NZ&B]#9F&LX2F'L G^1T\TC_$(_\DWH4V!!79
M$U?L1*[XK$7U$>17BY]2'DAVL3=ZD>WR8@_:RWQ9KHOB_G@AG.^ .]/PV3QW
M-X:9[6EAL*.'MM9QL<4+F)O6*&O<I+AADZ+&;0KJ-\FO72>O9HV\ZG4Y_@9Y
ME@T,U=L8Z_:HJ#\O>FB6S+1!"O*FQ3YM8V[85U^%UU9LD%J^1H)QF=CB%:**
M5HE0,%YSOZUXG,4[8QH?I9HX:X;@G%G"\^:)*5PFJ72#] HYAM),3FDJ5[^'
MKGZ77#FG5LZ=7KE.:MF*6DT<6[A(=/XB$;H%PN78$;E*PO@?5!/+\8/3IPC3
MSLCWL\0I26*YGM32UYBL6M.:VL@KMVJ-K(HE"N7>36W;6#HVZ1J]2-_$13H'
MMVCI7J"U:Y;.WCFZNL=4R+AA\>6F.^J8JBUDO#"1R0P_%A/L60\[S*+;+UFT
M_2&39_Z8NF/_A1+_GZ'-/D&TV+NX,B>2JMR(M[@25>M">*T3$57V:*J=*&KP
MI;X]5G1^.MT=!8P/5[(X5\O2O$7\QQ(F!@Q,#1:S.&%F<;:1Q?DVV=;%^M(
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MEJ91VV2F>Z"+\:DQQB9&Q$GOH:&N44W6Z_/RU.K)U-0$DE*$4E-($#T5FYA
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MFV/(<Q8^""+'F$)U<Q4#X_TTM-6+KBU4'U IS1+CX^()UX<0$AZ,1LFJ# S
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MI]9TMP@_S9GHDYQ..JV6J3$7?K8N\\&N+ "E :-G4SC>+:*WVL5N=FCQ: _
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M**GAGQ'N\?<8HCZB-/Y32J(_IB)I%Q69!ZDL.$-3M3A4]5&B\])$YC,H+,K
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M-7+]C@0%','+<P\)L<XB"_XD)BG-Y';QQ?[_Q/9]_Y'0>%M"DYP)$,<\+B^
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M4KXQEW*D'U,UT$W4QCS! )M$4^Q3;' 00FV?ZXQIKC7Z>>88"\&WKW''HRD
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M^_O+.8((#0U#*:X2%!2"O;TC>GH&:&GI8&IJKKY7"M(%!P?+]8OH[.QD<&"
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M A*]NR()Z([%KR,:/R$\(3W1A _&$300C7.;']8")BUJ7+"4OC+.L<8JTY;
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M'*VAJK*%MI8^A@8F69A=Y6#G-H_O'\JM2OL/G_/LZ"5/9/_NW4/6-JXS-K%
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M<!Y=W\^XY/ >QN&7L$HUP2+;"H,<,_2DK<KCW\85#M@T* 7K O'H",&W.X*
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M%B+EY.R$?V  81&A B)C2<E,);,HF^JV6CK&NFB>:*=LK(&T@5+"VC/Q:4C
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MA5+6PLS,C).GC#AE9(*-K3V.CDZXJD%B'S5;60DF*TWR<O-RJ)#K;FEOH4=
M5:\XE_:^+BH;J\DJSB8V+8[ *!V:8!^\=1H"(@.(%">3G)5,JM( (#^7*D.U
M$*]NQL9&U.9B"^*@9Z\N,+(TS="5*5H7^B@>J"&]3<:E(8/HFB1"*V,YX'N"
M/_SL/_*O]OXQ?V[Y<_8&G\0\W15'(:GNU<%XUX>C:8Y"TQ&#1IR0WU"22#+>
M/0FXM<5@WQ2*69V6D]7>'*MPYUB9*R<$?)@5>V!?[(-]ICLFH:8<=OD"39P;
M<44Q)-?H26G((JHVA8"::**ZTX@XG8%_5S).#6'J[;C&5;X<+77C0+$#7Q1;
M\V6I%7L+3?@TYR2?91NQ1W^2?2FG.)9BQ@_-_Y)_^I?_A/_GG_U?^:-]?\3G
M 5_B6N6'BR$ Y_I O+NB\>R(%J(>CD.]#IM:7RP-WEC4>*KE(DZ5.G!40,?!
M/&L.*))KSMXT)0!]")/DPSC%',+&]V..VO^$?8X_QS3Z%)[E,L=E&ES$*7NW
M"V'OC,1;P)C2!,]5"1 KF<O5'FHVL[D2Y)0Q.5S@+/NV9U^Z!9\F'N>3B"\Y
M$'8 ZRC97YPMEI[RVH%?$I<:165-&1F9Z:2EZ4G/$!W+*Z2PI$+6:3-=7?VT
M-'<*8>ZFMTL(M6P[6KO4H'%5E8'\PD)2]"F$A.MP]W+$T=D4'Q]K]*G^5)7'
M4%H8(40FD=*23(H*<V7=99*=F4%1?A[EA454EY1B*"^G5G2JL:61#M&K[OY!
M6CM[J6FHI[F]3G2U4G0NA^2,< +#/?#4VA(8YHB7UA0;UR]P##B,5Z(9VB(7
M?&2\E5JS'JTB3?YX-6OQ;M7ATQJ&GXR=GQ* [ S'LSWT;:!=/O=6E,!1B!J,
M,<JTX43<28PC#G'"^V..6/V$F Q'LFIU!!:YHJW6H*GWE['7XM$1H@:)O3K"
M\.V,(*@GFM#^6(*%1"FWN ?T1;T-2K4%X21;NV9_K.M$'RJ=,<NS4#,X7>+W
MXQN]ET#='H*\]Q#@OH_46 _*2_545\OXU!H$Y-91*>-=7]M(9UL7@X,C# R-
MT3\X1F^_TH2IEY;&=B$[3=15-E!35D-E:1D5E87DY2<2&^-%@(<QCF:?8&/V
M =&)]D3GN.(CU^I1Y(!'K0=>[4HY ;F>[F#UG+U:0]4 FG^[DNDK.M<>(?HM
M1*Y'WN\*P*U3QK@K1 VV*3]^G,BTY'C<"6QBCA&<;$)"I@71F29XIQS&/O6@
M@%\C[.I<<6CU5<=#"0)K.Z,([(Y1,XI]E6![A]@ (6L>33(W#4KVI^AXO197
M):.X)4C]8<2VT!&S^./81Q_ ->@#O/U_2D#XKW"+^0QK64.V^98X5[KC*^<?
M-9).Y%@.P4.9^/4FJOMP;O#&6:G7;?!0LS8MOT?.S@  __1)1$%4JCPP+G'&
MI$@IK^ J:\T#)]$EERP;?%+,"4DQ)3;=''VA S'9%FB2C^*:98JKK&4O67_:
M'O$3G2$X-OGBV*S!IL$="X,KEM7N6,J^E9(&)V6,S<O=98W*<0ME# I<<<ZP
MQR[\.'N-_PPSFS^FI. @B1$_1N?S0R)"#A 7;4E*H@>9J0'HDP-)30XE.36&
MF/A(@D*T>'F[BH]0?DQTE>=>A(2%B'])HJR\@(:F2B%#-33)MK&AC,;Z @R&
M- J*PL@K#"!=YCY(]-LK^!,\PS]&FW  79HQP4I]ZF)G?*I<\&SR$'W0HAV.
M5 /$,?-9Q,VF$S>5JM;RCAR*(WPPAI"!&-'_8%QDO3F);CN6.^)68H]'CB6G
M?'[%E^;_A5/6[XF=\*&P,%;5Q^+*?&K;ZND=&V9AZ3)+-VZQ=.TZYQ8O,C,S
MR]#@(&U-S=245U*87TAZ5@YI.=GBAU*)3@XG/C><X%Q?K!*,.)%PA.-I)S')
ML\*T4&Q;F9.:O:W4S-;VAJ$;B,*W1ZG;+C:ZV0\GI=FBS)ORPY"+K&'?UG!"
M.N,);8[#(]<?DV!K#KO+^O<TQSG(#?^H #EF#$FI241&11(;&T=B0C+Q<<F$
MA483%!1*<$@889'AQ,GG,@I3*&\M(*DLDJ->^]CK^2L^]'Z?GWG]C)_YOL?/
M=1_R8?1^/DLYSCY9'U_F6G)$?(^1Z(NUC*%G7R3NW6'B[_RQ;?!5RV)85'N)
M#CEQ(-.*?7IS]0? H_E.'!,[?ZK$'?-*T;M:+0Z-.KF^8)P5:1 1'^10XX]5
MF1?6Y3Y8E_EBH33F+/7%)-^+PWIG3//%1Q4'B#WRQ2C+2ZU#;)'G@Y6\;E\0
M@&>Q7%M5$N[Q?ARS-<+,U@)'!WN\7-WQU_C)]>L(C8I0RU DE680E!?%AXX'
M>-_U2SX/,^-0BCVF11KL:L3^B9CF>W-2_+Z)'.NDWIT#<?9\$FK"QR'&[(^Q
MDO?<.*%WXVB2$T>C[#D9;,=)C15F7M9$ZV/59HX=7>V<F9\37'B9J]>66;VS
MP<KJ!M=OK'+SYAH7+BPS/;W(F3-+]/=/JF4D>GLGY+G20V.,IE;!H8T]U#9T
M4=?0HTI7]QAGSRZS,'=5R/<Y1H9FF9N])+A9:=ZTK68)*X'A^_>>L+UU7PT,
M+\Q?8'[NO/K>JZ^$:'XC7/75MSQY\EQM3O?HT>/_*DBLB$)4E:S6=]MWS]^]
M_]N$]1_BX]UU_EWDW1C]CT7YK/ AH3Q*]K<R/V\#Q6^$][SFC<BK;]_\1I2
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MC-(<W,)\",]+($:(;X(X@_36$O*ZJBGLK"&WJ8*LRF(!1WFDZH78QB81%YU
M<E**D.(TDG/TQ MP\D[2X1#G@T.*'XX96IQR@G I",&[,HJ QB1"VS,(;=7C
M51J.19('9O&N6"9Z8)_F@VNN3EZ/Q+<F'E]#$OYUJ?@;4M$4)^"2'HI;<C A
M67+</+T M"(:VUK5.J[965EJN0@ETU<I,V%I:<GQX\<Q-S=77U,"Q$K-825
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M). Q7>Q<>'00NB!W OWM\70_R=Z]_XGC9C_%)\$4[V('/!L]Y%I\Y)S]\1-
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M$@%MU7YHZH+P:@Z5^5!*@$3BW15.L( Q']$AQT8_-<O3NM9=MN[8UKEB4>F
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M/6C=_IQ SQ_*7![ +^Q3/!(.$R#?#6H/(WP@F9CA#+69H)L<VZG>!\=&C1K
M-Z]Q%[OPMHR*69FSZ+6'',L%,R'@=KF.>(GM",OS(E5T0!=X'!>+]_"R_3D>
M#C_&P^MG^$=_CC;K%+XE-K@K@5_YOJW!&ZL:;VQKE;JY?MA6B5VJ$"GS$O'
MKL09CRI/0L46Q37%D%@C4AQ!9D$4 7Z6'/[L^^S]^1]@]N6_Q\_I??R\/\'8
M_ ?\8O\?\;'ISSBD.8!EG-B(7&?\RCT($/W2BGA7N>-:[89SDY?8.-&9@3#\
M!B(('4\@:B*9R,%8HOJCB.@)(Z0] )V0(VV#%UZB)SZR?HW]/^;'G_XS#IZ0
MX_I_0'ZN$65%-J0FF!.LM:"T*)7F1K$3;<VB(\-<6#S+C>M"EA3BM'Q%_/T2
MY\^?9W)JFJ[N7O$C56JYE]SL3/*RDRDNC*6H6(<^QX7 J,,X"W%VB-Z/9<HQ
M&6]+M=:Y8[47'F)C?)IU:-M#\>\(PZ<S!-_>2'Q$E!]*-%T1N"M- 65M^;0$
M$M$71>+I.(*K_7%*L,1$<Q@[C9&0?S/</&W0AO@0DQ1%OI#^[L$N^H>5QF&M
MM+8TB.VKID*IDY^?26IFJOC.).*3DX0,Y5!15DQ==3%]O;645B=BX?$YQKZ?
M<E3W&9_(^ODXXG/V)A_E<)X5AT2.%]MC*G-@(M>A9(R;B1Z9B'TT$GTU+G52
M=<RQR5\(7@C6HA.?AA_A![;O\8G[YUA&6.*9*#H?8(JQUPE5S+5FF 29BVVP
MP2E%?'"2-VXIO@0411 I_C]:*4W5F2CC$8EC6P!F=6Z<J++E:)D%1TO,Y;S,
MU #VT7SE_*PY5N2$J9!,:R436]:;2T^4ZN]<>B)QZ S#MBU8W@O$JEZKUANV
MJO'%I-1=[)4S1W,<^"+%DE^%'.;#T*-\$FW$QW$F?!AOS$<)IC(.5GR19LN7
M>GL.9CAP/,\-!T,(H?T9.%;H.)Q@SZ<A)GPFU[D_UHX#"4Z<2/?B9*87I[*]
M\&R2^>O)(* E1=9= +9Z/]PR@\4_AN"M#\<_2_!-9A2>8N/=L\/QJTQ$URSD
MN"T3C_I$' W18BO"1(>"L16Q*/#GH!SGH(S=\5@G+-)\<2D,Q[LB3M9)/ Y%
MH9AF^G TR96]8=8<%;S@G!V*78POCF$^A*7%,75VC@=/'@GY?*$&A#<W-]7D
M 26)0)&UM379O@T:;VYN"6Z\PYW5=<&0*TS/S'%QZ1IW[SU"Z3WV\N4WW+W[
M6-[;X.S9RRS,+\G:66?IT@TN7;S.RNTMKEV]Q<4+5W\M5SB_N,2YLQ?5[3NY
MOGR;[:U[:A:QTO]#R2162E\H&<U*V8EGSYZIB1OOLH>5! YE^XZ4OL/MOX^/
MWR;:_V?EW?C]]T7YW-ML[>^^58(&2N.Z5WRME)=0,HA%7LM[K^1S2J#X]9LW
MO'[U6N;I#:]>RWNOE6RUEW+&CWEP]P(7YPQ,=48Q+)BN1VQ+=8XMU05NM-6&
M,S&4QXTKW=S;.<?]^]=X\G2=YR]V>:G>=OV U\\?\\WSI[Q^?%]DFV]>K/'\
M_B)W+K<QTYO,2&L(0V)+Q\0?7YC)9_-6%R\>+?+LT14>/[S&HX?+/'PH?.C^
M.O?O[O+XP2,>/7@H_$[YD42I.2NZ>ODT]2UZ]-EBB^.]"(EQ0Q?C3$BL*Y&)
M/L3K@TD3?)&=GTI6GEXD73!5-B7Y.53E9-"0GD!W<@BC<1XLA)ISR6,/5^U_
MPA6['S#O]B,ZW'](IMM?$)]RD,A:5T)Z0P@:%E\Y%H?_9!*ZV71"YC()G<\B
MZGP>X>=ST9W+0K>8C?^<'LU4 O[3\MF1<#3MXOL+!=>5.A-3*K8TVDG\@Q,!
M@B%]_&V(CO<E/2=&SE=\0&$6><6YY,KYYA>D4UB<3E&)7GA=*@7YR10*%RS*
MBJ<P(XR"#%_JB[0LM,=P;SR5"X*[9I-/,)]PDN'(0[1%'J0IS93)CDBN+U2S
M>W.0AW?&V+C<P=6I8BX-IW%M/)FUA33N7\OFQ5H)KW<J>+Y9RM/U8AZO%'#_
M2@93=788XO90);AQH"Y,;;YV;^L,]W=FV=T88?-VMUK&XM)4#LNS.5P<2F*T
MUI>63%,&2BR9JK'C?+,;N].QW#^3P,I@,$MM'HR+S^C)-F)2<,O5H0QV+G?S
M:.L2#^[=8>?NEL@..[MW5;E[=YO[NSLB]T3O'G-WYPF[NX]$=N5SVZHHSW?E
M,\IG[^YNBFS)YW:YO_U SO>AR /NB^QLW14=VF%3CK&QN\KVS@WN;EYD_<J
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MGCY](-L'/'IT5W3Z@>C_$[7$Q,,'&SQYM,JSQZ+7-X;$YA>)/N<*M\NDVI!
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M\/;LQ6.>O;PO]O8^WWPM>G-SC.&6-"H3[>G,=F%(L.ZH8+<QP4\7NJ/9N=3
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M76UT='72U=E)9VN;@(QZ#-65%)?FDY 60W1R*'%IH40F:@E7;F6*]28TVI.
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MZQRC=V!";3@W=O&&6DMXZLI#%3AN;AVFO+*32Y<?,CDU2W7=$$6EG916]*A
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MTL*"T%-6EQZQMGB+QW=Z&>U(8:HCDOM]X3SH#6:RUHNV#!L*H\SH;4H2WVN
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M)S%! 8BS5)!8:52GU!]60%YC8PF4[1SP\/!"J_55F]<I6<)*AFE.3IZ:=:P
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MFAW>>I&)$#/,;3[C-Q_^>_[]G_\O_,VQGV(1;8)WI2^ZMG#T/=$$#<81/)9
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MG%*SB!OK&]0LXJB(2 +\ ^1:;IA;6F#OZ*!F$D=&1ZDE)I)34V1=2FAK;V=
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M_/R#?\VOWOG_8'SZ5^@U)^0^[(C+<2&\R U=A?RV48=W6R#^/>%$C<03,YI
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M0" R*HK$Q"12T]+(S,@D-SN'XL(BDN4SG7\ [JYN6%I88F)B@JVM+5X:#;I
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M,?4MM32TB<S5U5(IZUG?W$)+6QLEY24H-9M#8@/1ZEWQUEKAIS5%KS-'HS/
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M2:SL3Q&1X$9XI@ZO='O<"YRP+7/ N-). XE-:QRQ5&!-C2MV]9XX-?OAUA:
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M<>QO.""3EGF^ TX5'K@6ZW O\,*[.)B0Z@02&K,IZ:NA?;R;^NX&\BIRB94
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MPPHDW@>,55:3VO8MO8$"E_>I*O;]]+\OWR__><MWV^V_3"06^A9(O%^OY4^
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MU[AXO(-SP(=8QAS"*M<8VVIG;)J]L)?QX=83BE]?! &]X?ATR_$Z0G"4>]0
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M7I52LK:ZP^V;XI2/7V-N;D4,VI88['4QDJM,3<^+XWV+BNHF<;(G-$>]L7E
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MWVR2$[-)2L@B,2&#G)PB:NJ:Z!H<9O#2!!WG1TBK*2$P.P'WU'#<LR-QR8[
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MBZX ])MTF+9Y8=&B,AEM<"BSQDN<5-\2*SSS37'+,\:UT Q[F?RL2B7H+K/
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M?@3F^A":Y4%XL@.^P?HX.G^)I=4?T+E_153$*5(2SY">HD="[&D"?8X3'::
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M)QGCD[ 3R[!U.*9MP[?:%J]&9UR;/'!L\<:Y0X]]DQ=VM:XXU7G@+'SF*CI
M5^./?UT@X0WA)#5&$Y+J1F"X'7$)7O@$VN$18$M0M#?Z<!V.;I9LVOPIW_VO
M?\8__-U?86VRB^08/XJ%[PJR0LE)"R0EP8\X.3XFQH>DY! *"E*UZ-JN[@[Z
M1+[&)_8+OTPR.C[*X,@ _<.B<_L[:&JKI[JNA/**3,K+XBDK#B(KU49X[B,"
MW-X@U/LMDB/6D1F_@_Q,9RK*$D4VBVAL:Z!WN(_CYT]S[?8-<7!N<?O6+:[+
M?'?NU&GVCX[1U=I!K4JUDE\H_)M-;E:FZ(),\O.225.I GPLI1^-\=29XN1B
MA)_>3?@W3N:L FF_C>&Q,0X>/2SW/<'(R# CP\.TM;136]5 ?4T33;4M-%3+
M_5>4,SC0Q>2!089&FFAH3B<QPQUKGTU\:O<;?F7[)K_Q?)\-,=O9GFG"SGR9
M%\JL,:RRP[C&$>,*1RU5A(H<-JT0'I-MDRKU$L0%^^8 =)WA,FY^[$FUX&._
M#;SE] X_-/L)?[WG^_S-[K_C/8^/V!:[AQU)1NS*,&=7CNC;?&NM2-W><ID+
M2F1^D+9LVOQP'X[$92@"QX%0' 9"L.W68R.R9=OFBXW(EEV%*PX%3M@F6^&6
M[$A0IJ_PAB\Q.3('5J93UUW+T.%ACEXZR8DK9SEU^1R'3Q^G=V2(MIXN+9^P
MRB6LI84H+" ]/85DT0F)J0E$)\1@YR@R:F* L[LS02%!)"8E:E_/Y!4542#S
M7D%1"3DR]R4EI1,9$4-R?#+I26EDIV72W-!(:ULK&3F9O+]A'=]_ZZ?\>OT'
M;#/:A9&E,8:6AAB8[V&O^6X,+/=BYFBJY>Y/*$XF2P&R5:GH,@(Q"I)^#W'
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M8;56H-[7;6^UJ?8KD%C9R%_[Z=OE#[2\]FW^$/1-H/%K^D=@\:KX):OB1VF
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MB"^MM_&QZ09^M/57_-3T0_:DN[ [SXUM.4[L$@??K,H7ZP8]YG7^6@YBJ_H
MS*NEORH\V%OBS-9<6S;E6/-YICGO)^_E-[$[^+48GK\.WLJ;?AOY('P76]*L
MV97CR.Y\9RU]Q>X25W:*P;&SW!W#&F],ZZ7M1@4^!V-;K]=(Y5LUK_=E5\4:
M2/Q%CBGKTW:S(6$S7X9]@$'41[@5[,2ES!CK,E/V%IFPJ\R*796.[*EVPZA2
M[K'2!_,:E8HA"*N6("R: [!HD6NUB</?)F,O9%8G]U%BR98<8[:F[V97XA:,
M(]9AKO\ &Y]UN/OO)2[9G_SB-+)STR@N*Z2QM9'A,1F_(Y,<.7&$8\=/<%KD
MXOR%2YPY=Y;1\3&:VEHHJB@CNS"'S-QD,K.B2$\+("K2"F_=%P0&;1$^VDUH
ME GA27:$Y;@15.*%5X4.3^D/C_907#M"<>F*P*T["E>U[@K#I2-0*[3FT.*%
M>Y<_+FU>.#?J<*SQQ*;,&9MB>\S%T-@>^AD[?=]CI]L;;+7[>RQ\?X5SV(<X
M!KV+1\3[^,1]@D_*1GRRC/ O=B)$QCFX5$=@@3O!13YDM*=1-%!"26\)Y6V%
M%%6EDYD=37)""-'AOH2&Z(B."R(\+H" "'=\0^SQ\#7&.\"(U&QW(N*,<?7Z
M$#NWGV-F_P/ANS>)S[0@*M46GTA+7$)LR:G-HF.LD^:^-BH;JLDKRB<M/86X
MA!BBXZ.(3(HF(%*/7Y@O01'^>.E=T 4ZX^9OQ\<;W^3=3_Z*K3M^P*Z]/\#1
M[2,B$LR)S;(G4/C0+?ISO-*W$UAA2ZB,<W!W,+Y= 7BT>>,NY-;LBTN]'TZU
M/MA6>F!9[HQ%A0/6PC^VLK8MLL8VPQC[^%TX16QAK^TOV&OZ0QR<?LWVG=_E
MX\_^F \V_ GO;?T+MCC]!I=T,X*DS9#>$'RZ]+BW2OLM/CBW^N#0Y"$\[8I-
MK0OV-2XXU[GC5NN!4[$SCMF6V"5LU\;'P??76+O]A@\V_BT_>>?/^>7'\GSF
M;V,C<N0:OA7;P'7L</TEAH$?$]K@3;CP1W!;"/ZJ*%FS/[[U/EK!OJ!&;_SD
M&J[EMNAJG/&L=,9!9'1'Z%:,XHW05?N@%YGP+/? .M48\[BMN&;L(K3,A*AR
M(X(R-Z.+^1COV$\)2/Z2X/1MZ-.$4K<3D+(#GX0=<C^[\(FU);,ZCLK.0EKV
MU=%_J(OA0[V,'NAG_^0@^\<'&1_N8["OD[;6%@W<JZVOH;JJB-R,:,*#[ CR
MWX.]S=MLVOA?V;KM^S*6O\#&?CUIF8%4U^;1V%1%4V,+PT,3G#M[F=NW[W+M
M^E5.GS_)B?/'.7SZD%QOE,ZN+FIJZRD5F2NM+*:P+)."8A51'$5(H#G>'EN)
MCS(C)LR$Z# [DN/#R,_-EGFT4@.)F]N:Z.KN9'APB!&A\:%A#@SM8[Q_@.'N
M'OHZ.NEJ[Z"]K8W6]C;:NCMH;&^B6)XE)C5,XW]']QV86'R.B=EF7%SL2$M-
MH:&NFNZN%IDKZJF1>:JL;"T=4%96'DF)Z20FIHD<)8JNCR8D)H+$]$0*RN2^
M&O/)+HW$Q7\W;W[ZE_SE+_^(/_O%O^<O/_XS/G3^@!W1>]@K/&=68(U%B1VF
MI?8:.&Q8H5[HN8G>]L"FWEO3%[K!2'1#47@,1&A@L9/(@EV'Z-D.T8>-7EI>
M;E-Q<O;$&6(88X!3ELA!NC5&&1;L$0?14)PO\W9?'(9""3B60OBI3,(/)1%Y
M()F0T7ATO9$X"R]:MP9BVNR'4:,/>^0>]A0ZRERJPR;%"5-_4VS]K'#V<\ K
MR).HA CR1)>V]G:Q_\AAQB8/,# XS.B^$7HZ.FBJKJ&^LI(:L1VJJJNID'5G
M=Q<J[W"U\)"7OS=[3 PPL;/ RM4>)Q\/="H5C8\WWMX^PE=!^.E\\?,47O<6
MV9!U2$ 0:<FIM#6W4"7MA<5%XA8N\AGIB6VL)\;A#EC$N^.8%8!3GAZ;;&_,
MLSVQ+ W K$R/89$ON[,],,STQ*D@A,3F7&KVM=![>!_[CDXP<&"<UH$^BAOJ
M22LJ)#XC@]CD)&+C$\C(R*2FNI9^5<2P;TCXNEW[\JJZ7N:)LAIR"\M(R<PA
M)BF)F'0YIRB-B(I4G$0.3).],,OT$UE.(J0IF\B&/,*K<PBMS,%/CK,1G6P9
MI\<E,XH(D9FX^F)BJ@H)+Y9CRW)$IZ=B'QN$2W(H7G),<'XR$R([CV:FN';C
M-I<OW^;JE?M<O_*0(P?/,31PD-Z>"7K[)C52$<"#PX<9&#K(\.A1;MY^*G;C
M"E>O/]&*UZDZ&*I8\J&C9[ES_QE+J^+WBG]YX_9#+;5$=Z^TU7]0VC@J:QEG
M%1 Q<8+CQ\[S0(Y7=J2*(%;1Q/?N/M1 7V4^OR:5/U85JE,%Z]2GY5_/3_P[
MD%B!B<K2_G;Y0RZO?9L_!'T=%/YOD@)#-+!7F$RV7PFI?0KX?2&\H($>KP%E
MH;5\QHKD-X6!:,%R:R\=UD#B59:?*[Z:U<#-Z5LC[.](I"7?DZ8L-QHR'&G)
ML:-7;(0#/1'<NM#*JARWO/28Q:5I\7^F41&LJXL/6)R^R-W+O3R^TL32G096
M[M9Q?BR!UB)GBA*,R8TVH#[/G?.35<S=/<VKN:>LS,RR/+O(\MP**_,K&C"U
MJ"(89V>9E_TJE8+*9[H\=8YG-[JX-!E';\DVVC(_8+!T"T.5-EPYD ^SY[1(
MXN7Y1RQ/GV/N1CE/3X7Q\( G#R;]6+R4P:O[=3P[7<1 F3O9P5NH3#;A[%@6
MSY\>8G7Z*HLS][5H3I4'6!7I4I&FL[//Y%X>:!&:2X\/L;\SGLX"Z0NQ(_85
M.-*984Z+V';#8K=?/5['B]G+&MBLTD7,JX)W,P^EW2<L"['XB#NG.]E7[<M(
MF3V3I=8<*K%F+-^* S7^7!HO8?GQ2>G?A^*'BE\J?:& 8A7!.3TW*VN5DUJ!
MQ+)/=,'<HN@%V:^"FA1(K &="AA>FF%^<9:%I67Y^SD+"ZJ O-I> V._":3]
MUY#ZNO9?2]]T_M?IOW7,[X/$"XL+\CP++*[([W*>MD^EV)B79Y$^T8!4#=!4
MVRO2=](WLF]>@<5"JL#\K);76 '$\[)/:%X5\)-^4I')PFL*#%U9F.+5_'T6
M[A[GQJ$Z#C<&:R!Q;Z$5G6(O'A[-Y_']0TQ/76=V[K$&$L_(N,YJ.8Z?,:6*
M# JOSL[<X.FM_9P>R6=8QG5<[-6Q!D]ZJSRI*_+BV&0-4T\N,*\B?H7/9F4N
MFIT2>5*Y?T4FIF>DC;EGJ.)Q\R(?+Q:?,G7G ,?ZHZE-V4!%Y,_HR7B3T:+W
MZ<GZD.;TS5R=3&?A_H3(P"TY[Y'(CLC,K(HDO\KLS09N'/#A]GX[+@\:<:QU
MM\C-7FX?+Q:>O,%S.79)Y2&>4Y'"*\+O,H8*WUA894GZ6J7Y4#F)%4B\LCC-
MB_D[+-T_P/7)0OJ+76E(-J4B=B\UZ5:</U#(_)/]O%RY*HKFB98F0HV1PDF6
M%E]H^?1715>M+"]H+Y9 ;-JS+716>HN^,:$MVY31.C]N'A<=,G5)?I^5XZ99
M75ID=47TF.BL%^J%E])M+Z4M57!.BRB6?>HEF6R_>K$BM(R61H(51,OQ7,.?
M7FJ1R&K>5,"4 H 5L*Q>H"F]^4HIR)<*(/X=2*P!Q>K8WY+2U^I[>+F.6DLC
MOZ_+7].WR[?+_Y @\>\OO[_OZW^K3?67(@40BWC*MOPO@O5<C%IE[ZIC+E^^
MJP' #^XO<//&4TZ?OJ:EH#AW_AJ7+M_DXJ7KW+AQCPL7;C \?)!:E5NXJ9_1
M\=-4U?;0U+J/,^?OT"D&^;ZQ8]R\,T5-?1=5-6T</7I> XJ/';O ?C':Q\>/
M<N+$!6[=>J!%,JM\0$^?S* J2:LWV"_5FRDQJI02>KVHSTENW;S#Q0M7Y1Y%
MH<I$K5[@J^=:6'K.Y6NWZ1D:H[BZD8RB<L*2TPE.2B6NH(CD\G+2:ZJ$JHDN
MR">AM(3\YD:22XI(*2F@L*Z*\J9&:EI;J=.BP1HI*:FA,+^"PMPJ*DJ::*SK
MH;-MA,;&?LHJVRBJ:B&OJH&,BFIIKYBP@DP\4Z,Q#_?&*344O])D]%49!%2E
MX5V6B$M^%(;1[NR*<,8\W1^#1 ^,4SRQSP_",LM7G$%?K K$&<SUQ233"Y-4
M'2:Q[NSQMF:;Y5Y,[<QQ='?"V]^/H) 04E-3M;01"A!6 *\">U44J8H*5I'"
M*B>Q HA=75W1Z70:4*S23J2GIZ,*W:FH8P4JGSVK*NF?D;$YIK73W=U-164Y
MV5D91,=$X.&OP]3-F@\--_+]]6_QCN4F-ON:8QSIBD=&".'RG)E-133LZZ1W
M<IBNH3[RBJ7/4].(3T@@,BH2?7 @'KY>V'K(L[O:8N1B@8&+.;N<%4B\A5_M
M>)?_],9_X<\^^SXFV>Z8%.O8G>>"29$'#O5!.#:'8"8&H:E&WIA4>+);C,.M
MV39LS+!DHQB(GZ6:\'[\'GX3L96WP[;S;O!.?NKR&;]PW\ G8088Y+AB7"#G
M2;N["U3Z"D],:J3?&P*P;@["KC4$^^8UD-A2]IM5>[&WW)6MQ79\F6_)N@Q#
M/DK<SB>Q7[ A^%T,(M['0T4]EAMC6VZ*09$1NTLMV5WIP-X:-PPJ5:Y9;RP4
ML-T2C'ES("8-?E@U!\BU]#BT!F#;Z*M%WNTLM&93EBD;DW>S)7HS>T/78>CS
M+E;>GQ*6X$)J=@19>4FD9B2+,Y]+=6,UO</=3!P>X^C)HYPZ?8;S%ZYP\;(J
M]'..?>-C-+:U4E)504YA#FE9"22E!!,K_!02;(*O]R8"])L)B=I#1+(5P>GV
M^&0[XE;HC$N5#K<6/1XJ\K4O"EU_'-[]B?CTQ>/3'XNN+P*G5C\M3ZP6K=HL
M8U3KCE6A'3MB=K [8C,[_#_F0]._8YWA]UAO\%V^,/HN[E$J6M@4WXR=^*M4
M L5&!%5;$]*J(ZA=CW^S'GV#O\B*!ZXY3N@K@XANDOMN22&M+I&TTFA2<T/)
MR PE-45/;(Q.^,H.%YT!#FY;\=4;X*/?C5_P;I(R'8E,M<0G9CL>L5_B&/DI
M[@F;B*UP)B#;%ML( XSE6+W(7%Y+%E4J6KF^D+P25; NA<24&&(3(HE-BB0D
M6D]0I"\AD=YX!SEAZVG"%M/U_-4O_XR_??,_\?FN[[/;^I>XA6T3W>)"1+XC
M?JD&.,DUS4/>PSK^"]R+S EJT1'<[D-@FS>![;[XM_CAW>B'5X,O[K5>N%:Y
MXUKIC$>UL_"4/0XYICBD&& ;O0VS@'68>7^(G:P]PK[ W.U7;+?\>S88_35O
M?/$GO+O[>QCX?XJG.#HA3=Z$=N@); DD0/A: ;A^+3YXRSCI&MWQ;=+A4N:
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M,S0R*FT-B$YNH4SFKH)"T:5Y>61FI).2F$A\?!QQB0DD9J214YQ/266!_)Z
MIX<)SG9?XF;_&=8F[^!DOPF_ #O"8OR)SX@E)3]-*)VD[!1BDN,("@_!2^^#
MFZ^'EGK!+5CX/]H+OS0]$55Q1#:+7#9$X%7GAV>]#J\&'3XUGOB7R3R2XXAY
MP!:<(_8272(Z)<48Z^0]6!:885GGHD7[6O3XX[(O K\#B02) Q5P($&+(/89
MC<9S*!S7WB -Z+42&73L"<*Q.Q"C<D?,*I4N<6)+FA&?Q>_D$]&MGV88L"'?
MC.WE=AC7NV'9I,-9^"1 >-5[(!*=R+27EI-8YE-%HIM42A^;1E5(4_1,1SR1
M;:F$EL6RT]60+98[L7"SQ3LT@(#(4/21841+G\8F)!(=%T=T; RA82$R5P80
M%A:$7OK)3R_Z)":(BO8JRGIJL EUXU/K;?SPB[?XTS>^Q\<&7V#L9,Y>\SW8
M.UBA<W7&W].#Q)AH"G)SJ*FLU(K)=O?U4MO4H('$F5FJ$&>BC&LLL;%A!,<&
MXI<1BD=!.,X5$3C51V+?%(%UH\PAM7K,OR+3"G],9.XUR?'"+,T;S\)H8FMR
MR&TJI[:KE;;>7CH[^VAOZZ59;);:AE8:6CIH:&JCJK*.TN(*X;D"$I+2B4\4
MODK-)2>GE%RA@H)R*BIKZ!SHI[*KB8CB%-PS@C&+]V!OK"NVV4$$5*80UU1
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MG]6E6ZP\.<#C,R4<K+/C:,5N+M;OY5R]$>=:7;D^D<;R@W&>SU^79YB2-A3
MKOIO7FA1BR16+R7FA7<65^1Y5T4V%Z]P[WP]9X8B.=SJR5BUD\B$+>VYYE2G
M&E";9<504Q1S=T]HX.XKZ9]5!0Z_D/Y6I-K1VIH3726_OWPB\G*%J9L#'.F*
M%7UA3D^VL>@@:XYWQ3!__S OEQ[PXOF\Z*XEGK]0^DT!Q,+;ZD67T*JBER]8
M%>6XBDHP(<>\4B]<5Z3]52&E0T7G*=VIZ<^O2*9*1:*"?PL4*]*"&J4MT9;R
MHP*)OUJO*5_Y[?4\K,Z5_[Y=OEV^8?D6)/X7EN?J;;5(GA(A12KEA#)@1%RU
MWY4@SLTO<^;L9<;'CVC1O2H?L<H=W-L[PJU;=[7C5#OG+USER-%3W'_PE.G9
M92Y>OJ-]"C@R?EH,^L/DY-4R-'R4R8-GZ.P99N+ ,6[<>LRS9ZM45;73W3TB
M$XXHE:\4@^@8451PZM0ENGL&>?18)O+E%TS/+,@UGG#QTC6YWDDF]A]F>'B"
M_KX1<=+WT=;:2WN[NNY13I^[SK'35^@8&.?RG<?,29MWGLW3,S9)=ED5<3GY
M).07D*PBB,O+R6M6X' +^:U-%(M35=+=0F%' WGM=:0VE!-3GJ<57 G*32=(
M'/C$\A)RZ^LI;^NBN6^4EKXQ&CJ'J&SJH;"FC>S*!C*JZLAL:"*SI8FDQEJ2
MV^L)KRO$,MZ?72%.&$2ZX90;AJXTCH":%((:TK#*\&5OO#C5Z=X8IWFR)]6-
M'6FN&NU*=,$PR@6;* _L_5VP=[;%S<4%#P\='CZ^>.OU1,;&D9N;3U5--575
M5106%FH@<5A8F):+6$4.JWS$CHZ.&F"L@&,52:Q XJCH*%+24BDJ*9;Q:Z2I
M92U'8F9VEN8D^^E]L7(P9Y?E#K;9[6"KCS';(JS8GFC/CDQG=N:YLK?('=OZ
M8''$HW!OCD'7%(M7?1Q^=0F$-J<2U9I!;%L6\>TY&D4TI."9%\B77KOXWI?_
MP/_MQW_$WV[]"9L#]TH?N&!;Y*VEF5"%ZIPZ5:&C1'1]\?B/I.*]+P7K]G",
MZ@,PJ/73UMN*W=B<Z\BV; <VI5GQ6;P1'T7N9DNR)>][;^;/O_@!__,;?\R_
M^^F_Y__]V5_R98HU1N72U^5>!(ZE$C2>BFMGN%Q/ATFY.R9E[EKJ!P44JX)X
MV_*LV5Y@P]8\!>(:\I[*=QRU@]\$?L%?;?\>W_OD?^,]DQ^SQ?=SN7\+W.I\
M<!1#QK$U"/?^&#P&XW!H#\&DRA.K>A\L:CPQ+'' J-!6H[U"6_,M-!#DO?CM
MO!>UE?>D[?4!ZW&,WTULOA-YY2$R)C'$J8BVR&@MDC W.X\\X6F56U2E%FEJ
M:J*CHY.QL0F.'#O!(9&7X?']M/7V"(_6DE.22W12!#I_)RSL=V+EM!57_UUL
M4M&?OI_BK@#B!IT&^)HWNF/>K,.VPU>>(83@B22B#V81.YE+^&@&(2-I^ \D
M8-_HCV6=%Q;U'IA62W\5VPA?&+$]>@N?V_V,3[9_AXU[_I)-9G^'H<_[>!9:
MXE'OCG.+C*T8?5Z]T00-I1 A;8:/)1,^GDCD1")AHPF$".F%G#I#L&CTQ:3&
M [,*5\SR[;!)LT2?[DQ8H@/^(8;8NGR,I<O[V 2LPR;V2YSSC+1":5[UOOBU
MA1/<ETCT:";! XGX]T03,I1$T& \@?W1! Y$XM'JCV.U/'^E)VXE7KADN&*A
M-^'M#3]CR\Z/R,Z,)#L[ GV8/7OM/N5S\]]@%+23H+I0_!O""&@)(Z0[DLBA
M>,('$PCJBR-L))G0D00"!R/Q[=;CV^&#7ZL'/C7VZ/),L!>G:JO-#]AF]I=8
M./V @,@/"$WXE("8CW$,>AM3(:ND+]$WN!#<H0K>A1 J_!0UFDS4>(K6=NAX
M'!$'XXD\G(C?8 BZ+C]\.WWQ%V/1M=""7;X?\_=O_R?^X>?_"Y]]]CVV;OH^
MZS?\.9]M^2\XA7Q*8*$I(?6.Z-L\I2\""1V-)O9@"C&'T@B?3"=P(IT H4#9
MCCB<B:XW%,<F'=YR/[ZMWOA4N^(I1JAYP"8^W?-3OO_+_\A__IO_B9^\^[]A
M[/XAGFD&!%39RW.[$=#OCWXHE*#A:"+&DXG>GTZT&,41ZEG&9#S&DP@[D*:-
MN6=O.![=P3@T>6)=92>\:8UUS">8NOX07[\WB0[]@/3X311E6Y"?YTE!:335
MK:+#.FKH'NSDR,FC7+QZC6LR9UVZ=I-SEZZR_]!1&MO:J1$=7JUT954%Y>6E
ME)4645Y62%U=*9%1 7SZ^7O\U^_]&6^_]R;N.F=TWF[$Q$524E8L<E9+8WT+
MW9W=3([OX]B1"4Z<.,"9T\<9'.BCME;E+:ZCLZ-5YJ4VJNIJJ:RKH;ZEGJZN
M9DJ+4DA/U,F]VQ#JLP4WFT^Q-]^(OZ<]F:F)M,B\T=[518O(<7US"Y6U]117
M5).GOH1)SR(Q*8GX^%B"0]7+005J)A*7FD1.00;)J6%\]-&/>??M[[)CRR\P
MV/5KT?G;" IS(28E1&0E%'UL,*')D42DQA":&(%WF!\N 1XX^+G@'.2&9ZPW
M@;DAQ(CNCFE/(:PS =_V,#S: ]8*4[:XX]ZB0U?G@5>9"T&E[D15>!%3Y86/
MZ$BKM-WL3MV.68WHMR97]@C9"5]YCD>A&X_&MLL?IYY T8EAN*AU7PB>0K:*
MET:B"-R?@%VC-U8BZQ;5;AB7.?)QW';>"/Z4=^*V\%F6$9L*+-@B^M*BWA,7
MX1'WOC#<A"^=.@*Q;?21:XON:O#"1O2+H>@TDTH=+LVAA VD$]F>ABX[B"]L
MMK'!:!.FCA;H@GP)C1'95?TJ?1H<%DIHN,BSK+U\11>X.>/AY8;.SPV?8)&3
M>#T%7644C-3@DJW'+M.?+WQ-^,\?_H!=.C-\$P)Q]'9 '^(K^CJ"[/04!OIZ
M.'_N##=N7./L^;.,3XI>[NS0TDT4%A9H:9VRDY.TU$XJ<MTO.027-+T&K%J7
M!&)1KL>\,@";6I&)>GE6T3EJ;5<=A$V)'IO< -P+(P@I2R:Y(I>JM@:Z!OKI
M587I&EHI*ZNAI+Q&J['0U3W @<DC-#6VD1"?BL[33VR%:.&M=%)2<HB+2R-.
M]F?F%3(P,49U7QO^.;%XY$5BDQ&(>48 7C6BJUOSB6C,PS,GBH#2!*(;LXBJ
M2<,C48[Q<<3<RP'; +%=@IPQ\K?"+MT'EQ*YYRQ_2D::.'W_*H\6IGCXY"&/
M']QG;NH)#^[=Y.$#56E^BGMW'TB?7>70H5.,CAVCJW>"YM8AK7"=RD5\\?)#
MVCM50$(/=?6#(M,#M'<<D&//: #RD6.7.'/NEAQWG_T'SFH LTHW,3A\3(LB
M5B#QI:N/>/!PGNO7[O'TB0(NGC,[L\CTE"JDM*#9NVI13J@" 15XO;JZ%D'\
M3X%#Y:AJ+NWOT;=.ZQ]Z^3K ^V]%WS2^OZ-O (E?*2!D4?NT^C5 K'UNK8'$
M:_3RM_0<E5IB+<V$ E?$-]/ XT5>K$Q)HX]8>G*8&Y,Y3(I=TI]M3G>Z*361
MN^C,=.!<;R:SEP=Y-74158#MY=(TJXLS+"],L[+X3-IXS-+\=6Y?&6&T.Y7J
M;'O*DXRIB#.B)MZ2^A1G)CMSN'=UOQQ_F\7E1\PN/F5A=5XK2*9 ST4%.(L<
MOEIX" N7>'"FF!,=3HR4?LE8R3H.5J[G4,T6FC+6D2\V2TFZ$;?.=_%\X19+
MBX]1Q;46EJ:8G[G!S.T1[A[)X\J 'P_&W'@\8L?]/G,N-YO0E_(I!3Z_),O_
M/4::]#R^.<#B_#7FEL6WE#9FEA;DWE0$O[3W] DL/6;JYB@C8JL.UUBRK]J"
M@7(;)FI=Z<DSHRCH$VIBMM":82Z_ZYFY,2SGW)#^N"=M/-(^_5]8>22D4E#<
MDSZ[#<O7N7ZD@KX2.R:K;#C=:,?I>EOVY9MQ<3B=Q0>'M<_U51H E2]V96%>
MMI=XK@!362\O+0JIM!)?T?(B2RO+<HWGS*^\D/4+EL6?7=6 8K5^+G__]X'$
M?VCZINM_G5;DOE>6UD#O%7D.M:U%$K^.+OY'M"1]H?IC3J/%955P3;V$F&=I
M0?8OK*52T(K=:4"QBB)^PHN%^\+7UUFX/<2=PP6<[@D3"N5P6R 'VZ-9N'\8
MA,=?S$_Q?$;D;4;N36BMR*+*%R^\O/1$KG6'AW</,M(23T..(Z4IIN0D&]-2
M%\RYXZV\F+XKO+W R]D%%J9F6%0@L8IP%MZ?FY]A>G:&9[.SPG]3TC<B!XN7
MF+_9SIWQ,,[4;F,R[UV&<CYA7&SZN3L=L'J9EXMW18Y%%E>DC849&?\Y9N6Y
M9T0NEY8>:+RX?&=$^-67T0)#CI?MY$3%#B9*]G*HV4OXM5.>YZ+PYE.-[Q>D
M_]:B?J6/I/]5CN?9.9$']:)B=8J7R[=Y<KV7"V)+'VCV8:C,@;Y":[KS+*A/
MW4UU\EZZRKR9NC$I?/Z45Z(G%""\^&*!Q9?2Y\^7>:Y21VBZ2OCZY3->O93^
MYP:7CI;37FA'=ZX!_?E&'&SVX_Z%3I9GK\DQHA]>+&HYU-47YEJ:G*_PV[6O
M(Y"VI$MD^GNNZ5-UT(K0JNA,T:':.5^1'*=P($5RZ-JTJ?3K5_MD9A5Z+J3P
M*A4U_-47/.HX.5];OZ9OEV^7?V;Y%B3^%Q8E4TK^%*F(XM=YB=<$<&V_$L@K
M5V\R,GJ R4E5S.R:%DG<UMK/@0,GM8CBRU=N,39V4'X_QLR,RC$#,_,KG+]X
M3_OLK[*FFZ*29HZ=N";&_#4ZN@<Y=?8*3Z>61'F_XMBQBW+N"2Y=D8E;)DZ9
MEWCX<)8KE^^)@7^(UK9NQL8/<O38:4Z</,OA(R<Y=?H")\]<9&C?I/Q]FHL7
M;W#ZU"5&1PXQ/'20,V>O<_KL#0X>.<_0V%'.7;W/G2<+7+KUB,D3YVGL&22C
MI(+4HA+B\_()S\PDNB"/E.IRLEOJR&JL(KVV3/XN)JFVB*3Z$A(;RHBI+B2V
MMH2DIBK2&FO(;VVAK+.;LO9N:KH&J>\:IJ*IF]*&3HH;.\EK;"6SOI'TA@;2
M6QN)E_."*G)PR@S')-8+@TAQ8!/$6<H+1U<2BWM1)*Z%H3CD!VD%:"QR_3#(
MTK$IV9&-"?9LC+!BL]X<XR 'K'S$Z7)1T<"J )T7OOH@$M/2R2THH+BTA.K:
M&LK*R\G,R" T)!1?'Q^\O+SP]O;60&(G)R<M]80"B4-"0HB.BM8 XORB0LU9
M+:^LH$"V,[(RB8V/(R P 'M7>PRL#-AHMH5/K3:RP7N/W),Y6Q*MV9QFPY8L
M>W84N&!6Y8=C4Q@>';'X="?AW9&(5W,\?BT)>-9&XE@<B'UA );R;"8I+A@G
M.; YQ)!?.ZSCOV[[$>^X?X%1NB.F>>Y8E/I@6>6/17T UBW!V'=&X-X;2]!$
M)L$'<_$<2<6V*PHS^<VH4<^N*B]VE7JPMT@HSYD]8@PHVIUAQ_K@W?S:[F-^
MX_ I'_IMX\MD*XPJO+!K#<6]1^YU.!&?H03<NB+D&;PQ+==A5NZ-48D[NPL<
MV)YKS;8<2WE.,[Y,,V1=_$[>B]K&VZ%;><?_"WZPYX?\]?KO\.;>'[$]<"OV
M<GWW.CU>79'X#,;C+>T[M(5@6>^+I19!K( /)PTD-BBR8W>^)5NS3?@\4]K.
M,.#CI)W\6O\9;WM]S :?S[ )W490DC6I.?[DY*J"0VDD)Z22E9I%7E8^I05E
MU%75TMS03'-3"_7U#1I8W-[>(0YQ']5U#124EI)37$!29C+!D7J</:TQM]O)
M'O-U;#7]%5]:O<&>D(W8E[M@7NV*68,'5FT^F+=X82E&BT.K+Q[=(7CW1 K%
MX-T=@Z?TOTN;./P-_CBT^&,KQLG>$ANVYYNS+=.(K3&;,0F5^_?[ $O/7V,5
M^ F.8K!XU3CC5.^)39,/#AW!>$I[*DH\:CR3R#%93R1J(&7$_F1"QI+PWZ<
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M/J=^*PHP_&V@6-WSP_:ON7VW/_YKY;>!X=\6!78H^34(K#@W66)Y;3V0TSI
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M10<T60>)5Y96I3U765I>D?Y=$)EC>47Z2>TUL%?R_4<!W;>@\._*]UVKY"U
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M5WE][S@S]TXP]^RRG+_/_.)SJ=^<B)1)RK"\N,#JDO+@5@#B>CI+BV('EA1
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MN0U[\O=BD;T;C[3=Z&*W8N7W$3:I>["K=L*ZT0OK%CT.'4&X]T?B-YJ OTR
MO0:B\1R)Q7-?'.ZR=QV(PKDW'(?N4,V+V*8C$)MF/QPJ=7B4>N-?YD]$:1")
M%>&D5$805NB'>; 1G]E]PE;O;9A&6."2X450N2R^V_.IGVQG^NO#3)X^0,]H
M']6-5>069).8HBA#HHB,BR8L*@R]OP_>/A[H?=T)#G3'S]<*7]_=^ 9NQ"_D
M<]&)OV'3SO\-*X^?$)!C1GQ7&,$=840,)9%RJ(B$@P4$],7A5.>-6UN Z&0
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M#.53,EE!WL$*T@^4$#V:@5]7I$9=X-(>J'D3F]5Z8%JGQ).]Y4X8%SA@E>.
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M/SYI7@17!(O]#<"G/HBP?NF_B6QBIO.(V)\M_9=!V/YD0O8KC_-0O/L"T:F
M<:T!.)6Y8Y%DCEV<&5YQYOC'&F/O^Q4609NQ%5OG4.TN=L9/[(SH<7\T01.I
MFB=Q[)%L8@]G$7TP0](5>S84A7-/B-BT(-RZE9=VV#J%1[4.2V6W9+R:Y]AB
MF&3")_Y?\G[ EWP>OQO#<A?LV@)QZ8O$1>R6B^(G5C0J \&X]XN-Z_;!KM4#
MVQ8O;!0U18,G#JUZ+8!CH.3CE&:!H==G;+;])7M\OV1W\":VAVUF1\)N=F68
M8I!OC5&I(R:R>%=?(YC)6% OFRRDS^W;@_"0/)7G<L!D,MZR=Q^-P7U_'([#
M41I-C[4*$EKCSYX8<WZT_>_8YK(55^DC_ZP (HJB2:[.I+BKAH%CXYR\=IXK
M]VYR]>X-SEXZ(_.&,3IZ.FAJ;:*AN9'JVAHJ:N1Y5UU%1ED!V4TEQ#5FL270
MA ]\M_%9]%ZV9MJP39XGAH7N8O]B13_%EHM==F@/Q:HE"%.Q528- 6('_3&M
M\L>B/)"(WESB.G)Q2O#A(X,O^,6GOV3SSDV8F1OC:&^#LY,#MK:VV-K9:@%E
M75S<<//P)" TF/K.9G)K2[ -<><SQYV\Y[B5C[SW\%&@(5_&6K$]W84].9Y8
M% ?@7A-#I.23W"FVO[&8Q.(LXK)22<A((R,GGUPU]\@O)3=71/:Q26DX>.K8
M8R7/7"=;O*."-7[AQ+H"HAIR":A*(Z@JG>BZ/*(KLLEOJZ5S?(3&GBZJFUNI
M:&BFJJF5LMH&F2=5D5=?0W!>&A:QT@8)>DQ3_;')#L6K1/HM(XS K#CJ![KH
M&E;Q(<8X?/B$]L78Z=-7M!?W?4/3C,I\[?BIZXR/GV*@[P##_8?H:!NAJW.?
M-J=47X/UCQYD9/(HEZ_=Y[*BESAQCIMW'G+OX5.^N79;[C_/Q/11+<C=\,@!
M#AX\PX4+M[EV]3&G3EWET*%S7+_^F+-G53['V+?O"(=D_GCZU#7.G+K)\6/?
M:%^E7;E\EZM7[G+]VCWNWGFD\1(K8'AY21:RRJ-)38Q%U-^O7\UKE!,*)%:T
M$P\?/I3]4VV._1;H4XML)6JQKN;C;Q>Y/RQV_]O8?K<__B7EK4[\_RJKHG@K
M(NO@S)+HX:+(@O9; ^I6%)?Q=T%B65@ID'CM/@^N#7%X,(G)CA!N'"]DZ>$0
MK^_LX_6CDRR\OB/EFF=Y;8EY25/CT%5ZJD0#B>5O#>A<E+3G1%Y)7D^E3 ]D
M %QE[>D4-_?%<+#(F'V9>[C4%\^K*\,P?PL5Y$K1-2@JC#E98\XO*>J*!<VC
MDN67K+V^S-RU-DYW>=.?M8$CY3NY,^3-PN5*F+L@=5">Q+\-$B\OR*V:? L2
M2WH+<GYV7LJF@%HUSA1XM?1:TK@OY3O#W6-U'.^,8$+FJF>'XWEZI4\:Z8'<
M^^HW(+%*2P%XBG=5 <7R6Z6OT2.(_!K _ /R#X&FZOA_C;RU(?\:\GWY_W/(
M][7+'Q2MWQ<UO5D'C=_*=T%=Z2/1#45AH6RR]@)! ;@JH*#J2\4WO/R4ET^^
MYOKE<<Z<:./.S0D6YF[(]:+/WZ:Q3H^AO)-%3S606,::XJF>E_V\_*WH*$36
M\USW+%>@+RHXW.Q5'IUMX;S,P0^5;^>@R%69ER\_.LC:_#U16.6!KW1+>0,O
M:F-+>Z&A='9EGK65Q_#J!"\N5C)5:T=WYD;&R_?R]'0NJR^.R#A6G,'J*Q2Q
M(<MKDHX"BN5A)+*F0&)%W2%MO/!FB3D6F)5_9YEG4<:"\EA7E! HFI>9VZP\
M/L[#BPU<.I3!^8.9S-P;E7/?B+UX+.-&M9?JK[<XT&^>7]\GWV>KE'R?[?OG
ME!^V'[;_VNT'D%@V-5B5H7T+$J^_?5L79>C4L9F9&5Z^?,FK5Z^TB:WB,7H[
M!I4'L=K4@U(%F+MXZ2I'CYVFOW\_%R_>E,GQK!R[S=&C%[5)^)W;+S5OWJ'!
M0]RZ\QH55;JRNHN:NEY:V\?H[IVBJV="\R9N;![4 HF\>+7,TV<+'#FBHEL?
M9FKJ!&?.?L/ER[>X?N,>-V\^X*HL +ZY<H/S%RYSY.A)QO<?9G3?(:8/G.+4
MZ:MR_!9'CU]DZH!: )YBZN!I#LB"0,FT+!2F#YUA4JX='3]"2_L G3VC'#IZ
MCOZA"?I')CEX] QM74-4U[>)M)"16T)603F5]>VR&.JDMKV/AIX1ZGM'J16I
M[AVFMG^$DK9.LFMKR6VHI[2[G=*^=N*J"HFN+""^NIBX\GQ",U((28@G)363
M[/0<\C+SR<LKIKBLDHK:.JJ:&ZCM:2&_M8*@O%@<4O28I7IBG.>#8;$WIM4!
MLOB.QKU;>=HEX-&F )44W)ICV%ND8T.R#1N2;-B1[LR>+%EPY^NP*_''L4P6
M^)5AN%=%XUD9C4=Q)*XY(3@G^^,NBSG?F"!"X\.)2TF0A60V9945M'5VT#<X
M(/W40U]/+UUM[=145)*5D4Y\0BRQ<5$$A?@3%!Y 3&8<R;4Y)+7F$]6234Q/
M'E']N01UI^-4%XYYF1]&)3KV%BNZ"7>V9SFQ+=V>S:J\"99\F6#%EW$6O!^P
MD_^X\V]YUW4#)FG.&.6Z8BSW6%7ZX=88@6M]& XU0>L!ZJK\-/H)11NQI]R#
M'24N;"ZPTP#B3]),^"AY+^_%[N*=B&W\*FP[&U(MV9GOPNYB#PTL-BCUQ+32
M%[,J'ZSJ_+!O5:!=A$@D+IV1N/?&X-P9A753",;5ONPH=F%3K@W;\FS8DF;,
MQM@=?!6QF8_\/N7+T(W8E+M@5NZ&89D;)K4^F-7Z8B%B5;^>ME-G.(Y=X3CW
M1N+<%X5C3P3V,E&W;O;#K-X+PVH7MA5:LB%M%SOBMV 4NP6SZ&T8!&V0!;<A
M+H4NV%?IL&^2OE2\M_VQ^ XFB"3BHX [F?C[]2?BJSQO6R/P:8K$KR$.O]I8
M JNB""\/):8T@+A\#V)2+(B.-R ^<3>IF7N)3=@JOW>2G6--:JHUF:(_)84!
ME)5%45&71G5',54#E92.5)(W5D;V9"GQ(YD$=D?AI[QPE:=GB^*)]<"N48=C
MHP^VE>XXEWNBD_[393IB&Z@^KWX7)_=WR<DUHJ34!%NG/\5:]PO\,BW)'DJB
MZ'@I.:?*B3N00\AH,CZ2ODN3 MH5][0_EG4Z+.K<,:]W7?<BKG.1_G=@3X$5
M!NEF&,;NQ234 (<0,TR<M[+%Y&,L/ W0I^F(:TP@IC>)Q.D<TDZ7D"(2/IV!
M3[^,B;90D1#<VH.QE?XP;_#6N%&M&_18UGIA7.[ KGP3&5,&&"?MQEST:9O-
M.QB*^ 3M0!]I0$"V'>$M040,1!,SF4+2L6P2CV=K ''H5 K> S&XBWZYM8L.
MM 3CV.(O8]D7VQ8=5HJ#M=H#LS(%K-M@E&F"1<(N;'P_PM;Z[[ R^DL<G=_%
M5^H74^U'>&LD,:.9%%QJ)N]L#<F'\@C?EXC?<#2ZP7#<^R3]3C\-@+9N4O7P
MT3S;36MD#%:[2YLY823Y6"69L\GV??[N@W_/EUO^BL\V_CD?;/TKS")-\*P*
M('(DC?)K+91<:Y2Z%!"D:"8&XO'JB\:I*T3T.1B'KD#L6GPT3FJ[9CW6RM.W
MS@OK2@^L\YVP3###)<R0D"!#W&T_P<7F4P)"3(G,\B"V-I@X&6?I!S+).)Q+
MPG@F =TQ^/1$X3,<JWF/.K;+^&G629MYX]#HA:TL[ERD/AXR9KTK] 2(?GE)
MNUC8_YQ//_E?V+7E_\#-_B."?':A]]B.I_,6])Z&E.9$,-A>3G][)<WUQ927
MYI"3DTI24AS1,9%$1(9K7L1A82$DQ,=25EI$8T.-2#5U=14T-HI-;*F@MC*=
MZM($*@JC28[QQ-/)D.T;W^%'?_8?1/Z(+S[Z.9XN9H2%.!,2Z22VU1;/1)$<
M%QF+_NB;0[27*\HC._9 /G&'BHB<S"=B,H?PR0S1E23\QZ0?A\1>]XI-:O7'
MJ5;J7^J*:ZX#7NE6>,?OQ=KO"XR#-V*2:89YN1.V,NY48#>/WG"-ZSIT?RKA
M(BJ(8+2D&S:6O!Z84=I544'X#<82,!!+V' "?MUB]Y3'LM@VVUQ;3)*,-/[@
M7WI_R&>QV]E9*,>;]#B+O;)IDOY0@+3TN^>  ISUV+7KL!4Q:Y1G3KT;5HV>
MFMZY=03@UQ:(5:P!1KK/,?'\E-UN'[+9Y5V^<'Z'+]W?9T?H%DPS+3 K<<"T
MR@73>M$;T27'3I5^),&*XN) !A&R@ D_G(6_\F+>'X_+1#RV0Q%8B0XJ[UW/
M]BAI(S_V!)E@'F2)<Z0S/@D^A&:&DUB21H'T7>M8#_N.3G'T]'$N?7.)TZ=/
ML']LE/'1$0;[^NCJZ*"_MX_NKAZ9D[127%-)65<=.3WEF,0Z\UG 'CX.W2W/
M*S-YSEIIP>+,RL7.RY@TKY'Q5>>#B=@,XP8_#.OT8M-],:J4,5$52MQP,?$=
MN5B$.K/)7)Y'.[]BUYYM&.[9@;GQ7NRLK;"QML;&SA9[9R><W=SP5B\LU,N*
M^@K"<A+9XVW-)E]S-H=:LS76GJ]BK=F<(O8OSQ/SB@!L)!_GZBA\ZY,(;\@B
MM;F8TLYZJMH;9>[22$5-/94U#3(/JZ>DI)K,+)F?)(AM"I=Q%N"+4X@>W^0(
M0@J3B9#G>42+C/G&;/QK,O"O2,,W/Y'XJ@*J^SIH&>RCL;N;ZJ8VJAI;J9?Y
M3T-7-R6M3<3(7,<U/0KC6!_,4P/DV16#OB*5T/(,DN3^JLX61B:G.'[\+,=E
M[G7JY-><.:."'%]G<.2PS,DF&)M0+_2/,M!_D$&11IDWMC0-:"!Q[\ 4HY/'
M."OSPIMWGG'^XBV9[YWDFLP/'SQ^(<<><>+T18Z>.,?Q4Q<Y>%#12USFZZ_O
M<O;L#0T,5E[$*G"QHJTX?/@<Y\_?D'-2AE-79'^3,Z>O<U;*=.G"#:Y>N</-
M&_>Y?>L!]^X^UJ@FGCYYR>M7ZT&N5)1Y62/+7'I% XB?OWC%LV?/94[\6/Y^
MKLVEO[N8?@N4_.X"^H?MOXWMNWWR+RUO=> MH/)/%044KZK 3ZN*_U,!Q4H4
M *GT:XUE!1*+3JK]&_4V8TUY*#YA]O$9[EWJY\Z9-F;O3<+2-R(W4,';5A:4
M9[ "JI8T('B=%D$!Q I<4L#>B@82+VOGE*C/UU^P]N8I:PM76;@[PI7^( X5
M[68J;Q=7AN)X?6U(TKXI>;^2^^>9530 RG-21 /6%J2 "_,P>Y>UQY-<'(ZB
M)VL+4R7;N=+KQNL+):QI(/$S67O.HCZSUX!"&6O+"U)/D75>V]]X^6HT 6JM
M*Z) WV45;&_A"<S=8O[^$6Z?;.*TS%^O'JWDQ9T#4O\G+"^]EO(H;TYUOP(C
ME2>Q HKG)6U57EDC*S!/TE3>P;\%7OZ.?!<,U40=D[;3]K][[@_([]J-[_[]
MKR5O\_UNN?XYY/O:[A\5:?\5!=BJ_I%^5=S/2J<4!<JZY_:"'%O',Y1WKT;A
ML:1>)BB05U&4S+*Z^)HW2R]9F+G'BR>7>?S@%+.OKXD.OY T55\K/5K5 .*%
M%;'M*DU-'Z3,2K2TY&_-@UFNU_)<$)V9Y\VRC+$5!1)?X?JA"HXW>W*LRH"C
MU0;<FHJ#E\=D0#Y@37$#*PYB#;A6]5J5-!2PJT3T;NFIC(FOF;_3P[$./0/Y
M!HQ76/#P9!Y+3P]+69^PJCA]%6B[M"9IB?T065,O+D56%#@N=5]:76%Q3<JI
M &*4E[+R]!4#)^=0@/:BHGJYQ]*S$SR[-<*#:X,L/3^G'6-%!>]3GLZB QI(
M_ \!Q-]OG][*[]J[?S;YULOXA^V'[9]C^^\.)'X[D+Z[J;^585Y_\Z4,S&_>
M_*A-_:T\B=6D]O'C1]]^)J>,KWI *%X:-2SE63ZWR.DS%[E\Y097KMYFW]@A
MOOGF+O?NO># @3/:9/_&]2>:Q\9@_S2]O9-<N'2?_9-G:&D;T8#BZMH>C7ZB
MKJ&?!IGX5]=VR=\]7+W^B#MW7VJ?^:G)^P69H-^__Y*7+Q>9F5GAQ8MY[MQY
MR*6OKW%"%@ 3DX<8W3?-_OU'Y>]+L@BXPY4K]Z4,5SA\] (')0W%37?XV 4-
M()Z2Q<*ILU>T8T.C!VCK')(%QWX-)!X8GF)XWT&.G;S$N"Q U+G2BGJR\LK)
MSJN@N+R!NN8>ZML'J&T?I$/N;^@?IZRMEZ:1_=3U#U+<VD)N<STY;0VDM]00
M6II%8%$:0?FI!*;%X1'JC[NOCO#0<.(C8TF*22 N-HG4]"RR\O-)R\\A*BL)
M[Z00;*.]L$[TPC+3!]-\/49%LB_WPZX^'(_.!'2=B7BVQ.'3D8AM=3";T^SY
M-,Z<KY*MV9GCBD&^IRR\?7&H#D'7&H>N)0'W.BE#50P>I5%XY$DZ:7(N+A#_
MF& B$R))3DNFL*A(^JE5"V W/K%?VX^-C3&^;TQ;0!<4Y!&C@J!%1Q C$A<;
M24)R+%F5N11U5U$R7$]J=Q&I R5D3E83VIN-<WT49J5Z+&0A:U;FQ]X"'8;9
M[NQ*=6);@AV;8VWX*MR<=]PV\V\__S-^9?L%UFGNV!?I<:H*PK,IBM#^=%SK
MPC O]L:J)A S69COK?)A3X6.G:7N;"MR8G.^'9^FF_)ADB$?)1CP7O1.?A:X
MD1][?\XGD7O8EF[#GD(W]I9Y853AO<YQ7.>'37,P]AWA."E04H'#/5%8MP1C
M)N?VRG4["EW9DN/ IDQ9I*=9L"EA+U]$;.,]7TDW>!,[4DPT4$QY$>\I<\.X
MSEO[K-^\7M)O\,9>?9*O/.JZ0G#I#L.E1_+J#,-!?9K<'(AE@P_&-6[L*+)B
M8^I.-D9\P=;03S&,VHA]I@FN1?:XE+MB7ZW#H=%?X\O5]<40,)Q$T%@J?B.)
M6H ]'XU;-P:?@5C<.R*Q+/?'IEQY(NIQR7-"EV.-7ZH!^LA/"8SX@-#(CPB/
M_I*(Z"VDI%O+V(R@MBZ%AOH<6IM*Z.MMDO'13G-OJ^AW,Y6#=10/5Y W6DKR
M8!81/?&$2CG\%2=MF^AVBX_HFAZ?9C]<R]SQ+'#'-]L-WT0[;-TW867]/F$A
M.RDK=::\PAZ=_WLXZS\A(,6*_)Y$*HZ64'*F@K0C^83L2]:\51U; Z6=@C1/
M1JLFO;2I)Z:UKIC6N&#1(#I>[891@1W6&7:8A>]EC]M7F+MOX:--/^+/?_R_
M8^J\'7VR)^&5HJO]J62=*B/WFUJBC^02,):,=W^,%FC-HR4(EQ8_[-OT6#9Y
M2;]Y8MVLE_3=V5LL>I-KA%'Z+JSB=^ 4NAT;UX_Q\/J2^'@3/$0/7$(W$U+A
M3EQ?M 9XYIVK(/54,>$',_#6 $_E>:N"[@7BW!: ?;,/U@T>FEA*'F8E+ICE
MVV.<88YI\EY<DDUP\?T2>_.?8+OW;_'QVD!4JCWQTI\Q;3&D3Q?2<+>/PO-U
M)$QF$:JH+"1O+Z5?G8$:U[%-BTYTV!7S*G<LJCPQK_;4J /VEMEAE&V.M93=
MV'T#6PU^AHGI>VS<_-?\XI/_Q":GSW'*=B5A-(/ZF^T47JHF?"*5 .D3;UGX
MJ;K821[VW4$X] 1BV^Z+;:N/C".IDP*)J[VP4U008H?,0O9BY;D5/]TN_)RV
MX"OB[[N7A P/4JN#B!?]C^T.)GXPBOB1)$)%=_7]T7CT*Z_74,T;6@.)6[UQ
MDGYQK/,4.^9-0'T0X6+W@G-$ST)W8^?\'C;6/\':_,?8F/T,>XMW\+3_!#?K
M#]F[^4>$2YZ5^6'4EL9169I <7$"!?F))"5&$AT92FQTI-BR:)*3$\G/SZ6E
MI8&>KC;:VYKH[&BEMZ>#P<%.!OJ;Z.FLHK6AB-J*;$KRDL66^[-K\^?LWO(Y
M[O8F!.MM"0BPP,UW%^:Z+["+WH5'H3V>M=Y:8,,@J6?41!9QAPJ)/U1,U&0!
M$5/YA$]G$SHE[;P_'ITLEEU[0G!H]<-!VM2QR@W;;"N<TDS0B=B$;<(@;*/8
M'D.Q:3:8U[KC)-=Z*.Y@:;^ H01"))_(\31B)C*)&$LC1/0]>#R)L/TI<BZ!
M<+$;:8=R2=@OSZ>.(!P+[7#*M<9<;.>[3C_C5U[O\:G8AFW99EC7J3X(TBA8
M[,1>.;?[X]4?*K9-C[7RAI?%C%&]*T:U+E@V>VO'W+OEV=(9+,\Q(\WKV29P
M$[N<WN4SL[_A5WO^A)]O_\]\Y?@KS-17!L7VF%4Y8UHO]1#=\AV)(?)@.JEG
MU N=(N*/YQ-S/(^@ VD:2.PP&HWU0!C62D<4=4M+.&XUH>B*@[&+<<4ZT [7
M4%=\8_SDF1I'3JWT5U\SO?N'F#H\S;ES,E<Y>8*#DQ,<G9YF8GB$_HYN)H;&
MV#<P2E='%W4MC30-=U ^THA#FB]?!>[E?;]M?!1N(.UBQE?QMFQ)=Y3V=\=0
M>U'IC$&-#J,&/]G[LJ?2&Y/J (U^*7.JEM3>8JS#7+#3.^+L)>)BAYVU!0[6
MEK@[BWWV\D3GXXVGKX\&$(?%19.0DT%HNNA#DM0SP1_+5#\L<@(P+PI@KPI:
M6R3/F@I_')HCL6^(Q*92GBE%P>C*8TEL$1NQKXO>J1%Z]XW0)'6J;VZCNJZ)
MTK)JTC)RB4U.(SHSC?"L%(*S$_'/32"H-)60^FQ"VO();,E%7Y>!5UDBSIF1
MZ',32:DJIJRU4>9![=1(>A6UC;1T]=(S+O.ASE92ZLL)*LG$/BT,S^)$PIKR
M":K)(:6UBN+.9HKJ:YD^?(Q;-Q]R_NQUCAZYP-&CESA_\0Z#(T=H:!ZBK6N<
MKMXI^@<.,C1X6*.*Z&P?E6?2I/9UV+'3WW#_V1P/'L]Q_L)MF:LH[^-+&O7$
MV0O7M&!VEZ_=Y=;=IYR2^=ZY<]=EGGI? X:55[$"B4=&#LC^&&?/7I4Y[PS7
MKC_@Y*FO.7WZ*F?E>N7\\(UR4+AV1\IZGSNW'VK[6S?OR>\'/+BO@BN_T(+4
MK7^*OL+KU[,R7WTMQU3PNA?R]VO- 4/-O=\NK-7OWUU _[#]M[5]MV_^M>3M
M>NP/BUJ[*1WZ5C2@6,GZ6FUE507 0Z.=6!%1'H>L+<L?BMKA*:A@<S,W93%W
M!Q8>K1];GN&- MX6% "[R.KRNJQS$2L'H[>4  HX5H"< N[4[QE9/+[@S=P5
M7E_OY4*')P<+-G.T=!>W]B<R>WM$TKXEA5 @\2RS\S,:C<7"RJ(65&QY5NHR
MIX#BEU*>"UP[F,M@D0ECQ;NXT./&\PNEK,U?E'H]1]$,+&NBO#LE?PT<_HXH
M0%#*N:H\J:5\\XL+6J RQ?6ZNO12FD#JN?2 Q2?GN']YE(?7]O/ZR076EA1
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M)G0R4R2=X G%29M*X%0RWB.Q&@AM41>$<:D/9H7N.!8[X99GCEO"1ES\?T)
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ML2 )4V8\D2DQQ"182(R-(24VENR45,J+2VFH;Z2^N8FBVG(2B^P$IT6)41K
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MG9/VO2]\^Q4J)=V=![<T^;XKLJUX^=8#Z:.0X\60R+?(N/P0^5,R*GOIYQ]
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MRN-/A-H1;D()MT,!?']NDT1I"-VZ?9_//O^:\Q>NLG[L%(M+Q_[@B:L2@RB
M=7W]@O9IW\D3UUA:/,/"_&DV3K[.>Q]\S=77/Y8%_S%FYT^Q=NPRQV3AWML_
M2]_ ',?E^NLW[XOBA2N7/Z1#C(/:FD[:V\5@ZIUD<'"6\?$EJ>\$*ANU\EQ6
MGP]N;%QB:>F4MOA7H+$"BI7G\%65D?JMC[AR]2W.GKO,A8O7M) 97W]S@X\_
M^5*N=7@7GSQYB?/G'6"S*D<EWSMS^DTI_QH3D^MBN(S2U#Y$:_<8-?4]U#?V
M:\?JFP>H:^JCNK&3[.(J,@K$T"PM(:NBE/RF2HI[E%>D&'EB6*5W%!-78R>Q
MRDYJN1U[02HUM2KV:S.M[<U4UE:06Y)':EXZ88EB@,6&X9QJX'"FD8.Y!@ZJ
M3[=+3+B61^)98<%3]D<+P]B=X<VK-C>-MJ=ZL"/-DUV9ONS-#6)??A 'B\*T
M,!5N%69<R\RX%)OP*C(3E&<A-#V20$L8X9'A1,=$DI*21'IJ&O;T3/)R\RDH
M***LK(+&QF;**RK)S,XF(2F9*(L%O4%/2$@(X>$ZHB(M),GQ1)N-5#&N"TJ*
M9&P:Z!\=9&IIFJ&I$>H[&\DLR2$V(P&=U8BO+@"/($^<?5QE[XTU)5X#AU-S
MQ-#/RJ2@K(2&KA8&ED89.C%)W\D).D^,4;?63\%"*[;):LS]>>@ZTC&TI1+6
M($9QM84 Z:N[]'M[XA%^$[:%%V+WL,ONRN%"/XZ4!.!9;R2L5WGIV8B=R2=C
MO0;+1"XAW4GXM,3@T1B)4[6.?66![*T,9$>I+UOSW'DITY7GDX[P8NP1=B5Z
M\4S +G[\VJ_YBR=_S'Z]&\F-.22UYQ#9DJK%3TZ<+B)Z/ ?]8 I!O7%XM)MQ
M;HW M<W,T08CAZ6. U7A[!?:61K,2]E>/!F_CR>B7N.9R*V\;-["_J2=>!2Y
MXM4<A'N'\(-*IM:@Q[W)C'=;-)Z=%GQ[8PD:2"1L()G0[CB"Y%APCU4#B@*Z
M8_"4NIPJA!<*W-F>MI_7K%O98WH6+^,SZ,U;24WQI*8F@[+R;(I+\JFHE/EN
M;F9@:(#%E7DV3JUQ^OQ)SEP\QZG+YU@_=X*9M3FZAKIH:*^CJJ&,8KDW)T]X
M)]TL?!!,BBV0Q$0?_ .V$1"T%XLUD(+B%)&5,MI[6QF<&F1Z99KEC6763ZQR
M[-B:Z(PUT0=K4O:\%LZBO*N&\HY*RMK+*&C.):,V"=_8P_QNY[]GR\'_P&'_
MG^%G>H+ J&?8[OI7_'3+_XW=AJ?QS7=!5Q]&=+>5N/YD8F6>XP=3B9-YB.I/
M(+A;C5TXGC*6_KV1!/='$]AIPJ/"CZ#J0"+J0S%7^A.8>1"?Y!V$V@_@;GV)
MH^:G\4]\"?^DEPG*V(VAQ O_/!>"BEVQ-/L3W19 1(,O_B6N[(I_E7VI>PFJ
M#15>L!#1$86^U4CB6*+PK<C)2"Q)0O$#441*.T+*W G*.4)(VD%"XG9CL3F1
MEN,G8QI*5FXXF2+_>451V',,I.?HR"VSD%,31[+H@/ ,'X(SO:0]@22TFDF7
M>;</QI/:;\7:8<;29B2ZPX"NVD/&9B\N]M=PMN_$I]"9\-I@=+5Z0BO#"2X+
M):K!C+G60%A9$&'",_Y%GOCF.A%1ZHXN[S!^J<*/"=O1%;@2WQ!&7$,X,35A
M6"K"L);IB2LSD5QI):LQE<KN$MH'FQ@<[F)Z>ICYA5$F%WH9F6NG?[J9GO$&
M6OO*:>[(I;4IA9IR,_E9/B3&[B,XZ!F,YNVDYP5@$UFV9@5@2O7%F.)/7*Z1
M_+HTVH9K&9SN8G)^F*5C"ZR?E.?.R9,LKZYR?.T8&ZOKS$Y/T-?73F-+)95U
MA=0T%8M>*J:F.I.,^ !"7%]DYS,_XB__XO_$+W_Q;['&A5%6D4]S<SU=[6W,
M3TQR_O@&[URYRH?OO,=;;[PMSXP+;)P^R_3B(IU#_31W=U+?UDQ-0PT5%<4T
MUI716)N+-<:+HQ[/\JK3W[-;_ZS(\C8.YQW"K=H7WS8=(0,63).)6.93B5G)
M('HMFZAEE; NG8AQ&Q'#R9B&4H@<3L4\;"-J/!7K; :1(PK\"\0Y91?.\=O8
M;WF)5PS/L<7\ MMM>SA:[B=R'T7(<!R!(S'XC@B_CT3@(^0[*KJ_/P+W3@,N
M+0;<VR+QZHC!JUW%.#>)7M01UNJ'7^$^_-)>(R+W(#&B-Z+SO3'F>J(K<B.P
MQ GW(I&)*C?1+2K\31CN+2)/[48"1)9TPM^F!6GG2A91:UF85S,P+*9@D'Z&
MSR03/!:O7:>247HW&?"J#N% CBLO)>[FV<2=;,DZQ,YR+PY(']TZC 2-)F!9
MS9.R\M OV@F9LA$J%#*1C/^ 5?2?!?^>&-%W\ESI2R9I,I_RM29,5;$<,#CQ
MRM%7.>PM<A412%R2E?B$6%+E&5=04$QA02EYV45DI>5@3Y7G3E(:"7&)Q,;%
M8DV.([4HDZ[Y?DJ'J@B7YZ9'EC\[X@_R>]U+_(/WDSP;^AJ[HUW8:_7@<+(?
M;O90?/.,&"H22&K-I6BDEN:%'MKF>JCLJ:&DJ93"ZD(*R_,I*LLGKT#T9FXF
MG5UMK*PM<^'2139.'&=V;HZAH6&Z.[MID6=O74T=E955Y)<4DUZ80UIE 0G5
MV436"*\TIZ-O2].2TAJZT]!UI:!7\?O[<S%U9:-O2$=7D8*MM9BROB;J.EMI
M[^ZF;W"8D<D9!L<F&!P=97ATA,Y!]3*W&7M[!>&E-@**$C#6VC'6V3'59VE>
MQ*G=E1@+;!P,]N1(@!<N/MX$A87+^J6>IMY>2KI:R6ZO)Z>[D=R>)I+KRTFL
M*<-64T5J=0W%S1TT=8_0)>NYD>%%)D:7-4_BZ<GCC(^M4]\T)#IA@J&)8R+7
M5QD:6Z.[;TX+138RLL+$^!ISLR<8&5V2/JA\$HNLKE]B;N$,G=U36EZ+B:EU
MSJFOV2Z^+>O3DPP-SVHQB56BNJFI-=YXXV/>_^ +/OCP<RV_A@*89+6KK9,_
M^>P3WGGW70T@4FM>94BK[=;-.WPJ:\8WWWA']E]P7>Z[<4.,<I5XZ+;R:+RK
MA9=0X28<OY7#A13P<-M<9V]NF^OKQ]N_SFUS_O[%2/AR$R!^%"2^IX"?AS;<
MHW&+-T%B!4[=47LY=OO^'2&Q!Z4 ^1<5RD'%5KW[X"9W[ROORUL:V*2%KE"1
M(!1 =O<^*D:Q\KY4(+$4(,)Q1TZ*T:; L3OO\]W[,WQPIH'7C]7PW2?'Y-@'
MTL:O4+&0[]^1\NY*O9I'[DW92QVWI7W*HU/*T>+$WE)QDC\3^DC*%[KSJ;3A
M&VFW L1N""EP60'%FR"Q:INT47[?NR?M5MZ=MU3(#.4MK09%VGU+^GOSKM8'
M!8!=EV/?W%8@\6UNJ[&1-JFV.6*QJC:)7(L,WQ*;60'$"KQS@,/* U2!Z/\8
MP/RO(<?\_.<!V,UK_E/T7WK=/P4]VLY_3G* Q.IEQ9\"Q6INA&^55Z_PP!](
M'5?SJ_A<]+S&)PH@5B]&%.\(\VCA-X47[@LO*YY6>\V#]B%8JSS>;]]7?.+@
M'P40*U)Q@&\+7ZF0#BHAW$TMK(GPD'*OOR.R</=S[GY]C6_?6^7F9Z>Y=_TM
M.?:5U*L ;>$M:<\F2*S)I) *9>( B867I2_WE8>^>@$C[4#:\>"V"H_RC<CG
M=]Q^(,\:31Z4O,H]JIUR[(XFOTH6'$"Q^F) Q%OVHKC47FNO"($\\^X]N*_Q
M]BW1%;>55[_H%BVTAO3WCMR@SFMC)V4].@]_R@\_J*/^S/1X>[S]4VZ/06(1
M,B7<VJ<XHI34W^K8IL+?W#9_;PJEVFF?+XE247I%T3??WN+JM;<Y?>8BQX^?
M87GE%"IQW459E"L/8BW<A) *-S'8/T=7US@#0W,LK9QC?O$,/7W3C$VLLKBL
M8@1?H+=_1@OC,"V+^,^_E$6"U/GY9W?$(%BE7\[-S*PS.;FJ?2JHO)15V1<O
MOJN%AE#[$R=4/.*SG#KE *H54'SV[%7>?/-#/OC@<]YZ^P,M[MSE*V_RL2SP
MO_WN%I]\^J7F8:S"4JB0%.OK9S2P>WY^0^O#^^]]PSOO?,GRVGD&1N9IZQFG
MN6N$NN9^,63Z:&X=HDWS+.ZFH*2&]!PQX/(*R2PJ)K.X@(*:4LH[:Z@<::9F
MNIVRB292.@I):RL@JZ60K*ILZMNKZ1YHEW*;*:LM(Z/ 3FQZ N&)9OQM)GQR
MHCF2:>10CA'7\AB\ZQ+PKHW#HSP*UY((#N8$LSW%@]=2W#6 >'>ZET9[,_TX
MD!LL%()SB1'OFFB\JRQXE$7B6AB!>XX!76$<5C'V3$F11,5&DI!@)3TMA<P,
M.[DY>926EFM4555#<W,K!87%)"6G$!>?2'1,#&:S";U.CUYO(,H20[(ME43E
M@96536EE!76-C?0,]#,U-\W(Q(B,61UI]A2BK9&$A ?BZ>.&BX<SKIZN^ <'
M$)L43XH]32B#%&E#05$)C2W-#$T-,W=\GN4+ZRQ<7F?PY Q-*P-4+':1,5Q)
M0F<>B:TY1-?:,%?$8BB-Q#W=EQ=TV_F)ZZ]YT;J'PX7^N%7I<*G6X=9@Q*_3
M2L1X!O'SA:0LE9.V7(%U,I_0'A77,1;7>B,'*X(X5!W,OG)_=A1X\EJF&]O3
MW-F9Y,YK9F=^?60+/WOU"5YVW4-X2A39345B%)>1TI5/4G\^60M5)$P68!A(
M(Z K#O<V"T?;(G%J,W.H7L^^RE!VEP6QNS2(G47^O)KMP;.Q>W@^:CO;K;LY
M(.26<A"_(D\"6W5:@BCW=@.NC08\FE78BAC\^^,(&DXD="29L+XD@MIC\&L2
MWFF3^99KW.OTN%:%<J38A]U91]B:N)T7S<_Q6OB3N(8_353<?G+S#%16Y5!<
MDB=SG$])<8D&2"A/RHF)(187)\4(GV=U8X75TVM,K\[2-]Y'YV G+1U-PO^5
ME)474I"73D9J--%F/R(CW#'HCN#J^A)1T3Z45=JIJ,FGH:V&CH%.!F5.%X\O
M<_+\*4Z=.<7IDZ(_3JH7,V<X?N8$X\O3U/4T4=-11U5S!44B*_D52?B%[>+'
M/_M?^.U3_Q?V'_K_$*S[#>'6YSFJ^S4O^_Z4H#(/HOHL1 [&:7%L+0I<4S1B
M(W+,AG$LD8#!*+QZC;AU"C^T.@ NERI_=MGV<#!A!]Z)NPF/VX57\%,<<?\9
MSC[_P"[GOV*_W]^AS]Q-1+$3$=7>F-H,F'HMF :BB!B*D/)-1(U%8AZ*0M]C
M(D3.!S;J"*H/QZ?4!_=L)T++Y;XZ?RP- <0U!A);YX>IV 6?N%=Q-SR/CWX+
M.O,N[-G!(C^IM+7FT=5=0>] /0/#30R--HDNJJ.CMXQZT24%M6E8,\,)M![%
MSWH <[8[2>4!I-4$8:OVQRKUFH5_#(5'"4A[!9?8W[$_^I>X9KY&8(TG$;W2
MYI%$(D=%=H:3B9%]K)"*_ZMOCR2\28^Q,8S8IA",A<YX1&]AA]??X1?]"HG"
M4W'Y7IC3G=$G',8<[TI<:A#VHFC*6[)I&ZYC>*J7F:DQEN=G6%F>87YUG,F5
M(486!QB8ZZ=[K(.N?M$3794,=)70T9!*<580(3[/$>CS+ FQ3F2+'DO+#"3.
MYD]A12*U+?FTJ#$9:6%\MI_%M1E.G=O@W.4+G+MT1?CI'.=.G^?<R;.L+B\S
M.C9$J^C7ZN8J*NK+J:PMI:8JG\R$,,)<7V;[[W_$KW[VO_':ME^3FA%%<:GH
MY;IJ^KHZF1T;XZ24<?7,6=Z^^@97+E[CQ,89UC9.,S8[3W-/#TW=W31W=VDQ
M9&OKJVAIJ:*IL8#8!%_< UYFI\=OV!;R)+NL+W,H^P!NE;YX-841)'P:LY!.
MPO$<$D[D$K.>A7DQ'>.T#?UH@LBSE9#.:(([8@CKB25"9#QZ.EWT5 KF#A/!
M!:X$V0_AF;"=?1'/\YKA:7;%O89SD0=^PGO! Q;1#1;\1TQX#QOP'-+A.:C#
M7<7;;M?CT6'&H]V"9X<*31,O.B2.<+DVN,./P*I#!!?NQ)"_FZB\ T1GR_QF
M'B0B:S\AF;M$O[Z&1^%AO$0.O!J"M&1Y*J%DF,B7=36/I),E))XJQG:FA(23
M!42N9F*4OH9-V0@<C<=?Q<ONL>(K]?LT1[ O7W1?W$Z>B'F-WVM \6'VEOOB
MVJPG8"".B%D[8=)OOZ$X? :L>/5'XRGCY]DKNEXE@.PTX]<;B[^,5:3HVX+Y
M:DP5,1S6'^'5PR]QR'4W@2%>\NPQ$1L737)R$O;,+'G>99*<F$)\3#SQT7'$
MQ<1BM<JSS1I%5&HLJ=4YM*WTD3M<BG^1C%]!($>R/-F=?)BMIIWLC3J"6YS,
M<ZP??BGAZ'(M1)<E4=A32<="/\/')Y@Z,<OXR@3=(UVRAFBAL;6>VKHJZH17
M*BO+*"PLH*FEB9'Q41:69'TS.\ODQ!3C(Q,,]@S0W]G'0'>_\&,?K:WM5-;7
MDE==*FW+PUIC1U>33&AC,N'MJ41T"_]TR;Y'Q>\O)6:P2/14#A'U622T%,FZ
MHX)\J;.TO(*JZEKJF]MHZ^JAJZ]/UF1]](NL- YUD=)4(OR5@'^^/$^K,]!5
MIA%5GX.MLX*4MC(";5&\XKR?_9XN^(8&DV!+H7]D1&1^ 'M=!>DB:_:.6G)Z
M&LCO;2%'GA.9#?5DU310W2%]&9F3_BXQ.K+$\. <_;W3]'9/T=X^+GIO0 .)
M!\?7-9!X;.H$W7WS6BB)MK8Q!@<61)><9VQ\173B N.3ZRRO7M! 8O5%6F?W
MI/Q]DK?>^8*OO[G'&V]\)&O&-<V#>$C6H&K_YIL?RQI6@3YB,RN03:USY3_E
MS?7YEY_SR6>?RCEE#*LULRQXY0(5>_B]]S[2DCBKV,.;:V/'7H694/&(51QB
M!2(YUM=J+?WH]JBA^^C?C[=_?9N:OW]1TD!B:8<"B!^"Q)I])N<4L+,)WCA(
M\:(#*%;@D_(XO,TM;CRX(?_*;_EU&P6$/8SWJX GY8VH 4]B+\K]RMO8 ; ]
M!-GNW'=X*-X6(1+>?Z# ,;GOP;TO>'#C&G>_.LW-ST^CPD1P_VNY_EN'AZX"
MWY1L*6!:@=0*M%8@G?*\O_4P+O"MZT+?2EF.9%H/[BI06(%^<JW4H;PU':1
MP$=!8N7Y+&5(F:H>%5=6M5,J0R7INJM]7B][&1,%BJGXPIN W'W5?@42"VD@
ML19&X+:<4P":VCN\E!W>U0IP_QXP^V^A1^?G_^C\?X[^:Z[]<].?MOF?@S3/
M]TVO=O6WQH_JN,(U'+0)N#KHGD;J*Q'%PYODT.V.^[3XUMJ+ 16C6(1)O0!1
M.(D"7S6^4Z1>;H@,W9'[1/VK_(]J+U4([ZB]>@8(S\F]JMP'<O+!/>5=_SG*
M>YC[GXFPJG KPMO"=[<5."QMN"E">UMKFP**%1"M/)8=?*?U1_'C+6F7U/U
M>0:+?-Q7/*A"2BCO826C6OND_2KTA$;JO,B G'/$(7^H*S2 6)HBO[4Y%#VA
M9% EZ%,@N-2FT4VY_^;]Z\+WTG^D;8HT_?']/#S*!S^HG_[,]'A[O/U3;__3
M@\1J4\+F>//F\"3>W!X5PC\52*5,E2?QYO;M=S=X_X-/>./-]S206'D3J[ .
M%RZ\)?2V%I/X].G7.7GBJ@;R]G1-TM$Q1G?O)$VM@]0U]&BA&]3OB:DU#2A6
M@''?P*P63^[C3]7#7RW*[[%Q[(H8!.<T3V$%$BLOD),GU*> =_GTD^\X=>J:
M=DQY_FYL7-8\1=1>M4-Y!:M/"E4\8N7UK$#B:Z^_P]OO?,"[LMB_?.4-EE>.
M:7TX<_8RBXO'Q9A8U<)6J 1\GWUVD[??_H+YQ5-,S6_0/3Q+37,OC6V#-+>)
M,=7<3UU=MY;8KK*VC8R<(E(S\\C,*R"G*)_"JF*JQ%!JG^VE:;Z'\JD6\L=J
MR!PL)[.[A/RV$FI[ZV@=:J.IKX6R1C&N"NQ$)<>0F)]&;$D&_MDQN-A-N!=9
M"6G*(*@Y#<^J6 [EAG,@.X0]F0'L2/=AMUTHW8M=J6+ IGFQS^['H9Q@CN2'
MX5T515!#/*Y%$>RW![,_+1#/[ C,)<DD%6=@2;$2'6<A(3Z.S(P,S8.X6@S(
MP<%ANL2 5.$F2DK*-(#8$FW50.*8&"MFDQF#WD"T)48[EBCG<PN+J&ULHJ.G
ME];.#HU47,6ZACH*"O-(3(R7>T+Q\'!F[[Z=;-^Y#7=/-TR1$1A,$1@CS43&
M2'D)R=CM.51653,X-" \ML*Y2V<X<?DT:U=E/LZOT+S01V:7&,*5TJ[".,(S
MC 2GA.*?$L#S7EOXA?,3O&#:Q:X,-PZ7!.):H\.[-8J GGB"!Y((ZDM KSQ,
MIPO(WJ@G9;D"_5 Z@=WQ^'=9\>F(PJ4NG*/5(3A7!'.X($#F(9PCJ0'\_-"S
MO.9WD(CT6')K2\FO%V._J9SJH2:*!JO)&BK5/GE.GRXE>B2;@/8X1ZSC)A,'
M&_4<4-GOJT+86ZI"@OBQ*\>3[6E.[+0=8D?L'G9'[< C_B!^MJ/X9+II0*-?
M6X248<"KS8Q/9S0!?7'HQE,('(S#JS.20&ES:%<<0>VQN*N8R'5&7*K#.%CH
MPRZ[$Z_:]F@@\?,1S_!*\!.XAKU 5((3N0615%874%BL/-L*M+FNJ*BDNJJ"
MAMH*.CL:Z>UOIW>PD][A'GI'5#S)'OK'^V2>VZFIJ9)["LA,3R8A)H+HR$",
M.E>" O;CY;.3N,10*JJS*:\II+:EAH[^3D9G)ED_I8 ]T15G3G/QW$6N7KC"
MI?,7.7?Q/$L;*W1*'56MM115%Y)7DDY122)Q<9X</?P+CA[\*SQ=_IK P)]C
M2'R)B+S]&"K=,73H, S&8!Q-)';:3L)<#G'S.<2HV,.+F5H"+-.R'?^Q6-QZ
MC/@.1N.MO(AK@W O=./%P-_PS,$?$13V#,;P9_#U_!G;=OQO[#WZ(WRBGB.Z
MW(.XMG"B>R,Q]D<3,9J <3P!W9@%PX0%_;@%W7 D80-1A/59".NV$*H^YR_R
M8+ME"R\&_9+GO?^&K;X_X4#H/^"J_PV>^B?Q#'T*-[\G"0C=*G)BH*4UFY[>
M2AGW!H9&.QF;'-!H:*2#_L%&^H8:Z.BKI:FK@IK6 HKK;,1GBER'OD20Z55"
MS"_C%O0[7(-^ST'?W[+=_3]R5/\+O.*?P#]S"Y$MWD0/&HD8L6"93<4R;\<\
MDZ[%3;8HFDS%,!2'H3\&4W>D7!]*7&,P\14^A"7O(BKC(,EY;EA3#Q-FWH9?
M\$N$ANXA.RN"II8\FGJ*Z1BN8W2JE_7E>4X=6^?DQAKK&_.LG)IGZ<PBBZ=7
MF%Z;9W!B4)X/]70TE]/9F$=;33)Y:?XD1ATD/G(_.:++TE-]9>Z]*2M-I*FI
MD+:.*CI[&YF>'^',^>-<OGJ>*Z^+CK_V!A<N7>6<Z/23ZR=9G)UG=&1(KNVD
MJ:-9"X-35EY,=7DAJ=%!A+B\A,NN7Q'LMX.86%^2TR.P9R=3557.T& _DZ/#
M3 O-C(ZQ,#4KY2TQ)S0Q+>7*[^')&8:$!B8F&!@;9F"XEXZN!JIK<\DKC"8J
MT0-W_:ML"WB"':;GV9^ZF_TY1T4^0] KK_*3122=*B1F/1OSDHJQ:T,_D4#X
M<"S!?2I9713^'9$$*T]9H8!.,^'"4Z86F;L2'X)2]N-C?15/Z\LX1;V 4^(V
MW/*=\:KVQZ\UG,!>(T%#)N%S ^[]X7@.Z/#LU>.I :LF7)HC<!&]%#1B(W0R
M4?:1HEO\Y3GCAJ[N"/KR?>AR=Q.:NHW V"T$);Q$0/)6O&ROX)&]%\]R-WQ;
M0O#KBB!X.![30A;)I\M)NU"%[6P9Z><KL)T6';V>BVG)3O!$(E[2+Y\^*X%]
M\03U)N#7$<W>(F^>C-G&/QA?Y.>F+3R5L(L=!>XX-^CPZ8[6DG]Z=9GQ$E[T
M5R$WI"X%%KM(/YS:]+BT&44'1N'7'DV8Z%I+FPU=D0GO&"\.>>]FY_XM[#WP
M*EZ^SEAB3<0FQ6*.B<*:$$]L7!Q1\MP)#P\C5)Y-X18]^GB3!A!73K90.MM(
M7'<F?I5&_&L-^%;K\"H)EN>R#T>LTD:3!_XQ09@RHDFIS**TNYKNN4&F3RRP
M<&J)F=59IA>G65H1OE^98W9NDA'AR;&Q$?KZ>FEHJ*>SJY/6]G:J:^KHEF?G
MQ/@4"[.+K"ZNLCBSP/28_)Y:8&E>9&9VCMJ.)HK;:\CJK"2T(I' ^B3".],)
M:DP@I#D177LJIIYL(GOSB.S*)TIDTMI8@*VFB*S28M(R,DE)22<K.Y_LO"**
MRBII;&UC9&:*YM$^(F5=$)P73UBIC:CZ7(R5&4359F-K+Y,ZJ]%GQ+/3]3"'
MO-Q(SLR@?WB$ENXNLBM+B<I)(Z8LAZ2&$C+:J\AHJR:GO8&RKBY:AB>86CG!
MN2OO\MZ'WW#RY#7-DWAL9$E(Y8"8H[YID%JAFN9!JAH&J*EW4&W#(+V]<R+/
M*R*;BS2W#-'>-:[EM+AX^2-.GGY;2X0\-"*Z9?D,EZ^]+^N\SS606'U9IO),
M]/=/,3HZ)VO(B[SU]H=\\>6WVB?HF\F]U.>^7WW[-9]]_CG??"/K4+40E4T.
M\^G'7_+N.Q_R^>=?<E,9[0^7Q&IMK+R)O_KJ*PTHWC1J%6T:T3^T_>DZ^_'V
MKW=[=,[_>^B_JBP-)-X$:A[\$4#\/4BLKI$RY:1*6*> 8@U8XA8WY;_KW)!_
M%4Q\FYL/;FCGU W:Y_OWY>@#.?? X6U\1\F(V()*)!0INU EQ'*X52I0]B9W
MM?BOWW#_SJ=R[F,1CL^Y?^]KN=;A?:O%/E;RIH!=$2H->'J@/#$5&*; XIO:
MWPK,5K\=8/%WW+NM@&L%G#E 8I742]$?>Q)+WS=!7+E6B=U=!23>DG&X*77<
M5&"; ^A5,61OWKW!#06(2Q_OWW\$(!;20E9HUZDZ%2FP4-JCE2_72,$_E,CK
MOX0V=<)C^L?T0^/UCTF!N_^8'&"Q@QP\X2 E%XIO5<QJ!_\^Y#WM19["062O
M>=TJ\/^6\,!=(0=(K'AI$RA6_+ )$FLA5A0)?ZF8#"J^L?(J5L\)]:7UK=L.
MC^5;*@FB"I\BO/K@KGI1\HWPY U4'&4%$M\6^52D9$OU396O$CEJX4]$#E4(
M&*W-JB]2IO*X5Y[QZJ6/2EAW6\CQ$D?X41JB9$G%%%< \OU-DOXY/)T5..QX
MEMU3LJ+J$SG3P&^Y7]VKQ316WLBB%U2\8RWFL?:?]$?I%;E'>4QOSM</ZJ4_
M(SW>'F__G-MCD%@V)7B;RG93R#>WS6.;FSKG4-S?7Z,4[5=??Z?%<7OSK?>U
M\ T7+[W.>^]]QM6K[W'JU!4MU(0B!11?O?(ABPNGM/ 0EZ^\S^K:628F5YB:
M6F7]F(H7?(TUN79T;)&143&"ELY(F>_PZ6<WN'X#SI]_FV/'+W'JS!M<NOR!
M=N[,N=>Y?/5=SIY_@^75,V(4S#,YM<:"U*,\4^;G3FC&QT6Y5GF,O/ZZBCU\
M4?,B5FU6X+#*9'WRU#F-KKW^MG9N>45]BKC$PL/0&2J^\O+*&:9FUUE:/\OL
M\DGZAF>H:>RBLJ:-VOI.JJO;:&KJH;6MC]R",C*4T95?0%YA'H7EA90W5](P
MW$KI8#WIG<7$-&=A:D@CNM%.1JL89UV5U \VTS,S0,=H#]5MM5I(!EM^.C&Y
M8KAGQVK>/,&5*1C;<@AN3,6C/$8#B?=G!K,KW8]7;1YL5^!PNH\&#N^S^VH
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M00H,ZXS$IRX(EYQ#[+$\R_:@_\@NG[_D:,"/\0KX6WQ\?H:'^]\1&O:RR$@
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MTC^/)@,>C3H\ZW6XE/KAG..&5Y8'_IF>!&4(I7@1DZM'%^O#CMU/DYP<0=]
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M.A<[&5X99&Q^F*'1/OIZV^GJ:J2]LXKFUGSIRRG27\-(2CY$:.1+N <^Q<&
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M9)R1,3RC,8]#.G>>]=G),P&[V)GPT),XS9MCA5'XU:80W2QU:\@G.",>U[
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MC^JR!%J;"J0_YU&0GRM]/X=TT7>IHOLRTQ*Q6M-$CO.TV-L#PSTRC@PQ,CK
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M]C*ZN .8DEQ)-'K36)_'B=49;M^YSO5;-T0/GV9"],70\##MG1V45U:(WBC
M:LTF*S.=I$0CB8+4U%02$N-%!R5@S4LF.2.4Q QW8I)V\?+N?\L?_^#_S1_\
MQ_^%?_WO_K\XNQT2/=[*^,0P,S.33(Z/T:T(])HJRHKRR1,]9,L4?92:+G5*
M("9:1TR,7M.O17+ORM(B"O/2R;/H*+"&45X43K[5&W.: ^F)^\A*V$M<^$MX
M.OZ 8_O^E##_S93DQTC9:=+V9KG63'Z^F0+9+RFQ4E\G?;2EAFZ1Y^G9,1D_
M%F5,6F9A88:YV4FF)D>U_MO1TTEK=SMUS774-%2(;C;AX;P#QX//X;#O:?9O
M_PGA@8?(L<12495/G939VB-CB%Q_XOQIKKQV0R.(K]V[Q;FKEUD\+K(Q.4G?
M4#\=_1TRWK2)3FBDIK&:QFZ1E?8BZ1\1/'WD1_S%X3_CN<A-[,P4.2_PP*TF
M#/V$F?@%&_HYI1]3B9I.(7PBB<#!>,(G,PB=S,*E0X=+>Q3NTH<\6L/1#:=@
M&LTBMC66N,H(HFS>>"8=9+=^*Z_$;F5G^@$.Y#ESM-P'Q[I@D9\HW#KTN'?'
MXM$5BVN[C%D=4?A-IA"R8"%L/IN(*3/AXQD$CZ;B,YJ,]T@R 0.IQ/1FX%<4
MQ<%H1[:Z[\0IV)G(I&A,V:G4MC;*F++(C>LWN'[Y&F=.R!@E8\[PP""]/3WT
M]O?1(F-4C8RA%15EHLMJ&9D89.'4/ 4M11R+\^3/G9[ECYR?XOO^+_*4?C<O
MIQQFA\65W?D^["[R8U]E*(<;=#BTQ7.H+IH#%6&X-\7CWR)ZO,=*V?%VLCJ+
MT8D^3"S((#S#(&-2"#XIH?B;(_&WR1ADB\2K0(>WC-D>Y3I<R_4R9AMPJC1P
MN#B2?7DA[+4&<C0_')>2&-QE'%=P+H[&H3 2S^H$/&H2<*C0<:1<QO5:Z9>M
M)@*ZTT2?)>/>EH!G5S*>/2DRUJ7@VYF.=WTR8;49%/35TSDSPO#,%!U=O;2V
M=(DN[Y!QO4WT;A/E-0U4*>*XJ5WS()Y966/^Q#JSLIV85F%,9K00%.WM_?1T
M#VL>Q'6-'50WME.O%AOM':).K5G0W$9E0YO(=2?M74.BKQ8Y)W.TRY?N:K&"
M%Y8NB XXR>#($KV#\H[&EJ5_7.'^VY_)?!%M70J%!V]_R(5SUQD;G65H:$H+
M]_7FF^]K"]R=/G=%<)F+EV]P]]Y;,N?\3(LE?.KD>88&IQ@=693KEJ6OK7'K
ME@H7]CXW;ZH%E#_DTB45(FR.X6&9MXW,:Z2Q^F)-A0M3<]///ON*3S_]@O??
M_U#POD84J[GPAJ&NG"94& I%$JOYLIHK/S&&GZ3_'NG;A,O?A$>,SR-"2,%.
M$O\N,:0N^689WR2<OI(Z/.1 ^>H;U\C9C;+EP&.W?0S*EE0DL9VH_1V2^"&9
MID&1K ^AR#2-2)-R_WJ2^!&QIQ%XBB3>^+Q>\PX6._;AO1^1Q';8'TJ=4#>S
MD\1VCV)5KLHKSR0[]CK:GT,K[VN26.5_6)^'93W*]S?CFVW^W7@\?=?Y_UGQ
M7>WY".K\AOP]PM=RIN'Q]_I(AOY;^%V26.JA9$B]>PU*AI0\BUQ_7;8]CY+E
M#7R=_2&^E&=Y1!)OE+U11_MS*OE7_6#C.50YVKUE7P10VF.C?ZM_DD_PJ&\J
MH7^85V!OOX?GM']R3)U2V1Y"3C^"^JU!7:?*DV=4?Q32=(D=&^_DN_ D/4G_
MV-,3DOA;Z?$.OO$7.>4]_+@7L=HJJ! 42@^H8VK2_/$GG_'..RJVVP=:.(HO
MOU1YE=>QFFQ_I!V_?_]M;MV^PP?R^]-/O]3B%)\^+<;MXBEM49'5U?-??Q*H
M%A297UAG>GJ-$VN761?C0I' RA-E=/PX0V)@*,_BY>,7M=C#"TOGM'C#IT[?
MX.KU-\5X>$WR7]+"2DS.K#$U>X*AT06&1Y5'RRKSBV=9/W-#[G>.YI8!,>#7
MN7A)A<.XRLE35SBU+D;(F2L<7SW#XO))5E2<NM,7N'3Y)K=OWY/G>$V,BE>Y
M=OT65Z[<$,/C&A<O7N'<V<N</'F6R:DYRLJKR,W+)Z^@ %M!#L55)=2TUE+=
M64=Q>R5Y[67D]]90,-A ;E\MZ4V%)%?92"XRDY:3I:V,GV?+H;RDE*[V3OH&
M^L4(:R:C/)<P6P)NEFB<\@1%,6)0ZO"H$,-;#$[W,CT^)0:BJU(QU5@)-$7B
M'1% <&0H"4EJ0:54+%D6ZFKKZ.GI$^-O@HG)&9973S"UL(2UH(CDM"S2,RS8
MU&??N?D4%Q914ULM>8<YOG9<VN<D9\^<X<3JFAACHU1559*6D8XA/H[8Q'@2
M4Y-(-Z=KGG8][>V<7EOC\KD+7#AS5JXY+NVY1$M_&W$%*;ADA+ OPY?=5G]V
M%02RIR28@^41N%7'$MR80ER'%<M@.14S+=0O=%(^WB3M5D%F<SX)59E$%27B
M9XGDB-&3+2$'^8GSB_SG/7_),Z&[V6?QYE"Q&-W5X;BVQQ(TDD[TK(V$E1)2
M5RN)'LW&1XQ^Q]H(CM5$<+0FDH-586PO\.&5'#=>SG;FY?2CO))TF*WZ [P<
MM(OMOGO8Z[6//4Z[2#8GT=77J7E#JGC+)U?769I;EF?NH:JT@K+"8BTF:E%!
M"1F9V:2DF4E,SD!O3"(ZSD"X+H*@\ "<W8YR\,A.')WWD9H63V&1C6Q;!JF9
M)M*S4K'F9E-0D*?%?ZZIKJ*EI9D>%8=V9(C^8<'(" .C(PP.#U#?4$UV=@9)
MIE@BHP,)"'+ RW<K7CXO$19Q (O-0'%9%I4U>6+DE]+27BO&>K=&$,^OK+!\
MX@3'3YUD=7V=E1-J]?=%Z2-M6JB/DO(\"DNRR2_*E'*2"(_R)"S2A?@D'V*,
MKOA*^4Z!.T7FW(C*#R6J(IJ TC!\*D+PJ0W%OR$"WYHP0FIU9 SDTGR\B['S
M,PR=F*!KMI_JG@9LI;EDV;+(R$J7-DO#E)9 0HI!VDU'4E($T9'N>'EL(UC>
M14S, 6+C#J&//TJTT9$PDS,>@NB:6$I/--)PLY^B"\W$S^82-9E)P) 1KYYH
M?'K5(EJ1N+2&X=(>R;&F4 Y6^[.OU(M#1>XXYCKCIKQC=:^PW_TG[-CQGS'$
M[L52%(!WPCZ,#=&4KE72<*N'\FOMF$]58IC,)FI4Q5--PJ_'@&^O'L_N:%S;
MU()XT;@T1^$@<NA0%L*1?%\.65QQSG# (W8/7H$OXN[R*]Q<7B(\TI6&UC+&
MY@98O;#">U^\Q_UW[W/A_#D69Q?H[QW0%G8K+2W7_GB4GY=+9GH:YLP,S%F9
MI*6GD"FRDV(U$9D83%"T,_XA^_'QW\'!0S]C_Y&?XQ&Q!UUY&"DC\AY72ZAZ
MM9/B6VTDKA42-I5.P$@2_D,)!"@/8O4L77K<%:'7&JV%"7!I"\>I(0B7B@!\
MY'DV^;W('S_WK_G)"_^*@PX_("3D%2+"]E)2$,_$2"NG3RV+KE\7?:K^4#=#
M7_\@]8W-%)24BYSGD9Z>B2DA@<18 \9X@2F>./7.S;&DYL2A3_<C*M61R-0#
M^!A>P3'P!0Y[OH1'R"$BX_U)-<>1FY])6ULC4Q/C&CG8VB)M5%Z U9:.Q9Q&
M5KKHP\0$4E-2I7_8*"HJH;&NGO9FD9.Z"NE7^:+C<FALRJ6F)EWZ6AS%!>&4
MY >1EG@8/\^?$^;_%,:85^3W(>(CCQ 7X4J*,9BL3#WYA>E4UQ30W%A-3V<K
MXZ.#G#BQ*./(<1E3EN79%U@YOL#BTIR,71/T#O1*WVNC6?2C(B]+2W/(M1C0
MAQ_#Z<#3;'ONSPEPVT-6BH[BHASIJW6T]W8S,#'"^,(TLZN++)^2LL^O<_*L
M]-7CQZ7L969FYQF;F&1D<I+QZ6EI[UDM!GC;8"-IQ?'L]MO,KUQ_QO-!S[+%
MN),]%@<<R@,)[$DB>$ 1LHD$#=N]AR,$*CR+KQSS[#/BW*G'N2-:Y#D*;]E&
M#YDP])L(J0[3Y"DZ5^0AZ1A'HG>Q/V8G1Y(/X9;G@:?(B;LBB1M"I<]%XB;R
MY"E0]XJ<-A.](OWS>!Z1R[D8EO.TV-ZA(H?>8R:\1TWX*\_B7D%# NY90;SL
MMHVM3MM%U[@0DVP@KS2?MLXV)N6Y9Z:F1>;&&.CJH[.EG>:&)FT!T;+*"I$W
MZ2]%A125%M+1U\;\J5F*6HLXJG?EC_?_A/]R[&?\N=>S_#1L"\\9][,YW9$=
M-D_VEP9R2,:'0XUZCC3'<JA.+V.*'M_F9!('"LF?:J!TO!%;2PEIZ@N0,AOF
MZCQ2JK()RXLGL"B.P,H$ NM5'.]$O%OD.9IB<6V.PUG@V"BH-\@X).U;8\"K
M2=J\32VFFHQ[:R*N K?V)-DFX=*2*$C M2E.$(MG:SQ!@QD$#V?A-Y F;2OY
MNQ+PZ$[&MT?:L#F%@)I4T5EYE/:WT#,USNC4+(.#(H.](R*'8W3U#(F.[Q:Y
M;Z*YN9..SCYISUZZ!T8TM'4-2)YAAH:E;2>6M#_L5U8VD5M03D%Y+35M7;0.
MCU NLES:TD*5S%<:NZ7]I>R1R269,Z@%Z2XP/76*J<F3S,^?8V7E$HLR9SN^
M>DGF3;>Y<T>M_Z <!-[FC3?>Y\&#CV7_+9D+*@_@XYP_?U5;W/C-^^]Q[<8=
MKER[Q=V[]WGK_KN\^<8#7KW].I<N7N/4R7/:XL+KIRZQ(O/)M=6S+"_)'&[Y
M%&^__0'O//B(:U=?E>.B3Q=D#BGGSIR^Q,V;=^6>[_/I)[_F\\_L8=640\3'
M'W_"9Y_9PZMM?%FG8A%OD,-_G4'\-YU_DIZDOTO:D*N_'HH0VL!WG?\N?#.O
M_%)4D :-1-+PW7G_6] \C>4Z#:J<WRAR[JN'6^SXZB$V?FO8R/LH_R-R;^/8
M1CD*BFBS>Q/;]]6Q1Z3<ADUK)_ 45%E2(\G_*.2$NN;Q^WX+&V29@E;AAP^F
MROW6<S_!/R2(W(H,J,4=?_>];LC1WX1'UVA>O ]E\6LYDNWC>>QRM"'+WX8]
M!(KV1Q"!/42$U%/)T6.R]+LA(!X^Q]>_[==_,\_?A._*K\I4BL4.^^]OY]F0
M_>^^WY/T)/U32T](XF^EW^WXB@2VQR/>((D5-A3=1JSB#6_CCS[Z1/.^4!/K
MC;SJN"*(WW[['8TD5OA<CJDD.I4'[WS(O7MORV3_ :=/7WGX&>"\1@XK3$VM
MR@3^)I<NW=,(X*&11;I[9^@?7!!(OMEUS0ME:D8,B84S6MB)"Y?N:L2QBCVL
MPDI,SXJ!H)')5UD_<YU+5U[CS;<_XJVW/V%=\E55MM+3,R;&R&E.GKRHQ4-6
MY/5I,1S6U\]S2G#F[$6N7+G)Z_?>XJ,//Y5G_9@//_B(#]X7H^.==WGKK;?$
ML%&A,=[DU5?O<?;<1=H[NR@N+<&6*P:CS8*MP$9A12%EC964-)=3V%).:4\=
MY8/-E XUD]M30VIM'DG%%BRE>5CS<R@M*:&[O8.1P2'Z^GNI;*S1C-!011)G
M*Y(X!N<B':[%.CS+Q& L,^!1HL>_))Z8BC22*[.)RS81:8PA-#H<7:R!A"03
M61:K&(3U-#:UB7'825_?L+3G*$VM':1G9F-*R2 CPZ*1*05Y!107%5%:7$A[
M6POC8R/RGJ;$P%I@9GJ:SJXNLLQF8@P&]/%RWW@#L4GQI&:E:0NY-=?5,3<^
MSLFE94XN+S,OUPZ/#5#67$%TKI&CZ8'LS/1F1XXO>TN"V5\1RJ'*<)RK8_!I
M,!+2DD)H8PHQ+1G$MUM([,PAL<V*H3Z=X'(CGGE1',WP9T><$T\%[>2'GIOX
MH>]+;$ESX5!I"/O*@SA8JV)?QA(PG$;H6";&Q2)L9YM(798ZC%GQZQ(#7(S_
M8_71&AFP5\4D+O)A9YX'>W(\V&ER8'/H'IYSW<RAH,.$&H.(B \AK\2FD<2*
ML%T]?H)+8LC.C,_3T=1!95$9!=8<<K*MF+.R298V34A*DW9*(#@\DL"P$$$
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M,\G,EOOEY6'+R:.D1"T4U$1C4Q/EU958"FPD6%,(RS+@GA'&P>P@=N3XLZW
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M9VA$<7IZ%MFV7 I+RB@K%^-2[C<T/$IK9P=%E6*HVC*)MZ42DJ7'*36(_>8
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M=6W=O8R,SVBQ!3N[AFAH;-=B$M?5M5!944=Q4;E&_J:F9: WQ&,RI5-95<_
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M\>R?[O@&?_3M_XLG7OH!7@%.Y!:D"]DO%ER$I4SF1A<Z*3V11).!.)U6/--
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M#Q=+ZXK"O2T"YR89$1<A^B0"^RHU>XM\V&%VYD"&$X=BCW#8=Q<V;J\1H_7
M4I)(1UL9C8T55%974EE50UU]DY+[NKVMAZFQ6587UEF3*^"OK(GQ_S!5P,#
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ML[;UE\NT10]I"R3^#9!5&+^*K23WI3 ^.KCD)WU6,-::HUC^_O03(>C"F)=
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MN8<+FLA\=%>OOJGDI%M>EI\CGN/RY3M" 7W"&_?>YLS9RTH4\=TWWOQER>7
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M]S8];LUQ0H[B"&@QD#A63/%B(U7S8FP."/W86D598SF6^C(*ZHI)*<_$,R&
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M)BL_E=BT"'0FH:)NM&5ZHNN3B6@0?:<BA+#&,+3BWA'-&L+K0E!7^A%4[$%
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M<H.Q%\ZM:ZD&GZIH@AL2B&A/);PU!=_*:-S%<2?Q?ZO< $Y+<#3=A;,YW@I
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M08*^$B26O,I34U,*![$$RG^3Q,?'*Z"XI.3X'UVX3HI\CJ_.5^16EH.DOC@
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M7B1>.>$$%$3CGQ^%9[H*IQAWSGJ?Y67K%[#UO8!SB,AOZ&4<8FUP3''&.R>
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MHR\2:G0@),-)V,I0T@=2R)S)(5T\<^)<CN@#DF,Z@_")3(('C?CU")O5DT3
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MQ,3<,KT#X\(@=;"\M,>&<-IZA7/6T3%*<^L0]4T#M(C?[=WC="B??D[3V[]
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MC#F1*<YD%(:B2 \@*-2)J&@_&AHJ6-]<YK.O/N/!DX?,2J$F>L5<:FE'5=M
M15$Q66EIQ,?%$A4;17!$"'Y!OOCX>A(0Z(5O@!NVKB9<<SB#I=<E?!6"WMQ.
M<M#Y"-:YWB0,EE)[QX#FRTERMIH('<O#:S =[]%T/ =3Y#B[COHH,4Z2EVRX
M[/5MJ0H2].C/94&_%]-M.!M[5?8B_MCT;<[8?,S!JV]@*>@K5O1SUG@>=;<U
MJ)_UD[6I(G9.T,YDKACO##'N"EQ[XW QB'<8HK'M#L>B78Q=:P 6:G\LZD0?
M5;IS.<6$_2[O<=SJ-QR[_+<<N/"?L8P^3Z0FBI+U6MH^'Z3^4P,IZS5R4KK
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M:$<=L5NU1$OQQ]<J"5\JDY/RI>RJ2-IN(':I$O>N1-X..\-?.W_(S]SV\=O
MX^R/O\JI;'LN%;IB(OBW99W@48(/VC:'8]<6B8/$MP6_DKV&NQ->>A#KHO$;
MSI1#IX0NE!(P7X3_HEAG5L0\6JL@<+J0J.ER<A;4E,ZTT+K0R_#Z-!-+,\PM
M+["ROL;*ZKI8^]?DL%.34U,,3XYAF!E!-S] 1G<M/JIT0KJ+">TK);B_F*"!
M8L+&RHF9KB%AKIXHP<="C46$]!4(OI]/U% 9*=-B'9BL(W&Z@92E5I*6VH@>
M:R1,7T9^MQIEKQY-3S<]?0-B#>ZCN:T3P_ T0S/+](W/R5[$%35-%!;74%4M
M:*E9W-_5AVY@A++65N)+BH@M+R%5K,.2%W'']"3#2TM,BW8LKVSR^.%S?O>M
MD&&^@R]>_([K6_?I,TS('KG3T\NR?# \+'D3;W+O_A.VK]\2LLHM0=</F9E9
M$K+& !I-%UU=@PP-S8AG5F0<&U^D3\@^JJ8NC .S<FBLJ9E-(4/,BKDY3F?7
M).W:,9J:AVAHE+R*C:C4_4+6Z)0-Q4JU0?8<;M<-,3*VQ*V[4JX'(2-MW^?+
M;_Y!WL7U[;=_X,&#3[E]^S$;&[?$O%L5];O+[HT';&_?YM-/O^3KKW[@\\^^
MX>F3S^1=8)*1^-MO?_A'V4Z"UV6]/=B#/=B#/=B#/?C3AY>VGG]:_*7?DI%8
MVF7^.DCG7K]O#WXZL&<D_@F!-,E_'&+B=9#.O[HF'5Z_[;OO7L8E'AX:8WIJ
M@<]>?"W*>GG#UU__7HZ'-SN[R990LOJ-,^B[1N3ME@M+N[)BL[YY^[\H7JMR
M<CII6^;*R@VAS-SCZ=,OA0+VE,VM71:$ CHP."QPA+7U;;:V;S*_L";'(.SM
M'V=X;(&QJ54&1Q?%N7'9$"T9H>_<?<'SYS^PNG*;GIY)&E7=<KB).F4G=6J!
MS5TTZ?K1&X;1]PS0T66DIWN0T1$I,_@HVO8N:FL:J:JJ%5@M!VV7,O=75%0(
MI:Z+\<D)1L;'4+4THVYIH;FY32AT#>3EY9.6ED961B;%^?G455>*LMJ8F)YB
M:&J"VE:UO&U?"DV1GIU#=74]3>HVFE2M5)?5T"*.1J$ M[:WT]"FIJ*]0382
M>Y7'89KCBUEI(":5 5RK].5:N3>6-0'82L;>ZD N%7IP*LN)T[G.G"UTXT*9
M%Y>J?+E0X<W%:E],E<&R!["E2J!DU%"&8%+EQZE<)PXF6\@H>2";U 5BV22%
M;(C N2L)YVX%=I+'IT"KEG!,&H.X+-Y_M=R':R6>G$JWY6BR.0<3K_)>R!G>
M\C[*V^Y'V.=^&HM(1T(SHXC/22*C*)/<\CSRJPII,VHQ+HN^7^Q%LVY O=5#
MU9J6W!DEL7VBO4T*W.KC<:^+PZ,V#J>2,!SS@K!*\>1-L_W\G^__.?_WG_\+
M_MFO_@5O.AS$2Q6#ITZ!BQ1*HB,.=RD>[6 *;L9$;'2B?S1!6&A"N-H4R#55
ML.PA?5[*[%_DSH4\9TXH+/@D_!(?>)_@#8=]O.=YC%,)%CC4!.(JVNS0%H)Y
MDR]6F@#L17G.V@A<VB-QU<7@T96(A^@CEW8I)G00YE6B7\H\N%SLRJ4"9\ZE
M6G%2E'W4\R3'; ]QP?H(+KZFQ"7Y4U"<3'YQ*A6UA:@UC708=/3T24:0'KH&
M>]"/&V@:ZZ2DKY',CG(RNRLHFVJF8K:5DLE&LHRE)'?EHM!GDM"2A&V<%6=<
M#G/.X0!F+L<(B+ BMRB"@M(X\DL4XETIY!6D4"K&0:MKX_'31WSZXE/6U]>9
M&AVGKZ.3YH8&0;LY)"?&$AX>1&"P#X$A/@2%BF.09"1VP]W;!A/[,UQT.,XU
MKS/8A)MPV/D@;UB]P_L^IPCMSD']; 3=-].D+=7B/Y"._T0V7J-IN TDXMP3
M@U.GH"E].%92'-^6EQ[@4M^9Y+M@EN' I2@3?G;R;WCOS,\Q<3R,J?,AW.+-
MB5.)]HP5H+RI1?6HC_35!F)F2V6C8-!4#C[B'<Z&6,S%6-EVA^'0*VBY392M
M],&RS@>[6A_,\^PX$7*"=\U_R47G#[EH_28?G/PSSGKLPZ_"BY*E*C0O!JA_
MTD/22B71<R6RIW+ > :N_0DXBOH[=L?@T!F-K4:TH3D8>PD;?+&K<L.IW(6S
M$2?XP.(7[+_X=_SL_?^#O_GH_\U9_\/XUOB0,II#[GHMV=?K2=HH)VP^!]^)
M%'S'4@B:%._HCL6A/0P7T3_.HG_L6@7MJ_RQ4P=BU^"/E:"OJYEB#%(ML$JW
MP%)Q%0<Q!YV3K+GB<QIS_TN$9?BC&VIF9*:'WKY6U,H*ZBJ+J"C.(S<CE?B8
M*&($Y@L^I5(IZ>S0"=32VZ,7J*.CLQ6=OIGFEGHJJXHH+,J2$]ME9RM0)(3B
MY6')Q0L?8V%^%!.33\3OCXB)\J2J,H>6ECK:VULP&HV"OZ_R\.$306>?"7I[
MS,Z-+5;7%YE;F&9L8ECPTA'96-QEZ$3;K:5%WT2YJA@3]ZO\[=&?\Y;#)QP7
M<]%$\#LK,;^\>A.)6RZEX'$[&7>4Q&V5$[Y:1,!\+KY3F7(8"K<^*8YOG&S,
M=^^.QZ]'080AC0C!(^RSG3GD\@F'G YPQ/,HIR(N8)'G).:Z/R[-X7@(_N$J
MGG'LC<=E4('C0 *V/5%8:(,$'07*7MT^1BG<A.15GBJ'&;$1Y^QTD6*<!)\2
MO-4LSX5]0:=XV^L('P2=X52*&*M2/YQ:XPD:R2=]NYG<VUI2ME7$K%01ME!,
MT&P^?M.Y,OK/Y EZR,)W/(O0V6+R[VDIO*,E<JR08VD6_+W7?O[:]0/>#CO%
MOL0K',VPXKR8-Z:")]O4!>.H#,=>&2;H)1S'=D%+^EAL!+\R;PG%S9"$O^1!
M/))%H!2_>Z&$D.4RV9O8:3@->\$WG092"9\NHW!31]%,"^KY;D:V9AE?F65I
M:YV=VW?$&&XS-[O([/0LZVOK+*TN,[8TS<#Z%'F&1KP;4@GN+B)$\*C@@1+\
MC86$3501MZ D>:F)I)E&%*,U) U6$=M31'17(0F&<D*U.81U%) TH40QK29E
MNH7LB7:*>EO$>MA,?6L+RF8-2K7 9IV@&2$+#$W1.SA)O4I#644]I:6UE!17
M4]_00GM'#TWZ+C+%VAV<EDQX7C9I]=6HAOI9E791;&\S+-JPM++!\V>?@="'
MOO]&"F_U QNK-U$U:IF:7&)Y99NN[GZFIJ6/UCML7[\I[W+:O7&'^P^>")GC
MD>SAK-/WT"WD$\F35_K@/3(R(^0#O:A3O9 EFFC3]#,XO"#DE WQSENL;=QC
M9NZZF*/S8JZ-T*@TRD9BR;-8\C"6DM<I5;U"[AB3/[(O"'GIF^]A]]8CUH0<
M]=F74K9N6?1"<@A^].@%&QLWA.RTQL[.76[=>LCNKJCC_2<\>O@I#Q\\%<=G
M\N]GHKT_2-N_]F /]F /]F /]N G"Y(]2#( OX)_LO^\M 5)*-VSYT7\TX4]
M(_&?,+R:Y*_#Z_]_;##^;VTID&Z1/(FEK-BS0DF<GUOFP?VG?/_='_A>*"\/
M'W[!Z,@BO3T3&/MG:-48Z3-*H2#NL'/S*7,+VQB,$PP+Y6EF>H65%:%P;=\5
M"M4MV4C\U5<2H_H'7GSV.2NK:PP,##$T,L;.K;M"$=UB8GJ1J=D51B>69*^:
ML<E51L:%@CJQ*GL0+Z_=9GWSKBCW)L8!H:"U&JBNEV(.=U.CU%-2TT*U6D^;
M4"Z[!L=H:-.B;I.,<T*QFUE@8F*&GNX^ZNN55%1445Y9055-%;5U-:*L9@:&
M) ]B*0F>3BBJ*JJJ:V2/X]K:>FIJ:BDO+:,@+Y^ZJFIT;6WT29G8NSO%>YHI
MJ"XG-BV%U)P<ZE1J:NJ4J%6M='7T,F@88F9\AKF9>70Z/455I<07IA%5E8YW
M61Q6A4%<*PG I"H0\_I@K!I#<6J+P543ATU=")>+O#B1;L\!A1EG"URX6N7'
MN3)/+M?X8]T2A7M/"@Y:48Z4R5Y*/%<;("<^.IGMP,$D<_8EFG(XW9IKU0$X
MMB?@V9N!WU N[KVI6+5*QN% +M?Z<;'*ETL5/EPJ\>!\GC.GTFPXF6K%484Y
M[P6?YE=N!_F-LQ3/UP37U "B\Q.)2)&R^R>0D9]!864AM2UU:/JU],SU8]@8
M1K?11_6LAH(Q):E]%41K\PAKS21$G4Y@?1(.60&<]C?EUY<_X%^]]^?\/W[U
M?_+/W_ZW_)LC?\7^@/-XJF/QZDC"IS^=H/%<HB3ON/%,.2:MM38$"RDV<;/H
MOZ9@KBJ#Y3XY6^C*F1PG3J7:<C3Z&I\$7^!]]Z/\TO)]CH1>PE+TI[,J'#MU
M$-;- =CJ@G'H#,-1%XI#6S#.;6%X=L3)<4R#AK/Q$^_VT,<+C,.Q-0R36B_.
M%]IS(LF$0V%G.>)[DE.NQS%S/T]HG"=IV='D%R934)1!F>B39HU:T/4DDU.3
MC(Z-,KL\Q_#B!-KQ7BJ[562J2XBI2".H,([@XAB"BB+QR0G$.\<7^P0[SGH<
MY\#5M]A_[E><,_V0D'!;<G+"*2Y)$.6G4UZ3*[" THI\*BJ+:&BLH:NK@\6%
M>6[=W&5%'(?[^] T*ZDL+R G.PE%4B11,8%$1OL1$>U#2)@'OD&.F#F>Y=<'
M_YKC]@>QBKK&12FY7/AY3D5?XDBL"1YMB13M:&C_>I*R>SHY!(#DY>L]*AGN
MI61LX3CHPK#3AF*ED3Y>!&!6ZRM[=#J4^N*<YX6=U";GXURV/XJ=VQGLW$_A
M''J%L&(?:F?%W+IOH/F1D:P5)3$S981,Y.$[FH;'H *7OACLQ5C9ZD.P:1?C
MUQ* C<H/6\F+N,R5*^GF' \^SC[[MSCE\!['S'_-.Z?_@@_-?XF%&*\T,9ZJ
MQSW4/S.0)GEYKE;(WJL!4A*S_CB<>B*QZPC#0M3=4B/>(=!6M,&VUAO;"C?1
M!B=.A!SF;?._YXCM6QP5>,#F-[QK\P:G(D_A4.5!6%\2F>M5Y.S6$S.?3]B4
MH'<ISNY0*M[=<;CKI? '4;A(\63%>R0:M%1)B1,E0Z O5I7N6)4Y8U?FA*-
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MS7%L#,.]1X&WU*?S^02),L)$^='KY<0(C%HK(WRYF.#9/,+FBXA>*B=DNHC
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MOE;08E,RX?I\S%)]Q+RQPSK,%<=0#]R"O? .\2<X)H*@J$@"PL.)2$XDM;R
M;'4%,5696"9Z<<#W,D<BS3F18,O9=!>N%/EB41TJU@2Q?G3F$6ZH($Q?BGNE
MZ).\:-S$G/4M2L1/K*=^#5GXB_770YV#:V.6H-MTKB0%<CG:%_?L1)*;:LC5
M-Y'>UD!ZIYJXUAI"J@M0U)>3JZJELD6-IJ>;T:EI5K>N<_O18SKZC:3EY@M^
MTB%XWSR;F[OL;-YB:7:-B9%9IL87Y22Z"_.; H5\(F2+D6%I'5Y@:6&3C?4;
M,DI&WL>2%_'M^^SLOC0 ?_KIIW*(KALW;LBA)B3#L.15_.3)(_F:E.?ATT]?
M\.CA$YX^?<X77TH&XN_X]ML_R$EYI=C'QD$AF_0,L[XIQ0!_S/7=!_+OF=D-
M^HW3M+;UB[FW+&2G;5I:!^1XQ;H.*3S%"-V],_3VS=+1-29D##''EH0\M"H9
MJ9^(]TH&Z6_X\DOI?;\3,M]+64^2_5[FE]@S$N_!'NS!'NS!GSZ\LG.\#M*Y
M'Y]_M4:^@C_VW/\L_+'WO(+_U6NOX,?7_Z^>>77]_^J^_Q;\CSSWX_+_1Y[Y
M_P>\_LY7=?AOU>-_]=I/$?:,Q'_B(!'[*R/Q*[J7CD)G0$IB(L4<EE R#'_Q
MY=<\?_$%GTK&X$\_Y^'C9]R^\T!.BO+U-[^3MS%*^/SY5T))NBW'Q9N:W*"[
M:P*EJI/:>BTM;7WRMLG5]5O,+VUA')IF;&)9]@1^Z2DS(\?<V[WUG*&151H:
M>V2/&4D1DA*V=.A'Z17'F9E-[C_\G!&AO'4*I4K*#G[GWF>B/B]87[O+@_M?
MLG/]L;AW KUN$'V'%)-0E&$8H\<X1O_PA,!Q)N866=[>879M#;W10)FJFOJN
M%BJZU&1IJDAN*R6VN8"8U@)2NBO)Z*\1QW)"&H426YV ?U4B(76IA-6F$5Z=
M3D1E.N%%0K'.220J.XF8]&1BDY.)3THE,Z>0FGHU/7U##(](R<(6F5]8%>TR
M4M_01$EI%1D9N9045]"I[V%^9H'5Y346YY=8FE^FN[N'XM(2TK+2B4]7$)V1
M0$16 M%%*:0I"ZD::*%QJH/ZN0XJY[6D]U<3WI2)?V6"[/7L7Q!#5&D2B15I
MI-9DD=U80'%[.26=5>3IRE HLPDMC<<W)YS@HCCBQ'U9]074=:AH[FVGJ:L-
M39^.IMX62MK*""^-Q3['A\NRD=B32[6^7%7Z<ZTI",NV".RUL3A)<2V;X_!H
M4A#1GD->3S7-HUJ&EH99VEEB<7V1;D,/=4H5^<7E9&3FD9*4@2(NE?B8),)"
MH@@.#B,LXJ61V,K1BH,7C_"!R2><"37#O2X*1U445DWA6#2'8ZF)P$(3AGE;
MB+R]W$;:9B[^6S0%8J$.P%SEQY4Z3\Z5.W$LWYK]Z>9\%'^9#T).\9[K?GYC
M^29O6+S!1QX?<S'9!.LR=RS*/3"M\,2BSA^7]AB"AS+)W*RGX7DO&>O5!(YD
MX&I,P:8G'LON:*RZ(KC:)/JBWAOS6A^N%;MQ04J(%WZ5TP$7>._J._S-1_^1
M_6?>PS?*G=KV:G0#>KH&>N@?&61C=X>M&S=97ML0<V$>H]&(7J^EO5TRJ-52
M6%%"0449F?FYI&=ER"$ALK/3B8N-P-7)EH,'/N3DR2,DQ,?04%>'KETG>Z,K
ME<TTJIII:=?3W6]D?':6E?4-YL4<6%U<X<;V=7:O;[&TLLCPY"@]HX.H.C3D
MEA<2%!&(O8L5E\Q.BGJ_S3G7$SAF.^/1&HJ7,0'W805.?3&X# A:&TV5O3FE
M6,T2AHQGX3^2BM=@HNBG6!QZ(K#K#,5.&XQ9K3M7<VPX'WF1WYS_);_\Y*\Y
M<64?T0G^5%3E4Z^LHJ:QBB9-,WW#@RRL+K,I^N?ZS1ML[&RR<U/4^>:.G&1M
M8+@?;7<[+9W-E*M*22]))B$G"L\@&RZ9'V+?F=]PP/(C+D9?PU,5AG=O IY2
M;-J)5 )F,XE<+42Q4TWD6JEL>(V2#+D+>03/9!$X(<;8$(=C9R1.^G <U/Y8
ME3AR->XBYYT^Y)SU.USV/(AEC@4.S;XX]T7C/"S*%^7Z+TO&X"*B5RM0;->1
MM%-/U'HY@?-Y^/Z7)&M2+%W?\9>QLET$#3O4!W(AR9QC@:<Y&WB.LR&7N9;N
M@'-KI*B'J+/HTX#Y @(6"PA:*B!4U#=BO4S&L-42(E9*B5NK0K%11^QB)?'+
M-<0OU1!LS!9S1LP'A2W'G(]QPNH0EFZ7B4D)I:*^1/2Q@9W;NSQ]_E3P^">R
M%^3V]J8<=F)D=(B^02.=O;VTZ72TZO2T:G6"I[>B;FY K:ZFKEK0BK\+EF;G
ML# YA[W%%:*"?%%6E;,R-\W.YAH+LS.,#8^(=:$'=5,+9575<FB9I#0I!G8"
M<0D)*)(5I*0D45B41VU=)74"<W)3Q;508A*"" AUP\;Y"L<N?,"QJQ]R0;3%
M4HRK7;8=CE4>N+0%R09]N\XP/ 1M^H@Q#I[+)7:MG,3M:A)VZHC9KB%42OBW
ME(_?@J#1A6P\)Y+%V,7@88C'O-J3?1%G^#N[=_B5^P$.)9ARK5*,K3X._]%L
MPA=%?R\*&IDK)&0FGX"I'/$>,9X"78=3<1Y(DOF"8[?@J0,99"TUDCM<2YJT
M&Z4PEL"T<#P2 G"*]<(MQ1_/W%!\RB,):HPGL%G,(\$W'=2"%C0Q.'4D<*TA
MD"L"[3OC11L:2+FM)OIZ#1'7I5C(543L5!&X4H+O7 %>4WFX"_2;*2%^I9'*
M.V)M6]63T5M%>)D"1_%.RS!G'%."<,@(PBD[&(^"<+S+8_"JCL>M-A;KTE N
M9GAP/-J&TY&V7(BPQR3"$<L(5QPB//&,"B L)880A5A;!.^)SA-KG*J,E.82
M+H3;\Z'G.?8%7^)"IC,7L@1FNV);'8Y;4Q)^^CPBC%4$=Q;C6IO$U51_''(C
M":A((52LHU'-A82U%.)6DXJ56)-.IP;P49 ]YFD1^)9F$5)10'*[DC0QUQ/:
M&\@PMI-N;$/164^26+=3U>5B?2NGNDU%B^"=O<8!UJ]?ES^,Y9>68AP>8_/Z
M#1X_D4)J?<_]^T_86-^10U1<OWZ']?5=%N;7Z>\;$3C,]M8->:?49R^^Y(O/
MO^;39U)BWT>R=_UUP3=?A9/8V1&\>VM+_B^%G'CZ]*GL7?QJ1]8WWWR-E._A
MB\^_D$-V??/M=WSV^5?<NGT?@Y +M%HI2>D$N[L/99R;VZ"W=Y31T04A\VQ@
MZ)UD:_NAD'4^E^4A7<<H^LXQ-%I)OIFB?V!.EJ%FYK:$C'6;C>V[?/[Y=[),
M]\/OD(W$7W_UG9#O7GH/OT))!GPE!_X8]I2B/=B#/=B#/?C? 5Y?KU[]?GW]
M^F^=>[4._OB\E(OIU;D_=OWU__\C()4AO4N"'S\O_7[]':\?I?,_?O_K\.-G
M)?AQ63]^]M4SK_"_!Z\__\=^O_K_8Y#.OUZ/UW__&%XOY_7?_ZOP>EFOO_?'
M_W\,TGEIC%Z__]51PA\_^^K\3Q'VC,0_01#T+QCC/_Q7!F(I^_6GSS_GX:-G
MLF+U[7??"Z7C]SQ_\9506FX*)>>!O(514D0^??Z5O"5Y=?6F;,P='5FB7R@N
MNLYAV9OWX9,O^4'<^^S%U_0)A6AT?(GKNX^%4G.7::'<3,ULL;7SA.&1553J
M?IJ:C7+BN^86(UU=DW3JQ]!+(2QZQVG7]PLT"N5(VIZYP=S\=2;&5QD=7J)/
MVI:I':1=(\5$'A'OFF%H=)Z!X6EQG.'V@R=\^N77/'[Q@EL/[[%V?8/1V0G4
M/1H:^C34C^C(U%<1WUI$G*:85$,UV4,-I/55"D4^A8!:!:$-J42H,@AK2".X
M)IG@RB0B*M,(+TS!/RF2\.0X8I.22%"D4%I637.K#EU7'[W]HPR-S3 \,4.M
M9" 6UVIJE:2GYY">EDUU91W]!B/#@Z+>O?T,&H=H5K>0EIY!2$0XH5$1Q*8D
MDI"=0DY-$16:>BJ$LES1T4AI5R.Y'=4$E2FP3_+#)260D(($%%799-<64*]7
MTMK7CK)#C;)3196FAHR:'((S(O!,\,-/$4Q$=BPYXMZF[C:Z!WOI'QT4.$1'
M?S>Z@4Y:!]I)JL_$M2B$JX5>7*SPYG*#'R;-@3+*QN*& .Q:(G%HBL:^/A*G
MJ@CR!VL9V!UG8G>*V>MSC,R-T:QMI:JNCJ+2"K)S"E$HTHF.C)<-Q%Z>OKBZ
MNN/FX8ZCBP.7S"^Q[]Q!SGF98IOEBWN#*%L5B6U;%(Z=<=AJ([%J#\-*&XI=
M5S3.AG@\I+ 20RGX&)-PU4=AWN##^3(G3N3;<CC3FH/)INR+/,\'[@=YW_%#
M#GA_PJ4T,RS+7;"I]\:RP1?S1G^LFX)QT8HRVR,(&4JG[%8+U0\%C>PTXC.6
MC>- ,K9]"=ATQV#1%BQ[*=O6!6);X8M5KBN78\W9[W"0O_[D/_,??ONO.7#E
M RZ[7L GT9?N&0,+N\NL[*QS[\DC-G9V!'U,H--WTM;20HM:29/ THIR,O+R
M2,O.(2DEE:CH* ("?.2XK[$QX;BY.K#OH_<X?^X4596EZ-O;Z>[HHD/?05NK
M!IWX/3P^R?S**NM;U]D4N+2XPI0X-S(PP,C0  9#-VV2QW)[$Q5-=>24YQ,9
M&XJ3FS5GKQWEW>._YHSG*=PK_ @T).([EH+;B *'_CA<AZ6M^ZEX]"?A/Y).
MR&0V(5,Y1$A)OE:+B5TO)7@Z$_?^6&PT05RK=N-JGATF"@M.N1_GB-E^+EJ=
M)"DSB@9U)2WM:IK;FVGOT&(P]C,Y,\WBRC++ZVOBN"@;M)=7EUA96V)F?IK!
M\2%Z!KM1Z564-!2169I"8(0K5RRD>O]2#B%R/MX$U^90? >2\)U*QV<F@Z#Y
M',(713N7"XE:*Y4]<B.6BPF=E\)!2*$+4O$5[?*2#'^=T;A("<SJO#%),>4#
MDU_QX<6?B?KOYTJF"38MOJ(_$O"<2<=C-D,<LT3Y!:*L(B(62XA=JR1LL8C
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M?U4&8EP?AD%]"'K5 5RH#<&R,1;7MC2<U(E8EH9CE!. 6;%<-%74OS00O?(
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M\+N_^[L4"Q](BFX>E-<H<ZW8RO^_.3_*_^4Q*3OSU_VNRV/G-=/"9JVKJU,
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M+'>Y=$5&$E]10/V[=R4X_$BQFW3.G;2+)%W7M6O7&1N;$#I8].F-2^+XSQ6
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MRL5W/!/G@41,.\(Q: WD?*/(3^7&\1([CN9:<SS3BD.)INR/TN>CD#/\S/T
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M35LG_;U#K,FH+]''IB=FZ-)V4U-=2XF8F$K*2L5$F$MB8CP!@?XXNSMC[^J
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M,)1ST?8<\C7DF+\))T,M.19F(72,(9^$B-^2;3$K\\>XU!?K^G!\^W/P'RW
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M6RGLGG^_NW<>*L"P/-X3RMJ=N^+ZYAVN7=L599(;U]U2K)UOB# )$LO-]4Q
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MII9A*C1MJ,L-5%:)8V4+997-2AJUC?T4E;20GEE+5?60& <#8FP92$^O%W-
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M%[&T(-[:O*J Q4_$,W*6ED"Q5(H>/?Q<*$IW%:!8NI>0Q[MW'HFX-UB87U7
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M0O/"R-"D4517(,9B#=T#G:*\<VQ>WN;*]1TN"]ZZ<I6EQ67ZNWMHJ*ZA5%5
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MV1*!DZWA.&8/PK'&0)RT!N",R@^G"MQQ--8)Q[R/X]C5PSAZ_1CV^9S Q8(
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MY=4U*" 9F9.33[*R&(G)Z4A.S8*LO$9XVS8TMB S*P]*E0[U#78:RUUHL7?
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M87'Y'J;GUDAGZ"8Y6$UCQR(6RINB^9H]G/D%,;\L%S%VJ0"<__O"F_:)(24
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MG__\YWCQQ1>%EW%E9>5CH)B)\_!T/GX]\75<+F*^AW<E?D3?.D1_ON&Z?N
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M7!06YB$U/1F)Z0DHJ,R#?[P_=EW<@^=WOHJ7SWR(?4D7$=Z9C\2)*F0LT[A
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M==+XXM^[=Q^2L;<DO(E'1GG!.?9 7L?X^"*Z>D;1W-HGP-U&>Z^(.=C0W"U
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MA=,2R"VE2\S]E9DO>K#^$!WF3N2%9"'B; #TB568MH[BFTG*]S25?X9*/_,
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M+N/,L1,X?O@H3I\XB;-GSN+DZ=,X>/@03I\]BXBH*&1F9Z*P*!\EQ86HJ:R
MJJ8:RFHRD&M-:&JD^K51OFF[KKZ.^J =LLIR890TV!HQ.S6/S=OWJ ]M8G1L
M#':J)VT5U3LI DG19!2%AR J.APWPX/@$>2#JX&></:_AM->E[#;Y2@^=SV
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M;1#!OD)&JA Z7H/P*4^PK\C)6@$4WW!DX;(Y&1=U5"Y5-,Y)PW"LQ@]?9%_
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M+,8>K:#<H<"5\KLX5W,7/NU9B#36($G?@B15,U*4+<C2RA#66(*;M9GP;2O
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M-F&0E,O*M!T,-C- S;]Q.1B 9V& EMN5Z29V@\2LA_!G[@^O,#T' ]E,C<$
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M)Z;(8"]K!G,91.:R<# Z]B1FO(8!:@:.F0J$Z\;E8N]N+@.?QX'M=M>KH*!
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MD84)R):5(U]5C^;N3@P^7,+H@T7T+(Y0'C:TV3M1SU07LGJ4R!I1HVU#H\V
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M!S TN(P>URP4,BI79Q]D4B/R\VK$FT#M[;3WR#1B+Q\8F 2_2<0<_^P1RL+
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MA<"V#-RLCL')9!\$%L8@O:$ Q2T5*&NJ1)NV'>.38YB9GL8,&>NS$S/87-[
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M!D*6E]91)+U<R(]C=^<I-C?VL+2XCBV:*ZROL:SQ C'51>NJZR <?,7L0<P
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M+<?L9Y"0PPM$8M0'TI,BW #'[%>K730>6L2+6OZ:)I/-88?:GKW9A#>Q,$2
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M?M'U"5YO^@SG!NZC33\$C<<,E5F',844<H4,^4(66]OKU)^KWE%/R0#>6M_
M9&4<F60: 5\06JU6>*'V#?2CLZ\++9W->%!_'U_>^!*?WOH<'][] F_<^AB_
MN/LA?G3W!'YPZWW\MOX<FLS#F'RZ0N8EZ1$RA-B+>'OO$(NK&ZA4II"@]O0Y
MO'"8[-2F>N@T.AB,QJKW\)!$ .]C8W)H-7H!'/.";#:SC:[34W[&$(W&!;A4
M>Z'%'HC+JRLHC5<0B<?@]GFAUFHP.CHJ8O+*QZ08[A] >VL;AH:&!0 JTZA@
M]3H1SL00+Z5A#CC0+NW#E88[J!OIP(C? /MT N[U AP[1>BW,AA:#*!UUH:'
M4WI<R8W@8J(/5V-]N!T=0G-* TG1#5TQA-!D#I/L5;ZYB5W*W_;^'N8YG,-X
M&:%D'/Y8!/YHB&3$"Y7#B'M#K0)<_\Y'O\%_?/T?\8//WL!C91>\E-;BSB*U
MCO =QB$##X?\"??:5Q[3H7 $3I<;-H<31K,%!I,9=J<+Z4P&I7*)]&J>]%:(
M]&1"A* (!D/04)V/2&2PF!TH%B=$2*&5C75,+\Q2'\["%_2C;V@ =>W-&- K
MX2@GX%S*HS_O1.^D&SWS'K3/V-$T94+S).F#&0<&J6YZ9KRHSYI0'].C+^Z
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M%'$G3 LI2&9"&%@.H6?5C[9%)]I77&A9M*-NPH G$R8\+AGQ(*U#1\X!:38
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MZ.:OB&292L7>Q/RU#*==G>/2<2XP'=A<7Q3QB+6D%[H['Z*]]2XF)Q)TDCV
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M]#JF)U:HKQ<H[WXH-781[U=G<-%XX4 N6:3KYC$S,8MD+(N%N57L[CPC';T
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M3\["/AY ;FL<4WL<\F #&X>[8K&T7>JS![M[>+JW3]M=K"TMBX7IV)/8:#!
MJ59A1"'#Y;LW\<FE,SAWYPH>=S>COJ<5=9V-Z)+UHU79CR>:/K1[Y.BAMNLO
MF]$W;4'OD@.]&R1'NT%(]H*0[H>@W(^@8U*'6X%NG-4_$=[/)[NNX<ON.[@O
M:<6@24YRYD.XE$:TG$,PFT(@33(4BR 0"6-\8AS+E,?UU37QDHF!80:@JCKH
M$$LKJ_ 'V .?/52MD Q)H)#*83(8H:*R#(](T-38A+.?G\'=&W<P/""!R^U'
MB=IXA=J2P]X(0)AX:W/O*V9P:WY^$85"">%PE/HN,\FT/P"Y0@6I5 :U1H..
MSD[4U3_!P\</<85DC^MOE_0>+Z##=NO>P7-L4]HK2QN8G9S'1'D:A6P9R7B.
MTDV*S[_=U$>\@0A< >IGB1!"TUE($B;<LG;B,\TCO*^^@]>DE_&CSH_QO<?O
MX<V.LWAD[X=I(H0RM>\&&>MKS[8Q/C^)0"P E]<)B\T,J]6$3#*!M>4EH6AY
M)?Z=W6UL;)/.YD4N5U=$R)%"OHQ$E'1/("K">62R1:KW:51(+H)!TE,N)^*Y
M+#S1* PN-W1V)]14UUJ+%5:/!]Y$!,$BZ;]*"KJD%ST.%6Z/=>"#!Y?QVOE/
M\.'-2W"FXE@BN9NE>LAD65?%8#:Z8=136BJK"/,C)5:J.<YP4,3KM3@B8K$Z
M;R@+G<F'_B$U)&,&C,A,&)8:T#NB0K=4A79JCP8%]3VK$=T!)[$;C7H#ZN74
M/EH3.C1&#-M<,"52D%)9M $_8E/C,(1X04X7@OD4XN4""E-3J,S,DRY+(%^>
M%&VWN45]A.1D@V2"@9;M+=*UI7D83%[*BY[& B?IDWG,S&TBE9G$J$Q/^91#
MJ[<AGY^BL8_N(SE@L)5Y=FX=5D?56]CABJ.G7XFN;CF-1R;H]:2_[4D8C"&,
M2LT"(.[M5Z.]4RK&(@X=D<[.5N,R2RTP62(BM$1;QYBXEE]N,A#''IS\98K6
MX(+1XD,\54:N.$WZ.R<\1WE1,P_5__8V&SW \O(VZ>L$IJ:6J%_Q1!Y? <2[
M>\]$_/Z)\1GA93XY,2>^WN&O)Q@PGIF>Q]XNQQ"N,O?)VIRA^H*8^RI_NDT)
M'E'M/&^/3_Y?&@#_.OJZ_GB^QO7*(.:102N.5]MS;_\IR3$O,+A*<KA$LI)"
MWY ,C:T]&) H:&S*8&.+$:&O,#=,S:["3O,9JY-T \?0GN#%0->0+ZZ1#$^1
M?)H%2.REN4\V/XOQR15,3-,UE044.,Q$?@[)]"3)?)ADSP*9BN97PRIT=@RC
MJ:D7 P-R<#QR7O20%T;FO+)<U/CKLE7YWT8L@_R,JBR*9U%Q&5/D0WL[6YB>
MR-&<3 FM>E" Q&O+4W0E>]/RO)47<^60"]4T^!Z1%*=#.T^?\V1R%W/3$6BD
M=;AQ\4T!$DOZ&[&Q/BO2>/:4PVD<T'UT(]][='^U;+4#O\\OEIM_U?CW2&2(
M"G0<G'U&]<:'^-31::9G3VE\FTK"9NA#?^<M6#7]F*EP+.%MNH5CWK,W,:.5
M)$OL_2P4 ]](_RG-VKFUE2(LZD:T/OP0]Z[^#DWU5VDN&J=S5$<<DD(@U/Q@
M.O1M4*TBA!<N,=75,RK__N$./9;:C;:'BZ2O^ENA^.BW&'GUAY#^\N^A_-4_
M0O/*/T'ZBQ]"]MM?PWKC(M8S(4J# >(=ZB_\I2.U%Z7WI\SZ<5EFKLH-R1:U
MEP")N7VHRI;S2[#U63%\NQ\]5SO1?Z<?_?>IK1[U8ZAA"*IN)?0T=AAZ9;#1
M&&%J5D)Z0X+6SYHQ=&\(06,0^^LLM_S0(SYJO^,%XMVC1XHM9>GK:QE\%WDB
M9N&A@Y1CEN*O^(7D7M)?,!W74T*VC_1WC6HZ_5]+?"\[JAU/\SCQ\1K7J+;/
MV]KSF8]?>_R:VCX37W=\[G+\'%,M+:9_+ATF_EU[+M/Q_?_1ZVOT3=>^>*Q&
M+Z;S3=<>/\;;VK.^Z=I_B6KW'[^O-M>KT?%G'"<^QM?6GOM-US#5SO\ETTN0
M^"7]V>EX1ZTQ=^"J)S$KSZH16(LOR& P \>LQ'D2S'$&&2CF:QA YG 3M5AS
MW/>/>W#L[3Y%+ELFPS4,FZT*%+.'+6^-1J_PS&5#@P%*]H92:1VPV(+"V/8%
MTV2TS L#V.X.P>T["M60*B$6RXJ5UE=7.8]/!>#*X+%*92/#QBB WE"DB$BL
M+#Y[%"OGRZR"V4CG3W8Y%F1'EU1L+;8H@N'B5UY>_!FOTQF#RQF'VYU$)%H%
M4=E[AKVX&$SE_'H\"02"&00#:?@\<03]*80"*;%(D=]+]SI# B!/4YZ+A2DR
MOHM4'^/">Y@7H,EF)\B 7Q0+ "TMK(M/X]F3>)X,/?ZT=W9V42SFY7"P1QD9
M^S.+F*)SX[/S6&  G]IC@R:]XZNS**Y,(ST_ 5\Q!7LZ!D<N"?]D"99\$II$
M$*J(#S+V'/1Z8(_&X(FEX XFJ&[#9!2FX?$F8#1YB-U4!V3T*0QD(,:02+&7
M=Y[*&A$@M]<;A=7J@\GB@<[BPI!:AS&+%;J '_J0%]HPA\!P821N0UM8C=N>
M07QF:<%)0QW>D=_!J]WG\=.')_'K^Z?P1<]-M-DET.8]<,S$82U'H(TZ*3TM
MQO1JJ(TZ&,T&]/7W0B(9)J/31>T<1#))LE&:$)]')Y)9DHT /,2Y0@&KZ[Q8
M$B\FQ@;;4Q%[=VMC XMS"R@7QY%(9&%W^C P(L/@J P2J0+]PR,PF^W(9TI8
M7][ RN(Z)BH<_YKJR.6'3F?&L$2&SMX^/&YLQ,W[]]'9UX<1N10*C9+J)T8&
M-+7K3 GJH 6C$3-44T'(%@)0[9!<(H?6'0]N+FMQ;GX,YY;'\/%,+]XM-N'M
MS!/\RG4=KYFNXDJD Q=L]7B[YQS^^Y7?X*=UI_!VUR6\WO E?G+U79QJO@AC
MT8W"SA06GZUC_7 ;.^*E#0/#^SC<W<,!QP=?8^!R&JEH DZK V:CF636B#&5
M K<>W<<'GWV,U]_[+7[WT0GB]_'^IR=P]NXEW.A]@B?F80P7G9 OA*!8C4"]
MDX#R, GILR3&B.5(0O$\CK'=()HG-+@1[L59:Q-.R>[@_;ZK.-5]#5]TW,35
MK@=XV-]$W$+<BN;17KA(#LNSDYB>G\,ZM<D>OWQB8)ACGNYQ6)7JBR;^(F%V
M=@'!4 0NCP\N-_4WG5$L9J=5:R!7*-#2VH:+%R[BW;=^AT]/?HR6AA:DTWDL
MKJYC@^X7(/'.@0@QL;ZV+5Y8;6[L8FEIE73'%/7)K "'8[&$X$ @!*U&#[5:
M*\)7R.4*C$A&,3PTC+K'=71.*\+ '(B7:<^PO7.(S>U]+"ZO"^ UG6'O7.K[
M'#+%%R09\\)L<\-@<\+L=<,6"\!:"*,WJL-]_S!NQR0X&^K$"6<=7M/>Q,\&
MSN"5OK/X2'$?#[Q#&$@;H<K1O2FZ-^*$Q6W!B)3ZBE:#3#J-U<4E'%*[L^+E
M6)B\@OH^37S7-S<P.4WEHVMBO @@@]5./YP.#LN3P\3$+"8G9DA'A42XCU0V
MCP2QGV3%SK&CO0$X:>NF?A9*Q!'/9Q$O9V$)>="C&L75YL<X=?T"WCW[.4Y?
MOPJMRXGB]!S)_Q**Q5E$PCD1 DBO)1F2F3$R0OJ!]*]"885>[R&]&A>A%_A%
M&W_UX?=G:2P@W4^Z>UC"H2?4T)!>,?J#4)-.Z;::T.VUHBMH1[/+A'JM#@TR
M#9JE6C2/J=&KM4!%91RU.& ,A)&C?NY)DOY-)5$A.6,N3E%?R)?@\) NSI6P
M1S(F/"IW#['(?7U\1GC;3DZNBC& @5FYPDYZ,2_&$/:@Y! 4!I,+X4@*:^L[
M8KQCVMY^1N/0'@J%&2J3A\:#M(@_W]D]AO:N,?%RTN9(D RGJ0\&,3BL1U>/
M0KRDY'-V9P*9W#R*Y17Q50N?X^.\'1S6B;&(OW I%!<P/;,!KR\-@]%#^M>+
M>+)$;;TL0B$9C%3?I+/M]@ 6:"QA[(=#& 6#29+-L@@1L;C(8:0VL+RR2;R%
MN=EE*ONL"-?#?82__.'8[AR?>'-CNUI (BYKK;RUN<-Q,+@VX'_3N>KYE_2O
MH6K]U>JU"A#3+.OH-]<S,<VY:C5<:PEN8YXOZ(UV2.5ZR%4F>&E^E$R/(YN?
MQNS\FOC:*EN8AS^4@X?D.RA>0DP@EI@A>2NA?\""(8E9A#))9^F>!9(;DJ<9
MNK=4F4<R-2Z\BUD.=08''*X0[ X._>.%B?J)SQ<AO3@C\#VFK\.4?2T7Q_E?
M3WQ_M5Z^K@G:HY^,ISZCOGZPMXNU9=)Y/AJ7%?TTEHQ@8;9$5U4AM,.#76(&
M@JMIB#QQO5)R7X/$VYBL^"$;O(NKYWZ#N]=.0J?LIWXR)])A3V(1ZY;*)Y+A
M^ZG,U;(='3C.WU!N_E7CWR.^3B#"Q#S!IOXEDN'#M*T!XN(WY75G8PH1OP;#
M/?<QW/T N;B33NY063@N\3XQR1+E^3FE]9S!&7YS(/)*\W\!G!]B=3D/G?0Q
M&N^<P(/K[Z&WZSZ-'6DZ1\:^6 "7'B@JB0Y]&R3*4N6C/Y1%&N.HG@\YU 5[
M0N]O8C$>0'*H"Y[;%V'X['?0G/@UM._^&JK?_AI*FN.8KIS%C-. IRM3= \O
M4KA+S$#XGS[CQV69ZY+#GXB7.]Q/CSXY69]<1U@=@J9%!<G]00S='\#0PP$H
M6N6PC=@0T 40,8<0,P>0MD01&O' \%"-KB_;H6Y5HQ2KX(#F'K]'_,@C>:A1
M[1"U%FTI7WR$\\8=DF64%0=ON0W%%=0WC_T[EM1+^@NFXS+-='Q\K]'Q\WQN
M<9&=, IB#LKK8QRGFO[_)CK^K-K^_PC7QI7C:=>VQ^GXN1=?<-?2X6V-F8ZG
M^\>.OWB^]KM&O,_U4CMV?)^W_Q(?O^XX\>_CS_ZF8[7?+](W'?N7Z'B:3)Q&
M[5G_%CJ>;HW_4NDE2/R2_I>@W^^0U8[.GXTRV%M=S(Z!D&IH"=Y6/W'DZS@T
M!7L45Q4LAYM@@*IV'P,\7X'$Q!S_<W9FD0S5!$QF-Z+1'(K%&1$R(AHM"F#2
M[HR*Q8(8=%6H; * U>D]T.K96\J+!!DVE<E%I++CF)M;$X;OW/P*&;Y%,IPG
MA$<4ZY3U]3VD4A/@U;79<[BI91 -3?UH[QPEH]LHCK.QK=&Y!=C+0#(?'Q[1
MBUB9O+B<+Y 5J^JKU X!9G-H"8XGS)]2LB<7YU7$&+:%!-OM[-V<1"A(1I8_
MA0P93J7B+ KY2>1S$XA&TK#;?&)_?GZ=C/<-FFASS$?V8DR+\FQM'PIO-C;8
M.60" \3\Z7TN5T H%(';[4>&RKI !CZOIK^PO([U;3($:* ALX2F_@?8I+^;
M['5(!L#4]BH2,^/P%;+PY'/P54IPE?,P)*/014+0!0(P^@.(%\>1*DW"&TH@
M&LL),(&-NS$I>[CU4MVU43T81'B)*8Y3R8OL49[Y4VO^A%RE9M!*@\:./O1*
ME5 [G)!93%"Z;%"'7)#''>B.Z/$H+,?UV!@^<;7C'=U#O*VZBU_W7<#;?9=Q
MU=",+R7W<%E1C^Z4'B,E.V1Y.]1)&X)3261GB\AP2(TP39JC4;&(U^K*2A44
M/7R*E=5UE,<G$4VFX GX4:B4L<M>022K+((LQZLKJYB?GL-T90KCI7'$HTDX
M'5X8K0Z,*=5XW-",=T^>PI6K-\F U F0GC^/90":03]>P"Z6S" 0B4-E,$!C
M,B&22M&S*LB7"DBDXIB<GL#"RCPFEJ?AS%$=9[PP3(1A6B+YWB_ ^+R U@TW
M;BYJ<79V%!]/]N'D>!?>*3;CIZ';^(GK&M[T4#TD>G#9TXKW)5?Q-S??Q$^:
M/\6[(S=P8HBXYPK.CMQ'IU^*Z'H>2]3BJP<;V-S9PNX.&;G[U%]INTEU,C\U
MCTJ^C) W")U*!R,#K#H]QA1R=/;VX.Z#>_C\B]/XW;MOXZVWW\#;)][&VZ??
MPY=--U'OED(Z%X)Z(P7M=A8V3$+[K(#1O1B&=J,8WH^B;\N'ABDM'I;EN)V1
MX**_$Y^9GN +?9T(/7%7WX'+_0_PSO6/\=UW?H;_^LH_XF>G7H?,KL'TVAS6
M=S>QM;,M\BW X9T#'&SO8W]K#]O4%Q:/ZK](_3L8XGYHA\_CA\UL@TYK$*"Q
M9&0,CQ[6X='=A[AYY09:&UN%=_ BM??*^B;UJ5UL47H,?G%8" X[P?M3$W/4
M/RM(ISC< /5=ZF-^/\<+]U%?\\)JM4.KU<-FX_ UI(.,',>\!Q+)*/61,/7A
M)6QL;&-YE0S4E0VQ0%]E:AK!: PV-X/"E$>+!5JS!4J]"<,J-0P^-^R9"&11
M.[KC1C3G#&B8-.$2U=W'D4Z<BA('6O&ALP$?F!_A0],CO"^_A=^VG\7'C1=P
ML^T>&KN;</;"&=37UR-)<LD+0;&0,PC"SE_/]I^*$".+"PM()I.D=^QPVDG7
MF9UB$38S]>U(.",6'IL:GT>4^KW-XH37$Q3@.GL9,XAJ=GEA)_T0C,=1F)C
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MQ84US-)B3Q;JU%2J)/[-2]ID\F[SPFKS8*9<Q0*M)N68+\Y*'G QGT6I-*.
MF70Z(QWPIEK,<PQA'C.OI4B.IG($BV71?["%[8,=;.QM8V&]CK7]/6S)S'I)
M%F^)TCR\\2R"V1DXHRE8 E%8_!&8O2&$).^JM#S=VD9*!E2]TP&]UX%)KQW#
M=A,Z]&/H-DUA,N!%H%2 /Y.#U1N6O S"8'!A4F>%48[Z:3N&1J9PI[D= V,3
M<$1"\!52\,RG89B/HK/HP+V\&;>RT[B6&,/=PC3N%/2X$.[#A7@_+N6'<7%V
M'"<S?7C#?A,O#9Y$>W@8@84XRO5Y]?G\:GU-%?IC21=I"LAG.SM3AL5B06M'
M.T:G= @GXZBMK4I>[$N>'*KZ0MJ"F4(9Z7@:04FST^:$V6A6] 5]_4.X=?<^
MSEZX@ENWF]'3/8"1X0FU^<_ X*C20"B&V4I-@4J+2RNH+)*GE!OB;:LV0#EX
M<(B-G4W,UQ<1R"?0:1C!V;8;:).%U7C: >-*#(9'.?0_C.+&IA4?+T_@S4H_
M7BAUX+O99GS)<Q%?LYW'QXDNO.^]C^<F+N"7.T_@:^-G\8J]"6_9[N)U_0U\
MO^<DOM;T!OI3!DB.8%.62AM2[NO;&PHHKBTL8J98DGJ813J9033"S]R]&!P>
M0?_ $,9U4Q@='T-/;S>:[S7AULVKZ.ALP9 LH&ZVR^^Q-G1%IZ%?B<-U. ?O
MXP58]F<QOIG!X&8<PP<9=&Z'<'W1A(_S0SA=&,2IK)29[PZ>-UW&-X8^QF^W
MO857QB_B(_,=?*B_C=?Z+^#%]E-XL^,\[ABZX"F%L?%X%UL/]K"YNX/-C2VL
MUNK86MG [OJV HD3\8RTF00"4D^]GI"B_#"9K!@<'$%O[P#L-I>T(2E'N>9U
M>N%Q>N#S^&6BFL%<=0&U^JJ4$:WRZUBJ-4#BF5(%N:SD3;H(OR^LK,F=#B\<
M#H_R9VK2(.'0FEC:IL4N_5(8V4Q!VG!%VNV,>K$P)/5A2NI-,!B5OFQ1U8F5
MU7745I90G)?^(![ F$V/MHD^=!B&,> V8BSJ@;=>1N+Q&MP'\QA:BZ%IP8Y+
ME6E<6;?@\IX-9[8-^&!Y%"=F>_%:O@UOY#OP8:$'%]/]N&B\APM=UW#A]B6<
MOW1>;>9XX<)5.-P!5"7\'>D;*%S[<:-+;E3H]7@PK9_&V(@.;?>[T'JO$RZK
M'U'I:^/A/+*I,HIY<BC/(N*/(Q9*J(T:^4(D*!H(QZ2?BD@?N(25Y560[YLO
M&=K;NC QJL>4SHC)21-T>C.F#%;51OB2:ZV^#:<]A OG[N#V[1Z9#/;B\N46
M?/3Q=5R[T:D T,EIR6];2+T([.X>Q[DS-W#B]0]Q^N.+N'/K/H:&QF'Q2'\=
MCZ#79<8K=R_C6W?.X,W1%K2EO+AK,N'NX!2&IKP8T?LQ-.G!H$[Z($L8$],^
M] Z;%-=Q2M(73Y=@=P?A\H60R9=0E[YN?6L'2P2)E];4"[JMK0<R?NQ(7YZ4
M-$ZK\8"\P!V=$XJ*:'C4HKX^,9F\,)N]RG(R$B']#FF3^"(AK906Q)%(7E$?
MS<S4%"\QOU;A\QU=$XHZHK-G$NV=.AC,!-_FD2^MPA\J*G"8W/@>7U;R):2H
M*/B;&ZKRY2;'I%Q>^J#:CMH8;'K:)>%'U=C)%X]\;T9+3O*_YF6,"<D8$PB2
M9J*HOKKA1HJ9;%&-F9IH8SY?Y)(3G%^PK*UNJO%%D\9XHTW2/WO"_EG7GLE/
M6IB_7$1Q+O;I!2J%OQOE=/1;E, :97?O4.86%:E_(^@;&),Z%L'8A F=7<.X
MW]J'YOL],B8887,&I;[KU)=5DY/L%Q,HS:Q@N;XC<Z8L+'8W]$8+K X7(K&T
MU/,E&7/XI1G#;X3%HS875.='^I,6K<Y]HDQL(_V-.:OD$0/F?TY"R>7[^ #5
MN3P,4X.X?O4CV"PCTK>5Y;G&XIP Z\.'M+"E]5<C\^@?SQ\\W);Y1Q%A_RBZ
MFM_%FR_\(D;ZKLG-+>4O.U]%2R%^/ E7E/,S*N.H+A[-VAHWY?J16TTT5YH^
MD2<7^:?AAZH'QVZI?%=_B$(>8'M]#LF  >TW/T3;S0_@,/3B8/]H T'Y1_#@
M(0$$5A3Q@*#OHT<-*V+I35"=#V.@[13.O/UEW#K_*A(1&W:V">)PO"'P0&5<
M/E]16<4B9#3EQP.6DQP9"Z6R&%!T&2SW2@$E72_&WGL98R]^!Y//?P]3+SV/
M]N]]"X9K%U!/1/!H:X,/239)/GT>E?.)-.HERT0K9Q:/9',CBZ7:% )YW#]S
M#W?>NXG6#V7^>5KF92?NH>]L+XSW#!@XWX][K]_%G9>:,'5C$N7 C#PG=8IU
M395BHVY]6H_JAM)/P.'CRAKPB3(//DN?R3/YM!RO9YK0*I1KL.>??QY_[L_]
M.?Q7_]5_A9_ZJ9_"K_[JK^)+7_J2 @[_S)_Y,_B+?_$O*C<$3?D,I5JMXL__
M^3^//_$G_@3>>><=F<N0W_T383@:#J&MM8['X7@\*)I[S2TMF'_IEWX)_]*_
M]"_AK_R5O_($)#[NYW'WFAR__K2?3PNO'_>+X.?8V!A.G#B!&S=N*/!<$RW.
M3_NE^:'=UY3RN[FG_C#1_-">95G\<__</X>O?.4K\,CZX/<C6IR>EGJ]CJ]_
M_>NJ'!G&[Z;_\K_\+ZOZ<?7J5>1RN2,?/HGO9^D729Z!Q,_D#XVP<;*#H7Y6
M8^5U?E*QQ\VR9*%)().[G6]N;F-]8Q-;F[O8W^/D'%A9J2.=SLK"HO$I*X6^
ML?]:6SN SY=$+KL@B]2'6%[:E\5)718B,VJ!'(H4U,9!\=0,EE>WU0[=5,KV
MSAX*Q3ED<W,(AW)J 4V0F(MS+JSY>2\7^-K&/V9K" -#1F5%3/\U"@I:+],]
MP6!^<DD0N%RN*\NM3*8"BS6(HBR8JHO;RC*,"W^[(X)4JHQ$@KR:"1DH?0HT
MYN]"H2+/UL6/FK(<IL5T-)9%.))4"W9N:C5ML"*=*2J .)4M(9DM8'9^ ?75
M-<S,EE&I5K I^<C\W9.%'C\')GT']?" Y2(399GP[1_N8FUC!?7U%=16ES&[
M6%76<EO[#[&U]TCR;$_BOHR@Y*,WE('#'X?1[H?>XH;1X863O*PS)7BR"8QZ
MK+ 78W!7,C"58M!E@] 78K"4,YA*<F.\&!RQ%*9M7L6_R8WZDK&BXF%V.@)J
M,9F;F<?<<AW+.]O(+5?AFDE@JAC$U&P(^FH4NDH(73D+6G(&=-=<Z-SPXMZF
M$^>7)O%J_#Z^;[N(5TT7<=W?"6LE@.6'FZ@L+6%U=5V5^>'^ 1:K"VI#ME@D
M"I^7<3&B;W  _2,CDC8[TL6B/"/EM40 ?E[*(*4^JR>_L\E@P4#?(%J:6]'2
MTHZ+EZ[CRU_[-EY]_6W<N=<&[A#O<'KA]DB="<749]H9*:?UM6ULK&_)4?)6
MC@=2+K3"X6)K2]I!=:6&2"Z)0<,$FOK:</[>57SKK>?QQK6/T.X=PU0]#-U!
M AV[/EQ8UN/]ZC!.S/7AK5(W7H[=PTN^6W@WT(R/PQUXQ]N";^HNX'NF:W@[
MV(Y+^3%<R8SB0T<+?M!S$M<]/7 N)[",76S(BF-C?T=]UC,_-X=<1NI;-(&(
ME"OY?"<-9NBFC1C536)P=!2CX^,8&1W!Z.@PK#:3+/Z-F#)/8L(ZB7[;&/J#
MTW"MYA![M(R(Z'0]A_%Z"J,;DK:M!#HW@[A9L^"#3!_>B;;CPT07+I9&<,)_
M#]^:.(/?Z'H;O];R.K[5]Q%.&&_CZQWOXY<NOX!?._\"7KSS 09\4UB3.._)
M,H=6\/N'!UBIK6"Y4D-]<5D6IS7$8VE8S Y,Z\VPV]RJ[ S3TNZ&QC$X, J3
MT:8 7I\WJ-(:](?DMUO*S8U,OH!%Z6\6E^I86EJ3_F1# <6%/.E?N"%E2 '$
M5HOSB1JE+>JG3 @%8RIL;O+&#3?)S<J-[VB!S TDR5'=W=F/OKYA.%U^!;Q5
M%VM8KB^CO%!&O)2$/>G%J-^(;K<._1%I3ZL%>/8JL.W/0;>=1<>*'TW+#MS;
M]>#6H1.7#ZTXLV? V7T#3F_K\,'*$#Y8',3%)1V:%XSX:/@J+G1<Q9AQ'%.&
M*;2U=^+TF0NX<;<%DU8'2@LU;.\=J+Z4&__Q!1,_^;-+.^CNZD-[:S>FQHU8
MFEW!7'X1$>GC0H&THL;)9RM(AG,(NL/PV'TJGSV>H++>CD7BF"F*FUP1+K=/
MM0FKU0G#E 5.:?]VFP=Z*1.G/!,.)Y"0?,LD\]"-&7'AW&VT'[VHNW.O#_?:
MA]$].(V1*0>&IFR2%B=&]0[<;QO"K5L=N'.[ [U=(QCL&\/HV!2,I(58F(>W
M6L*IT2Z<M0_C7LZ-OMDXFLUFW.W586#$B?YA)\;U 3A\.1C,$0R.V-#5JX?1
M$H33$Q>-(E^J8&EE0[U0K$F?L"3UHKZZB97ZAJ*;(%5#J52#VQW#]+34GUQ5
MQHJ<^LQ^=-R"KIX)# T;I4]?E/Y\"?%X'@[IZTC/$XU*7^Z)R=A&?ODYD'[(
M+&--/%[&QA;41G-#(Q:U 1WI(_H&3-)/63$RX<:T*23Q#.->R[#$6\:";$VI
M@Y07HS9E;:PW^M0+3%H2<TPDW03C& IE,3^_*F''42PMRN)'820*^.9X6*DN
M8VU]1WUM,R_MJD&;DU'72$_P6.H*QY 'AX^5-?_,S*SJ7UE_^()76U@<ER_:
M9/V?/F&9-/3ILB @U)BK:;^E/L@Y73V0N1F_>F!?52*5R/:!+,97U1PED9 Y
M@3<B[=B*WL%1M'7UH[-K3/K#@(QS7/@V7LA3EU?6,#LW+^UF5>K1EK(>/I#Z
MH\)D0$?*NO4)J"?7/B?1YJ2::L)S\L"J!;2*CRR^%3+W -N;RP@'K&BZ=0KW
M[IR#VSDM#@BJ,LY\A@#Q)^!GPUNY_F 3"Y4D/+8>M-]^':]]_Q]B;.B6NL?G
MR>W+_"?-%0$\+4YRIK0A/-+?HXS1?O)XY$0[/:Y*/G6!?XX /_6O<47-TUD8
M"@0\P,.#52R6(ACMN()S[WP7-\Z_B75E"2QN)8ZTGGO2SL6#1P3(']* @T8?
MJXI_F2#QQV_\%IHNOHG%V20>'M)JFF%\.I\^5]&21&5P$E<MS50E/)%.<+><
M1V:\#R/OO8J)5YZ#X:7OP_C2#S#T_'<Q\O9K<#7?QF:I(%5!ZL-3 /U/6NBU
M:I,$L;7&2&65(48FYRNSRW"..^$8D/E,MQWV^U8,G1Z$O\N/S? &9@PSF+BH
MP^V7FF"];\%B<H'56-IVPQJ<=>MX/5.JZE^C?JB,.Z:\)K54]),G5$0TT>)X
M[-(S>29/B]9O$.RE52J!V#_]I_^TL@@^?_Z\K'>YP65#:,U+Z]7_Z#_ZC_"?
M_J?_*2Y>O"AS+O*X-^[1PI37Z4:[SKZ)@*YF!:N!L%J_J@G=, ['W1\7 M($
M1__=?_??Q<_\S,\\ :?ICL]H_O&<JH&N#.LX",O?VGTJS[5PC[OCD5:UO_S+
MOXQ__I__YY5U+=-(>3KN?): ,H^:J/[B2(\+XTNW3"/]X/WC?O&^1F^A/7O<
M#<^_\YWOX%_X%_X%?/O;WX;/YU/7?QQY.MSCX:^NKN*[W_TN_L/_\#]\ @8S
MK#_Z1_\H_M@?^V,*I/\7_\5_\5-@,=V>.7/F4V5&/Y_6+YH\ XF?R1^8_"0:
MV-,-5O.31W:(Y+FA!>,ZP3-9;.[LL--K@,6T2J(%7UT6%WQ#2/!B;FX.I*B@
M'.RSLVUL_,,-CV*QH@PX\PHDGJ]L(9NO(9FN(!#*R2(YK/B)"^5%[,DSC2X9
M:D?O2#2%L3$CK-8 JM5-907,1?5";5=9#I,J8FU#!A%Y+IV=4QO7$3RFU3"I
M)PA$DXLX(6&3[H([\$\;/!(?@K\IQ:\YKK.K#?:XRW=;QX@"D]<V'DJ:#R5]
MNRK^=GOPR-(LK"S-N C+9,KB!T$$@LD%.%U!M5"CU3"!8H+&\606Z7P)&]L[
M.) )Y=;V+JJ+"UCDYEXRX#0&!W(*[:G/W*G,:V[\M;'!\U6LKB^COKHD"[AE
MK*S5L;*Z)K^E3#98#@<H2SK]/DEC8E;RJXAI;C9C<F+<8,&PP0!3T ]'.@IK
M)H3)E \](3/NNL;1%C&C)^7"4#8 73Z.T6@ _78;ADP$>NS0DP/3Y(6?0$FJ
MU  G-G>Q<_ (VU(/5B7N^:4JIL)NC(4=&(L[,1R79XM>3"Y%H=M.H7/#CRLU
M(]XI]N,'D3OXEOT"OC=U&N];;H@[.U:PA\KJ,I;65G$H"S[6GX5*%:E$$F:C
M"1ZW&[%X##U]O7COPP_PW(LOXJ1,5!Q^/[9D )I=6D)N9E992(Z,3:*UM1,W
MKMW&V=,7<./Z'30UM>#,N<M2+\9A=_HP.6V!^\CR<&Y^$;2 CTDY[<NB^/'A
M(^QN[&"YNH1#J>,'DCY^(C6_4$5^=@;^9!1]$\.XU7X/IZ]?P-=?^#:^\O*W
M\,*%M_!6UWG<STW#C#*&D44/XFAYY,?5N@$WEPVXOVI%1]V.YJH)M\IZ7)_5
MX]K\-&XNF'%_Q8';\T9<RXSA<G@ 'TTWH<4W@KG'Z]B1&?V>+ S6M[=D$3^'
M7"ZO-B.S2[[HS18I:QL,=B<F)*\&"!+K:,EHAM5FP=#P (SF:80203C"+O08
MAM!F'$3F8!%SDN]IK,.]/0?36@ZZ>@(#*V%TUGVXNVS'Y=DI7"B.XGQA&!<*
M(^K\+?]]_$K76_C%.R_A-]O?QLM35_&^LQ5O3-_"U^Z_B]^^]#*N3K=C'AO8
MEE:\(XO-]=TM]29Z7LHH&4M(&PPK:[4QW92450<&!T9@L[A@L]*:TP;=I$%9
M>YM-=F5M3'[A4K$L;2V'8"@,M\>/:"R%U?J6U/UM!1"3Z[M8F),V$,'$^#2F
M)DT*@)[4&10X3"":ULOUE0W%7;RXL** X=7Z)K:W]A583("8X+)>;\*@U)6^
MP3%%SS(F^=G:U8J^\0'<[KZ+CVZ?P?MWSJ+9.@1C)0;'9A&NPWE8#F<QLI5&
MRY(7MR3_[NQY<//0I4#BLP<&G-R?Q,<[XSBU/HY+&P8TK5K05I%%8\H,<\R)
M8#((7\"GK)S'QJ9POZ,'MR5_.@>'%37$['Q%O8SC9VZ<F 8"08P,C<+O#6)%
M\F"ENHZ%V3IF2Z3<D'ZYOH^5Y5TDI'_UD%]TRH;Q,3V&AR9@D#32\GY#^O"%
MZB+TT])G&LPP2/X;]!95'E;1*2,M@TTPFJ3-N-Q()=.2IT:<.WL=K>V#DC=6
MJ7]>Z6><&)JRHG_2+/V-'=-."<\50L_0%+K[Q]$_.(%^.8Z.3L%B<R&:+6#:
M[T.7U8B^B ?#Y3C&:AF,S";1(G7Z7N\D^H?LF-2'H)L*2-LWX4[SD++ );50
M*E/%;&4-Y?EEZ4M)/;*F0"X%#,MQL;8BUPAV-8#40G%>^GP[.CJES"2^L60)
MZ5Q%RC<D:6 :'4@F9V2,\:&W=U3B.B;C@D,!Q?%X48XI9=W;TS,A^1*6<8Y]
ME2Q2)*_U!K^,&>/H[)J"R1R5?F45@? L)J:\:)7K?8,F^5V2>#U *#(CXUU1
M45&HS5<C!1G'MJ5-9!$*%Q"5OGMDQ*A>2E8D?7Q)6:VNR1C1P#W(D;RZ+G6>
M-"M2ES>D+SZ0?KA2E;$TE4,JG5>T$IO2A]%*G&TF*65&D'AW]].?_U&U\?['
MD=_/,\_D]Q+.O1H@S^\%S#'[60+4 ZF$!]QK0B[2HEA1C!P^;E!7[<O"<Y\;
M%.]A8VL;]8U-K&YNPVSQHKUM5/J^ ^47W>[L'LA<:UMM"EN7<9BT)<2]"$!3
M%;T#10M8E/5 T\]#COO_=!@-D%@F? 3,CH'$CQ[LH%2(H+/C*LZ??5/&D7:Y
MUP .Q!/YP[SE(EVC6N-S#^6Y+90+,K^;O(?[UU_!^0^_!KNA0^Z1OH @,9^1
M4Y5N+J2/RDK]DVNBC;\-_U58V@U-E?!$GE=Z[-;Q'RJ0AC]TQ[^<#]/"E@!A
MPW].DG>PM52$9:09M\Z^@J9+)U#*AZ3LUJ3,6+;,MR.OE-_\0U!F!QOK,E^-
M3*.OY21.OOD5M-W\$/L;W("*>27YJ&@I)-U/9N*?DZAX_4YE?6-^JW.I?^2=
MQ@.IWW,%I"?[,?+AJ]"]]0(,K_T ^A=).?$<!E]_$2.G/T#.;L'.4DWR1\J6
M_OU!B);1#). $N,NIP]V'F!G>4?BO8WX9!2M[]S'E>]>0?-K]S%Z;@S])P?0
M^D8K6E]O@;79C(5D57GW!.A59=BH9:P'4GI'=QKU3[VMH?)<N6@\>5SYK!(>
M/DN?R1=>6,>>!B8I,S,S^-[WOH?_XK_X+_"__6__F\R-]6JMKX&Q%/:C!'^_
M__WOXR_]I;^$O_[7_[K,EP+J'MW^Y;_\E_&?_^?_^1/PF!04!)GGY^<_$T ]
M'@>N&^+QN/*/5LE/"T'BKWWM:_CW_KU_#W_K;_TMA5<\+8PK+5K]LE[D49OW
M:.$P3$V6CO;[" :#F)V=_13 2>$S!&M_Z[=^2U%MD(^9<=3N'9=BL0BOUZLL
MC8^'P7/&X6G1-@*D,9!F$:T)UZ#A<%BE@1C+<='RD.5$H/:%%UY0;G\_PC0P
M;EI\M2/+C.7+%P$:"$R+88+_/_=S/X?_Z__ZOQ0%B7;OC_R1/Z*._]__]__!
M+>M4K;YH^7Y<OVCR#"1^)G]@\N,VL-_-/>^Q0Z!J[GC.#E'C)2;M!#=G8/]&
M4'-[:Q?K:P2/MZ1C([C9 ##X#+UX( N8?5J[;AY@01:ZN5Q5%JT5&1PVY'Q1
M%K3SF)V3 2->!C>,,\KBQ>./(Y6=49__5V6A7YY;1#R9A]7FA\L905J>X:8L
M3D\"L^(/ >! *(N:3,06ES81CN8QKG.H3?)H39R1<&A)3 !XOKJEK)9I24QN
M/M),F$P^692;T#\X+8MVCU)N1N1TQU%=V$)-%O +BUL@+06MH6E-3.6GP,%@
M6C0I_D040$QK8IX3D,A*&MR>D"S\$Q*'$N87E[$C"S9R#M,*NU2>05D&(>;9
M[NX.]O>XF-N7/&U\GK^^MB&+N%69S*]+_JUA=;4F \6"#&*+6)8\KBW59<!=
M16UQ S6)9S&_!+\WC5AD!I%P0=(7D/R4])B=F+38H+/;H/>[,!WW8"!H0;-K
M M?M@V@*3*(E845WUHO14AP#B0#:G69T6<WH-ULP8K)B8LH*EYN?0\_) G);
MTB#+!ZD#FSL'6%[;1'9V#B:?/.^P8-!IPI#?@LE< -.U)";6T^A8]N/2[#1.
MI/OP:KP-S[FOXQL3'^&YD9.X'QG%_.--S&U*FK;6L2,+OV59I/*%0S04@=UJ
MA\/F@$W20)ZC%U]^";_QI=_&MW[P'%K[>Y%=F$-Q>1'9:@7!3 93-CN&)Z;0
MVS^"UM8N914Z-C()L\FA/J%-9DOP2YD4YZH2CN1=K:X XFPBB\>TBN?::_L
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M13O!>P22*_-+F)^K23^TBN4E;G:W_@18)LC,9_D<G_'Y(K"Y_9@FO44@!'N
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M<_B5IE?Q@]$+:"T9,%H/8&(UA+'5($Q[:=@."YA<CV)D.8B^)1_:E]RXE)W
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M3L!T>'P"[>V=N'KQ"MX_\1X^_. D6CNZ$280/C^'0F4.N7()"Z0"F)V!/Q)
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M>QO%_57<3YKPJJ$)7QXZB=\8_A"_/O8QOF&[BC>273@U.XZ[TD[[]Z*XG)K
M:U-W\/V^2_C(U(4;/AW:HE:,%T,83_DQZ+-AR&V%B2^4RB7$Y^>0FJ\@G"U
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M/%T'J/RD_R&!([G/N=;,S)(L1-N>@,0$DS1@Z7<%B2E:E)Y$\<>/XX\K#('
M&/G35?R(F(D2\'ST8%]9QSYZM"MSKQB&AV4\O_">C ,FF8.NJC0IO/!)DI@?
MASB0\:8!$M,J>0>'>RN8R7HP,7@#9S_\+BY\_ (F9%S<7N7&/)(_HH>2+Y]P
M$A_E$X$ZU1:/KBE$[RA/5/X<J1*>-/R2)]2O)[>>",M"TJ7 81Y%"3C*42&%
M!'!I8;PK<]EL -UWSN#6N3<PUMN$G4U:ZG'.OB]^',@S5/K3"$\N-E1^[V^M
M()=P8*S_.JZ<?1XGW_TJ7)8.;*\7E?^2N?+_=\;N)R>,$>LDTZ0!FEI!'9T?
MO0!X="CSY%H"<6L31N]\!RWG?@,)3Q=VU@N2U@UQ_4#YQ#JB^D59LRANGC^
MNJD)0]*T$7^VIT/U0H)UEI<>;3_$3* (RST#.EYMQMUO7T7W*\TP79Y0&]<-
MG^S%![]^ N__Y@F<_L;[Z#W;ALW"&D!*;;ZL9-9( -*=2[HEO;00YUCPH-$6
M&.:G5,5#'FA$2LDG<7PFS^1WBC9F4*Q6JP)YN?G<AQ]^J*Q<*9Q/:+B )MSS
M@#0('W_\L0)=*02%:4G,S=8^"R2FGP13"1(3\"6_+ZDF_M$_^D<RW_<^ 4ZU
M< B.TH*8H.OMV[<5L*S131!4I?ML-JNL:FGI2HY@AD$ E9OA<8,Y6O*2PH%
M+#>:TZQT:35,RV!23] JF5:\!)\9'W( T_J70JM:@L2,][ESYQ1(3$H)@K/<
MV(W@*0%C6A8SO-=>>TV%SW-:3I/3F!S+!%09QE_[:W]-@;S,3PJ!:/(U,P[,
M=UI74[27_11:4),O6;.Z)M\RT\<- @EV_T& Q$]O7$<W!,W)N_PT2*QQ$A^?
MBQZO9U\D>082/Y,_U,)&JS5D#2#6!H//:N!:(^=!;JG9AP84[QR!Q'R&0G^V
M^ G_/#>OX^[K%>E@E^0:^<^4$R6;FP?*(LSMBBG0DU;!-D=(66"-3UH1"*9
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MG,1_X2_\!<7!3$MB7J<0Z";=Q#_X!_] W><&=YH%MR8$77_Q%W]161J3NY@
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MT4D+PI)OT601;D]$\:O2>FZ#GS)O[J&0*<'G"F!S=5L61H^Q7M]$-II#+E[
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M*/*#?C<\?:@XF*DL.P4</Y+VO[V,<M:'R9%[N'?S?4P.W\%<D:   1+.UQN
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M21GZV-HZQ'"PA60BAT0\@T*^@K*4JU9M*@NT7H\;\G%SNZ;R952MTHJXH39
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MU@YRF-N,XF[;@VMU.]XOF_"U]!)^QG<//[;T'GYJX7U\X)G'2L8+1RX"1RR
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M,P4TN?'<SJ%Z!JGGESR/GC_+Y)Q'_M:>::?*GQZ9SS0"PP2+=2"8O_E,?!U
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M'%B@+^9""K%."]Y*"6N)&&;#0<PGHEC*);&43V"E(,=,! ^#3LR%')CUV?#
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MHA5FM=+$\=&Y B[&M"P<;V-WE];$4K;1&/O[A^HSZ(U-?K(M]TEY:.$[.VO
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M,_0:6<S??P-?^L*_Q)6W?@*IB 7'^Z.+&\G? 6([?!)(S'I_O(].S8?Y![^
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M?R")2E7Z9G\'@^&>I$7W.%MRSY;D/9*QIB?Q\WCX< TW;LWA^LTY!0S?O+V
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M42XQ\OD6FE)7!*H(%,?BM'@>*C IE:R@6NG!XXE(?2>5E76GT\-@,,1XS$_
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M<'BD_KQQ)"2\WADIH'AC>Q_'9YQH:6U[>/ 8U5(7L5 >06\:L4@>R41)VJR
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MW=E"L3: Q1O#]+(%A7)/RG6,2GV$^24+;(Z@R-9",)20= )J4Z^]W>.+%P#
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M8.WTTQ+K_ GK5L[Y5]<K,L-Y_=.2KNN?MK_J^7RZV)?TO4B3.J&?DWC4=8O
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M^[Y7B>7AO(^?5G,QSH4[RURI5-0YZX"^./N]+L[/:+&J <1G9Z<R]FC/;]:
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M[K5:5^H0?\V!EKDKV:*6IWVD]>W+YG96'CR9EA?C*[*]4Y:=6$76UC.F)(;
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M.7PE!YTSJ10ZLJ'U>H#?M99C?&;#%+#SVK?K&W%)I$N:?T(6M#VQ'$EFRO9
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M'=P]R)+?@B377L/WYO ]"@D+V8WU O8/V"V@E,8B C*<ASL0XO_DG_P3:P]
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M3K[^M4=FF; 1RF@_]W6LUVV\6V \K3_J>!Y"A#:2-O:P_L#>9#.2,AL&VIY
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M%?ONP&J#H*"NS1R1/-SF_)[G^Q3BF7;@.Y?K\S"2ZT,20S9S?9:T'7[Y$-D
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MN9)6HV^!ZRJ5AO3ZAY;:G7UIM?M&,D$D0DKRF7V\OM[MHE@\T7.:1B;BMTJ
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M/3P\OB/<$":!VH[5(+V6BXO+0%7<P_?S1,[/>.7]P'Q,L7* ='0$)+C2SY#
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M\#O&?]CY*:/*)M%W!)ZCG2!\\0*F/;%^@ 1''1S9"6PD4!.SG_[:B:9E:YO
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44,-\!GPBY-8     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6842916544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arbutus Biopharma Corp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,625,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 644,038,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001447028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6845158544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 166,779<span></span>
</td>
<td class="nump">$ 72,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">14,525<span></span>
</td>
<td class="nump">39,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Accrued revenue</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Investment tax credits receivable</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,196<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">183,882<span></span>
</td>
<td class="nump">116,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">12,912<span></span>
</td>
<td class="nump">12,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(9,729)<span></span>
</td>
<td class="num">(11,199)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">3,183<span></span>
</td>
<td class="nump">1,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">10,070<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">352,642<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">162,514<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">712,291<span></span>
</td>
<td class="nump">118,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">8,827<span></span>
</td>
<td class="nump">9,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">5,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">883<span></span>
</td>
<td class="nump">5,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,578<span></span>
</td>
<td class="nump">20,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">9,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">7,497<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">146,324<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">164,612<span></span>
</td>
<td class="nump">30,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, authorized - unlimited number with no par value, Issued and outstanding: 54,570,691 (December 31, 2014 - 22,438,169)</a></td>
<td class="nump">834,240<span></span>
</td>
<td class="nump">290,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">30,206<span></span>
</td>
<td class="nump">26,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Deficit</a></td>
<td class="num">(266,985)<span></span>
</td>
<td class="num">(205,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(49,782)<span></span>
</td>
<td class="num">(22,313)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">547,679<span></span>
</td>
<td class="nump">88,035<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 712,291<span></span>
</td>
<td class="nump">$ 118,178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3-4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a(1)<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 14<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 18<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 9<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 5<br> -Subparagraph c<br> -Article 7<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 10<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 32<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 21<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 1<br> -Subparagraph g<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph i<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828156192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common shares, par value (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">54,570,691<span></span>
</td>
<td class="nump">22,438,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">54,570,691<span></span>
</td>
<td class="nump">22,438,169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6845453584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Collaborations and contracts</a></td>
<td class="nump">$ 13,309<span></span>
</td>
<td class="nump">$ 11,738<span></span>
</td>
<td class="nump">$ 10,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing fees, milestone and royalty payments</a></td>
<td class="nump">11,564<span></span>
</td>
<td class="nump">3,215<span></span>
</td>
<td class="nump">5,040<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">24,873<span></span>
</td>
<td class="nump">14,953<span></span>
</td>
<td class="nump">15,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research, development, collaborations and contracts</a></td>
<td class="nump">51,505<span></span>
</td>
<td class="nump">38,713<span></span>
</td>
<td class="nump">21,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">26,438<span></span>
</td>
<td class="nump">8,683<span></span>
</td>
<td class="nump">5,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">529<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition costs</a></td>
<td class="nump">9,656<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">39,007<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total expenses</a></td>
<td class="nump">127,195<span></span>
</td>
<td class="nump">48,387<span></span>
</td>
<td class="nump">27,617<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(102,322)<span></span>
</td>
<td class="num">(33,434)<span></span>
</td>
<td class="num">(12,152)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (losses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">674<span></span>
</td>
<td class="nump">853<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains</a></td>
<td class="nump">21,771<span></span>
</td>
<td class="nump">4,127<span></span>
</td>
<td class="nump">1,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Decrease (increase) in fair value of warrant liability</a></td>
<td class="nump">3,341<span></span>
</td>
<td class="num">(10,383)<span></span>
</td>
<td class="num">(3,530)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability', window );">Increase in fair value of contingent consideration</a></td>
<td class="num">(770)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (losses)</a></td>
<td class="nump">25,016<span></span>
</td>
<td class="num">(5,403)<span></span>
</td>
<td class="num">(1,911)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income taxes</a></td>
<td class="num">(77,306)<span></span>
</td>
<td class="num">(38,837)<span></span>
</td>
<td class="num">(14,063)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Deferred income tax recovery</a></td>
<td class="nump">16,185<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (61,121)<span></span>
</td>
<td class="num">$ (38,837)<span></span>
</td>
<td class="num">$ (14,063)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per common share (in USD per share)</a></td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (1.80)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per common share (in USD per share)</a></td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (1.80)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average number of common shares (in shares)</a></td>
<td class="nump">45,462,324<span></span>
</td>
<td class="nump">21,603,136<span></span>
</td>
<td class="nump">15,302,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average number of common shares (in shares)</a></td>
<td class="nump">45,462,324<span></span>
</td>
<td class="nump">21,603,136<span></span>
</td>
<td class="nump">15,302,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other Comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="num">$ (27,469)<span></span>
</td>
<td class="num">$ (6,489)<span></span>
</td>
<td class="num">$ (3,135)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (88,590)<span></span>
</td>
<td class="num">$ (45,326)<span></span>
</td>
<td class="num">$ (17,198)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Fair Value Of Contingent Consideration Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=34752592&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=35737396<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 7<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 7<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6845971296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Deficit</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2012</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,305,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2012</a></td>
<td class="nump">$ 40,919<span></span>
</td>
<td class="nump">$ 181,786<span></span>
</td>
<td class="nump">$ 24,786<span></span>
</td>
<td class="num">$ (152,964)<span></span>
</td>
<td class="num">$ (12,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">$ 735<span></span>
</td>
<td class="num">(346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common shares pursuant to exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common shares pursuant to exercise of warrants</a></td>
<td class="nump">2,143<span></span>
</td>
<td class="nump">$ 2,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares in conjunction with the private (public in 2015) offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares in conjunction with the private (public in 2015) offering, net of issuance costs</a></td>
<td class="nump">32,038<span></span>
</td>
<td class="nump">$ 32,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(3,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,048,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
<td class="nump">59,194<span></span>
</td>
<td class="nump">$ 216,702<span></span>
</td>
<td class="nump">25,343<span></span>
</td>
<td class="num">(167,027)<span></span>
</td>
<td class="num">(15,824)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">2,616<span></span>
</td>
<td class="nump">$ 5,034<span></span>
</td>
<td class="num">(2,418)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common shares pursuant to exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common shares pursuant to exercise of warrants</a></td>
<td class="nump">11,791<span></span>
</td>
<td class="nump">$ 11,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares in conjunction with the private (public in 2015) offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares in conjunction with the private (public in 2015) offering, net of issuance costs</a></td>
<td class="nump">56,477<span></span>
</td>
<td class="nump">$ 56,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(6,489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,489)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(38,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,837)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,438,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="nump">88,035<span></span>
</td>
<td class="nump">$ 290,004<span></span>
</td>
<td class="nump">26,208<span></span>
</td>
<td class="num">(205,864)<span></span>
</td>
<td class="num">(22,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">22,093<span></span>
</td>
<td class="nump">$ 16,687<span></span>
</td>
<td class="nump">5,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">1,651<span></span>
</td>
<td class="nump">$ 4,186<span></span>
</td>
<td class="num">(2,535)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common shares pursuant to exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common shares pursuant to exercise of warrants</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">$ 371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares in conjunction with the private (public in 2015) offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares in conjunction with the private (public in 2015) offering, net of issuance costs</a></td>
<td class="nump">142,177<span></span>
</td>
<td class="nump">$ 142,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Increase of equity instruments in conjunction with the acquisition of Arbutus Inc. (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,973,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Increase of equity instruments in conjunction with the acquisition of Arbutus Inc.</a></td>
<td class="nump">381,942<span></span>
</td>
<td class="nump">$ 380,815<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(27,469)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,469)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(61,121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,570,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">$ 547,679<span></span>
</td>
<td class="nump">$ 834,240<span></span>
</td>
<td class="nump">$ 30,206<span></span>
</td>
<td class="num">$ (266,985)<span></span>
</td>
<td class="num">$ (49,782)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6814044560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common shares in conjunction with the private (public in 2015) offering, net of issuance costs of</a></td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="nump">$ 4,085<span></span>
</td>
<td class="nump">$ 2,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6845226720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="num">$ (61,121,000)<span></span>
</td>
<td class="num">$ (38,837,000)<span></span>
</td>
<td class="num">$ (14,063,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Items not involving cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(16,185,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">589,000<span></span>
</td>
<td class="nump">529,000<span></span>
</td>
<td class="nump">613,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(80,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange (gains) losses</a></td>
<td class="num">(21,966,000)<span></span>
</td>
<td class="num">(4,218,000)<span></span>
</td>
<td class="num">(18,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value of warrant liability</a></td>
<td class="num">(3,341,000)<span></span>
</td>
<td class="nump">10,383,000<span></span>
</td>
<td class="nump">3,530,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">770,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">39,007,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net change in non-cash operating items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">628,000<span></span>
</td>
<td class="num">(1,887,000)<span></span>
</td>
<td class="nump">889,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInUnbilledReceivables', window );">Accrued revenue</a></td>
<td class="nump">349,000<span></span>
</td>
<td class="num">(360,000)<span></span>
</td>
<td class="nump">2,008,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_IncreaseDecreaseOtherDeferredCostsNet', window );">Deferred expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">167,000<span></span>
</td>
<td class="nump">231,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Investment tax credits receivable</a></td>
<td class="num">(188,000)<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
<td class="num">(31,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">159,000<span></span>
</td>
<td class="num">(773,000)<span></span>
</td>
<td class="num">(776,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(2,489,000)<span></span>
</td>
<td class="nump">6,253,000<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(13,090,000)<span></span>
</td>
<td class="nump">13,171,000<span></span>
</td>
<td class="num">(153,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(54,785,000)<span></span>
</td>
<td class="num">(12,421,000)<span></span>
</td>
<td class="num">(6,737,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Disposition (acquisition) of investments</a></td>
<td class="nump">9,645,000<span></span>
</td>
<td class="num">(41,982,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired through acquisition</a></td>
<td class="nump">324,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment</a></td>
<td class="num">(2,287,000)<span></span>
</td>
<td class="num">(1,056,000)<span></span>
</td>
<td class="num">(725,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">7,682,000<span></span>
</td>
<td class="num">(42,958,000)<span></span>
</td>
<td class="num">(725,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares, net of issuance costs</a></td>
<td class="nump">142,177,000<span></span>
</td>
<td class="nump">56,477,000<span></span>
</td>
<td class="nump">32,038,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">1,651,000<span></span>
</td>
<td class="nump">2,616,000<span></span>
</td>
<td class="nump">389,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Issuance of common shares pursuant to exercise of warrants</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">1,583,000<span></span>
</td>
<td class="nump">289,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">143,870,000<span></span>
</td>
<td class="nump">60,676,000<span></span>
</td>
<td class="nump">32,716,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of foreign currency rate changes on cash and cash equivalents</a></td>
<td class="num">(2,175,000)<span></span>
</td>
<td class="num">(1,827,000)<span></span>
</td>
<td class="num">(3,561,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase in cash and cash equivalents</a></td>
<td class="nump">94,592,000<span></span>
</td>
<td class="nump">3,470,000<span></span>
</td>
<td class="nump">21,693,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">72,187,000<span></span>
</td>
<td class="nump">68,717,000<span></span>
</td>
<td class="nump">47,024,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">166,779,000<span></span>
</td>
<td class="nump">72,187,000<span></span>
</td>
<td class="nump">68,717,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_FairValueOfWarrantsExercisedOnACashlessBasis', window );">Fair value of warrants exercised on a cashless basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(116,000)<span></span>
</td>
<td class="nump">1,404,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Investment tax credits received</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Acquisition of Arbutus Inc. net of cash acquired</a></td>
<td class="nump">381,618,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research, development, collaborations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Items not involving cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,869,000<span></span>
</td>
<td class="nump">2,343,000<span></span>
</td>
<td class="nump">622,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Items not involving cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 14,224,000<span></span>
</td>
<td class="nump">$ 940,000<span></span>
</td>
<td class="nump">$ 281,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_FairValueOfWarrantsExercisedOnACashlessBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value of warrants exercised on a cashless basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_FairValueOfWarrantsExercisedOnACashlessBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_IncreaseDecreaseOtherDeferredCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of other deferred costs. Does not include deferred finance costs or deferred acquisition costs of insurance companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_IncreaseDecreaseOtherDeferredCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Article 4<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInUnbilledReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInUnbilledReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3098-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6833196416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Future Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of business and future operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the &#8220;Company&#8221; or &#8220;Arbutus&#8221;) is a Canadian biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (&#8220;HBV&#8221;). The Company is also developing a pipeline focused on advancing novel RNA interference therapeutics (RNAi) leveraging the Company&#8217;s expertise in Lipid Nanoparticle (LNP) technology.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective July 31, 2015, the corporate name changed from Tekmira Pharmaceuticals Corporation (Tekmira) to Arbutus Biopharma Corporation. Also effective July 31, 2015, the corporate name of the wholly-owned subsidiary, OnCore Biopharma, Inc. (OnCore) changed to Arbutus Biopharma, Inc. (Arbutus Inc.). Including Arbutus Inc., the Company has </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> wholly-owned subsidiaries: Protiva Biotherapeutics Inc. (Protiva), Protiva Biotherapeutics (USA) Inc. (Protiva USA), and Protiva Agricultural Development Company Inc. (&#8220;PADCo&#8221;). In March 2016, Monsanto exercised its option to acquire 100% of the outstanding shares in PADCo - refer to note 13 subsequent events.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company&#8217;s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company&#8217;s ability to continue to fund these programs in the future.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6827536944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant accounting policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant accounting policies</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of presentation</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation) was incorporated on October&#160;6, 2005 as an inactive wholly owned subsidiary of Inex Pharmaceuticals Corporation (Inex). Pursuant to a &#8220;Plan of Arrangement&#8221; effective April&#160;30, 2007, the business and substantially all of the assets and liabilities of Inex were transferred to the Company. The consolidated financial statements for all periods presented herein include the consolidated operations of Inex until April&#160;30, 2007 and the operations of the Company thereafter.&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> wholly-owned subsidiaries as at December 31, 2015: Arbutus Biopharma, Inc. (formerly OnCore Biopharma, Inc.) Protiva Biotherapeutics Inc. (Protiva), Protiva Biotherapeutics (USA) Inc. (Protiva USA), and Protiva Agricultural Development Company Inc. (&#8220;PADCo&#8221;). Protiva and Protiva USA were acquired on May 30, 2008. PADCo was incorporated on January 9, 2014. Arbutus Inc. was acquired by way of a Merger Agreement on March 4, 2015, which included Arbutus Inc.'s wholly-owned subsidiary, Enantigen Therapeutics, Inc. (Enantigen) - see note 3. Enantigen was merged with Arbutus Inc. on September 30, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements include the accounts of the Company and three of its wholly-owned subsidiaries, Arbutus Inc., Protiva and Protiva USA. All intercompany transactions and balances have been eliminated on consolidation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records its investment in PADCo using the equity method. The Company has determined that PADCo is a variable interest entity (&#8220;VIE&#8221;) of which it is not the primary beneficiary. The Company is not the primary beneficiary as it does not have the power to make decisions that most significantly affect the economic performance of the VIE nor does the Company have the right to receive benefits or the obligation to absorb losses that in either case could potentially be significant to the VIE. PADCo is described further in note 4(b). In March 2016, Monsanto exercised its option to acquire PADCo - refer to note 13 subsequent events.</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring the use of management estimates relate to purchase price allocation, valuation of intangible assets and goodwill, recognition of revenue, stock-based compensation, valuation of warrant liability and financial instrument, and the amounts recorded as accrued liabilities, contingent consideration, and income tax recovery.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and cash equivalents</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents are all highly liquid instruments with an original maturity of three months or less when purchased. Cash equivalents are recorded at cost plus accrued interest. The carrying value of these cash equivalents approximates their fair value.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-term and long-term investments</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company acquired guaranteed investment certificates and a term deposit during the year, which are classified as short-term and long-term investments on the balance sheet respectively. Short-term investments have original maturities exceeding three months, and have remaining maturities less than one year. Long-term investments have remaining maturities exceeding twelve months. Short-term and long-term investments accrue interest daily based on a fixed interest rate for the term. The carrying value of these investments are recorded at cost plus accrued interest, which approximates their fair value. All investments are governed by the Board approved Investment Policy for the Company.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair value of financial instruments</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We measure certain financial instruments and other items at fair value.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 inputs are quoted market prices for identical instruments available in active markets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#8217;s assumptions about market assumptions that would be used to price the asset or liability.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:0px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term and long-term investments, accounts receivable, accounts payable and accrued liabilities, warrants and financial instruments. Long-term investments approximate fair value due to the interest rates being at prevailing market rates.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying values of cash and cash equivalents, short-term investments, accounts receivable and accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As quoted prices for the warrants are not readily available, the Company has used a Black-Scholes pricing model, as described in note 6, to estimate fair value. These are level 3 inputs as defined above.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company used a discounted cash flow model to determine the fair value of the financial instrument related to Monsanto&#8217;s call option to acquire the equity or all of the assets of PADCo, as described in note 4. The fair value was determined at the date of recognition, and at each reporting date. The initial fair value of the financial instrument was nil, and there has been no change to its fair value as at December 31, 2015. The assumptions used in the discounted cash flow model are level 3 inputs as defined above.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the fair value of the contingent consideration, the Company uses a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, time to complete the program development, and overall biotech indices, as in note 9. The fair value was determine at the date of recognition to be </font><font style="font-family:inherit;font-size:10pt;">$6,727,000</font><font style="font-family:inherit;font-size:10pt;">. The Company determined the fair value of the contingent consideration has increased by </font><font style="font-family:inherit;font-size:10pt;">$770,000</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$7,497,000</font><font style="font-family:inherit;font-size:10pt;"> and the increase in fair value has been recorded in other losses in the statement of operations and comprehensive loss for the year-ended December 31, 2015. The assumptions used in the discounted cash flow model are level 3 inputs as defined above.&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,779</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,779</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Guaranteed investment certificate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,070</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,070</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,374</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,374</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instrument</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,380</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,380</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Guaranteed investment certificates</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,161</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,161</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instrument</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company&#8217;s warrants:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability at beginning</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants issued in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warrants exercised</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase (decrease) in fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability at end</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the period</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,208</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,383</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(455</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(334</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,341</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company&#8217;s contingent consideration:</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="26%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="22%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="22%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="22%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability at beginning</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the period </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">value of contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability at end</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the period</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;(1) As at acquisition date of March 4, 2015 - see note 3 below.</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory includes materials assigned for the manufacture of products for collaborative partners and manufacturing costs for products awaiting acceptance by collaborative partners. Inventory is carried at the lower of cost and net realizable value and measured using first-in-first-out method. The cost of inventories includes all costs of purchase, costs of manufacturing and other costs incurred in bringing the inventories to their present location and condition.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Materials purchased for the Company&#8217;s own research and development products are not recorded as inventory but are expensed as incurred.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and equipment</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment is recorded at cost less impairment losses, accumulated depreciation, related government grants and investment tax credits. The Company records depreciation using the straight-line method over the estimated useful lives of the capital assets as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="77%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Useful life (years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements are depreciated over their estimated useful lives but in no case longer than the lease term, except where lease renewal is reasonably assured. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If there is a major event indicating that the carrying value of property and equipment may be impaired then management will perform an impairment test and if the carrying value exceeds the recoverable value, based on undiscounted future cash flows, then such assets are written down to their fair values.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and intangible assets</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consist of in-process research and development arising from the Company&#8217;s acquisition of Arbutus Inc. - see note 3. In-process research and development (IPR&amp;D) intangible assets are classified as indefinite-lived and are not amortized. IPR&amp;D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives, which are the respective patent terms. Amortization begins when intangible assets with finite lives are put into use. If there is a major event indicating that the carrying value of intangible assets may be impaired, then management will perform an impairment test and if the carrying value exceeds the recoverable value, based on discounted future cash flows, then such assets are written down to their fair values. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets of Arbutus Inc. - see note 3. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is subject to a two-step impairment test on an annual basis, unless the Company identifies impairment indicators that would require earlier testing. The first step compares the fair value of the reporting unit to its carrying amount, which includes the goodwill. When the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not to be impaired, and the second step of the impairment test is unnecessary. If the carrying amount exceeds the implied fair value of the reporting unit, the second step measures the amount of the impairment loss. If the carrying amount exceeds the fair value of the reporting unit, an impairment loss is recognized equal to that excess.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company reviews the recoverable amount of intangible assets on an annual basis, and the annual evaluation for goodwill is performed as of December 31 each year. In addition, the Company evaluates for events or changes in the business that could indicate impairment and earlier testing. Such indicators include, but are not limited to, on an ongoing basis: (a) industry and market considerations such as increased competitive environment or adverse change in legal factors including an adverse assessment by regulators; (b) an accumulation of costs significantly in excess of the amount originally expected for the development of the asset; (c) current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the asset; and (d) if applicable, a sustained decrease in share price. </font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company earns revenue from research and development collaboration and contract services, licensing fees, milestone and royalty payments. Revenues associated with multiple element arrangements are attributed to the various elements based on their relative fair values or are recognized as a single unit of accounting when relative fair values are not determinable. Non-refundable payments received under collaborative research and development agreements are recorded as revenue as services are performed and related expenditures are incurred. Non-refundable upfront license fees from collaborative licensing and development arrangements are recognized as the Company fulfills its obligations related to the various elements within the agreements, in accordance with the contractual arrangements with third parties and the term over which the underlying benefit is being conferred. The Company evaluates new arrangements for any substantive milestones by considering: whether substantive uncertainty exists upon execution of the arrangement; if the event can only be achieved based in whole or in part on the Company&#8217;s performance, or occurrence of a specific outcome resulting from the Company&#8217;s performance; any future performance required, and payment is reasonable relative to all deliverables; and, the payment terms in the arrangement. Payments received upon the achievement of substantive milestones are recognized as revenue in their entirety. Payments received upon the occurrence of milestones that are non-substantive are deferred and recognized as revenue over the estimated period of performance applicable to the associated collaborative agreement.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue earned under research and development manufacturing collaborations where the Company bears some or all of the risk of a product manufacturing failure is recognized when the purchaser accepts the product and there are no remaining rights of return.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue earned under research and development collaborations where the Company does not bear any risk of product manufacturing failure is recognized in the period the work is performed. For contracts where the manufacturing amount is specified, revenue is recognized as product is manufactured in proportion to the total amount specified under the contract.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue and expenses under the contract with the United States Government Department of Defense (&#8220;DoD&#8221;) are being recorded using the percentage-of-completion method. Contract progress is based on costs incurred to date. Expenses under the contract are recorded in the Company&#8217;s consolidated statement of operations and comprehensive income (loss) as they are incurred. Government contract revenues related to expenses incurred under the contract are recorded in the same period as those expenses. Expenses accrued under the contract but not yet invoiced are recorded in the Company&#8217;s balance sheet as accrued liabilities and accrued revenues. Equipment purchased under the contract is recorded on the Company&#8217;s balance sheet as deferred expense and deferred revenue and amortized, on a straight-line basis, over the life of the contract.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash or other compensation received in advance of meeting the revenue recognition criteria is recorded on the balance sheet as deferred revenue. Revenue meeting recognition criteria but not yet received or receivable is recorded on the balance sheet as accrued revenue.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases and lease inducements</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leases entered into are classified as either capital or operating leases. Leases which substantially transfer all benefits and risks of ownership of property to the Company are accounted for as capital leases. At the time a capital lease is entered into, an asset is recorded together with its related long-term obligation to reflect the purchase and financing.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other leases are accounted for as operating leases wherein rental payments are expensed as incurred.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease inducements represent leasehold improvement allowances and reduced or free rent periods and are amortized on a straight-line basis over the term of the lease and are recorded as a reduction of rent expense.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and development costs</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are charged as an expense in the period in which they are incurred.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income or loss per share</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income or loss per share is calculated based on the weighted average number of common shares outstanding. Diluted loss per share does not differ from basic loss per share for the years ended December 31, 2015, 2014 and 2013, since the effect of the Company&#8217;s stock options and warrants is anti-dilutive.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the computation of basic and diluted net income (loss) per common share:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the year ended December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(61,121</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,837</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,063</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">45,462,324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,603,136</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,302,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.92</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, potential common shares of </font><font style="font-family:inherit;font-size:10pt;">2,899,331</font><font style="font-family:inherit;font-size:10pt;"> were excluded from the calculation of income per common share because their inclusion would be anti-dilutive (</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> &#8211; </font><font style="font-family:inherit;font-size:10pt;">2,221,233</font><font style="font-family:inherit;font-size:10pt;">; </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2013</font><font style="font-family:inherit;font-size:10pt;"> &#8211; </font><font style="font-family:inherit;font-size:10pt;">3,064,767</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Government grants and refundable investment tax credits</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government grants and tax credits provided for current expenses is included in the determination of income or loss for the year, as a reduction of the expenses to which it relates. Government grants and tax credits towards the acquisition of property and equipment is deducted from the cost of the related property and equipment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign currency translation and change in reporting currency</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The functional currency of the Company and two of its integrated subsidiaries (Protiva and Protiva USA), is the Canadian dollar, and the functional currency of Arbutus Inc. is the U.S. dollar. Foreign currency monetary assets and liabilities are translated into the functional currency at the rate of exchange prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month&#8217;s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is using United States dollars as its reporting currency. All assets and liabilities are translated using the exchange rate at the balance sheet date. Revenues, expenses and other income (losses) are translated using the average rate for the period, except for large transactions, for which the exchange rate on the date of the transaction is used. Equity accounts are translated using the historical rate. As the translation differences from the Company&#8217;s functional currency of Canadian dollars to the Company&#8217;s reporting currency of US dollars are unrealized gains and losses, the differences are recorded in other comprehensive income (loss), and do not impact the calculation of Income or Loss per Share.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2016, the Company changed its functional currency from the Canadian dollar to the U.S. dollar based on management's analysis of the changes in the primary economic environment in which the Company operates.  The change in functional currency is accounted for prospectively from January 1, 2016 and financial statements prior to and including the year-ended December 31, 2015 have not been restated for the change in functional currency. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred income taxes</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes are accounted for using the asset and liability method of accounting. Deferred income taxes are recognized for the future income tax consequences attributable to differences between the carrying values of assets and liabilities and their respective income tax bases and for loss carry-forwards. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the periods in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax laws or rates is included in earnings in the period that includes the enactment date. When realization of deferred income tax assets does not meet the more-likely-than-not criterion for recognition, a valuation allowance is provided.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based compensation</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company grants stock options to employees and directors pursuant to a share incentive plan described in note 6. Compensation expense is recorded for issued stock options using the fair value method with a corresponding increase in additional paid-in capital. Any consideration received on the exercise of stock options is credited to share capital.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of stock options is measured at the grant date and amortized on a straight-line basis over the vesting period.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Replacement awards</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Replacement awards are share-based payment awards exchanged for awards held by employees of Arbutus Inc. As part of the Company&#8217;s acquisition of Arbutus Inc., Arbutus shares were exchanged for Arbutus Inc.&#8217;s shares subject to repurchase rights held by Arbutus Inc.&#8217;s employees - see note 3.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at the date of acquisition of Arbutus Inc., the Company determined the total fair value of replacement awards and attributed a portion of the replacement awards to pre-combination service as part of the total acquisition consideration, and a portion to post-combination service, which is recognized as compensation expense over the expiry period of repurchase provision rights subsequent to the acquisition date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The replacement awards consist of common shares that were issued at acquisition. Accordingly, as stock compensation expense related to these awards is recognized, share capital is increased by a corresponding amount. Replacement awards are excluded in the calculation of basic net income (loss) per share until the repurchase rights have expired.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for the warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company&#8217;s own stock, on the understanding that in compliance with applicable securities laws, the registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies warrants in its consolidated balance sheet as a liability which is revalued at each balance sheet date subsequent to the initial issuance. The Company uses the Black-Scholes pricing model to value the warrants. Determining the appropriate fair-value model and calculating the fair value of registered warrants requires considerable judgment. A small change in the estimates used may cause a relatively large change in the estimated valuation. The estimated volatility of the Company&#8217;s common stock at the date of issuance, and at each subsequent reporting period, is based on historic fluctuations in the Company&#8217;s stock price. The risk-free interest rate is based on the Government of Canada rate for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is based on the historical pattern of exercises of warrants.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment information</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in a single reporting segment. Substantially all of the Company&#8217;s revenues to date were earned from customers or collaborators based in the United States. Substantially all of the Company&#8217;s premises, property and equipment are located in Canada and the United States.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent accounting pronouncements</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842): Recognition and Measurement of Financial Assets and Financial Liabilities. The update supersedes Topic 840, Leases and requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP.  Topic 842 retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. The amendments in this update are effective for fiscal years beginning after December 15, 2018 for public business entities, which for the Company means January 1, 2019. The Company does not plan to early adopt this update. The extent of the impact of this adoption has not yet been determined.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, the FASB issued ASU 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The update eliminates the requirement to retrospectively adjust the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill during the measurement period when new information is obtained about the facts and circumstances that existed as of the acquisition date, that if known, would have affected the measurement of the amounts initially recognized or would have resulted in the recognition of additional assets or liabilities. The amendments in this update are effective for fiscal years beginning after December 15, 2015, which for the Company means January 1, 2016, and should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update. Early application is permitted for financial statements that have not been issued. The Company has adopted this update and applied it to the acquisition of Arbutus Inc.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASC 606). The standard is intended to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS by creating a new Topic 606, Revenue from Contracts with Customers. This guidance supersedes the revenue recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition - Construction-Type and Production-Type Contracts. The core principle of the accounting standard is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1) retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date to defer the effective date of Update 2014-09 for all entities by one year. The new guidance would be effective for fiscal years beginning after December 15, 2017, which for the Company means January 1, 2018. Entities are permitted to adopt in accordance with the original effective date if they choose. The Company has not yet determined the extent of the impact of adoption.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern. The update is intended to provide guidance in GAAP about management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures. Under amendments to GAAP, the assessment period is within one year after the date that the financial statements are issued (or available to be issued). The amendments are effective for the annual period ending after December 15, 2016, which for the Company means January 1, 2017, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not plan to early adopt this update. The extent of the impact of this adoption has not yet been determined.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6833205728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Merger with Arbutus Biopharma, Inc. (formerly OnCore BioPharma, Inc.)</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160; &#160;&#160;Purchase Price Allocation</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 11, 2015, the Company entered into a Merger Agreement to acquire </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding shares of Arbutus Inc. (formerly OnCore Biopharma, Inc.) and its wholly-owned subsidiary, Enantigen (see note 9). Arbutus Inc. was a privately owned U.S. company focused on discovery, development and commercialization of an all-oral cure regimen for patients with HBV. The merger was approved by the Company&#8217;s shareholders on March 3, 2015 and closed on March 4, 2015. Arbutus Inc.&#8217;s results of operations and fair value of assets acquired and liabilities assumed are included in the Company&#8217;s consolidated financial statements from the date of acquisition.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transaction has been accounted for using the acquisition method based on ASC 805, Business Combinations, with Arbutus (formerly Tekmira) identified as the acquirer, based on managements&#8217; analysis and evaluation of the form of the acquisition, the relative contribution and rights of the predecessor groups post-closing, and the relative number of shares issued by the Company on acquisition of Arbutus Inc. Under the acquisition method, the consideration transferred is measured at fair value; common shares as consideration are issued at the market price as at the acquisition date. The excess of the purchase price over the preliminary fair value assigned to the net assets acquired has been recorded as goodwill. Acquisition costs were expensed as incurred. The Company recorded $</font><font style="font-family:inherit;font-size:10pt;">9,656,000</font><font style="font-family:inherit;font-size:10pt;"> of acquisition costs for the year ended December 31, 2015 (2014 - </font><font style="font-family:inherit;font-size:10pt;">$462,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company issued consideration with a total fair value of </font><font style="font-family:inherit;font-size:10pt;">$381,942,000</font><font style="font-family:inherit;font-size:10pt;"> on acquisition. Of this consideration, </font><font style="font-family:inherit;font-size:10pt;">23,973,315</font><font style="font-family:inherit;font-size:10pt;"> common shares were issued, which is comprised of </font><font style="font-family:inherit;font-size:10pt;">20,347,906</font><font style="font-family:inherit;font-size:10pt;"> common shares issued without subjects and </font><font style="font-family:inherit;font-size:10pt;">3,625,412</font><font style="font-family:inherit;font-size:10pt;"> common shares issued to Arbutus Inc.&#8217;s founding executives and subject to repurchase provisions. The fair value of the common shares issued without subjects has been determined to be the Company&#8217;s NASDAQ closing price of $</font><font style="font-family:inherit;font-size:10pt;">18.26</font><font style="font-family:inherit;font-size:10pt;"> on the date prior to the acquisition&#8217;s consummation, March 4, 2015. The total fair value of the common shares issued subject to repurchase provision has been determined to be $</font><font style="font-family:inherit;font-size:10pt;">66,196,000</font><font style="font-family:inherit;font-size:10pt;">, using the Black-Scholes pricing model with assumed risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">0.74%</font><font style="font-family:inherit;font-size:10pt;">, volatility of </font><font style="font-family:inherit;font-size:10pt;">81%</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> dividend yield and an expected life of </font><font style="font-family:inherit;font-size:10pt;">4 years</font><font style="font-family:inherit;font-size:10pt;">. Of the total fair value, $</font><font style="font-family:inherit;font-size:10pt;">9,262,000</font><font style="font-family:inherit;font-size:10pt;"> has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of </font><font style="font-family:inherit;font-size:10pt;">$56,934,000</font><font style="font-family:inherit;font-size:10pt;"> will be recognized as compensation expense over the period of expiry of repurchase provision rights and is not included in the total acquisition consideration. In July 2015, in conjunction with amendments to the employment contracts of Arbutus Inc.&#8217;s founding executives, the Company amended the repurchase provision rights period of expiry from August 2018 to August 2017. This amendment results in an acceleration of compensation expense recognized in each subsequent period by approximately </font><font style="font-family:inherit;font-size:10pt;">$1,900,000</font><font style="font-family:inherit;font-size:10pt;"> per quarter, effective in Q3 2015. The Company recorded </font><font style="font-family:inherit;font-size:10pt;">$16,687,000</font><font style="font-family:inherit;font-size:10pt;"> in stock-based compensation expense related to services performed during the period of expiration of repurchase provision rights from the acquisition date through to December 31, 2015. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at the acquisition date, </font><font style="font-family:inherit;font-size:10pt;">3,625,412</font><font style="font-family:inherit;font-size:10pt;"> shares were issued and outstanding which were and continue to remain subject to a repurchase provision. Subsequent to the acquisition date and the July 2015 amendment to the repurchase provision rights, the rights expire at a rate of </font><font style="font-family:inherit;font-size:10pt;">302,120</font><font style="font-family:inherit;font-size:10pt;"> on November 30, 2015 and February 29, 2016 and at a rate of </font><font style="font-family:inherit;font-size:10pt;">503,552</font><font style="font-family:inherit;font-size:10pt;"> shares every three months thereafter commencing May 31, 2016.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has further reserved </font><font style="font-family:inherit;font-size:10pt;">184,332</font><font style="font-family:inherit;font-size:10pt;"> shares for the future exercise of Arbutus Inc. stock options. The total fair value of Arbutus Inc. stock options at the date of acquisition has been determined to be $</font><font style="font-family:inherit;font-size:10pt;">3,287,000</font><font style="font-family:inherit;font-size:10pt;">, using the Black-Scholes pricing model with an assumed risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">0.97%</font><font style="font-family:inherit;font-size:10pt;">, volatility of </font><font style="font-family:inherit;font-size:10pt;">78%</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> dividend yield and an expected life of </font><font style="font-family:inherit;font-size:10pt;">8 years</font><font style="font-family:inherit;font-size:10pt;">, which are consistent with the assumption inputs used by the Company to determine the fair value of its options. Of the total fair value, $</font><font style="font-family:inherit;font-size:10pt;">1,127,000</font><font style="font-family:inherit;font-size:10pt;"> has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of </font><font style="font-family:inherit;font-size:10pt;">$2,160,000</font><font style="font-family:inherit;font-size:10pt;"> will be recognized as compensation expense over the vesting period of the stock options through to December 2018. The Company has included </font><font style="font-family:inherit;font-size:10pt;">$463,000</font><font style="font-family:inherit;font-size:10pt;"> compensation expense related to the vesting of Arbutus Inc. stock options from the acquisition date through to December 31, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate fair value of consideration transferred to acquire Arbutus Inc.&#8217;s outstanding shares has been determined to be </font><font style="font-family:inherit;font-size:10pt;">$381,942,000</font><font style="font-family:inherit;font-size:10pt;">, and has been attributed to fair values of assets acquired and liabilities assumed. The Company has refined the preliminary allocation of the purchase price for intangible assets, goodwill, contingent consideration and deferred tax liability from what was disclosed in prior periods. The following table summarizes the Company&#8217;s finalized purchase price allocation as at December 31, 2015:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consideration paid:</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Common shares issued without subjects</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371,553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Common shares issued subject to repurchase provision</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Common shares issuable for Arbutus Inc. stock options</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,127</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identifiable assets acquired and liabilities assumed:</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Cash</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Accounts receivable</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Property and equipment</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Goodwill</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,580</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Other non-current liabilities (note 9)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,727</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Deferred income tax liability</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(162,509</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total purchase price allocation</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of intangible assets is estimated to be </font><font style="font-family:inherit;font-size:10pt;">$391,649,000</font><font style="font-family:inherit;font-size:10pt;">. The fair value of each IPR&amp;D asset is estimated using the income approach. The income approach uses valuation techniques to discount future economic benefits attributed to the subject intangible asset to a present value. Present value is based on current market expectations about those future amounts and includes management&#8217;s estimates of risk-adjusted future incremental earnings that may be achieved upon regulatory approval, promotion, and distribution associated with the rights and includes estimated cash flows of approximately </font><font style="font-family:inherit;font-size:10pt;">20 years</font><font style="font-family:inherit;font-size:10pt;"> and a discount rate of approximately </font><font style="font-family:inherit;font-size:10pt;">13.7%</font><font style="font-family:inherit;font-size:10pt;">. The identifiable intangible assets acquired consist of in-process research and development (IPR&amp;D) HBV assets, as summarized in the table below:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Cyclophilins</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,007</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Immune Modulators</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Antigen Inhibitors</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; cccDNA Sterilizers</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total IPR&amp;D</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">391,649</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All IPR&amp;D acquired is currently classified as indefinite-lived and is not currently being amortized. IPR&amp;D becomes definite-lived upon the completion or abandonment of the associated research and development efforts, and will be amortized from that time over an estimated useful life based on respective patent terms. The fair value of each IPR&amp;D asset will continue to be evaluated on a quarterly basis for indicators of impairment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the fair values above, an amount of $</font><font style="font-family:inherit;font-size:10pt;">162,514,000</font><font style="font-family:inherit;font-size:10pt;"> has been allocated to goodwill, which represents the excess of the purchase price over the fair values assigned to the net assets acquired. Goodwill is attributable to synergies expected to arise after the Company&#8217;s acquisition of Arbutus Inc. The full amount of the value of goodwill has been assigned to the entire Company, since management has determined that the Company has only </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> reporting unit. The goodwill is not deductible for tax purposes, and is not amortized, but will be evaluated for impairment on an annual basis or more often if the Company identifies impairment indicators that would require earlier testing.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reconciliation of preliminary to final purchase price allocation</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2015, the Company finalized the purchase price allocation and made revisions to certain preliminary estimated fair values of assets acquired and liabilities assumed. The following table presents a summary of revisions and adjustments made to the preliminary estimates as previously disclosed to the finalized purchase price allocation:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="46%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preliminary Amounts Recognized as of Acquisition Date </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measurement Period Adjustments</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(2)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts Recognized as of Acquisition Date (as adjusted)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identifiable assets acquired and liabilities assumed:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Cash</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Accounts receivable</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Property and equipment</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389,652</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,997</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Goodwill</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,580</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,580</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Other non-current liabilities (note 8)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,736</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,991</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,727</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Deferred income tax liability</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(155,865</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,644</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(162,509</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total purchase price allocation</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preliminary purchase price as of the acquisition date of March 4, 2015 as previously disclosed in the notes to consolidated financial statements included in the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The measurement period is from the acquisition date of March 4, 2015 to the date the Company finalized the purchase price allocation on December 31, 2015. </font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The measurement period adjustment for intangible assets acquired was made as the Company revised certain royalty rates on future sales of various intangible assets acquired. This resulted in an increase in deferred income tax liability associated with the intangible assets. In addition, the Company revised its preliminary tax rate based on management's revised analysis of a combined federal and state tax rate in the jurisdiction in which the Company expects the deferred tax liability to be settled or realized. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The measurement period adjustment for other non-current liabilities relate to the contingent consideration payable to former Enantigen shareholders upon the achievement of certain regulatory, development and sales milestones, as described in note 9. The adjustment relates to management's revision to the probabilities used in a probability weighted assessment of the likelihood of milestones being met and timing of such payments.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the above measurement period adjustments, the increase to goodwill of </font><font style="font-family:inherit;font-size:10pt;">$6,649,000</font><font style="font-family:inherit;font-size:10pt;"> results in a final goodwill allocation of </font><font style="font-family:inherit;font-size:10pt;">$162,514,000</font><font style="font-family:inherit;font-size:10pt;">. As described in note 2 and further below, the Company conducts its annual goodwill impairment test on December 31st.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pro forma information</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amount of net loss of Arbutus Inc. included in the consolidated statements of operations from the acquisition date, through the period ended December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$13,658,000</font><font style="font-family:inherit;font-size:10pt;">. Arbutus Inc. did not earn any revenues from the acquisition date through the year-ended December 31, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the unaudited pro forma results for the year ended December 31, 2015 and 2014. The pro forma financial information combines the results of operations of Arbutus, Arbutus Inc., Protiva, Protiva USA, and Enantigen as though the businesses had been combined as of the beginning of fiscal 2014. The pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the merger had taken place at the beginning of fiscal 2014. The pro forma financial information presented includes acquisition costs, amortization charges for acquired tangible assets, impairment charge on acquired intangible assets (as described in note 3b below), but does not include amortization charges for acquired intangible assets as these assets have not yet been put in use.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="47%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pro forma information</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross Revenue</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,873</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,953</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(109,387</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,088</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(67,416</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(56,491</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.38</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.24</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Impairment evaluations for intangible assets and goodwill</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the recoverable amount of intangible assets on an annual basis and performs an annual evaluation of goodwill as of December 31 each year, unless there is an event or change in the business that could indicate impairment and earlier testing.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of intangible assets</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 28, 2015, the Company announced that the development of the cyclophilin drug candidate, OCB-030 has been discontinued. The decision was based on extensive preclinical evaluations performed by the Company of OCB-030 and other competitive cyclophilin inhibitors following the acquisition of Arbutus Inc., which concluded that cyclophilins do not play a meaningful role in HBV biology. Although the final conclusion was made subsequent to the period end, it reflected management&#8217;s best estimate as at September 30, 2015, and as such, the Company recorded an estimated impairment charge of $</font><font style="font-family:inherit;font-size:10pt;">37,990,000</font><font style="font-family:inherit;font-size:10pt;"> and a corresponding income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$15,196,000</font><font style="font-family:inherit;font-size:10pt;">  related to the decrease in deferred tax liability for the discontinuance of OCB-030 in the consolidated statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As noted above, the Company finalized its purchase price allocation during the fourth quarter of 2015 by making certain revisions to estimates which included adjustments to the fair value of individual intangible assets acquired. The fair value of cyclophilin inhibitors has been adjusted to be </font><font style="font-family:inherit;font-size:10pt;">$39,007,000</font><font style="font-family:inherit;font-size:10pt;"> as compared to management's best estimate of </font><font style="font-family:inherit;font-size:10pt;">$37,990,000</font><font style="font-family:inherit;font-size:10pt;"> previously written off in the third quarter. The incremental adjustment to fair value of </font><font style="font-family:inherit;font-size:10pt;">$1,017,000</font><font style="font-family:inherit;font-size:10pt;"> as well as the corresponding incremental adjustment to income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$989,000</font><font style="font-family:inherit;font-size:10pt;"> are cumulatively reflected in the Company's consolidated statement of operations and comprehensive loss for the year-ended December 31, 2015. For all other IPR&amp;D, fair values of the intangible assets were calculated to be above the respective carrying values; therefore, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment was recorded. The following table summarizes the carrying values, net of impairment of the intangible assets as at December 31, 2015:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Cyclophilins</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Immune Modulators</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Antigen Inhibitors</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; cccDNA Sterilizers</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total IPR&amp;D</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">352,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Annual impairment evaluation of goodwill</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 31, the Company conducted its annual impairment evaluation of goodwill. Goodwill was recorded as a result of the acquisition of Arbutus Inc. as described in note 3(a), and has a carrying value of $</font><font style="font-family:inherit;font-size:10pt;">162,514,000</font><font style="font-family:inherit;font-size:10pt;">. As part of the evaluation of the recoverability of goodwill, the Company has identified only </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> reporting unit to which the total carrying amount of goodwill has been assigned. The income approach is used to estimate the fair value of the reporting unit, which requires estimating future cash flows and risk-adjusted discount rates. Changes in these estimates and assumptions could materially affect the determination of fair value of the reporting unit and may result in impairment charges in future periods. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015, the fair value of the reporting unit exceeded the carrying value of the reporting unit, and as such the second step of the impairment test, which measures the amount of impairment charge, was not required. In addition to the income approach, the Company considered the market capitalization of approximately </font><font style="font-family:inherit;font-size:10pt;">$242,844,000</font><font style="font-family:inherit;font-size:10pt;"> as at December 31, 2015. Although the Company&#8217;s carrying value of </font><font style="font-family:inherit;font-size:10pt;">$547,679,000</font><font style="font-family:inherit;font-size:10pt;"> exceeded the market capitalization, the Company reconciled the income approach determination of fair value with the market capitalization by considering macroeconomic factors, and as such, the Company does not believe that market capitalization appropriately reflected the value of the Company for the purpose of testing goodwill impairment. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> impairment charge on goodwill was recorded for the year ended December 31, 2015.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1497-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1490-128463<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1486-128463<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1500-128463<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1524-128463<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7000-128479<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4922-128472<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4934-128472<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4926-128472<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1383-128463<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6996-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6827469008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, Contracts and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations, contracts and licensing agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborations, contracts and licensing agreements</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables set forth revenue recognized under collaborations, contracts and licensing agreements:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborations and contracts</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DoD (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,764</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,407</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,806</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto (b)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BMS (d)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,741</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">526</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna (e)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other RNAi collaborators (g)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development collaborations and contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Licensing fees, milestone and royalty payments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto licensing fees and milestone payments (b)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alnylam and Acuitas licensing fees and milestone payments (c)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna licensing fee (e)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Spectrum royalty payments (f)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total licensing fees, milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,564</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,215</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,040</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,873</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,953</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,465</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth deferred collaborations and contracts revenue:</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DoD (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto current portion (b)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna current portion (e)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,221</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">868</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,779</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto long-term portion (b)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna long-term portion (e)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,271</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total deferred revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,081</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,716</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160; &#160;&#160;Contract with United States Government&#8217;s Department of Defense (&#8220;DoD&#8221;) to develop TKM-Ebola</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July&#160;14, 2010, the Company signed a contract with the DoD to advance TKM-Ebola, an RNAi therapeutic utilizing the Company&#8217;s lipid nanoparticle technology to treat Ebola virus infection.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the initial phase of the contract, funded as part of the Transformational Medical Technologies program, the Company was eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;">$34,700,000</font><font style="font-family:inherit;font-size:10pt;">. This initial funding was for the development of TKM-Ebola including completion of preclinical development, filing an Investigational New Drug application with the United States Food and Drug Administration (&#8220;FDA&#8221;) and completing a Phase 1 human safety clinical trial. On May 8, 2013, the Company announced that the contract had been modified to support development plans that integrate recent advancements in lipid nanoparticle (&#8220;LNP&#8221;) formulation and manufacturing technologies. The contract modification increased the stage one targeted funding by an additional </font><font style="font-family:inherit;font-size:10pt;">$6,970,000</font><font style="font-family:inherit;font-size:10pt;">. On April 22, 2014, the Company and the DoD signed a contract modification to further increase the stage one targeted funding by </font><font style="font-family:inherit;font-size:10pt;">$2,100,000</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$43,819,000</font><font style="font-family:inherit;font-size:10pt;">. The additional funding was to compensate the Company for unrecovered overheads related to the temporary stop-work period that occurred in 2012 and to provide additional overhead funding should it be required. </font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The DoD had the option of extending the contract beyond the initial funding period to support the advancement of TKM-Ebola through to the completion of clinical development and FDA approval. Based on the contract&#8217;s budget this would have provided the Company with up to </font><font style="font-family:inherit;font-size:10pt;">$140,000,000</font><font style="font-family:inherit;font-size:10pt;"> in funding for the entire program. In December 2014, the DoD exercised an option valued at </font><font style="font-family:inherit;font-size:10pt;">$7,000,000</font><font style="font-family:inherit;font-size:10pt;"> to manufacture TKM-Ebola-Guinea, developed by the Company targeting the Ebola-Guinea strain responsible for the current outbreak in West Africa.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the contract, the Company is reimbursed for costs incurred, including an allocation of overhead costs, and is paid an incentive fee. At the beginning of the fiscal year, the Company estimates its labor and overhead rates for the year ahead. At the end of the year the actual labor and overhead rates are calculated and revenue is adjusted accordingly. The Company&#8217;s actual labor and overhead rates will differ from its estimated rates based on actual costs incurred and the proportion of the Company&#8217;s efforts on contracts and internal products versus indirect activities. Within minimum and maximum collars, the amount of incentive fee the Company can earn under the contract varies based on costs incurred versus budgeted costs.&#160;&#160;During the contractual period, incentive fee revenue and total costs are impacted by management&#8217;s estimate and judgments which are continuously reviewed and adjusted as necessary using the cumulative catch-up method.&#160;&#160;For the years ended December 31, 2014 and 2015, the Company believes it can reliably estimate the final contract costs so has recognized the portion of expected incentive fee which has been earned to date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 1, 2015, the Company received formal notification from the DoD that, due to the unclear development path for TKM-Ebola and TKM-Ebola-Guinea, the Ebola-Guinea Manufacturing and the Ebola-Guinea IND submission statements of work had been terminated, subject to the completion of certain post-termination obligations. &#160;The TKM-Ebola portion of the contract was completed in November 2015. The Company is currently conducting contract close out procedures with the DoD. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Option and Services Agreements with Monsanto Company (&#8220;Monsanto&#8221;)</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2014, the Company and Monsanto signed an Option Agreement and a Services Agreement (together, the &#8220;Agreements&#8221;). Under the Agreements, Monsanto has an option to obtain a license to use the Company&#8217;s proprietary delivery technology and related intellectual property for use in agriculture. Over the option period, which is expected to be approximately </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> years, the Company will provide lipid formulations for Monsanto&#8217;s research and development activities, and Monsanto will make certain payments to the Company to maintain its option rights. The maximum potential value of the transaction is </font><font style="font-family:inherit;font-size:10pt;">$86,200,000</font><font style="font-family:inherit;font-size:10pt;"> following the successful completion of milestones. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2015, the arrangement was amended to extend the option period by approximately </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> months, with payments up to </font><font style="font-family:inherit;font-size:10pt;">$2,000,000</font><font style="font-family:inherit;font-size:10pt;"> for the extension period. From inception of the contract to December 31, 2015, the Company had received </font><font style="font-family:inherit;font-size:10pt;">$19,300,000</font><font style="font-family:inherit;font-size:10pt;"> from Monsanto. The amounts received relate to research services and use of the Company&#8217;s technology over the option period, and are recognized as revenue on a straight-line basis over the extended option period.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the completion of the Phase A extension period in October 2015, no further research activities were conducted under the arrangement, as Monsanto did not elect to proceed to Phase B of the research plan. As such, the Company revised its estimate of the option period, over which payments received from Monsanto is recognized as revenue, to be from inception to December 31, 2015 as the Company believes it no longer has any further obligations to provide future research activities to Monsanto. This resulted in the full release of Monsanto deferred revenue and a recognition of </font><font style="font-family:inherit;font-size:10pt;">$14,981,000</font><font style="font-family:inherit;font-size:10pt;"> in Monsanto revenue for the year-ended December 31, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Agreements, the Company has established a wholly-owned subsidiary, PADCo. The Company has determined that PADCo is a variable interest entity (&#8220;VIE&#8221;); however, Monsanto is the primary beneficiary of the arrangement. PADCo was established to perform research and development activities, which have been funded by Monsanto in return for a call option to acquire the equity or all of the assets of PADCo. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto would pay the Company an option exercise fee and would receive a worldwide, exclusive right to use the Company&#8217;s proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. The Company retains all rights to therapeutics uses of all current intellectual property and intellectual property developed under the Agreements. The Company&#8217;s initial investment is not significant, and the Company has no implied or unfunded commitments and the maximum exposure to loss is limited to the amount of investment in the entity. The Company has included its investment in PADCo in other assets. There were no significant assets or liabilities for PADCo as at December 31, 2015. There was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> equity income or loss with respect to PADCo recorded for the periods ended December 31, 2014 and December 31, 2015. In March 2016, Monsanto exercised its option to acquire </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding shares of PADCo and will pay the Company an exercise fee of </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> - refer to note 13 for the subsequent event.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">License and collaboration with Alnylam Pharmaceuticals, Inc. (Alnylam) and Acuitas Therapeutics Inc. (Acuitas)</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Milestone receipts and payments</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2013, Alnylam initiated a Phase III trial with ALN-TTR02, also known as patisiran, and the associated </font><font style="font-family:inherit;font-size:10pt;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;"> development milestone was paid to the Company in December 2013. In addition, the Company earned a </font><font style="font-family:inherit;font-size:10pt;">$150,000</font><font style="font-family:inherit;font-size:10pt;"> milestone in March 2014 from Acuitas (formerly AlCana Technologies, Inc.) subsequent to Acuitas receiving a milestone payment from Alnylam with respect to Alnylam initiating a Phase III trial for ALN-TTR02.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2013, the Company initiated Phase I/II clinical trial for TKM-PLK1, resulting in a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$375,000</font><font style="font-family:inherit;font-size:10pt;"> to Alnylam.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Arbitration with Alnylam and Ascletis Pharmaceuticals (Hangzhou) Co. Ltd. (&#8220;Ascletis&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 21, 2013, the Company transferred manufacturing process technology to Ascletis to enable them to produce ALN-VSP, a product candidate licensed to them by Alnylam. The Company believed that under its licensing agreement with Alnylam, the technology transfer to Ascletis triggered a $</font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;"> milestone obligation from Alnylam to the Company. However, Alnylam demanded a declaration that the Company had not yet met its milestone obligations. The Company disputed Alnylam&#8217;s position. To remedy this dispute, the Company and Alnylam commenced arbitration proceedings as provided for under the agreement.&#160; The hearing date for this arbitration took place in May 2015, and in March 2016, the arbitration proceeding with Alnylam has concluded resulting in no milestone payment to the Company. &#160;The Company has not recorded any revenue in respect of this milestone for the year-ended December 31, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;&#160;&#160;Bristol-Myers Squibb (&#8220;BMS&#8221;) collaboration</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 10, 2010 the Company announced the expansion of its research collaboration with BMS. Under the new agreement, BMS uses small interfering RNA (&#8220;siRNA&#8221;) molecules formulated by the Company in LNP technology to silence target genes of interest.&#160;&#160;BMS is conducting the preclinical work to validate the function of certain genes and share the data with the Company.&#160;&#160;The Company can use the preclinical data to develop RNAi therapeutic drugs against the therapeutic targets of interest.&#160;&#160;The Company received </font><font style="font-family:inherit;font-size:10pt;">$3,000,000</font><font style="font-family:inherit;font-size:10pt;"> from BMS concurrent with the signing of the agreement and recorded the amount as deferred revenue. The Company is required to provide a pre-determined number of LNP batches over the </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year agreement.&#160;&#160;BMS has a first right to negotiate a licensing agreement on certain RNAi products developed by the Company that evolve from BMS validated gene targets.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from the May 10, 2010 agreement with BMS is being recognized as the Company produces the related LNP batches.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue earned for the year-ended December 31, 2014 relates to batches shipped to BMS during the period. In August 2014, the agreement expired and both companies' obligations under the agreement ended.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;&#160;&#160;License and Development and Supply Agreement with Dicerna Pharmaceuticals, Inc. (&#8220;Dicerna&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 16, 2014, the Company signed a License Agreement and a Development and Supply Agreement (together, the &#8220;Agreements&#8221;) with Dicerna to development, manufacture, and commercialization of products directed to treatment of Primary Hyperoxaluria 1 (&#8220;PH1&#8221;), In consideration for the rights granted under the Agreements, Dicerna paid the Company an upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$2,500,000</font><font style="font-family:inherit;font-size:10pt;">. The Company is also entitled to receive payments from Dicerna on the manufacturing and services provided, as well as further payments with the achievement of development and regulatory milestones of </font><font style="font-family:inherit;font-size:10pt;">$22,000,000</font><font style="font-family:inherit;font-size:10pt;"> in aggregate, and potential commercial royalties. Further, under the Agreements, a joint development committee has been established to provide guidance and direction on the progression of the collaboration.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined the deliverables under the Agreements included the rights granted, participation in the joint development committee, materials manufactured and other services provided, as directed under the joint development committee.  The license and participation in the joint development committee have been determined by the Company to not have standalone value due to the uniqueness of the subject matter under the Agreements. Therefore, these deliverables are treated as one unit of accounting and recognized as revenue over the performance period, which the Company has estimated to be approximately </font><font style="font-family:inherit;font-size:10pt;">28</font><font style="font-family:inherit;font-size:10pt;"> months as at December 31, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has determined that manufacturing services and other services provided have standalone value, as a separate statement of work is executed and invoiced for each manufacturing or service work order. The relative fair values are determined as a batch price or fee is estimated upon the execution of each work order, with actual expenditures charged at comparable market rates with embedded margins on each work order. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturing work orders are invoiced at the time of execution of the work order, at the initiation of manufacture, and at the release of materials. The Company has deferred the recognition of revenue on all cash deposit payments received for manufacturing work orders until acceptance of inventory.&#160;&#160;Revenue from service work orders is recognized as the services are performed.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company believes the development and regulatory milestones are substantive, due to the existence of substantive uncertainty upon the execution of the arrangement, and that the achievement of the development and regulatory events are based in part on the Company&#8217;s performance and the occurrence of a specific outcome resulting from performance. The Company has not received any milestone payments to date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;&#160;&#160;Agreements with Spectrum Pharmaceuticals, Inc. (&#8220;Spectrum&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 6, 2006, the Company signed a number of agreements with Talon Therapeutics, Inc. (&#8220;Talon&#8221;, formerly Hana Biosciences, Inc.) including the grant of worldwide licenses (the &#8220;Talon License Agreement&#8221;) for </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> of the Company&#8217;s chemotherapy products, Marqibo&#174;, Alocrest &#8482; (Optisomal Vinorelbine) and Brakiva &#8482; (Optisomal Topotecan).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 9, 2012, the Company announced that Talon had received accelerated approval for Marqibo from the FDA for the treatment of adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Marqibo is a liposomal formulation of the chemotherapy drug vincristine. In the year ended December 31, 2012, the Company received a milestone of $</font><font style="font-family:inherit;font-size:10pt;">1,000,000</font><font style="font-family:inherit;font-size:10pt;"> based on the FDA&#8217;s approval of Marqibo and will receive royalty payments based on Marqibo&#8217;s commercial sales. There are no further milestones related to Marqibo but the Company is eligible to receive total milestone payments of up to </font><font style="font-family:inherit;font-size:10pt;">$18,000,000</font><font style="font-family:inherit;font-size:10pt;"> on Alocrest and Brakiva.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Talon was acquired by Spectrum in July 2013. The acquisition did not affect the terms of the license between Talon and the Company. On September 3, 2013, Spectrum announced that they had shipped the first commercial orders of Marqibo. In the year ended December 31, 2015, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$240,000</font><font style="font-family:inherit;font-size:10pt;"> in Marqibo royalty revenue (2014 - </font><font style="font-family:inherit;font-size:10pt;">$190,000</font><font style="font-family:inherit;font-size:10pt;">, 2013 -</font><font style="font-family:inherit;font-size:10pt;">$40,000</font><font style="font-family:inherit;font-size:10pt;">). In the year ended December 31, 2015, the Company accrued </font><font style="font-family:inherit;font-size:10pt;">$6,000</font><font style="font-family:inherit;font-size:10pt;"> in royalties due to TPC in respect of the Marqibo royalty earned by the Company (see note 9).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;&#160;&#160;Other RNAi collaborators</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;The Company had active research agreements with a number of other RNAi collaborators.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6833188416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property and equipment</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">December&#160;31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">depreciation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">book value</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,748</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,189</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">492</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,912</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,729</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,183</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">December&#160;31, 2014</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">depreciation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">book value</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,281</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,796</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,959</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,199</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,760</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015, all of the Company&#8217;s property and equipment are currently in use and </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment has been recorded.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6827536944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Share capital</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share capital</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160; &#160;Financing</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 22, 2013, the Company completed an underwritten public offering of </font><font style="font-family:inherit;font-size:10pt;">3,750,000</font><font style="font-family:inherit;font-size:10pt;"> common shares, at a price of </font><font style="font-family:inherit;font-size:10pt;">$8.00</font><font style="font-family:inherit;font-size:10pt;"> per share, representing gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$30,000,000</font><font style="font-family:inherit;font-size:10pt;">. On November 1, 2013, the offering&#8217;s underwriter completed the exercise of its over-allotment option to purchase a further </font><font style="font-family:inherit;font-size:10pt;">562,500</font><font style="font-family:inherit;font-size:10pt;"> shares at </font><font style="font-family:inherit;font-size:10pt;">$8.00</font><font style="font-family:inherit;font-size:10pt;"> bringing the aggregate financing gross proceeds to </font><font style="font-family:inherit;font-size:10pt;">$34,500,000</font><font style="font-family:inherit;font-size:10pt;">. The cost of the financing, including commissions and professional fees, was </font><font style="font-family:inherit;font-size:10pt;">$2,462,000</font><font style="font-family:inherit;font-size:10pt;">, resulting in net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$32,038,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 26, 2014, the Company completed an underwritten public offering of </font><font style="font-family:inherit;font-size:10pt;">2,125,000</font><font style="font-family:inherit;font-size:10pt;"> common shares, at a price of </font><font style="font-family:inherit;font-size:10pt;">$28.50</font><font style="font-family:inherit;font-size:10pt;"> per share, representing gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$60,562,000</font><font style="font-family:inherit;font-size:10pt;">. The Company also granted the underwriters a </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-day option to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">318,750</font><font style="font-family:inherit;font-size:10pt;"> shares for an additional </font><font style="font-family:inherit;font-size:10pt;">$9,084,000</font><font style="font-family:inherit;font-size:10pt;"> to cover any over-allotments. The underwriters did not exercise the option. The cost of financing, including commissions and professional fees, was </font><font style="font-family:inherit;font-size:10pt;">$4,085,000</font><font style="font-family:inherit;font-size:10pt;">, resulting in net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$56,477,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 25, 2015, the Company announced that it had completed an underwritten public offering of </font><font style="font-family:inherit;font-size:10pt;">7,500,000</font><font style="font-family:inherit;font-size:10pt;"> common shares, at a price of </font><font style="font-family:inherit;font-size:10pt;">$20.25</font><font style="font-family:inherit;font-size:10pt;"> per share, representing gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$151,875,000</font><font style="font-family:inherit;font-size:10pt;">. The Company also granted the underwriters a </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-day option to purchase an additional </font><font style="font-family:inherit;font-size:10pt;">1,125,000</font><font style="font-family:inherit;font-size:10pt;"> shares for an additional </font><font style="font-family:inherit;font-size:10pt;">$22,781,000</font><font style="font-family:inherit;font-size:10pt;"> to cover any over-allotments. The underwriters did not exercise the option. The cost of financing, including commissions and professional fees, was </font><font style="font-family:inherit;font-size:10pt;">$9,700,000</font><font style="font-family:inherit;font-size:10pt;">, resulting in net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$142,177,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;&#160;&#160;Authorized share capital</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s authorized share capital consists of an unlimited number of common and preferred shares without par value.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;&#160;&#160;Warrants to purchase common shares</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">18,750</font><font style="font-family:inherit;font-size:10pt;"> warrants exercised for </font><font style="font-family:inherit;font-size:10pt;">$42,000</font><font style="font-family:inherit;font-size:10pt;"> in cash (</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> &#8211; </font><font style="font-family:inherit;font-size:10pt;">610,478</font><font style="font-family:inherit;font-size:10pt;"> warrants for </font><font style="font-family:inherit;font-size:10pt;">$1,583,000</font><font style="font-family:inherit;font-size:10pt;">) and </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> warrants were exercised using the cashless exercise provision (</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;"> &#8211; </font><font style="font-family:inherit;font-size:10pt;">6,000</font><font style="font-family:inherit;font-size:10pt;"> warrants for </font><font style="font-family:inherit;font-size:10pt;">5,285</font><font style="font-family:inherit;font-size:10pt;"> common shares).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s warrant activity for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="37" rowspan="1"></td></tr><tr><td width="12%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="4%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="3%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="4%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="3%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common shares</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">purchasable upon</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">exercise of</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted average</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">exercise price (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">average exercise</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Range of</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">exercise prices</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Range of</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">exercise prices</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted average remaining contractual life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Aggregate</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">intrinsic value</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Aggregate</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">intrinsic value</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,014,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$2.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$2.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercised</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(616,478</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.09</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.80</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.03</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">398,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercised</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(18,750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.88</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.62</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">379,500</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.95</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.13</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$2.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$2.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.62</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,217</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">879</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value in the table above is calculated based on the difference between the exercise price of the warrants and the quoted price of the Company&#8217;s common stock as of the reporting date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the Company&#8217;s warrants were exercisable as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average Black-Scholes option-pricing assumptions and the resultant fair values are as follows for warrants outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">49.07</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85.22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected average term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.6 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of warrants outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate fair value of warrants outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">883</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of warrants outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">379,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">398,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The value of the Company&#8217;s warrants are particularly sensitive to changes in the Company&#8217;s share price and the estimated share price volatility.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;&#160;&#160;Stock-based compensation</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> share-based compensation plans; the &#8220;2007 Plan&#8221;, the &#8220;2011 Plan&#8221;, two &#8220;Designated Plans&#8221; (together, the &#8220;Arbutus Plans&#8221;), the &#8220;Protiva Option Plan&#8221;, and the "OnCore Option Plan" (see note 3 above).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 22, 2011, the shareholders of the Company approved an omnibus stock-based compensation plan (the &#8220;2011 Plan&#8221;). The Company&#8217;s pre-existing 2007 Plan was limited to the granting of stock options as equity incentive awards whereas the 2011 Plan also allows for the issuance of tandem stock appreciation rights, restricted stock units and deferred stock units (collectively, and including options, referred to as &#8220;Awards&#8221;). The 2011 Plan replaces the 2007 Plan. The 2007 Plan will continue to govern the options granted thereunder. No further options will be granted under the Company&#8217;s 2007 Plan.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Company&#8217;s 2007 Plan the Board of Directors granted options to employees, directors and consultants of the Company.&#160;&#160;The exercise price of the options was determined by the Company&#8217;s Board of Directors but was always at least equal to the closing market price of the common shares on the day preceding the date of grant and the term of options granted did not exceed </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years.&#160;&#160;The options granted generally vested over </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;"> for employees and immediately for directors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Company&#8217;s 2011 Plan the Board of Directors may grant options, and other types of Awards, to employees, directors and consultants of the Company.&#160;&#160;The exercise price of the options is determined by the Company&#8217;s Board of Directors but will be at least equal to the closing market price of the common shares on the day preceding the date of grant and the term may not exceed </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years.&#160;&#160;Options granted generally vest over </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;"> for employees and immediately for directors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, the Company granted a total of </font><font style="font-family:inherit;font-size:10pt;">200,000</font><font style="font-family:inherit;font-size:10pt;"> options in 2013 to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> executive officers in conjunction with their new appointments as executive officers. These options were granted in accordance with the policies of the Toronto Stock Exchange and pursuant to newly designated share compensation plans (the &#8220;Designated Plans&#8221;). The Designated Plans are governed by substantially the same terms as the 2011 Plan. Hereafter, information on options governed by the 2007 Plan, the 2011 Plan, and the Designated Plans is presented on a consolidated basis as the terms of the four plans are similar. Information on the Protiva Option Plan and the OnCore Option Plan is presented separately.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the Company&#8217;s annual general and special meeting of shareholders on May 8, 2014 and July 9, 2015, the shareholders of the Company approved respectively, a </font><font style="font-family:inherit;font-size:10pt;">800,000</font><font style="font-family:inherit;font-size:10pt;"> and a </font><font style="font-family:inherit;font-size:10pt;">3,500,000</font><font style="font-family:inherit;font-size:10pt;"> increase in the number of stock-based compensation awards that the Company is permitted to issue.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock option activity for the Arbutus Plans</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td width="31%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">optioned</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">intrinsic</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">value (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">intrinsic</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">value (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,648,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,301</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.52</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64,085</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.87</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,730,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431,125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.63</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(622,752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,530,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,309,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(398,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(151,207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,290,263</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.53</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.22</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,376</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">994</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options under the Arbutus Plans expire at various dates from March 28, 2016 to December 2, 2025.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information pertaining to stock options outstanding at December 31, 2015 under the Arbutus Plans:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23" rowspan="1"></td></tr><tr><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Options outstanding December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Options exercisable December 31, 2015</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Range of</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Exercise prices (US$)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Number</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">of options</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">average</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">remaining</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">contractual</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">average</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">exercise</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Number</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">of options</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">average</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">exercise</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">102,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">102,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.52</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.88</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,475</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,475</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$2.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$2.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">83,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">83,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$3.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$4.70</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">288,960</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">268,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$5.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$7.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">261,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">175,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$8.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$10.04</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">176,813</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,189</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$10.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$13.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">129,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">79,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$13.40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$17.57</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,126,875</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17.02</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17.57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$17.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,290,263</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.22</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">938,730</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.98</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, 2015, there were </font><font style="font-family:inherit;font-size:10pt;">938,730</font><font style="font-family:inherit;font-size:10pt;"> options exercisable (December 31, 2014 - </font><font style="font-family:inherit;font-size:10pt;">1,088,908</font><font style="font-family:inherit;font-size:10pt;">; December 31, 2013 &#8211; </font><font style="font-family:inherit;font-size:10pt;">1,377,091</font><font style="font-family:inherit;font-size:10pt;">) . The weighted average remaining contractual life of exercisable options as at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">6.1</font><font style="font-family:inherit;font-size:10pt;"> years. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of in-the-money options exercisable at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$994,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s non-vested stock option activity and related information for the year ended December 31, 2015 is as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">optioned</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fair value (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fair value (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,309,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.89</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(250,461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested options forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148,853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,351,541</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.69</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.34</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average remaining contractual life for options expected to vest at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">9.1</font><font style="font-family:inherit;font-size:10pt;"> years and the weighted average exercise price for these options was </font><font style="font-family:inherit;font-size:10pt;">$15.54</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">C$21.51</font><font style="font-family:inherit;font-size:10pt;">) per share.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of options expected to vest as at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;"> (December 31, 2014 - </font><font style="font-family:inherit;font-size:10pt;">$2,626,000</font><font style="font-family:inherit;font-size:10pt;">; December 31, 2013 -</font><font style="font-family:inherit;font-size:10pt;">$943,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total fair value of options that vested during the year ended December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$1,718,000</font><font style="font-family:inherit;font-size:10pt;"> (2014 - </font><font style="font-family:inherit;font-size:10pt;">$2,505,000</font><font style="font-family:inherit;font-size:10pt;">; 2013 -</font><font style="font-family:inherit;font-size:10pt;">$955,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation assumptions for the Arbutus Plans</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 3, 2015, the Company de-listed from the Toronto Stock Exchange. All stock options granted after March 3, 2015 were denominated in US dollars based on the Company's stock price on the NASDAQ. The methodology and assumptions used  to estimate the fair value of stock options at date of grant under the Black-Scholes option-pricing model remain unchanged. Assumptions on the dividend yield are based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. Assumptions about the Company&#8217;s expected stock-price volatility are based on the historical volatility of the Company&#8217;s publicly traded stock. The risk-free interest rate used for each grant is equal to the </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> coupon rate for instruments with a similar expected life. Expected life assumptions are based on the Company&#8217;s historical data. Based on an analysis of its historical forfeitures, the Company  has applied a forfeiture rate to all unvested options held as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeitures are higher than estimated. The weighted average option pricing assumptions and the resultant fair values are as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">76.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected average option term</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.5 years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.8 years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.6 years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Protiva Option Plan</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 30, 2008, as a condition of the acquisition of Protiva Biotherapeutics Inc., a total of </font><font style="font-family:inherit;font-size:10pt;">350,457</font><font style="font-family:inherit;font-size:10pt;"> common shares of the Company were reserved for the exercise of </font><font style="font-family:inherit;font-size:10pt;">519,073</font><font style="font-family:inherit;font-size:10pt;"> Protiva share options (&#8220;Protiva Options&#8221;). The Protiva Options have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">C$0.30</font><font style="font-family:inherit;font-size:10pt;">, were fully vested and exercisable as of May 30, 2008. As at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the outstanding options expire at various dates from April 3, 2017 to March 1, 2018 and upon exercise each option will be converted into approximately </font><font style="font-family:inherit;font-size:10pt;">0.6752</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company (the same ratio at which Protiva common shares were exchanged for Company common shares at completion of the acquisition of Protiva). The Protiva Options are not part of the Arbutus Plans and the Company is not permitted to grant any further Protiva Options.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth outstanding options under the Protiva Option Plan:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of Protiva</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equivalent number</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Company</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">475,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,350</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(675</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">472,885</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319,274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(675</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">433,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292,845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(358,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(242,164</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,065</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,445</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.23</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,236</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.22</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average remaining contractual life of exercisable Protiva Options as at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">1.8</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of Protiva Options outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$187,000</font><font style="font-family:inherit;font-size:10pt;">. The intrinsic value of Protiva Options exercised in the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$1,249,000</font><font style="font-family:inherit;font-size:10pt;"> (2014 - </font><font style="font-family:inherit;font-size:10pt;">$378,000</font><font style="font-family:inherit;font-size:10pt;">; 2013 -</font><font style="font-family:inherit;font-size:10pt;">$8,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OnCore Option Plan</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As described in note 3 above, as at the acquisition date, the Company reserved </font><font style="font-family:inherit;font-size:10pt;">184,332</font><font style="font-family:inherit;font-size:10pt;"> shares for the future exercise of OnCore (Arbutus Inc.) stock options. The total fair value of OnCore stock options at the date of acquisition has been determined to be </font><font style="font-family:inherit;font-size:10pt;">$3,287,000</font><font style="font-family:inherit;font-size:10pt;">, using the Black-Scholes pricing model with an assumed risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">0.97%</font><font style="font-family:inherit;font-size:10pt;">, volatility of </font><font style="font-family:inherit;font-size:10pt;">78%</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> dividend yield and an expected life of </font><font style="font-family:inherit;font-size:10pt;">8</font><font style="font-family:inherit;font-size:10pt;"> years, which are consistent with the assumption inputs used by the Company to determine the fair value of its options. Of the total fair value, </font><font style="font-family:inherit;font-size:10pt;">$1,127,000</font><font style="font-family:inherit;font-size:10pt;"> has been attributed as pre-combination service and included as part of the total acquisition consideration. The post-combination attribution of </font><font style="font-family:inherit;font-size:10pt;">$2,160,000</font><font style="font-family:inherit;font-size:10pt;"> will be recognized as compensation expense over the vesting period of the stock options through to December 2018. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the merger, the Company is not permitted to grant any further options under the OnCore Option Plan. The Company has included </font><font style="font-family:inherit;font-size:10pt;">$463,000</font><font style="font-family:inherit;font-size:10pt;"> of compensation expense related to the vesting of Arbutus Inc. stock options from the acquisition date through to December 31, 2015, which includes an estimated forfeiture rate consistent with the Company's forfeiture estimate under the Arbutus Plans.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth outstanding options under the OnCore Option Plan:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of OnCore</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equivalent number</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Company</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, March 4, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,040</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,332</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, 2015, there were </font><font style="font-family:inherit;font-size:10pt;">86,658</font><font style="font-family:inherit;font-size:10pt;"> OnCore options (</font><font style="font-family:inherit;font-size:10pt;">87,269</font><font style="font-family:inherit;font-size:10pt;"> Arbutus equivalent) exercisable with a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.57</font><font style="font-family:inherit;font-size:10pt;">. The weighted average remaining contractual life of exercisable options as at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">8.9</font><font style="font-family:inherit;font-size:10pt;"> years. The aggregate intrinsic value of in-the-money options exercisable at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$337,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the OnCore Option Plan's non-vested stock option activity and related information for the period from acquisition to December 31, 2015 is as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OnCore Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equivalent number</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Company</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fair value (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested at March 4, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,128</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,354</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested options forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,382</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,063</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.42</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average remaining contractual life for options expected to vest at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">8.9</font><font style="font-family:inherit;font-size:10pt;"> years and the weighted average exercise price for these options was </font><font style="font-family:inherit;font-size:10pt;">$0.57</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate intrinsic value of options expected to vest as at December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$695,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total fair value of options that vested during the period from acquisition on March 4, 2015 to December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$620,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based compensation expense</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense is comprised of: (1) the vesting options awarded to employees under the Arbutus and OnCore option plans calculated in accordance with the fair value method as described above; and (2) the expiration of repurchase rights related to the post-combination service portion of the total fair value of shares issued to Arbutus Inc.'s employees as described in note 3 above.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total stock-based compensation has been recorded in the consolidated statement of operations and comprehensive income (loss) as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research, development, collaborations and contracts expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,225</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">940</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">22,093</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,283</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">903</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, 2015, there remains </font><font style="font-family:inherit;font-size:10pt;">$11,972,000</font><font style="font-family:inherit;font-size:10pt;"> of unearned compensation expense related to unvested employee stock options to be recognized as expense over a weighted-average period of approximately </font><font style="font-family:inherit;font-size:10pt;">16</font><font style="font-family:inherit;font-size:10pt;"> months, as well as a remaining </font><font style="font-family:inherit;font-size:10pt;">$35,967,000</font><font style="font-family:inherit;font-size:10pt;"> unearned compensation expense related to unexpired repurchase rights on shares issued to Arbutus Inc. employees to be recognized as expense over a weighted average period of approximately </font><font style="font-family:inherit;font-size:10pt;">12</font><font style="font-family:inherit;font-size:10pt;"> months.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Awards outstanding and available for issuance</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Combining all of the Company&#8217;s share-based compensation plans, at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company has </font><font style="font-family:inherit;font-size:10pt;">2,519,831</font><font style="font-family:inherit;font-size:10pt;"> options outstanding and a further </font><font style="font-family:inherit;font-size:10pt;">3,135,980</font><font style="font-family:inherit;font-size:10pt;"> Awards available for issuance.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph d<br> -Article 4<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Article 4<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6827551680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Government Grants and Refundable Investment Tax Credits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract', window );"><strong>Government Grants And Refundable Investment Tax Credits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock', window );">Government grants and refundable investment tax credits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Government grants and refundable investment tax credits</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government grants and refundable investment tax credits have been recorded as a reduction in research and development expenses. </font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a) Government grants</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2014, the Company entered into a Manufacturing and Clinical Trial Agreement with the University of Oxford to provide the new TKM-Ebola-Guinea therapeutic product for clinical studies in West Africa. The University of Oxford is the representative of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), who conducted clinical studies of TKM-Ebola-Guinea in Ebola virus infected patients, with funding provided by the Wellcome Trust. In January 2015, the Company received </font><font style="font-family:inherit;font-size:10pt;">$1,098,000</font><font style="font-family:inherit;font-size:10pt;"> from ISARIC for materials manufactured and used in the March 2015 TKM-Ebola-Guinea Phase II single arm trial conducted in Sierra Leone. In June 2015, the Company announced closing of the enrollment for the trial as it reached a futility boundary, which was a predefined statistical endpoint. No further funding is expected under this grant. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government grants for the year ended December 31, 2015 include </font><font style="font-family:inherit;font-size:10pt;">$1,245,000</font><font style="font-family:inherit;font-size:10pt;"> in funding from the U.S. National Institutes of Health (2014 - </font><font style="font-family:inherit;font-size:10pt;">$172,000</font><font style="font-family:inherit;font-size:10pt;">). </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b) Refundable investment tax credits</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s estimated claim for refundable Scientific Research and Experimental Development investment tax credits for the year ended December 31, 2015 is </font><font style="font-family:inherit;font-size:10pt;">$196,000</font><font style="font-family:inherit;font-size:10pt;"> (2014 - </font><font style="font-family:inherit;font-size:10pt;">$52,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about government grants and investment tax credits netted against expenses in the statement of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6592375680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income taxes</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax (recovery) expense varies from the amounts that would be computed by applying the combined Canadian federal and provincial income tax rate of </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;"> (2014 -  </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;">; 2013 &#8211; </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;">) to the loss before income taxes as shown in the following tables:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computed taxes (recoveries) at Canadian&#160;federal and provincial tax rates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(20,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,486</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Differences due to change in enacted tax rates</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permanent and other differences</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance - other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,676</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,599</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,407</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Difference due to income taxed at foreign rates</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(7,874</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax recovery</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(16,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company has investment tax credits available to reduce Canadian federal income taxes of </font><font style="font-family:inherit;font-size:10pt;">$7,969,000</font><font style="font-family:inherit;font-size:10pt;"> (December&#160;31, 2014 - </font><font style="font-family:inherit;font-size:10pt;">$7,866,000</font><font style="font-family:inherit;font-size:10pt;">) and provincial income taxes of </font><font style="font-family:inherit;font-size:10pt;">$3,869,000</font><font style="font-family:inherit;font-size:10pt;"> (December&#160;31, 2014 - </font><font style="font-family:inherit;font-size:10pt;">$3,401,000</font><font style="font-family:inherit;font-size:10pt;">), expiring between 2027 and 2035. In addition, the Company has research and development credits of </font><font style="font-family:inherit;font-size:10pt;">$483,000</font><font style="font-family:inherit;font-size:10pt;"> available for indefinite carry-forward, which can be used to reduce future taxable income in the U.S.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, 2015, the Company has scientific research and experimental development expenditures of </font><font style="font-family:inherit;font-size:10pt;">$51,823,000</font><font style="font-family:inherit;font-size:10pt;">  (December 31, 2014 - </font><font style="font-family:inherit;font-size:10pt;">$49,907,000</font><font style="font-family:inherit;font-size:10pt;">) available for indefinite carry-forward and </font><font style="font-family:inherit;font-size:10pt;">$24,745,000</font><font style="font-family:inherit;font-size:10pt;"> (December&#160;31, 2014 - </font><font style="font-family:inherit;font-size:10pt;">$25,301,000</font><font style="font-family:inherit;font-size:10pt;">) of net operating losses due to expire between 2027 and 2035 and which can be used to offset future taxable income in Canada.  </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31, 2015, the Company has </font><font style="font-family:inherit;font-size:10pt;">$17,235,000</font><font style="font-family:inherit;font-size:10pt;"> of net operating losses due to expire between 2030 and 2035, which can be used to offset future taxable income in the U.S. Future use of a portion of the U.S. loss carry-forwards is subject to limitations under the Internal Revenue Code Section 382. As a result of ownership changes occurred on October 1, 2014 and March 4, 2015, the Company's ability to use these losses may be limited. Losses incurred to date may be further limited if a subsequent change in control occurs.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 23, 2011, the Company was registered as a corporation under the Business Activity Act in the province of British Columbia. Under this program, provincial corporation tax charged on foreign income earned from the Company&#8217;s patents will be eligible for a </font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;"> tax refund up to a maximum of </font><font style="font-family:inherit;font-size:10pt;">C$8,000,000</font><font style="font-family:inherit;font-size:10pt;">. Significant components of the Company&#8217;s deferred tax assets are shown below:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-capital loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13,932</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,578</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development deductions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13,474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Book amortization in excess of tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,142</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,745</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized for tax purposes in excess of revenue recognized for accounting purposes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">281</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,086</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax value in excess of accounting value in lease inducements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal investment tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,303</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provincial investment tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(146,324</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront license fees</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(104,830</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,818</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(41,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,818</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(146,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The comparative figures in the above table have been recast to increase the deferred tax assets before valuation allowance by </font><font style="font-family:inherit;font-size:10pt;">$8,424,000</font><font style="font-family:inherit;font-size:10pt;"> and the valuation allowance by </font><font style="font-family:inherit;font-size:10pt;">$8,424,000</font><font style="font-family:inherit;font-size:10pt;"> as at December 31, 2014 to be consistent with current year's disclosure. The comparative figures in the income tax expense reconciliation table have also been recast to reflect these changes. These adjustments have no impact on the consolidated financial position, consolidated results of operations or the consolidated cash flows.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6827551680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and commitments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies and commitments</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property lease</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The minimum rent and estimated operating cost commitment, net of lease inducements, is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,229,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">938,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">938,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,652,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s lease expense, for the year ended December 31, 2015 of </font><font style="font-family:inherit;font-size:10pt;">$1,158,000</font><font style="font-family:inherit;font-size:10pt;"> has been recorded in the consolidated statements of operations and comprehensive loss (2014 of </font><font style="font-family:inherit;font-size:10pt;">$1,133,000</font><font style="font-family:inherit;font-size:10pt;">; 2013 -</font><font style="font-family:inherit;font-size:10pt;">$1,225,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product development partnership with the Canadian Government</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a Technology Partnerships Canada (TPC) agreement with the Canadian Federal Government on November 12, 1999.&#160;&#160;Under this agreement, TPC agreed to fund </font><font style="font-family:inherit;font-size:10pt;">27%</font><font style="font-family:inherit;font-size:10pt;"> of the costs incurred by the Company, prior to March 31, 2004, in the development of certain oligonucleotide product candidates up to a maximum contribution from TPC of </font><font style="font-family:inherit;font-size:10pt;">$7,179,000</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">C$9,330,000</font><font style="font-family:inherit;font-size:10pt;">).&#160;&#160;As at December 31, 2015, a cumulative contribution of </font><font style="font-family:inherit;font-size:10pt;">$2,675,000</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">C$3,702,000</font><font style="font-family:inherit;font-size:10pt;">) had been received and the Company does not expect any further funding under this agreement.&#160;&#160;In return for the funding provided by TPC, the Company agreed to pay royalties on the share of future licensing and product revenue, if any, that is received by the Company on certain non-siRNA oligonucleotide product candidates covered by the funding under the agreement.&#160;&#160;These royalties are payable until a certain cumulative payment amount is achieved or until a pre-specified date.&#160;&#160;In addition, until a cumulative amount equal to the funding actually received under the agreement has been paid to TPC, the Company agreed to pay </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;"> royalties on any royalties the Company receives for Marqibo. For the year ended December 31, 2015, the Company earned royalties on Marqibo sales in the amount of </font><font style="font-family:inherit;font-size:10pt;">$240,000</font><font style="font-family:inherit;font-size:10pt;"> (see note 4(f)), resulting in </font><font style="font-family:inherit;font-size:10pt;">$6,000</font><font style="font-family:inherit;font-size:10pt;"> recorded by the Company as royalty payable to TPC (2014 - </font><font style="font-family:inherit;font-size:10pt;">$190,000</font><font style="font-family:inherit;font-size:10pt;">; 2013 -</font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;">).&#160;The cumulative amount paid or accrued up to December 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$12,000</font><font style="font-family:inherit;font-size:10pt;">, resulting in the contingent amount due to TPC being </font><font style="font-family:inherit;font-size:10pt;">$2,664,000</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">C$3,687,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">License agreement with Marina Biotech, Inc. (&#8220;Marina&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 29, 2012 the Company announced a worldwide, non-exclusive license to a novel RNAi payload technology called Unlocked Nucleobase Analog (&#8220;UNA&#8221;) from Marina for the development of RNAi therapeutics.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">UNA technology can be used in the development of RNAi therapeutics, which treat disease by silencing specific disease causing genes. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the license agreement the Company paid Marina an upfront fee of </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;">. A further license payment of </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2013 and the Company will make milestone payments of up to </font><font style="font-family:inherit;font-size:10pt;">$3,250,000</font><font style="font-family:inherit;font-size:10pt;"> and royalties on each product developed by the Company that uses Marina&#8217;s UNA technology. The payments to Marina are expensed to research, development, collaborations and contracts expense.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective August 9, 2013, Marina&#8217;s UNA technology was acquired by Arcturus Therapeutics, Inc. (&#8220;Arcturus&#8221;) and the UNA license agreement between the Company and Marina was assigned to Arcturus. The terms of the license are otherwise unchanged. On December 22, 2014, the Company received clearance from Health Canada to conduct a Phase I Clinical Study with TKM-HBV, which utilizes Arcturus&#8217; UNA technology. The dosing of first subject in the Phase I clinical trial of TKM-HBV occurred in January 2015, which  resulted in a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$250,000</font><font style="font-family:inherit;font-size:10pt;"> to Arcturus.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Arbitration with the University of British Columbia (&#8220;UBC&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain early work on lipid nanoparticle delivery systems and related inventions was undertaken at UBC.&#160;&#160;These inventions are licensed to the Company by UBC under a license agreement, initially entered in 1998 as amended in 2001, 2006 and 2007. The Company has granted sublicenses under the UBC license to Alnylam as well as to Talon.&#160;&#160;Alnylam has in turn sublicensed back to the Company under the licensed UBC patents for discovery, development and commercialization of RNAi products. In 2009, the Company entered into a supplemental agreement with UBC, Alnylam and Acuitas, in relation to a separate research collaboration to be conducted among UBC, Alnylam and Acuitas to which the Company has license rights. The settlement agreement signed in late 2012 to resolve the litigation among the Company, Alnylam, and Acuitas, provided for the effective termination of all obligations under such supplemental agreement as between and among all litigants (see note 4(c)).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 10, 2014, UBC filed a notice of arbitration against the Company and on January 16, 2015, filed a Statement of Claim, which alleges entitlement to </font><font style="font-family:inherit;font-size:10pt;">$3,500,000</font><font style="font-family:inherit;font-size:10pt;"> in allegedly unpaid royalties based on publicly available information, and an unspecified amount based on non-public information. UBC also seeks interest and costs, including legal fees. The Company is currently disputing UBC&#8217;s allegations, and no dates have been scheduled for this arbitration. However, the Company notes that arbitration is subject to inherent uncertainty and an arbitrator could rule against the Company. The Company has not recorded an estimate of the possible loss associated with this arbitration, due to the uncertainties related to both the likelihood and amount of any possible loss or range of loss. However, the defense of arbitration and related matters are costly and may divert the attention of the Company&#8217;s management and other resources that would otherwise be engaged in other activities. Costs related to the arbitration have been recorded by the Company as incurred.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingent consideration from OnCore acquisition of Enantigen and License Agreements between Enantigen and Blumberg and Drexel</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, OnCore acquired all of the outstanding shares of Enantigen pursuant to a stock purchase agreement. Through this transaction, OnCore acquired a HBV surface antigen secretion inhibitor program and a capsid assembly inhibitor program, each of which are now assets of Arbutus, following the Company&#8217;s merger with Arbutus Inc. - see note 3.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the stock purchase agreement, OnCore agreed to pay up to a total of </font><font style="font-family:inherit;font-size:10pt;">$21,000,000</font><font style="font-family:inherit;font-size:10pt;"> to Enantigen&#8217;s selling stockholders upon the achievement of certain triggering events related to Enantigen&#8217;s </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> programs in pre-clinical development related to HBV therapies. The first triggering event is the enrollment of first patient in Phase 1b clinical trial in HBV patients, which the Company does not expect to occur in the next twelve-month period.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The regulatory, development and sales milestone payments have an estimated fair value of approximately </font><font style="font-family:inherit;font-size:10pt;">$6,727,000</font><font style="font-family:inherit;font-size:10pt;"> as at the date of acquisition of Arbutus Inc., and have been treated as contingent consideration payable in the purchase price allocation (note 3), based on information available at the date of acquisition, using a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, time to complete the program development, and overall biotech indices.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration is considered as a financial liability, and measured at its fair value at each reporting period with any changes in fair value from the previous reporting period recorded in the statement of operations and comprehensive loss. For the period ended December 31, 2015, the Company performed an evaluation of the fair value of the contingent consideration using the probability weighted assessment of likelihood of milestone payments as described above. The Company determined the fair value of the contingent consideration has increased by </font><font style="font-family:inherit;font-size:10pt;">$770,000</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$7,497,000</font><font style="font-family:inherit;font-size:10pt;"> and the increase in fair value has been recorded in other losses in the statement of operations and comprehensive loss for the year-ended December 31, 2015. </font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Drexel and Blumberg</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, OnCore entered into a license agreement with Blumberg and Drexel that granted an exclusive, worldwide, sub-licensable license to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> different compound series: cccDNA inhibitors, capsid assembly inhibitors and HCC inhibitors.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, OnCore paid a license initiation fee of </font><font style="font-family:inherit;font-size:10pt;">$150,000</font><font style="font-family:inherit;font-size:10pt;"> and issued warrants to Blumberg and Drexel. Under this license agreement, OnCore also agreed to pay up to </font><font style="font-family:inherit;font-size:10pt;">$3,500,000</font><font style="font-family:inherit;font-size:10pt;"> in development and regulatory milestones per licensed compound series, up to </font><font style="font-family:inherit;font-size:10pt;">$92,500,000</font><font style="font-family:inherit;font-size:10pt;"> in sales performance milestones per licensed product, and royalties in the mid-single digits based upon the proportionate net sales of licensed products in any commercialized combination. The Company is obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from the sub-licensees, subject to customary exclusions.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2014, OnCore entered into an additional license agreement with Blumberg and Drexel pursuant to which it received an exclusive, worldwide, sub-licensable license under specified patents and know-how controlled by Blumberg and Drexel covering epigenetic modifiers of cccDNA and STING agonists. In consideration for these exclusive licenses, OnCore made an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;">. Under this agreement, the Company will be required to pay up to </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> for each licensed product upon the achievement of a specified regulatory milestone and a low single digit royalty, based upon the proportionate&#160;net sales of compounds covered by this intellectual property&#160;in any commercialized combination. The Company is also obligated to pay Blumberg and Drexel a double digit percentage of all amounts received from its sub-licensees, subject to exclusions.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Research Collaboration and Funding Agreement with Blumberg</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, Arbutus Inc. entered into a research collaboration and funding agreement with Blumberg under which the Company will provide </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> per year of research funding for </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years, renewable at the Company&#8217;s option for an additional </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years, for Blumberg to conduct research projects in HBV and liver cancer pursuant to a research plan to be agreed upon by the parties. Blumberg has exclusivity obligations to Arbutus with respect to HBV research funded under the agreement. In addition, the Company has the right to match any third party offer to fund HBV research that falls outside the scope of the research being funded under the agreement. Blumberg has granted the Company the right to obtain an exclusive, royalty bearing, worldwide license to any intellectual property generated by any funded research project. If the Company elects to exercise its right to obtain such a license, the Company will have a specified period of time to negotiate and enter into a mutually agreeable license agreement with Blumberg. This license agreement will include the following pre negotiated upfront, milestone and royalty payments: an upfront payment in the amount of </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;">; up to </font><font style="font-family:inherit;font-size:10pt;">$8,100,000</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of specified development and regulatory milestones; up to </font><font style="font-family:inherit;font-size:10pt;">$92,500,000</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of specified commercialization milestones; and royalties at a low single to mid-single digit rates based upon the proportionate&#160;net sales of licensed&#160;products from any commercialized combination.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NeuroVive Pharmaceutical AB (&#8220;NeuroVive&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2014, Arbutus Inc. entered into a license agreement with NeuroVive that granted them an exclusive, worldwide, sub-licensable license to develop, manufacture and commercialize, for the treatment of HBV, oral dosage form sanglifehrin based cyclophilin inhibitors (including OCB-030). Under this license agreement, the Company has been granted a non-exclusive, royalty free right and license and right of reference to NeuroVive&#8217;s relevant regulatory approvals and filings for the sole purpose of developing, manufacturing and commercializing licensed products for the treatment of HBV. Under this license agreement, the Company has (1)&#160;an option to expand its exclusive license to include treatment of viral diseases other than HBV and (2)&#160;an option, exercisable upon specified conditions, to expand its exclusive license to include development, manufacture and commercialization of non-oral variations of licensed products for treatment of viral diseases other than HBV. NeuroVive retains all rights with respect to development, manufacture and commercialization of licensed products and non-oral variations of licensed products for all indications (other than HBV) for which the Company has not exercised its option.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, Arbutus Inc. paid NeuroVive a license fee of </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;">. As described in note 3 above, Arbutus Inc. became our wholly owned subsidiary by way of a Merger Agreement, which does not trigger any milestone payments. We have conducted significant research and analysis on the NeuroVive Product, OCB-030. Based on this research and analysis, we have decided to discontinue the OCB-030 development program.&#160; Otherwise, the license agreement and ongoing relationship with NeuroVive remains in full effect.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cytos Biotechnology Ltd (&#8220;Cytos&#8221;)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;30, 2014, Arbutus Inc. entered into an exclusive, worldwide, sub-licensable (subject to certain restrictions with respect to licensed viral infections other than hepatitis) license to </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> different series of compounds. The licensed compounds are Qbeta-derived virus-like particles that encapsulate TLR9, TLR7 or RIG-I agonists and may or may not be conjugated with antigens from the hepatitis virus or other licensed viruses.&#160; The Company has an option to expand this license to include additional viral infections other than influenza and Cytos will retain all rights for influenza, all non-viral infections, and all viral infections (other than hepatitis) for which it has not exercised its option.&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In partial consideration for this license, the Company is obligated to pay Cytos up to a total of </font><font style="font-family:inherit;font-size:10pt;">$67,000,000</font><font style="font-family:inherit;font-size:10pt;"> for each of the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> licensed compound series upon the achievement of specified development and regulatory milestones; for hepatitis and each additional licensed viral infection, up to a total of </font><font style="font-family:inherit;font-size:10pt;">$110,000,000</font><font style="font-family:inherit;font-size:10pt;"> upon the achievement of specified sales performance milestones; and tiered royalty payments in the high-single to low-double digits, based upon the proportionate&#160;net sales of licensed products in any&#160;commercialized combination.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6833196416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations of Business Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentrations of business risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations of business risk</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit risk</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk is defined by the Company as an unexpected loss in cash and earnings if a collaborative partner is unable to pay its obligations in due time. The Company&#8217;s main source of credit risk is related to its accounts receivable balance which principally represents temporary financing provided to collaborative partners in the normal course of operations.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not currently maintain a provision for bad debts as the majority of accounts receivable are from collaborative partners or government agencies and are considered low risk.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at December 31, 2015 was the accounts receivable balance of </font><font style="font-family:inherit;font-size:10pt;">$1,008,000</font><font style="font-family:inherit;font-size:10pt;"> (2014 - </font><font style="font-family:inherit;font-size:10pt;">$1,903,000</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All accounts receivable balances were current as at December 31, 2015 and December 31, 2014.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant collaborators and customers risk</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We depend on a small number of collaborators and customers for a significant portion of our revenues (see note 4).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity Risk</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liquidity risk results from the Company&#8217;s potential inability to meet its financial liabilities, for example payments to suppliers.&#160;&#160;The Company ensures sufficient liquidity through the management of net working capital and cash balances.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s liquidity risk is primarily attributable to its cash and cash equivalents, and short-term investments. The Company limits exposure to liquidity risk on its liquid assets through maintaining its cash and cash equivalent, and short-term investments with high-credit quality financial institutions. Due to the nature of these investments, the funds are available on demand to provide optimal financial flexibility.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company believes that its current sources of liquidity are sufficient to cover its likely applicable short term cash obligations. The Company&#8217;s financial obligations include accounts payable and accrued liabilities which generally fall due within </font><font style="font-family:inherit;font-size:10pt;">45</font><font style="font-family:inherit;font-size:10pt;"> days. The net liquidity of the Company is considered to be the cash and cash equivalents and short-term investments less accounts payable and accrued liabilities.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and&#160;short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">181,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,827</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">172,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign currency risk</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of the Company&#8217;s operations are subject to foreign currency transaction and translation risk as the Company&#8217;s revenues and expenses are denominated in both Canadian and US dollars. The fluctuation of the US dollar in relation to the Canadian dollar will consequently have an impact upon the Company&#8217;s reported income or loss and may also affect the value of the Company&#8217;s assets, liabilities, and the amount of shareholders&#8217; equity both as recorded in the Company&#8217;s financial statements, in the Canadian functional currency, and as reported, for presentation purposes, in the US dollar.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company manages its US dollar exchange rate risk by, whenever possible, using cash received from US dollar revenues and financing to pay US dollar expenses. Prior to the financing in October 2013 (note 6(a)), which was denominated in US dollars, the Company&#8217;s policy was to convert all but a working capital level of US dollars into Canadian dollars. Given the Company&#8217;s increasing level of US dollar expenses, its policy is now to maintain US and Canadian dollar cash and investment and short-term investment balances based on long term forecasts of currency needs thereby creating a natural currency hedge.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has not entered into any agreements or purchased any instruments to hedge possible currency risks. The Company&#8217;s exposure to US dollar currency expressed in Canadian dollars was as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in C$)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents and short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">213,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,071</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,942</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">206,607</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An analysis of the Company&#8217;s sensitivity to foreign currency exchange rate movements is not provided in these financial statements as the Company&#8217;s US dollar cash holdings and expected US dollar revenues are sufficient to cover US dollar expenses for the foreseeable future.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6327-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6827472176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplementary information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplementary information</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities is comprised of the following:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development accruals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,358</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License fee accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fee accruals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">640</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred lease inducements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payroll accruals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,331</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,873</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">591</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,328</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6591808448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Interim financial data (unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interim financial data (unaudited)</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="31%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,065</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,006</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,420</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,138</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,758</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(102,322</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,982</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(61,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.57</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="31%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,423</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,844</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,747</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(33,434</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(38,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.91</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=35737889&amp;loc=d3e1280-108306<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section G<br> -Subsection 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 302<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6826016800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent events</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(a) Protiva USA Reorganization</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2016, the Company undertook a corporate reorganization merging Protiva USA into Arbutus Inc., which acquired Protiva USA's assets and assumed Protiva USA's liabilities in exchange for Arbutus Inc. shares. The reorganization did not result in any adverse Canadian and U.S. tax consequences.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(b) Monsanto Option Exercise</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 4, 2016, Monsanto exercised its option to acquire </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding shares of Protiva Agricultural Development Company Inc. (PADCo), pursuant under its Option Agreement with the Company. Monsanto will pay the Company </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> in exercise fee, which the Company will record in the statement of operations and comprehensive loss for the period ended March 31, 2016.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6845969712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of presentation</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (formerly Tekmira Pharmaceuticals Corporation) was incorporated on October&#160;6, 2005 as an inactive wholly owned subsidiary of Inex Pharmaceuticals Corporation (Inex). Pursuant to a &#8220;Plan of Arrangement&#8221; effective April&#160;30, 2007, the business and substantially all of the assets and liabilities of Inex were transferred to the Company. The consolidated financial statements for all periods presented herein include the consolidated operations of Inex until April&#160;30, 2007 and the operations of the Company thereafter.&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> wholly-owned subsidiaries as at December 31, 2015: Arbutus Biopharma, Inc. (formerly OnCore Biopharma, Inc.) Protiva Biotherapeutics Inc. (Protiva), Protiva Biotherapeutics (USA) Inc. (Protiva USA), and Protiva Agricultural Development Company Inc. (&#8220;PADCo&#8221;). Protiva and Protiva USA were acquired on May 30, 2008. PADCo was incorporated on January 9, 2014. Arbutus Inc. was acquired by way of a Merger Agreement on March 4, 2015, which included Arbutus Inc.'s wholly-owned subsidiary, Enantigen Therapeutics, Inc. (Enantigen) - see note 3. Enantigen was merged with Arbutus Inc. on September 30, 2015.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements include the accounts of the Company and three of its wholly-owned subsidiaries, Arbutus Inc., Protiva and Protiva USA. All intercompany transactions and balances have been eliminated on consolidation.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records its investment in PADCo using the equity method. The Company has determined that PADCo is a variable interest entity (&#8220;VIE&#8221;) of which it is not the primary beneficiary. The Company is not the primary beneficiary as it does not have the power to make decisions that most significantly affect the economic performance of the VIE nor does the Company have the right to receive benefits or the obligation to absorb losses that in either case could potentially be significant to the VIE. PADCo is described further in note 4(b).</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring the use of management estimates relate to purchase price allocation, valuation of intangible assets and goodwill, recognition of revenue, stock-based compensation, valuation of warrant liability and financial instrument, and the amounts recorded as accrued liabilities, contingent consideration, and income tax recovery.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and cash equivalents</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents are all highly liquid instruments with an original maturity of three months or less when purchased. Cash equivalents are recorded at cost plus accrued interest. The carrying value of these cash equivalents approximates their fair value.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-term and long-term investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Short-term and long-term investments</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company acquired guaranteed investment certificates and a term deposit during the year, which are classified as short-term and long-term investments on the balance sheet respectively. Short-term investments have original maturities exceeding three months, and have remaining maturities less than one year. Long-term investments have remaining maturities exceeding twelve months. Short-term and long-term investments accrue interest daily based on a fixed interest rate for the term. The carrying value of these investments are recorded at cost plus accrued interest, which approximates their fair value. All investments are governed by the Board approved Investment Policy for the Company.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value of financial instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair value of financial instruments</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We measure certain financial instruments and other items at fair value.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 inputs are quoted market prices for identical instruments available in active markets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#8217;s assumptions about market assumptions that would be used to price the asset or liability.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:0px;text-align:justify;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term and long-term investments, accounts receivable, accounts payable and accrued liabilities, warrants and financial instruments. Long-term investments approximate fair value due to the interest rates being at prevailing market rates.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying values of cash and cash equivalents, short-term investments, accounts receivable and accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As quoted prices for the warrants are not readily available, the Company has used a Black-Scholes pricing model, as described in note 6, to estimate fair value. These are level 3 inputs as defined above.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company used a discounted cash flow model to determine the fair value of the financial instrument related to Monsanto&#8217;s call option to acquire the equity or all of the assets of PADCo, as described in note 4. The fair value was determined at the date of recognition, and at each reporting date. The initial fair value of the financial instrument was nil, and there has been no change to its fair value as at December 31, 2015. The assumptions used in the discounted cash flow model are level 3 inputs as defined above.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the fair value of the contingent consideration, the Company uses a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, time to complete the program development, and overall biotech indices, as in note 9.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory includes materials assigned for the manufacture of products for collaborative partners and manufacturing costs for products awaiting acceptance by collaborative partners. Inventory is carried at the lower of cost and net realizable value and measured using first-in-first-out method. The cost of inventories includes all costs of purchase, costs of manufacturing and other costs incurred in bringing the inventories to their present location and condition.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Materials purchased for the Company&#8217;s own research and development products are not recorded as inventory but are expensed as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and equipment</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment is recorded at cost less impairment losses, accumulated depreciation, related government grants and investment tax credits. The Company records depreciation using the straight-line method over the estimated useful lives of the capital assets as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="77%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Useful life (years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements are depreciated over their estimated useful lives but in no case longer than the lease term, except where lease renewal is reasonably assured.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of property and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If there is a major event indicating that the carrying value of property and equipment may be impaired then management will perform an impairment test and if the carrying value exceeds the recoverable value, based on undiscounted future cash flows, then such assets are written down to their fair values.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and intangible assets</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The costs incurred in establishing and maintaining patents for intellectual property developed internally are expensed in the period incurred.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets consist of in-process research and development arising from the Company&#8217;s acquisition of Arbutus Inc. - see note 3. In-process research and development (IPR&amp;D) intangible assets are classified as indefinite-lived and are not amortized. IPR&amp;D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives, which are the respective patent terms. Amortization begins when intangible assets with finite lives are put into use. If there is a major event indicating that the carrying value of intangible assets may be impaired, then management will perform an impairment test and if the carrying value exceeds the recoverable value, based on discounted future cash flows, then such assets are written down to their fair values. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets of Arbutus Inc. - see note 3. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is subject to a two-step impairment test on an annual basis, unless the Company identifies impairment indicators that would require earlier testing. The first step compares the fair value of the reporting unit to its carrying amount, which includes the goodwill. When the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not to be impaired, and the second step of the impairment test is unnecessary. If the carrying amount exceeds the implied fair value of the reporting unit, the second step measures the amount of the impairment loss. If the carrying amount exceeds the fair value of the reporting unit, an impairment loss is recognized equal to that excess.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company reviews the recoverable amount of intangible assets on an annual basis, and the annual evaluation for goodwill is performed as of December 31 each year. In addition, the Company evaluates for events or changes in the business that could indicate impairment and earlier testing. Such indicators include, but are not limited to, on an ongoing basis: (a) industry and market considerations such as increased competitive environment or adverse change in legal factors including an adverse assessment by regulators; (b) an accumulation of costs significantly in excess of the amount originally expected for the development of the asset; (c) current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the asset; and (d) if applicable, a sustained decrease in share price. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company earns revenue from research and development collaboration and contract services, licensing fees, milestone and royalty payments. Revenues associated with multiple element arrangements are attributed to the various elements based on their relative fair values or are recognized as a single unit of accounting when relative fair values are not determinable. Non-refundable payments received under collaborative research and development agreements are recorded as revenue as services are performed and related expenditures are incurred. Non-refundable upfront license fees from collaborative licensing and development arrangements are recognized as the Company fulfills its obligations related to the various elements within the agreements, in accordance with the contractual arrangements with third parties and the term over which the underlying benefit is being conferred. The Company evaluates new arrangements for any substantive milestones by considering: whether substantive uncertainty exists upon execution of the arrangement; if the event can only be achieved based in whole or in part on the Company&#8217;s performance, or occurrence of a specific outcome resulting from the Company&#8217;s performance; any future performance required, and payment is reasonable relative to all deliverables; and, the payment terms in the arrangement. Payments received upon the achievement of substantive milestones are recognized as revenue in their entirety. Payments received upon the occurrence of milestones that are non-substantive are deferred and recognized as revenue over the estimated period of performance applicable to the associated collaborative agreement.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue earned under research and development manufacturing collaborations where the Company bears some or all of the risk of a product manufacturing failure is recognized when the purchaser accepts the product and there are no remaining rights of return.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue earned under research and development collaborations where the Company does not bear any risk of product manufacturing failure is recognized in the period the work is performed. For contracts where the manufacturing amount is specified, revenue is recognized as product is manufactured in proportion to the total amount specified under the contract.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue and expenses under the contract with the United States Government Department of Defense (&#8220;DoD&#8221;) are being recorded using the percentage-of-completion method. Contract progress is based on costs incurred to date. Expenses under the contract are recorded in the Company&#8217;s consolidated statement of operations and comprehensive income (loss) as they are incurred. Government contract revenues related to expenses incurred under the contract are recorded in the same period as those expenses. Expenses accrued under the contract but not yet invoiced are recorded in the Company&#8217;s balance sheet as accrued liabilities and accrued revenues. Equipment purchased under the contract is recorded on the Company&#8217;s balance sheet as deferred expense and deferred revenue and amortized, on a straight-line basis, over the life of the contract.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash or other compensation received in advance of meeting the revenue recognition criteria is recorded on the balance sheet as deferred revenue. Revenue meeting recognition criteria but not yet received or receivable is recorded on the balance sheet as accrued revenue.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePolicyTextBlock', window );">Leases and lease inducements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases and lease inducements</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leases entered into are classified as either capital or operating leases. Leases which substantially transfer all benefits and risks of ownership of property to the Company are accounted for as capital leases. At the time a capital lease is entered into, an asset is recorded together with its related long-term obligation to reflect the purchase and financing.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other leases are accounted for as operating leases wherein rental payments are expensed as incurred.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease inducements represent leasehold improvement allowances and reduced or free rent periods and are amortized on a straight-line basis over the term of the lease and are recorded as a reduction of rent expense.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and development costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and development costs</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are charged as an expense in the period in which they are incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income or loss per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income or loss per share</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income or loss per share is calculated based on the weighted average number of common shares outstanding. Diluted loss per share does not differ from basic loss per share for the years ended December 31, 2015, 2014 and 2013, since the effect of the Company&#8217;s stock options and warrants is anti-dilutive.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock', window );">Government grants and refundable investment tax credits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Government grants and refundable investment tax credits</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government grants and tax credits provided for current expenses is included in the determination of income or loss for the year, as a reduction of the expenses to which it relates. Government grants and tax credits towards the acquisition of property and equipment is deducted from the cost of the related property and equipment.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation and change in reporting currency</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign currency translation and change in reporting currency</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The functional currency of the Company and two of its integrated subsidiaries (Protiva and Protiva USA), is the Canadian dollar, and the functional currency of Arbutus Inc. is the U.S. dollar. Foreign currency monetary assets and liabilities are translated into the functional currency at the rate of exchange prevailing at the balance sheet date. Non-monetary assets and liabilities are translated at historical exchange rates. The previous month&#8217;s average rate of exchange is used to translate revenue and expense transactions. Exchange gains and losses are included in income or loss for the period.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is using United States dollars as its reporting currency. All assets and liabilities are translated using the exchange rate at the balance sheet date. Revenues, expenses and other income (losses) are translated using the average rate for the period, except for large transactions, for which the exchange rate on the date of the transaction is used. Equity accounts are translated using the historical rate. As the translation differences from the Company&#8217;s functional currency of Canadian dollars to the Company&#8217;s reporting currency of US dollars are unrealized gains and losses, the differences are recorded in other comprehensive income (loss), and do not impact the calculation of Income or Loss per Share.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2016, the Company changed its functional currency from the Canadian dollar to the U.S. dollar based on management's analysis of the changes in the primary economic environment in which the Company operates.  The change in functional currency is accounted for prospectively from January 1, 2016 and financial statements prior to and including the year-ended December 31, 2015 have not been restated for the change in functional currency. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Deferred income taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred income taxes</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes are accounted for using the asset and liability method of accounting. Deferred income taxes are recognized for the future income tax consequences attributable to differences between the carrying values of assets and liabilities and their respective income tax bases and for loss carry-forwards. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the periods in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax laws or rates is included in earnings in the period that includes the enactment date. When realization of deferred income tax assets does not meet the more-likely-than-not criterion for recognition, a valuation allowance is provided.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based compensation</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company grants stock options to employees and directors pursuant to a share incentive plan described in note 6. Compensation expense is recorded for issued stock options using the fair value method with a corresponding increase in additional paid-in capital. Any consideration received on the exercise of stock options is credited to share capital.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of stock options is measured at the grant date and amortized on a straight-line basis over the vesting period.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ReplacementAwardsPolicyTextBlock', window );">Replacement awards</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Replacement awards</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Replacement awards are share-based payment awards exchanged for awards held by employees of Arbutus Inc. As part of the Company&#8217;s acquisition of Arbutus Inc., Arbutus shares were exchanged for Arbutus Inc.&#8217;s shares subject to repurchase rights held by Arbutus Inc.&#8217;s employees - see note 3.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at the date of acquisition of Arbutus Inc., the Company determined the total fair value of replacement awards and attributed a portion of the replacement awards to pre-combination service as part of the total acquisition consideration, and a portion to post-combination service, which is recognized as compensation expense over the expiry period of repurchase provision rights subsequent to the acquisition date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The replacement awards consist of common shares that were issued at acquisition. Accordingly, as stock compensation expense related to these awards is recognized, share capital is increased by a corresponding amount. Replacement awards are excluded in the calculation of basic net income (loss) per share until the repurchase rights have expired.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for the warrants under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company&#8217;s own stock, on the understanding that in compliance with applicable securities laws, the registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies warrants in its consolidated balance sheet as a liability which is revalued at each balance sheet date subsequent to the initial issuance. The Company uses the Black-Scholes pricing model to value the warrants. Determining the appropriate fair-value model and calculating the fair value of registered warrants requires considerable judgment. A small change in the estimates used may cause a relatively large change in the estimated valuation. The estimated volatility of the Company&#8217;s common stock at the date of issuance, and at each subsequent reporting period, is based on historic fluctuations in the Company&#8217;s stock price. The risk-free interest rate is based on the Government of Canada rate for bonds with a maturity similar to the expected remaining life of the warrants at the valuation date. The expected life of the warrants is based on the historical pattern of exercises of warrants</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment information</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in a single reporting segment. Substantially all of the Company&#8217;s revenues to date were earned from customers or collaborators based in the United States. Substantially all of the Company&#8217;s premises, property and equipment are located in Canada and the United States.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent accounting pronouncements</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842): Recognition and Measurement of Financial Assets and Financial Liabilities. The update supersedes Topic 840, Leases and requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP.  Topic 842 retains a distinction between finance leases and operating leases, with cash payments from operating leases classified within operating activities in the statement of cash flows. The amendments in this update are effective for fiscal years beginning after December 15, 2018 for public business entities, which for the Company means January 1, 2019. The Company does not plan to early adopt this update. The extent of the impact of this adoption has not yet been determined.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, the FASB issued ASU 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The update eliminates the requirement to retrospectively adjust the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill during the measurement period when new information is obtained about the facts and circumstances that existed as of the acquisition date, that if known, would have affected the measurement of the amounts initially recognized or would have resulted in the recognition of additional assets or liabilities. The amendments in this update are effective for fiscal years beginning after December 15, 2015, which for the Company means January 1, 2016, and should be applied prospectively to adjustments to provisional amounts that occur after the effective date of this update. Early application is permitted for financial statements that have not been issued. The Company has adopted this update and applied it to the acquisition of Arbutus Inc.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASC 606). The standard is intended to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and IFRS by creating a new Topic 606, Revenue from Contracts with Customers. This guidance supersedes the revenue recognition requirements in ASC 605, Revenue Recognition, and supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition - Construction-Type and Production-Type Contracts. The core principle of the accounting standard is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those good or services. The amendments should be applied by either (1) retrospectively to each prior reporting period presented; or (2) retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date to defer the effective date of Update 2014-09 for all entities by one year. The new guidance would be effective for fiscal years beginning after December 15, 2017, which for the Company means January 1, 2018. Entities are permitted to adopt in accordance with the original effective date if they choose. The Company has not yet determined the extent of the impact of adoption.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern. The update is intended to provide guidance in GAAP about management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures. Under amendments to GAAP, the assessment period is within one year after the date that the financial statements are issued (or available to be issued). The amendments are effective for the annual period ending after December 15, 2016, which for the Company means January 1, 2017, and for annual periods and interim periods thereafter. Early application is permitted. The Company does not plan to early adopt this update. The extent of the impact of this adoption has not yet been determined.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the policy for the government grants and refundable investment tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_GovernmentGrantsAndRefundableInvestmentTaxCreditsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ReplacementAwardsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Replacement Awards [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ReplacementAwardsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The accounting policy for the warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6390181&amp;loc=d3e202-110218<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section CC<br> -Subsection 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 206<br> -Paragraph b<br> -Subparagraph i, ii<br> -Chapter 2<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 6<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=27724398&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6872867&amp;loc=d3e40691-111596<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section M<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 2, 12<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements (both lessor and lessee). This disclosure may address (1) lease classification (that is, operating versus capital), (2) how the term of a lease is determined (for example, the circumstances in which a renewal option is considered part of the lease term), (3) how rental revenue or expense is recognized for a lease that contains rent escalations, (4) an entity's accounting treatment for deferred rent, including that which arises from lease incentives, rent abatements, rent holidays, or tenant allowances (5) an entity's accounting treatment for contingent rental payments and (6) an entity's policy for reviewing, at least annually, the residual values of sales-type and direct-finance leases. The disclosure also may indicate how the entity accounts for its capital leases, leveraged leases or sale-leaseback transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453394&amp;loc=d3e39740-112701<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6482485&amp;loc=d3e14754-158437<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6456037&amp;loc=d3e48589-112741<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6389767&amp;loc=d3e17916-109280<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section B<br> -Paragraph Question 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6827657392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Assets measured at fair value on a recurring basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,779</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,779</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Guaranteed investment certificate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,070</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,070</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,374</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,374</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instrument</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,380</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,380</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,187</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Guaranteed investment certificates</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,974</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,161</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,161</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instrument</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ChangesInFairValueOfWarrantsTableTextBlock', window );">Changes in fair value of warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company&#8217;s warrants:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability at beginning</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants issued in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warrants exercised</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase (decrease) in fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability at end</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the period</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,379</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,208</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,383</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(455</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(334</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,341</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">883</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Changes in fair value of contingent consideration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company&#8217;s contingent consideration:</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="26%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="22%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="22%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="22%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability at beginning</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the period </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">value of contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability at end</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of the period</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;(1) As at acquisition date of March 4, 2015 - see note 3 below.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Property and equipment estimated useful lives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records depreciation using the straight-line method over the estimated useful lives of the capital assets as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="77%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Useful life (years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer and office equipment </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net income (loss) per common share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the computation of basic and diluted net income (loss) per common share:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the year ended December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(61,121</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,837</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,063</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">45,462,324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,603,136</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,302,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted income (loss) per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.92</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ChangesInFairValueOfWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the tabular disclosure for the change in fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ChangesInFairValueOfWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of property, plant and equipment, estimated useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6827976592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of finalized acquisition purchase price allocation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s finalized purchase price allocation as at December 31, 2015:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consideration paid:</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Common shares issued without subjects</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">371,553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Common shares issued subject to repurchase provision</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Common shares issuable for Arbutus Inc. stock options</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,127</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identifiable assets acquired and liabilities assumed:</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Cash</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Accounts receivable</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Property and equipment</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Goodwill</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,580</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Other non-current liabilities (note 9)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,727</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Deferred income tax liability</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(162,509</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total purchase price allocation</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock', window );">Schedule of identifiable intangible assets acquired</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The identifiable intangible assets acquired consist of in-process research and development (IPR&amp;D) HBV assets, as summarized in the table below:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Cyclophilins</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,007</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Immune Modulators</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Antigen Inhibitors</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; cccDNA Sterilizers</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total IPR&amp;D</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">391,649</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock', window );">Summary of revisions and adjustments to business acquisition purchase price allocation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The following table presents a summary of revisions and adjustments made to the preliminary estimates as previously disclosed to the finalized purchase price allocation:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="46%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preliminary Amounts Recognized as of Acquisition Date </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Measurement Period Adjustments</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(2)</sup></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts Recognized as of Acquisition Date (as adjusted)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identifiable assets acquired and liabilities assumed:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Cash</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">324</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Accounts receivable</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Property and equipment</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389,652</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,997</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391,649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Goodwill</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,580</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,580</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Other non-current liabilities (note 8)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,736</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,991</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,727</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160;Deferred income tax liability</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(155,865</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,644</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(162,509</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total purchase price allocation</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preliminary purchase price as of the acquisition date of March 4, 2015 as previously disclosed in the notes to consolidated financial statements included in the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The measurement period is from the acquisition date of March 4, 2015 to the date the Company finalized the purchase price allocation on December 31, 2015. </font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business acquisition, pro forma financial information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pro forma financial information presented includes acquisition costs, amortization charges for acquired tangible assets, impairment charge on acquired intangible assets (as described in note 3b below), but does not include amortization charges for acquired intangible assets as these assets have not yet been put in use.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="47%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="24%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pro forma information</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross Revenue</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,873</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,953</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(109,387</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,088</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(67,416</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(56,491</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per share</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.38</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.24</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock', window );">Schedule of intangible assets net of impairment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the carrying values, net of impairment of the intangible assets as at December 31, 2015:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Cyclophilins</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Immune Modulators</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; Antigen Inhibitors</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPR&amp;D &#8211; cccDNA Sterilizers</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,102</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total IPR&amp;D</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">352,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Revisions and Adjustments To Business Acquisition Purchase Price Allocation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_SummaryofRevisionsandAdjustmentsToBusinessAcquisitionPurchasePriceAllocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1486-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of characteristics and cost, by total and major class, of indefinite-lived intangible assets acquired as part of a business combination. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. The future benefit is not expected to diminish over a stated period of time. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4922-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6779985536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, Contracts and Licensing Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueDisclosureAbstract', window );"><strong>Deferred Revenue Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of revenue recognized under collaborations, contracts and licensing agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables set forth revenue recognized under collaborations, contracts and licensing agreements:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ended December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborations and contracts</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DoD (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,764</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,407</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,806</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto (b)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">BMS (d)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,741</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">526</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna (e)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other RNAi collaborators (g)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total research and development collaborations and contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Licensing fees, milestone and royalty payments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto licensing fees and milestone payments (b)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10,256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alnylam and Acuitas licensing fees and milestone payments (c)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna licensing fee (e)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Spectrum royalty payments (f)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">240</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total licensing fees, milestone and royalty payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11,564</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,215</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,040</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,873</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,953</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,465</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Schedule of deferred collaborations and contracts revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth deferred collaborations and contracts revenue:</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DoD (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto current portion (b)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna current portion (e)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,221</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">868</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,779</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Monsanto long-term portion (b)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dicerna long-term portion (e)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,271</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total deferred revenue</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,081</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,716</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6833341840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">December&#160;31, 2015</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">depreciation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">book value</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,910</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,748</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,189</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">492</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">307</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,912</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,729</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,183</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">December&#160;31, 2014</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">depreciation</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">book value</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,281</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,796</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(364</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,959</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,199</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,760</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6827781456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s warrant activity for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="37" rowspan="1"></td></tr><tr><td width="12%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="4%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="3%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="5%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="4%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="3%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Common shares</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">purchasable upon</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">exercise of</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted average</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">exercise price (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">average exercise</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Range of</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">exercise prices</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Range of</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">exercise prices</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted average remaining contractual life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Aggregate</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">intrinsic value</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Aggregate</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">intrinsic value</font></div><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,014,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$2.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$2.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercised</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(616,478</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.09</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.80</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.03</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">398,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercised</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(18,750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.88</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.62</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">379,500</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.95</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.13</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$2.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3.35</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$2.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2.62</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,217</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">879</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average Black-Scholes option-pricing assumptions and resultant fair values</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average Black-Scholes option-pricing assumptions and the resultant fair values are as follows for warrants outstanding at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> are as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">49.07</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85.22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected average term (years)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">0.6 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.5 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of warrants outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate fair value of warrants outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">883</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,099</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of warrants outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">379,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">398,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity for the Arbutus Plans</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock option activity for the Arbutus Plans</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td width="31%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">optioned</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">intrinsic</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">value (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">intrinsic</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">value (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,648,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,301</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.52</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64,085</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.87</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,730,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431,125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.63</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(622,752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,530,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,309,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(398,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(151,207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,290,263</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.53</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.22</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,376</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">994</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock', window );">Summary of stock options outstanding by exercise price range</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information pertaining to stock options outstanding at December 31, 2015 under the Arbutus Plans:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23" rowspan="1"></td></tr><tr><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Options outstanding December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Options exercisable December 31, 2015</font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Range of</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Exercise prices (US$)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Number</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">of options</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">outstanding</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">average</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">remaining</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">contractual</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">average</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">exercise</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Number</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">of options</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">exercisable</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">average</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">exercise</font></div><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">102,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">102,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.52</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.88</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,475</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,475</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$2.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$2.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">83,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">83,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$3.24</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$4.70</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">288,960</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">268,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$5.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$7.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">261,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">175,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$8.38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$10.04</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">176,813</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">99,189</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$10.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$13.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">129,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">79,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$13.40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$17.57</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,126,875</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17.02</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,002</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17.57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$1.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">to</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$17.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,290,263</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.22</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">938,730</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.98</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of non-vested stock option activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s non-vested stock option activity and related information for the year ended December 31, 2015 is as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">optioned</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fair value (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fair value (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,309,625</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.89</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(250,461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested options forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148,853</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,351,541</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.69</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.34</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Schedule of weighted average option pricing assumptions and the resultant fair values</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average option pricing assumptions and the resultant fair values are as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">76.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected average option term</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.5 years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.8 years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.6 years</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of allocation of stock-based compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total stock-based compensation has been recorded in the consolidated statement of operations and comprehensive income (loss) as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research, development, collaborations and contracts expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,225</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">940</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">22,093</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,283</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">903</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_ProtivaOptionPlanMember', window );">Protiva Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth outstanding options under the Protiva Option Plan:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td width="45%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of Protiva</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equivalent number</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Company</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (C$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">475,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,350</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(675</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">472,885</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319,274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(675</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">433,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">292,845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(358,675</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(242,164</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,065</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,445</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.23</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,236</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.30</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.22</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_OnCoreOptionPlanMember', window );">OnCore Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of non-vested stock option activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the OnCore Option Plan's non-vested stock option activity and related information for the period from acquisition to December 31, 2015 is as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OnCore Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equivalent number</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Company</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fair value (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested at March 4, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,128</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,354</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested options forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested at December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,382</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97,063</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.42</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth outstanding options under the OnCore Option Plan:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number of OnCore</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equivalent number</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Company</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">common shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">average exercise</font></div><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">price (US$)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, March 4, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,040</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited, canceled or expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">N/A</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,040</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,332</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the schedule of share based compensation for the shares authorized under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_TemporalDiagramOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph i<br> -Article 4<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 28<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number of fully vested share options (or share units) and share options expected to vest at the date of the latest statement of financial position, weighted-average exercise price (or conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term for both options (or share units) currently outstanding and options (or share units) exercisable (or convertible).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abus_ProtivaOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abus_ProtivaOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abus_OnCoreOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abus_OnCoreOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6825819104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax (recovery) expense varies from the amounts that would be computed by applying the combined Canadian federal and provincial income tax rate of </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;"> (2014 -  </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;">; 2013 &#8211; </font><font style="font-family:inherit;font-size:10pt;">26%</font><font style="font-family:inherit;font-size:10pt;">) to the loss before income taxes as shown in the following tables:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computed taxes (recoveries) at Canadian&#160;federal and provincial tax rates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(20,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,486</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Differences due to change in enacted tax rates</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permanent and other differences</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,498</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance - other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,676</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,599</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,407</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Difference due to income taxed at foreign rates</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(7,874</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax recovery</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(16,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of deferred tax assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant components of the Company&#8217;s deferred tax assets are shown below:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As at December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-capital loss carryforwards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13,932</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,578</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development deductions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13,474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,006</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Book amortization in excess of tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,142</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,745</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share issue costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized for tax purposes in excess of revenue recognized for accounting purposes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">281</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,086</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax value in excess of accounting value in lease inducements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal investment tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6,303</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provincial investment tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3,879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(146,324</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront license fees</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(104,830</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,818</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(41,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,818</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(146,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6816504864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of minimum rent and estimated operating cost commitment, net of lease inducements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The minimum rent and estimated operating cost commitment, net of lease inducements, is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="87%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,229,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">938,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">938,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31, 2019</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,652,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6786309664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations of Business Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NetLiquidityDisclosureTableTextBlock', window );">Net liquidity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The net liquidity of the Company is considered to be the cash and cash equivalents and short-term investments less accounts payable and accrued liabilities.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #646464;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and&#160;short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">181,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,827</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">172,477</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock', window );">Schedule of exposure to US dollar currency expressed in Canadian dollars</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s exposure to US dollar currency expressed in Canadian dollars was as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in C$)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents and short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">213,419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1,071</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,942</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(8,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,494</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">206,607</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NetLiquidityDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the full tabular disclosure for the net liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NetLiquidityDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-term intercompany foreign balances, including related intercompany entity, underlying foreign currencies and amounts of intercompany foreign currency transactions that are of a long-term investment nature (that is settlement is not planned or anticipated in the foreseeable future), as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntercompanyForeignCurrencyBalancesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6811098560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities is comprised of the following:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="73%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development accruals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,358</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License fee accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fee accruals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">640</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,294</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred lease inducements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payroll accruals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2,331</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,873</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">591</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,328</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6812499072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of interim financial data (unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="31%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,682</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,065</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,686</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,006</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,420</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,138</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,758</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(102,322</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,982</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(61,121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.57</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td width="31%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Q4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,362</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14,953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,958</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,423</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,844</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,747</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(33,434</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(38,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.91</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(1.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=35737889&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6825865600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business and Future Operations Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>subsidiary</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements', window );">Wholly-owned subsidiaries</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of wholly owned subsidiaries included in the reporting of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6829229232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>subsidiary </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 04, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements', window );">Wholly-owned subsidiaries | subsidiary</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Fair value of contingent consideration</a></td>
<td class="nump">$ 7,497<span></span>
</td>
<td class="nump">$ 7,497<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">$ 770<span></span>
</td>
<td class="nump">$ 770<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common shares excluded from calculation of income per common share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,899,331<span></span>
</td>
<td class="nump">2,221,233<span></span>
</td>
<td class="nump">3,064,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of wholly owned subsidiaries included in the reporting of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828656512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 04, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 166,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Guaranteed investment certificate</a></td>
<td class="nump">14,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Term deposit</a></td>
<td class="nump">10,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">191,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants</a></td>
<td class="nump">883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,099<span></span>
</td>
<td class="nump">$ 5,379<span></span>
</td>
<td class="nump">$ 4,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">7,497<span></span>
</td>
<td class="nump">$ 6,727<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities', window );">Financial instrument</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Total Liabilities</a></td>
<td class="nump">8,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">166,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Guaranteed investment certificate</a></td>
<td class="nump">14,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Term deposit</a></td>
<td class="nump">10,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">191,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants</a></td>
<td class="nump">883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">7,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities', window );">Financial instrument</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Total Liabilities</a></td>
<td class="nump">$ 8,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents disclosure of all significant concentrations of credit risk or market risk arising from the subject financial instrument (as defined), whether from an individual counterparty or groups of counterparties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 15<br> -Paragraph 83<br> -URI http://asc.fasb.org/extlink&amp;oid=39740004&amp;loc=d3e34841-113949<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueConcentrationOfRiskDerivativeFinancialInstrumentsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Trading Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28360136&amp;loc=d3e22054-111558<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Available-for-Sale Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 1<br> -Subparagraph a, f, g<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureRecurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregation of the liabilities reported on the balance sheet measured at fair value on a recurring basis by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureRecurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6829339216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Changes in Fair Value of the Company's Warrants (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Liability at beginning of the period</a></td>
<td class="nump">$ 5,099<span></span>
</td>
<td class="nump">$ 5,379<span></span>
</td>
<td class="nump">$ 4,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_OpeningLiabilityOfWarrantsIssuedInThePeriod', window );">Warrants issued in the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_FairValueOfWarrantsExercisedInThePeriod', window );">Fair value of warrants exercised in the period</a></td>
<td class="num">(334)<span></span>
</td>
<td class="num">(10,208)<span></span>
</td>
<td class="num">(1,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_IncreaseDecreaseInValueOfWarrants', window );">Increase (decrease) in fair value of warrants</a></td>
<td class="num">(3,341)<span></span>
</td>
<td class="nump">10,383<span></span>
</td>
<td class="nump">3,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_FairValueWarrantsForeignExchangeGainLoss', window );">Foreign exchange loss</a></td>
<td class="num">(541)<span></span>
</td>
<td class="num">(455)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Liability at end of the period</a></td>
<td class="nump">$ 883<span></span>
</td>
<td class="nump">$ 5,099<span></span>
</td>
<td class="nump">$ 5,379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_FairValueOfWarrantsExercisedInThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value of warrants exercised in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_FairValueOfWarrantsExercisedInThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_FairValueWarrantsForeignExchangeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gains and losses from changes in foreign exchanges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_FairValueWarrantsForeignExchangeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_IncreaseDecreaseInValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the increase decrease in value of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_IncreaseDecreaseInValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_OpeningLiabilityOfWarrantsIssuedInThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the opening liability of warrants issues in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_OpeningLiabilityOfWarrantsIssuedInThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6637613264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Changes in Fair Value of Contingent Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward', window );"><strong>Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration Fair Value, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Liability at beginning of the period</a></td>
<td class="nump">$ 6,727<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase in fair value of contingent consideration</a></td>
<td class="nump">770<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Liability at end of the period</a></td>
<td class="nump">$ 7,497<span></span>
</td>
<td class="nump">$ 7,497<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration Fair Value, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationFairValueLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828836528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abus_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer and office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer and office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abus_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=abus_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6842731872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Computation of Basic and Diluted Net Income (Loss) Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,264)<span></span>
</td>
<td class="num">$ (28,982)<span></span>
</td>
<td class="num">$ (14,886)<span></span>
</td>
<td class="num">$ (11,989)<span></span>
</td>
<td class="num">$ (6,168)<span></span>
</td>
<td class="num">$ (8,604)<span></span>
</td>
<td class="num">$ (6,081)<span></span>
</td>
<td class="num">$ (17,984)<span></span>
</td>
<td class="num">$ (61,121)<span></span>
</td>
<td class="num">$ (38,837)<span></span>
</td>
<td class="num">$ (14,063)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,462,324<span></span>
</td>
<td class="nump">21,603,136<span></span>
</td>
<td class="nump">15,302,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic income (loss) per common share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (1.80)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted income (loss) per common share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (1.80)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6851956032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May. 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 28, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>reporting_unit </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 03, 2015 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Jan. 11, 2015</div></th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,656,000<span></span>
</td>
<td class="nump">$ 462,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.48%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.07%<span></span>
</td>
<td class="nump">85.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected average term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter', window );">Acceleration of compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,007,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit related to impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,185,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,514,000<span></span>
</td>
<td class="nump">$ 162,514,000<span></span>
</td>
<td class="nump">$ 162,514,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_MarketCapitalizationValue', window );">Market capitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,844,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,844,000<span></span>
</td>
<td class="nump">242,844,000<span></span>
</td>
<td class="nump">$ 242,844,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,416,000)<span></span>
</td>
<td class="num">(56,491,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Company's carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547,679,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547,679,000<span></span>
</td>
<td class="nump">547,679,000<span></span>
</td>
<td class="nump">547,679,000<span></span>
</td>
<td class="nump">88,035,000<span></span>
</td>
<td class="nump">$ 59,194,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,919,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_StockRepurchaseRightsExpirationRateShares', window );">Stock repurchase rights expiration rate (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, percentage of outstanding shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,656,000<span></span>
</td>
<td class="nump">$ 462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Fair value of consideration issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,942,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Common shares issued for acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,973,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice', window );">Business acquisition, fair value amount attributed as pre-combination service and included as part of acquisition consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice', window );">Business acquisition, post-combination attribution recognized as compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,934,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,687,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_StockRepurchaseRightsExpirationRateShares', window );">Stock repurchase rights expiration rate (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PeriodofEstimatedCashFlowsUsedInFairValue', window );">Period of estimated cash flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets acquired, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391,649,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Measurement period adjustments, intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,997,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Measurement period adjustments, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,649,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,865,000<span></span>
</td>
<td class="nump">162,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,514,000<span></span>
</td>
<td class="nump">162,514,000<span></span>
</td>
<td class="nump">162,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,658,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">Arbutus Inc. | Scenario, forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_StockRepurchaseRightsExpirationRateShares', window );">Stock repurchase rights expiration rate (in shares) | shares</a></td>
<td class="nump">503,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">Arbutus Inc. | Common shares issued without subjects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Fair value of consideration issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,553,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,553,000<span></span>
</td>
<td class="nump">371,553,000<span></span>
</td>
<td class="nump">371,553,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Common shares issued for acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,347,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">Arbutus Inc. | Common shares issued subject to repurchase provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Fair value of consideration issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,196,000<span></span>
</td>
<td class="nump">$ 9,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,262,000<span></span>
</td>
<td class="nump">$ 9,262,000<span></span>
</td>
<td class="nump">$ 9,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Common shares issued for acquisition | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,625,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected average term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued and outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,625,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">Arbutus Inc. | Abutus stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Fair value of consideration issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,287,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected average term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice', window );">Business acquisition, fair value amount attributed as pre-combination service and included as part of acquisition consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice', window );">Business acquisition, post-combination attribution recognized as compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future exercise | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,332<span></span>
</td>
<td class="nump">184,332<span></span>
</td>
<td class="nump">184,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDCyclophilinsMember', window );">Cyclophilin | Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets acquired, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,007,000<span></span>
</td>
<td class="nump">$ 39,007,000<span></span>
</td>
<td class="nump">$ 37,990,000<span></span>
</td>
<td class="nump">$ 39,007,000<span></span>
</td>
<td class="nump">$ 39,007,000<span></span>
</td>
<td class="nump">$ 39,007,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Measurement period adjustments, intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,017,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit related to impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 989,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_OtherIPRDMember', window );">Other IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Equity Interest Issued Or Issuable Value Assigned Attributed As Post Combination Service And Not Included As Part Of Total Purchase Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Equity Interest Issued Or Issuable Value Assigned Attributed As Pre Combination Service And Included As Part Of Total Purchase Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination Acceleration Of Share Based Compensation Expense Per Quarter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinessCombinationAccelerationOfShareBasedCompensationExpensePerQuarter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_MarketCapitalizationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Market Capitalization Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_MarketCapitalizationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_PeriodofEstimatedCashFlowsUsedInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of Estimated Cash Flows Used In Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_PeriodofEstimatedCashFlowsUsedInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_StockRepurchaseRightsExpirationRateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchase Rights Expiration Rate Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_StockRepurchaseRightsExpirationRateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=34752592&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1500-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=34752592&amp;loc=d3e961-128460<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Reporting Unit<br> -URI http://asc.fasb.org/extlink&amp;oid=6523643<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_SharesIssuedWithoutSubjectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_SharesIssuedWithoutSubjectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_SharesIssuedSubjectToRepurchaseProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_SharesIssuedSubjectToRepurchaseProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_AbutusStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_AbutusStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDCyclophilinsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDCyclophilinsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_OtherIPRDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_OtherIPRDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828085360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Purchase Price Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 04, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Identifiable assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 162,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Identifiable assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired intangible assets</a></td>
<td class="nump">391,649<span></span>
</td>
<td class="nump">389,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">162,514<span></span>
</td>
<td class="nump">155,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(3,580)<span></span>
</td>
<td class="num">(3,580)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other non-current liabilities</a></td>
<td class="num">(6,727)<span></span>
</td>
<td class="num">(4,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent', window );">Deferred income tax liability</a></td>
<td class="num">(162,509)<span></span>
</td>
<td class="num">(155,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total purchase price allocation</a></td>
<td class="nump">381,942<span></span>
</td>
<td class="nump">381,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abus_SharesIssuedWithoutSubjectsMember', window );">Common shares issued without subjects | Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Consideration paid</a></td>
<td class="nump">371,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abus_SharesIssuedSubjectToRepurchaseProvisionMember', window );">Common shares issued subject to repurchase provision | Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Consideration paid</a></td>
<td class="nump">9,262<span></span>
</td>
<td class="nump">$ 66,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abus_CommonShareIssuableForArbutusInc.StockOptionsMember', window );">Common share issuable for Arbutus Inc. stock options | Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Consideration paid</a></td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the accrued liabilities and accounts payable assumed in the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_SharesIssuedWithoutSubjectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_SharesIssuedWithoutSubjectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_SharesIssuedSubjectToRepurchaseProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_SharesIssuedSubjectToRepurchaseProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_CommonShareIssuableForArbutusInc.StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_CommonShareIssuableForArbutusInc.StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828041728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Summary of Acquired Identifiable Intangible Assets (Details) - Arbutus Inc. - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Mar. 04, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">IPR&amp;D Cyclophilins</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets acquired</a></td>
<td class="nump">$ 39,007<span></span>
</td>
<td class="nump">$ 37,990<span></span>
</td>
<td class="nump">39,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">IPR&amp;D Immune Modulators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">IPR&amp;D Antigen Inhibitors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">IPR&amp;D cccDNA Sterilizers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDCyclophilinsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDCyclophilinsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDImmuneModulatorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDImmuneModulatorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDAntigenInhibitorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDAntigenInhibitorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDcccDNASterilizersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDcccDNASterilizersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828653232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Reconciliation of Preliminary to Final Purchase Price Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">10 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 04, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 162,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,514<span></span>
</td>
<td class="nump">$ 162,514<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase Price</a></td>
<td class="nump">381,942<span></span>
</td>
<td class="nump">$ 381,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">324<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="nump">324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash', window );">Measurement Period Adjustments, Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets', window );">Measurement Period Adjustments, Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable', window );">Measurement Period Adjustments, Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment', window );">Measurement Period Adjustments, Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired intangible assets</a></td>
<td class="nump">391,649<span></span>
</td>
<td class="nump">389,652<span></span>
</td>
<td class="nump">391,649<span></span>
</td>
<td class="nump">391,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Measurement Period Adjustments, Acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">162,514<span></span>
</td>
<td class="nump">155,865<span></span>
</td>
<td class="nump">162,514<span></span>
</td>
<td class="nump">162,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Measurement Period Adjustments, Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(3,580)<span></span>
</td>
<td class="num">(3,580)<span></span>
</td>
<td class="num">(3,580)<span></span>
</td>
<td class="num">(3,580)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities', window );">Measurement Period Adjustments, Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other non-current liabilities</a></td>
<td class="num">(6,727)<span></span>
</td>
<td class="num">(4,736)<span></span>
</td>
<td class="num">(6,727)<span></span>
</td>
<td class="num">(6,727)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities', window );">Measurement Period Adjustments, Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,991)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent', window );">Deferred income tax liability</a></td>
<td class="num">(162,509)<span></span>
</td>
<td class="num">(155,865)<span></span>
</td>
<td class="num">(162,509)<span></span>
</td>
<td class="num">(162,509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability', window );">Measurement Period Adjustments, Deferred income tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total purchase price allocation</a></td>
<td class="nump">$ 381,942<span></span>
</td>
<td class="nump">$ 381,942<span></span>
</td>
<td class="nump">381,942<span></span>
</td>
<td class="nump">$ 381,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred', window );">Measurement Period Adjustments, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Payable and Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsPayableandAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Accounts Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Non-Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expenses and Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpensesandOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the accrued liabilities and accounts payable assumed in the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinsessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1500-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1500-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to property, plant, and equipment acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1500-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=34752592&amp;loc=d3e961-128460<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6842773632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Pro Forma Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract', window );"><strong>Pro forma information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Gross Revenue</a></td>
<td class="nump">$ 24,873<span></span>
</td>
<td class="nump">$ 14,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax', window );">Loss from operations</a></td>
<td class="num">(109,387)<span></span>
</td>
<td class="num">(51,088)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (67,416)<span></span>
</td>
<td class="num">$ (56,491)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted', window );">Basic and diluted loss per share (in USD per share)</a></td>
<td class="num">$ (1.38)<span></span>
</td>
<td class="num">$ (1.24)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Pro Forma Earnings (Loss) Per Share Basic And Diluted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinessAcquisitionProFormaEarningsLossPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma income from continuing operations before changes in accounting and extraordinary items, net of tax effect, for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6838788192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Carrying Value of Intangible Assets After Impairment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, carrying value after impairments</a></td>
<td class="nump">$ 352,642<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, carrying value after impairments</a></td>
<td class="nump">352,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">Arbutus Inc. | IPR&amp;D Cyclophilins</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, carrying value after impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">Arbutus Inc. | IPR&amp;D Immune Modulators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, carrying value after impairments</a></td>
<td class="nump">183,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">Arbutus Inc. | IPR&amp;D Antigen Inhibitors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, carrying value after impairments</a></td>
<td class="nump">36,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member', window );">Arbutus Inc. | IPR&amp;D cccDNA Sterilizers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, carrying value after impairments</a></td>
<td class="nump">$ 133,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abus_ArbutusInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDCyclophilinsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDCyclophilinsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDImmuneModulatorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDImmuneModulatorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDAntigenInhibitorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDAntigenInhibitorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDcccDNASterilizersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_IPRDcccDNASterilizersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6855456448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, Contracts and Licensing Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 16, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 13, 2014</div></th>
<th class="th">
<div>Jan. 13, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 21, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May. 10, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 09, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 22, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May. 08, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 14, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May. 06, 2006 </div>
<div>chemotherapy_products</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,686,000<span></span>
</td>
<td class="nump">$ 4,065,000<span></span>
</td>
<td class="nump">$ 3,440,000<span></span>
</td>
<td class="nump">$ 4,682,000<span></span>
</td>
<td class="nump">$ 4,350,000<span></span>
</td>
<td class="nump">$ 4,362,000<span></span>
</td>
<td class="nump">$ 1,811,000<span></span>
</td>
<td class="nump">$ 4,430,000<span></span>
</td>
<td class="nump">$ 24,873,000<span></span>
</td>
<td class="nump">$ 14,953,000<span></span>
</td>
<td class="nump">$ 15,465,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing fees, milestone and royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,564,000<span></span>
</td>
<td class="nump">3,215,000<span></span>
</td>
<td class="nump">5,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">$ 1,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,716,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,081,000<span></span>
</td>
<td class="nump">15,716,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NumberOfChemotherapyProductsWithWorldwideLicenses', window );">Number of chemotherapy products with worldwide licenses | chemotherapy_products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contracts revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,309,000<span></span>
</td>
<td class="nump">11,738,000<span></span>
</td>
<td class="nump">10,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_DoDMember', window );">DoD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PotentialContractFundingAmount', window );">Potential contract funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_OptionalExcercisedContractualOptionAmount', window );">Optional exercised contractual option, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contracts revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,764,000<span></span>
</td>
<td class="nump">8,407,000<span></span>
</td>
<td class="nump">9,806,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_MonsantoMember', window );">Monsanto</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ApproximateOptionPeriod', window );">Approximate option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_MaximumPotentialTransactionValue', window );">Maximum potential transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_OptionPeriodExtension', window );">Option period extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NearTermContractPayments', window );">Payments from inception of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,981,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing fees, milestone and royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,256,000<span></span>
</td>
<td class="nump">2,744,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contracts revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,725,000<span></span>
</td>
<td class="nump">1,080,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_BMSMember', window );">BMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LengthOfAgreementWithBristolMyersSquibb', window );">Length of agreement with Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contracts revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,741,000<span></span>
</td>
<td class="nump">526,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_DicernaMember', window );">Dicerna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing fees, milestone and royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,053,000<span></span>
</td>
<td class="nump">131,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PerformancePeriodtoRecognizeRevenue', window );">Performance period to recognize revenue</a></td>
<td class="text">28 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contracts revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,820,000<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_TalonTherapeuticsMember', window );">Talon Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PotentialContractFundingAmount', window );">Potential contract funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_ContractExtensionMember', window );">Contract extension | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PotentialContractFundingAmount', window );">Potential contract funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_AlnylamLicenseAgreementMember', window );">Alnylam License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing fees, milestone and royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_MarqiboCommercialSalesMember', window );">Marqibo Commercial Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contracts revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_MarqiboMember', window );">Marqibo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued royalties</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContractModificationsAxis=abus_IncreaseToSupportDevelopmentPlansMember', window );">Increase to support development plans | DoD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PotentialContractFundingAmount', window );">Potential contract funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContractModificationsAxis=abus_IncreasedFundingForStageOneMember', window );">Increased funding for stage one | DoD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PotentialContractFundingAmount', window );">Potential contract funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContractModificationsAxis=abus_StageOneMember', window );">Stage one | DoD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PotentialContractFundingAmount', window );">Potential contract funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abus_PADCo.Member', window );">PADCo.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=abus_AlnylamandAscletisPharmaceuticalsMember', window );">Alnylam and Ascletis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing fees, milestone and royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event | PADCo. | Monsanto</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_OptionalExcercisedContractualOptionAmount', window );">Optional exercised contractual option, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, percentage of outstanding shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ApproximateOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the approximate period of the option agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ApproximateOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LengthOfAgreementWithBristolMyersSquibb">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Length Of Agreement With Bristol-Myers Squibb</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LengthOfAgreementWithBristolMyersSquibb</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_MaximumPotentialTransactionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum potential transaction value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_MaximumPotentialTransactionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents a milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NearTermContractPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payments for the near term as part of the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NearTermContractPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NumberOfChemotherapyProductsWithWorldwideLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Chemotherapy Products With Worldwide Licenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NumberOfChemotherapyProductsWithWorldwideLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_OptionPeriodExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option period extension</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_OptionPeriodExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_OptionalExcercisedContractualOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of an option exercise that was embedded in a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_OptionalExcercisedContractualOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_PerformancePeriodtoRecognizeRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance Period to Recognize Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_PerformancePeriodtoRecognizeRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_PotentialContractFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the potential contract funding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_PotentialContractFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Subparagraph 5<br> -Article 9<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Subparagraph a<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35755396&amp;loc=d3e33749-111570<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 9<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 11<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_DoDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_DoDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_MonsantoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_MonsantoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_BMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_BMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_DicernaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_DicernaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_TalonTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_TalonTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_ContractExtensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_ContractExtensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_AlnylamLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_AlnylamLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_MarqiboCommercialSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_MarqiboCommercialSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_MarqiboMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_MarqiboMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ContractModificationsAxis=abus_IncreaseToSupportDevelopmentPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ContractModificationsAxis=abus_IncreaseToSupportDevelopmentPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ContractModificationsAxis=abus_IncreasedFundingForStageOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ContractModificationsAxis=abus_IncreasedFundingForStageOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ContractModificationsAxis=abus_StageOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ContractModificationsAxis=abus_StageOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abus_PADCo.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abus_PADCo.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=abus_AlnylamandAscletisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=abus_AlnylamandAscletisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abus_PADCo.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abus_PADCo.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abus_MonsantoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abus_MonsantoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6847681632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, Contracts and Licensing Agreements - Revenue Recognized Under Collaborations, Contracts and Licensing Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_CollaborationsAndContractsAbstract', window );"><strong>Collaborations and contracts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contracts revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,309<span></span>
</td>
<td class="nump">$ 11,738<span></span>
</td>
<td class="nump">$ 10,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract', window );"><strong>Licensing fees, milestone and royalty payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing fees, milestone and royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,564<span></span>
</td>
<td class="nump">3,215<span></span>
</td>
<td class="nump">5,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 12,686<span></span>
</td>
<td class="nump">$ 4,065<span></span>
</td>
<td class="nump">$ 3,440<span></span>
</td>
<td class="nump">$ 4,682<span></span>
</td>
<td class="nump">$ 4,350<span></span>
</td>
<td class="nump">$ 4,362<span></span>
</td>
<td class="nump">$ 1,811<span></span>
</td>
<td class="nump">$ 4,430<span></span>
</td>
<td class="nump">24,873<span></span>
</td>
<td class="nump">14,953<span></span>
</td>
<td class="nump">15,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_DoDMember', window );">DoD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_CollaborationsAndContractsAbstract', window );"><strong>Collaborations and contracts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contracts revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,764<span></span>
</td>
<td class="nump">8,407<span></span>
</td>
<td class="nump">9,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_MonsantoMember', window );">Monsanto</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_CollaborationsAndContractsAbstract', window );"><strong>Collaborations and contracts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contracts revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,725<span></span>
</td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract', window );"><strong>Licensing fees, milestone and royalty payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing fees, milestone and royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,256<span></span>
</td>
<td class="nump">2,744<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_BMSMember', window );">BMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_CollaborationsAndContractsAbstract', window );"><strong>Collaborations and contracts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contracts revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,741<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_AlnylamLicenseAgreementMember', window );">Alnylam License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract', window );"><strong>Licensing fees, milestone and royalty payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing fees, milestone and royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_DicernaMember', window );">Dicerna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_CollaborationsAndContractsAbstract', window );"><strong>Collaborations and contracts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contracts revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,820<span></span>
</td>
<td class="nump">510<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract', window );"><strong>Licensing fees, milestone and royalty payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing fees, milestone and royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_OtherRNAiCollaboratorsMember', window );">Other RNAi Collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_CollaborationsAndContractsAbstract', window );"><strong>Collaborations and contracts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contracts revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_SpectrumMember', window );">Spectrum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract', window );"><strong>Licensing fees, milestone and royalty payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licensing fees, milestone and royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_CollaborationsAndContractsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_CollaborationsAndContractsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LicensingFeesMilestoneAndRoyaltyPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_DoDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_DoDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_MonsantoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_MonsantoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_BMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_BMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_AlnylamLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_AlnylamLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_DicernaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_DicernaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_OtherRNAiCollaboratorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_OtherRNAiCollaboratorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_SpectrumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_SpectrumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6829389472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborations, Contracts and Licensing Agreements - Deferred Collaborations and Contracts Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Nov. 16, 2014</div></th>
<th class="th"><div>May. 10, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue current portion</a></td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">$ 5,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue long-term portion</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">9,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Total deferred revenue</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">15,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_DoDMember', window );">DoD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue current portion</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_MonsantoMember', window );">Monsanto</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue long-term portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_BMSMember', window );">BMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Total deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_DicernaMember', window );">Dicerna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue current portion</a></td>
<td class="nump">853<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue long-term portion</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">$ 1,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Total deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_DoDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_DoDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_MonsantoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_MonsantoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_BMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_BMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_DicernaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_DicernaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6833155280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6843101856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Property and Equipment Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 12,912<span></span>
</td>
<td class="nump">$ 12,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(9,729)<span></span>
</td>
<td class="num">(11,199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">3,183<span></span>
</td>
<td class="nump">1,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abus_LaboratoryEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">5,910<span></span>
</td>
<td class="nump">5,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(3,748)<span></span>
</td>
<td class="num">(4,451)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">2,162<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">4,681<span></span>
</td>
<td class="nump">5,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(4,189)<span></span>
</td>
<td class="num">(4,796)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">2,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(1,487)<span></span>
</td>
<td class="num">(1,588)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">527<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(305)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 14<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abus_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=abus_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6856776448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Details)<br> CAD / shares in Units, $ / shares in Units, CAD in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>compensation_plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 25, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 04, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 26, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 02, 2013 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 22, 2013 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 22, 2011</div></th>
<th class="th">
<div>May. 30, 2008 </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 22, 2013 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>compensation_plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>compensation_plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>CAD </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($) </div>
<div>executive_officers </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>CAD </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD / shares</div>
</th>
<th class="th">
<div>Jul. 09, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>May. 08, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during underwritten public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125,000<span></span>
</td>
<td class="nump">562,500<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price at public offering (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.50<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,562,000<span></span>
</td>
<td class="nump">$ 34,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,477,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,038,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Period for option to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs, including commissions and professional fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,085,000<span></span>
</td>
<td class="nump">2,462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ProceedsFromIssuanceOfCommonStockNet', window );">Proceeds from issuance of common stock, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,477,000<span></span>
</td>
<td class="nump">$ 32,038,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_WarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,750<span></span>
</td>
<td class="nump">18,750<span></span>
</td>
<td class="nump">610,478<span></span>
</td>
<td class="nump">610,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,583,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common shares issued from warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,285<span></span>
</td>
<td class="nump">5,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NumberofShareBasedCompensationPlans', window );">Number of share-based compensation plans | compensation_plan</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,309,625<span></span>
</td>
<td class="nump">1,309,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments', window );">Number of executive officers granted options with new appointments | executive_officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of stock-based compensation awards approved to be issued</a></td>
<td class="nump">3,135,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,135,980<span></span>
</td>
<td class="nump">3,135,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">938,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938,730<span></span>
</td>
<td class="nump">938,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,088,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,377,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of exercisable options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of in-the-money options exercisable | $</a></td>
<td class="nump">$ 994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 994,000<span></span>
</td>
<td class="nump">$ 994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life for options expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Average exercise price for options expected to vest | (per share)</a></td>
<td class="nump">$ 15.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.54<span></span>
</td>
<td class="nump">$ 15.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 21.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of option expected to vest | $</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,626,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 943,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of options that vested during period | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 955,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.48%<span></span>
</td>
<td class="nump">0.48%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.07%<span></span>
</td>
<td class="nump">49.07%<span></span>
</td>
<td class="nump">85.22%<span></span>
</td>
<td class="nump">85.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected average term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unearned compensation expense | $</a></td>
<td class="nump">$ 11,972,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,972,000<span></span>
</td>
<td class="nump">$ 11,972,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unearned compensation expense, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 months<span></span>
</td>
<td class="text">16 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">2,519,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,519,831<span></span>
</td>
<td class="nump">2,519,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PotentialProceedsOfAdditionalSharesAuthorized', window );">Potential Proceeds of Additional Shares Authorized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,781,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,084,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abus_CashlessExerciseProvisionMember', window );">Cashless Exercise Provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_WarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member', window );">Unexpired repurchase rights on shares issued to Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unearned compensation expense | $</a></td>
<td class="nump">$ 35,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,967,000<span></span>
</td>
<td class="nump">$ 35,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unearned compensation expense, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_A2007PlanMember', window );">2007 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_A2007PlanMember', window );">2007 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_A2011PlanMember', window );">2011 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_A2011PlanMember', window );">2011 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_DesignatedPlansMember', window );">Designated Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_ArbutusPlansMember', window );">Arbutus Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,309,625<span></span>
</td>
<td class="nump">1,309,625<span></span>
</td>
<td class="nump">431,125<span></span>
</td>
<td class="nump">431,125<span></span>
</td>
<td class="nump">270,250<span></span>
</td>
<td class="nump">270,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised - Aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,386,000<span></span>
</td>
<td class="nump">CAD 6,887<span></span>
</td>
<td class="nump">$ 6,926,000<span></span>
</td>
<td class="nump">CAD 7,650<span></span>
</td>
<td class="nump">$ 535,000<span></span>
</td>
<td class="nump">CAD 551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">2,290,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,290,263<span></span>
</td>
<td class="nump">2,290,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,530,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,730,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,648,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_ProtivaOptionPlanMember', window );">Protiva Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of in-the-money options exercisable | $</a></td>
<td class="nump">$ 187,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,000<span></span>
</td>
<td class="nump">$ 187,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Option exercise price (in CAD per share) | CAD / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_ProtivaOptionPlanMember', window );">Protiva Option Plan | Revised new common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_ProtivaOptionPlanMember', window );">Protiva Option Plan | Protiva Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of exercisable options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised - Aggregate intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,249,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_OnCoreOptionPlanMember', window );">OnCore Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of stock-based compensation awards approved to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Fair value of consideration issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,287,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">86,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,658<span></span>
</td>
<td class="nump">86,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of exercisable options</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of in-the-money options exercisable | $</a></td>
<td class="nump">$ 337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 337,000<span></span>
</td>
<td class="nump">$ 337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life for options expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Average exercise price for options expected to vest | $ / shares</a></td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of option expected to vest | $</a></td>
<td class="nump">$ 695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 695,000<span></span>
</td>
<td class="nump">$ 695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of options that vested during period | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected average term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice', window );">Business acquisition, fair value amount attributed as pre-combination service and included as part of acquisition consideration | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice', window );">Business acquisition, post-combination attribution recognized as compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">183,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,040<span></span>
</td>
<td class="nump">183,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_OnCoreOptionPlanMember', window );">OnCore Option Plan | Equivalent number of Company common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">87,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,269<span></span>
</td>
<td class="nump">87,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">184,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,332<span></span>
</td>
<td class="nump">184,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Equity Interest Issued Or Issuable Value Assigned Attributed As Post Combination Service And Not Included As Part Of Total Purchase Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Equity Interest Issued Or Issuable Value Assigned Attributed As Pre Combination Service And Included As Part Of Total Purchase Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPreCombinationServiceAndIncludedAsPartOfTotalPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of additional shares authorized in which underwriters have the option to purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Executive Officers Granted Options With New Appointments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NumberofShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Share-Based Compensation Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NumberofShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_PotentialProceedsOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The potential cash inflow from the additional capital contribution to the entity if an option is exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_PotentialProceedsOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of the option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Footnote 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section D<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_CashlessExerciseProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_CashlessExerciseProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_UnexpiredRepurchaseRightsOnSharesIssuedtoArbutusInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abus_A2007PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abus_A2007PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abus_A2011PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abus_A2011PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abus_DesignatedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abus_DesignatedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abus_ArbutusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abus_ArbutusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abus_ProtivaOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abus_ProtivaOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_RevisedNewCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_RevisedNewCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_ProtivaShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_ProtivaShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abus_OnCoreOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abus_OnCoreOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_EquivalentNumberOfCompanyCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_EquivalentNumberOfCompanyCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828164752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Summary of Warrant Activity (Details)<br> CAD / shares in Units, $ / shares in Units, CAD in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>CAD </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>CAD </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward', window );"><strong>Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Balance, Common shares purchasable upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,014,728<span></span>
</td>
<td class="nump">379,500<span></span>
</td>
<td class="nump">398,250<span></span>
</td>
<td class="nump">1,014,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Exercised, Common shares purchasable upon exercise of warrants</a></td>
<td class="num">(18,750)<span></span>
</td>
<td class="num">(18,750)<span></span>
</td>
<td class="num">(616,478)<span></span>
</td>
<td class="num">(616,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Balance, Weighted average exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 2.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 2.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 2.90<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="nump">$ 2.67<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice', window );">Exercised, Weighted average exercise price | (per share)</a></td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="nump">CAD 2.88<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="nump">CAD 3.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BalanceWeightedaverageremainingcontractuallife', window );">Balance, Weighted average remaining contractual life</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue', window );">Balance, Aggregate intrinsic value</a></td>
<td class="nump">$ 879<span></span>
</td>
<td class="nump">CAD 1,217<span></span>
</td>
<td class="nump">$ 5,343<span></span>
</td>
<td class="nump">CAD 5,902<span></span>
</td>
<td class="nump">$ 5,298<span></span>
</td>
<td class="nump">CAD 5,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward', window );"><strong>Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ClassOfWarrantorRightOutstandExcercisePriceRange', window );">Balance, Range of exercise prices | (per share)</a></td>
<td class="nump">$ 2.03<span></span>
</td>
<td class="nump">CAD 2.60<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="nump">CAD 2.60<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="nump">CAD 2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ClassOfWarrantsOrRightsExcercisedPriceRange', window );">Exercised, Range of exercise prices | (per share)</a></td>
<td class="nump">2.03<span></span>
</td>
<td class="nump">2.60<span></span>
</td>
<td class="nump">2.35<span></span>
</td>
<td class="nump">2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward', window );"><strong>Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ClassOfWarrantorRightOutstandExcercisePriceRange', window );">Balance, Range of exercise prices | (per share)</a></td>
<td class="nump">2.62<span></span>
</td>
<td class="nump">3.35<span></span>
</td>
<td class="nump">3.03<span></span>
</td>
<td class="nump">3.35<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="nump">CAD 3.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ClassOfWarrantsOrRightsExcercisedPriceRange', window );">Exercised, Range of exercise prices | (per share)</a></td>
<td class="nump">$ 2.62<span></span>
</td>
<td class="nump">CAD 3.35<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="nump">CAD 3.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BalanceWeightedaverageremainingcontractuallife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the class of warrant or right price of warrants or rights contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BalanceWeightedaverageremainingcontractuallife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the class of warrant or right, exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the class of warrant or right price of warrants or rights intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ClassOfWarrantOrRightPriceOfWarrantsOrRightsIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ClassOfWarrantorRightOutstandExcercisePriceRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the range of prices for outstanding warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ClassOfWarrantorRightOutstandExcercisePriceRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ClassOfWarrantsOrRightsExcercisedPriceRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the price range for warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ClassOfWarrantsOrRightsExcercisedPriceRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph i<br> -Subparagraph 2<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6778653008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Black-Scholes Option-pricing Assumptions (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">49.07%<span></span>
</td>
<td class="nump">85.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.48%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected average term (years)</a></td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_FairValueOfWarrantsOutstandingPerWarrant', window );">Fair value of warrants outstanding (in USD per share)</a></td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="nump">$ 12.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Aggregate fair value of warrants outstanding</a></td>
<td class="nump">$ 883<span></span>
</td>
<td class="nump">$ 5,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares)</a></td>
<td class="nump">379,500<span></span>
</td>
<td class="nump">398,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_FairValueOfWarrantsOutstandingPerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value of the warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_FairValueOfWarrantsOutstandingPerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph i<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph i<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6842823696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Stock Option Activity (Details)<br> CAD / shares in Units, $ / shares in Units, CAD in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>CAD </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>CAD </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,125,000<span></span>
</td>
<td class="nump">1,309,625<span></span>
</td>
<td class="nump">1,309,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance - Number of optioned common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,519,831<span></span>
</td>
<td class="nump">2,519,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_ArbutusPlansMember', window );">Arbutus Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance - Number of optioned common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,530,138<span></span>
</td>
<td class="nump">1,530,138<span></span>
</td>
<td class="nump">1,730,765<span></span>
</td>
<td class="nump">1,730,765<span></span>
</td>
<td class="nump">1,648,846<span></span>
</td>
<td class="nump">1,648,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance - Weighted average exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.29<span></span>
</td>
<td class="nump">CAD 6.95<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
<td class="nump">CAD 4.45<span></span>
</td>
<td class="nump">$ 4.54<span></span>
</td>
<td class="nump">CAD 4.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance - Aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,004<span></span>
</td>
<td class="nump">CAD 16,573<span></span>
</td>
<td class="nump">$ 6,826<span></span>
</td>
<td class="nump">CAD 7,030<span></span>
</td>
<td class="nump">$ 2,301<span></span>
</td>
<td class="nump">CAD 2,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,309,625<span></span>
</td>
<td class="nump">1,309,625<span></span>
</td>
<td class="nump">431,125<span></span>
</td>
<td class="nump">431,125<span></span>
</td>
<td class="nump">270,250<span></span>
</td>
<td class="nump">270,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted - Weighted average exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.34<span></span>
</td>
<td class="nump">CAD 13.63<span></span>
</td>
<td class="nump">$ 7.30<span></span>
</td>
<td class="nump">CAD 7.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(398,293)<span></span>
</td>
<td class="num">(398,293)<span></span>
</td>
<td class="num">(622,752)<span></span>
</td>
<td class="num">(622,752)<span></span>
</td>
<td class="num">(124,246)<span></span>
</td>
<td class="num">(124,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised - Weighted average exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.93<span></span>
</td>
<td class="nump">CAD 5.03<span></span>
</td>
<td class="nump">$ 4.18<span></span>
</td>
<td class="nump">CAD 4.62<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="nump">CAD 3.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised - Aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,386<span></span>
</td>
<td class="nump">CAD 6,887<span></span>
</td>
<td class="nump">$ 6,926<span></span>
</td>
<td class="nump">CAD 7,650<span></span>
</td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">CAD 551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options forfeited, cancelled or expired - Number of optioned common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151,207)<span></span>
</td>
<td class="num">(151,207)<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
<td class="num">(64,085)<span></span>
</td>
<td class="num">(64,085)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options forfeited, cancelled or expired - Weighted average exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.09<span></span>
</td>
<td class="nump">CAD 19.29<span></span>
</td>
<td class="nump">$ 7.42<span></span>
</td>
<td class="nump">CAD 8.20<span></span>
</td>
<td class="nump">$ 21.23<span></span>
</td>
<td class="nump">CAD 21.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance - Number of optioned common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,290,263<span></span>
</td>
<td class="nump">2,290,263<span></span>
</td>
<td class="nump">1,530,138<span></span>
</td>
<td class="nump">1,530,138<span></span>
</td>
<td class="nump">1,730,765<span></span>
</td>
<td class="nump">1,730,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance - Weighted average exercise price | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.22<span></span>
</td>
<td class="nump">CAD 15.53<span></span>
</td>
<td class="nump">$ 6.29<span></span>
</td>
<td class="nump">CAD 6.95<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
<td class="nump">CAD 4.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance - Aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 994<span></span>
</td>
<td class="nump">CAD 1,376<span></span>
</td>
<td class="nump">$ 15,004<span></span>
</td>
<td class="nump">CAD 16,573<span></span>
</td>
<td class="nump">$ 6,826<span></span>
</td>
<td class="nump">CAD 7,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abus_ArbutusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abus_ArbutusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6828131584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Stock Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range1Member', window );">Range 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise prices - Low</a></td>
<td class="nump">$ 1.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise prices - High</a></td>
<td class="nump">$ 1.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">102,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance - Weighted average exercise price</a></td>
<td class="nump">$ 1.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares) | shares</a></td>
<td class="nump">102,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 1.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range2Member', window );">Range 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise prices - Low</a></td>
<td class="nump">1.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise prices - High</a></td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">120,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance - Weighted average exercise price</a></td>
<td class="nump">$ 1.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares) | shares</a></td>
<td class="nump">120,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 1.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range3Member', window );">Range 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise prices - Low</a></td>
<td class="nump">2.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise prices - High</a></td>
<td class="nump">$ 2.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">83,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance - Weighted average exercise price</a></td>
<td class="nump">$ 2.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares) | shares</a></td>
<td class="nump">83,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range4Member', window );">Range 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise prices - Low</a></td>
<td class="nump">3.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise prices - High</a></td>
<td class="nump">$ 4.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">288,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance - Weighted average exercise price</a></td>
<td class="nump">$ 3.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares) | shares</a></td>
<td class="nump">268,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 3.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range5Member', window );">Range 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise prices - Low</a></td>
<td class="nump">5.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise prices - High</a></td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">261,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance - Weighted average exercise price</a></td>
<td class="nump">$ 6.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares) | shares</a></td>
<td class="nump">175,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range6Member', window );">Range 6</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise prices - Low</a></td>
<td class="nump">8.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise prices - High</a></td>
<td class="nump">$ 10.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">176,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance - Weighted average exercise price</a></td>
<td class="nump">$ 9.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares) | shares</a></td>
<td class="nump">99,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 9.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range7Member', window );">Range 7</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise prices - Low</a></td>
<td class="nump">10.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise prices - High</a></td>
<td class="nump">$ 13.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">129,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance - Weighted average exercise price</a></td>
<td class="nump">$ 11.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares) | shares</a></td>
<td class="nump">79,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 11.90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range8Member', window );">Range 8</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise prices - Low</a></td>
<td class="nump">13.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise prices - High</a></td>
<td class="nump">$ 17.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">1,126,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance - Weighted average exercise price</a></td>
<td class="nump">$ 17.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares) | shares</a></td>
<td class="nump">10,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 17.57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_TotalRangeMember', window );">Total Range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise prices - Low</a></td>
<td class="nump">1.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise prices - High</a></td>
<td class="nump">$ 17.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding (in shares) | shares</a></td>
<td class="nump">2,290,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years)</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance - Weighted average exercise price</a></td>
<td class="nump">$ 11.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable (in shares) | shares</a></td>
<td class="nump">938,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price</a></td>
<td class="nump">$ 4.98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range7Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range7Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range8Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_Range8Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_TotalRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=abus_TotalRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6832627520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Non-vested Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,230<span></span>
</td>
<td class="nump">441,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue', window );">Non-vested, beginning balance, weighted average fair value | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 9.30<span></span>
</td>
<td class="nump">$ 8.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,125,000<span></span>
</td>
<td class="nump">1,309,625<span></span>
</td>
<td class="nump">1,309,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 15.20<span></span>
</td>
<td class="nump">$ 11.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250,461)<span></span>
</td>
<td class="num">(250,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue', window );">Options vested | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 8.77<span></span>
</td>
<td class="nump">$ 6.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Non-vested options forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(148,853)<span></span>
</td>
<td class="num">(148,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Non-vested options forfeited | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 14.27<span></span>
</td>
<td class="nump">$ 11.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,351,541<span></span>
</td>
<td class="nump">1,351,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue', window );">Non-vested, ending balance, weighted average fair value | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 15.69<span></span>
</td>
<td class="nump">$ 11.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the share based compensation arrangement for the share based payment award for the fair value of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the share based compensation arrangement concerning the fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6818264320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Weighted Average Option Pricing Assumptions (Details) - Arbutus Plans<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.88%<span></span>
</td>
<td class="nump">101.08%<span></span>
</td>
<td class="nump">111.61%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.39%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected average option term</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section D<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abus_ArbutusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abus_ArbutusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6846843040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Outstanding Options Under the Protiva Option Plan (Details)<br></strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD / shares </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>CAD / shares </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>CAD / shares </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance - Number of optioned common shares (in shares)</a></td>
<td class="nump">2,519,831<span></span>
</td>
<td class="nump">2,519,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,519,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_ProtivaShareOptionsMember', window );">Protiva Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance - Number of optioned common shares (in shares)</a></td>
<td class="nump">67,000<span></span>
</td>
<td class="nump">67,000<span></span>
</td>
<td class="nump">433,740<span></span>
</td>
<td class="nump">433,740<span></span>
</td>
<td class="nump">472,885<span></span>
</td>
<td class="nump">472,885<span></span>
</td>
<td class="nump">67,000<span></span>
</td>
<td class="nump">433,740<span></span>
</td>
<td class="nump">472,885<span></span>
</td>
<td class="nump">475,885<span></span>
</td>
<td class="nump">475,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, Weighted average exercise price | (per share)</a></td>
<td class="nump">CAD 0.30<span></span>
</td>
<td class="nump">CAD 0.30<span></span>
</td>
<td class="nump">CAD 0.30<span></span>
</td>
<td class="nump">CAD 0.30<span></span>
</td>
<td class="nump">CAD 0.30<span></span>
</td>
<td class="nump">CAD 0.30<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">CAD 0.30<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(358,675)<span></span>
</td>
<td class="num">(358,675)<span></span>
</td>
<td class="num">(38,145)<span></span>
</td>
<td class="num">(38,145)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised - Weighted average exercise price | (per share)</a></td>
<td class="nump">CAD 0.30<span></span>
</td>
<td class="nump">CAD 0.23<span></span>
</td>
<td class="nump">CAD 0.30<span></span>
</td>
<td class="nump">CAD 0.27<span></span>
</td>
<td class="nump">CAD 0.30<span></span>
</td>
<td class="nump">CAD 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options forfeited, canceled or expired (in shares)</a></td>
<td class="num">(8,065)<span></span>
</td>
<td class="num">(8,065)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options forfeited, cancelled or expired - Weighted average exercise price | (per share)</a></td>
<td class="nump">CAD 0.30<span></span>
</td>
<td class="nump">CAD 0.23<span></span>
</td>
<td class="nump">CAD 0.30<span></span>
</td>
<td class="nump">CAD 0.27<span></span>
</td>
<td class="nump">CAD 0.30<span></span>
</td>
<td class="nump">CAD 0.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abus_EquivalentNumberOfCompanyCommonSharesMember', window );">Equivalent number of Company common shares | Protiva Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance - Number of optioned common shares (in shares)</a></td>
<td class="nump">45,236<span></span>
</td>
<td class="nump">45,236<span></span>
</td>
<td class="nump">292,845<span></span>
</td>
<td class="nump">292,845<span></span>
</td>
<td class="nump">319,274<span></span>
</td>
<td class="nump">319,274<span></span>
</td>
<td class="nump">45,236<span></span>
</td>
<td class="nump">292,845<span></span>
</td>
<td class="nump">319,274<span></span>
</td>
<td class="nump">321,299<span></span>
</td>
<td class="nump">321,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(242,164)<span></span>
</td>
<td class="num">(242,164)<span></span>
</td>
<td class="num">(25,754)<span></span>
</td>
<td class="num">(25,754)<span></span>
</td>
<td class="num">(1,350)<span></span>
</td>
<td class="num">(1,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options forfeited, canceled or expired (in shares)</a></td>
<td class="num">(5,445)<span></span>
</td>
<td class="num">(5,445)<span></span>
</td>
<td class="num">(675)<span></span>
</td>
<td class="num">(675)<span></span>
</td>
<td class="num">(675.00)<span></span>
</td>
<td class="num">(675.00)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abus_ProtivaShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abus_ProtivaShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_EquivalentNumberOfCompanyCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_EquivalentNumberOfCompanyCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6816503136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Outstanding Options Under the OnCore Option Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance - Number of optioned common shares (in shares)</a></td>
<td class="nump">2,519,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_OnCoreOptionPlanMember', window );">OnCore Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance - Number of optioned common shares (in shares)</a></td>
<td class="nump">183,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance - Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 0.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options forfeited, canceled or expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance - Number of optioned common shares (in shares)</a></td>
<td class="nump">183,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance - Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 0.57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abus_EquivalentNumberOfCompanyCommonSharesMember', window );">Equivalent number of Company common shares | OnCore Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance - Number of optioned common shares (in shares)</a></td>
<td class="nump">184,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options forfeited, canceled or expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance - Number of optioned common shares (in shares)</a></td>
<td class="nump">184,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abus_OnCoreOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abus_OnCoreOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_EquivalentNumberOfCompanyCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_EquivalentNumberOfCompanyCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6838864208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Non-vested Stock Option Activity OnCore Option Plan (Details)<br></strong></div></th>
<th class="th" colspan="2">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,230<span></span>
</td>
<td class="nump">441,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue', window );">Non-vested, beginning balance, weighted average fair value | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 9.30<span></span>
</td>
<td class="nump">$ 8.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250,461)<span></span>
</td>
<td class="num">(250,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue', window );">Options vested | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 8.77<span></span>
</td>
<td class="nump">$ 6.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Non-vested options forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(148,853)<span></span>
</td>
<td class="num">(148,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested, ending balance (in shares)</a></td>
<td class="nump">1,351,541<span></span>
</td>
<td class="nump">1,351,541<span></span>
</td>
<td class="nump">1,351,541<span></span>
</td>
<td class="nump">1,351,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue', window );">Non-vested, ending balance, weighted average fair value | (per share)</a></td>
<td class="nump">CAD 15.69<span></span>
</td>
<td class="nump">$ 11.34<span></span>
</td>
<td class="nump">CAD 15.69<span></span>
</td>
<td class="nump">$ 11.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_OnCoreOptionPlanMember', window );">OnCore Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested, beginning balance (in shares)</a></td>
<td class="nump">128,510<span></span>
</td>
<td class="nump">128,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue', window );">Non-vested, beginning balance, weighted average fair value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested (in shares)</a></td>
<td class="num">(32,128)<span></span>
</td>
<td class="num">(32,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue', window );">Options vested | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Non-vested options forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested, ending balance (in shares)</a></td>
<td class="nump">96,382<span></span>
</td>
<td class="nump">96,382<span></span>
</td>
<td class="nump">96,382<span></span>
</td>
<td class="nump">96,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue', window );">Non-vested, ending balance, weighted average fair value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abus_EquivalentNumberOfCompanyCommonSharesMember', window );">Equivalent number of Company common shares | OnCore Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested, beginning balance (in shares)</a></td>
<td class="nump">129,417<span></span>
</td>
<td class="nump">129,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested (in shares)</a></td>
<td class="num">(32,354)<span></span>
</td>
<td class="num">(32,354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Non-vested options forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested, ending balance (in shares)</a></td>
<td class="nump">97,063<span></span>
</td>
<td class="nump">97,063<span></span>
</td>
<td class="nump">97,063<span></span>
</td>
<td class="nump">97,063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the share based compensation arrangement for the share based payment award for the fair value of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the share based compensation arrangement concerning the fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abus_OnCoreOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abus_OnCoreOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_EquivalentNumberOfCompanyCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_EquivalentNumberOfCompanyCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6827931504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Location Of Expenses for Stock-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 22,093<span></span>
</td>
<td class="nump">$ 3,283<span></span>
</td>
<td class="nump">$ 903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research, development, collaborations and contracts expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">7,868<span></span>
</td>
<td class="nump">2,343<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 14,225<span></span>
</td>
<td class="nump">$ 940<span></span>
</td>
<td class="nump">$ 281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6593272704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Government Grants and Refundable Investment Tax Credits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems', window );"><strong>Government Grants and Refundable Investment Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contracts revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,309<span></span>
</td>
<td class="nump">$ 11,738<span></span>
</td>
<td class="nump">$ 10,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Revenue from government grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTaxCredit', window );">Investment tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_ISARICMember', window );">ISARIC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems', window );"><strong>Government Grants and Refundable Investment Tax Credits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contracts revenue</a></td>
<td class="nump">$ 1,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_GovernmentGrantsandRefundableInvestmentTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount deducted from an entities' taxes, reflecting a percentage of an amount invested in certain assets spread over the useful life of those assets; includes deferred investment tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_ISARICMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=abus_ISARICMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6845480560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 23, 2011 </div>
<div>CAD</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Canadian federal and provincial income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Scientific research and experimental development expenditures available for indefinite carry-forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,932<span></span>
</td>
<td class="nump">$ 6,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred tax assets, operating loss carryforwards, subject to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PatentTaxRefundPercentage', window );">Patent tax refund percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Income tax refund maximum from patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,494<span></span>
</td>
<td class="nump">37,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Income tax refund maximum from patents | CAD</a></td>
<td class="nump">CAD 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember', window );">Investment tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Investment tax credits available to reduce Canadian federal income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,969<span></span>
</td>
<td class="nump">7,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Investment tax credits available to reduce provincial income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,869<span></span>
</td>
<td class="nump">3,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Scientific research and experimental development expenditures available for indefinite carry-forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,823<span></span>
</td>
<td class="nump">49,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred tax assets, operating loss carryforwards, subject to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,745<span></span>
</td>
<td class="nump">25,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember', window );">Recast adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_PatentTaxRefundPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the patent tax refund percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_PatentTaxRefundPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_InvestmentCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6785147840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Computed taxes (recoveries) at Canadian federal and provincial tax rates</a></td>
<td class="num">$ (20,100)<span></span>
</td>
<td class="num">$ (10,097)<span></span>
</td>
<td class="num">$ (3,486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Differences due to change in enacted tax rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Permanent and other differences</a></td>
<td class="nump">8,113<span></span>
</td>
<td class="nump">3,498<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance - other</a></td>
<td class="nump">3,676<span></span>
</td>
<td class="nump">6,599<span></span>
</td>
<td class="nump">2,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Difference due to income taxed at foreign rates</a></td>
<td class="num">(7,874)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Deferred income tax recovery</a></td>
<td class="num">$ (16,185)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32059-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Subparagraph 1<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph h<br> -Subparagraph 2<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6827724336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ComponentsofDeferredTaxAssetsLineItems', window );"><strong>Components of Deferred Tax Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Non-capital loss carryforwards</a></td>
<td class="nump">$ 13,932<span></span>
</td>
<td class="nump">$ 6,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development deductions</a></td>
<td class="nump">13,474<span></span>
</td>
<td class="nump">14,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_DeferredTaxAssetBookAmortizationInExcessOfTax', window );">Book amortization in excess of tax</a></td>
<td class="nump">2,142<span></span>
</td>
<td class="nump">2,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share issue costs</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes', window );">Revenue recognized for tax purposes in excess of revenue recognized for accounting purposes</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">4,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements', window );">Tax value in excess of accounting value in lease inducements</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">In-process research and development</a></td>
<td class="num">(146,324)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_DeferredTaxAssetUpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(104,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(41,494)<span></span>
</td>
<td class="num">(37,818)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(146,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ComponentsofDeferredTaxAssetsLineItems', window );"><strong>Components of Deferred Tax Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investment tax credits</a></td>
<td class="nump">6,303<span></span>
</td>
<td class="nump">5,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ComponentsofDeferredTaxAssetsLineItems', window );"><strong>Components of Deferred Tax Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investment tax credits</a></td>
<td class="nump">$ 3,879<span></span>
</td>
<td class="nump">$ 3,322<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ComponentsofDeferredTaxAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ComponentsofDeferredTaxAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_DeferredTaxAssetBookAmortizationInExcessOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred tax asset book amortization in excess of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_DeferredTaxAssetBookAmortizationInExcessOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred tax asset revenue recognized for tax purpose in excess of revenue recognized for accounting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred tax asset tax value in excess of accounting value in lease inducements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_DeferredTaxAssetUpfrontLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Upfront License Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_DeferredTaxAssetUpfrontLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Liability<br> -URI http://asc.fasb.org/extlink&amp;oid=6510232<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Subparagraph b(2)<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences net of deferred tax asset attributable to deductible temporary differences and carryforwards after valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6816188400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies and Commitments - Minimum Rent and Estimated Operating Cost Commitment, Net Lease Inducements (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Year ended December 31, 2016</a></td>
<td class="nump">$ 1,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Year ended December 31, 2017</a></td>
<td class="nump">938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Year ended December 31, 2018</a></td>
<td class="nump">938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Year ended December 31, 2019</a></td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum rent and estimated operating cost commitment, net of lease inducements</a></td>
<td class="nump">$ 3,652<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6851495072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Commitments (Details)<br> CAD in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="2">53 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 16, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 29, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2014 </div>
<div>USD ($) </div>
<div>compound_series</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2004 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2004 </div>
<div>CAD</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD</div>
</th>
<th class="th">
<div>Jan. 11, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2014 </div>
<div>USD ($) </div>
<div>compound_series</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,133,000<span></span>
</td>
<td class="nump">$ 1,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PercentOfCostsFundedByTPC', window );">Percent of costs funded by TPC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_MaximumContributionForProduct', window );">Maximum contribution for product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,179,000<span></span>
</td>
<td class="nump">CAD 9,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_CumulativeContributionforProduct', window );">Cumulative contribution for product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,675,000<span></span>
</td>
<td class="nump">CAD 3,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyGuaranteesCommitmentsPercentage', window );">Royalty guarantees commitments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability', window );">Increase in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abus_OnCoreBiopharmaInc.Member', window );">OnCore | Enantigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Business combination, high end of payment upon achievement of certain triggering events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ProgramsInPreClinicalDevelopment', window );">Programs in pre-clinical development | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business combination, regulatory, development and sales milestone payments estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,727,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability', window );">Increase in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=abus_ArbitrationWithTheUniversityOfBritishColumbiaMember', window );">Arbitration with the University of British Columbia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought for allegedly unpaid royalties</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_MarinaBiotechInc.Member', window );">Marina</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_UpfrontFee', window );">Upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_ArcturusMember', window );">Arcturus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_BlumbergandDrexelMember', window );">Blumberg and Drexel | OnCore</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense', window );">Development and regulatory milestones payment per licensed compound series, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense', window );">Sales performance milestones payment per licensed product, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_Numberofseriesofcompounds', window );">Number of series of compounds | compound_series</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_BlumbergMember', window );">Blumberg | Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContractualObligationAmountOfResearchFundingPerYear', window );">Research funding per year under research collaboration and funding agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ResearchFundingPeriod', window );">Research funding period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ResearchFundingPeriodRenewableOption', window );">Research funding period, renewable option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment', window );">Research funding agreement exclusive license upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments', window );">Research funding agreement exclusive license maximum development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments', window );">Research funding agreement license maximum commercialization milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_NeuroViveMember', window );">NeuroVive | Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">License fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=abus_CytosMember', window );">Cytos | Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense', window );">Development and regulatory milestones payment per licensed compound series, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense', window );">Sales performance milestones payment per licensed product, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_Numberofseriesofcompounds', window );">Number of series of compounds | compound_series</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=abus_MarqiboMember', window );">Marqibo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyPayable', window );">Royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltiesPaidOrAccrued', window );">Royalties paid or accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 3,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ContingenciesandCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ContingenciesandCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ContractualObligationAmountOfResearchFundingPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligation Amount Of Research Funding Per Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ContractualObligationAmountOfResearchFundingPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_CumulativeContributionforProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the cumulative contribution for a product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_CumulativeContributionforProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Fair Value Of Contingent Consideration Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Maximum Development And Regulatory Milestone Payments Per License</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Maximum Sales Performance Milestone Payments Per License</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LicenseAgreementMaximumSalesPerformanceMilestonePaymentsPerLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_MaximumContributionForProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum contribution for the product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_MaximumContributionForProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents a milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_Numberofseriesofcompounds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of series of compounds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_Numberofseriesofcompounds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_PercentOfCostsFundedByTPC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percent of costs funded by TPC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_PercentOfCostsFundedByTPC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ProgramsInPreClinicalDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Programs In Pre-Clinical Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ProgramsInPreClinicalDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Funding Agreement Right To Obtain Exclusive License Maximum Commercialization Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumCommercializationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Funding Agreement Right To Obtain Exclusive License Maximum Development And Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ResearchFundingAgreementRightToObtainExclusiveLicenseMaximumDevelopmentAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Funding Agreement Right To Obtain Exclusive License Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ResearchFundingAgreementRightToObtainExclusiveLicenseUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ResearchFundingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Funding Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ResearchFundingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ResearchFundingPeriodRenewableOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Funding Period Renewable Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ResearchFundingPeriodRenewableOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltiesPaidOrAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of royalties paid or accrued of an entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltiesPaidOrAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyGuaranteesCommitmentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty guarantees commitments percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyGuaranteesCommitmentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_UpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_UpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abus_OnCoreBiopharmaInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abus_OnCoreBiopharmaInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abus_EnantigenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abus_EnantigenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=abus_ArbitrationWithTheUniversityOfBritishColumbiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=abus_ArbitrationWithTheUniversityOfBritishColumbiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_MarinaBiotechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_MarinaBiotechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_ArcturusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_ArcturusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_BlumbergandDrexelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_BlumbergandDrexelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_BlumbergMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_BlumbergMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abus_ArbutusInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abus_ArbutusInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_NeuroViveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_NeuroViveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=abus_CytosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=abus_CytosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=abus_MarqiboMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=abus_MarqiboMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6825984288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Concentrations of Business Risk (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">$ 1,008<span></span>
</td>
<td class="nump">$ 1,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6825764976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Concentrations of Business Risk - Net Liquidity of the Company (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 181,304<span></span>
</td>
<td class="nump">$ 112,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Less: Accounts payable and accrued liabilities</a></td>
<td class="num">(8,827)<span></span>
</td>
<td class="num">(9,328)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NetLiquidity', window );">Net liquidity</a></td>
<td class="nump">$ 172,477<span></span>
</td>
<td class="nump">$ 102,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NetLiquidity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net liquidity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NetLiquidity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Article 7<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Subparagraph 1, 5<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6832290240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Concentrations of Business Risk - Foreign Currency Exposure (Details)<br> CAD in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>CAD</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceLineItems', window );"><strong>Intercompany Foreign Currency Balance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments | $</a></td>
<td class="nump">$ 181,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable | $</a></td>
<td class="nump">1,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Accrued revenue | $</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued liabilities | $</a></td>
<td class="num">$ (8,827)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=abus_ForeignCurrencyExposureMember', window );">Foreign currency exposure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceLineItems', window );"><strong>Intercompany Foreign Currency Balance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 213,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 75,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledReceivablesCurrent', window );">Accrued revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,061)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,494)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ExposureToUSDollar', window );">Exposure to US dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 206,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">CAD 73,296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ExposureToUSDollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the exposure to U.S. Dollar.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ExposureToUSDollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Article 7<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 15<br> -Subparagraph 1, 5<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntercompanyForeignCurrencyBalanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntercompanyForeignCurrencyBalanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=abus_ForeignCurrencyExposureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=abus_ForeignCurrencyExposureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6786355504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplementary Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">$ 2,610<span></span>
</td>
<td class="nump">$ 2,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AccruedResearchandDevelopmentCurrent', window );">Research and development accruals</a></td>
<td class="nump">2,358<span></span>
</td>
<td class="nump">2,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AccruedLicenseFeeCurrent', window );">License fee accruals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fee accruals</a></td>
<td class="nump">640<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseIncentivePayableCurrent', window );">Deferred lease inducements</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AccruedPayrollCurrent', window );">Payroll accruals</a></td>
<td class="nump">2,331<span></span>
</td>
<td class="nump">2,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 8,827<span></span>
</td>
<td class="nump">$ 9,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_AccruedLicenseFeeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued License Fee, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_AccruedLicenseFeeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_AccruedPayrollCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Payroll, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_AccruedPayrollCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_AccruedResearchandDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_AccruedResearchandDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncentivePayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e40010-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e40019-112707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6584307&amp;loc=d3e41614-112719<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Lease Incentive<br> -URI http://asc.fasb.org/extlink&amp;oid=6516590<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncentivePayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6832247104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 12,686<span></span>
</td>
<td class="nump">$ 4,065<span></span>
</td>
<td class="nump">$ 3,440<span></span>
</td>
<td class="nump">$ 4,682<span></span>
</td>
<td class="nump">$ 4,350<span></span>
</td>
<td class="nump">$ 4,362<span></span>
</td>
<td class="nump">$ 1,811<span></span>
</td>
<td class="nump">$ 4,430<span></span>
</td>
<td class="nump">$ 24,873<span></span>
</td>
<td class="nump">$ 14,953<span></span>
</td>
<td class="nump">$ 15,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(11,758)<span></span>
</td>
<td class="num">(58,138)<span></span>
</td>
<td class="num">(14,420)<span></span>
</td>
<td class="num">(18,006)<span></span>
</td>
<td class="num">(10,747)<span></span>
</td>
<td class="num">(6,844)<span></span>
</td>
<td class="num">(9,423)<span></span>
</td>
<td class="num">(5,958)<span></span>
</td>
<td class="num">(102,322)<span></span>
</td>
<td class="num">(33,434)<span></span>
</td>
<td class="num">(12,152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,264)<span></span>
</td>
<td class="num">$ (28,982)<span></span>
</td>
<td class="num">$ (14,886)<span></span>
</td>
<td class="num">$ (11,989)<span></span>
</td>
<td class="num">$ (6,168)<span></span>
</td>
<td class="num">$ (8,604)<span></span>
</td>
<td class="num">$ (6,081)<span></span>
</td>
<td class="num">$ (17,984)<span></span>
</td>
<td class="num">$ (61,121)<span></span>
</td>
<td class="num">$ (38,837)<span></span>
</td>
<td class="num">$ (14,063)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in USD per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
<td class="num">$ (1.80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6833121824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Monsanto - PADCo. - Subsequent event<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 09, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, percentage of outstanding shares acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_OptionalExcercisedContractualOptionAmount', window );">Optional exercised contractual option, amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_OptionalExcercisedContractualOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of an option exercise that was embedded in a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_OptionalExcercisedContractualOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abus_MonsantoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abus_MonsantoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abus_PADCo.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abus_PADCo.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>96
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MU:#(ND21=8DBZ_)95C;]L_7R-U!+ P04    "  ;;FE(2'4%[L4    K @
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M.9*A2B55J>95*JDE'X8%>F-_[.<0)40\B3+TJ:0^-;Q/)16E5M;<^K4+WI>
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MLV& "BAIS_2K&+[!:&%C!7/!E/M%>:^TX'=*@#A]]VO3NG7P7_;A2%LGD)%
M)D*T_900CX3X04@^)20C(5D0L+?B#N)"-<U2*0:D.FIO1W0P<&E%C#(R[I4+
MW?GZ["V+2)CBFQ7Z@#EY#/&8"8&-^FH)\K'$B<SH9*W >8Z(5WNXS"';_;^;
MB!<^8\>/1Y__X2)9""1.(!D%%CY:[]1C=@[S91>&:Z#S')2$^\T:Z#('D61+
M%OWBV9_,059N6A3*1=]J?TI3=AK(9V(OR2)_,H/JY^HADZ4=K> 'E573*G05
MVEQ!=_M*(328[L*G38!J\Y1, 8-2V^W.[*6?+A]HT=W?BNG!ROX"4$L#!!0
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MM(&<&TBOP6KJRC@01=F7FW7;G!?=J1RFA[BU>#L$L9$7MO?=^',<W^GJZT8
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MG4YSIQ]]<WH[G+Z<D&_^ U!+ P04    "  ;;FE(A!+S>I\!  "Q P  &
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M;#S4%M&!-Y'=;2CI_?M9$@FM"^&#CTVZ4BEQ.)P>R/)*J_]02P,$%     @
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M"YX9SCESQI=RTN;#]@ .?4JA[ [WS@U;0FS=@V3V3@^@_)]6&\F<3TU'[&"
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M_F3CH3:(#KR)[.Z>DLZ_GSF1T+@0;GQLTI5*B</^]$#F5UK^!U!+ P04
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M/C;I2J7$X7!\(,LKK;X 4$L#!!0    ( !MN:4AMQN"[H@$  +$#   9
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MZ/S)QD-M$1UX$]G=AI+>OY\ED="Z$#[XV*0KE1*'P^F!+*^T^@]02P,$%
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M+Q^;=*52XK"?'LC\2LLO4$L#!!0    ( !MN:4@J_R*/H@$  +$#   9
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M/IQL.M06T4,PD3UL*>G#^UD3!:V/X><0V_E*S8G'X?Q UE=:_0=02P,$%
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MP@<?FW2E4N)P.#V0Y956_P%02P,$%     @ &VYI2%.QJ@JB 0  L0,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C N>&ULC5/!;N,@$/T5Q <4AZ2[;>18
M2EJM=@\K53VT9V*/;51@7,!Q]^\7L.,F4:3V8ICQ>V_>,) /:-]<"^#)AU;&
M;6CK?;=FS)4M:.%NL ,3_M1HM? AM USG051)9)6C&?9#Z:%-+3(4^[)%CGV
M7DD#3Y:X7FMA_^U X;"A"WI,/,NF]3'!BIS-O$IJ,$ZB(1;J#=TNUKM51"3
MBX3!G>Q)]+Y'?(O!GVI#LV@!%)0^*HBP'. !E(I"H?#[I/E9,A)/]T?U7ZG;
MX'XO'#R@>I65;X/9C)(*:M$K_XS#;YA:N(V")2J7OJ3LG4=]I%"BQ<>X2I/6
M8?S#[R?:=0*?"'PFW&7)^%@HV7P47A2YQ8&X3L39+=8!;J-(4";!FTMAZG[,
M'HHPKYP=HM 99C=B>,(L9@0+ZE=+\/,2.WY"YU_3EQ<.EXF^G!Q^H_[J0F"5
M!%:3 +_:XCEF>5&$G9RI!MNDJ^-(B;WQX^'-V?EV;GF:R2>\R#O1P%]A&VD<
MV:,/DTU#K1$]!!/9S2TE;7@_<Z"@]G'[,^SM>*7&P&-W?"#S*RW^ U!+ P04
M    "  ;;FE(5HR;5[P"  # "P  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6R-5MMNHS 0_17$!Q0\)K>*(#5=K78?5JKZL/OL)$Z""CAK.TWW[]<V
M"65<1_%+P.;,.6.8.9GR+.2;.G"NDX^VZ=0R/6A]?,PRM3GPEJD'<>2=>;(3
MLF7:+.4^4T?)V=8%M4T&>3[-6E9W:56ZO1=9E>*DF[KC+S)1I[9E\M^*-^*\
M3$EZW7BM]P=M-[*JS(:X;=WR3M6B2R3?+=,G\KB"PD(<XG?-SVITG]CDUT*\
MV<7/[3+-;0Z\X1MM*9BYO/-GWC26R2C_O9!^:MK \?V5_;L[KDE_S11_%LV?
M>JL/)ML\3;9\QTZ-?A7G'_QRAHDEW(A&N=]D<U):M->0-&G91W^M.W<]]T^F
M< D+!\ E (: >>X2[X5<FM^89E4IQ3E11V8_'GDT<&E)#'-B<E-NZ4[?[[Y7
MD!=E]FZ)$&;58\!AR(#(#'M0 K#$"D;A<#^<>AE2%TY[]<GB/D'A$12.H+@<
M<1(\(L9,[XM,/)$)(I@%13!F?E]DZHE,1P04@AI3I!'QMF:>QFQ,0/*@",9$
ME,3<$YDC@O!),(;>%UEX(@M$$"YMC)G<%R&YWT#Y^*,LP@V4(YF(\B)?^I0@
MBG"!>:"("B/@ZP"BN'$>!((\0L?O:D(1!0GK8%"$>1"_^0GJ;*!A'0PJ(G3\
M_B>HN2'L,AXHI@Y\"R"HP>%&'6!03!WX-D#&/4YF\[ .,@*(<!OB.P%!;4[#
M?N.!(@R'^&9 QIU.;KTW9 <THM[ MP,8MSJY\8>*0$ CO U\/P#4ZO2&#@9%
MV!OX?@#C5B_"=H P0"/*&GP[ -3I-/QY/%!$68-O!X Z_89=8U#AVULVFK!:
M+O=ND%3)1IPZW8]2P^XPK#ZYD2[[A%?ED>WY+R;W=:>2M=!FSG,CWDX(S4T6
M^8,QBX,9IX=%PW?:WL[,O>P'S'ZAQ?$Z+P]#>_4?4$L#!!0    ( !MN:4A"
MJ_DMV $  $4%   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;(U4S8Z;
M,!!^%8L'6!,"A$8$:;/5JCU46NVA/3MD^-':F+5-V+Y];1,(1DCT@CW#]S,C
M>YSV7'S("D"A+T8;>?(JI=HCQC*O@!'YQ%MH])^""T:4#D6)92N 7"V)41SX
M?HP9J1LO2VWN360I[Q2M&W@32':,$?'W#)3W)V_GC8GWNJR42> LQ1/O6C-H
M9,T;)* X><^[XSDQ" OX74,O9WMD:K]P_F&"G]>3YYL2@$*NC +1RPU>@%(C
MI(T_[YH/2T.<[T?U5]NMKOY")+QP^J>^JDH7ZWOH"@7IJ'KG_0^XMQ 9P9Q3
M:;\H[Z3B;*1XB)&O8:T;N_;#GWBDK1.".R&8"(EO"Q^,;)G?B2)9*GB/9$O,
MV>V.&BZ,B%9&NC9I0]O]D+UE0;A+\<T(.9CS@ DLYH' 6GW5(G MSL&,'FS3
M]XL*]Y:^']RC;]L"X4(@M +AO<5@M447L]\VB18FD2,0KIJXF&C;)%Z8Q(Y
MO&KB8@[;)H>%R<$12%9-7,Q_G$FR,$GF I&_:N)BEA</S^XY U':<98HYUVC
MA@L]9:<7XSFP<_* 9VE+2OA%1%DW$EVXTM-F!ZW@7($NPG_2AU;I-VT**!3*
M; ]Z+X8Q'P+%V_'1FE[.[!]02P,$%     @ &VYI2';,%6?6 0  104  !D
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MW)Q:*0LN1'KG4K3ND4X%A]KZ[;W;ZWAO8V%5=WZ%TU]!\0-02P,$%     @
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MFMC'-BIP/,!Q]_8#[+AQ%*F["9SC[^\(2#&B>;,=@"/O2FJ[3SKG^AVEMNI
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MG7\_<R*A<2'\YF.3KE1*'/:7!S*_TO(_4$L#!!0    ( !MN:4AF1'HAKP$
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M>S/>V[%PV)U>X?Q74/P'4$L#!!0    ( !MN:4@,\*K=I $  +$#   9
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M(J%S(7SPL4E7*B4.Q],#65YI_1]02P,$%     @ &VYI2.Y3O/2$ 0  -P,
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MB>_5Y,NV96/:B_WR&G8RMP!T M +8'17 #L!O GP74'<">)> .X+DDZ0/"M
MG0#=!+;XMEBFU"LB299R=O%$2_3YB^8*YSJ(BNRI^@HS-#MH9\\9C)(T..M
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M+EB;"SVT'_>I/?7=!P4[B.XV;N_KX1PT# 0_WXYU][/EXA]02P,$%     @
M&VYI2' K;-5E @  )P@  !D   !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
MC99=CZ(P%(;_"N%^AT+Y-$@R8#:[%YM,YF+WNFH5,D#9MNKLO]]^(!921V^D
M+>][SG.J[3&_$/K!:HRY\]FU/5N[->?#RO/8KL8=8B]DP+UX<R"T0UQ,Z=%C
M \5HKTQ=ZP4 Q%Z'FMXM<K7V1HN<G'C;]/B-.NS4=8C^*W%++FO7=Z\+[\VQ
MYG+!*W)O\NV;#O>L(;U#\6'MOOJK32852O"[P1=FC!W)OB7D0TY^[M<ND BX
MQ3LN(R#Q..,*MZT,)!+_'6/>4DJC.;Y&_ZZJ%?1;Q'!%VC_-GM<"%KC.'A_0
MJ>7OY/(#CR5$,N".M$Q].KL3XZ2[6ERG0Y_ZV?3J>=%O4C#:[(9@- 23P8^_
M-,#1 &^&\$M#.!K"A<'3I:B-V"".BIR2B\,&)'\=_DK(J0PB(CNB>J:F:G_U
MZKF ,,F]LPPTTY1:$RB-/RD\$=V:(IBG* /#'M@25*8" IMD8TKB]#$$7-0)
ME1^.=3X1(%P$"%6 < R0S2%[7:G6)$H3@<PJJF8BF%A%&U,4 C]ZS!LM>".3
M-P167JV)E<:JJ!XJ-G;%7<QX@1G/,'TK9FRD^ 9A:"6=B7P0@-2*.Y>E4?@8
M.5D@)S/DP(J<+)"MA56FR@<PA59D4P4C^,0FIPOB=$9LS5*F)G%T!W@F"J/(
MRCL303]XS)LM>+,9K_7[+C/CA*3VG:NR)\[C)KMW'C6N9]RG':9'U9B8LR.G
MGNL+:5J=>M]K(._CQ7HI>J)N8;<P13Z@(_Z%Z+'IF;,E7-SVZJ(_$,*QH ,O
MXGS5HFM/DQ8?N!PF8DQU(],33H9K6Y[^&Q3_ 5!+ P04    "  ;;FE(S[8'
M9AL"  "$!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R-5=N.FS 0
M_17$!ZRYFFQ$D#:7JGVHM-J']ME)G(#6QM1VPO;OZPLA#G*3O&#/<,[QF0&&
MLF?\4]08R^"+DE8LPEK*;@Z V-68(O'".MRJ.P?&*9(JY$<@.H[1WI H 4D4
M04!1TX95:7+OO"K929*FQ>\\$"=*$?^[Q(3UBS .+XF/YEA+G0!5"4;>OJ&X
M%0UK XX/B_ MGF^@1AC KP;WPMD'VON6L4\=_-@OPDA;P 3OI%9 :CGC%29$
M"ZF#_PR:UR,UT=U?U+^9:I7[+1)XQ<CO9B]K938*@ST^H!.1'ZS_CH<2<BVX
M8T28:[ ["<GHA1(&%'W9M6G-VML[LVB@^0G)0$A&0@SO$M*!D#Y+R 9"=B5D
M=PGY0,@G!&!K-YU;(XFJDK,^$!W2KU,\5W"N191RH-HE3&@>B,V>JS3+2W#6
M0C>8I<4D%A-#'V;E8N(1 90#KXWDUL8R<>B)]X"'B+6+2",?9.-"X.RQS732
MK=3PTZ%;\+% -A'(C$!F!=+76Y.M[87%%-9DD10^T,H%18]]Y!,?N>-CEGMM
M6 @TD**(O"Z>P*QSKU,'L?$C_EL+G-0"W9YFF;<8Z!Q19*_^GCX#6L,[9H'S
M[5',CV;JB6#'3JVTK]V8'0?K6Z*_W4E^I0:NG8]7F:KLT!'_1/S8M"+8,JDF
M@QD*!\8D5M:B%]6?6OT2QH#@@]3;0C?.3DD;2-9=9O[XXZG^ 5!+ P04
M"  ;;FE(R9,X)P "  "T!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6R5E=N.FS 0AE_%X@$6S"D'$:3-5E5[46FU%^VUDPP'K8VI[83MV]<VA 4W
M:LA-?.#_OYD!9YQU7+S+"D"A#T8;N?,JI=JM[\MC!8S()]Y"HY\47#"B]%*4
MOFP%D),U,>J'09#ZC-2-EV=V[U7D&3\K6C?P*I \,T;$GSU0WNT\[%TWWNJR
M4F;#SS-_])UJ!HVL>8,$%#OO&6_W.#82J_A90R<G<V22/W#^;A;?3SLO,#D
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M"F6F*ST7?5/M%XJWUSMBO*CROU!+ P04    "  ;;FE("5 #+MH"    "P
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MG?JKN>-<,!D;C.0&.<CC:-O(V4ZHVUC>5^:$9AJ"'R_GS?;0._L'4$L#!!0
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M  =)6K\9^5L%83 %&4!!DN4#<XO11_.".?BTP3!XP<1G)R6YYPN#2<A81A<
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M:VYN^(DQ"<J>MU)G5ZGI.P0$3E)O4[7G=B#90++V-EZ'&5_\!U!+ P04
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M4T:?9PR^KC FR-<W/*[@6OV.,<'^_,"88'^.CS$HN%B/L5+3O[,XJ:T@[ =
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MJ\Y/ZSQHA['N;_MQ'U;?Y@+(+'SK/%G,8F"@9YA0&/-B,O1"A&T(>!Q@Q[$
MPQZP)]R#%46$,0\FPS'BF^TEQIA'BT%+\MU"),H\V0S%F&>;01-_N5J:Y?6
M$Q.1D4>#F#,HK'? >@>*>#C@C@/>.^!#;V(GRF)(=6#4,$6,D1BCEA9%%8LP
M*K$HPD%XQ"R<F(69M,]82\>!-))6%,UY0.28C9 <S=FD&%"!IFQ"@G"?+BDG
M8&4&#-A3%LHL+,A(8M2]27$BT8 ?3(AQC@[%-\N3C-"@'BV("=33=QMRM]L
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MR:L2<C!W(P9K#)Y"+&U$BJ8@]S8DQ]D4YL'%Y&=,(@N9K 9[U6 MD!J!XK)
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M'YMTI5+B<+P\D/65UO\ 4$L#!!0    ( !MN:4A%T3@$]0(  (8-   9
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M==Z/GPEC0_+CY:OG^NFU_@M02P,$%     @ &VYI2#3E5,NB"0  %#\  !D
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M^]$I 295#)4,N1-N*X_[H-!'2GOV$8DQ'PO()!BS! SU,&8%&8(Q:\A0C-E
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M+W-H965T-38N>&ULC57+;N,@%/T5Y ^HWX]$CJ4Z4=59C%1U,;,F"8FM@O$
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MY9R9#FL6@O:W^V*ZM*I_4$L#!!0    ( !MN:4CCYI"Y_@,  &P5   9
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M/PP8V&$+)+?4N9!X(+;"8;&&T8$EEPQ3P[DBCGD6<;1L@369*VB\_PV(PBL
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M=V1,4I6(NJ !J-3?Q31IZ%'J8:;&W/9;.Y&LO_X^3/\PY7]02P,$%     @
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MZJ+^V#1E]V_.:GZ>QC"^/'BN=GLQ/$AFD^0:MZD:UO85;Z..;:?Q-_BX0ND
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M=0K><BZ8Y (/DFLO7X*N@YIMQ7!+!X7C:\$X$/QP><NYOFK-_@-02P,$%
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MR9;OV*E5C^+\C=L>\C'A1K32_$TV)ZE$=PE)DXZ]3M>F-]?S]$L);%@\ -D
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M.GVNFJ^F_EYT/W5U%U6^[7^YV_]\./T?4$L#!!0    ( !MN:4@#Q1<IG@$
M + #   9    >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;(53RV[;,!#\%8(?
M$%*27S%D 8V*H#T$"')HS[2ULHCPH9"TY?Q]^9!5VS"2B[B[G!G.DMIRT.;=
M=@ .G:10=H,[Y_HU(7;7@63V0?>@_$ZKC63.IV9/;&^ -9$D!<DI71#)N,)5
M&6NOIBKUP0FNX-4@>Y"2F<\G$'K8X R?"V]\W[E0(%5))E[#)2C+M4(&V@W^
MD:WK(B BX ^'P5[$*'C?:OT>DM_-!M-@ 03L7%!@?CE"#4($(7_PQZCY_\A
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M])V[&G(CN!*-M+_)ZB"5:,\A:=*RM^%:=_9Z&OXI@0N+!R 7@"X!"'X:@%T
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M*'-+33'#H3\,E-B?OV$N'U*SOU!+ P04    "  ;;FE(>0>]33D"  !Y!P
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M%:+6<*_SNOOT]M>ZT<5=XGM%^LM>L[*[WNPW,NQEN(#V CH(AGYP >L%[%/
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M^=JD'R@U3O?GZS#=R?H?4$L#!!0    ( !MN:4A3K0.BP,$  )_[ @ 4
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MH<:[M,R*=><IZ_WXW_[;?SN)YQ9CWL"'C9W7GY1Y6Y]]\Z\-Q"SRJMAF:X+
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M$^E<\TWQK.O+:#*.)[-^/%T,HDN@*BF]KY0%QAX.X_%H'@^FBX8X<K.&>PJ
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M=3GVD@39JXC%PP8<^:'/EV&[7CQ7@D7HKMP8>9%?DY51A'R 889P[09BE[Y
MX^)(QXI ;48$),X>6TTK=V]__OK]"^CP.JOVJH]?&B)QQ4I.I[V-K:CX/)F
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MA(]U96U"%[L/#5SN#G@TJ"6!$%V1-P!FVZ,< ,)8FI$=4["#M",<F/E.)^@
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M)"86M<O0Q^W27VCK''VJAE0+-1+^ZC?K_5'M^7P;Y3K$3IM!M-3JDH<B%I"
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M7JS0DG'I"-80"-:XC\@ D-\6E52>^\DE61*\2'2"2T\09#O C>^:>JM=4\G
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MPQI]L:]\A2I7_D'@4\9MH8050, '$Y(]/6B 2/2_\*E09NGJMA1!E%(9,:Y
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MO?3"S1J+RR.39EP&A'KS^H9[W(M!8IM*<<)W!/Y!]'#<P1JJ9),>,(Q8EGI
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M#M:F-1-*?P[=YZR8VG'.F"0ISF;%?Q_?<WC><S0>7X#X[X@%V:]% NU8_9^
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MB&K  1*TE0K\6->2N8V6MTC6OQPKJ8-!(T@=ZI7KFA+X)Z1V*/9\E\ZP<?@
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M%?6FV9T*X&7I%O^6=!3F<[N@>TNW#2 ;I?O,PJ*Z%'IN00](J+1E=B6>='5
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MM9?]8/?/Q;TV5'N.^O^\3M>9=5MCN9RS5B[M^E-$LZ[,H]'.@R!%@[9$P91
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M]V:&P?E/HOH0]SJM=1HBB+[.M?7*I.ET\?1YX$Y6BV-!:(TZ 7D>6;%G%>.
M\2%T^^YFE#O,/@-#;IL^2==I@RF&H3T>1*%%4.G:+DM^0;$VJ[F$67C1PR[N
M"[4>#(!2B+_W]YNU!<YP6!J][*7 O33>8V5.G49X32 QC9:Z2.PN7>B7X')P
MQQ#@+T<+C,1.,V9"%'^,:K=O'IRT8L,^"6)^O[P@L!K8T(B?/!9JHNP>\:B3
M+/Z<;F%AS2C>2FR73MA1L?XF5M 8C%PZI+>Y>@'SR+UDWYKT[U?=7'%L\/%!
M[X'<;!<&Y]KS>2<B*BA56 J76+7=A%\QP^<S&'\^S%N*@IBNE+W1FK*=?\,T
M[A37\%5O8"]:B,@9S?/_O#%9_AC-<,NP"AX^A46 :&3UG^?B<6S"$CK726(0
MGLM3^B \'H/]&4P?;GR]YU3X9":"62(CB:0&('[OK<3Q6J A%:XN37S)BC49
M-#F>.!KHC8W[E)[C(0V*Z\K6+J?\0H[F$,(7#'.YLTD;]AV>_&PHOH980%5#
MGK_ELDWKA?4';&OOGB>NM$G7UA9"&@LNF*^.&G3*V4X$H.8)%8#Y3JNGP!L\
MC,:6/3*V>I? KE/]E%Y8[\[3K_-VP%\%&W"&'Z^0W7JKG3>*3/D#%Q9GXLA)
MQE$@R+*_K(CM'UTJ0W*@ZG!M:?Z7.]?KRB!CW4C)MP1R?>*J!HBCOE2MT(P]
M"N2#SW*J$X?,8NADXP2R+5./L*G>.C4NH=\SR5ELB,T+\C([HUF^$/[@1)$W
MAO&_1\;?0VBO5IPTWD!&]XHME5O3!MRMK)<B;SK1T030($!: [VTX?PUN" 6
MN$-[4;4X9X?,VH#-M[$,(S;\Y:ZA30 G="G;/+O&^C0RB13ZQ8,!1A94 9%_
MC5QPD9"K. ^;;8,U%[&::<]KZPQ"IZ,%TW2X!O7.G #^(U2BU.TGS4[3ID<;
MC*N];+TL_J*&W=QBM+*PKK 6-/Y<4$]!7XKK>O^Y%@-O)'LJ14V9%9-3T8:?
MJ==?6_W^QE!\ZOP"_B0Y*SK!-MK=B(*O$;S,?Y@]T]:UCB?EX6'%&OOLBXBT
MU-K36G;JG-M"-$VRH7N]M@$@K)#"D/<KX^4RLOK:66N.SX],\NX@8LO5[#/Y
M9GE2#9G9%?YI6*P) D<%)-$JT5UF%O8+^VZ]ZH@MX[0J#E4:(2LWB% 77,?A
M D.F+ZB>#EN:)(3%SV!2>916I>=B'ZPCA-@6"4033T(0&=Y7?]"B>O^PVCS6
M<O0X[1>#/?Q:V*(G4L$F"IM$J+I(4EN/WF<'8'5>99>A>-[=[D V9#T8=^6]
M#%2ZZ1*: 5W@Y=DP9*,):F$#HBT)AK4>+ZCH$QF-,*/8>4$;ID<1 2RR(KK?
MO$&A:DSJ#A]D7@?;\X<@E"IXVEY"$9-H'UCF\&RL'0PPGSB$R B H7T$=F4N
MMB"B&,=;9)&/"/ :YRE'RO@VY6LC0XFQBS^\JU>$1N%.4U.[N-R)[S=2.R$=
M+^UPS<3,0/E>_A!T>U;QN:D*J@3!R-CSQ+%F!AP\[&;@AX!>[IIYAZW#]EQM
M&LS,>*/\8[.-; -E,MJ E9FNF<2J<O (I8_7%ZH(G GK()>96G[QB*D91'"(
MW"NQ8]#28SW;J,ZFAVX>(P3.1_SE80E,PSF(U1:YNF*R63N'N6L<QFKD+KDS
MLB0Z\]NS5W$0+!ORB!BA\]OUVB,LTRW2F=4C&5#X9D=GY0>:H&&47^ZM2>X3
M#V%0$I6'M>D;U(W=E;W4#:6:I,H@U!"PV:JV)E>5=K\Y$QOC:\I):MX.% !I
MBR+LYA=C+]/LQ2I'03*U<UG-#D#+@?&QM?3VL.0(F\U:QTKA\U2:5&RJT7Q^
MC+_^(N&1%+NA\.I$MH V.:VIGQ9'NY@;ND]CLQ# !@^/G*U+%_VCJR\Y: (4
M-W)9OULX8B3;V%F;P&K\'@^8\6ZIMJHO$V_#3$AI4*[P ,P,4[:X<-/:1A);
M $#<:HI0Y/ESS(3>(>L+VBF+)Q?O\AR[H1=+"=[JKA/M<LG6H?H?N;8F^]JL
M2)# SC)82S:] X#1APQ%8Z:Q5FM .(&'[=+DUE^(.,'9U 1M(/<EE#G\;6IN
MJ0LAIQ/QY\/BEA?[4FKB*:E4!<.(L0@3..8SC/*<V=@BQ&(CTT7\R843"$5@
M=E]LL(=56&A+_/5,\(AP-9B7V0$_8U[M6!,>,/?""XRE0Y=MLK)U:&Z7<-0/
M$E!S00XI'VYKZ<=>:O.SL7[,G 7H>H-EVT0JM,@/!@U&3IO50%Q8C792.[@'
M5]MIUN HKI)H[,'FF)7]YP%8-XR?#89\KW<*5C#$FJMOQ8"0+M@1-O&NCS$S
MD#ALHE'=-NYJ.:?O4R#1T<I>$CDB@A?''G$DIRWOZ*6(H^Y@(__VS0"9CF\'
M2G>_)(-4PI% > B8)5V[<CPS:^WV7QE*P?.:*X<XT,_->H-AD%'/^['VV2LR
M.4G6/_Z;<YQF\H&9DSH$P<W5[% 0ZN^1,1'#9X"WLU>7[U^<NVB*G7Q/))_B
M23>+I0[DFRTVA&\:ELF5-7>Q4 YDG __1\XKHA=AS79*^SI@^2-"7),2AYE-
M7A-3'\-Q,+NR2IZ9A0HPY- *]U)*X+"0NC.+5&#[75.=4"<-$&*B!-VK^G<J
M$(EX*JW 4LIEOZJOMV0X<U9%7%$ST,OW'^F;BWZ9FSB(LP^;!Z!RDZH\?PZ2
MF L5P:/V@T-'PG>K/70V"_?A&UV+$._MX4&XY ,F4J#]P;RL;]_/_D7A.RQK
M>*BFXH=7-A+Z0%M*8/-Q*VL+=(.13Q*6X,>'!%$+++I9G\CWEY=O>W:09<9U
MT7>,.0//S25MDJUCO%?V563W;[P@9PI.8HL-B=!52]Q0U$@E;-LU(8POB_A%
MYUH'I[GT1(%?@2\61H[,J%*Z; 7)U?9,XFK=P*F'O6,W-"6$$ALA?'EG.!57
M](0-MH=KD!9=CA *I@+]1,)3 [ !#02PAKY-=YHHPTQF%S3:$"()'6X] <.S
M]BHGQEU,:F@NA"VPAO>0S+Q.2Z7+XK#-V=6>N"W#"[Q*MI#XE5,0W>7I#^'R
MO">)]>;1R%N7OLBO[M+%6U8*+PF?1;(^U(6Q:.3F1M#UN!<Q$PZE9S%GE!>Q
MW(M>:8-!?9UU'U4MX[:GF1T<OM3FH"D(5X6=9M1<"@M&UJ!9.%IX#+:BCX8H
MP93+[?QPO]MS9(\DVRUW^WJA"'EST+DH,S?97]:@]N22[LG4E4ZX&"/N?1I&
M?<G2B+"^>M2+A.XTUQ537L?K&]1)&>6B 'V_\7T<GG+E1K8&L6 6D=;'H0CJ
M.*$UU)U+6R"X<:IH\2G07H:VOZL;+-;>2'-UO^,[S;JF.1D/>"7WQBD2=?+0
MNWR/#5_1$%7?R />&J\7=JK+J'VE:<E[S24A,/8F21:JB_XTM[&61-*O7 0X
M7J@K*SZ>7;Z_RD;]T3D/V$HU2XZ$6)N2]B#9 _TP/CB#TJ[LY__.\9S. 4]X
M9Q3*Q9: >S+]\O?V-=@!.061O=%CKU^]>Y\U2E;"I65J!@/M.#&<#LS!VCD4
MH^>[$L:V*EI&EX%79NA>^*YN8)VI3BE[@8)I["NU!P0$[[W,8'@QB/>97>!L
MT,Y"O/SBP^-#;:)-%OHS.V>#H+15F^*(DB7Q>E-9#%R;L@V6N+A,$MHW&.K>
M><]O..8,+ML]%7="BKMC5Y+DK>$1L6=JR6G$'/$?(GKYW@ ;_L3^'QH5*WX[
M<5[1AROQ).EZ6"Q-X6#T6 *Z%E*5:XN[>E:<!TR+6#Q"HI$#MZF*N[HZ?\"W
MGI5A!RYK37)O/^F8.$?9R=W'' MV!B]OR!"MR4",-XI$$3&X/-PBASTF)E2=
MZ8&]:.?/Q>4YLUJBJZ;V4NH%D#,N06 _,HT3@F3K$QF1#'?!89+CGN$]M[?'
MPM=]!0\:G\*#)EA\9N\<N([Z$]M!:2^1G&C1VAMKP%EZ&#6QV>P2)791 FRX
M*%(BI*=.N7UOXP.X#F]UZ2Y/4WKO^-A%]CTEN,.YF*/EY,P2K!((5M7'P^!J
M6.+FVKQ%6B\2G>#2TPJR&>%2K)98<9FSKQF9T7^3)UPVF([X7#5%%3XAJ+X>
M["_+A[NE>ZW)W+2)EWL3.ZQBZT&^AZFZ&=1N!C/7U=R; 8,!S&6MA-F9T1I_
MQ,UFLR?_U<(N',%THU:GJ!,\B7/*;;B%Y/.;$&6;*6ONBA)J%A8RD:36:"U>
M9^TXPPMHD; %>X.^.@]H9BC\T? 8 \(5J$M?O=$I5V^<V] +[Q4&38ZKG)K/
M]JK(6+O<]H]5Y$ZNU?>!$EN#2GUBT-"^;&TO%VSGPW9K$2J:/9"GW)0&SO9<
MTMCD,VAUR*E GHLX'@5B+4HGC,S46%E((8Z&\=\5#I!U=V9AQ.=<+_]ZJ%W@
MI\-;):0-U\]SB\9N@-T-ZG@8;B6KFR[<\BPK1J-\/)X2XA_^[S[Y_EBI$2P)
M.RR']E'Y\X.N/%+T\_ZX[YKPGUQ[%EXU+?+!N-(OET^432NS;D'7;#(9R,^K
M!.ZL;3S.J^E8?KZ*(?&:AN9_'IQZ5SZ8].V_71>_ZK+XXS(O)F/U+OG@Z-+O
MLL$TGZJ5DS_MPA;0T:C0"RN?'%G88=Z?3NV_3UHOKXN@NI +>?3]8BGW1>1Z
M9QZ.USS58_.FFS<\MVM @>).SI)GA /\XGPQNX,S1,BWKZ*#US5BO>:O34#1
MF4%4.4\O@8V-MPH!Q>QYHZ:J6]YX_RNRSWC<Y8!+7Q=8^IKWZ*S()T.NKSS(
MAU3W^6Q0<%7J(5S :5MWE6UD.NOG99^K*\.O [J;9]5P*-WA<6CI;F@;27>#
M@51^'N2#2LHW#^47N/*=CU0*DOJW.V*I-W8\<JBPO5:A9]VF\Q4' Y<>B#U5
MBQ^/\10PG<2!<%A28+.$OKT:FEXP$WIO-I^[@OC&(14[)<]HT>?_=;#=0-2:
MW]6+ QM#KJ-UT,/ '!VAU.7XLTE5Q*4YC;\1 '3:.Y\35 -V]A@]C7R4B+80
MO?H16 VMY'.O6/RHR(NR:-2"1P($U&V$9>=?UA@YO^8G?^F:85@-\VI4YH,2
MWE[DH_X@+P8C%/8'_3(? =/G<O/M4^0R\H9T<4%Y*4&/=-4D+GY-)\V=DP*W
M7@595[<Z64CXK5=(."69ZV.&VA<G=FAZD*RGV.F$'>[O9UM;Y:I9:87?EGQ#
MNJ+RE4<:,6(7/].[+?P<5PU/N 1SXOD:C(M\.!S$V\>#/EU$X30O1V7D45N;
MR*]P[T7SXK%&&CR8%/FT*K/7&E+4$!^36QP$Y&/1AQJGB0(F= +'^"V6-%TN
M8LE1TEU1C(RBYI56F:2PU8MJ# _8_.8FO.( !/=1-76 I@7<J"&*P5WKM "[
M'])Y_XG&B5A!)E_5:\:%"^#@,N<ZCR8ON,"R,QI(?PH-65)-'RJ[ 6UWX0C<
MJ]FFV!WH^.BID-$:Q_E?7_S1%GS%T%)SRZQ RK>/^/1SA=3\][_]]^SJ<0Y=
MWF%^)-V&:8Z%T?TVK^_O#\!&?]@L!(TQ*R9 +ON#1KM+*73]>GVWO%Y2P\$H
MKP;-_N;S^<L?+[/W: 7!.X\=#K##4G;+-7]FSEBP.S3)1PX1^20%DNF4^?XT
M5]#^"40L+H=DK;+C3-;_R-#N9PN+5P7/LA,:90A7"GAG8R6H5"[9W&Q8<!>"
M^1Q)@NWY4KR)[[RX:G3'J94A,SA*@CH:)?2@DY?@A [)6\CU4<ZSMV:\;VF\
MC@(:1>6;443;83?J6*(0C))&FDYB?ZW4DFTB[51S,LU'PQ(8P!3$[I"&#H?Y
M9#0$&1T_?CI%Q9&<1%XG0%ZK? Q2T#GJBM,I+D5G@BNCIB=&545]G$Z$@S-0
MV$QJ>Y";W23#%D*])76GA$[B,NS$.GZT%+@?,"^RS.]WV<^'V79/TM<[\K2A
MV? 5XJ<7_8N?&PG'(A3S(%U9IY(G'8GY6*HTW^/3%5(A5G6%<6EI!PTEN2UX
M?\.B4TU2_")"8BG4,B,[K!=TGPQ'Y4UN?<0Y*EV.G9]S0L@L,XVZSZ I FQI
MKF3C0N8:9)D?X"R"Y T^BU8:&UPSBSUG\&5KG9?!=AA81#P@2=D%Y=G(#&N?
MYQH!7"&@5>LG1>NM76*]L-]O4=<R_M1G65GEDS$:=$#'FH)L3%G5.I*.XK&*
M_C0?3) VG V+O#]!8Y!5W,Y&X[PJB)0,008@6O(B4"(;."VL"$V,(@14NU5#
M"9<+E5+\PN[G$[221@YN'G9J?2BQ[8IK**U"%U*\_YLDKB$HP*$\?.5A0.;*
MXXX[^L9B[UXZ@. N:F8C< 6)4H!'3.^;>^]36+_V?9V\1)C^C;5#[K[EFY\G
MKE[3Q.&OH8=AO<M>;EX2$#N9YT85>1^J/JJ(TWS2']EBB02%#HRZ'&9X[=C1
M\N*']X3K3?)'/JZ*;%B.LI=+=.C.LK,:A)I\4O:S8<'M62!X]^/ELA%M?W9[
M;NWZTX$<CZ[ H/Z$BD$^ /9?P'C@4A?]O((AOSD)H-M-V@?V9I!Z^ZAMCDN#
MENGA*"MA%=A7<KE:/ZYF7(;U<GY8[N&:=NQN#MW!,@_[:*WN]^V">H_+\O:!
M4A8#]K^\Q^"9[>$^G-#9S3G0UWY63/M99;QBIZ&6XXH.X8 ,\A(&!P.S_6R3
M)/P9FK:JT;#M*MI$]-9=E7=TMBCR93NI[^<1]A4Z)-Q](9OV .Z7/2T6L%]2
M3O%<X+Y4>5D-[2X&K6 ?)[B+>5D63N*54>5!^\EH LN/?E-W3"T:8//5DWPT
M<C<RT@Y>7A;T\G$A^QD :3ZC*U_P=HZ+4:O5W4%^=B'$W8JCA1MSA3&"EXG"
M>B007&\V?Q&7QIO9M5*8T <T+=@1!;>5&3^Z+,M4M;DJ'\'L04TI)JA75-/2
M6=I!A%A\GHDM?;>YV=,?98YG!?29BD25(2@S":O[ &CMV:"/.@SJ(44)8\-?
MSJ9 :Z?B-P,^'#F*7[D&_;(@[UE>#=G0/1SW4RLPS$M>@?$4I:MJ,CR^ B40
M<EB!(8EHXW[2[S  HG*&/\Z- QG68#@E::S(BRDO I#S43\X223 78GO)'G>
M%!" !^UPZ<#-,8Q.MQ/P\>P2LY6S?WN#'IW7H(;M_EO;:1:_JLGF""J;GFB>
M;G;7#5+0@ E66=,>+3J7E#?0Z;K:)QPX,VPK5M7.KIZ='V_T\3VT>D<^994_
M:,I54Q_I;^GAX!4N!5+7,?#\8I>W(!W=4A <M !!%T1_/O_TQI:OZ94O. $X
MC_BU"[S1<"4G2"QZTS[],X:;6O9&?6,^Z V&^(%( /@!"F*],=VWT8#]S^5T
MDGUGO?=GHP)DYS'>D4$/Y)82/3&V3^JQQ!_\%\CBR3$":YY.0 C!QZ?XU&C<
MVE'10SXR!6E\F ^J@1Y3,<G'0[3@P&@F\*,<!CU!!_@7?%RFAS3,!N-I/NSS
M:DV'] \&"40633I\QEWV>Q.Z]&6!BS<9AZ98?>V:)\5/OF;?QX7)P=:EJSDW
M#1- \)ZIJB:QF_MUK^%X^<BK.,W1.GP9[LU<1@5)&E7RW&7W>WDN7O6X6O!R
MB3&6\.3C$C%$<-U_)S^_,]G"*B^[FO: 2_T.I)1>6<*_[Q+YS_T><-/?P<&"
M#5<]F>4BP</<U'YO)&2LWQO*;XE0%[T&>#P&)%C217$7.A'@XC_+P5P< O*C
M==%&&YN#*W>J[?AI#UM(JXTS[BW<D3!ENONC:L#<GL1:3=Z_(>'^K>@HVI]'
MU22?5".,%.H-*_=/"7I;7_XMLI_DZA#6$ RW'/>)MHU[PQ)^#/JV1:WH5HFB
M]HAH*9S4 =*:(4@W0R QICDL[DV-N=4YEGR9URO."!.D$*#'%<BZ)(X!@1SC
MS[*%Z")C& _Z()P,81X5_AC ^/(^#' $NN\HF$@U0!\LJ'>#WFB QWA0Q:8R
M*D&5'*(_OT)Z6/6*"70[&F*W4]7ML>E,28,$#:-7XN)5+=2Z@KD,82X%Z,TC
MI-:C7HF^@'P(.EV!JF@5S*9 93L?P7Q^_.=+:-L;CF.SH5LTQ;B)(1+Z00]^
MA^6!]07>,^D^FV((+*&/(G4QI<$-D6>V\!\40^'@C%@7[;%.6N#A0.XR&.,Q
MG$ZK%D>?[S_7) +S7_S+0^+DB4*?9VOF9 !JMVEY<Y03.) :CVX\MXNK>P@?
M;^P:#3-L966V[Z(R6Y-&^2]]BD37C5Z%[]73Z-;',^!;$UQW^&4PSHI^F4_@
MZE0]5$7(+FP^DC^A'5Q0?@#$I*+L@R WA!,.O_= ZS8?T!\@X8 H@XU!'IQD
MDP'=2Q"*X/_AR/T-OS\;8._8M.J!2E9.)OD4Q*5A#R2\WJ3*RA%\@*RIA^QL
MV -=%AL#983&HP+(PP!N^ABN+W#*8CS,"Z"[HQZJE1,T=-.(^SVXS<48+B'0
ML FTGJ(<-IV2CCOEZ0&/GG)K$-+@LI73O()) "G!.P17&'AD.>0_^M2JXJ$4
M8Z0#2.>@?UB!*3XQ[H&HB6'9??H#&J@5I[_=91WSHM-%G0XF2&*)44PG;8P8
M/8T8PUPOXCPY2 G07O.F\G6L,Y$=#4:TN\0WK?%G<H^6?HS?Z;Q=R3MQOJX;
M\!UQ$XK0CRJK*J"MM,[3'OTS06Z1)OA 3H&EP![!@3&MI/\SX-1Y-2J([XSQ
M) *-5^_?-,D]!M:!5#!$#E%4O7*,_1:C(V-&4_0 . *&[!)Y'\FI&80$O4U=
MD)T]67+OI"0\M?- H.]F[&\1[=,"_GB$! PD]S[=2/@%%A&V+RWJ%TAU?L>J
M(?X#Y"$B\<O<2? ?6S%_ @22?YL:):!MN[1K6-AQ!"@TMA>,$)AZ@K*.!!W8
M+W[TK8I$G;AUIOI'KIT=>;OMV@:68$ U6H9)?JY0S $),ON^7M>8><J!0(@M
M1J5<EY]4Y80"9&;8Q6F%K*:PB1T@?_:G S(_EJ0V3?M!0+P!\.?K3_)&VTX>
M(<='C/E:DK!XJU;FB0Q%DU7_ZQU9J3D[1L7J6IBYWTJM:M&+0%  >7B8#4J@
MPI35TD<JW$]H.J6(]6=( ?$7:5U.N\O2IHO1>.AUT*+L5..21UD YQ]7D;=J
MH7^2%Q4%YY1#T&4J]9+QUXYRW*;&5 ,T[,-QGL)H803A6_4HAY.<^SXK*W0#
MZ'$..H]SDO<Y$&F85]70ZZ)%/1F-:7K5$#COR.PY_E,&GG")JFZY:H$X$S[R
M^V\@UTA0$$5FZ$@8D.-.D'.\L7W=?3PBZ?C1244YR=$=;819S$+4<HZ18 9P
M%$JTRN)O SJ\W+!5C#$^;%2&C\DNTQ&HOB#>CBFC0,;Q36EBN/^_T0ZT$[O&
M!J"J@Z[H294/!B6=]JC10*]EQUNH'VFY=?$A)&I0?2 $_BZ^3)?IW8"G)P%C
M/0=9*RJJN#("V9E S#^>6V#>3UPXQP7@:7P>"^_ F3,UH_ Z0(S:58:WM21N
MZH65"2BIP,2\^6.&"96CWP%11(IZ0;__@9D QO;@G^<FU(\"JJYK+!S?J%M
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M#'KC\"R\3B(?ZBT*)8$  4N!Z.4*@2<T*QQYU!19:[LV<-3>PXV8P=,Y!7'
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M72YX;6Q02P$"% ,4    "  ;;FE(2'4%[L4    K @  "P
M@ %< @  7W)E;',O+G)E;'-02P$"% ,4    "  ;;FE('[(B'U8"  !5*P
M&@              @ %* P  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    "  ;;FE(?*I[W,T#  ".$0  $               @ '8!0
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !MN:4B L^](/P$  &D#   1
M              "  =,)  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M !MN:4B97)PC$ 8  )PG   3              "  4$+  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ &VYI2".'1/QZ @  0@T   T
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M2P$"% ,4    "  ;;FE(_7)_P<4!  #,!   &               @ '6(
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ &VYI2/?Z2<FD
M!   3Q8  !@              ( !T2(  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( !MN:4BTLE(8(P4  $L9   8              "
M :LG  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  ;;FE(
M+^DZ_MP!  "\!   &               @ $$+0  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ &VYI2!RM9,6M!0  +1\  !@
M     ( !%B\  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M !MN:4B$$O-ZGP$  +$#   8              "  ?DT  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    "  ;;FE(AIXW,*(!  "Q P  &
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M970Q,RYX;6Q02P$"% ,4    "  ;;FE(2Z*50J,!  "Q P  &0
M    @ $)0   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M !MN:4C="LI)H@$  +$#   9              "  >-!  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ &VYI2&W&X+NB 0  L0,  !D
M             ( !O$,  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    "  ;;FE(G1<$?*$!  "Q P  &0              @ &510  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !MN:4@J_R*/H@$
M +$#   9              "  6U'  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ &VYI2%"=KN&C 0  L0,  !D              ( !
M1DD  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  ;;FE(
M4[&J"J(!  "Q P  &0              @ $@2P  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( !MN:4A6C)M7O (  , +   9
M      "  ?E,  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ &VYI2$*K^2W8 0  104  !D              ( ![$\  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  ;;FE(=LP59]8!  !%!0
M&0              @ '[40  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( !MN:4A?V(_YK $  !8$   9              "  0A4  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ &VYI2)@5*?6C
M 0  L0,  !D              ( !ZU4  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    "  ;;FE(VD)8]#D"  !7"   &0
M@ '%5P  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( !MN
M:4@&2Y::L $  !8$   9              "  35:  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ &VYI2.H"TM:C 0  L0,  !D
M         ( !'%P  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    "  ;;FE(9D1Z(:\!   6!   &0              @ 'V70  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !MN:4@,\*K=I $  +$#
M   9              "  =Q?  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ &VYI2$OC#*FD 0  L0,  !D              ( !MV$
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  ;;FE([E.\
M](0!   W P  &0              @ &28P  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( !MN:4AG*LF+5 (  +L'   9
M  "  4UE  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M&VYI2-8?X#\A P  9PX  !D              ( !V&<  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    "  ;;FE(<"MLU64"   G"   &0
M            @ $P:P  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( !MN:4C/M@=F&P(  (0&   9              "  <QM  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ &VYI2,F3."<  @
MM 8  !D              ( !'G   'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    "  ;;FE("5 #+MH"    "P  &0              @ %5
M<@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( !MN:4A>
M"AI\X@8  (4J   9              "  69U  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ &VYI2$T(]Z 6 P  N0T  !D
M     ( !?WP  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M"  ;;FE(P)0#&R\"  #E!P  &0              @ ',?P  >&PO=V]R:W-H
M965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !MN:4BA!X-NI0,  ,L2   9
M              "  3*"  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L!
M A0#%     @ &VYI2,FJ_.@; @  [P4  !D              ( !#H8  'AL
M+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  ;;FE(!DKR6S4"
M  !2"   &0              @ %@B   >&PO=V]R:W-H965T<R]S:&5E=#0T
M+GAM;%!+ 0(4 Q0    ( !MN:4C#HZ)HGP8  +\H   9              "
M <R*  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ &VYI
M2(H$)F@N!   514  !D              ( !HI$  'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    "  ;;FE(#P;IG*,"   1"P  &0
M        @ $'E@  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( !MN:4CX_N;%IP$  +$#   9              "  >&8  !X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ &VYI2$71. 3U @  A@T
M !D              ( !OYH  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    "  ;;FE(-.54RZ()   4/P  &0              @ 'KG0
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( !MN:4@3;. I
MM ,  &T1   9              "  <2G  !X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ &VYI2%J0U_%* @  A0<  !D
M ( !KZL  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    "  ;
M;FE(!NGQBF4$  #+%0  &0              @ $PK@  >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( !MN:4CU<?!9904  +,A   9
M          "  <RR  !X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#
M%     @ &VYI2$US-#28 @  3PD  !D              ( !:+@  'AL+W=O
M<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    "  ;;FE(75-_*!\"  #
M!@  &0              @ $WNP  >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM
M;%!+ 0(4 Q0    ( !MN:4CCYI"Y_@,  &P5   9              "  8V]
M  !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ &VYI2&+<
MBWQ6 @  SP@  !D              ( !PL$  'AL+W=O<FMS:&5E=',O<VAE
M970U."YX;6Q02P$"% ,4    "  ;;FE(Q8G9E8P#  ##$   &0
M    @ %/Q   >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M !MN:4B\L>3A/0(  "0'   9              "  1+(  !X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ &VYI2-_I6*X] @  ,@<  !D
M             ( !ALH  'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    "  ;;FE(JS! ?A4#  !V#0  &0              @ 'ZS   >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( !MN:4@\GT9X9@(
M !\(   9              "  4;0  !X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ &VYI2#'9X<W= @  X0L  !D              ( !
MX](  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    "  ;;FE(
MXUGR_,D!  #/!   &0              @ 'WU0  >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( !MN:4AZYR&7# 4  $H<   9
M      "  ??7  !X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ &VYI2 /%%RF> 0  L ,  !D              ( !.MT  'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    "  ;;FE(0OP<Q-,!  #1!
M&0              @ $/WP  >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+
M 0(4 Q0    ( !MN:4CN_,V<DP(  %0)   9              "  1GA  !X
M;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ &VYI2'D'O4TY
M @  >0<  !D              ( !X^,  'AL+W=O<FMS:&5E=',O<VAE970W
M,"YX;6Q02P$"% ,4    "  ;;FE(Q!$'J' #  !A#@  &0
M@ %3Y@  >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( !MN
M:4CZ*T^UEP$  )\#   9              "  ?KI  !X;"]W;W)K<VAE971S
M+W-H965T-S(N>&UL4$L! A0#%     @ &VYI2%.M Z+ P0  G_L" !0
M         ( !R.L  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L%!@    !1 %$
**18  +JM 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.1.900</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>277</ContextCount>
  <ElementCount>370</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>85</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statement of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>Consolidated Statement of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003501 - Statement - Consolidated Statement of Stockholders Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statement of Stockholders Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Nature of Business and Future Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperations</Role>
      <ShortName>Nature of Business and Future Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc</Role>
      <ShortName>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Collaborations, Contracts and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreements</Role>
      <ShortName>Collaborations, Contracts and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Government Grants and Refundable Investment Tax Credits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCredits</Role>
      <ShortName>Government Grants and Refundable Investment Tax Credits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Contingencies and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ContingenciesAndCommitments</Role>
      <ShortName>Contingencies and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Concentrations of Business Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRisk</Role>
      <ShortName>Concentrations of Business Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Supplementary Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/SupplementaryInformation</Role>
      <ShortName>Supplementary Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Interim Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/InterimFinancialDataUnaudited</Role>
      <ShortName>Interim Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables</Role>
      <ShortName>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaInc</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Collaborations, Contracts and Licensing Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsTables</Role>
      <ShortName>Collaborations, Contracts and Licensing Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/PropertyAndEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/ShareCapital</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Contingencies and Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsTables</Role>
      <ShortName>Contingencies and Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/ContingenciesAndCommitments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Concentrations of Business Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskTables</Role>
      <ShortName>Concentrations of Business Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRisk</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Supplementary Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/SupplementaryInformationTables</Role>
      <ShortName>Supplementary Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/SupplementaryInformation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Interim Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedTables</Role>
      <ShortName>Interim Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/InterimFinancialDataUnaudited</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Nature of Business and Future Operations Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperationsNarrativeDetails</Role>
      <ShortName>Nature of Business and Future Operations Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/NatureOfBusinessAndFutureOperations</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/SignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Significant Accounting Policies - Changes in Fair Value of the Company's Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfCompanysWarrantsDetails</Role>
      <ShortName>Significant Accounting Policies - Changes in Fair Value of the Company's Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Significant Accounting Policies - Changes in Fair Value of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/SignificantAccountingPoliciesChangesInFairValueOfContingentConsiderationDetails</Role>
      <ShortName>Significant Accounting Policies - Changes in Fair Value of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Significant Accounting Policies - Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/SignificantAccountingPoliciesEstimatedUsefulLivesDetails</Role>
      <ShortName>Significant Accounting Policies - Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2402408 - Disclosure - Significant Accounting Policies - Computation of Basic and Diluted Net Income (Loss) Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/SignificantAccountingPoliciesComputationOfBasicAndDilutedNetIncomeLossPerCommonShareDetails</Role>
      <ShortName>Significant Accounting Policies - Computation of Basic and Diluted Net Income (Loss) Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncNarrativeDetails</Role>
      <ShortName>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncPurchasePriceAllocationDetails</Role>
      <ShortName>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Summary of Acquired Identifiable Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncSummaryOfAcquiredIdentifiableIntangibleAssetsDetails</Role>
      <ShortName>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Summary of Acquired Identifiable Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Reconciliation of Preliminary to Final Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncReconciliationOfPreliminaryToFinalPurchasePriceAllocationDetails</Role>
      <ShortName>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Reconciliation of Preliminary to Final Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2403406 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncProFormaInformationDetails</Role>
      <ShortName>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2403407 - Disclosure - Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Carrying Value of Intangible Assets After Impairment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncCarryingValueOfIntangibleAssetsAfterImpairmentDetails</Role>
      <ShortName>Merger with Arbutus Biopharma Inc. (formerly OnCore BioPharma, Inc.) - Carrying Value of Intangible Assets After Impairment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/MergerWithArbutusBiopharmaIncFormerlyOncoreBiopharmaIncTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Collaborations, Contracts and Licensing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDetails</Role>
      <ShortName>Collaborations, Contracts and Licensing Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Collaborations, Contracts and Licensing Agreements - Revenue Recognized Under Collaborations, Contracts and Licensing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsRevenueRecognizedUnderCollaborationsContractsAndLicensingAgreementsDetails</Role>
      <ShortName>Collaborations, Contracts and Licensing Agreements - Revenue Recognized Under Collaborations, Contracts and Licensing Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Collaborations, Contracts and Licensing Agreements - Deferred Collaborations and Contracts Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/CollaborationsContractsAndLicensingAgreementsDeferredCollaborationsAndContractsRevenueDetails</Role>
      <ShortName>Collaborations, Contracts and Licensing Agreements - Deferred Collaborations and Contracts Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Property and Equipment - Property and Equipment Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/PropertyAndEquipmentPropertyAndEquipmentSummaryDetails</Role>
      <ShortName>Property and Equipment - Property and Equipment Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ShareCapitalDetails</Role>
      <ShortName>Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/ShareCapitalTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Share Capital - Summary of Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ShareCapitalSummaryOfWarrantActivityDetails</Role>
      <ShortName>Share Capital - Summary of Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Share Capital - Black-Scholes Option-pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ShareCapitalBlackScholesOptionPricingAssumptionsDetails</Role>
      <ShortName>Share Capital - Black-Scholes Option-pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2406405 - Disclosure - Share Capital - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ShareCapitalStockOptionActivityDetails</Role>
      <ShortName>Share Capital - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2406406 - Disclosure - Share Capital - Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ShareCapitalStockOptionsOutstandingDetails</Role>
      <ShortName>Share Capital - Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2406407 - Disclosure - Share Capital - Non-vested Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityDetails</Role>
      <ShortName>Share Capital - Non-vested Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2406408 - Disclosure - Share Capital - Weighted Average Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ShareCapitalWeightedAverageOptionPricingAssumptionsDetails</Role>
      <ShortName>Share Capital - Weighted Average Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2406409 - Disclosure - Share Capital - Outstanding Options Under the Protiva Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderProtivaOptionPlanDetails</Role>
      <ShortName>Share Capital - Outstanding Options Under the Protiva Option Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2406410 - Disclosure - Share Capital - Outstanding Options Under the OnCore Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ShareCapitalOutstandingOptionsUnderOncoreOptionPlanDetails</Role>
      <ShortName>Share Capital - Outstanding Options Under the OnCore Option Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2406411 - Disclosure - Share Capital - Non-vested Stock Option Activity OnCore Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ShareCapitalNonVestedStockOptionActivityOncoreOptionPlanDetails</Role>
      <ShortName>Share Capital - Non-vested Stock Option Activity OnCore Option Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2406412 - Disclosure - Share Capital - Location Of Expenses for Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ShareCapitalLocationOfExpensesForStockBasedCompensationDetails</Role>
      <ShortName>Share Capital - Location Of Expenses for Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2407401 - Disclosure - Government Grants and Refundable Investment Tax Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCreditsDetails</Role>
      <ShortName>Government Grants and Refundable Investment Tax Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/GovernmentGrantsAndRefundableInvestmentTaxCredits</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/IncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Income Taxes - Income Tax Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/IncomeTaxesIncomeTaxReconciliationDetails</Role>
      <ShortName>Income Taxes - Income Tax Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Income Taxes - Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/IncomeTaxesDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Contingencies and Commitments - Minimum Rent and Estimated Operating Cost Commitment, Net Lease Inducements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsMinimumRentAndEstimatedOperatingCostCommitmentNetLeaseInducementsDetails</Role>
      <ShortName>Contingencies and Commitments - Minimum Rent and Estimated Operating Cost Commitment, Net Lease Inducements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Contingencies and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsDetails</Role>
      <ShortName>Contingencies and Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/ContingenciesAndCommitmentsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Concentrations of Business Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskDetails</Role>
      <ShortName>Concentrations of Business Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Concentrations of Business Risk - Net Liquidity of the Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskNetLiquidityOfCompanyDetails</Role>
      <ShortName>Concentrations of Business Risk - Net Liquidity of the Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Concentrations of Business Risk - Foreign Currency Exposure (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/ConcentrationsOfBusinessRiskForeignCurrencyExposureDetails</Role>
      <ShortName>Concentrations of Business Risk - Foreign Currency Exposure (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Supplementary Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/SupplementaryInformationDetails</Role>
      <ShortName>Supplementary Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/SupplementaryInformationTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Interim Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedDetails</Role>
      <ShortName>Interim Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/InterimFinancialDataUnauditedTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="abus-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2413401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tekmirapharm.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.tekmirapharm.com/role/SubsequentEvents</ParentRole>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abus-20151231.xml</File>
    <File>abus-20151231.xsd</File>
    <File>abus-20151231_cal.xml</File>
    <File>abus-20151231_def.xml</File>
    <File>abus-20151231_lab.xml</File>
    <File>abus-20151231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>102
<FILENAME>0001628280-16-012462-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-16-012462-xbrl.zip
M4$L#!!0    ( !MN:4B7PR@YO2L" )CF(P 1    86)U<RTR,#$U,3(S,2YX
M;6SLO=EV&EFV*/I\SU?DS><KY^J;'+7SC-7NH]IIRVF[*D\]Y< 0MJE"H I
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MZJ[A[W/Q]ZR4^MX"83J=[@@HW>J];W4[UWW7NNN.6KT7*1QK<6T$I7$ 3NX
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M)[LL:3D",4JAFZ?&91J(TPH.;P1G3G!X(SA;",ZGP:C5*_[6"$^Y16R)(HT
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MVR"WN9$^_&2M"W<#S\$E._I4&_S75A\</?@Y=Y?S(1MFZ4+3@)!D]UEO<)=
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M.H%;HN6)) ^1*W*XLH'4U@*2!]H?;,O;5D[Q>=L K+5.2AUO>^^+BIZ_@[>
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M@;";Z+U!$)6\)_]0;S'Q)82[07 PP-DRX,@[12B2T3.0=4RQE[8 W)((-+8
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ME"E9A\D;"_K &4LKOF:<A=?&MUEGR:B;C=Y.I='@0&S 2-* HS'!22D$B2*
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MJ'-3@5&4T0F$I8_8>BMX@*@4U .5D9"@9,7)5GRNP6-+J)Z.Q89R&@:DUH2
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MN9!>*^7A%$SC$X6-K\0G5X2N@;X6IJ=BL$%V'$'<!$ZH( ;C-$J'EK6DR-I
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M>K/G0NC@24@DG//6(U#J#(-&)QR!/0PR*&PMJS1(/S\=-ARX&&)JPI%>*FK
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MS4C6 RB'K5%_+(E(JX'2B-7BK]>I,[;5F]W@%+GO-#(HF[4@KHKNMMWA>ZB
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M9$B%>>0$-@=B;YDD8TQE<-2\7AOP?02CW\EFN<O9[>UX"\]^JLKL5)A64T'
M<X*VU+5I&14CIF&Q8/%XLY6#"?J.R]O6SD1=HJY)-SYT,=GH2'7P 5!]J4,P
M#-;<A'8.XVW':?3[JDO\=/?KS;Q?G-W_<Y$EZ'=7EPM3,O\\%9QZSI!SX?3
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M5"*SGD5-,?I0*G^?W3$OORY6N+Z?O4^?_W4K+6K=OK/K7^+EW=7OCYL>-K3
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M-9:C_*$9\D#'MT,367UI-3K'.49+E.6,@M?]E&V#,5F".X&UG$H (/K(+ER
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M O>E9BO&32.W@'AW.IA@LLHI]D^0,:2AJCCW&#WA.U.S%<LF9<H8V3K4HG/
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M9O'GYLIJ""E5I:'I%,A[4]$#E=A(.\"ZDL7>>QC XXY"C/!S3G$=O\<"*X:
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M6VL!JC?6LS&A2U_HW?;'RV@3#>0=',Y;%:^5C8F#56IT5Y*MB:B;(NV38$P
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MHXQ=]=^'G?<]%BW=D45Y;$S&EC(QQSJX>6/5EF5%5 WUN0I0>Q/H-.1].5W
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M$I<)$<G@]R  PQ+#MOXC%6*\ ;Y,L?5O5#;$ E?D:?8Y4N2@\=C6+FK]F!#
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M#3 :K<:JB'2P!C-* "A@J;*,XCH.$:R<TE)")55"%Y@$)&?75$H^9,!$Y_%
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M\$1+L:R)YLAC4U-U4=1<3SGYB:6C*I?R''3KH/$N!] _-P^@/\DAKS#5?=3
M,&JI;#&5_!\:L^CX2^CZ\G.1!G,\@TB+ ^+1X"3@-66VC+]WN/RT*DD@254I
M@>:94YIYRL[))5V%"/!;=I:NGYH6>%"LEP=5IVF3(J]+W%'',&/591I5"IXO
M68%NYO:C[ZTR"E=UF03KAZ[R#GC"^-[/25U Y[>;KS=5P3YAE@1%64)K"OH
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MPZ$<T>TCBW%^I]TC@)[]<"-X#J+8'S-B_M(_"Q \C"RMBIW#M/ZF-(R)C8A
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M>:M>\9AC!/"'C00W^F:-6O*Y:L#5H2Z:3;@ ,A;^%!O^L;K^-',M !?+I\W
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M/,L:JRJ%6X7[< VW,C(J,?A#92;JZB&KP&,#^BIOC;V[>D];OE92.FJQXD@
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MV4N8^U/AEI!86"33<!;B-8F0%4O<CVC1=!D!P[$'A'%.@*UR0ED'?BLQBO6
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MDK9V3B$(L),(T]6&R1IZUN]?@*T<S).$^>C5=GC#:\-]E7(B 4+.RAVDF0.
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M[%=6EU\73+#67GT$6I,(A.X[=0>#RCHL'@I%V #P$QR-..A"=H[=L:OQ()3
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MO[._4>_T,-O_5'!?IRD+/?B3J/<&:QS;;49;D<8%H>K;P.8C&,:!\W()\8W
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MCBKC?U'O+3P:)!.J:,ISG-^;+I0:K5QJM*W8\<;P4"6C<Q=^Y'.2:QNWPZ9
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M06G;K^K[.EAZ8"G"&E=/A>V7&29,<B%2!JL0B36EMA-!@\'NIV/7!5>L'=4
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M%!CNI>&+UT"3#S#XV*>SRXNHR,D^A,XOY- 'C.B[SB\@D#TT0MDWY,7(N=
MBQ;:U%(N1Z?=:OU5(TN4)FAMTA$*G$U(L75ZF7.,QAEJ<1%&!>"^+L&*LBM
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M#^%VC#!TYBR911,'7T:_PM/YG!8 ?&V:!D[ X8V:3_K> I'2\6 7N"+A3*,
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M'NV?EUD+RG(ZR^DLI]NATN8.^M5E-K]VG6WKYF+Z\X\_I.+XUO,6[S[%T0*
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M?L@?(Q<$/RVBF$2Q8I )#C#2+\B>KD!H:BL6C5\,C1%A,Q?'^DGDFN3O8"'
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M#"\*>\[FP#&8^A-.C>2!&U?P"PL61>K9X$-L3#)R&PG[;C!!<(-%W(@?PJ?
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MOIT0R1 Q4G<RJRV(H,#!B[HF2OD$5,TC#]):]$PK,G@V**#!+K6]3SN%M4&
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M-D%*2#KD(S>%#]K QR6>J%JD&3!""@MEL$2LJ&!W8\* *9&OV2P$]?U?N>+
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M#,<R#;MC.<<42AO7IA%459>8^AJ+-CXCM6MVK%[MY&H$U^P5)Z,#X_4GV),
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M!H7GAIA9]>S>=!Y*?H6_SGTN7RLRV!T,&LK$N2QK#:809H;7QM<!#P0>+_+
MG[_'DY> >A./7K71<.;%K%$YLF?)=: U0?^_:NR98+MY."<83^K?> [HE?GI
MB53>T0SF-I8/DQE]HA94C&9?4$'\\J27LYT+JQ(T,#P>7O6-1LKZ4Y_9)^81
M#)1:S!.RF&N??&%V1'REJBFN>[QR! )4&FXT%BFKV>&+_%R)7$!Q0F/)GLA6
MF X*HDAPS3KKOBP1B]G!! 3?%I(,4WF1WY!31?*6>%8LD05LOB[<@CCA#+!Q
MGX\)5\?IW;\!\CAY9B1/(1AJ?+Z&#G$N _XO0,4NA(L)!KG(,2X)_>)-^4KJ
M<8;I,(HEII_"U$>!"$H!C0 6^1X2%$54<"\SBL6A%4-,!84LPR@W/FB]O"PL
M&KX@T" %HN!K>$F\A#"\/I HEW/%"1>\,Z?"A?$/Q.;Z\.SYX+DDJ'Q"0=3J
MB7EQ4>X*6 57!J:Z(K%P^42:-,?C+_+EL[&>+P<,E@8!1_YDT2*7I\_GM"*Y
M8 @?E>%K%#37YI =+)+#9".OSPOSR[>:R.L36)7..'">X7X?"(4'G -L*.#&
MD@RG9"P>Q#E8IOH_>OQI72DN^:-"T%4(D9SILU\Y,H:T,M"?* NJ3'=+>P[&
M+]5J AD"X,;4511R!I)$'FDHRZ9L:"X]%6%MQ&BVE8I7X^5W>%Y!RC5QE )%
M52; 5OA=A$>>BZZOJ1 RA;C+Y(U9''A"W/O>S$N$NC SDH3!?8CL+VCRDW'&
MT*B=@&\:+3)W*_J#/RN7%^?&!#Y$U/N;"%$)YJBPWWCPZ$6Y-0K&Z016*,Y+
M=>/+^OP>"(['^)8SE?Y=<3&N6QR+(>YPR>_QW A<_<$XNWLO+LP/DV26O70=
M41V"$G!9D/@+X3\6FK0L0B(/S$CA"Z(?Z":E<V=E^WAI2O,$'NR^-X1WB(?-
MI+N(7J:T&'$U<Y-+R@V@R)V'NEE8I<QX -<&TW%AT!=NXX(Q&'JPJ!LS^QY5
M*ER72,Z8\!DL AC=R%&RIF$J-+&\OV3YBT?C*X#I^^QM<''/)N_1\&1SD,\N
M8LA$:QX6GXF)3_BRFF/\($QI-$+J,0R;'@\Y4N#J"TJ3E.<JZM5JEGJ\7;L4
M$LP_0"-!KH0(1VQTN4LGL9<'C@'*8 ;'/'H$>(%F@N7F@8QM</P.LP$Q#P02
M-T3A@OG) MSDA=AHN3 R)EB'/@C(Q)N#&N0^SV(F$0KAY08-2Y+( Q6Q]"$>
M&8@V< BR6^*EERE=1'%6#\5\R5<4,BOB94,)708#WP&>+JQ0M&J77H/PX"N'
MRG75A&, P,-='! YG\+@'%R+-)C('A#9N^,3N8R,@'/R_.S\YM#1?<1+1"B?
M%,Z7$3[F"R*C"$L; -<@.[ HPH@33^;"X&5% /'YC-,Y, ;:E&)MN5A9R2NK
M<UZN_7J\Z]G:K5*[;'!,4W\*MHMT%\([@$"FN/-Y;UIKY)K,&EG2R$0%@&L7
M341!@4*KY*R+YM/*[+(KO&@BB@V@4Y9;6[BHTHV5?I'03KAVOK#:[W@ /J9P
M,^ZX)XH<!%,N*?JMTJ0*^-/JPU&3XR7@7H(F"P15"P3%LAR"M&9@_)^0$T4%
M@?+E*;QFA%HP00O!0\M"1-[X=^ZFN<4AB+1\\(<\AB.C2:XPKGP1&@(3T>/(
MI!)*0,VGAQ!X0H2M!84R>%6&,#/.0]*;>$OH2BO$S3Q%C)NAS6.$:8)!0V1[
MQ/UKH='2N!\,R34B=%3Z/?>4,Q<Q0]W*#BM?HAC]>#"8)QQC;\(FCX6=(8WA
M_&81ULM-WA+]+HS/ZZ#.PYT9!7.K;,/2KH,B1[.72R\,$D0\6;SXM%4*EQX@
MS"\IH(+S\B3D7K=DU$Q 5$VCXL1Q;DE.5^B^-,ERJ)9$^ZK *'!*;FCMD\^M
M+=3XA<[9J&6>5VLI:?XXRUPH"^T[//]HQ(A@E&"E<(X7_R&AGM6X>#8R:$\_
ME1'M$ML]Y9&E/(08945AI*K(A\KD<L0SOH8A9MGVFD@P$KX3(":-J"**;@SV
M*DM-0E2082)X2\CXG)=VX:35+5+\^!1&?ZP$1BZ,6U&Y2-H#Y:D\*]@C'7 ,
M_DJMA:JE$-+Q,[&93]*+RP63Q(1PAQ<C=V&^>0'_(XHTR <4HV<D+%LKQ,8'
M8V,1J9([[7'%2BPMR=\#$9?ZF@B3[J_+,B#7',VC7.]?@XI%X_DL-V3LSH?K
M\+KX9GUX+\28-!T+LWY9!P08%A-LV3T_#Z?GI4W4O$#553XU8#!0K#+^6WA
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M>,\^1R$8F$Q<GW_^_>OXO8E@%@.R@,'5@3'!_@8H;&1W^DV3&$=W:9+&QL?
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M9-=8=X$@A1D9[%NQD5!DA@J\6W$79-@L$YXU,P%E19>H#\'J$C?&" OAHSZ
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MHMSX.2@WL<I#DHU')/G9;<P.K\KOQ&R*ISZV!M$XZU/\_>>W67)^X[KK=U<
M(?X"AA&F5:KA]RC ^ISD&W3G0Q!YW__R'__GS^4=6.RPC (L,I+$&%] WRK[
M+6\2Z@L?OO+%KZ\^?T3O^S_#?W[[^(KY<_@"1G;N3#]/1Y>##_V/@^GLP^7%
M>.@,/WT>#\:C_G@VOKQX]9<'P%C'L&_^"D3[!3SEUPBL="<&/@=75>ZK;6[$
MUPL_E;F"T_14VR5\YKZI#6'+7ZSZ,_=4X8WN0S5_I?Y;R'[STDAD21U)%/J
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ML$%AQ0Z%#619I@NNS;<[]=IG8"!-.ST,'UFS?OMOKB 0)],Z0=,:#"D^>JH
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M96551&IOK11\0F6:Z,ROKT:S7QX-=IL1=WZC[>Q[HRGW&=-1O0>H,;6!&1E
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M\YOAK%3]HETTN=*&U.C[<#Q0I^V@JEM5.^;@,*48Z@H.E]<CJ <JOHBCU=9
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M("J45&9W+BQ A,?AJW40W7.>L"R$-8FXO.""P^"G05S'UH$+M\-ZQLL* B>
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M3E=R9#II,Z29ZL5_#%(B/<&$E HG:-5Z@#563/[J,[;FR'H0=882UY$_U@8
MG]Q%9P1))?5K;0P(/T#&.QM(IIK^O;9Y8(!<-?D.NP!):T4_!RF!?C 8<CN#
MB.O('^L#X$O:'4%<2?VJP0 P)EP1DH_BA\LEPC,2/1'/Y)3]*9ZW;^',49[I
M)SUKUONOATM*EI!R)#RIC NO""PHG'T^D"N%0;P8^*<+_-?"XXV+E!CD/0HU
M0XDJ;N@K(:Y2D#$%.69_/F"BL7VH)7]QH3PXZRJ4J((PLE@F'TR[RB2J0-]2
M<984=A5'5&%B^=S+\"2!>U' 06)9-R:^:!I"%24V)F)Z%8XH&V'O"KD0,X3G
MHSF%:K'.#AQ9]]OM9?WJ6B'L1CA&&&-,3?#WX^'1F^'1D3-PSA!S?<)""L4?
M>?J_.@D'!V#/27@X*9/?#HND"TQ#!KT)_EW]+C:PKJR+U%0LC BMZ^4[G;&:
M?ACK;U-:/8,S*/P8+U])E$WJW<('B$-X!CE _O-906<@=5;SYNB-^+>^U4@*
M&E>AMJJ2$M#8G%<:W=_V]E:EYN<VHY;6<;P!Z]AKNT$;NEO<0I?,,?H3>M^P
M!ZE5!K-!B(TV=[*1$2D>:U+(CL*\M^!GL.![,/7A\UF?)E]G.2=';TZ.AIL8
MK2)FNZ5J+!J"ZU::S$Y#T2B0L5O$?G33:0V=6O=U>&1T7[/D'#)S8H*.I+A7
MD&K87B-_,[G:45HL-TR>0:VZ=G00K6[I"T(AFN.Q#I">/RU52VY8GPU<&M5L
M6![4JWG@:)9.S-.)F>Y-H*"<:\BOT,\0>8BO)K,Q"98 KS9L +4\&M5O\,6:
MU"\8.@E'68 OH*/Y[BV@H)T^CE,CM5H_:7AD]),:QNZ==(H8\9$G=WA/@2]W
MYN\6$':-\%41J=&1<(7$/^D.W8G&4VYII**$E*-I.1&QO58XNP%BKA$C#4<"
MYT94E*?8H*^WJD^UU)?S*D=[5WM5TEJ3V1TG[H\%\<7ZG)V+J8.O^JJPGFB]
M%D\:>EWZ0@R06>K_]9\?CH?O_\>)N.S566[YC73/#AP:%-W072L5K36\[\!Y
M?0@W9 S8XL(GC[VG1S.Q>CV^:=MAE4LCJ3J*[%Y?L\D29C>/ B'E0@;#'N 5
M81M18@.'>LT>=])LRDIO.&68.9+;;BF<(SP7"V\$=<L'B/?8FZXF4[\3_=$<
MRDNIQ3J*Z>V5TWL'IY%:_6;+1_,"OUI5N[I^KVKFKX)+$ :WXK=X<<XX"N3P
MI,<C/!\3QM/B,A0# 8.7V O=-?;MGA].H]F8HK\U9C-P-#1'8E.O$W1. L^1
M^#+U?HUB21*CDP&Y-\*\UGO%D!J(U6^U?32'D.K&C=T+(,5'Q&1/%$W#5Y=X
M1FB@4'515BV=&CT=)6&DY+!:YN=(=D%%SLG0VR'U?"$/D&+9%E\HP&KG^1;.
M0NQ)0[U42=+RY3UX&E/HH6[>4W?B]3[5>X-/E?)P(B:JTZ5LG)2/(Q@YFM->
MQ=5:Z#$;]^91/\6^?U,>87LJ?">GRTLL- 1%*W2;&+/5ZGOD!T./C&H[JOIN
MMG6<!BK^&#$&>_6H-N3J.\\'P[9U5C?9?%7942+:N]Y/UE552\V45@XYS>RX
M#I*?,FM1>-(^4MC64TT#T4:-E4($A;Z4_NGD.>RZ-KLOS,J5ZQ=B'PP+L7Q_
MVKUUUR7FD*+@ F$@3!'X9X"#;QB$PA>2)[R[**..4*U[,#PVN@>*GI,0="1%
MYU5"<Z\EW1"]QKL6].K3G8Z-DU.3SG9TD*MI[3[#7C.Y^J2F8^- V*R[W1L>
MOT(ZA_0[XHL1G88\9*>(*'4 ,7'(NX8@]5<3,8=0F'W319U]6=2ON$X,0VK$
M*;I\2?-R$I)R)GSMO)IIALX$CP5'^?Y&O?]5%=CKOE$Q8T#I"N'Y'\ /X60F
M^A7 <R0Z3K1P&LU$/[L,E@!1&7OH,7B_**YZ?_?DS='[Y[ R&2'7<!V%5^Y;
MIXCC-:C"[*2@=W)VZ6D.UZ)]!?*'/BGTFV+9:%PE#V-#QI4@V5M,>_7=4")?
M@LP.R,O93@WS1BMZ]TQ6)# Y"E1V4VAO41V4&E)W 1B\H<B%(]_7U\"\H%75
M VBTK%*P9U.6I7$Y"IB3(MM;5WOEYL-KD]D-A3X*Q/*&KNZ)7.;X6[>_M2$V
M6NC;9[+00NQ2N&<9[ XG:AWI[PUY$X9\%P:!:-7);.3^#!&%WJ4GV@#-4+1K
MFO?C7\YX>\%J--C27M2&#%:CE98:XW6R@ W+B[V)MK:%[E&L]1C5!_I/#/&M
MC9C1#D; K@$7#9B>G!QA[R)4CY(T\BYJ;T.N/K(U-$2V(JJYDY@RVR.BG$EX
MW^LMV]#KA #ZD*\?^X>&))ZV>MWQ!?U-=#W@2B8]BJEM*6-A791IK%_?"]\:
M>F%,)LI8C@GMN!YZ]*TZ,O5]Z*TA9&;6RKZ?Z(8P/=.^XH94UX)#HU9+@88*
MK5:^B-W?O=JC!NGNL-90J?=&WQJ\T:I.N7O^Y9UH93@&2\2['77.U:N?J]X9
MYBI5W='U=[2Y3WW@_KAS%^(]FRPE QFED7?),18&ZD&?<$)?%O6#X#M#:""G
M1/&WXC;0[)R(WV 9,70R''=R%,RJ94VMMM98R1G):VS7U1#?>S^9G3\M(6:0
M71"J;E X!0RJ8^#B:=^8])J<FI0[;%#NP(F9.I.9$[-U9H1&ET0,Y!7CT?'S
MF/7.&\0UP7] IJX&$"T4#6 C5ZQK$>_CC78EW=B?2\D>194++H,'Q292LAZ$
MG9C37L,U:HBBG7J:],&Z?;X/J\9.7_)D.UN CJWJQY+YSAO%).3R:V;R"XI1
MLS!U^?*&[:$CET93J/>IQ=\9AEK=3-\J+2\YW-M!6SL0BT71=\!S&T(EF\9I
MX>-ZEJ 9[TTAHZ/-.P#KS/NE+(*B@O>3?8,26:8+;$Z1)JJ-RBREP]4ID^7Z
M[LXK-$YY^"[WFS#?5-=L(-NHTE)XN*32-/M!\]CWTKCUNX>"#;7K0\#O#"'@
M0BADMR._WR&:+\2:8?0 *9C#9XI&=N32V.T^-'6[F*&C.28NSCXF&9D FF,T
M0ZX:\]2W6$6KW! ?R6N1.FFYEE#]]H#I]&F&GI,2=&**>Q5%[:"/#LG/T( I
M\I'\0N%7"&0C>B-^ 1"-3AOA6R@_;2MJG@*&>G7C9X11W\^/31L/]>8A2N@4
MPNC#.0DH)T;E .Y(7/'I)NPDT!R%;3\<%)4\7@ \E_<SI/J,/]# M$^S<</J
MPK/1BLJ+J$8KTOP=A'/6DOM*Q'^SV*7;&TU+!>J[][B\)!=Y.HGL96RGEG6C
M"967;OU-*,7BY,#LC:BD2='10J[WS^3H[(JIY@SYH?#LKB&/KA"1%R??R(_\
M!0'!R@_<N$&M!Z/1N,K>;+-QI9!4DJ8$I>8\#4M=2:JO6'DEH?W-N5$?%93H
MM+>\-[>"GI.[7K\Q. O]*_30Z[JIWCP:#:6\"]AH*.G]M1%#1W'<Z[ZHEW52
MLKL1;M1R.:;4J.7=SL*N;?^-+VI;+6Z/C\2_<N2I09&OXE][[>F&Z!$B;$&N
M/F8H_W76W Y&$<,I@S]#(<#Y0]?/-I3JU@:*AJ8[=5(23D1CAYN^SYQ50:)V
M=AJ>&(X*E12QFW-0N%SZZN)_0/M>H5Y)H[YWF,[EY4CMZ-7I5<W9J[?4DZKO
M-4-3/FZ5@O:])],8/:;_>DJU,[^8:$S#6Z6B_JWG_-\.GYCW"2R72(@L'^D'
M&),(O7HF'\&H>1PP9>JK]9\/. WA@5(LF(;LGZ/CHZ/W,KGH*PRFD!XX& 3P
M\T'Y,?)]V:0Q 29F%HYX*+E]H21<?CYXFE(??4(<!@<.%U@_'V""<1A\\D@
M$+X4+Z0(!TY4< DI(MZ]*NB%5(_(AYV@#X=&Z(7'%D)71^VS.2L%&:K?;TV8
M%+SK"M;>%7)E\OH%A-%7NGD"OOI]'_#1DX!@J(:- OII]%G4SP>N^E2!22B$
M9:H.;R/3#5B)GN:;!2J]M%V:6S&< 7G5#/;.X /TB3I/9Q:NJ:R]LOIXY8-
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M[\FWNS,914LE,;VQ;!2M-+)2JEKFSDI2N*C2L'W0O_K6]PH,VWO)IM EOE_
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M,QQ,>$]-MV.$,I>REM(%O5-QV'W81_8&MF[R_/U5_L:!WOO'7_X_4$L#!!0
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M"<#M$_[_N?UQ5LUQ.Q,5S:R;]?0#./F;97Y73RNL(9_^[<<PC^R(WAG%!AI
M&$7*02NT\@1@Q3#'P'$GT?-5K\,EROF65F=8MG[X%":R/@:2%OZD?X8DPIP
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M+]A.&3:#AC/#+ SJKJ7 *F<(JD!2$B:];*#?O3+1(^0]\.6NV1X\>O9WS B
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M"'&(&H6ITU:!6L=$*"DDI\/\8+W2YC5K^S3\3KB6WR1+>$P,U.@R_O5.&8
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M )P9KD<F@0JOT?$D&"Z2HD-3I?HE9.\$W*;+/TC"9^TR":SF8=;$.R@5 X1
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MXHD%G)+UA#U$A,,DL[/UH-BS4+@=Q%))/!Z/[3OU,5X^Q?3434B\HTN&N*4
MT1@+CJWRS$&A-Q-6$G$WC*C5LY"X'<1Z4>R>P_ N7[JOX^EJ4LQN_EZ6DS^*
MZ;Z0^2;=,P4\4$3 H-E 1Y&1RLH*1>-$7TD0FK%)CU<IK4/784!"XOWLN]$\
M!DA^R<]X]?J*3ZK)->N^;ID,!/$<2QA(C+#D&EA/XZ,8#D'XWR&6[F:A'\>W
M>= :\D>'R9.Y!XOCR;\.W9T>.U2&()? 2:>Q%@!IIA2%&T" UT;UI*OOO21M
MAZ#?Y#SK%*BAWGR>S]L9TV)C;:3@1GOB(0O_K/##,#')?+?>SNYXY$2WYG%8
M_BG<3-(CA"#C'OM@5+&@AT-000*X@-^-6[,Q[5OP-Z6!^E]^XVG5WH;DUAP2
MFPW$K>ET4"XH<\'25R3,F7/FJFDBROOR9'=G-3>F0P.WYG%@I=#T:GF;S^/7
M]Q/S1;,,&**L-MH:[#@)IS71]1FM>-J;[T$Y,).H>!I*/4C\RK(^F+?F><,,
MQ7@#)(V)KP$HE%P@4BT$$I]DWPS*FWDLN5O!Z4RQ56DQFLHJK)P@CGEL+?*4
M*%$MC0/24ZZ_85H>[6!V\:%VBA,IL,'"Q\+P0=09K2LO@D?*#=9Z.)E^1\?<
MI4'UW7/(T/3]X3'&68,QC<1 &:/C#2SVS%@F934Y$B8[*-V]1:SW!V,>ATH/
M>UC%/ V?PM<.'/7/VF6>.ZR4%5ARYS#BQ.K:!PPE37(M=I3YM?<#_A2D>B#X
MQ]O1/->C13Z)A=P":IN'O?-Y3.&X+@&N'Q[;O!\]K M5K).;UPN;3=Y/1[-&
MGIXN/I<I;X07Q@ON23"8K*#"UJ!ZJP:K/"3RQLN;E.%@^E^&;07<H>DR%\RG
MIRL]ZRDMWBP6JWP2K_'+U7*;Q^B %_-@QTPQCC5ADL? -*@4 @C4DX=\8*6/
MSDJ^LD-@3^6*.JW5A_Q^-1_?AO6_GY=?BKBWFK/(X5$R&9-J0 Z%]QQ10FA0
M&:ME,8V3:B-VYCH=)K^TCG*2';6V SXNR_'O5_=KA?. .;6C?6:0!MH'\2LX
MITQ307S-YTB983E7A\,0+>'9A[:S^KS(_[T*0+@O,?W:8<ML1X\LL#1QBH0E
M*8XQHMJQ>FD>NB0#_/B0TV'::.U@=AYV.*S![NJ3&8()Y5PR%^0:P-Y05RMR
MC#DZ6+OI9'H=IO])$'UWG# T@V0X#'!NPA^\CGVU?<: 0YR;]9LYJ926$M!J
M68JII%=$W5D>IU-G/[V30.F#UJU45"<*$TTX9\0ZS2B2G.-J60**I,U]?,;K
M@9[\+2#6!R.T6FS;<ZVPIYY;0R6$&B&-'[5<BX9[[I]&K<95M], ^N[X8'"G
M_D#(?S:R^W*>CT>+!H?^JQVR8!X+ZK6%B$M.M*# D-I8YJ:GA'PGEUIO3)\=
M%#\)E?,$4CRF6[^Z_D<9D^NOLZ#FB\><+\=%5S08,%-!I8*<6R0L)!)J!5&-
MLQ=I.<_[O+-_>_(CI5Z ZY&CGN0!>K*D#_DT"-:)*<,:&G#1X4&RL"=IL+\(
MT#SN30T5Y!4 TKND:H6=.:H[Y9S6P3J/_''A;\N'BM,WKO2K>?PSJM_K),)J
ML2AN9L?*H2,&S@"#P@(#*!<$(&*<(5LE'T+C<1)7=>;M[DL>=0=@+P9N.?Y]
M,V>[F@=9&J1K44XV%S9/3;Z]1F_#,3) (+,*6<8IE](@2T%UT$, TBIB=I9U
MH9M'MQUA=1ZAM)[V^WFQM\##WGZ9=018(YQ0 E(,+0B'=K5,YWG2!5KKU<#Z
M%BG)^/3 !GY4S"NAMKK;7-Y]*!:_^WF>5T+P0''=ID-D##G.N?>&.Q8%I!%,
M5(OGP>I(88[6ZWIURAP=074F/G%?@R$9U*Y_E$'[*J;AV$S@E-<'R3#6$'#$
M)*#.0 ^ 0KX^6IU(.EM:KPS6.Z^T M:9N<467XI)/IN<P"M/A\@,UL$:I X@
M"ZC5/KX=JQ;/&$C*.MMZ);&S<<H)4)V93S[E\[M$_HA=,Z(XI00AZBU'G!+H
M>!5V!)702;4%6Z\V=C:^2( H)3+K- -++9?SXO-JN4[ /,^?V/X?\_F7H$^I
MV>3-+*:J>DS1_*E<CJ;OZU"TUY79P<PM P%URI!4P0@P1"F);;TE*45I661:
MKX76"9M>*A'.O _*Q?+5=;XKEX/8"R?-+[. & NP0T8(K)0+YQ*K51E%<-)^
MN PG^243XI0]\<RE.\ZG^::2\=7UZP&N\02;A5GF\_]W%2:_.\JWK?$SXH2!
M1D.IM,-.*0^LKHTQD)9 %EZ&^_V<0/;Q/'.ZIE8^V;N"/5IHLP$R+25V#F(,
M%8E)2+S75204U("GG?*7Y6KO!*DA7-XL7DKD=ZL([W97;'][RB5.HP]D$!@%
M.';<"JFPEU"C^BX""9,FI"[+&W\6)),>.\5K@\<',Q^*F]MEM,R*C4"-MOIF
M1KN.ML8#9,X!J1CV#GBL 6',56G/PC'.25HD\F5XY#M%J@?)$\3C7=#;X@+,
MZ+X(&MIFIA_R1=#E\HDOYWZU7,WS-3?O+\M]]%B99I(+IK!UC.*  '&ZOK!2
M)#$_R&5YZ[L&+45T;"X8RVNW6!9WZYB'T>+63\L_%K\M8H*MVN>S2W0T'B"C
M@>DAL5(R(QG6D 5;H+:*%4URK,++\,%WBE2??M4WL_O5<F&+Q;A<S1I?Y'W;
M*Z-8$F5Q^&_,S^*X$X^JNT4H31Q<J)O]9'C.$Z'V(1^7-[/B/X%W)_EL65P7
MHV\+W<TF;\./X]52D2_6?N.#%0B."W'K:A:9-MP$6>FLD]XQ;9Q]W(0J$"2)
M0R_+X3]<N,_#\?5+]-'TS>RZG-^M?_HFDGDT5>/U]ET'G(Z#)3K-E[F:_&NU
M6,:0^,?U'LG?[7PSLP18X8P1UG$E@0'X\:I.&IIT>X4NXUY@:.#VP+MO[N[#
MX1*G>77]<J<=507GF'$R&]VZR"@.-*<Z+-S2VM"UGJ>5/KL,7WL?@/7!-Y'1
M\T^CKUOWF<YG@2C+?1SR>H\,2H!!%.(:(\IYK.A6Y7T(_\%IO' 9/NYVH>F!
MZA4_5A<VCX+O4=SM.[4:]<^\X3SFZU (.H.QQ(I6H8K(<9243 E=EL^Z"Z!Z
MY(\&+)!A((P"VB..D90B(",KYD;:X"2[#EV6VS@1BQX(6;FG/^3WY3RRW6\!
MZWT[^_4.F<$(..P$I%Q;Q!@'KKK+15;Y-")?AA.X5612'':_CN:_Y\NM_[#X
MSUIAW>N@V]DA@SHHK< CH:V"\3F!])5W$<4<@DEDO R7;*O(G.?6<!&,EUB?
M</0N7VY4C;?EXLCT_Z^/D7'(# F62URK@X8:HZNTQX@(FW2]C"[#4]LU6'T]
MVKHMIP'VQ>:^<@]3?-LXBP7:"=>4< -0$&4".54O2.JD4'ET6:[9DU'I42M[
M-#D/[/_7.V1.*^2#\8DP#F(.*H[KG'J(29WV%OBR_)RM(/-(\J'4J*WDU1/7
MUOYJM=OIGV.J3V,%MZ$]!Z=[<<5UD47<6Z80CP6/J8GIF2DTFEE(@#SXA*"C
MX^*,Q74-828&8IFUDA5TK%C[; L( Z:GJA/IQ74;$_34XKK' 34::''=M.H5
M#G%J 5#68X\8A$$%Q]7:%6!ID6A',TFW^=$:TW=O]8KCD.I#%?T.B@'8@!^T
M0AF#)5"!&D3["E1BO!QL-K9$WNBC*D :IO]EV%; [9U1CZI><5%\VD+H;G?5
M*X 'PG*)""42<>NH-?69(L)YTQ,?G#'Y?&/R'5>]XCA@3^6*WJI7$*8%E,@I
M3#T1 2\O=;4LIUC:E>V?BU]:1SF%>;9AQG%:U;N$8'@_*6[7O+!%PE!9T&"]
MX=YQ"C@WPDOC6;7 \+LDL7-9-2^2V*A[J,]S39%8DQAY:0F"WF$K X["DD<9
M&Q]6]R.,AFGTM8/9F=BAO8JS7D"'J0D*(]/2 \"$=O4VDV*XY3%.IM_1I6?3
MH/KN.61HEM#P&.-T;>2$FL1>!UN04>LLAX(8YV-ZF>WD,$DK6WO&FL2-L=Y?
MD_@X5(;PHOE,Z6B=5=PR18 4UH9C%B(%MD!1XDA?53Q;N-=,O6;H%< +>X3T
M+E^JSXOE?#3>%][<T1<SX*U7F"AJH84X9K8'I(+6>9ET,ITG.OI4WCPOLA?&
MM/'%:/A%W,1?1M,#8=G=?C@#"G.ME*6>!QL44(M(Y:BE++# (,7KV;BM0^X_
MF3:7M@E6\WGTPJQ;OI_G]Z-BLGUB$=I?+6_S>:\/21O/)^CQT"&#O;+,01[^
M1%)69$'()[G&.I?ZW^66Z8ADE[R3PBAY$"#'OU!M_?.9"E"[(+(,I9(90[36
MJ@(=R+3T5IV_%/KN]TDZA2YL6[R?E_?Y?/D0W?K+[<EZOXF/ZF5?[/Q^)K'W
MGF+I#628&!!I4,$ND4V*U>W\<=7WN#':(M&%[8SD+ 9M?#&S1J&8_X9 PKR0
MSCE179U2'OZ5POV=OSK['KD_G2@#>ZV*%#&.48JYH,)8[SFA]69E,,E%V/D#
MN*%P5"***9<(ZZ4O6EK[]M7UXOWH8=UC%G\R7^5/F^ZZI.A](AE (E97D#IH
M7((B[JRO37DA=%+6M,Z?XIV;12^"5A=V]K\K9^.-.?#D=VM3N2__^<X)9!A;
M*P01WD,>H&"!67@%/$0N*72M\Q>+Y]XD@Z;1A6T.FU_G8=F33Z.O3W[YB$9/
M6^30-#)OA<(0,"$8XD@21^OH0V: 2RJ9UOE;S^]QH[1,J>%NETI+W$65]G?&
MH2]FE 1)A"17GG#/!#%&5&&3C 2D!^E>',+E:\O(#N_%= 1A-@[KVA:B>#_/
MI\5=0&C^\*GTX<_IG^.AL@[D"P*22,""XNJ)#(?WAHY $60..>"_OX?*7@&G
M&/<0<\(%,\[0+6,#R9E(RUU]M,A(?ZC<F*"G/E0^#JBA/E1N+XX=2(L1$D1K
M(!'21  ,*SR<2LPB/+ X]L8T;QC'?AQF%Q^EC U%PF@)M6).>!RP0]7>](SH
MBXMC;TR_H\.5TZ#Z[CGD4N+8S\<89XUC5TY#*2R1$GN,//'05<M6TO.DMTQG
MC&-OC/7^./;C4#F/@6O"@5=,MG7I/LU'L\7&:H<-MG.383+J#2;88 H8U]P:
M!8"J0-#>]*17MF&*IFJ8'<(U7*?(X(-[,:!(&TX!Y=[JF/(25"J=4D -,U*Q
M:[X\'\#)=Z:ME3N(2]A[*=KJE[*PG9V/>YL0YTS8]/J1:DK#I+*]YW'1'<M_
MPT#TTD3GQ8:$4PB1$D0Q )T6FDH@0446*'&2H#U/NO1!"-J.<#^__'V^F,7H
M$%?W/87,,FXLTI S&H0,IHQ35UL%/JVH]7E2P@] 8K<)]26+\@&]29!,!./#
M,QF?P@*AG$.T AT(D?3<[3RY\@<GJ--A/K]<KN+"'M?0CS#^]KN9EY)0R@WT
MR#N#"+6\IJM!;)B1@D.5P"?C>V%B=[AO7@+BE@J&49 'P3(&B./:4K9>))F"
MYZE&, 3!VQ;.YV'ODU2J5AB\BQEDC@&/E6&>Q=)!P @%?:W029^4#>(\%1A:
M9/$!('UA,OR\K[-,H"_'W$C"',#4,5L]! K08I"6#^(\%6:'(*C3H;TXT7SN
MVLB0$($P,=HK#XWBT"GVJ-CAI()'\.)OX<X"[L#>!THEB20$,8ZL-98H0V0U
M>0==6@KMR[H'2\2B1T)V6[:6"4@E-XQ!8%FP #U$O%HVMVDWH? RKJ*Z!.J_
MKT"/>EGH(,5,.62D< 0S1A# M5L,)V8RO8Q[HHM ?#B.R.VB1D?S<Z\SR2CU
M !ACJ!-(,&@XTY6TT ;P-+'ZI[TOZ@#R"[-]A_PZV6LAK \H<\F0T-HA5@5,
MZG!:IL5__GGOCEI#^OQ">SWKL![SS7KZ$=6[OY\):1U6R&IJ8])QH@ T%930
MBK0J4G_:ZZ36@+XPL7PQ[^*5=$'3DU1 QRE%1/O*+ZP%=VDB^L][R]0RWN<7
MU-6"-G7?GRSKM=KJO7X_,\H)01VQA!H@+=6VIK=FPB>]9H>7<7LT9*"'*Z@'
MF)$!4<P-<L&LMH(0;Z3#U06'UL8FI25!?XJ[HY:AO;B[HUUOA7J[2-HU@<P'
M$<$5"<H=\"X@K04$M;@@)BE7*_HSWRJUA/3PLHY\7-W=C>8/5]?5IGZZW1_O
MTC8;_XR91NKIS;8@Y6^++T]OJC<SK/EFSQX\=J@,8PXI<B)FM:$QZ;0C!DN.
MB;8>.'Q(R^D&D .SKU7DQ?O1?/F83N')=CB4J*2E+V0Q?ST&UG %L+3204K5
M%C[,$>NI6,?>_"7=L40Y!$S_!*E. .,(XJ!A"(B@"(AX4>'A@.Z)QXY*==([
M*S3-@'(4E!>?WT('V* 2")NPA<-)S@%CU7*]%?;R,J TI=_1B2[2H/KN.:1W
MSDC-@'(VQCC=HW9"!A0),,5:>P6(1\9;@J$.DY.0>P@MOK0,*(VQWI\!Y3A4
M>MC#!XY#_?#KZ%_EW$Q' 9S].L*1(V5,&VH\1)89HXB@0:NS6T0%TCSI[5+'
MY;[/K3MT"_'YN>UQ^N]&=X?/D(31,N$\\(!J&#8SH8PA+FEE06!!S6#UCLYH
M?QR/M0CJ?_DM0#,T+>:2V>QT?>?-^P_6/ 1;_?ZV"*T7^Y6>UUMG7H91D>0.
M(!B.>$\%C9 $0<]43(\\*,VG4SJ4;8.52M,W=W>K6?YK.5E-(]@-Z/IZC\QS
MIK3T1H'P(4LYQBY.UQ!,O36>]Z.T#)&VK0"62E\U6Q8W^>S-[+;X7#0C\(XN
MF<9 $&,)%UYAQ9!V1(8):XBT9$ EA5UW%OO?*X7;02R5Q./QV+Y3'Y?Y/(B/
M_^1-2+RC2X;"I(0#Q(19"RJ-T9C'"0LA$40TR33M++"^5Q*W@]APXR!V/+O<
MBW!/\6H'9I%I'PY(*) D*O[54J*B&XDHA[%2OJ^$P,V8MK>+G>%28'AWSI^>
M)55Z<8N\G>HITWHW6J[F3U/(SR9^M?[1_?8&_[P??S>:Q[]]R???I[<PF2H9
MP6LY)_KYVEF6^-K/MH$.9PQAV)D9HDG0PN'.&<&"1*\=PMQ2IB @EF ?9)G0
M!@MYR(_9S:(?"SKL7$'S@BG[A\B\0IQ!")$$UFIG/ M:_A8 XD%/%S5[ PW:
M)./.<BFMPC34V(&=B]0/G\+$#]P1-.B= 2R88TA KQD%"&$&:T( #GKRF"66
M3VF+!\JN<>M!1]^-19C!06=K@]X9M9Y8S:"V@FC&@Z5C;+UGD<:#=>:W2L^F
MO'(R<'\*GAF:0W[HK'*Z=^?MZ',YCR@_U-_?[]O9V2$#GANK<3C+)9=  8N?
MR%<NDHJ[=V8DMXI^V0$^/>SWM_EHD=^6T\F;N_MY^66MR^SV[#7HE6&K:-@&
MW@BJH750>E3O!4+3PEX[\]!WP0+M@]0#'YCR[GZUS.>')<"!'AG&T#.* ?=8
MA-61L,AZ:=3CI+"2SOSW7=*_'8!ZH+U?S0/BJWG,RN*+K_%OAT7 [DZ9!O&]
M2E"PG7"8R<#AU-2GH75)]FAG[OTN.: UC,ZI^/U]7BZ23,IUQPP0B*'R @"F
ME9"6$P6JA3I*TG(:],X,I[LI6H6I!WY0X_'J+EXEQY?E]_-\7&R++L<78I$<
MLXFZ*^?+XC_5&[.C4_VV]8D,>RTI%HB:L'.X"I:]%UOPK&1V6)6S.N2Q,P%Z
M3NFT_^WTOFX9HQ9CA0D*8EV!H) 'D5PMTO"!E:0_AV0Z'J0.[]Q>N]OH^D+M
M8_AG;D;WQ7(T[><K>CH:__YQ'*R&?'%UO]FDQ3AF?8Q7I.L?''B-VO*$SGAO
MM)Z&#C;4)&K2^6PQVFRV^6AVDV\<,(]-WH\>UDG9_AC-)TWNE4X?/!/A7,;0
M6L@D9Y [@B2GD'''M6#B8 *%KN^=#JYPL6N)S2^F3OQ&QCTPA@LM$<<4(1H$
MB]U"R&2BI=#RS56?C++S9JM?G =[]14.J!AD=>B.ZTFSC!E(J.(8VUA$1EHM
M#*E6+E!:":G>+K-Z(_M+C2 =P3YTP>WL#M]&/&N8,0ZMX\XK@(S11'K,?+40
M&(SPX5Y6)9%C!TU/ N."J3NX:Z4S$/7TJR*% .#QJP=>HSYOEEEOO 7 21),
M$2*@@ 36Z\,L*==4=TZ@1%#+U@!(I R$C2CSM%F&$"'.6.4YC^6Q"10.;"?&
M?3#^AN4Z:8<R)P"00AF;+XJ;673*Q,\>")M_M7&&E#14*4L!@C'%DL$Q7^EF
MDK%HX[!<%2U0J0T83GAOWX!0W[;, -2"<LZ=T]X H11[9"7@=)*4Z^[>HXV]
M="H&*21Z/R^7Q9?1UCMR4.#M:)YQ*A0C!G-C"$=,0XTKB<PQXTGZ0F>Y\-L@
M5CM I%#L:F;*& ?>C&"OM\Y,X"EC!6%>$40-0<[5TQ22)VVNSO*YMT&O5G#H
MXZ)H;6\>#CU]UBXCE +IE6 >0628";.OEV&$&6+RB?/;Y:= V ,GI,/RN+#9
MI+$!V,7GXG-9XHCUEC(8KSY(,,EJ== I,5@G02)OO'0Y#@?3_S)L*^ .S>]Q
MP7QZNB9D1HO;:;Y8N*_AV"D6>9V9=[]*=*!;9@BA2D +N+..8BXEKI5NQ'O+
MU-9,-SHOZ<K.8$WAAP]Y^&#,&?Y'P.*NG*W7?<#PW-<GH]Z&]7IM$; 0.Q8S
MFU539LHE!==WYLX9#B>TB.D))NWZJQN%_P /[.R0<0,-5/%UM!#_?WM?NN1&
MCJ3Y?Q]C'J ;][$VLV8X:V6FDF2JZAK;7V%49DBB%9.AYI%5.4^_ ,E@'DJ2
M03 .!*6VME9V9D0 ^-P!=[A_<! 4.HBMV'=6V"1ST%FD*!\%: O0%.E'.LO]
M9!8)-^O8Y/O/$8W)_*'YFG#&)PJF@ @V%P)ID0CFEPBF]ZN:2;MVI[,H53X:
MTAW$*3KSKWGY][=82.%C^6UW0^S'Z9>OJ^7[74_>+)?K\G95-2X@FO[%@EDN
M8Z$(X[U24DB@+:V'RYU,JLG462@M'XWJ#?$>=E(?(WHG D#[9PH"-]/#.10=
M+(FLD/9Q?MBDV.OY1FIDP9]4^/J2_LD3(T^>*N)^3X7%40+*- ?4><_V:0)(
M\N5B)$CA-3E>!,,H)9I;'*)?0?8NP%\G?T_OUG<G1?CLN0(B(3B2GEH)0"0K
M*E@G*CA$*"^>1A+^57O#[^-49JPK]_[S?\?"2?/5^\7&/SAA9@^^4V!/C.4$
M,( =!3K\8_>*[BQ.\M/.]_Q'9G;;@G,H;3D9E3[R5N$A,H:*X,*&==!R(Z79
M;V0"9C!;,]V"U)KHP44P7:5&Y&;F\U*$;#,(6D,DD59,*(8YD\3INN,":IMT
M<6)GAK\5"9R3"#@/G3X2EZOJYL]M>,"N%]/YEP_E8EK=;L,&[\J_-G\Z>ORI
MT0<*Q3AS5!D/E!'!1<8*VOW />RK5D]+D9T.3^IT 6<?>C39N%:Q]_&<81FZ
MO>GS,<TY\$K!A7$!(B0PD 0[IC10]> (-WE59A]25]H!,,5XU)%K=7N[07HR
MVVJH6J^^5HM8L?>0_3C]9L$<=)&.&Q9>#SUQ5/(Z6RI\V(6-*_/4OOR[P;&?
ML_<W97F[] '%N)!-YC?E)OL1TQY1C8^L%B??+3!6P?TR7FE)J-2(4?LX7$62
M3,QPZ:CNEHVVD>R+7O7I-%J?7J+E8EYD6Z)B8T=/<:K::*-P,*RZGBIO<' ?
M"9<!NAH^X4A2???ALE@=VJ^!$.]CI=OV=KDSS_4T,]7RZ"T$QUXKT&9(A!%L
ME8@$-P_WL]( D\3-ZHRW/N3ZUAZ(B12<X\OKZX5F&K];$ @,\ H+ # 2EDG/
M93T$3FQ294Q^17K0%9(IRK"++.SC 0?=XN\>+,*&CA(+I&.2$B894OMDD@#*
M):7!Q+6)^5+8>G9Z=]VM>WNB&-[!UPH,,;6"*V44#HN8]T;ML2(8)7D8\HIT
MHP,0AX[%F6I^7RYB*#$N8_'G5;S0YK?R)CP:K[Y)C=&=_'"!'./2860Q5]1J
M(,D^OBU\6$"38G?@"M6M5YS3PS;5@13HYO3M\;C-T5<+$_0:>.%)/+8;?@P_
M[0<@L$M+Z5Q3E+<C)'/>@?O)=/''9+8NG]2="_NW\F95WOY>+N[@L76KLT8+
M&] UW#*F%:0&&<#4'F!I$O,15QEDSD4&.9SB.TKH_:-<KO9K_DFU;JF9PB-D
MG'#,0LHP8\"B)QE%H--.[5U3M#P#U'-6W=T9E5\VVZ@WNX#:J4K=';16 "<1
MYPI(*".K"A/L\'XSKGQ2U@=>8_Q^>/ OR1B&_=?-.E[=^/[SY^E-<(@WW2GK
MSL6K,-^5?ZEOWZH@F4T<[U0F\?PO%DIA[[Q@@%A)L0(&.D.A)E 9XA!+V]%<
M4XB^7X!S7A]K$!KDMSMKJ[ >"FX%,9(HXAQAF.X3^IB"M+7Q&F/_0T/?@R;O
MK\6-%R O-U*-)PI7#V_"G Q]7VT#$.\7F[#WIUE9.^'3+_.C:GO9AXL "7)*
M*R (#I-?&O\8O0A#2;OL\9KR$H/@G//2^K[>%&XBLG&DVUG8H>/Y75N%BE)C
M'(.XY1088,G=WI-')&W_=$UYEER@'RS(]=(D_&L>A+P)]3Z65'M"^ T>TN8\
MT9/QUHY2&>G%Y:VZ+Q>3+^7',HH\;"I--5\M)C>K]606 R/HE/X/W\.">2&<
MUX(XY3TR  'D]_%)8M)8WM>8@1JGP'(.*'^_G 2[N9C.E].;C:'L)*!\LM&"
M&Z.L%/&4@(%0&.]!7=U#.))6/0M=99(L%QF,0,ECU#%,[OGM/G!>Q5^]7Z^6
MJ\G\-DSTA@M EY.BO4X68:<%/"5>&."]XD Y7U>CD#$[GS2)KBF!.'J9C6 _
M<C8VSPQUAYN7RSI6: ^]P4I3%-0MR,@A7I]LEV$/F11$>CS)?FV3:RQRNHH)
MI;Y\691?)JL7%GW0N72@3X6"*AX,Q<(J1H%0S/JZB)^TBB15MD _$Z[#B6@T
M?F"=LMLS*[KWZKYOLB"(0**\BO>Y N)P@-3OER>?=L ;76V>=G@)]*#>KU%]
M/DZ7?_I%6=9![8]AFAY1UZ:?*(2 SAIG""!:.RHAW5\R(;'32;> HVM*W7:,
M:!^U1AY/:>SNCMW&RSZ6RW)Q7][Z:N'7J_6BK ]V'-&KL[]5> $P=4H:Z %P
MUBJ*]^Z792#IW 6ZQEQKU] VUK1E>?./+]5]@/ ^Z'34,[S[.6H8?J)AV]\6
M;S;_1"B>QY0.[N :O5< )I!D$!AEF+4$>$YJ4IA$.#$$>$T9T"Y@[&4]>F3N
M;]3]*:$_F.AC;MC)=PLK $->X."CQGO0;3R[5 \7 I:V+;_&!&3;4(Y@Y[P_
MK%1[@;]789GM;9/<I/F".18K!R.J,$=4""IH?95>K'V8YI!=;2HP+VD,M#>H
M-_1_5+. P6RZ>DC8';S^D4([K;BCUDFG8?C'TWW9+BD-2KNVX!KS<)UA.K!2
MV>G]]+:<WUZ@4D\_47B*%!?6"6N@,!QJ36I\I2!I=W'B:\Q)=83HP.H4DUR)
M:A1?+<(>.LP98<-&1#+$05B0ZPNYI78PK4+]-69=6D8RY8S"9<Q,M0J6^-,Z
MQJR7'Q9E /#3=+ZE^X3]<-C9J/GMF_G-;'V[>6*R6+W_O#'A'W9W-AS:?6;3
MMV(S/1E#.+C8"$%B--J+0 *>5'< 7U/N8ZRB&GBV5,O5J^-\5ZVRF#$7]:\P
MSBLA&(.8&N0D<DC4M"2I%$FJ9XFO*6,R9G'UX)ZHV48GRMO711.-Y'QYS-=M
M]H%"2&X Y1X @CV3$-C'1 "W/*E\ [[&U$HG>(XG'!4GWT 4J(8]* !@UJ*P
M896 4JPHI,X_;C%04JT\?(U)G#P%TL-<<'??9M5#6>ZLP^LXO*LVJ8IR6P-@
MN3$63_\>:PH&H_+_RM7'\J;Z,C]Q,+2S-@N&/,&24N&)](Q#"R3:[XVD2XMZ
M75/J*3<1C%G#=X24:K'[57SN6 ZLWXX4""E/!7?"6\, <_$:PUH0E.NTB,LU
M)M2RELL(W*$G3,3.#ZY^UU8!.36*.",\#7L4SSS;WQ0:C"Q*JF"%?^;=VH<^
M);;RH5J%7DS#UG17P3+EJH6S/A)K:"-.K1+8(1P\-&R$W.]6E$\J*TRN*7'6
M.::/BO*?_WR$,W3XS\WOGO]J]^8S4/_ZZZ]_K,H_[Z:+R;?0E;M_W%1W_]R@
MNNG9CJ7U-HINPZ+8;5278:7>$"J^P].6J\ETMGS>S?+O ,%M4+L\%^>]@+M8
MC9]H#T<@;/ UCQ=$ BRM)00'C1+:.HK$J:!>1Z"U=<GA,>Q:NT@1&.,AHRP2
M C4*NT!CS Y":TC:@:3S$ZN3V:S;9::IHKPT6P/AO%F%(EJWJ_]],ZO"%__K
M/U:+#<]H]\MJO@IK@)MMVOZO_UB67^(/7>OVFWE8S<K?5I/5IMUZ%3MQA^F1
MMPH05F7G+?,:! .L*0 $UI+!3O:D?P/=8MI8*:JN .W!PS_0V9/W5AY]KS!6
M$0\(HAQKSL(8 4;U,($R*-N[3%N173-]N BJJ]6,WC7BQ)VF^2E$[XH03RN$
M9KZJ^:TM[\M9]2WV>N<9G[ZW_O3;A6,6*&"AUIH1@ F%W-=#=H0F%37HC#_6
MDO1>7G#?.DP]:,8OY;Q<3&:AS^KV+HA@N8IW3MV7376CT?N%T8(P9 4/@V:&
M0V7-'E)/7!I]>ES:T050?<;7-W6;_@IC6'Z=?HNEF]QO[S^<EZ$_^UN%0)A9
M'KPXXY!A#'D#7 T'9[ O4]-?M"9Q&]4ULCT%;=Y5\^UYX"=5PM1-F"73U</Q
M*,VN<WUTY'U8'A;E8PFSG^&C@^J,* V:Q1"52CI-/8">4>0EH5X0*T]Q;7Z&
MC\(.UA'E >.<!?2D#,L ISL(D55I]^#E%SYJK"C=A8_.PCG7\-%V0*&+)P)&
MSYXKH$"466&=(=(R(Q #:C=V#&CBU5>C"1$U%?Q+>MP%$.:0]CT(R^/ YK?1
MOKV;W)4G(P9=-%=0Z;F1  >)8"SC82QD:U"Q!#[;$%2B;IR;TNT/TY\*VPJX
MN47&1JRGE[,/(N_^?C(+?:FO18C=G\P?=B4_-FGN@_&/<S]18(604]03(#6D
M"C"D43T@975?NM'25K93D5:]0-S#FE8#<,(;>_I8\$>\,UA";P1VDFALA'Y$
MB:?55[EV9^P"!'M4@Y-&Z<6$D18I[QAU4(45&?,-]7:W*S(!FFS]GS1Q')#I
M16",6+JY.0M#"/5R*_]^;IY%ZXX;]->?+C!4@&.A(3$@UH@P"M6C%1ZJM"M_
MN[+=J1!7;>/0UZ;A@NJ3>][W\YNQ/E:SF:\6\<%36XA.&R^XH!801YCW7##L
MH+>/<3&1>(%OQOF/Y#A@;J(8K^[WK_"%8080:#GWF/G(&-8![!VT0,*TVZDZ
MU?),5*V?67"F?%*L=/+241^>7ZX6Z\W^XN507IS7W-=?.>0!]-^3PD, K-9&
M4:.5)$1;4&]ZA.0XK3;B#Z3^XY#;""S"'_V:@]>:*ZC8\.^ Q(8Q;Y@P!->@
M<I%V0*?;VCMY38:,A).%(7A>7WYP:]"L.\'B!KL:,-82*4J,A%*['="2H+0K
MHKJMI9/7+!B1\$9@%_8"VOW_()7/Y720G</Q'A2: D(<#:L*E59Q!*VL3;(T
M%"<%:KJM[9/7O,E;7CVQ$)\<A=YU?W-SZ4_>7^,P#L0&:,BD!\(A&19#*1B%
M1C,CO1(GXZ4_>7]E@6$ 4!NF*1.1#,PW9;4V$#K!;4_IXJYY?XT5I3/>WWDX
M7Q?OSQ&KH5):"(BT)TA@!>JQ(TA[8M</E&IN+/BCO+_S(/Q)HVI$% E>BM .
M84"4AP QSB&O077(BVSSWHFZT0>?*@W3GPK;"KBYI?)'K*>CX_U!PC!$3 KG
M  5A]R65JET<H_NJOS D[Z^Q2%-Y?^=!G"GO#P(%,=.  28E=]89ANM!2'6R
MU,ZX>7^ISM@%"&;,#..:&R>QEUI;AKT+FR17#X0":+/U?]+$<9PBE@;&B*6;
MF[,PA% SX?T)"#02%E%!E;"281GK.6^["8'KBZ*9Q/MK#'$#WM]Y..2P:6A>
M[?(,KE_K#1;* ."#[E)K9'"[J>/8!& M($0:2$=V**3#>%\.\(]+KP<HUNL%
MTH18KD4P# )YXQ#:+Q/8]F79.M;FEE2J\_J]YTEC7,H]T,4<#7M0("PHU51
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MW@!5#YPJVM,1I:.I@OZ$6W4.8*XY@"=#W?_X?Z?E(O3WZ\/;\KZ<G<@.-/M
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M^;-<FNKN4YAB42JFVJ22XQ0+TVL:Q#/99JBW0#Z\J^8Q9[S).QU4J8N^6P@
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M4>U* J^JNDS7]<HV$]=Q+&SXT/#]P+>"$+FFYV/?QX83FZOF*U<D__#[EQY
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ML<KYU-YC6BG)R@+4419Y,;Y/B&[;'KVK_.-P8A2%* D"&!C8CMS$" )S7ZK
M22RT!W-28)HU6.'ADX^R1^NG=?3ID+!X'XO%E(G=JVE+O#I7O"+GLWI\&5M5
MYS']Q=;]V?CGRLD/\+''PO,-*O+FO?#]P^&!&X66X:/01'8"?1]:..Q;]9#!
M7ZY6T-9T<8.I Q.3=8]1(&]502I'CC\QG](:?03<Q(0*3 XF)E9JPO!L9//-
M MXV[-C,0"$E"Y@MJ+2FT--Q1&<573N?R0/)=V1E8BM$ ?W* $>!9P2L*PS[
M4'#DB5WH(OSU(MU?ZO*6 1$H6TBBR;DH7[P)MD:B1 6X9^CS&PQIRF^?,G$R
M1Y4D;2EYIBS\%[GB*!ZX\KUVST.6WR2$5+]E6U+514ZH4GTN'M-M_7B9/K;I
M::]7R/#M .$P=$PO"6++L2S88; M-^#/_I2WK#D7'/"":PKX#-SUD)NTL&Q!
M@_L.M4 RH]X%'+GBK.R+"9<HU%FI%\@J9W7!=#FFJ)G',DYM="T@_]1G6S%%
MAQ/+3;MM=D-4BR/;MPS/\7PC#A)LF('=']NUH>MR;?N0_>YW&#.D:>3+6'4R
M**/[9*9\]1D/)])56<:6D:U*HR_4]!O1ZTB:;Z]6V(->$M%OLP/3=*'C.K[;
M?[UO(:%GMKF_5+-:?"WJ="LW?^7GA4\%M% B-OQ["%/?]=&V>F*\"W.SC($N
M#OO%11Q2=G/?QWF;EN0JK<B&;2^C6M*DI@=K(-'C_B-=J@*_I>7FXKZIKGTJ
M\@<:7,GFTXXMUU]<-Y^N/A?;;5*4[(,K/W!CP\&.ER1^X-F8G2UUK21TW"1P
M M,6NI]S?KBZ-RXQ0!\:_.#0QB>KIU>/X/!SG:&@L?0,=+:>@<%:^L?&7G:3
M1&LQ^(/9##JC12_RG-\+O!=[SH]4XZ:N9745/3> :G?@B9BSH-ZSC&BV)$*>
MWQBZ(&A+B, KY"'#,6/?3VPO\6$"(XJ_0VN$9K"Z)V56;+[4:5G/&GS?1"JB
MH,^-XA93MEVI5\ K<I/E.2L@7*7T0VL"?LIR4#5HC]^,ORSOSAH?E;ITD4'Q
MAXB"TX<^[H[Q0\<[?A:F"7*"7N$[9L*^.7H;:O0<*O[G+JL?S_.*;0)G!=KG
MV/].LIM;^E_X0,KTAB1I5OZ-/12S2DS#B*,(01=%,'2<*#;<WHK0MPW^B+=4
M"^:/A&?@6P<>I"UZ<$WAMT_UB!PJ61ZY7 =ZE@=;<RB=U-AWWH%$3CXM#[[V
MA>SGIZN:A!JT*=CZ,%5+#U*UZZ)\\>%NZ0ZDC)#A$WL=8FD::7@"V9ZHT8>W
M)G?9L47Y!7>>!2SK+YF=XGU(P+05C+^]EI*Z@<D>4S!"&WE>@KP .78/U0\2
MN,K)34K_V32E"RF(7((:MH)Z: VWGG;@0.OU^8H4<@Z<ID*ASW.SER?^]D/4
M)EYSD,;"Q*C^\&-4)<91H+@DH< ?\]0C6N#G^64SSSX:<I%GA":U(@HMZ#HH
M-,,(=Z:$CN6[?$= %FV"]F,F3^/<G)-$54Z?H]0P@[=GKC?P6?PC]*<Y*P\S
M]*OIR@]-2"Z;"NC+&D/Q1)<65U_@<\QD10;%_>1'K#2HIDAKN4&+/R??-=']
M/2G*:Y*]S$0CUW <[-*QZH8Q]"TS#ON*28A<VYRV#*$*M?;*Q'X-:1#)ZQ[K
M C93C'7ZQ)LKIO#V[-6,P=K^1V"P][V7.#@=.<5V#$5=Z<<HA"AG1==V#:5>
MFWMC8N FON_:R ^0XUNQ&[I!W*/UDS#IMFG@?.J@*HA3?#-&;Y+45@R2;T1W
M)"Y;#&??B\;KX!],[&19F&@OFIA7EKH7S74BP\8QCA+DARCTPM ;9CV1&WF\
M(K=4_+.*G]PFM/^[RT.9UW_$VHM"=F;>Y2'F1=YT\**\2?/L7PU\1'$4VVS3
MVI)O+MNZ:O/7B^LDR^DHS=+M%_J3[I[-_G(+*_3LQ#619Z, VKYM1!&T,(PC
M&!BN8;WUS.^T8/1-G _QGX$G%C275!S:P&:]@Q5@;P;XHS=DXC-Y2L@_D>]-
MZ]QE9'<3VUS,.9S$=.=36N]*<G%]0=.(]D;'E<VR0M/%;@P1MOP((\OK&K*@
MC;D>41_Q]9I/@+>(V*BG\2/+2=5>@7N]:W\\X!2KG<K0R*?%FAD4$]8]>7LX
MX(^OY'L-(CK>_IQ8*E]R<T+W1A"Y#!$;8T"AK%.)O C9K2-3F<-YW:1;UT5Y
MUTI?+VN1XWL!=D(S\)'A1;YI&H&=6#@(W00%P5O#1%U#^D9-#Z\1FA8@.$#(
MDVGH(E?D:<6I29[N.C\>TX[-(Y72LH"9GUI["ET=B$^&-B1;M6U])C<9:R*O
M/Z5W9.5 A"(/^FX40]/&'F)OF'?-Q ARW?@J_>6:,YQ.8?:@ $/%)RWRA)V6
MZ4FX$E-E09I.)# 56?]R4SS\2HUL<Q?ZA^<IRS$"7I&5T5S-JR+CX1>*^@R_
M1O32])7^BY5A(3-.$BI#?NBY+DQH%M1_/?T)UYM]PE^J61.&%(2!X9<",5[>
ME@!ME$@F9"?94##B#^T],M*E*)E_A,O!+D9V!?X1C79E2;\]R:IUNOW?)"UQ
MOHG3FJQL)AE)!!,#>VZ4(!N9?M]4Y'@^[^B6;D#S2.]P@1888,CHG&,#&#;^
M@2]/W]LB, ES8H(@19H"?3A&Q1&M&,W<_+HQWH1"84\2G46@XNZNR+_4Q?K/
M=CW]8E=7==HLGZY"QW82SXEC)TDB9/M^; \BEB2(.V]0T-0T,XP6(F@PGO77
M&1[ %)URC&.7=P(R&;%2TQ%I3I7-3T[Q<W*VHH38^15*I3$O9C(*.>)7K<O=
MU39;)]LBK5<A"AS;]8+ 08F/' _YD=&W$01F)"92(M\\C2:UB$ #251_A'CB
ME1M=%$FI"Q<[RI3DP/23PB%#T5)T0@K["UF09X!'!2"=9VW87"O9IC>KR'9<
M',$H#%W'MQ([]N*H_WX+A=P3(+%OU3SZ!S" H>$?^(+4O#WH];$B-N Y"5$P
MUI]8?&2<R[$R_QB7Q%V,[0_"\Q+"7M7;GN<;\OU_DL>5'UM>A W+Q[9OV#!T
M0SHAZMKQPB@0G(H(?OM$LX\6%6A@ 8I+>+HA2AKW#$,C7W*3"FZJU,TBGG)P
M>N(@R=?\^C 2_\OIP2@F!/2B+9Q\)O=%6=.I!]MNMJM6V/=LV\8TZXA<Y*(D
MPLE0-L&VAP5E0ZZ1B=2CJ_@-Z$ +3UA$))GDUA+]),I)BBA_ZI3E549."\PX
M$A>C,R/->"DW*GCA5YV_%=M=7J?E8Y)MZ<!=^19T$H/.=Q(WL$S#13C&PUX/
M0W03ANBW3Z,S RK0PA+5%V'.>(5%)UU2BL+-E#(E>4;!20F1I6LIVB&-_X5H
MC&."7RV:KT=I36Z*\G%E)#:*/!?%MIF8@6M&T(5]*RX*N=Y&E/WN:92BP01Z
M4*(Z(<@6KTKH(TI*(S@Y4J803\P_J0]R1"U%'231O]"&,2SP*\/?R7;[/_/B
M6_Z%I%61D\UY5>U(N;)M#\5NZ/D0V?3KC=@QALJI0?\JIA&RK4RC%@S=AS\9
M/-#C RU 4>609I-70Z8@4DI-)#A4IBQ'2#FI,6.)7(K:C+;CA>ZH849DI^AE
M?^J^V6\2A2'"R(U-!]D^A!#[AM6VXQE.Y'#76^6^7;/B#+LE6U02N\DD27M;
M8/3S)28LPE0IW&/ZA(,C.C*.K_GU8R3^5[:?CF%"1"_V>]02^I-J988^AJP=
M@TZ;PBBT_03W+?F1[8HJANCW3Z49ASLJ&V3BJB%,';]NZ&1-4CGX"5.H'<]X
M>$,]9%E;CGY(6_"*@HQC0UQ#6L5JVX*>Y89)!&-L)1#YM@U]LV_+"V+N!1OY
M%B;6D2ZNCE(2(0)%M407=^/4A(LVY7IRP 67HLAPMS1-D;+AJ*K(,\)[_P?;
MD)K5[4TC^085.5L'(ODZ(U5,(6R+:E>2X72N9WK(LN,@,J!M![X9NC0_HKE2
MZ 6A[22\[R*K;53?,#K V9S=?X(4[*'.=E>0$)&OC$&]#EG&M1F:;"NFZ-*"
M=XBUMWGD-Q])6I$J::ZT^2W+L[O=77?W617O2+?JN_(BPXSL.'9=/W1-MO_,
M,'L0L>T;(O?\*&Y:<U;1)-<DWQ Z.R=KTEQ^;9MG@(XR3^S>']64\^GGC&R+
M">@ %+1(ST"+%71@^^O*J9CNR!GXQ"X2^OJ-;!_H)^@0NIWX)G(Q7D_HJ28'
M+4-0=1GW_-8TG1PJEM3S_.NW@JD*G?YYT$H"WS$3ST21A\(X\#L<T$ NUP$;
M?:W/)ZR^%F$5(5ZIMFKB7).\GC%]!5E.Q;5H2DO+%-8]J>.U5<)![TI>9>R3
M4UAI)M6++.V3I$42^A;T(BN"T,$^\B*$ DR1.'X0.[:%N"I?.MN?3V@#74(K
M0+YJJ=7#NW:Q9;"7+;<#L4H$5]Q-[TUR)2R4%EU9-I7+;D*'1 LDBOW(PBX,
M8A^&;A3:B0,;(!!CB@EI45W^YN<3W5"3Z I0KUAS];"N6W(9ZD4K[D"K"L$5
M]]$[TUL) V7E5I9+Q6J[LIS(Q:YKPL (_##$[":T/L6V/9,FMD6=;I5*[)MM
M"NGJ (][F'>#^JX;U,VY,K;<0JHZNTO;5RY[(5@7%7LVN"^VGX&<U.P^\BVS
MD"K 9K=N[\W7(LAO>T>I"BMUC,;*[2*U=KS <M/_KE25WRHY*15DC5<_/V?5
MGVQI[7?V8GB=9GF=D8/',;!EFM@/;". @14$M'7';4H4KDTA\#ZV,*X1?:.Q
MP=5HXA-DLZT[G^3IQ,!3P^\RAILB6PH=/5#P*=+U+=GLMN3B^CRGTR(:7>_3
M_#$I2I+=Y.WZROHQ:A^'^YI>;<G*-B/;<@,KC&P_"%V,/=/O<?BNS74:3U_K
MFJ>!/6"6=AQ"!AUFT(,&'6KP1X.;\W4'C5[A$\%Y'2(FC.I]H>=55U%*3VBH
M/O<L0U<UVO?\C57-3/+OP:,-L(M?V$L8+ !$C^Q6;/@]JU9F8GJ!9WBT"<OQ
MO"2Q(J-OT80AUQT)*MK1K*E/H &&K;F;G28X%)R@<(ZBDT\BIV)23 PE2=2T
M,_$H0R?W(8[G=1DJIL22%WL,5;$CK4RLO;BXHWGIR@@L,W!"SW"Q%<0NMD-L
M]RU:7L1U@DE%.W,I4PMOK#:)$"JI39JX5*1-;]$XC3KM.1)1)PEF%ZI.,I:\
MI4[2[' ]+O@L3</?[YLMUK\URW*K #N)Z<:N:3H.3=JPX\1)WV  ;:Z%2@7-
M:-:F?I*S[B<YI(,G\([@2!Y/:]+$%(I)THLI8H\,_-%B$WF.<22- N\P3D>G
MU .,__F9W+=O&E>@OB7@^E@?_857\H\\VGB2AU=47"%Y\XJX2D,*Y1U++,%\
M>^+],<O)>4WNJA7R4>PYT WL(/3"D,:4< @B=N1S75RNHUW-(L]9UF)X00-8
M,"55Z@*^%'4N]L7B@T+BM22Q BR>2&IU^&(92:X6RPK]/5EPBIY6M^S_\#]W
MV4.Z[0X@?KDMROHK*>_.\P=2M><25T[D63Z.(S=V;&A@(\;!4+T,8Y?K?C0-
MS>J>P%.49V!-_Q>0/=AF,;5B<#_0[[P#V1ZPX(Q>(?^<$_QYJ!><[S>LL_\%
M!SC/&MJ_[&D_YZ!=3P6 F\13!0'UGEB&=.HP['FY0!=WO,()U^MB1[_^,UD3
MBN!J2SZ1>F7%3H"A:[K82EPK]ET?6T-;*!;:X2S7@F8Y[$&!<D E)GB2O/%I
MFW[*Q&1L8&L/B!U3EGH\2UZL7F7EA"Z-8W$9$C32AD)EOQ(3EM_SJVR[)9M]
M6U5_2-F!MI%$GAVX9NQ!$T$'X6$2[;OVZH&45P6OOHQH2&3$'&(2&3CECFRH
MRCR0_,0.4>4,\NG,1-2)B4T/ZD!L:,;4X9I6<8[S<T)V%)"Z#.U184BAO,/)
MI3>7Z2-KC>96W9#\F*442L;V%78(Z.\^46(Z.);G^(9GN8[A^9[M.99K#"O)
M;FQZJYS<L$WY7\43(>58N,9BV([%%[#%DX#[%G\SB4D[@=ON39#+H]0[2"S5
MFL<IX[*QRP-'])'F(X<CM&9GHD1R)'#:?+,,G=5OYI$T4#.O7 O8_?K*U^+W
M+W&QW:;ERK<MPW,,;"++3PR:D,9FU+?B>2'7V2_9[Q::=HJ?\1K65NL"_/X%
M;!I0 NNK,FQQK$UK)DI,W@:.OC8<Q5-P)+#PK)DK):O-Y+";_?+EEX[$L6O-
M+TT_ML \@J0%K"J/05^HZ2IB66ZTJ[*<5!4J[JZRO.DZ^^L6OY+O=41M^W.5
MN$Z":/,)='$40]-/XL#"$'I&'& 7"MT6HZA)S66^WTAY0TKP+:MO 2RO=O6N
M E%6W-^FY5T*SO/U+^"GZZ*\(^7V$5SDJ*!CAO[^LOG]6?.!G\7R656NX,M>
M9_""F)CW ,$!PB=7QC*0H$$Y\;HQ'W4GLE/%W"\C%U5M5*&UOPKDF9](_3'[
MYR[;9/7C09,L_]VW&]@X-I$1T; 7QXX!G<!W;!NRZZ2P8QHV]WY)):UIUD:*
MD4[;.Y "^94:)CFRTLE)%),VQM^ [ZFF-;-R'F73Q:Y /CLYRVKV4^ZV6U!3
M VA2!39[[FDP;WZ?'W;NL7DO#T7',F&E]"X@-U9K3Z&K(^H[^ET=A"F<^)[C
MVJ%M6#@(V(.O9@\&18:EZ_RW  3-,>3PX#%YK;;Q9,,S_:**;-@%52C-TTV6
MYMVG!&O&NMS%EW,OP%-B@4KX='@E$L)F/RE>\23KFIVVC.1=MY$C#HY+<RHN
MX?T< ZYI,*DREF54T>/!W]I#[ DT,/1\VK;O^('''KSSFDI,;(2^%TA>WJ&H
M\0EE>YBA'T(^ U>/AS\8>W>'*I^(*O0,[I#79C6>T*S'?(QR*;%BYRQ-@U6;
M=U1]M? H6GH^:.[CL-<_<OS$=J 3&IX;!(D3VG;<-0D="PF] C&J(<UZ^MK(
M'7$6:1RG8I5C[71*UHN%F=1:)'Z-)8[2\"AREZ%G:DPY4@96P,^()3)$=3+;
MD/:H_M<RS:MK0I/6C;ER$V0[-K)=P_,C/T;0,& /(4I0(K9!56G3VK>L7M*?
MW[);9"_+;"VX8U4MR=)+8-.P.WXA[ P\00H.H,Z^%G:40[$5L?&N6)8,JC7M
M[=4Q5?R-D,G/9%W<Y-F_R.9\0_(ZN\Z:36-51>I6P"D<F!_N':._V]V1#3O7
M1']Q<+1I91NN%2'?-5P_B2,?V]#H<U (#2ATKFAFJ)I32H9HM/A.ZCIIN5ZJ
MUU0(_-XV<&@<:*T#O7G-%MX# T%G87=VE/WVP,K9@X-"CXF%DSFZRF(#T"QD
MO!VRYO,1UT:05Q!?EL4#G884>;H]S]EVL.:GYSD%EVZ[S=)9?G.>LQ+WEM0$
M;OZQ:X_E,LPK&G!QPJ*OXV",:%B.]C,6&)G\VT9FP*9] U[*U@09'- ^XP[V
M *M6W@1V1\SA/(Z=*@OWFXI =F /.#"([9%L3 )[F\#>J+,#;[\+9PMLG%FX
MT^6VV<SD?+Y]..H9/[9K9T;?+F"/SYS6%\L883/.FKN#5\TG+TMRGV8;_/V>
MY!4[J'51WY*R_=W*-4T+!@[T#!-'0>2&1FCTMI@AW^V>R[9 <W+286-;DQBX
M]C:D@N$#:0-PQ@FXNEXPP[Q\E@ZPC.EZ:WKW#UCD;+M89W[S#QL"ND^\XZD\
MKY.GFN$K[W0_X,1?/4<ZZP&:/#I#F> I^BI]"C_V?!1;D>E[+LU,;-?S7=S#
M3Q*3ZT;"Q8&>N;"@*+8OCM;IRQ'3=8.EU"F>!>V*/VHOO._,5MV8K@\MK>PA
MWY?FJ(F<]-,TQ1(U7>6'JZ(HHD5?>46EWV:ONQS<3[8*O2!!=N*%<6R:1@ Q
MMMP>NA$$YB+*+"* -6=FHZ]6701)<Y=-=#ETD562 V-_D(+(@45SU#]D>L\/
M7NZ0HF2JZH:\OV8H9KR\17B5A*'CNCXR$RO!R'+<V!^659#E<1VF6P;2F<L6
MTL%S&>Q-7YW0[.*EE"1>N8']7?6+V2H/FOO'TLH-(OUDC@+#2W=,4U48T0U^
MN%+"&"[TU0]&>VB.H@&U]YZ4]>,E'=YUMW?UGEFSHK!C-_!LB^9PD/Y_R[>'
MG:MQ$G#M"5T68NV;,5I@S:R1]*CFJQR,<.WTI8-IO+J(VD%O*OT3,_9L.!QQ
MNK\LOGQPU(43U0_&=Z$?KX"@@!.-%015'AL1.$>M%QQ#CSTCL2'R$L_&@6F@
M )K)L%80)N[(T#D+YMEW0V@)KO.X7SJ\+M[S2ZDV+#S&ZO"C6)2=M2<M-L[.
MR\K;D78!7IMCDGJ>UU0VLF9Q 3D6\FT?A8Z'#=O%7AQ$ UK;F&TQ6P2C]O7K
M;@J2#9AF/PX@Y,+IIY^ZO+>("6>248$@'SYF#^PK]I;.'@95N&NBR:5,!UEL
MF)N6!8T32'FOS#-E/,1K.DY@V0Z*$IB8"/HFAMZ^-FQ[\TT215#.OMJL+=1-
MY>8Y)H.Z/+R4Z=^2@IP:-TTVNY/I&HL-=%/SH'4&)^\9WF#WUZ+8?,NVVU4(
M0R=T',OSK3A&L0.1$_9?CTTL=#";^TLUAY(>AUA@X*>$3\>UL"$FNV\2H449
M^U9/")DP-\O0'7'8Q<@^(3>J^WM1]RISD$JMO,!T0Q]YGFG$7A@ZB6GY?=M^
M+':QH9H69TXMQ^G%2++%Q&0ZGN64AB9U_9V\!\G; <9YI.@D;1PZI8;V98F8
M(IN.*)Q*QOCWC5>*J@T\KXZOL.G:'L06"@/LV)[G6(8];'ZW W>5DYNT)INO
M(OO)%V4!EUZ$K5Z\,%;\$-9]B[4I;Z8M6K#=PQ7=1+PH*KEWFR\*M>:*0/6L
M),!= (>O%\#W6XH[JYL/=G8?_H/WW95$-Z@O"KW^'>O/GM]\14EZA7DF.UTG
MRO+FWUWU-:MT__+#V-<Y)W?'R1WKB^P72]G"ODQR7NQI7R;,N8_[=5:DKUKA
MNHEA((1<'%B!9R+?B_KD,T*&CZ3RMF69,$WBQGU 4'%BMRRNYSM'J+^++&RQ
MYT5ZEZI)[Y;EF?D/($[6L19[)%&V@\UY3O&4UZ8]N:BD_RPE$5PH._I/-RKT
MXAQ;23]1![?W5AS\KKGG:95$01 G%*D?>E801=CRK!Z\9QI&GP%.O[=T!&B)
MG$\LW6MO@LN+_$,'43R'6QAE,VP_U>W@)>U&W=MZ^/NS]DK!V7?K:'#A1#M4
M%?2A92Q%+8T4C?M7E?ELAJI* Y,:@%X8L K"&-O0BB,WCD.$'&B8J,=NQD$X
M;RUE!/!E5% 4A-QET3I]L41W'UA8B:3M,=3>#^AEZ'V7/6:V:LA$/6=I-1"Y
M'C1'X>.X@Z8I=RCH(#]<D4,%)_I*&\H\-D=!(R;M>]I?T^\'O]PGEJL$AAB%
M0>@&)O9=UW*BI#_>&P4^-@22L47BGR8GZV&"C'4@ NKT^Y!U/<Y7YACO_>F+
M'=-X?$DECZ'S4).??&)O]/LM?+SESHG*'\IZU8]7!%%'C<92B&+_S5 0Z2UH
M?D<.['A<(8B#P,5.[+C("&,WBH='.R,O2/"\!9$1P)=1$%$0G)=%Z_0%$=U]
M8&$%D:''M/8^"<SOL\?,5A"9J.<LK2 BUX/F*(@<=] T!1$%'>2'*XBHX$1?
M0429QS071/IC9:^OK9%Z9;FVCRQL!VX<.$Z"0FSW=\)$$8JM55W4Z59KT6,T
M1J%CL(,YW KYE?T3<-^?S[POLS4!Z;89:]3$24H;X_VHM8HQJ0LG+%CLSSB?
MG=BN0=Y';>(M)ZDO0RCK%N^ZXJ".!37%!<5>F>>>,%3D54;]W?R+KV6:5VU
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MN?"GH-RVH4_WY<PQCQ2I&F:Y7.?\7%-<TC;%^:W"X,3)W7NC5U!6&80^ E%
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M&R)FA'4["M7H->GU:W^Z^1*5.UK<%75=;#[Q.ON'XJ3T-?YQRS[IMGU=&B3
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MG*RU++<@G1.4]DB<,(<7)$]_/]@A@0;LJDR/8/G0;<<+$;QL+@R3. 91["<
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MFD#DN478''UCP:IL%C.KF<>\ZKKM9=D<GK=<,XRTW!X8L!=HXI 22&(<$(\
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M_WA?W-?\/?*Z6/.?Y9NO_)AT6]RHK>M7/I4;9Y?OJJ>\WI?K;>'\Y5__1PR
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M-*_)U8*322)R_SB<@!K:[[<HT2-_;7(59G&4@2Q 21HCX*8I"8*A11<'0#B
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M$=?#7D;\;&@I\7RIW5V5SS<L41R.LRF>JF;N(G]OD'%ASDRASHZ),LF"2M]
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M)":-UO20G'2>=LX(W.F0.PRZP[$[S\'W]6(=CM]I#9CY.,<4KB\(\"Q=:(=
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MV%KNA"><A6C3\_#O"C:"\?GL+?3,LO8XGJRL8R(]%\\5S8-2=T_96Q[/)&#
M$4(<HD9AZK15H'8I$$K<#3TO5J7H];6 \#CLC]C@6I]1>ZA5T&A;Z_5&&8
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M8)VH09:6GL]EZIVPXOG$UQ7N_=2&:6%9!UDBG*(PS!&>(LLI=Z@6RZ3>A3U
M<]8'G=J N ?F_#;]6DPF<7^H&F95C68'?;8WRHC"P&N&XU673$&CB'&U5Q ,
M?QJ'#C[=V$>YLSY8U!K2/1JACZ/[.-!@/#=UCMX7HR!%D5:T*JG+##'" 4.4
M ,899K%T91W]4 L3*\(T/UTIUS2<YM>C17[YY:PL6L?*2 D;J]#D2_G;9QM3
M+K;&BB^?S#A&@!'@H$'<@V"4+=35\!CK[VZL<C&:O%F2M /N"7<UPNS\O@BN
MWV6QN(]I/2N4SFY/@P"KK&(8.NO"_["!VF*/G!!Q!YKOJ_E_'F&38 8#P61P
MN10C$#"@9 4"USSQ@Q]@V-02%](#I<.0_L%\% 6QMPA;(S7@(9CDA.@-.-[2
MU*3_YN'64Q_E#1*Q)^13')+'L\DV5^3Q,QF3W!F+=)ARI9'$86&J+\4CE5I7
M[O"J,)T[(>U2X5@@3^APG"Z+OQO70AFBO18,8LV8Y]("[3%680S"P?V1?\*'
M]2C?;5]>?>.VF<#.0@-T>*VUL6B$X*02(\Q@YY,=WY(VMWV(+0'<@T]PR.;&
M_+##&X=TF'GG.2/!5<(@FBOKL(<5,$:#Q'38 2Z_MLN\7E'O?KZ8EY/B,CID
MFZ%^OLGSQ4FFB<]!BM4Y@8LK7TS#6(K1Y&.YOBJOP6S1I'FF)8+>:RDI=<03
M!H/[12'C3B@.B8.G29*=S_.=9\E??S"#Q@I(J&'2&:&59-K6PLCPW]E,'>VJ
M]KE7?PRH?820J_%5<453DCQ[/@L>JHU[B"#N(5+,G!2D$HMBDWK3PO"XDJK.
M5UEQ'(H]90#$8AO/ED<69C2;W1?3ZW^,)KOKE31IGV$,#<6:P_!AA=G1,JYT
M#:+4Y[. =:367UFX:AO</OS3PQ9"7UV(X]8Q)J1ST&CD)6"0P!HRAO;-LV_'
MMVR7,2U@>:KLC_V[^+N:9=(+'C?K>)B^@=$*$83KKX"AQ%R0 58I;I<P+6+Z
M!I,_+$&,6D1B<7[ 0+"AF%<">I8:P0ZPIG&[I&D-T5Z2;$.PFG\9?<\?<7QG
M.NTKSV<*"D6\]@ ZYD*([Y"KYU@J4AV8 59 ;I<H;8#9 T<^SO*[47'IOM^M
M2G)/+U?U>9] L8,Q#5IGAB$J8QTG SQ6UD*M:&U)-4T\X3' PLGM\J=]:/N.
MMYO&V1DG1% K+#(&0$H=$Z VG$+8?8<W6W-X.]]/ZR*^/A"]7DQ*>9?/%O<?
M)Z/59FZ,WU8W-OY]5LYW14.[&V8@"(I#4(>L%50)ZA"T&T&%8T:?4;IJ2T1I
M%=!^@J/E[7(25]1M'K0R+E;:"G^?Y"NU32_5;8CRBG^M?KY5O-V!5"NOR("F
MFAH-XLZU,8X8+2J="*)3;_I-S5I]"VP\$?2GM'B[3W;L:I9IC*F!A@7' 3'F
M+/:Z6KD0V)'$)),!9KIV;>L.![,'QKPOI]?-EPE?>3ICU%DJ8#P=RIB5"(H'
MD9A+W908Y%WU+3'D>!3[.1@[FEX7,45N)75@K_L^GBPOB^GUW\OR\L]B,MG!
ME";-,XT,@PYB:R#!0B'H3+6V);A*72\<X'4F+1&G U![8%(#MCP,7H"8Y8L<
M1HIZZ! 1]6=@"$U<#!S@5?(M,2(1N-XB\+VA=X:=))8B@#QS$C+JI:F6#@0
MJ9M,\FS=BR38^G D'M*G8V+_HAS_<5-.@C+FT0%:W#=(>FC:18@7(0HH :P)
MQTR#$"/RFNR.)KH< ]R8[#1GIB.X^^5:\Y2:[8TR(YAWE$-)'>>QQB5[^)@H
M@N>35].^RK=SZCB0AW6LI\&&>(->,L=]L/J,*\KB?;-64>YJ5 ,XY\BS9!JD
MG]LY$.<>J/:LH/9^5KW>()-!HC"Y6^"AYTX:QY"O!--.]+9!\18)U JD/7#E
M]U$LMKXZ'OFIN+Y9S"^6BWF(^V*0MX,QNYIE1G* K?80 @@"@$+JVIP[9WL[
M*/86>=,BL"=QC0YRB3*"M+2"&,&%".XD-=:0A]6#5 MS>#9.Y^%8!TPY&L[^
M9Z)&AY6WMLEB40?L*+8*"B\= T+4].>4)U9,&?9\U(WCW!;&/5"H.H]JRMNO
M(2B-RHMW3P5SF,=;FJ?S(N"R.<NT1NV^$<V.ZC=3@@7@M3,L1,+(0X:8J'=6
M<.HVU;"GN&ZHV*<>>K1X7T;?'T%WD.';UC1S4EH=)GVH%3',$1WFC4I8J63G
M%:/.AW0M0]VOI]7,Q<K@*B'7<*BA]0A!8;&JG4616GES@#OI?2XS'8AJ'T=O
M4M:^=X#DL 0>2(4!#%,_U%0P5@EH86KP-L"\U<YITQK(?1P*+&]OR^EJQ'O/
M_SU[-*-60 .E--QC*ZB _,%6>HT3@[@!KC.VH= 7I>R/ K./=>O+R]4&T&CR
M<51<OIN:T5T1+/JN->K76V3!-V,HF$\*98AV;8AW;95W*;&GYQ.^=<"3=C#M
M@2Z?8CG":7[I1K-I\.'G3[(?KXIQL;-ZS][&62QY$1 T2DLMD&> U[G_P4+[
MQ,VS 09>'9"H=7C[S8U>G02)52]G^4V\;_I;OCYL]+Z<Q]RDBZO@S3=+@6[2
M4P9  !99 (%%QFEKL:\6TV0L$7LVT587YJI3K$_B51_D36>.8\Z),,$\*T"A
M%I*H^CL2,M%,#3#XZH \1\,Y@/RC(_*.,FL<4<PSZAWV!JGP[VH_62+ $G/4
M!EAG\:3Y1@?"_,"I?JMJ?5PA>9,OBO&#TWUN);:L15( +[P1'%'KB6=RK0JA
M%$&GNEZZ#LT^E$$-!\3%#\]G" +(@U\>'"G.D>&"8E^)IL49%5%J5]';P^1D
M;/M=1?D<ON]\_FX^7^:7S4CSN$6F'>58."2-,4%&9+78')@76CIP/JDW?='F
M"'1/09QF63B[FF7*8\=B.>&('>7>0D8J(2T'Y[-%V2^%TB'NT85X!,EVW_1$
M7D3BAD6#]IF'!H<Y 1LH&%"06<O\JK"VQ-XYO>_NYXY%WWO7]9,',V&P@)9@
M'OH%7A&LA*N$03AU(V;8GD,;NGT131Z!:B\K#9OQK>6-*R7E-![2W'-?]<YV
M&:&(4VV) M(QIXW#@E1B&NO/Y]K%5/5N8TD+:/9 FF>CW'L5]:O/9]11#\.T
MI2E%$$IH&..56%2"Q(6&(9/D..V6[8/:KV^Y]8[JK<]F3FH.-'>&4.Z4U0SY
M&ASJ4ZO/#) C1VISN]N8!.3I-G;W<F1GNXP+Z!C4)&9,A3^,ME148H:)^GRJ
MN+;+ES9!/<$N[U[2O-X@$QC+,'Y J=74*$!D7,-9"V:]2"Q'/\ 8M5VVM(+F
M,#9O]YN;IGUD%F$HG&=86@0H4 )274<("B;ZO /<L&W9]'0$<)^QT_OJ4M F
M 5/]<,: #N$!-T9:  P)(::K!?(4)S)F@)-5VU%2*H1]<*+9PON3]6 +@VL&
M (T;@IA@Z\)'5 FA$>KK5I2[?%:4<>UNMNB'#0EJ?%%]/AG&-Y#%8:PDWC(=
ML_\%AT1SO[ZH3Q( A-IW%6U;]N$M\N)8,'L)@/YKN2F(]J7<XH"O^/UU-,\O
MX[08YL25,C_E0:1YL<@_Y[-OQ3C_N%+0IWQ<7D]7O>S;*^[ZU0%L32"F'#,E
M/$.0(< KL*U3B?N' W2L6^3LP)32EWU<&V^[G(5(8CWPM5%?_?+B;G4MJ/N>
MS\;%?/>,>G!G&90A0N%60ZN9-0H'8$P-"$D].3! C[UMR]HES*?CW>HK:8EV
MV_O*O T@&.-"_**-#+&1MJR"0R*Y;Y?P[=SLT#WK6D/YU,9N%?FF&K=5XXP(
MCBD#%C!%D/$X5N2H!'80)P81 SPXUY<Q2X'UQ,8KD48/;3.MN1' D[A>YR30
M#D!=B8MIZI0XP"*U/1FG%%1/;8P^Y'^N?K5[-:M)!YG"X<NA4GCBL5: J/!'
M+3A+30(;8(7;OHQ2*K0G-DQ'4.II^PQ!;Y51R"%D#=&&0((JL1E&B=[3X15T
MSX!11R%[:B.EQNN8-WI]J7;J<1\9"'@*+: CX?L)LSS#@%;B&^U2\]W C\BL
MH^$]L;DZCEPONL@@M5@JPX*5=H;%8FL,5\+S\*TE<FN :2P]6:TCT.V!6KO.
MG/IREA?7TW7)O/']E]EH.A^--Q?QK/XU6>NY7@UL<+:XFQ=FC!/F$0/8&RZE
MU("C>N$&.I5*VX,W(/JX[:1%X@Y"&SW0/(SL0; =['SR7.:0)H8H0:FEU%L,
M'0)U0"U\ZCP[R OE6B35,2 .=-O;0V@5](9RS3T52))Z:04REYK^  ]>?U_O
M;[IIM]>Y=;7K?1B*;V#7&TAJ'!(& X& 1H8J6 L$O4B\%0<>O$#^]FAQ+)9#
M.2$VI$/G71X7XT9#Q:C504=$>ZLAI @BRPFUT.X[FWW"K(0'SSS^?ZP68,KY
M[ON/CN@V,R%@A!0$*X<]EI9C0G %%%7FASN*UI0W*0D&[>C@%)9D?G%E1O,;
M/RG_G)_8:-3C.,Q6O&B62:(5L0%W"$U0-*>:5*<.J;1B7P0VM!.EC& 3 A<9
MJ 1-$ #(2AB@S^A"F'94NN\@Z2%@]N#VK:.3!W<FJB]J:O<QTAVM,A=<'\2]
M\E*!>%\<P<S5(@*6N-0_9+X<J-H7%V:VA>7IZ++W*.G.=AD+09!A5G*(*5->
M"2) )6:(D,^G%FPKNF[&GR1H>SD$-L_#:V[4]-+FW_))N;IWVGV/:9'[S_4T
M:)T9:K!F$BHH,5?!R0&.52(KBN6YL^E0S;\X)M8VQ#VPZN_Y-)^-)O'&M<O;
M8EK$67M1?,N;\JI1^PQ3'Y#T5 AE"1#A*]6\%IOI\SGYTPVSN@#Y#9P70T!J
MQA$&%GM)!19 UXZ!TRPQ#AX@:UIRB(Z&L)]-E!@C?)R5WXH0HNK[W^8A])Y>
MW*UNG9E>JW$@]KJ,Y/Y8\O#.,LRLL(I1P:@U1@M"(:P $8ZXLYGCCB'#R[V8
M;F$>[.8=8=IQ3;WG$$EGC'(25V(P3,_'O^Y2Q3MW]@Y#N-]C:O&"H@#*ZN/Y
M4L;S1=-Q,<F?"/"E;,^<=?WJ#' ;/WPDC?+&2**4K0I;!)^4)^;,#W!"[9'.
M U-:#U](=9O76J@OH^\;-U0'+_5JYX43>UIFU#H%N3(.0>1Y, D,FTK4,);S
M"4"'0YHM-[6UHZ%>R!AT.RY6.M_)O(?',@BXH=[*>"H!0FZ%\ZH20FAX/D63
M!DRS9'7TL2828O6(Q\7T\VB27UP%1 (&B_N/D]&ZIMUJ86?7HDBC#C*/*$*0
MA_E&!M$QY1)5"Y<,V=1]WN:987+-PVE^'3<6?TPF=J*JOA+0]/.3\?M2T5XT
MR+#3U%CMM*,&&F$!8;(6#*2NS WP3/A@&=B*8GI@W/94WNH;^FTZRT>3XE\[
M4R(/Z2;33@I,%'(*$"!8/$R!*A"8<":-G<U3X_YM(3M56!^L'17KZRO6)^;-
MS6AZG<_?3>N?5T+ 79QMW$F&F+)8:.&=0Q;$Y&1=K6<P&K[D-,8V/Y;^;\9V
MJ*X>^-K\?G8UFT6Y5OBO17PW5;?E<I6&L^=*]UUD[VD$&5>48.DL!E Z;0S2
MHM8N 2SQ?M(!'KT?['<R3$WWD8QS>Q=,P3IC[5W@T/2Z^#K)U7R>+^;N^WBR
MC->-_+TL+_\L)KNNWCVHGTP IAE * 0,&'$M&?>^CG,A272U!U@<8+"$[U)?
M_>20!4=KGMM\_><CD#;IS TV&9IWDADD*(#< X@P,LAZ3*MT!::H2TQ('&!5
MNQZW"SJ#_R3\4^-QG 3FX</.BV][TJ.;-,^H$]@R0Q2#GA+IC,.V=LA8:L37
M? O@J?_\I8^$H=;YL)=R1^-^$K+]-@T.Q22_?!CUGDSK_>TS2#FEDENKD)0P
M"(U%;>.94HF'[YIO!?P0=#L>^)U\&WT-KPXLHF&@:P[%G[P8Q^J8>K6_M3KD
M$\S^*P1JWCASWA+)-*& $@(UTDC4.Q?(I]:@2UW ?]/LZ0SUDYBJ>OLT3YT:
M7^TA<UI9:!C'0JH@,%8&UZ)#CA-GQ^:K]6=$N&ZA/PGK/L[R$-]<5A_,9NM>
M3=<73:S#G(-(V*3## @+$*4>08<0)4I*\+!]:VVB$4Q=HS]33G:@B9,&#!]'
M]_&KBAGMX_%L&73\<']\4@BQJ\.,,X^$%L(@HSS'F-@'8)SFB5[> &O%GC2:
M:%$%)^%F]7%]RK_ETYWW">QMFWDI /0A;B*&2 J$I+PZY\. ((F,&^#B]DD8
M=QS:@SKET,KIA@Q!:#AD1D%K(''(8L/K!5',$BN7#3"C[22G&@Z$]W3\>C?]
MEL_;.D6SH[,, B 0Q%"*\ ?B% %5?7 <.YIX4\\ 5X:[YUM[,/? NS#%K[9U
M?#D+<HSS_'+N V9K&5:_V<&S_8TSA[BP2#D(&-'$(R90A2V7Q)_=ZF^7G"@[
M1K\'ND5L5J5/@^+B8!^50=W!LQVM,N,0IE8)9( B% 97 566G",!^[IB[&1;
M6ETPJSV\^[!@C[C_2L9O"%Z:)'@?T$OFJ9782N^X$UPSR51]31^7TB=FA UP
MKNS3F'6&?X^3Z)=R\]4D,;!Q)YGE6@%N 6:>6^6M :[^!F-5M7X7C<^&@ETI
M8%#A0RMA0\:E5<8;#P ,$X($Q'+[  #L[>*Y<C&:G%^X<""\I^.7+Z:CZ;BE
M\'1'9YEFB@LL"0;:*$N8Q@\?''6B\V,#9Q2>M@=SS\Y=5<XS)JC>WI;35:7/
MAB[=JVTSA17"7%''@-  *.TTJ'U9G'IZ?H"GD[NDP@Y'K@W4^XX@#KP]<V_;
MS#%BD.' .H&1E-1!5=MR@."^(LEM!:A]W!9P(IJU@7O/-/M]%//O%]5H=RZR
M[6B6$2UX_)["!$$]-T%<68="3LO$BK2#O(KB1.0Z$O)!^6:M^&29\8(+YAR&
MS DO(?#<U?$5P8G'? [?>S\#W_]X>'O@E[NZRL>+BROW?;PZ*/0IH'(Q7:T1
M3B_C'S$N_C::[-DL.*2;C!!',3 ,(^L9E4!X02H0A$:)2VP#W&UOD6,= MS7
MSL"+<:YO3'N>+[!OJZ!A-QG0 "DJL<5<:TE03#:H/S6.$V?/P\]OO25+UB'
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MXS%V4@FCF4_<"AD@+=+5^#P4/P["'OCPOAC'D[@-Z/#LR0S$F\P1)498Y:B
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M(18;VT"TCV3:,MY"7\E_;T>W(3Z9?RZ7US>+U=U@N[)J][7-+/->6"[CO>5
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M4]@=^UI%>EA&L!V[EU&H-,(NIA[K6(H^^"-UX!U"[\2]C(-/'7=^SN[$QNY
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M0@X2+(3W80*P$&A:[<\KAU)O,AW0'LP);5_[^)^.L+Z<Y<7U](G_8(NK(&#
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M=5RXI0>G@O4\MU7A(&N MX+0-LG=!>J2F!2?9C_V3E)=+.*!<:H[S9$W I0
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M%.)6X'S:%PAQSL0-0S]P36F()Q==VPAVA\&-L6W9HTWSH! B)8AB #HM-)5
M@I(M4.+,#7[ T;+#W>!;XEG_^_ZOBUG/SDE$UU,(EG%CD8:<T;A!8<HX=0?;
MVL/,TIT##GP=ZDG1))O&?(0,*$=),A&-+<]D2N<'0CF':$ET($1FVNV PW#'
M<4#DLZC_\Z ,F'Q80S>'P._?#5Y*0BDWT"/O#"+4\@-?#6*M1^&.$]U#Y,W(
MMOOAYL]%BELJ&$9Q+U'Q?Q''!Z^"]2+3;!Y;5] A;/A-\:@?T;A(#6Q$.-J8
M07 ,>*P,\RPU'@=&*.@/2JCTF55XQM8)M4'Q& "71G9V])LE:B)_.>9&$N8
MIH[9,JDPDA:#W#H\X.5*0 ]L&=V1D(WY9KX9("$"86*T5QX:Q:%3[$$9Q9FM
MQ> X0E&&MN_G,V9@.<Y222()08PC:XTERA!93MY!E]L]XZ7<KV;2L4,0E"'U
MCSJ&'E!\:B.K]'Y@ E+)#6,06!:M90\1+Y?-;>[M/)SZ%6>;1'[-@J^5%NT@
MQ4PY9*1P!#-&$, 'UR7.+CI?_?ZQK[S!AOUP V;:</S-^T7-:HM$IS,)E'H
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M^M?LYKYX1'OWXZZX2J;&_/O\.A+\0[0[3GE2*PX1#*8.8441-E9HB PWH"0
MHFHZ%X)- >&I2[4=0G?AH3\Q\W\MHUV[;8UU <Y^'20X89E6T #+C:0RJD::
M'@@@U(0<KMTC[2)2]X2U#_/U7WY5I$XT1>3M)@-ISPT1]7& "2-"0D>Y8E1%
M22L73PWMZI[Q>['ZO)P.TAH@=<][VJ=B=9NYDZ57 Q8$&AG50^,M95XCZ>R!
MFLYG!E35OH&<&*XN('%.*-5A"N^^_#ME;RXVZW?WF_5FMKB.NN[[8K7_[;'(
MJJKO!\.Y,RK.7QK'*.#Q\/?E4JPFF36T!UA.H&&LM$GE#C:@<KHJ:GWSK]]^
MF?>)S>?4:X%S!BT!FB!EF6!,68S*11HH,Q/(V O:>!HD;Q<A5ZDX\ 'Y[U;;
M*5?#T;E7 \',VR@IPF/G*"4<X8,5XA7-Q%+U%O;CQU+#).[0Q3-%]XW4&'LM
MC&3$*6V$CQ1/>=T\RN[Y2GQM9REMJ:]GZ^(ZQ>T5B_5><")RON["/O7/AV?>
MSWYN+Q;^GJVNJZ<Q7?B-P#TPA@LM$<<4(>J1LR4)979@W0@=0%6A=#3)J5M.
M=!$'<#-;I"+UY]*='CT6XI%)J.(86VZ@ES82E)2+$$A,IP1&#WQ_>H&83_<.
MP7,^F>F7!P/CT#KNO +(&$VDC\=IN1#H,)L,@/+8=P0#6<3+,:!57"E/7SW3
MB?'7QX+UT:0'P$FB#28""DC@87V83:?X<RY#EHT1+Y.K$%;BZN/' D*$.&.5
MYQP#B@@4#NPGQCVCF;K# %WZ#7'U N+E<-46Z_G710I03)\]T[OGV8<#4M)0
MI2P%"&IF@<'0E).T%F8>YT,,VVN PTV0,$MZ=]T6*C#Y]R<#@%I0SKESVAL@
ME&(/, 1.9^[,0TRL:4*&+Z5?#GO?KY:;^??9/BKC["9]Y/' J5",&,R-(1PQ
M#34N3Q&.&<]4K ;HD6Z"T<T0,8?;[Q9FF8I,5F/V\T_O_.)6$.850=00Y-QA
MFD+R3*&N[3(>!Z\;H6$7>29;D_%\^9%?G@LDE57R2C"/(#+,Q-D?EF&$F5#8
M1>\&^26$[P _^61Y6-CBNK)=W\;G4E=4XHA-U\,P)3R0:# ?E&:GIM.:.!-+
M3YV3_?,@YPPTL_6WFV*]=C^*U=4\=<U8[EIMG#X,S[P6#"$TM3< W%E',9<2
M'U0UQ,6$7-V]LGW9&DMRL+3MTE)<ORW^CK2X72ZVZSYC)IUZ)U!OXWJ]M@A8
MB!V37!YDD:FS(<,C.E '@Z(&^7&! ;;]ZDY-/(.?HR\$;J"!*G5J%(*@.$%L
MQ6&RPF:>7P/TIPP'/$TQ(P<YZ9[Q^^PFI6C>IT^^^Y*H,5O\K+X7U1@B, 5$
MU!,@D!:)J#*DCBJ'W=2XZ?38'@ZZVF-/#M[^N2A^W*7N.Q^*NWW'L7W TWXF
M;];K^^)ZL]P[LMXLKO[G-/SR1PS,<IF:Y1KOE9)" FW+&_5H6N?&K0W0X30<
M-';&K0[,U0^)>F=<'8=G H%;T7(.)852(BND?9 MF^G='.+!VKN;(Y?H76'F
M;)FQ1T^%9%&KN!U+0)GF@#KOV<%]#\ETP@TRN/8<W[/(U@'G_S'[,;^]OSW+
M^U^>"Q )P9'TU$H )&=0P=)?S"%"TPE+R.+=LCG2]14V?>;\./I.P)X8RPE@
M #L*=/S#'H3$69RIO Q1E>[]/&F*"7UA[*PG_,1;P4-D#!51HXL[;TK7E.9@
M$T2:32=>L@$N5\%-%EE_0<[(25J7 #UY:SNZTCJV8_U9H8CHY8,'X2C!T%K(
MT@G)'4&R-.($$S93OQBB"=S[*=(YM[J =TI9V)GL]GZU2WV<+Z]WIOS;XN_M
M/YV$<*4!@F*<.:J,!\J(:!G@U,=IOW#H85>](CK)"NL0)L]5"6J:&5V@<+:5
MZS3[5!.HB-/>SOD4[HZ\$K@P+I(("0PDP8XI#52Y.,)-IEH]QLNS%G'6#/%S
M_,^E#UQ=7\_3>F<W.W2K^\VWY6K^W^+Z&=!4?#,P!UT*G8T:C8>>."IYJ7T(
M'TW7Z;CXNL=..SSH(LUHM;PJBNNUCU1,&^AL<55L[V#2Y<OF;)W+T^\&C%4T
M28Q76A(J-6+4/BQ7D4G5_.AOPVJ:#UT9'I_/4^OS4VJY=#^S*PB]/?W/V1]-
M?",X&/=[3Y4W.%J$A,M(NI)\PI',^HY#-$-Z/'5[XE87>^QNMNN]4E&*J%FN
M-R?S@D^\%M!V2801;%,W:*X]/$BT 28S%F^ $>I][JO-,2 S;.KTMOY\.?G*
M[P8"@0%>81&Y@H1ETG-9+H$3FUF[LG8QDTEBJ"TNY "I+-]3NB6/&A&_/1BB
MZ4R)!=(Q20F3#*G#7:< RF5>[XI7B#1%\HY-A/UTR]F>Z?1S]+6 (::I5[DR
M"L?-TWNC#K0B&&5J5/(55^TPH&]?K5DNH@V7;E+2]IE^WLP_WQ0?BZOXZ&:>
M[\,].W! CG'I,+*8*VHUD.1PNR9\W+@S?;O@%:I]\2C?,;<\<CNSS6<^[9D[
M^6HP42: %YZD1.CX8_SIL "!7>XM]@#O7/OUS37)A2%[2<Y5BH6G]LO6/AIL
MI*[AEJ7BVM0@ Y@Z$%B:['NRU^N+0?)OR/$+V__\JUAO#F?-69%HZ#/!(V2<
M<,Q"RC!CP")=1I8("'1N"N[K/<Q .#9DV._SM_[8FIQO]@[3<RU;6_A: $XB
MSA604*8@%4RPPP>GA_*9=Y%PB/&A(Q2"QAAWR1UXM%6O[C?S[\6[+U_F5Y%/
MV^D4Y>3^/=]\>UO\K>[NEO/%9NNG/7<W7G_$H!3VS@L&B)44*V"@,Q1J I4A
M#K%<Z^_UZJ=[Y@QY7RZ)4"':H[5O!>NAX%80(XDBSA&&Z2&\!5.0NR>_WBD-
MB6T=2(&^7T<RK=?JZC_W\_4V$F97+[KL?;-S]+Q;;:]$/M\4I=$Q_[HX"?G+
M!@Z1),@IK8 @.&X<TO@'+U%<2F;O;OAZW]4;CX:\I;\K#>BMQSVM="?!+2K:
MOWTKJ,0UQC%(YKG  $ON#I8+RNVB U_O[X;$MMX<D4^/HG\N(CRVKOR'8H"/
M<F&B5K=-HWRTWE*Y*U+F37&MOA>KV=?B0Y%2<*(!;I:+;7.!^]E-<D"A<[+3
M_PP#\T(XKP5QRGMD  +('WS(Q)!,B7N]V1P_LX=\8?#[5A3/Z]5\L9Y?;0_H
M5BX,SGXT<&.4E2(EWQD(A?$>E!6&A".YY0K1Z^7K(/DW @%)GN&X,2RN#Q<C
MR_2K1_VK*FX>;0I4<Y,,T;($GA(O#/!><:"<+ZO:R!0QDBF KQ?3D^#W".RO
MVK3Y14%HT5B[;&)!>^@-5IJB"+?((X=X681$1ILYTUF'7J_21\OC20BC^OIU
M57R=;9YH$KW*X9$Y!055JA&!A56I7:5BUI>%4Z55)+,X 7J]R!\C>T>CNY;7
MN8=HG_8UT=\_&0@BD"BOK+,<$(<C2?UA:_,VTTV"7N__!\B]#D3CN="U#_/U
M7WY5%.7%PX<HXB>@7G6(( 1TUCA# -':40GIH86-Q$[+3.C6#@F8>%)S2_SH
MHLC90W[7OG/TSC/Y(3)^];VX]LN5O]_<KXHR)>P$*FN/%;P F#HE#?0 .&L5
MQ0>ET3*0F;&%7F_QNV1+992NBZO_^;K\_K_SQ?<H#PFC>/]S0B=^A,[=;\.;
M[1^)%+]Z[X[:NY7>"X ))!D$1AEF+0&>DS)$4B*<[:A]O5MOBP6=[(,/>3M;
M47F<SA,5BU.*Y]EW@Q6 (2]PU,JMX<2FC,ERN1"P7 ?(Z]5VFVP8@8_BD")9
MZKV?EG%[[\P=4>7S@3F6:LPCJC!'5 @J:-D2-143SE5!7R^9!\[)GBRITG7R
MK^5-I,'-?/,SPY9Z?I"@G5;<4>NDTS#^X>FASJJ4!N4V]'F]X>V$'ST#TLZ_
MSZ^+Q?4%<'P\1/ 4*2ZL$]9 83C4FI3TE8+D]G+&K[>='7"C9RBFZ]-,"*97
M@Y8XRINPT6B3#'$0#P)2+E8[F-M_I?9]W@OT*EW AYS\ILLBI-4FZ@^?[].=
MQOK]JH@$_#Q?[,+?BM7W: >JQ?6;Q=7-_?7VB=EJ\^[+5O%XO^]G=,S.'\S<
MPE:X&4,X&A4(06(T.K!  IY9&P:_WJN-F<T]2]IRO7EVG6^7FT%(VT7S"\9Y
M)01C$%.#G$0.B3),3RI%,JM*X]?;N+&SN@.E2MUL\51</\^:=#@OUJ>T^VH#
M!"&Y 91[  CV3$)@'ZZ)N.69)7;P:R9OZ[P8C],P"6Y/X8059Q  8-:B:-Y+
M0"E6%%+G'XPJE%DW%K]>#PZ?F1W(D;N]NUG^+(K]J?0\'=XNMQ=9Q:[6RGI[
M2#W^]U1?-QYF_W^Q^5!<+;\NSB3"M_;-P) G6%(J/)&><6B!1 =;4+I<W^3K
MI>80V3=FZ=@':"U7^U^EYT[=KG8[D8"0\E1P)[PU##"7VB&7C*!<Y_JV7J]J
M1\/3$:APCR*"6T_4_^U; 7)J%'%&>!IM,L\\.W0KCX<[RJR,B&O?Z$[<_=LW
MXW*\6.^7FSB+>33D]_6<<]I#U1HD==! G%HEL$,XZI78"'FPSY3/; Q 7B]E
M.^'' \C^S_\^9D6<\E_;WS[]Y?[MWPB[*?ZZG:]F=W$ZM_]SM;S=,64[NWW4
MXY^)]=OHH+UIOX[GQ#90Z#>:VF(SF]^L?YUJ\2.2X3K"MOW2XM^6-Q&%ZYW7
M+9YQA?J\WN8^GMKG3[X8K(,L,D4C3Y7"CFBG-8YH$-I:(M YEU)+BVVJD^@I
MNC36K108XR&C+ 7&:A1M5F-,24)#<M,8AWCAWA"4GAYH/7&B X7NS2)N.<7'
MR-SM],NMYDQ'^A-O!1"W3^<M\QK$4U93  C<+]%A)R<$MNY1L6R+#?TA[6Q?
M^I/O!6,5\8 @RK'F+*X18%0N$RB3&4PT0+0UPNMJ^,DB;0<(2GD?\3/?U.+:
M%M^+F^5=FO5>)]HU?S^!HPIO!\<L4,!"K34C !,*N2^7[ C-+,0QR!;3#?%^
MV3:1.\#5'\6B6,UNXIS5]>U\,4_:0JJ16Q59E=X/1@O"D!4\+IH9#I4U!Y)Z
MXG+#R4>S4UV(K#:(/&2'V<'T;<-#]LBNY@@(R35WWC. 952$24DPBL2$6IWW
MKJUUSJTN+UNV!0#_CB*Z_C:_2S4 W<=W[^N%F-0>*PB$F>61'\8APQCR!KB2
M')S!Z2A_74+GV(U'2USIT(_V=KG8%5MX5*Y27<5#9+[Y.4''F>926T DQDH3
M'_\4C%/D)8I'(I+\7%>%%L_#"ZIE'.[6?JW4_F%Y<^.7J_3@N?.RU8\' "'G
MC#D9 <\09Q(#6Q+=49!;F7: 6U)#X&NXFDKC+!I!R:$C:^Y>$ *F A!+I<%$
M>VN91E*4I 7<9L:]U4;_W:ZOY6:VVK1_+ \$K-W(44T.Y]S$9NLZ9:AWW('N
MMVK\TZ4\B?([9"D=N\[M?B;!(^*M8MX)+9&"A"B+2O(2QKMR$KQ@ 1H'YX?L
MN1A,^SL*J!:2<@@XYQX);2((]B2UWN0F(PQ0%QN>& V'KZ,3E2=;Q/8?[6QS
M\KSJ:29!&QR5 0&I)@HH*S34H&2%C\S(C&%Z%;'>1*QIGH_ ?OI7M\;3<Y\+
MEAH&''$>8P%-1('CL"2J 38S"Z)ZWIS<"=)B6Z/W^D6+4K^L'83)]&M-VM[M
MIFK3"9( :RR AF "+0">H(->@)W/+&E0.^FNL^CN8<G0B%@_@C/IP*#]WR-7
MOA3S7GQ\IV<0E.,"*0^(1MPH+J#0_N 1$C2SX6?U]+W7DVNXW!Z"[77T-O_7
ME=ZOBF,Z<&/9Y0U/)1A-M+882$RYMEX(BLR>&0)SDFE]U<[X>Z$'WDC8/J;#
MKO<++,.@<Y AY"%$!! C+=F35BJ;V\JW=H+@SO_N%J_'6:_\'80M-J;K*V$(
M@ )9001S"D13UY;LELS*3(\[K)W2^&+E9QR,'TC,U[O%U7)5/+0MGF ,F$RE
M QP55'LHL(A;']SRA5"/*'/GDK%>DR>+ !R)]@Z+8N@!E#)2D].2A%;9S#3M
M\45T5892>\F3M3C1156][=SBU\ZD2_[R7(C[)&566&>(M,P(Q(#:+P,#"C*M
MMB$"JGO./ZV4=P'A!^V[>%C8XCH=76]GM\793,HV/A>H]-Q($$U1BK%,5>Q1
MN2W$OT\(S9E8:LQ9T!@/<JR:=!Y\G]W$N92Z:IK^;/%SWZ-KJ[@>392K.T3
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MTD@F)3NH )KF-G>KW2/QQ8K/./C>85S]HQY=^\7\<Q$Q]0)"ZB'$1#".C3-
M$<P4](1"HYF1C@AP[OKI-:2^"!AJR+1AFC*1RA'S;6?J'0D%SZT:-,0;O(:@
MU%I(?3U.##:DWA&KH5):"(BT)TA@!<IE($@G5 B\>\Z?#*FO1_@AQ/:,(*0^
M*B-".X0!41X"Q#B'O"2J0[ZKZ]NN0^HK8ZF+D/IZ/!A!2#TD#$/$I' .4!"5
M7:G4?D'>Z"FU9>L5#KDA]?78,]"0>@@4Q$P#!J*APJ/98A@N%R'5:S.9!H_A
M"^@^X)!ZKKEQ$D?;5EN&O<,&N'(A%,"NZL=W'%)?F7VG0^KK$:^WD'H!@4;"
M(BJH$E8R+)TOIPF!FU[:1%WV5 BIKT?#(:C=/8?4PTCMN-%*#X1#4D(C!2L)
MID1N'L>D0^IS3Z;.N35D>.]]HX^\I37"Z!O_8% & !^W=6HC2;&BCF,3"6L!
M(=) .B''6X<@;+@<=R.L&Y=,[,RC;L1A]ZW@!=*$6*Y%U+<$\L8A=#A!\30[
M%?4(RO9D)(N?XQ*/MLJ1-C.#@+"@5%,!D:1<>YS*@)6DYU9/,EA^DJ+4()>[
M$+!TM_9FO;XOKNW]*DY_%T6Y\ZH]JO:V+M=Q4M^J/5APS!M!B5,>.>H<T4P\
M[#B"9;;J&FY0^X @WS:S1G \/*H9K!;7[L?=?+4=X5!!N,6#X>RW@Y2$00F$
M2$4J)<'8X;U'2P'$1&:X4O5@]5]EX]-PS8UAG@E-,W@$\M2O-1(YJBAW#$"G
M(GJ5\P"4Y)1QHVH[S+S[\+[I",NEW!R7< S<%L%(<&^A%,93 S5PJ?/\GO0<
MJ4Q;9,AAYI,4I 9YW'],[/O5<C/_/IMV4*S4  %+M,$>8*Z$<=L>9X0A&G6#
M<VWO7X-BB\"MP-0R!A@D3%FGD2 E"2W5$RIKTQ"46@N*K<>)P0;%$@F)LPY"
MH8W@D HI<;D,(,!TP@A[X/S)H-AZA!^"_C>"H%@ML"5..<8$%-QI32@]L(:;
MZ<0O9F*IBZ#8>CP80U"LD,8 )E$TV*+H:XR%/)PUW+R@^_!6X9 =%%N+/0,-
MBA4$(V<]50PZ 9#"!)2+8)#*S*ZTDPZ*S3V&+Z#[@(-BD?.2R52+ "25V$,F
M0+D0C7+O5P>X2>6Q[W10;#WBY1Q9>_-^B^>]V7_Z@#KZ0K""HKC=>4XX\2CN
M>]ZI<K(&H>F%/]=ETK(%,@Y!_^XY.M81&W=:*+&%@%E J,2B)!B1-G.'F71T
M;.X1U3FWA@SO@47'6N<P401IZ8WRUID45;\GK$4R\]9Z@-MOER#L)CJV'NO&
M)1,]W$=S#R+AF"."*6>X!:G;:$E.;"?D.NP9CJW?1=?CY+@$8^!WT40AK>/^
M*",*I$U6C"E5!(8\[<KP[ZQBYR3%J$$.OX286,E\Y)>EEC#")&94/-(*J'F-
MB6T-\FTS:PA'PU&;[,G:UD=*ZC9V0C0ZD1 U9^91/*>!$CKR/"G5)2-\/*_;
MCI9]/2@&R>@A2-RHH] M$]@[P#&U)OZ!C.&\)#< )+/20&[QYM%&H?>EA37-
MX"G(4T\FST7S"@H0JB1R$-&H5E @+-=[-NET;=Q14.[K^39HOG<8J/M('U97
MF_GW^>;G!&-R-3;8,68%@9)@8)5CJ20WE4 R*]FY6YW7F-PB"!5M(LLY T(;
MX)P'WI4D--YE-BX:HA^T(2BU%I-;CQ,##052J>JXU888S*6C"BKQB(PBTSTR
M1#AUS_=3H4#UZ#[@4""HJ(4PE:4AAD0=5V%HRH5X(:83KYC'OM.A0/6(EQ,*
MI%:?[S?WZ_3=,S% OS\97%P?!01[:G'<9K5B!I73PSXW=6W O*W+EF63]!NR
M,=A1U(\4&##'O</4:.> %!(<MM9H;+P&IC9V&G7.K2'#>V!1/]A[[   TL4-
M2'LHC8<E815D$^H=T"$(NXGZJ<>Z<<E$#U$_@G"/)';><26U9LYX4I*3V,[,
MDY$7\JH,RM9C?^KQ<USB,?#8'Z^D%Y!I+PPV3#,6-862])+(S$C^EU83;P"B
MU""7QR5@;Q:;U7RQGE\=:X78^C<#0@PQ)14DD%J#@ ?LL']9)C+C(FJG);P*
M4:]\'8'8_!$?W!SNQ/Y8+=>MF.['OQ8HXQ@)):''PDL E."J)*F6+#/4H78(
MT8"-F&$*R>6\'()XG(N2^G65?07E59]%D(Q9((E@1*> $@V@%'L6<.M8YKU?
M[7I\(XY8:$V@>N/R"PC?YI8BA[!@QG($% -0EQ<M' J3"?OJ@3KC#]_.AGW;
MS!K#,3'2\&V@J8AF(&8*,ZZD@(BPDA&115WU9G\]+(;%Z"%(7-WE?UIN9C>=
M6?Y5/A^8D5BZ^!^D"&+$$V@/AW2*+<R3+O%JV;1LV;3 W!%(U+ 3(H"5%!)!
M7;0M)7',*>,/&Q@VF0XU^:K?M2Y-3?-V"J(TREP(BP FG%N1(OHIEPI3=; Y
M-<Z]8P6OVF+_,M@@XT<@G_W&*CCE@*0*2:$=5 @K+0[D]![D=A'.#%88::7_
M 5P-9;%S7-(Q]% %8HVQ2&C)P#:BBRMRT,$=S#2P8&:LPJLD#8#)XY*O 40J
M:"DP%Q(1KZ/2S1WFU!S(2UQN7D9FJ,*K#/7"UGX26!]/?Y))K!X*89P4WB .
M)7228NLA\8( S^@@DUAWUS;J?O-MN9K_M[C>M@%ZQ+-MVHK^^<L6_2&A]=+,
MULL^'+BF&$LGC$8>LVBB&&<CL;&#C%&,,A/UAQ@*WQ#H:J:[=LJ>W@[Q[%6>
M2:5MX6L!2PZ5]22:X!K%0T=*+4M.,^:F4W%[*-"L='9WR=-AB\GO2\SLOG/1
MUP+ED7P(8F.EC?1D@%$12<H4Y\X:>NX4'I&8](G'YF2C(4;FY$!OOP9/9S\_
M?B8PHP&B@'JKE"3*1J;!DCR&\%S_PZ2P=3D_E\V0/QL1J (B]L\$+W&T "V#
MTCMD%6 N'BK[*4'(NTJ>>6F(R"-_-B)P!43@LA$4X4I A)@D(/47-Q#S<DH8
MY<;C#K%!Q: 0D4?^;$20"HC8/Q.2?@DLP] K8C 2#)'#H>H8ST3$:!(>^D)$
M'OFS$4$K((*6VY971BN.J202 L&5M.1@M!.;>6K4CME_:8C((W\V(E@%1+ 2
MI A3#9$%!#%G4CD8K/=3HH*@KIK!OS1$Y)$_&Q&\ B+VSX2DZ.*HUBCM'+>4
M<,-*U88RF7O763M4^Z4A(H_\V8@0%1"Q?R9@1CU&0&IF!7?Q3//,Q2E9XAS2
M5F>&1(XFO+@O1.21/P<1V[#C[3=/H^+I<\$PP9&64=&17@E#XXI "5:B!,Y#
M1O5@V9>'C M9,#9/[I_99=XN_6  )MIR*0I$Z"@OP!#BY<Y=GQ)9_,LI_3:^
M:X_FV#HZ>5G^7:SV*[Z=GXPI:/&S00"&7:0S1I9R&\FM.(M$CO:OLHCAZ=3I
M[!NDK<K,14P=F^3\\^ZN#\EY\MD *7- (8DU!80:Q8FB.R+KB$Z?Z;,;XJDS
M8<FYC*ECDYQ=>/J[+X^"[/9A=UT)T?$9!,89)41 %<UHPY!F#,D]Z1%Q)M.;
M,?5;D8')4V/\[4JT/I^/M/U<.UK]0Y',QOA[LUQL8_#N9S>?BM4M.B=FW<XF
M$ 8M%PA+C:SFS"N;NNAN64*,-J2C:Z?^LO?Z%;I!<WM<61,#STJ2*FH27#)"
MA7> ,6C,7B'7'!J:652E]FU>GPD5 SO?^N;Q6%7'_;\D?U%/JN/O,PB($&:0
ML10B+P7SGMMR9Y,,HDSQFOK5Z$!5QXOYVYOJF+GPWQ=\:I^!M77(;J85TM6X
MAX0IIXWCADBZ#;U,3#) ^,QTFQ$5#AN8,CE(MG>957A_>SM;_7SWY=^S=-9O
M)MP;$WF,-54Z0H9I*16%#,7_YXXKHX@Z5SZBG<6:F]EZ?:#^N]6'A*)S*8''
M7PI"2,,@L%!08S2*BS2L7"0C^,6D\U5F]K(ETG9POE9)H'M(23%1WT8:&ZL8
M\XQZ+@ MIV\%F4X^3Q,L7#9#Q:Y <#3,Y9FG E(6>F>I90+9.'$ L2J7 *R9
MSA:1P;7G^)Y%M@XX_X_Y8GY[?WN6][\\%Q@E$AH=U1#C)<1<<@?VR[#0X.ED
MOV;Q;MD<Z;I P.Q'-00\?BX2@RJ'C# "TV@G:DH<+I?!M)M.(% C"+B =!T@
MX-FSKDJ0V>D7 XR+DP(J#8TW."I1V-MRH<+SS.(V \1("\I"HZ3-"7]]=@*E
MX^AC<76_FF_FQ=K,;FZ*:_US_]QZ_^#ZP\G.G U_(5ALHZ;.@*=Q#R46,H])
MI#06SE,1S^O)G$=-P6(Y!#[TM;557UO=O:_ZR %:!Z!'1!/H//'&Q?\I6:4U
M&[\"W1NVJNRDK3&JL:WVT*_C<5N/6EOILR,$Q:0R6@ / $?6$@$E/&@?/K=P
M3?5#N8-2WGTCKUV6]+5K_N*,/OSC@6"G+DNRQ@O&FBAA6"F+#7$BGFC\<)@Y
M8#*1.J HM;YQVB5[VMT7SP6A7#)<$!PHFM+5H^J.+*%2"E,NE-/<_/ !50SH
M&X<=<N=R&"YW,RM#5=R/JZ?7>M7P=WZ<0!%EG'J/)89"*\6A/[B*-(==-1-\
M4<!KG"V7(^ZPU,-DKNN"[>00@7IKI/,*0V\1A(P0\<AJ-../Z1D@SIKD2 [$
M].QFMK@JRH"#V2[@8%5&M%X]1+3>S+\<15F]48+V1$*'H.16P)2VC1$YJ S<
MRH[B5B8.M%:9TI@>=T2O/%N3_<(1 \-4F90((1"CTO#D+SO<OT">N=G5KMO0
M9NS4(%#8&8LZC'/:NO2G%<Z$!>'&8((Q%0Q@;*G!6,59> 6M'&:5]"I].B\M
MB%[Y&\%K2@Q!P@HGE%+.QETSDM!"E<I/R,Q#;4".W*:A5+/V>5N<Z,"/EN(^
MW\YNSX57/7XL$(\L TIJEQKQ:<N](?M%."[@A.#4/=^7C=&]0_"<K=O]ZX,!
M\*C*.<Z0]5Q3IAPQ=+\0+RT?_\729>P[@H$LXN4HP^]7R\W\^^PA,/QT=:DC
MCP?F-7(&*TR\XR0NV4$?)^H\EIHQF)E/.F NUV70LG$BYG#[W<(L5T559C__
M=(A$XXYJBCS!6DI#A8C'J_*66T>=R&Q9., XFB9XW0@-AYR16R4PZ_+! ^-1
M"KRP#E.2"ME8P/".^)XX;S+UD &"KG\]I'-N=0'O!ZH^:S8\=0%\BG:TCE/Y
MJYK-5F_,(#6E5D)&E27",J7C-K^W3315)+?-W@#!W"&4CMMQK7*G6_ ^2ZS'
M7?22RVI'Y/7Z_G;WN^UV4!/1#7PH&"V%ULQ'31@!:U- N2X):17)K#PZQ#U[
M$##OGF4]8?^77-='ZROS/"_">[W!@X=8>Z0$I\+',Q9Z)F!),$#<U&M7]8;Q
M5MF48UI]*F[OEJO9C9W/OJYFM^T4:CT%ZAYF$0Q%F$M@"28("F>5%J0D*^1N
MZMU+6D7_\/G9Z?;_=KGX7JPWQ?5VK1=L]54&"MQ";(P30$2**$V=5ZPD!!$F
MLSCN@&*=!K6MM\"2(;M,]D?5'UO[X\UB%T;XI-;&]A_M;%/XV7RUO8>N#O4^
MYQ4,((((I*1GR5^FK!/TP"9%,Y7^ 45O#4%R1L3A$0CBO[9[CTKAE7?%5?SQ
MTS+]ZE'YM^V_':KC=":)ETTL$*R LR!NEE@JAQ0%R96Q8Y0T=.I=@D8ABIVR
MN%.%S=W>W2Q_%L7'8O4]JIM'"'6SA5W\Z=V7#\75\NLBJ:^[?<DLUW4=L0U_
M,V@)K64*$20I,$JDJ[F2O(R+S,OKT715ZE@-[)=['0;N/3EQ]S9:-,J2N#_X
MYB98KPPBH)5CTEC/+4;*.+#OTLP59?3<S<=K@%\1L%$2*62I5APR'#=YY'!J
M<"R,-EQD^ER&>'G4$)1:"_"KQXF!!OA!0I#27,7MVUBF(212EF042DTG/JL'
MOI\*\*M']P$'^!GON6">Q%.?.V6$I4Z5"T$H-X-A@ #*8]_I +]ZQ,NYEU"K
MS_>;^_76 WPZW.OW)P.G1*66V! RBZ VR'J!'0;,.<R]G<[FD,N699/T&[*K
MI*,P+^64A))KZ"S&"%!$"=QMK38YG#+;V XQ9*#WTZAS;@T9W@=?YR/SJ_3(
MV/GW^76TN3[,-JUT%*GZ[8 M40"E"%&FH^KK@+:TW)4L -,I<]DE-)N2BI:X
M.%:A^=?R)@YS$XVV/L3FUZ\'Y+E)H1]$,.8=$8AA&8]A2"FUS.O6BTR]"DX?
M?!R;Z'R8K__RJZ)XLXA *=:;+@7GN6\'H0 10BKHD0.IJ[V,B$SD-MAYD*N,
M33.V;1!BTP 7NQ*:G YXIW:*U.BN?H.<)CX:H(X6O[,I<\L02)DA$0+[ UTA
MD9F:,J)>BMT)RA 8V/8]T?SK8OYE?K7M6W.UO%]L4J6QY<W\:MY/K8??9U'A
M&NCX2T$JQW$\Q!U7416VCB!%D%.* 6^UACW5>#A%]4IWT)4&"%)ZBQ'$4BNM
MC'0:65DNGB,Z'8=:$P!XN@.T0>(^I3EN2,5FK19Q=YQ]3EIN_-T_BMGZ/K)1
M;0[[UKO%AU0?)U4<C/OJO,]KX:;W LY]Y!'RB DHH+=1BX<XZBE"0F4L/->V
MH9U%'@BO?^YK5WW\5A2;/U;+^[NXB',WO55>#UIHA+PV6%O+A:#> %4NG"HZ
MG7SY)IB_;)W '6B]CV9]^/'_FQ>K^.EO/_\LOA<W9VYMJPT0F&.46*TLM@IR
MJKDFK%PXA%9,!EG-PN XQIHC=I<HVY\CV_N#WU=P]HZWUC@!&>"A<_'(!191
MG-+,74D&Q7)+$@\;<XW XACJ6J!ZE^![L[B[WZRW](!G&SF=>"MP; $!FC(,
MN)8J=:@Y$!(P.9U$^98X?PQ?%Y.Z)S3A+#3MWPJ> :%$-#$L4%XPPP17#V)I
M,B/G!G@-T!^:\DC=J?KUC*[@YXOXN_GLYF/D[I9:9K9S%%4)>[ATZ("@$)YJ
M#&C\K\#:^6C![HF%I9Q.T$-'*ELG;.@ LSO_P&%==KZ^NEDF>:YB=)][-T O
MH&0>8$(,XY0C;@\;/O%\BDI;V\!8MLN##B!G9NMO:G&=_D@AU]]G-[\<'0]+
M. &]RF,$(84TT%HGK;1".9[.G]WRM;8@,T%M@!!L$ E/F^6T1.P.L/9FF_1]
M6Q]@IU\,@F"*&8S+,PPXB3'WAX4*0Z=3G[ ]5#5*X0Z@].<R:@_%ZO;1O$_@
MYYFG@Y9>,V@HP-  J*$WV)=+DA!G6IH#C'5H#S27D[5/G2I'EPJ2:9FL)VB,
MI((S17GIPM8L\J:CJ__-<C.[&2EJFB)N%[O,PS5=GE)>;8" D3'(<!!/:V2=
M)D0J>=A>%<TL/C/  ZPWS;P51G2 P+)HY=OEYF.QV=P4R6)^LTC:7[TMK=Y
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MP.6.81DRYRY)*QX^U2]I'I>0VW%DOE"W:?;+8]SX30)^5G ]]3>C8!!S#"/
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MAR>SES/YJ<0V1-..9;+'^G]-BJ9C$B/C$6!0 FX( RART$4**T\,.W?6=++
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M,2YX;6Q02P$"% ,4    "  ;;FE(B7&QPQP:  !7* $ $0
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M2P$"% ,4    "  ;;FE(B@@-DLRI  "9I0@ %0              @ % YP,
K86)U<RTR,#$U,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$  #^1!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
